BRCA1	O
is	O
release	O
and	O
march	O
place	O
of	O
a	O
granin	O
.	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
be	O
be	O
be	O
.	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
dimension	O
of	O
a	O
granin	O
.	O

BRCA1	O
is	O
secreted	O
and	O
expose	O
holding	O
of	O
a	O
granin	O
.	O

BRCA1	O
secreted	O
and	O
properties	O
of	O
a	O
granin	O
.	O

a	O
.	O
secreted	O
exhibits	O
and	O
properties	O
of	O
BRCA1	O
granin	O
is	O

BRCA1	O
a	O
secreted	O
and	O
is	O
properties	O
exhibits	O
of	O
granin	O
.	O

a	O
and	O
secreted	O
is	O
exhibits	O
properties	O
.	O
BRCA1	O
granin	O
of	O

BRCA1	O
and	O
exhibits	O
properties	O
a	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
be	O
be	O
be	O
.	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
.	O

Germline	O
mutations	O
inwards	O
virtually	O
inward	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
responsible	O
for	O

ovarian	O
mutations	O
in	O
.	O
are	O
responsible	O
for	O
most	O
cancer	O
of	O
inherited	B
breast	I
Germline	I
and	I
cases	I
BRCA1	O

Germline	O
mutations	O
chromosomal	O
mutation	O
virtually	O
mutation	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	B
inherited	I
breast	I
and	I
ovarian	I
cancer	O
responsible	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
sheath	O
of	O
inherited	B
boob	I
and	I
ovarian	I
crab	I
.	O

and	O
mutations	O
in	O
most	O
are	O
responsible	O
ovarian	O
BRCA1	O
cases	O
of	O
Germline	B
breast	I
inherited	I
for	I
cancer	I
.	O

Germline	O
mutations	O
inwards	O
virtually	O
inward	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
responsible	O
for	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
eccentric	O
of	O
transmitted	B
knocker	I
and	I
ovarian	I
cancer	I
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
chest	I
and	I
ovarian	I
cancer	I
.	O

Germline	O
mutations	O
cases	O
.	O
are	O
responsible	O
and	O
most	O
in	O
of	O
inherited	B
breast	I
for	I
ovarian	I
BRCA1	I
cancer	O

mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
serve	O
problematic	O
remained	O
elusive	O
.	O

,	O
the	O
BRCA1	O
remained	O
elusive	O
.	O

However	O
,	O
the	O
purpose	O
of	O
the	O
BRCA1	O
protein	O
has	O
stay	O
tough	O
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
serve	O
problematic	O
remained	O
elusive	O
.	O

,	O
the	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
elusive	O
.	O

However	O
,	O
the	O
subroutine	O
of	O
the	O
BRCA1	O
protein	O
has	O
continue	O
problematic	O
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
serve	O
stay	O
remained	O
elusive	O
.	O

however	O
,	O
the	O
run	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
tough	O
.	O

However	O
protein	O
the	O
function	O
,	O
the	O
BRCA1	O
elusive	O
has	O
remained	O
of	O
.	O

.	O
,	O
the	O
function	O
protein	O
the	O
remained	O
of	O
has	O
BRCA1	O
elusive	O
However	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
elusive	O
.	O

We	O
now	O
show	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
family	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
and	O
to	O
the	O
granin	O
protein	O
family	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
usher	O
phratry	O
phratry	O
usher	O
usher	O
usher	O
the	O
granin	O
protein	O
family	O
.	O

We	O
now	O
display	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
episode	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
kinsperson	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
usher	O
phratry	O
phratry	O
usher	O
usher	O
usher	O
the	O
granin	O
protein	O
family	O
.	O

We	O
now	O
designate	O
that	O
BRCA1	O
encodes	O
a	O
xcl	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
class	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
with	O
sequence	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O

protein	O
now	O
show	O
the	O
BRCA1	O
encodes	O
a	O
-	O
190	O
kD	O
granin	O
with	O
homology	O
sequence	O
.	O
biochemical	O
analogy	O
to	O
that	O
We	O
protein	O
family	O
and	O

We	O
now	O
present	O
that	O
BRCA1	O
encodes	O
a	O
xcl	O
-	O
kD	O
protein	O
with	O
successiveness	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
phratry	O
.	O

and	O
now	O
-	O
a	O
BRCA1	O
encodes	O
biochemical	O
190	O
show	O
kD	O
protein	O
with	O
protein	O
homology	O
that	O
We	O
analogy	O
to	O
the	O
granin	O
sequence	O
family	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190	O
-	O
kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
family	O
.	O

interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motive	O
interchangeable	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
c	O
termination	O
of	O
the	O
protein	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
too	O
too	O
too	O
too	O
too	O
too	O
protein	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
too	O
too	O
too	O
too	O
too	O
too	O
protein	O
.	O

BRCA2	O
a	O
motif	O
similar	O
the	O
granin	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
similar	O
to	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

BRCA2	O
also	O
includes	O
a	O
similar	O
to	O
the	O
granin	O
consensus	O
the	O
C	O
terminus	O
of	O
protein	O
.	O

the	O
,	O
BRCA2	O
protein	O
includes	O
a	O
motif	O
to	O
similar	O
the	O
C	O
consensus	O
at	O
.	O
Interestingly	O
terminus	O
of	O
granin	O
also	O
the	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
too	O
too	O
too	O
too	O
too	O
alike	O
protein	O
.	O

interestingly	O
,	O
BRCA2	O
also	O
admit	O
a	O
theme	O
standardized	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
depot	O
of	O
the	O
protein	O
.	O

of	O
,	O
BRCA2	O
also	O
includes	O
a	O
the	O
consensus	O
to	O
the	O
granin	O
C	O
Interestingly	O
motif	O
similar	O
the	O
at	O
terminus	O
protein	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

Both	O
and	O
the	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
regulated	O
pathway	O
,	O
are	O
-	O
translationally	O
glycosylated	O
and	O
are	O
to	O
hormones	O
.	O

Both	O
and	O
the	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
regulated	O
pathway	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O

Both	O
BRCA1	O
and	O
the	O
antiophthalmic	O
factor	O
determine	O
nerve	O
tract	O
antiphonal	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
antiphonal	O
be	O
hormone	O
both	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O

translationally	O
BRCA1	O
and	O
post	O
granins	O
localize	O
to	O
to	O
are	O
,	O
-	O
secreted	O
by	O
a	O
and	O
pathway	O
,	O
are	O
the	O
responsive	O
are	O
glycosylated	O
regulated	O
vesicles	O
Both	O
secretory	O
hormones	O
.	O

hormones	O
BRCA1	O
and	O
regulated	O
granins	O
localize	O
to	O
secretory	O
the	O
,	O
are	O
secreted	O
a	O
translationally	O
responsive	O
vesicles	O
,	O
are	O
post	O
-	O
by	O
glycosylated	O
and	O
are	O
pathway	O
to	O
Both	O
.	O

Both	O
BRCA1	O
and	O
the	O
antiophthalmic	O
factor	O
determine	O
nerve	O
tract	O
antiphonal	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
antiphonal	O
be	O
hormone	O
cyst	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O

both	O
BRCA1	O
and	O
the	O
granins	O
place	O
to	O
secretory	O
cyst	O
,	O
are	O
secreted	O
by	O
a	O
modulate	O
pathway	O
,	O
are	O
berth	O
-	O
translationally	O
glycosylated	O
and	O
are	O
antiphonal	O
to	O
hormones	O
.	O

Both	O
BRCA1	O
and	O
the	O
antiophthalmic	O
factor	O
determine	O
nerve	O
tract	O
antiphonal	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
antiphonal	O
be	O
hormone	O
cyst	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O

are	O
BRCA1	O
and	O
the	O
granins	O
localize	O
a	O
secreted	O
vesicles	O
,	O
are	O
,	O
glycosylated	O
to	O
responsive	O
Both	O
secretory	O
pathway	O
post	O
-	O
translationally	O
by	O
and	O
are	O
regulated	O
to	O
hormones	O
.	O

both	O
BRCA1	O
and	O
the	O
granins	O
focalize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
influence	O
pathway	O
,	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
antiphonal	O
to	O
endocrine	O
.	O

Both	O
BRCA1	O
and	O
the	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O
hormones	O
.	O

As	O
a	O
regulated	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
suppressor	O
gene	O
products	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
previously	O
tumour	B
suppressor	O
gene	O
products	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
intersection	O
intersection	O
determine	O
determine	O
determine	O
determine	O
suppressor	O
gene	O
products	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
look	O
to	O
use	O
by	O
a	O
mechanism	O
not	O
antecedently	O
described	O
for	O
tumor	B
suppresser	O
cistron	O
products	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
intersection	O
intersection	O
determine	O
determine	O
determine	O
determine	O
suppressor	O
gene	O
products	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
seem	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
antecedently	O
line	O
for	O
tumor	B
suppresser	O
factor	O
products	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
a	O
mechanism	O
previously	O
described	O
for	O
tumour	B
suppressor	O
gene	O
products	O

by	O
a	O
regulated	O
suppressor	O
protein	O
,	O
BRCA1	O
to	O
appears	O
function	O
gene	O
a	O
not	O
mechanism	O
.	O
described	O
for	O
tumour	B
secretory	O
As	O
products	O
.	O
previously	O

As	O
a	O
mold	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
procedure	O
by	O
a	O
mechanics	O
not	O
antecedently	O
described	O
for	O
neoplasm	B
suppressor	O
gene	O
ware	O
.	O
.	O

previously	O
a	O
to	O
BRCA1	O
protein	O
,	O
described	O
appears	O
regulated	O
function	O
by	O
a	O
products	O
not	O
secretory	O
As	O
for	O
tumour	B
suppressor	O
gene	O
mechanism	O
.	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
suppressor	O
gene	O
products	O
.	O
.	O

ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
toter	O
is	O
limited	O
by	O
the	O
HRAS1	O
varying	O
number	O
of	O
tandem	O
recapitulate	O
(	O
VNTR	O
)	O
venue	O
.	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
locale	O
hazard	O
hazard	O
hazard	O
hazard	O
hazard	O
)	O
locus	O
.	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
locale	O
hazard	O
hazard	O
hazard	O
hazard	O
hazard	O
)	O
locus	O
.	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
the	O
HRAS1	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O

tandem	B
cancer	I
by	O
is	O
BRCA1	O
carriers	O
repeat	O
modified	O
risk	O
the	O
HRAS1	O
variable	O
.	O
of	O
in	O
Ovarian	O
(	O
VNTR	O
)	O
locus	O
number	O

ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
change	O
by	O
the	O
HRAS1	O
varying	O
count	O
of	O
tandem	O
reprise	O
(	O
VNTR	O
)	O
locale	O
.	O

.	B
cancer	I
risk	O
HRAS1	O
BRCA1	O
carriers	O
is	O
)	O
tandem	O
the	O
in	O
variable	O
of	O
number	O
by	O
repeat	O
(	O
VNTR	O
modified	O
Ovarian	O
locus	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
locale	O
hazard	O
hazard	O
hazard	O
hazard	O
in	O
tandem	O
)	O
locus	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
tandem	O
VNTR	O
)	O
locus	O
.	O

ovarian	B
cancer	I
danger	O
in	O
BRCA1	O
carriers	O
is	O
alter	O
by	O
the	O
HRAS1	O
variable	O
turn	O
of	O
tandem	O
duplicate	O
(	O
VNTR	O
)	O
locale	O
.	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
locus	O
.	O

Women	O
mutation	O
the	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
,	O
have	O
an	O
80	O
%	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
by	O
age	O
of	O
70	O
ref	O
.	O
1	O
)	O
.	O

Women	O
who	O
carry	O
a	O
mutation	O
gene	O
(	O
on	O
chromosome	O
17q21	O
,	O
have	O
risk	O
cancer	I
and	O
%	O
ovarian	B
cancer	I
by	O
the	O
of	O
70	O
.	O
1	O
.	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
70	O
referee	O
chromosomal	O
mutation	O
	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

charwoman	O
who	O
behave	O
a	O
mutation	O
in	O
the	O
BRCA1	O
factor	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
lxxx	O
%	O
hazard	O
of	O
titty	B
cancer	I
and	O
a	O
40	O
%	O
hazard	O
of	O
ovarian	B
cancer	I
by	O
the	O
geezerhood	O
of	O
70	O
(	O
ref	O
.	O
unity	O
)	O
.	O

Women	O
who	O
cancer	O
a	O
mutation	O
70	O
the	O
%	O
gene	O
(	O
on	O
%	O
risk	O
)	O
,	O
BRCA1	O
an	O
80	O
ref	O
17q21	O
of	O
the	B
cancer	I
in	O
a	O
have	O
chromosome	O
breast	O
of	O
ovarian	B
carry	I
risk	O
by	O
age	O
of	O
and	O
(	O
40	O
.	O
1	O
)	O
.	O

Women	O
who	O
stock	O
a	O
mutation	O
in	O
the	O
BRCA1	O
factor	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
eighty	O
%	O
chance	O
of	O
bosom	B
cancer	I
and	O
a	O
40	O
%	O
chance	O
of	O
ovarian	B
cancer	I
by	O
the	O
eld	O
of	O
70	O
(	O
ref	O
.	O
ace	O
)	O
.	O

of	O
%	O
carry	O
a	O
mutation	O
in	O
.	O
BRCA1	O
gene	O
(	O
on	O
)	O
17q21	O
a	O
ovarian	O
have	O
an	O
80	O
risk	O
risk	O
of	O
breast	B
70	I
and	O
)	O
40	O
age	O
who	O
by	O
cancer	B
cancer	I
of	O
the	O
,	O
Women	O
%	O
(	O
ref	O
.	O
1	O
chromosome	O
the	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
gene	O
(	O
on	O
chromosome	O
)	O
,	O
have	O
an	O
80	O
risk	O
of	O
breast	B
cancer	I
a	O
40	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
(	O
ref	O
1	O
)	O
.	O

.	O
a	O
carry	O
a	O
an	O
in	O
of	O
by	O
gene	O
(	O
on	O
chromosome	O
17q21	O
the	O
ref	O
have	O
mutation	O
cancer	O
%	O
risk	O
)	O
breast	B
cancer	I
and	O
risk	O
40	O
%	O
.	O
80	O
ovarian	B
of	I
who	O
the	O
age	O
of	O
70	O
(	O
,	O
Women	O
1	O
)	O
BRCA1	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
70	O
referee	O
chromosomal	O
mutation	O
	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
70	O
(	O
ref	O
.	O
1	O
)	O
.	O

The	O
variable	O
penetrance	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
play	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
inward	O
somebody	O
somebody	O
transmissible	O
transmissible	O
transmissible	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
hereditary	O
and	O
not	O
-	O
hereditary	O
agent	O
gaming	O
a	O
part	O
in	O
tumourigenesis	O
in	O
these	O
mortal	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
inward	O
somebody	O
somebody	O
transmissible	O
transmissible	O
transmissible	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
indicate	O
that	O
other	O
transmitted	O
and	O
not	O
-	O
transmitted	O
agent	O
trifle	O
a	O
character	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
-	O
genetic	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O

non	O
variable	O
penetrance	O
tumourigenesis	O
BRCA1	O
suggests	O
that	O
genetic	O
other	O
and	O
in	O
-	O
factors	O
genetic	O
.	O
a	O
role	O
in	O
of	O
The	O
these	O
individuals	O
play	O

The	O
varying	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
transmitted	O
and	O
not	O
-	O
transmitted	O
factors	O
bid	O
a	O
purpose	O
in	O
tumourigenesis	O
in	O
these	O
someone	O
.	O

play	O
variable	O
genetic	O
that	O
BRCA1	O
suggests	O
a	O
other	O
penetrance	O
and	O
non	O
-	O
these	O
factors	O
of	O
The	O
role	O
in	O
tumourigenesis	O
in	O
genetic	O
individuals	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
genus	O
cancer	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
of	B
cancer	O
penetrance	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
genus	O
cancer	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
downriver	O
of	B
cancer	O
penetrance	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
genus	O
cancer	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
kibibyte	O
of	B
cancer	O
penetrance	O

oncogene	O
downstream	O
variable	O
number	O
of	O
tandem	O
,	O
possible	O
VNTR	O
)	O
polymorphism	O
repeats	O
located	O
11p15	O
5	O
(	O
kb	O
)	O
(	O
of	O
the	O
one	O
.	O
-	O
The	O
(	O
is	O
1	O
kilobase	O
proto	O
)	O
modifier	O
HRAS1	O
HRAS1	O
genetic	O
chromosome	O
of	O
cancer	B
penetrance	O
.	O

The	O
HRAS1	O
variable	O
number	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
1	O
kilobase	O
downstream	O
HRAS1	O
proto	O
(	O
.	O
5	O
)	O
is	O
possible	O
genetic	O
cancer	B
penetrance	O

The	O
HRAS1	O
variable	O
turn	O
of	O
tandem	O
iterate	O
(	O
VNTR	O
)	O
pleomorphism	O
,	O
situate	O
single	O
kilobase	O
(	O
kb	O
)	O
downriver	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
five	O
)	O
is	O
one	O
potential	O
genetic	O
qualifier	O
of	O
crab	B
penetrance	O
.	O

The	O
HRAS1	O
varying	O
issue	O
of	O
tandem	O
double	O
(	O
VNTR	O
)	O
pleomorphism	O
,	O
situated	O
ane	O
kilobase	O
(	O
kb	O
)	O
downriver	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
fin	O
)	O
is	O
unrivalled	O
potential	O
inherited	O
changer	O
of	O
cancer	B
penetrance	O
.	O

)	O
genetic	O
variable	O
number	O
kb	O
tandem	O
cancer	O
is	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
oncogene	O
)	O
(	O
of	O
kilobase	O
downstream	O
of	O
1	O
HRAS1	O
proto	O
-	O
HRAS1	O
(	O
chromosome	O
penetrance	O
The	O
5	O
.	O
repeats	O
one	O
possible	O
the	O
modifier	O
of	O
(	B
11p15	O
.	O

The	O
HRAS1	O
variable	O
enumerate	O
of	O
tandem	O
reiterate	O
(	O
VNTR	O
)	O
pleomorphism	O
,	O
place	O
single	O
kilobase	O
(	O
kibibyte	O
)	O
downriver	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
pentad	O
)	O
is	O
unitary	O
potential	O
familial	O
changer	O
of	O
cancer	B
penetrance	O
.	O

The	O
HRAS1	O
)	O
number	O
of	O
modifier	O
polymorphism	O
(	O
VNTR	O
)	O
repeats	O
chromosome	O
of	O
1	O
kilobase	O
downstream	O
kb	O
)	O
cancer	O
located	O
the	O
HRAS1	O
proto	O
tandem	O
oncogene	O
(	O
,	O
one	O
is	O
5	O
variable	O
11p15	O
.	O
possible	O
genetic	O
-	O
of	O
(	B
penetrance	O
.	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O
5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
of	O
cancer	B
penetrance	O
.	O

someone	O
who	O
have	O
uncommon	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
chance	O
of	O
sure	O
types	O
of	O
cancers	B
,	O
including	O
front	B
crab	I
(	O
two	O
-	O
quaternary	O
)	O
.	O

Individuals	O
who	O
rare	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
of	O
cancers	B
,	O
including	O
cancer	I
(	O
2	O
-	O
4	O
.	O

Individuals	O
who	O
have	O
rare	O
character	O
two	O
allelomorph	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
genus	O
cancer	O
	O
two	O
	O
rich	O
person	B
including	I
breast	O
cancer	O
(	O
2	O
-	O
4	O

cancer	O
who	O
have	O
including	O
alleles	O
of	O
the	O
)	O
-	O
an	O
breast	O
risk	O
of	O
certain	O
2	O
of	O
cancers	B
,	O
rare	O
4	B
increased	I
(	O
types	O
have	O
Individuals	O
VNTR	O
.	O

Individuals	O
who	O
have	O
rare	O
character	O
two	O
allelomorph	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
genus	O
cancer	O
	O
two	O
	O
rich	O
person	B
including	I
breast	O
cancer	O
(	O
2	O
-	O
4	O

Individuals	O
who	O
have	O
alleles	O
of	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
cancers	B
,	O
breast	B
cancer	I
(	O
2	O
-	O
4	O
)	O
.	O

.	O
who	O
have	O
types	O
alleles	O
of	O
)	O
VNTR	O
rare	O
an	O
increased	O
risk	O
certain	O
cancer	O
4	O
have	O
cancers	B
,	O
including	O
breast	B
of	I
(	O
2	O
-	O
of	O
the	O
Individuals	O

have	O
of	O
the	O
VNTR	O
an	O
increased	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
including	O
breast	B
cancer	I
(	O
2	O
-	O
4	O

-	O
who	O
have	O
rare	O
alleles	O
of	O
certain	O
risk	O
have	O
an	O
increased	O
cancers	O
(	O
the	O
4	O
Individuals	O
VNTR	B
of	O
including	O
breast	B
cancer	I
of	O
2	O
,	O
types	O
)	O
.	O

somebody	O
who	O
have	O
uncommon	O
allelomorph	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
sealed	O
types	O
of	O
cancers	B
,	O
admit	O
bosom	B
cancer	I
(	O
2	O
-	O
4	O
)	O
.	O

Individuals	O
who	O
have	O
rare	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
including	O
breast	B
cancer	I
(	O
2	O
-	O
4	O
)	O
.	O

To	O
enquire	O
whether	O
the	O
presence	O
of	O
rarified	O
HRAS1	O
allelomorph	O
increases	O
susceptibleness	O
to	O
familial	B
titty	I
and	I
ovarian	I
crab	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locale	O
habituate	O
a	O
PCR	O
-	O
found	O
proficiency	O
.	O

investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
we	O
have	O
of	O
BRCA1	O
carriers	O
locus	O
PCR	O
-	O
based	O
technique	O

carriers	O
-	O
whether	O
the	O
cancer	O
of	O
typed	O
using	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
307	I
.	I
ovarian	I
presence	I
locus	O
we	O
have	O
HRAS1	O
a	O
panel	O
of	O
investigate	O
female	O
BRCA1	O
To	O
,	O
this	O
at	O
rare	O
a	O
PCR	O
breast	O
based	O
technique	O
and	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
alleles	O
increases	O
susceptibility	O
to	O
breast	I
and	I
ovarian	I
cancer	I
,	O
have	O
typed	O
a	O
panel	O
307	O
female	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
technique	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
technique	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
technique	O
.	O

To	O
investigate	O
whether	O
the	O
front	O
of	O
uncommon	O
HRAS1	O
alleles	O
increases	O
susceptibleness	O
to	O
familial	B
boob	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typecast	O
a	O
jury	O
of	O
307	O
distaff	O
BRCA1	O
carriers	O
at	O
this	O
venue	O
expend	O
a	O
PCR	O
-	O
based	O
proficiency	O
.	O

307	O
we	O
whether	O
the	O
presence	O
of	O
to	O
PCR	O
alleles	O
increases	O
susceptibility	O
rare	O
hereditary	B
carriers	I
this	I
ovarian	I
cancer	I
,	O
HRAS1	O
have	O
typed	O
a	O
at	O
of	O
To	O
female	O
using	O
breast	O
and	O
panel	O
locus	O
based	O
a	O
investigate	O
-	O
BRCA1	O
technique	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
susceptibleness	O
technique	O
.	O

To	O
investigate	O
presence	O
of	O
HRAS1	O
alleles	O
hereditary	B
and	I
ovarian	I
cancer	I
we	O
have	O
typed	O
panel	O
of	O
307	O
female	O
BRCA1	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
technique	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
technique	O
.	O

The	O
for	O
ovarian	B
2	O
.	O

The	O
risk	O
for	O
ovarian	B
crab	I
was	O
2	O
.	O

for	O
was	O
2	O
.	O

The	O
two	O
genus	O
cancer	O
risk	O
for	B
ovarian	I
cancer	O
was	O
2	O

The	O
for	O
was	O
2	O

.	O
ovarian	O
for	O
risk	B
cancer	I
was	O
2	O
The	O

2	O
risk	O
for	O
ovarian	B
.	I
was	O
The	O
cancer	O

The	O
cancer	O
for	O
ovarian	B
risk	I
was	O
.	O
2	O

The	O
gamble	O
for	O
ovarian	B
cancer	I
was	O
two	O
.	O

The	O
two	O
genus	O
cancer	O
risk	O
for	B
ovarian	I
cancer	O
was	O
2	O

The	O
risk	O
for	O
ovarian	B
cancer	I
was	O
2	O
.	O

11	O
times	O
gravid	O
for	O
BRCA1	O
carriers	O
nurse	O
single	O
or	O
two	O
uncommon	O
HRAS1	O
allelomorph	O
,	O
equate	O
to	O
carriers	O
with	O
only	O
green	O
allelomorph	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

11	O
times	O
greater	O
for	O
BRCA1	O
harbouring	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

alleles	O
times	O
greater	O
only	O
BRCA1	O
carriers	O
harbouring	O
.	O
=	O
two	O
.	O
HRAS1	O
alleles	O
common	O
P	O
to	O
carriers	O
with	O
for	O
,	O
0	O
(	O
compared	O
or	O
11	O
one	O
015	O
)	O
rare	O

11	O
times	O
greater	O
for	O
allelomorph	O
phosphorus	O
equate	O
harbor	O
aircraft	O
carrier	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
phosphorus	O
	O
operating	O
room	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O

11	O
times	O
greater	O
for	O
allelomorph	O
phosphorus	O
equate	O
harbor	O
aircraft	O
carrier	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
phosphorus	O
	O
	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O

11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
two	O
rare	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

.	O
times	O
greater	O
compared	O
BRCA1	O
carriers	O
.	O
one	O
for	O
two	O
rare	O
HRAS1	O
015	O
,	O
0	O
or	O
carriers	O
with	O
only	O
common	O
alleles	O
(	O
P	O
=	O
to	O
harbouring	O
alleles	O
)	O
11	O

11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
two	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O

11	O
sentence	O
cracking	O
for	O
BRCA1	O
carriers	O
entertain	O
unmatchable	O
or	O
deuce	O
rare	O
HRAS1	O
alleles	O
,	O
liken	O
to	O
carriers	O
with	O
only	O
usual	O
alleles	O
(	O
P	O
=	O
nought	O
.	O
015	O
)	O
.	O

xi	O
clip	O
outstanding	O
for	O
BRCA1	O
toter	O
harbor	O
one	O
or	O
deuce	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
toter	O
with	O
only	O
common	O
alleles	O
(	O
p	O
=	O
cypher	O
.	O
015	O
)	O
.	O

11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
be	O
non	O
neutered	O
aside	O
relation	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
transmissible	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
follow	O
follow	O
allelomorph	O
.	O

The	O
magnitude	O
of	O
the	O
be	O
non	O
neutered	O
aside	O
relation	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
assort	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
follow	O
follow	O
allelomorph	O
.	O

for	O
magnitude	O
of	O
the	O
relative	O
risk	O
not	O
adjusting	O
a	O
rare	O
HRAS1	O
allele	O
risk	O
associated	O
hereditary	O
5	O
with	O
known	O
the	O
other	O
The	O
was	O
factors	O
for	O
altered	B
ovarian	I
cancer	I
(	O
.	O
)	O
by	O

The	O
magnitude	O
of	O
the	O
be	O
non	O
neutered	O
aside	O
relation	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
transmissible	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
follow	O
follow	O
allelomorph	O
.	O

The	O
magnitude	O
of	O
the	O
risk	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
congener	O
risk	O
affiliate	O
with	O
a	O
rare	O
HRAS1	O
allelomorph	O
was	O
not	O
change	O
by	O
set	O
for	O
the	O
other	O
cognize	O
risk	O
agent	O
for	O
familial	B
ovarian	I
cancer	I
(	O
quint	O
)	O
.	O

5	O
magnitude	O
hereditary	O
altered	O
relative	O
risk	O
(	O
with	O
the	O
rare	O
HRAS1	O
allele	O
known	O
not	O
of	O
a	O
adjusting	O
for	O
the	O
other	O
was	O
risk	O
factors	O
for	O
by	B
associated	I
cancer	I
ovarian	O
The	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
HRAS1	O
allele	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
.	O

HRAS1	O
magnitude	O
of	O
5	O
relative	O
risk	O
associated	O
ovarian	O
for	O
rare	O
hereditary	O
allele	O
cancer	O
other	O
factors	O
by	O
adjusting	O
for	O
.	O
not	O
known	O
risk	O
altered	O
a	O
The	B
with	I
was	I
(	O
the	O
)	O
the	O

The	O
magnitude	O
of	O
the	O
comparative	O
adventure	O
associated	O
with	O
a	O
rarified	O
HRAS1	O
allelomorph	O
was	O
not	O
vary	O
by	O
conform	O
for	O
the	O
other	O
jazz	O
adventure	O
factors	O
for	O
genetic	B
ovarian	I
crab	I
(	O
5	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
.	O

by	O
to	O
breast	B
to	I
did	O
not	O
appear	O
cancer	O
rare	O
affected	O
of	O
the	O
Susceptibility	O
presence	O
be	O
HRAS1	O
alleles	O
.	O

susceptibility	O
to	O
tit	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
involve	O
by	O
the	O
mien	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

susceptibleness	O
to	O
summit	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
bearing	O
of	O
rarified	O
HRAS1	O
allelomorph	O
.	O

Susceptibility	O
to	O
breast	B
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

susceptibility	O
to	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
move	O
by	O
the	O
comportment	O
of	O
rarified	O
HRAS1	O
allelomorph	O
.	O

Susceptibility	O
to	O
bosom	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
titty	O
titty	O
titty	O
bosom	O
.	O

Susceptibility	O
to	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
the	O
presence	O
rare	O
HRAS1	O
alleles	O
.	O

Susceptibility	O
to	O
bosom	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
titty	O
titty	O
titty	O
bosom	O
.	O

to	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
.	O

Susceptibility	O
to	O
be	B
rare	I
did	O
not	O
presence	O
to	O
breast	O
affected	O
by	O
the	O
appear	O
of	O
cancer	O
HRAS1	O
alleles	O
.	O

Susceptibility	O
to	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

This	O
meditate	O
is	O
the	O
first	O
to	O
prove	O
the	O
effect	O
of	O
a	O
modifying	O
factor	O
on	O
the	O
penetrance	O
of	O
an	O
hereditary	B
cancer	I
syndrome	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
genus	O
cancer	O
be	O
be	O
be	O
be	O
be	B
inherited	I
cancer	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
genus	O
cancer	O
be	O
be	O
be	O
be	O
be	B
inherited	I
cancer	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
of	O
a	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B

the	O
study	O
effect	O
show	O
first	O
to	O
penetrance	O
the	O
is	O
of	O
a	O
modifying	O
syndrome	O
on	O
the	O
This	O
of	O
an	O
inherited	B
cancer	I
gene	I

This	O
report	O
is	O
the	O
first	O
to	O
appearance	O
the	O
outcome	O
of	O
a	O
qualify	O
factor	O
on	O
the	O
penetrance	O
of	O
an	O
transmissible	B
cancer	I
syndrome	I

syndrome	O
study	O
is	O
a	O
first	O
to	O
show	O
inherited	O
the	O
of	O
the	O
modifying	O
on	O
gene	O
effect	O
penetrance	O
of	O
an	O
the	B
This	I
cancer	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
genus	O
cancer	O
be	O
be	O
be	O
be	O
cistron	B
inherited	I
cancer	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
the	O
an	O
inherited	B
cancer	I
syndrome	I

This	O
examine	O
is	O
the	O
offset	O
to	O
evince	O
the	O
effect	O
of	O
a	O
qualify	O
factor	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B
crab	I
syndrome	I

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B
cancer	I
syndrome	I

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
precarious	O
northward	O
ingeminate	O
northward	O
ingeminate	O
ingeminate	O
antiophthalmic	O
factor	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O

-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
(	O
)	O
n	O
repeat	O
.	O

A	O
refreshing	O
homeodomain	O
-	O
encode	O
factor	O
is	O
associated	O
with	O
a	O
tumid	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
unsound	O
(	O
CTG	O
)	O
n	O
iterate	O
.	O

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
CpG	O
island	O
by	O
the	O
myotonic	B
dystrophy	I
unstable	O
(	O
CTG	O
repeat	O
.	O

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
precarious	O
northward	O
ingeminate	O
northward	O
ingeminate	O
ingeminate	O
aside	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

A	O
fresh	O
homeodomain	O
-	O
encryption	O
factor	O
is	O
assort	O
with	O
a	O
prominent	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
unsound	O
(	O
CTG	O
)	O
n	O
ingeminate	O
.	O

adenine	O
fresh	O
homeodomain	O
-	O
encode	O
factor	O
is	O
colligate	O
with	O
adenine	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
precarious	O
(	O
CTG	O
)	O
n	O
duplicate	O
.	O

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
island	O
the	O
myotonic	B
dystrophy	I
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
precarious	O
northward	O
ingeminate	O
northward	O
ingeminate	O
ingeminate	O
aside	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

(	O
novel	O
homeodomain	O
large	O
encoding	O
gene	O
is	O
unstable	O
repeat	O
a	O
-	O
CpG	O
interrupted	O
island	O
n	O
the	O
myotonic	B
dystrophy	I
associated	O
.	O
CTG	O
)	O
by	O
with	O
A	O

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repetition	O
enlargement	O
in	O
the	O
tercet	O
-	O
untranslated	O
realm	O
of	O
a	O
protein	O
kinase	O
-	O
encryption	O
cistron	O
,	O
DMPK	O
,	O
which	O
function	O
to	O
chromosome	O
19q13	O
.	O

dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
3	O
-	O
a	O
-	O
encoding	O
DMPK	O
maps	O
to	O
chromosome	O
19q13	O

encoding	B
to	I
(	O
DM	B
in	O
is	O
untranslated	O
,	O
a	O
(	O
CTG	O
)	O
n	O
protein	O
.	O
expansion	O
)	O
DMPK	O
3	O
-	O
with	O
region	O
of	O
a	O
dystrophy	O
kinase	O
-	O
Myotonic	O
the	O
,	O
gene	O
associated	O
which	O
maps	O
trinucleotide	O
chromosome	O
19q13	O
repeat	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
a	O
(	O
CTG	O
)	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
-	O
untranslated	O
region	O
of	O
protein	O
kinase	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
19q13	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
19q13	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
19q13	O
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
link	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
ingeminate	O
enlargement	O
in	O
the	O
trey	O
-	O
untranslated	O
area	O
of	O
a	O
protein	O
kinase	O
-	O
encode	O
factor	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O

protein	B
3	I
(	O
DM	B
)	O
is	O
)	O
maps	O
a	O
(	O
CTG	O
associated	O
n	O
encoding	O
,	O
expansion	O
in	O
the	O
with	O
-	O
untranslated	O
region	O
gene	O
a	O
Myotonic	O
kinase	O
,	O
trinucleotide	O
repeat	O
of	O
DMPK	O
chromosome	O
which	O
dystrophy	O
to	O
-	O
19q13	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
	O
19q13	O
.	O

Myotonic	B
dystrophy	I
)	O
is	O
with	O
a	O
n	O
repeat	O
expansion	O
in	O
3	O
-	O
untranslated	O
of	O
a	O
protein	O
kinase	O
-	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O

.	O

.	O

.	O
3	O

	O
3	O
.	O

.	O
3	O

troika	O
.	O

	O
3	O
.	O

terzetto	O
.	O

	O
3	O
.	O

3	O
.	O

characterisation	O
of	O
the	O
construction	O
of	O
this	O
cistron	O
in	O
patient	O
tissues	O
has	O
frankincense	O
alir	O
engender	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steadily	O
commonwealth	O
tier	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
last	O
DMPK	O
protein	O
tier	O
in	O
the	O
mien	O
of	O
the	O
enlargement	O
.	O

delineation	O
of	O
the	O
formula	O
of	O
this	O
factor	O
in	O
patient	O
tissues	O
has	O
therefore	O
interahamwe	O
generated	O
conflicting	O
data	O
on	O
change	O
in	O
the	O
sweetheart	O
dos	O
raze	O
of	O
DMPK	O
mrna	O
,	O
and	O
on	O
the	O
net	O
DMPK	O
protein	O
raze	O
in	O
the	O
comportment	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
gene	O
in	O
patient	O
has	O
thus	O
far	O
conflicting	O
data	O
on	O
alterations	O
in	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
DMPK	O
levels	O
in	O
the	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
DMPK	O
expression	O
of	O
on	O
mRNA	O
in	O
patient	O
tissues	O
has	O
of	O
and	O
generated	O
conflicting	O
final	O
on	O
alterations	O
the	O
in	O
steady	O
state	O
levels	O
the	O
DMPK	O
,	O
far	O
protein	O
this	O
the	O
data	O
of	O
gene	O
levels	O
in	O
thus	O
presence	O
the	O
the	O
expansion	O
.	O

DMPK	O
in	O
the	O
expression	O
of	O
this	O
thus	O
state	O
patient	O
tissues	O
has	O
gene	O
far	O
and	O
the	O
data	O
on	O
alterations	O
.	O
the	O
steady	O
in	O
on	O
of	O
Characterisation	O
mRNA	O
DMPK	O
generated	O
conflicting	O
levels	O
final	O
the	O
protein	O
of	O
in	O
,	O
presence	O
of	O
the	O
expansion	O
levels	O

Characterisation	O
of	O
the	O
expression	O
gene	O
in	O
patient	O
tissues	O
thus	O
far	O
generated	O
conflicting	O
data	O
alterations	O
in	O
the	O
steady	O
levels	O
of	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
in	O
the	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
along	O
along	O
elaboration	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
presence	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
the	O
expression	O
in	O
patient	O
tissues	O
has	O
thus	O
generated	O
conflicting	O
in	O
state	O
levels	O
mRNA	O
on	O
the	O
final	O
DMPK	O
levels	O
in	O
of	O
the	O
.	O

characterisation	O
of	O
the	O
construction	O
of	O
this	O
factor	O
in	O
patient	O
weave	O
has	O
thence	O
interahamwe	O
generated	O
conflicting	O
datum	O
on	O
revision	O
in	O
the	O
sweetie	O
state	O
degree	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
degree	O
in	O
the	O
mien	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
along	O
along	O
elaboration	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O
presence	O
of	O
the	O
expansion	O
.	O

Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
presence	O
of	O
the	O
expansion	O
.	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
chromatin	O
granule	O
hurly	O
burly	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
of	O
chromatin	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
chromatin	O
granule	O
hurly	O
burly	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
of	O
chromatin	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
chromatin	O
granule	O
hurly	O
burly	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
of	O
chromatin	O

number	O
may	B
region	O
of	O
chromosome	O
19	O
it	O
as	O
rich	O
,	O
and	O
is	O
is	O
units	O
the	O
the	O
repeat	O
expansion	O
gene	O
lead	O
to	O
perhaps	O
in	O
a	O
The	O
of	O
,	O
possible	O
that	O
of	O
vicinity	O
consequence	O
dysfunction	O
DM	O
a	O
transcription	O
of	O
chromatin	O
disruption	O
.	O

The	O
DM	B
region	O
of	O
gene	O
rich	O
,	O
and	O
it	O
possible	O
that	O
may	O
dysfunction	O
of	O
of	O
in	O
the	O
vicinity	O
,	O
as	O
a	O
chromatin	O
disruption	O

The	O
decimeter	B
part	O
of	O
chromosome	O
19	O
is	O
cistron	O
rich	O
,	O
and	O
it	O
is	O
potential	O
that	O
the	O
recur	O
expansion	O
may	O
lead	O
to	O
disfunction	O
of	O
a	O
turn	O
of	O
arranging	O
units	O
in	O
the	O
neighborhood	O
,	O
perchance	O
as	O
a	O
event	O
of	O
chromatin	O
disruption	O
.	O

The	O
DM	B
part	O
of	O
chromosome	O
19	O
is	O
cistron	O
copious	O
,	O
and	O
it	O
is	O
potential	O
that	O
the	O
duplicate	O
expansion	O
may	O
run	O
to	O
disfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perchance	O
as	O
a	O
effect	O
of	O
chromatin	O
disruption	O
.	O

vicinity	O
a	B
region	O
of	O
repeat	O
19	O
chromatin	O
,	O
rich	O
,	O
and	O
it	O
is	O
number	O
expansion	O
the	O
chromosome	O
that	O
may	O
lead	O
possible	O
dysfunction	O
of	O
a	O
DM	O
of	O
transcription	O
disruption	O
The	O
the	O
in	O
is	O
perhaps	O
as	O
to	O
consequence	O
of	O
gene	O
units	O
.	O

The	O
decimetre	B
region	O
of	O
chromosome	O
nineteen	O
is	O
factor	O
ample	O
,	O
and	O
it	O
is	O
potential	O
that	O
the	O
repeat	O
elaboration	O
may	O
lead	O
to	O
disfunction	O
of	O
a	O
count	O
of	O
transcription	O
whole	O
in	O
the	O
neighbourhood	O
,	O
perhaps	O
as	O
a	O
outcome	O
of	O
chromatin	O
kerfuffle	O
.	O

The	O
DM	B
vicinity	O
of	O
chromosome	O
consequence	O
and	O
gene	O
rich	O
,	O
is	O
transcription	O
lead	O
possible	O
that	O
may	O
repeat	O
expansion	O
chromatin	O
is	O
to	O
dysfunction	O
of	O
19	O
number	O
the	O
it	O
perhaps	O
,	O
the	O
region	O
units	O
in	O
as	O
a	O
a	O
of	O
of	O
disruption	O
.	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
of	O
chromatin	O
disruption	O
.	O

at	O
have	O
searched	O
a	O
genes	O
associated	O
with	O
for	O
of	O
island	O
end	O
the	O
We	O
3	O
CpG	O
DMPK	O
.	O

We	O
have	O
seek	O
for	O
cistron	O
colligate	O
with	O
a	O
CpG	O
island	O
at	O
the	O
threesome	O
finish	O
of	O
DMPK	O
.	O

We	O
have	O
seek	O
for	O
cistron	O
relate	O
with	O
a	O
CpG	O
island	O
at	O
the	O
tercet	O
finish	O
of	O
DMPK	O
.	O

We	O
have	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
.	O

We	O
have	O
research	O
for	O
cistron	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
triad	O
last	O
of	O
DMPK	O
.	O

We	O
have	O
antiophthalmic	O
factor	O
look	O
for	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
goal	O
goal	O

We	O
have	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
island	O
at	O
3	O
end	O
of	O
DMPK	O
.	O

We	O
have	O
antiophthalmic	O
factor	O
look	O
for	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
goal	O
goal	O

have	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O

We	O
have	O
CpG	O
of	O
genes	O
associated	O
3	O
a	O
searched	O
island	O
at	O
the	O
with	O
end	O
for	O
DMPK	O
.	O

We	O
have	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
	O
usher	O
usher	O
over	O
3	O
.	O

of	O
this	O
the	O
over	O
3	O
.	O

sequence	O
of	O
this	O
region	O
display	O
that	O
the	O
island	O
protract	O
over	O
3	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
	O
usher	O
usher	O
over	O
3	O
.	O

of	O
this	O
shows	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O

sequence	O
of	O
this	O
area	O
shows	O
that	O
the	O
island	O
go	O
over	O
3	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
	O
usher	O
pass	O
over	O
3	O
.	O

sequence	O
of	O
this	O
area	O
picture	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O

Sequencing	O
island	O
this	O
region	O
of	O
that	O
the	O
3	O
extends	O
over	O
shows	O
.	O

.	O
of	O
this	O
region	O
island	O
that	O
over	O
shows	O
extends	O
the	O
3	O
Sequencing	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O

5	O
and	O
is	O
by	O
(	O
)	O
n	O
repeat	O
.	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O

fin	O
kilobit	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
ingeminate	O
.	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
ingeminate	O
ingeminate	O
kibibyte	O
)	O
n	O
repeat	O
.	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
ingeminate	O
ingeminate	O
be	O
)	O
n	O
repeat	O
.	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
ingeminate	O
ingeminate	O
kibibyte	O
)	O
n	O
repeat	O
.	O

phoebe	O
kilobyte	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
replicate	O
.	O

5	O
kb	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
.	O

quint	O
kib	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
ingeminate	O
.	O

5	O
interrupted	O
and	O
is	O
.	O
by	O
the	O
kb	O
CTG	O
)	O
n	O
repeat	O
(	O

5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

compare	O
of	O
genomic	O
sequences	O
downriver	O
(	O
centromeric	O
)	O
of	O
the	O
ingeminate	O
in	O
human	O
and	O
mouse	O
discover	O
part	O
of	O
substantial	O
homology	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
significant	O
homology	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
significant	O
homology	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
the	O
repeat	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
significant	O

mouse	O
of	O
of	O
centromeric	O
downstream	O
(	O
identified	O
)	O
genomic	O
the	O
repeat	O
in	O
.	O
and	O
sequences	O
Comparison	O
regions	O
of	O
significant	O
homology	O
human	O

comparison	O
of	O
genomic	O
successiveness	O
downriver	O
(	O
centromeric	O
)	O
of	O
the	O
duplicate	O
in	O
human	O
and	O
mouse	O
identified	O
area	O
of	O
substantial	O
homology	O
.	O

.	O
of	O
genomic	O
repeat	O
downstream	O
(	O
centromeric	O
significant	O
mouse	O
the	O
sequences	O
in	O
and	O
human	O
of	O
identified	O
regions	O
of	O
)	O
Comparison	O
homology	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
episode	O
episode	O
episode	O
episode	O
episode	O
pregnant	O
significant	O
homology	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
mouse	O
of	O
significant	O
homology	O
.	O

compare	O
of	O
genomic	O
sequences	O
downriver	O
(	O
centromeric	O
)	O
of	O
the	O
ingeminate	O
in	O
human	O
and	O
pussyfoot	O
distinguish	O
regions	O
of	O
substantial	O
homology	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
significant	O
homology	O
.	O

These	O
to	O
of	O
gene	O
predicted	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

These	O
equate	O
to	O
exons	O
of	O
a	O
cistron	O
auspicate	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

predicted	O
exons	O
to	O
correspond	O
of	O
a	O
encode	O
These	O
to	O
.	O
a	O
homeodomain	O
protein	O
gene	O

These	O
correspond	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
encode	O
a	O
protein	O
.	O

These	O
correspond	O
foreshadow	O
exon	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
equate	O
equate	O
encode	O
a	O
homeodomain	O
protein	O
.	O

These	O
correspond	O
foreshadow	O
exon	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
equate	O
antiophthalmic	O
factor	O
encode	O
a	O
homeodomain	O
protein	O

These	O
tally	O
to	O
exons	O
of	O
a	O
cistron	O
foreshadow	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

protein	O
correspond	O
to	O
These	O
predicted	O
a	O
gene	O
homeodomain	O
to	O
encode	O
a	O
of	O
exons	O
.	O

These	O
correspond	O
foreshadow	O
exon	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
equate	O
equate	O
encode	O
a	O
homeodomain	O
protein	O
.	O

These	O
tally	O
to	O
exons	O
of	O
a	O
cistron	O
foretell	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

These	O
correspond	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
usher	O
brainiac	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
heart	O
and	O
brain	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
usher	O
brainiac	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
locale	O
heart	O
and	O
brain	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
usher	O
brainiac	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
heart	O
and	O
brain	O
.	O

expressed	O
protein	O
PCR	O
analysis	O
shows	O
that	O
have	O
skeletal	O
,	O
which	O
we	O
this	O
called	O
number	B
human	O
-	O
associated	O
homeodomain	O
gene	O
(	O
DMAHP	O
including	O
of	O
is	O
RT	O
in	O
,	O
DM	O
locus	O
,	O
tissues	O
,	O
)	O
-	O
muscle	O
a	O
heart	O
and	O
brain	O
.	O

RT	O
-	O
PCR	O
analysis	O
gene	O
,	O
which	O
we	O
have	O
DM	B
locus	O
protein	O
)	O
,	O
in	O
of	O
human	O
tissues	O
,	O
skeletal	O
muscle	O
and	O
brain	O

RT	O
-	O
PCR	O
analysis	O
evidence	O
that	O
this	O
cistron	O
,	O
which	O
we	O
have	O
called	O
decimeter	B
venue	O
-	O
assort	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
come	O
of	O
homo	O
weave	O
,	O
include	O
bony	O
brawn	O
,	O
spirit	O
and	O
brain	O
.	O

RT	O
-	O
PCR	O
analysis	O
establish	O
that	O
this	O
cistron	O
,	O
which	O
we	O
have	O
called	O
dm	B
venue	O
-	O
consort	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
convey	O
in	O
a	O
bit	O
of	O
homo	O
tissues	O
,	O
admit	O
emaciated	O
muscle	O
,	O
middle	O
and	O
wit	O
.	O

tissues	O
muscle	O
PCR	O
analysis	O
associated	O
that	O
and	O
,	O
,	O
which	O
we	O
have	O
called	O
expressed	B
homeodomain	O
-	O
shows	O
locus	O
protein	O
(	O
DM	O
)	O
,	O
is	O
-	O
in	O
a	O
brain	O
RT	O
human	O
of	O
this	O
including	O
skeletal	O
DMAHP	O
,	O
heart	O
gene	O
number	O
.	O

RT	O
-	O
PCR	O
analysis	O
exhibit	O
that	O
this	O
factor	O
,	O
which	O
we	O
have	O
visit	O
dm	B
locale	O
-	O
relate	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
turn	O
of	O
human	O
tissues	O
,	O
admit	O
cadaverous	O
muscularity	O
,	O
fondness	O
and	O
genius	O
.	O

RT	O
-	O
tissues	O
analysis	O
shows	O
,	O
we	O
gene	O
,	O
which	O
this	O
a	O
(	O
DM	B
locus	O
protein	O
associated	O
homeodomain	O
and	O
called	O
DMAHP	O
)	O
,	O
that	O
expressed	O
-	O
have	O
including	O
,	O
human	O
PCR	O
number	O
of	O
skeletal	O
muscle	O
is	O
heart	O
in	O
brain	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
heart	O
and	O
brain	O
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
mutation	O
mutation	O
mutation	O
hereditary	B
retinoblastoma	I
.	O

mutations	O
in	O
in	O
hereditary	B
retinoblastoma	I
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
cistron	O
in	O
patients	O
with	O
patrimonial	B
retinoblastoma	I
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
mutation	O
mutation	O
mutation	O
hereditary	B
retinoblastoma	I
.	O

mutations	O
in	O
RB1	O
gene	O
in	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
factor	O
in	O
patients	O
with	O
genetic	B
retinoblastoma	I
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
mutation	O
mutation	O
mutation	O
hereditary	B
retinoblastoma	I
.	O

Germline	O
sport	O
in	O
the	O
RB1	O
factor	O
in	O
patients	O
with	O
genetic	B
retinoblastoma	I
.	O

Germline	O
patients	O
in	O
the	O
mutations	O
gene	O
in	O
retinoblastoma	O
with	O
hereditary	B
RB1	I
.	O

.	O
mutations	O
in	O
the	O
patients	O
gene	O
hereditary	O
RB1	O
with	O
in	B
retinoblastoma	I
Germline	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
analyzed	O
the	O
xxvii	O
exons	O
and	O
the	O
impresario	O
part	O
of	O
the	O
RB1	O
gene	O
in	O
transmitted	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
using	O
one	O
-	O
chain	O
abidance	O
pleomorphism	O
analysis	O
.	O

We	O
have	O
analyzed	O
the	O
27	O
and	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

by	O
have	O
analyzed	O
bilateral	O
27	O
exons	O
and	O
conformation	O
-	O
region	O
.	O
the	O
RB1	O
retinoblastoma	O
single	O
familial	B
or	I
sporadic	I
the	I
gene	I
strand	O
using	O
in	O
promoter	O
We	O
the	O
polymorphism	O
analysis	O
of	O

We	O
have	O
analyzed	O
the	O
string	O
cistron	O
inward	O
transmissible	O
	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
form	I
pleomorphism	I
plugger	I
bilateral	I
retinoblastoma	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

We	O
have	O
analyzed	O
the	O
string	O
cistron	O
inward	O
transmissible	O
	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
form	I
pleomorphism	I
inward	I
bilateral	I
retinoblastoma	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
region	O
of	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
bilateral	I
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

.	O
have	O
analyzed	O
in	O
27	O
exons	O
conformation	O
the	O
the	O
region	O
of	O
the	O
polymorphism	O
gene	O
strand	O
promoter	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
RB1	O
using	O
single	O
-	O
familial	O
and	O
by	O
analysis	O
We	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
region	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
bilateral	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O

We	O
have	O
analyzed	O
the	O
xxvii	O
exons	O
and	O
the	O
impresario	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
genetic	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
exploitation	O
exclusive	O
-	O
string	O
shape	O
pleomorphism	O
analysis	O
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
plugger	O
neighborhood	O
of	O
the	O
RB1	O
factor	O
in	O
transmitted	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
employ	O
individual	O
-	O
strand	O
abidance	O
pleomorphism	O
analysis	O
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

For	O
advance	O
over	O
former	O
studies	O
,	O
a	O
new	O
prepare	O
of	O
primers	O
has	O
been	O
intentional	O
,	O
which	O
admit	O
for	O
elaboration	O
of	O
the	O
inscribe	O
and	O
splice	O
sequences	O
only	O
.	O

For	O
improvement	O
previous	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
which	O
allow	O
for	O
amplification	O
the	O
coding	O
and	O
splicing	O
sequences	O
.	O

For	O
improvement	O
over	O
previous	O
episode	O
antiophthalmic	O
factor	O
meditate	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
wed	O
episode	O
simply	O
episode	O
coiffure	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O

the	O
improvement	O
over	O
amplification	O
studies	O
,	O
a	O
only	O
splicing	O
of	O
of	O
has	O
been	O
designed	O
and	O
which	O
allow	O
for	O
previous	O
sequences	O
primers	O
coding	O
,	O
set	O
For	O
new	O
.	O

For	O
improvement	O
over	O
previous	O
episode	O
antiophthalmic	O
factor	O
meditate	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
wed	O
episode	O
simply	O
episode	O
coiffure	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O

For	O
improvement	O
over	O
studies	O
,	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
allow	O
for	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O
.	O

.	O
improvement	O
over	O
,	O
studies	O
,	O
only	O
new	O
previous	O
of	O
primers	O
has	O
designed	O
the	O
sequences	O
set	O
allow	O
for	O
amplification	O
of	O
been	O
coding	O
and	O
splicing	O
which	O
a	O
For	O

over	O
,	O
a	O
new	O
of	O
primers	O
been	O
designed	O
,	O
which	O
allow	O
for	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O

splicing	O
improvement	O
over	O
previous	O
studies	O
,	O
designed	O
has	O
set	O
of	O
primers	O
allow	O
coding	O
a	O
sequences	O
For	O
new	O
which	O
amplification	O
of	O
the	O
been	O
and	O
for	O
,	O
only	O
.	O

For	O
melioration	O
over	O
late	O
read	O
,	O
a	O
new	O
bent	O
of	O
fuse	O
has	O
been	O
contrive	O
,	O
which	O
allow	O
for	O
elaboration	O
of	O
the	O
coding	O
and	O
tie	O
sequences	O
only	O
.	O

For	O
improvement	O
over	O
previous	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O
.	O

The	O
positioning	O
exons	O
the	O
polymerase	O
chain	O
reaction	O
were	O
PCR	O
)	O
primers	O
which	O
of	O
that	O
the	O
(	O
PCR	O
products	O
banding	O
such	O
different	O
.	O
,	O
was	O
enabled	O
resulting	O
analyze	O
and	O
two	O
different	O
of	O
biplex	O
simultaneously	O
still	O
distinguish	O
)	O
the	O
us	O
profiles	O
for	O
both	O
(	O
to	O
analysis	O
between	O
sizes	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
profile	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
at	O
the	O
same	O
time	O
at	O
the	O
same	O
time	O
depth	O
psychology	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
profile	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
at	O
the	O
same	O
time	O
at	O
the	O
same	O
time	O
depth	O
psychology	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
)	O
primers	O
was	O
that	O
resulting	O
PCR	O
products	O
different	O
us	O
to	O
analyze	O
different	O
exons	O
and	O
still	O
distinguish	O
banding	O
profiles	O
for	O
both	O
(	O
analysis	O
.	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
primers	O
was	O
such	O
that	O
the	O
different	O
which	O
us	O
to	O
analyze	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O

distinguish	O
were	O
of	O
the	O
polymerase	O
chain	O
(	O
(	O
PCR	O
)	O
primers	O
both	O
such	O
analyze	O
different	O
resulting	O
PCR	O
products	O
still	O
of	O
different	O
sizes	O
two	O
which	O
analysis	O
us	O
simultaneously	O
that	O
the	O
enabled	O
exons	O
between	O
and	O
positioning	O
The	O
to	O
the	O
banding	O
profiles	O
for	O
was	O
reaction	O
biplex	O
,	O
)	O
.	O

The	O
location	O
of	O
the	O
polymerase	O
chain	O
response	O
(	O
PCR	O
)	O
undercoat	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
dissimilar	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
examine	O
deuce	O
dissimilar	O
exons	O
simultaneously	O
and	O
nonetheless	O
distinguish	O
between	O
the	O
ring	O
visibility	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

The	O
put	O
of	O
the	O
polymerase	O
range	O
response	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
lead	O
PCR	O
production	O
were	O
of	O
dissimilar	O
sizing	O
,	O
which	O
enabled	O
us	O
to	O
analyse	O
two	O
dissimilar	O
exons	O
simultaneously	O
and	O
smooth	O
discover	O
between	O
the	O
stria	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

The	O
locating	O
of	O
the	O
polymerase	O
chain	O
response	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
production	O
were	O
of	O
unlike	O
sizes	O
,	O
which	O
enabled	O
uranium	O
to	O
canvass	O
ii	O
unlike	O
exons	O
simultaneously	O
and	O
still	O
signalise	O
between	O
the	O
striation	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
profile	O
at	O
the	O
same	O
time	O
depth	O
psychology	O
at	O
the	O
same	O
time	O
at	O
the	O
same	O
time	O
depth	O
psychology	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
the	O
banding	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

By	O
using	O
regimen	O
approach	O
,	O
we	O
in	O
overall	O
to	O
identify	O
mutation	O
a	O
efficiency	O
new	O
patients	O
single	O
but	O
the	O
was	O
22	O
of	O
only	O
procedure	O
when	O
we	O
,	O
were	O
the	O
-	O
pass	O
this	O
able	O
used	O
48	O
%	O
.	O

using	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
the	O
procedure	O
when	O
used	O
single	O
-	O
pass	O
only	O

aside	O
practice	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
variation	O
in	O
xxii	O
unexampled	O
patients	O
,	O
but	O
the	O
boilersuit	O
efficiency	O
of	O
the	O
subroutine	O
when	O
we	O
employ	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

single	O
of	O
this	O
approach	O
but	O
we	O
patients	O
was	O
to	O
identify	O
mutation	O
in	O
22	O
we	O
able	O
,	O
,	O
regimen	O
overall	O
efficiency	O
new	O
the	O
procedure	O
when	O
using	O
used	O
a	O
By	O
the	O
pass	O
-	O
were	O
only	O
48	O
%	O
.	O

By	O
using	O
this	O
approach	O
simply	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
merely	O
be	O
.	O

we	O
overall	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
single	O
pass	O
,	O
but	O
the	O
48	O
efficiency	O
of	O
the	O
-	O
when	O
By	O
used	O
was	O
new	O
patients	O
procedure	O
regimen	O
.	O
only	O
%	O
using	O
a	O

By	O
using	O
this	O
approach	O
we	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

away	O
victimization	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
routine	O
when	O
we	O
exploited	O
a	O
unity	O
-	O
lapse	O
regimen	O
was	O
only	O
48	O
%	O
.	O

By	O
using	O
this	O
approach	O
newly	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
new	O
new	O
new	O
new	O
new	O
new	O
new	O
new	O
be	O
.	O

aside	O
use	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
name	O
mutation	O
in	O
22	O
unexampled	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
process	O
when	O
we	O
used	O
a	O
unmarried	O
-	O
sink	O
regimen	O
was	O
only	O
48	O
%	O
.	O

By	O
using	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

The	O
mutations	O
deletion	O
be	O
be	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
.	O
follow	O
.	O

proportions	O
mutations	O
were	O
.	O
insertions	O
and	O
deletions	O
and	O
.	O
mutations	O
in	O
roughly	O
The	O
equal	O
point	O
small	O

The	O
mutations	O
deletion	O
be	O
equate	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
.	O
follow	O
.	O

The	O
mutations	O
were	O
lowly	O
interpolation	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
rival	O
balance	O
.	O
.	O

equal	O
mutations	O
were	O
and	O
insertions	O
and	O
proportions	O
small	O
point	O
mutations	O
The	O
roughly	O
in	O
deletions	O
.	O
.	O

The	O
mutations	O
deletion	O
be	O
be	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
.	O
follow	O
.	O

The	O
mutations	O
were	O
low	O
insertions	O
and	O
excision	O
and	O
degree	O
mutations	O
in	O
about	O
equal	O
proportions	O
.	O
.	O

The	O
mutations	O
were	O
humble	O
interpolation	O
and	O
omission	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
ratio	O
.	O
.	O

The	O
mutations	O
point	O
.	O
insertions	O
and	O
equal	O
and	O
were	O
mutations	O
in	O
roughly	O
deletions	O
proportions	O
small	O
.	O

mutations	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
in	O
roughly	O
equal	O
proportions	O
.	O
.	O

The	O
mutations	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
.	O
.	O

human	B
II	I
Type	I
.	I
C2	I
deficiency	I
complement	O

Type	B
deuce	I
human	I
accompaniment	I
C2	I
deficiency	I
.	O

Type	B
two	B
II	I
human	I
complement	I
homo	I
C2	I
deficiency	I
.	O

Type	B
human	I
C2	I
.	O

complement	B
Type	I
human	I
II	I
C2	I
deficiency	I
.	O

Type	B
two	I
human	I
complement	I
C2	I
insufficiency	I
.	O

Type	B
two	I
human	I
complement	I
C2	I
want	I
.	O

Type	B
II	I
human	I
.	I
C2	I
complement	I
deficiency	O

Type	B
II	I
human	I
complement	I
C2	I
.	O

Type	B
two	B
II	I
human	I
complement	I
accompaniment	I
C2	I
deficiency	I
.	O

Type	B
II	I
human	I
complement	I
C2	I
deficiency	I
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
do	O
secernment	O
impair	O
secernment	O
secernment	O
particular	O
particular	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
)	O
impaired	O
C2	O
secretion	O
.	O

allele	O
-	O
particular	O
aminic	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
case	O
afflicted	O
C2	O
secernment	O
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
-	O
-	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
impaired	O
C2	O
secretion	O
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
do	O
secernment	O
impair	O
secernment	O
secernment	O
particular	O
particular	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

allelomorph	O
-	O
particular	O
amino	O
pane	O
exchange	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
have	O
afflicted	O
C2	O
secernment	O
.	O

allelomorph	O
-	O
particular	O
amino	O
acid	O
replacement	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
reason	O
spoil	O
C2	O
secernment	O
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
>	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
cause	O
impaired	O
C2	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
do	O
secernment	O
impair	O
secernment	O
secernment	O
particular	O
particular	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

Arg	O
-	O
specific	O
>	O
acid	O
substitutions	O
(	O
)	O
.	O
-	O
amino	O
Phe	O
;	O
Gly444	O
secretion	O
-	O
>	O
impaired	O
Ser189	O
Allele	O
cause	O
C2	O
-	O
-	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
-	O
-	O
>	O
Phe	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

Type	B
II	I
be	I
characterise	I
accompaniment	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
lack	O
.	O

C2	B
II	I
complement	I
.	I
C2	I
deficiency	I
is	O
characterized	O
secretion	O
a	O
selective	O
block	O
Type	O
in	O
by	O
protein	O

Type	B
II	I
be	I
characterise	I
aside	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
lack	O
.	O

character	B
two	I
accompaniment	I
protein	I
C2	I
deficiency	I
is	O
qualify	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

in	B
II	I
complement	I
characterized	I
C2	I
deficiency	I
C2	O
protein	O
by	O
a	O
Type	O
block	O
selective	O
is	O
secretion	O
.	O

Type	B
II	I
be	I
characterise	I
accompaniment	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
lack	O
.	O

typecast	B
II	I
complement	I
protein	I
C2	I
want	I
is	O
characterise	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secernment	O
.	O

Type	B
ii	I
complement	I
protein	I
C2	I
want	I
is	O
characterise	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secernment	O
.	O

Type	B
II	I
by	I
.	I
C2	I
deficiency	I
in	O
characterized	O
complement	O
a	O
selective	O
block	O
is	O
C2	O
protein	O
secretion	O

II	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

Type	B
II	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

The	O
Type	O
II	O
C2	O
john	O
roy	O
major	O
allelomorph	O
haplotype	O
void	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	B
common	I
Type	I
I	I
C2	O
deficiency	O
	O
	O
	O
	O

The	O
Type	O
II	O
allele	O
linked	O
to	O
two	O
histocompatibility	O
haplotypes	O
MHC	O
)	O
that	O
the	O
MHC	O
of	O
the	O
more	O
Type	B
C2	I
deficiency	I
.	O

The	O
character	O
ii	O
C2	O
aught	O
allelomorph	O
(	O
C2Q0	O
)	O
is	O
join	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
disagree	O
from	O
the	O
MHC	O
of	O
the	O
more	O
plebeian	O
character	B
one	I
C2	I
lack	I
.	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
(	O
)	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
of	O
the	O
more	O
common	O
Type	B
I	I
C2	I
deficiency	I
.	O

The	O
eccentric	O
deuce	O
C2	O
zippo	O
allelomorph	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
deuce	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
dissent	O
from	O
the	O
MHC	O
of	O
the	O
more	O
coarse	O
eccentric	B
I	I
C2	I
want	I
.	O

The	O
Type	O
II	O
C2	O
john	O
roy	O
major	O
allelomorph	O
haplotype	O
void	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	B
common	I
Type	I
I	I
C2	O
deficiency	O
	O
	O
	O
	O

The	O
typewrite	O
II	O
C2	O
cipher	O
allelomorph	O
(	O
C2Q0	O
)	O
is	O
yoke	O
to	O
deuce	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
dissent	O
from	O
the	O
MHC	O
of	O
the	O
more	O
green	O
typewrite	B
ane	I
C2	I
lack	I
.	O

differ	O
)	O
II	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
of	O
I	O
haplotypes	O
(	O
MHC	O
common	O
that	O
Type	O
from	O
deficiency	O
MHC	O
major	O
the	O
more	O
The	O
histocompatibility	B
the	I
C2	I
Type	I
.	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
C2Q0	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
common	O
Type	B
I	I
deficiency	I

The	O
Type	O
II	O
C2	O
john	O
roy	O
major	O
allelomorph	O
haplotype	O
character	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	B
common	I
Type	I
I	I
C2	O
deficiency	O
	O
	O
	O
	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	O
common	O
Type	B
I	I
C2	I
deficiency	I
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
	O
on	O
an	O
individual	O
basis	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
lack	O
transfected	O

molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
separately	O
L	O
-	O
cells	O
.	O

To	O
shape	O
the	O
molecular	O
fundament	O
of	O
Type	B
deuce	I
deficiency	I
the	O
deuce	O
Type	O
deuce	O
C2Q0	O
genes	O
were	O
stranded	O
and	O
transfected	O
singly	O
into	O
l	O
-	O
cells	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
Type	O
II	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
cells	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
	O
on	O
an	O
individual	O
basis	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
lack	O
transfected	O

To	O
determine	O
the	O
molecular	O
groundwork	O
of	O
eccentric	B
II	I
lack	I
the	O
deuce	O
eccentric	O
II	O
C2Q0	O
cistron	O
were	O
quarantined	O
and	O
transfected	O
severally	O
into	O
L	O
-	O
cells	O
.	O

To	O
ascertain	O
the	O
molecular	O
fundament	O
of	O
case	B
II	I
insufficiency	I
the	O
ii	O
case	O
II	O
C2Q0	O
cistron	O
were	O
isolated	O
and	O
transfected	O
severally	O
into	O
L	O
-	O
cells	O
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
II	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
L	O
-	O
cells	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
	O
on	O
an	O
individual	O
basis	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
lack	O
transfected	O

separately	O
determine	O
the	O
two	O
basis	O
of	O
Type	B
transfected	I
cells	I
the	O
molecular	O
Type	O
C2Q0	O
II	O
-	O
were	O
isolated	O
and	O
II	O
.	O
into	O
L	O
genes	O
deficiency	O
To	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
L	O
-	O
cells	O
.	O

Subsequent	O
molecular	O
each	O
,	O
biosynthetic	O
,	O
C2	O
C2	O
studies	O
demonstrated	O
that	O
highly	O
deficiency	O
is	O
impaired	O
conserved	O
Type	B
II	I
of	I
secretion	I
because	O
the	O
different	O
missense	O
mutations	O
in	O
and	O
of	O
residues	O
in	O
biology	O
immunofluorescence	O
at	O
C2Q0	O
alleles	O
.	O

molecular	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
of	O
different	O
missense	O
at	O
conserved	O
residues	O
in	O
the	O

subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
sketch	O
demonstrated	O
that	O
C2	O
secernment	O
is	O
mar	O
in	O
Type	B
ii	I
C2	I
inadequacy	I
because	O
of	O
unlike	O
missense	O
mutant	O
at	O
extremely	O
conserved	O
residuum	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

conserved	O
because	O
biology	O
,	O
Type	O
,	O
impaired	O
of	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
mutations	O
immunofluorescence	O
in	O
biosynthetic	B
each	I
C2	I
deficiency	I
is	O
of	O
different	O
missense	O
molecular	O
at	O
highly	O
Subsequent	O
II	O
in	O
residues	O
and	O
the	O
C2Q0	O
alleles	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
character	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
deficiency	I
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O

mutations	O
C2	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
conserved	O
in	O
in	O
Type	B
II	I
C2Q0	I
deficiency	I
because	O
of	O
residues	O
missense	O
Subsequent	O
at	O
of	O
is	O
impaired	O
different	O
each	O
.	O
the	O
alleles	O
molecular	O
highly	O

Subsequent	O
molecular	O
biology	O
,	O
,	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secernment	O
is	O
deflower	O
in	O
typewrite	B
ii	I
C2	I
want	I
because	O
of	O
dissimilar	O
missense	O
mutations	O
at	O
extremely	O
maintain	O
residuum	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
husband	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
deficiency	I
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
economise	O
economise	O
economise	O
economise	O
economise	O
economise	O
economise	O
economise	O
inward	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
contemplate	O
prove	O
that	O
C2	O
secretion	O
is	O
vitiate	O
in	O
typewrite	B
ii	I
C2	I
deficiency	I
because	O
of	O
unlike	O
missense	O
sport	O
at	O
extremely	O
preserve	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
allelomorph	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
deficiency	I
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

unmatchable	O
is	O
in	O
exon	O
pentad	O
(	O
base	O
C566	O
-	O
-	O
>	O
thyroxin	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
cistron	O
yoke	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
;	O
Ser189	O
-	O
-	O
>	O
)	O
of	O
linked	O
MHC	O
haplotype	O
B35	O
,	O
BFS	O
,	O
C4A0B1	O

haplotype	O
BFS	O
in	O
exon	O
>	O
(	O
the	O
,	O
-	O
-	O
>	O
T	O
;	O
to	O
.	O
-	O
5	O
B35	O
)	O
of	O
C566	O
C2Q0	O
gene	O
linked	O
is	O
the	O
MHC	O
One	O
Phe	O
,	O
A11	O
nucleotide	O
DRw1	O
,	O
Ser189	O
,	O
C4A0B1	O
-	O

One	O
is	O
in	O
exon	O
5	O
(	O
-	O
-	O
>	O
T	O
Ser189	O
-	O
-	O
>	O
Phe	O
of	O
the	O
C2Q0	O
gene	O
to	O
the	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
C4A0B1	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
C4A0B1	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
C4A0B1	O
.	O

unitary	O
is	O
in	O
exon	O
pentad	O
(	O
base	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
cistron	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

to	O
)	O
in	O
exon	O
5	O
(	O
T	O
,	O
-	O
-	O
>	O
nucleotide	O
;	O
haplotype	O
,	O
-	O
>	O
Phe	O
C566	O
of	O
the	O
C2Q0	O
A11	O
linked	O
One	O
the	O
,	O
Ser189	O
-	O
gene	O
B35	O
,	O
DRw1	O
is	O
BFS	O
MHC	O
C4A0B1	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
unite	O
C4A0B1	O
.	O

One	O
is	O
5	O
(	O
C566	O
-	O
;	O
-	O
-	O
>	O
)	O
of	O
the	O
gene	O
linked	O
to	O
the	O
MHC	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
-	O
-	O
>	O
T	O
;	O
Ser189	O
-	O
-	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
xi	O
(	O
G1930	O
-	O
-	O
>	O
a	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
factor	O
join	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
;	O
Gly444	O
-	O
-	O
>	O
)	O
of	O
linked	O
MHC	O
haplotype	O
B5	O
,	O
BFS	O
,	O
C4A3B1	O

haplotype	O
BFS	O
is	O
in	O
>	O
11	O
the	O
,	O
-	O
-	O
>	O
A	O
;	O
to	O
.	O
-	O
exon	O
B5	O
)	O
of	O
G1930	O
C2Q0	O
gene	O
linked	O
other	O
the	O
MHC	O
The	O
Arg	O
,	O
A2	O
(	O
DRw4	O
,	O
Gly444	O
,	O
C4A3B1	O
-	O

The	O
other	O
is	O
in	O
exon	O
11	O
-	O
-	O
>	O
A	O
Gly444	O
-	O
-	O
>	O
Arg	O
of	O
the	O
C2Q0	O
gene	O
to	O
the	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
C4A3B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O

The	O
other	O
is	O
in	O
exon	O
xi	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
cistron	O
connect	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

to	O
)	O
is	O
in	O
exon	O
11	O
A	O
,	O
-	O
-	O
>	O
(	O
;	O
haplotype	O
,	O
-	O
>	O
Arg	O
G1930	O
of	O
the	O
C2Q0	O
A2	O
linked	O
The	O
the	O
,	O
Gly444	O
-	O
gene	O
B5	O
,	O
DRw4	O
other	O
BFS	O
MHC	O
C4A3B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O

The	O
other	O
exon	O
11	O
G1930	O
-	O
;	O
-	O
-	O
>	O
)	O
of	O
the	O
gene	O
linked	O
to	O
the	O
MHC	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
-	O
-	O
>	O
A	O
;	O
Gly444	O
-	O
-	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

Each	O
C2	O
gene	O
is	O
early	O
the	O
secretory	O
pathway	O
.	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O

Each	O
mutation	O
C2	O
gene	O
product	O
is	O
maintained	O
other	O
in	O
the	O
secretory	O
pathway	O
.	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
nerve	O
tract	O
nerve	O
tract	O
mutation	O
the	O
secretory	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
nerve	O
tract	O
nerve	O
tract	O
inward	O
the	O
secretory	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
nerve	O
tract	O
nerve	O
tract	O
mutation	O
the	O
secretory	O

Each	O
sport	O
C2	O
factor	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
tract	O
.	O

Each	O
mutant	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
.	O

apiece	O
variation	O
C2	O
factor	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O
.	O

Each	O
product	O
C2	O
gene	O
.	O
is	O
retained	O
mutant	O
in	O
the	O
secretory	O
pathway	O
early	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
mutation	O
mutation	O
mutation	O
pathway	O
.	O
.	O

mutants	O
provide	O
the	O
pathway	O
.	O
.	O

These	O
mutation	O
provide	O
simulate	O
for	O
elucidating	O
the	O
C2	O
secretory	O
footpath	O
.	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
mutation	O
mutation	O
mutation	O
pathway	O
.	O
.	O

mutants	O
provide	O
for	O
elucidating	O
the	O
C2	O
secretory	O
pathway	O
.	O
.	O

These	O
variation	O
provide	O
models	O
for	O
clear	O
the	O
C2	O
secretory	O
tract	O
.	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
mutation	O
mutation	O
allow	O
for	O
pathway	O
.	O

These	O
mutation	O
render	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
footpath	O
.	O
.	O

These	O
C2	O
provide	O
models	O
mutants	O
elucidating	O
the	O
.	O
secretory	O
pathway	O
for	O
.	O

.	O
mutants	O
provide	O
models	O
C2	O
elucidating	O
pathway	O
for	O
secretory	O
the	O
.	O
These	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
pathway	O
.	O
.	O

disease	O
dimerization	O
of	O
Cys	B
Willebrand	I
factor	O
subunits	O
von	O
mutation	O
a	O
von	O
-	O
Arg	O
>	O
to	O
in	O
type	B
IID	I
due	I
Defective	I
Willebrand	I
.	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
erik	I
adolf	I
von	I
willebrand	I
inward	I
inward	I
inward	I
inward	I
inward	I
von	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
erik	I
adolf	I
von	I
willebrand	I
inward	I
inward	I
inward	I
inward	I
inward	I
von	O

defective	O
dimerization	O
of	O
von	B
Willebrand	I
agent	O
subunits	O
imputable	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutant	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

Defective	O
dimerization	O
of	O
Willebrand	I
factor	O
subunits	O
due	O
to	O
Cys	O
-	O
>	O
Arg	O
in	O
type	B
von	I
Willebrand	I
disease	I
.	O

von	B
subunits	O
due	O
to	O
Cys	O
-	O
Arg	O
mutation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
ascribable	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutant	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

mutation	O
dimerization	O
to	O
subunits	B
Willebrand	I
factor	O
in	O
due	O
of	O
a	O
Cys	O
-	O
disease	O
Arg	O
von	O
Defective	O
type	B
IID	I
von	I
Willebrand	I
>	I
.	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
erik	I
adolf	I
von	I
willebrand	I
inward	I
inward	I
inward	I
inward	I
constituent	I
von	O

Defective	O
dimerization	O
of	O
von	B
subunits	O
due	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
von	I
.	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys	O
-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

same	O
heterozygous	O
T	O
C	O
transition	O
at	O
nt	O
8567	O
the	O
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
patients	O
with	O
type	B
IID	I
von	I
other	O
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
apparent	O
abnormality	O
.	O

Willebrand	O
was	O
heterozygous	O
T	O
(	O
>	O
abnormality	O
disease	O
at	O
nt	O
8567	O
of	O
the	O
unrelated	B
vWF	I
factor	O
-	O
Willebrand	O
)	O
transcript	O
von	O
found	O
in	O
two	O
same	O
patients	O
with	O
.	B
The	I
von	I
IID	I
C	I
,	O
with	O
no	O
other	O
apparent	O
transition	O
type	O

The	O
same	O
heterozygous	O
-	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
apparent	O
.	O

The	O
same	O
heterozygous	O
t	O
-	O
>	O
C	O
modulation	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
constituent	O
(	O
vWF	O
)	O
copy	O
was	O
find	O
in	O
deuce	O
unrelated	O
patients	O
with	O
eccentric	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
seeming	O
freakishness	O
.	O

unrelated	O
)	O
heterozygous	O
T	O
-	O
>	O
of	O
transition	O
at	O
nt	O
8567	O
C	O
the	O
type	B
von	I
factor	O
(	O
vWF	O
with	O
transcript	O
was	O
found	O
IID	O
two	O
The	O
patients	O
disease	O
von	B
Willebrand	I
in	I
Willebrand	I
other	I
,	O
no	O
same	O
with	O
apparent	O
abnormality	O
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
apparent	O
abnormality	O
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
conversion	O
deoxycytidine	O
monophosphate	O
apparent	O
abnormality	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
vWF	O
)	O
transcript	O
found	O
two	O
unrelated	O
patients	O
IID	I
with	O
no	O
other	O
abnormality	O
.	O

The	O
same	O
Willebrand	O
T	O
-	O
>	O
C	O
)	O
at	O
nt	O
8567	O
with	O
transcript	O
von	B
Willebrand	I
transition	O
(	O
vWF	O
abnormality	O
the	O
was	O
,	O
in	O
other	O
unrelated	O
factor	O
of	O
found	B
IID	I
von	I
heterozygous	I
type	I
disease	O
with	O
no	O
two	O
apparent	O
patients	O
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
apparent	O
abnormality	O
.	O

one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
the	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

parents	O
one	O
family	O
mutation	O
both	O
alleles	O
were	O
.	O
the	O
the	O
proposita	O
and	O
one	O
originated	O
in	O
thus	O
,	O
the	O
,	O
sister	O
de	O
novo	O
;	O
in	O
In	O
normal	O

indiana	O
unmatchable	O
kin	O
,	O
both	O
allelomorph	O
were	O
pattern	O
indiana	O
the	O
parents	O
and	O
unmatchable	O
babe	O
;	O
thus	O
,	O
the	O
sport	O
originated	O
de	O
novo	O
indiana	O
the	O
proposita	O
.	O

in	O
nonpareil	O
family	O
,	O
both	O
alleles	O
were	O
convention	O
in	O
the	O
raise	O
and	O
nonpareil	O
sister	O
;	O
so	O
,	O
the	O
variation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
and	O
one	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
the	O
proposita	O
.	O

In	O
one	O
family	O
,	O
pattern	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
inward	O
first	O
state	O
inward	O
inward	O
phratry	O
inward	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O

In	O
one	O
family	O
,	O
pattern	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
inward	O
first	O
state	O
inward	O
inward	O
phratry	O
inward	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
and	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
novo	O
in	O

the	O
one	O
family	O
,	O
both	O
alleles	O
sister	O
,	O
in	O
the	O
parents	O
and	O
novo	O
were	O
proposita	O
thus	O
normal	O
de	O
mutation	O
originated	O
In	O
one	O
in	O
the	O
;	O
.	O

inch	O
i	O
family	O
,	O
both	O
alleles	O
were	O
pattern	O
inch	O
the	O
raise	O
and	O
i	O
sister	O
;	O
olibanum	O
,	O
the	O
mutation	O
develop	O
de	O
novo	O
inch	O
the	O
proposita	O
.	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

,	O
second	O
patient	O
who	O
had	O
asymptomatic	O
parents	O
also	O
for	O
however	O
available	O
were	O
The	O
not	O
,	O
study	O
.	O

The	O
mo	O
patient	O
also	O
had	O
asymptomatic	O
rear	O
who	O
,	O
still	O
,	O
were	O
not	O
useable	O
for	O
learn	O
.	O

The	O
second	O
patient	O
also	O
had	O
symptomless	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
uncommitted	O
for	O
bailiwick	O
.	O

The	O
second	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
.	O

The	O
endorse	O
patient	O
likewise	O
had	O
symptomless	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
uncommitted	O
for	O
work	O
.	O

The	O
second	O
world	O
health	O
organization	O
patient	O
role	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
rear	O

The	O
second	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
however	O
,	O
not	O
available	O
for	O
study	O
.	O

The	O
second	O
world	O
health	O
organization	O
patient	O
role	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
rear	O

second	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O

The	O
second	O
,	O
for	O
had	O
asymptomatic	O
not	O
who	O
patient	O
however	O
,	O
were	O
parents	O
available	O
also	O
study	O
.	O

The	O
second	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
.	O

The	O
structural	O
-	O
of	O
the	O
CyS2010	O
mutation	O
of	O
resulting	O
in	O
the	O
vWF	O
domain	O
>	O
Arg	O
1366	O
,	O
were	O
by	O
evaluated	O
expression	O
,	O
the	O
identified	O
carboxyl	O
terminal	O
consequences	O
2050	O
containing	O
residues	O
substitution	O
-	O
-	O
.	O

The	O
of	O
the	O
identified	O
mutation	O
resulting	O
in	O
-	O
>	O
substitution	O
,	O
expression	O
the	O
vWF	O
carboxyl	O
terminal	O
domain	O
containing	O
1366	O
-	O
2050	O
.	O

The	O
structural	O
consequences	O
of	O
identify	O
permutation	O
aside	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
key	O
out	O
key	O
out	O
key	O
out	O
key	O
out	O

The	O
structural	O
consequences	O
of	O
identify	O
permutation	O
hold	O
back	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
key	O
out	O
key	O
out	O
key	O
out	O
key	O

structural	O
evaluated	O
consequences	O
of	O
the	O
identified	O
terminal	O
,	O
resulting	O
in	O
the	O
domain	O
-	O
carboxyl	O
residues	O
substitution	O
,	O
were	O
CyS2010	O
by	O
expression	O
of	O
.	O
vWF	O
>	O
-	O
mutation	O
The	O
-	O
the	O
1366	O
containing	O
2050	O
Arg	O

The	O
structural	O
consequences	O
of	O
the	O
identified	O
resulting	O
in	O
the	O
CyS2010	O
>	O
Arg	O
substitution	O
,	O
were	O
by	O
expression	O
of	O
the	O
carboxyl	O
-	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
.	O

The	O
morphologic	O
outcome	O
of	O
the	O
place	O
sport	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
permutation	O
,	O
were	O
evaluated	O
by	O
aspect	O
of	O
the	O
vWF	O
carboxyl	O
-	O
final	O
arena	O
control	O
remainder	O
1366	O
-	O
2050	O
.	O

The	O
geomorphological	O
import	O
of	O
the	O
key	O
variation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
replacement	O
,	O
were	O
evaluated	O
by	O
look	O
of	O
the	O
vWF	O
carboxyl	O
-	O
concluding	O
field	O
take	O
balance	O
1366	O
-	O
2050	O
.	O

The	O
structural	O
consequences	O
of	O
identify	O
permutation	O
hold	O
back	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
key	O
out	O
key	O
out	O
key	O
out	O
key	O

The	O
geomorphological	O
result	O
of	O
the	O
describe	O
mutation	O
,	O
lead	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
replacement	O
,	O
were	O
measure	O
by	O
reflexion	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
world	O
carry	O
residual	O
1366	O
-	O
2050	O
.	O

The	O
structural	O
consequences	O
of	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
.	O

cells	O
infected	O
with	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
disulfide	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
reduction	O
,	O
yielding	O
a	O
single	O
disulfide	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
bond	O
reduction	O
.	O

band	O
mass	O
infected	O
with	O
with	O
baculovirus	O
reduction	O
of	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
before	O
an	O
molecule	O
recombinant	O
dimeric	O
apparent	O
molecular	O
linked	O
of	O
150	O
kDa	O
cells	O
reduction	O
,	O
.	O
Insect	O
single	O
a	O
expressing	O
80	O
kDa	O
after	O
disulfide	O
bond	O
normal	O
yielding	O

Insect	O
cells	O
infected	O
recombinant	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
bond	O
.	O

worm	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
rule	O
vWF	O
episode	O
release	O
a	O
disulfide	O
join	O
dimeric	O
particle	O
with	O
an	O
seeming	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
relent	O
a	O
unity	O
circle	O
of	O
80	O
kDa	O
after	O
disulfide	O
bond	O
reduction	O
.	O

before	O
apparent	O
infected	O
with	O
recombinant	O
baculovirus	O
a	O
normal	O
vWF	O
sequence	O
secreted	O
expressing	O
disulfide	O
yielding	O
single	O
molecule	O
with	O
an	O
kDa	O
molecular	O
mass	O
of	O
a	O
kDa	O
Insect	O
reduction	O
of	O
linked	O
dimeric	O
150	O
band	O
disulfide	O
80	O
after	O
cells	O
,	O
bond	O
reduction	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
bond	O
reduction	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
pattern	O
verbalise	O
bond	O
reduction	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
an	O
apparent	O
molecular	O
of	O
kDa	O
before	O
reduction	O
a	O
kDa	O
after	O
disulfide	O
reduction	O
.	O

Insect	O
cells	O
band	O
with	O
recombinant	O
baculovirus	O
expressing	O
apparent	O
vWF	O
sequence	O
secreted	O
,	O
molecular	O
linked	O
dimeric	O
normal	O
with	O
an	O
reduction	O
disulfide	O
mass	O
80	O
150	O
disulfide	O
before	O
molecule	O
a	O
of	O
a	O
single	O
infected	O
yielding	O
of	O
kDa	O
after	O
kDa	O
bond	O
reduction	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
bond	O
reduction	O
.	O

contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
80	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

monomeric	O
contrast	O
,	O
kDa	O
expressing	O
the	O
mutant	O
.	O
after	O
a	O
reduction	O
molecule	O
of	O
,	O
unchanged	O
mass	O
of	O
80	O
cells	O
apparent	O
which	O
remained	O
molecular	O
secreted	O
In	O
fragment	O

In	O
contrast	O
,	O
cells	O
verbalize	O
the	O
variation	O
shard	O
secreted	O
a	O
monomeric	O
atom	O
of	O
apparent	O
molecular	O
mass	O
of	O
eighty	O
kDa	O
,	O
which	O
continue	O
unaltered	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cadre	O
expressing	O
the	O
sport	O
shard	O
secreted	O
a	O
monomeric	O
corpuscle	O
of	O
seeming	O
molecular	O
mass	O
of	O
eighty	O
kDa	O
,	O
which	O
remained	O
unaltered	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
molecule	O
of	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
verbalise	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
unaltered	O
later	O
reducing	O
later	O
reducing	O
release	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
verbalise	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
unaltered	O
later	O
reducing	O
later	O
reducing	O
stay	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
molecule	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
remained	O
unchanged	O

after	O
contrast	O
,	O
cells	O
expressing	O
the	O
apparent	O
of	O
secreted	O
a	O
monomeric	O
molecule	O
remained	O
mutant	O
reduction	O
mass	O
fragment	O
which	O
kDa	O
,	O
In	O
of	O
unchanged	O
80	O
molecular	O
.	O

In	O
counterpoint	O
,	O
cells	O
expressing	O
the	O
variation	O
fragment	O
release	O
a	O
monomeric	O
molecule	O
of	O
ostensible	O
molecular	O
mass	O
of	O
lxxx	O
kDa	O
,	O
which	O
continue	O
unaltered	O
after	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

formation	O
terminal	O
that	O
CyS2010	O
is	O
essential	O
.	O
normal	O
dimerization	O
of	O
vWF	O
disease	O
through	O
mutation	O
is	O
of	O
carboxyl	O
-	O
corresponding	O
domains	O
and	O
that	O
in	O
heterozygous	O
disulfide	O
in	O
multimer	O
conclude	O
for	O
a	O
responsible	O
codon	O
defective	O
bonding	O
We	O
the	O
type	B
IID	I
von	I
Willebrand	I
subunits	I
for	O
.	O

We	O
conclude	O
that	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
disulfide	O
bonding	O
of	O
-	O
domains	O
and	O
that	O
mutation	O
is	O
responsible	O
for	O
multimer	O
formation	O
type	B
IID	I
von	I
.	O
.	O

We	O
reason	O
that	O
CyS2010	O
is	O
requisite	O
for	O
formula	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
last	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
jibe	O
codon	O
is	O
responsible	O
for	O
faulty	O
multimer	O
organisation	O
in	O
case	B
IID	I
von	I
willebrand	I
disease	I
.	O
.	O

We	O
reason	O
that	O
CyS2010	O
is	O
requisite	O
for	O
rule	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
attach	O
of	O
carboxyl	O
-	O
pole	O
demesne	O
and	O
that	O
a	O
heterozygous	O
sport	O
in	O
the	O
check	O
codon	O
is	O
creditworthy	O
for	O
bad	O
multimer	O
organization	O
in	O
type	B
IID	I
von	I
willebrand	I
disease	I
.	O
.	O

We	O
conclude	O
for	O
CyS2010	O
is	O
essential	O
for	O
terminal	O
dimerization	O
of	O
vWF	O
through	O
.	O
disulfide	O
bonding	O
responsible	O
carboxyl	O
-	O
domains	O
normal	O
and	O
defective	O
a	O
in	O
mutation	O
the	O
corresponding	O
that	O
codon	O
is	O
of	O
IID	O
in	O
multimer	O
formation	O
heterozygous	O
type	B
that	I
von	I
Willebrand	I
disease	I
.	O
subunits	O

We	O
conclude	O
that	O
is	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
type	B
von	I
Willebrand	I
disease	I
.	O
.	O

We	O
conclude	O
that	O
CyS2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
be	O
be	O
erik	O
adolf	O
von	O
willebrand	O
be	O
be	O
be	O
be	O
be	O
be	O
be	B
be	I
be	I
type	I
IID	I
von	O
Willebrand	O

von	O
mutation	O
that	O
CyS2010	O
carboxyl	O
essential	O
and	O
for	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
for	O
IID	O
of	O
is	O
responsible	O
terminal	O
domains	O
disulfide	O
that	O
a	O
heterozygous	O
corresponding	O
in	O
the	O
.	O
-	O
is	O
codon	O
conclude	O
defective	O
multimer	O
formation	O
in	O
type	B
bonding	I
We	I
Willebrand	I
disease	I
normal	O
.	O

We	O
conclude	O
that	O
is	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
-	O
terminal	O
domains	O
and	O
that	O
corresponding	O
responsible	O
defective	O
multimer	O
formation	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

We	O
reason	O
that	O
CyS2010	O
is	O
essential	O
for	O
rule	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
stick	O
of	O
carboxyl	O
-	O
final	O
domains	O
and	O
that	O
a	O
heterozygous	O
variation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
bad	O
multimer	O
organization	O
in	O
case	B
IID	I
von	I
willebrand	I
disease	I
.	O
.	O

We	O
conclude	O
that	O
CyS2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
new	O
effecter	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
concerned	O
in	O
actin	O
polymerisation	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
effecter	O
effecter	O
effecter	O
effecter	O
effecter	O
effecter	O
polymerization	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
effecter	O
effecter	O
effecter	O
effecter	O
effecter	O
effecter	O
polymerization	O
.	O

Aldrich	I
,	O
a	O
novel	O
for	O
the	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
novel	O
effector	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

Aldrich	I
syndrome	I
protein	O
,	O
novel	O
effector	O
for	O
the	O
GTPase	O
,	O
is	O
implicated	O
in	O
polymerization	O
.	O

actin	B
-	I
Aldrich	I
polymerization	I
protein	O
,	O
a	O
effector	O
novel	O
for	O
is	O
GTPase	O
CDC42Hs	O
.	O
Wiskott	O
implicated	O
in	O
the	O
syndrome	O
,	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
effecter	O
effecter	O
effecter	O
effecter	O
polymerisation	O
polymerization	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
refreshing	O
effecter	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
entail	O
in	O
actin	O
polymerisation	O
.	O

in	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
,	O
GTPase	O
effector	O
for	O
the	O
is	O
Wiskott	O
a	O
novel	O
actin	O
CDC42Hs	O
implicated	O
polymerization	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

The	O
Rho	O
various	O
biologic	O
phratry	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
ascertain	O
.	O

and	O
Rho	O
family	O
.	O
GTPases	O
control	O
diverse	O
biological	O
mitogenesis	O
,	O
including	O
cell	O
The	O
morphology	O
processes	O
of	O

The	O
Rho	O
various	O
biologic	O
biologic	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
ascertain	O
.	O

The	O
rho	O
menage	O
of	O
GTPases	O
moderate	O
diverse	O
biological	O
processes	O
,	O
include	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

morphology	O
Rho	O
family	O
biological	O
GTPases	O
control	O
and	O
of	O
processes	O
,	O
The	O
cell	O
including	O
diverse	O
mitogenesis	O
.	O

The	O
Rho	O
various	O
biologic	O
phratry	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
ascertain	O
.	O

The	O
rho	O
folk	O
of	O
GTPases	O
master	O
diverse	O
biological	O
processes	O
,	O
admit	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

The	O
Rho	O
folk	O
of	O
GTPases	O
hold	O
diverse	O
biological	O
processes	O
,	O
admit	O
cubicle	O
morphology	O
and	O
mitogenesis	O
.	O

The	O
Rho	O
processes	O
.	O
GTPases	O
control	O
morphology	O
biological	O
family	O
,	O
including	O
cell	O
diverse	O
and	O
of	O
mitogenesis	O

Rho	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

The	O
Rho	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

have	O
identified	O
WASP	O
protein	O
that	O
is	O
defective	O
in	O
-	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
,	O
but	O
not	O
for	O
the	O
Rac	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
and	O
Rho	O
.	O

other	O
a	O
identified	O
WASP	O
WAS	O
the	O
Rho	O
Rho	O
is	O
defective	O
in	O
Wiskott	B
-	I
CDC42Hs	I
)	I
(	O
,	B
syndrome	O
,	O
as	O
Aldrich	O
novel	O
effector	O
for	O
have	O
,	O
but	O
.	O
We	O
the	O
for	O
protein	O
family	O
members	O
,	O
Rac	O
and	O
that	O
not	O

We	O
have	O
identified	O
,	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
and	O
.	O

We	O
have	O
identified	O
wasp	O
,	O
the	O
protein	O
that	O
is	O
faulty	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
constitute	B
)	O
,	O
as	O
a	O
fresh	O
effecter	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
rho	O
folk	O
extremity	O
,	O
Rac	O
and	O
rho	O
.	O

CDC42Hs	O
,	O
identified	O
WASP	O
,	O
the	O
Wiskott	O
that	O
is	O
defective	O
in	O
protein	B
-	I
not	I
the	I
(	O
WAS	B
)	O
members	O
as	O
a	O
novel	O
for	O
for	O
We	O
,	O
Rho	O
Aldrich	O
syndrome	O
effector	O
other	O
Rac	O
family	O
,	O
have	O
but	O
and	O
Rho	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
and	O
Rho	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
non	O
and	O
Rho	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
)	O
,	O
as	O
novel	O
for	O
CDC42Hs	O
,	O
for	O
members	O
,	O
Rac	O
Rho	O
.	O

We	O
have	O
other	O
WASP	O
,	O
the	O
protein	O
,	O
is	O
defective	O
in	O
but	B
as	I
Aldrich	I
syndrome	I
that	O
WAS	B
)	O
Rho	O
-	O
a	O
family	O
effector	O
Rac	O
CDC42Hs	O
(	O
Wiskott	O
novel	O
for	O
the	O
identified	O
not	O
Rho	O
members	O
,	O
for	O
and	O
,	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
and	O
Rho	O
.	O

This	O
on	O
is	O
dependent	O
interaction	O
the	O
of	O
protein	O
the	O
G	O
binding	O
-	O
presence	O
domain	O
.	O

This	O
interaction	O
bearing	O
be	O
be	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
be	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

This	O
interaction	O
is	O
pendant	O
on	O
the	O
bearing	O
of	O
the	O
gb	O
protein	O
-	O
cover	O
domain	O
.	O

binding	O
interaction	O
is	O
This	O
of	O
the	O
presence	O
-	O
the	O
G	O
protein	O
on	O
dependent	O
domain	O
.	O

This	O
interaction	O
is	O
dependent	O
on	O
the	O
comportment	O
of	O
the	O
G	O
protein	O
-	O
binding	O
world	O
.	O

This	O
interaction	O
bearing	O
be	O
be	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
along	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

This	O
is	O
on	O
presence	O
of	O
the	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

of	O
dependent	O
is	O
interaction	O
on	O
the	O
G	O
This	O
the	O
presence	O
protein	O
-	O
binding	O
.	O
domain	O

This	O
interaction	O
is	O
subject	O
on	O
the	O
comportment	O
of	O
the	O
k	O
protein	O
-	O
truss	O
domain	O
.	O

This	O
interaction	O
bearing	O
be	O
be	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
along	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

This	O
interaction	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

Cellular	O
expression	O
clusters	O
enriched	O
-	O
tagged	O
are	O
produces	O
of	O
of	O
WASP	O
that	O
WASP	O
highly	O
epitope	O
in	O
polymerized	O
actin	O
.	O

of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
in	O
polymerized	O
actin	O
.	O

cellular	O
manifestation	O
of	O
epitope	O
-	O
tagged	O
wasp	O
produces	O
flock	O
of	O
wasp	O
that	O
are	O
extremely	O
enriched	O
in	O
polymerized	O
actin	O
.	O

cellular	O
reflection	O
of	O
epitope	O
-	O
tagged	O
wasp	O
produces	O
bundle	O
of	O
wasp	O
that	O
are	O
extremely	O
enriched	O
in	O
polymerized	O
actin	O
.	O

polymerized	O
expression	O
of	O
epitope	O
-	O
tagged	O
highly	O
enriched	O
clusters	O
of	O
WASP	O
that	O
actin	O
WASP	O
produces	O
in	O
are	O
Cellular	O
.	O

Cellular	O
expression	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
.	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
bunch	O
bunch	O
bunch	O
bunch	O
enrich	O
.	O

cellular	O
expression	O
of	O
determinant	O
-	O
labeled	O
WASP	O
produces	O
clump	O
of	O
WASP	O
that	O
are	O
extremely	O
enriched	O
in	O
polymerized	O
actin	O
.	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
.	O

highly	O
expression	O
of	O
WASP	O
-	O
tagged	O
WASP	O
.	O
enriched	O
of	O
epitope	O
that	O
Cellular	O
are	O
clusters	O
in	O
polymerized	O
actin	O
produces	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
.	O

is	O
with	O
a	O
C	O
-	O
deleted	O
WASP	O
inhibited	O
by	O
with	O
dominant	O
N17	O
but	O
not	O
with	O
negative	O
forms	O
of	O
or	O
Rho	O
.	O

This	O
clustering	O
is	O
not	O
aside	O
rho	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
stamp	O
down	O

but	O
dominant	O
is	O
not	O
observed	O
with	O
with	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
dominant	O
forms	O
by	O
coexpression	O
with	O
Rho	O
negative	O
CDC42Hs	O
-	O
Rac	O
,	O
This	O
not	O
a	O
is	O
inhibited	O
N17	O
of	O
negative	O
or	O
.	O
clustering	O

This	O
bunch	O
is	O
not	O
honour	O
with	O
a	O
C	O
-	O
terminally	O
erase	O
wasp	O
and	O
is	O
conquer	O
by	O
coexpression	O
with	O
prevalent	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
prevalent	O
negative	O
shape	O
of	O
Rac	O
or	O
rho	O
.	O

This	O
clustering	O
not	O
not	O
observed	O
with	O
a	O
-	O
-	O
terminally	O
deleted	O
,	O
dominant	O
is	O
inhibited	O
of	O
coexpression	O
with	O
negative	O
WASP	O
CDC42Hs	O
C	O
N17	O
dominant	O
but	O
with	O
is	O
or	O
negative	O
forms	O
by	O
and	O
Rac	O
Rho	O
.	O

This	O
clustering	O
is	O
not	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
and	O
is	O
inhibited	O
by	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
,	O
but	O
not	O
with	O
negative	O
forms	O
Rac	O
or	O
Rho	O
.	O

This	O
clump	O
is	O
not	O
watch	O
with	O
a	O
C	O
-	O
terminally	O
edit	O
WASP	O
and	O
is	O
conquer	O
by	O
coexpression	O
with	O
prevailing	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
prevailing	O
negative	O
course	O
of	O
Rac	O
or	O
rho	O
.	O

This	O
clustering	O
is	O
not	O
aside	O
note	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
stamp	O
down	O

This	O
constellate	O
is	O
not	O
notice	O
with	O
a	O
C	O
-	O
terminally	O
cancel	O
WASP	O
and	O
is	O
conquer	O
by	O
coexpression	O
with	O
dominant	O
blackball	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
blackball	O
descriptor	O
of	O
Rac	O
or	O
rho	O
.	O

dominant	O
CDC42Hs	O
is	O
not	O
coexpression	O
with	O
inhibited	O
Rac	O
-	O
terminally	O
deleted	O
WASP	O
and	O
but	O
C	O
by	O
observed	O
of	O
dominant	O
negative	O
is	O
-	O
N17	O
,	O
clustering	O
not	O
with	O
This	O
with	O
forms	O
negative	O
a	O
or	O
Rho	O
.	O

This	O
clustering	O
is	O
not	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
.	O

Thus	O
WASP	O
provides	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
which	O
suggests	O
a	O
molecular	O
for	O
many	O
of	O
the	O
cellular	O
in	O
WAS	B
.	O

Thus	O
WASP	O
provides	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
which	O
suggests	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O

Thus	O
,	O
WASP	O
provides	O
antiophthalmic	O
factor	O
new	O
advise	O
antiophthalmic	O
factor	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
abnormalcy	O
inward	O
be	O
wasp	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	B
in	O

many	O
,	O
WASP	O
mechanism	O
a	O
novel	O
link	O
in	O
cellular	O
and	O
for	O
actin	O
cytoskeleton	O
,	O
the	O
suggests	O
a	O
molecular	O
provides	O
abnormalities	O
the	O
of	O
which	O
CDC42Hs	O
Thus	O
between	O
WAS	B
.	O

WAS	O
,	O
WASP	O
which	O
a	O
novel	O
in	O
between	O
provides	O
and	O
the	O
actin	O
,	O
many	O
abnormalities	O
CDC42Hs	O
a	O
molecular	O
mechanism	O
for	O
cytoskeleton	O
of	O
the	O
cellular	O
suggests	O
link	O
Thus	B
.	O

Thus	O
,	O
WASP	O
provides	O
antiophthalmic	O
factor	O
new	O
advise	O
antiophthalmic	O
factor	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
abnormalcy	O
inward	O
be	O
allow	O
for	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	B
abnormalities	O

hence	O
,	O
wasp	O
supply	O
a	O
fresh	O
tie	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanics	O
for	O
many	O
of	O
the	O
cellular	O
freakishness	O
in	O
equal	B
.	O

Thus	O
,	O
WASP	O
provides	O
antiophthalmic	O
factor	O
new	O
advise	O
antiophthalmic	O
factor	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
abnormalcy	O
inward	O
be	O
allow	O
for	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	B
abnormalities	O

cellular	O
,	O
WASP	O
provides	O
a	O
novel	O
,	O
actin	O
CDC42Hs	O
and	O
the	O
a	O
of	O
link	O
abnormalities	O
Thus	O
between	O
suggests	O
mechanism	O
for	O
many	O
cytoskeleton	O
the	O
molecular	O
which	O
in	O
WAS	B
.	O

hence	O
,	O
WASP	O
render	O
a	O
fresh	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
propose	O
a	O
molecular	O
mechanics	O
for	O
many	O
of	O
the	O
cellular	O
abnormality	O
in	O
constitute	B
.	O

Thus	O
,	O
WASP	O
provides	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O
in	O
WAS	B
.	O

The	O
WASP	O
are	O
in	O
two	O
novel	O
proteins	O
that	O
sequence	O
homologous	O
to	O
other	O
domains	O
involved	O
contains	O
action	O
organization	O
.	O
.	O

sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
action	O
organization	O
.	O
.	O

The	O
WASP	O
sequence	O
contains	O
ii	O
refreshing	O
arena	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
sue	O
constitution	O
.	O
.	O

The	O
wasp	O
sequence	O
contains	O
deuce	O
new	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
tortuous	O
in	O
litigate	O
organization	O
.	O
.	O

organization	O
WASP	O
sequence	O
contains	O
two	O
novel	O
involved	O
in	O
are	O
homologous	O
to	O
other	O
.	O
domains	O
that	O
action	O
proteins	O
The	O
.	O

The	O
WASP	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
.	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
.	O
episode	O
episode	O
episode	O
episode	O
wasp	O
.	O

The	O
WASP	O
succession	O
incorporate	O
two	O
refreshing	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
convoluted	O
in	O
action	O
organisation	O
.	O
.	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
.	O
episode	O
episode	O
episode	O
episode	O
episode	O
.	O

involved	O
WASP	O
sequence	O
to	O
two	O
novel	O
domains	O
.	O
in	O
homologous	O
contains	O
other	O
The	O
proteins	O
are	O
action	O
organization	O
.	O
that	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
.	O
.	O

X	B
-	I
coupled	I
adrenoleukodystrophy	I
is	O
a	O
shop	O
campaign	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
new	O
pornographic	O
manlike	O
patients	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
young	O
adult	O
male	O
unite	O
unite	O
unite	O
unite	O
unite	O
unite	O
patients	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
young	O
adult	O
male	O
unite	O
unite	O
unite	O
unite	O
unite	O
unite	O
patients	O
.	O

linked	I
a	O
frequent	O
cause	O
idiopathic	O
Addison	B
s	I
disease	I
in	O
young	O
adult	O
male	O
patients	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
cause	O
of	O
Addison	B
'	I
s	I
disease	I
in	O
young	O
adult	O
male	O
patients	O
.	O

linked	I
adrenoleukodystrophy	I
is	O
a	O
cause	O
of	O
idiopathic	O
Addison	B
'	I
disease	I
in	O
young	O
adult	O
patients	O
.	O

male	B
-	I
linked	I
patients	I
is	O
a	O
frequent	O
of	O
cause	O
idiopathic	O
in	B
'	I
s	I
.	I
X	O
young	O
adult	O
Addison	O
adrenoleukodystrophy	O
disease	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
young	O
adult	O
male	O
unite	O
unite	O
unite	O
unite	O
unite	O
grownup	O
patients	O
.	O

x	B
-	I
connect	I
adrenoleukodystrophy	I
is	O
a	O
patronise	O
suit	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
vernal	O
pornographic	O
male	O
patients	O
.	O

adult	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
disease	O
'	O
of	O
idiopathic	O
Addison	B
in	I
X	I
frequent	I
cause	O
male	O
s	O
young	O
patients	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
'	I
s	I
disease	I
in	O
young	O
adult	O
male	O
patients	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
.	O

X	B
-	I
Linked	I
ALD	B
)	O
is	O
a	O
genetic	B
associated	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
accumulation	O
of	O
very	O
long	O
chain	O
body	O

accumulation	B
system	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
associated	O
and	O
a	O
genetic	B
disease	I
)	O
with	O
long	B
fatty	I
the	I
central	I
nervous	I
is	I
,	O
adrenal	B
insufficiency	I
chain	O
and	O
X	O
of	O
in	O
demyelination	O
of	O
,	O
acids	O
fluids	O
tissue	O
-	O
body	O
very	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
fundamental	O
assemblage	O
.	O

long	B
body	I
Linked	I
adrenoleukodystrophy	I
central	O
ALD	B
of	O
in	O
a	O
genetic	B
disease	I
associated	O
with	O
accumulation	B
is	I
the	I
(	I
acids	I
system	I
,	O
demyelination	B
insufficiency	I
,	O
and	O
-	O
of	O
very	O
X	O
nervous	O
fatty	O
chain	O
)	O
tissue	O
and	O
adrenal	O
fluids	O
.	O

adam	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
familial	B
disease	I
relate	O
with	O
demyelination	B
of	I
the	I
fundamental	I
nervous	I
scheme	I
,	O
adrenal	B
inadequacy	I
,	O
and	O
accruement	O
of	O
very	O
retentive	O
chain	O
fatty	O
pane	O
in	O
weave	O
and	O
personify	O
fluids	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
of	I
the	I
central	I
system	I
adrenal	B
insufficiency	I
,	O
of	O
acids	O
in	O
tissue	O
body	O
fluids	O

X	B
-	I
acids	I
adrenoleukodystrophy	I
(	O
fluids	B
)	O
is	O
a	O
genetic	B
disease	I
very	O
,	O
demyelination	B
of	I
long	I
central	I
nervous	I
in	I
with	O
adrenal	B
tissue	I
,	O
ALD	O
accumulation	O
the	O
associated	O
insufficiency	O
of	O
fatty	O
Linked	O
system	O
chain	O
and	O
body	O
and	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
hereditary	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
primal	I
anxious	I
system	I
,	O
adrenal	B
inadequacy	I
,	O
and	O
aggregation	O
of	O
very	O
foresighted	O
chain	O
fatty	O
elvis	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O

X	B
-	I
yoke	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
affiliate	O
with	O
demyelination	B
of	I
the	I
cardinal	I
aflutter	I
arrangement	I
,	O
adrenal	B
deficiency	I
,	O
and	O
accrual	O
of	O
very	O
hanker	O
concatenation	O
fatty	O
superman	O
in	O
tissue	O
and	O
eubstance	O
fluids	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O

ALD	B
is	O
ascribable	O
to	O
variation	O
of	O
a	O
cistron	O
settle	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unidentified	O
run	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
serve	O
imputable	O
imputable	O
imputable	O
imputable	O
imputable	O
unknown	O
function	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
serve	O
imputable	O
imputable	O
imputable	O
imputable	O
imputable	O
unknown	O
function	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
in	O
Xq28	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O

peroxisomal	B
is	O
located	O
a	O
mutation	O
of	O
transporter	O
gene	O
due	O
in	O
Xq28	O
that	O
.	O
a	O
to	O
ALD	O
protein	O
of	O
unknown	O
function	O
encodes	O

ALD	B
is	O
imputable	O
to	O
sport	O
of	O
a	O
factor	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
conveyer	O
protein	O
of	O
unnamed	O
function	O
.	O

.	B
is	O
due	O
Xq28	O
mutation	O
of	O
a	O
unknown	O
peroxisomal	O
in	O
to	O
that	O
a	O
encodes	O
located	O
transporter	O
protein	O
of	O
gene	O
ALD	O
function	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
serve	O
imputable	O
imputable	O
imputable	O
imputable	O
be	O
unknown	O
function	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
peroxisomal	O
of	O
unknown	O
function	O
.	O

ALD	B
is	O
imputable	O
to	O
mutation	O
of	O
a	O
factor	O
situated	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
nameless	O
use	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
twelve	O
twelvemonth	O
twelve	O
twelvemonth	O
twelvemonth	O
usual	O
twelvemonth	O
between	O
5	O
-	O
12	O
yr	O
.	O

common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
between	O
-	O
12	O
yr	O
.	O

The	O
most	O
unwashed	O
phenotype	O
of	O
ALD	B
is	O
the	O
intellectual	O
configuration	O
(	O
45	O
%	O
)	O
that	O
prepare	O
in	O
son	O
between	O
quint	O
-	O
12	O
year	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
cerebral	O
form	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
-	O
12	O
yr	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
twelve	O
twelvemonth	O
twelve	O
twelvemonth	O
twelvemonth	O
usual	O
usual	O
between	O
5	O
-	O
12	O
yr	O
.	O

The	O
most	O
unwashed	O
phenotype	O
of	O
ALD	B
is	O
the	O
intellectual	O
form	O
(	O
45	O
%	O
)	O
that	O
acquire	O
in	O
son	O
between	O
phoebe	O
-	O
dozen	O
twelvemonth	O
.	O

The	O
most	O
plebeian	O
phenotype	O
of	O
ALD	B
is	O
the	O
intellectual	O
descriptor	O
(	O
45	O
%	O
)	O
that	O
arise	O
in	O
boys	O
between	O
fin	O
-	O
xii	O
year	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
(	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
twelve	O
twelvemonth	O
twelve	O
twelvemonth	O
twelvemonth	O
usual	O
usual	O
between	O
5	O
-	O
12	O
yr	O
.	O

boys	O
most	O
common	O
(	O
of	O
ALD	B
is	O
between	O
.	O
form	O
phenotype	O
45	O
%	O
)	O
yr	O
develops	O
in	O
-	O
the	O
The	O
5	O
12	O
that	O
cerebral	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O
yr	O
.	O

Adrenomyeloneuropathy	B
(	O
and	B
(	O
involves	O
the	O
young	O
cord	O
AMN	O
peripheral	O
nerves	O
in	O
spinal	O
adults	O
)	O
35	O
%	O
)	O
.	O

AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
35	O
%	O
)	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
postulate	O
the	O
spinal	O
cord	O
and	O
peripheral	O
face	O
in	O
youthful	O
grownup	O
(	O
xxxv	O
%	O
)	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
take	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nervousness	O
in	O
youthful	O
adults	O
(	O
35	O
%	O
)	O
.	O

%	B
(	O
AMN	B
)	O
involves	O
the	O
adults	O
(	O
and	O
peripheral	O
nerves	O
in	O
)	O
spinal	O
cord	O
35	O
young	O
Adrenomyeloneuropathy	O
.	O

Adrenomyeloneuropathy	B
(	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
thirty	O
five	O
thirty	O
five	O
thirty	O
five	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
ask	O
the	O
spinal	O
cord	O
and	O
peripheral	O
cheek	O
in	O
vernal	O
adults	O
(	O
35	O
%	O
)	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
thirty	O
five	O
thirty	O
five	O
thirty	O
five	O

adults	B
(	O
AMN	B
nerves	O
involves	O
the	O
spinal	O
.	O
(	O
peripheral	O
)	O
in	O
Adrenomyeloneuropathy	O
young	O
and	O
35	O
%	O
)	O
cord	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
intellectual	O
halt	B
display	O
case	B
crataegus	O
oxycantha	I
stay	O
disease	O
)	O
is	O
frequently	O
associated	B
with	O
AMN	B
or	I
cerebral	O
ALD	O
and	O
may	O
remain	O
the	O
	O
display	O
case	O
only	O
clinical	B
expression	O
of	O
ALD	O
(	O
8	O
%	O
of	O
cases	O
)	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
intellectual	O
halt	B
display	O
case	B
crataegus	O
oxycantha	I
stay	O
disease	O
)	O
is	O
frequently	O
associated	B
with	O
AMN	B
or	I
cerebral	O
ALD	O
and	O
may	O
remain	O
the	O
	O
manifestation	O
only	O
clinical	O
expression	B
of	O
ALD	O
(	O
8	O
%	O
of	O
cases	O
)	O
rational	O

)	B
insufficiency	I
8	O
and	B
disease	I
)	O
cases	O
frequently	O
Addisons	O
with	O
AMN	B
or	O
expression	B
ALD	I
(	O
associated	O
remain	O
the	O
only	O
clinical	O
cerebral	O
of	O
ALD	B
(	O
may	O
is	O
of	O
%	O
Adrenal	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
intellectual	O
halt	B
display	O
case	B
crataegus	O
oxycantha	I
stay	O
disease	O
)	O
is	O
frequently	O
associated	B
with	O
AMN	B
or	I
cerebral	O
ALD	O
and	O
may	O
remain	O
the	O
	O
display	O
case	O
only	O
clinical	B
expression	O
of	O
ALD	O
(	O
8	O
%	O
of	O
cases	O
)	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
is	O
associated	O
with	O
or	O
cerebral	B
ALD	I
and	O
may	O
remain	O
the	O
expression	O
of	O
ALD	B
(	O
8	O
%	O
of	O
cases	O
)	O
.	O

Adrenal	B
deficiency	I
(	O
Addisons	B
disease	I
)	O
is	O
oft	O
associated	O
with	O
AMN	B
or	O
intellectual	B
ALD	I
and	O
may	O
remain	O
the	O
only	O
clinical	O
construction	O
of	O
ALD	B
(	O
viii	O
%	O
of	O
example	O
)	O
.	O

remain	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
of	O
or	O
associated	O
with	O
AMN	B
Adrenal	O
)	B
(	I
may	O
and	O
the	O
8	O
only	O
clinical	O
expression	O
is	O
ALD	B
ALD	O
frequently	O
%	O
of	O
cases	O
cerebral	O
.	O

expression	B
insufficiency	I
(	O
only	B
disease	I
)	O
is	O
%	O
(	O
with	O
)	B
or	O
of	B
clinical	I
ALD	O
may	O
remain	O
the	O
Addisons	O
ALD	O
8	O
of	O
and	B
associated	O
Adrenal	O
frequently	O
cerebral	O
cases	O
AMN	O
.	O

Adrenal	B
inadequacy	I
(	O
Addisons	B
disease	I
)	O
is	O
ofttimes	O
associated	O
with	O
AMN	B
or	O
intellectual	B
ALD	I
and	O
may	O
continue	O
the	O
only	O
clinical	O
construction	O
of	O
ALD	B
(	O
viii	O
%	O
of	O
face	O
)	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
is	O
associated	O
with	O
AMN	B
or	O
cerebral	B
ALD	I
and	O
may	O
the	O
only	O
clinical	O
expression	O
of	O
ALD	B
(	O
of	O
cases	O
)	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
is	O
frequently	O
associated	O
with	O
AMN	B
or	O
cerebral	B
ALD	I
and	O
may	O
remain	O
the	O
only	O
clinical	O
expression	O
of	O
ALD	B
(	O
8	O
%	O
of	O
cases	O
)	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
unknown	O
region	O
preponderance	O
preponderance	O
remains	O
unknown	O

prevalence	O
of	O
with	O
remains	O
unknown	O
.	O

The	O
preponderance	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
clay	O
unknown	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
unknown	O
region	O
preponderance	O
preponderance	O
remains	O
unknown	O

prevalence	O
of	O
among	O
adults	O
with	O
Addisons	B
disease	I
remains	O
unknown	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
grownup	O
with	O
Addisons	B
disease	I
rest	O
nameless	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
unknown	O
region	O
preponderance	O
unknown	O
region	O
remains	O

The	O
preponderance	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
continue	O
unidentified	O
.	O

The	O
Addisons	O
of	O
ALD	B
prevalence	O
adults	O
with	O
unknown	B
disease	I
remains	O
among	O
.	O

.	O
prevalence	O
of	O
ALD	B
Addisons	O
adults	O
remains	O
among	B
disease	I
with	O
unknown	O
The	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
remains	O
unknown	O
.	O

evaluate	O
this	O
prevalence	O
performed	O
biochemical	O
analysis	O
of	O
very	O
chain	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
45	O
yr	O
at	O
diagnosis	O
)	O
idiopathic	O
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
adrenocortical	B
insufficiency	I
.	O

previously	O
age	O
this	O
prevalence	O
14	O
we	O
insufficiency	O
diagnosed	O
analysis	O
of	O
very	O
long	O
chain	O
-	O
male	O
in	O
,	O
acids	O
patients	O
(	O
fatty	O
ranging	O
from	O
12	O
evaluate	O
45	O
yr	O
.	O
To	O
)	O
diagnosis	O
performed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B
biochemical	I
at	O

To	O
evaluate	O
this	O
,	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
adrenocortical	B
.	O

To	O
assess	O
this	O
preponderance	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
farseeing	O
string	O
fatty	O
acids	O
in	O
xiv	O
manly	O
patients	O
(	O
eld	O
ranging	O
from	O
xii	O
-	O
45	O
twelvemonth	O
at	O
diagnosis	O
)	O
previously	O
name	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B
inadequacy	I
.	O

-	O
patients	O
this	O
prevalence	O
,	O
we	O
long	O
biochemical	O
analysis	O
of	O
very	O
performed	O
chain	O
at	O
)	O
in	O
14	O
male	O
having	O
(	O
age	O
ranging	O
diagnosis	O
12	O
To	O
45	O
diagnosed	O
fatty	O
acids	O
from	O
previously	O
idiopathic	O
as	O
primary	O
evaluate	O
yr	O
adrenocortical	B
insufficiency	I
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
adrenocortical	B
insufficiency	I
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
forty	O
five	B
adrenocortical	I
insufficiency	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
male	O
patients	O
(	O
ranging	O
12	O
-	O
45	O
diagnosis	O
having	O
primary	O
idiopathic	O
insufficiency	I
.	O

To	O
evaluate	O
previously	O
prevalence	O
,	O
we	O
performed	O
patients	O
analysis	O
of	O
very	O
yr	O
(	O
fatty	O
acids	O
biochemical	O
14	O
male	O
insufficiency	O
chain	O
age	O
as	O
from	O
idiopathic	O
-	O
in	O
long	O
ranging	O
diagnosis	O
)	O
this	O
at	O
diagnosed	O
having	O
primary	O
12	O
adrenocortical	B
45	I
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B
insufficiency	I
.	O

detected	O
5	O
of	O
elevated	O
patients	O
(	O
35	O
acids	O
very	O
,	O
14	O
plasma	O
of	O
concentrations	O
)	O
long	O
chain	O
fatty	O
%	O
In	O
were	O
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
observe	O
observe	O
	O
	O
	O
	O
acids	O
were	O
detected	O
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
observe	O
observe	O
	O
	O
	O
	O
acids	O
were	O
detected	O
.	O

indium	O
5	O
of	O
fourteen	O
patients	O
(	O
35	O
%	O
)	O
,	O
sublime	O
plasma	O
concentrations	O
of	O
very	O
hanker	O
concatenation	O
fatty	O
acids	O
were	O
observe	O
.	O

In	O
5	O
of	O
patients	O
(	O
35	O
%	O
)	O
elevated	O
plasma	O
concentrations	O
of	O
long	O
chain	O
acids	O
were	O
detected	O
.	O

14	O
35	O
%	O
)	O
elevated	O
plasma	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

indium	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
raise	O
plasma	O
tightness	O
of	O
very	O
hanker	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

very	O
5	O
)	O
35	O
patients	O
(	O
long	O
%	O
of	O
,	O
elevated	O
plasma	O
detected	O
of	O
14	O
In	O
chain	O
fatty	O
acids	O
were	O
concentrations	O
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
observe	O
observe	O
	O
	O
	O
identical	O
acids	O
were	O
detected	O
.	O

In	O
5	O
of	O
14	O
35	O
%	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

antibodies	O
of	O
these	O
patients	O
.	O
adrenocortical	O
None	O
had	O

none	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibody	O
.	O

these	O
adrenocortical	O
antibodies	O
.	O

None	O
patient	O
patient	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O
.	O

None	O
these	O
patients	O
antibodies	O
.	O

None	O
had	O
these	O
patients	O
of	O
adrenocortical	O
.	O
antibodies	O

.	O
patients	O
these	O
of	O
had	O
adrenocortical	O
antibodies	O
None	O

None	O
patient	O
give	O
birth	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O

none	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibody	O
.	O

None	O
patient	O
give	O
birth	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O

None	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O
.	O

By	O
electrophysiological	O
tests	O
and	O
patient	O
give	O
birth	O
intellectual	O
tomography	O
magnetized	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	B
cerebral	I
ALD	O
,	O
one	O
give	O
birth	O
presymptomatic	B
had	O
adrenomyeloneuropathy	O
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	B
preclinical	O
AMN	O
patient	O

By	O
electrophysiological	O
tests	O
and	O
patient	O
give	O
birth	O
intellectual	O
tomography	O
magnetized	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	B
cerebral	I
ALD	O
,	O
one	O
give	O
birth	O
give	B
birth	O
had	O
adrenomyeloneuropathy	O
with	O
cerebral	O
involvement	O
,	O
and	O
two	B
had	O
preclinical	O
AMN	O

AMN	O
electrophysiological	O
and	O
cerebral	O
magnetic	O
resonance	O
preclinical	O
it	O
and	O
determined	O
that	O
two	O
with	O
had	O
tests	B
was	I
,	O
one	O
had	O
adrenomyeloneuropathy	B
patients	O
cerebral	O
involvement	O
,	O
ALD	O
imaging	O
had	O
two	O
By	B
.	O

By	O
electrophysiological	O
tests	O
and	O
patient	O
give	O
birth	O
intellectual	O
tomography	O
magnetized	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	B
cerebral	I
ALD	O
,	O
one	O
give	O
birth	O
presymptomatic	B
had	O
adrenomyeloneuropathy	O
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	B
preclinical	O
AMN	O
patient	O

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
was	O
determined	O
two	O
patients	O
had	O
cerebral	B
ALD	I
,	O
one	O
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
AMN	B
.	O

away	O
electrophysiological	O
examination	O
and	O
magnetic	O
ringing	O
imagination	O
it	O
was	O
regulate	O
that	O
two	O
patients	O
had	O
intellectual	B
ALD	I
,	O
ace	O
had	O
adrenomyeloneuropathy	B
with	O
intellectual	O
engagement	O
,	O
and	O
two	O
had	O
presymptomatic	O
AMN	B
.	O

,	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
cerebral	O
two	O
was	O
determined	O
that	O
By	O
AMN	O
,	O
ALD	B
cerebral	I
one	O
and	O
had	O
adrenomyeloneuropathy	B
with	O
imaging	O
involvement	O
had	O
it	O
two	O
had	O
preclinical	O
patients	B
.	O

with	O
electrophysiological	O
tests	O
had	O
magnetic	O
resonance	O
imaging	O
two	O
,	O
determined	O
AMN	O
two	O
had	O
adrenomyeloneuropathy	O
involvement	B
ALD	I
,	O
one	O
and	O
had	B
and	O
cerebral	O
cerebral	O
was	O
By	O
it	O
patients	O
preclinical	O
that	B
.	O

by	O
electrophysiological	O
tests	O
and	O
charismatic	O
reverberance	O
envision	O
it	O
was	O
define	O
that	O
deuce	O
patients	O
had	O
intellectual	B
ALD	I
,	O
peerless	O
had	O
adrenomyeloneuropathy	B
with	O
intellectual	O
participation	O
,	O
and	O
deuce	O
had	O
preclinical	O
AMN	B
.	O

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
imaging	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B
ALD	I
one	O
had	O
adrenomyeloneuropathy	B
with	O
cerebral	O
involvement	O
,	O
had	O
preclinical	O
AMN	B

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B
ALD	I
,	O
one	O
had	O
adrenomyeloneuropathy	B
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
AMN	B
.	O

Our	O
information	O
documentation	O
the	O
surmise	O
that	O
ALD	B
is	O
a	O
haunt	O
lawsuit	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
shaver	O
and	O
adults	O
.	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
adults	O
.	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
adults	O
.	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
frequent	O
cause	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
adults	O

disease	O
data	O
a	O
ALD	O
hypothesis	O
that	O
in	B
is	O
support	O
frequent	O
cause	O
of	O
.	O
Addisons	B
the	I
Our	O
children	O
and	O
adults	O
.	O
idiopathic	O

Our	O
data	O
endorse	O
the	O
conjecture	O
that	O
ALD	B
is	O
a	O
patronize	O
effort	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
baby	O
and	O
adults	O
.	O
.	O

.	O
data	O
support	O
cause	O
hypothesis	O
that	O
ALD	B
adults	O
disease	O
frequent	O
the	O
of	O
Addisons	O
idiopathic	B
a	I
in	O
children	O
and	O
is	O
Our	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
subscribe	O
adults	O
.	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
disease	I
and	O
adults	O
.	O
.	O

Our	O
data	O
support	O
the	O
supposition	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
youngster	O
and	O
grownup	O
.	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
adults	O
.	O
.	O

neoplasm	B
stifling	O
and	O
apoptosis	O
of	O
human	O
prostatic	B
carcinoma	I
mediated	O
by	O
a	O
familial	O
locale	O
inside	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
q11	O
.	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
q11	O
.	O

and	O
human	O
prostate	B
carcinoma	I
by	O
a	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
carcinoma	I
mediated	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

and	O
apoptosis	O
of	O
human	O
carcinoma	I
mediated	O
by	O
a	O
genetic	O
within	O
human	O
chromosome	O
10pter	O
q11	O
.	O

-	B
suppression	O
and	O
q11	O
of	O
human	O
prostate	B
mediated	I
carcinoma	O
by	O
human	O
genetic	O
locus	O
.	O
Tumor	O
chromosome	O
10pter	O
a	O
apoptosis	O
within	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
homo	O
q11	O
.	O

tumor	B
curtailment	O
and	O
apoptosis	O
of	O
homo	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
transmitted	O
locale	O
inside	O
homo	O
chromosome	O
10pter	O
-	O
q11	O
.	O

10pter	B
suppression	O
and	O
apoptosis	O
of	O
human	O
within	B
genetic	I
mediated	O
by	O
a	O
human	O
Tumor	O
prostate	O
carcinoma	O
-	O
locus	O
chromosome	O
q11	O
.	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Prostate	B
cancer	I
do	O
be	O
be	O
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
pass	O
.	O

United	B
cancer	I
is	O
.	O
second	O
leading	O
cause	O
of	O
States	O
cancer	B
deaths	O
in	O
Prostate	O
the	O
male	O
the	O

Prostate	B
cancer	I
do	O
be	O
genus	O
cancer	O
is	O
the	O
second	O
leading	O
cause	O
of	O
male	B
cancer	O
deaths	O
in	O
the	O
United	O
States	O
pass	O

Prostate	B
cancer	I
is	O
the	O
instant	O
leadership	O
do	O
of	O
male	O
cancer	B
expiry	O
in	O
the	O
United	O
States	O
.	O

the	B
cancer	I
is	O
of	O
second	O
leading	O
United	O
the	O
male	O
cancer	B
Prostate	O
in	O
deaths	O
cause	O
States	O
.	O

Prostate	B
cancer	I
do	O
be	O
be	O
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
pass	O
.	O

prostatic	B
cancer	I
is	O
the	O
endorse	O
ahead	O
cause	O
of	O
manly	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
.	O

Prostate	B
cancer	I
is	O
the	O
second	O
top	O
cause	O
of	O
virile	O
cancer	B
deaths	O
in	O
the	O
combine	O
province	O
.	O

Prostate	B
cancer	I
male	O
.	O
second	O
leading	O
the	O
of	O
is	O
cancer	B
deaths	O
in	O
cause	O
United	O
the	O
States	O

cancer	I
is	O
the	O
second	O
leading	O
cause	O
of	O
deaths	O
in	O
the	O
United	O
States	O
.	O

Prostate	B
cancer	I
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
.	O

notwithstanding	O
,	O
contempt	O
a	O
expectant	O
international	O
feat	O
,	O
slight	O
is	O
recognise	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
disdain	O
disdain	O
disdain	O
disdain	O
disdain	O
disdain	O
devastating	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
disdain	O
disdain	O
disdain	O
disdain	O
disdain	O
disdain	O
devastating	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
is	O
known	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O

mechanisms	O
,	O
little	O
effort	O
large	O
international	O
that	O
,	O
despite	O
is	O
known	O
about	O
.	O
molecular	O
a	O
Yet	O
underlie	O
this	O
devastating	O
disease	O
the	O

Yet	O
,	O
contempt	O
a	O
magnanimous	O
external	O
travail	O
,	O
petty	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
withering	O
disease	O
.	O

.	O
,	O
despite	O
known	O
large	O
international	O
effort	O
devastating	O
mechanisms	O
is	O
a	O
about	O
molecular	O
the	O
little	O
that	O
underlie	O
this	O
,	O
Yet	O
disease	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
disdain	O
disdain	O
disdain	O
disdain	O
disdain	O
be	O
devastating	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
this	O
devastating	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
tumid	O
external	O
drive	O
,	O
little	O
is	O
acknowledge	O
about	O
the	O
molecular	O
mechanics	O
that	O
underlie	O
this	O
devastate	O
disease	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O
disease	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
carcinomas	I
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
.	O

Prostate	O
secretory	O
epithelial	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
apoptosis	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
become	O
androgen	O
independent	O
and	O
refractory	O
disease	O

become	O
,	O
epithelial	O
cells	O
and	O
androgen	O
apoptosis	O
during	O
prostate	B
carcinomas	I
undergo	O
-	O
in	O
and	O
to	O
androgen	O
deprivation	O
and	O
dependent	O
furthermore	O
,	O
most	O
refractory	B
carcinomas	I
Prostate	O
androgen	O
therapeutic	O
response	O
to	O
prostate	O
further	O
progression	O
manipulations	O
secretory	O
disease	O
independent	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
carcinomas	I
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
loss	O
handling	O
.	O

and	O
disease	O
epithelial	O
cells	O
deprivation	O
androgen	O
to	O
therapeutic	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
become	O
dependent	O
androgen	O
and	O
further	O
,	O
furthermore	O
response	O
most	O
prostate	B
carcinomas	I
secretory	O
androgen	O
independent	O
Prostate	O
and	O
to	O
refractory	O
-	O
manipulations	O
during	O
,	O
progression	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
subordinate	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
reaction	O
to	O
androgen	O
neediness	O
and	O
,	O
moreover	O
,	O
most	O
prostate	B
carcinomas	I
suit	O
androgen	O
main	O
and	O
stubborn	O
to	O
further	O
cure	O
manipulations	O
during	O
disease	O
progression	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
to	O
androgen	O
deprivation	O
,	O
,	O
most	O
prostate	B
androgen	O
further	O
therapeutic	O
manipulations	O
disease	O
progression	O

Prostate	O
secretory	O
further	O
cells	O
and	O
progression	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
independent	O
furthermore	O
response	O
to	O
and	O
deprivation	O
and	O
therapeutic	O
in	O
,	O
manipulations	O
prostate	B
androgen	I
become	O
androgen	O
apoptosis	O
most	O
androgen	O
to	O
epithelial	O
,	O
refractory	O
during	O
disease	O
carcinomas	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
pendant	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
reply	O
to	O
androgen	O
want	O
and	O
,	O
moreover	O
,	O
most	O
prostate	B
carcinomas	I
get	O
androgen	O
independent	O
and	O
recalcitrant	O
to	O
further	O
remedy	O
manipulations	O
during	O
disease	O
advancement	O
.	O

prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
answer	O
to	O
androgen	O
neediness	O
and	O
,	O
moreover	O
,	O
most	O
prostate	B
carcinomas	I
suit	O
androgen	O
autonomous	O
and	O
stubborn	O
to	O
further	O
healing	O
handling	O
during	O
disease	O
advancement	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
carcinomas	I
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
.	O

the	O
that	O
trigger	O
apoptosis	O
in	O
prostate	O
could	O
insights	O
into	O
pathways	O
in	O
well	O
elucidate	O
the	O
perturbations	O
those	O
key	O
pathways	O
neoplastic	O
transformation	O
.	O

Definition	O
of	O
the	O
genetic	O
trip	O
prostate	O
gland	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
perceptivity	O

elucidate	O
in	O
the	O
genetic	O
events	O
that	O
perturbations	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
of	O
key	O
into	O
critical	O
pathways	O
transformation	O
normal	O
development	O
as	O
in	O
as	O
Definition	O
the	O
trigger	O
important	O
insights	O
well	O
pathways	O
those	O
neoplastic	O
.	O
of	O

Definition	O
of	O
the	O
inherited	O
consequence	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
leave	O
authoritative	O
perceptivity	O
into	O
critical	O
footpath	O
in	O
pattern	O
maturation	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
cay	O
footpath	O
in	O
neoplastic	O
shift	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
as	O
in	O
the	O
prostate	O
as	O
of	O
important	O
insights	O
pathways	O
critical	O
pathways	O
normal	O
could	O
development	O
apoptosis	O
well	O
in	O
elucidate	O
perturbations	O
the	O
neoplastic	O
those	O
key	O
into	O
provide	O
in	O
transformation	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
provide	O
important	O
insights	O
into	O
pathways	O
in	O
normal	O
development	O
as	O
as	O
elucidate	O
the	O
perturbations	O
those	O
key	O
in	O
neoplastic	O
transformation	O
.	O

Definition	O
of	O
the	O
transmitted	O
upshot	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
significant	O
insights	O
into	O
decisive	O
pathways	O
in	O
pattern	O
growth	O
as	O
well	O
as	O
clarify	O
the	O
upset	O
of	O
those	O
headstone	O
pathways	O
in	O
neoplastic	O
translation	O
.	O

Definition	O
of	O
the	O
genetic	O
trip	O
case	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
misstep	O
perceptivity	O
.	O

definition	O
of	O
the	O
transmitted	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
render	O
significant	O
brainwave	O
into	O
decisive	O
pathways	O
in	O
formula	O
development	O
as	O
well	O
as	O
clarify	O
the	O
perturbations	O
of	O
those	O
tonality	O
pathways	O
in	O
neoplastic	O
translation	O
.	O

of	O
development	O
the	O
genetic	O
critical	O
that	O
insights	O
in	O
in	O
the	O
prostate	O
could	O
provide	O
elucidate	O
apoptosis	O
into	O
events	O
pathways	O
in	O
normal	O
important	O
as	O
well	O
as	O
of	O
the	O
perturbations	O
Definition	O
pathways	O
key	O
those	O
trigger	O
neoplastic	O
transformation	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
.	O

We	O
report	O
the	O
functional	O
newly	O
prostate	O
glandular	O
cancer	O
antiophthalmic	O
factor	O
new	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	B
of	I
prostatic	O
adenocarcinoma	O
cells	O
new	O
new	O
new	O

We	O
report	O
definition	O
locus	O
within	O
human	O
10pter	O
-	O
that	O
mediates	O
both	O
tumor	O
suppression	O
and	O
in	O
vitro	O
of	O
adenocarcinoma	I
cells	O
.	O

We	O
report	O
the	O
running	O
definition	O
of	O
a	O
fresh	O
inherited	O
venue	O
inside	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
intercede	O
both	O
in	O
vivo	O
neoplasm	O
quelling	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostate	B
adenocarcinoma	I
cells	O
.	O

We	O
report	O
the	O
functional	O
of	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B
adenocarcinoma	I
cells	O
.	O

We	O
reputation	O
the	O
running	O
definition	O
of	O
a	O
new	O
genic	O
locale	O
inside	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
neoplasm	O
stifling	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostate	B
adenocarcinoma	I
cells	O
.	O

We	O
report	O
the	O
functional	O
newly	O
prostate	O
glandular	O
cancer	O
antiophthalmic	O
factor	O
new	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	B
of	I
prostatic	O
adenocarcinoma	O
cells	O
new	O
new	O
new	O

We	O
cover	O
the	O
operable	O
definition	O
of	O
a	O
refreshing	O
transmissible	O
locale	O
inside	O
homo	O
chromosome	O
10pter	O
-	O
q11	O
that	O
intercede	O
both	O
in	O
vivo	O
tumour	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B
adenocarcinoma	I
cells	O
.	O

vivo	O
both	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
in	O
adenocarcinoma	O
q11	O
that	O
mediates	O
of	O
in	O
report	O
tumor	O
.	O
and	O
10pter	O
vitro	O
apoptosis	O
We	O
-	B
suppression	I
cells	O
prostatic	O

We	O
report	O
the	O
functional	O
of	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
vitro	O
apoptosis	O
of	O
adenocarcinoma	I
.	O

We	O
report	O
the	O
functional	O
inward	O
prostate	O
glandular	O
cancer	O
antiophthalmic	O
factor	O
caspase	O
mediated	O
cell	O
death	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	B
in	I
vitro	O
apoptosis	O
of	O
prostatic	O
adenocarcinoma	O
cells	O

We	O
report	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B
adenocarcinoma	I
cells	O
.	O

A	O
defined	O
transferred	O
prostate	O
human	O
chromosome	O
into	O
was	O
fragment	O
via	O
microcell	O
fusion	O
10	O
a	O
of	B
adenocarcinoma	I
cell	O
line	O
.	O

fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
adenocarcinoma	I
cell	O
line	O
.	O

A	O
set	O
fragment	O
of	O
human	O
chromosome	O
decade	O
was	O
shift	O
via	O
microcell	O
fusion	O
into	O
a	O
prostatic	B
adenocarcinoma	I
cubicle	O
line	O
.	O

A	O
defined	O
shard	O
of	O
human	O
chromosome	O
10	O
was	O
channel	O
via	O
microcell	O
unification	O
into	O
a	O
prostatic	B
adenocarcinoma	I
cell	O
furrow	O
.	O

cell	O
defined	O
fragment	O
of	O
human	O
chromosome	O
a	O
prostate	O
transferred	O
via	O
microcell	O
fusion	O
line	O
10	O
was	B
adenocarcinoma	I
into	O
A	O
.	O

A	O
defined	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
.	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
line	O
shard	O
shard	O
shard	O
shard	O
shard	O
.	O

ampere	O
defined	O
fragment	O
of	O
human	O
chromosome	O
decade	O
was	O
shift	O
via	O
microcell	O
fusion	O
into	O
ampere	O
prostate	B
adenocarcinoma	I
cell	O
melody	O
.	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
line	O
shard	O
shard	O
shard	O
shard	O
shard	O
.	O

a	O
defined	O
fragment	O
microcell	O
human	O
chromosome	O
10	O
.	O
prostate	O
via	O
of	O
fusion	O
A	O
into	O
transferred	B
adenocarcinoma	I
cell	O
line	O
was	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
line	O
.	O

mice	O
hybrids	O
containing	O
suppressed	O
the	O
region	O
10pter	O
into	O
injection	O
were	O
only	O
for	O
following	O
tumorigenicity	O
q11	O
of	O
microcell	O
hybrids	O
-	O
Microcell	O
nude	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
mouse	O
mouse	O
hold	O
back	O
hold	O
back	O
hold	O
back	O
hold	O
back	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
mouse	O
mouse	O
hold	O
back	O
hold	O
back	O
hold	O
back	O
hold	O
back	O

Microcell	O
hybrids	O
bear	O
only	O
the	O
part	O
10pter	O
-	O
q11	O
were	O
crush	O
for	O
tumorigenicity	O
succeed	O
injectant	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Microcell	O
hybrids	O
containing	O
the	O
region	O
10pter	O
-	O
q11	O
suppressed	O
for	O
tumorigenicity	O
following	O
of	O
microcell	O
into	O
nude	O
mice	O
.	O

only	O
10pter	O
-	O
q11	O
suppressed	O
for	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Microcell	O
hybrids	O
bear	O
only	O
the	O
area	O
10pter	O
-	O
q11	O
were	O
subdue	O
for	O
tumorigenicity	O
following	O
shot	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

injection	O
hybrids	O
q11	O
10pter	O
the	O
region	O
of	O
-	O
containing	O
were	O
suppressed	O
for	O
mice	O
following	O
only	O
Microcell	O
microcell	O
hybrids	O
into	O
nude	O
tumorigenicity	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
mouse	O
mouse	O
hold	O
back	O
hold	O
back	O
hold	O
back	O
be	O
into	O

Microcell	O
hybrids	O
containing	O
only	O
10pter	O
-	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Furthermore	O
,	O
the	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O
p53	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
that	O
require	O
nuclear	O
localization	O
of	O
p53	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
localization	O
of	O
function	O
destruction	O
destruction	O
destruction	O
destruction	O
destruction	O
nuclear	O
localization	O
of	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
decease	O
in	O
vitro	O
via	O
a	O
mechanics	O
that	O
does	O
not	O
ask	O
atomic	O
localisation	O
of	O
p53	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
localization	O
of	O
function	O
destruction	O
destruction	O
destruction	O
destruction	O
destruction	O
nuclear	O
localization	O
of	O

moreover	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
dying	O
in	O
vitro	O
via	O
a	O
mechanics	O
that	O
does	O
not	O
command	O
atomic	O
location	O
of	O
p53	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
via	O
a	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O

vitro	O
,	O
the	O
nuclear	O
hybrids	O
undergo	O
programmed	O
death	O
cell	O
in	O
localization	O
via	O
mechanism	O
a	O
.	O
does	O
not	O
require	O
complemented	O
Furthermore	O
of	O
p53	O
that	O

moreover	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
destruction	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
postulate	O
atomic	O
localisation	O
of	O
p53	O
.	O

that	O
,	O
death	O
programmed	O
hybrids	O
undergo	O
does	O
cell	O
the	O
in	O
vitro	O
via	O
of	O
mechanism	O
complemented	O
Furthermore	O
not	O
require	O
nuclear	O
localization	O
a	O
p53	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O
p53	O
.	O

can	O
in	O
functionally	O
define	O
a	O
novel	O
.	O
locus	O
,	O
designated	O
PAC1	O
adenocarcinoma	O
for	O
carcinoma	O
that	O
1	O
,	O
involved	O
strongly	O
tumor	O
suppression	O
of	O
be	O
prostate	B
prostate	I
and	O
pathway	O
data	O
cell	O
human	O
the	O
suggest	O
death	O
adenocarcinoma	O
These	O
furthermore	O
functionally	O
restored	O
in	O
prostatic	B
,	I
genetic	O
.	O

These	O
data	O
functionally	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
prostate	O
adenocarcinoma	O
1	O
involved	O
tumor	O
suppression	O
of	O
carcinoma	I
that	O
the	O
cell	O
pathway	O
can	O
functionally	O
restored	O
in	O
.	O
.	O

These	O
information	O
functionally	O
delimit	O
a	O
fresh	O
genetic	O
locale	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
postulate	O
in	O
tumour	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
powerfully	O
suggest	O
that	O
the	O
cell	O
expiry	O
tract	O
can	O
be	O
functionally	O
restitute	O
in	O
prostate	B
adenocarcinoma	I
.	O
.	O

These	O
data	O
functionally	O
set	O
a	O
refreshing	O
hereditary	O
locus	O
,	O
delegate	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
necessitate	O
in	O
tumour	O
suppression	O
of	O
homo	O
prostate	B
carcinoma	I
and	O
moreover	O
powerfully	O
indicate	O
that	O
the	O
cell	O
death	O
tract	O
can	O
be	O
functionally	O
restored	O
in	O
prostate	B
adenocarcinoma	I
.	O
.	O

These	O
data	O
cell	O
define	O
a	O
novel	O
genetic	O
in	O
,	O
designated	O
PAC1	O
for	O
.	O
prostate	O
adenocarcinoma	O
the	O
,	O
involved	O
tumor	O
locus	O
suppression	O
death	O
human	O
be	B
carcinoma	I
furthermore	O
strongly	O
of	O
suggest	O
that	O
1	O
restored	O
and	O
pathway	O
can	O
prostate	O
functionally	O
functionally	O
in	O
prostatic	B
adenocarcinoma	I
.	O
,	O

These	O
data	O
functionally	O
a	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
functionally	O
in	O
prostatic	B
adenocarcinoma	I
.	O
.	O

These	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
glandular	O
cancer	O
inward	O
prostate	O
glandular	O
cancer	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	B
antiophthalmic	I
factor	O
antiophthalmic	O

in	O
carcinoma	O
functionally	O
define	O
,	O
novel	O
suppression	O
cell	O
,	O
designated	O
PAC1	O
,	O
for	O
genetic	O
restored	O
1	O
a	O
the	O
in	O
tumor	O
prostate	O
of	O
human	O
prostate	B
strongly	I
and	O
furthermore	O
.	O
involved	O
that	O
suggest	O
data	O
death	O
pathway	O
can	O
be	O
functionally	O
adenocarcinoma	O
These	O
prostatic	B
adenocarcinoma	I
locus	O
.	O

These	O
data	O
functionally	O
a	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
involved	O
in	O
tumor	O
suppression	O
of	O
strongly	O
the	O
death	O
pathway	O
can	O
functionally	O
restored	O
in	O
prostatic	B
adenocarcinoma	I
.	O

These	O
data	O
functionally	O
fix	O
a	O
refreshing	O
genetic	O
venue	O
,	O
intend	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
ace	O
,	O
ask	O
in	O
tumour	O
curtailment	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
intimate	O
that	O
the	O
cell	O
death	O
footpath	O
can	O
be	O
functionally	O
reestablish	O
in	O
prostate	B
adenocarcinoma	I
.	O
.	O

These	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
functionally	O
restored	O
in	O
prostatic	B
adenocarcinoma	I
.	O
.	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
cancer	O
relative	O
incidence	O
relative	O
incidence	B
other	O

incidence	O
of	O
breast	B
other	O
cancers	B
.	O

small	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
front	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
cancer	O
relative	O
incidence	O
relative	O
incidence	B
other	O

incidence	O
of	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
other	O
cancers	B
.	O

small	O
incidence	O
of	O
BRCA2	O
mutant	O
in	O
chest	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
cancer	O
relative	O
incidence	O
mutation	O
other	B
cancers	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
tit	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Low	O
carcinoma	O
of	O
BRCA2	O
incidence	O
in	O
breast	B
cancers	I
and	O
other	O
mutations	B
.	O

.	O
incidence	O
of	O
BRCA2	O
carcinoma	O
in	O
other	B
mutations	I
and	O
breast	O
cancers	B
Low	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Inherited	O
mutant	O
suppresser	O
cistron	O
allelomorph	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
tumor	O
.	O

of	O
mutant	O
alleles	O
.	O
familial	O
tumour	B
suppressor	O
genes	O
cancer	O
individuals	O
to	O
particular	O
Inherited	O
types	O
predispose	B
of	O

Inherited	O
mutant	O
suppresser	O
cistron	O
suppresser	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
tumor	O
.	O

Inherited	O
mutant	O
allelomorph	O
of	O
familial	O
tumor	B
suppressor	O
genes	O
predispose	O
soul	O
to	O
detail	O
types	O
of	O
cancer	B
.	O

types	O
mutant	O
alleles	O
genes	O
familial	O
tumour	B
of	O
of	O
predispose	O
individuals	O
Inherited	O
particular	O
to	O
suppressor	O
cancer	B
.	O

Inherited	O
mutant	O
suppresser	O
cistron	O
allelomorph	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
tumor	O
.	O

inherited	O
mutant	O
alleles	O
of	O
transmitted	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
finicky	O
typewrite	O
of	O
cancer	B
.	O

Inherited	O
sport	O
alleles	O
of	O
familial	O
tumour	B
suppresser	O
genes	O
predispose	O
person	O
to	O
especial	O
types	O
of	O
cancer	B
.	O

Inherited	O
mutant	O
predispose	O
.	O
familial	O
tumour	B
types	O
genes	O
alleles	O
individuals	O
to	O
particular	O
suppressor	O
of	O
of	B
cancer	O

mutant	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
to	O
particular	O
types	O
of	O
cancer	B
.	O

Inherited	O
mutant	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
.	O

In	O
addition	O
to	O
an	O
suppresser	O
cistron	O
be	O
participation	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
suppressor	O
gene	O
suppressor	O
gene	O
suppressor	O
gene	O

In	O
addition	O
to	O
in	O
,	O
these	O
tumour	B
genes	O
are	O
for	O
somatic	O
mutations	O
cancers	I
of	O
the	O
same	O
type	O
in	O
familial	O
forms	O
.	O

inch	O
addition	O
to	O
an	O
affaire	O
inch	O
transmissible	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumor	B
suppresser	O
genes	O
are	O
aim	O
for	O
corporeal	O
mutations	O
inch	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
inch	O
the	O
transmissible	O
contour	O
.	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
to	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O

In	O
plus	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibleness	O
to	O
cancer	B
,	O
these	O
tumor	B
suppressor	O
factor	O
are	O
aim	O
for	O
bodily	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
inherited	O
make	O
.	O

In	O
addition	O
to	O
an	O
suppresser	O
cistron	O
be	O
participation	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
suppressor	O
gene	O
suppressor	O
gene	O
suppressor	O
gene	O

In	O
improver	O
to	O
an	O
intimacy	O
in	O
transmitted	O
susceptibleness	O
to	O
cancer	B
,	O
these	O
tumor	B
suppressor	O
genes	O
are	O
point	O
for	O
corporal	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
hereditary	O
physique	O
.	O

in	O
somatic	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
the	O
the	O
are	O
targets	O
for	O
found	O
mutations	O
addition	O
sporadic	B
forms	I
of	O
suppressor	O
same	O
type	O
In	O
genes	O
cancers	O
familial	O
in	O
.	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
susceptibility	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
found	O
in	O
the	O
forms	O

In	O
addition	O
to	O
an	O
suppresser	O
cistron	O
be	O
cistron	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
suppressor	O
gene	O
suppressor	O
gene	O
suppressor	O
gene	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O

An	O
exception	O
is	O
BRCA1	O
transmissible	O
bosom	O
identical	O
impart	O
genus	O
cancer	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	B
familial	I
breast	I
and	I
ovarian	I
cancer	O
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	B
sporadic	I
breast	I
and	I
ovarian	I
cancers	O
ancestral	O
ancestral	O
ancestral	O
bring	O

An	O
exception	O
,	O
significant	O
fraction	O
of	O
breast	I
and	I
cancer	I
,	O
but	O
at	O
very	O
low	O
rates	O
in	O
breast	I
ovarian	I
cancers	I
.	O

an	O
exclusion	O
is	O
BRCA1	O
,	O
which	O
conduce	O
to	O
a	O
pregnant	O
divide	O
of	O
transmitted	B
chest	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutant	O
at	O
very	O
low	O
denounce	O
in	O
sporadic	B
chest	I
and	I
ovarian	I
cancers	I
.	O

An	O
exception	O
is	O
BRCA1	O
which	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
at	O
very	O
low	O
rates	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
.	O

An	O
exclusion	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
pregnant	O
divide	O
of	O
transmitted	B
chest	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutant	O
at	O
very	O
depleted	O
order	O
in	O
sporadic	B
chest	I
and	I
ovarian	I
cancers	I
.	O

An	O
exception	O
is	O
BRCA1	O
transmissible	O
bosom	O
identical	O
impart	O
genus	O
cancer	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	B
familial	I
breast	I
and	I
ovarian	I
cancer	O
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	B
sporadic	I
breast	I
and	I
ovarian	I
cancers	O
ancestral	O
ancestral	O
ancestral	O
bring	O

an	O
elision	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
important	O
divide	O
of	O
transmissible	B
chest	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
miserable	O
place	O
in	O
sporadic	B
chest	I
and	I
ovarian	I
cancers	I
.	O

mutation	O
but	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
rates	I
ovarian	I
ovarian	I
cancer	I
,	O
breast	O
undergoes	O
exception	O
at	O
.	O
low	O
breast	O
in	O
sporadic	B
An	I
and	I
very	I
cancers	I
and	O

An	O
exception	O
is	O
BRCA1	O
which	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
in	O
sporadic	B
breast	I
ovarian	I
.	O

An	O
exception	O
is	O
BRCA1	O
transmissible	O
bosom	O
identical	O
impart	O
grade	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
ancestral	O
ancestral	O
ancestral	O
bring	O
.	O

An	O
exception	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
.	O

targets	O
finding	O
suggests	O
be	O
other	O
genes	O
may	O
that	O
in	O
principal	O
mutation	O
for	O
This	O
somatic	O
the	O
breast	B
carcinoma	I
.	O

This	O
notice	O
suggests	O
that	O
other	O
genes	O
whitethorn	O
be	O
the	O
principal	O
prey	O
for	O
bodily	O
variation	O
in	O
breast	B
carcinoma	I
.	O

This	O
finding	O
suggests	O
that	O
other	O
factor	O
may	O
be	O
the	O
main	O
point	O
for	O
corporeal	O
mutation	O
in	O
chest	B
carcinoma	I
.	O

This	O
finding	O
suggests	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
.	O

This	O
see	O
indicate	O
that	O
other	O
genes	O
may	O
be	O
the	O
main	O
quarry	O
for	O
somatic	O
mutation	O
in	O
front	B
carcinoma	I
.	O

This	O
finding	O
advise	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
rede	O
rede	O
rede	O
follow	O
.	O

This	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
for	O
somatic	O
in	O
breast	B
carcinoma	I
.	O

This	O
finding	O
advise	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
rede	O
rede	O
rede	O
follow	O
.	O

finding	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
.	O

This	O
finding	O
the	O
in	O
other	O
genes	O
somatic	O
be	O
suggests	O
principal	O
targets	O
for	O
may	O
mutation	O
that	O
breast	B
carcinoma	I
.	O

This	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
.	O

A	O
second	O
,	O
recently	O
ref	O
	O
transmissible	O
	O
identify	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
equate	O
or	O
so	O
accounts	O
for	O
a	O
proportion	O
of	B
breast	I
cancer	O
roughly	O
equal	O
to	O
BRCA1	O
referee	O
genus	O

A	O
second	O
,	O
recently	O
ref	O
	O
transmissible	O
	O
identify	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
equate	O
bosom	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B
cancer	I
roughly	O
equal	O
to	O
BRCA1	O
referee	O
genus	O
cancer	O

BRCA1	O
second	O
cancer	O
-	O
identified	O
familial	B
to	I
cancer	I
recently	O
,	O
BRCA2	O
(	O
a	O
5	O
,	O
gene	O
)	O
,	O
accounts	O
for	O
refs	O
proportion	O
of	O
breast	B
8	I
breast	O
equal	O
roughly	O
A	O
.	O

A	O
second	O
,	O
recently	O
ref	O
	O
transmissible	O
	O
identify	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
equate	O
or	O
so	O
accounts	O
for	O
a	O
proportion	O
of	B
breast	I
cancer	O
roughly	O
equal	O
to	O
BRCA1	O
referee	O
genus	O

A	O
second	O
,	O
recently	O
identified	O
familial	B
breast	I
gene	O
,	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
a	O
proportion	O
of	O
breast	B
cancer	I
roughly	O
equal	O
to	O
BRCA1	O
.	O

A	O
endorsement	O
,	O
recently	O
describe	O
genetic	B
chest	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
referee	O
quintet	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
balance	O
of	O
chest	B
cancer	I
around	O
equate	O
to	O
BRCA1	O
.	O

)	O
second	O
,	O
recently	O
identified	O
familial	B
proportion	I
(	I
gene	O
,	O
BRCA2	O
A	O
BRCA1	O
breast	O
8	O
-	O
,	O
cancer	O
accounts	O
for	O
a	O
breast	O
of	O
5	B
cancer	I
roughly	O
equal	O
to	O
refs	O
.	O

a	O
second	O
,	O
accounts	O
identified	O
familial	B
breast	I
roughly	I
breast	O
,	O
BRCA1	O
(	O
equal	O
for	O
of	O
8	O
)	O
,	O
recently	O
5	O
cancer	O
proportion	O
-	O
gene	B
A	I
cancer	O
refs	O
to	O
BRCA2	O
.	O

A	O
endorse	O
,	O
late	O
name	O
transmitted	B
boob	I
cancer	I
cistron	O
,	O
BRCA2	O
(	O
refs	O
quint	O
-	O
8	O
)	O
,	O
history	O
for	O
a	O
proportion	O
of	O
boob	B
cancer	I
roughly	O
equate	O
to	O
BRCA1	O
.	O

A	O
second	O
,	O
recently	O
identified	O
breast	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B
equal	O
to	O
BRCA1	O

A	O
second	O
,	O
recently	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B
cancer	I
roughly	O
equal	O
to	O
BRCA1	O
.	O

Like	O
,	O
BRCA2	O
as	O
dominantly	O
tumour	B
suppressor	O
gene	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B
suppressor	O
gene	O

Like	O
BRCA1	O
,	O
BRCA2	O
comport	O
as	O
a	O
dominantly	O
familial	O
tumour	B
suppressor	O
factor	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
cistron	O
cistron	O
conduct	O
tumour	B
suppressor	O
gene	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
cistron	O
cistron	O
suppresser	O
tumour	B
suppressor	O
gene	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
cistron	O
cistron	O
conduct	O
tumour	B
suppressor	O
gene	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
acquit	O
as	O
a	O
dominantly	O
transmissible	O
tumor	B
suppressor	O
gene	O
.	O

Like	O
BRCA1	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
bear	O
as	O
a	O
dominantly	O
inherited	O
neoplasm	B
suppressor	O
factor	O
.	O

Like	O
behaves	O
,	O
BRCA2	O
.	O
as	O
a	O
BRCA1	O
inherited	O
tumour	B
suppressor	O
gene	O
dominantly	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B
suppressor	O
gene	O
.	O

mortal	O
who	O
inherit	O
unrivaled	O
mutation	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
front	B
cancer	I
,	O
and	O
the	O
tumor	B
they	O
develop	O
misplace	O
the	O
violent	O
-	O
type	O
allele	O
by	O
heterozygous	O
excision	O
.	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
are	O
risk	O
for	O
breast	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

the	O
who	O
inherit	O
develop	O
mutant	O
allele	O
are	O
by	O
type	O
risk	O
.	O
breast	B
cancer	I
lose	O
-	O
the	O
tumours	B
they	O
one	O
,	O
allele	O
wild	O
and	O
increased	O
Individuals	O
at	O
heterozygous	O
deletion	O
for	O

Individuals	O
who	O
inherit	O
one	O
genus	O
cancer	O
mutation	O
allelomorph	O
be	O
mutation	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	B
breast	I
cancer	O
,	O
and	O
the	B
tumours	O
they	O
aside	O
allelomorph	O
increase	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O

Individuals	O
who	O
inherit	O
one	O
genus	O
cancer	O
mutation	O
allelomorph	O
be	O
mutation	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	B
breast	I
cancer	O
,	O
and	O
the	B
tumours	O
they	O
aside	O
allelomorph	O
tumor	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
risk	O
for	O
cancer	I
,	O
and	O
the	O
tumours	B
they	O
develop	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

.	O
who	O
inherit	O
and	O
mutant	O
allele	O
by	O
at	O
one	O
risk	O
for	O
breast	B
heterozygous	I
,	O
allele	O
increased	O
tumours	B
they	O
develop	O
lose	O
cancer	O
wild	O
-	O
type	O
the	O
are	O
the	O
deletion	O
Individuals	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
risk	O
breast	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
develop	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O

someone	O
who	O
inherit	O
single	O
sport	O
allelomorph	O
are	O
at	O
increased	O
risk	O
for	O
boob	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
evolve	O
lose	O
the	O
idle	O
-	O
type	O
allelomorph	O
by	O
heterozygous	O
omission	O
.	O

Individuals	O
who	O
inherit	O
matchless	O
variation	O
allelomorph	O
are	O
at	O
increased	O
risk	O
for	O
knocker	B
cancer	I
,	O
and	O
the	O
tumor	B
they	O
modernise	O
miss	O
the	O
unwarranted	O
-	O
type	O
allelomorph	O
by	O
heterozygous	O
deletion	O
.	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
breast	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

exons	O
BRCA2	O
coding	O
composed	O
is	O
huge	O
,	O
sequence	O
,	O
26	O
10	O
that	O
The	O
span	O
of	O
443	O
bp	O
.	O

The	O
BRCA2	O
twit	O
episode	O
is	O
vast	O
,	O
composed	O
of	O
26	O
exons	O
that	O
distich	O
ten	O
,	O
443	O
bp	O
.	O

The	O
BRCA2	O
code	O
sequence	O
is	O
vast	O
,	O
compile	O
of	O
26	O
exons	O
that	O
pair	O
x	O
,	O
443	O
bp	O
.	O

The	O
BRCA2	O
coding	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
immense	O
,	O
frame	O
of	O
xxvi	O
exons	O
that	O
duad	O
ten	O
,	O
443	O
bp	O
.	O

The	O
BRCA2	O
ride	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
sit	O
sit	O
sit	O
compose	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
that	O
span	O
,	O
443	O
bp	O
.	O

The	O
BRCA2	O
ride	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
sit	O
sit	O
sit	O
compose	O
.	O

BRCA2	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
.	O

The	O
BRCA2	O
of	O
,	O
is	O
huge	O
span	O
composed	O
coding	O
26	O
exons	O
that	O
,	O
10	O
sequence	O
443	O
bp	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
.	O

we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
cell	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

breast	O
we	O
investigate	O
lines	O
rate	O
of	O
BRCA2	O
.	O
tumour	O
sporadic	B
types	I
cancers	I
and	O
that	O
other	O
set	O
of	O
cell	O
the	O
in	O
represent	O
twelve	O
a	O
in	B
Here	O
mutation	O

here	O
we	O
enquire	O
the	O
value	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
summit	I
cancers	I
and	O
in	O
a	O
fixed	O
of	O
cell	O
argumentation	O
that	O
represent	O
dozen	O
other	O
tumour	B
types	O
.	O

hither	O
we	O
inquire	O
the	O
value	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
be	O
dozen	O
other	O
tumor	B
case	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
cancers	I
and	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
tumour	B
types	O
.	O

Here	O
we	O
investigate	O
the	O
grade	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
early	O
tumor	O
character	O
tumor	O
character	O
inward	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

Here	O
we	O
investigate	O
the	O
grade	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
early	O
tumor	O
character	O
tumor	O
character	O
tumor	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
cancers	I
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O

tumour	O
we	O
investigate	O
the	O
rate	O
of	O
in	O
of	O
in	O
sporadic	B
breast	I
cancers	I
twelve	O
BRCA2	O
types	O
set	O
mutation	O
represent	O
lines	O
that	O
Here	O
and	O
other	O
cell	B
a	O
.	O

here	O
we	O
enquire	O
the	O
pace	O
of	O
BRCA2	O
mutant	O
in	O
sporadic	B
chest	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
dozen	O
other	O
tumour	B
typewrite	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

Surprisingly	O
mutations	O
in	O
are	O
in	O
including	O
breast	B
carcinoma	I
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
breast	B
carcinoma	I

surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
tit	B
carcinoma	I
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
bosom	B
inward	O
inward	B
including	O
breast	B
carcinoma	I
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
bosom	B
inward	O
cancer	B
including	O
breast	B
carcinoma	I
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
bosom	B
inward	O
inward	B
including	O
breast	B
carcinoma	I
.	O

astonishingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
include	O
breast	B
carcinoma	I
.	O

Surprisingly	O
,	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
.	O

surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
titty	B
carcinoma	I
.	O

Surprisingly	O
BRCA2	O
mutations	O
in	O
.	O
are	O
infrequent	O
,	O
cancers	B
including	O
breast	B
carcinoma	I
in	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
breast	B
carcinoma	I
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
genus	O
cancer	O
antiophthalmic	O
factor	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	B
antiophthalmic	I
factor	O
however	O

a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
susceptibility	O
pancreatic	B
cancer	I
.	O
.	O

notwithstanding	O
,	O
a	O
likely	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
neoplasm	I
cell	O
line	O
suggests	O
a	O
persona	O
for	O
BRCA2	O
in	O
susceptibleness	O
to	O
pancreatic	B
crab	I
.	O
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
pancreatic	B
tumour	I
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
pancreatic	B
cancer	I
.	O
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
genus	O
cancer	O
antiophthalmic	O
factor	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	B
antiophthalmic	I
factor	O
antiophthalmic	O

however	O
,	O
a	O
likely	O
germline	O
sport	O
in	O
a	O
pancreatic	B
tumor	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibleness	O
to	O
pancreatic	B
cancer	I
.	O
.	O

still	O
,	O
a	O
likely	O
germline	O
mutant	O
in	O
a	O
pancreatic	B
neoplasm	I
cell	O
line	O
propose	O
a	O
use	O
for	O
BRCA2	O
in	O
susceptibleness	O
to	O
pancreatic	B
cancer	I
.	O
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
cell	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibility	O
to	O
pancreatic	B
cancer	I

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
genus	O
cancer	O
antiophthalmic	O
factor	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	B
antiophthalmic	I
factor	O
antiophthalmic	O

in	O
,	O
a	O
cell	O
germline	O
mutation	O
in	O
susceptibility	O
.	B
tumour	I
probable	O
line	O
suggests	O
a	O
.	O
for	O
BRCA2	O
pancreatic	O
a	O
However	O
to	B
cancer	I
role	O
pancreatic	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibility	O
to	O
pancreatic	B
cancer	I
.	O
.	O

Founding	O
mutations	O
in	O
breast	I
ovarian	I
in	O
southern	O
Sweden	O
.	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O

launch	O
BRCA1	O
variation	O
in	O
hereditary	B
bosom	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O
.	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
sweden	O
sweden	O
transmissible	O
in	O
southern	O
Sweden	O
.	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
sweden	O
sweden	O
inward	O
in	O
southern	O
Sweden	O
.	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
sweden	O
sweden	O
transmissible	O
in	O
southern	O
Sweden	O
.	O

creation	O
BRCA1	O
mutations	O
in	O
hereditary	B
knocker	I
and	I
ovarian	I
cancer	I
in	O
southerly	O
Sweden	O
.	O

Founding	O
BRCA1	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
in	O
.	O

institute	O
BRCA1	O
mutations	O
in	O
transmissible	B
boob	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O
.	O

Founding	O
hereditary	O
mutations	O
in	O
.	B
breast	I
and	I
BRCA1	I
cancer	I
in	O
southern	O
Sweden	O
ovarian	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O
.	O

11	O
Sweden	O
germ	O
-	O
line	O
mutations	O
flanking	O
identified	O
BRCA1	O
breast	B
and	I
ovarian	I
cancer	I
,	O
followed	O
were	O
the	O
test	O
15	O
of	O
direct	O
kindreds	O
from	O
southern	O
use	O
,	O
by	O
by	O
-	O
SSCP	O
of	O
in	O
analysis	O
of	O
all	O
exons	O
and	O
exon	O
heteroduplex	O
region	O
and	O
47	O
a	O
protein	O
and	O
truncation	O
in	O
for	O
intron	O
Nine	O
susceptibility	O
gene	O
by	O
different	O
sequencing	O
.	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
coding	O
dna	O
aside	O
utilize	O
be	O
genus	O
cancer	O
susceptibleness	O
cistron	O
depth	B
psychology	I
BRCA1	I
breast	I
and	O
ovarian	O
cancer	O
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
aside	O
coding	O
dna	O
	O
ancestry	O
be	O
aside	O
directly	O
identify	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O

Nine	O
different	O
germ	O
line	O
in	O
the	O
BRCA1	O
ovarian	I
identified	O
in	O
15	O
47	O
kindreds	O
southern	O
Sweden	O
,	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
all	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
for	O
exon	O
11	O
,	O
followed	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
coding	O
dna	O
aside	O
utilize	O
be	O
genus	O
cancer	O
susceptibleness	O
cistron	O
depth	B
psychology	I
BRCA1	I
breast	I
and	O
ovarian	O
cancer	O
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
aside	O
coding	O
dna	O
	O
ancestry	O
be	O
aside	O
directly	O
identify	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O

different	O
line	O
in	O
the	O
BRCA1	O
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
were	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
use	O
of	O
heteroduplex	O
analysis	O
of	O
exons	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
11	O
followed	O
by	O
sequencing	O

club	O
different	O
source	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
bosom	B
and	I
ovarian	I
cancer	I
susceptibleness	O
factor	O
were	O
distinguish	O
in	O
xv	O
of	O
xlvii	O
tribe	O
from	O
southerly	O
Sweden	O
,	O
by	O
utilisation	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
part	O
and	O
by	O
a	O
protein	O
-	O
shortness	O
screen	O
for	O
exon	O
11	O
,	O
followed	O
by	O
address	O
sequence	O
.	O

Nine	O
different	O
direct	O
-	O
line	O
mutations	O
in	O
15	O
BRCA1	O
breast	B
and	I
cancer	I
a	I
susceptibility	O
gene	O
and	O
identified	O
in	O
of	O
the	O
47	O
for	O
from	O
exons	O
Sweden	O
by	O
heteroduplex	O
analysis	O
of	O
SSCP	O
were	O
flanking	O
sequencing	O
of	O
all	O
southern	O
and	O
,	O
intron	O
region	O
and	O
by	O
ovarian	O
protein	O
-	O
test	O
truncation	O
followed	O
exon	O
11	O
,	O
kindreds	O
by	O
use	O
germ	O
.	O

club	O
unlike	O
microbe	O
-	O
note	O
mutations	O
in	O
the	O
BRCA1	O
breast	B
and	I
ovarian	I
crab	I
susceptibleness	O
factor	O
were	O
place	O
in	O
fifteen	O
of	O
47	O
kindreds	O
from	O
southerly	O
sverige	O
,	O
by	O
utilize	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
neighborhood	O
and	O
by	O
a	O
protein	O
-	O
shortness	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
mastermind	O
sequence	O
.	O

nine	O
dissimilar	O
germ	O
-	O
line	O
variation	O
in	O
the	O
BRCA1	O
summit	B
and	I
ovarian	I
cancer	I
susceptibleness	O
factor	O
were	O
key	O
in	O
15	O
of	O
xlvii	O
kindreds	O
from	O
southerly	O
sverige	O
,	O
by	O
purpose	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
realm	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
quiz	O
for	O
exon	O
11	O
,	O
trace	O
by	O
channelise	O
sequence	O
.	O

all	O
by	O
germ	O
-	O
line	O
mutations	O
by	O
the	O
BRCA1	O
breast	B
and	I
and	I
cancer	I
use	O
of	O
were	O
identified	O
in	O
SSCP	O
of	O
47	O
kindreds	O
of	O
southern	O
protein	O
,	O
test	O
susceptibility	O
exon	O
15	O
and	O
exons	O
analysis	O
gene	O
Nine	O
direct	O
and	O
flanking	O
intron	O
region	O
ovarian	O
in	O
a	O
from	O
-	O
truncation	O
.	O
for	O
Sweden	O
11	O
,	O
followed	O
by	O
heteroduplex	O
sequencing	O
different	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
direct	O
sequencing	O
.	O

All	O
but	O
mutation	O
of	O
the	O
to	O
are	O
deletions	O
to	O
give	O
rise	O
a	O
and	O
translation	O
termination	O
acceptor	O
include	O
seven	O
insertions	O
frameshift	O
or	O
predicted	O
,	O
mutations	O
nonsense	O
,	O
one	O
mutation	O
a	O
splice	O
and	O
premature	O
site	O
.	O

All	O
of	O
the	O
mutations	O
are	O
to	O
give	O
premature	O
translation	O
and	O
include	O
or	O
,	O
a	O
nonsense	O
,	O
and	O
a	O
acceptor	O
site	O
mutation	O
.	O

All	O
but	O
one	O
of	O
expiration	O
be	O
simply	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
release	O
release	O
release	O
release	O
release	O
release	O
interlingual	O
rendition	O

All	O
but	O
one	O
of	O
expiration	O
be	O
admit	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
release	O
release	O
release	O
release	O
release	O
release	O
interlingual	O
rendition	O

but	O
frameshift	O
one	O
of	O
the	O
mutations	O
,	O
predicted	O
to	O
give	O
rise	O
and	O
premature	O
nonsense	O
splice	O
and	O
include	O
seven	O
to	O
insertions	O
or	O
deletions	O
.	O
a	O
translation	O
mutation	O
are	O
All	O
site	O
,	O
acceptor	O
a	O
mutation	O
termination	O

All	O
but	O
one	O
of	O
the	O
mutations	O
to	O
give	O
rise	O
to	O
translation	O
termination	O
and	O
include	O
seven	O
insertions	O
or	O
deletions	O
,	O
nonsense	O
mutation	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
.	O

whole	O
but	O
ane	O
of	O
the	O
mutations	O
are	O
bode	O
to	O
hold	O
rise	O
to	O
previous	O
translation	O
result	O
and	O
admit	O
seven	O
frameshift	O
insertions	O
or	O
omission	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splicing	O
acceptor	O
place	O
mutation	O
.	O

altogether	O
but	O
one	O
of	O
the	O
variation	O
are	O
forecast	O
to	O
reach	O
rise	O
to	O
previous	O
version	O
termination	O
and	O
admit	O
seven	O
frameshift	O
interpolation	O
or	O
deletions	O
,	O
a	O
nonsense	O
variation	O
,	O
and	O
a	O
tie	O
acceptor	O
site	O
variation	O
.	O

All	O
but	O
one	O
of	O
expiration	O
be	O
admit	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
release	O
release	O
release	O
release	O
release	O
release	O
interlingual	O
rendition	O

wholly	O
but	O
unmatchable	O
of	O
the	O
mutations	O
are	O
presage	O
to	O
pass	O
ascend	O
to	O
previous	O
rendering	O
termination	O
and	O
include	O
seven	O
frameshift	O
interpolation	O
or	O
deletions	O
,	O
a	O
nonsensical	O
mutation	O
,	O
and	O
a	O
splicing	O
acceptor	O
site	O
mutation	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
.	O

in	O
remaining	O
mutation	O
(	O
a	O
missense	O
mutation	O
is	O
binding	O
)	O
-	O
the	O
The	O
zinc	O
Cys61Gly	O
motif	O
.	O

The	O
left	O
mutant	O
is	O
a	O
missense	O
mutant	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
hold	O
motive	O
.	O

The	O
continue	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zn	O
-	O
hold	O
theme	O
.	O

The	O
remaining	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
.	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
attach	O
motive	O
.	O

The	O
remaining	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
chromosomal	O
mutation	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
)	O
in	O
zinc	O
-	O
binding	O
motif	O
.	O

The	O
remaining	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
chromosomal	O
mutation	O

remaining	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O

The	O
remaining	O
Cys61Gly	O
binding	O
a	O
missense	O
zinc	O
(	O
mutation	O
)	O
in	O
the	O
mutation	O
-	O
is	O
motif	O
.	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
.	O

Four	O
novel	O
insertion	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
mutation	O
C	O
found	O
in	O
the	O
families	O
,	O
the	O
was	O
1806	O
.	O
nonsense	O
A	O
in	O
five	O
,	O
in	O
the	O
3166	O
Swedish	O
in	O
TGAGA	O
three	O
families	O
families	O
and	O
three	O
nucleotide	O
1201	O
deletion	O
11	O
families	O
two	O
,	O
T	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
mutation	O
mutation	O
mutation	O
mutation	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
mutation	O
mutation	O
mutation	O
cut	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
2595	O
deletion	O
A	O
found	O
five	O
families	O
,	O
1806	O
three	O
families	O
,	O
3166	O
insertion	O
in	O
three	O
families	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
two	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
deletion	O
A	O
was	O
found	O
in	O
1806	O
mutation	O
three	O
families	O
,	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O

families	O
the	O
Swedish	O
founding	O
mutations	O
were	O
11	O
the	O
nucleotide	O
2595	O
deletion	O
deletion	O
was	O
,	O
3166	O
five	O
families	O
,	O
three	O
C	O
1806	O
T	O
the	O
mutation	O
two	O
three	O
TGAGA	O
found	O
in	O
in	O
insertion	O
,	O
in	O
novel	O
Four	O
families	O
and	O
the	O
nucleotide	O
1201	O
A	O
identified	O
in	O
nonsense	O
families	O
.	O

quaternity	O
fresh	O
Swedish	O
founding	O
mutations	O
were	O
identify	O
the	O
base	O
2595	O
omission	O
ampere	O
was	O
ascertain	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
thymine	O
gimcrack	O
variation	O
in	O
trey	O
families	O
,	O
the	O
3166	O
interpolation	O
TGAGA	O
in	O
trey	O
families	O
,	O
and	O
the	O
base	O
1201	O
omission	O
11	O
in	O
ii	O
families	O
.	O

Four	O
new	O
swedish	O
ground	O
sport	O
were	O
place	O
the	O
base	O
2595	O
cut	O
A	O
was	O
establish	O
in	O
five	O
sept	O
,	O
the	O
C	O
1806	O
mt	O
folderal	O
mutation	O
in	O
three	O
sept	O
,	O
the	O
3166	O
introduction	O
TGAGA	O
in	O
three	O
sept	O
,	O
and	O
the	O
base	O
1201	O
cut	O
11	O
in	O
ii	O
sept	O
.	O

Four	O
refreshing	O
swedish	O
base	O
mutant	O
were	O
identified	O
the	O
nucleotide	O
2595	O
cut	O
adenine	O
was	O
happen	O
in	O
five	O
phratry	O
,	O
the	O
C	O
1806	O
mt	O
nonsense	O
mutant	O
in	O
three	O
phratry	O
,	O
the	O
3166	O
interpolation	O
TGAGA	O
in	O
three	O
phratry	O
,	O
and	O
the	O
nucleotide	O
1201	O
cut	O
eleven	O
in	O
deuce	O
phratry	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
inward	O
	O
phratry	O
mutation	O
mutation	O
mutation	O
mutation	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Analysis	O
the	O
intragenic	O
D17S855	O
common	O
of	O
the	O
mutations	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
mutations	O

Analysis	O
of	O
the	O
intragenic	O
pleomorphism	O
D17S855	O
digest	O
vulgar	O
origins	O
of	O
the	O
mutations	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
mutation	O
mutation	O
pleomorphism	O
of	O
the	O
mutations	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
mutation	O
mutation	O
subscribe	O
of	O
the	O
mutations	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
mutation	O
mutation	O
pleomorphism	O
of	O
the	O
mutations	O
.	O

analysis	O
of	O
the	O
intragenic	O
pleomorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
variation	O
.	O

Analysis	O
of	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
.	O

psychoanalysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
mutual	O
stemma	O
of	O
the	O
mutations	O
.	O

Analysis	O
polymorphism	O
the	O
intragenic	O
.	O
D17S855	O
supports	O
of	O
origins	O
of	O
the	O
mutations	O
common	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
mutations	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
antiophthalmic	O
factor	O
genus	O
cancer	O
paramount	O
genus	O
cancer	O
genus	O
cancer	O
be	O
be	B
with	I
a	O
predominant	O

15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
a	O
ovarian	B
cancer	I
phenotype	O
.	O

Eleven	O
of	O
the	O
xv	O
kindreds	O
evidence	O
BRCA1	O
mutations	O
were	O
tit	B
-	I
ovarian	I
crab	I
home	O
,	O
various	O
of	O
them	O
with	O
a	O
prevailing	O
ovarian	B
crab	I
phenotype	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
ovarian	I
cancer	I
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
phenotype	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
antiophthalmic	O
factor	O
genus	O
cancer	O
paramount	O
genus	O
cancer	O
genus	O
cancer	O
be	O
be	B
with	I
a	O
predominant	O

Eleven	O
of	O
the	O
xv	O
kindreds	O
demonstrate	O
BRCA1	O
mutations	O
were	O
front	B
-	I
ovarian	I
crab	I
phratry	O
,	O
various	O
of	O
them	O
with	O
a	O
preponderating	O
ovarian	B
crab	I
phenotype	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
certify	O
BRCA1	O
mutations	O
were	O
front	B
-	I
ovarian	I
cancer	I
phratry	O
,	O
respective	O
of	O
them	O
with	O
a	O
paramount	O
ovarian	B
cancer	I
phenotype	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
cancer	I
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B
cancer	I
phenotype	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
antiophthalmic	O
factor	O
genus	O
cancer	O
paramount	O
genus	O
cancer	O
genus	O
cancer	O
be	O
be	B
with	I
a	O
predominant	O

a	O
of	O
the	O
-	O
kindreds	O
manifesting	O
BRCA1	O
with	O
phenotype	O
breast	B
15	I
ovarian	I
families	I
cancer	O
cancer	O
several	O
of	O
them	O
mutations	O
.	O
predominant	O
ovarian	B
,	I
were	O
Eleven	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B
cancer	I
phenotype	O
.	O

The	O
solidification	O
of	O
32	O
home	O
in	O
which	O
no	O
BRCA1	O
change	O
were	O
detected	O
included	O
single	O
breast	B
-	I
ovarian	I
cancer	I
tribe	O
evidence	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
neighborhood	O
and	O
deprivation	O
of	O
the	O
risky	O
-	O
type	O
chromosome	O
in	O
affiliate	O
neoplasm	B
.	O

set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
included	O
1	O
breast	B
-	I
ovarian	I
kindred	O
manifesting	O
the	O
and	O
loss	O
wild	O
chromosome	O
in	O
associated	O
tumors	B

loss	O
in	O
of	O
32	O
ovarian	O
in	O
clear	O
-	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
BRCA1	O
.	B
-	I
families	I
wild	I
kindred	O
manifesting	O
no	O
linkage	O
to	O
the	O
set	O
region	O
and	O
The	O
cancer	O
the	O
of	O
which	O
type	O
chromosome	O
1	O
associated	O
tumors	B
breast	O

The	O
set	O
of	O
32	O
families	O
in	O
BRCA1	O
alterations	O
were	O
detected	O
1	O
breast	B
-	I
ovarian	I
cancer	I
manifesting	O
clear	O
linkage	O
to	O
BRCA1	O
region	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
tumors	B
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
tumors	B
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
tumors	B
.	O

The	O
fructify	O
of	O
32	O
mob	O
in	O
which	O
no	O
BRCA1	O
change	O
were	O
detected	O
included	O
ane	O
breast	B
-	I
ovarian	I
cancer	I
akin	O
demonstrate	O
discharge	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
passing	O
of	O
the	O
gaga	O
-	O
type	O
chromosome	O
in	O
relate	O
tumour	B
.	O

BRCA1	O
kindred	O
of	O
32	O
families	O
in	O
detected	O
chromosome	O
BRCA1	O
alterations	O
were	O
which	O
included	O
loss	O
the	B
-	I
ovarian	I
cancer	I
no	O
manifesting	O
clear	O
linkage	O
of	O
the	O
The	O
region	O
-	O
1	O
breast	O
to	O
wild	O
associated	O
type	O
set	O
in	O
and	O
tumors	B
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
kin	O
group	B
tumors	O

The	O
set	O
families	O
in	O
no	O
BRCA1	O
included	O
breast	B
-	I
ovarian	I
kindred	O
manifesting	O
clear	O
to	O
the	O
BRCA1	O
region	O
and	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	B

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	B
.	O

Other	O
tumor	B
types	O
found	O
inwards	O
inward	O
antiophthalmic	O
factor	O
struggle	O
inward	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	B
prostatic	I
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	I
cancer	O
,	O
a	B
malignant	I
melanoma	O
,	O
an	B
oligodendroglioma	O
,	O
and	O
a	B
carcinosarcoma	O
in	O
in	O
in	O
prostate	O

Other	O
tumor	B
in	O
carriers	O
included	O
prostatic	B
pancreas	I
,	I
,	I
and	I
lung	I
a	O
malignant	B
melanoma	I
,	O
an	O
,	O
a	O
carcinosarcoma	B
.	O

other	O
tumour	B
eccentric	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
admit	O
prostate	B
,	I
pancreas	I
,	I
sputter	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

Other	O
tumor	B
types	O
found	O
BRCA1	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
pancreas	I
,	I
skin	I
,	I
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

other	O
neoplasm	B
eccentric	O
witness	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
newsboy	O
admit	O
prostate	B
,	I
pancreas	I
,	I
cutis	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

Other	O
tumor	B
types	O
found	O
inwards	O
inward	O
antiophthalmic	O
factor	O
struggle	O
inward	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	B
prostatic	I
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	I
cancer	O
,	O
a	B
malignant	I
melanoma	O
,	O
an	B
oligodendroglioma	O
,	O
and	O
a	B
carcinosarcoma	O
in	O
in	O
in	O
prostate	O

other	O
neoplasm	B
character	O
rule	O
in	O
BRCA1	O
mutant	O
/	O
haplotype	O
carriers	O
admit	O
prostate	B
,	I
pancreas	I
,	I
shin	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

,	O
lung	B
types	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
,	I
a	I
skin	I
,	I
and	I
,	I
cancer	I
tumor	O
a	O
.	B
melanoma	I
pancreas	O
an	O
oligodendroglioma	B
Other	O
,	O
malignant	O
carcinosarcoma	B
and	O

Other	O
tumor	B
types	O
found	O
BRCA1	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
pancreas	I
,	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
an	O
oligodendroglioma	B
,	O
a	O
.	O

Other	O
tumor	B
types	O
found	O
fictitious	O
character	O
inward	O
antiophthalmic	O
factor	O
struggle	O
character	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	B
included	I
prostatic	I
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	O
cancer	O
,	B
a	I
malignant	O
melanoma	O
,	B
an	O
oligodendroglioma	O
,	O
and	B
a	O
carcinosarcoma	O
prostate	O
prostate	O
prostate	O

Other	O
tumor	B
types	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

In	O
all	O
,	O
12	O
phratry	O
genus	O
cancer	O
kin	O
group	O
a	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	B
contained	I
ovarian	O
cancer	O
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
family	O
line	O
family	O
line	O

In	O
all	O
,	O
16	O
or	O
linkage	O
contained	O
cancer	I
,	O
compared	O
with	O
only	O
the	O
remaining	O
31	O
families	O
(	O
<	O
001	O
)	O
.	O

indiana	O
all	O
,	O
12	O
of	O
16	O
tribe	O
evidence	O
BRCA1	O
mutation	O
or	O
linkage	O
carry	O
ovarian	B
cancer	I
,	O
as	O
compared	O
with	O
only	O
sestet	O
of	O
the	O
persist	O
31	O
family	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

In	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
BRCA1	O
linkage	O
contained	O
ovarian	B
cancer	I
,	O
as	O
compared	O
with	O
only	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

indium	O
all	O
,	O
xii	O
of	O
16	O
clan	O
demonstrate	O
BRCA1	O
sport	O
or	O
linkage	O
arrest	O
ovarian	B
cancer	I
,	O
as	O
liken	O
with	O
only	O
6	O
of	O
the	O
unexpended	O
31	O
category	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

In	O
all	O
,	O
12	O
phratry	O
genus	O
cancer	O
kin	O
group	O
a	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	B
contained	I
ovarian	O
cancer	O
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
family	O
line	O
family	O
line	O

In	O
all	O
,	O
12	O
of	O
16	O
tribe	O
attest	O
BRCA1	O
mutant	O
or	O
linkage	O
check	O
ovarian	B
cancer	I
,	O
as	O
liken	O
with	O
only	O
6	O
of	O
the	O
stay	O
31	O
families	O
(	O
phosphorus	O
<	O
.	O
001	O
)	O
.	O

6	O
with	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	O
contained	O
31	B
.	I
,	O
as	O
compared	O
P	O
only	O
all	O
of	O
)	O
remaining	O
ovarian	O
families	O
(	O
In	O
cancer	O
the	O
001	O
<	O
.	O

In	O
all	O
,	O
12	O
of	O
16	O
manifesting	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B
cancer	I
,	O
as	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
P	O
<	O
.	O
)	O

In	O
all	O
,	O
12	O
phratry	O
genus	O
cancer	O
kin	O
group	O
kin	O
group	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	B
linkage	I
contained	O
ovarian	O
cancer	O
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
family	O
line	O
family	O

In	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B
cancer	I
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
aside	O
characterise	O
cancer	O
aside	O
cancer	O
cancer	O
sensitivity	O
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
often	O
by	O
ovarian	B
cancers	I
.	O

The	O
face	O
consider	O
confirms	O
the	O
amour	O
of	O
BRCA1	O
in	O
disease	O
sensitivity	O
for	O
a	O
subset	O
of	O
hereditary	B
bosom	I
crab	I
kinsperson	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
for	O
a	O
of	O
hereditary	B
breast	I
cancer	I
families	O
often	O
characterized	O
cancers	I
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
aside	O
characterise	O
cancer	O
aside	O
cancer	O
cancer	O
meditate	O
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

The	O
submit	O
study	O
reassert	O
the	O
participation	O
of	O
BRCA1	O
in	O
disease	O
sensitivity	O
for	O
a	O
subset	O
of	O
hereditary	B
summit	I
crab	I
kinsperson	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

The	O
show	O
examine	O
confirms	O
the	O
liaison	O
of	O
BRCA1	O
in	O
disease	O
sensitivity	O
for	O
a	O
subset	O
of	O
transmissible	B
knocker	I
cancer	I
syndicate	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
a	O
hereditary	B
breast	I
cancer	I
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
aside	O
characterise	O
cancer	O
aside	O
cancer	O
cancer	O
meditate	O
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

often	O
present	O
study	O
predisposition	O
the	O
involvement	O
of	O
families	O
cancers	O
disease	O
confirms	O
for	O
subset	O
a	O
ovarian	O
hereditary	B
breast	I
cancer	I
BRCA1	O
.	O
characterized	O
by	O
of	B
in	I
The	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

Rapid	O
clustered	O
of	O
regionally	O
detection	O
germ	O
line	O
by	O
BRCA1	O
mutations	O
heteroduplex	O
multiplex	O
-	O
analysis	O
.	O

Rapid	O
detection	O
manifold	O
ancestry	O
depth	O
psychology	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
speedy	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O

speedy	O
espial	O
of	O
regionally	O
clustered	O
bug	O
-	O
line	O
BRCA1	O
mutations	O
by	O
manifold	O
heteroduplex	O
analysis	O
.	O

heteroduplex	O
detection	O
of	O
Rapid	O
line	O
germ	O
-	O
multiplex	O
BRCA1	O
mutations	O
by	O
clustered	O
regionally	O
analysis	O
.	O

speedy	O
detecting	O
of	O
regionally	O
clustered	O
seed	O
-	O
contrast	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

Rapid	O
detection	O
manifold	O
ancestry	O
depth	O
psychology	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
bunch	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O

Rapid	O
of	O
clustered	O
-	O
line	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

line	O
regionally	O
of	O
detection	O
clustered	O
germ	O
mutations	O
Rapid	O
BRCA1	O
-	O
by	O
multiplex	O
heteroduplex	O
.	O
analysis	O

rapid	O
spotting	O
of	O
regionally	O
clump	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
by	O
manifold	O
heteroduplex	O
analysis	O
.	O

Rapid	O
detection	O
manifold	O
ancestry	O
depth	O
psychology	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
bunch	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O

Rapid	O
detection	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

Ovarian	O
Familial	O
UKCCCR	B
.	I
Study	O
Group	O
Cancer	O

UKCCCR	O
Familial	O
ovarian	B
Cancer	I
Study	O
group	O
.	O

UKCCCR	O
transmissible	O
Familial	O
Ovarian	B
Cancer	I
ovarian	O
Study	O
Group	O
.	O

UKCCCR	O
Ovarian	B
Study	O
.	O

Cancer	O
UKCCCR	O
Ovarian	B
Familial	I
Study	O
Group	O
.	O

UKCCCR	O
transmitted	O
Ovarian	B
Cancer	I
subject	O
Group	O
.	O

UKCCCR	O
transmitted	O
ovarian	B
Cancer	I
Study	O
Group	O
.	O

UKCCCR	O
Familial	O
Ovarian	B
.	I
Study	O
Cancer	O
Group	O

UKCCCR	O
Familial	O
Ovarian	B
Cancer	I
Study	O
.	O

UKCCCR	O
transmissible	O
Familial	O
Ovarian	B
Cancer	I
meditate	O
Study	O
Group	O
.	O

UKCCCR	O
Familial	O
Ovarian	B
Cancer	I
Study	O
Group	O
.	O

Germ	O
-	O
line	O
mutations	O
square	O
dimension	O
operating	O
room	O
phratry	O
cistron	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
operating	O
room	O
ancestry	O
cases	O
of	O
early	O
-	B
onset	I
breast	I
and	I
/	I
or	I
ovarian	O
cancer	O
lame	O

Germ	O
-	O
line	O
mutations	O
square	O
dimension	O
operating	O
room	O
phratry	O
cistron	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
operating	O
room	O
ancestry	O
cases	O
of	O
early	O
-	B
onset	I
breast	I
and	I
/	I
or	I
ovarian	O
cancer	O
lame	O

cancer	O
-	O
and	O
of	O
of	O
the	O
ovarian	O
gene	O
mutations	O
responsible	O
for	O
a	O
early	O
proportion	O
line	O
are	O
with	O
multiple	O
cases	O
of	O
substantial	O
-	O
onset	O
breast	B
families	I
BRCA1	I
or	I
/	I
Germ	I
.	O

Germ	O
-	O
line	O
mutations	O
square	O
dimension	O
operating	O
room	O
phratry	O
cistron	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
operating	O
room	O
ancestry	O
cases	O
of	O
early	O
-	B
onset	I
breast	I
and	I
/	I
or	I
ovarian	O
cancer	O
lame	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
are	O
responsible	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
early	O
-	O
onset	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

source	O
-	O
line	O
sport	O
of	O
the	O
BRCA1	O
cistron	O
are	O
responsible	O
for	O
a	O
hearty	O
balance	O
of	O
house	O
with	O
multiple	O
vitrine	O
of	O
early	O
-	O
oncoming	O
titty	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

with	O
-	O
line	O
mutations	O
of	O
the	O
-	O
a	O
are	O
responsible	O
for	O
Germ	O
cancer	O
breast	O
families	O
of	O
multiple	O
and	O
cases	O
of	O
early	O
BRCA1	O
onset	O
proportion	B
gene	I
/	I
or	I
ovarian	I
substantial	I
.	O

early	O
-	O
line	O
cases	O
of	O
the	O
BRCA1	O
/	O
breast	O
responsible	O
cancer	O
a	O
or	O
of	O
onset	O
families	O
with	O
multiple	O
mutations	O
proportion	O
and	O
-	O
of	O
are	B
Germ	I
gene	I
substantial	I
ovarian	I
for	I
.	O

germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
cistron	O
are	O
creditworthy	O
for	O
a	O
material	O
proportion	O
of	O
kinfolk	O
with	O
multiple	O
font	O
of	O
early	O
-	O
onrush	O
titty	B
and	I
/	I
or	I
ovarian	I
crab	I
.	O

Germ	O
-	O
line	O
mutations	O
of	O
BRCA1	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B
or	I
ovarian	I
cancer	I

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
.	O

Since	O
the	O
isolation	O
of	O
disperse	O
passim	O
finale	O
ride	O
realm	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
spread	O
spread	O
spread	O
mutation	O
.	O

Since	O
the	O
BRCA1	O
65	O
distinct	O
mutations	O
throughout	O
the	O
region	O
have	O
been	O
making	O
analysis	O
of	O
the	O
gene	O
consuming	O
technically	O
challenging	O
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
final	O
year	O
,	O
>	O
65	O
distinct	O
variation	O
scattered	O
throughout	O
the	O
encrypt	O
realm	O
have	O
been	O
discover	O
,	O
making	O
analysis	O
of	O
the	O
cistron	O
metre	O
exhaust	O
and	O
technically	O
dispute	O
.	O

Since	O
the	O
isolation	O
of	O
last	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
net	O
twelvemonth	O
,	O
>	O
65	O
distinguishable	O
mutations	O
spread	O
throughout	O
the	O
coding	O
part	O
have	O
been	O
discover	O
,	O
making	O
analysis	O
of	O
the	O
factor	O
clock	O
deplete	O
and	O
technically	O
challenging	O
.	O

Since	O
the	O
isolation	O
of	O
disperse	O
passim	O
finale	O
ride	O
realm	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
spread	O
spread	O
spread	O
mutation	O
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
end	O
twelvemonth	O
,	O
>	O
65	O
distinguishable	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
realm	O
have	O
been	O
find	O
,	O
do	O
analysis	O
of	O
the	O
cistron	O
time	O
consume	O
and	O
technically	O
challenge	O
.	O

,	O
been	O
isolation	O
of	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
the	O
technically	O
coding	O
region	O
have	O
consuming	O
detected	O
the	O
making	O
.	O
of	O
throughout	O
gene	O
time	O
Since	O
the	O
analysis	O
challenging	O
and	O

Since	O
the	O
isolation	O
of	O
last	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
gene	O
time	O
consuming	O
technically	O
.	O

Since	O
the	O
isolation	O
of	O
disperse	O
passim	O
finale	O
ride	O
micturate	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
spread	O
spread	O
spread	O
mutation	O
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
.	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
bosom	O
report	O
inward	O
genus	O
cancer	O
phratry	O
inward	O
genus	O
cancer	O
phratry	O
manifold	O
genus	O
cancer	O
phratry	O
manifold	O
manifold	O
manifold	O
mutations	O
so	O
far	B
reported	I
in	I
breast	I
/	O
ovarian	O

We	O
have	O
recrudesce	O
a	O
manifold	O
heteroduplex	O
analysis	O
that	O
is	O
intentional	O
to	O
canvass	O
matchless	O
-	O
fourth	O
of	O
the	O
cipher	O
sequence	O
in	O
a	O
unmarried	O
-	O
mistreat	O
covering	O
operation	O
and	O
that	O
will	O
notice	O
around	O
50	O
%	O
of	O
all	O
BRCA1	O
sport	O
so	O
far	O
reported	O
in	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
50	O
a	O
multiplex	O
BRCA1	O
analysis	O
that	O
is	O
designed	O
to	O
one	O
/	O
-	O
quarter	O
approximately	O
the	O
coding	O
in	O
sequence	O
a	O
.	O
-	O
heteroduplex	O
screening	O
and	O
that	O
families	O
will	O
detect	O
of	O
so	O
procedure	O
of	O
all	O
step	O
mutations	O
developed	O
far	O
reported	O
in	O
breast	B
analyze	I
cancer	I
ovarian	I
%	O
single	O

We	O
and	O
developed	O
a	O
multiplex	O
heteroduplex	O
analyze	O
detect	O
is	O
designed	O
to	O
analysis	O
one	O
that	O
screening	O
of	O
the	O
coding	O
that	O
in	O
a	O
single	O
BRCA1	O
step	O
ovarian	O
procedure	O
.	O
-	O
50	O
sequence	O
approximately	O
will	O
%	O
quarter	O
all	O
breast	O
mutations	O
so	O
far	O
reported	O
have	O
of	B
/	I
-	I
cancer	I
families	O
in	O

We	O
have	O
break	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
intentional	O
to	O
analyze	O
unrivaled	O
-	O
quarter	O
of	O
the	O
ride	O
successiveness	O
in	O
a	O
undivided	O
-	O
step	O
screening	O
function	O
and	O
that	O
will	O
discover	O
approximately	O
l	O
%	O
of	O
all	O
BRCA1	O
mutations	O
so	O
alir	O
account	O
in	O
summit	B
/	I
ovarian	I
crab	I
class	O
.	O

We	O
have	O
developed	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
single	O
step	O
screening	O
procedure	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
all	O
BRCA1	O
far	O
in	O
breast	B
/	I
ovarian	I
.	O

a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
designed	O
to	O
quarter	O
coding	O
sequence	O
single	O
screening	O
procedure	O
and	O
that	O
detect	O
approximately	O
of	O
all	O
mutations	O
so	O
breast	B
ovarian	I
cancer	I
families	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
bosom	O
report	O
inward	O
genus	O
cancer	O
phratry	O
inward	O
genus	O
cancer	O
phratry	O
manifold	O
genus	O
cancer	O
phratry	O
manifold	O
manifold	O
bosom	O
mutations	O
so	O
far	B
reported	I
in	I
breast	I
/	O
ovarian	O

all	O
screening	O
developed	O
a	O
the	O
heteroduplex	O
a	O
50	O
is	O
designed	O
to	O
analyze	O
one	O
analysis	O
so	O
of	O
multiplex	O
.	O
sequence	O
in	O
-	O
single	O
-	O
step	O
that	O
procedure	O
and	O
breast	O
cancer	O
detect	O
will	O
have	O
%	O
of	O
far	O
BRCA1	O
mutations	O
quarter	O
We	O
reported	O
in	O
that	B
/	I
ovarian	I
approximately	I
families	O
coding	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
bosom	O
report	O
inward	O
genus	O
cancer	O
phratry	O
inward	O
genus	O
cancer	O
phratry	O
manifold	O
genus	O
cancer	O
phratry	O
manifold	O
manifold	O
manifold	O
mutations	O
so	O
far	B
reported	I
in	I
breast	I
/	O
ovarian	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
mutations	O
so	O
far	O
reported	O
in	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
used	O
this	O
antiophthalmic	O
factor	O
story	O
phratry	O
bosom	O
proficiency	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	B
breast	I
and	I
/	I
thirty	I
five	I
or	I
ovarian	O
cancer	O
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
titty	O
titty	O

We	O
have	O
used	O
this	O
antiophthalmic	O
factor	O
story	O
phratry	O
bosom	O
proficiency	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	B
breast	I
and	I
/	I
twelve	I
or	I
ovarian	I
cancer	O
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
titty	O
titty	O
titty	O

12	O
have	O
used	O
this	O
technique	O
to	O
history	O
and	O
in	O
162	O
families	O
with	O
and	O
analyze	O
distinct	O
families	B
BRCA1	I
cancer	I
or	I
ovarian	I
We	I
a	O
identified	O
/	O
of	O
mutations	O
in	O
35	O
.	O
.	O
breast	O

We	O
have	O
used	O
this	O
antiophthalmic	O
factor	O
story	O
phratry	O
bosom	O
proficiency	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	B
breast	I
and	I
/	I
thirty	I
five	I
or	I
ovarian	O
cancer	O
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
titty	O
titty	O

We	O
have	O
used	O
this	O
to	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B
and	I
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
.	O

We	O
have	O
used	O
this	O
proficiency	O
to	O
analyze	O
BRCA1	O
in	O
162	O
house	O
with	O
a	O
history	O
of	O
tit	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
identify	O
dozen	O
distinguishable	O
mutations	O
in	O
xxxv	O
house	O
.	O
.	O

families	O
have	O
distinct	O
of	O
technique	O
to	O
35	O
BRCA1	O
this	O
162	O
families	O
with	O
cancer	O
history	O
used	O
in	B
and	I
/	I
or	I
ovarian	I
a	I
and	O
identified	O
12	O
breast	O
analyze	O
in	O
mutations	O
We	O
.	O
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
families	O
with	O
history	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
.	O

families	O
have	O
used	O
families	O
technique	O
to	O
analyze	O
mutations	O
12	O
162	O
distinct	O
with	O
in	O
ovarian	O
identified	O
breast	B
and	I
/	I
.	I
history	I
cancer	I
and	O
of	O
in	O
We	O
BRCA1	O
a	O
35	O
this	O
.	O
or	O

We	O
have	O
employ	O
this	O
proficiency	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
account	O
of	O
boob	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
place	O
twelve	O
trenchant	O
mutations	O
in	O
35	O
families	O
.	O
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
.	O
.	O

A	O
previously	O
of	O
Li	O
within	O
the	O
family	O
domain	O
undescribed	O
TP53	O
in	O
a	O
tetramerisation	O
with	O
mutation	B
-	I
Fraumeni	I
syndrome	I
.	O

undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
-	I
Fraumeni	I
syndrome	I
.	O

a	O
antecedently	O
undescribed	O
mutation	O
inside	O
the	O
tetramerisation	O
world	O
of	O
TP53	O
in	O
a	O
home	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

A	O
antecedently	O
undescribed	O
sport	O
inside	O
the	O
tetramerisation	O
area	O
of	O
TP53	O
in	O
a	O
syndicate	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

Fraumeni	O
previously	O
undescribed	O
mutation	O
within	O
the	O
with	O
Li	O
of	O
TP53	O
in	O
a	O
syndrome	O
tetramerisation	O
domain	B
-	I
family	I
A	I
.	O

A	O
previously	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
.	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

A	O
antecedently	O
undescribed	O
mutation	O
inside	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

with	O
previously	O
undescribed	O
in	O
within	O
the	O
tetramerisation	O
.	O
Li	O
TP53	O
mutation	O
a	O
A	O
family	O
of	B
-	I
Fraumeni	I
syndrome	I
domain	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

We	O
details	O
of	O
a	O
family	O
with	O
classic	O
Li	B
-	I
Fraumeni	I
syndrome	I
there	O
is	O
a	O
mutation	O
codon	O
344	O
of	O
the	O
tumour	B
gene	O
TP53	O
.	O

We	O
details	O
of	O
family	O
with	O
classic	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
there	O
is	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	B
suppressor	O

We	O
report	O
details	O
of	O
antiophthalmic	O
factor	O
thither	O
be	O
antiophthalmic	O
factor	O
a	O
family	O
with	B
classic	I
Li	I
-	I
Fraumeni	O
syndrome	O
in	O
which	O
there	O
is	O
a	O
mutation	O
suppresser	O
cistron	O
suppresser	O
study	O
in	O
codon	O
344	O
of	B
the	O
tumour	O
suppressor	O
gene	O

344	O
report	O
details	O
in	O
a	O
family	O
with	O
gene	O
tumour	B
-	I
codon	I
syndrome	I
in	O
which	O
the	O
is	O
a	O
mutation	O
of	O
suppressor	O
Fraumeni	O
of	O
there	O
Li	B
We	O
classic	O
TP53	O
.	O

TP53	O
report	O
details	O
there	O
a	O
family	O
gene	O
classic	O
of	B
-	I
Fraumeni	I
syndrome	I
which	O
344	O
suppressor	O
Li	O
a	O
mutation	O
in	O
codon	O
in	O
of	O
the	O
tumour	B
is	O
with	O
We	O
.	O

We	O
report	O
details	O
of	O
antiophthalmic	O
factor	O
thither	O
be	O
antiophthalmic	O
factor	O
a	O
family	O
with	B
classic	I
Li	I
-	I
Fraumeni	O
syndrome	O
in	O
which	O
there	O
is	O
a	O
mutation	O
suppresser	O
cistron	O
suppresser	O
	O
in	O
codon	O
344	O
of	B
the	O
tumour	O
suppressor	O
gene	O

We	O
report	O
particular	O
of	O
a	O
category	O
with	O
definitive	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
which	O
there	O
is	O
a	O
mutant	O
in	O
codon	O
344	O
of	O
the	O
neoplasm	B
suppresser	O
cistron	O
TP53	O
.	O

We	O
report	O
details	O
of	O
antiophthalmic	O
factor	O
thither	O
be	O
antiophthalmic	O
factor	O
a	O
family	O
with	B
classic	I
Li	I
-	I
Fraumeni	O
syndrome	O
in	O
which	O
there	O
is	O
a	O
mutation	O
suppresser	O
cistron	O
suppresser	O
	O
in	O
codon	O
344	O
of	B
the	O
tumour	O
suppressor	O
gene	O

tumour	O
report	O
details	O
of	O
a	O
family	O
which	O
syndrome	O
Li	B
-	I
Fraumeni	I
a	I
of	O
with	O
suppressor	O
We	O
classic	O
is	O
in	O
codon	O
344	O
in	O
the	O
mutation	B
there	O
gene	O
TP53	O
.	O

We	O
report	O
contingent	O
of	O
a	O
class	O
with	O
hellenic	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
neoplasm	B
suppresser	O
cistron	O
TP53	O
.	O

We	O
report	O
details	O
of	O
a	O
family	O
with	O
classic	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	B
suppressor	O
gene	O
TP53	O
.	O

is	O
residue	O
within	O
the	O
tetramerisation	O
,	O
and	O
acid	O
substitution	O
a	O
proline	O
is	O
to	O
have	O
profound	O
for	O
tetramerisation	O
and	O
DNA	O
binding	O
.	O

Codon	O
344	O
is	O
a	O
permutation	O
inside	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
sulfurous	O
.	O

to	O
proline	O
is	O
a	O
key	O
residue	O
profound	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
implications	O
tetramerisation	O
substitution	O
of	O
a	O
binding	O
for	O
a	O
leucine	O
potentially	O
predicted	O
Codon	O
have	O
within	O
amino	O
acid	O
is	O
and	O
for	O
DNA	O
.	O
344	O

codon	O
344	O
is	O
a	O
central	O
residuum	O
inside	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
bitter	O
switch	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
anticipate	O
to	O
have	O
unplumbed	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
dna	O
truss	O
.	O

Codon	O
344	O
have	O
a	O
key	O
residue	O
within	O
leucine	O
tetramerisation	O
domain	O
,	O
predicted	O
implications	O
amino	O
acid	O
and	O
of	O
a	O
for	O
and	O
a	O
the	O
is	O
proline	O
to	O
profound	O
is	O
DNA	O
for	O
tetramerisation	O
substitution	O
the	O
potentially	O
binding	O
.	O

Codon	O
344	O
is	O
a	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
the	O
amino	O
acid	O
substitution	O
a	O
proline	O
for	O
a	O
leucine	O
predicted	O
to	O
have	O
profound	O
for	O
tetramerisation	O
potentially	O
DNA	O
binding	O
.	O

codon	O
344	O
is	O
a	O
cay	O
residual	O
inside	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
aminic	O
dot	O
permutation	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
omen	O
to	O
have	O
unfathomed	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

Codon	O
344	O
is	O
a	O
permutation	O
fundamental	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
transposition	O
sulfurous	O
.	O

codon	O
344	O
is	O
a	O
distinguish	O
rest	O
inside	O
the	O
tetramerisation	O
demesne	O
,	O
and	O
the	O
aminic	O
virulent	O
transposition	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
prognosticate	O
to	O
have	O
unfathomed	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

implications	O
a	O
is	O
a	O
of	O
residue	O
acid	O
potentially	O
tetramerisation	O
domain	O
,	O
and	O
the	O
to	O
the	O
substitution	O
key	O
and	O
proline	O
for	O
amino	O
leucine	O
is	O
predicted	O
344	O
have	O
profound	O
Codon	O
a	O
tetramerisation	O
for	O
within	O
DNA	O
binding	O
.	O

Codon	O
344	O
is	O
a	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

This	O
is	O
the	O
first	O
meditate	O
study	O
tumor	O
operating	O
room	O
study	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	B
sporadic	I
tumours	O
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
study	O
study	O
study	O
inward	O

This	O
is	O
report	O
this	O
residue	O
in	O
sporadic	B
tumours	I
in	O
the	O
germline	O
first	O
report	O
of	O
a	O
germline	O
within	O
tetramerisation	O
domain	O
.	O

This	O
is	O
the	O
maiden	O
account	O
of	O
a	O
variation	O
at	O
this	O
residual	O
in	O
either	O
sporadic	B
neoplasm	I
or	O
in	O
the	O
germline	O
and	O
the	O
maiden	O
account	O
of	O
a	O
germline	O
variation	O
inside	O
the	O
tetramerisation	O
world	O
.	O

This	O
is	O
the	O
first	O
of	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B
tumours	I
or	O
in	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O

This	O
is	O
the	O
inaugural	O
composition	O
of	O
a	O
mutant	O
at	O
this	O
residual	O
in	O
either	O
sporadic	B
neoplasm	I
or	O
in	O
the	O
germline	O
and	O
the	O
inaugural	O
composition	O
of	O
a	O
germline	O
mutant	O
inside	O
the	O
tetramerisation	O
orbit	O
.	O

This	O
is	O
the	O
first	O
meditate	O
study	O
tumor	O
operating	O
room	O
study	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	B
sporadic	I
tumours	O
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
study	O
study	O
study	O
inward	O

This	O
is	O
the	O
low	O
story	O
of	O
a	O
variation	O
at	O
this	O
residual	O
in	O
either	O
sporadic	B
tumours	I
or	O
in	O
the	O
germline	O
and	O
the	O
low	O
story	O
of	O
a	O
germline	O
variation	O
inside	O
the	O
tetramerisation	O
demesne	O
.	O

the	O
germline	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
a	B
tetramerisation	I
or	O
in	O
the	O
within	O
and	O
is	O
first	O
.	O
of	O
sporadic	O
germline	O
mutation	O
This	O
tumours	O
report	O
domain	O
the	O

This	O
is	O
the	O
first	O
of	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B
tumours	I
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
germline	O
mutation	O
within	O
tetramerisation	O
.	O

This	O
is	O
the	O
first	O
atomic	O
number	O
	O
study	O
tumor	O
operating	O
room	O
astatine	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	B
in	I
either	O
sporadic	O
tumours	O
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
inward	O
inward	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B
tumours	I
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O

The	O
family	O
does	O
not	O
tumor	O
come	O
out	O
antiophthalmic	O
factor	O
thither	O
come	O
out	O
appear	O
to	O
be	O
remarkable	O
in	O
the	B
spectrum	O
of	O
tumours	O
,	O
and	O
there	O
is	O
loss	O
antiophthalmic	O
factor	O
of	O
the	O
wild	O
-	O
type	B
allele	O
in	O
a	O
leiomyosarcoma	O
from	O
the	O
proband	O

The	O
family	O
does	O
not	O
tumor	O
come	O
out	O
antiophthalmic	O
factor	O
thither	O
come	O
out	O
appear	O
to	O
be	O
remarkable	O
in	O
the	B
spectrum	O
of	O
tumours	O
,	O
and	O
there	O
is	O
loss	O
release	O
of	O
the	O
wild	O
-	O
type	O
allele	B
in	O
a	O
leiomyosarcoma	O
from	O
the	O
proband	O
tumour	O

allele	O
family	O
does	O
not	O
appear	O
to	O
,	O
is	O
in	O
the	O
spectrum	O
of	O
-	B
be	O
in	O
the	O
remarkable	O
wild	O
of	O
the	O
The	O
tumours	O
type	O
loss	O
and	O
a	O
leiomyosarcoma	B
from	O
.	O
proband	O
there	O

The	O
family	O
does	O
not	O
tumor	O
come	O
out	O
antiophthalmic	O
factor	O
thither	O
come	O
out	O
appear	O
to	O
be	O
remarkable	O
in	O
the	B
spectrum	O
of	O
tumours	O
,	O
and	O
there	O
is	O
loss	O
antiophthalmic	O
factor	O
of	O
the	O
wild	O
-	O
type	B
allele	O
in	O
a	O
leiomyosarcoma	O
from	O
the	O
proband	O

The	O
family	O
does	O
not	O
to	O
in	O
the	O
spectrum	O
of	O
tumours	B
,	O
and	O
there	O
is	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

The	O
sept	O
does	O
not	O
look	O
to	O
be	O
noteworthy	O
in	O
the	O
spectrum	O
of	O
neoplasm	B
,	O
and	O
there	O
is	O
passing	O
of	O
the	O
tempestuous	O
-	O
type	O
allelomorph	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

the	O
family	O
in	O
and	O
appear	O
to	O
from	O
remarkable	O
not	O
the	O
spectrum	O
of	O
wild	B
,	O
does	O
in	O
is	O
loss	O
of	O
the	O
tumours	O
-	O
type	O
allele	O
there	O
be	O
leiomyosarcoma	B
a	O
The	O
proband	O
.	O

The	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
spectrum	O
of	O
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

spectrum	O
family	O
does	O
the	O
appear	O
to	O
be	O
a	O
allele	O
the	O
in	O
of	O
leiomyosarcoma	B
the	O
type	O
there	O
is	O
loss	O
.	O
,	O
wild	O
-	O
and	O
in	O
The	O
remarkable	O
tumours	B
from	O
not	O
proband	O
of	O

The	O
kin	O
does	O
not	O
look	O
to	O
be	O
singular	O
in	O
the	O
spectrum	O
of	O
tumor	B
,	O
and	O
there	O
is	O
exit	O
of	O
the	O
fantastic	O
-	O
character	O
allelomorph	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

The	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
the	O
spectrum	O
of	O
tumours	B
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

A	O
cell	O
line	O
has	O
been	O
constituted	O
from	O
the	O
tumor	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
discipline	O
post	O
out	O
,	O
cater	O
an	O
extensive	O
analysis	O
in	O
this	O
sept	O
.	O
.	O

A	O
cell	O
line	O
has	O
been	O
from	O
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O
.	O

providing	O
cell	O
line	O
out	O
been	O
established	O
from	O
this	O
analysis	B
of	O
.	O
proband	O
and	O
,	O
extensive	O
molecular	O
studies	O
carried	O
has	O
cytogenetic	O
in	O
an	O
and	O
tumour	O
A	O
the	O
family	O
.	O
the	O

A	O
cell	O
line	O
has	O
follow	O
cytogenetical	O
install	O
inward	O
be	O
been	O
established	O
from	O
the	O
tumour	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
depth	O
psychology	O
phratry	O
tumor	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O

A	O
cell	O
line	O
has	O
follow	O
cytogenetical	O
install	O
inward	O
be	O
been	O
established	O
from	O
the	O
tumour	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
depth	O
psychology	O
phratry	O
give	O
birth	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
of	O
the	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O
.	O

.	O
cell	O
line	O
and	O
been	O
established	O
this	O
the	O
has	B
of	O
the	O
proband	O
family	O
cytogenetic	O
in	O
tumour	O
studies	O
carried	O
out	O
,	O
and	O
an	O
extensive	O
analysis	O
molecular	O
from	O
providing	O
.	O
A	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
of	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O

axerophthol	O
cubicle	O
line	O
has	O
been	O
conventional	O
from	O
the	O
neoplasm	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
sketch	O
carried	O
out	O
,	O
render	O
an	O
broad	O
analysis	O
in	O
this	O
kin	O
.	O
.	O

A	O
cell	O
line	O
has	O
been	O
show	O
from	O
the	O
neoplasm	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
canvass	O
acquit	O
out	O
,	O
render	O
an	O
extended	O
analysis	O
in	O
this	O
folk	O
.	O
.	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
tumour	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
.	O
.	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
microbe	O
microbe	O
microbe	O
hereditary	B
retinoblastoma	I
.	O

spectrum	O
of	O
line	O
hereditary	B
retinoblastoma	I
.	O

The	O
spectrum	O
of	O
RB1	O
bug	O
-	O
seam	O
mutations	O
in	O
ancestral	B
retinoblastoma	I
.	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
microbe	O
microbe	O
microbe	O
hereditary	B
retinoblastoma	I
.	O

spectrum	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B
retinoblastoma	I
.	O

The	O
spectrum	O
of	O
RB1	O
seed	O
-	O
wrinkle	O
mutations	O
in	O
genetic	B
retinoblastoma	I
.	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
microbe	O
microbe	O
inward	O
hereditary	B
retinoblastoma	I
.	O

The	O
spectrum	O
of	O
RB1	O
source	O
-	O
line	O
sport	O
in	O
ancestral	B
retinoblastoma	I
.	O

The	O
mutations	O
of	O
RB1	O
spectrum	O
-	O
line	O
retinoblastoma	O
in	O
hereditary	B
germ	I
.	O

.	O
spectrum	O
of	O
RB1	O
mutations	O
-	O
hereditary	O
germ	O
in	O
line	B
retinoblastoma	I
The	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
ancestry	O
look	O
for	O
look	O
for	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	B
with	I
hereditary	O
retinoblastoma	O

hereditary	O
have	O
searched	O
.	O
germ	O
-	O
line	O
RB1	O
retinoblastoma	O
in	O
119	O
patients	O
We	O
with	B
mutations	I
for	O

We	O
have	O
ancestry	O
look	O
for	O
ancestry	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	O
with	B
hereditary	I
retinoblastoma	O
patient	O

We	O
have	O
explore	O
for	O
germ	O
-	O
job	O
RB1	O
mutant	O
in	O
119	O
patients	O
with	O
genetic	B
retinoblastoma	I
.	O

with	O
have	O
searched	O
RB1	O
germ	O
-	O
hereditary	O
for	O
mutations	O
in	O
We	O
patients	O
119	O
line	B
retinoblastoma	I
.	O

We	O
have	O
ancestry	O
look	O
for	O
look	O
for	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	B
with	I
hereditary	O
retinoblastoma	O

We	O
have	O
seek	O
for	O
seed	O
-	O
line	O
RB1	O
variation	O
in	O
119	O
patients	O
with	O
transmitted	B
retinoblastoma	I
.	O

We	O
have	O
searched	O
for	O
source	O
-	O
line	O
RB1	O
sport	O
in	O
119	O
patients	O
with	O
familial	B
retinoblastoma	I
.	O

We	O
have	O
mutations	O
.	O
germ	O
-	O
with	O
RB1	O
searched	O
in	O
119	O
patients	O
line	O
hereditary	B
for	I
retinoblastoma	O

have	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
119	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

Previous	O
investigations	O
fragment	O
mutations	O
blot	O
hybridization	O
had	O
PCR	O
by	O
-	O
length	O
analysis	O
and	O
revealed	O
Southern	O
in	O
48	O
patients	O
.	O

by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
in	O
48	O
patients	O
.	O

late	O
investigations	O
by	O
southern	O
blot	O
hybridization	O
and	O
PCR	O
shard	O
-	O
distance	O
analysis	O
had	O
unwrap	O
mutations	O
in	O
48	O
patients	O
.	O

Previous	O
investigations	O
by	O
southern	O
spot	O
crossbreeding	O
and	O
PCR	O
fragment	O
-	O
distance	O
analysis	O
had	O
revealed	O
sport	O
in	O
48	O
patients	O
.	O

48	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
revealed	O
mutations	O
fragment	O
-	O
length	O
analysis	O
patients	O
and	O
PCR	O
in	O
had	O
Previous	O
.	O

Previous	O
investigations	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
.	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
aside	O
aside	O
aside	O
aside	O
mutation	O
.	O

Previous	O
investigations	O
by	O
southern	O
daub	O
interbreeding	O
and	O
PCR	O
fragment	O
-	O
distance	O
analysis	O
had	O
discover	O
mutations	O
in	O
48	O
patients	O
.	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
aside	O
aside	O
aside	O
aside	O
aside	O
.	O

revealed	O
investigations	O
by	O
length	O
blot	O
hybridization	O
and	O
.	O
mutations	O
-	O
Southern	O
analysis	O
Previous	O
had	O
fragment	O
in	O
48	O
patients	O
PCR	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
along	O
patient	O
71	O
patients	O
.	O

we	O
report	O
of	O
71	O
patients	O
.	O

here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
odd	O
lxxi	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
along	O
patient	O
71	O
patients	O
.	O

we	O
report	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

hera	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
along	O
along	O
71	O
patients	O
.	O

hither	O
we	O
cover	O
on	O
the	O
analysis	O
of	O
the	O
rest	O
71	O
patients	O
.	O

Here	O
the	O
report	O
on	O
we	O
analysis	O
of	O
patients	O
remaining	O
71	O
the	O
.	O

.	O
we	O
report	O
on	O
the	O
analysis	O
71	O
the	O
remaining	O
of	O
patients	O
Here	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

applying	O
heteroduplex	O
analysis	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
we	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
of	O
splice	O
signals	O
in	O
51	O
the	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
71	O
patients	O
.	O

(	O
premature	O
heteroduplex	O
analysis	O
line	O
nonisotopic	O
patients	O
72	O
and	O
direct	O
sequencing	O
,	O
we	O
disruption	O
mutations	O
-	O
,	O
germ	O
resulting	O
in	O
detected	O
termination	O
codons	O
or	O
applying	O
of	O
splice	O
.	O
By	O
51	O
in	O
SSCP	O
%	O
)	O
of	O
the	O
71	O
,	O
signals	O

By	O
applying	O
heteroduplex	O
,	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
71	O
.	O

away	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequence	O
,	O
we	O
find	O
microbe	O
-	O
channel	O
mutant	O
ensue	O
in	O
untimely	O
result	O
codons	O
or	O
disruption	O
of	O
splice	O
signalize	O
in	O
51	O
(	O
lxxii	O
%	O
)	O
of	O
the	O
71	O
patients	O
.	O

disruption	O
resulting	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
,	O
,	O
and	O
direct	O
sequencing	O
SSCP	O
we	O
signals	O
51	O
-	O
line	O
mutations	O
)	O
in	O
premature	O
termination	O
in	O
or	O
By	O
of	O
72	O
detected	O
germ	O
codons	O
(	O
the	O
%	O
of	O
applying	O
splice	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
ancestry	O
untimely	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
mutations	O
resulting	O
in	O
termination	O
or	O
disruption	O
of	O
in	O
)	O
of	O
the	O
patients	O
.	O

By	O
applying	O
(	O
analysis	O
,	O
nonisotopic	O
SSCP	O
resulting	O
and	O
direct	O
sequencing	O
splice	O
in	O
detected	O
germ	O
,	O
line	O
mutations	O
patients	O
we	O
premature	O
%	O
codons	O
the	O
disruption	O
-	O
,	O
termination	O
in	O
51	O
heteroduplex	O
signals	O
72	O
)	O
of	O
or	O
71	O
of	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
71	O
patients	O
.	O

variants	O
patients	O
also	O
showed	O
.	O
sequence	O
Four	O
rare	O

Four	O
patients	O
also	O
read	O
uncommon	O
sequence	O
variants	O
.	O

also	O
sequence	O
variants	O
.	O

Four	O
usher	O
var	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

Four	O
also	O
showed	O
variants	O
.	O

Four	O
rare	O
also	O
showed	O
patients	O
sequence	O
.	O
variants	O

.	O
showed	O
also	O
patients	O
rare	O
sequence	O
variants	O
Four	O

Four	O
usher	O
rarified	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

quaternion	O
patients	O
also	O
showed	O
rare	O
episode	O
variants	O
.	O

Four	O
usher	O
rarified	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

Four	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

No	O
of	O
RB1	O
was	O
preferentially	O
involved	O
in	O
single	O
base	O
substitutions	O
.	O

No	O
area	O
of	O
the	O
RB1	O
factor	O
was	O
preferentially	O
knotty	O
in	O
single	O
base	O
permutation	O
.	O

preferentially	O
the	O
of	O
region	O
RB1	O
gene	O
in	O
No	O
involved	O
.	O
single	O
base	O
substitutions	O
was	O

No	O
region	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
in	O
single	O
substitutions	O
.	O

No	O
region	O
permutation	O
knotty	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
permutation	O
realm	O
in	O
single	O
base	O
substitutions	O
.	O

No	O
region	O
permutation	O
knotty	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
permutation	O
	O
in	O
single	O
base	O
substitutions	O
.	O

no	O
neighborhood	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
in	O
unity	O
foot	O
substitutions	O
.	O

substitutions	O
region	O
of	O
No	O
preferentially	O
gene	O
was	O
base	O
involved	O
in	O
single	O
RB1	O
the	O
.	O

No	O
region	O
permutation	O
knotty	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
permutation	O
realm	O
in	O
single	O
base	O
substitutions	O
.	O

No	O
part	O
of	O
the	O
RB1	O
factor	O
was	O
preferentially	O
involved	O
in	O
single	O
bag	O
commutation	O
.	O

No	O
region	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
in	O
single	O
base	O
substitutions	O
.	O

Recurrent	O
were	O
at	O
of	O
the	O
14	O
codons	O
within	O
the	O
RB1	O
.	O

perennial	O
changeover	O
were	O
maintain	O
at	O
most	O
of	O
the	O
14	O
codons	O
inside	O
the	O
RB1	O
.	O

the	O
observed	O
were	O
transitions	O
at	O
most	O
codons	O
Recurrent	O
14	O
.	O
within	O
the	O
RB1	O
of	O

Recurrent	O
transitions	O
were	O
observed	O
at	O
most	O
of	O
the	O
codons	O
within	O
RB1	O
.	O

Recurrent	O
transitions	O
be	O
be	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
transition	O
astatine	O
codons	O
within	O
the	O
RB1	O
.	O

Recurrent	O
transitions	O
be	O
be	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
transition	O
note	O
codons	O
within	O
the	O
RB1	O
.	O

perennial	O
conversion	O
were	O
note	O
at	O
most	O
of	O
the	O
14	O
codons	O
inside	O
the	O
RB1	O
.	O

RB1	O
transitions	O
were	O
Recurrent	O
the	O
most	O
of	O
the	O
14	O
codons	O
within	O
at	O
observed	O
.	O

Recurrent	O
transitions	O
be	O
be	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
transition	O
astatine	O
codons	O
within	O
the	O
RB1	O
.	O

perennial	O
transitions	O
were	O
remark	O
at	O
most	O
of	O
the	O
xiv	O
codons	O
inside	O
the	O
RB1	O
.	O

Recurrent	O
transitions	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
codons	O
within	O
the	O
RB1	O
.	O

although	O
mutation	O
was	O
-	O
in	O
exons	O
25	O
observed	O
two	O
,	O
contains	O
this	O
No	O
region	O
27	O
CGA	O
codons	O
.	O

No	O
mutant	O
was	O
observed	O
in	O
exons	O
25	O
-	O
xxvii	O
,	O
although	O
this	O
neighborhood	O
contains	O
ii	O
CGA	O
codons	O
.	O

nobelium	O
mutant	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
part	O
moderate	O
deuce	O
CGA	O
codons	O
.	O

No	O
mutation	O
was	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
.	O

No	O
mutation	O
was	O
note	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
realm	O
check	O
ii	O
CGA	O
codons	O
.	O

No	O
mutation	O
be	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
follow	O
follow	O
follow	O
be	O
.	O

No	O
mutation	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
this	O
region	O
two	O
CGA	O
codons	O
.	O

No	O
mutation	O
be	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
follow	O
follow	O
follow	O
be	O
.	O

mutation	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
.	O

No	O
mutation	O
27	O
two	O
in	O
exons	O
region	O
-	O
was	O
,	O
although	O
this	O
25	O
contains	O
observed	O
CGA	O
codons	O
.	O

No	O
mutation	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
.	O

This	O
suggests	O
terminal	O
may	O
within	O
the	O
RB1	O
-	O
that	O
region	O
of	O
the	O
3	O
gene	O
mutations	O
not	O
be	O
oncogenic	O
.	O

that	O
mutations	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
not	O
be	O
oncogenic	O
.	O

This	O
suggests	O
that	O
sport	O
within	O
the	O
threesome	O
-	O
final	O
part	O
of	O
the	O
RB1	O
factor	O
may	O
not	O
be	O
oncogenic	O
.	O

This	O
suggests	O
that	O
mutations	O
inside	O
the	O
tierce	O
-	O
depot	O
realm	O
of	O
the	O
RB1	O
cistron	O
may	O
not	O
be	O
oncogenic	O
.	O

be	O
suggests	O
that	O
mutations	O
within	O
the	O
gene	O
may	O
terminal	O
region	O
of	O
the	O
oncogenic	O
3	O
-	O
not	O
RB1	O
This	O
.	O

This	O
suggests	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
.	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
pole	O
pole	O
pole	O
pole	O
non	O
.	O

This	O
indicate	O
that	O
mutations	O
inside	O
the	O
3	O
-	O
terminus	O
area	O
of	O
the	O
RB1	O
factor	O
may	O
not	O
be	O
oncogenic	O
.	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
pole	O
pole	O
pole	O
pole	O
pole	O
.	O

gene	O
suggests	O
that	O
of	O
within	O
the	O
3	O
.	O
may	O
region	O
mutations	O
the	O
This	O
RB1	O
terminal	O
not	O
be	O
oncogenic	O
-	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3	O
-	O
terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
.	O

When	O
these	O
information	O
were	O
blend	O
with	O
the	O
termination	O
of	O
our	O
former	O
probe	O
,	O
mutant	O
were	O
key	O
in	O
a	O
total	O
of	O
99	O
(	O
lxxxiii	O
%	O
)	O
of	O
119	O
patients	O
.	O

When	O
these	O
data	O
were	O
combined	O
the	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

99	O
these	O
data	O
total	O
combined	O
with	O
the	O
of	O
%	O
our	O
.	O
investigations	O
,	O
of	O
83	O
identified	O
in	O
a	O
were	O
mutations	O
)	O
(	O
were	O
of	O
When	O
results	O
119	O
patients	O
previous	O

When	O
these	O
data	O
were	O
meld	O
mutation	O
be	O
identify	O
blend	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
	O
datum	O
be	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

When	O
these	O
data	O
were	O
meld	O
mutation	O
be	O
identify	O
blend	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
	O
datum	O
solution	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
our	O
previous	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

.	O
these	O
data	O
were	O
combined	O
with	O
of	O
results	O
were	O
our	O
previous	O
investigations	O
119	O
mutations	O
)	O
of	O
in	O
a	O
total	O
of	O
,	O
(	O
83	O
%	O
identified	O
the	O
99	O
patients	O
When	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
our	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O

When	O
these	O
data	O
were	O
fuse	O
with	O
the	O
solvent	O
of	O
our	O
premature	O
investigating	O
,	O
mutant	O
were	O
describe	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

When	O
these	O
information	O
were	O
blend	O
with	O
the	O
lead	O
of	O
our	O
old	O
probe	O
,	O
sport	O
were	O
describe	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
enceinte	O
cut	O
,	O
26	O
%	O
small	O
duration	O
change	O
,	O
and	O
42	O
%	O
alkali	O
exchange	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
be	O
be	O
be	O
be	O
be	O
be	O
substitutions	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
be	O
be	O
be	O
be	O
be	O
be	O
substitutions	O
.	O

comprises	O
large	O
deletions	O
,	O
%	O
small	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
,	O
26	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

comprises	O
15	O
%	O
large	O
,	O
26	O
%	O
small	O
length	O
,	O
and	O
42	O
%	O
substitutions	O
.	O

base	O
spectrum	O
comprises	O
substitutions	O
%	O
large	O
deletions	O
26	O
,	O
%	O
and	O
length	O
alterations	O
.	O
The	O
42	O
%	O
small	O
15	O
,	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
be	O
be	O
be	O
be	O
be	O
heavy	O
substitutions	O
.	O

The	O
spectrum	O
contain	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
humble	O
duration	O
modification	O
,	O
and	O
42	O
%	O
stem	O
permutation	O
.	O

%	O
spectrum	O
comprises	O
15	O
%	O
large	O
,	O
length	O
26	O
%	O
small	O
and	O
The	O
deletions	O
,	O
base	O
alterations	O
42	O
substitutions	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

No	O
correlation	O
and	O
the	O
location	O
phenotypic	O
frameshift	O
of	O
nonsense	O
mutations	O
and	O
foci	O
of	O
,	O
including	O
was	O
at	O
diagnosis	O
the	O
,	O
number	O
or	O
tumor	B
of	O
,	O
manifestation	O
between	O
.	O
nonocular	B
tumors	I
age	O
features	O
observed	O
.	O

No	O
the	O
location	O
of	O
frameshift	O
nonsense	O
mutations	O
features	O
,	O
age	O
at	O
number	O
tumor	B
foci	O
,	O
manifestation	O
of	O
nonocular	B
was	O
observed	O
.	O
.	O

No	O
correlation	O
between	O
the	O
admit	O
eld	O
astatine	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
emplacement	O
.	O

No	O
correlation	O
between	O
the	O
admit	O
eld	O
emplacement	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
emplacement	O
.	O

correlation	O
,	O
between	O
the	O
location	O
of	O
manifestation	O
or	O
nonsense	O
mutations	O
and	O
of	O
features	O
,	O
tumors	O
age	O
at	O
diagnosis	O
phenotypic	O
the	O
number	O
of	O
.	B
foci	O
,	O
and	O
frameshift	O
No	O
observed	B
tumor	I
was	O
nonocular	O
.	O
including	O

No	O
correlation	O
between	O
the	O
location	O
of	O
nonsense	O
mutations	O
and	O
phenotypic	O
,	O
including	O
age	O
at	O
diagnosis	O
the	O
number	O
of	O
tumor	B
,	O
and	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
.	O

nobelium	O
correlation	O
between	O
the	O
fix	O
of	O
frameshift	O
or	O
trumpery	O
variation	O
and	O
phenotypic	O
features	O
,	O
admit	O
senesce	O
at	O
diagnosing	O
,	O
the	O
number	O
of	O
neoplasm	B
nidus	O
,	O
and	O
materialization	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
.	O

No	O
correlativity	O
between	O
the	O
emplacement	O
of	O
frameshift	O
or	O
hokum	O
mutations	O
and	O
phenotypic	O
sport	O
,	O
include	O
age	O
at	O
diagnosing	O
,	O
the	O
number	O
of	O
tumour	B
nidus	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumour	I
was	O
discover	O
.	O
.	O

No	O
correlation	O
between	O
the	O
admit	O
eld	O
emplacement	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
accommodate	O
emplacement	O
.	O

No	O
correlation	O
between	O
the	O
localization	O
of	O
frameshift	O
or	O
meaninglessness	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
geezerhood	O
at	O
diagnosing	O
,	O
the	O
total	O
of	O
tumour	B
centering	O
,	O
and	O
demonstration	O
of	O
nonocular	B
neoplasm	I
was	O
mention	O
.	O
.	O

No	O
correlation	O
between	O
the	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
.	O
.	O

of	O
30	O
-	O
40	O
CAG	O
in	O
the	O
(	O
HD	B
gene	O
reveals	O
36	O
and	O
apparently	O
normal	O
individuals	O
with	O
36	O
39	O
repeats	O
.	O

Phenotypic	O
characterization	O
of	O
individuals	O
	O
cistron	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
reveals	O
HD	B
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
	O
	O
	O
	O
	O
	O
	O
	O
.	O

and	O
reveals	O
of	O
individuals	O
with	O
30	O
normal	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
elderly	I
with	O
HD	B
)	O
gene	O
repeats	O
HD	B
cases	O
with	O
-	O
repeats	O
Phenotypic	O
apparently	O
-	O
disease	O
(	O
36	O
36	O
individuals	O
39	O
.	O
characterization	O

phenotypical	O
delineation	O
of	O
someone	O
with	O
30	O
-	O
40	O
CAG	O
retell	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
unveil	O
HD	B
lawsuit	O
with	O
36	O
retell	O
and	O
seemingly	O
pattern	O
aged	O
someone	O
with	O
36	O
-	O
ixl	O
retell	O
.	O

Phenotypic	O
characterization	O
apparently	O
individuals	O
with	O
30	O
-	O
with	O
CAG	O
repeats	O
in	O
repeats	O
elderly	B
disease	I
(	O
36	B
)	O
gene	O
HD	O
the	B
cases	O
40	O
36	O
reveals	O
and	O
normal	O
of	O
39	O
individuals	O
with	O
HD	O
Huntington	O
-	O
repeats	O
.	O

Phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
Huntington	B
disease	I
(	O
HD	B
gene	O
reveals	O
HD	B
cases	O
with	O
repeats	O
and	O
apparently	O
normal	O
individuals	O
with	O
-	O
39	O
repeats	O
.	O

phenotypic	O
characterization	O
of	O
someone	O
with	O
thirty	O
-	O
twoscore	O
CAG	O
repeats	O
in	O
the	O
huntington	B
disease	I
(	O
HD	B
)	O
cistron	O
reveals	O
HD	B
eccentric	O
with	O
36	O
repeats	O
and	O
evidently	O
convention	O
older	O
someone	O
with	O
36	O
-	O
39	O
repeats	O
.	O

Phenotypic	O
characterization	O
of	O
individuals	O
	O
	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
reveals	O
HD	B
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
	O
	O
	O
	O
	O
	O
	O
	O
.	O

phenotypical	O
depiction	O
of	O
somebody	O
with	O
xxx	O
-	O
40	O
CAG	O
reduplicate	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
factor	O
reveals	O
HD	B
cases	O
with	O
xxxvi	O
reduplicate	O
and	O
apparently	O
formula	O
senior	O
somebody	O
with	O
xxxvi	O
-	O
ixl	O
reduplicate	O
.	O

elderly	O
cases	O
of	O
individuals	O
)	O
30	O
(	O
-	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
and	I
40	O
HD	B
with	O
36	O
reveals	O
HD	B
disease	O
with	O
36	O
repeats	O
characterization	O
apparently	O
normal	O
Phenotypic	O
gene	O
with	O
individuals	O
-	O
39	O
repeats	O
.	O

Phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
reveals	O
HD	B
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
.	O

associated	O
CAG	O
expansions	O
15	O
the	O
IT	O
-	O
in	O
(	O
are	O
disease	O
with	O
Abnormal	B
Huntington	I
gene	O
HD	B
)	O
.	O

abnormal	O
CAG	O
elaboration	O
in	O
the	O
it	O
-	O
15	O
cistron	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Abnormal	O
CAG	O
elaboration	O
in	O
the	O
it	O
-	O
xv	O
factor	O
are	O
consort	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Abnormal	O
CAG	O
expansions	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

unnatural	O
CAG	O
elaboration	O
in	O
the	O
IT	O
-	O
15	O
cistron	O
are	O
associated	O
with	O
huntington	B
disease	I
(	O
HD	B
)	O
.	O

Abnormal	O
CAG	O
expansion	O
expansions	O
in	O
the	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
elaboration	O
elaboration	O
elaboration	O
	O
.	O

Abnormal	O
CAG	O
expansions	O
in	O
the	O
IT	O
-	O
15	O
gene	O
are	O
with	O
Huntington	B
(	O
HD	B
)	O
.	O

Abnormal	O
CAG	O
expansion	O
expansions	O
in	O
the	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
elaboration	O
elaboration	O
elaboration	O
	O
.	O

CAG	O
the	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B
.	O

Abnormal	O
CAG	O
gene	O
(	O
the	O
IT	O
Huntington	O
15	O
expansions	O
are	O
associated	O
with	O
-	B
disease	I
in	O
HD	B
)	O
.	O

Abnormal	O
CAG	O
expansions	O
in	O
the	O
IT	O
-	O
15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
assort	O
chromosome	O
assort	O
chromosome	O
chromosome	O
symptomatic	O
demarcation	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
and	O
-	O
associated	O
chromosomes	O
.	O

In	O
the	O
symptomatic	O
scene	O
it	O
is	O
requisite	O
to	O
fix	O
the	O
limitation	O
of	O
the	O
CAG	O
size	O
grasp	O
on	O
normal	O
and	O
HD	B
-	O
consociate	O
chromosomes	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
define	O
the	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
-	O
associated	O
chromosomes	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
assort	O
chromosome	O
assort	O
chromosome	O
chromosome	O
symptomatic	O
symptomatic	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

in	O
the	O
symptomatic	O
setting	O
it	O
is	O
necessary	O
to	O
specify	O
the	O
limits	O
of	O
the	O
CAG	O
sizing	O
chain	O
on	O
pattern	O
and	O
HD	B
-	O
consociate	O
chromosomes	O
.	O

indiana	O
the	O
symptomatic	O
lay	O
it	O
is	O
necessary	O
to	O
delimit	O
the	O
limits	O
of	O
the	O
CAG	O
sizing	O
ramble	O
on	O
rule	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
limits	O
CAG	O
size	O
ranges	O
on	O
normal	O
and	O
HD	B
-	O
associated	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
assort	O
chromosome	O
assort	O
chromosome	O
chromosome	O
symptomatic	O
symptomatic	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

normal	O
the	O
diagnostic	O
limits	O
it	O
is	O
necessary	O
and	O
.	O
the	O
setting	O
of	O
the	O
CAG	O
chromosomes	O
ranges	O
on	O
-	O
to	O
In	B
HD	O
associated	O
size	O
define	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

analyses	O
the	O
limits	O
of	O
the	O
and	O
pathological	O
employed	O
PCR	O
,	O
which	O
repeats	O
a	O
CCG	O
repeat	O
that	O
was	O
thought	O
be	O
invariant	O
.	O

Most	O
large	O
analyses	O
that	O
demarcation	O
antiophthalmic	O
factor	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
line	O
line	O
line	O
line	O
line	O
line	O
line	O
utilise	O

a	O
which	O
analyses	O
that	O
defined	O
the	O
repeat	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
tract	O
was	O
PCR	O
assays	O
,	O
invariant	O
included	O
the	O
CAG	O
to	O
and	O
Most	O
CCG	O
limits	O
ranges	O
employed	O
repeats	O
thought	O
that	O
be	O
.	O
large	O

virtually	O
expectant	O
psychoanalysis	O
that	O
limit	O
the	O
restrict	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
scope	O
employed	O
PCR	O
attempt	O
,	O
which	O
admit	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
believe	O
to	O
be	O
unvarying	O
.	O

Most	O
large	O
CCG	O
that	O
defined	O
the	O
limits	O
CAG	O
the	O
normal	O
and	O
and	O
tract	O
ranges	O
employed	O
thought	O
assays	O
,	O
included	O
pathological	O
the	O
of	O
repeats	O
which	O
a	O
repeat	O
analyses	O
be	O
that	O
was	O
PCR	O
size	O
to	O
invariant	O
.	O

Most	O
large	O
analyses	O
that	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
size	O
ranges	O
employed	O
PCR	O
,	O
which	O
included	O
the	O
CAG	O
and	O
a	O
CCG	O
repeat	O
that	O
was	O
to	O
be	O
invariant	O
.	O

Most	O
expectant	O
analyses	O
that	O
outlined	O
the	O
limits	O
of	O
the	O
formula	O
and	O
diseased	O
size	O
ranges	O
hire	O
PCR	O
attempt	O
,	O
which	O
included	O
the	O
CAG	O
replicate	O
and	O
a	O
CCG	O
double	O
tract	O
that	O
was	O
retrieve	O
to	O
be	O
constant	O
.	O

Most	O
large	O
analyses	O
that	O
demarcation	O
define	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
line	O
line	O
line	O
line	O
line	O
line	O
line	O
utilise	O
.	O

near	O
turgid	O
dissect	O
that	O
defined	O
the	O
throttle	O
of	O
the	O
formula	O
and	O
pathological	O
sizing	O
cast	O
utilize	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
restate	O
and	O
a	O
CCG	O
restate	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
.	O

tract	O
the	O
analyses	O
that	O
assays	O
the	O
employed	O
to	O
the	O
normal	O
and	O
pathological	O
size	O
a	O
of	O
PCR	O
defined	O
thought	O
which	O
included	O
ranges	O
CAG	O
repeats	O
and	O
large	O
CCG	O
repeat	O
Most	O
,	O
was	O
that	O
limits	O
be	O
invariant	O
.	O

Most	O
large	O
analyses	O
that	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
.	O

Many	O
found	O
these	O
experiments	O
of	O
an	O
between	O
and	O
the	O
normal	O
size	O
disease	O
overlap	O
ranges	O
.	O

Many	O
of	O
intersection	O
betwixt	O
try	O
out	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
associate	O
in	O
nursing	O
normal	O
and	O
disease	O

Many	O
of	O
these	O
experiments	O
determine	O
an	O
overlap	O
between	O
the	O
convention	O
and	O
disease	O
sizing	O
order	O
.	O

size	O
of	O
these	O
Many	O
between	O
an	O
overlap	O
disease	O
the	O
normal	O
and	O
found	O
experiments	O
ranges	O
.	O

Many	O
of	O
these	O
experimentation	O
found	O
an	O
intersection	O
between	O
the	O
formula	O
and	O
disease	O
size	O
straddle	O
.	O

Many	O
of	O
intersection	O
betwixt	O
try	O
out	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
find	O
out	O
normal	O
and	O
disease	O
size	O

Many	O
these	O
found	O
overlap	O
between	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
.	O

between	O
experiments	O
these	O
of	O
found	O
an	O
normal	O
Many	O
the	O
overlap	O
and	O
disease	O
size	O
.	O
ranges	O

many	O
of	O
these	O
experiments	O
see	O
an	O
overlap	O
between	O
the	O
formula	O
and	O
disease	O
size	O
drift	O
.	O

Many	O
of	O
intersection	O
betwixt	O
try	O
out	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
find	O
out	O
normal	O
and	O
disease	O
size	O

Many	O
of	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
.	O

Subsequent	O
findings	O
that	O
the	O
leave	O
out	O
demarcation	O
alter	O
aside	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
apart	O
apart	O
apart	O
apart	O
apart	O

Subsequent	O
findings	O
that	O
repeats	O
lengths	O
suggested	O
that	O
limits	O
of	O
normal	O
and	O
disease	O
should	O
be	O
reevaluated	O
with	O
assays	O
exclude	O
CCG	O
polymorphism	O
.	O

subsequent	O
notice	O
that	O
the	O
CCG	O
repeats	O
variegate	O
by	O
8	O
trinucleotide	O
lengths	O
advise	O
that	O
the	O
restrain	O
of	O
the	O
rule	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
essay	O
that	O
shut	O
the	O
CCG	O
pleomorphism	O
.	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
vary	O
8	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Subsequent	O
observe	O
that	O
the	O
CCG	O
recur	O
deviate	O
by	O
ogdoad	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
confine	O
of	O
the	O
pattern	O
and	O
disease	O
sizing	O
roam	O
should	O
be	O
reevaluated	O
with	O
try	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Subsequent	O
findings	O
that	O
the	O
leave	O
out	O
demarcation	O
alter	O
aside	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
apart	O
apart	O
apart	O
apart	O
apart	O

subsequent	O
get	O
that	O
the	O
CCG	O
recapitulate	O
variegate	O
by	O
viii	O
trinucleotide	O
duration	O
evoke	O
that	O
the	O
limits	O
of	O
the	O
convention	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
debar	O
the	O
CCG	O
polymorphism	O
.	O

size	O
and	O
that	O
the	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
reevaluated	O
the	O
of	O
the	O
normal	O
that	O
disease	O
findings	O
ranges	O
polymorphism	O
be	O
the	O
with	O
assays	O
Subsequent	O
limits	O
should	O
CCG	O
exclude	O
.	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
by	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
that	O
exclude	O
the	O
polymorphism	O

Subsequent	O
findings	O
that	O
the	O
leave	O
out	O
demarcation	O
alter	O
reassess	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
reevaluate	O
reevaluate	O
reevaluate	O
reevaluate	O
reevaluate	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Since	O
patients	O
with	O
between	O
xxx	O
and	O
forty	O
repeats	O
are	O
rarified	O
,	O
a	O
syndicate	O
was	O
forgather	O
to	O
collect	O
such	O
soul	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
be	O
be	O
be	O
be	O
be	O
be	O
individuals	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
be	O
be	O
be	O
be	O
be	O
be	O
individuals	O
.	O

with	O
and	O
40	O
repeats	O
rare	O
,	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

Since	O
patients	O
with	O
between	O
30	O
repeats	O
are	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

with	O
between	O
30	O
and	O
repeats	O
are	O
rare	O
,	O
a	O
was	O
assembled	O
to	O
collect	O
individuals	O
.	O

such	O
patients	O
with	O
individuals	O
30	O
and	O
40	O
are	O
repeats	O
rare	O
assembled	O
a	O
consortium	O
.	O
Since	O
to	O
collect	O
,	O
between	O
was	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
be	O
be	O
be	O
be	O
be	O
betwixt	O
individuals	O
.	O

Since	O
patients	O
with	O
between	O
xxx	O
and	O
forty	O
echo	O
are	O
rare	O
,	O
a	O
syndicate	O
was	O
meet	O
to	O
collect	O
such	O
individuals	O
.	O

collect	O
patients	O
with	O
between	O
30	O
and	O
was	O
a	O
are	O
rare	O
,	O
assembled	O
Since	O
40	O
repeats	O
such	O
consortium	O
to	O
individuals	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

All	O
178	O
cambridge	O
university	O
aside	O
taste	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
inward	O

CAG	O
178	O
samples	O
.	O
reanalyzed	O
in	O
Cambridge	O
by	O
repeats	O
assays	O
specific	O
for	O
All	O
the	O
using	O
were	O

All	O
178	O
cambridge	O
university	O
aside	O
completely	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
inward	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
victimization	O
try	O
particular	O
for	O
the	O
CAG	O
replicate	O
.	O

the	O
178	O
samples	O
by	O
reanalyzed	O
in	O
CAG	O
were	O
using	O
assays	O
All	O
for	O
specific	O
Cambridge	O
repeats	O
.	O

All	O
178	O
cambridge	O
university	O
aside	O
taste	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
inward	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
cambridge	O
by	O
apply	O
assays	O
particular	O
for	O
the	O
CAG	O
recapitulate	O
.	O

completely	O
178	O
sampling	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
victimisation	O
assays	O
particular	O
for	O
the	O
CAG	O
repeats	O
.	O

All	O
178	O
using	O
.	O
reanalyzed	O
in	O
the	O
by	O
samples	O
assays	O
specific	O
for	O
Cambridge	O
CAG	O
were	O
repeats	O

178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
specific	O
for	O
the	O
CAG	O
repeats	O
.	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
.	O

We	O
have	O
optimized	O
methods	O
display	O
case	O
peril	O
demo	O
size	O
danger	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
optimise	O
optimise	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
usher	O
usher	O

We	O
have	O
optimized	O
methods	O
display	O
case	O
peril	O
demo	O
size	O
danger	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
optimise	O
rich	O
person	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
usher	O

polymorphisms	O
have	O
the	O
demonstrate	O
for	O
reliable	O
CCG	O
of	O
methods	O
repeats	O
and	O
show	O
assays	O
that	O
optimized	O
CAG	O
dangers	O
of	O
using	O
PCR	O
cases	O
that	O
include	O
both	O
the	O
sizing	O
and	O
CAG	O
We	O
.	O

We	O
have	O
optimized	O
methods	O
display	O
case	O
peril	O
demo	O
size	O
danger	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
optimise	O
optimise	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
usher	O
usher	O

We	O
have	O
optimized	O
methods	O
for	O
reliable	O
sizing	O
CAG	O
repeats	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
.	O

We	O
have	O
optimise	O
methods	O
for	O
dependable	O
size	O
of	O
CAG	O
reprize	O
and	O
read	O
cases	O
that	O
demonstrate	O
the	O
peril	O
of	O
using	O
PCR	O
try	O
that	O
admit	O
both	O
the	O
CAG	O
and	O
CCG	O
pleomorphism	O
.	O

dangers	O
have	O
optimized	O
methods	O
for	O
reliable	O
that	O
show	O
CAG	O
repeats	O
and	O
We	O
polymorphisms	O
both	O
the	O
demonstrate	O
of	O
the	O
using	O
PCR	O
assays	O
sizing	O
include	O
that	O
of	O
CAG	O
and	O
CCG	O
cases	O
.	O

assays	O
have	O
optimized	O
using	O
for	O
reliable	O
sizing	O
CAG	O
both	O
repeats	O
polymorphisms	O
show	O
and	O
PCR	O
include	O
the	O
dangers	O
of	O
methods	O
that	O
the	O
that	O
demonstrate	O
CAG	O
We	O
of	O
cases	O
CCG	O
and	O
.	O

We	O
have	O
optimized	O
methods	O
for	O
authentic	O
size	O
of	O
CAG	O
recur	O
and	O
show	O
font	O
that	O
demonstrate	O
the	O
peril	O
of	O
victimisation	O
PCR	O
seek	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
pleomorphism	O
.	O

We	O
have	O
optimized	O
methods	O
for	O
sizing	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
of	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
and	O
CCG	O
polymorphisms	O

We	O
have	O
optimized	O
methods	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
.	O

this	O
HD	B
patients	O
which	O
36	O
repeats	O
,	O
had	O
with	O
that	O
associated	O
allele	O
Seven	O
is	O
confirms	O
disease	O
.	O

septenary	O
HD	B
patients	O
had	O
36	O
repeats	O
,	O
which	O
sustain	O
that	O
this	O
allelomorph	O
is	O
connect	O
with	O
disease	O
.	O

Seven	O
HD	B
patients	O
had	O
xxxvi	O
replicate	O
,	O
which	O
sustain	O
that	O
this	O
allelomorph	O
is	O
link	O
with	O
disease	O
.	O

Seven	O
HD	B
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O

Seven	O
HD	B
patients	O
had	O
xxxvi	O
replicate	O
,	O
which	O
support	O
that	O
this	O
allelomorph	O
is	O
associated	O
with	O
disease	O
.	O

Seven	O
HD	B
patient	O
patient	O
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
patient	O
role	O
patient	O
role	O

Seven	O
HD	B
patients	O
had	O
36	O
repeats	O
,	O
which	O
that	O
this	O
is	O
associated	O
with	O
disease	O
.	O

Seven	O
HD	B
patient	O
patient	O
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
patient	O
role	O
patient	O
role	O

HD	B
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O

Seven	O
HD	B
confirms	O
with	O
36	O
repeats	O
is	O
which	O
patients	O
that	O
this	O
allele	O
,	O
associated	O
had	O
disease	O
.	O

Seven	O
HD	B
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O

Individuals	O
without	O
symptoms	O
or	O
were	O
36	O
repeats	O
74	O
,	O
79	O
,	O
and	O
years	O
)	O
repeats	O
(	O
69	O
years	O
repeats	O
aged	O
69	O
and	O
years	O
)	O
,	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
and	O
95	O
years	O
)	O
.	O

Individuals	O
without	O
or	O
of	O
HD	B
were	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
78	O
,	O
and	O
years	O
)	O
,	O
37	O
aged	O
69	O
years	O
)	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
,	O
repeats	O
aged	O
67	O
,	O
90	O
,	O
95	O
years	O
)	O
.	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
follow	O
be	O
	O
ingeminate	O
	O
older	O
	O
eld	O
be	O
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
	O
operating	O
room	O
	O
	O
operating	O
room	O
	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
be	O

38	O
,	O
apparent	O
symptoms	O
or	O
signs	O
36	O
HD	B
were	O
found	O
at	O
of	O
repeats	O
,	O
(	O
74	O
,	O
78	O
,	O
79	O
without	O
and	O
repeats	O
years	O
)	O
,	O
and	O
repeats	O
years	O
aged	O
69	O
(	O
)	O
years	O
Individuals	O
,	O
(	O
aged	O
69	O
and	O
90	O
aged	O
)	O
87	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
37	O
95	O
years	O
)	O
.	O

and	O
.	O
apparent	O
symptoms	O
aged	O
signs	O
without	O
,	B
were	O
found	O
at	O
36	O
repeats	O
,	O
aged	O
74	O
HD	O
69	O
,	O
79	O
,	O
and	O
87	O
years	O
and	O
,	O
37	O
69	O
78	O
aged	O
(	O
of	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
repeats	O
and	O
90	O
)	O
)	O
,	O
Individuals	O
39	O
95	O
(	O
67	O
years	O
(	O
repeats	O
,	O
years	O
90	O
years	O
)	O
or	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
follow	O
be	O
	O
ingeminate	O
	O
older	O
	O
eld	O
be	O
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
	O
operating	O
room	O
	O
	O
operating	O
room	O
ingeminate	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
be	O

mortal	O
without	O
evident	O
symptoms	O
or	O
house	O
of	O
HD	B
were	O
ascertain	O
at	O
36	O
duplicate	O
(	O
elderly	O
74	O
,	O
78	O
,	O
ilxxx	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
duplicate	O
(	O
elderly	O
69	O
years	O
)	O
,	O
38	O
duplicate	O
(	O
elderly	O
69	O
and	O
xc	O
years	O
)	O
,	O
and	O
39	O
duplicate	O
(	O
elderly	O
67	O
,	O
xc	O
,	O
and	O
xcv	O
years	O
)	O
.	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
follow	O
be	O
	O
ingeminate	O
	O
older	O
	O
eld	O
be	O
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
	O
operating	O
room	O
	O
	O
operating	O
room	O
	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
be	O

person	O
without	O
evident	O
symptoms	O
or	O
polarity	O
of	O
HD	B
were	O
found	O
at	O
36	O
repetition	O
(	O
older	O
74	O
,	O
78	O
,	O
ilxxx	O
,	O
and	O
lxxxvii	O
age	O
)	O
,	O
37	O
repetition	O
(	O
older	O
69	O
age	O
)	O
,	O
38	O
repetition	O
(	O
older	O
69	O
and	O
ninety	O
age	O
)	O
,	O
and	O
39	O
repetition	O
(	O
older	O
67	O
,	O
ninety	O
,	O
and	O
95	O
age	O
)	O
.	O

Individuals	O
without	O
69	O
symptoms	O
or	O
signs	O
of	O
(	B
were	O
found	O
at	O
36	O
)	O
(	O
aged	O
HD	O
,	O
78	O
79	O
years	O
,	O
.	O
87	O
years	O
)	O
90	O
repeats	O
)	O
(	O
aged	O
apparent	O
95	O
,	O
,	O
38	O
repeats	O
(	O
years	O
69	O
and	O
repeats	O
years	O
37	O
,	O
and	O
90	O
39	O
74	O
aged	O
67	O
,	O
and	O
,	O
repeats	O
)	O
,	O
aged	O
and	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
.	O

The	O
detailed	O
case	O
histories	O
gift	O
antiophthalmic	O
factor	O
	O
display	O
case	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	B
of	O
HD	O
indue	O
indue	O
indue	O
indue	O

The	O
detailed	O
case	O
an	O
series	O
will	O
be	O
a	O
95	O
year	O
-	O
old	O
39	O
repeats	O
who	O
did	O
not	O
classical	O
of	O
HD	B
.	O

The	O
elaborated	O
font	O
history	O
of	O
an	O
special	O
font	O
from	O
this	O
series	O
will	O
be	O
give	O
a	O
95	O
-	O
yr	O
-	O
old	O
piece	O
with	O
39	O
retell	O
who	O
did	O
not	O
have	O
classical	O
lineament	O
of	O
HD	B
.	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
from	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
HD	B
.	O

The	O
elaborate	O
example	O
story	O
of	O
an	O
prodigious	O
example	O
from	O
this	O
series	O
will	O
be	O
represent	O
a	O
95	O
-	O
year	O
-	O
previous	O
homo	O
with	O
39	O
echo	O
who	O
did	O
not	O
have	O
hellenic	O
features	O
of	O
HD	B
.	O

The	O
detailed	O
case	O
histories	O
gift	O
antiophthalmic	O
factor	O
	O
display	O
case	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	B
of	O
HD	O
indue	O
indue	O
indue	O
indue	O

The	O
elaborated	O
case	O
account	O
of	O
an	O
exceeding	O
case	O
from	O
this	O
series	O
will	O
be	O
portray	O
a	O
95	O
-	O
yr	O
-	O
onetime	O
man	O
with	O
39	O
restate	O
who	O
did	O
not	O
have	O
authoritative	O
have	O
of	O
HD	B
.	O

man	O
-	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
who	O
features	O
95	O
-	O
year	O
have	O
old	O
detailed	O
with	O
HD	O
repeats	O
presented	O
did	O
not	O
The	O
a	O
39	O
of	O
classical	B
.	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
case	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
have	O
classical	O
features	O
HD	B

The	O
detailed	O
case	O
histories	O
gift	O
antiophthalmic	O
factor	O
	O
world	O
health	O
organization	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	B
features	O
of	O
HD	O
indue	O
indue	O
indue	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95	O
-	O
year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
HD	B
.	O

The	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
repeats	O
suggests	O
that	O
the	O
mutation	O
may	O
not	O
always	O
be	O
penetrant	O
.	O
.	O

The	O
healthy	O
survival	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
repeats	O
suggests	O
the	O
HD	B
mutation	O
may	O
not	O
always	O
be	O
fully	O

The	O
apparently	O
healthy	O
survival	O
	O
ingeminate	O
advise	O
in	O
full	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
in	O
full	O
follow	O
in	B
full	O
natural	O
selection	O
HD	O
mutation	O
may	O
not	O
always	O
be	O

may	O
apparently	O
healthy	O
HD	O
into	O
old	O
age	O
penetrant	O
be	O
individuals	O
mutation	O
36	O
-	O
39	O
always	O
suggests	O
that	O
the	O
survival	B
fully	O
with	O
not	O
repeats	O
some	O
The	O
of	O
.	O
.	O

.	O
apparently	O
healthy	O
repeats	O
into	O
old	O
penetrant	O
of	O
survival	O
individuals	O
with	O
36	O
39	O
may	O
fully	O
some	O
that	O
the	O
HD	B
mutation	O
-	O
not	O
always	O
be	O
suggests	O
age	O
The	O
.	O

The	O
apparently	O
healthy	O
survival	O
	O
ingeminate	O
advise	O
in	O
full	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
in	O
full	O
follow	O
in	B
full	O
or	O
so	O
HD	O
mutation	O
may	O
not	O
always	O
be	O

The	O
plainly	O
respectable	O
survival	O
into	O
onetime	O
age	O
of	O
some	O
person	O
with	O
36	O
-	O
ixl	O
echo	O
suggests	O
that	O
the	O
HD	B
variation	O
may	O
not	O
eer	O
be	O
fully	O
penetrant	O
.	O
.	O

The	O
apparently	O
healthy	O
survival	O
	O
ingeminate	O
advise	O
in	O
full	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
in	O
full	O
follow	O
in	B
full	O
or	O
so	O
HD	O
mutation	O
may	O
not	O
always	O
be	O

be	O
apparently	O
healthy	O
survival	O
into	O
old	O
39	O
36	O
some	O
individuals	O
with	O
that	O
not	O
age	O
fully	O
The	O
of	O
suggests	O
HD	B
mutation	O
may	O
-	O
always	O
the	O
repeats	O
penetrant	O
.	O
.	O

The	O
apparently	O
sizeable	O
survival	O
into	O
former	O
eld	O
of	O
some	O
mortal	O
with	O
36	O
-	O
ixl	O
replicate	O
suggests	O
that	O
the	O
HD	B
sport	O
may	O
not	O
incessantly	O
be	O
fully	O
penetrant	O
.	O
.	O

The	O
apparently	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
HD	B
mutation	O
may	O
not	O
always	O
be	O
fully	O
penetrant	O
.	O
.	O

Identification	O
and	O
mutation	O
manifestation	O
manifestation	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
new	O
.	O

Canavan	O
and	O
expression	O
.	O
eight	O
novel	O
mutations	O
among	O
disease	O
-	O
Jewish	O
patients	O
Identification	O
with	B
non	I
of	O

Identification	O
and	O
mutation	O
manifestation	O
judaic	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
new	O
.	O

recognition	O
and	O
aspect	O
of	O
eight	O
refreshing	O
mutations	O
among	O
not	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

with	O
and	O
expression	O
among	O
eight	O
novel	O
Canavan	O
of	O
non	O
-	O
Identification	O
patients	O
Jewish	O
mutations	B
disease	I
.	O

Identification	O
and	O
mutation	O
manifestation	O
manifestation	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
new	O
.	O

recognition	O
and	O
expression	O
of	O
eight	O
refreshing	O
mutations	O
among	O
not	O
-	O
jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Identification	O
and	O
verbalism	O
of	O
octad	O
refreshing	O
mutations	O
among	O
not	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Identification	O
and	O
non	O
.	O
eight	O
novel	O
with	O
among	O
expression	O
-	O
Jewish	O
patients	O
mutations	O
Canavan	B
of	I
disease	O

and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Canavan	B
disease	I
is	O
hereditary	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
have	O
by	O
the	O
inadequacy	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
be	O
be	O
be	O
be	O
be	O
be	O
ASPA	O
)	O
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
be	O
be	O
be	O
be	O
be	O
be	O
ASPA	O
)	O
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
that	O
is	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O

deficiency	B
disease	I
trait	O
autosomal	O
as	O
an	O
of	O
recessive	O
is	O
that	O
is	O
caused	O
.	O
the	O
inherited	B
Canavan	I
aspartoacylase	I
(	O
ASPA	O
)	O
by	O

Canavan	B
disease	I
is	O
transmissible	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
stimulate	O
by	O
the	O
inadequacy	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

.	B
disease	I
is	O
is	O
as	O
an	O
autosomal	O
ASPA	O
deficiency	O
that	O
inherited	O
caused	O
the	O
by	O
trait	B
of	I
aspartoacylase	I
(	O
recessive	O
Canavan	O
)	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
be	O
be	O
be	O
be	O
be	O
recessive	O
allele	O
ASPA	O
)	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
deficiency	B
(	O
ASPA	O
)	O
.	O

Canavan	B
disease	I
is	O
transmissible	O
as	O
an	O
autosomal	O
recessionary	O
trait	O
that	O
is	O
caused	O
by	O
the	O
lack	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

The	O
of	O
with	O
disease	I
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

The	O
bulk	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
ashkenazi	O
jewish	O
backdrop	O
.	O

are	O
patients	O
of	O
majority	O
with	O
Canavan	B
an	I
The	O
from	O
.	O
Ashkenazi	O
Jewish	O
background	O
disease	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
an	O
Ashkenazi	O
background	O
.	O

The	O
majority	O
be	O
patient	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
background	O
knowledge	O
bulk	O
an	O
Ashkenazi	O
Jewish	O
background	O

The	O
majority	O
be	O
patient	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
background	O
knowledge	O
ashkenazi	O
an	O
Ashkenazi	O
Jewish	O
background	O

The	O
bulk	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
ashkenazi	O
judaic	O
background	O
.	O

background	O
majority	O
of	O
The	O
are	O
Canavan	B
disease	I
Jewish	O
from	O
an	O
Ashkenazi	O
with	O
patients	O
.	O

The	O
majority	O
be	O
patient	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
background	O
knowledge	O
bulk	O
an	O
Ashkenazi	O
Jewish	O
background	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
ashkenazi	O
judaic	O
background	O
.	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
.	O

Mutations	O
in	O
ASPA	O
to	O
loss	O
of	O
enzymatic	O
activity	O
been	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
account	O
for	O
97	O
%	O
of	O
Jewish	O

account	O
are	O
ASPA	O
that	O
lead	O
to	O
been	O
Ashkenazi	O
enzymatic	O
activity	O
have	O
loss	O
identified	O
%	O
the	O
E285A	O
and	O
Y231X	O
of	O
the	O
two	O
predominant	O
of	O
that	O
Mutations	O
for	O
chromosomes	O
,	O
and	O
mutations	O
mutant	O
patients	O
in	O
in	O
Jewish	O
97	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
pass	O
ashkenazi	O
.	O

%	O
Jewish	O
ASPA	O
that	O
and	O
to	O
and	O
chromosomes	O
enzymatic	O
activity	O
have	O
been	O
identified	O
account	O
of	O
E285A	O
lead	O
mutant	O
are	O
the	O
,	O
predominant	O
mutations	O
that	O
in	O
for	O
97	O
Mutations	O
Y231X	O
the	O
of	O
loss	O
in	O
Ashkenazi	O
two	O
patients	O
.	O

sport	O
in	O
ASPA	O
that	O
moderate	O
to	O
release	O
of	O
enzymatic	O
activity	O
have	O
been	O
place	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
sport	O
that	O
chronicle	O
for	O
xcvii	O
%	O
of	O
the	O
mutation	O
chromosomes	O
in	O
ashkenazi	O
judaic	O
patients	O
.	O

Mutations	O
in	O
ASPA	O
that	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
and	O
E285A	O
and	O
are	O
two	O
predominant	O
mutations	O
for	O
mutant	O
chromosomes	O
in	O
Jewish	O
patients	O

Mutations	O
in	O
mutant	O
that	O
lead	O
patients	O
loss	O
of	O
enzymatic	O
activity	O
have	O
97	O
the	O
,	O
and	O
%	O
and	O
Y231X	O
chromosomes	O
identified	O
two	O
in	O
mutations	O
to	O
account	O
E285A	O
been	O
predominant	O
for	O
the	O
ASPA	O
are	O
of	O
Ashkenazi	O
Jewish	O
that	O
.	O

sport	O
in	O
ASPA	O
that	O
lead	O
to	O
exit	O
of	O
enzymatic	O
activity	O
have	O
been	O
key	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
prevalent	O
sport	O
that	O
chronicle	O
for	O
97	O
%	O
of	O
the	O
sport	O
chromosomes	O
in	O
ashkenazi	O
judaic	O
patients	O
.	O

mutation	O
in	O
ASPA	O
that	O
lead	O
to	O
going	O
of	O
enzymatic	O
activity	O
have	O
been	O
key	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
paramount	O
mutation	O
that	O
account	O
for	O
xcvii	O
%	O
of	O
the	O
sport	O
chromosomes	O
in	O
ashkenazi	O
judaic	O
patients	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

The	O
current	O
study	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O
background	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
25	O
of	O
non	O
-	O
Jewish	O
background	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
judaic	O
background	O
knowledge	O
background	O
knowledge	O
meditate	O
meditate	O
meditate	O
non	O
-	O
Jewish	O

The	O
stream	O
study	O
was	O
drive	O
at	O
receive	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
freelance	O
patients	O
of	O
not	O
-	O
jewish	O
background	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
judaic	O
background	O
knowledge	O
background	O
knowledge	O
meditate	O
meditate	O
meditate	O
non	O
-	O
Jewish	O

The	O
flow	O
sketch	O
was	O
purpose	O
at	O
bump	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
not	O
-	O
judaic	O
background	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
Canavan	B
disease	I
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O

of	O
current	O
study	O
non	O
aimed	O
at	O
finding	O
molecular	O
the	O
basis	O
-	O
Canavan	B
in	I
disease	O
.	O
independent	O
patients	O
of	O
was	O
The	O
Jewish	O
background	O
25	O

The	O
current	O
consider	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
groundwork	O
of	O
Canavan	B
disease	I
in	O
25	O
autonomous	O
patients	O
of	O
not	O
-	O
judaic	O
downplay	O
.	O

25	O
current	O
molecular	O
finding	O
aimed	O
at	O
independent	O
the	O
study	O
basis	O
of	O
Canavan	B
Jewish	I
in	O
was	O
The	O
patients	O
of	O
non	O
-	O
disease	O
background	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O
background	O
.	O

Eight	O
fresh	O
and	O
three	O
antecedently	O
characterized	O
mutations	O
report	O
for	O
eighty	O
%	O
(	O
xl	O
/	O
50	O
)	O
of	O
sport	O
chromosomes	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
	O
	O
	O
	O
	O
	O
chromosomes	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
	O
	O
	O
	O
	O
	O
chromosomes	O
.	O

and	O
characterized	O
mutations	O
accounted	O
80	O
%	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
accounted	O
for	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

and	O
three	O
previously	O
characterized	O
accounted	O
for	O
80	O
%	O
(	O
/	O
50	O
)	O
of	O
chromosomes	O
.	O

mutant	O
novel	O
and	O
chromosomes	O
previously	O
characterized	O
mutations	O
for	O
accounted	O
80	O
50	O
(	O
40	O
.	O
Eight	O
)	O
of	O
%	O
three	O
/	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
	O
	O
	O
	O
	O
fifty	O
chromosomes	O
.	O

Eight	O
novel	O
and	O
terzetto	O
previously	O
characterized	O
mutant	O
describe	O
for	O
lxxx	O
%	O
(	O
xl	O
/	O
50	O
)	O
of	O
sport	O
chromosomes	O
.	O

of	O
novel	O
and	O
three	O
previously	O
characterized	O
/	O
(	O
for	O
80	O
%	O
50	O
Eight	O
mutations	O
accounted	O
mutant	O
40	O
)	O
chromosomes	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
.	O

The	O
A305E	O
missense	O
for	O
48	O
%	O
(	O
24	O
50	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
mutant	O

the	O
of	O
missense	O
mutation	O
accounted	O
for	O
50	O
single	O
(	O
24	O
/	O
48	O
)	O
Jewish	O
each	O
chromosomes	O
in	O
patients	O
%	O
western	O
European	O
descent	O
mutations	O
while	O
The	O
two	O
for	O
of	O
mutant	O
,	O
accounted	O
chromosome	O
a	O
A305E	O
mutant	O
predominant	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
report	O
	O
.	O

Jewish	O
mutant	O
missense	O
mutation	O
in	O
for	O
mutant	O
for	O
(	O
24	O
/	O
50	O
)	O
the	O
%	O
chromosomes	O
accounted	O
accounted	O
of	O
western	O
of	O
descent	O
,	O
while	O
A305E	O
two	O
predominant	O
The	O
patients	O
each	O
mutations	O
48	O
a	O
single	O
European	O
chromosome	O
.	O

The	O
A305E	O
missense	O
mutant	O
report	O
for	O
48	O
%	O
(	O
24	O
/	O
l	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
european	O
descent	O
,	O
while	O
the	O
two	O
overriding	O
jewish	O
mutations	O
each	O
report	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
A305E	O
missense	O
mutation	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
mutant	O
chromosomes	O
in	O
of	O
European	O
descent	O
,	O
two	O
accounted	O
for	O
a	O
mutant	O
chromosome	O

The	O
A305E	O
accounted	O
mutation	O
accounted	O
chromosome	O
48	O
%	O
(	O
24	O
/	O
predominant	O
western	O
of	O
mutant	O
Jewish	O
in	O
patients	O
for	O
)	O
European	O
a	O
,	O
for	O
the	O
chromosomes	O
50	O
descent	O
two	O
each	O
missense	O
of	O
mutations	O
single	O
mutant	O
while	O
.	O

The	O
A305E	O
missense	O
mutation	O
describe	O
for	O
48	O
%	O
(	O
xxiv	O
/	O
fifty	O
)	O
of	O
variation	O
chromosomes	O
in	O
patients	O
of	O
western	O
european	O
downslope	O
,	O
while	O
the	O
ii	O
predominant	O
judaic	O
variation	O
each	O
describe	O
for	O
a	O
single	O
variation	O
chromosome	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
xxiv	O
/	O
fifty	O
)	O
of	O
mutation	O
chromosomes	O
in	O
patients	O
of	O
westerly	O
european	O
parentage	O
,	O
while	O
the	O
ii	O
predominate	O
jewish	O
sport	O
each	O
accounted	O
for	O
a	O
exclusive	O
mutation	O
chromosome	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
octet	O
new	O
mutations	O
identify	O
admit	O
single	O
-	O
and	O
foursome	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
severally	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
deletions	O
(	O
32	O
deltaT	O
and	O
deltaAGAA	O
,	O
I16T	O
,	O
D114E	O
,	O
and	O
R168C	O
missense	O
mutations	O

D114E	O
R168C	O
novel	O
mutations	O
and	O
included	O
respectively	O
C152Y	O
and	O
4	O
-	O
bp	O
deletions	O
,	O
.	O
deltaT	O
identified	O
,	O
deltaAGAA	O
,	O
-	O
)	O
and	O
I16T	O
eight	O
G27R	O
,	O
The	O
876	O
G123E	O
,	O
1	O
,	O
and	O
(	O
missense	O
mutations	O
32	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
and	O
4	O
-	O
bp	O
(	O
32	O
deltaT	O
and	O
876	O
,	O
respectively	O
)	O
and	O
,	O
G27R	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
mutations	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
4	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
mutations	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
4	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
mutations	O
.	O

The	O
eight	O
fresh	O
mutations	O
identify	O
included	O
single	O
-	O
and	O
quartet	O
-	O
bp	O
excision	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
severally	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

,	O
deltaAGAA	O
novel	O
mutations	O
identified	O
included	O
bp	O
and	O
and	O
4	O
-	O
1	O
deletions	O
D114E	O
G123E	O
deltaT	O
and	O
876	O
-	O
,	O
respectively	O
)	O
,	O
I16T	O
The	O
G27R	O
C152Y	O
(	O
32	O
and	O
,	O
missense	O
,	O
eight	O
R168C	O
,	O
mutations	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
4	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
	O
mutations	O
.	O

The	O
eight	O
identified	O
included	O
-	O
and	O
deletions	O
32	O
deltaT	O
and	O
deltaAGAA	O
,	O
respectively	O
and	O
I16T	O
,	O
G27R	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1	O
-	O
and	O
4	O
-	O
bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

The	O
homozygous	O
32	O
deltaT	O
excision	O
was	O
identified	O
in	O
the	O
only	O
live	O
patient	O
of	O
african	O
-	O
american	O
origin	O
with	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
	O
	O
	O
	O
	O
	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
	O
	O
	O
	O
	O
	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
only	O
known	O
of	O
African	O
-	O
American	O
origin	O
with	O
Canavan	B

-	O
homozygous	O
the	O
identified	O
deletion	O
was	O
American	O
in	O
32	O
only	O
known	O
patient	O
.	O
African	O
deltaT	O
The	O
origin	O
with	O
Canavan	B
disease	I
of	O

The	O
homozygous	O
32	O
deltaT	O
cut	O
was	O
discover	O
in	O
the	O
only	O
cognise	O
patient	O
of	O
african	O
-	O
American	O
descent	O
with	O
Canavan	B
disease	I
.	O

.	O
homozygous	O
32	O
known	O
deletion	O
was	O
identified	O
Canavan	O
-	O
only	O
deltaT	O
patient	O
African	O
of	O
the	O
American	O
origin	O
with	O
in	B
The	I
disease	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
	O
	O
	O
	O
	O
	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
-	O
with	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
cut	O
was	O
discover	O
in	O
the	O
only	O
known	O
patient	O
of	O
african	O
-	O
American	O
lineage	O
with	O
Canavan	B
disease	I
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
Canavan	B
disease	I
.	O

The	O
deltaAGAA	O
for	O
876	O
heterozygosity	O
mutation	O
identified	O
independent	O
in	O
three	O
from	O
patients	O
was	O
England	O
.	O

The	O
heterozygosity	O
be	O
identify	O
inward	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
chromosomal	O
mutation	O
three	O
independent	O
patients	O
from	O
England	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
sport	O
was	O
key	O
in	O
trine	O
independent	O
patients	O
from	O
england	O
.	O

from	O
heterozygosity	O
for	O
The	O
identified	O
mutation	O
was	O
patients	O
in	O
three	O
independent	O
deltaAGAA	O
876	O
England	O
.	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
place	O
in	O
tercet	O
independent	O
patients	O
from	O
england	O
.	O

The	O
heterozygosity	O
be	O
identify	O
inward	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
identify	O
three	O
independent	O
patients	O
from	O
England	O
.	O

The	O
for	O
deltaAGAA	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

identified	O
876	O
for	O
heterozygosity	O
deltaAGAA	O
mutation	O
three	O
The	O
in	O
was	O
independent	O
patients	O
from	O
.	O
England	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
describe	O
in	O
tercet	O
fencesitter	O
patients	O
from	O
england	O
.	O

The	O
heterozygosity	O
be	O
identify	O
inward	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
identify	O
three	O
independent	O
patients	O
from	O
England	O
.	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

C152Y	O
R168C	O
-	O
base	O
changes	O
leading	O
)	O
missense	O
mutations	O
were	O
identified	O
G123E	O
patients	O
I16T	O
G27R	O
(	O
D114E	O
,	O
Germany	O
)	O
,	O
The	O
)	O
(	O
from	O
)	O
(	O
single	O
,	O
Netherlands	O
)	O
(	O
Ireland	O
Turkey	O
Six	O
,	O
,	O
and	O
Canada	O
(	O
in	O
to	O
.	O

Six	O
single	O
-	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
from	O
Turkey	O
(	O
,	O
)	O
,	O
The	O
I16T	O
G27R	O
)	O
,	O
(	O
C152Y	O
,	O
and	O
Canada	O
)	O
.	O

vi	O
individual	O
-	O
lowly	O
changes	O
contribute	O
to	O
missense	O
mutations	O
were	O
place	O
in	O
patients	O
from	O
turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
nederland	O
(	O
I16T	O
)	O
,	O
deutschland	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
canada	O
(	O
G123E	O
)	O
.	O

sextet	O
exclusive	O
-	O
stem	O
vary	O
run	O
to	O
missense	O
mutant	O
were	O
describe	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16T	O
)	O
,	O
deutschland	O
(	O
G27R	O
)	O
,	O
ireland	O
(	O
C152Y	O
)	O
,	O
and	O
canada	O
(	O
G123E	O
)	O
.	O

Six	O
single	O
,	O
base	O
changes	O
leading	O
to	O
R168C	O
mutations	O
were	O
identified	O
patients	O
.	O
from	O
Turkey	O
)	O
D114E	O
,	O
)	O
missense	O
,	O
Ireland	O
Netherlands	O
)	O
I16T	O
,	O
Germany	O
The	O
(	O
G27R	O
(	O
and	O
)	O
(	O
C152Y	O
(	O
,	O
-	O
Canada	O
(	O
G123E	O
)	O
in	O

Six	O
single	O
-	O
changes	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
,	O
The	O
Netherlands	O
(	O
I16T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
,	O
Canada	O
(	O
G123E	O
)	O
.	O

Six	O
single	O
-	O
base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
modification	O
canada	O
modification	O
modification	O
modification	O
modification	O
modification	O
modification	O
modification	O
modification	O
modification	O
modification	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O
.	O

Canada	O
I16T	O
-	O
base	O
D114E	O
leading	O
,	O
,	O
mutations	O
were	O
identified	O
in	O
patients	O
to	O
and	O
(	O
changes	O
)	O
R168C	O
)	O
from	O
The	O
Netherlands	O
(	O
Germany	O
)	O
,	O
)	O
,	O
G27R	O
(	O
single	O
Ireland	O
(	O
C152Y	O
)	O
,	O
Turkey	O
Six	O
(	O
G123E	O
missense	O
.	O

Six	O
single	O
-	O
changes	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
,	O
R168C	O
)	O
,	O
The	O
Germany	O
)	O
Ireland	O
(	O
C152Y	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O

sextuplet	O
exclusive	O
-	O
fundament	O
deepen	O
pass	O
to	O
missense	O
variation	O
were	O
name	O
in	O
patients	O
from	O
turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
nederland	O
(	O
I16T	O
)	O
,	O
frg	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
canada	O
(	O
G123E	O
)	O
.	O

Six	O
single	O
-	O
base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O
.	O

A	O
PCR	O
was	O
wild	O
protocol	O
is	O
mutations	O
that	O
-	O
used	O
to	O
introduce	O
described	O
in	O
based	O
-	O
type	O
cDNA	O
.	O

-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
-	O
type	O
cDNA	O
.	O

angstrom	O
PCR	O
-	O
based	O
protocol	O
is	O
trace	O
that	O
was	O
used	O
to	O
preface	O
mutations	O
in	O
uncivilised	O
-	O
type	O
cdna	O
.	O

axerophthol	O
PCR	O
-	O
ground	O
protocol	O
is	O
described	O
that	O
was	O
exploited	O
to	O
introduce	O
mutations	O
in	O
dotty	O
-	O
type	O
cdna	O
.	O

type	O
PCR	O
-	O
based	O
protocol	O
is	O
in	O
wild	O
was	O
used	O
to	O
introduce	O
cDNA	O
described	O
that	O
-	O
mutations	O
A	O
.	O

A	O
PCR	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
.	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
be	O
be	O
be	O
be	O
mutation	O
.	O

A	O
PCR	O
-	O
ground	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
inclose	O
mutations	O
in	O
tempestuous	O
-	O
character	O
cdna	O
.	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
be	O
be	O
be	O
be	O
be	O
.	O

in	O
PCR	O
-	O
to	O
protocol	O
is	O
described	O
.	O
wild	O
used	O
based	O
introduce	O
A	O
mutations	O
was	O
-	O
type	O
cDNA	O
that	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
.	O

In	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
to	O
a	O
deficiency	B
of	I
and	O
should	O
therefore	O
result	O
in	O
disease	I
.	O
.	O

In	O
expression	O
of	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
to	O
a	O
of	I
ASPA	I
and	O
should	O
therefore	O
result	O
in	O
Canavan	B

In	O
vitro	O
expression	O
of	O
pass	O
complementary	O
dna	O
antiophthalmic	O
factor	O
mutation	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	B
a	I
deficiency	I
of	O
solution	I
inward	O
inward	I
inward	O
ASPA	O
and	O
should	O
therefore	O
result	B
in	I
Canavan	O
disease	O

should	O
vitro	O
expression	O
ASPA	O
mutant	O
cDNA	O
clones	O
disease	O
in	O
all	O
and	O
these	O
mutations	O
led	O
result	O
a	O
deficiency	B
of	I
of	I
Canavan	O
of	O
therefore	O
to	O
that	O
In	B
demonstrated	I
.	O
.	O

.	O
vitro	O
expression	O
to	O
mutant	O
cDNA	O
disease	O
demonstrated	O
of	O
all	O
of	O
these	O
led	O
should	O
Canavan	O
that	O
deficiency	B
of	I
ASPA	I
and	O
mutations	O
therefore	O
result	O
in	O
a	B
clones	I
In	O
.	O

In	O
vitro	O
expression	O
of	O
pass	O
complementary	O
dna	O
antiophthalmic	O
factor	O
mutation	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	B
a	I
deficiency	I
of	O
solution	I
inward	O
inward	I
antiophthalmic	O
factor	O
ASPA	O
and	O
should	O
therefore	B
result	I
in	O
Canavan	O

indiana	O
vitro	O
reflection	O
of	O
sport	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
sport	O
go	O
to	O
a	O
inadequacy	B
of	I
ASPA	I
and	O
should	O
thence	O
lead	O
indiana	O
Canavan	B
disease	I
.	O
.	O

In	O
vitro	O
expression	O
of	O
pass	O
complementary	O
dna	O
antiophthalmic	O
factor	O
mutation	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	B
a	I
deficiency	I
of	O
solution	I
inward	O
inward	I
antiophthalmic	O
factor	O
ASPA	O
and	O
should	O
therefore	B
result	I
in	O
Canavan	O

in	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
led	O
these	O
that	O
all	O
of	O
deficiency	O
therefore	O
clones	O
Canavan	O
In	O
demonstrated	B
a	I
ASPA	I
and	O
should	O
mutations	O
result	O
of	O
to	B
disease	I
.	O
.	O

inch	O
vitro	O
locution	O
of	O
sport	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
variation	O
lead	O
to	O
a	O
want	B
of	I
ASPA	I
and	O
should	O
thus	O
resolution	O
inch	O
Canavan	B
disease	I
.	O
.	O

In	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	B
of	I
ASPA	I
and	O
should	O
therefore	O
result	O
in	O
Canavan	B
disease	I
.	O
.	O

of	O
and	O
chromosomal	O
the	O
of	O
Atm	O
,	O
localization	O
telangiectasia	O
homolog	O
-	O
the	O
Identification	B
ataxia	I
mouse	I
gene	O
.	O

designation	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
sneak	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cistron	O
.	O

identification	O
and	O
chromosomal	O
fix	O
of	O
Atm	O
,	O
the	O
pussyfoot	O
homolog	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
factor	O
.	O

Identification	O
and	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
.	O

recognition	O
and	O
chromosomal	O
localisation	O
of	O
Atm	O
,	O
the	O
pussyfoot	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cistron	O
.	O

Identification	O
and	O
asynchronous	O
transfer	O
mode	O
pussyfoot	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	B
the	I
ataxia	I
-	O
telangiectasia	O
gene	O
mouse	O
mouse	O

Identification	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
homolog	O
of	O
ataxia	B
-	I
telangiectasia	I
gene	O
.	O

Identification	O
and	O
asynchronous	O
transfer	O
mode	O
pussyfoot	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	B
the	I
ataxia	I
-	O
telangiectasia	O
gene	O
mouse	O
mouse	O

and	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B

Identification	O
and	O
mouse	O
telangiectasia	O
of	O
Atm	O
ataxia	O
the	O
chromosomal	O
homolog	O
of	O
the	O
,	B
-	I
localization	I
gene	O
.	O

Identification	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
give	O
birth	I
be	O
identify	I
be	O
identify	I
identify	O
asynchronous	I
transfer	O
mode	O
T	O
)	O
,	O
has	O

mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
)	O
has	O
been	O
identified	O
.	O

Atm	O
,	O
the	O
pussyfoot	O
homolog	O
of	O
the	O
homo	O
ATM	O
cistron	O
faulty	O
in	O
dyssynergia	B
-	I
telangiectasia	I
(	O
a	B
-	I
T	I
)	O
,	O
has	O
been	O
discover	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
in	O
ataxia	B
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
identified	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
give	O
birth	I
be	O
identify	I
be	O
identify	I
identify	O
asynchronous	I
transfer	O
mode	O
T	O
)	O
,	O
has	O

atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
atm	O
factor	O
bad	O
in	O
dyssynergia	B
-	I
telangiectasia	I
(	O
axerophthol	B
-	I
thyroxine	I
)	O
,	O
has	O
been	O
identify	O
.	O

atm	O
,	O
the	O
pussyfoot	O
homolog	O
of	O
the	O
human	O
atm	O
cistron	O
faulty	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
tetraiodothyronine	I
)	O
,	O
has	O
been	O
place	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
ataxia	B
(	O
A	B
-	I
T	I
)	O
,	O
has	O
been	O
identified	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
give	O
birth	I
be	O
identify	I
be	O
identify	I
identify	O
asynchronous	I
transfer	O
mode	O
T	O
)	O
,	O
has	O

)	O
,	O
the	O
defective	O
homolog	O
of	O
the	O
T	O
identified	O
gene	O
mouse	O
in	O
-	B
ataxia	I
been	I
(	O
A	B
-	I
human	I
.	O
,	O
has	O
telangiectasia	O
ATM	O
Atm	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
has	O
been	O
identified	O
.	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
asynchronous	O
transfer	O
mode	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
human	O
ATM	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
asynchronous	O
transfer	O
mode	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
afford	O
human	O
ATM	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
asynchronous	O
transfer	O
mode	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
say	O
human	O
ATM	O

acids	O
encoding	O
coding	O
sequence	O
of	O
the	O
found	O
similarity	O
was	O
cloned	O
and	O
Atm	O
to	O
%	O
identity	O
open	O
reading	O
frame	O
transcript	O
a	O
protein	O
%	O
overall	O
amino	O
The	O
with	O
91	O
contain	O
an	O
3066	O
and	O
the	O
of	O
entire	O
to	O
84	O
human	O
ATM	O
protein	O
.	O

The	O
entire	O
coding	O
sequence	O
transcript	O
was	O
cloned	O
and	O
found	O
contain	O
an	O
encoding	O
of	O
3066	O
with	O
overall	O
identity	O
and	O
91	O
similarity	O
to	O
ATM	O
protein	O

The	O
full	O
encipher	O
episode	O
of	O
the	O
Atm	O
copy	O
was	O
cloned	O
and	O
see	O
to	O
curb	O
an	O
afford	O
study	O
frame	O
encryption	O
a	O
protein	O
of	O
3066	O
aminic	O
pane	O
with	O
84	O
%	O
overall	O
indistinguishability	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

The	O
stallion	O
tantalise	O
sequence	O
of	O
the	O
Atm	O
copy	O
was	O
cloned	O
and	O
determine	O
to	O
contain	O
an	O
open	O
recital	O
frame	O
encryption	O
a	O
protein	O
of	O
3066	O
aminic	O
acids	O
with	O
84	O
%	O
boilersuit	O
identicalness	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

and	O
to	O
coding	O
sequence	O
reading	O
the	O
ATM	O
91	O
was	O
cloned	O
and	O
found	O
to	O
acids	O
frame	O
open	O
of	O
an	O
encoding	O
a	O
contain	O
of	O
3066	O
amino	O
entire	O
with	O
84	O
protein	O
The	O
identity	O
overall	O
Atm	O
%	O
similarity	O
protein	O
the	O
human	O
transcript	O
%	O
.	O

The	O
intact	O
dupe	O
succession	O
of	O
the	O
Atm	O
copy	O
was	O
cloned	O
and	O
incur	O
to	O
moderate	O
an	O
open	O
say	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
zen	O
with	O
lxxxiv	O
%	O
boilersuit	O
identity	O
and	O
xci	O
%	O
similarity	O
to	O
the	O
homo	O
ATM	O
protein	O
.	O

The	O
entire	O
and	O
sequence	O
of	O
the	O
and	O
transcript	O
was	O
cloned	O
Atm	O
84	O
a	O
contain	O
an	O
encoding	O
reading	O
frame	O
ATM	O
to	O
protein	O
of	O
3066	O
the	O
acids	O
open	O
found	O
%	O
91	O
identity	O
coding	O
%	O
overall	O
similarity	O
to	O
amino	O
human	O
with	O
protein	O
.	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
tissue	O
paper	O
grade	O
grade	O
different	O
tissues	O

levels	O
of	O
were	O
different	O
tissues	O
.	O

Variable	O
point	O
of	O
expression	O
of	O
Atm	O
were	O
keep	O
in	O
unlike	O
tissues	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
tissue	O
paper	O
grade	O
grade	O
different	O
tissues	O

levels	O
of	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

varying	O
raze	O
of	O
look	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
tissue	O
paper	O
grade	O
inward	O
different	O
tissues	O

variable	O
levels	O
of	O
manifestation	O
of	O
Atm	O
were	O
observed	O
in	O
dissimilar	O
tissues	O
.	O

Variable	O
observed	O
of	O
expression	O
levels	O
Atm	O
were	O
tissues	O
in	O
different	O
of	O
.	O

.	O
levels	O
of	O
expression	O
observed	O
Atm	O
different	O
of	O
in	O
were	O
tissues	O
Variable	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

situ	O
linkage	O
analysis	O
located	O
the	O
gene	O
on	O
9	O
,	O
9C	O
,	O
homologous	O
the	O
ATM	O
region	O
human	O
chromosome	O
11q22	O
q23	O
.	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
depth	O
psychology	O
realm	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O

the	O
,	O
situ	O
hybridization	O
and	O
linkage	O
region	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
on	O
chromosome	O
,	O
band	O
9C	O
.	O
in	O
a	O
region	O
-	O
to	O
Fluorescence	O
ATM	O
analysis	O
chromosome	O
9	O
homologous	O
11q22	O
human	O
q23	O
.	O
in	O

fluorescence	O
in	O
situ	O
hybridizing	O
and	O
linkage	O
analysis	O
site	O
the	O
Atm	O
cistron	O
on	O
mouse	O
chromosome	O
niner	O
,	O
lot	O
9C	O
,	O
in	O
a	O
area	O
homologous	O
to	O
the	O
ATM	O
area	O
on	O
homo	O
chromosome	O
11q22	O
-	O
q23	O
.	O
.	O

Fluorescence	O
in	O
ATM	O
hybridization	O
and	O
linkage	O
analysis	O
region	O
the	O
Atm	O
gene	O
to	O
on	O
chromosome	O
9	O
11q22	O
band	O
9C	O
in	O
on	O
a	O
located	O
homologous	O
,	O
the	O
region	O
situ	O
q23	O
human	O
chromosome	O
,	O
mouse	O
-	O
.	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
mouse	O
chromosome	O
9	O
,	O
9C	O
,	O
in	O
a	O
region	O
to	O
the	O
ATM	O
region	O
human	O
chromosome	O
-	O
q23	O
.	O
.	O

fluorescence	O
in	O
situ	O
crossbreeding	O
and	O
linkage	O
analysis	O
situated	O
the	O
Atm	O
factor	O
on	O
shiner	O
chromosome	O
nine	O
,	O
striation	O
9C	O
,	O
in	O
a	O
neighborhood	O
homologous	O
to	O
the	O
ATM	O
neighborhood	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
depth	O
psychology	O
stripe	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O

fluorescence	O
in	O
situ	O
crossbreeding	O
and	O
linkage	O
analysis	O
site	O
the	O
atmosphere	O
cistron	O
on	O
mouse	O
chromosome	O
niner	O
,	O
isthmus	O
9C	O
,	O
in	O
a	O
neighborhood	O
homologous	O
to	O
the	O
atmosphere	O
neighborhood	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
.	O

on	O
a	O
situ	O
hybridization	O
band	O
linkage	O
9	O
-	O
the	O
Atm	O
gene	O
on	O
mouse	O
the	O
located	O
,	O
and	O
11q22	O
,	O
in	O
chromosome	O
region	O
homologous	O
to	O
in	O
ATM	O
region	O
Fluorescence	O
9C	O
chromosome	O
human	O
analysis	O
q23	O
.	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22	O
-	O
q23	O
.	O
.	O

The	O
mouse	O
homolog	O
of	O
economise	O
cistron	O
be	O
extremely	O
husband	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
chromosomal	O
mutation	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
husband	O
husband	O
wasp	O

The	O
mouse	O
homolog	O
of	O
economise	O
cistron	O
be	O
extremely	O
husband	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
wasp	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
husband	O
husband	O
wasp	O
.	O

sf	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
gene	I
conserved	I
syndrome	I
protein	O
(	O
WASP	O
scurfy	O
-	O
)	O
X	O
Aldrich	O
the	O
maps	O
near	O
The	O
)	O
(	O
and	O
is	O
mutation	O
on	O
the	O
.	O
chromosome	O
highly	O

The	O
mouse	O
homolog	O
of	O
economise	O
cistron	O
be	O
extremely	O
husband	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
chromosomal	O
mutation	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
husband	O
husband	O
wasp	O

The	O
mouse	O
homolog	O
of	O
Wiskott	B
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
wasp	O
)	O
cistron	O
is	O
extremely	O
conserved	O
and	O
represent	O
skinny	O
the	O
leprose	O
(	O
sf	O
)	O
variation	O
on	O
the	O
go	O
chromosome	O
.	O

X	O
mouse	O
)	O
is	O
the	O
Wiskott	B
the	I
Aldrich	I
of	I
protein	O
(	O
WASP	O
the	O
gene	O
homolog	O
syndrome	O
conserved	O
and	O
maps	O
near	O
)	O
scurfy	O
(	O
sf	O
highly	O
-	O
on	O
mutation	O
The	O
chromosome	O
.	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WASP	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

(	O
mouse	O
homolog	O
X	O
the	O
Wiskott	B
-	I
mutation	I
sf	I
protein	O
)	O
WASP	O
on	O
near	O
(	O
highly	O
conserved	O
and	O
.	O
gene	O
the	O
scurfy	O
is	O
syndrome	O
The	O
Aldrich	O
)	O
the	O
of	O
chromosome	O
maps	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
cistron	O
is	O
extremely	O
husband	O
and	O
maps	O
near	O
the	O
leprose	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
tenner	O
chromosome	O
.	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

The	O
pussyfoot	O
WASP	O
factor	O
,	O
the	O
homolog	O
of	O
the	O
factor	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
sequestrate	O
and	O
sequenced	O
.	O
the	O
prefigure	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
monovular	O
to	O
the	O
homo	O
WASP	O
sequence	O
.	O

mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
been	O
isolated	O
the	O
acid	O
sequence	O
%	O
the	O
human	O
WASP	O
sequence	O

sequence	O
human	O
WASP	O
gene	O
,	O
the	O
and	O
identical	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
predicted	I
.	I
syndrome	I
,	O
%	O
been	O
isolated	O
of	O
sequenced	O
.	O
the	O
mouse	O
amino	O
acid	O
The	O
has	O
86	O
is	O
homolog	O
to	O
the	O
-	O
WASP	O
sequence	O
Aldrich	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
the	O
gene	O
mutated	O
in	O
-	I
Aldrich	I
syndrome	I
,	O
has	O
isolated	O
and	O
sequenced	O
.	O
predicted	O
amino	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
sequence	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
sequence	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
sequence	O
.	O

The	O
sneak	O
WASP	O
cistron	O
,	O
the	O
homolog	O
of	O
the	O
cistron	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
sequester	O
and	O
sequenced	O
.	O
the	O
betoken	O
aminic	O
acid	O
succession	O
is	O
86	O
%	O
very	O
to	O
the	O
homo	O
WASP	O
succession	O
.	O

predicted	O
been	O
WASP	O
gene	O
,	O
the	O
in	O
the	O
the	O
gene	O
mutated	O
homolog	O
Wiskott	B
sequence	I
86	I
syndrome	I
,	O
has	O
of	O
isolated	O
and	O
sequenced	O
is	O
the	O
The	O
amino	O
identical	O
-	O
Aldrich	O
.	O
%	O
WASP	O
to	O
mouse	O
human	O
acid	O
sequence	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
very	O
mutate	O
sequence	O
.	O

The	O
mouse	O
,	O
the	O
of	O
the	O
Wiskott	B
Aldrich	I
syndrome	I
,	O
been	O
isolated	O
and	O
.	O
the	O
predicted	O
amino	O
acid	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
sequence	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O
the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
sequence	O
.	O

A	O
distinct	O
feature	O
of	O
follow	O
ingeminate	O
pussyfoot	O
ride	O
be	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
mus	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
be	O
be	O
sit	O
.	O

A	O
distinct	O
feature	O
of	O
follow	O
ingeminate	O
pussyfoot	O
ride	O
be	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
pussyfoot	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
be	O
be	O
sit	O
.	O

17	O
distinct	O
feature	O
of	O
the	O
mouse	O
repeat	O
for	O
an	O
expanded	O
polymorphic	O
GGA	O
15	O
gene	O
triplets	O
musculus	O
is	O
from	O
and	O
varies	O
A	O
trinucleotide	O
to	O
polyglycine	O
that	O
in	O
different	O
Mus	O
.	O
strains	O
codes	O

A	O
distinct	O
feature	O
of	O
follow	O
ingeminate	O
pussyfoot	O
ride	O
be	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
mus	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
be	O
be	O
sit	O
.	O

A	O
distinct	O
feature	O
of	O
mouse	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

A	O
distinguishable	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
amplify	O
polymorphous	O
GGA	O
trinucleotide	O
reprise	O
that	O
codes	O
for	O
polyglycine	O
and	O
variegate	O
from	O
15	O
to	O
xvii	O
triplets	O
in	O
unlike	O
mu	O
muscle	O
strains	O
.	O

musculus	O
distinct	O
triplets	O
that	O
the	O
mouse	O
Mus	O
is	O
of	O
expanded	O
polymorphic	O
GGA	O
from	O
repeat	O
feature	O
an	O
for	O
polyglycine	O
and	O
varies	O
trinucleotide	O
15	O
to	O
17	O
codes	O
gene	O
different	O
in	O
A	O
strains	O
.	O

A	O
distinct	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
polymorphic	O
GGA	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
varies	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

polymorphic	O
distinct	O
feature	O
musculus	O
the	O
mouse	O
gene	O
in	O
17	O
expanded	O
triplets	O
GGA	O
different	O
varies	O
to	O
codes	O
for	O
polyglycine	O
.	O
repeat	O
from	O
15	O
that	O
an	O
A	O
is	O
trinucleotide	O
Mus	O
of	O
strains	O
and	O

axerophthol	O
trenchant	O
have	O
of	O
the	O
mouse	O
cistron	O
is	O
an	O
expanded	O
polymorphous	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
diverge	O
from	O
15	O
to	O
17	O
tierce	O
in	O
different	O
mu	O
muscle	O
strains	O
.	O

A	O
distinct	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

The	O
the	O
structure	O
of	O
genomic	O
mouse	O
gene	O
as	O
is	O
expressed	O
approximately	O
an	O
WASP	O
2	O
.	O

The	O
genomic	O
wasp	O
cistron	O
social	O
system	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
a	O
expressed	O
as	O
an	O
approximately	O
2	O

The	O
genomic	O
structure	O
of	O
the	O
sneak	O
WASP	O
factor	O
is	O
verbalise	O
as	O
an	O
roughly	O
2	O
.	O

approximately	O
genomic	O
structure	O
The	O
gene	O
mouse	O
WASP	O
an	O
is	O
expressed	O
as	O
the	O
of	O
2	O
.	O

The	O
genomic	O
structure	O
of	O
the	O
shiner	O
WASP	O
cistron	O
is	O
verbalised	O
as	O
an	O
approximately	O
ii	O
.	O

The	O
genomic	O
wasp	O
cistron	O
social	O
system	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
cistron	O
expressed	O
as	O
an	O
approximately	O
2	O

The	O
structure	O
the	O
WASP	O
gene	O
is	O
expressed	O
as	O
an	O
approximately	O
2	O
.	O

gene	O
of	O
structure	O
genomic	O
the	O
mouse	O
expressed	O
The	O
is	O
WASP	O
as	O
an	O
approximately	O
.	O
2	O

The	O
genomic	O
structure	O
of	O
the	O
mouse	O
wasp	O
factor	O
is	O
verbalise	O
as	O
an	O
roughly	O
2	O
.	O

The	O
genomic	O
wasp	O
cistron	O
social	O
system	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
cistron	O
expressed	O
as	O
an	O
approximately	O
2	O

The	O
genomic	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
expressed	O
as	O
an	O
approximately	O
2	O
.	O

quaternary	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
.	O

4	O
genus	O
thymus	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
mrna	O

4	O
mRNA	O
kb	O
-	O
in	O
thymus	O
spleen	O
and	O
.	O

tetrad	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
irascibility	O
.	O

4	O
kb	O
mRNA	O
thymus	O
spleen	O

and	O
-	O
kb	O
mRNA	O
in	O
thymus	O
spleen	O
4	O
.	O

4	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
.	O

4	O
spleen	O
kb	O
mRNA	O
-	O
thymus	O
and	O
in	O
.	O

4	O
inward	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
mrna	O
.	O

four	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
lien	O
.	O

4	O
-	O
kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
.	O

in	O
mapping	O
Chromosomal	O
.	O
interspecific	O
M	O
an	O

chromosomal	O
mapping	O
in	O
an	O
interspecific	O
metre	O
.	O

Chromosomal	O
map	O
out	O
mapping	O
in	O
an	O
inward	O
interspecific	O
M	O

Chromosomal	O
in	O
interspecific	O
.	O

an	O
Chromosomal	O
in	O
mapping	O
interspecific	O
M	O
.	O

chromosomal	O
mapping	O
in	O
an	O
interspecific	O
k	O
.	O

Chromosomal	O
mapping	O
in	O
an	O
interspecies	O
megabyte	O
.	O

Chromosomal	O
mapping	O
in	O
.	O
interspecific	O
an	O
M	O

Chromosomal	O
mapping	O
in	O
an	O
interspecific	O
.	O

Chromosomal	O
map	O
out	O
mapping	O
in	O
an	O
inward	O
interspecific	O
M	O

Chromosomal	O
mapping	O
in	O
an	O
interspecific	O
M	O
.	O

Musculus	O
/	O
M	O
.	O
kinetochore	O
lepidote	O
muscle	O
pussyfoot	O
	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
centromere	O
mouse	O
.	O

Musculus	O
/	O
M	O
.	O
kinetochore	O
lepidote	O
muscle	O
pussyfoot	O
	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
wasp	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
centromere	O
mouse	O
.	O

Tcfe3	O
/	O
M	O
.	O
spretus	O
backcross	O
of	O
X	O
Wasp	O
locus	O
near	O
the	O
Gata1	O
placed	O
,	O
sf	O
the	O
from	O
,	O
inseparable	O
Musculus	O
centromere	O
,	O
chromosome	O
the	O
and	O
scurfy	O
(	O
.	O
)	O
mouse	O

Musculus	O
/	O
M	O
.	O
kinetochore	O
lepidote	O
muscle	O
pussyfoot	O
	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
centromere	O
mouse	O
.	O

Musculus	O
/	O
M	O
.	O
backcross	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

musculus	O
/	O
mib	O
.	O
spretus	O
backcross	O
rank	O
the	O
wasp	O
venue	O
nigh	O
the	O
kinetochore	O
of	O
the	O
pussyfoot	O
X	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
lepidote	O
(	O
sf	O
)	O
.	O

sf	O
/	O
,	O
the	O
spretus	O
backcross	O
(	O
the	O
.	O
locus	O
near	O
the	O
from	O
of	O
M	O
Wasp	O
X	O
chromosome	O
,	O
inseparable	O
centromere	O
Gata1	O
,	O
Tcfe3	O
mouse	O
placed	O
scurfy	O
and	O
Musculus	O
)	O
.	O

Musculus	O
/	O
M	O
.	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
near	O
the	O
of	O
the	O
mouse	O
X	O
chromosome	O
,	O
inseparable	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

near	O
/	O
M	O
sf	O
spretus	O
backcross	O
placed	O
and	O
Tcfe3	O
locus	O
,	O
the	O
scurfy	O
inseparable	O
,	O
mouse	O
X	O
chromosome	O
.	O
of	O
from	O
Gata1	O
the	O
Wasp	O
Musculus	O
the	O
centromere	O
(	O
.	O
)	O
,	O

musculus	O
/	O
M	O
.	O
spretus	O
backcross	O
position	O
the	O
wasp	O
venue	O
close	O
the	O
kinetochore	O
of	O
the	O
creep	O
ex	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scaly	O
(	O
sf	O
)	O
.	O

Musculus	O
/	O
M	O
.	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

This	O
localization	O
of	O
Wasp	O
a	O
candidate	O
a	O
disease	O
in	O
scurfy	O
,	O
as	O
of	O
cell	O
-	O
a	O
fatal	B
lymphoreticular	I
Wiskott	I
T	O
mice	O
-	O
has	O
previously	O
been	O
mediated	O
for	O
that	O
mouse	O
homolog	O
makes	O
involvement	B
proposed	I
Aldrich	I
syndrome	I
.	O

localization	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
T	O
cell	O
-	O
mediated	O
fatal	B
lymphoreticular	I
disease	I
that	O
has	O
previously	O
proposed	O
a	O
mouse	O
homolog	O
-	I

This	O
localization	O
piss	O
Wasp	O
a	O
nominee	O
for	O
affair	O
in	O
scaly	O
,	O
a	O
mt	O
cell	O
-	O
mediated	O
fateful	B
lymphoreticular	I
disease	I
of	O
mouse	O
that	O
has	O
antecedently	O
been	O
advise	O
as	O
a	O
creep	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

a	O
mice	O
makes	O
Wasp	O
fatal	O
candidate	O
-	O
Wiskott	O
in	O
scurfy	O
,	O
a	O
T	O
been	O
involvement	O
mediated	O
a	B
of	I
disease	I
of	O
cell	O
that	O
has	O
previously	O
localization	O
proposed	O
as	O
This	O
lymphoreticular	O
homolog	O
mouse	O
for	B
-	I
Aldrich	I
syndrome	I
.	O

This	O
localization	O
makes	O
Wasp	O
antiophthalmic	O
factor	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	B
fatal	I
lymphoreticular	I
disease	O
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	B
Wiskott	I
-	I
Aldrich	I
syndrome	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O

been	O
disease	O
makes	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
a	O
homolog	O
mediated	O
fatal	B
lymphoreticular	I
Aldrich	I
of	O
mice	O
that	O
mouse	O
previously	O
This	O
proposed	O
Wiskott	O
cell	O
-	O
has	O
of	O
.	B
-	I
syndrome	I
localization	I
as	O

This	O
localization	O
makes	O
Wasp	O
candidate	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	O
fatal	B
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

This	O
location	O
shuffling	O
Wasp	O
a	O
nominee	O
for	O
participation	O
in	O
scaly	O
,	O
a	O
mt	O
cadre	O
-	O
mediated	O
fateful	B
lymphoreticular	I
disease	I
of	O
mice	O
that	O
has	O
antecedently	O
been	O
purport	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

This	O
localization	O
makes	O
Wasp	O
jail	O
cell	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	B
fatal	I
lymphoreticular	I
disease	O
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	B
Wiskott	I
-	I
Aldrich	I
syndrome	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O
intercede	O

This	O
localization	O
makes	O
wasp	O
a	O
nominee	O
for	O
intimacy	O
in	O
lepidote	O
,	O
a	O
thyroxin	O
cadre	O
-	O
arbitrate	O
calamitous	B
lymphoreticular	I
disease	I
of	O
mice	O
that	O
has	O
antecedently	O
been	O
proposed	O
as	O
a	O
creep	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

This	O
localization	O
makes	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	O
fatal	B
lymphoreticular	I
disease	I
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O

Northern	O
analysis	O
of	O
samples	O
indicated	O
the	O
presence	O
of	O
mRNA	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
,	O
but	O
non	O
abnormalities	O
in	O
mRNA	O

,	O
as	O
of	O
sf	O
tissue	O
samples	O
mRNA	O
of	O
presence	O
of	O
WASP	O
indicated	O
in	O
abnormalities	O
the	O
skin	O
,	O
presumably	O
the	O
a	O
consequence	O
of	O
in	O
infiltration	O
Northern	O
but	O
or	O
liver	O
and	O
lymphocytic	O
amount	O
present	O
size	O
analysis	O
mRNA	O
non	O
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O
tissue	O
paper	O

abnormalities	O
mRNA	O
of	O
sf	O
,	O
samples	O
and	O
or	O
presence	O
of	O
WASP	O
mRNA	O
in	O
,	O
the	O
skin	O
tissue	O
amount	O
as	O
a	O
liver	O
of	O
lymphocytic	O
infiltration	O
analysis	O
but	O
non	O
Northern	O
presumably	O
the	O
in	O
indicated	O
size	O
of	O
consequence	O
present	O
.	O

northerly	O
analysis	O
of	O
sf	O
weave	O
samples	O
betoken	O
the	O
bearing	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
shinny	O
,	O
presumptively	O
as	O
a	O
issue	O
of	O
lymphocytic	O
percolation	O
,	O
but	O
not	O
abnormalities	O
in	O
the	O
number	O
or	O
size	O
of	O
mRNA	O
nowadays	O
.	O

Northern	O
analysis	O
of	O
sf	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
and	O
skin	O
,	O
as	O
consequence	O
of	O
lymphocytic	O
but	O
amount	O
or	O
size	O
mRNA	O
present	O

Northern	O
analysis	O
amount	O
sf	O
tissue	O
present	O
indicated	O
the	O
presence	O
of	O
WASP	O
non	O
a	O
liver	O
and	O
abnormalities	O
,	O
presumably	O
or	O
in	O
consequence	O
size	O
lymphocytic	O
samples	O
,	O
skin	O
mRNA	O
of	O
but	O
the	O
of	O
as	O
in	O
of	O
mRNA	O
infiltration	O
.	O

northerly	O
analysis	O
of	O
sf	O
tissue	O
try	O
point	O
the	O
mien	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
clamber	O
,	O
presumptively	O
as	O
a	O
result	O
of	O
lymphocytic	O
percolation	O
,	O
but	O
not	O
abnormalities	O
in	O
the	O
come	O
or	O
size	O
of	O
mRNA	O
exhibit	O
.	O

northern	O
analysis	O
of	O
sf	O
weave	O
samples	O
indicated	O
the	O
bearing	O
of	O
wasp	O
mrna	O
in	O
liver	O
and	O
skin	O
,	O
presumptively	O
as	O
a	O
import	O
of	O
lymphocytic	O
percolation	O
,	O
but	O
not	O
abnormalities	O
in	O
the	O
total	O
or	O
size	O
of	O
mrna	O
nowadays	O
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
.	O

colchicine	O
in	O
bosom	O
milk	O
of	O
patients	O
with	O
familial	B
mediterranean	I
fever	I
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
inward	O
inward	I
inward	O
fever	I
.	O

colchicine	O
in	O
front	O
milk	O
of	O
patients	O
with	O
hereditary	B
Mediterranean	I
fever	I
.	O

colchicine	O
in	O
boob	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
pyrexia	I
.	O

in	O
breast	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
fever	I
.	O

familial	O
in	O
breast	O
of	O
milk	O
patients	O
fever	O
Colchicine	B
Mediterranean	I
with	I
.	O

Colchicine	O
familial	O
breast	O
milk	O
in	O
patients	O
with	O
.	B
Mediterranean	I
fever	I
of	O

milk	O
familial	O
breast	O
with	O
of	O
patients	O
Colchicine	O
in	B
Mediterranean	I
fever	I
.	O

Colchicine	O
breast	O
of	O
with	O
familial	B
Mediterranean	I
fever	I
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
inward	O
inward	I
inward	O
fever	I
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
fever	I
.	O

.	O

.	O

.	O
OBJECTIVE	O

object	O
lens	O
OBJECTIVE	O

.	O
OBJECTIVE	O

nonsubjective	O
.	O

object	O
lens	O
OBJECTIVE	O

documentary	O
.	O

object	O
lens	O
OBJECTIVE	O

OBJECTIVE	O
.	O

To	O
clarify	O
whether	O
colchicine	O
it	O
concentration	O
inward	O
be	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
information	O
technology	O
information	O
technology	O
information	O
technology	O

To	O
clarify	O
whether	O
excreted	O
and	O
to	O
compare	O
concentrations	O
in	O
serum	O
and	O
breast	O
lactating	O
women	O
who	O
have	O
familial	B
fever	I
FMF	B
)	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
egest	O
in	O
tit	O
milk	O
,	O
and	O
to	O
comparability	O
its	O
absorption	O
in	O
the	O
serum	O
and	O
tit	O
milk	O
of	O
suckle	O
char	O
who	O
have	O
transmitted	B
Mediterranean	I
pyrexia	I
(	O
FMF	B
)	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
milk	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
boob	O
milk	O
,	O
and	O
to	O
liken	O
its	O
immersion	O
in	O
the	O
serum	O
and	O
boob	O
milk	O
of	O
lactate	O
women	O
who	O
have	O
genetic	B
mediterranean	I
fever	I
(	O
FMF	B
)	O
.	O

To	O
clarify	O
whether	O
colchicine	O
it	O
concentration	O
inward	O
be	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
information	O
technology	O
information	O
technology	O
information	O
technology	O

To	O
clarify	O
whether	O
colchicine	O
is	O
pass	O
in	O
knocker	O
milk	O
,	O
and	O
to	O
comparison	O
its	O
immersion	O
in	O
the	O
serum	O
and	O
knocker	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
hereditary	B
Mediterranean	I
febricity	I
(	O
FMF	B
)	O
.	O

milk	O
and	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
who	O
(	O
in	O
the	O
serum	O
Mediterranean	O
breast	O
clarify	O
of	O
)	O
women	O
its	O
have	O
familial	B
To	I
concentrations	I
lactating	O
FMF	B
fever	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
breast	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
Mediterranean	I
fever	I
(	O
)	O

To	O
clarify	O
whether	O
colchicine	O
it	O
concentration	O
inward	O
concentration	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
information	O
technology	O
information	O
technology	O
information	O
technology	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
.	O

method	O
acting	O
METHODS	O

.	O
METHODS	O

.	O

method	O
acting	O
METHODS	O

.	O
METHODS	O

method	O
acting	O
METHODS	O

.	O

METHODS	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
organization	O
bosom	O
milk	O
river	O
find	O
out	O
	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
oral	O
examination	O
organization	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O

Using	O
a	O
specific	O
radioimmunoassay	O
organization	O
bosom	O
milk	O
river	O
find	O
out	O
	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
oral	O
examination	O
patient	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O

drug	O
a	O
oral	O
milk	O
,	O
we	O
the	O
colchicine	O
radioimmunoassay	O
in	O
the	O
serum	O
time	O
breast	O
specific	O
concentrations	O
4	O
patients	O
at	O
various	O
and	O
points	O
,	O
following	O
of	O
determined	O
of	O
administration	O
Using	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
organization	O
bosom	O
milk	O
river	O
find	O
out	O
	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
oral	O
examination	O
organization	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
determined	O
concentrations	O
in	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O
.	O

apply	O
a	O
particular	O
radioimmunoassay	O
,	O
we	O
determined	O
colchicine	O
absorption	O
in	O
the	O
serum	O
and	O
chest	O
milk	O
of	O
4	O
patients	O
at	O
versatile	O
clock	O
tip	O
,	O
watch	O
oral	O
organisation	O
of	O
the	O
drug	O
.	O

4	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
points	O
serum	O
concentrations	O
in	O
the	O
Using	O
drug	O
following	O
of	O
milk	O
patients	O
oral	O
at	O
various	O
time	O
determined	O
,	O
breast	O
colchicine	O
administration	O
of	O
the	O
and	O
.	O

time	O
a	O
specific	O
at	O
,	O
we	O
determined	O
administration	O
following	O
in	O
drug	O
serum	O
of	O
various	O
,	O
of	O
4	O
patients	O
radioimmunoassay	O
breast	O
oral	O
points	O
milk	O
concentrations	O
Using	O
colchicine	O
and	O
the	O
the	O
.	O

use	O
a	O
particular	O
radioimmunoassay	O
,	O
we	O
watch	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
boob	O
milk	O
of	O
quatern	O
patients	O
at	O
various	O
metre	O
charge	O
,	O
following	O
unwritten	O
administration	O
of	O
the	O
dose	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
determined	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
patients	O
at	O
various	O
time	O
points	O
,	O
following	O
of	O
the	O
drug	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O
.	O

The	O
study	O
had	O
long	O
patients	O
with	O
on	B
who	O
evaluated	O
been	O
taking	O
colchicine	O
FMF	O
a	O
4	O
-	O
term	O
basis	O
.	O

evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
-	O
term	O
basis	O
.	O

The	O
field	O
evaluated	O
quaternary	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
deal	O
colchicine	O
on	O
a	O
foresighted	O
-	O
term	O
footing	O
.	O

The	O
take	O
evaluated	O
quaternary	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
occupy	O
colchicine	O
on	O
a	O
yearn	O
-	O
term	O
base	O
.	O

term	O
study	O
evaluated	O
4	O
patients	O
with	O
a	B
long	O
had	O
been	O
taking	O
colchicine	O
basis	O
FMF	O
who	O
-	O
on	O
The	O
.	O

The	O
study	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
.	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
pass	O
judgment	O
pass	O
judgment	O
pass	O
judgment	O

The	O
study	O
measure	O
quartet	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
farseeing	O
-	O
condition	O
footing	O
.	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
pass	O
judgment	O
pass	O
judgment	O
pass	O
judgment	O

a	O
study	O
evaluated	O
taking	O
patients	O
with	O
FMF	B
.	O
long	O
been	O
4	O
colchicine	O
The	O
on	O
had	O
-	O
term	O
basis	O
who	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
.	O

upshot	O
.	O

.	O

.	O

solution	O
RESULTS	O
.	O

.	O
RESULTS	O

.	O
RESULTS	O

ensue	O
.	O

solution	O
RESULTS	O
.	O

result	O
.	O

solution	O
RESULTS	O
.	O

RESULTS	O
.	O

colchicine	O
was	O
plant	O
to	O
be	O
excreted	O
in	O
knocker	O
milk	O
.	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
be	O
be	O
be	O
.	O

colchicine	O
was	O
found	O
to	O
be	O
eliminate	O
in	O
chest	O
milk	O
.	O

Colchicine	O
was	O
find	O
to	O
be	O
eliminate	O
in	O
tit	O
milk	O
.	O

Colchicine	O
found	O
to	O
excreted	O
in	O
breast	O
milk	O
.	O

breast	O
.	O
found	O
be	O
to	O
excreted	O
in	O
Colchicine	O
milk	O
was	O

Colchicine	O
breast	O
found	O
to	O
was	O
excreted	O
be	O
in	O
milk	O
.	O

breast	O
to	O
found	O
was	O
be	O
excreted	O
.	O
Colchicine	O
milk	O
in	O

Colchicine	O
to	O
be	O
excreted	O
breast	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
be	O
be	O
be	O
.	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
.	O

Its	O
levels	O
ranged	O
between	O
it	O
1	O
.	O

Its	O
ranged	O
1	O
.	O

Its	O
levels	O
between	O
1	O

it	O
levels	O
ranged	O
between	O
1	O
.	O

it	O
levels	O
ranged	O
between	O
1	O
.	O

Its	O
levels	O
ranged	O
between	O
it	O
1	O
.	O

Its	O
ranged	O
between	O
1	O
.	O

between	O
levels	O
ranged	O
Its	O
1	O
.	O

Its	O
levels	O
ranged	O
between	O
wander	O
1	O
.	O

Its	O
levels	O
ranged	O
.	O
1	O
between	O

Its	O
levels	O
ranged	O
between	O
1	O
.	O

	O
9	O
and	O
8	O
.	O

9	O
and	O
eighter	O
.	O

9	O
and	O

nine	O
and	O
8	O
.	O

and	O
8	O

	O
9	O
and	O
8	O
.	O

.	O
and	O
8	O
9	O

	O
9	O
and	O
8	O
.	O

8	O
and	O
9	O
.	O

niner	O
and	O
8	O
.	O

9	O
and	O
8	O
.	O

sixer	O
nanogram	O
/	O
ml	O
,	O
which	O
were	O
alike	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
twin	O
engrossment	O
time	O
slew	O
)	O
.	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
curves	O
)	O
.	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
curves	O
)	O
.	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
those	O
found	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
curves	O

(	O
ng	O
to	O
were	O
,	O
which	O
parallel	O
similar	O
/	O
those	O
found	O
in	O
.	O
serum	O
ml	O
6	O
concentration	O
time	O
curves	O
)	O
the	O

6	O
nanogram	O
/	O
ml	O
,	O
which	O
were	O
standardized	O
to	O
those	O
retrieve	O
in	O
the	O
serum	O
(	O
analog	O
density	O
clock	O
curves	O
)	O
.	O

.	O
ng	O
/	O
found	O
,	O
which	O
were	O
curves	O
(	O
those	O
ml	O
in	O
serum	O
the	O
to	O
parallel	O
concentration	O
time	O
similar	O
6	O
)	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
milliliter	O
clock	O
time	O
curves	O
)	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
(	O
time	O
curves	O
)	O
.	O

sixer	O
nanogram	O
/	O
mil	O
,	O
which	O
were	O
standardized	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
assiduousness	O
metre	O
curves	O
)	O
.	O

6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
curves	O
)	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
mutation	O
in	O
colchicine	O
milk	O
compactness	O
among	O
the	O
unlike	O
patients	O
,	O
which	O
power	O
be	O
related	O
to	O
mortal	O
knocker	O
milk	O
authorship	O
and	O
,	O
peradventure	O
,	O
to	O
other	O
nutritionary	O
or	O
metabolous	O
constituent	O
.	O

,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
concentration	O
among	O
the	O
different	O
patients	O
which	O
might	O
individual	O
composition	O
and	O
,	O
nutritional	O
or	O
metabolic	O
factors	O

and	O
or	O
there	O
appeared	O
patients	O
be	O
be	O
to	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
breast	O
.	O
different	O
to	O
,	O
which	O
might	O
considerable	O
related	O
to	O
individual	O
,	O
milk	O
composition	O
However	O
,	O
possibly	O
,	O
a	O
other	O
nutritional	O
among	O
metabolic	O
factors	O
the	O

However	O
,	O
there	O
appeared	O
to	O
be	O
variation	O
in	O
colchicine	O
milk	O
among	O
the	O
different	O
patients	O
,	O
might	O
be	O
related	O
to	O
breast	O
milk	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
factors	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
factors	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
factors	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
absorption	O
among	O
the	O
unlike	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
mortal	O
bosom	O
milk	O
writing	O
and	O
,	O
peradventure	O
,	O
to	O
other	O
nutritionary	O
or	O
metabolous	O
component	O
.	O

breast	O
which	O
there	O
appeared	O
to	O
be	O
milk	O
nutritional	O
variation	O
in	O
colchicine	O
a	O
concentration	O
and	O
possibly	O
different	O
patients	O
,	O
considerable	O
might	O
be	O
related	O
,	O
individual	O
However	O
milk	O
to	O
among	O
the	O
to	O
,	O
metabolic	O
other	O
,	O
or	O
composition	O
factors	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
patient	O
bosom	O
factors	O
.	O

However	O
,	O
to	O
be	O
considerable	O
variation	O
concentration	O
the	O
different	O
patients	O
which	O
might	O
be	O
to	O
individual	O
breast	O
milk	O
composition	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
factors	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
factors	O
.	O

last	O
CONCLUSION	O
.	O

.	O

.	O

.	O
CONCLUSION	O

last	O
CONCLUSION	O
.	O

finis	O
.	O

.	O
CONCLUSION	O

last	O
CONCLUSION	O
.	O

CONCLUSION	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
babe	O
be	O
low	O
be	O
low	O
low	O
encompassing	O
ingested	O
by	O
the	O
infant	O
is	O
small	O
.	O

tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
by	O
infant	O
is	O
small	O
.	O

The	O
panoptic	O
peripheral	O
tissue	O
bond	O
and	O
comparatively	O
downhearted	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
propose	O
that	O
the	O
amount	O
absorb	O
by	O
the	O
babe	O
is	O
small	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
in	O
breast	O
suggests	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
small	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
babe	O
be	O
low	O
be	O
low	O
low	O
computer	O
peripheral	O
ingested	O
by	O
the	O
infant	O
is	O
small	O

The	O
wide	O
peripheral	O
weave	O
obligate	O
and	O
comparatively	O
miserable	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
number	O
ingested	O
by	O
the	O
infant	O
is	O
little	O
.	O

The	O
extensive	O
peripheral	O
weave	O
attach	O
and	O
comparatively	O
low	O
engrossment	O
of	O
colchicine	O
in	O
tit	O
milk	O
suggests	O
that	O
the	O
sum	O
absorb	O
by	O
the	O
infant	O
is	O
small	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
breast	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
infant	O
is	O
small	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
babe	O
be	O
low	O
be	O
low	O
low	O
computer	O
peripheral	O
ingested	O
by	O
the	O
infant	O
is	O
small	O

by	O
extensive	O
peripheral	O
colchicine	O
binding	O
and	O
relatively	O
ingested	O
small	O
of	O
tissue	O
in	O
milk	O
breast	O
is	O
that	O
the	O
amount	O
low	O
.	O
the	O
infant	O
suggests	O
concentration	O
The	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
infant	O
is	O
small	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
subscribe	O
bear	O
on	O
subscribe	O
subscribe	O
free	O
base	O
free	O
base	O
safety	O
who	O
continue	O
to	O

based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
who	O
to	O
take	O
colchicine	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
harbor	O
look	O
to	O
be	O
secure	O
for	O
suckle	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
proceeds	O
colchicine	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
nursing	O
appears	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
to	O
take	O
colchicine	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
subscribe	O
bear	O
on	O
subscribe	O
subscribe	O
free	O
base	O
free	O
base	O
free	O
base	O
who	O
continue	O

moreover	O
,	O
based	O
on	O
our	O
clinical	O
know	O
,	O
suckle	O
appears	O
to	O
be	O
safe	O
for	O
lactate	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
select	O
colchicine	O
.	O

moreover	O
,	O
found	O
on	O
our	O
clinical	O
have	O
,	O
nurse	O
appears	O
to	O
be	O
dependable	O
for	O
lactating	O
char	O
with	O
FMF	B
who	O
continue	O
to	O
pack	O
colchicine	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
to	O
for	O
lactating	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
take	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
subscribe	O
bear	O
on	O
subscribe	O
subscribe	O
free	O
base	O
free	O
base	O
free	O
base	O
who	O
continue	O

FMF	O
,	O
based	O
to	O
our	O
clinical	O
experience	O
who	O
.	O
appears	O
on	O
be	O
safe	O
for	O
colchicine	O
women	O
with	O
to	B
,	O
Furthermore	O
continue	O
take	O
lactating	O
nursing	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
take	O
colchicine	O
.	O

Abnormal	O
dystrophy	I
protein	O
levels	O
only	O
myopathy	B
in	O
mice	O
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B
in	O
mice	O

unnatural	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
modest	O
myopathy	B
in	O
mice	O
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
mouse	O
mouse	O
simply	O
myopathy	B
in	O
mice	O
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
mouse	O
mouse	O
garden	O
truck	B
myopathy	O
in	O
mice	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
mouse	O
mouse	O
simply	O
myopathy	B
in	O
mice	O
.	O

unnatural	O
myotonic	B
dystrophy	I
protein	O
kinase	O
floor	O
produce	O
only	O
modest	O
myopathy	B
in	O
mice	O
.	O

Abnormal	O
myotonic	B
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
grade	O
produce	O
only	O
balmy	O
myopathy	B
in	O
mouse	O
.	O

Abnormal	O
kinase	B
dystrophy	I
protein	O
.	O
levels	O
produce	O
myotonic	O
mild	O
myopathy	B
in	O
mice	O
only	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B
in	O
mice	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
expansion	O

(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
protein	O
(	O
DMPK	O
)	O
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
normally	O
colligate	O
with	O
CTG	O
repetition	O
enlargement	O
inside	O
the	O
gene	O
for	O
decimeter	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
with	O
CTG	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O

myotonic	B
dystrophy	I
(	O
dm	B
)	O
is	O
ordinarily	O
associated	O
with	O
CTG	O
recapitulate	O
expansions	O
inside	O
the	O
cistron	O
for	O
dm	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

myotonic	B
dystrophy	I
(	O
dm	B
)	O
is	O
unremarkably	O
affiliate	O
with	O
CTG	O
repeat	O
expansions	O
inside	O
the	O
cistron	O
for	O
dm	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
repeat	O
the	O
gene	O
for	O
DM	O
-	O
protein	O
kinase	O
(	O
DMPK	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
diabetes	O

-	B
dystrophy	I
(	O
repeat	B
)	O
is	O
commonly	O
protein	O
.	O
CTG	O
DM	O
expansions	O
within	O
the	O
)	O
for	O
DM	O
(	O
associated	O
Myotonic	O
kinase	O
DMPK	O
gene	O
with	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

effect	O
of	O
altered	O
of	O
DMPK	O
,	O
which	O
is	O
expressed	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
transgene	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
in	O
mice	O
.	O

overexpressing	O
,	O
of	O
altered	O
cell	O
levels	O
mice	O
a	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
disrupting	O
lineages	O
muscle	O
expression	O
all	O
during	O
development	O
in	O
was	O
examined	O
by	O
effect	O
the	O
endogenous	O
.	O
The	O
and	O
gene	O
of	O
normal	O
human	O
DMPK	O
transgene	O
in	O
DMPK	O
Dmpk	O

The	O
effect	O
of	O
expression	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
in	O
.	O

The	O
upshot	O
of	O
altered	O
expression	O
floor	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
brawn	O
cell	O
blood	O
during	O
ontogeny	O
,	O
was	O
study	O
by	O
interrupt	O
the	O
endogenic	O
Dmpk	O
factor	O
and	O
overexpressing	O
a	O
formula	O
human	O
DMPK	O
transgene	O
in	O
mice	O
.	O

disrupting	O
during	O
of	O
altered	O
expression	O
levels	O
ubiquitously	O
DMPK	O
,	O
which	O
is	O
of	O
expressed	O
Dmpk	O
and	O
muscle	O
cell	O
lineages	O
human	O
development	O
,	O
was	O
gene	O
by	O
The	O
the	O
a	O
in	O
all	O
examined	O
overexpressing	O
transgene	O
normal	O
DMPK	O
effect	O
endogenous	O
in	O
mice	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
in	O
mice	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
gist	O
in	O
mice	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
lineages	O
during	O
development	O
was	O
by	O
disrupting	O
the	O
gene	O
human	O
DMPK	O
transgene	O
mice	O
.	O

The	O
effect	O
overexpressing	O
altered	O
expression	O
levels	O
of	O
during	O
,	O
which	O
is	O
endogenous	O
development	O
in	O
all	O
DMPK	O
cell	O
lineages	O
mice	O
expressed	O
,	O
normal	O
examined	O
transgene	O
disrupting	O
muscle	O
ubiquitously	O
was	O
gene	O
and	O
of	O
Dmpk	O
a	O
human	O
DMPK	O
by	O
in	O
the	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
in	O
mice	O
.	O

(	O
-	O
/	O
mice	O
showed	O
only	O
inconsistent	O
and	O
size	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
with	O
the	O
highest	O
DMPK	O
transgene	O
enhanced	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
neonatal	O
mortality	O
.	O

expression	O
at	O
-	O
/	O
and	O
)	O
mortality	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
animals	O
neck	O
head	O
-	O
in	O
muscle	O
fibres	O
changes	O
older	O
age	O
,	O
(	O
with	O
the	O
.	O
Nullizygous	O
transgene	O
DMPK	O
mice	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
neonatal	O
showed	O
highest	O

Nullizygous	O
(	O
-	O
-	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
neonatal	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
prove	O
only	O
discrepant	O
and	O
tiddler	O
sizing	O
shift	O
in	O
head	O
and	O
neck	O
muscle	O
character	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
eminent	O
DMPK	O
transgene	O
face	O
prove	O
hypertrophic	B
myocardiopathy	I
and	O
enhanced	O
neonatal	O
mortality	O
.	O

animals	O
muscle	O
-	O
/	O
-	O
)	O
minor	O
showed	O
only	O
inconsistent	O
and	O
mice	O
size	O
highest	O
transgene	O
head	O
and	O
neck	O
cardiomyopathy	O
fibres	O
at	O
older	O
DMPK	O
,	O
Nullizygous	O
with	O
showed	O
changes	O
in	O
age	O
expression	O
enhanced	O
hypertrophic	B
and	I
(	O
the	O
neonatal	O
mortality	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
neonatal	O
mortality	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
usher	O
astatine	O
neonatal	O
mortality	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
neck	O
muscle	O
fibres	O
older	O
,	O
animals	O
with	O
DMPK	O
cardiomyopathy	I
and	O
enhanced	O
mortality	O
.	O

Nullizygous	O
(	O
expression	O
/	O
-	O
)	O
mice	O
muscle	O
only	O
inconsistent	O
and	O
the	O
fibres	O
changes	O
in	O
showed	O
and	O
neck	O
mortality	O
size	O
at	O
hypertrophic	O
age	O
enhanced	O
animals	O
head	O
minor	O
older	O
DMPK	O
transgene	O
-	O
highest	O
showed	B
cardiomyopathy	I
and	O
,	O
neonatal	O
with	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
neonatal	O
mortality	O
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
manly	B
symptom	O
sterility	B
manly	O
sterility	B
sterility	O
fiber	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
cataract	B
male	B
-	I
infertility	I
.	O

nevertheless	O
,	O
both	O
simulation	O
lack	O
other	O
frequent	O
dm	B
symptoms	O
including	O
the	O
character	O
-	O
type	O
subject	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
manlike	B
-	I
sterility	I
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
fibre	O
-	O
dependent	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
infertility	I
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
manly	B
symptom	O
sterility	B
manly	O
sterility	B
sterility	O
symptom	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

withal	O
,	O
both	O
models	O
want	O
other	O
patronize	O
dm	B
symptoms	O
including	O
the	O
fiber	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
virile	B
-	I
sterility	I
.	O

nevertheless	O
,	O
both	O
models	O
want	O
other	O
frequent	O
dm	B
symptoms	O
including	O
the	O
character	O
-	O
type	O
qualified	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
manly	B
-	I
sterility	I
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
-	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
manly	B
symptom	O
sterility	B
manly	O
sterility	B
sterility	O
symptom	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

cataract	O
,	O
both	O
the	O
lack	O
other	O
frequent	O
,	B
infertility	O
including	O
models	O
fibre	O
type	O
-	O
-	O
atrophy	B
,	O
myotonia	B
DM	O
.	B
and	O
male	B
dependent	I
symptoms	I
However	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

These	O
results	O
strengthen	O
the	O
competition	O
rivalry	O
manifestation	O
simpleton	O
rivalry	O
contention	O
that	O
simple	O
loss	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
developing	O
developing	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
rival	O
simple	O
.	O

These	O
results	O
strengthen	O
the	O
competition	O
rivalry	O
manifestation	O
simpleton	O
rivalry	O
contention	O
that	O
simple	O
loss	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
developing	O
all	O
important	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
rival	O
simple	O

.	O
results	O
development	O
expression	O
contention	O
that	O
disease	O
loss	O
the	O
or	O
gain	O
-	O
only	O
-	O
strengthen	O
-	O
DMPK	O
is	O
not	O
the	O
of	O
crucial	O
requirement	O
for	O
of	O
simple	O
the	O
of	O
These	O
.	O

These	O
results	O
strengthen	O
the	O
competition	O
rivalry	O
manifestation	O
simpleton	O
rivalry	O
contention	O
that	O
simple	O
loss	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
developing	O
developing	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
rival	O
simple	O
.	O

These	O
results	O
strengthen	O
the	O
contention	O
that	O
simple	O
-	O
or	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
.	O

These	O
answer	O
strengthen	O
the	O
disceptation	O
that	O
unsubdivided	O
passing	O
-	O
or	O
gather	O
-	O
of	O
-	O
verbalism	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
requisite	O
for	O
developing	O
of	O
the	O
disease	O
.	O
.	O

DMPK	O
results	O
strengthen	O
the	O
contention	O
that	O
crucial	O
-	O
-	O
or	O
gain	O
These	O
.	O
for	O
of	O
expression	O
is	O
development	O
not	O
the	O
only	O
simple	O
requirement	O
-	O
loss	O
of	O
the	O
disease	O
of	O
.	O

only	O
results	O
strengthen	O
not	O
contention	O
that	O
simple	O
of	O
for	O
or	O
.	O
-	O
the	O
the	O
requirement	O
of	O
DMPK	O
is	O
the	O
-	O
development	O
crucial	O
expression	O
-	O
These	O
loss	O
of	O
disease	O
gain	O
.	O

These	O
resolution	O
tone	O
the	O
rivalry	O
that	O
uncomplicated	O
expiration	O
-	O
or	O
derive	O
-	O
of	O
-	O
aspect	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
demand	O
for	O
maturation	O
of	O
the	O
disease	O
.	O
.	O

These	O
results	O
strengthen	O
the	O
contention	O
simple	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
is	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
the	O
disease	O
.	O

These	O
results	O
strengthen	O
the	O
contention	O
that	O
simple	O
loss	O
-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
.	O
.	O

Mice	O
the	O
dystrophy	I
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	B
.	O

Mice	O
miss	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
arise	O
a	O
late	O
onrush	O
liberalist	O
myopathy	B
.	O

develop	O
myotonic	O
the	O
lacking	B
dystrophy	I
protein	O
late	O
Mice	O
a	O
.	O
onset	O
progressive	O
myopathy	B
kinase	O

Mice	O
lacking	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
develop	O
late	O
onset	O
myopathy	B
.	O

Mice	O
lacking	O
modernise	O
antiophthalmic	O
factor	O
the	B
myotonic	I
dystrophy	O
protein	O
kinase	O
develop	O
a	O
imperfect	O
muscular	O
dystrophy	O
late	O
onset	B
progressive	O

Mice	O
lacking	O
modernise	O
antiophthalmic	O
factor	O
the	B
myotonic	I
dystrophy	O
protein	O
kinase	O
develop	O
a	O
imperfect	O
onrush	O
late	O
onset	O
progressive	B
myopathy	O

Mice	O
missing	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
prepare	O
a	O
late	O
onslaught	O
progressive	O
myopathy	B
.	O

myopathy	O
lacking	O
the	O
Mice	B
develop	I
protein	O
kinase	O
progressive	O
a	O
late	O
onset	O
dystrophy	O
myotonic	B
.	O

Mice	O
lacking	O
modernise	O
antiophthalmic	O
factor	O
the	B
myotonic	I
dystrophy	O
protein	O
kinase	O
develop	O
a	O
imperfect	O
muscular	O
dystrophy	O
late	O
onset	B
progressive	O

Mice	O
wanting	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
produce	O
a	O
previous	O
attack	O
progressive	O
myopathy	B
.	O

Mice	O
lacking	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	B
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
antiophthalmic	O
factor	O
elaboration	O
be	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
)	B
is	I
an	I
autosomal	O
dominant	O
disorder	O
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
predominant	O
predominant	O

Myotonic	B
dystrophy	I
)	O
disorder	I
resulting	O
from	O
expansion	O
of	O
CTG	O
repeat	O
in	O
untranslated	O
region	O
of	O
a	O
putative	O
kinase	O
DMPK	O
)	O
.	O

myotonic	B
dystrophy	I
(	O
decimeter	B
)	O
is	O
an	O
autosomal	B
dominant	I
unhinge	I
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
recur	O
in	O
the	O
tierce	O
untranslated	O
area	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
is	O
dominant	I
disorder	I
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
is	O
an	O
autosomal	B
prevailing	I
perturb	I
leave	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
echo	O
in	O
the	O
trio	O
untranslated	O
area	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
antiophthalmic	O
factor	O
elaboration	O
be	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
)	B
is	I
an	I
autosomal	O
dominant	O
disorder	O
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
predominant	O
predominant	O

myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
prevailing	I
distract	I
lead	O
from	O
the	O
enlargement	O
of	O
a	O
CTG	O
recapitulate	O
in	O
the	O
ternion	O
untranslated	O
neighborhood	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

3	B
in	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
resulting	O
from	O
the	O
a	O
DMPK	O
a	O
CTG	O
repeat	O
kinase	O
the	O
dystrophy	O
untranslated	O
.	O
of	O
expansion	O
putative	O
protein	O
Myotonic	O
of	O
region	O
)	O
(	O

Myotonic	B
dystrophy	I
(	O
DM	B
is	O
autosomal	B
dominant	I
disorder	I
resulting	O
from	O
the	O
expansion	O
of	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
putative	O
protein	O
kinase	O
DMPK	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
antiophthalmic	O
factor	O
elaboration	O
be	O
antiophthalmic	O
factor	O
associate	O
in	O
nursing	B
)	I
is	I
an	O
autosomal	O
dominant	O
disorder	O
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
predominant	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

mice	O
elucidate	O
the	O
have	O
of	O
DMPK	O
in	O
-	B
(	O
we	O
role	O
developed	O
deficient	B
Dmpk	I
pathogenesis	O
Dmpk	O
-	O
/	O
DM	O
To	O
)	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk	O
-	O
/	O
mouse	O
mouse	O
use	O
use	O
use	O
use	O
-	O
)	O
mice	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk	O
-	O
/	O
mouse	O
mouse	O
use	O
use	O
use	O
use	O
-	O
)	O
mice	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
dm	B
pathogenesis	O
we	O
have	O
originate	O
Dmpk	B
lacking	I
(	O
Dmpk	O
-	O
/	O
-	O
)	O
mouse	O
.	O

To	O
elucidate	O
the	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
have	O
developed	O
Dmpk	B
deficient	I
Dmpk	O
-	O
-	O
)	O
mice	O
.	O

role	O
in	O
DM	B
pathogenesis	O
have	O
developed	O
deficient	I
(	O
Dmpk	O
-	O
/	O
-	O
)	O
mice	O
.	O

To	O
clear	O
the	O
purpose	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
lacking	I
(	O
Dmpk	O
-	O
/	O
-	O
)	O
mice	O
.	O

(	O
elucidate	O
pathogenesis	O
in	O
of	O
DMPK	O
Dmpk	O
DM	B
the	O
we	O
have	O
developed	O
mice	B
deficient	I
role	O
To	O
-	O
/	O
-	O
)	O
Dmpk	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk	O
-	O
/	O
mouse	O
mouse	O
use	O
use	O
use	O
diabetes	O
mellitus	O
-	O
)	O
mice	O

To	O
elucidate	O
the	O
role	O
in	O
DM	B
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk	O
-	O
/	O
-	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk	O
-	O
/	O
-	O
)	O
mice	O
.	O

DM	O
-	O
/	O
,	O
mice	O
develop	O
a	O
features	O
that	O
onset	O
-	O
progressive	B
myopathy	I
skeletal	I
-	O
shares	O
some	O
pathological	O
late	O
Dmpk	O
with	B
.	O

Dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
apportion	O
apportion	O
apportion	O
apportion	O
features	B
with	O

Dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
apportion	O
apportion	O
apportion	O
apportion	O
features	B
with	O

Dmpk	O
-	O
/	O
-	O
mice	O
modernize	O
a	O
former	O
-	O
oncoming	O
,	O
progressive	B
cadaverous	I
myopathy	I
that	O
shares	O
some	O
pathological	O
lineament	O
with	O
decimetre	B
.	O

Dmpk	O
-	O
/	O
mice	O
develop	O
a	O
late	O
-	O
,	O
progressive	B
skeletal	I
myopathy	I
shares	O
some	O
features	O
with	O
DM	B
.	O

-	O
a	O
late	O
-	O
,	O
progressive	B
myopathy	I
that	O
shares	O
some	O
pathological	O
features	O
with	O
DM	B
.	O

Dmpk	O
-	O
/	O
-	O
mouse	O
modernize	O
a	O
late	O
-	O
onslaught	O
,	O
progressive	B
emaciated	I
myopathy	I
that	O
shares	O
some	O
diseased	O
boast	O
with	O
DM	B
.	O

that	O
-	O
-	O
a	O
mice	O
develop	O
shares	O
late	O
/	O
onset	O
,	O
progressive	B
DM	I
myopathy	I
-	O
Dmpk	O
some	O
pathological	O
features	O
with	O
skeletal	B
.	O

Dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
diabetes	O
mellitus	O
diabetes	O
mellitus	O
apportion	O
apportion	O
apportion	O
modernise	O
features	B
with	O

Dmpk	O
-	O
/	O
-	O
a	O
late	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
features	O
.	O

Dmpk	O
-	O
/	O
-	O
mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
features	O
with	O
DM	B
.	O

Muscles	O
from	O
inward	O
fiber	O
senesce	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
mutation	O
.	O

and	O
from	O
mature	O
.	O
show	O
variation	O
in	O
fibre	O
fibrosis	O
,	O
increased	O
fibre	B
Muscles	I
degeneration	O
size	B
mice	O

Muscles	O
from	O
inward	O
fiber	O
size	O
of	O
it	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	B
increased	I
fibre	O
degeneration	B
and	O
fibrosis	O

Muscles	O
from	O
senesce	O
mice	O
evidence	O
fluctuation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
devolution	I
and	O
fibrosis	B
.	O

degeneration	O
from	O
mature	O
fibre	O
show	O
variation	O
and	O
mice	O
size	O
,	O
Muscles	O
fibre	B
increased	I
in	O
fibrosis	B
.	O

Muscles	O
from	O
inward	O
fiber	O
senesce	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
mutation	O
.	O

brawniness	O
from	O
mature	O
mice	O
shew	O
variation	O
in	O
character	O
sizing	O
,	O
increased	O
character	B
degeneration	I
and	O
fibrosis	B
.	O

muscularity	O
from	O
mature	O
mice	O
indicate	O
variation	O
in	O
fibre	O
sizing	O
,	O
increased	O
fibre	B
retrogression	I
and	O
fibrosis	B
.	O

Muscles	O
from	O
size	O
.	O
show	O
variation	O
degeneration	O
fibre	O
mature	O
,	O
increased	O
fibre	B
in	I
and	O
mice	B
fibrosis	O

from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
.	O

Muscles	O
from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
whitney	O
young	O
mouse	O
whitney	O
young	O
mouse	O
mouse	O
modification	O
usher	O
generation	O
compared	O
to	O
young	O

-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
generation	O
to	O
young	O
mice	O
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mouse	O
show	O
ultrastructural	O
interchange	O
in	O
muscularity	O
and	O
a	O
50	O
%	O
lessen	O
in	O
pull	O
genesis	O
equate	O
to	O
young	O
mouse	O
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
changes	O
in	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
to	O
young	O
mice	O
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
whitney	O
young	O
mouse	O
whitney	O
young	O
mouse	O
mouse	O
modification	O
modification	O
generation	O
compared	O
to	O
young	O

grown	O
Dmpk	O
-	O
/	O
-	O
mice	O
designate	O
ultrastructural	O
changes	O
in	O
sinew	O
and	O
a	O
fifty	O
%	O
diminution	O
in	O
hale	O
genesis	O
compared	O
to	O
young	O
mice	O
.	O

pornographic	O
Dmpk	O
-	O
/	O
-	O
mouse	O
prove	O
ultrastructural	O
vary	O
in	O
heftiness	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
propagation	O
liken	O
to	O
young	O
mouse	O
.	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
muscle	O
50	O
%	O
decrease	O
in	O
force	O
generation	O
compared	O
to	O
young	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
whitney	O
young	O
mouse	O
whitney	O
young	O
mouse	O
mouse	O
modification	O
modification	O
generation	O
compared	O
to	O
young	O

force	O
Dmpk	O
-	O
muscle	O
-	O
mice	O
show	O
generation	O
.	O
in	O
/	O
and	O
a	O
50	O
mice	O
decrease	O
in	O
to	O
ultrastructural	O
Adult	O
compared	O
young	O
%	O
changes	O

Adult	O
Dmpk	O
-	O
/	O
-	O
mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
generation	O
compared	O
to	O
young	O
mice	O
.	O

Our	O
results	O
indicate	O
that	O
pinched	O
brawn	O
social	O
system	O
follow	O
serve	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	B
DM	O
pathology	O
.	O
nasal	O
nasal	O
nasal	O
be	O

Our	O
results	O
DMPK	O
the	O
maintenance	O
of	O
muscle	O
structure	O
function	O
and	O
suggest	O
decrease	O
in	O
DMPK	O
levels	O
may	O
to	O
pathology	O
.	O
.	O

Our	O
results	O
designate	O
that	O
DMPK	O
may	O
be	O
essential	O
for	O
the	O
maintenance	O
of	O
wasted	O
muscle	O
structure	O
and	O
serve	O
and	O
indicate	O
that	O
a	O
diminish	O
in	O
DMPK	O
flush	O
may	O
conduce	O
to	O
decimetre	B
pathology	O
.	O
.	O

Our	O
results	O
indicate	O
that	O
may	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	O
DM	B
pathology	O
.	O
.	O

Our	O
resultant	O
show	O
that	O
DMPK	O
may	O
be	O
essential	O
for	O
the	O
sustentation	O
of	O
haggard	O
muscle	O
structure	O
and	O
function	O
and	O
indicate	O
that	O
a	O
reduction	O
in	O
DMPK	O
storey	O
may	O
contribute	O
to	O
dm	B
pathology	O
.	O
.	O

Our	O
results	O
indicate	O
that	O
pinched	O
brawn	O
social	O
system	O
follow	O
serve	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	B
DM	O
pathology	O
.	O
nasal	O
nasal	O
nasal	O
be	O

Our	O
results	O
signal	O
that	O
DMPK	O
may	O
be	O
essential	O
for	O
the	O
sustainment	O
of	O
bony	O
brawn	O
structure	O
and	O
function	O
and	O
indicate	O
that	O
a	O
decrease	O
in	O
DMPK	O
point	O
may	O
impart	O
to	O
dm	B
pathology	O
.	O
.	O

a	O
suggest	O
indicate	O
that	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
levels	O
pathology	O
and	O
function	O
and	O
to	O
that	O
results	O
decrease	O
.	O
DMPK	O
muscle	O
may	O
contribute	O
Our	O
structure	B
in	O
.	O
DM	O

Our	O
results	O
indicate	O
that	O
may	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
may	O
contribute	O
to	O
pathology	O
.	O

Our	O
results	O
indicate	O
that	O
pinched	O
brawn	O
social	O
system	O
follow	O
point	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	B
DM	O
pathology	O
.	O
nasal	O
nasal	O
nasal	O
be	O

Our	O
results	O
indicate	O
that	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	O
DM	B
pathology	O
.	O
.	O

The	O
Brca1	B
suppressor	O
gene	O
tumor	O
is	O
for	O
proliferation	O
embryonic	O
cellular	O
the	O
in	O
required	O
mouse	O
.	O

The	O
tumor	B
needed	O
suppresser	O
suppresser	O
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
be	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

The	O
tumor	B
suppressor	O
factor	O
Brca1	O
is	O
need	O
for	O
embryonal	O
cellular	O
proliferation	O
in	O
the	O
creep	O
.	O

the	O
tumor	B
suppressor	O
The	O
for	O
is	O
required	O
in	O
embryonic	O
cellular	O
proliferation	O
Brca1	O
gene	O
mouse	O
.	O

The	O
neoplasm	B
suppressor	O
cistron	O
Brca1	O
is	O
mandatory	O
for	O
embryotic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

The	O
tumor	B
needed	O
suppresser	O
suppresser	O
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
tumour	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

The	O
suppressor	O
Brca1	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

for	O
gene	B
suppressor	O
tumor	O
Brca1	O
is	O
cellular	O
The	O
embryonic	O
required	O
proliferation	O
in	O
the	O
.	O
mouse	O

The	O
tumour	B
suppressor	O
factor	O
Brca1	O
is	O
needful	O
for	O
embryologic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

The	O
tumor	B
needed	O
suppresser	O
suppresser	O
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
tumour	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

The	O
tumor	B
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

predisposition	O
of	O
the	O
are	O
gone	O
in	O
humans	O
BRCA1	O
ovarian	O
with	O
and	O
to	O
Mutations	B
breast	I
associated	I
cancers	I
.	O

Mutations	O
of	O
the	O
BRCA1	O
locomote	O
in	O
mankind	O
are	O
associated	O
with	O
sensitivity	O
to	O
knocker	B
and	I
ovarian	I
cancers	I
.	O

mutant	O
of	O
the	O
BRCA1	O
live	O
in	O
humankind	O
are	O
associated	O
with	O
sensitivity	O
to	O
knocker	B
and	I
ovarian	I
cancers	I
.	O

Mutations	O
of	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

sport	O
of	O
the	O
BRCA1	O
gone	O
in	O
homo	O
are	O
connect	O
with	O
sensitivity	O
to	O
chest	B
and	I
ovarian	I
cancers	I
.	O

Mutations	O
of	O
be	O
assort	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
follow	O
follow	O
homo	O
.	O

Mutations	O
of	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
with	O
predisposition	O
breast	B
and	I
ovarian	I
cancers	I
.	O

Mutations	O
of	O
be	O
assort	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
follow	O
follow	O
homo	O
.	O

of	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B

Mutations	O
of	O
associated	O
ovarian	O
gone	O
in	O
breast	O
are	O
the	O
with	O
predisposition	O
to	O
humans	B
and	I
BRCA1	I
cancers	I
.	O

Mutations	O
of	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

We	O
prove	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mouse	O
are	O
pattern	O
and	O
fat	O
and	O
want	O
tumors	B
by	O
eld	O
eleven	O
months	O
.	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
calendar	O
month	O
hither	O
hither	O
hither	O
hither	O
hither	O
eleven	O
months	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
calendar	O
month	O
hither	O
hither	O
hither	O
hither	O
hither	O
eleven	O
months	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
are	O
normal	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
eleven	O

lack	O
show	O
mice	O
/	O
Brca1	O
+	O
tumors	O
-	O
here	O
are	O
normal	O
and	O
.	O
and	O
that	O
We	B
by	O
age	O
eleven	O
months	O
fertile	O

We	O
designate	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
shiner	O
are	O
normal	O
and	O
rich	O
and	O
deficiency	O
tumour	B
by	O
mature	O
eleven	O
months	O
.	O

.	O
show	O
here	O
normal	O
Brca1	O
+	O
/	O
eleven	O
lack	O
are	O
that	O
and	O
and	O
fertile	O
mice	O
tumors	B
by	O
age	O
-	O
We	O
months	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
calendar	O
month	O
hither	O
hither	O
hither	O
hither	O
tumor	O
eleven	O
months	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
lack	O
age	O
eleven	O
months	O
.	O

We	O
evidence	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
rich	O
and	O
deficiency	O
tumour	B
by	O
geezerhood	O
xi	O
months	O
.	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/	O
-	O
mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
eleven	O
months	O
.	O

Homozygous	O
(	O
-	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

Homozygous	O
Brca1	O
(	O
v	O
-	O
6	O
)	O
variation	O
mouse	O
die	O
before	O
day	O
septenary	O
.	O

mutant	O
5	O
(	O
Brca1	O
-	O
6	O
die	O
Homozygous	O
mice	O
.	O
before	O
day	O
7	O
)	O

Homozygous	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
die	O
before	O
7	O
.	O

Homozygous	O
Brca1	O
mutation	O
mouse	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
	O
mutation	O
die	O
before	O
day	O
7	O
.	O

Homozygous	O
Brca1	O
mutation	O
mouse	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
	O
	O
die	O
before	O
day	O
7	O
.	O

Homozygous	O
Brca1	O
(	O
fivesome	O
-	O
sise	O
)	O
sport	O
mice	O
die	O
before	O
day	O
sevener	O
.	O

7	O
Brca1	O
(	O
Homozygous	O
mutant	O
6	O
)	O
day	O
mice	O
die	O
before	O
-	O
5	O
.	O

Homozygous	O
Brca1	O
mutation	O
mouse	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
	O
mutation	O
die	O
before	O
day	O
7	O
.	O

homozygous	O
Brca1	O
(	O
quintet	O
-	O
sextuplet	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
seven	O
.	O

Homozygous	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

of	O
embryogenesis	O
.	O

	O
5	O
of	O
embryogenesis	O
.	O

	O
5	O
of	O
embryogenesis	O
.	O

5	O
of	O

	O
5	O
of	O
embryogenesis	O
.	O

quintuplet	O
of	O
embryogenesis	O
.	O

embryogenesis	O
of	O
5	O
.	O

.	O
of	O
embryogenesis	O
5	O

fin	O
of	O
embryogenesis	O
.	O

of	O
embryogenesis	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
are	O
poorly	O
,	O
no	O
of	O
mesoderm	O
formation	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoderm	O
formation	O

sport	O
embryos	O
are	O
poorly	O
acquire	O
,	O
with	O
no	O
show	O
of	O
mesoderm	O
formation	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
organization	O
organization	O
fertilized	O
egg	O
of	O
mesoderm	O
formation	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
organization	O
organization	O
nobelium	O
of	O
mesoderm	O
formation	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
organization	O
organization	O
fertilized	O
egg	O
of	O
mesoderm	O
formation	O

mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoblast	O
constitution	O
.	O

Mutant	O
embryos	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
.	O

mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
show	O
of	O
mesoblast	O
formation	O
.	O

Mutant	O
developed	O
are	O
poorly	O
.	O
,	O
with	O
embryos	O
evidence	O
of	O
mesoderm	O
formation	O
no	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoderm	O
formation	O
.	O

The	O
extraembryonic	O
part	O
is	O
abnormal	O
,	O
but	O
accumulation	O
with	O
barbaric	O
-	O
type	O
tetraploid	O
conceptus	O
does	O
not	O
saving	O
the	O
deadliness	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
realm	O
realm	O
realm	O
realm	O
realm	O
realm	O
lethality	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
realm	O
realm	O
realm	O
realm	O
realm	O
realm	O
lethality	O
.	O

region	O
,	O
but	O
aggregation	O
wild	O
-	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
aggregation	O
with	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

region	O
is	O
abnormal	O
,	O
aggregation	O
with	O
wild	O
-	O
type	O
embryos	O
does	O
not	O
rescue	O
lethality	O
.	O

the	O
extraembryonic	O
region	O
lethality	O
abnormal	O
,	O
but	O
with	O
aggregation	O
wild	O
does	O
type	O
tetraploid	O
.	O
The	O
not	O
rescue	O
-	O
is	O
embryos	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
realm	O
realm	O
realm	O
realm	O
realm	O
character	O
lethality	O
.	O

The	O
extraembryonic	O
neighborhood	O
is	O
unnatural	O
,	O
but	O
collection	O
with	O
godforsaken	O
-	O
eccentric	O
tetraploid	O
embryos	O
does	O
not	O
saving	O
the	O
lethality	O
.	O

rescue	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
embryos	O
type	O
with	O
wild	O
-	O
does	O
The	O
but	O
aggregation	O
the	O
tetraploid	O
not	O
lethality	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

In	O
vivo	O
,	O
mutant	O
jail	O
cell	O
serve	O
follow	O
fertilized	O
egg	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
melt	O
off	O
melt	O
off	O

In	O
vivo	O
,	O
do	O
but	O
show	O
reduced	O
proliferation	O
accompanied	O
decreased	O
expression	O
of	O
and	O
mdm	O
-	O
2	O
,	O
regulator	O
p53	O
activity	O
.	O

indiana	O
vivo	O
,	O
sport	O
embryos	O
do	O
not	O
register	O
increased	O
apoptosis	O
but	O
register	O
reduced	O
cell	O
proliferation	O
companion	O
by	O
diminish	O
face	O
of	O
cyclin	O
eastward	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activeness	O
.	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
not	O
increased	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

In	O
vivo	O
,	O
variation	O
embryos	O
do	O
not	O
present	O
increased	O
apoptosis	O
but	O
demonstrate	O
foreshorten	O
cadre	O
proliferation	O
accompanied	O
by	O
decreased	O
manifestation	O
of	O
cyclin	O
east	O
and	O
mdm	O
-	O
ii	O
,	O
a	O
governor	O
of	O
p53	O
activity	O
.	O

In	O
vivo	O
,	O
mutant	O
jail	O
cell	O
serve	O
follow	O
fertilized	O
egg	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
melt	O
off	O
melt	O
off	O

indium	O
vivo	O
,	O
mutation	O
conceptus	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
prove	O
trim	O
cadre	O
proliferation	O
accompanied	O
by	O
diminish	O
expression	O
of	O
cyclin	O
eastward	O
and	O
mdm	O
-	O
ii	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

cyclin	O
expression	O
,	O
mutant	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
-	O
of	O
accompanied	O
by	O
decreased	O
a	O
of	O
vivo	O
E	O
activity	O
mdm	O
cell	O
2	O
,	O
In	O
proliferation	O
and	O
p53	O
regulator	O
.	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
exhibit	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
a	O
regulator	O
of	O
activity	O

In	O
vivo	O
,	O
mutant	O
jail	O
cell	O
serve	O
follow	O
jail	O
cell	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
melt	O
off	O
melt	O
off	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm	O
-	O
2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

dramatically	O
expression	O
of	O
inhibitor	O
-	O
dependent	O
kinase	O
cyclin	O
mutant	O
is	O
the	O
increased	O
The	O
in	O
p21	O
embryos	O
.	O

The	O
face	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutation	O
conceptus	O
.	O

The	O
saying	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutation	O
embryos	O
.	O

The	O
expression	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
.	O

The	O
formula	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
variation	O
embryos	O
.	O

The	O
expression	O
mutation	O
fertilized	O
egg	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
chromosomal	O
mutation	O
chromosomal	O

The	O
expression	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
is	O
dramatically	O
in	O
the	O
mutant	O
embryos	O
.	O

The	O
expression	O
mutation	O
fertilized	O
egg	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
chromosomal	O
mutation	O
chromosomal	O

expression	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O

The	O
expression	O
p21	O
mutant	O
-	O
dependent	O
in	O
inhibitor	O
of	O
is	O
dramatically	O
increased	O
kinase	O
the	O
cyclin	O
embryos	O
.	O

The	O
expression	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
.	O

blastocyst	O
these	O
in	O
fact	O
observations	O
is	O
the	O
vivo	O
impaired	O
mutant	O
grossly	O
growth	O
Buttressing	O
is	O
that	O
in	O
vitro	O
.	O

buttress	O
these	O
in	O
vivo	O
notice	O
is	O
the	O
fact	O
that	O
variation	O
blastocyst	O
increment	O
is	O
grossly	O
afflicted	O
in	O
vitro	O
.	O

buttressing	O
these	O
in	O
vivo	O
watching	O
is	O
the	O
fact	O
that	O
mutation	O
blastocyst	O
maturation	O
is	O
grossly	O
spoil	O
in	O
vitro	O
.	O

Buttressing	O
these	O
in	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
.	O

buttressing	O
these	O
in	O
vivo	O
observance	O
is	O
the	O
fact	O
that	O
mutation	O
blastocyst	O
maturation	O
is	O
grossly	O
afflicted	O
in	O
vitro	O
.	O

Buttressing	O
these	O
inward	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

Buttressing	O
these	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
growth	O
is	O
impaired	O
in	O
vitro	O
.	O

Buttressing	O
these	O
inward	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

these	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
.	O

Buttressing	O
these	O
that	O
impaired	O
observations	O
is	O
is	O
fact	O
in	O
mutant	O
blastocyst	O
growth	O
the	O
grossly	O
vivo	O
in	O
vitro	O
.	O

Buttressing	O
these	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
.	O

Thus	O
,	O
of	O
death	O
of	O
Brca1	O
mutant	O
due	O
-	O
6	O
)	O
required	O
to	O
prior	O
to	O
for	O
may	O
be	O
the	O
embryos	O
a	O
different	O
of	O
the	O
proliferative	O
gastrulation	O
(	O
failure	O
the	O
development	O
the	O
5	O
burst	O
germ	O
layers	O
.	O

,	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
failure	O
of	O
the	O
burst	O
for	O
the	O
development	O
different	O

Thus	O
,	O
the	O
last	O
of	O
Brca1	O
(	O
5	O
-	O
six	O
)	O
variation	O
embryos	O
anterior	O
to	O
gastrulation	O
whitethorn	O
be	O
imputable	O
to	O
a	O
loser	O
of	O
the	O
proliferative	O
volley	O
compulsory	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
stratum	O
.	O

for	O
a	O
the	O
death	O
may	O
Brca1	O
to	O
the	O
-	O
6	O
)	O
mutant	O
embryos	O
proliferative	O
5	O
gastrulation	O
of	O
of	O
due	O
to	O
prior	O
failure	O
of	O
the	O
,	O
burst	O
required	O
Thus	O
be	O
development	O
the	O
(	O
different	O
germ	O
layers	O
.	O

Thus	O
,	O
the	O
death	O
crataegus	O
oxycantha	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O

proliferative	O
due	O
the	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
for	O
development	O
gastrulation	O
may	O
be	O
germ	O
to	O
a	O
failure	O
the	O
the	O
Thus	O
burst	O
the	O
prior	O
to	O
of	O
of	O
.	O
different	O
layers	O
,	O
required	O

Thus	O
,	O
the	O
death	O
Brca1	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
.	O

Thus	O
,	O
the	O
decease	O
of	O
Brca1	O
(	O
pentad	O
-	O
6	O
)	O
sport	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
imputable	O
to	O
a	O
loser	O
of	O
the	O
proliferative	O
burst	O
involve	O
for	O
the	O
exploitation	O
of	O
the	O
unlike	O
microbe	O
level	O
.	O

Thus	O
,	O
the	O
death	O
needed	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
needful	O
needful	O
needful	O
needful	O
needful	O
needful	O
needful	O
needful	O
developing	O
.	O

Thus	O
,	O
the	O
end	O
of	O
Brca1	O
(	O
five	O
-	O
6	O
)	O
sport	O
conceptus	O
anterior	O
to	O
gastrulation	O
may	O
be	O
imputable	O
to	O
a	O
loser	O
of	O
the	O
proliferative	O
burst	O
command	O
for	O
the	O
development	O
of	O
the	O
dissimilar	O
germ	O
bed	O
.	O

Thus	O
,	O
the	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
.	O

Increased	O
coronary	B
heart	I
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O
levels	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
ester	O
gene	O
despite	O
increased	O
HDL	O
levels	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
hdl	O
grade	O
grade	O
eye	O
eye	O
eye	O
despite	O
increased	O
HDL	O
levels	O
.	O

increase	O
coronary	B
nerve	I
disease	I
in	O
nipponese	O
-	O
american	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
factor	O
despite	O
increase	O
HDL	O
flush	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
hdl	O
grade	O
grade	O
eye	O
eye	O
eye	O
despite	O
increased	O
HDL	O
levels	O
.	O

Increased	O
coronary	B
core	I
disease	I
in	O
nipponese	O
-	O
American	O
humanity	O
with	O
sport	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
disdain	O
increased	O
hdl	O
levels	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
in	O
the	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O

mutation	O
coronary	B
heart	I
despite	I
in	O
Japanese	O
-	O
men	O
American	O
with	O
increased	O
in	O
cholesteryl	O
the	O
.	O
transfer	O
protein	O
gene	O
disease	O
Increased	O
HDL	O
levels	O
ester	O

increase	O
coronary	B
gist	I
disease	I
in	O
nipponese	O
-	O
American	O
valet	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
channelize	O
protein	O
gene	O
contempt	O
increase	O
HDL	O
levels	O
.	O

ester	O
coronary	B
men	I
-	I
in	O
Japanese	O
transfer	O
American	O
heart	O
with	O
mutation	O
in	O
HDL	O
cholesteryl	O
disease	O
Increased	O
protein	O
gene	O
despite	O
increased	O
the	O
levels	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O
levels	O
.	O

high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
relationship	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

genetically	O
high	O
density	O
with	O
(	O
HDL	O
)	O
.	O
CHD	O
strongly	O
)	O
determined	O
and	O
coronary	O
(	O
general	O
inverse	O
relationship	O
lipoprotein	O
show	B
heart	I
disease	I
a	O
are	B
Plasma	O
levels	O

plasma	O
high	O
compactness	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
powerfully	O
genetically	O
dictated	O
and	O
picture	O
a	O
oecumenical	O
inverse	O
kinship	O
with	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

Plasma	O
gamy	O
denseness	O
lipoprotein	O
(	O
HDL	O
)	O
stage	O
are	O
powerfully	O
genetically	O
compulsive	O
and	O
show	O
a	O
general	O
opposite	O
relationship	O
with	O
coronary	B
pump	I
disease	I
(	O
CHD	B
)	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
determined	O
and	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B
heart	I
CHD	B
)	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
opposite	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
eye	O
eye	O
concentration	O
concentration	O
concentration	O
be	O
with	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
opposite	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
eye	O
eye	O
concentration	O
concentration	O
concentration	O
high	O
school	O
with	B
coronary	I
heart	I
disease	O
(	B
CHD	O
)	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
determined	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B
heart	I
disease	I
(	O

CHD	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
show	O
inverse	O
are	O
strongly	O
genetically	O
determined	O
disease	O
)	O
)	O
general	O
levels	O
heart	O
with	O
coronary	B
Plasma	I
and	I
(	O
relationship	B
a	O
.	O

plasm	O
eminent	O
concentration	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
powerfully	O
genetically	O
determined	O
and	O
evidence	O
a	O
general	O
opposite	O
relationship	O
with	O
coronary	B
inwardness	I
disease	I
(	O
CHD	B
)	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
.	O

The	O
cholesteryl	O
ester	O
(	O
CETP	O
)	O
mediates	O
the	O
of	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
in	O
the	O
reverse	O
transport	O
of	O
the	O

in	O
lipoproteins	O
ester	O
transfer	O
protein	O
(	O
of	O
to	O
mediates	O
the	O
transfer	O
CETP	O
cholesteryl	O
transport	O
cholesterol	O
HDL	O
to	O
other	O
)	O
and	O
is	O
a	O
of	O
participant	O
The	O
the	O
the	O
esters	O
from	O
key	O
from	O
liver	O
periphery	O
cholesteryl	O
the	O
reverse	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
ester	O
.	O

transport	O
the	O
ester	O
transfer	O
to	O
(	O
from	O
the	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
in	O
)	O
HDL	O
protein	O
from	O
lipoproteins	O
and	O
esters	O
a	O
key	O
participant	O
cholesteryl	O
the	O
reverse	O
The	O
other	O
cholesterol	O
of	O
CETP	O
periphery	O
to	O
is	O
liver	O
.	O

The	O
cholesteryl	O
ester	O
transport	O
protein	O
(	O
CETP	O
)	O
intermediate	O
the	O
transport	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
headstone	O
player	O
in	O
the	O
invert	O
transport	O
of	O
cholesterin	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
from	O
HDL	O
to	O
lipoproteins	O
is	O
a	O
key	O
the	O
from	O
the	O
periphery	O
the	O
liver	O

The	O
cholesteryl	O
from	O
transfer	O
protein	O
liver	O
CETP	O
)	O
mediates	O
the	O
transfer	O
reverse	O
and	O
esters	O
from	O
transport	O
to	O
other	O
the	O
cholesteryl	O
is	O
periphery	O
key	O
(	O
in	O
HDL	O
of	O
a	O
the	O
cholesterol	O
ester	O
lipoproteins	O
of	O
to	O
the	O
participant	O
.	O

The	O
cholesteryl	O
ester	O
transportation	O
protein	O
(	O
CETP	O
)	O
liaise	O
the	O
transportation	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
discover	O
player	O
in	O
the	O
reverse	O
raptus	O
of	O
cholesterin	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

The	O
cholesteryl	O
ester	O
transportation	O
protein	O
(	O
CETP	O
)	O
intermediate	O
the	O
transportation	O
of	O
cholesteryl	O
esters	O
from	O
hdl	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
player	O
in	O
the	O
verso	O
ravish	O
of	O
cholesterin	O
from	O
the	O
fringe	O
to	O
the	O
liver	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
be	O
find	O
out	O
inward	O
	O
	O
capital	O
of	O
hawaii	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O

A	O
prevalence	O
of	O
different	O
CETP	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
1	O
%	O
;	O
14G	O
,	O
0	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
Heart	O
Program	O
mutations	O
associated	O
with	O
CETP	O
35	O
%	O
)	O
HDL	O
chol	O
+	O
10	O
for	O
D442G	O

increased	O
,	O
)	O
found	O
two	O
different	O
CETP	O
gene	O
469	O
(	O
D442G	O
,	O
5	O
in	O
1	O
for	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
%	O
%	O
)	O
CETP	O
and	O
were	O
prevalence	O
3	O
,	O
mutations	O
men	O
+	O
Japanese	O
ancestry	O
levels	O
the	O
Honolulu	O
(	O
Program	O
and	O
mutations	O
.	O
associated	O
with	O
decreased	O
high	O
of	O
-	O
35	O
%	O
Heart	O
was	O
A	O
%	O
of	O
in	O
(	O
chol	O
10	O
5	O
HDL	O
D442G	O
)	O
.	O

high	O
CETP	O
gene	O
mutations	O
D442G	O
,	O
.	O
1	O
%	O
14G	O
A	O
,	O
0	O
.	O
%	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
decreased	O
-	O
%	O
)	O
and	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
)	O
.	O

A	O
high	O
preponderance	O
of	O
deuce	O
dissimilar	O
CETP	O
factor	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
unity	O
%	O
;	O
intron	O
14G	O
A	O
,	O
cipher	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
triad	O
,	O
469	O
humankind	O
of	O
nipponese	O
blood	O
in	O
the	O
Honolulu	O
center	O
Program	O
and	O
mutations	O
were	O
connect	O
with	O
fall	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
stage	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
.	O

associated	O
chol	O
D442G	O
in	O
(	O
different	O
CETP	O
and	O
mutations	O
two	O
prevalence	O
469	O
5	O
.	O
1	O
%	O
35	O
intron	O
14G	O
A	O
,	O
0	O
5	O
.	O
%	O
D442G	O
.	O
was	O
found	O
of	O
3	O
Japanese	O
,	O
men	O
levels	O
,	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
of	O
mutations	O
(	O
)	O
10	O
decreased	O
CETP	O
A	O
-	O
)	O
%	O
were	O
gene	O
increased	O
HDL	O
high	O
and	O
(	O
+	O
with	O
%	O
for	O
)	O
;	O
,	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
be	O
find	O
out	O
inward	O
	O
	O
mutation	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
thirty	O

A	O
gamy	O
preponderance	O
of	O
deuce	O
unlike	O
CETP	O
factor	O
sport	O
(	O
D442G	O
,	O
quintet	O
.	O
ace	O
%	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
quintet	O
%	O
)	O
,	O
was	O
witness	O
in	O
3	O
,	O
469	O
men	O
of	O
japanese	O
line	O
in	O
the	O
Honolulu	O
pith	O
program	O
and	O
sport	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
storey	O
(	O
+	O
ten	O
%	O
for	O
D442G	O
)	O
.	O

axerophthol	O
heights	O
preponderance	O
of	O
deuce	O
dissimilar	O
CETP	O
cistron	O
mutations	O
(	O
D442G	O
,	O
quintuplet	O
.	O
ane	O
%	O
;	O
intron	O
14G	O
axerophthol	O
,	O
0	O
.	O
quintuplet	O
%	O
)	O
,	O
was	O
ascertain	O
in	O
3	O
,	O
469	O
gentleman	O
of	O
nipponese	O
filiation	O
in	O
the	O
Honolulu	O
centre	O
Program	O
and	O
mutations	O
were	O
consort	O
with	O
fall	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
hdl	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
CETP	O
gene	O
D442G	O
,	O
5	O
1	O
intron	O
14G	O
A	O
,	O
0	O
.	O
5	O
found	O
3	O
,	O
men	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
(	O
-	O
%	O
)	O
and	O
increased	O
chol	O
(	O
for	O
)	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
mutations	O
(	O
D442G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-	O
35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442G	O
)	O
.	O

However	O
,	O
the	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
mutations	O
%	O
in	O
men	O
without	O
mutations	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
homo	O
mutation	O
mutation	O
be	O
be	O
be	O
in	O
men	O
without	O
mutations	O
.	O

yet	O
,	O
the	O
boilersuit	O
preponderance	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
homo	O
with	O
mutations	O
and	O
xvi	O
%	O
in	O
homo	O
without	O
mutations	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
homo	O
mutation	O
mutation	O
be	O
be	O
be	O
in	O
men	O
without	O
mutations	O
.	O

however	O
,	O
the	O
boilersuit	O
preponderance	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
sport	O
and	O
16	O
%	O
in	O
men	O
without	O
sport	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
in	O
men	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O

%	O
,	O
the	O
in	O
prevalence	O
of	O
definite	O
was	B
CHD	O
21	O
men	O
in	O
with	O
men	O
.	O
and	O
16	O
%	O
overall	O
However	O
without	O
mutations	O
mutations	O

notwithstanding	O
,	O
the	O
overall	O
preponderance	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
mankind	O
with	O
variation	O
and	O
16	O
%	O
in	O
mankind	O
without	O
variation	O
.	O

mutations	O
,	O
was	O
definite	O
prevalence	O
of	O
and	O
CHD	B
the	O
21	O
%	O
in	O
without	O
with	O
overall	O
However	O
16	O
%	O
in	O
men	O
men	O
mutations	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O
.	O

The	O
proportional	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
relation	O
relation	O
relation	O
1	O
.	O

The	O
relation	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O

The	O
proportional	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
single	O
.	O

relative	O
risk	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O

CHD	O
relative	O
risk	O
RR	O
(	O
)	O
1	O
The	B
was	O
of	O
.	O

The	O
CHD	O
risk	O
(	O
relative	O
)	O
of	O
.	B
was	O
1	O
RR	O

(	O
CHD	O
risk	O
of	O
RR	O
)	O
The	O
relative	B
was	O
1	O
.	O

The	O
risk	O
RR	O
of	O
CHD	B
was	O
1	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
relation	O
relation	O
relation	O
1	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
be	O
	O
be	O
	O
	O
homo	O
homo	O
,	O
the	O
RR	O
was	O
1	O
.	O

men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
,	O
RR	O
was	O
1	O
.	O

43	O
in	O
men	O
with	O
sport	O
(	O
phosphorus	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
ingredient	O
,	O
the	O
RR	O
was	O
ane	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
.	O
05	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
RR	O
was	O
1	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
be	O
	O
be	O
	O
	O
homo	O
homo	O
,	O
the	O
RR	O
was	O
1	O
.	O

43	O
in	O
valet	O
with	O
mutations	O
(	O
p	O
<	O
.	O
05	O
)	O
;	O
after	O
modification	O
for	O
CHD	B
risk	O
element	O
,	O
the	O
RR	O
was	O
ane	O
.	O

43	O
in	O
men	O
with	O
sport	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adaptation	O
for	O
CHD	B
risk	O
constituent	O
,	O
the	O
RR	O
was	O
unity	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
)	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
,	O
the	O
RR	O
was	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
be	O
	O
be	O
	O
	O
homo	O
homo	O
,	O
the	O
RR	O
was	O
1	O
.	O

factors	O
in	O
men	O
)	O
mutations	O
(	O
P	O
,	O
.	O
05	O
with	O
;	O
after	O
adjustment	O
1	O
CHD	B
risk	O
RR	O
<	O
43	O
the	O
was	O
for	O
.	O

43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
,	O
the	O
RR	O
was	O
1	O
.	O

lv	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
extra	O
allowance	O
for	O
HDL	O
raze	O
,	O
the	O
RR	O
was	O
ane	O
.	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
1	O
.	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
1	O
.	O

P	O
02	O
)	O
;	O
additional	O
adjustment	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O

55	O
(	O
P	O
=	O
.	O
;	O
after	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O

P	O
=	O
.	O
02	O
;	O
after	O
additional	O
adjustment	O
for	O
levels	O
,	O
the	O
RR	O
1	O
.	O

was	O
(	O
P	O
1	O
.	O
02	O
)	O
after	O
;	O
additional	O
,	O
for	O
HDL	O
.	O
55	O
the	O
RR	O
adjustment	O
=	O
levels	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
phosphorus	O
grade	O
1	O
.	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
extra	O
modification	O
for	O
hdl	O
point	O
,	O
the	O
RR	O
was	O
1	O
.	O

RR	O
(	O
P	O
=	O
.	O
02	O
levels	O
for	O
after	O
additional	O
adjustment	O
,	O
55	O
)	O
;	O
was	O
HDL	O
the	O
1	O
.	O

55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O

)	O
(	O
P	O
=	O
.	O
008	O
68	O
.	O

68	O
(	O
phosphorus	O
=	O
.	O
008	O
)	O
.	O

P	O
008	O
)	O
.	O

68	O
phosphorus	O
	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

68	O
P	O
=	O
)	O
.	O

68	O
.	O
P	O
=	O
(	O
008	O
.	O
)	O

.	O
=	O
P	O
(	O
.	O
008	O
)	O
68	O

68	O
	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

68	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

68	O
	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

68	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

standardized	O
RR	O
values	O
were	O
hold	O
for	O
the	O
D442G	O
mutation	O
unique	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442G	O
mutation	O
prevail	O
prevail	O
prevail	O
alone	O
.	O

interchangeable	O
RR	O
values	O
were	O
hold	O
for	O
the	O
D442G	O
mutation	O
unique	O
.	O

standardised	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442G	O
variation	O
unique	O
.	O

RR	O
values	O
obtained	O
for	O
the	O
D442G	O
mutation	O
alone	O
.	O

D442G	O
RR	O
values	O
obtained	O
were	O
for	O
alone	O
Similar	O
mutation	O
the	O
.	O

Similar	O
D442G	O
values	O
were	O
RR	O
for	O
the	O
.	O
mutation	O
alone	O
obtained	O

were	O
D442G	O
values	O
the	O
obtained	O
for	O
Similar	O
RR	O
mutation	O
alone	O
.	O

Similar	O
values	O
obtained	O
the	O
D442G	O
mutation	O
alone	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442G	O
mutation	O
prevail	O
prevail	O
prevail	O
alone	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442G	O
mutation	O
alone	O
.	O

Increased	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	B
prevalence	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
.	O

Increased	O
CHD	B
in	O
mutations	O
was	O
primarily	O
observed	O
for	O
chol	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
mg	O
/	O
dl	O
men	O
with	O
CHD	B

mg	O
;	B
in	O
men	O
with	O
mutations	O
chol	O
low	O
observed	O
for	O
HDL	O
was	O
41	O
men	O
and	O
mg	O
/	O
dl	O
primarily	O
for	O
HDL	O
chol	O
with	O
60	O
Increased	O
/	O
mutations	O
-	O
60	O
>	O
without	O
prevalence	O
had	O
CHD	O
CHD	B
dl	O
.	O

Increased	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	B
prevalence	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
hdl	O
.	O

men	O
CHD	B
in	O
men	O
/	O
mutations	O
60	O
mutations	O
observed	O
for	O
HDL	O
chol	O
41	O
mg	O
primarily	O
mg	O
with	O
without	O
;	O
for	O
-	O
chol	O
>	O
60	O
CHD	O
/	O
dl	O
Increased	O
dl	O
and	O
with	O
was	O
had	O
low	O
HDL	B
prevalence	O
.	O

increased	O
CHD	B
in	O
world	O
with	O
variation	O
was	O
mainly	O
maintain	O
for	O
HDL	O
chol	O
xli	O
-	O
sixty	O
milligram	O
/	O
deciliter	O
;	O
for	O
HDL	O
chol	O
>	O
sixty	O
milligram	O
/	O
deciliter	O
world	O
with	O
and	O
without	O
variation	O
had	O
humbled	O
CHD	B
preponderance	O
.	O

Increased	O
CHD	B
in	O
men	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
60	O
mg	O
/	O
;	O
HDL	O
chol	O
>	O
/	O
without	O
mutations	O
had	O
CHD	B
prevalence	O

Increased	O
CHD	B
without	O
men	O
with	O
prevalence	O
was	O
primarily	O
observed	O
for	O
HDL	O
dl	O
for	O
-	O
60	O
men	O
/	O
dl	O
mutations	O
41	O
HDL	O
had	O
>	O
mutations	O
mg	O
mg	O
chol	O
chol	O
/	O
and	O
in	O
;	O
with	O
low	O
CHD	B
60	O
.	O

increase	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
principally	O
observed	O
for	O
HDL	O
chol	O
xli	O
-	O
lx	O
magnesium	O
/	O
decilitre	O
;	O
for	O
HDL	O
chol	O
>	O
lx	O
magnesium	O
/	O
decilitre	O
men	O
with	O
and	O
without	O
mutations	O
had	O
depression	O
CHD	B
preponderance	O
.	O

increased	O
CHD	B
in	O
men	O
with	O
variation	O
was	O
mainly	O
ascertained	O
for	O
hdl	O
chol	O
xli	O
-	O
lx	O
magnesium	O
/	O
decilitre	O
;	O
for	O
hdl	O
chol	O
>	O
lx	O
magnesium	O
/	O
decilitre	O
men	O
with	O
and	O
without	O
variation	O
had	O
broken	O
CHD	B
preponderance	O
.	O

Increased	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	B
prevalence	O
.	O

so	O
,	O
hereditary	O
CETP	B
inadequacy	I
seem	O
to	O
be	O
an	O
autonomous	O
gamble	O
agent	O
for	O
CHD	B
,	O
primarily	O
imputable	O
to	O
increased	O
CHD	B
preponderance	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
xli	O
and	O
60	O
mg	O
/	O
decilitre	O
.	O

,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
for	O
CHD	B
,	O
primarily	O
due	O
increased	O
CHD	B
with	O
mutation	O
and	O
between	O
60	O
mg	O
/	O
dl	O

and	O
mg	O
genetic	O
CETP	B
due	I
appears	O
prevalence	O
41	O
an	O
independent	O
risk	O
factor	O
for	O
the	B
.	O
primarily	O
deficiency	O
between	O
increased	O
CHD	B
be	O
in	O
men	O
with	O
,	O
D442G	O
mutation	O
Thus	O
to	O
cholesterol	O
HDL	O
to	O
and	O
60	O
CHD	O
/	O
dl	O
,	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
an	O
independent	O
risk	O
factor	O
CHD	B
,	O
primarily	O
due	O
to	O
CHD	B
prevalence	O
in	O
men	O
the	O
D442G	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
dl	O
.	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
dl	O
.	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
dl	O
.	O

thus	O
,	O
transmissible	O
CETP	B
inadequacy	I
appears	O
to	O
be	O
an	O
autonomous	O
adventure	O
factor	O
for	O
CHD	B
,	O
mainly	O
referable	O
to	O
increased	O
CHD	B
preponderance	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterin	O
between	O
41	O
and	O
60	O
milligram	O
/	O
deciliter	O
.	O

the	O
increased	O
genetic	O
CETP	B
deficiency	I
appears	O
factor	O
60	O
an	O
independent	O
risk	O
to	O
for	O
and	B
cholesterol	O
primarily	O
due	O
to	O
be	O
CHD	B
prevalence	O
in	O
HDL	O
with	O
Thus	O
D442G	O
41	O
CHD	O
,	O
men	O
between	O
/	O
and	O
,	O
mg	O
mutation	O
dl	O
.	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
hdl	O
dl	O
.	O

Thus	O
,	O
deficiency	I
appears	O
be	O
an	O
for	O
,	O
primarily	O
due	O
increased	O
CHD	B
prevalence	O
men	O
with	O
the	O
D442G	O
mutation	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O
.	O

suggest	O
HDL	O
concentration	O
and	O
the	O
of	O
cholesterol	O
HDL	O
(	O
.	O
e	O
cholesterol	O
)	O
determine	O
the	O
-	O
atherogenicity	O
of	O
HDL	O
fraction	O
.	O

The	O
findings	O
suggest	O
that	O
tightness	O
ship	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i	O
.	O
e	O
.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
hdl	O
.	O

)	O
e	O
suggest	O
that	O
both	O
HDL	O
the	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
anti	O
atherogenicity	O
(	O
i	O
.	O
fraction	O
.	O
,	O
reverse	O
the	O
transport	O
The	O
determine	O
concentration	O
through	O
HDL	O
cholesterol	O
of	O
-	O
HDL	O
.	O
findings	O

The	O
witness	O
advise	O
that	O
both	O
hdl	O
tightness	O
and	O
the	O
dynamics	O
of	O
cholesterin	O
enthrall	O
through	O
hdl	O
(	O
i	O
.	O
e	O
.	O
,	O
reverse	O
cholesterin	O
enthrall	O
)	O
decide	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
hdl	O
divide	O
.	O

The	O
findings	O
determine	O
that	O
both	O
HDL	O
concentration	O
reverse	O
the	O
dynamics	O
of	O
transport	O
anti	O
through	O
HDL	O
of	O
i	O
.	O
.	O
cholesterol	O
,	O
and	O
cholesterol	O
e	O
)	O
the	O
suggest	O
HDL	O
-	O
atherogenicity	O
(	O
transport	O
the	O
fraction	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
transport	O
through	O
HDL	O
(	O
.	O
e	O
.	O
,	O
reverse	O
transport	O
)	O
determine	O
the	O
-	O
atherogenicity	O
the	O
HDL	O
fraction	O
.	O

The	O
incur	O
suggest	O
that	O
both	O
hdl	O
denseness	O
and	O
the	O
kinetics	O
of	O
cholesterin	O
transport	O
through	O
hdl	O
(	O
i	O
.	O
e	O
.	O
,	O
overturn	O
cholesterin	O
transport	O
)	O
settle	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
hdl	O
divide	O
.	O

The	O
findings	O
suggest	O
that	O
tightness	O
	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i	O
.	O
e	O
.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
hdl	O
.	O

The	O
feel	O
propose	O
that	O
both	O
HDL	O
assiduity	O
and	O
the	O
dynamics	O
of	O
cholesterin	O
enchant	O
through	O
HDL	O
(	O
i	O
.	O
e	O
.	O
,	O
overthrow	O
cholesterin	O
enchant	O
)	O
regulate	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
divide	O
.	O

anti	O
,	O
suggest	O
that	O
i	O
HDL	O
HDL	O
the	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
)	O
and	O
(	O
both	O
of	O
e	O
.	O
through	O
reverse	O
cholesterol	O
transport	O
findings	O
determine	O
the	O
The	O
.	O
atherogenicity	O
-	O
concentration	O
HDL	O
fraction	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i	O
.	O
e	O
.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
gene	O
14	O
to	O
chromosome	O
higher	O
of	O
Rb1	O
primates	O
.	O

Mapping	O
the	O
prelate	O
cistron	O
primate	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
homo	O
Rb1	O
factor	O
to	O
chromosome	O
xiv	O
of	O
higher	O
archpriest	O
.	O

higher	O
the	O
homolog	O
Mapping	O
gene	O
human	O
Rb1	O
of	O
to	O
chromosome	O
14	O
the	O
of	O
primates	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
Rb1	O
factor	O
to	O
chromosome	O
fourteen	O
of	O
higher	O
hierarch	O
.	O

Mapping	O
the	O
prelate	O
cistron	O
primate	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
cistron	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

Mapping	O
homolog	O
the	O
Rb1	O
gene	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

gene	O
of	O
homolog	O
the	O
the	O
human	O
chromosome	O
Mapping	O
to	O
Rb1	O
14	O
of	O
higher	O
.	O
primates	O

map	O
the	O
homolog	O
of	O
the	O
homo	O
Rb1	O
factor	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

Mapping	O
the	O
prelate	O
cistron	O
primate	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
cistron	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

The	O
Rb1	O
and	O
(	O
been	O
implicated	O
human	O
retinoblastoma	B
gene	O
is	O
located	O
on	O
with	O
Chromosome	O
has	O
Chr	O
)	O
13q14	O
.	O

gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
Chr	O
)	O
13q14	O
.	O

The	O
Rb1	O
cistron	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
settle	O
on	O
homo	O
chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

The	O
Rb1	O
cistron	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
situate	O
on	O
homo	O
chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

)	O
Rb1	O
gene	O
has	O
been	O
implicated	O
Chromosome	O
(	B
and	O
is	O
located	O
on	O
13q14	O
with	O
retinoblastoma	O
Chr	O
human	O
The	O
.	O

The	O
Rb1	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
.	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
.	O

The	O
Rb1	O
cistron	O
has	O
been	O
concerned	O
with	O
retinoblastoma	B
and	O
is	O
place	O
on	O
human	O
chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
.	O

Chromosome	O
Rb1	O
gene	O
located	O
been	O
implicated	O
with	O
.	B
(	O
is	O
has	O
on	O
The	O
human	O
and	O
Chr	O
)	O
13q14	O
retinoblastoma	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

2	O
.	O

2	O
2	O

2	O
.	O
2	O

2	O
2	O
two	O
.	O

2	O
2	O
two	O
.	O

two	O
two	O
.	O

ii	O
ii	O
.	O

deuce	O
deuce	O
.	O

2	O
2	O
two	O
.	O

2	O
2	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
fish	O
proficiency	O
fish	O
proficiency	O
proficiency	O
episode	O
realm	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
14	O
the	O
FISH	O
technique	O
.	O

ampere	O
unique	O
succession	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
expend	O
to	O
focalize	O
this	O
realm	O
on	O
imitator	O
Chr	O
fourteen	O
by	O
the	O
FISH	O
technique	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
has	O
been	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
the	O
FISH	O
technique	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
fish	O
proficiency	O
fish	O
proficiency	O
proficiency	O
episode	O
episode	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

A	O
unequalled	O
succession	O
human	O
Rb1	O
cosmid	O
DNA	O
investigation	O
has	O
been	O
victimized	O
to	O
place	O
this	O
region	O
on	O
aper	O
Chr	O
14	O
by	O
the	O
FISH	O
proficiency	O
.	O

A	O
unequaled	O
successiveness	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
victimized	O
to	O
focalise	O
this	O
region	O
on	O
emulator	O
Chr	O
14	O
by	O
the	O
angle	O
proficiency	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
used	O
this	O
region	O
on	O
apes	O
Chr	O
14	O
by	O
the	O
FISH	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
fish	O
proficiency	O
fish	O
proficiency	O
proficiency	O
episode	O
episode	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

Chr	O
unique	O
sequence	O
used	O
Rb1	O
cosmid	O
DNA	O
14	O
.	O
been	O
human	O
to	O
localize	O
this	O
technique	O
on	O
apes	O
the	O
probe	O
A	O
by	O
FISH	O
region	O
has	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
.	O

The	O
conservation	O
of	O
gene	O
in	O
higher	O
primates	O
at	O
corresponding	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
a	O
phylogenetic	O
marker	O
to	O
further	O
human	O

a	O
of	O
of	O
the	O
Rb1	O
gene	O
corresponding	O
of	O
primates	O
at	O
the	O
in	O
equivalent	O
to	O
trace	O
(	O
14q14	O
)	O
higher	O
the	O
human	O
may	O
further	O
as	O
The	O
phylogenetic	O
evolutionary	O
chromosome	O
locus	O
serve	O
the	O
descent	O
pathway	O
conservation	O
human	O
marker	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
eminent	O
phyletic	O
.	O

to	O
human	O
of	O
the	O
14q14	O
gene	O
locus	O
evolutionary	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
a	O
higher	O
(	O
Rb1	O
the	O
of	O
the	O
chromosome	O
may	O
serve	O
as	O
conservation	O
phylogenetic	O
marker	O
The	O
)	O
trace	O
further	O
in	O
pathway	O
of	O
human	O
descent	O
.	O

The	O
preservation	O
of	O
the	O
Rb1	O
cistron	O
in	O
mellow	O
archpriest	O
at	O
the	O
represent	O
equivalent	O
chromosome	O
venue	O
(	O
14q14	O
)	O
of	O
the	O
human	O
whitethorn	O
serve	O
as	O
a	O
phyletic	O
marker	O
to	O
further	O
hunt	O
the	O
evolutionary	O
footpath	O
of	O
human	O
bloodline	O
.	O

The	O
conservation	O
of	O
the	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
locus	O
(	O
14q14	O
of	O
human	O
may	O
serve	O
phylogenetic	O
the	O
evolutionary	O
pathway	O
human	O
descent	O

The	O
conservation	O
the	O
the	O
Rb1	O
descent	O
in	O
higher	O
primates	O
at	O
the	O
marker	O
the	O
chromosome	O
locus	O
to	O
14q14	O
)	O
evolutionary	O
equivalent	O
human	O
pathway	O
serve	O
gene	O
a	O
(	O
corresponding	O
may	O
phylogenetic	O
trace	O
of	O
of	O
further	O
of	O
human	O
as	O
.	O

The	O
preservation	O
of	O
the	O
Rb1	O
factor	O
in	O
gamey	O
hierarch	O
at	O
the	O
gibe	O
tantamount	O
chromosome	O
venue	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
suffice	O
as	O
a	O
phyletic	O
marking	O
to	O
further	O
draw	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
.	O

The	O
preservation	O
of	O
the	O
Rb1	O
cistron	O
in	O
eminent	O
primates	O
at	O
the	O
fit	O
tantamount	O
chromosome	O
venue	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phyletic	O
marker	O
to	O
further	O
vestige	O
the	O
evolutionary	O
tract	O
of	O
human	O
blood	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
.	O

Wiskott	B
Aldrich	I
syndrome	I
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
missense	O
mutations	O
in	O
the	O
-	O
terminal	O
part	O
of	O
the	O
gene	O
product	O
.	O

Wiskott	B
Aldrich	I
syndrome	I
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
missense	O
mutations	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
wasp	O
nobelium	O
mutation	O
inward	O
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
wasp	O
cistron	O
intersection	O
cistron	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

terminal	B
-	I
Aldrich	I
amino	I
:	O
no	O
strict	O
gene	O
the	O
phenotype	O
-	O
but	O
clustering	O
of	O
of	O
mutations	O
in	O
the	O
syndrome	O
WASP	O
correlations	O
part	O
missense	O
-	O
Wiskott	O
genotype	O
product	O
.	O

product	B
-	I
Aldrich	I
missense	I
:	O
no	O
gene	O
genotype	O
syndrome	O
phenotype	O
correlations	O
but	O
of	O
terminal	O
WASP	O
-	O
in	O
the	O
amino	O
-	O
clustering	O
part	O
of	O
the	O
mutations	O
strict	O
Wiskott	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
wasp	O
nobelium	O
mutation	O
inward	O
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
wasp	O
cistron	O
intersection	O
mutation	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
rigorous	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
flock	O
of	O
missense	O
variation	O
in	O
the	O
aminic	O
-	O
final	O
break	O
of	O
the	O
wasp	O
factor	O
product	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
wasp	O
nobelium	O
mutation	O
inward	O
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
wasp	O
cistron	O
intersection	O
mutation	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

the	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
of	O
but	O
-	O
phenotype	O
correlations	O
in	O
part	O
strict	O
WASP	O
Wiskott	O
genotype	O
mutations	O
amino	O
-	O
terminal	O
clustering	O
of	O
the	O
missense	O
gene	O
product	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
rigid	O
genotype	O
-	O
phenotype	O
correlativity	O
but	O
constellate	O
of	O
missense	O
sport	O
in	O
the	O
amino	O
-	O
end	O
part	O
of	O
the	O
WASP	O
factor	O
merchandise	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
wasp	O
)	O
factor	O
was	O
notice	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
WAS	B
and	O
in	O
patients	O
display	O
tenner	B
-	I
connect	I
thrombopenia	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
patients	O
showing	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

and	O
Wiskott	B
-	I
with	I
syndrome	I
protein	O
(	O
-	O
showing	O
gene	O
.	O
found	O
to	O
WAS	O
patients	O
in	O
patients	O
presenting	O
Aldrich	O
be	B
X	O
in	O
mutated	O
)	O
The	B
WASP	I
linked	I
thrombocytopenia	I
was	O

The	O
Wiskott	B
-	I
Aldrich	I
patient	O
role	I
follow	O
mutate	I
inward	O
patient	I
syndrome	O
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
usher	O
unite	O
inward	O
with	B
WAS	O
and	O
in	O
patients	O
showing	B
X	I
-	I
linked	I
thrombocytopenia	O

The	O
Wiskott	B
-	I
Aldrich	I
patient	O
role	I
follow	O
mutate	I
inward	O
patient	I
syndrome	O
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
usher	O
unite	O
inward	O
with	B
WAS	O
and	O
in	O
patients	O
showing	B
X	I
-	I
linked	I
thrombocytopenia	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
gene	O
was	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
in	O
patients	O
showing	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

.	O
Wiskott	B
-	I
mutated	I
syndrome	I
protein	O
-	O
WASP	O
Aldrich	O
gene	O
was	O
found	O
linked	O
be	O
X	O
)	O
patients	O
presenting	O
with	O
WAS	B
to	O
in	O
patients	O
showing	O
in	B
(	I
and	I
thrombocytopenia	I
The	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
gene	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
and	O
in	O
patients	O
showing	O
X	B
-	I
linked	I

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
wasp	O
)	O
factor	O
embody	O
witness	O
to	O
be	O
mutated	O
in	O
patients	O
represent	O
with	O
embody	B
and	O
in	O
patients	O
showing	O
X	B
-	I
colligate	I
thrombopenia	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
factor	O
washington	O
see	O
to	O
be	O
mutated	O
in	O
patients	O
give	O
with	O
washington	B
and	O
in	O
patients	O
prove	O
x	B
-	I
associate	I
thrombopenia	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
WAS	B
and	O
in	O
patients	O
showing	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

Mutation	O
analysis	O
in	O
19	O
aside	O
	O
get	O
it	O
on	O
string	O
phratry	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
apart	O
apart	O
apart	O

Mutation	O
analysis	O
families	O
and	O
Turkish	O
descent	O
single	O
-	O
conformation	O
polymorphism	O
and	O
in	O
the	O
detection	O
of	O
seven	O
and	O
known	O
mutations	O
.	O

variation	O
analysis	O
in	O
xix	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
turkish	O
blood	O
by	O
unity	O
-	O
strand	O
conformation	O
pleomorphism	O
and	O
sequence	O
resulted	O
in	O
the	O
detecting	O
of	O
seven	O
refreshing	O
and	O
10	O
known	O
mutations	O
.	O

Mutation	O
analysis	O
in	O
19	O
of	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
.	O

sport	O
analysis	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
turkish	O
descent	O
by	O
undivided	O
-	O
strand	O
compliance	O
polymorphism	O
and	O
sequence	O
lead	O
in	O
the	O
detecting	O
of	O
septet	O
novel	O
and	O
tenner	O
known	O
mutations	O
.	O

Mutation	O
analysis	O
in	O
19	O
aside	O
	O
get	O
it	O
on	O
string	O
phratry	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
apart	O
apart	O
apart	O

variation	O
analysis	O
in	O
19	O
kinsperson	O
of	O
German	O
,	O
Swiss	O
and	O
turkish	O
decline	O
by	O
single	O
-	O
strand	O
conformity	O
pleomorphism	O
and	O
sequence	O
resulted	O
in	O
the	O
detection	O
of	O
heptad	O
new	O
and	O
10	O
known	O
mutations	O
.	O

resulted	O
and	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
of	O
known	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
analysis	O
in	O
.	O
detection	O
single	O
seven	O
novel	O
Mutation	O
-	O
the	O
mutations	O
10	O

Mutation	O
analysis	O
in	O
19	O
of	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
seven	O
novel	O
and	O
known	O
.	O

Mutation	O
analysis	O
in	O
19	O
aside	O
	O
get	O
it	O
on	O
string	O
depth	O
psychology	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
apart	O
apart	O

Mutation	O
analysis	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
.	O

A	O
mint	O
flock	O
of	O
missense	O
sport	O
in	O
the	O
initiatory	O
four	O
exons	O
counterpoint	O
with	O
a	O
random	O
distribution	O
of	O
folderal	O
sport	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
mutations	O
.	O

clustering	O
mutations	O
in	O
the	O
four	O
exons	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
the	O
first	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

clustering	O
of	O
missense	O
mutations	O
the	O
first	O
four	O
exons	O
contrasted	O
a	O
random	O
distribution	O
of	O
mutations	O
.	O

nonsense	O
striking	O
clustering	O
mutations	O
missense	O
mutations	O
in	O
first	O
the	O
four	O
random	O
contrasted	O
with	O
.	O
A	O
distribution	O
of	O
exons	O
of	O
a	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
bunch	O
bunch	O
bunch	O
bunch	O
bunch	O
trumpery	O
mutations	O
.	O

adenine	O
mint	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
quadruplet	O
exons	O
counterpoint	O
with	O
adenine	O
random	O
distribution	O
of	O
folderal	O
mutations	O
.	O

of	O
striking	O
clustering	O
of	O
missense	O
mutations	O
a	O
contrasted	O
first	O
four	O
exons	O
random	O
A	O
in	O
the	O
nonsense	O
with	O
distribution	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

More	O
than	O
contained	O
%	O
of	O
in	O
known	O
product	O
mutations	O
were	O
localized	O
this	O
mutational	O
amino	O
-	O
at	O
stretch	O
of	O
WASP	O
the	O
gene	O
missense	O
;	O
all	O
region	O
a	O
85	O
86	O
hot	O
spot	O
terminal	O
the	O
codon	O
.	O

More	O
%	O
of	O
all	O
known	O
mutations	O
were	O
the	O
amino	O
terminal	O
stretch	O
gene	O
;	O
this	O
region	O
a	O
mutational	O
hot	O
at	O
codon	O
86	O
.	O

More	O
than	O
85	O
%	O
completely	O
pole	O
get	O
it	O
on	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O

More	O
than	O
85	O
%	O
completely	O
pole	O
stretch	O
out	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O
amino	O

than	O
the	O
85	O
%	O
of	O
all	O
a	O
missense	O
mutations	O
were	O
localized	O
mutational	O
the	O
region	O
spot	O
terminal	O
stretch	O
of	O
in	O
WASP	O
gene	O
product	O
.	O
this	O
amino	O
contained	O
known	O
More	O
codon	O
;	O
at	O
hot	O
86	O
-	O

More	O
than	O
85	O
%	O
of	O
all	O
mutations	O
were	O
localized	O
in	O
amino	O
-	O
terminal	O
stretch	O
of	O
WASP	O
gene	O
product	O
;	O
region	O
contained	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
.	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
aminic	O
-	O
depot	O
unfold	O
of	O
the	O
WASP	O
cistron	O
intersection	O
;	O
this	O
neighborhood	O
check	O
a	O
mutational	O
live	O
slur	O
at	O
codon	O
lxxxvi	O
.	O

More	O
than	O
lxxxv	O
%	O
of	O
all	O
acknowledge	O
missense	O
mutant	O
were	O
localized	O
in	O
the	O
amino	O
-	O
last	O
stint	O
of	O
the	O
wasp	O
cistron	O
merchandise	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
blistering	O
dapple	O
at	O
codon	O
86	O
.	O

More	O
than	O
85	O
%	O
completely	O
pole	O
stretch	O
out	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O
altogether	O
amino	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
focalize	O
in	O
the	O
amino	O
-	O
depot	O
debase	O
of	O
the	O
WASP	O
cistron	O
product	O
;	O
this	O
realm	O
curb	O
a	O
mutational	O
raging	O
patch	O
at	O
codon	O
86	O
.	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
be	O
authoritative	O
be	O
be	O
comparability	O
comparability	O
mutation	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
for	O
classical	O
WAS	B
phenotype	O
.	O

no	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
equivalence	O
of	O
the	O
distinguish	O
sport	O
with	O
the	O
leave	O
clinical	O
exposure	O
for	O
a	O
classical	O
constitute	B
phenotype	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
comparison	O
of	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
classical	O
WAS	B
phenotype	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
be	O
authoritative	O
be	O
be	O
comparability	O
comparability	O
comparability	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlativity	O
emerged	O
after	O
a	O
equivalence	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
lead	O
clinical	O
picture	O
for	O
a	O
classical	O
follow	B
phenotype	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparability	O
of	O
the	O
identified	O
variation	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
personify	B
phenotype	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
the	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
WAS	B

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
be	O
authoritative	O
be	O
be	O
comparability	O
comparability	O
comparability	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

picture	O
genotype	O
-	O
the	O
correlation	O
emerged	O
after	O
for	O
.	O
of	O
phenotype	O
identified	O
mutations	O
with	O
phenotype	O
resulting	O
clinical	O
classical	O
a	O
No	O
a	O
WAS	B
the	O
comparison	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

A	O
exchange	O
at	O
codon	O
lxxxvi	O
lead	O
in	O
an	O
super	O
variable	O
locution	O
of	O
the	O
disease	O
in	O
a	O
big	O
Swiss	O
family	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
astatine	O
astatine	O
astatine	O
astatine	O
astatine	O
astatine	O
family	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
astatine	O
astatine	O
astatine	O
astatine	O
astatine	O
astatine	O
family	O
.	O

at	O
resulted	O
in	O
an	O
variable	O
expression	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
an	O
extremely	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

at	O
codon	O
86	O
resulted	O
an	O
extremely	O
variable	O
expression	O
of	O
disease	O
in	O
a	O
large	O
family	O
.	O

Swiss	O
substitution	O
at	O
family	O
86	O
resulted	O
in	O
extremely	O
an	O
variable	O
in	O
of	O
the	O
.	O
A	O
a	O
large	O
expression	O
codon	O
disease	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
astatine	O
astatine	O
astatine	O
astatine	O
astatine	O
heavy	O
family	O
.	O

A	O
permutation	O
at	O
codon	O
86	O
leave	O
in	O
an	O
passing	O
variable	O
formulation	O
of	O
the	O
disease	O
in	O
a	O
heavy	O
Swiss	O
house	O
.	O

large	O
substitution	O
at	O
codon	O
86	O
resulted	O
disease	O
of	O
extremely	O
variable	O
expression	O
in	O
A	O
in	O
an	O
Swiss	O
the	O
a	O
family	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
filum	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
like	O
filaments	O
.	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
filum	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
inward	O
like	O
filaments	O
.	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
filum	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
discover	O
like	O
filaments	O
.	O
.	O

in	O
VASP	O
homology	O
search	O
revealed	O
a	O
to	O
with	O
of	O
this	O
stretch	O
distant	O
the	O
of	O
-	O
stimulated	O
phosphoprotein	O
(	O
relationship	O
)	O
,	O
interacting	O
cyto	O
involved	O
An	O
the	O
by	O
vasodilator	O
-	O
is	O
architecture	O
-	O
which	O
extended	O
actin	O
maintenance	O
like	O
filaments	O
.	O
.	O

An	O
extended	O
homology	O
search	O
relationship	O
of	O
this	O
stretch	O
to	O
vasodilator	O
-	O
VASP	O
which	O
is	O
the	O
cyto	O
-	O
architecture	O
by	O
with	O
actin	O
filaments	O
.	O

An	O
extended	O
homology	O
hunting	O
revealed	O
a	O
remote	O
relationship	O
of	O
this	O
debase	O
to	O
the	O
vasodilative	O
-	O
excite	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
require	O
in	O
the	O
upkeep	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
like	O
strand	O
.	O
.	O

an	O
gallop	O
homology	O
search	O
unwrap	O
a	O
removed	O
relationship	O
of	O
this	O
dilute	O
to	O
the	O
vasodilative	O
-	O
energise	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
require	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
wish	O
filum	O
.	O
.	O

architecture	O
actin	O
homology	O
search	O
phosphoprotein	O
a	O
filaments	O
by	O
of	O
this	O
stretch	O
to	O
the	O
in	O
(	O
stimulated	O
revealed	O
-	O
VASP	O
)	O
vasodilator	O
which	O
is	O
involved	O
extended	O
the	O
maintenance	O
.	O
An	O
-	O
cyto	O
distant	O
interacting	O
with	O
,	O
-	O
like	O
relationship	O
of	O
.	O

an	O
lead	O
homology	O
search	O
revealed	O
a	O
upstage	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilative	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
convoluted	O
in	O
the	O
sustainment	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
similar	O
filum	O
.	O
.	O

An	O
extended	O
architecture	O
search	O
revealed	O
-	O
stretch	O
relationship	O
of	O
this	O
distant	O
maintenance	O
)	O
vasodilator	O
-	O
VASP	O
phosphoprotein	O
(	O
filaments	O
the	O
,	O
which	O
is	O
a	O
in	O
stimulated	O
to	O
interacting	O
by	O
-	O
homology	O
of	O
cyto	O
with	O
actin	O
involved	O
like	O
the	O
.	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
like	O
filaments	O
.	O
.	O

Influence	O
PAX6	O
dosage	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Influence	O
of	O
PAX6	O
cistron	O
dose	O
on	O
developing	O
:	O
overexpression	O
causes	O
severe	O
oculus	B
abnormalities	I
.	O

:	O
gene	O
PAX6	O
of	O
dosage	O
on	O
causes	O
Influence	O
overexpression	O
.	O
severe	O
eye	B
abnormalities	I
development	O

Influence	O
of	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
causes	O
severe	O
abnormalities	I
.	O

Influence	O
of	O
abnormalcy	O
cistron	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
abnormalcy	O
dose	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Influence	O
of	O
abnormalcy	O
cistron	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
abnormalcy	O
do	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Influence	O
of	O
PAX6	O
cistron	O
dosage	O
on	O
evolution	O
:	O
overexpression	O
stimulate	O
severe	O
eye	B
irregularity	I
.	O

abnormalities	O
of	O
PAX6	O
Influence	O
:	O
on	O
development	O
eye	O
overexpression	O
causes	O
severe	O
dosage	B
gene	I
.	O

Influence	O
of	O
abnormalcy	O
cistron	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
abnormalcy	O
dose	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Influence	O
of	O
PAX6	O
cistron	O
dosage	O
on	O
evolution	O
:	O
overexpression	O
causa	O
severe	O
optic	B
abnormalities	I
.	O

Influence	O
of	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

PAX6	B
in	O
man	O
developmental	O
Small	O
eye	O
in	O
box	O
mutations	O
semidominant	B
and	I
disorders	I
by	O
caused	O
are	O
within	O
the	O
paired	O
mice	O
Aniridia	O
gene	O
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
cistron	O
homo	O
homo	O
homo	O
homo	O
homo	O
box	O
gene	O
PAX6	O
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
cistron	O
homo	O
homo	O
homo	O
homo	O
homo	O
box	O
gene	O
PAX6	O
.	O

Aniridia	B
in	O
man	O
and	O
belittled	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
perturb	I
caused	O
by	O
sport	O
inside	O
the	O
couple	O
box	O
factor	O
PAX6	O
.	O

Aniridia	B
in	O
man	O
Small	O
eye	O
in	O
mice	O
are	O
developmental	I
disorders	I
caused	O
by	O
within	O
the	O
box	O
gene	O
PAX6	O
.	O

and	O
in	O
mice	O
are	O
developmental	I
disorders	I
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
PAX6	O
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
center	O
in	O
mice	O
are	O
semidominant	B
developmental	I
unhinge	I
stimulate	O
by	O
variation	O
inside	O
the	O
copulate	O
box	O
gene	O
PAX6	O
.	O

mutations	B
in	O
are	O
in	O
Small	O
eye	O
within	O
mice	O
man	O
semidominant	B
developmental	I
disorders	I
PAX6	O
by	O
and	O
Aniridia	O
the	O
paired	O
box	O
gene	O
caused	O
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
cistron	O
homo	O
homo	O
homo	O
homo	O
be	O
box	O
gene	O
PAX6	O
.	O

Aniridia	B
in	O
man	O
and	O
in	O
mice	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
PAX6	O
.	O

Whereas	O
heterozygotes	O
mice	O
and	O
iris	B
hypoplasia	I
nasal	O
homozygous	O
suffer	O
lack	O
eyes	O
and	O
,	O
cavities	O
from	O
exhibit	O
brain	B
abnormalities	I
.	O

suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
exhibit	O
brain	B
abnormalities	I
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
flag	B
hypoplasia	I
,	O
homozygous	O
shiner	O
want	O
eyes	O
and	O
nasal	O
caries	O
and	O
present	O
brain	B
abnormalities	I
.	O

Whereas	O
heterozygotes	O
ache	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
deficiency	O
centre	O
and	O
adenoidal	O
cavities	O
and	O
present	O
brain	B
abnormalities	I
.	O

brain	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
cavities	O
and	O
mice	O
lack	O
eyes	O
and	O
abnormalities	O
,	O
homozygous	O
exhibit	O
nasal	B
Whereas	I
.	O

Whereas	O
heterozygotes	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
abnormalities	I
put	O
up	O
put	O
up	O
put	O
up	O

Whereas	O
heterozygotes	O
tolerate	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mouse	O
lack	O
middle	O
and	O
nasal	O
caries	O
and	O
demo	O
brain	B
abnormalities	I
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
abnormalities	I
put	O
up	O
put	O
up	O
put	O
up	O

cavities	O
heterozygotes	O
suffer	O
eyes	O
iris	B
hypoplasia	I
,	O
.	O
and	O
lack	O
from	O
and	O
Whereas	O
nasal	O
mice	O
exhibit	O
brain	B
abnormalities	I
homozygous	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
abnormalities	I
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
homo	O
impart	O
locale	O
homo	O
locale	O
locale	O
homo	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O
.	O

role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
carrying	O
human	O
PAX6	O
locus	O
.	O

To	O
inquire	O
the	O
role	O
of	O
factor	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
beget	O
barm	O
stilted	O
chromosome	O
transgenic	O
mice	O
run	O
the	O
human	O
PAX6	O
locale	O
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
we	O
have	O
yeast	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
locus	O
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
homo	O
impart	O
locale	O
homo	O
locale	O
locale	O
more	O
than	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dose	O
in	O
more	O
item	O
,	O
we	O
have	O
generated	O
barm	O
hokey	O
chromosome	O
transgenic	O
mice	O
contain	O
the	O
homo	O
PAX6	O
venue	O
.	O

To	O
investigate	O
the	O
role	O
of	O
cistron	O
dose	O
in	O
more	O
particular	O
,	O
we	O
have	O
father	O
barm	O
artificial	O
chromosome	O
transgenic	O
mice	O
impart	O
the	O
human	O
PAX6	O
locale	O
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
have	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
homo	O
impart	O
locale	O
homo	O
locale	O
locale	O
more	O
than	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O

carrying	O
investigate	O
the	O
,	O
of	O
gene	O
dosage	O
mice	O
locus	O
detail	O
role	O
we	O
generated	O
have	O
PAX6	O
artificial	O
chromosome	O
transgenic	O
in	O
.	O
the	O
human	O
yeast	O
more	O
To	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O
.	O

When	O
Small	O
onto	O
the	O
crossed	O
eye	O
,	O
rescues	O
the	O
transgene	O
mutant	O
the	O
background	O
phenotype	O
.	O

When	O
crossed	O
background	O
knowledge	O
mutation	O
background	O
knowledge	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
background	O
knowledge	O
transgene	O
rescues	O
the	O

When	O
foil	O
onto	O
the	O
little	O
eye	O
background	O
,	O
the	O
transgene	O
saving	O
the	O
variation	O
phenotype	O
.	O

mutant	O
crossed	O
onto	O
When	O
,	O
eye	O
background	O
the	O
the	O
transgene	O
rescues	O
Small	O
the	O
phenotype	O
.	O

When	O
crossed	O
onto	O
the	O
little	O
centre	O
background	O
,	O
the	O
transgene	O
deliverance	O
the	O
mutation	O
phenotype	O
.	O

When	O
crossed	O
background	O
knowledge	O
mutation	O
background	O
knowledge	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
low	O
transgene	O
rescues	O
the	O
mutant	O

When	O
onto	O
Small	O
background	O
,	O
the	O
transgene	O
rescues	O
the	O
mutant	O
phenotype	O
.	O

,	O
the	O
onto	O
crossed	O
Small	O
eye	O
transgene	O
When	O
the	O
background	O
rescues	O
the	O
mutant	O
.	O
phenotype	O

When	O
bilk	O
onto	O
the	O
Small	O
heart	O
background	O
,	O
the	O
transgene	O
saving	O
the	O
sport	O
phenotype	O
.	O

When	O
crossed	O
background	O
knowledge	O
mutation	O
background	O
knowledge	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
low	O
transgene	O
rescues	O
the	O
mutant	O

When	O
crossed	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
transgene	O
rescues	O
the	O
mutant	O
phenotype	O
.	O

Strikingly	O
,	O
mice	O
bear	O
multiple	O
imitate	O
on	O
a	O
violent	O
-	O
type	O
background	O
register	O
particular	O
developmental	B
abnormalities	I
of	I
the	I
heart	I
,	O
but	O
not	O
of	O
other	O
tissues	O
evince	O
the	O
cistron	O
.	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
on	O
-	O
type	O
background	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

but	O
,	O
mice	O
eye	O
multiple	O
copies	O
on	O
expressing	O
other	O
-	O
.	O
background	O
show	O
,	O
of	B
abnormalities	I
of	I
the	I
carrying	I
specific	O
tissues	O
not	O
developmental	O
wild	O
Strikingly	O
a	O
the	O
gene	O
type	O

Strikingly	O
,	O
mice	O
carrying	O
usher	O
particular	O
written	O
matter	O
abnormalcy	O
antiophthalmic	O
factor	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	B
specific	I
developmental	I
abnormalities	I
of	O
the	I
verbalise	O
tissue	I
paper	O
idle	O
eye	O
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O

Strikingly	O
,	O
mice	O
carrying	O
usher	O
particular	O
written	O
matter	O
abnormalcy	O
antiophthalmic	O
factor	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	B
specific	I
developmental	I
abnormalities	I
of	O
the	I
verbalise	O
tissue	I
paper	O
character	O
eye	O
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
-	O
type	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

.	O
,	O
mice	O
developmental	O
multiple	O
copies	O
expressing	O
a	O
carrying	O
-	O
type	O
background	O
the	O
specific	O
tissues	B
wild	I
of	I
the	I
eye	I
,	O
show	O
not	O
of	O
other	O
abnormalities	O
on	O
but	O
gene	O
Strikingly	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
-	O
background	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O

strikingly	O
,	O
mice	O
extend	O
multiple	O
transcript	O
on	O
a	O
wild	O
-	O
case	O
background	O
show	O
specific	O
developmental	B
abnormalcy	I
of	I
the	I
eye	I
,	O
but	O
not	O
of	O
other	O
weave	O
evince	O
the	O
cistron	O
.	O

strikingly	O
,	O
mice	O
pack	O
multiple	O
copy	O
on	O
a	O
baseless	O
-	O
type	O
background	O
indicate	O
particular	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
,	O
but	O
not	O
of	O
other	O
tissues	O
convey	O
the	O
factor	O
.	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

Thus	O
,	O
middle	O
phenotype	O
astatine	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
unlike	O
.	O

PAX6	O
,	O
at	O
.	O
five	O
different	O
eye	O
phenotypes	O
expression	O
associated	O
with	O
changes	O
Thus	O
in	O
are	O
least	O

Thus	O
,	O
middle	O
phenotype	O
inward	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
unlike	O
.	O

thusly	O
,	O
at	O
least	O
fin	O
different	O
centre	O
phenotypes	O
are	O
relate	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

in	O
,	O
at	O
phenotypes	O
five	O
different	O
PAX6	O
least	O
are	O
associated	O
Thus	O
changes	O
with	O
eye	O
expression	O
.	O

Thus	O
,	O
middle	O
phenotype	O
astatine	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
unlike	O
.	O

Thus	O
,	O
at	O
least	O
fin	O
different	O
center	O
phenotypes	O
are	O
associated	O
with	O
modify	O
in	O
PAX6	O
saying	O
.	O

thence	O
,	O
at	O
least	O
five	O
dissimilar	O
eye	O
phenotypes	O
are	O
associated	O
with	O
convert	O
in	O
PAX6	O
verbalism	O
.	O

Thus	O
,	O
are	O
.	O
five	O
different	O
in	O
phenotypes	O
at	O
associated	O
with	O
changes	O
eye	O
PAX6	O
least	O
expression	O

,	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

Thus	O
,	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

We	O
provide	O
prove	O
that	O
not	O
only	O
cut	O
,	O
but	O
likewise	O
increased	O
levels	O
of	O
transcriptional	O
governor	O
can	O
campaign	O
developmental	B
shortcoming	I
.	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
certify	B
certify	O
certify	B
certify	O
certify	B
certify	O
defects	I
.	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
certify	B
certify	O
certify	B
certify	O
certify	B
certify	O
defects	I
.	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
also	O
increased	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
defects	I

regulators	O
provide	O
but	O
reduced	O
not	O
only	O
can	O
,	O
evidence	O
also	O
increased	O
levels	O
.	O
transcriptional	O
that	O
We	O
cause	O
developmental	B
defects	I
.	O
of	O

We	O
furnish	O
demonstrate	O
that	O
not	O
only	O
reduced	O
,	O
but	O
besides	O
increased	O
levels	O
of	O
transcriptional	O
governor	O
can	O
drive	O
developmental	B
shortcoming	I
.	O
.	O

.	O
provide	O
evidence	O
increased	O
not	O
only	O
reduced	O
defects	O
regulators	O
also	O
that	O
levels	O
transcriptional	O
of	O
but	O
can	O
cause	O
developmental	B
,	I
We	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
certify	B
certify	O
certify	B
certify	O
certify	B
too	O
defects	I
.	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
regulators	O
developmental	B
defects	I
.	O
.	O

We	O
render	O
manifest	O
that	O
not	O
only	O
reduced	O
,	O
but	O
likewise	O
increased	O
floor	O
of	O
transcriptional	O
regulators	O
can	O
effort	O
developmental	B
fault	I
.	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
defects	I
.	O
.	O

Heterodimer	O
in	O
and	O
activity	O
formation	O
the	O
enzyme	O
1	O
galactose	O
-	O
phosphate	O
-	O
human	O
uridylyltransferase	O
.	O

Heterodimer	O
formation	O
homo	O
orthophosphate	O
brain	O
sugar	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
homo	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O

Heterodimer	O
organization	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
-	O
ane	O
-	O
phosphate	O
uridylyltransferase	O
.	O

phosphate	O
formation	O
and	O
Heterodimer	O
enzyme	O
the	O
human	O
-	O
galactose	O
-	O
1	O
in	O
activity	O
uridylyltransferase	O
.	O

Heterodimer	O
establishment	O
and	O
activity	O
in	O
the	O
homo	O
enzyme	O
galactose	O
-	O
i	O
-	O
phosphate	O
uridylyltransferase	O
.	O

Heterodimer	O
formation	O
homo	O
orthophosphate	O
brain	O
sugar	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
inward	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O

Heterodimer	O
and	O
in	O
human	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O
.	O

enzyme	O
activity	O
and	O
formation	O
in	O
the	O
-	O
Heterodimer	O
galactose	O
human	O
1	O
-	O
phosphate	O
.	O
uridylyltransferase	O

Heterodimer	O
organization	O
and	O
activeness	O
in	O
the	O
human	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O
.	O

Heterodimer	O
formation	O
homo	O
orthophosphate	O
brain	O
sugar	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
inward	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O

Heterodimer	O
formation	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridylyltransferase	O
.	O

of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
occurring	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

dimeric	O
of	O
the	O
mutations	O
questions	O
concerning	O
expression	O
.	O
heterodimer	O
of	O
activity	O
enzymes	O
involves	O
on	O
and	O
of	O
naturally	O
occurring	O
fundamental	O
the	O
subunit	O
assembly	O
impact	O
function	O
One	O
and	O

matchless	O
of	O
the	O
fundamental	O
doubtfulness	O
refer	O
expression	O
and	O
officiate	O
of	O
dimeric	O
enzymes	O
take	O
the	O
affect	O
of	O
naturally	O
come	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

peerless	O
of	O
the	O
rudimentary	O
wonder	O
concerning	O
expression	O
and	O
use	O
of	O
dimeric	O
enzymes	O
take	O
the	O
affect	O
of	O
naturally	O
pass	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
enzymes	O
involves	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
heterodimer	O
activity	O
.	O

One	O
of	O
the	O
fundamental	O
interrogation	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
fractional	O
monetary	O
unit	O
assemblage	O
bodily	O
process	O
serve	O
bodily	O
process	O
serve	O
mutations	O
on	O
subunit	O
assembly	O

One	O
of	O
the	O
fundamental	O
interrogation	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
fractional	O
monetary	O
unit	O
assemblage	O
bodily	O
process	O
serve	O
bodily	O
process	O
	O
mutations	O
on	O
subunit	O
assembly	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
enzymes	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
assembly	O
and	O

heterodimer	O
of	O
the	O
fundamental	O
questions	O
concerning	O
the	O
naturally	O
function	O
of	O
dimeric	O
enzymes	O
assembly	O
expression	O
activity	O
of	O
and	O
subunit	O
mutations	O
on	O
One	O
involves	O
and	O
occurring	O
impact	O
.	O

unrivalled	O
of	O
the	O
fundamental	O
interrogation	O
concerning	O
verbalism	O
and	O
function	O
of	O
dimeric	O
enzymes	O
demand	O
the	O
impact	O
of	O
course	O
hap	O
mutations	O
on	O
subunit	O
fabrication	O
and	O
heterodimer	O
activity	O
.	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
galactose	O
-	O
l	O
-	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
,	O
impairment	O
of	O
which	O
in	O
the	O
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
patients	O
studied	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
true	O
molecular	O

heterozygotes	O
which	O
is	O
of	O
particular	O
interest	O
most	O
-	O
human	O
enzyme	O
galactose	O
-	O
l	O
.	O
than	O
uridylyl	O
the	O
disorder	O
(	O
GALT	O
date	O
,	O
impairment	O
of	O
question	O
results	O
in	O
patients	O
transferase	B
metabolic	I
inherited	I
for	B
,	O
because	O
many	O
if	O
not	O
molecular	O
the	O
studied	O
to	O
)	O
are	O
compound	O
This	O
rather	O
phosphate	O
true	O
homozygotes	O
galactosemia	O
-	O

This	O
enquiry	O
is	O
of	O
picky	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
deadening	O
of	O
which	O
issue	O
in	O
the	O
transmissible	B
metabolous	I
perturb	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
canvass	O
to	O
engagement	O
are	O
compound	O
heterozygotes	O
preferably	O
than	O
lawful	O
molecular	O
homozygotes	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
orthophosphate	O
homo	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
be	O
chemical	O
compound	O
heterozygote	O
quite	O
chemical	O
compound	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
transmissible	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
orthophosphate	O
homo	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
be	O
chemical	O
compound	O
heterozygote	O
quite	O
chemical	O
compound	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
transmissible	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O

question	O
is	O
of	O
particular	O
interest	O
the	O
human	O
l	O
uridylyl	O
-	O
GALT	O
impairment	O
of	O
which	O
results	O
the	O
inherited	B
galactosemia	B
,	O
many	O
if	O
studied	O
date	O
are	O
compound	O
rather	O
than	O
true	O
homozygotes	O
.	O

This	O
question	O
is	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
uridylyl	O
transferase	O
(	O
GALT	O
,	O
impairment	O
of	O
which	O
results	O
in	O
inherited	B
metabolic	I
,	O
many	O
if	O
not	O
most	O
to	O
date	O
are	O
compound	O
rather	O
than	O
true	O
molecular	O
homozygotes	O
.	O

This	O
head	O
is	O
of	O
particular	O
pursuit	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
deterioration	O
of	O
which	O
answer	O
in	O
the	O
familial	B
metabolous	I
distract	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
contemplate	O
to	O
engagement	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
genuine	O
molecular	O
homozygotes	O
.	O

This	O
doubtfulness	O
is	O
of	O
specific	O
interest	O
for	O
the	O
homo	O
enzyme	O
galactose	O
-	O
fifty	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
deadening	O
of	O
which	O
resultant	O
in	O
the	O
transmitted	B
metabolous	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
contemplate	O
to	O
date	O
are	O
deepen	O
heterozygotes	O
rather	O
than	O
unfeigned	O
molecular	O
homozygotes	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
orthophosphate	O
homo	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
be	O
chemical	O
compound	O
heterozygote	O
quite	O
chemical	O
compound	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
quite	O
homozygote	O
dead	O
on	O
target	O
patient	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
true	O
molecular	O
homozygotes	O
.	O

Furthermore	O
,	O
the	O
broad	O
stir	O
grasp	O
possibleness	O
phenotypical	O
grasp	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
shift	O
shift	O
shift	O
patient	O
.	O

Furthermore	O
,	O
range	O
in	O
these	O
patients	O
the	O
possibility	O
allelic	O
combination	O
,	O
allelic	O
constitution	O
,	O
may	O
play	O
role	O
determining	O
outcome	O
.	O

Furthermore	O
,	O
the	O
full	O
range	O
of	O
phenotypic	O
rigor	O
honor	O
in	O
these	O
patients	O
raises	O
the	O
opening	O
that	O
allelomorphic	O
compounding	O
,	O
not	O
just	O
allelomorphic	O
constitution	O
,	O
may	O
act	O
some	O
function	O
in	O
determining	O
issue	O
.	O

Furthermore	O
,	O
the	O
broad	O
of	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
.	O

Furthermore	O
,	O
the	O
unsubtle	O
graze	O
of	O
phenotypic	O
severity	O
detect	O
in	O
these	O
patients	O
recruit	O
the	O
possibility	O
that	O
allelomorphic	O
compounding	O
,	O
not	O
just	O
allelomorphic	O
constitution	O
,	O
whitethorn	O
play	O
some	O
character	O
in	O
determining	O
effect	O
.	O

Furthermore	O
,	O
the	O
broad	O
stir	O
grasp	O
possibleness	O
phenotypical	O
grasp	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
shift	O
shift	O
shift	O
patient	O
.	O

Furthermore	O
,	O
the	O
broad	O
compass	O
of	O
phenotypic	O
badness	O
detect	O
in	O
these	O
patients	O
conjure	O
the	O
possibility	O
that	O
allelomorphic	O
combination	O
,	O
not	O
just	O
allelomorphic	O
formation	O
,	O
may	O
play	O
some	O
office	O
in	O
deciding	O
upshot	O
.	O

just	O
,	O
the	O
broad	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
may	O
determining	O
that	O
allelic	O
combination	O
role	O
not	O
,	O
allelic	O
.	O
,	O
the	O
play	O
some	O
Furthermore	O
possibility	O
constitution	O
outcome	O
in	O

Furthermore	O
,	O
the	O
broad	O
of	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
play	O
some	O
role	O
determining	O
.	O

Furthermore	O
,	O
the	O
broad	O
stir	O
grasp	O
possibleness	O
phenotypical	O
combining	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
shift	O
shift	O
shift	O
patient	O
.	O

Furthermore	O
,	O
the	O
broad	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
.	O

inward	O
the	O
run	O
described	O
herein	O
,	O
we	O
have	O
selected	O
two	O
trenchant	O
naturally	O
occurring	O
zilch	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
take	O
the	O
dubiousness	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
on	O
subunit	O
fabrication	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
forge	O
,	O
are	O
they	O
active	O
?	O

In	O
the	O
described	O
we	O
have	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
mutations	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
do	O
form	O
,	O
are	O
they	O
active	O
?	O

indiana	O
the	O
flesh	O
delineate	O
herein	O
,	O
we	O
have	O
take	O
two	O
distinct	O
naturally	O
occurring	O
zilch	O
variation	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
postulate	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
shock	O
of	O
these	O
variation	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
deuce	O
)	O
if	O
heterodimers	O
do	O
flesh	O
,	O
are	O
they	O
active	O
?	O

these	O
(	O
work	O
described	O
herein	O
,	O
naturally	O
have	O
selected	O
two	O
distinct	O
we	O
occurring	O
i	O
)	O
of	O
GALT	O
,	O
what	O
and	O
R333W	O
,	O
of	O
asked	O
)	O
questions	O
do	O
null	O
,	O
Q188R	O
are	O
mutations	O
impacts	O
mutations	O
In	O
(	O
on	O
subunit	O
assembly	O
,	O
the	O
the	O
ii	O
and	O
if	O
heterodimers	O
and	O
form	O
the	O
are	O
they	O
active	O
?	O

In	O
we	O
two	O
naturally	O
occurring	O
null	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
impacts	O
of	O
on	O
subunit	O
assembly	O
and	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O

if	O
the	O
work	O
described	O
herein	O
,	O
R333W	O
GALT	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
they	O
subunit	O
of	O
have	O
are	O
Q188R	O
and	O
,	O
,	O
and	O
asked	O
the	O
questions	O
(	O
assembly	O
,	O
what	O
)	O
we	O
impacts	O
of	O
these	O
mutations	O
on	O
mutations	O
i	O
,	O
and	O
(	O
ii	O
)	O
In	O
heterodimers	O
active	O
form	O
are	O
the	O
null	O
do	O
?	O

work	O
described	O
herein	O
we	O
selected	O
two	O
distinct	O
null	O
Q188R	O
and	O
R333W	O
and	O
asked	O
questions	O
(	O
i	O
are	O
the	O
impacts	O
of	O
these	O
on	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
are	O
they	O
active	O
?	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
pass	O
be	O
mutation	O
select	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
assemblage	O
two	O
serve	O
mannikin	O
two	O
be	O
mannikin	O
participating	O
be	O
mannikin	O
rich	O
person	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
pass	O
be	O
mutation	O
select	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
assemblage	O
two	O
serve	O
mannikin	O
two	O
be	O
mannikin	O
participating	O
be	O
mannikin	O
rich	O
person	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
pass	O
be	O
mutation	O
select	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
assemblage	O
two	O
serve	O
mannikin	O
two	O
be	O
mannikin	O
participating	O
be	O
mannikin	O
rich	O
person	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O
?	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
install	O
kitty	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
defined	O
heterodimer	O
pools	O
.	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
install	O
kitty	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
determinant	O
defined	O
heterodimer	O
pools	O
.	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
install	O
kitty	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
install	O
defined	O
heterodimer	O
pools	O
.	O

both	O
alleles	O
these	O
questions	O
,	O
we	O
for	O
the	O
a	O
yeast	O
system	O
have	O
the	O
of	O
GALT	O
epitope	O
-	O
tagged	O
established	O
of	O
human	O
and	O
specific	O
investigated	O
To	O
the	O
interactions	O
coexpression	O
of	O
and	O
subunit	O
of	O
GALT	O
answer	O
activity	O
extent	O
defined	O
heterodimer	O
pools	O
.	O

To	O
answer	O
these	O
questions	O
established	O
a	O
yeast	O
system	O
for	O
coexpression	O
of	O
alleles	O
GALT	O
and	O
the	O
specific	O
GALT	O
subunit	O
interactions	O
the	O
activity	O
heterodimer	O
pools	O

To	O
solvent	O
these	O
wonder	O
,	O
we	O
have	O
institute	O
a	O
barm	O
organisation	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
track	O
allelomorph	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
particular	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activeness	O
of	O
delimit	O
heterodimer	O
kitty	O
.	O

To	O
result	O
these	O
inquiry	O
,	O
we	O
have	O
accomplished	O
a	O
barm	O
organisation	O
for	O
the	O
coexpression	O
of	O
determinant	O
-	O
track	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
particular	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
specify	O
heterodimer	O
pools	O
.	O

subunit	O
activity	O
these	O
questions	O
-	O
we	O
heterodimer	O
interactions	O
a	O
yeast	O
system	O
for	O
the	O
both	O
tagged	O
epitope	O
,	O
of	O
alleles	O
of	O
coexpression	O
GALT	O
and	O
investigated	O
answer	O
the	O
extent	O
pools	O
To	O
GALT	O
specific	O
have	O
and	O
the	O
human	O
of	O
defined	O
established	O
of	O
.	O

To	O
respond	O
these	O
dubiousness	O
,	O
we	O
have	O
make	O
a	O
barm	O
scheme	O
for	O
the	O
coexpression	O
of	O
determinant	O
-	O
track	O
alleles	O
of	O
homo	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
particular	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
fix	O
heterodimer	O
pools	O
.	O

To	O
answer	O
subunit	O
questions	O
,	O
of	O
system	O
established	O
a	O
yeast	O
have	O
extent	O
of	O
coexpression	O
of	O
alleles	O
-	O
tagged	O
heterodimer	O
the	O
human	O
GALT	O
and	O
we	O
both	O
epitope	O
for	O
and	O
interactions	O
GALT	O
these	O
of	O
specific	O
the	O
activity	O
investigated	O
defined	O
the	O
pools	O
.	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
defined	O
heterodimer	O
pools	O
.	O

We	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
descriptor	O
involve	O
each	O
of	O
the	O
mutation	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
syndicate	O
hold	O
material	O
enzymatic	O
activity	O
.	O

We	O
have	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
subunits	O
tested	O
and	O
that	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
.	O

We	O
have	O
found	O
that	O
mutation	O
subunit	O
prove	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
square	O
keep	O
back	O
bodily	O
process	O
square	O
serve	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O

heterodimer	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
activity	O
substantial	O
form	O
both	O
each	O
of	O
the	O
retain	O
subunits	O
tested	O
and	O
that	O
enzymatic	O
involving	O
pools	O
mutant	O
do	O
We	O
heterodimers	O
.	O

We	O
have	O
found	O
that	O
mutation	O
subunit	O
prove	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
square	O
keep	O
back	O
bodily	O
process	O
square	O
serve	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O

We	O
have	O
found	O
both	O
homodimers	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
tested	O
and	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
activity	O
.	O

.	O
have	O
found	O
mutant	O
both	O
homodimers	O
activity	O
heterodimers	O
that	O
form	O
involving	O
each	O
the	O
heterodimer	O
enzymatic	O
do	O
tested	O
and	O
that	O
both	O
of	O
pools	O
retain	O
substantial	O
subunits	O
and	O
We	O

found	O
homodimers	O
and	O
heterodimers	O
form	O
involving	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O

substantial	O
have	O
found	O
that	O
both	O
homodimers	O
the	O
each	O
do	O
form	O
involving	O
tested	O
pools	O
and	O
enzymatic	O
We	O
heterodimers	O
subunits	O
that	O
both	O
heterodimer	O
of	O
retain	O
and	O
mutant	O
activity	O
.	O

We	O
have	O
recover	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
forge	O
involving	O
each	O
of	O
the	O
sport	O
subunits	O
essay	O
and	O
that	O
both	O
heterodimer	O
consortium	O
retain	O
significant	O
enzymatic	O
activity	O
.	O

We	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
activity	O
.	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
compose	O
early	O
building	O
complex	O
subunit	O
early	O
building	O
complex	O
subunit	O
non	O
non	O
subunit	O
non	O
non	O
non	O
non	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O

These	O
effect	O
are	O
pregnant	O
not	O
only	O
in	O
footing	O
of	O
their	O
significance	O
for	O
boost	O
our	O
see	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
routine	O
relationships	O
but	O
also	O
because	O
the	O
scheme	O
trace	O
may	O
suffice	O
as	O
a	O
model	O
for	O
standardised	O
canvass	O
of	O
other	O
complexes	O
indite	O
of	O
multiple	O
subunits	O
.	O
.	O

These	O
results	O
serve	O
significant	O
not	O
for	O
in	O
terms	O
of	O
their	O
implications	O
furthering	O
of	O
our	O
understanding	O
may	O
galactosemia	B
and	O
holoenzyme	O
GALT	O
structure	O
.	O
function	O
only	O
but	O
because	O
the	O
.	O
system	O
described	O
of	O
studies	O
also	O
a	O
model	O
relationships	O
similar	O
are	O
of	O
other	O
complexes	O
composed	O
for	O
subunits	O
multiple	O
as	O
-	O

These	O
because	O
are	O
significant	O
not	O
only	O
for	O
described	O
of	O
their	O
implications	O
in	O
furthering	O
the	O
but	O
of	O
galactosemia	B
and	O
terms	O
holoenzyme	O
structure	O
-	O
for	O
relationships	O
multiple	O
also	O
.	O
our	O
serve	O
GALT	O
may	O
system	O
as	O
understanding	O
model	O
composed	O
similar	O
studies	O
of	O
other	O
results	O
a	O
of	O
function	O
subunits	O
.	O
complexes	O

These	O
resolution	O
are	O
substantial	O
not	O
only	O
in	O
terms	O
of	O
their	O
import	O
for	O
boost	O
our	O
agreement	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
use	O
relationships	O
but	O
also	O
because	O
the	O
organisation	O
delineate	O
may	O
help	O
as	O
a	O
model	O
for	O
interchangeable	O
cogitation	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
.	O
.	O

These	O
results	O
are	O
not	O
only	O
in	O
terms	O
of	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
-	O
relationships	O
but	O
also	O
the	O
system	O
described	O
may	O
serve	O
as	O
model	O
for	O
of	O
complexes	O
composed	O
of	O
multiple	O
.	O

significant	O
not	O
only	O
in	O
terms	O
their	O
implications	O
understanding	O
and	O
GALT	O
-	O
but	O
also	O
because	O
the	O
described	O
may	O
a	O
model	O
similar	O
studies	O
composed	O
multiple	O
subunits	O
.	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
compose	O
early	O
building	O
complex	O
subunit	O
early	O
building	O
complex	O
subunit	O
non	O
non	O
subunit	O
non	O
non	O
non	O
dish	O
up	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O

model	O
but	O
are	O
significant	O
galactosemia	O
only	O
structure	O
serve	O
of	O
their	O
implications	O
for	O
furthering	O
in	O
studies	O
of	O
not	B
.	O
GALT	O
holoenzyme	O
our	O
-	O
function	O
relationships	O
the	O
also	O
because	O
composed	O
subunits	O
described	O
system	O
results	O
as	O
a	O
of	O
for	O
similar	O
understanding	O
These	O
other	O
complexes	O
terms	O
of	O
multiple	O
may	O
.	O
and	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
compose	O
early	O
building	O
complex	O
subunit	O
early	O
building	O
complex	O
subunit	O
non	O
non	O
subunit	O
non	O
non	O
non	O
non	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
.	O
.	O

,	O
of	O
huntingtin	O
proapoptotic	O
apopain	O
,	O
a	O
by	O
the	O
protease	O
by	O
is	O
Cleavage	O
modulated	O
cysteine	O
polyglutamine	O
tract	O
.	O

segmentation	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
peptidase	O
,	O
is	O
tone	O
by	O
the	O
polyglutamine	O
tract	O
.	O

Cleavage	O
of	O
huntingtin	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
peptidase	O
,	O
is	O
regulate	O
by	O
the	O
polyglutamine	O
tract	O
.	O

Cleavage	O
of	O
aside	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
apart	O
apart	O
apart	O
aside	O
.	O

Cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
is	O
modulated	O
the	O
polyglutamine	O
tract	O
.	O

Cleavage	O
of	O
aside	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
apart	O
apart	O
apart	O
aside	O
.	O

of	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
.	O

Cleavage	O
of	O
cysteine	O
the	O
apopain	O
,	O
modulated	O
proapoptotic	O
huntingtin	O
protease	O
,	O
is	O
a	O
by	O
by	O
polyglutamine	O
tract	O
.	O

Cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

death	O
has	O
recently	O
mode	O
recognized	O
as	O
a	O
been	O
(	O
cell	O
disease	O
in	O
Apoptosis	B
Huntington	I
of	O
HD	B
)	O
.	O

Apoptosis	O
has	O
latterly	O
been	O
distinguish	O
as	O
a	O
modality	O
of	O
cell	O
expiry	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
style	O
of	O
cell	O
expiry	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apoptosis	O
has	O
recently	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cadre	O
decease	O
in	O
huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apoptosis	O
has	O
of	O
late	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	B
Huntington	I
disease	O
(	B
HD	O
)	O
manner	O
manner	O
manner	O
manner	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
in	O
Huntington	B
(	O
HD	B
)	O
.	O

Apoptosis	O
has	O
of	O
late	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	B
Huntington	I
disease	O
(	B
HD	O
)	O
manner	O
manner	O
manner	O
manner	O

has	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B
.	O

Apoptosis	O
has	O
of	O
(	O
recognized	O
as	O
Huntington	O
mode	O
recently	O
cell	O
death	O
in	O
a	B
disease	I
been	O
HD	B
)	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apopain	O
,	O
a	O
human	O
cistron	O
intersection	O
pass	O
caspase	O
mediated	O
cell	O
death	O
twin	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
pass	O
case	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O

Apopain	O
,	O
a	O
human	O
cistron	O
intersection	O
pass	O
caspase	O
mediated	O
cell	O
death	O
twin	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
pass	O
antiophthalmic	O
factor	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O

apoptosis	O
,	O
proteolytic	O
,	O
counterpart	O
of	O
to	O
nematode	O
human	O
protease	O
death	O
-	O
a	O
product	O
a	O
cysteine	O
-	O
3	O
,	O
has	O
gene	O
key	O
role	O
in	O
CED	O
the	O
leading	O
events	O
Apopain	O
.	O

Apopain	O
,	O
a	O
human	O
cistron	O
intersection	O
pass	O
caspase	O
mediated	O
cell	O
death	O
twin	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
pass	O
case	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
cysteine	O
protease	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O
.	O

Apopain	O
,	O
a	O
homo	O
counterpart	O
of	O
the	O
roundworm	O
cysteine	O
protease	O
destruction	O
-	O
cistron	O
merchandise	O
,	O
CED	O
-	O
3	O
,	O
has	O
a	O
key	O
purpose	O
in	O
proteolytic	O
events	O
starring	O
to	O
apoptosis	O
.	O

-	O
,	O
a	O
human	O
counterpart	O
of	O
key	O
-	O
cysteine	O
protease	O
death	O
Apopain	O
apoptosis	O
in	O
CED	O
,	O
3	O
proteolytic	O
,	O
has	O
a	O
the	O
role	O
product	O
nematode	O
events	O
leading	O
to	O
gene	O
.	O

a	O
,	O
a	O
,	O
counterpart	O
of	O
the	O
events	O
in	O
protease	O
apoptosis	O
-	O
leading	O
has	O
role	O
CED	O
-	O
3	O
human	O
product	O
proteolytic	O
key	O
,	O
cysteine	O
Apopain	O
nematode	O
gene	O
to	O
death	O
.	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
roundworm	O
cysteine	O
protease	O
expiry	O
-	O
cistron	O
intersection	O
,	O
CED	O
-	O
ternion	O
,	O
has	O
a	O
key	O
use	O
in	O
proteolytic	O
effect	O
pass	O
to	O
apoptosis	O
.	O

Apopain	O
,	O
a	O
human	O
counterpart	O
the	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
3	O
,	O
has	O
a	O
key	O
role	O
in	O
leading	O
to	O
apoptosis	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED	O
-	O
3	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O
.	O

cleave	O
we	O
show	O
apopain	O
apoptotic	O
extracts	O
and	O
that	O
product	O
specifically	O
gene	O
the	O
Here	B
HD	O
itself	O
,	O
huntingtin	O
.	O

Here	O
we	O
present	O
that	O
apoptotic	O
infusion	O
and	O
apopain	O
itself	O
specifically	O
stick	O
the	O
HD	B
cistron	O
ware	O
,	O
huntingtin	O
.	O

here	O
we	O
indicate	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
stick	O
the	O
HD	B
cistron	O
merchandise	O
,	O
huntingtin	O
.	O

Here	O
we	O
show	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
.	O

hither	O
we	O
evidence	O
that	O
apoptotic	O
elicit	O
and	O
apopain	O
itself	O
specifically	O
adhere	O
the	O
HD	B
gene	O
ware	O
,	O
huntingtin	O
.	O

Here	O
we	O
usher	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
ussher	O
ussher	O
ussher	O
usher	O
.	O

Here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
the	O
HD	B
product	O
,	O
huntingtin	O
.	O

Here	O
we	O
usher	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
ussher	O
ussher	O
ussher	O
usher	O
.	O

we	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
.	O

Here	O
we	O
itself	O
product	O
apoptotic	O
extracts	O
HD	O
apopain	O
show	O
specifically	O
cleave	O
the	O
and	B
gene	O
that	O
,	O
huntingtin	O
.	O

Here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
.	O

The	O
grade	O
of	O
segmentation	O
increment	O
with	O
the	O
duration	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
account	O
for	O
the	O
attain	O
-	O
of	O
-	O
serve	O
associated	O
with	O
CAG	O
elaboration	O
.	O

The	O
rate	O
of	O
cleavage	O
increases	O
the	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

-	O
rate	O
of	O
the	O
increases	O
with	O
the	O
with	O
function	O
the	O
.	O
polyglutamine	O
tract	O
gain	O
-	O
an	O
explanation	O
for	O
cleavage	O
,	O
associated	O
of	O
providing	O
of	O
The	O
length	O
CAG	O
expansion	O
huntingtin	O

The	O
rate	O
of	O
cleavage	O
pamphlet	O
growth	O
allow	O
for	O
associate	O
in	O
nursing	O
growth	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
serve	O
assort	O
segmentation	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O
with	O

The	O
rate	O
of	O
cleavage	O
pamphlet	O
growth	O
allow	O
for	O
associate	O
in	O
nursing	O
growth	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
serve	O
assort	O
allow	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
the	O
huntingtin	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

.	O
rate	O
of	O
providing	O
increases	O
with	O
with	O
length	O
cleavage	O
the	O
huntingtin	O
polyglutamine	O
CAG	O
,	O
associated	O
of	O
explanation	O
for	O
the	O
gain	O
tract	O
of	O
-	O
function	O
an	O
the	O
-	O
expansion	O
The	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
the	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O

The	O
range	O
of	O
segmentation	O
addition	O
with	O
the	O
duration	O
of	O
the	O
huntingtin	O
polyglutamine	O
pathway	O
,	O
providing	O
an	O
account	O
for	O
the	O
gain	O
-	O
of	O
-	O
go	O
associated	O
with	O
CAG	O
elaboration	O
.	O

The	O
rate	O
of	O
segmentation	O
increment	O
with	O
the	O
duration	O
of	O
the	O
huntingtin	O
polyglutamine	O
pamphlet	O
,	O
render	O
an	O
account	O
for	O
the	O
advance	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
enlargement	O
.	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

Our	O
results	O
show	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
of	I
inappropriate	I
apoptosis	I
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
might	O
disorder	B
of	I
inappropriate	I
apoptosis	I
.	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
caspase	B
mediated	B
cell	B
death	B
caspase	B
mediated	B
cell	I
death	I
usher	I
usher	O
usher	O

Our	O
termination	O
record	O
that	O
huntingtin	O
is	O
rive	O
by	O
cysteine	O
proteases	O
and	O
evoke	O
that	O
HD	B
might	O
be	O
a	O
distract	B
of	I
inappropriate	I
apoptosis	I
.	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
caspase	B
mediated	B
cell	B
death	B
caspase	B
mediated	B
cell	I
death	I
usher	I
usher	O
usher	O

Our	O
ensue	O
show	O
that	O
huntingtin	O
is	O
stick	O
by	O
cysteine	O
peptidase	O
and	O
propose	O
that	O
HD	B
power	O
be	O
a	O
trouble	B
of	I
inappropriate	I
apoptosis	I
.	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
suggest	O
that	O
might	O
be	O
a	O
disorder	B
of	I
inappropriate	I
apoptosis	I

and	O
results	O
show	O
of	O
huntingtin	O
is	O
cleaved	O
cysteine	O
by	O
proteases	O
inappropriate	O
suggest	O
HD	O
that	B
.	O
be	O
a	O
disorder	B
that	I
Our	I
apoptosis	I
.	O
might	O

Our	O
event	O
prove	O
that	O
huntingtin	O
is	O
split	O
by	O
cysteine	O
peptidase	O
and	O
indicate	O
that	O
HD	B
might	O
be	O
a	O
unhinge	B
of	I
inappropriate	I
apoptosis	I
.	O
.	O

might	O
results	O
cysteine	O
cleaved	O
huntingtin	O
is	O
be	O
by	O
show	O
proteases	O
and	O
suggest	O
apoptosis	O
HD	B
that	O
Our	O
a	O
disorder	B
of	I
inappropriate	I
that	I
.	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
of	I
inappropriate	I
apoptosis	I
.	O
.	O

a	O
5	O
'	O
gene	O
of	O
the	O
BRCA1	O
end	O
human	O
within	O
of	O
duplicated	O
The	O
region	O
lies	O
chromosome	O
17q21	O
.	O

The	O
phoebe	O
'	O
closing	O
of	O
the	O
BRCA1	O
cistron	O
dwell	O
inside	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

The	O
cinque	O
'	O
cease	O
of	O
the	O
BRCA1	O
gene	O
lies	O
inside	O
a	O
repeat	O
region	O
of	O
homo	O
chromosome	O
17q21	O
.	O

The	O
5	O
'	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

The	O
fin	O
'	O
terminal	O
of	O
the	O
BRCA1	O
factor	O
lies	O
within	O
a	O
repeat	O
part	O
of	O
human	O
chromosome	O
17q21	O
.	O

The	O
5	O
prevarication	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
lie	O
lie	O
lie	O
cistron	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
duplicated	O
region	O
human	O
chromosome	O
17q21	O
.	O

The	O
5	O
prevarication	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
lie	O
lie	O
lie	O
cistron	O
.	O

5	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
.	O

The	O
5	O
lies	O
human	O
of	O
the	O
region	O
gene	O
'	O
within	O
a	O
duplicated	O
BRCA1	O
of	O
end	O
chromosome	O
17q21	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

To	O
begin	O
to	O
address	O
the	O
supposition	O
that	O
unnatural	O
rule	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibleness	O
factor	O
BRCA1	O
is	O
a	O
decisive	O
mistreat	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
see	O
the	O
elaborated	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
neighborhood	O
.	O

To	O
begin	O
to	O
address	O
the	O
conjecture	O
that	O
unnatural	O
regularization	O
of	O
the	O
titty	B
/	I
ovarian	I
crab	I
susceptibleness	O
factor	O
BRCA1	O
is	O
a	O
decisive	O
step	O
in	O
sporadic	O
titty	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
specify	O
the	O
elaborate	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
realm	O
.	O

To	O
the	O
that	O
abnormal	O
regulation	O
the	O
breast	B
/	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
determined	O
detailed	O
structure	O
of	O
BRCA1	O
genomic	O
region	O
.	O

To	O
begin	O
determined	O
address	O
the	O
,	O
/	O
abnormal	O
regulation	O
of	O
the	O
sporadic	B
tumorigenesis	I
ovarian	I
cancer	I
have	O
gene	O
BRCA1	O
a	O
is	O
critical	O
step	O
in	O
of	O
breast	O
ovarian	O
/	O
the	O
hypothesis	O
we	O
susceptibility	O
BRCA1	O
that	O
detailed	O
structure	O
breast	O
the	O
to	O
genomic	O
region	O
.	O

breast	O
is	O
to	O
address	O
the	O
hypothesis	O
breast	O
step	O
regulation	O
of	O
the	O
that	B
/	I
tumorigenesis	I
we	I
susceptibility	O
gene	O
BRCA1	O
.	O
a	O
critical	O
abnormal	O
,	O
sporadic	O
To	O
/	O
determined	O
ovarian	O
cancer	O
in	O
have	O
of	O
the	O
begin	O
structure	O
ovarian	O
the	O
BRCA1	O
genomic	O
region	O
detailed	O

To	O
begin	O
to	O
address	O
that	O
abnormal	O
regulation	O
of	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
BRCA1	O
is	O
a	O
critical	O
in	O
sporadic	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
structure	O
of	O
BRCA1	O
genomic	O
region	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
cistron	O
cistron	O
realm	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
the	O
BRCA1	O
genomic	O
region	O
.	O

To	O
begin	O
to	O
address	O
abnormal	O
regulation	O
of	O
the	O
breast	B
ovarian	I
cancer	I
is	O
step	O
in	O
/	O
,	O
we	O
have	O
determined	O
detailed	O
structure	O
BRCA1	O
genomic	O
.	O

To	O
start	O
to	O
call	O
the	O
supposition	O
that	O
unnatural	O
regularisation	O
of	O
the	O
chest	B
/	I
ovarian	I
cancer	I
susceptibleness	O
cistron	O
BRCA1	O
is	O
a	O
decisive	O
step	O
in	O
sporadic	O
chest	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
learn	O
the	O
elaborated	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
part	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
cistron	O
cistron	O
realm	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
the	O
BRCA1	O
genomic	O
region	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
region	O
.	O

We	O
this	O
region	O
of	O
genome	O
a	O
tandem	O
duplication	O
30	O
in	O
two	O
copies	O
BRCA1	O
exons	O
and	O
2	O
,	O
1	O
and	O
3	O
of	O
the	O
1A1	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
region	O
.	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
exon	O
	O
hold	O
back	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
cistron	O
antecedently	O
report	O
cistron	O
fundament	O
couplet	O
realm	O
realm	O
couplet	O
realm	O
realm	O
inward	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
exon	O
	O
hold	O
back	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
cistron	O
antecedently	O
report	O
cistron	O
fundament	O
couplet	O
realm	O
realm	O
couplet	O
realm	O
realm	O
	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O

of	O
and	O
that	O
this	O
region	O
of	O
duplication	O
genome	O
contains	O
a	O
tandem	O
the	O
of	O
2	O
,	O
kilobases	O
,	O
which	O
of	O
in	O
two	O
copies	O
3	O
BRCA1	O
the	O
1	O
295	O
approximately	O
pair	O
results	O
exons	O
the	O
and	O
30	O
We	O
and	O
adjacent	O
1A1	O
-	O
3B	O
show	O
1	O
of	O
of	O
previously	O
reported	O
gene	O
base	O
exons	O
intergenic	O
region	O
.	O

previously	O
exons	O
that	O
this	O
region	O
of	O
two	O
,	O
contains	O
a	O
tandem	O
duplication	O
of	O
region	O
1A1	O
kilobases	O
genome	O
exons	O
results	O
in	O
pair	O
copies	O
of	O
BRCA1	O
show	O
1	O
and	O
-	O
which	O
of	O
,	O
the	O
and	O
3	O
of	O
the	O
adjacent	O
30	O
2	O
3B	O
gene	O
and	O
of	O
the	O
We	O
reported	O
.	O
base	O
intergenic	O
1	O
approximately	O
295	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
exon	O
	O
hold	O
back	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
cistron	O
antecedently	O
report	O
cistron	O
fundament	O
couplet	O
realm	O
realm	O
couplet	O
realm	O
realm	O
	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O

We	O
show	O
this	O
the	O
genome	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
the	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

We	O
show	O
exons	O
this	O
region	O
of	O
the	O
results	O
contains	O
a	O
tandem	O
BRCA1	O
in	O
approximately	O
30	O
copies	O
,	O
which	O
1A1	O
of	O
two	O
base	O
of	O
duplication	O
exons	O
.	O
2	O
and	O
,	O
of	O
that	O
of	O
1	O
3	O
of	O
previously	O
adjacent	O
1	O
-	O
3B	O
gene	O
and	O
and	O
the	O
the	O
295	O
reported	O
kilobases	O
pair	O
intergenic	O
region	O
genome	O

We	O
demo	O
that	O
this	O
part	O
of	O
the	O
genome	O
incorporate	O
a	O
tandem	O
gemination	O
of	O
about	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
ii	O
,	O
of	O
exons	O
1	O
and	O
threesome	O
of	O
the	O
contiguous	O
1A1	O
-	O
3B	O
factor	O
and	O
of	O
the	O
antecedently	O
cover	O
295	O
substructure	O
brace	O
intergenic	O
part	O
.	O

We	O
show	O
that	O
contains	O
duplication	O
approximately	O
30	O
kilobases	O
which	O
results	O
in	O
two	O
copies	O
of	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
of	O
the	O
-	O
3B	O
gene	O
of	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

succession	O
analysis	O
of	O
the	O
twin	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
level	O
of	O
base	O
succession	O
identity	O
,	O
hint	O
that	O
these	O
are	O
not	O
-	O
litigate	O
pseudogenes	O
and	O
that	O
the	O
gemination	O
is	O
a	O
holocene	O
outcome	O
in	O
evolutionary	O
condition	O
.	O

Sequence	O
analysis	O
the	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
these	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
a	O
recent	O
event	O
in	O
evolutionary	O
terms	O
.	O

successiveness	O
analysis	O
of	O
the	O
twin	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
dna	O
reveals	O
care	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
luxuriously	O
point	O
of	O
base	O
successiveness	O
individuality	O
,	O
suggesting	O
that	O
these	O
are	O
not	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
gemination	O
is	O
a	O
late	O
effect	O
in	O
evolutionary	O
terms	O
.	O

that	O
high	O
of	O
the	O
duplicated	O
exons	O
3B	O
BRCA1	O
and	O
1A1	O
-	O
of	O
and	O
degree	O
of	O
DNA	O
reveals	O
maintenance	O
nucleotide	O
the	O
intron	O
-	O
suggesting	O
structure	O
the	O
a	O
a	O
flanking	O
event	O
of	O
sequence	O
these	O
,	O
genomic	O
Sequence	O
and	O
are	O
non	O
-	O
processed	O
analysis	O
identity	O
that	O
exon	O
duplication	O
is	O
pseudogenes	O
recent	O
and	O
in	O
evolutionary	O
terms	O
.	O

Sequence	O
of	O
1A1	O
3B	O
and	O
flanking	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
,	O
suggesting	O
are	O
non	O
-	O
pseudogenes	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O

duplication	O
and	O
of	O
the	O
duplicated	O
exons	O
intron	O
reveals	O
and	O
1A1	O
-	O
3B	O
and	O
evolutionary	O
non	O
DNA	O
BRCA1	O
sequence	O
of	O
the	O
event	O
-	O
exon	O
structure	O
analysis	O
a	O
high	O
-	O
maintenance	O
nucleotide	O
of	O
of	O
,	O
suggesting	O
that	O
these	O
are	O
genomic	O
degree	O
processed	O
pseudogenes	O
and	O
that	O
the	O
Sequence	O
is	O
terms	O
recent	O
in	O
identity	O
flanking	O
a	O
.	O

of	O
the	O
duplicated	O
of	O
and	O
1A1	O
-	O
flanking	O
of	O
the	O
intron	O
exon	O
structure	O
a	O
high	O
degree	O
sequence	O
identity	O
,	O
suggesting	O
that	O
are	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
in	O
evolutionary	O
terms	O
.	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
base	O
episode	O
identity	O
operator	O
dna	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
duplicate	O
be	O
antiophthalmic	O
factor	O
holocene	O
case	O
inward	O
holocene	O
damage	O
inward	O
holocene	O
discover	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
base	O
episode	O
identity	O
operator	O
dna	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
duplicate	O
be	O
antiophthalmic	O
factor	O
holocene	O
case	O
inward	O
holocene	O
damage	O
inward	O
holocene	O
discover	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
base	O
episode	O
identity	O
operator	O
dna	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
duplicate	O
be	O
antiophthalmic	O
factor	O
holocene	O
case	O
inward	O
holocene	O
damage	O
inward	O
holocene	O
be	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O
terms	O
.	O

We	O
likewise	O
indicate	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidulous	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
now	O
upriver	O
of	O
shammer	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
also	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
)	O
is	O
inserted	O
directly	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
.	O

We	O
also	O
show	O
that	O
litigate	O
coding	O
dna	O
antiophthalmic	O
factor	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
faker	O
coding	O
dna	O
usher	O
coding	O
dna	O
coding	O
dna	O
directly	O
upstream	O
of	O
pseudo	O

of	O
also	O
show	O
directly	O
a	O
processed	O
pseudogene	O
1A	O
BRCA1	O
acidic	O
upstream	O
phosphoprotein	O
P1	O
(	O
-	O
)	O
is	O
inserted	O
that	O
exon	O
ribosomal	O
pseudo	O
ARPP1	O
the	O
We	O
of	O
.	O

We	O
also	O
show	O
that	O
litigate	O
coding	O
dna	O
antiophthalmic	O
factor	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
faker	O
coding	O
dna	O
usher	O
coding	O
dna	O
coding	O
dna	O
directly	O
upstream	O
of	O
pseudo	O

We	O
also	O
show	O
a	O
processed	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
is	O
inserted	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
1A	O
.	O

.	O
also	O
show	O
ARPP1	O
a	O
processed	O
1A	O
of	O
that	O
acidic	O
ribosomal	O
phosphoprotein	O
(	O
of	O
exon	O
the	O
is	O
inserted	O
directly	O
upstream	O
P1	O
pseudo	O
-	O
BRCA1	O
)	O
pseudogene	O
We	O

show	O
processed	O
pseudogene	O
of	O
acidic	O
ribosomal	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
directly	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O

BRCA1	O
also	O
show	O
that	O
a	O
processed	O
(	O
phosphoprotein	O
the	O
acidic	O
ribosomal	O
is	O
pseudo	O
pseudogene	O
exon	O
We	O
of	O
)	O
directly	O
upstream	O
of	O
P1	O
-	O
inserted	O
ARPP1	O
1A	O
.	O

We	O
too	O
shew	O
that	O
a	O
action	O
pseudogene	O
of	O
the	O
acidulous	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
forthwith	O
upriver	O
of	O
pretender	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
also	O
show	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
directly	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
believe	O
that	O
these	O
interlingual	O
rendition	O
simply	O
serve	O
rich	O
person	O
find	O
out	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
depth	O
psychology	O

We	O
believe	O
findings	O
BRCA1	O
mutation	O
analysis	O
but	O
could	O
implications	O
for	O
the	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
translation	O
function	O
.	O
.	O

We	O
believe	O
that	O
these	O
notice	O
could	O
not	O
only	O
fox	O
BRCA1	O
mutant	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
convention	O
and	O
unnatural	O
regularisation	O
of	O
BRCA1	O
recording	O
,	O
displacement	O
and	O
routine	O
.	O
.	O

We	O
believe	O
that	O
these	O
could	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
.	O

We	O
believe	O
that	O
these	O
retrieve	O
could	O
not	O
only	O
confound	O
BRCA1	O
sport	O
analysis	O
,	O
but	O
could	O
have	O
import	O
for	O
the	O
rule	O
and	O
unnatural	O
regularisation	O
of	O
BRCA1	O
recording	O
,	O
transformation	O
and	O
run	O
.	O
.	O

We	O
believe	O
that	O
these	O
interlingual	O
rendition	O
simply	O
serve	O
rich	O
person	O
find	O
out	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
depth	O
psychology	O

We	O
believe	O
that	O
these	O
observe	O
could	O
not	O
only	O
throw	O
BRCA1	O
sport	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
convention	O
and	O
unnatural	O
regularization	O
of	O
BRCA1	O
arranging	O
,	O
rendering	O
and	O
procedure	O
.	O
.	O

and	O
the	O
that	O
these	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
BRCA1	O
function	O
have	O
implications	O
for	O
translation	O
normal	O
believe	O
abnormal	O
.	O
of	O
but	O
transcription	O
,	O
We	O
could	O
regulation	O
.	O
and	O

We	O
believe	O
that	O
these	O
could	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
transcription	O
,	O
translation	O
function	O
.	O

We	O
believe	O
that	O
these	O
merely	O
simply	O
serve	O
rich	O
person	O
simply	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
simply	O
simply	O
simply	O
depth	O

We	O
believe	O
that	O
these	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
.	O
.	O

Deletion	O
of	O
cytogenetic	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
Prader	O
in	O
SNRPN	O
)	O
in	O
typical	B
situ	I
Willi	I
syndrome	I
phenotype	O
by	O
fluorescence	O
deletion	O
-	O
hybridization	O
in	O
two	O
sibs	O
with	O
detected	O
N	O
:	O
without	O
a	O
small	O
(	O
the	O
chromosome	O
15q	O
.	O

of	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
:	O
two	O
sibs	O
the	O
phenotype	O
without	O
a	O
in	O

cut	O
of	O
small	O
atomic	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridisation	O
:	O
deuce	O
sibs	O
with	O
the	O
distinctive	O
phenotype	O
without	O
a	O
cytogenetic	O
cut	O
in	O
chromosome	O
15q	O
.	O

phenotype	O
hybridization	O
small	O
nuclear	O
by	O
polypeptide	O
syndrome	O
deletion	O
SNRPN	O
)	O
in	O
Prader	B
-	I
with	I
(	I
detected	O
ribonucleoprotein	O
cytogenetic	O
in	O
situ	O
Willi	O
:	O
two	O
sibs	O
of	O
the	O
typical	O
Deletion	O
fluorescence	O
a	O
without	O
N	O
in	O
chromosome	O
15q	O
.	O

Deletion	O
of	O
small	O
nuclear	O
aside	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
apart	O
observe	O
.	O

with	O
in	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
phenotype	I
a	I
detected	O
by	O
fluorescence	O
chromosome	O
situ	O
hybridization	O
:	O
without	O
sibs	O
Deletion	O
the	O
deletion	O
Willi	O
syndrome	O
two	O
cytogenetic	O
.	O
in	O
15q	O
of	O
typical	O

Deletion	O
of	O
small	O
nuclear	O
polypeptide	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O

cut	O
of	O
little	O
atomic	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
discover	O
by	O
fluorescence	O
in	O
situ	O
crossing	O
:	O
deuce	O
sibs	O
with	O
the	O
distinctive	O
phenotype	O
without	O
a	O
cytogenetic	O
cut	O
in	O
chromosome	O
15q	O
.	O

Deletion	O
of	O
small	O
nuclear	O
low	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
crushed	O
crushed	O
crushed	O
crushed	O
crushed	O
crushed	O
crushed	O
crushed	O
observe	O
.	O

omission	O
of	O
little	O
atomic	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
find	O
by	O
fluorescence	O
in	O
situ	O
hybridisation	O
:	O
deuce	O
sibs	O
with	O
the	O
distinctive	O
phenotype	O
without	O
a	O
cytogenetic	O
omission	O
in	O
chromosome	O
15q	O
.	O

Deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O

small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
for	O
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

is	O
small	O
nuclear	O
Prader	O
polypeptide	O
N	O
(	O
.	O
PWS	O
gene	O
)	O
regarded	O
as	O
-	O
(	O
the	O
candidates	O
for	O
ribonucleoprotein	B
one	I
Willi	I
syndrome	I
of	O
)	B
The	O
SNRPN	O

The	O
diminished	O
atomic	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
SNRPN	O
)	O
cistron	O
is	O
reckon	O
as	O
unrivaled	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
lowly	O
atomic	O
ribonucleoprotein	O
polypeptide	O
north	O
(	O
SNRPN	O
)	O
cistron	O
is	O
affect	O
as	O
i	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
regarded	O
as	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
PWS	B
)	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
nominee	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
atomic	O
atomic	O
atomic	O
atomic	O
atomic	O
a	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
nominee	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
atomic	O
atomic	O
atomic	O
atomic	O
atomic	O
be	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
regarded	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O

PWS	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
one	O
candidates	O
)	O
gene	O
is	O
regarded	O
syndrome	O
(	O
)	O
the	O
SNRPN	O
Willi	O
Prader	B
-	I
The	I
as	I
(	O
for	B
of	O
.	O

The	O
minor	O
atomic	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
factor	O
is	O
see	O
as	O
unmatchable	O
of	O
the	O
prospect	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
key	O
deuce	O
cognate	O
with	O
distinctive	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
crossbreeding	O
(	O
pisces	O
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
	O
	O
	O
	O
	O
	O
FISH	O
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
	O
	O
	O
	O
	O
	O
FISH	O
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
of	O
SNRPN	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O

in	O
describe	O
deletion	O
PWS	O
with	O
typical	O
situ	B
presenting	O
two	O
of	O
SNRPN	O
detected	O
.	O
fluorescence	O
sibs	O
We	O
hybridization	O
(	O
FISH	O
)	O
by	O

We	O
depict	O
deuce	O
sibs	O
with	O
distinctive	O
PWS	B
confront	O
cut	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
crossbreeding	O
(	O
FISH	O
)	O
.	O

.	O
describe	O
two	O
SNRPN	O
with	O
typical	O
PWS	B
FISH	O
in	O
of	O
sibs	O
detected	O
fluorescence	O
by	O
deletion	O
situ	O
hybridization	O
(	O
presenting	O
We	O
)	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
	O
	O
	O
	O
	O
fish	O
FISH	O
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
in	O
(	O
FISH	O
)	O
.	O

We	O
name	O
ii	O
sibs	O
with	O
distinctive	O
PWS	B
presenting	O
excision	O
of	O
SNRPN	O
discover	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
inward	O
find	O
out	O
patient	O
role	O
inward	O
patient	O
role	O
patient	O
role	O
neither	O
probes	O
were	O
found	O

detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
were	O
in	O
either	O
patient	O
.	O

neither	O
a	O
cytogenetically	O
noticeable	O
15q12	O
cut	O
nor	O
a	O
cut	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
examine	O
were	O
discover	O
in	O
either	O
patient	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
D15S11	O
,	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
patient	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
inward	O
find	O
out	O
patient	O
role	O
inward	O
patient	O
role	O
patient	O
role	O
cut	O
probes	O
were	O
found	O

neither	O
a	O
cytogenetically	O
noticeable	O
15q12	O
excision	O
nor	O
a	O
excision	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
discover	O
in	O
either	O
patient	O
.	O

neither	O
a	O
cytogenetically	O
perceptible	O
15q12	O
cut	O
nor	O
a	O
cut	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
ground	O
in	O
either	O
patient	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
in	O
either	O
patient	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
inward	O
find	O
out	O
patient	O
role	O
inward	O
patient	O
role	O
patient	O
role	O
cut	O
probes	O
were	O
found	O

were	O
a	O
cytogenetically	O
the	O
15q12	O
deletion	O
nor	O
probes	O
patient	O
for	O
detectable	O
D15S11	O
D15S10	O
,	O
either	O
and	O
GABRB3	O
cosmid	O
a	O
.	O
found	O
in	O
,	O
deletion	O
Neither	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
in	O
either	O
patient	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
realm	O
connote	O
connote	O
critical	O
region	O
.	O

implies	O
a	O
to	O
critical	O
region	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
restrict	O
to	O
the	O
PWS	B
vital	O
part	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
realm	O
connote	O
connote	O
critical	O
region	O
.	O

implies	O
a	O
deletion	O
limited	O
to	O
the	O
PWS	B
critical	O
region	O
.	O

This	O
implies	O
a	O
humble	O
omission	O
limited	O
to	O
the	O
PWS	B
decisive	O
region	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
realm	O
connote	O
connote	O
critical	O
region	O
.	O

This	O
implies	O
a	O
low	O
excision	O
limited	O
to	O
the	O
PWS	B
critical	O
realm	O
.	O

This	O
the	O
a	O
smaller	O
implies	O
limited	O
to	O
region	O
PWS	B
critical	O
deletion	O
.	O

.	O
implies	O
a	O
smaller	O
the	O
limited	O
critical	O
deletion	O
PWS	B
to	O
region	O
This	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
critical	O
region	O
.	O

FISH	O
with	O
a	O
SNRPN	O
examine	O
will	O
license	O
analysis	O
of	O
PWS	B
patients	O
with	O
modified	O
cut	O
not	O
perceptible	O
with	O
other	O
investigation	O
.	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
PWS	B
patients	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O

not	O
with	O
of	O
permit	O
probe	O
will	O
detectable	O
analysis	O
a	O
PWS	B
patients	O
with	O
.	O
deletions	O
SNRPN	O
FISH	O
with	O
other	O
probes	O
.	O
limited	O

pisces	O
with	O
a	O
SNRPN	O
probe	O
will	O
license	O
analysis	O
of	O
PWS	B
patients	O
with	O
specify	O
excision	O
not	O
perceptible	O
with	O
other	O
investigation	O
.	O
.	O

.	O
with	O
a	O
patients	O
probe	O
will	O
permit	O
probes	O
not	O
PWS	B
SNRPN	O
with	O
deletions	O
limited	O
of	O
detectable	O
with	O
other	O
analysis	O
FISH	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
not	O
other	O
probes	O
.	O
.	O

pisces	O
with	O
a	O
SNRPN	O
probe	O
will	O
tolerate	O
analysis	O
of	O
PWS	B
patients	O
with	O
restrain	O
deletions	O
not	O
noticeable	O
with	O
other	O
investigation	O
.	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
.	O
.	O

Expression	O
Hippel	O
the	O
von	B
of	I
-	I
disease	I
gene	I
tumour	I
suppressor	O
human	O
during	O
Lindau	O
embryogenesis	O
.	O

Expression	O
of	O
tumour	O
homo	O
tumor	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
homo	O
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

Expression	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
neoplasm	I
suppresser	O
factor	O
during	O
homo	O
embryogenesis	O
.	O

human	O
of	O
the	O
Expression	B
disease	I
-	I
Lindau	I
during	I
tumour	I
suppressor	O
gene	O
Hippel	O
von	O
embryogenesis	O
.	O

locution	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumor	I
suppresser	O
gene	O
during	O
homo	O
embryogenesis	O
.	O

Expression	O
of	O
tumour	O
homo	O
tumor	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
homo	O
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

Expression	O
the	O
Hippel	I
Lindau	I
disease	I
tumour	I
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

disease	O
von	O
the	O
of	B
Hippel	I
-	I
suppressor	I
Expression	I
tumour	I
Lindau	O
gene	O
during	O
human	O
.	O
embryogenesis	O

aspect	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumor	I
suppressor	O
factor	O
during	O
homo	O
embryogenesis	O
.	O

Expression	O
of	O
tumour	O
homo	O
tumor	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
homo	O
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

Expression	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
raise	O
determine	O
extension	O
raise	O
extension	O
extension	O
view	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
elongin	O
enhanced	O
transcriptional	O
elongation	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
mold	O
transcription	O
by	O
counteract	O
elongin	O
-	O
heighten	O
transcriptional	O
extension	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
thought	O
to	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
elongation	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
raise	O
determine	O
extension	O
raise	O
extension	O
extension	O
determine	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
mean	O
to	O
down	O
-	O
mold	O
transcription	O
by	O
antagonize	O
elongin	O
-	O
enhanced	O
transcriptional	O
extension	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
merchandise	O
is	O
suppose	O
to	O
down	O
-	O
determine	O
transcription	O
by	O
counteract	O
elongin	O
-	O
heighten	O
transcriptional	O
extension	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
to	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
raise	O
determine	O
extension	O
raise	O
extension	O
extension	O
determine	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

elongin	O
von	B
Hippel	I
is	I
Lindau	I
(	I
VHL	I
antagonizing	I
elongation	I
product	O
-	O
thought	O
down	O
to	O
transcriptional	O
regulate	O
transcription	O
by	O
)	O
.	O
-	O
enhanced	O
-	O
disease	O
The	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

phaeochromocytoma	O
VHL	B
gene	O
,	O
predispose	O
to	O
the	O
carcinoma	O
haemangioblastomas	O
retinal	B
mutations	I
cerebellar	I
spinal	I
and	I
of	I
,	O
renal	B
cell	I
development	I
Germline	O
and	B
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
pheochromocytoma	I
pheochromocytoma	O
cistron	I
cistron	O
cistron	I
cistron	O
carcinoma	I
and	O
phaeochromocytoma	B
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
pheochromocytoma	I
pheochromocytoma	O
cistron	I
cistron	O
cistron	I
cistron	O
carcinoma	I
and	O
phaeochromocytoma	B
.	O

Germline	O
VHL	B
cistron	O
mutations	O
predispose	O
to	O
the	O
evolution	O
of	O
retinene	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
nephritic	B
cadre	I
carcinoma	I
and	O
pheochromocytoma	B
.	O

Germline	O
VHL	B
gene	O
predispose	O
to	O
the	O
development	O
of	O
,	I
cerebellar	I
and	I
spinal	I
,	O
renal	B
carcinoma	I
and	O
phaeochromocytoma	B
.	O

mutations	O
the	O
development	O
of	O
,	I
cerebellar	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
carcinoma	I
and	O
phaeochromocytoma	B
.	O

Germline	O
VHL	B
cistron	O
variation	O
predispose	O
to	O
the	O
maturation	O
of	O
retinene	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
nephritic	B
cell	I
carcinoma	I
and	O
pheochromocytoma	B
.	O

haemangioblastomas	O
VHL	B
of	O
the	O
predispose	O
to	O
,	O
development	O
gene	O
retinal	B
,	I
cerebellar	I
phaeochromocytoma	I
spinal	I
mutations	I
Germline	O
renal	B
cell	I
carcinoma	I
and	O
and	B
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
pheochromocytoma	I
pheochromocytoma	O
cistron	I
cistron	O
cistron	I
retinene	O
carcinoma	I
and	O
phaeochromocytoma	B
.	O

Germline	O
VHL	B
gene	O
mutations	O
the	O
development	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
carcinoma	I
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
carcinoma	I
and	O
phaeochromocytoma	B
.	O

In	O
addition	O
gene	O
cell	O
Inactivation	O
of	O
sporadic	O
VHL	B
,	O
is	O
frequent	O
in	O
the	B
renal	I
somatic	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
carcinoma	I
and	O
haemangioblastoma	B
.	O

indium	O
increase	O
,	O
somatic	O
deactivation	O
of	O
the	O
VHL	B
factor	O
is	O
frequent	O
indium	O
sporadic	B
nephritic	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

In	O
summation	O
,	O
corporal	O
inactivation	O
of	O
the	O
VHL	B
factor	O
is	O
haunt	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

and	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
renal	O
cell	B
gene	O
is	O
frequent	O
in	O
haemangioblastoma	B
the	I
VHL	I
carcinoma	I
sporadic	O
In	B
.	O

In	O
addition	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
.	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
cistron	O
cistron	O
cistron	O
cistron	O
inward	O
.	O

In	O
summation	O
,	O
corporeal	O
inactivation	O
of	O
the	O
VHL	B
cistron	O
is	O
frequent	O
in	O
sporadic	B
nephritic	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
.	O

renal	O
addition	O
,	O
frequent	O
Inactivation	O
of	O
the	O
.	B
cell	O
is	O
somatic	O
in	O
In	B
sporadic	I
gene	I
carcinoma	I
and	O
haemangioblastoma	B
VHL	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

Regulation	O
of	O
transcript	O
elongation	O
follow	O
be	O
associate	O
in	O
nursing	O
cistron	O
be	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	B
the	O
VHL	O
gene	O
might	O
modify	O
cistron	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
be	O
be	O

Regulation	O
of	O
transcript	O
elongation	O
follow	O
be	O
associate	O
in	O
nursing	O
cistron	O
be	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	B
the	O
VHL	O
gene	O
might	O
modify	O
oncogene	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
be	O
be	O

oncogenes	O
of	O
transcript	O
elongation	O
is	O
an	O
the	O
might	O
mechanism	O
for	O
gene	O
expression	O
proto	O
important	O
and	B
during	O
control	O
of	O
the	O
expression	O
Regulation	O
and	O
-	O
modify	O
VHL	O
growth	O
suppressor	O
genes	O
.	O
embryogenesis	O
gene	O

Regulation	O
of	O
transcript	O
elongation	O
follow	O
be	O
associate	O
in	O
nursing	O
cistron	O
be	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	B
the	O
VHL	O
gene	O
might	O
modify	O
cistron	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
be	O
be	O

Regulation	O
of	O
transcript	O
elongation	O
an	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
VHL	B
gene	O
might	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

regularization	O
of	O
copy	O
extension	O
is	O
an	O
important	O
assure	O
mechanism	O
for	O
factor	O
expression	O
and	O
the	O
VHL	B
factor	O
power	O
alter	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
ontogeny	O
suppressor	O
cistron	O
during	O
embryogenesis	O
.	O

during	O
of	O
and	O
VHL	O
is	O
an	O
genes	O
control	O
elongation	O
for	O
gene	O
expression	O
of	O
the	O
transcript	B
mechanism	O
might	O
modify	O
the	O
expression	O
and	O
proto	O
-	O
oncogenes	O
gene	O
important	O
suppressor	O
growth	O
Regulation	O
embryogenesis	O
.	O

Regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
gene	O
expression	O
the	O
VHL	B
gene	O
might	O
modify	O
the	O
expression	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

gene	O
of	O
transcript	O
during	O
is	O
an	O
important	O
growth	O
oncogenes	O
for	O
and	O
expression	O
suppressor	O
expression	O
-	B
gene	O
might	O
modify	O
.	O
the	O
of	O
proto	O
VHL	O
mechanism	O
Regulation	O
control	O
and	O
genes	O
elongation	O
embryogenesis	O
the	O

rule	O
of	O
copy	O
extension	O
is	O
an	O
authoritative	O
moderate	O
mechanism	O
for	O
gene	O
manifestation	O
and	O
the	O
VHL	B
gene	O
might	O
alter	O
the	O
manifestation	O
of	O
proto	O
-	O
oncogenes	O
and	O
increment	O
suppressor	O
cistron	O
during	O
embryogenesis	O
.	O

Regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
VHL	B
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
4	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

embryogenesis	O
therefore	O
investigated	O
,	O
expression	O
of	O
VHL	B
.	O
post	O
human	O
conception	O
by	O
in	O
6	O
weeks	O
studies	O
at	O
4	O
the	O
situ	O
and	O
10	O
hybridization	O
during	O
We	O
mRNA	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
cross	O
take	O
at	O
4	O
,	O
sextuplet	O
and	O
tenner	O
workweek	O
situation	O
excogitation	O
.	O

We	O
thus	O
investigated	O
the	O
look	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
cross	O
studies	O
at	O
foursome	O
,	O
sestet	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
by	O
in	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
post	O
conception	O
.	O

We	O
therefore	O
investigated	O
the	O
manifestation	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
hebdomad	O
send	O
concept	O
send	O
concept	O
meditate	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

We	O
therefore	O
investigated	O
the	O
manifestation	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
hebdomad	O
send	O
concept	O
send	O
concept	O
meditate	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
by	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O

post	O
therefore	O
investigated	O
the	O
expression	O
of	O
situ	B
at	O
during	O
human	O
embryogenesis	O
by	O
10	O
VHL	O
conception	O
studies	O
mRNA	O
and	O
,	O
6	O
We	O
in	O
weeks	O
4	O
hybridization	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mrna	O
during	O
homo	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
quartet	O
,	O
six	O
and	O
10	O
workweek	O
stake	O
creation	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

Although	O
VHL	B
mRNA	O
was	O
carry	O
in	O
all	O
ternion	O
seed	O
level	O
,	O
stiff	O
manifestation	O
was	O
noted	O
in	O
the	O
primal	O
unquiet	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

Although	O
VHL	B
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
in	O
the	O
central	O
nervous	O
,	O
kidneys	O
,	O
testis	O
and	O
.	O

Although	O
VHL	B
mRNA	O
was	O
note	O
inward	O
verbalise	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
egg	O
kidney	O
egg	O
egg	O
microbe	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

,	O
VHL	B
mRNA	O
nervous	O
expressed	O
in	O
all	O
lung	O
testis	O
layers	O
system	O
strong	O
expression	O
was	O
,	O
in	O
the	O
central	O
was	O
and	O
,	O
kidneys	O
noted	O
germ	O
Although	O
three	O
.	O

Although	O
VHL	B
mRNA	O
was	O
note	O
inward	O
verbalise	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
egg	O
kidney	O
egg	O
egg	O
microbe	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

Although	O
VHL	B
mRNA	O
expressed	O
in	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
the	O
central	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

.	O
VHL	B
mRNA	O
noted	O
expressed	O
in	O
lung	O
three	O
was	O
layers	O
,	O
strong	O
was	O
,	O
and	O
germ	O
the	O
central	O
nervous	O
system	O
expression	O
kidneys	O
,	O
testis	O
in	O
all	O
Although	O

mRNA	O
in	O
all	O
three	O
layers	O
,	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O

testis	O
VHL	B
mRNA	O
was	O
expressed	O
in	O
was	O
strong	O
germ	O
layers	O
,	O
the	O
kidneys	O
all	O
and	O
Although	O
three	O
in	O
nervous	O
system	O
,	O
expression	O
,	O
central	O
noted	O
lung	O
.	O

Although	O
VHL	B
mrna	O
was	O
expressed	O
in	O
all	O
trinity	O
bug	O
bed	O
,	O
strong	O
formulation	O
was	O
noted	O
in	O
the	O
primal	O
nervous	O
organization	O
,	O
kidneys	O
,	O
egg	O
and	O
lung	O
.	O

Although	O
VHL	B
mRNA	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

inside	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
evince	O
inside	O
nephritic	O
tubules	O
intimate	O
that	O
the	O
VHL	B
cistron	O
product	O
may	O
have	O
a	O
particular	O
function	O
in	O
kidney	O
growing	O
.	O

Within	O
the	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
VHL	B
gene	O
product	O
may	O
a	O
specific	O
role	O
in	O
kidney	O
.	O

Within	O
the	O
kidney	O
,	O
mrna	O
be	O
cistron	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
inward	O
use	O
developing	O
inward	O
verbalise	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

a	O
the	O
kidney	O
may	O
VHL	B
mRNA	O
was	O
development	O
in	O
within	O
have	O
tubules	O
suggesting	O
that	O
role	O
VHL	B
gene	O
product	O
,	O
kidney	O
renal	O
specific	O
the	O
expressed	O
Within	O
differentially	O
.	O

Within	O
the	O
kidney	O
,	O
mrna	O
be	O
cistron	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
inward	O
use	O
developing	O
inward	O
verbalise	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

Within	O
the	O
kidney	O
VHL	B
mRNA	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
gene	O
product	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

.	O
the	O
kidney	O
the	O
VHL	B
mRNA	O
development	O
differentially	O
,	O
within	O
renal	O
tubules	O
that	O
a	O
kidney	O
expressed	B
gene	O
product	O
may	O
have	O
suggesting	O
specific	O
role	O
in	O
VHL	O
was	O
Within	O

kidney	O
mRNA	O
was	O
differentially	O
within	O
renal	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O

in	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
that	O
tubules	O
expressed	O
within	O
renal	O
gene	O
specific	O
was	O
kidney	O
Within	B
differentially	O
VHL	O
may	O
have	O
a	O
suggesting	O
role	O
product	O
the	O
development	O
.	O

inside	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
extract	O
inside	O
renal	O
tubules	O
advise	O
that	O
the	O
VHL	B
factor	O
ware	O
may	O
have	O
a	O
particular	O
persona	O
in	O
kidney	O
ontogeny	O
.	O

Within	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

Two	O
instead	O
tie	O
VHL	B
mrna	O
characterized	O
by	O
comprehension	O
(	O
isoform	O
ace	O
)	O
or	O
censure	O
(	O
isoform	O
ii	O
)	O
of	O
exon	O
deuce	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

Two	O
alternatively	O
VHL	B
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
isoform	O
II	O
)	O
of	O
2	O
are	O
transcribed	O
in	O
adult	O
.	O

Two	O
alternatively	O
spliced	O
VHL	B
characterise	O
aside	O
mrna	O
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
inward	O
grownup	O
tissue	O
paper	O
grownup	O
grownup	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O

2	O
alternatively	O
spliced	O
of	B
mRNAs	O
characterized	O
by	O
tissues	O
in	O
isoform	O
exon	O
)	O
or	O
exclusion	O
transcribed	O
isoform	O
II	O
)	O
VHL	O
adult	O
I	O
are	O
(	O
(	O
Two	O
inclusion	O
.	O

Two	O
alternatively	O
spliced	O
VHL	B
characterise	O
aside	O
mrna	O
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
inward	O
grownup	O
tissue	O
paper	O
grownup	O
grownup	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O

Two	O
alternatively	O
spliced	O
mRNAs	O
characterized	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
II	O
)	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

.	O
alternatively	O
spliced	O
(	B
mRNAs	O
characterized	O
tissues	O
inclusion	O
VHL	O
isoform	O
I	O
)	O
exclusion	O
2	O
adult	O
(	O
II	O
)	O
of	O
exon	O
or	O
are	O
transcribed	O
in	O
isoform	O
by	O
Two	O

spliced	O
characterized	O
by	O
inclusion	O
isoform	O
I	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O

in	O
alternatively	O
spliced	O
VHL	B
mRNAs	O
characterized	O
exclusion	O
)	O
(	O
isoform	O
I	O
II	O
are	O
by	O
adult	O
Two	O
inclusion	O
isoform	O
of	O
exon	O
2	O
or	O
transcribed	O
)	O
(	O
tissues	O
.	O

Two	O
alternatively	O
tie	O
VHL	B
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
i	O
)	O
or	O
censure	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
two	O
are	O
canned	O
in	O
pornographic	O
tissues	O
.	O

Two	O
alternatively	O
spliced	O
VHL	B
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

To	O
inquire	O
if	O
the	O
ii	O
isoforms	O
are	O
differentially	O
extract	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
turn	O
transcribed	O
from	O
xiii	O
foetal	O
tissues	O
(	O
eight	O
-	O
tenner	O
weeks	O
gestation	O
)	O
.	O

To	O
investigate	O
if	O
the	O
two	O
are	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

tissues	O
investigate	O
if	O
13	O
two	O
isoforms	O
are	O
weeks	O
-	O
during	O
.	O
,	O
VHL	B
fetal	O
8	O
reverse	O
transcribed	O
from	O
the	O
mRNA	O
10	O
(	O
was	O
expressed	O
To	O
differentially	O
gestation	O
)	O
embryogenesis	O

To	O
investigate	O
if	O
the	O
	O
mrna	O
be	O
override	O
	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
hebdomad	O
pregnancy	O
verbalise	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

To	O
investigate	O
if	O
the	O
	O
mrna	O
be	O
override	O
	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
hebdomad	O
pregnancy	O
override	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
during	O
embryogenesis	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

.	O
investigate	O
if	O
was	O
two	O
isoforms	O
weeks	O
differentially	O
the	O
during	O
embryogenesis	O
,	O
gestation	B
mRNA	O
10	O
expressed	O
transcribed	O
from	O
13	O
fetal	O
VHL	O
(	O
8	O
-	O
reverse	O
are	O
tissues	O
)	O
To	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
during	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O

To	O
inquire	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
state	O
during	O
embryogenesis	O
,	O
VHL	B
mrna	O
was	O
inverse	O
transcribed	O
from	O
xiii	O
foetal	O
tissues	O
(	O
octad	O
-	O
10	O
weeks	O
pregnancy	O
)	O
.	O

To	O
enquire	O
if	O
the	O
deuce	O
isoforms	O
are	O
differentially	O
carry	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reversion	O
transcribed	O
from	O
thirteen	O
foetal	O
tissues	O
(	O
octonary	O
-	O
x	O
weeks	O
gestation	O
)	O
.	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mrna	O
inside	O
foetal	O
weave	O
reflected	O
that	O
visualise	O
by	O
in	O
situ	O
crossing	O
and	O
the	O
proportion	O
of	O
the	O
two	O
VHL	B
isoforms	O
was	O
standardized	O
between	O
weave	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
within	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

the	O
quantitative	O
distribution	O
ratio	O
VHL	B
mRNA	O
within	O
similar	O
isoforms	O
reflected	O
.	O
seen	O
by	O
of	O
VHL	O
hybridization	O
and	O
the	O
of	O
in	O
was	O
two	O
situ	B
tissues	O
The	O
fetal	O
between	O
tissues	O
that	O

The	O
quantitative	O
distribution	O
of	O
aside	O
inward	O
mrna	O
hybridisation	O
foetal	O
VHL	B
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
alike	O
betwixt	O
tissue	O
paper	O
ratio	O
of	O
the	O
two	B
VHL	O
isoforms	O
was	O
similar	O
between	O
tissues	O

The	O
quantitative	O
distribution	O
of	O
aside	O
inward	O
mrna	O
hybridisation	O
foetal	O
VHL	B
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
alike	O
betwixt	O
betwixt	O
ratio	O
of	O
the	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
within	O
fetal	O
reflected	O
that	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

.	O
quantitative	O
distribution	O
situ	O
VHL	B
mRNA	O
similar	O
fetal	O
of	O
reflected	O
that	O
seen	O
between	O
in	O
was	O
tissues	O
and	O
the	O
ratio	O
of	O
by	O
two	O
VHL	B
isoforms	O
hybridization	O
within	O
the	O
tissues	O
The	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
within	O
fetal	O
reflected	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
the	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
inside	O
foetal	O
tissues	O
reflected	O
that	O
learn	O
by	O
in	O
situ	O
hybridizing	O
and	O
the	O
proportion	O
of	O
the	O
ii	O
VHL	B
isoforms	O
was	O
like	O
between	O
tissues	O
.	O

The	O
quantitative	O
dispersion	O
of	O
VHL	B
mRNA	O
inside	O
foetal	O
weave	O
mull	O
that	O
control	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
deuce	O
VHL	B
isoforms	O
was	O
interchangeable	O
between	O
weave	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
developing	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
human	O
development	O
.	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
developing	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
pattern	O
human	O
development	O
.	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
developing	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
human	O
development	O
.	O
.	O

-	O
compatible	O
genes	O
regulated	O
by	O
the	O
yet	B
role	O
product	O
have	O
not	O
VHL	O
been	O
of	O
elongation	O
our	O
findings	O
are	O
gene	O
with	O
the	O
a	O
transcriptional	O
VHL	B
Although	O
mediated	O
have	O
identified	O
,	O
that	O
may	O
normal	O
hypothesis	O
the	O
in	O
control	O
human	O
development	O
.	O
.	O

Although	O
the	O
genes	O
regulated	O
gene	O
product	O
have	O
not	O
yet	O
identified	O
,	O
compatible	O
hypothesis	O
that	O
mediated	O
transcriptional	O
elongation	O
may	O
have	O
role	O
in	O
development	O
.	O

Although	O
the	O
genes	O
regularize	O
by	O
the	O
VHL	B
cistron	O
intersection	O
have	O
not	O
hitherto	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
possibility	O
that	O
VHL	B
-	O
liaise	O
check	O
of	O
transcriptional	O
extension	O
whitethorn	O
have	O
a	O
office	O
in	O
formula	O
human	O
developing	O
.	O
.	O

Although	O
the	O
genes	O
regularize	O
by	O
the	O
VHL	B
cistron	O
product	O
have	O
not	O
notwithstanding	O
been	O
identified	O
,	O
our	O
see	O
are	O
compatible	O
with	O
the	O
theory	O
that	O
VHL	B
-	O
intercede	O
dominance	O
of	O
transcriptional	O
extension	O
whitethorn	O
have	O
a	O
role	O
in	O
convention	O
homo	O
growth	O
.	O
.	O

may	O
in	O
genes	O
regulated	O
findings	O
the	O
development	B
have	O
product	O
have	O
not	O
yet	O
been	O
-	O
are	O
our	O
by	O
,	O
compatible	O
with	O
identified	O
hypothesis	O
that	O
VHL	B
the	O
mediated	O
control	O
.	O
Although	O
elongation	O
transcriptional	O
VHL	O
a	O
role	O
the	O
normal	O
human	O
gene	O
of	O
.	O

Although	O
the	O
cistron	O
order	O
by	O
the	O
VHL	B
factor	O
product	O
have	O
not	O
yet	O
been	O
place	O
,	O
our	O
recover	O
are	O
compatible	O
with	O
the	O
guess	O
that	O
VHL	B
-	O
arbitrate	O
ascendance	O
of	O
transcriptional	O
extension	O
may	O
have	O
a	O
character	O
in	O
convention	O
human	O
ontogenesis	O
.	O
.	O

Although	O
the	O
may	O
regulated	O
by	O
normal	O
not	B
gene	O
product	O
have	O
VHL	O
control	O
with	O
identified	O
,	O
compatible	O
findings	O
are	O
development	O
been	O
the	O
hypothesis	O
that	O
the	B
-	O
our	O
yet	O
a	O
have	O
elongation	O
genes	O
of	O
transcriptional	O
role	O
in	O
VHL	O
human	O
mediated	O
.	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
.	O
.	O

Genetic	O
in	O
hereditary	B
cancer	I
role	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O

transmissible	O
heterogeneousness	O
in	O
patrimonial	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
heterogeneousness	O
heterogeneousness	O
heterogeneousness	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
heterogeneousness	O
heterogeneousness	O
inward	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
heterogeneousness	O
heterogeneousness	O
heterogeneousness	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneousness	O
in	O
patrimonial	B
breast	I
cancer	I
:	O
purpose	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
heterogeneity	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
.	O

genic	O
heterogeneity	O
in	O
familial	B
bosom	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

Genetic	O
breast	O
in	O
hereditary	B
.	I
cancer	I
:	O
heterogeneity	O
of	O
BRCA1	O
and	O
BRCA2	O
role	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

The	O
common	O
hereditary	O
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
of	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
operating	O
room	O
cistron	O
cistron	O
transmissible	O
transmissible	O
transmissible	O
BRCA1	O
or	O
BRCA2	O
genes	O

The	O
uncouth	O
inherited	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
ascribe	O
to	O
the	O
heritage	O
of	O
sport	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
operating	O
room	O
cistron	O
cistron	O
transmissible	O
transmissible	O
transmissible	O
BRCA1	O
or	O
BRCA2	O
genes	O

The	O
vernacular	O
familial	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
assign	O
to	O
the	O
heritage	O
of	O
variation	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
cistron	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
to	O
the	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O

attributed	O
common	O
hereditary	O
BRCA1	O
of	O
breast	B
cancer	I
been	O
have	O
largely	O
or	O
to	O
inheritance	O
the	O
.	O
mutations	O
in	O
the	O
forms	O
The	O
BRCA2	O
genes	O
of	O

The	O
coarse	O
inherited	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
mostly	O
ascribe	O
to	O
the	O
heritage	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
factor	O
.	O

of	O
common	O
been	O
cancer	O
of	O
breast	B
mutations	I
have	O
hereditary	O
largely	O
attributed	O
to	O
BRCA2	O
inheritance	O
forms	O
The	O
in	O
the	O
BRCA1	O
or	O
the	O
genes	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

However	O
,	O
it	O
is	O
genus	O
cancer	O
be	O
explicate	O
aside	O
non	O
not	O
yet	O
clear	O
what	O
proportion	O
of	B
hereditary	I
breast	I
cancer	O
is	O
explained	O
by	O
BRCA1	O
and	O
susceptibleness	O
southward	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
bosom	O
bosom	O

However	O
,	O
it	O
is	O
genus	O
cancer	O
be	O
explicate	O
aside	O
non	O
not	O
yet	O
clear	O
what	O
proportion	O
of	B
hereditary	I
breast	I
cancer	O
is	O
explained	O
by	O
BRCA1	O
and	O
susceptibleness	O
however	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
bosom	O
bosom	O

)	O
,	O
susceptibility	O
explained	O
not	O
yet	O
s	O
what	O
is	O
of	O
hereditary	B
breast	I
by	I
is	O
it	O
proportion	O
BRCA1	O
and	O
BRCA2	O
or	O
cancer	O
some	O
other	O
unidentified	O
by	O
clear	O
(	O
gene	O
However	O
.	O

However	O
,	O
it	O
is	O
genus	O
cancer	O
be	O
explicate	O
aside	O
non	O
not	O
yet	O
clear	O
what	O
proportion	O
of	B
hereditary	I
breast	I
cancer	O
is	O
explained	O
by	O
BRCA1	O
and	O
susceptibleness	O
southward	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
bosom	O
bosom	O

However	O
,	O
it	O
is	O
not	O
yet	O
clear	O
proportion	O
of	O
breast	I
cancer	I
is	O
explained	O
by	O
BRCA1	O
and	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
yet	O
gain	O
what	O
dimension	O
of	O
inherited	B
front	I
crab	I
is	O
explained	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unnamed	O
susceptibleness	O
cistron	O
(	O
s	O
)	O
.	O

BRCA1	O
,	O
it	O
is	O
not	O
yet	O
some	O
breast	O
proportion	O
of	O
hereditary	B
However	I
)	I
unidentified	O
by	O
explained	O
and	O
susceptibility	O
BRCA2	O
or	O
by	O
clear	O
other	O
is	O
what	O
gene	O
(	O
s	O
cancer	O
.	O

by	O
,	O
it	O
BRCA2	O
not	O
yet	O
clear	O
gene	O
unidentified	O
of	O
)	B
breast	I
(	I
or	O
other	O
by	O
BRCA1	O
and	O
is	O
is	O
susceptibility	O
some	O
explained	O
proportion	O
However	O
what	O
cancer	O
s	O
hereditary	O
.	O

still	O
,	O
it	O
is	O
not	O
nonetheless	O
unclouded	O
what	O
balance	O
of	O
transmissible	B
titty	I
cancer	I
is	O
explicate	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unnamed	O
susceptibleness	O
gene	O
(	O
s	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
is	O
explained	O
by	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
(	O
s	O
)	O

However	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
is	O
explained	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
genus	I
cancer	I
hazard	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	O
genus	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
genus	I
cancer	I
hazard	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	O
genus	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
genus	I
cancer	I
hazard	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	I
genus	I
cancer	O
genus	O

the	O
American	O
the	O
proportion	O
of	O
hereditary	B
or	I
hereditary	I
explained	O
by	O
BRCA1	O
breast	O
BRCA2	O
additional	O
genes	O
sample	O
of	O
North	O
cancer	O
hereditary	B
breast	I
confer	I
susceptibility	O
assess	O
We	O
evidence	O
may	O
in	O
a	O
and	O
that	O
or	O
cancers	O
describe	B
breast	I
for	I
ovarian	I
cancer	I
risk	O
.	O

We	O
describe	O
the	O
proportion	O
cancer	I
explained	O
by	O
BRCA1	O
or	O
in	O
a	O
American	O
cancers	I
and	O
evidence	O
susceptibility	O
genes	O
that	O
may	O
hereditary	B
breast	I
cancer	I
risk	O

We	O
identify	O
the	O
proportion	O
of	O
patrimonial	B
chest	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
try	O
of	O
North	O
american	O
patrimonial	B
chest	I
cancers	I
and	O
assess	O
the	O
grounds	O
for	O
extra	O
susceptibleness	O
cistron	O
that	O
whitethorn	O
confabulate	O
patrimonial	B
chest	I
or	I
ovarian	I
cancer	I
adventure	O
.	O

We	O
delineate	O
the	O
dimension	O
of	O
genetic	B
breast	I
crab	I
excuse	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
try	O
of	O
North	O
American	O
genetic	B
breast	I
cancers	I
and	O
nates	O
the	O
certify	O
for	O
extra	O
susceptibility	O
cistron	O
that	O
may	O
confab	O
genetic	B
breast	I
or	I
ovarian	I
crab	I
endangerment	O
.	O

that	O
breast	O
the	O
proportion	O
of	O
hereditary	B
cancer	I
may	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
the	O
North	O
sample	O
of	O
a	O
American	O
hereditary	B
in	I
cancers	I
and	O
assess	O
describe	O
evidence	O
for	O
risk	O
We	O
genes	O
susceptibility	O
breast	O
confer	O
hereditary	B
breast	I
or	I
ovarian	I
cancer	I
additional	O
.	O

We	O
draw	O
the	O
proportion	O
of	O
genetic	B
chest	I
cancer	I
excuse	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
union	O
American	O
genetic	B
chest	I
crab	I
and	O
buttocks	O
the	O
certify	O
for	O
extra	O
susceptibleness	O
factor	O
that	O
may	O
confab	O
genetic	B
chest	I
or	I
ovarian	I
cancer	I
risk	O
.	O

We	O
describe	O
that	O
proportion	O
of	O
or	B
BRCA1	I
cancer	I
explained	O
by	O
breast	O
for	O
hereditary	O
in	O
a	O
American	O
of	O
North	O
cancer	O
BRCA2	B
breast	I
cancers	I
and	O
hereditary	O
the	O
sample	O
or	O
confer	O
may	O
genes	O
the	O
additional	O
susceptibility	O
hereditary	B
breast	I
assess	I
ovarian	I
evidence	I
risk	O
.	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
ovarian	I
cancer	I
risk	O
.	O

Twenty	O
-	O
through	O
and	O
through	O
	O
	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	B
risk	I
breast	O
cancer	O
research	O
programs	O

research	O
-	O
three	O
.	O
were	O
identified	O
through	O
two	O
programs	O
-	O
risk	O
breast	B
Twenty	I
cancer	O
high	O
families	O

Twenty	O
-	O
through	O
and	O
through	O
	O
be	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	B
risk	I
breast	O
cancer	O
research	O
programs	O

xx	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
front	B
cancer	I
enquiry	O
curriculum	O
.	O

cancer	O
-	O
three	O
two	O
were	O
identified	O
research	O
families	O
high	O
-	O
Twenty	O
breast	B
risk	I
through	O
programs	O
.	O

Twenty	O
-	O
through	O
and	O
through	O
	O
	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	B
risk	I
breast	O
cancer	O
research	O
programs	O

Twenty	O
-	O
three	O
house	O
were	O
identified	O
through	O
ii	O
high	O
-	O
adventure	O
titty	B
cancer	I
research	O
programs	O
.	O

Twenty	O
-	O
trio	O
families	O
were	O
identified	O
through	O
two	O
eminent	O
-	O
gamble	O
summit	B
cancer	I
research	O
programs	O
.	O

Twenty	O
-	O
high	O
.	O
were	O
identified	O
cancer	O
two	O
three	O
-	O
risk	O
breast	B
through	I
research	O
families	O
programs	O

-	O
three	O
families	O
were	O
identified	O
through	O
two	O
risk	O
breast	B
cancer	I
research	O
programs	O
.	O

Twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B
cancer	I
research	O
programs	O
.	O

Genetic	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B
or	I
ovarian	I
and	O
markers	O
on	O
chromosomes	O
(	O
BRCA1	O
)	O
and	O
13q	O
BRCA2	O
)	O
.	O

Genetic	O
was	O
undertaken	O
establish	O
linkage	O
between	O
the	O
breast	B
or	I
ovarian	I
cancer	I
and	O
markers	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O

Genetic	O
analysis	O
was	O
undertaken	O
display	O
case	O
install	O
marking	O
along	O
to	O
establish	O
linkage	O
between	O
the	B
breast	I
or	I
ovarian	I
cancer	O
cases	O
and	O
markers	O
on	O
chromosomes	O
be	O
be	O
be	O
display	O
case	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O

BRCA1	O
analysis	O
was	O
17q	O
to	O
establish	O
linkage	O
BRCA2	O
13q	O
breast	B
(	I
ovarian	I
cancer	I
cases	O
and	O
markers	O
on	O
chromosomes	O
undertaken	O
(	O
or	O
)	O
and	O
the	O
Genetic	O
between	O
)	O
.	O

)	O
analysis	O
was	O
and	O
to	O
establish	O
BRCA2	O
between	O
undertaken	O
breast	B
or	I
ovarian	I
cases	I
BRCA1	O
(	O
the	O
on	O
chromosomes	O
17q	O
(	O
cancer	O
)	O
and	O
13q	O
markers	O
linkage	O
Genetic	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
display	O
case	O
install	O
marking	O
along	O
to	O
establish	O
linkage	O
between	O
the	B
breast	I
or	I
ovarian	I
cancer	O
cases	O
and	O
markers	O
on	O
chromosomes	O
be	O
be	O
be	O
undertake	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O

genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
tit	B
or	I
ovarian	I
cancer	I
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
display	O
case	O
install	O
marking	O
along	O
to	O
establish	O
linkage	O
between	O
the	B
breast	I
or	I
ovarian	I
cancer	O
cases	O
and	O
markers	O
on	O
chromosomes	O
be	O
be	O
be	O
undertake	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O

13q	O
analysis	O
was	O
undertaken	O
to	O
establish	O
cases	O
ovarian	O
the	O
breast	B
or	I
on	I
)	I
linkage	O
(	O
Genetic	O
between	O
markers	O
17q	O
(	O
BRCA1	O
cancer	O
and	O
chromosomes	O
and	O
BRCA2	O
)	O
.	O

genetic	O
analysis	O
was	O
undertaken	O
to	O
show	O
linkage	O
between	O
the	O
bosom	B
or	I
ovarian	I
cancer	I
face	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B
or	I
ovarian	I
cancer	I
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Mutation	O
BRCA1	O
in	O
the	O
analysis	O
and	O
genes	O
undertaken	O
was	O
also	O
all	O
in	O
BRCA2	O
families	O
.	O

Mutation	O
analysis	O
inwards	O
cistron	O
inward	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
inward	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
cistron	O
was	O
also	O
tackle	O
in	O
all	O
family	O
.	O

all	O
analysis	O
in	O
Mutation	O
genes	O
and	O
BRCA2	O
in	O
was	O
also	O
undertaken	O
BRCA1	O
the	O
families	O
.	O

mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
likewise	O
tackle	O
in	O
all	O
category	O
.	O

Mutation	O
analysis	O
inwards	O
cistron	O
inward	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
depth	O
psychology	O
also	O
undertaken	O
in	O
all	O
families	O

Mutation	O
in	O
BRCA1	O
BRCA2	O
genes	O
was	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

genes	O
the	O
in	O
analysis	O
BRCA1	O
and	O
also	O
Mutation	O
was	O
BRCA2	O
undertaken	O
in	O
all	O
.	O
families	O

mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
cistron	O
was	O
besides	O
attempt	O
in	O
all	O
families	O
.	O

Mutation	O
analysis	O
inwards	O
cistron	O
inward	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
depth	O
psychology	O
also	O
undertaken	O
in	O
all	O
families	O

Mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

The	O
convention	O
of	O
patrimonial	B
cancer	I
in	O
xiv	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
examine	O
was	O
assign	O
to	O
BRCA1	O
by	O
a	O
compounding	O
of	O
linkage	O
and	O
variation	O
examine	O
.	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
14	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

by	O
pattern	O
of	O
to	B
cancer	I
in	O
14	O
and	O
of	O
%	O
.	O
of	O
the	O
BRCA1	O
combination	O
studied	O
was	O
attributed	O
hereditary	O
23	O
linkage	O
a	O
families	O
61	O
The	O
(	O
mutation	O
analyses	O
)	O

The	O
pattern	O
of	O
hereditary	B
gene	O
linkage	B
	O
phratry	B
study	O
genus	I
cancer	O
cancer	O
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
combining	O
chromosomal	O
mutation	O
	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O

The	O
pattern	O
of	O
hereditary	B
gene	O
linkage	B
	O
phratry	B
study	O
genus	I
cancer	O
cancer	O
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
combining	O
chromosomal	O
mutation	O
study	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
in	O
14	O
(	O
%	O
)	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

.	O
pattern	O
of	O
families	B
cancer	I
in	O
and	O
(	O
hereditary	O
%	O
)	O
of	O
mutation	O
23	O
linkage	O
61	O
was	O
attributed	O
to	O
BRCA1	O
the	O
a	O
combination	O
of	O
studied	O
14	O
by	O
analyses	O
The	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
in	O
14	O
(	O
%	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O

The	O
pattern	O
of	O
transmissible	B
cancer	I
in	O
14	O
(	O
lxi	O
%	O
)	O
of	O
the	O
23	O
kin	O
analyse	O
was	O
assign	O
to	O
BRCA1	O
by	O
a	O
combining	O
of	O
linkage	O
and	O
sport	O
study	O
.	O

The	O
rule	O
of	O
inherited	B
cancer	I
in	O
fourteen	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
family	O
learn	O
was	O
assign	O
to	O
BRCA1	O
by	O
a	O
compounding	O
of	O
linkage	O
and	O
mutant	O
analyses	O
.	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

were	O
families	O
No	O
.	O
to	O
BRCA2	O
attributed	O

No	O
folk	O
were	O
assign	O
to	O
BRCA2	O
.	O

No	O
phratry	O
families	O
were	O
attributed	O
be	O
to	O
BRCA2	O
.	O

No	O
were	O
to	O
.	O

attributed	O
No	O
were	O
families	O
to	O
BRCA2	O
.	O

No	O
kinsfolk	O
were	O
assign	O
to	O
BRCA2	O
.	O

No	O
families	O
were	O
ascribe	O
to	O
BRCA2	O
.	O

No	O
families	O
were	O
.	O
to	O
attributed	O
BRCA2	O

No	O
families	O
were	O
attributed	O
to	O
.	O

No	O
phratry	O
families	O
were	O
attributed	O
ascribe	O
to	O
BRCA2	O
.	O

No	O
families	O
were	O
attributed	O
to	O
BRCA2	O
.	O

Five	O
families	O
allow	O
for	O
certify	O
	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
license	O

and	O
families	O
(	O
.	O
%	O
)	O
provided	O
evidence	O
BRCA2	O
linkage	O
to	O
both	O
Five	O
BRCA1	O
against	O
22	O

Five	O
families	O
allow	O
for	O
certify	O
	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
license	O

quintuplet	O
fellowship	O
(	O
xxii	O
%	O
)	O
provided	O
certify	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

BRCA1	O
families	O
(	O
evidence	O
%	O
)	O
and	O
22	O
against	O
linkage	O
Five	O
both	O
to	O
provided	O
BRCA2	O
.	O

Five	O
families	O
allow	O
for	O
certify	O
	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
license	O

Five	O
fellowship	O
(	O
22	O
%	O
)	O
allow	O
certify	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

quint	O
family	O
(	O
22	O
%	O
)	O
supply	O
tell	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

Five	O
families	O
against	O
.	O
%	O
)	O
BRCA1	O
evidence	O
(	O
linkage	O
to	O
both	O
provided	O
and	O
22	O
BRCA2	O

families	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

Five	O
families	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
phratry	O
mutation	O
mutation	O
five	O
families	O
.	O

BRCA1	O
or	O
detected	O
five	O
families	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
quintuplet	O
kinsperson	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
phratry	O
mutation	O
mutation	O
five	O
families	O
.	O

BRCA1	O
or	O
mutations	O
were	O
detected	O
in	O
these	O
five	O
families	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
discover	O
in	O
these	O
phoebe	O
class	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
phratry	O
mutation	O
operating	O
room	O
five	O
families	O

nobelium	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
quintet	O
mob	O
.	O

No	O
in	O
or	O
BRCA2	O
BRCA1	O
were	O
detected	O
families	O
these	O
five	O
mutations	O
.	O

.	O
BRCA1	O
or	O
BRCA2	O
in	O
were	O
five	O
mutations	O
these	O
detected	O
families	O
No	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
five	O
families	O
.	O

%	O
BRCA1	O
or	O
families	O
status	O
of	O
four	O
BRCA2	O
be	O
17	O
not	O
)	O
The	O
could	O
(	O
determined	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
condition	O
of	O
four	O
fellowship	O
(	O
seventeen	O
%	O
)	O
could	O
not	O
be	O
dictated	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
condition	O
of	O
quaternity	O
family	O
(	O
xvii	O
%	O
)	O
could	O
not	O
be	O
decide	O
.	O

The	O
BRCA1	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
position	O
of	O
four	O
fellowship	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
limit	O
.	O

The	O
BRCA1	O
phratry	O
operating	O
room	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
family	O
line	O
family	O

The	O
BRCA1	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
17	O
%	O
could	O
not	O
be	O
determined	O
.	O

The	O
BRCA1	O
phratry	O
operating	O
room	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
family	O
line	O
family	O

BRCA1	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O

The	O
BRCA1	O
(	O
be	O
status	O
of	O
could	O
families	O
or	O
17	O
%	O
)	O
four	O
not	O
BRCA2	O
determined	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
.	O

BRCA1	O
and	O
hereditary	O
the	O
explain	O
the	O
exists	O
of	O
BRCA2	B
breast	I
cancer	I
that	O
majority	O
in	O
probably	O
North	O
American	O
population	O
.	O

BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
North	O
American	O
population	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
excuse	O
the	O
majority	O
of	O
transmissible	B
boob	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
universe	O
.	O

BRCA1	O
and	O
BRCA2	O
believably	O
excuse	O
the	O
bulk	O
of	O
transmitted	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
american	O
population	O
.	O

American	O
and	O
BRCA2	O
probably	O
explain	O
the	O
in	O
the	O
hereditary	B
breast	I
cancer	I
that	O
population	O
majority	O
of	O
North	O
exists	O
BRCA1	O
.	O

BRCA1	O
and	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
bosom	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
excuse	O
the	O
majority	O
of	O
familial	B
tit	I
crab	I
that	O
exists	O
in	O
the	O
North	O
American	O
universe	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
.	O

in	O
and	O
BRCA2	O
cancer	O
explain	O
the	O
majority	O
.	O
the	B
breast	I
probably	I
that	O
BRCA1	O
exists	O
hereditary	O
North	O
American	O
population	O
of	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
.	O

nevertheless	O
,	O
ace	O
or	O
more	O
extra	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explicate	O
some	O
proportion	O
of	O
genetic	B
bosom	I
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
	I
	O
	I
	O
	I
	O
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
	I
	O
	I
	O
	I
	O
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
be	O
found	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I

proportion	O
,	O
yet	O
genes	O
more	O
additional	O
of	O
may	O
one	O
be	O
found	O
that	O
.	O
some	O
or	O
However	O
hereditary	B
breast	I
cancer	I
.	O
explain	O

notwithstanding	O
,	O
unrivalled	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
bump	O
that	O
explicate	O
some	O
symmetry	O
of	O
hereditary	B
bosom	I
cancer	I
.	O
.	O

.	O
,	O
one	O
found	O
more	O
additional	O
genes	O
cancer	O
proportion	O
be	O
or	O
that	O
some	O
explain	O
yet	O
of	O
hereditary	B
breast	I
may	I
However	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
	I
	O
	I
	O
	I
cistron	O
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
proportion	O
breast	I
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
extra	O
cistron	O
may	O
hitherto	O
be	O
plant	O
that	O
excuse	O
some	O
proportion	O
of	O
hereditary	B
chest	I
cancer	I
.	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
.	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
pisces	O
the	O
fishes	O
middle	O
middle	O
chromosomal	O
mutation	O
chromosomal	B
mutation	I
chromosomal	I
mutation	I
episode	O
fish	O

mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
fish	B
eye	I
disease	I
)	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lasso	O
branchpoint	O
succession	O
is	O
a	O
address	O
get	O
of	O
an	O
inherited	B
human	I
unhinge	I
(	O
fish	B
-	I
center	I
disease	I
)	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
is	O
a	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
eye	I
disease	I
)	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
pisces	O
the	O
fishes	O
middle	O
middle	O
chromosomal	O
mutation	O
chromosomal	B
mutation	I
chromosomal	I
mutation	I
chromosomal	O
mutation	O

an	O
intronic	O
mutant	O
in	O
a	O
riata	O
branchpoint	O
episode	O
is	O
a	O
direct	O
case	O
of	O
an	O
genetic	B
human	I
disorder	I
(	O
fish	B
-	I
middle	I
disease	I
)	O
.	O

an	O
intronic	O
mutant	O
in	O
a	O
lasso	O
branchpoint	O
sequence	O
is	O
a	O
unmediated	O
cause	O
of	O
an	O
inherited	B
human	I
distract	I
(	O
pisces	B
-	I
oculus	I
disease	I
)	O
.	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
direct	O
an	O
inherited	B
human	I
disorder	I
(	O
fish	B
-	I
eye	I
disease	I

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
pisces	O
the	O
fishes	O
middle	O
middle	O
chromosomal	O
mutation	O
chromosomal	B
mutation	I
chromosomal	I
mutation	I
chromosomal	O
mutation	O

(	O
intronic	O
mutation	O
direct	O
a	O
lariat	O
branchpoint	O
fish	O
.	O
a	O
in	O
cause	O
of	O
an	O
)	B
human	I
disorder	I
eye	O
sequence	B
An	I
-	I
disease	I
inherited	O
is	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
fish	B
-	I
eye	I
disease	I
)	O
.	O

The	O
first	O
step	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O
structure	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
results	O
formation	O
of	O
a	O
lariat	O
structure	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
reata	O
social	O
system	O
social	O
system	O
footfall	O
footfall	O
footfall	O
of	O
a	O
lariat	O

The	O
first	O
step	O
in	O
the	O
wed	O
of	O
an	O
intron	O
from	O
atomic	O
predecessor	O
of	O
mrna	O
results	O
in	O
the	O
formation	O
of	O
a	O
lasso	O
construction	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
reata	O
social	O
system	O
social	O
system	O
footfall	O
footfall	O
footfall	O
of	O
a	O
lariat	O

The	O
low	O
step	O
in	O
the	O
marry	O
of	O
an	O
intron	O
from	O
atomic	O
precursors	O
of	O
mRNA	O
lead	O
in	O
the	O
organisation	O
of	O
a	O
lasso	O
structure	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
precursors	O
of	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O

nuclear	O
first	O
step	O
of	O
the	O
splicing	O
of	O
intron	O
an	O
from	O
a	O
precursors	O
mRNA	O
of	O
.	O
in	O
the	O
formation	O
in	O
The	O
lariat	O
structure	O
results	O

The	O
first	O
step	O
in	O
the	O
wed	O
of	O
an	O
intron	O
from	O
atomic	O
predecessor	O
of	O
mrna	O
solvent	O
in	O
the	O
formation	O
of	O
a	O
lasso	O
structure	O
.	O

results	O
first	O
intron	O
of	O
the	O
splicing	O
in	O
an	O
step	O
from	O
nuclear	O
precursors	O
lariat	O
mRNA	O
in	O
The	O
the	O
formation	O
of	O
a	O
of	O
structure	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O
structure	O
.	O

adenine	O
discrete	O
intronic	O
base	O
sequence	O
,	O
bed	O
as	O
the	O
branchpoint	O
part	O
,	O
plays	O
adenine	O
central	O
office	O
in	O
this	O
process	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
base	O
base	O
base	O
base	O
base	O
base	O
process	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
base	O
base	O
base	O
base	O
base	O
base	O
process	O
.	O

intronic	O
,	O
known	O
as	O
branchpoint	O
region	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
as	O
the	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

intronic	O
nucleotide	O
sequence	O
,	O
as	O
the	O
branchpoint	O
region	O
,	O
a	O
central	O
role	O
in	O
process	O
.	O

this	O
distinct	O
intronic	O
process	O
sequence	O
,	O
known	O
the	O
as	O
branchpoint	O
central	O
,	O
plays	O
.	O
A	O
role	O
in	O
region	O
nucleotide	O
a	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
base	O
base	O
base	O
base	O
base	O
episode	O
process	O
.	O

A	O
decided	O
intronic	O
base	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
realm	O
,	O
plays	O
a	O
fundamental	O
function	O
in	O
this	O
action	O
.	O

in	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
a	O
,	O
the	O
branchpoint	O
region	O
central	O
A	O
known	O
as	O
this	O
plays	O
role	O
process	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

We	O
here	O
line	O
a	O
point	O
mutation	O
in	O
such	O
a	O
episode	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
hither	O
hither	O
hither	O
sequence	O
.	O

We	O
here	O
identify	O
a	O
bespeak	O
variation	O
in	O
such	O
a	O
sequence	O
.	O

We	O
here	O
line	O
a	O
guide	O
mutation	O
in	O
such	O
a	O
successiveness	O
.	O

here	O
describe	O
point	O
mutation	O
in	O
such	O
a	O
sequence	O
.	O

such	O
here	O
describe	O
point	O
a	O
mutation	O
sequence	O
We	O
a	O
in	O
.	O

We	O
such	O
describe	O
a	O
here	O
mutation	O
in	O
.	O
a	O
sequence	O
point	O

a	O
such	O
describe	O
in	O
point	O
mutation	O
We	O
here	O
a	O
sequence	O
.	O

We	O
describe	O
point	O
in	O
such	O
a	O
sequence	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
hither	O
hither	O
hither	O
sequence	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
sequence	O
.	O

Three	O
sisters	O
coding	O
shown	O
to	O
(	O
from	O
mutations	B
-	I
eye	I
disease	I
the	O
lecithin	B
)	O
,	O
(	O
disorder	O
which	O
caused	O
is	O
by	O
fish	O
in	O
suffer	O
gene	O
for	O
were	O
)	O
cholesterol	O
acyltransferase	O
a	O
FED	O
LCAT	O
.	O

Three	O
shown	O
to	O
suffer	O
from	O
-	I
eye	I
FED	B
)	O
a	O
disorder	O
by	O
in	O
the	O
gene	O
for	O
lecithin	O
cholesterol	O
(	O
LCAT	O
)	O
.	O

Three	O
sisters	O
were	O
shown	O
put	O
up	O
antiophthalmic	O
factor	O
babe	O
to	O
suffer	B
from	I
fish	I
-	I
eye	O
disease	B
(	O
FED	O
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O

Three	O
sisters	O
were	O
shown	O
put	O
up	O
antiophthalmic	O
factor	O
distract	O
to	O
suffer	B
from	I
fish	I
-	I
eye	O
disease	B
(	O
FED	O
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O

sisters	O
is	O
were	O
shown	O
to	O
suffer	O
for	O
fish	B
-	I
eye	I
disease	I
lecithin	O
FED	B
gene	O
acyltransferase	O
a	O
disorder	O
which	O
(	O
caused	O
by	O
mutations	O
.	O
the	O
)	O
coding	O
from	O
Three	O
LCAT	O
in	O
(	O
cholesterol	O
)	O
,	O

Three	O
sisters	O
were	O
shown	O
to	O
suffer	O
-	I
eye	I
disease	I
(	O
)	O
,	O
a	O
disorder	O
which	O
caused	O
by	O
mutations	O
in	O
gene	O
coding	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

trey	O
sisters	O
were	O
express	O
to	O
suffer	O
from	O
angle	B
-	I
center	I
disease	I
(	O
feast	B
)	O
,	O
a	O
distract	O
which	O
is	O
caused	O
by	O
sport	O
in	O
the	O
factor	O
tantalize	O
for	O
lecithin	O
cholesterin	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

troika	O
baby	O
were	O
evidence	O
to	O
meet	O
from	O
fish	B
-	I
centre	I
disease	I
(	O
eat	B
)	O
,	O
a	O
cark	O
which	O
is	O
caused	O
by	O
mutant	O
in	O
the	O
cistron	O
coding	O
for	O
lecithin	O
cholesterin	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

Three	O
sisters	O
were	O
shown	O
put	O
up	O
antiophthalmic	O
factor	O
distract	O
to	O
suffer	B
from	I
fish	I
-	I
eye	O
disease	B
(	O
FED	O
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O
cholesterin	O

triplet	O
sisters	O
were	O
point	O
to	O
suffer	O
from	O
fish	B
-	I
eye	I
disease	I
(	O
FED	B
)	O
,	O
a	O
perturb	O
which	O
is	O
stimulate	O
by	O
mutations	O
in	O
the	O
factor	O
dupe	O
for	O
lecithin	O
cholesterin	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

Three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B
-	I
eye	I
disease	I
(	O
FED	B
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

intron	O
4	O
the	O
LCAT	O
gene	O
of	O
)	O
three	O
probands	O
revealed	O
compound	O
22C	O
for	O
the	O
a	O
mutation	O
in	O
exon	O
,	O
which	O
is	O
reported	O
4	O
underlie	O
a	O
FED	B
in	O
of	O
mutation	O
to	O
point	O
and	O
located	O
missense	O
Sequencing	O
phenotype	O
(	O
IVS4	O
T	O
-	O
heterozygosity	O
all	O
.	O

Sequencing	O
of	O
the	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
a	O
missense	O
mutation	O
exon	O
which	O
is	O
reported	O
the	O
a	O
point	O
mutation	O
in	O
intron	O
(	O
IVS4	O
T	O
)	O
.	O

sequence	O
of	O
the	O
LCAT	O
cistron	O
of	O
all	O
iii	O
probands	O
revealed	O
combine	O
heterozygosity	O
for	O
a	O
missense	O
mutant	O
in	O
exon	O
foursome	O
which	O
is	O
describe	O
to	O
underlie	O
the	O
flow	B
phenotype	O
,	O
and	O
a	O
charge	O
mutant	O
place	O
in	O
intron	O
foursome	O
(	O
IVS4	O
tetraiodothyronine	O
-	O
22C	O
)	O
.	O

sequence	O
of	O
the	O
LCAT	O
factor	O
of	O
all	O
three	O
probands	O
discover	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
foursome	O
which	O
is	O
account	O
to	O
underlie	O
the	O
course	B
phenotype	O
,	O
and	O
a	O
manoeuvre	O
mutation	O
located	O
in	O
intron	O
foursome	O
(	O
IVS4	O
thymine	O
-	O
22C	O
)	O
.	O

Sequencing	O
of	O
mutation	O
LCAT	O
gene	O
of	O
all	O
4	O
probands	O
revealed	O
compound	O
for	O
.	O
a	O
missense	O
point	O
in	O
exon	O
which	O
three	O
is	O
located	O
to	O
4	O
the	O
phenotype	B
,	O
reported	O
and	O
a	O
mutation	O
IVS4	O
FED	O
in	O
intron	O
underlie	O
(	O
the	O
T	O
-	O
22C	O
)	O
heterozygosity	O

Sequencing	O
of	O
the	O
gene	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
is	O
reported	O
to	O
underlie	O
the	O
FED	B
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
(	O
T	O
-	O
22C	O
)	O
.	O

Sequencing	O
of	O
the	O
LCAT	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
FED	B
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
cistron	O
deoxythymidine	O
monophosphate	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
(	O
IVS4	O
T	O
-	O
22C	O
)	O

T	O
the	O
the	O
LCAT	O
in	O
of	O
is	O
mutation	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
all	O
IVS4	O
mutation	O
gene	O
point	O
4	O
which	O
a	O
reported	O
to	O
underlie	O
,	O
FED	B
phenotype	O
)	O
exon	O
a	O
and	O
of	O
located	O
in	O
intron	O
4	O
(	O
missense	O
Sequencing	O
-	O
22C	O
three	O
.	O

Sequencing	O
of	O
the	O
gene	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
exon	O
4	O
which	O
is	O
reported	O
,	O
point	O
located	O
in	O
intron	O
(	O
IVS4	O
T	O
-	O
22C	O
)	O

sequence	O
of	O
the	O
LCAT	O
factor	O
of	O
all	O
trio	O
probands	O
revealed	O
intensify	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
fed	B
phenotype	O
,	O
and	O
a	O
betoken	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
IVS4	O
tonne	O
-	O
22C	O
)	O
.	O

Sequencing	O
of	O
the	O
LCAT	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
FED	B
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
IVS4	O
T	O
-	O
22C	O
)	O
.	O

performing	O
in	O
vitro	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
on	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
shown	O
to	O
cause	O
a	O
null	O
complete	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
intron	O
retention	O
.	O

allele	O
,	O
in	O
vitro	O
leukocytes	O
of	O
retention	O
as	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
was	O
of	O
from	O
expression	O
isolated	O
the	O
patient	O
mRNA	O
this	O
gene	O
defect	O
performing	O
shown	O
to	O
.	O
By	O
null	O
a	O
LCAT	O
the	O
result	O
of	O
complete	O
intron	O
minigenes	O
cause	O

By	O
performing	O
in	O
expression	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
intron	O
.	O

aside	O
do	O
in	O
vitro	O
face	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
obscure	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
factor	O
fault	O
was	O
render	O
to	O
crusade	O
a	O
null	O
allelomorph	O
as	O
the	O
result	O
of	O
finish	O
intron	O
retentiveness	O
.	O

was	O
the	O
in	O
vitro	O
expression	O
of	O
PCR	O
minigenes	O
and	O
reverse	O
transcriptase	O
LCAT	O
on	O
cause	O
null	O
from	O
leukocytes	O
of	O
result	O
patient	O
,	O
this	O
a	O
defect	O
By	O
shown	O
as	O
mRNA	O
isolated	O
gene	O
allele	O
complete	O
the	O
of	O
performing	O
to	O
intron	O
retention	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
intron	O
retention	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
manifestation	O
antiophthalmic	O
factor	O
intron	O
retention	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
of	O
the	O
patient	O
this	O
defect	O
was	O
shown	O
a	O
result	O
of	O
complete	O
retention	O
.	O

By	O
performing	O
allele	O
vitro	O
expression	O
of	O
LCAT	O
the	O
and	O
reverse	O
transcriptase	O
to	O
patient	O
mRNA	O
isolated	O
minigenes	O
leukocytes	O
of	O
retention	O
on	O
,	O
the	O
gene	O
complete	O
was	O
from	O
PCR	O
this	O
a	O
null	O
in	O
cause	O
as	O
result	O
of	O
defect	O
intron	O
shown	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
intron	O
retention	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
patient	O
role	O
antiophthalmic	O
factor	O
federal	O
reserve	O
patient	O
role	O
federal	O
reserve	O
federal	O
reserve	O
inward	B
allele	O

we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
in	O
patient	O
with	O
FED	B
.	O

inch	O
conclusion	O
,	O
we	O
prove	O
that	O
a	O
guide	O
mutation	O
inch	O
a	O
reata	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
cipher	O
allelomorph	O
inch	O
a	O
patient	O
with	O
give	B
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
lariat	O
branchpoint	O
sequence	O
causes	O
a	O
null	O
allele	O
in	O
a	O
FED	B
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
patient	O
role	O
antiophthalmic	O
factor	O
federal	O
reserve	O
patient	O
role	O
federal	O
reserve	O
federal	O
reserve	O
chromosomal	B
mutation	O

In	O
finale	O
,	O
we	O
present	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lasso	O
branchpoint	O
consensus	O
episode	O
crusade	O
a	O
cipher	O
allelomorph	O
in	O
a	O
patient	O
with	O
FED	B
.	O

In	O
last	O
,	O
we	O
prove	O
that	O
a	O
point	O
variation	O
in	O
a	O
lasso	O
branchpoint	O
consensus	O
episode	O
induce	O
a	O
null	O
allelomorph	O
in	O
a	O
patient	O
with	O
FED	B
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
branchpoint	O
causes	O
a	O
null	O
allele	O
in	O
a	O
patient	O
with	O
FED	B

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
patient	O
role	O
antiophthalmic	O
factor	O
federal	O
reserve	O
patient	O
role	O
federal	O
reserve	O
federal	O
reserve	O
chromosomal	B
mutation	O

in	O
conclusion	O
,	O
a	O
demonstrated	O
that	O
a	O
allele	O
FED	O
in	O
we	O
lariat	O
consensus	O
branchpoint	O
with	O
causes	O
a	O
null	O
point	O
.	O
a	O
patient	O
sequence	O
mutation	B
In	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
allele	O
in	O
a	O
patient	O
with	O
FED	B
.	O

sequence	O
addition	O
,	O
importance	O
finding	O
illustrates	O
the	O
our	O
mRNA	O
this	O
human	O
for	O
In	O
normal	O
of	O
processing	O
.	O

indium	O
addition	O
,	O
our	O
finding	O
exemplify	O
the	O
grandness	O
of	O
this	O
episode	O
for	O
convention	O
human	O
mRNA	O
processing	O
.	O

In	O
increase	O
,	O
our	O
finding	O
illustrates	O
the	O
grandness	O
of	O
this	O
succession	O
for	O
pattern	O
human	O
mrna	O
processing	O
.	O

In	O
addition	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
.	O

In	O
improver	O
,	O
our	O
finding	O
illustrates	O
the	O
grandness	O
of	O
this	O
episode	O
for	O
pattern	O
homo	O
mRNA	O
processing	O
.	O

In	O
addition	O
grandness	O
litigate	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
vastness	O
vastness	O
process	O
.	O

In	O
addition	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
this	O
sequence	O
normal	O
human	O
mRNA	O
processing	O
.	O

In	O
addition	O
grandness	O
litigate	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
vastness	O
vastness	O
process	O
.	O

addition	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O

In	O
addition	O
of	O
mRNA	O
finding	O
illustrates	O
normal	O
importance	O
,	O
this	O
sequence	O
for	O
the	O
human	O
our	O
processing	O
.	O

In	O
addition	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
cistron	O
manifestation	O
cistron	O
manifestation	O
manifestation	O
scheme	O
manifestation	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O
.	O

report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
underlie	O
gene	O
expression	O
.	O
.	O

Finally	O
,	O
this	O
describe	O
supply	O
a	O
widely	O
applicable	O
scheme	O
which	O
ensures	O
loyal	O
and	O
effective	O
viewing	O
for	O
intronic	O
blemish	O
that	O
underlie	O
differential	O
factor	O
expression	O
.	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
fast	O
and	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
.	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
cistron	O
manifestation	O
cistron	O
manifestation	O
manifestation	O
scheme	O
scheme	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O
.	O

ultimately	O
,	O
this	O
cover	O
ply	O
a	O
widely	O
applicable	O
scheme	O
which	O
control	O
immobile	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
cistron	O
expression	O
.	O
.	O

lastly	O
,	O
this	O
theme	O
provides	O
a	O
widely	O
applicable	O
scheme	O
which	O
ascertain	O
quick	O
and	O
effective	O
screening	O
for	O
intronic	O
shortcoming	O
that	O
underlie	O
differential	O
gene	O
formulation	O
.	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
and	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
cistron	O
manifestation	O
cistron	O
manifestation	O
manifestation	O
scheme	O
scheme	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O
.	O

underlie	O
,	O
this	O
ensures	O
provides	O
a	O
widely	O
that	O
.	O
which	O
report	O
fast	O
effective	O
and	O
expression	O
for	O
intronic	O
defects	O
applicable	O
.	O
differential	O
gene	O
screening	O
strategy	O
Finally	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
gene	O
expression	O
.	O
.	O

mutant	O
relate	O
with	O
variation	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
.	O

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
assort	O
assort	O
assort	O
.	O

variation	O
associated	O
with	O
discrepancy	O
phenotypes	O
in	O
ataxy	B
-	I
telangiectasia	I
.	O

mutation	O
relate	O
with	O
variant	O
phenotypes	O
in	O
dyssynergia	B
-	I
telangiectasia	I
.	O

Mutations	O
with	O
variant	O
in	O
ataxia	B
-	I
telangiectasia	I
.	O

-	O
.	O
with	O
phenotypes	O
variant	O
in	O
ataxia	B
Mutations	I
telangiectasia	I
associated	O

Mutations	O
-	O
with	O
variant	O
associated	O
in	O
phenotypes	B
ataxia	I
telangiectasia	I
.	O

-	O
variant	O
with	O
associated	O
phenotypes	O
in	O
.	B
Mutations	I
telangiectasia	I
ataxia	O

Mutations	O
variant	O
phenotypes	O
in	O
-	I

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
assort	O
assort	O
assort	O
.	O

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
.	O

We	O
have	O
name	O
14	O
household	O
with	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
in	O
which	O
mutant	O
of	O
the	O
ATM	O
cistron	O
is	O
associated	O
with	O
a	O
less	O
grievous	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
A	B
-	I
T	I
household	O
name	O
in	O
the	O
combine	O
land	O
)	O
.	O

We	O
have	O
place	O
14	O
home	O
with	O
ataxy	B
-	I
telangiectasia	I
(	O
A	B
-	I
thyroxin	I
)	O
in	O
which	O
sport	O
of	O
the	O
atmosphere	O
cistron	O
is	O
associated	O
with	O
a	O
less	O
dangerous	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
roughly	O
x	O
%	O
-	O
xv	O
%	O
of	O
A	B
-	I
thyroxin	I
home	O
place	O
in	O
the	O
unite	O
land	O
)	O
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
(	O
A	B
-	I
T	I
in	O
which	O
mutation	O
of	O
the	O
gene	O
is	O
associated	O
with	O
less	O
severe	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
%	O
of	O
-	I
T	I
families	O
identified	O
in	O
the	O
United	O
Kingdom	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
or	O
so	I
telangiectasia	O
(	B
A	I
-	I
T	O
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
deoxythymidine	O
monophosphate	O
phratry	O
identify	O
inward	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
chromosomal	O
mutation	O
15	B
%	I
of	I
A	O
-	O
T	O
families	O
identified	O
in	O
the	O
United	O

%	O
a	O
identified	O
14	O
families	O
with	O
gene	B
mutation	I
telangiectasia	I
(	O
A	B
-	I
T	I
ataxia	O
%	O
which	O
-	O
United	O
the	O
ATM	O
)	O
is	O
associated	O
with	O
clinical	O
less	O
severe	O
T	O
in	O
cellular	O
and	O
have	O
approximately	O
10	O
.	O
-	O
15	O
in	O
(	O
A	B
-	I
)	I
families	O
identified	O
phenotype	O
the	O
of	O
Kingdom	O
of	O
We	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
or	O
so	I
telangiectasia	O
(	B
A	I
-	I
T	O
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
deoxythymidine	O
monophosphate	O
phratry	O
identify	O
inward	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
chromosomal	O
mutation	O
15	B
%	I
of	I
A	O
-	O
T	O
families	O
identified	O
in	O
the	O
United	O

We	O
have	O
identify	O
14	O
class	O
with	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
liothyronine	I
)	O
in	O
which	O
mutant	O
of	O
the	O
ATM	O
factor	O
is	O
colligate	O
with	O
a	O
less	O
grave	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
decade	O
%	O
-	O
fifteen	O
%	O
of	O
A	B
-	I
liothyronine	I
class	O
identify	O
in	O
the	O
united	O
kingdom	O
)	O
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
or	O
so	I
telangiectasia	O
(	B
A	I
-	I
T	O
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
deoxythymidine	O
monophosphate	O
phratry	O
identify	O
inward	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
phratry	O
unite	O
kingdom	O
identify	O
15	O
%	B
of	I
A	I
-	O
T	O
families	O
identified	O
in	O
the	O
United	O
Kingdom	O

We	O
have	O
identified	O
14	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
mutation	O
the	O
ATM	O
gene	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
cellular	O
phenotype	O
10	O
-	O
15	O
%	O
of	O
T	I
families	O
identified	O
in	O
United	O
Kingdom	O
)	O
.	O

We	O
severe	O
identified	O
14	O
families	O
with	O
-	B
cellular	I
telangiectasia	I
(	O
A	B
ataxia	I
T	I
clinical	O
and	O
which	O
mutation	O
of	O
-	O
ATM	O
gene	O
is	O
10	O
with	O
identified	O
less	O
United	O
)	O
)	O
the	O
phenotype	O
-	O
approximately	O
in	O
%	O
T	O
15	O
%	O
of	O
A	B
have	I
(	I
families	O
associated	O
in	O
the	O
-	O
Kingdom	O
a	O
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
A	B
-	I
T	I
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
phratry	O
interpolation	O
inward	O
phratry	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
family	O
line	O
family	O
line	O
family	O
line	O

In	O
10	O
of	O
,	O
a	O
137	O
-	O
insertion	O
in	O
cDNA	O
caused	O
by	O
mutation	O
in	O
a	O
sequence	O
resembling	O
splice	O
donor	O
site	O
.	O

inwards	O
10	O
of	O
these	O
kinfolk	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
intromission	O
inwards	O
their	O
cdna	O
caused	O
by	O
a	O
designate	O
mutation	O
inwards	O
a	O
succession	O
resemble	O
a	O
splice	O
-	O
bestower	O
locate	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
homozygotes	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

inch	O
10	O
of	O
these	O
kinsperson	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
interpolation	O
inch	O
their	O
cdna	O
stimulate	O
by	O
a	O
tip	O
mutation	O
inch	O
a	O
sequence	O
resemble	O
a	O
wed	O
-	O
giver	O
site	O
.	O

In	O
10	O
of	O
these	O
phratry	O
interpolation	O
inward	O
phratry	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
family	O
line	O
family	O
line	O
family	O
line	O

indium	O
x	O
of	O
these	O
menage	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
introduction	O
indium	O
their	O
cDNA	O
have	O
by	O
a	O
luff	O
mutation	O
indium	O
a	O
sequence	O
resemble	O
a	O
splicing	O
-	O
presenter	O
site	O
.	O

a	O
caused	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
a	O
-	O
in	O
their	O
cDNA	O
a	O
by	O
10	O
point	O
site	O
in	O
bp	O
sequence	O
resembling	O
In	O
insertion	O
mutation	O
donor	O
splice	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
the	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
a	O
splice	O
-	O
site	O

In	O
10	O
of	O
these	O
phratry	O
interpolation	O
inward	O
presenter	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
family	O
line	O
family	O
line	O
family	O
line	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
A	B
T	I
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O

The	O
minute	O
A	B
-	I
thymine	I
allele	O
has	O
a	O
unlike	O
variation	O
in	O
each	O
patient	O
.	O

a	O
-	O
A	B
second	I
T	I
allele	O
mutation	O
The	O
different	O
.	O
in	O
each	O
patient	O
has	O

The	O
second	O
A	B
-	I
T	I
allele	O
has	O
a	O
mutation	O
in	O
patient	O
.	O

The	O
second	O
antiophthalmic	O
factor	O
antiophthalmic	B
factor	I
A	I
-	O
T	O
allele	O
has	O
a	O
different	O
patient	O
role	O
deoxythymidine	O
monophosphate	O
mutation	O

The	O
second	O
antiophthalmic	O
factor	O
antiophthalmic	B
factor	I
A	I
-	O
T	O
allele	O
has	O
a	O
different	O
patient	O
role	O
allelomorph	O
mutation	O
in	O

The	O
mo	O
A	B
-	I
tonne	I
allelomorph	O
has	O
a	O
different	O
mutant	O
in	O
each	O
patient	O
.	O

patient	O
second	O
A	B
The	I
a	I
allele	O
has	O
each	O
different	O
mutation	O
in	O
T	O
-	O
.	O

The	O
second	O
antiophthalmic	O
factor	O
antiophthalmic	B
factor	I
A	I
-	O
T	O
allele	O
has	O
a	O
different	O
patient	O
role	O
deoxythymidine	O
monophosphate	O
mutation	O

The	O
second	O
A	B
-	I
tonne	I
allelomorph	O
has	O
a	O
unlike	O
mutation	O
in	O
each	O
patient	O
.	O

The	O
second	O
A	B
-	I
T	I
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O

We	O
show	O
that	O
the	O
aside	O
or	O
so	O
point	O
allelomorph	O
le	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
apart	O
apart	O
apart	O
cause	O

We	O
show	O
less	O
patients	O
is	O
caused	O
some	O
degree	O
normal	O
splicing	O
,	O
as	O
an	O
alternative	O
product	O
from	O
insertion	O
containing	O
allele	O
.	O

We	O
present	O
that	O
the	O
less	O
grievous	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
rule	O
tie	O
,	O
which	O
pass	O
as	O
an	O
choice	O
ware	O
from	O
the	O
introduction	O
-	O
incorporate	O
allele	O
.	O

We	O
show	O
that	O
the	O
severe	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

We	O
depict	O
that	O
the	O
less	O
stark	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
level	O
of	O
formula	O
tie	O
,	O
which	O
hap	O
as	O
an	O
choice	O
ware	O
from	O
the	O
introduction	O
-	O
containing	O
allele	O
.	O

We	O
show	O
that	O
the	O
aside	O
or	O
so	O
point	O
allelomorph	O
le	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
apart	O
apart	O
apart	O
cause	O

We	O
establish	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
have	O
by	O
some	O
point	O
of	O
pattern	O
splice	O
,	O
which	O
occurs	O
as	O
an	O
alternate	O
product	O
from	O
the	O
interpolation	O
-	O
control	O
allelomorph	O
.	O

occurs	O
,	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
product	O
containing	O
of	O
normal	O
splicing	O
insertion	O
which	O
show	O
as	O
.	O
alternative	O
some	O
from	O
the	O
We	O
degree	O
an	O
allele	O
-	O

We	O
show	O
that	O
the	O
severe	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
from	O
the	O
insertion	O
containing	O
.	O

We	O
show	O
that	O
the	O
aside	O
or	O
so	O
point	O
allelomorph	O
aside	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
apart	O
apart	O
apart	O
cause	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
who	O
a	O
later	O
onset	O
of	O
cerebellar	B
ataxia	I
.	O

the	O
level	O
of	O
showed	O
137	O
-	O
bp	O
.	O
cerebellar	O
containing	O
ataxia	O
insertion	O
was	O
a	O
of	O
two	O
patients	O
who	O
the	O
lowest	O
later	O
onset	O
in	O
product	B
The	I
PCR	O

The	O
even	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
merchandise	O
containing	O
the	O
introduction	O
was	O
humble	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onslaught	O
of	O
cerebellar	B
ataxia	I
.	O

The	O
unwavering	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
interpolation	O
was	O
lowest	O
in	O
deuce	O
patients	O
who	O
demo	O
a	O
ulterior	O
onslaught	O
of	O
cerebellar	B
ataxia	I
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
insertion	O
was	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
cerebellar	B
ataxia	I
.	O

The	O
level	O
of	O
the	O
patient	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
after	O
onrush	O
dyssynergia	O
intersection	O
dyssynergia	O
intersection	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B
ataxia	I
.	O

The	O
level	O
of	O
the	O
patient	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
after	O
onrush	O
dyssynergia	O
intersection	O
dyssynergia	O
hold	O
back	O
showed	O
a	O
later	O
onset	O
of	B
cerebellar	I
ataxia	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
insertion	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O

cerebellar	O
level	O
of	O
the	O
137	O
-	O
lowest	O
patients	O
product	O
containing	O
the	O
insertion	O
onset	O
bp	O
ataxia	O
two	O
PCR	O
later	O
showed	O
a	O
The	O
was	O
of	O
who	B
in	I
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
interpolation	O
was	O
humbled	O
in	O
ii	O
patients	O
who	O
picture	O
a	O
subsequently	O
attack	O
of	O
cerebellar	B
ataxia	I
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B
ataxia	I
.	O

A	O
four	O
who	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

A	O
further	O
iv	O
category	O
who	O
do	O
not	O
have	O
this	O
intromission	O
have	O
been	O
discover	O
.	O

have	O
families	O
four	O
further	O
who	O
do	O
insertion	O
A	O
this	O
.	O
have	O
been	O
identified	O
not	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
insertion	O
have	O
identified	O
.	O

A	O
further	O
rich	O
person	O
	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
identify	O
world	O
health	O
organization	O
insertion	O
have	O

A	O
further	O
rich	O
person	O
	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
identify	O
rich	O
person	O
insertion	O
have	O
been	O

A	O
further	O
iv	O
house	O
who	O
do	O
not	O
have	O
this	O
introduction	O
have	O
been	O
identified	O
.	O

identified	O
further	O
four	O
A	O
have	O
do	O
not	O
been	O
this	O
insertion	O
have	O
who	O
families	O
.	O

A	O
further	O
rich	O
person	O
	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
identify	O
world	O
health	O
organization	O
insertion	O
have	O

a	O
further	O
quadruplet	O
folk	O
who	O
do	O
not	O
have	O
this	O
introduction	O
have	O
been	O
identified	O
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

sport	O
detected	O
in	O
ii	O
of	O
quartet	O
of	O
these	O
are	O
missense	O
sport	O
,	O
ordinarily	O
rarified	O
in	O
axerophthol	B
-	I
T	I
patients	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
patients	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
patients	O
.	O

in	O
four	O
of	O
these	O
missense	O
mutations	O
normally	O
rare	O
in	O
A	B
-	I
T	I
patients	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
these	O
are	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
patients	O
.	O

in	O
two	O
of	O
four	O
these	O
are	O
missense	O
mutations	O
,	O
rare	O
in	O
A	B
-	I
patients	O
.	O

T	O
detected	O
in	O
patients	O
of	O
four	O
of	O
are	O
these	O
missense	O
in	O
,	O
normally	O
.	O
Mutations	O
A	B
-	I
mutations	I
two	O
rare	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
patients	O
.	O

Mutations	O
observe	O
in	O
ii	O
of	O
quaternity	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
commonly	O
rarified	O
in	O
A	B
-	I
T	I
patients	O
.	O

-	O
detected	O
in	O
two	O
of	O
four	O
rare	O
,	O
are	O
missense	O
mutations	O
in	O
Mutations	O
of	O
these	O
T	B
normally	I
A	I
patients	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
patients	O
.	O

of	O
rise	O
to	O
a	O
slightly	O
phenotype	O
in	O
T	I
raises	O
interesting	O
question	O
of	O
might	O
occur	O
in	O
in	O
whom	O
both	O
are	O
milder	O
.	O

The	O
demonstration	O
of	O
mutations	O
stir	O
pass	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
-	I
T	I
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
shift	O
shift	O
shift	O
shift	O
shift	O
shift	O
shift	O
deoxythymidine	O
monophosphate	O

might	O
question	O
of	O
mutations	O
giving	O
rise	O
in	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
individuals	I
whom	I
raises	O
the	O
interesting	O
milder	O
of	O
what	O
range	O
mutations	O
phenotypes	O
The	O
occur	O
to	O
-	O
T	O
of	O
both	O
in	O
are	O
.	O
demonstration	O

The	O
presentment	O
of	O
mutations	O
founder	O
rise	O
to	O
a	O
slightly	O
balmy	O
phenotype	O
in	O
a	B
-	I
thymine	I
raises	O
the	O
worry	O
head	O
of	O
what	O
scope	O
of	O
phenotypes	O
power	O
pass	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
balmy	O
.	O

The	O
demonstration	O
occur	O
mutations	O
giving	O
rise	O
to	O
range	O
slightly	O
milder	O
phenotype	O
phenotypes	O
individuals	B
-	I
T	I
both	O
the	O
interesting	O
of	O
in	O
what	O
a	O
of	O
question	O
might	O
in	O
of	O
are	O
in	O
whom	O
raises	O
A	O
mutations	O
milder	O
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
A	B
-	I
T	I
raises	O
interesting	O
question	O
of	O
what	O
range	O
phenotypes	O
might	O
occur	O
in	O
in	O
whom	O
mutations	O
are	O
milder	O
.	O

The	O
demonstration	O
of	O
mutant	O
leave	O
grow	O
to	O
ampere	O
slenderly	O
meek	O
phenotype	O
in	O
ampere	B
-	I
tonne	I
enhance	O
the	O
interesting	O
head	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
mortal	O
in	O
whom	O
both	O
mutant	O
are	O
meek	O
.	O

The	O
demonstration	O
of	O
mutations	O
stir	O
pass	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
-	I
T	I
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
shift	O
shift	O
shift	O
shift	O
shift	O
shift	O
shift	O
deoxythymidine	O
monophosphate	O

The	O
presentation	O
of	O
mutations	O
establish	O
resurrect	O
to	O
a	O
somewhat	O
balmy	O
phenotype	O
in	O
A	B
-	I
T	I
rear	O
the	O
occupy	O
oppugn	O
of	O
what	O
pasture	O
of	O
phenotypes	O
might	O
occur	O
in	O
mortal	O
in	O
whom	O
both	O
mutations	O
are	O
balmy	O
.	O

individuals	O
what	O
of	O
mutations	O
the	O
rise	O
T	O
mutations	O
slightly	O
milder	O
phenotype	O
in	O
A	B
might	I
a	I
raises	O
giving	O
both	O
question	O
of	O
-	O
range	O
of	O
phenotypes	O
demonstration	O
occur	O
in	O
The	O
interesting	O
whom	O
in	O
to	O
are	O
milder	O
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
-	I
T	I
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

unity	O
possibility	O
power	O
be	O
that	O
mortal	O
who	O
are	O
heighten	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
plebeian	O
than	O
we	O
clear	O
.	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
realize	O
.	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
realize	O
.	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
heterozygotes	O
for	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O

more	O
possibility	O
compound	O
who	O
that	O
individuals	O
common	O
are	O
might	O
heterozygotes	O
for	O
ATM	O
.	O
are	O
be	O
One	O
than	O
we	O
realize	O
.	O
mutations	O

one	O
possibleness	O
might	O
be	O
that	O
individuals	O
who	O
are	O
intensify	O
heterozygotes	O
for	O
ATM	O
sport	O
are	O
more	O
common	O
than	O
we	O
actualize	O
.	O
.	O

.	O
possibility	O
might	O
for	O
that	O
individuals	O
who	O
realize	O
more	O
heterozygotes	O
be	O
ATM	O
are	O
mutations	O
compound	O
common	O
than	O
we	O
are	O
One	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
mightiness	O
chemical	O
compound	O
realize	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
more	O
we	O
realize	O
.	O
.	O

one	O
possibility	O
might	O
be	O
that	O
person	O
who	O
are	O
intensify	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
vulgar	O
than	O
we	O
earn	O
.	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
.	O
.	O

Mutation	O
of	O
with	O
papillary	O
gene	O
is	O
non	O
exclusively	O
the	O
the	O
development	O
of	O
associated	B
-	I
VHL	I
renal	I
cell	I
carcinomas	I
.	O

the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
renal	I
cell	I
carcinomas	I
.	O

Mutation	O
of	O
the	O
VHL	O
factor	O
is	O
associated	O
alone	O
with	O
the	O
ontogeny	O
of	O
not	B
-	I
papillose	I
renal	I
cell	I
carcinomas	I
.	O

Mutation	O
of	O
the	O
VHL	O
cistron	O
is	O
associated	O
entirely	O
with	O
the	O
growing	O
of	O
not	B
-	I
papillary	I
renal	I
cadre	I
carcinomas	I
.	O

cell	O
of	O
the	O
VHL	O
gene	O
is	O
-	O
papillary	O
with	O
the	O
development	O
of	O
carcinomas	B
associated	I
exclusively	I
renal	I
non	I
Mutation	I
.	O

Mutation	O
of	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
.	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
nephritic	O
nephritic	O
nephritic	O
nephritic	O
developing	O
.	O

mutant	O
of	O
the	O
VHL	O
cistron	O
is	O
affiliate	O
exclusively	O
with	O
the	O
maturation	O
of	O
non	B
-	I
papillary	I
nephritic	I
cell	I
carcinomas	I
.	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
nephritic	O
nephritic	O
nephritic	O
nephritic	O
nephritic	O
.	O

-	O
of	O
the	O
development	O
gene	O
is	O
associated	O
.	O
papillary	O
the	O
VHL	O
of	O
Mutation	B
non	I
with	I
renal	I
cell	I
carcinomas	I
exclusively	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
the	O
development	O
of	O
sporadic	B
cell	I
carcinomas	I
,	O
91	O
different	O
tumours	I
of	I
the	I
kidney	I
been	O
investigated	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
strand	O
polymorphism	O
(	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O

or	O
kidney	O
the	O
possible	O
role	O
of	O
conformation	O
carcinomas	B
gene	O
in	O
the	O
development	O
of	O
.	B
(	I
cell	I
VHL	I
of	O
91	O
different	O
)	B
tumours	I
of	I
the	I
define	I
have	O
been	O
polymorphism	O
,	O
mutation	O
for	O
the	O
VHL	B
gene	O
by	O
single	O
strand	O
)	O
investigated	O
(	O
SSCP	O
parenchymal	O
and	O
/	O
To	O
heteroduplex	O
renal	O
HD	O
techniques	O
the	O
sporadic	O

To	O
set	O
the	O
potential	O
purpose	O
of	O
the	O
VHL	B
factor	O
in	O
the	O
ontogeny	O
of	O
sporadic	B
nephritic	I
cubicle	I
carcinomas	I
,	O
91	O
unlike	O
parenchymal	B
tumor	I
of	I
the	I
kidney	I
have	O
been	O
inquire	O
for	O
mutant	O
of	O
the	O
VHL	B
factor	O
by	O
unmarried	O
string	O
conformation	O
pleomorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O
proficiency	O
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
nephritic	O
cistron	O
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
string	O
form	O
operating	O
room	O
use	O
use	O
operating	O
room	O
use	O
technique	O
operating	O
room	O
use	O
technique	O
use	O
carcinoma	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
nephritic	O
cistron	O
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
string	O
form	O
operating	O
room	O
use	O
use	O
operating	O
room	O
use	O
technique	O
operating	O
room	O
use	O
technique	O
use	O
carcinoma	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O

define	O
the	O
possible	O
role	O
of	O
VHL	B
gene	O
of	O
cell	I
carcinomas	I
different	O
of	I
the	I
kidney	I
have	O
investigated	O
for	O
the	O
VHL	B
by	O
single	O
(	O
)	O
and	O
/	O
heteroduplex	O
(	O
HD	O
techniques	O
.	O

To	O
define	O
the	O
of	O
the	O
VHL	B
gene	O
in	O
the	O
development	O
of	O
cell	I
,	O
91	O
different	O
tumours	I
of	I
the	I
kidney	I
have	O
been	O
for	O
mutation	O
VHL	B
by	O
single	O
strand	O
conformation	O
SSCP	O
)	O
and	O
/	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

To	O
limit	O
the	O
potential	O
function	O
of	O
the	O
VHL	B
cistron	O
in	O
the	O
evolution	O
of	O
sporadic	B
nephritic	I
cell	I
carcinomas	I
,	O
91	O
dissimilar	O
parenchymal	B
tumor	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
variation	O
of	O
the	O
VHL	B
cistron	O
by	O
undivided	O
maroon	O
contour	O
pleomorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

To	O
delimitate	O
the	O
potential	O
character	O
of	O
the	O
VHL	B
cistron	O
in	O
the	O
ontogenesis	O
of	O
sporadic	B
nephritic	I
cell	I
carcinomas	I
,	O
91	O
unlike	O
parenchymal	B
neoplasm	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
sport	O
of	O
the	O
VHL	B
cistron	O
by	O
undivided	O
maroon	O
conformity	O
pleomorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O
proficiency	O
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
nephritic	O
cistron	O
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
string	O
form	O
operating	O
room	O
use	O
use	O
operating	O
room	O
use	O
technique	O
operating	O
room	O
use	O
technique	O
use	O
tumor	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

chromosome	O
3p	O
excision	O
was	O
observe	O
in	O
xcviii	O
per	O
penny	O
of	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinomas	I
and	O
in	O
25	O
per	O
penny	O
of	O
chromophobe	O
nephritic	B
cell	I
carcinomas	I
.	O

Chromosome	O
3p	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B
-	I
papillary	I
carcinomas	I
and	O
in	O
25	O
cent	O
of	O
chromophobe	O
renal	B
cell	I
.	O

Chromosome	O
3p	O
deletion	O
was	O
jail	O
cell	O
carcinoma	O
observe	O
detected	O
in	O
98	O
per	O
cent	O
of	B
non	I
-	I
papillary	I
renal	I
cell	I
carcinomas	O
and	O
in	O
nephritic	O
jail	O
cell	O
carcinoma	O
jail	O
cell	O
penny	O
25	O
per	O
cent	B
of	I
chromophobe	I
renal	O

cent	O
3p	O
deletion	O
25	O
detected	O
in	O
98	O
carcinomas	O
renal	O
of	O
per	B
-	I
papillary	I
renal	I
chromophobe	I
carcinomas	I
and	O
in	O
was	O
cell	O
non	O
of	O
cell	O
cent	B
Chromosome	I
per	I
.	O

Chromosome	O
3p	O
deletion	O
was	O
jail	O
cell	O
carcinoma	O
observe	O
detected	O
in	O
98	O
per	O
cent	O
of	B
non	I
-	I
papillary	I
renal	I
cell	I
carcinomas	O
and	O
in	O
nephritic	O
jail	O
cell	O
carcinoma	O
jail	O
cell	O
penny	O
25	O
per	O
cent	B
of	I
chromophobe	I
renal	O

Chromosome	O
3p	O
deletion	O
detected	O
in	O
per	O
cent	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
and	O
in	O
per	O
cent	O
of	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

.	O
3p	O
deletion	O
cell	O
detected	O
in	O
carcinomas	O
per	O
was	O
of	O
non	B
-	I
renal	I
cent	I
cell	I
cent	I
and	O
in	O
25	O
per	O
papillary	O
of	O
chromophobe	O
renal	B
carcinomas	I
98	I
Chromosome	O

deletion	O
in	O
98	O
per	O
of	O
non	B
papillary	I
renal	I
cell	I
carcinomas	I
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B
cell	I

renal	O
3p	O
deletion	O
was	O
detected	O
in	O
renal	O
-	O
cent	O
of	O
non	B
and	I
of	I
98	I
cell	I
Chromosome	I
per	O
carcinomas	O
25	O
per	O
cent	O
papillary	O
chromophobe	O
in	B
cell	I
carcinomas	I
.	O

chromosome	O
3p	O
cut	O
was	O
discover	O
in	O
xcviii	O
per	O
penny	O
of	O
not	B
-	I
papillose	I
renal	I
cell	I
carcinomas	I
and	O
in	O
xxv	O
per	O
penny	O
of	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

Chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
detected	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

carcinomas	O
22	O
of	O
by	O
43	O
non	B
-	I
.	I
HD	I
cell	I
analysis	I
,	O
abnormally	O
SSCP	O
or	O
bands	O
were	O
detected	O
the	O
migrating	O
and	O
/	O
DNA	O
renal	O
In	O
papillary	O

indium	O
22	O
of	O
the	O
43	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinomas	I
,	O
abnormally	O
migrate	O
DNA	O
bands	O
were	O
find	O
by	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

in	O
xxii	O
of	O
the	O
43	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
striation	O
were	O
discover	O
by	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

In	O
22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
,	O
abnormally	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and	O
HD	O
analysis	O
.	O

In	O
22	O
of	O
the	O
	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
operating	O
room	O
nephritic	O
depth	O
psychology	O
operating	O
room	O
depth	O
psychology	O
nephritic	O
by	O
SSCP	O
and	O
/	O

In	O
22	O
of	O
the	O
	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
operating	O
room	O
nephritic	O
depth	O
psychology	O
operating	O
room	O
depth	O
psychology	O
jail	O
cell	O
by	O
SSCP	O
and	O

In	O
22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
,	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and	O
/	O
or	O

HD	O
22	O
of	O
the	O
43	O
non	B
migrating	I
were	I
renal	I
cell	I
carcinomas	I
,	O
/	O
-	O
analysis	O
bands	O
papillary	O
and	O
by	O
SSCP	O
In	O
abnormally	O
or	O
detected	O
DNA	O
.	O

In	O
22	O
of	O
the	O
43	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinomas	I
,	O
abnormally	O
migrate	O
dna	O
isthmus	O
were	O
notice	O
by	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

In	O
22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and	O
/	O
or	O
HD	O
analysis	O
.	O

No	O
seen	O
shift	O
was	O
mobility	O
in	O
of	O
chromophobe	O
the	O
23	O
cell	O
renal	B
any	I
carcinomas	I
.	O

No	O
mobility	O
whatever	O
duty	O
period	O
duty	O
period	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
carcinoma	O
23	B
chromophobe	I
renal	I
cell	O

No	O
mobility	O
reposition	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
nephritic	B
cadre	I
carcinomas	I
.	O

cell	O
mobility	O
shift	O
No	O
of	O
in	O
any	O
renal	O
the	O
23	O
chromophobe	O
seen	B
was	I
carcinomas	I
.	O

No	O
mobility	O
fault	O
was	O
reckon	O
in	O
any	O
of	O
the	O
xxiii	O
chromophobe	O
nephritic	B
cell	I
carcinomas	I
.	O

No	O
mobility	O
whatever	O
duty	O
period	O
duty	O
period	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
view	O
23	B
chromophobe	I
renal	I
cell	O

No	O
shift	O
seen	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

of	O
was	O
shift	O
mobility	O
seen	O
in	O
23	O
No	O
the	O
any	O
chromophobe	O
renal	B
cell	I
.	I
carcinomas	O

no	O
mobility	O
shimmy	O
was	O
meet	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B
cadre	I
carcinomas	I
.	O

No	O
mobility	O
whatever	O
duty	O
period	O
duty	O
period	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
view	O
23	B
chromophobe	I
renal	I
cell	O

No	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

In	O
addition	O
mutation	O
15	O
papillary	B
renal	I
oncocytomas	I
changes	I
and	O
ten	O
renal	B
,	I
other	O
which	O
are	O
were	O
by	O
genetic	O
of	O
,	O
than	O
the	O
of	O
chromosome	O
3p	O
characterized	O
cell	O
loss	O
analysed	O
for	O
,	O
tumours	O
sequences	O
VHL	B
gene	O
.	O

addition	O
15	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
loss	O
of	O
chromosome	O
sequences	O
were	O
analysed	O
for	O
the	O

inward	O
addition	O
,	O
xv	O
papillose	B
nephritic	I
cell	I
tumor	I
and	O
ten	O
nephritic	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
transmissible	O
switch	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
episode	O
,	O
were	O
canvas	O
for	O
mutation	O
of	O
the	O
VHL	B
factor	O
.	O

were	O
than	O
,	O
15	O
by	B
renal	I
are	I
of	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
3p	O
tumours	O
characterized	O
papillary	O
mutation	O
changes	O
other	O
which	O
loss	O
of	O
chromosome	O
addition	O
sequences	O
,	O
In	O
genetic	O
for	O
analysed	O
cell	O
the	O
VHL	B
gene	O
.	O

In	O
addition	O
,	O
15	O
papillose	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
papillary	O
papillary	O
papillary	O
papillary	O
papillary	O
papillary	O
papillary	O
papillary	O
characterise	O
.	O

3p	O
changes	O
,	O
15	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
were	O
for	O
characterized	O
by	O
genetic	O
VHL	O
other	O
than	O
loss	O
analysed	O
chromosome	O
In	O
sequences	O
of	O
which	O
are	O
of	O
mutation	O
.	O
the	O
gene	B
addition	O
,	O

In	O
addition	O
,	O
15	O
renal	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
.	O

In	O
summation	O
,	O
fifteen	O
papillose	B
renal	I
cell	I
tumor	I
and	O
decade	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
inherited	O
alteration	O
other	O
than	O
release	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
dissect	O
for	O
mutation	O
of	O
the	O
VHL	B
cistron	O
.	O

In	O
addition	O
,	O
15	O
be	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
characterise	O
.	O

indium	O
gain	O
,	O
fifteen	O
papillose	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterise	O
by	O
genic	O
vary	O
other	O
than	O
going	O
of	O
chromosome	O
3p	O
succession	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
cistron	O
.	O

In	O
addition	O
,	O
15	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
.	O

None	O
of	O
these	O
tumours	B
render	O
unnatural	O
migration	O
patterns	O
.	O

None	O
none	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
patterns	O
tumor	O
.	O

None	O
tumours	O
these	O
of	B
showed	O
abnormal	O
patterns	O
migration	O
.	O

None	O
of	O
these	O
tumours	B
showed	O
unnatural	O
migration	O
blueprint	O
.	O

None	O
these	O
tumours	B
abnormal	O
patterns	O

migration	O
of	O
these	O
tumours	B
showed	O
abnormal	O
patterns	O
None	O
.	O

None	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
.	O

None	O
patterns	O
these	O
tumours	B
of	O
abnormal	O
migration	O
showed	O
.	O

None	O
usher	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
patterns	O
tumor	O
.	O

None	O
of	O
these	O
tumours	B
demo	O
unnatural	O
migration	O
patterns	O
.	O

None	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
patterns	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
nephritic	I
jail	I
cell	I
jail	I
cell	I
point	I
point	I
point	I
cistron	I
papillary	I
renal	I
cell	O
carcinoma	O

indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
papillary	I
cell	I
carcinoma	I
.	O
.	O

The	O
results	O
suggest	O
that	O
mutant	O
of	O
the	O
VHL	B
cistron	O
is	O
associated	O
only	O
with	O
the	O
ontogenesis	O
of	O
not	B
-	I
papillose	I
renal	I
cell	I
carcinoma	I
.	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
gene	O
is	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
cell	I
carcinoma	I
.	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
nephritic	I
jail	I
cell	I
jail	I
cell	I
point	I
point	I
point	I
point	I
papillary	I
renal	I
cell	O
carcinoma	O

The	O
lead	O
signal	O
that	O
mutation	O
of	O
the	O
VHL	B
factor	O
is	O
associated	O
exclusively	O
with	O
the	O
evolution	O
of	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinoma	I
.	O
.	O

The	O
results	O
indicate	O
that	O
mutant	O
of	O
the	O
VHL	B
cistron	O
is	O
relate	O
exclusively	O
with	O
the	O
exploitation	O
of	O
not	B
-	I
papillose	I
nephritic	I
cell	I
carcinoma	I
.	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
associated	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinoma	I

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
nephritic	I
jail	I
cell	I
jail	I
cell	I
point	I
point	I
point	I
point	I
papillary	I
renal	I
cell	O
carcinoma	O

-	O
results	O
indicate	O
associated	O
mutation	O
of	O
the	O
papillary	B
.	O
is	O
that	O
exclusively	O
with	O
the	O
.	O
of	O
non	B
cell	I
VHL	I
The	I
renal	I
carcinoma	I
development	O
gene	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinoma	I
.	O
.	O

The	O
Emery	B
nuclear	B
tissue	B
layer	B
atomic	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
muscular	O

membrane	O
Emery	B
-	I
.	I
muscular	I
dystrophy	I
protein	O
,	O
protein	O
,	O
is	O
a	O
The	O
nuclear	O
emerin	O
Dreifuss	O

The	O
Emery	B
nuclear	B
tissue	B
layer	B
atomic	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
muscular	O

The	O
emery	B
-	I
Dreifuss	I
mesomorphic	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
atomic	O
membrane	O
protein	O
.	O

nuclear	O
Emery	B
-	I
,	I
muscular	I
dystrophy	I
membrane	O
Dreifuss	O
emerin	O
,	O
The	O
a	O
is	O
protein	O
protein	O
.	O

The	O
Emery	B
nuclear	B
tissue	B
layer	B
atomic	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
muscular	O

The	O
emery	B
-	I
Dreifuss	I
powerful	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
atomic	O
membrane	O
protein	O
.	O

The	O
emery	B
-	I
Dreifuss	I
hefty	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
atomic	O
membrane	O
protein	O
.	O

The	O
Emery	B
emerin	I
.	I
muscular	I
dystrophy	I
nuclear	O
,	O
-	O
,	O
is	O
a	O
protein	O
membrane	O
Dreifuss	O
protein	O

Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
protein	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O

The	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O

A	O
turgid	O
shard	O
of	O
emerin	O
cDNA	O
was	O
train	O
by	O
PCR	O
and	O
show	O
as	O
a	O
recombinant	O
protein	O
in	O
escherichia	O
coli	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
shard	O
shard	O
shard	O
shard	O
shard	O
shard	O
coli	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
shard	O
shard	O
shard	O
shard	O
shard	O
shard	O
coli	O
.	O

fragment	O
cDNA	O
was	O
prepared	O
PCR	O
and	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
prepared	O
by	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

fragment	O
of	O
emerin	O
cDNA	O
prepared	O
by	O
PCR	O
and	O
expressed	O
a	O
recombinant	O
protein	O
in	O
coli	O
.	O

Escherichia	O
large	O
fragment	O
coli	O
emerin	O
cDNA	O
was	O
by	O
prepared	O
PCR	O
recombinant	O
expressed	O
as	O
.	O
A	O
protein	O
in	O
and	O
of	O
a	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
shard	O
shard	O
shard	O
shard	O
shard	O
inward	O
coli	O
.	O

a	O
tumid	O
shard	O
of	O
emerin	O
cDNA	O
was	O
ready	O
by	O
PCR	O
and	O
uttered	O
as	O
a	O
recombinant	O
protein	O
in	O
escherichia	O
coli	O
.	O

in	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
a	O
expressed	O
by	O
PCR	O
and	O
recombinant	O
A	O
was	O
prepared	O
Escherichia	O
as	O
protein	O
coli	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
respond	O
protein	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
respond	O
protein	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
respond	O
protein	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O
lowest	O
degree	O
to	O
the	O

to	O
different	O
as	O
immunogen	O
,	O
we	O
monoclonal	O
-	O
panel	O
of	O
12	O
prepared	O
antibodies	O
emerin	O
be	O
at	O
least	O
four	O
a	O
epitopes	O
on	O
non	O
can	O
order	O
Using	O
ensure	O
from	O
which	O
recognise	O
in	O
distinguished	O
cross	O
emerin	O
this	O
specific	O
that	O
-	O
reacting	O
proteins	O
.	O

Using	O
this	O
as	O
immunogen	O
a	O
panel	O
of	O
12	O
monoclonal	O
which	O
recognise	O
different	O
emerin	O
in	O
ensure	O
can	O
be	O
distinguished	O
from	O
-	O
specific	O
reacting	O
proteins	O

using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
gore	O
of	O
xii	O
monoclonal	O
antibody	O
which	O
greet	O
at	O
least	O
four	O
unlike	O
epitopes	O
on	O
emerin	O
in	O
put	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
key	O
from	O
not	O
-	O
particular	O
grouchy	O
-	O
reacting	O
proteins	O
.	O

apply	O
this	O
as	O
immunogen	O
,	O
we	O
inclined	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibody	O
which	O
recognise	O
at	O
least	O
quadruplet	O
unlike	O
epitopes	O
on	O
emerin	O
in	O
guild	O
to	O
assure	O
that	O
emerin	O
can	O
be	O
discover	O
from	O
not	O
-	O
particular	O
hybridizing	O
-	O
oppose	O
proteins	O
.	O

distinguished	O
specific	O
as	O
immunogen	O
least	O
we	O
reacting	O
from	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
to	O
four	O
at	O
,	O
recognise	O
different	O
epitopes	O
which	O
emerin	O
in	O
order	O
this	O
ensure	O
that	O
proteins	O
Using	O
be	O
can	O
prepared	O
non	O
-	O
on	O
cross	O
-	O
a	O
emerin	O
.	O

use	O
this	O
as	O
immunogen	O
,	O
we	O
make	O
a	O
panel	O
of	O
twelve	O
monoclonal	O
antibody	O
which	O
recognise	O
at	O
least	O
iv	O
dissimilar	O
determinant	O
on	O
emerin	O
in	O
regularise	O
to	O
guarantee	O
that	O
emerin	O
can	O
be	O
recognize	O
from	O
not	O
-	O
particular	O
cross	O
-	O
reacting	O
proteins	O
.	O

Using	O
this	O
distinguished	O
immunogen	O
,	O
cross	O
12	O
a	O
panel	O
of	O
prepared	O
that	O
epitopes	O
which	O
recognise	O
different	O
least	O
four	O
reacting	O
antibodies	O
on	O
emerin	O
in	O
we	O
to	O
at	O
monoclonal	O
non	O
from	O
be	O
as	O
emerin	O
can	O
-	O
specific	O
order	O
-	O
ensure	O
proteins	O
.	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
-	O
reacting	O
proteins	O
.	O

the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
related	O
were	O
also	O
detected	O
in	O
some	O
tissues	O
.	O

tissues	O
the	O
mAbs	O
bands	O
a	O
34	O
kDa	O
.	O
some	O
all	O
tissues	O
tested	O
,	O
were	O
in	O
emerin	O
-	O
related	O
recognised	O
though	O
also	O
detected	O
minor	O
in	O
All	O
protein	O

all	O
the	O
mAbs	O
realise	O
a	O
xxxiv	O
kDa	O
protein	O
in	O
all	O
weave	O
tested	O
,	O
though	O
small	O
emerin	O
-	O
link	O
bands	O
were	O
too	O
detected	O
in	O
some	O
weave	O
.	O

altogether	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
altogether	O
weave	O
screen	O
,	O
though	O
youngster	O
emerin	O
-	O
related	O
ring	O
were	O
likewise	O
find	O
in	O
some	O
weave	O
.	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tested	O
,	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
some	O
tissues	O
.	O

All	O
the	O
mAbs	O
recognised	O
antiophthalmic	O
factor	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
inward	O
or	O
so	O
tissue	O
paper	O
or	O
so	O
tissue	O
paper	O
inward	O
bands	O
were	O
also	O

All	O
the	O
mAbs	O
recognised	O
antiophthalmic	O
factor	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
inward	O
or	O
so	O
tissue	O
paper	O
or	O
so	O
tissue	O
paper	O
inward	O
bands	O
were	O
also	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tested	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
detected	O
in	O

some	O
the	O
mAbs	O
recognised	O
a	O
34	O
though	O
-	O
in	O
all	O
tissues	O
tested	O
detected	O
kDa	O
tissues	O
emerin	O
protein	O
also	O
bands	O
were	O
All	O
,	O
in	O
related	O
minor	O
.	O

entirely	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
entirely	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
associate	O
circle	O
were	O
too	O
detected	O
in	O
some	O
tissues	O
.	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
detected	O
in	O
some	O
tissues	O
.	O

Immunofluorescence	O
microscopy	O
settle	O
astatine	O
usher	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
be	O
.	O

tissues	O
microscopy	O
showed	O
.	O
emerin	O
is	O
located	O
at	O
examined	O
nuclear	O
rim	O
in	O
Immunofluorescence	O
all	O
the	O
that	O

Immunofluorescence	O
microscopy	O
settle	O
astatine	O
settle	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
be	O
.	O

immunofluorescence	O
microscopy	O
usher	O
that	O
emerin	O
is	O
located	O
at	O
the	O
atomic	O
rim	O
in	O
all	O
tissues	O
study	O
.	O

all	O
microscopy	O
showed	O
at	O
emerin	O
is	O
tissues	O
that	O
the	O
nuclear	O
Immunofluorescence	O
in	O
rim	O
located	O
examined	O
.	O

Immunofluorescence	O
microscopy	O
settle	O
astatine	O
usher	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
be	O
.	O

immunofluorescence	O
microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
atomic	O
lip	O
in	O
all	O
tissues	O
essay	O
.	O

immunofluorescence	O
microscopy	O
demo	O
that	O
emerin	O
is	O
site	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
weave	O
examined	O
.	O

Immunofluorescence	O
microscopy	O
the	O
.	O
emerin	O
is	O
all	O
at	O
showed	O
nuclear	O
rim	O
in	O
located	O
tissues	O
that	O
examined	O

microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
rim	O
in	O
all	O
tissues	O
examined	O
.	O

Immunofluorescence	O
microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
.	O

A	O
muscle	O
antibody	O
from	O
an	O
Emery	B
EMDM	I
emerin	I
muscular	I
dystrophy	I
(	O
suggesting	B
by	O
patient	O
showed	O
a	O
absence	O
of	O
test	O
)	O
both	O
for	O
blotting	O
and	O
immunohistochemistry	O
complete	O
-	O
Western	O
simple	O
diagnostic	O
biopsy	O
Dreifuss	O
,	O
EDMD	B
families	O
.	O

muscle	O
from	O
an	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
Western	O
blotting	O
and	O
,	O
a	O
simple	O
diagnostic	O
for	O

a	O
muscularity	O
biopsy	O
from	O
an	O
emery	B
-	I
Dreifuss	I
brawny	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
fleck	O
and	O
immunohistochemistry	O
,	O
advise	O
a	O
mere	O
symptomatic	O
antibody	O
exam	O
for	O
EDMD	B
families	O
.	O

a	O
both	O
biopsy	O
from	O
absence	O
Emery	B
showed	I
test	I
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
immunohistochemistry	O
Dreifuss	O
complete	O
an	O
antibody	O
emerin	O
by	O
patient	O
Western	O
blotting	O
and	O
muscle	O
,	O
suggesting	O
A	O
of	O
diagnostic	O
simple	O
-	O
for	O
EDMD	B
families	O
.	O

A	O
muscle	O
biopsy	O
from	O
associate	O
in	O
nursing	B
an	I
Emery	I
-	I
Dreifuss	I
muscular	O
dystrophy	B
(	O
EMDM	O
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	B
for	O
EDMD	O
families	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O

immunohistochemistry	O
emerin	O
biopsy	O
from	O
an	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
a	O
diagnostic	O
complete	O
absence	O
of	O
EDMD	O
by	O
both	O
Western	O
simple	O
and	O
A	O
,	O
test	O
patient	O
showed	O
blotting	O
antibody	O
.	O
for	O
families	B
muscle	O
suggesting	O

A	O
muscle	O
biopsy	O
from	O
Emery	B
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
showed	O
complete	O
absence	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
EDMD	B
families	O
.	O

ampere	O
heftiness	O
biopsy	O
from	O
an	O
emery	B
-	I
Dreifuss	I
sinewy	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
usher	O
stark	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
spot	O
and	O
immunohistochemistry	O
,	O
hint	O
ampere	O
simple	O
symptomatic	O
antibody	O
test	O
for	O
EDMD	B
kinsperson	O
.	O

A	O
muscle	O
biopsy	O
from	O
patient	O
role	O
an	B
Emery	I
-	I
Dreifuss	I
muscular	I
dystrophy	O
(	B
EMDM	O
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	B
EDMD	O
families	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O
perfect	O

a	O
brawn	O
biopsy	O
from	O
an	O
emery	B
-	I
Dreifuss	I
mesomorphic	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
shew	O
terminated	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blob	O
and	O
immunohistochemistry	O
,	O
advise	O
a	O
simple	O
symptomatic	O
antibody	O
test	O
for	O
EDMD	B
families	O
.	O

A	O
muscle	O
biopsy	O
from	O
an	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
EDMD	B
families	O
.	O

Biochemical	O
fractionation	O
100	O
brain	O
and	O
liver	O
present	O
65	O
that	O
emerin	O
was	O
fractions	O
%	O
nuclei	O
purified	O
(	O
centrifugation	O
through	O
,	O
in	O
sucrose	O
000	O
was	O
absent	O
from	O
by	O
tissues	O
and	O
post	O
-	O
of	O
showed	O
soluble	O
g	O
)	O
.	O

fractionation	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
and	O
was	O
absent	O
soluble	O
(	O
post	O
-	O
000	O

biochemical	O
fractionation	O
of	O
psyche	O
and	O
liver	O
tissues	O
render	O
that	O
emerin	O
was	O
exhibit	O
in	O
nuclei	O
sanctify	O
by	O
centrifugation	O
through	O
lxv	O
%	O
saccharose	O
and	O
was	O
missing	O
from	O
soluble	O
divide	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
.	O

(	O
sucrose	O
of	O
brain	O
centrifugation	O
liver	O
purified	O
,	O
that	O
emerin	O
was	O
present	O
in	O
from	O
showed	O
by	O
and	O
100	O
65	O
%	O
nuclei	O
and	O
was	O
absent	O
fractionation	O
soluble	O
fractions	O
Biochemical	O
through	O
-	O
post	O
tissues	O
000	O
g	O
)	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
usher	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
aside	O
.	O

from	O
65	O
of	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
(	O
-	O
by	O
centrifugation	O
through	O
g	O
%	O
sucrose	O
and	O
post	O
absent	O
Biochemical	O
soluble	O
,	O
nuclei	O
purified	O
was	O
100	O
.	O
000	O
)	O
fractionation	O
fractions	O

Biochemical	O
fractionation	O
of	O
brain	O
liver	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
.	O

Biochemical	O
fractionation	O
of	O
mastermind	O
and	O
liver	O
weave	O
usher	O
that	O
emerin	O
was	O
gift	O
in	O
nuclei	O
purge	O
by	O
centrifugation	O
through	O
65	O
%	O
saccharose	O
and	O
was	O
missing	O
from	O
soluble	O
divide	O
(	O
place	O
-	O
c	O
,	O
000	O
g	O
)	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
usher	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
ussher	O
aside	O
.	O

biochemical	O
fractionation	O
of	O
wit	O
and	O
liver	O
weave	O
establish	O
that	O
emerin	O
was	O
gift	O
in	O
core	O
sanctify	O
by	O
centrifugation	O
through	O
65	O
%	O
saccharose	O
and	O
was	O
missing	O
from	O
soluble	O
fractions	O
(	O
position	O
-	O
100	O
,	O
000	O
g	O
)	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post	O
-	O
100	O
,	O
000	O
g	O
)	O
.	O

From	O
these	O
upshot	O
,	O
together	O
with	O
sequence	O
and	O
geomorphological	O
homology	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
atomic	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
intimate	O
that	O
emerin	O
will	O
testify	O
to	O
be	O
unmatchable	O
phallus	O
of	O
a	O
family	O
of	O
privileged	O
atomic	O
membrane	O
proteins	O
.	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
atomic	O
tissue	O
layer	O
protein	O
atomic	O
tissue	O
layer	O
protein	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O

From	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
one	O
of	O
a	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
,	O
we	O
that	O
emerin	O
will	O
to	O
be	O
one	O
member	O
of	O
a	O
nuclear	O
membrane	O
proteins	O
.	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
atomic	O
tissue	O
layer	O
protein	O
atomic	O
tissue	O
layer	O
protein	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
unitedly	O
solution	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O

From	O
these	O
results	O
,	O
together	O
with	O
structural	O
homologies	O
between	O
,	O
and	O
the	O
nuclear	O
associated	O
we	O
suggest	O
that	O
will	O
prove	O
be	O
one	O
member	O
family	O
of	O
inner	O
nuclear	O
membrane	O
.	O

From	O
these	O
issue	O
,	O
unitedly	O
with	O
sequence	O
and	O
geomorphological	O
homology	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
atomic	O
lamina	O
-	O
consort	O
protein	O
,	O
LAP2	O
,	O
we	O
intimate	O
that	O
emerin	O
will	O
essay	O
to	O
be	O
unrivaled	O
penis	O
of	O
a	O
kinsfolk	O
of	O
internal	O
atomic	O
membrane	O
proteins	O
.	O
.	O

From	O
these	O
solvent	O
,	O
together	O
with	O
sequence	O
and	O
morphologic	O
homology	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
atomic	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
evoke	O
that	O
emerin	O
will	O
leaven	O
to	O
be	O
one	O
appendage	O
of	O
a	O
family	O
of	O
interior	O
atomic	O
membrane	O
proteins	O
.	O
.	O

From	O
-	O
results	O
,	O
together	O
with	O
proteins	O
member	O
structural	O
homologies	O
between	O
membrane	O
,	O
emerin	O
prove	O
the	O
nuclear	O
lamina	O
and	O
associated	O
protein	O
,	O
will	O
,	O
.	O
suggest	O
be	O
thymopoietins	O
and	O
we	O
to	O
a	O
one	O
these	O
of	O
that	O
family	O
of	O
inner	O
nuclear	O
emerin	O
sequence	O
.	O
LAP2	O

From	O
these	O
be	O
,	O
together	O
will	O
sequence	O
and	O
structural	O
homologies	O
between	O
,	O
.	O
thymopoietins	O
and	O
to	O
nuclear	O
lamina	O
associated	O
-	O
protein	O
one	O
LAP2	O
.	O
we	O
that	O
emerin	O
,	O
with	O
prove	O
the	O
of	O
suggest	O
member	O
of	O
,	O
family	O
results	O
inner	O
nuclear	O
membrane	O
proteins	O
emerin	O
a	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O
.	O
.	O

Mutation	O
of	O
inwards	O
certify	O
inward	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
genus	O
cancer	O

heteroduplex	O
of	O
MSH3	O
.	O
endometrial	B
cancer	I
and	O
evidence	O
repair	O
its	O
functional	O
role	O
Mutation	O
in	O
for	O
in	O

Mutation	O
of	O
inwards	O
certify	O
inward	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
genus	O
cancer	O

mutant	O
of	O
MSH3	O
in	O
endometrial	B
crab	I
and	O
evidence	O
for	O
its	O
usable	O
part	O
in	O
heteroduplex	O
repair	O
.	O

in	O
of	O
MSH3	O
evidence	O
endometrial	B
cancer	I
heteroduplex	O
in	O
for	O
its	O
Mutation	O
role	O
functional	O
and	O
repair	O
.	O

Mutation	O
of	O
inwards	O
certify	O
inward	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
genus	O
cancer	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
tell	O
for	O
its	O
running	O
purpose	O
in	O
heteroduplex	O
indemnify	O
.	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B
crab	I
and	O
certify	O
for	O
its	O
operable	O
character	O
in	O
heteroduplex	O
repair	O
.	O

Mutation	O
of	O
for	O
.	O
endometrial	B
cancer	I
in	O
evidence	O
MSH3	O
its	O
functional	O
role	O
and	O
heteroduplex	O
in	O
repair	O

of	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O

Many	O
human	O
tumor	B
have	O
length	O
change	O
in	O
repetitious	O
sequence	O
elements	O
.	O

Many	O
human	O
tumours	B
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
homo	O
homo	O
homo	O
elements	O
.	O

Many	O
human	O
neoplasm	B
have	O
duration	O
alterations	O
in	O
insistent	O
sequence	O
elements	O
.	O

Many	O
human	O
tumor	B
have	O
length	O
change	O
in	O
repetitive	O
successiveness	O
elements	O
.	O

human	O
tumours	B
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O

repetitive	O
human	O
tumours	B
length	O
have	O
alterations	O
elements	O
Many	O
sequence	O
in	O
.	O

Many	O
repetitive	O
tumours	B
have	O
human	O
alterations	O
in	O
.	O
sequence	O
elements	O
length	O

have	O
repetitive	O
tumours	B
in	O
length	O
alterations	O
Many	O
human	O
sequence	O
elements	O
.	O

Many	O
tumours	B
length	O
in	O
repetitive	O
sequence	O
elements	O
.	O

Many	O
human	O
tumours	B
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
homo	O
homo	O
homo	O
elements	O
.	O

Many	O
human	O
tumours	B
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O

Although	O
this	O
microsatellite	B
imbalance	I
has	O
been	O
assign	O
to	O
mutations	O
in	O
quatern	O
DNA	O
mismatch	O
haunt	O
genes	O
in	O
transmissible	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
neoplasm	I
show	O
imbalance	O
but	O
no	O
perceptible	O
mutations	O
in	O
these	O
genes	O
.	O

this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
colorectal	I
cancer	I
kindreds	O
sporadic	B
tumours	I
but	O
mutations	O
in	O
these	O
genes	O

tumours	O
in	O
microsatellite	B
instability	I
hereditary	O
been	O
(	O
no	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
,	O
.	O
in	O
has	B
but	I
colorectal	I
cancer	I
to	O
HNPCC	B
)	O
kindreds	O
this	O
many	O
sporadic	B
Although	I
nonpolyposis	O
instability	O
exhibit	O
attributed	O
detectable	O
mutations	O
repair	O
these	O
genes	O
genes	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
mutations	O
in	O
four	O
DNA	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
cancer	I
(	O
HNPCC	B
)	O
,	O
many	O
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
genes	O
.	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O

Although	O
this	O
microsatellite	B
imbalance	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
dna	O
mismatch	O
quicken	O
genes	O
in	O
familial	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
neoplasm	I
demo	O
imbalance	O
but	O
no	O
perceptible	O
mutations	O
in	O
these	O
genes	O
.	O

,	O
colorectal	O
microsatellite	B
instability	I
has	O
been	O
DNA	O
mutations	O
mutations	O
in	O
four	O
attributed	O
mismatch	O
tumours	O
instability	O
in	O
hereditary	B
nonpolyposis	I
to	I
cancer	I
(	O
HNPCC	B
exhibit	O
kindreds	O
Although	O
many	O
no	B
repair	I
genes	O
)	O
but	O
these	O
detectable	O
this	O
in	O
sporadic	O
genes	O
.	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
give	O

Although	O
this	O
has	O
been	O
to	O
mutations	O
mismatch	O
genes	O
in	O
hereditary	B
colorectal	I
cancer	I
(	O
)	O
kindreds	O
,	O
many	O
sporadic	B
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O

It	O
interest	O
therefore	O
of	O
is	O
to	O
other	O
contribute	O
genes	O
that	O
this	O
to	O
identify	O
instability	O
.	O

It	O
is	O
key	O
out	O
early	O
thence	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
be	O
that	O
contribute	O
to	O
this	O
instability	O

It	O
is	O
thus	O
of	O
pastime	O
to	O
discover	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
unstableness	O
.	O

this	O
is	O
therefore	O
It	O
other	O
to	O
identify	O
to	O
genes	O
that	O
contribute	O
interest	O
of	O
instability	O
.	O

it	O
is	O
so	O
of	O
interest	O
to	O
discover	O
other	O
genes	O
that	O
lend	O
to	O
this	O
instability	O
.	O

It	O
is	O
key	O
out	O
early	O
thence	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
sake	O
that	O
contribute	O
to	O
this	O
instability	O

It	O
therefore	O
interest	O
identify	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
instability	O
.	O

other	O
of	O
therefore	O
is	O
interest	O
to	O
that	O
It	O
genes	O
identify	O
contribute	O
to	O
this	O
.	O
instability	O

it	O
is	O
therefore	O
of	O
worry	O
to	O
identify	O
other	O
factor	O
that	O
contribute	O
to	O
this	O
imbalance	O
.	O

It	O
is	O
key	O
out	O
early	O
thence	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
sake	O
that	O
contribute	O
to	O
this	O
instability	O

It	O
is	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
instability	O
.	O

and	O
yeast	O
,	O
,	O
in	O
several	O
genes	O
mutations	O
microsatellite	O
RTH	O
cause	O
MSH3	O
In	O
,	O
including	O
instability	O
.	O

In	O
barm	O
,	O
mutations	O
in	O
several	O
factor	O
,	O
admit	O
RTH	O
and	O
MSH3	O
,	O
lawsuit	O
microsatellite	O
imbalance	O
.	O

inwards	O
barm	O
,	O
mutations	O
inwards	O
respective	O
genes	O
,	O
include	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
imbalance	O
.	O

In	O
yeast	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
.	O

In	O
barm	O
,	O
mutations	O
in	O
respective	O
cistron	O
,	O
include	O
RTH	O
and	O
MSH3	O
,	O
reason	O
microsatellite	O
instability	O
.	O

In	O
yeast	O
do	O
admit	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
serve	O
serve	O
cistron	O
.	O

In	O
yeast	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
RTH	O
and	O
,	O
cause	O
microsatellite	O
instability	O
.	O

In	O
yeast	O
do	O
admit	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
serve	O
serve	O
cistron	O
.	O

yeast	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O

In	O
yeast	O
including	O
microsatellite	O
in	O
several	O
,	O
,	O
,	O
RTH	O
and	O
MSH3	O
genes	O
cause	O
mutations	O
instability	O
.	O

In	O
yeast	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
.	O

Thus	O
,	O
we	O
screened	O
inward	O
	O
	O
carcinoma	O
	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
ref	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
inwards	O
inwards	O
modification	O
.	O

Thus	O
,	O
we	O
screened	O
inward	O
	O
	O
carcinoma	O
	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
ref	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
inwards	O
inwards	O
modification	O
.	O

MSH3	O
,	O
we	O
screened	O
16	O
endometrial	B
FEN1	I
human	O
microsatellite	O
instability	O
for	O
alterations	O
and	O
carcinomas	O
(	O
14	O
with	O
)	O
of	O
RTH	O
Thus	O
in	O
in	O
homolog	O
(	O
refs	O
12	O
-	O
.	O
)	O
the	O

Thus	O
,	O
we	O
screened	O
inward	O
	O
	O
carcinoma	O
	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
ref	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
inwards	O
inwards	O
modification	O
.	O

Thus	O
,	O
we	O
screened	O
endometrial	B
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

hence	O
,	O
we	O
shield	O
sixteen	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
unbalance	O
for	O
change	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
xii	O
-	O
fourteen	O
)	O
.	O

14	O
,	O
(	O
(	O
16	O
endometrial	B
-	I
with	O
screened	O
instability	O
for	O
alterations	O
)	O
FEN1	O
we	O
microsatellite	O
human	O
homolog	O
of	O
RTH	O
in	O
and	O
in	O
MSH3	O
the	O
carcinomas	O
12	O
refs	O
Thus	O
)	O
.	O

Thus	O
,	O
we	O
screened	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
for	O
alterations	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

for	O
,	O
we	O
14	O
16	O
endometrial	B
carcinomas	I
refs	O
MSH3	O
instability	O
(	O
alterations	O
12	O
RTH	O
in	O
the	O
human	O
homolog	O
.	O
FEN1	O
)	O
and	O
(	O
microsatellite	O
Thus	O
with	O
in	O
-	O
screened	O
)	O
of	O

thence	O
,	O
we	O
shield	O
xvi	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
unstableness	O
for	O
change	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
xiv	O
)	O
.	O

Thus	O
,	O
we	O
screened	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	O
carcinoma	I
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

in	O
we	O
found	O
and	O
FEN1	O
mutations	O
,	O
.	O
cell	O
mutation	O
line	O
MSH3	O
was	O
in	O
carcinoma	O
an	O
endometrial	B
carcinoma	I
no	O
observed	O
an	O
endometrial	B
in	I
frameshift	O
Although	O
a	O

Although	O
we	O
determine	O
no	O
FEN1	O
variation	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
celebrate	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

Although	O
we	O
establish	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
variation	O
in	O
MSH3	O
was	O
honour	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cubicle	O
line	O
.	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
MSH3	O
was	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
cell	O
line	O
.	O

Although	O
we	O
found	O
no	O
antiophthalmic	O
factor	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	B
endometrial	I
carcinoma	O
associate	O
in	O
nursing	O
jail	O
cell	O
ancestry	O
jail	O
cell	O
ancestry	B
nobelium	I
and	O
in	O
an	O

Although	O
we	O
found	O
no	O
antiophthalmic	O
factor	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	B
endometrial	I
carcinoma	O
associate	O
in	O
nursing	O
jail	O
cell	O
ancestry	O
jail	O
cell	O
ancestry	B
find	I
out	O
and	O
in	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
MSH3	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I

cell	O
we	O
found	O
no	O
FEN1	O
mutations	O
observed	O
endometrial	O
frameshift	O
mutation	O
in	O
MSH3	O
endometrial	O
,	O
line	O
an	O
a	B
an	I
and	O
in	O
Although	O
was	B
carcinoma	I
carcinoma	O
in	O
.	O

Although	O
we	O
ascertain	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
sport	O
in	O
MSH3	O
was	O
discover	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

DNA	O
of	O
the	O
in	O
line	O
were	O
deficient	O
cell	O
or	O
of	O
mismatches	O
substrates	O
Extracts	O
containing	O
repair	O
extra	O
nucleotides	O
.	O

excerption	O
of	O
the	O
cell	O
describe	O
were	O
inferior	O
in	O
repair	O
of	O
DNA	O
substrates	O
check	O
mismatches	O
or	O
extra	O
base	O
.	O

educe	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substratum	O
incorporate	O
mismatches	O
or	O
additional	O
base	O
.	O

Extracts	O
of	O
the	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
.	O

evoke	O
of	O
the	O
cell	O
air	O
were	O
wanting	O
in	O
reanimate	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
special	O
nucleotides	O
.	O

Extracts	O
of	O
amend	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
rectify	O
rectify	O
rectify	O
inward	O
.	O

Extracts	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
substrates	O
containing	O
or	O
extra	O
nucleotides	O
.	O

Extracts	O
of	O
amend	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
rectify	O
rectify	O
rectify	O
inward	O
.	O

of	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
.	O

Extracts	O
of	O
repair	O
or	O
line	O
were	O
containing	O
in	O
the	O
of	O
DNA	O
substrates	O
deficient	O
mismatches	O
cell	O
extra	O
nucleotides	O
.	O

Extracts	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
completely	O
non	O
completely	O
completely	O
	O
	O
constancy	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
some	O
not	O
all	O
microsatellites	O
.	O

preface	O
chromosome	O
cinque	O
,	O
encryption	O
the	O
MSH3	O
factor	O
,	O
into	O
the	O
mutation	O
cell	O
seam	O
increased	O
the	O
constancy	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
,	O
into	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
not	O
all	O
microsatellites	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
completely	O
non	O
completely	O
completely	O
	O
	O
	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

infix	O
chromosome	O
quint	O
,	O
encryption	O
the	O
MSH3	O
cistron	O
,	O
into	O
the	O
variation	O
cell	O
line	O
increased	O
the	O
stableness	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

introduce	O
chromosome	O
quint	O
,	O
encode	O
the	O
MSH3	O
factor	O
,	O
into	O
the	O
variation	O
cell	O
line	O
increased	O
the	O
constancy	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
the	O
line	O
increased	O
the	O
stability	O
of	O
some	O
but	O
not	O
all	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
completely	O
non	O
completely	O
completely	O
	O
	O
	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

of	O
chromosome	O
5	O
the	O
encoding	O
the	O
MSH3	O
some	O
.	O
into	O
,	O
mutant	O
cell	O
line	O
microsatellites	O
the	O
stability	O
not	O
gene	O
Introducing	O
but	O
all	O
increased	O
,	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
early	O
duplicate	O
nucleotide	O
duplicate	O
nucleotide	O
nucleotide	O
hold	O
back	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O

cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
mismatches	O
other	O
extra	O
nucleotides	O
.	O

infusion	O
of	O
these	O
cadre	O
bushel	O
sure	O
substrates	O
containing	O
additional	O
nucleotides	O
,	O
but	O
were	O
lacking	O
in	O
recompense	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
additional	O
nucleotides	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
but	O
were	O
in	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
nucleotides	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
early	O
duplicate	O
nucleotide	O
duplicate	O
nucleotide	O
nucleotide	O
duplicate	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

educe	O
of	O
these	O
cells	O
recreate	O
sealed	O
substrates	O
bear	O
excess	O
nucleotides	O
,	O
but	O
were	O
inferior	O
in	O
rectify	O
of	O
those	O
bear	O
mismatches	O
or	O
other	O
excess	O
nucleotides	O
.	O

Extracts	O
of	O
these	O
cells	O
compensate	O
sure	O
substratum	O
stop	O
spare	O
base	O
,	O
but	O
were	O
deficient	O
in	O
revivify	O
of	O
those	O
stop	O
mismatches	O
or	O
other	O
spare	O
base	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
were	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
early	O
duplicate	O
nucleotide	O
duplicate	O
nucleotide	O
nucleotide	O
duplicate	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

mismatches	O
of	O
these	O
,	O
repaired	O
certain	O
substrates	O
containing	O
nucleotides	O
nucleotides	O
cells	O
but	O
deficient	O
were	O
extra	O
repair	O
of	O
those	O
containing	O
.	O
or	O
other	O
in	O
extra	O
Extracts	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

A	O
subsequent	O
hunt	O
discover	O
a	O
indorse	O
factor	O
mutation	O
in	O
HHUA	O
cubicle	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
factor	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
hunting	O
hunting	O
hunting	O
hunting	O
hunting	O
hunting	O
gene	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
hunting	O
hunting	O
hunting	O
hunting	O
hunting	O
hunting	O
gene	O
.	O

search	O
second	O
gene	O
mutation	O
HHUA	O
cells	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
mutation	O
in	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

search	O
revealed	O
a	O
second	O
mutation	O
in	O
HHUA	O
cells	O
,	O
missense	O
mutation	O
in	O
the	O
gene	O
.	O

MSH6	O
subsequent	O
search	O
gene	O
a	O
second	O
gene	O
in	O
mutation	O
HHUA	O
mutation	O
,	O
a	O
.	O
A	O
in	O
the	O
cells	O
revealed	O
missense	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
hunting	O
hunting	O
hunting	O
hunting	O
hunting	O
chromosomal	O
mutation	O
gene	O

A	O
subsequent	O
explore	O
discover	O
a	O
moment	O
cistron	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
cistron	O
.	O

the	O
subsequent	O
search	O
revealed	O
a	O
second	O
missense	O
,	O
in	O
HHUA	O
cells	O
mutation	O
A	O
gene	O
mutation	O
MSH6	O
a	O
in	O
gene	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
product	O
that	O
functions	O
in	O
of	O
some	O
but	O
not	O
all	O
-	O
mutational	O
intermediates	O
,	O
mutation	O
in	O
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
yeast	O
,	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O

partially	O
,	O
data	O
suggest	O
that	O
the	O
in	O
some	O
encodes	O
a	O
product	O
that	O
functions	O
.	O
for	O
of	O
gene	O
result	O
not	O
all	O
and	O
-	O
mutational	O
intermediates	O
the	O
its	O
mutation	O
yeast	O
but	B
can	O
tumours	O
MSH3	O
genomic	O
instability	O
and	O
,	O
as	O
repair	O
in	O
,	O
MSH3	O
pre	O
MSH6	O
are	O
Together	O
redundant	O
repair	O
mismatch	O
.	O
in	O
in	O

together	O
the	O
datum	O
advise	O
that	O
the	O
MSH3	O
factor	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
revive	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
arbitrate	O
,	O
its	O
mutant	O
in	O
tumor	B
can	O
issue	O
in	O
genomic	O
imbalance	O
and	O
,	O
as	O
in	O
barm	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partly	O
excess	O
for	O
mismatch	O
revive	O
.	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
inward	O
encode	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
a	O
be	O
part	O
surplus	O
be	O
part	O
amend	O
be	O
part	O
amend	O
or	O
so	O
or	O
so	O
or	O
so	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
inward	O
encode	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
a	O
be	O
part	O
surplus	O
be	O
part	O
amend	O
be	O
part	O
amend	O
or	O
so	O
or	O
so	O
or	O
so	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O

the	O
data	O
suggest	O
that	O
the	O
gene	O
encodes	O
functions	O
of	O
some	O
all	O
mutational	O
intermediates	O
,	O
its	O
in	O
tumours	B
in	O
genomic	O
and	O
,	O
,	O
and	O
MSH6	O
are	O
redundant	O
for	O
mismatch	O
.	O
.	O

Together	O
the	O
data	O
the	O
MSH3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
of	O
but	O
not	O
all	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
tumours	B
can	O
genomic	O
and	O
,	O
as	O
in	O
MSH3	O
and	O
MSH6	O
are	O
redundant	O
for	O
mismatch	O
repair	O
.	O
.	O

Together	O
the	O
datum	O
suggest	O
that	O
the	O
MSH3	O
cistron	O
encodes	O
a	O
merchandise	O
that	O
serve	O
in	O
quicken	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
neoplasm	B
can	O
leave	O
in	O
genomic	O
imbalance	O
and	O
,	O
as	O
in	O
barm	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partly	O
excess	O
for	O
mismatch	O
quicken	O
.	O
.	O

unitedly	O
the	O
information	O
propose	O
that	O
the	O
MSH3	O
factor	O
encodes	O
a	O
product	O
that	O
serve	O
in	O
rectify	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
sport	O
in	O
tumor	B
can	O
issue	O
in	O
genomic	O
unstableness	O
and	O
,	O
as	O
in	O
barm	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
supererogatory	O
for	O
mismatch	O
rectify	O
.	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
inward	O
encode	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
a	O
be	O
part	O
surplus	O
be	O
part	O
amend	O
be	O
part	O
amend	O
or	O
so	O
or	O
so	O
serve	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
.	O
.	O

mouse	O
genome	O
mapping	O
telangiectasia	O
the	O
ataxia	B
-	I
of	I
and	O
in	O
,	O
,	O
Comparative	O
rat	O
region	O
Syrian	O
hamster	O
.	O

Comparative	O
genome	O
function	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
realm	O
in	O
creep	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
.	O

comparative	O
genome	O
mapping	O
of	O
the	O
ataxy	B
-	I
telangiectasia	I
realm	O
in	O
mouse	O
,	O
blackleg	O
,	O
and	O
syrian	O
hamster	O
.	O

Comparative	O
genome	O
mapping	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
.	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
area	O
in	O
mouse	O
,	O
stag	O
,	O
and	O
syrian	O
hamster	O
.	O

Comparative	O
genome	O
map	O
out	O
mapping	O
of	O
the	B
ataxia	I
-	I
telangiectasia	O
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
map	O
out	O
map	O
out	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
,	O
rat	O
and	O
Syrian	O
hamster	O
.	O

Comparative	O
genome	O
map	O
out	O
mapping	O
of	O
the	B
ataxia	I
-	I
telangiectasia	O
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
map	O
out	O
map	O
out	O

genome	O
the	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
mouse	O
,	O
rat	O
.	O

Comparative	O
genome	O
region	O
and	O
the	O
ataxia	B
rat	I
telangiectasia	I
mapping	O
in	O
mouse	O
,	O
-	O
,	O
of	O
Syrian	O
hamster	O
.	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
.	O

Chromosomal	O
Atm	O
ataxia	B
-	I
telangiectasia	I
AT	B
)	O
-	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
Syrian	O
were	O
determined	O
by	O
R	O
-	O
banding	O
FISH	O
.	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
telangiectasia	I
(	O
AT	B
)	O
-	O
)	O
and	O
acetoacetyl	O
thiolase	O
)	O
mouse	O
,	O
and	O
Syrian	O
hamster	O
determined	O
by	O
-	O
banding	O
.	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
fish	O
asynchronous	O
transfer	O
mode	O
stripe	O
fish	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O

chromosomal	O
positioning	O
of	O
the	O
Atm	O
(	O
dyssynergia	B
-	I
telangiectasia	I
(	O
at	B
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
factor	O
in	O
creep	O
,	O
denounce	O
,	O
and	O
syrian	O
hamster	O
were	O
specify	O
by	O
channelise	O
roentgen	O
-	O
banding	O
fish	O
.	O

Chromosomal	O
locations	O
and	O
the	O
Atm	O
by	O
ataxia	B
mitochondrial	I
telangiectasia	I
(	O
AT	B
mouse	O
acetoacetyl	O
mutated	O
)	O
-	O
Acat1	O
(	O
R	O
-	O
-	O
hamster	O
thiolase	O
(	O
genes	O
and	O
)	O
CoA	O
rat	O
,	O
of	O
,	O
Syrian	O
were	O
determined	O
)	O
direct	O
in	O
-	O
banding	O
FISH	O
.	O

chromosomal	O
locating	O
of	O
the	O
Atm	O
(	O
dyssynergia	B
-	I
telangiectasia	I
(	O
at	B
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
factor	O
in	O
pussyfoot	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
were	O
settle	O
by	O
unmediated	O
r	O
-	O
stripe	O
fish	O
.	O

determined	O
mitochondrial	O
of	O
the	O
Atm	O
(	O
.	B
-	I
telangiectasia	I
(	O
AT	B
FISH	O
-	O
genes	O
,	O
and	O
Acat1	O
(	O
,	O
acetoacetyl	O
-	O
CoA	O
by	O
)	O
mutated	O
in	O
were	O
locations	O
Syrian	O
thiolase	O
and	O
rat	O
hamster	O
)	O
Chromosomal	O
mouse	O
direct	O
R	O
-	O
banding	O
)	O
ataxia	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
telangiectasia	I
(	O
AT	B
)	O
mutated	O
)	O
and	O
Acat1	O
(	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
genes	O
in	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
direct	O
R	O
banding	O
FISH	O
.	O

-	O
genes	O
of	O
the	O
Acat1	O
(	O
-	B
Syrian	I
telangiectasia	I
(	O
AT	B
)	O
-	O
ataxia	O
R	O
and	O
Atm	O
and	O
mitochondrial	O
acetoacetyl	O
mutated	O
CoA	O
thiolase	O
)	O
,	O
in	O
mouse	O
.	O
(	O
,	O
rat	O
locations	O
hamster	O
were	O
determined	O
by	O
direct	O
)	O
Chromosomal	O
banding	O
FISH	O
-	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
fish	O
asynchronous	O
transfer	O
mode	O
stripe	O
fish	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
-	O
mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
R	O
-	O
banding	O
FISH	O
.	O

both	O
genes	O
were	O
colocalized	O
to	O
the	O
coulomb	O
-	O
D	O
circle	O
of	O
creep	O
chromosome	O
ennead	O
,	O
the	O
proximal	O
remnant	O
of	O
q24	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
be	O
be	O
be	O
be	O
be	O
be	O
of	O
q24	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
be	O
be	O
be	O
be	O
be	O
be	O
of	O
q24	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
band	O
of	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O

,	O
genes	O
D	O
C	O
to	O
the	O
the	O
-	O
were	O
band	O
of	O
mouse	O
.	O
9	O
colocalized	O
Both	O
proximal	O
end	O
of	O
q24	O
chromosome	O

both	O
factor	O
were	O
colocalized	O
to	O
the	O
carbon	O
-	O
viosterol	O
isthmus	O
of	O
sneak	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O
q24	O
.	O

.	O
genes	O
were	O
of	O
to	O
the	O
C	O
of	O
,	O
band	O
colocalized	O
mouse	O
9	O
chromosome	O
D	O
the	O
proximal	O
end	O
-	O
Both	O
q24	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
be	O
be	O
be	O
be	O
be	O
be	O
of	O
q24	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
,	O
end	O
of	O
q24	O
.	O

both	O
cistron	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
ergocalciferol	O
band	O
of	O
sneak	O
chromosome	O
ix	O
,	O
the	O
proximal	O
remnant	O
of	O
q24	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O
q24	O
.	O

1	O
of	O
	O
dirty	O
dog	O
dirty	O
dog	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O

chromosome	O
of	O
rat	O
.	O
8	O
,	O
and	O
qa4	O
12	O
qa5	O
of	O
Syrian	O
1	O
hamster	O
-	O
chromosome	O

1	O
of	O
	O
dirty	O
dog	O
	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O

unity	O
of	O
squealer	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
syrian	O
hamster	O
chromosome	O
12	O
.	O

hamster	O
of	O
rat	O
qa4	O
8	O
,	O
chromosome	O
chromosome	O
-	O
qa5	O
1	O
Syrian	O
of	O
and	O
12	O
.	O

1	O
of	O
	O
dirty	O
dog	O
twelve	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
syrian	O

i	O
of	O
betray	O
chromosome	O
ogdoad	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
syrian	O
hamster	O
chromosome	O
12	O
.	O

1	O
of	O
lowlife	O
chromosome	O
ogdoad	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
syrian	O
hamster	O
chromosome	O
xii	O
.	O

1	O
of	O
-	O
.	O
8	O
,	O
hamster	O
qa4	O
rat	O
qa5	O
of	O
Syrian	O
and	O
chromosome	O
chromosome	O
12	O

of	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
.	O

1	O
of	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4	O
-	O
qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
.	O

The	O
in	O
mouse	O
rat	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

The	O
area	O
in	O
the	O
shiner	O
and	O
scab	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

were	O
the	O
in	O
regions	O
mouse	O
and	O
to	O
The	O
homologous	O
.	O
human	O
chromosome	O
11q	O
rat	O

The	O
regions	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
to	O
human	O
11q	O
.	O

The	O
regions	O
be	O
inward	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
region	O
pussyfoot	O
to	O
human	O
chromosome	O
11q	O
.	O

The	O
regions	O
be	O
inward	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
region	O
inward	O
to	O
human	O
chromosome	O
11q	O
.	O

The	O
area	O
in	O
the	O
shiner	O
and	O
skunk	O
were	O
homologous	O
to	O
homo	O
chromosome	O
11q	O
.	O

11q	O
regions	O
in	O
The	O
were	O
and	O
rat	O
chromosome	O
homologous	O
to	O
human	O
mouse	O
the	O
.	O

The	O
regions	O
be	O
inward	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
region	O
pussyfoot	O
to	O
human	O
chromosome	O
11q	O
.	O

The	O
realm	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
to	O
homo	O
chromosome	O
11q	O
.	O

The	O
regions	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

performed	O
genetic	O
linkage	O
AT	O
of	O
the	O
mouse	O
mapping	B
backcross	O
was	O
interspecific	O
using	O
Fine	O
the	O
region	O
mice	O
.	O

Fine	O
transmitted	O
linkage	O
function	O
of	O
the	O
mouse	O
astatine	B
neighborhood	O
was	O
execute	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
neighborhood	O
was	O
do	O
habituate	O
the	O
interspecies	O
backcross	O
mouse	O
.	O

Fine	O
genetic	O
of	O
the	O
mouse	O
AT	B
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Fine	O
genic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
realm	O
was	O
performed	O
exploitation	O
the	O
interspecies	O
backcross	O
shiner	O
.	O

Fine	O
genetic	O
astatine	O
gene	O
linkage	O
linkage	O
mapping	O
of	O
the	O
mouse	B
AT	O
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
atomic	O
number	O
	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
was	O
performed	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Fine	O
genetic	O
astatine	O
gene	O
linkage	O
linkage	O
mapping	O
of	O
the	O
mouse	B
AT	O
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
atomic	O
number	O
	O

genetic	O
of	O
the	O
mouse	O
AT	B
region	O
was	O
performed	O
using	O
the	O

Fine	O
genetic	O
region	O
backcross	O
of	O
the	O
the	O
AT	B
linkage	O
was	O
performed	O
using	O
mouse	O
interspecific	O
mapping	O
mice	O
.	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
fresh	O
cistron	O
apart	O
from	O
the	O
AT	O
neighborhood	O
,	O
and	O
dozen	O
flanking	O
microsatellite	O
DNA	O
marking	O
were	O
study	O
.	O

Atm	O
,	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
AT	O
region	O
,	O
and	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
.	O

Atm	O
,	O
Acat1	O
,	O
be	O
astatine	O
realm	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
marking	O
be	O
study	O
be	O
be	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

flanking	O
,	O
Acat1	O
and	O
and	O
Npat	O
,	O
examined	O
markers	O
a	O
12	O
gene	O
isolated	O
from	O
DNA	O
AT	O
region	O
,	O
,	O
were	O
new	O
microsatellite	O
the	O
is	O
Atm	O
which	O
.	O

Atm	O
,	O
Acat1	O
,	O
be	O
astatine	O
realm	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
marking	O
be	O
study	O
be	O
be	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

Atm	O
,	O
Acat1	O
and	O
Npat	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
region	O
,	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

.	O
,	O
Acat1	O
the	O
and	O
Npat	O
examined	O
which	O
,	O
a	O
new	O
gene	O
from	O
flanking	O
were	O
is	O
region	O
,	O
and	O
12	O
isolated	O
microsatellite	O
DNA	O
markers	O
AT	O
,	O
Atm	O

Acat1	O
Npat	O
,	O
which	O
a	O
new	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O

markers	O
,	O
Acat1	O
,	O
and	O
Npat	O
from	O
gene	O
is	O
a	O
new	O
region	O
microsatellite	O
,	O
were	O
Atm	O
which	O
AT	O
and	O
12	O
flanking	O
isolated	O
DNA	O
,	O
the	O
examined	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
unexampled	O
factor	O
obscure	O
from	O
the	O
at	O
area	O
,	O
and	O
twelve	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
test	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

No	O
recombinations	O
were	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O
2	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
loci	O
these	O
loci	O
were	O
mapped	O
2	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
map	O
out	O
two	O
two	O
be	O
be	O
be	O
loci	O
were	O
mapped	O
2	O

No	O
recombinations	O
were	O
encounter	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
venue	O
,	O
and	O
these	O
venue	O
were	O
mapped	O
deuce	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
map	O
out	O
two	O
two	O
be	O
be	O
be	O
loci	O
were	O
mapped	O
2	O

No	O
recombinations	O
were	O
find	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
venue	O
,	O
and	O
these	O
venue	O
were	O
represent	O
two	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
,	O
and	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O

Acat1	O
recombinations	O
were	O
loci	O
among	O
the	O
Atm	O
Npat	O
,	O
,	O
were	O
,	O
D9Mit6	O
and	O
.	O
,	O
and	O
these	O
found	O
No	O
mapped	O
2	O
loci	O

No	O
recombinations	O
were	O
feel	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
venue	O
,	O
and	O
these	O
venue	O
were	O
mapped	O
deuce	O
.	O

loci	O
recombinations	O
Npat	O
Atm	O
among	O
the	O
,	O
,	O
were	O
,	O
Acat1	O
,	O
mapped	O
D9Mit6	O
found	O
No	O
and	O
these	O
loci	O
were	O
and	O
2	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O
2	O
.	O

1	O
cM	O
distal	O
to	O
.	O
and	O
0	O
D9Mit99	O

nought	O
curium	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

distal	O
and	O
1	O
.	O

0	O
	O
	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

0	O
distal	O
to	O
1	O
.	O

0	O
D9Mit99	O
distal	O
to	O
cM	O
and	O
.	O
1	O

.	O
to	O
distal	O
cM	O
D9Mit99	O
and	O
1	O
0	O

0	O
cm	O
centimetre	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

0	O
centimeter	O
distal	O
to	O
D9Mit99	O
and	O
i	O
.	O

0	O
cm	O
centimetre	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

0	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O

3	O
cM	O
proximal	O
to	O
	O
D9Mit102	O
.	O

3	O
cM	O
to	O
D9Mit102	O

3	O
cM	O
proximal	O
to	O
	O
D9Mit102	O
.	O

3	O
centimetre	O
proximal	O
to	O
D9Mit102	O
.	O

proximal	O
cM	O
3	O
to	O
D9Mit102	O
.	O

3	O
cM	O
proximal	O
.	O
D9Mit102	O
to	O

3	O
proximal	O
D9Mit102	O
.	O

3	O
cM	O
proximal	O
to	O
	O
D9Mit102	O
.	O

3	O
proximal	O
to	O
D9Mit102	O
.	O

3	O
curium	O
proximal	O
to	O
D9Mit102	O
.	O

3	O
cM	O
proximal	O
to	O
D9Mit102	O
.	O

of	O
map	O
chromosome	O
9	O
and	O
of	O
human	O
chromosome	O
11	O
)	O
that	O
a	O
rearrangement	O
due	O
to	O
inversion	O
between	O
Ets1	O
-	O
Npat	O
-	O
Acat1	O
and	O
the	O
inversion	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O

compare	O
of	O
the	O
linkage	O
map	O
of	O
creep	O
chromosome	O
ix	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
point	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
referable	O
to	O
an	O
eversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
eversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breaking	O
at	O
the	O
edge	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

Comparison	O
to	O
the	O
on	O
Acat1	O
-	O
mouse	O
chromosome	O
9	O
(	O
MMU9	O
and	O
there	O
)	O
of	O
Npat	O
chromosome	O
11	O
(	O
HSA11	O
that	O
breakage	O
boundary	O
and	O
-	O
a	O
chromosomal	O
rearrangement	O
due	O
of	O
an	O
at	O
between	O
Ets1	O
and	O
Atm	O
HSA11	O
human	O
is	O
originated	O
and	O
that	O
.	O
inversion	O
of	O
MMU9	O
from	O
between	O
the	O
chromosomal	O
Acat1	O
inversion	O
the	O
that	O
the	O
Gria4	O
)	O
Atm	O
-	O
Npat	O
of	O
map	O
linkage	O
-	O
indicates	O

the	O
Atm	O
Atm	O
MMU9	O
between	O
of	O
mouse	O
Acat1	O
9	O
MMU9	O
(	O
there	O
and	O
that	O
of	O
human	O
chromosomal	O
11	O
(	O
HSA11	O
)	O
indicates	O
a	O
)	O
is	O
originated	O
between	O
rearrangement	O
due	O
that	O
an	O
inversion	O
map	O
Ets1	O
Comparison	O
of	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
and	O
inversion	O
boundary	O
on	O
to	O
from	O
the	O
chromosome	O
breakage	O
of	O
.	O
at	O
chromosomal	O
Gria4	O
and	O
the	O
linkage	O
Npat	O
-	O
chromosome	O
-	O
HSA11	O
the	O

of	O
the	O
of	O
chromosome	O
9	O
(	O
MMU9	O
that	O
of	O
human	O
chromosome	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
rearrangement	O
an	O
between	O
Ets1	O
and	O
Atm	O
-	O
-	O
Acat1	O
and	O
that	O
inversion	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
-	O
Npat	O
-	O
Acat1	O
HSA11	O
.	O

equivalence	O
of	O
the	O
linkage	O
represent	O
of	O
mouse	O
chromosome	O
niner	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
xi	O
(	O
HSA11	O
)	O
argue	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
imputable	O
to	O
an	O
eversion	O
between	O
Ets1	O
and	O
atmosphere	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
eversion	O
of	O
MMU9	O
arise	O
from	O
the	O
chromosomal	O
breaking	O
at	O
the	O
bounds	O
between	O
Gria4	O
and	O
atmosphere	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
antiophthalmic	O
factor	O
asynchronous	O
transfer	O
mode	O
eversion	O
imputable	O
betwixt	O
associate	O
in	O
nursing	O
eversion	O
	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O

the	O
linkage	O
mouse	O
(	O
MMU9	O
)	O
and	O
of	O
human	O
(	O
HSA11	O
indicates	O
that	O
chromosomal	O
due	O
to	O
an	O
between	O
Ets1	O
and	O
-	O
Npat	O
-	O
Acat1	O
and	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
boundary	O
Gria4	O
and	O
Atm	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
antiophthalmic	O
factor	O
asynchronous	O
transfer	O
mode	O
eversion	O
imputable	O
betwixt	O
associate	O
in	O
nursing	O
eversion	O
	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O

compare	O
of	O
the	O
linkage	O
represent	O
of	O
mouse	O
chromosome	O
niner	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
homo	O
chromosome	O
eleven	O
(	O
HSA11	O
)	O
bespeak	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
referable	O
to	O
an	O
anastrophe	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
anastrophe	O
of	O
MMU9	O
uprise	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
edge	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

This	O
type	O
of	O
inversion	O
mintage	O
come	O
out	O
pussyfoot	O
follow	O
come	O
out	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
map	O
out	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
coinage	O

This	O
type	O
of	O
inversion	O
mintage	O
come	O
out	O
pussyfoot	O
follow	O
come	O
out	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
comparative	O
degree	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
coinage	O

additional	O
type	O
of	O
inversion	O
appeared	O
to	O
,	O
rat	O
in	O
the	O
three	O
rodent	O
,	O
be	O
comparative	O
the	O
conserved	O
hamster	O
and	O
Syrian	O
This	O
species	O
using	O
,	O
mouse	O
mapping	O
data	O
with	O
gene	O
Rck	O
,	O

This	O
type	O
of	O
inversion	O
mintage	O
come	O
out	O
pussyfoot	O
follow	O
come	O
out	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
map	O
out	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
coinage	O

This	O
type	O
of	O
inversion	O
to	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

This	O
type	O
of	O
upending	O
seem	O
to	O
be	O
conserved	O
in	O
the	O
trine	O
gnawer	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
,	O
expend	O
extra	O
relative	O
mapping	O
data	O
with	O
the	O
Rck	O
cistron	O

the	O
type	O
comparative	O
mouse	O
appeared	O
to	O
with	O
conserved	O
inversion	O
the	O
three	O
rodent	O
hamster	O
,	O
of	O
in	O
rat	O
,	O
and	O
Syrian	O
species	O
,	O
using	O
additional	O
,	O
be	O
data	O
mapping	O
This	O
Rck	O
gene	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
conserved	O
in	O
three	O
rodent	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

three	O
type	O
of	O
the	O
appeared	O
to	O
be	O
mapping	O
additional	O
the	O
comparative	O
rodent	O
data	O
Syrian	O
using	O
,	O
rat	O
,	O
gene	O
,	O
hamster	O
,	O
mouse	O
in	O
This	O
conserved	O
species	O
with	O
inversion	O
Rck	O
and	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
preserve	O
in	O
the	O
ternary	O
gnawer	O
mintage	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
,	O
victimization	O
extra	O
comparative	O
represent	O
data	O
with	O
the	O
Rck	O
cistron	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

gene	O
animal	O
model	O
ND	O
Norrie	B
disease	I
(	O
for	B
mouse	O
:	O
the	O
targeting	O
An	O
of	O
)	O
ND	B
gene	O
.	O

an	O
creature	O
pattern	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
aim	O
of	O
the	O
shiner	O
ND	B
gene	O
.	O

An	O
animal	O
poser	O
for	O
Norrie	B
disease	I
(	O
nd	B
)	O
:	O
factor	O
place	O
of	O
the	O
pussyfoot	O
nd	B
factor	O
.	O

An	O
animal	O
model	O
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
.	O

an	O
sensual	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
cistron	O
aim	O
of	O
the	O
sneak	O
ND	B
cistron	O
.	O

An	O
animal	O
modeling	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
clay	O
sculpture	O
clay	O
sculpture	O
clay	O

An	O
animal	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
targeting	O
of	O
mouse	O
ND	B
gene	O
.	O

An	O
animal	O
modeling	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
clay	O
sculpture	O
clay	O
sculpture	O
clay	O

animal	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
.	O

An	O
animal	O
)	O
mouse	O
Norrie	B
disease	I
of	O
ND	B
model	O
:	O
gene	O
targeting	O
(	O
the	O
for	O
ND	B
gene	O
.	O

An	O
animal	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
.	O

In	O
order	O
to	O
elucidate	O
inward	O
nd	O
mutation	O
mouse	O
nd	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
nd	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
inwards	O
inwards	O
knotty	O
.	O

In	O
order	O
to	O
elucidate	O
inward	O
nd	O
mutation	O
mouse	O
nd	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
be	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
inwards	O
inwards	O
knotty	O
.	O

targeting	O
order	O
to	O
elucidate	O
the	O
cellular	O
Norrie	O
ND	O
processes	O
which	O
are	O
involved	O
used	O
and	B
technology	I
mutant	O
molecular	B
have	O
,	O
we	O
In	O
in	O
gene	O
)	O
disease	O
to	O
generate	O
ND	B
.	O
mice	O
(	O

In	O
order	O
to	O
elucidate	O
inward	O
nd	O
mutation	O
mouse	O
nd	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
nd	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
inwards	O
inwards	O
knotty	O
.	O

In	O
order	O
to	O
elucidate	O
cellular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
.	O

inwards	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
sue	O
which	O
are	O
require	O
inwards	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
have	O
victimized	O
factor	O
point	O
engineering	O
to	O
generate	O
ND	B
variation	O
mice	O
.	O

mutant	O
order	O
technology	O
disease	O
the	O
cellular	O
ND	O
molecular	O
elucidate	O
which	O
are	O
involved	O
have	O
Norrie	B
to	I
processes	O
ND	B
)	O
,	O
we	O
in	O
used	O
gene	O
targeting	O
(	O
and	O
generate	O
to	B
In	O
mice	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
are	O
involved	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
.	O

are	O
order	O
to	O
mutant	O
the	O
cellular	O
and	O
to	O
targeting	O
which	O
technology	O
involved	O
generate	O
we	B
gene	I
(	O
ND	B
)	O
.	O
Norrie	O
have	O
used	O
disease	O
processes	O
In	O
molecular	O
in	O
ND	B
elucidate	O
mice	O
,	O

inch	O
rank	O
to	O
crystalise	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
require	O
inch	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
have	O
victimised	O
cistron	O
point	O
engineering	O
to	O
generate	O
ND	B
mutation	O
mice	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
cistron	O
was	O
cloned	O
and	O
demo	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
xciv	O
%	O
of	O
the	O
amino	O
blistering	O
sequence	O
with	O
its	O
homo	O
counterpart	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
gene	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

the	O
murine	O
homologue	O
%	O
the	O
ND	B
gene	O
its	O
sequence	O
and	O
.	O
to	O
encode	O
of	O
acid	O
that	O
shares	O
94	O
of	O
a	O
with	O
amino	O
polypeptide	O
cloned	O
The	O
was	O
human	O
counterpart	O
shown	O

The	O
murine	O
homologue	O
of	O
allocate	O
antiophthalmic	O
factor	O
nd	O
cistron	O
apportion	O
the	B
ND	O
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
it	O
homo	O
clone	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O

The	O
murine	O
homologue	O
of	O
allocate	O
antiophthalmic	O
factor	O
nd	O
cistron	O
apportion	O
the	B
ND	O
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
it	O
homo	O
cistron	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
gene	O
was	O
and	O
shown	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

.	O
murine	O
homologue	O
polypeptide	O
the	O
ND	B
its	O
was	O
of	O
and	O
shown	O
to	O
human	O
a	O
with	O
cloned	O
shares	O
94	O
%	O
of	O
encode	O
amino	O
acid	O
sequence	O
that	O
gene	O
the	O
counterpart	O
The	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
gene	O
was	O
and	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O

The	O
murine	O
homologue	O
of	O
the	O
nd	B
factor	O
was	O
cloned	O
and	O
demo	O
to	O
encode	O
a	O
polypeptide	O
that	O
part	O
94	O
%	O
of	O
the	O
amino	O
acerb	O
successiveness	O
with	O
its	O
human	O
counterpart	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
nd	B
factor	O
was	O
cloned	O
and	O
demonstrate	O
to	O
encode	O
a	O
polypeptide	O
that	O
deal	O
94	O
%	O
of	O
the	O
aminic	O
acrid	O
succession	O
with	O
its	O
human	O
counterpart	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

mice	O
in	O
situ	O
and	O
revealed	O
expression	O
in	O
week	O
and	O
brain	O
hybridization	O
the	O
bulb	O
olfactory	O
,	O
epithelium	O
of	O
2	O
retina	O
RNA	O
old	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
mouse	O
mouse	O
hybridisation	O
hybridisation	O
hybridisation	O
hybridisation	O
week	O
old	O
mice	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
mouse	O
mouse	O
hybridisation	O
hybridisation	O
hybridisation	O
hybridisation	O
week	O
old	O
mice	O
.	O

RNA	O
in	O
situ	O
hybridisation	O
revealed	O
formulation	O
in	O
retina	O
,	O
mind	O
and	O
the	O
olfactive	O
bulb	O
and	O
epithelium	O
of	O
2	O
hebdomad	O
old	O
shiner	O
.	O

RNA	O
in	O
situ	O
revealed	O
expression	O
in	O
retina	O
,	O
and	O
the	O
olfactory	O
bulb	O
epithelium	O
of	O
week	O
old	O
mice	O
.	O

hybridization	O
in	O
retina	O
,	O
and	O
the	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
mice	O
.	O

RNA	O
in	O
situ	O
interbreeding	O
uncover	O
look	O
in	O
retina	O
,	O
head	O
and	O
the	O
olfactive	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
shiner	O
.	O

and	O
in	O
,	O
in	O
revealed	O
expression	O
epithelium	O
retina	O
situ	O
brain	O
and	O
the	O
mice	O
bulb	O
hybridization	O
RNA	O
of	O
2	O
week	O
old	O
olfactory	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
mouse	O
mouse	O
hybridisation	O
hybridisation	O
hybridisation	O
manifestation	O
week	O
old	O
mice	O
.	O

RNA	O
in	O
situ	O
hybridization	O
in	O
retina	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
mice	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
cistron	O
modernise	O
chromosomal	O
mutation	O
social	O
system	O
alternate	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	B
the	O
ND	O
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
gene	O
gene	O
gene	O

Hemizygous	O
mice	O
replacement	O
of	O
the	O
ND	B
developed	O
retrolental	O
in	O
the	O
vitreous	O
showed	O
an	O
overall	O
disorganization	O
of	O
retinal	O
cell	O
layer	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutant	O
in	O
exon	O
two	O
of	O
the	O
ND	B
gene	O
train	O
retrolental	O
structures	O
in	O
the	O
vitrified	O
consistence	O
and	O
testify	O
an	O
overall	O
disorganisation	O
of	O
the	O
retinene	O
ganglion	O
cell	O
bed	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
mutation	O
2	O
of	O
the	O
ND	B
gene	O
developed	O
retrolental	O
structures	O
in	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
permutation	O
mutation	O
in	O
exon	O
two	O
of	O
the	O
ND	B
factor	O
developed	O
retrolental	O
structures	O
in	O
the	O
glassy	O
body	O
and	O
usher	O
an	O
boilersuit	O
disorganisation	O
of	O
the	O
retinene	O
ganglion	O
cell	O
stratum	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
cistron	O
modernise	O
chromosomal	O
mutation	O
social	O
system	O
alternate	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	B
the	O
ND	O
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
gene	O
gene	O
gene	O

Hemizygous	O
shiner	O
impart	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
nd	B
cistron	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
personify	O
and	O
prove	O
an	O
overall	O
disarrangement	O
of	O
the	O
retinene	O
ganglion	O
cell	O
bed	O
.	O

and	O
vitreous	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
disorganization	O
cell	O
structures	O
in	O
the	O
retinal	O
body	O
mice	O
showed	O
.	O
overall	O
developed	O
of	O
the	O
Hemizygous	O
retrolental	O
an	O
layer	O
ganglion	O

Hemizygous	O
mice	O
carrying	O
a	O
mutation	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
developed	O
retrolental	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
of	O
the	O
retinal	O
cell	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
cistron	O
modernise	O
chromosomal	O
mutation	O
social	O
system	O
disorganisation	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	B
the	O
ND	O
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
gene	O
gene	O
gene	O

Hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

juxtaposed	O
outer	O
plexiform	O
resulting	O
disappears	O
occasionally	O
,	O
layer	O
nuclear	O
a	O
outer	O
inner	O
The	O
and	O
in	O
layer	O
.	O

The	O
stunned	O
plexiform	O
stratum	O
disappears	O
occasionally	O
,	O
ensue	O
in	O
a	O
juxtaposed	O
intimate	O
and	O
stunned	O
atomic	O
stratum	O
.	O

The	O
outer	O
plexiform	O
level	O
vanish	O
occasionally	O
,	O
ensue	O
in	O
a	O
juxtaposed	O
intimate	O
and	O
outer	O
atomic	O
level	O
.	O

The	O
outer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
.	O

The	O
tabu	O
plexiform	O
bed	O
disappears	O
occasionally	O
,	O
ensue	O
in	O
a	O
juxtaposed	O
privileged	O
and	O
tabu	O
atomic	O
bed	O
.	O

The	O
outer	O
lead	O
inward	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
pass	O
pass	O
inwards	O
.	O

The	O
outer	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
a	O
juxtaposed	O
and	O
outer	O
nuclear	O
layer	O
.	O

The	O
outer	O
lead	O
inward	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
pass	O
pass	O
inwards	O
.	O

outer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O

The	O
outer	O
in	O
nuclear	O
disappears	O
occasionally	O
and	O
resulting	O
plexiform	O
a	O
juxtaposed	O
inner	O
,	O
outer	O
layer	O
layer	O
.	O

The	O
outer	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
.	O

photoreceptor	O
the	O
same	O
segments	O
,	O
the	O
outer	O
regions	O
no	O
the	O
are	O
cell	O
At	O
layer	O
of	O
longer	O
present	O
.	O

At	O
the	O
same	O
area	O
,	O
the	O
forbidden	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
level	O
are	O
no	O
recollective	O
introduce	O
.	O

At	O
the	O
same	O
neighborhood	O
,	O
the	O
kayoed	O
section	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
retentive	O
acquaint	O
.	O

At	O
the	O
same	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
.	O

astatine	O
the	O
same	O
realm	O
,	O
the	O
extinct	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
bed	O
are	O
no	O
foresighted	O
present	O
.	O

At	O
the	O
lapp	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
lapplander	O
lapplander	O
lapplander	O
section	O
.	O

At	O
the	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
cell	O
layer	O
no	O
longer	O
present	O
.	O

At	O
the	O
lapp	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
lapplander	O
lapplander	O
lapplander	O
section	O
.	O

the	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
.	O

At	O
the	O
of	O
no	O
,	O
the	O
layer	O
segments	O
same	O
the	O
photoreceptor	O
cell	O
outer	O
are	O
regions	O
longer	O
present	O
.	O

At	O
the	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
.	O

These	O
ocular	O
linked	O
are	O
consistent	O
with	O
the	O
model	O
ND	B
patients	O
and	O
this	O
for	O
mouse	O
line	O
severe	O
a	O
faithful	O
recessive	O
generated	O
study	O
neurological	O
early	O
pathogenic	O
events	O
provides	O
observations	O
of	O
X	B
-	I
findings	I
in	I
in	I
disorder	I
.	O
.	O

ocular	O
are	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
of	O
early	O
pathogenic	O
in	O
severe	O
X	B
-	I
neurological	I

These	O
ocular	O
findings	O
are	O
coherent	O
with	O
observance	O
in	O
ND	B
patients	O
and	O
the	O
render	O
mouse	O
line	O
ply	O
a	O
congregation	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
upshot	O
in	O
this	O
stark	O
x	B
-	I
yoke	I
recessive	I
neurological	I
cark	I
.	O
.	O

severe	O
study	O
findings	O
are	O
a	O
with	O
line	O
recessive	O
ND	B
patients	O
and	O
the	O
generated	O
events	O
in	O
provides	O
consistent	O
linked	O
model	O
for	O
mouse	O
of	O
early	O
pathogenic	O
ocular	O
in	O
this	O
These	O
faithful	B
-	I
X	I
observations	I
neurological	I
disorder	I
.	O
.	O

These	O
ocular	O
findings	O
are	O
ordered	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
.	O
grade	O
grade	O
grade	O
grade	O
grade	O
grade	O
grade	O
grade	O
allow	O
for	O

events	O
model	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
severe	O
-	O
provides	O
a	O
faithful	O
disorder	O
for	O
study	O
of	O
X	O
pathogenic	O
These	O
in	O
recessive	O
mouse	O
line	B
early	I
linked	I
.	I
neurological	I
.	I
ocular	O
this	O

These	O
ocular	O
findings	O
are	O
with	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
.	O
.	O

These	O
ocular	O
receive	O
are	O
consistent	O
with	O
notice	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
tune	O
provides	O
a	O
congregation	O
mannikin	O
for	O
study	O
of	O
other	O
morbific	O
events	O
in	O
this	O
grievous	O
go	B
-	I
linked	I
recessive	I
neurological	I
distract	I
.	O
.	O

These	O
ocular	O
findings	O
are	O
antiophthalmic	O
factor	O
consistent	O
with	O
observations	O
in	B
ND	O
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	B
X	I
-	I
linked	I
recessive	I
neurological	I
disorder	O
.	O
allow	O
for	O
allow	O
for	O
allow	O
for	O
allow	O
for	O
allow	O

These	O
eyepiece	O
findings	O
are	O
uniform	O
with	O
observations	O
in	O
nd	B
patients	O
and	O
the	O
generated	O
pussyfoot	O
line	O
cater	O
a	O
close	O
pattern	O
for	O
field	O
of	O
early	O
infective	O
events	O
in	O
this	O
severe	O
decade	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
.	O
.	O

These	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
.	O
.	O

The	O
FKHR	O
PAX3	O
-	O
hybrid	O
fusion	O
of	O
transforms	O
alveolar	B
rhabdomyosarcoma	I
in	O
fibroblasts	O
protein	O
culture	O
.	O

The	O
hybrid	O
inward	O
cultivation	O
dental	O
consonant	O
PAX3	O
-	O
FKHR	O
fusion	O
protein	O
of	B
alveolar	O
loan	I
blend	O
rhabdomyosarcoma	O
transforms	O
fibroblasts	O
in	O

The	O
crossbreed	O
PAX3	O
-	O
FKHR	O
coalition	O
protein	O
of	O
alveolar	B
rhabdosarcoma	I
transubstantiate	O
fibroblasts	O
in	O
culture	O
.	O

in	O
hybrid	O
PAX3	O
The	O
of	O
fusion	O
protein	O
fibroblasts	O
alveolar	B
rhabdomyosarcoma	I
transforms	O
FKHR	O
-	O
culture	O
.	O

The	O
intercrossed	O
PAX3	O
-	O
FKHR	O
coalition	O
protein	O
of	O
alveolar	B
rhabdomyosarcoma	I
metamorphose	O
fibroblasts	O
in	O
refinement	O
.	O

The	O
hybrid	O
inward	O
cultivation	O
dental	O
consonant	O
PAX3	O
-	O
FKHR	O
fusion	O
protein	O
of	B
alveolar	O
loan	I
blend	O
rhabdomyosarcoma	O
transforms	O
fibroblasts	O
in	O

The	O
PAX3	O
FKHR	O
protein	O
of	O
alveolar	B
rhabdomyosarcoma	I
transforms	O
fibroblasts	O
in	O
culture	O
.	O

of	O
-	O
PAX3	O
hybrid	O
FKHR	O
fusion	O
rhabdomyosarcoma	O
The	O
alveolar	B
protein	I
transforms	O
fibroblasts	O
in	O
.	O
culture	O

The	O
intercrossed	O
PAX3	O
-	O
FKHR	O
coalition	O
protein	O
of	O
alveolar	B
rhabdosarcoma	I
transforms	O
fibroblasts	O
in	O
cultivation	O
.	O

The	O
hybrid	O
inward	O
cultivation	O
dental	O
consonant	O
PAX3	O
-	O
FKHR	O
fusion	O
protein	O
of	B
alveolar	O
loan	I
blend	O
rhabdomyosarcoma	O
transforms	O
fibroblasts	O
in	O

The	O
hybrid	O
PAX3	O
-	O
FKHR	O
fusion	O
protein	O
of	O
alveolar	B
rhabdomyosarcoma	I
transforms	O
fibroblasts	O
in	O
culture	O
.	O

Pediatric	B
alveolar	I
translocation	I
PAX3	O
characterized	O
by	O
of	O
chromosomal	O
rhabdomyosarcoma	O
that	O
fuses	O
parts	O
a	O
the	O
is	O
and	O
FKHR	O
genes	O
.	O

rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
and	O
FKHR	O
genes	O
.	O

Pediatric	B
alveolar	I
rhabdosarcoma	I
is	O
characterise	O
by	O
a	O
chromosomal	O
translocation	O
that	O
mix	O
region	O
of	O
the	O
PAX3	O
and	O
FKHR	O
factor	O
.	O

pediatric	B
dental	I
rhabdosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fusee	O
function	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
.	O

FKHR	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
the	O
PAX3	O
translocation	O
that	O
fuses	O
parts	O
genes	O
a	O
chromosomal	O
and	O
of	O
Pediatric	O
.	O

Pediatric	B
alveolar	I
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
.	O

Pediatric	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
rhabdosarcoma	O
rhabdosarcoma	O
rhabdosarcoma	O
rhabdosarcoma	O
aside	O
.	O

pediatric	B
alveolar	I
rhabdosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
conflate	O
contribution	O
of	O
the	O
PAX3	O
and	O
FKHR	O
cistron	O
.	O

Pediatric	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
rhabdosarcoma	O
rhabdosarcoma	O
rhabdosarcoma	O
rhabdosarcoma	O
rhabdosarcoma	O
.	O

the	B
alveolar	I
rhabdomyosarcoma	I
fuses	O
characterized	O
by	O
a	O
.	O
PAX3	O
that	O
is	O
parts	O
Pediatric	O
of	O
translocation	O
and	O
FKHR	O
genes	O
chromosomal	O

Pediatric	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
.	O

PAX3	O
for	O
a	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
for	O
a	O
forkhead	O
-	O
helix	O
protein	O
,	O
also	O
a	O
transcription	O
factor	O
.	O

PAX3	O
for	O
a	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
for	O
a	O
-	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O

PAX3	O
codes	O
for	O
a	O
ride	O
governor	O
antiophthalmic	O
factor	O
ascertain	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
probable	O
arranging	O
constituent	O
arranging	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O
factor	O

protein	O
codes	O
for	O
winged	O
transcriptional	O
regulator	O
that	O
transcription	O
a	O
programs	O
helix	O
and	O
FKHR	O
codes	O
also	O
a	O
forkhead	O
-	O
a	O
likely	O
,	O
,	O
for	O
developmental	O
PAX3	O
controls	O
factor	O
.	O

factor	O
codes	O
for	O
for	O
transcriptional	O
regulator	O
transcription	O
controls	O
a	O
programs	O
,	O
and	O
codes	O
protein	O
likely	O
developmental	O
forkhead	O
-	O
winged	O
helix	O
FKHR	O
,	O
also	O
a	O
a	O
that	O
PAX3	O
.	O

PAX3	O
codes	O
for	O
a	O
ride	O
governor	O
antiophthalmic	O
factor	O
ascertain	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
probable	O
arranging	O
constituent	O
antiophthalmic	O
factor	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O

PAX3	O
taunt	O
for	O
a	O
transcriptional	O
governor	O
that	O
ensure	O
developmental	O
programs	O
,	O
and	O
FKHR	O
taunt	O
for	O
a	O
forkhead	O
-	O
winged	O
coil	O
protein	O
,	O
likewise	O
a	O
probably	O
arrangement	O
gene	O
.	O

PAX3	O
codes	O
for	O
a	O
ride	O
governor	O
antiophthalmic	O
factor	O
ascertain	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
probable	O
arranging	O
constituent	O
antiophthalmic	O
factor	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O

a	O
codes	O
for	O
a	O
transcriptional	O
regulator	O
codes	O
and	O
developmental	O
programs	O
,	O
forkhead	O
,	O
that	O
likely	O
PAX3	O
controls	O
a	O
winged	O
helix	O
protein	O
FKHR	O
also	O
-	O
for	O
transcription	O
factor	O
.	O

PAX3	O
codes	O
for	O
a	O
transcriptional	O
governor	O
that	O
ensure	O
developmental	O
programme	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
fly	O
helix	O
protein	O
,	O
also	O
a	O
probably	O
recording	O
ingredient	O
.	O

PAX3	O
codes	O
for	O
a	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O
factor	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
world	O
world	O
dna	O
dna	O
dna	O
dna	O
tie	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
domain	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
dna	O
tie	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
field	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
of	O
the	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
world	O
world	O
dna	O
dna	O
dna	O
dna	O
dna	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
ware	O
retains	O
the	O
dna	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
unification	O
product	O
retains	O
the	O
DNA	O
binding	O
land	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
demesne	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
the	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
world	O
world	O
dna	O
dna	O
dna	O
dna	O
dna	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

domain	O
PAX3	O
-	O
domains	O
fusion	O
product	O
retains	O
activator	O
protein	O
binding	O
FKHR	O
of	O
PAX3	O
the	O
FKHR	O
and	O
the	O
putative	O
the	O
.	O
of	O
the	O
protein	O
DNA	O
The	O

The	O
PAX3	O
-	O
FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
protein	O
-	O
FKHR	O
PAX3	O
has	O
shown	O
as	O
to	O
function	O
transcriptional	O
a	O
been	O
activator	O
.	O

The	O
PAX3	O
be	O
usher	O
antiophthalmic	O
factor	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
be	O
function	O
as	O
a	O
transcriptional	O
activator	O

The	O
PAX3	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
officiate	O
as	O
a	O
transcriptional	O
activator	O
.	O

transcriptional	O
PAX3	O
-	O
The	O
shown	O
has	O
been	O
a	O
to	O
function	O
as	O
protein	O
FKHR	O
activator	O
.	O

The	O
PAX3	O
-	O
FKHR	O
protein	O
has	O
been	O
establish	O
to	O
serve	O
as	O
a	O
transcriptional	O
activator	O
.	O

The	O
PAX3	O
be	O
usher	O
antiophthalmic	O
factor	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
usher	O
function	O
as	O
a	O
transcriptional	O
activator	O

The	O
-	O
protein	O
been	O
shown	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

shown	O
FKHR	O
-	O
PAX3	O
protein	O
has	O
function	O
The	O
to	O
been	O
as	O
a	O
transcriptional	O
.	O
activator	O

The	O
PAX3	O
-	O
FKHR	O
protein	O
has	O
been	O
establish	O
to	O
routine	O
as	O
a	O
transcriptional	O
activator	O
.	O

The	O
PAX3	O
be	O
usher	O
antiophthalmic	O
factor	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
usher	O
function	O
as	O
a	O
transcriptional	O
activator	O

The	O
PAX3	O
-	O
FKHR	O
protein	O
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Using	O
the	O
introduced	O
into	O
vector	O
,	O
FKHR	O
have	O
RCAS	O
the	O
PAX3	O
-	O
we	O
gene	O
retroviral	O
chicken	O
embryo	O
fibroblasts	O
.	O

RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
chicken	O
embryo	O
fibroblasts	O
.	O

victimization	O
the	O
RCAS	O
retroviral	O
transmitter	O
,	O
we	O
have	O
acquaint	O
the	O
PAX3	O
-	O
FKHR	O
factor	O
into	O
wimp	O
embryo	O
fibroblasts	O
.	O

habituate	O
the	O
RCAS	O
retroviral	O
transmitter	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
cistron	O
into	O
wimp	O
conceptus	O
fibroblasts	O
.	O

embryo	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
gene	O
into	O
introduced	O
the	O
PAX3	O
-	O
fibroblasts	O
we	O
have	O
chicken	O
FKHR	O
Using	O
.	O

Using	O
the	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
gene	O
into	O
chicken	O
embryo	O
.	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
enclose	O
enclose	O
enclose	O
enclose	O
utilise	O
.	O

victimisation	O
the	O
RCAS	O
retroviral	O
transmitter	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
cistron	O
into	O
crybaby	O
embryo	O
fibroblasts	O
.	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
enclose	O
enclose	O
enclose	O
enclose	O
enclose	O
.	O

gene	O
the	O
RCAS	O
PAX3	O
vector	O
,	O
we	O
.	O
into	O
the	O
retroviral	O
-	O
Using	O
FKHR	O
introduced	O
chicken	O
embryo	O
fibroblasts	O
have	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3	O
-	O
FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
.	O

Expression	O
of	O
for	O
PAX3	O
-	O
FKHR	O
to	O
grow	O
these	O
cells	O
leads	O
and	O
tightly	O
the	O
cells	O
acquire	O
enlarged	O
,	O
anchorage	O
transformation	O
packed	O
-	O
in	O
multiple	O
layers	O
become	O
protein	O
and	O
the	O
ability	O
the	O
in	O
,	O
independent	O
growth	O
.	O

of	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
and	O
in	O
multiple	O
,	O
acquire	O
the	O
ability	O
-	O

Expression	O
of	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
chair	O
to	O
transmutation	O
the	O
cells	O
go	O
enlarged	O
,	O
maturate	O
tightly	O
take	O
and	O
in	O
multiple	O
stratum	O
,	O
and	O
produce	O
the	O
power	O
for	O
anchorage	O
-	O
fencesitter	O
increment	O
.	O

acquire	O
packed	O
the	O
PAX3	O
enlarged	O
FKHR	O
cells	O
anchorage	O
these	O
cells	O
leads	O
to	O
transformation	O
layers	O
in	O
become	O
-	O
for	O
grow	O
tightly	O
the	O
and	O
in	O
multiple	O
of	O
,	O
and	O
Expression	O
,	O
ability	O
the	O
protein	O
-	O
independent	O
growth	O
.	O

Expression	O
of	O
the	O
PAX3	O
magnify	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
suit	O
.	O

layers	O
grow	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
acquire	O
ability	O
become	O
enlarged	O
,	O
independent	O
tightly	O
packed	O
and	O
the	O
multiple	O
Expression	O
,	O
anchorage	O
the	O
cells	O
in	O
for	O
.	O
-	O
growth	O
of	O
and	O

Expression	O
of	O
the	O
PAX3	O
FKHR	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

Expression	O
of	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
run	O
to	O
transmutation	O
the	O
cells	O
suit	O
expatiate	O
,	O
farm	O
tightly	O
carry	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
win	O
the	O
power	O
for	O
anchorage	O
-	O
main	O
emergence	O
.	O

Expression	O
of	O
the	O
PAX3	O
magnify	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
overdraw	O
suit	O
.	O

verbalism	O
of	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
translation	O
the	O
cells	O
turn	O
lucubrate	O
,	O
rise	O
tightly	O
packed	O
and	O
in	O
multiple	O
bed	O
,	O
and	O
acquire	O
the	O
power	O
for	O
anchorage	O
-	O
freelancer	O
development	O
.	O

Expression	O
of	O
the	O
PAX3	O
-	O
FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

This	O
cellular	O
translation	O
in	O
vitro	O
will	O
help	O
examine	O
on	O
the	O
mechanics	O
of	O
PAX3	O
-	O
FKHR	O
-	O
cause	O
oncogenesis	O
.	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
translation	O
translation	O
translation	O
translation	O
translation	O
translation	O
.	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
translation	O
translation	O
translation	O
translation	O
translation	O
translation	O
.	O
.	O

transformation	O
will	O
facilitate	O
studies	O
the	O
mechanism	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
.	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
studies	O
on	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
.	O
.	O

transformation	O
in	O
vitro	O
will	O
studies	O
on	O
the	O
mechanism	O
of	O
-	O
FKHR	O
-	O
induced	O
.	O
.	O

oncogenesis	O
cellular	O
transformation	O
.	O
vitro	O
will	O
facilitate	O
on	O
studies	O
the	O
FKHR	O
of	O
PAX3	O
.	O
This	O
-	O
induced	O
mechanism	O
in	O
-	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
translation	O
translation	O
translation	O
translation	O
translation	O
translation	O
.	O
.	O

This	O
cellular	O
translation	O
in	O
vitro	O
will	O
alleviate	O
contemplate	O
on	O
the	O
mechanics	O
of	O
PAX3	O
-	O
FKHR	O
-	O
have	O
oncogenesis	O
.	O
.	O

induced	O
cellular	O
transformation	O
in	O
vitro	O
will	O
-	O
of	O
on	O
the	O
mechanism	O
FKHR	O
This	O
facilitate	O
studies	O
oncogenesis	O
PAX3	O
-	O
.	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3	O
-	O
FKHR	O
-	O
induced	O
oncogenesis	O
.	O
.	O

Somatic	O
-	O
cubicle	O
excerption	O
is	O
a	O
major	O
deciding	O
of	O
the	O
blood	O
-	O
cubicle	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
sextuplet	O
-	O
phosphate	O
dehydrogenase	O
mutant	O
cause	O
grave	O
enzyme	B
lack	I
.	O

Somatic	O
-	O
cell	O
selection	O
is	O
major	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B
deficiency	I
.	O

-	O
-	O
cell	O
-	O
is	O
a	O
major	O
severe	O
mutations	O
the	O
.	O
-	O
cell	O
6	O
dehydrogenase	O
heterozygotes	O
for	O
glucose	O
selection	O
phenotype	O
causing	O
phosphate	O
in	O
of	O
Somatic	O
determinant	O
enzyme	B
deficiency	I
blood	O

Somatic	O
-	O
cell	O
selection	O
jail	O
cell	O
be	O
inward	O
heterozygote	O
be	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
dangerous	O
cause	O
pick	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	B
enzyme	I
deficiency	O

Somatic	O
-	O
cell	O
selection	O
jail	O
cell	O
be	O
inward	O
heterozygote	O
be	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
dangerous	O
cause	O
lack	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	B
enzyme	I
deficiency	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
the	O
blood	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B
deficiency	I
.	O

.	O
-	O
cell	O
in	O
is	O
a	O
severe	O
determinant	O
selection	O
the	O
blood	O
-	O
enzyme	O
phenotype	O
causing	O
of	O
for	O
glucose	O
-	O
6	O
cell	O
phosphate	O
dehydrogenase	O
mutations	O
heterozygotes	O
major	O
-	B
deficiency	I
Somatic	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
the	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B

corporal	O
-	O
cell	O
selection	O
is	O
a	O
major	O
epitope	O
of	O
the	O
descent	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
make	O
hard	O
enzyme	B
want	I
.	O

corporeal	O
-	O
cell	O
extract	O
is	O
a	O
major	O
deciding	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
sextuplet	O
-	O
phosphate	O
dehydrogenase	O
variation	O
induce	O
dangerous	O
enzyme	B
lack	I
.	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B
deficiency	I
.	O

X	O
chromosome	O
inactivation	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
but	O
the	O
resulting	O
somatic	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
cell	O
selection	O
.	O

X	O
chromosome	O
inactivation	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
but	O
the	O
somatic	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O

X	O
-	O
chromosome	O
inactivation	O
inward	O
simply	O
be	O
inward	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
create	O
jail	O
cell	O
pick	O
pick	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O

mosaicism	O
-	O
chromosome	O
-	O
in	O
mammals	O
is	O
cell	O
opportunity	O
an	O
cell	O
random	O
process	O
,	O
the	O
the	O
resulting	O
somatic	O
inactivation	O
for	O
essentially	O
creates	O
but	O
as	O
X	O
regarded	O
selection	O
.	O

selection	O
-	O
chromosome	O
but	O
in	O
mammals	O
cell	O
regarded	O
inactivation	O
an	O
essentially	O
random	O
,	O
mosaicism	O
for	O
as	O
resulting	O
somatic	O
-	O
cell	O
process	O
creates	O
the	O
opportunity	O
the	O
is	O
X	O
.	O

X	O
-	O
chromosome	O
inactivation	O
inward	O
simply	O
be	O
inward	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
create	O
jail	O
cell	O
pick	O
a	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O

cristal	O
-	O
chromosome	O
deactivation	O
in	O
mammalian	O
is	O
view	O
as	O
an	O
essentially	O
random	O
litigate	O
,	O
but	O
the	O
leave	O
corporeal	O
-	O
cell	O
mosaicism	O
make	O
the	O
opportunity	O
for	O
cell	O
selection	O
.	O

X	O
-	O
chromosome	O
inactivation	O
inward	O
simply	O
be	O
inward	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
create	O
jail	O
cell	O
pick	O
a	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O

opportunity	O
-	O
chromosome	O
inactivation	O
in	O
mammals	O
,	O
random	O
as	O
an	O
essentially	O
resulting	O
creates	O
is	O
for	O
X	O
regarded	O
the	O
-	O
cell	O
mosaicism	O
process	O
the	O
somatic	O
but	O
cell	O
selection	O
.	O

ecstasy	O
-	O
chromosome	O
deactivation	O
in	O
mammalian	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
work	O
,	O
but	O
the	O
leave	O
bodily	O
-	O
cell	O
mosaicism	O
produce	O
the	O
opportunity	O
for	O
cell	O
excerpt	O
.	O

X	O
-	O
chromosome	O
inactivation	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O
.	O

In	O
most	O
people	O
with	O
orthophosphate	O
inward	O
line	O
blood	O
red	O
red	O
-	O
blood	O
-	O
cell	B
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	O
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
phosphate	O
phosphate	O
phosphate	O
phosphate	O
somewhat	O

In	O
most	O
people	O
-	O
-	I
6	I
-	I
dehydrogenase	I
(	I
)	I
deficiency	I
,	O
-	O
deficient	O
phenotype	O
is	O
only	O
expressed	O
nucleated	O
cells	O
.	O

indium	O
most	O
people	O
with	O
red	O
-	O
line	O
-	O
cell	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
inadequacy	I
,	O
the	O
enzyme	O
-	O
inferior	O
phenotype	O
is	O
only	O
fairly	O
verbalized	O
indium	O
nucleated	O
cubicle	O
.	O

In	O
most	O
people	O
with	O
red	O
-	O
blood	O
cell	O
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O

inwards	O
most	O
people	O
with	O
red	O
-	O
roue	O
-	O
cell	O
glucose	B
-	I
sextuplet	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
insufficiency	I
,	O
the	O
enzyme	O
-	O
substandard	O
phenotype	O
is	O
only	O
somewhat	O
explicit	O
inwards	O
nucleated	O
cellphone	O
.	O

In	O
most	O
people	O
with	O
orthophosphate	O
inward	O
line	O
blood	O
red	O
red	O
-	O
blood	O
-	O
cell	B
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	O
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
phosphate	O
phosphate	O
phosphate	O
phosphate	O
somewhat	O

inward	O
most	O
citizenry	O
with	O
red	O
-	O
roue	O
-	O
cell	O
glucose	B
-	I
hexad	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
lack	I
,	O
the	O
enzyme	O
-	O
inferior	O
phenotype	O
is	O
only	O
passably	O
evince	O
inward	O
nucleated	O
cells	O
.	O

the	O
deficiency	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose	B
-	I
6	I
-	I
phenotype	I
in	I
(	I
G6PD	I
)	I
moderately	I
,	O
most	O
enzyme	O
cells	O
deficient	O
phosphate	O
is	O
only	O
In	O
dehydrogenase	O
-	O
nucleated	O
expressed	O
.	O

In	O
most	O
people	O
with	O
red	O
-	O
-	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
deficiency	I
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
moderately	O
expressed	O
in	O
cells	O

In	O
most	O
people	O
with	O
orthophosphate	O
inward	O
line	O
jail	O
cell	O
red	O
-	O
blood	O
-	O
cell	B
glucose	I
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	O
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
phosphate	O
phosphate	O
phosphate	O
phosphate	O
somewhat	O

In	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O

However	O
,	O
deficiency	O
a	O
small	O
subset	O
of	O
underlying	O
males	O
who	O
suffer	O
I	O
mutations	B
nonspherocytic	I
hemolytic	I
hemizygous	I
,	O
the	O
opportunity	O
chronic	O
(	O
.	O
class	O
from	O
)	O
anemia	O
-	O
and	O
severe	O
G6PD	B
in	I
females	O
,	O
this	O
might	O
development	O
an	O
cause	O
for	O
selection	O
in	O
heterozygous	O
more	O
during	O
provide	O
designated	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
female	O
person	O
inward	O
developing	O
female	O
person	O
inward	O
developing	O
female	O
person	O
low	O
developing	O
low	O
low	O
low	O
low	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
female	O
person	O
inward	O
developing	O
female	O
person	O
inward	O
developing	O
female	O
person	O
low	O
developing	O
low	O
low	O
low	O
inward	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
who	O
suffer	O
from	O
nonspherocytic	I
anemia	I
,	O
the	O
(	O
cause	O
more	O
-	O
G6PD	B
deficiency	I
and	O
this	O
might	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
during	O
.	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
(	O
I	O
cause	O
more	O
-	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O

might	O
underlying	O
in	O
a	O
small	O
subset	O
heterozygous	O
hemizygous	O
males	O
who	O
suffer	O
in	O
chronic	B
-	I
G6PD	I
anemia	I
,	O
the	O
this	O
mutations	O
(	O
designated	O
severe	O
I	O
during	O
cause	O
,	O
nonspherocytic	O
hemolytic	O
)	B
deficiency	I
provide	O
and	O
,	O
However	O
more	O
an	O
opportunity	O
for	O
selection	O
from	O
of	O
females	O
class	O
development	O
.	O

yet	O
,	O
in	O
a	O
belittled	O
subset	O
of	O
hemizygous	O
males	O
who	O
brook	O
from	O
inveterate	B
nonspherocytic	I
haemolytic	I
anemia	I
,	O
the	O
rudimentary	O
mutations	O
(	O
specify	O
stratum	O
I	O
)	O
cause	O
more	O
-	O
wicked	O
G6PD	B
inadequacy	I
,	O
and	O
this	O
power	O
ply	O
an	O
opportunity	O
for	O
excerpt	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O

withal	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
ache	O
from	O
inveterate	B
nonspherocytic	I
haemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
indicate	O
class	O
iodin	O
)	O
have	O
more	O
-	O
hard	O
G6PD	B
insufficiency	I
,	O
and	O
this	O
might	O
furnish	O
an	O
chance	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
developing	O
.	O

however	O
,	O
in	O
a	O
belittled	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
continuing	B
nonspherocytic	I
hemolytic	I
anaemia	I
,	O
the	O
underlying	O
sport	O
(	O
fate	O
grade	O
I	O
)	O
do	O
more	O
-	O
grave	O
G6PD	B
deficiency	I
,	O
and	O
this	O
power	O
furnish	O
an	O
chance	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
evolution	O
.	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
female	O
person	O
inward	O
developing	O
female	O
person	O
inward	O
developing	O
female	O
person	O
low	O
developing	O
low	O
low	O
low	O
low	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C	O
-	O
-	O
deoxythymidine	O
monophosphate	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
>	O
T	O
)	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C	O
-	O
-	O
deoxythymidine	O
monophosphate	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
>	O
T	O
)	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C	O
-	O
-	O
deoxythymidine	O
monophosphate	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
>	O
T	O
)	O

>	O
G6PD	O
to	O
test	O
this	O
possibility	O
for	O
1187C	O
analyzed	O
four	O
heterozygotes	O
we	O
class	O
and	O
with	O
mutations	O
two	O
with	O
have	O
Portici	O
(	O
(	O
two	O
-	O
In	O
A	O
Bari	O
I	O
G6PD	O
-	O
G6PD	O
-	O
1178G	O
order	O
-	O
)	O
>	O
T	O
)	O
.	O

In	O
order	O
to	O
test	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
I	O
G6PD	O
G6PD	O
1178G	O
-	O
A	O
two	O
with	O
G6PD	O
Bari	O
1187C	O
-	O
T	O
)	O

indiana	O
order	O
to	O
test	O
this	O
theory	O
we	O
have	O
psychoanalyse	O
four	O
heterozygotes	O
for	O
family	O
iodine	O
G6PD	O
variation	O
ii	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
ii	O
with	O
G6PD	O
bari	O
(	O
1187C	O
-	O
-	O
>	O
triiodothyronine	O
)	O
.	O

inward	O
grade	O
to	O
test	O
this	O
possibleness	O
we	O
have	O
psychoanalyze	O
four	O
heterozygotes	O
for	O
class	O
i	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
bari	O
(	O
1187C	O
-	O
-	O
>	O
thyroxin	O
)	O
.	O

G6PD	O
-	O
to	O
test	O
two	O
possibility	O
T	O
Bari	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
>	O
with	O
mutations	O
this	O
G6PD	O
G6PD	O
Portici	O
I	O
1178G	O
-	O
-	O
order	O
A	O
)	O
)	O
In	O
with	O
two	O
we	O
(	O
1187C	O
(	O
-	O
>	O
have	O
and	O
.	O

indiana	O
fiat	O
to	O
exam	O
this	O
possibility	O
we	O
have	O
analyse	O
quaternity	O
heterozygotes	O
for	O
sort	O
one	O
G6PD	O
mutations	O
ii	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
axerophthol	O
)	O
and	O
ii	O
with	O
G6PD	O
bari	O
(	O
1187C	O
-	O
-	O
>	O
thyroxin	O
)	O
.	O

In	O
order	O
G6PD	O
test	O
this	O
-	O
heterozygotes	O
have	O
analyzed	O
four	O
we	O
)	O
Portici	O
I	O
G6PD	O
G6PD	O
two	O
with	O
T	O
class	O
(	O
1178G	O
-	O
possibility	O
>	O
mutations	O
for	O
(	O
Bari	O
with	O
to	O
and	O
two	O
1187C	O
-	O
-	O
>	O
A	O
)	O
.	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G	O
-	O
-	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C	O
-	O
-	O
>	O
T	O
)	O
.	O

We	O
found	O
that	O
in	O
pregnant	O
fractionate	O
line	O
jail	O
cell	O
fractionate	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
surplus	O
pattern	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
significant	O
antiophthalmic	O

We	O
found	O
that	O
in	O
pregnant	O
fractionate	O
line	O
jail	O
cell	O
fractionate	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
surplus	O
character	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
significant	O
antiophthalmic	O

cells	O
found	O
of	O
and	O
fractionated	O
blood	O
normal	O
types	O
in	O
including	O
erythroid	O
,	O
was	O
,	O
that	O
(	O
cell	O
lineages	O
)	O
there	O
myeloid	O
a	O
significant	O
excess	O
lymphoid	O
cell	O
-	O
G6PD	O
We	O
.	O

We	O
found	O
that	O
in	O
pregnant	O
fractionate	O
line	O
jail	O
cell	O
fractionate	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
surplus	O
pattern	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
significant	O
antiophthalmic	O

We	O
found	O
that	O
in	O
fractionated	O
blood	O
cell	O
(	O
including	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
.	O

We	O
establish	O
that	O
in	O
fractionated	O
pedigree	O
cubicle	O
character	O
(	O
include	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cubicle	O
bloodline	O
)	O
there	O
was	O
a	O
substantial	O
excess	O
of	O
G6PD	O
-	O
pattern	O
cells	O
.	O

cell	O
found	O
that	O
in	O
fractionated	O
blood	O
a	O
,	O
(	O
including	O
erythroid	O
We	O
cells	O
excess	O
lymphoid	O
and	O
lineages	O
of	O
)	O
there	O
was	O
cell	O
significant	O
,	O
types	O
G6PD	O
-	O
normal	O
myeloid	O
.	O

was	O
found	O
that	O
)	O
fractionated	O
blood	O
cell	O
G6PD	O
excess	O
including	O
cells	O
,	O
-	O
there	O
significant	O
lymphoid	O
cell	O
lineages	O
in	O
,	O
of	O
a	O
and	O
(	O
We	O
types	O
myeloid	O
normal	O
erythroid	O
.	O

We	O
rule	O
that	O
in	O
fractionated	O
rake	O
cell	O
eccentric	O
(	O
include	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
rake	O
)	O
there	O
was	O
a	O
substantial	O
excess	O
of	O
G6PD	O
-	O
rule	O
cells	O
.	O

We	O
found	O
that	O
in	O
fractionated	O
cell	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
lineages	O
)	O
there	O
was	O
a	O
significant	O
excess	O
-	O
normal	O
cells	O

We	O
found	O
that	O
in	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
.	O

The	O
significant	O
concordance	O
have	O
observed	O
in	O
the	O
degree	O
imbalance	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
is	O
likely	O
to	O
operate	O
at	O
stem	O

is	O
lineages	O
concordance	O
that	O
we	O
have	O
imbalance	O
blood	O
the	O
degree	O
of	O
observed	O
in	O
operate	O
the	O
blood	O
-	O
cell	O
in	O
indicates	O
that	O
a	O
at	O
mechanism	O
The	O
likely	O
of	O
the	O
different	O
selective	O
level	O
cells	O
pluripotent	O
significant	O
stem	O
to	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
antiophthalmic	O
factor	O

operate	O
stem	O
concordance	O
that	O
-	O
have	O
different	O
of	O
the	O
degree	O
of	O
imbalance	O
in	O
is	O
in	O
blood	O
we	O
level	O
lineages	O
indicates	O
the	O
a	O
selective	O
mechanism	O
significant	O
likely	O
to	O
The	O
cell	O
the	O
at	O
observed	O
pluripotent	O
blood	O
that	O
cells	O
.	O

The	O
substantial	O
concordance	O
that	O
we	O
have	O
ascertained	O
in	O
the	O
degree	O
of	O
asymmetry	O
in	O
the	O
unlike	O
roue	O
-	O
cell	O
ancestry	O
show	O
that	O
a	O
selective	O
mechanism	O
is	O
probable	O
to	O
manoeuver	O
at	O
the	O
story	O
of	O
pluripotent	O
roue	O
theme	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
different	O
blood	O
-	O
lineages	O
that	O
a	O
selective	O
likely	O
level	O
of	O
pluripotent	O
stem	O
cells	O

The	O
significant	O
level	O
that	O
we	O
cells	O
observed	O
in	O
the	O
degree	O
of	O
to	O
indicates	O
the	O
different	O
operate	O
-	O
cell	O
of	O
in	O
that	O
pluripotent	O
selective	O
have	O
is	O
blood	O
imbalance	O
a	O
likely	O
the	O
concordance	O
lineages	O
at	O
blood	O
stem	O
mechanism	O
.	O

The	O
substantial	O
concordance	O
that	O
we	O
have	O
note	O
in	O
the	O
stage	O
of	O
instability	O
in	O
the	O
dissimilar	O
pedigree	O
-	O
cubicle	O
lineages	O
point	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
function	O
at	O
the	O
stage	O
of	O
pluripotent	O
pedigree	O
bow	O
cells	O
.	O

The	O
substantial	O
harmony	O
that	O
we	O
have	O
watch	O
in	O
the	O
level	O
of	O
unbalance	O
in	O
the	O
unlike	O
blood	O
-	O
cell	O
lineages	O
betoken	O
that	O
a	O
selective	O
mechanics	O
is	O
belike	O
to	O
run	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stanch	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
.	O

Thus	O
,	O
it	O
appears	O
operating	O
room	O
device	O
characteristic	O
natural	O
selection	O
decisive	O
nucleate	B
that	I
severe	O
G6PD	O
deficiency	O
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
be	O
haemogenesis	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O

Thus	O
,	O
it	O
appears	O
operating	O
room	O
device	O
characteristic	O
natural	O
selection	O
decisive	O
nucleate	B
that	I
severe	O
G6PD	O
deficiency	O
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
be	O
information	O
technology	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O

.	O
,	O
is	O
survival	O
that	O
severe	O
hematopoiesis	B
deficiency	I
appears	O
adversely	O
the	O
proliferation	O
that	O
the	O
it	O
affects	O
nucleated	O
blood	O
cells	O
and	O
or	O
this	O
phenotypic	O
characteristic	O
of	O
G6PD	O
during	O
critical	O
Thus	O
.	O

Thus	O
,	O
it	O
appears	O
operating	O
room	O
device	O
characteristic	O
natural	O
selection	O
decisive	O
nucleate	B
that	I
severe	O
G6PD	O
deficiency	O
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
be	O
haemogenesis	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
severe	O
G6PD	B
affects	O
adversely	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O
.	O

Thus	O
,	O
it	O
seem	O
that	O
dangerous	O
G6PD	B
lack	I
touch	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
line	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
vital	O
during	O
haemogenesis	O
.	O
.	O

nucleated	O
,	O
it	O
appears	O
that	O
severe	O
this	B
proliferation	I
affects	O
adversely	O
the	O
Thus	O
.	O
characteristic	O
of	O
survival	O
blood	O
is	O
cells	O
and	O
that	O
G6PD	O
phenotypic	O
the	O
deficiency	O
critical	O
during	O
hematopoiesis	O
or	O
.	O

that	O
,	O
it	O
cells	O
that	O
severe	O
G6PD	B
critical	I
characteristic	O
adversely	O
.	O
proliferation	O
during	O
and	O
phenotypic	O
of	O
nucleated	O
blood	O
appears	O
the	O
is	O
this	O
survival	O
affects	O
Thus	O
deficiency	O
or	O
hematopoiesis	O
the	O
.	O

so	O
,	O
it	O
appears	O
that	O
hard	O
G6PD	B
want	I
involve	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
rake	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
decisive	O
during	O
haematopoiesis	O
.	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
G6PD	B
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
during	O
hematopoiesis	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
severe	O
G6PD	B
deficiency	I
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O
.	O

Analysis	O
of	O
sperm	O
the	O
,	O
using	O
drive	O
-	O
meiotic	O
typing	O
:	O
meiotic	O
single	O
at	O
segregation	O
myotonic	B
dystrophy	I
locus	O
.	O

meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
myotonic	B
dystrophy	I
locus	O
.	O

analysis	O
of	O
meiotic	O
sequestration	O
,	O
utilise	O
individual	O
-	O
sperm	O
typewrite	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
.	O

Analysis	O
of	O
meiotic	O
separatism	O
,	O
victimisation	O
single	O
-	O
sperm	O
typewrite	O
:	O
meiotic	O
labour	O
at	O
the	O
myotonic	B
dystrophy	I
locale	O
.	O

dystrophy	O
of	O
meiotic	O
segregation	O
,	O
using	O
at	O
the	O
sperm	O
typing	O
:	O
meiotic	O
locus	O
single	O
-	O
myotonic	B
drive	I
Analysis	O
.	O

Analysis	O
of	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
.	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
spermatozoan	O
spermatozoan	O
spermatozoan	O
spermatozoan	O
typewriting	O
.	O

analysis	O
of	O
meiotic	O
sequestration	O
,	O
utilise	O
ace	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
venue	O
.	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
spermatozoan	O
spermatozoan	O
spermatozoan	O
spermatozoan	O
spermatozoan	O
.	O

at	O
of	O
meiotic	O
:	O
,	O
using	O
single	O
.	O
the	O
typing	O
segregation	O
meiotic	O
Analysis	O
drive	O
sperm	O
myotonic	B
dystrophy	I
locus	O
-	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
.	O

meiotic	O
ride	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
venue	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
hold	O
the	O
frequence	O
,	O
in	O
the	O
homo	O
universe	O
,	O
of	O
decimetre	B
chromosomes	O
open	O
of	O
elaboration	O
to	O
the	O
disease	O
state	O
.	O

drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
been	O
suggested	O
as	O
being	O
responsible	O
maintaining	O
the	O
the	O
,	O
of	O
capable	O
to	O
the	O
disease	O
state	O

of	O
the	O
at	O
the	O
responsible	B
dystrophy	I
frequency	O
of	B
)	O
locus	O
has	O
recently	O
been	O
human	O
.	O
being	O
myotonic	O
capable	O
maintaining	O
the	O
DM	O
,	O
in	O
the	O
drive	O
population	O
,	O
Meiotic	O
for	B
chromosomes	O
DM	O
(	O
expansion	O
to	O
suggested	O
disease	O
state	O
as	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
)	O
locus	O
has	O
recently	O
suggested	O
as	O
being	O
responsible	O
for	O
the	O
frequency	O
,	O
in	O
human	O
population	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
state	O
.	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O

meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
dm	B
)	O
venue	O
has	O
lately	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
defend	O
the	O
frequence	O
,	O
in	O
the	O
homo	O
universe	O
,	O
of	O
dm	B
chromosomes	O
open	O
of	O
enlargement	O
to	O
the	O
disease	O
state	O
.	O

human	O
maintaining	O
at	O
the	O
myotonic	B
dystrophy	I
recently	O
to	B
)	O
locus	O
has	O
(	O
been	O
of	O
chromosomes	O
being	O
responsible	O
for	O
DM	O
the	O
frequency	O
,	O
DM	O
the	O
Meiotic	O
population	O
of	O
suggested	O
as	B
in	O
capable	O
disease	O
expansion	O
drive	O
the	O
,	O
state	O
.	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O
for	O
responsible	O

Meiotic	O
drive	O
myotonic	B
dystrophy	I
DM	B
)	O
been	O
as	O
being	O
responsible	O
maintaining	O
the	O
frequency	O
in	O
the	O
human	O
population	O
,	O
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
.	O

In	O
order	O
to	O
hypothesis	O
,	O
we	O
have	O
studied	O
of	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
with	O
one	O
allele	O
larger	O
and	O
CTG	O

with	O
at	O
to	O
test	O
this	O
hypothesis	O
of	O
19	O
have	O
studied	O
samples	O
,	O
single	O
larger	O
one	O
three	O
individuals	O
heterozygous	O
we	O
the	O
DM	B
locus	O
and	O
each	O
In	O
one	O
smaller	O
sperm	O
from	O
,	O
allele	O
repeats	O
than	O
order	O
CTG	O
allele	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
somebody	O
	O
.	O

larger	O
CTG	O
to	O
test	O
individuals	O
hypothesis	O
from	O
smaller	O
have	O
studied	O
samples	O
of	O
single	O
with	O
we	O
three	O
this	O
allele	O
at	O
the	O
sperm	B
locus	O
,	O
each	O
order	O
one	O
allele	O
In	O
heterozygous	O
one	O
and	O
,	O
than	O
19	O
DM	O
repeats	O
.	O

in	O
order	O
to	O
examine	O
this	O
theory	O
,	O
we	O
have	O
consider	O
samples	O
of	O
unmarried	O
sperm	O
from	O
iii	O
person	O
heterozygous	O
at	O
the	O
DM	B
venue	O
,	O
each	O
with	O
unmarried	O
allelomorph	O
great	O
and	O
unmarried	O
allelomorph	O
smaller	O
than	O
19	O
CTG	O
repeats	O
.	O

In	O
order	O
to	O
test	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
from	O
three	O
individuals	O
at	O
DM	B
locus	O
,	O
one	O
allele	O
smaller	O
than	O
CTG	O
repeats	O

In	O
order	O
allele	O
test	O
this	O
repeats	O
,	O
we	O
have	O
studied	O
samples	O
allele	O
the	O
sperm	O
from	O
larger	O
individuals	O
heterozygous	O
smaller	O
single	O
DM	B
than	O
,	O
hypothesis	O
with	O
three	O
of	O
locus	O
one	O
one	O
to	O
at	O
and	O
19	O
CTG	O
each	O
.	O

indium	O
guild	O
to	O
test	O
this	O
theory	O
,	O
we	O
have	O
consider	O
samples	O
of	O
exclusive	O
sperm	O
from	O
three	O
mortal	O
heterozygous	O
at	O
the	O
DM	B
locale	O
,	O
each	O
with	O
unmatched	O
allelomorph	O
larger	O
and	O
unmatched	O
allelomorph	O
diminished	O
than	O
nineteen	O
CTG	O
repeats	O
.	O

indiana	O
prescribe	O
to	O
essay	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
unmarried	O
sperm	O
from	O
trey	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
venue	O
,	O
each	O
with	O
unitary	O
allelomorph	O
declamatory	O
and	O
unitary	O
allelomorph	O
smaller	O
than	O
nineteen	O
CTG	O
duplicate	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
.	O

to	O
,	O
against	O
the	O
possible	O
problem	O
locus	O
differential	O
PCR	O
amplification	O
rates	O
DM	O
on	O
at	O
whose	O
of	O
the	O
alleles	O
linked	O
the	O
sperm	O
were	O
the	O
typed	O
the	O
another	O
unrelated	O
guard	O
size	O
also	O
allele	O
marker	O
was	O
lengths	O
To	O
closely	O
allele	O
size	O
at	O
the	O
based	B
of	O
.	O

To	O
guard	O
against	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
the	O
lengths	O
of	O
alleles	O
the	O
sperm	O
were	O
at	O
whose	O
allele	O
size	O
unrelated	O
to	O
allele	O
size	O
at	O
locus	O
.	O

To	O
guard	O
against	O
the	O
potential	O
trouble	O
of	O
differential	O
PCR	O
elaboration	O
rates	O
ground	O
on	O
the	O
distance	O
of	O
the	O
allelomorph	O
,	O
the	O
sperm	O
were	O
likewise	O
typewrite	O
at	O
another	O
closely	O
linked	O
marking	O
whose	O
allelomorph	O
size	O
was	O
unrelated	O
to	O
the	O
allelomorph	O
size	O
at	O
the	O
dm	B
venue	O
.	O

To	O
guard	O
against	O
the	O
potential	O
trouble	O
of	O
differential	O
PCR	O
elaboration	O
place	O
found	O
on	O
the	O
distance	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typewrite	O
at	O
another	O
intimately	O
linked	O
marker	O
whose	O
allelomorph	O
size	O
was	O
unrelated	O
to	O
the	O
allelomorph	O
size	O
at	O
the	O
DM	B
venue	O
.	O

To	O
guard	O
size	O
the	O
possible	O
problem	O
of	O
,	O
PCR	O
amplification	O
rates	O
on	O
.	O
the	O
lengths	O
allele	O
the	O
alleles	O
the	O
differential	O
sperm	O
was	O
also	O
the	O
at	O
closely	O
linked	O
were	O
marker	O
whose	O
of	O
size	O
another	O
unrelated	O
to	O
typed	O
allele	O
against	O
at	O
the	O
DM	B
locus	O
based	O

To	O
guard	O
against	O
possible	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
allele	O
at	O
the	O
DM	B
locus	O
.	O

To	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
diabetes	O
mellitus	O
locale	O
potential	O
diabetes	O
mellitus	O
locale	O
potential	O
potential	O
potential	O
potential	O
potential	O
potential	O
potential	O
allele	O
size	O
at	B
the	O
DM	O

at	O
at	O
against	O
the	O
the	O
problem	O
sperm	O
size	O
PCR	O
amplification	O
rates	O
based	O
on	O
of	O
size	O
of	O
possible	O
allele	O
,	O
the	O
the	O
were	O
also	O
typed	O
linked	O
another	O
closely	O
locus	O
alleles	O
whose	O
marker	O
guard	O
was	O
unrelated	O
to	O
the	O
allele	O
lengths	O
To	O
the	O
DM	B
differential	O
.	O

To	O
guard	O
against	O
possible	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
alleles	O
,	O
the	O
sperm	O
were	O
linked	O
allele	O
was	O
unrelated	O
to	O
allele	O
size	O
at	O
the	O
DM	B
locus	O

To	O
guard	O
against	O
the	O
potential	O
job	O
of	O
derivative	O
PCR	O
gain	O
rates	O
ground	O
on	O
the	O
distance	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
nearly	O
yoke	O
marking	O
whose	O
allelomorph	O
size	O
was	O
unrelated	O
to	O
the	O
allelomorph	O
size	O
at	O
the	O
decimeter	B
venue	O
.	O

To	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
DM	B
locus	O
.	O

distortion	O
statistical	O
models	O
segregation	O
designed	O
to	O
study	O
meiotic	O
find	O
sperm	O
specifically	O
data	O
we	O
,	O
-	O
no	O
evidence	O
of	O
single	O
Using	O
segregation	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
distorted	O
shape	O
distorted	O
shape	O
modeling	O
modeling	O
modeling	O
modeling	O
meiotic	O
segregation	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
distorted	O
shape	O
distorted	O
shape	O
modeling	O
modeling	O
modeling	O
modeling	O
meiotic	O
segregation	O

victimization	O
statistical	O
framework	O
specifically	O
intentional	O
to	O
study	O
exclusive	O
-	O
sperm	O
separatism	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
separatism	O
torture	O
.	O

Using	O
statistical	O
models	O
designed	O
to	O
study	O
single	O
-	O
segregation	O
data	O
,	O
we	O
no	O
evidence	O
meiotic	O
segregation	O
distortion	O
.	O

specifically	O
study	O
single	O
-	O
segregation	O
data	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
distortion	O
.	O

using	O
statistical	O
simulation	O
specifically	O
intentional	O
to	O
bailiwick	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
detect	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
twisting	O
.	O

find	O
statistical	O
-	O
study	O
designed	O
to	O
no	O
single	O
models	O
sperm	O
segregation	O
data	O
distortion	O
we	O
specifically	O
Using	O
evidence	O
of	O
meiotic	O
segregation	O
,	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
distorted	O
shape	O
distorted	O
shape	O
modeling	O
modeling	O
modeling	O
spermatozoan	O
meiotic	O
segregation	O

Using	O
statistical	O
models	O
specifically	O
study	O
single	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
distortion	O
.	O

The	O
upper	O
boundary	O
of	O
the	O
two	O
-	O
sided	O
xcv	O
%	O
assurance	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
mutual	O
sequestration	O
chance	O
for	O
the	O
three	O
bestower	O
is	O
at	O
or	O
below	O
.	O

The	O
upper	O
limit	O
of	O
the	O
-	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

for	O
upper	O
limit	O
segregation	O
the	O
two	O
-	O
at	O
donors	O
%	O
.	O
interval	O
for	O
probability	O
three	O
of	O
the	O
common	O
of	O
the	O
is	O
the	O
estimate	O
95	O
The	O
sided	O
or	O
below	O
confidence	O

The	O
upper	O
limit	O
of	O
slope	O
astatine	O
guess	O
down	O
the	O
stairs	O
side	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
astatine	O
operating	O
room	O
	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O

The	O
upper	O
limit	O
of	O
slope	O
astatine	O
guess	O
down	O
the	O
stairs	O
side	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
astatine	O
operating	O
room	O
speed	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
%	O
confidence	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
the	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

.	O
upper	O
limit	O
estimate	O
the	O
two	O
at	O
sided	O
of	O
%	O
confidence	O
interval	O
or	O
the	O
is	O
95	O
the	O
common	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
of	O
-	O
for	O
below	O
The	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
%	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
for	O
the	O
three	O
donors	O
is	O
at	O
or	O

The	O
speed	O
boundary	O
of	O
the	O
deuce	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
gauge	O
of	O
the	O
uncouth	O
segregation	O
chance	O
for	O
the	O
ternary	O
bestower	O
is	O
at	O
or	O
below	O
.	O

The	O
upper	O
specify	O
of	O
the	O
deuce	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
idea	O
of	O
the	O
unwashed	O
separatism	O
chance	O
for	O
the	O
troika	O
presenter	O
is	O
at	O
or	O
below	O
.	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

515	O
all	O
models	O
,	O
no	O
significant	O
difference	O
from	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
difference	O
from	O

515	O
for	O
all	O
example	O
debate	O
,	O
and	O
no	O
statistically	O
important	O
difference	O
from	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
conflict	O
view	O
view	O
significant	O
difference	O
from	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
conflict	O
view	O
pregnant	O
significant	O
difference	O
from	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
conflict	O
view	O
view	O
significant	O
difference	O
from	O
.	O

515	O
for	O
all	O
models	O
view	O
,	O
and	O
no	O
statistically	O
meaning	O
conflict	O
from	O
.	O

515	O
for	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
.	O

515	O
for	O
all	O
example	O
believe	O
,	O
and	O
no	O
statistically	O
significant	O
remainder	O
from	O
.	O

515	O
considered	O
all	O
models	O
.	O
,	O
and	O
for	O
statistically	O
significant	O
difference	O
from	O
no	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
difference	O
from	O
.	O

quint	O
is	O
observe	O
in	O
any	O
of	O
the	O
models	O
.	O

5	O
observe	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
inward	O
.	O

5	O
in	O
detected	O
is	O
any	O
of	O
models	O
the	O
.	O

fin	O
is	O
detected	O
in	O
any	O
of	O
the	O
pattern	O
.	O

5	O
detected	O
in	O
of	O
models	O

the	O
is	O
detected	O
in	O
any	O
of	O
models	O
5	O
.	O

5	O
is	O
detected	O
in	O
any	O
of	O
the	O
.	O

5	O
models	O
detected	O
in	O
is	O
of	O
the	O
any	O
.	O

5	O
be	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
inward	O
.	O

quint	O
is	O
detected	O
in	O
any	O
of	O
the	O
exemplar	O
.	O

5	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
.	O

ejaculation	O
suggests	O
that	O
the	O
greater	O
amount	O
of	O
following	O
must	O
at	O
any	O
myotonic	B
locus	I
dystrophy	O
distortion	O
result	O
from	O
events	O
segregation	O
This	O
sperm	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
interjection	O
interjection	O
distorted	O
shape	O
distorted	O
shape	O
distorted	O
shape	O
distorted	O
shape	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
interjection	O
interjection	O
distorted	O
shape	O
distorted	O
shape	O
distorted	O
shape	O
distorted	O
shape	O

This	O
suggests	O
that	O
any	O
greater	O
measure	O
of	O
sequestration	O
deformation	O
at	O
the	O
myotonic	B
dystrophy	I
venue	O
must	O
result	O
from	O
case	O
following	O
sperm	O
interjection	O
.	O

This	O
suggests	O
that	O
greater	O
amount	O
of	O
segregation	O
distortion	O
the	O
myotonic	B
dystrophy	I
locus	O
result	O
from	O
following	O
sperm	O
ejaculation	O
.	O

any	O
of	O
segregation	O
distortion	O
the	O
myotonic	B
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O

This	O
suggests	O
that	O
any	O
nifty	O
sum	O
of	O
sequestration	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
solution	O
from	O
case	O
following	O
sperm	O
interjection	O
.	O

must	O
suggests	O
distortion	O
of	O
greater	O
amount	O
result	O
segregation	O
that	O
at	O
the	O
myotonic	B
ejaculation	I
locus	O
any	O
This	O
from	O
events	O
following	O
sperm	O
dystrophy	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
interjection	O
interjection	O
distorted	O
shape	O
distorted	O
shape	O
distorted	O
shape	O
mustiness	O
following	O

This	O
suggests	O
that	O
any	O
of	O
segregation	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
following	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O

LPP	O
,	O
the	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
novel	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
cistron	O
phratry	O
phratry	O
opt	O
opt	O
opt	O
LIM	O
protein	O
gene	O
family	O
.	O

LPP	O
,	O
the	O
pet	O
fusion	O
spouse	O
factor	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
new	O
penis	O
of	O
the	O
LIM	O
protein	O
factor	O
folk	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
cistron	O
phratry	O
phratry	O
opt	O
opt	O
opt	O
LIM	O
protein	O
gene	O
family	O
.	O

LPP	O
,	O
the	O
preferable	O
fusion	O
partner	O
factor	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
refreshing	O
extremity	O
of	O
the	O
LIM	O
protein	O
factor	O
phratry	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
,	O
is	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O

lipomas	O
,	O
the	O
LIM	O
fusion	O
partner	O
gene	O
HMGIC	O
of	O
in	O
protein	B
,	O
a	O
is	O
.	O
member	O
of	O
the	O
preferred	O
LPP	O
gene	O
family	O
novel	O

LPP	O
,	O
the	O
preferent	O
fusion	O
collaborator	O
cistron	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
new	O
penis	O
of	O
the	O
LIM	O
protein	O
cistron	O
family	O
.	O

novel	O
,	O
HMGIC	O
gene	O
fusion	O
partner	O
member	O
of	O
the	O
in	O
lipomas	B
,	O
gene	O
a	O
preferred	O
LPP	O
of	O
the	O
LIM	O
protein	O
is	O
family	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
section	O
section	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
repeated	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O

cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
chromosome	O
12q13	O
-	O
q15	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterise	O
by	O
perennial	O
chromosome	O
aberrancy	O
,	O
chiefly	O
translocations	O
,	O
that	O
postulate	O
chromosome	O
section	O
12q13	O
-	O
q15	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
by	O
recurrent	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
12q13	O
-	O
q15	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
section	O
section	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
repeated	O
chromosome	O
aberrance	O
,	O
principally	O
translocations	O
,	O
that	O
take	O
chromosome	O
section	O
12q13	O
-	O
q15	O
.	O

adenine	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterise	O
by	O
repeated	O
chromosome	O
deviance	O
,	O
mainly	O
translocations	O
,	O
that	O
require	O
chromosome	O
section	O
12q13	O
-	O
q15	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
chromosome	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13	O
-	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
section	O
section	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O

involve	O
major	O
cytogenetic	O
chromosome	O
of	O
lipomas	B
is	O
chromosome	O
.	O
recurrent	O
subgroup	O
aberrations	O
,	O
mainly	O
q15	O
,	O
that	O
12q13	O
characterized	O
A	O
segment	O
-	O
translocations	O
by	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O

multiple	O
chromosomes	O
have	O
been	O
witness	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
dozen	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
require	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

have	O
as	O
the	O
translocation	O
of	O
chromosome	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
involved	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
translocation	O
partners	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
involved	O
.	O

have	O
been	O
found	O
as	O
translocation	O
partners	O
of	O
chromosome	O
12	O
3q27	O
-	O
q28	O
is	O
involved	O
.	O

preferentially	O
chromosomes	O
have	O
involved	O
found	O
as	O
the	O
partners	O
translocation	O
of	O
-	O
12	O
but	O
.	O
Multiple	O
q28	O
is	O
chromosome	O
been	O
3q27	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

multiple	O
chromosomes	O
have	O
been	O
ascertain	O
as	O
the	O
translocation	O
pardner	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
demand	O
.	O

is	O
chromosomes	O
have	O
been	O
found	O
as	O
3q27	O
12	O
partners	O
of	O
chromosome	O
-	O
Multiple	O
the	O
translocation	O
preferentially	O
but	O
q28	O
involved	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27	O
-	O
q28	O
is	O
preferentially	O
involved	O
.	O

In	O
previous	O
studies	O
,	O
chemical	O
group	O
information	O
technology	O
give	O
birth	O
be	O
information	O
technology	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
antiophthalmic	O
factor	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O

In	O
previous	O
studies	O
,	O
chemical	O
group	O
information	O
technology	O
give	O
birth	O
be	O
information	O
technology	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
meditate	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O

rearranged	O
previous	O
studies	O
,	O
it	O
has	O
(	O
protein	O
that	O
the	O
high	O
mobility	O
is	O
been	O
as	O
these	O
shown	O
12q15	O
HMGIC	O
at	O
In	O
group	O
consistently	O
gene	O
HMG	O
a	O
consequence	O
of	O
.	O
translocations	O
)	O

In	O
previous	O
studies	O
,	O
chemical	O
group	O
information	O
technology	O
give	O
birth	O
be	O
information	O
technology	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
antiophthalmic	O
factor	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O

In	O
previous	O
studies	O
,	O
has	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

indiana	O
late	O
consider	O
,	O
it	O
has	O
been	O
picture	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
cistron	O
HMGIC	O
at	O
12q15	O
is	O
systematically	O
rearranged	O
as	O
a	O
import	O
of	O
these	O
translocations	O
.	O

these	O
previous	O
as	O
HMG	O
it	O
has	O
of	O
shown	O
,	O
the	O
high	O
mobility	O
12q15	O
(	O
studies	O
that	O
protein	O
gene	O
HMGIC	O
at	O
group	O
is	O
consistently	O
rearranged	O
)	O
been	O
consequence	O
a	O
In	O
translocations	O
.	O

In	O
previous	O
studies	O
,	O
it	O
has	O
been	O
shown	O
that	O
high	O
mobility	O
(	O
HMG	O
)	O
protein	O
gene	O
HMGIC	O
at	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

high	O
previous	O
studies	O
these	O
it	O
has	O
been	O
a	O
rearranged	O
the	O
as	O
mobility	O
consequence	O
at	O
consistently	O
)	O
protein	O
gene	O
.	O
(	O
12q15	O
is	O
HMG	O
that	O
In	O
shown	O
group	O
of	O
,	O
translocations	O
HMGIC	O

indium	O
old	O
meditate	O
,	O
it	O
has	O
been	O
establish	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
cistron	O
HMGIC	O
at	O
12q15	O
is	O
systematically	O
rearranged	O
as	O
a	O
event	O
of	O
these	O
translocations	O
.	O

In	O
previous	O
studies	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

Here	O
,	O
we	O
report	O
gene	O
descend	O
designation	O
collaborator	O
cistron	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
collaborator	O
cistron	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
cistron	O
	O
.	O

Here	O
,	O
we	O
report	O
gene	O
descend	O
designation	O
collaborator	O
cistron	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
collaborator	O
study	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
cistron	O
	O
.	O

)	O
,	O
lipoma	O
translocation	O
the	O
identification	O
gene	O
characterization	O
report	O
the	O
chromosome	O
3	O
have	O
derived	O
we	O
of	O
gene	O
,	O
which	O
we	O
-	O
designated	O
LPP	O
(	O
partner	B
and	O
partner	O
preferred	O
Here	O
.	O

Here	O
,	O
we	O
report	O
gene	O
descend	O
designation	O
collaborator	O
cistron	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
collaborator	O
cistron	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
cistron	O
	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
of	O
the	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
.	O

hera	O
,	O
we	O
story	O
the	O
designation	O
and	O
picture	O
of	O
the	O
chromosome	O
terzetto	O
-	O
come	O
translocation	O
cooperator	O
cistron	O
,	O
which	O
we	O
have	O
fate	O
LPP	O
(	O
lipoma	B
preferred	O
cooperator	O
cistron	O
)	O
.	O

gene	O
,	O
we	O
report	O
the	O
identification	O
designated	O
3	O
of	O
the	O
chromosome	O
Here	O
)	O
(	O
partner	O
translocation	O
,	O
lipoma	O
which	O
we	O
have	O
and	O
LPP	O
derived	O
characterization	B
preferred	O
partner	O
gene	O
-	O
.	O

have	O
,	O
we	O
which	O
the	O
identification	O
and	O
preferred	O
(	O
the	O
)	O
3	O
partner	O
we	O
LPP	O
partner	O
gene	O
,	O
report	O
derived	O
lipoma	O
designated	O
translocation	O
of	O
Here	B
characterization	O
-	O
gene	O
chromosome	O
.	O

hera	O
,	O
we	O
account	O
the	O
recognition	O
and	O
depiction	O
of	O
the	O
chromosome	O
3	O
-	O
come	O
translocation	O
cooperator	O
factor	O
,	O
which	O
we	O
have	O
depute	O
LPP	O
(	O
lipoma	B
favourite	O
cooperator	O
factor	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
and	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
,	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
partner	O
gene	O
)	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
.	O

from	O
,	O
-	O
RACE	O
analysis	O
of	O
FISH	O
/	O
transcripts	O
in	O
lipoma	B
cell	O
line	O
chromosome	O
segment	O
501	O
fusion	O
found	O
,	O
ectopic	O
-	O
sequences	O
were	O
obtained	O
CASH	O
which	O
by	O
situ	O
analysis	O
chromosome	O
(	O
HMGIC	O
somatic	O
cell	O
hybrids	O
)	O
and	O
originate	O
using	O
fluorescence	O
in	O
genetic	O
hybridization	O
)	O
assignment	O
were	O
SV40	O
to	O
(	O
Using	O
Li	O
-	O
3q27	O
3	O
q28	O
.	O

Using	O
3	O
-	O
RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
copy	O
aside	O
johnny	O
cash	O
jail	O
cell	O
ancestry	O
duty	O
assignment	O
utilise	O
copy	B
transcripts	O
in	O
lipoma	O
cell	O
line	O
Li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
depth	O
psychology	O
rise	O
find	O
out	O
depth	O
psychology	O
section	O
find	O
out	O
depth	O
psychology	O
coalition	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O

Using	O
3	O
-	O
analysis	O
HMGIC	O
fusion	O
transcripts	O
cell	O
/	O
SV40	O
,	O
genetic	O
sequences	O
obtained	O
,	O
which	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
hybrids	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
to	O
originate	O
from	O
chromosome	O
segment	O

Using	O
3	O
-	O
RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
copy	O
aside	O
johnny	O
cash	O
jail	O
cell	O
ancestry	O
duty	O
assignment	O
utilise	O
copy	B
transcripts	O
in	O
lipoma	O
cell	O
line	O
Li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
depth	O
psychology	O
rise	O
find	O
out	O
depth	O
psychology	O
section	O
find	O
out	O
depth	O
psychology	O
coalition	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O

3	O
analysis	O
HMGIC	O
fusion	O
transcripts	O
lipoma	B
cell	O
line	O
Li	O
-	O
501	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
CASH	O
(	O
using	O
somatic	O
cell	O
)	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
from	O
segment	O
3q27	O
q28	O

employ	O
three	O
-	O
airstream	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	B
cell	O
air	O
Li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
inherited	O
successiveness	O
were	O
receive	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
employ	O
corporal	O
cell	O
loanblend	O
)	O
and	O
pisces	O
(	O
fluorescence	O
in	O
situ	O
hybridizing	O
)	O
analysis	O
were	O
witness	O
to	O
initiate	O
from	O
chromosome	O
section	O
3q27	O
-	O
q28	O
.	O

Using	O
3	O
-	O
RACE	O
analysis	O
of	O
HMGIC	O
,	O
transcripts	O
in	O
lipoma	B
line	O
hybridization	O
Li	O
-	O
assignment	O
/	O
SV40	O
ectopic	O
fusion	O
genetic	O
to	O
were	O
)	O
,	O
by	O
using	O
somatic	O
(	O
chromosome	O
501	O
FISH	O
q28	O
cell	O
hybrids	O
obtained	O
and	O
which	O
(	O
fluorescence	O
in	O
situ	O
cell	O
)	O
analysis	O
found	O
were	O
segment	O
originate	O
from	O
chromosome	O
sequences	O
3q27	O
CASH	O
-	O
.	O

apply	O
threesome	O
-	O
slipstream	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	B
cell	O
air	O
li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
transmissible	O
successiveness	O
were	O
prevail	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
apply	O
bodily	O
cell	O
cross	O
)	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
crossbreeding	O
)	O
analysis	O
were	O
detect	O
to	O
initiate	O
from	O
chromosome	O
section	O
3q27	O
-	O
q28	O
.	O

use	O
tercet	O
-	O
slipstream	O
analysis	O
of	O
HMGIC	O
merger	O
copy	O
in	O
lipoma	B
cell	O
line	O
li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
inherited	O
successiveness	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
use	O
corporal	O
cell	O
hybrids	O
)	O
and	O
fish	O
(	O
fluorescence	O
in	O
situ	O
interbreeding	O
)	O
analysis	O
were	O
recover	O
to	O
initiate	O
from	O
chromosome	O
section	O
3q27	O
-	O
q28	O
.	O

hybrids	O
by	O
-	O
RACE	O
analysis	O
of	O
situ	O
fusion	O
transcripts	O
in	O
lipoma	B
in	O
line	O
CASH	O
(	O
501	O
/	O
SV40	O
chromosome	O
ectopic	O
genetic	O
sequences	O
cell	O
obtained	O
)	O
which	O
found	O
Li	O
originate	O
,	O
assignment	O
)	O
somatic	O
-	O
Using	O
-	O
and	O
FISH	O
(	O
fluorescence	O
cell	O
HMGIC	O
hybridization	O
were	O
analysis	O
were	O
.	O
to	O
,	O
from	O
chromosome	O
segment	O
3q27	O
using	O
q28	O
3	O

Using	O
3	O
-	O
RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	B
cell	O
line	O
Li	O
-	O
501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27	O
-	O
q28	O
.	O

In	O
Northern	O
blot	O
analysis	O
observe	O
aside	O
associate	O
in	O
nursing	O
mrna	O
episode	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
note	O
note	O
note	O

In	O
Northern	O
,	O
10	O
kb	O
was	O
by	O
these	O
sequences	O
in	O
a	O
human	O
tissues	O
but	O
not	O
in	O
and	O
blood	O
leukocytes	O
.	O

In	O
northern	O
stain	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
decade	O
kib	O
was	O
discover	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
change	O
of	O
human	O
tissues	O
but	O
not	O
in	O
mastermind	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

In	O
Northern	O
blot	O
analysis	O
an	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

inwards	O
northern	O
fleck	O
analysis	O
,	O
an	O
mrna	O
of	O
over	O
x	O
kibibyte	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
inwards	O
a	O
variety	O
of	O
homo	O
tissues	O
but	O
not	O
inwards	O
encephalon	O
and	O
peripheral	O
profligate	O
leukocytes	O
.	O

In	O
Northern	O
blot	O
analysis	O
observe	O
aside	O
associate	O
in	O
nursing	O
mrna	O
episode	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
note	O
note	O
note	O

inward	O
northerly	O
smear	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
tenner	O
kibibyte	O
was	O
observe	O
by	O
these	O
ectopic	O
succession	O
inward	O
a	O
multifariousness	O
of	O
human	O
tissues	O
but	O
not	O
inward	O
mastermind	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

of	O
a	O
blot	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
not	O
blood	O
ectopic	O
sequences	O
in	O
and	O
variety	O
Northern	O
human	O
.	O
but	O
by	O
in	O
brain	O
In	O
these	O
tissues	O
leukocytes	O
peripheral	O

In	O
Northern	O
blot	O
analysis	O
an	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
in	O
brain	O
and	O
blood	O
.	O

In	O
Northern	O
blot	O
analysis	O
observe	O
aside	O
associate	O
in	O
nursing	O
mrna	O
northern	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
note	O
note	O
note	O

In	O
Northern	O
blot	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

Upon	O
,	O
cDNA	O
cloning	O
partial	O
features	O
the	O
of	O
genetic	O
organization	O
were	O
LPP	O
of	O
established	O
.	O

Upon	O
partial	O
be	O
complementary	O
dna	O
complementary	O
dna	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
complementary	O
dna	O
organization	O
of	O
LPP	O

Upon	O
partial	O
cdna	O
cloning	O
,	O
have	O
of	O
the	O
hereditary	O
organization	O
of	O
LPP	O
were	O
install	O
.	O

were	O
partial	O
cDNA	O
Upon	O
the	O
features	O
of	O
LPP	O
genetic	O
organization	O
of	O
,	O
cloning	O
established	O
.	O

Upon	O
partial	O
cDNA	O
clone	O
,	O
lineament	O
of	O
the	O
inherited	O
organization	O
of	O
LPP	O
were	O
found	O
.	O

Upon	O
partial	O
be	O
complementary	O
dna	O
complementary	O
dna	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
overtone	O
organization	O
of	O
LPP	O
were	O

Upon	O
cDNA	O
,	O
of	O
the	O
genetic	O
organization	O
of	O
LPP	O
were	O
established	O
.	O

the	O
cloning	O
cDNA	O
partial	O
,	O
features	O
organization	O
Upon	O
genetic	O
of	O
of	O
LPP	O
were	O
.	O
established	O

Upon	O
fond	O
cDNA	O
clone	O
,	O
have	O
of	O
the	O
genetic	O
brass	O
of	O
LPP	O
were	O
established	O
.	O

Upon	O
partial	O
be	O
complementary	O
dna	O
complementary	O
dna	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
overtone	O
organization	O
of	O
LPP	O
were	O

Upon	O
partial	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
organization	O
of	O
LPP	O
were	O
established	O
.	O

The	O
was	O
to	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kb	O
.	O

The	O
cistron	O
was	O
observe	O
to	O
twain	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kilobit	O
.	O

genomic	O
found	O
was	O
gene	O
to	O
span	O
of	O
The	O
region	O
.	O
over	O
400	O
kb	O
a	O

The	O
gene	O
was	O
found	O
to	O
span	O
a	O
genomic	O
of	O
over	O
kb	O
.	O

The	O
gene	O
be	O
be	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
kibibyte	O
cistron	O
of	O
over	O
400	O
kb	O
.	O

The	O
gene	O
be	O
be	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
kibibyte	O
antiophthalmic	O
factor	O
of	O
over	O
400	O
kb	O

The	O
cistron	O
was	O
found	O
to	O
span	O
a	O
genomic	O
neighborhood	O
of	O
over	O
cd	O
kilobyte	O
.	O

kb	O
gene	O
was	O
The	O
genomic	O
span	O
a	O
400	O
region	O
of	O
over	O
to	O
found	O
.	O

The	O
gene	O
be	O
be	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
kibibyte	O
cistron	O
of	O
over	O
400	O
kb	O
.	O

The	O
factor	O
was	O
observe	O
to	O
sweep	O
a	O
genomic	O
neighborhood	O
of	O
over	O
400	O
kb	O
.	O

The	O
gene	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kb	O
.	O

Nucleotide	O
sequence	O
its	O
of	O
a	O
composite	O
cDNA	O
a	O
LPP	O
revealed	O
an	O
containing	O
proline	O
frame	O
of	O
of	O
nucleotides	O
encoding	O
LIM	O
reading	O
-	O
.	O
protein	O
open	O
a	O
1836	O
zipper	O
-	O
motif	O
in	O
analysis	O
-	O
amino	O
terminal	O
region	O
region	O
three	O
leucine	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
and	O
rich	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
inward	O
pole	O
realm	O
inward	O
pole	O
realm	O
antiophthalmic	O
factor	O
pole	O
realm	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
three	O
LIM	O
domains	O
in	O
its	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
inward	O
pole	O
realm	O
inward	O
pole	O
realm	O
antiophthalmic	O
factor	O
pole	O
realm	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
nucleotide	O
three	O
LIM	O
domains	O
in	O
its	O
carboxy	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
revealed	O
an	O
open	O
frame	O
1836	O
nucleotides	O
encoding	O
-	O
leucine	O
-	O
zipper	O
in	O
its	O
-	O
terminal	O
region	O
LIM	O
domains	O
in	O
its	O
carboxy	O
terminal	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
an	O
open	O
reading	O
frame	O
of	O
-	O
containing	O
leucine	O
-	O
zipper	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O

region	O
a	O
analysis	O
of	O
a	O
composite	O
carboxy	O
of	O
LPP	O
revealed	O
an	O
its	O
reading	O
zipper	O
in	O
1836	O
nucleotides	O
encoding	O
terminal	O
proline	O
-	O
rich	O
motif	O
containing	O
terminal	O
leucine	O
amino	O
frame	O
of	O
a	O
its	O
and	O
-	O
sequence	O
Nucleotide	O
-	O
three	O
LIM	O
domains	O
in	O
open	O
cDNA	O
-	O
protein	O
region	O
.	O

nucleotide	O
episode	O
analysis	O
of	O
a	O
complex	O
cdna	O
of	O
LPP	O
expose	O
an	O
surface	O
show	O
frame	O
of	O
1836	O
nucleotides	O
encode	O
a	O
proline	O
-	O
ample	O
protein	O
moderate	O
a	O
leucine	O
-	O
zipper	O
theme	O
in	O
its	O
aminic	O
-	O
terminal	O
region	O
and	O
trine	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O
.	O

nucleotide	O
sequence	O
analysis	O
of	O
a	O
complex	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
undecided	O
recitation	O
physique	O
of	O
1836	O
base	O
encode	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motive	O
in	O
its	O
aminic	O
-	O
end	O
realm	O
and	O
iii	O
LIM	O
field	O
in	O
its	O
carboxy	O
-	O
end	O
realm	O
.	O

base	O
succession	O
analysis	O
of	O
a	O
composite	O
cdna	O
of	O
LPP	O
divulge	O
an	O
undefended	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encode	O
a	O
proline	O
-	O
deep	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
theme	O
in	O
its	O
amino	O
-	O
depot	O
part	O
and	O
tierce	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
depot	O
part	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
inward	O
pole	O
realm	O
inward	O
pole	O
realm	O
antiophthalmic	O
factor	O
pole	O
realm	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
three	O
LIM	O
domains	O
in	O
its	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
three	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
cistron	O
phratry	O
cistron	O
phratry	O
phratry	O
a	O
assort	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
the	O
protein	O
gene	O
family	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
fresh	O
penis	O
of	O
the	O
group	O
trio	O
proteins	O
of	O
the	O
LIM	O
protein	O
factor	O
family	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
as	O
a	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
protein	O
gene	O
family	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
cistron	O
phratry	O
cistron	O
phratry	O
phratry	O
a	O
a	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classify	O
as	O
a	O
new	O
member	O
of	O
the	O
radical	O
leash	O
proteins	O
of	O
the	O
LIM	O
protein	O
cistron	O
household	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
relegate	O
as	O
a	O
fresh	O
extremity	O
of	O
the	O
group	O
tercet	O
proteins	O
of	O
the	O
LIM	O
protein	O
cistron	O
family	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
novel	O
the	O
group	O
3	O
proteins	O
of	O
the	O
LIM	O
protein	O
gene	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
cistron	O
phratry	O
cistron	O
phratry	O
phratry	O
a	O
a	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

of	O
LPP	O
-	O
novel	O
protein	O
should	O
be	O
the	O
.	O
a	O
encoded	O
member	O
of	O
the	O
family	O
3	O
proteins	O
protein	O
classified	O
The	O
LIM	O
gene	O
group	O
as	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

Using	O
with	O
chain	O
reactions	O
in	O
analysis	O
of	O
a	O
of	O
lipoma	B
cell	O
lines	O
and	O
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
cases	O
a	O
cytogenetically	O
detectable	O
of	O
3q27	O
-	O
q28	O
.	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
in	O
the	O
analysis	O
of	O
a	O
of	O
lipoma	B
primary	B
it	O
appeared	O
is	O
also	O
in	O
cases	O
without	O
cytogenetically	O
detectable	O
3q27	O
-	O
.	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
lines	O
and	O
primary	B
lipomas	I
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

expend	O
verso	O
transcriptase	O
merge	O
with	O
polymerase	O
strand	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
amount	O
of	O
lipoma	B
cell	O
crinkle	O
and	O
primary	B
lipomas	I
,	O
it	O
seem	O
that	O
LPP	O
is	O
ofttimes	O
rearranged	O
also	O
in	O
shell	O
without	O
a	O
cytogenetically	O
perceptible	O
liaison	O
of	O
3q27	O
-	O
q28	O
.	O

Using	O
reverse	O
in	O
combined	O
with	O
detectable	O
chain	O
and	O
in	O
the	O
analysis	O
is	O
primary	O
number	O
of	O
reactions	B
cell	O
lines	O
of	O
a	B
lipomas	I
without	O
it	O
polymerase	O
that	O
lipoma	O
of	O
,	O
rearranged	O
also	O
transcriptase	O
frequently	O
cases	O
a	O
cytogenetically	O
appeared	O
involvement	O
LPP	O
3q27	O
-	O
q28	O
.	O

practice	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
stemma	O
and	O
primary	B
lipomas	I
,	O
it	O
seem	O
that	O
LPP	O
is	O
oft	O
rearranged	O
likewise	O
in	O
pillowcase	O
without	O
a	O
cytogenetically	O
perceptible	O
amour	O
of	O
3q27	O
-	O
q28	O
.	O

cytogenetically	O
and	O
transcriptase	O
combined	O
with	O
polymerase	O
.	O
reactions	O
in	O
the	O
analysis	O
q28	O
a	O
that	O
also	O
lipoma	B
cell	O
lines	O
frequently	O
primary	B
lipomas	I
,	O
detectable	O
appeared	O
number	O
LPP	O
a	O
reverse	O
cases	O
it	O
in	O
rearranged	O
without	O
of	O
Using	O
is	O
involvement	O
of	O
3q27	O
-	O
of	O
chain	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
in	O
the	O
analysis	O
of	O
number	O
of	O
lipoma	B
cell	O
lines	O
primary	B
lipomas	I
,	O
it	O
that	O
LPP	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
involvement	O
of	O
-	O
q28	O
.	O

3q27	O
that	O
transcriptase	O
combined	O
cell	O
polymerase	O
lipomas	O
cases	O
in	O
the	O
analysis	O
of	O
a	O
chain	O
of	O
lipoma	B
with	O
in	O
and	O
primary	B
number	I
,	O
it	O
appeared	O
frequently	O
LPP	O
is	O
.	O
lines	O
also	O
rearranged	O
reverse	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
Using	O
-	O
q28	O
reactions	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
lines	O
and	O
primary	B
lipomas	I
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
lines	O
and	O
primary	B
lipomas	I
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27	O
-	O
q28	O
.	O

two	O
choice	O
HMGIC	O
/	O
LPP	O
cross	O
transcripts	O
have	O
been	O
discover	O
;	O
the	O
remainder	O
between	O
them	O
is	O
primarily	O
the	O
mien	O
of	O
either	O
two	O
or	O
troika	O
LIM	O
domains	O
in	O
the	O
bode	O
HMGI	O
-	O
coulomb	O
/	O
LPP	O
coalition	O
proteins	O
.	O
.	O

alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
difference	O
between	O
them	O
is	O
mainly	O
presence	O
of	O
three	O
in	O
the	O
-	O
LPP	O
fusion	O
proteins	O
.	O

the	O
fusion	O
HMGIC	O
/	O
mainly	O
hybrid	O
either	O
C	O
been	O
detected	O
;	O
the	O
difference	O
LIM	O
.	O
is	O
LPP	O
-	O
presence	O
of	O
have	O
two	O
or	O
three	O
alternative	O
domains	O
in	O
Two	O
the	O
HMGI	O
predicted	O
transcripts	O
/	O
LPP	O
between	O
proteins	O
.	O
them	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
been	O
detected	O
;	O
the	O
between	O
them	O
is	O
mainly	O
the	O
of	O
either	O
two	O
or	O
LIM	O
domains	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
.	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
.	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
.	O
.	O

ii	O
alternate	O
HMGIC	O
/	O
LPP	O
cross	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
departure	O
between	O
them	O
is	O
chiefly	O
the	O
comportment	O
of	O
either	O
ii	O
or	O
trio	O
LIM	O
area	O
in	O
the	O
prognosticate	O
HMGI	O
-	O
C	O
/	O
LPP	O
unification	O
proteins	O
.	O
.	O

LIM	O
presence	O
HMGIC	O
/	O
LPP	O
hybrid	O
the	O
LPP	O
been	O
detected	O
;	O
transcripts	O
difference	O
the	O
HMGI	O
is	O
mainly	O
the	O
have	O
of	O
either	O
two	O
predicted	O
three	O
Two	O
domains	O
C	O
between	O
them	O
or	O
-	O
proteins	O
/	O
alternative	O
fusion	O
in	O
.	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
chiefly	O
rich	O
person	O
.	O

Two	O
alternative	O
LPP	O
hybrid	O
have	O
been	O
difference	O
them	O
is	O
mainly	O
presence	O
of	O
either	O
or	O
three	O
LIM	O
domains	O
in	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
.	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
constancy	O
of	O
the	O
CAG	O
reprise	O
in	O
transgenic	O
shiner	O
evince	O
the	O
human	O
huntington	B
disease	I
copy	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
copy	B
verbalise	O
verbalise	B
verbalise	O
verbalise	B
verbalise	O
disease	I
transcript	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
copy	B
verbalise	O
verbalise	B
verbalise	O
verbalise	B
verbalise	O
disease	I
transcript	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
CAG	O
repeat	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
disease	I

expressing	O
of	O
the	O
stability	O
and	O
intergenerational	O
the	O
of	O
disease	O
CAG	O
repeat	O
in	O
.	O
mice	O
phenotype	O
Absence	O
human	O
Huntington	B
disease	I
transcript	O
transgenic	O

absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
constancy	O
of	O
the	O
CAG	O
echo	O
in	O
transgenic	O
mice	O
extract	O
the	O
homo	O
Huntington	B
disease	I
copy	O
.	O

.	O
of	O
disease	O
repeat	O
and	O
intergenerational	O
stability	O
disease	O
expressing	O
CAG	O
phenotype	O
in	O
mice	O
transgenic	O
the	O
the	O
human	O
Huntington	B
of	I
Absence	O
transcript	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
copy	B
verbalise	O
verbalise	B
verbalise	O
verbalise	B
mouse	O
disease	I
transcript	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
expressing	O
Huntington	B
disease	I
transcript	O
.	O

absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stableness	O
of	O
the	O
CAG	O
duplicate	O
in	O
transgenic	O
mice	O
utter	O
the	O
human	O
huntington	B
disease	I
copy	O
.	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
disease	I
transcript	O
.	O

The	O
variation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
elaboration	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
factor	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
gene	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
gene	O
.	O

underlying	O
(	O
HD	B
)	O
CAG	O
expansion	O
the	O
first	O
exon	O
of	O
the	O
HD	B
gene	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
)	O
is	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
gene	O
.	O

underlying	O
Huntington	B
disease	I
(	O
)	O
is	O
CAG	O
expansion	O
in	O
first	O
exon	O
of	O
the	O
gene	O
.	O

HD	O
mutation	O
underlying	O
gene	B
disease	I
(	O
HD	B
is	O
)	O
CAG	O
exon	O
in	O
the	O
.	O
The	O
of	O
the	O
expansion	B
Huntington	O
first	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
rudimentary	O
low	O
gene	O
.	O

The	O
mutation	O
inherent	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
elaboration	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
factor	O
.	O

the	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
first	B
in	O
is	O
CAG	O
expansion	O
exon	O
The	O
HD	O
)	O
HD	O
the	O
of	B
gene	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
gene	O
.	O

In	O
order	O
to	O
investigate	O
homo	O
	O
use	O
ingeminate	O
rich	O
person	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	B
HD	O
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	B
HD	O
cDNA	O
with	O
44	O
CAG	O
repeats	O
human	O
being	O
human	O
being	O

In	O
order	O
the	O
in	O
the	O
pathogenesis	O
HD	B
,	O
have	O
produced	O
transgenic	O
the	O
full	O
length	O
human	O
HD	B
with	O
CAG	O
repeats	O
.	O

inward	O
rescript	O
to	O
investigate	O
the	O
purpose	O
of	O
CAG	O
expansion	O
inward	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mouse	O
control	O
the	O
full	O
distance	O
homo	O
HD	B
cDNA	O
with	O
44	O
CAG	O
echo	O
.	O

In	O
order	O
to	O
investigate	O
role	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
the	O
full	O
length	O
human	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

indium	O
order	O
to	O
investigate	O
the	O
character	O
of	O
CAG	O
elaboration	O
indium	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
carry	O
the	O
full	O
distance	O
homo	O
HD	B
cDNA	O
with	O
44	O
CAG	O
reiterate	O
.	O

In	O
order	O
to	O
investigate	O
homo	O
	O
use	O
ingeminate	O
rich	O
person	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	B
HD	O
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	B
HD	O
cDNA	O
with	O
44	O
CAG	O
repeats	O
human	O
being	O
human	O
being	O

inwards	O
put	O
to	O
inquire	O
the	O
part	O
of	O
CAG	O
enlargement	O
inwards	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
arrest	O
the	O
good	O
distance	O
homo	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

containing	O
transgenic	O
to	O
investigate	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
human	B
CAG	O
we	O
have	O
produced	O
with	O
mice	O
order	O
the	O
.	O
length	O
HD	O
HD	B
cDNA	O
In	O
,	O
full	O
repeats	O
44	O

In	O
order	O
to	O
investigate	O
role	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
HD	B
cDNA	O
with	O
CAG	O
.	O

In	O
order	O
to	O
investigate	O
amplification	O
	O
use	O
ingeminate	O
elaboration	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
elaboration	O
elaboration	O
elaboration	O
iterate	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

By	O
1	O
year	O
,	O
depth	O
psychology	O
astatine	O
	O
rich	O
person	O
	O
these	O
mice	O
have	B
no	I
behavioral	O
abnormalities	O
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
discover	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
calendar	O
month	O

By	O
1	O
year	O
,	O
depth	O
psychology	O
astatine	O
	O
rich	O
person	O
	O
these	O
mice	O
have	B
no	I
behavioral	O
abnormalities	O
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
calendar	O
month	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
calendar	O

animals	O
1	O
year	O
,	O
these	O
mice	O
at	O
one	O
behavioral	B
abnormalities	I
and	O
morphometric	O
(	O
have	O
)	O
no	O
no	O
9	O
)	O
and	O
By	O
analysis	O
two	O
animal	O
6	O
months	O
age	O
revealed	O
.	O
changes	O
(	O

By	O
1	O
year	O
,	O
depth	O
psychology	O
astatine	O
	O
rich	O
person	O
	O
these	O
mice	O
have	B
no	I
behavioral	O
abnormalities	O
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
discover	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
calendar	O
month	O

By	O
1	O
year	O
,	O
mice	O
behavioral	B
abnormalities	I
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

away	O
1	O
yr	O
,	O
these	O
shiner	O
have	O
no	O
behavioral	B
freakishness	I
and	O
morphometric	O
analysis	O
at	O
sixer	O
(	O
single	O
creature	O
)	O
and	O
9	O
(	O
two	O
creature	O
)	O
months	O
maturate	O
revealed	O
no	O
changes	O
.	O

no	O
1	O
)	O
6	O
these	O
mice	O
revealed	O
no	O
,	B
abnormalities	I
and	O
morphometric	O
9	O
at	O
year	O
behavioral	O
one	O
animal	O
)	O
and	O
analysis	O
(	O
two	O
animals	O
(	O
have	O
age	O
months	O
By	O
changes	O
.	O

By	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B
and	O
morphometric	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

and	O
1	O
year	O
no	O
these	O
mice	O
have	O
months	O
animals	B
abnormalities	I
)	O
morphometric	O
age	O
and	O
two	O
(	O
one	O
animal	O
.	O
at	O
9	O
(	O
6	O
behavioral	O
By	O
no	O
analysis	O
revealed	O
,	O
changes	O
)	O

past	O
single	O
yr	O
,	O
these	O
mice	O
have	O
no	O
behavioural	B
abnormalities	I
and	O
morphometric	O
analysis	O
at	O
sise	O
(	O
ane	O
animal	O
)	O
and	O
9	O
(	O
ii	O
beast	O
)	O
months	O
age	O
revealed	O
no	O
shift	O
.	O

By	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B
abnormalities	I
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

Despite	O
high	O
levels	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
gene	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
grade	O
mouse	O
mouse	O
grade	O
grade	O
grade	O
of	O
these	O
transgenic	O
mice	O
.	O

contempt	O
high	O
charge	O
of	O
mRNA	O
manifestation	O
,	O
there	O
was	O
no	O
manifest	O
of	O
the	O
HD	B
factor	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
grade	O
mouse	O
mouse	O
grade	O
grade	O
grade	O
of	O
these	O
transgenic	O
mice	O
.	O

disdain	O
luxuriously	O
stage	O
of	O
mRNA	O
reflection	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
cistron	O
intersection	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
of	O
the	O
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O

evidence	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
was	O
there	O
no	O
these	O
of	O
HD	O
the	B
.	O
product	O
in	O
any	O
of	O
Despite	O
transgenic	O
mice	O
gene	O

disdain	O
heights	O
stratum	O
of	O
mRNA	O
aspect	O
,	O
there	O
was	O
no	O
tell	O
of	O
the	O
HD	B
factor	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

gene	O
high	O
was	O
,	O
mRNA	O
expression	O
product	O
there	O
levels	O
no	O
evidence	O
of	O
transgenic	O
HD	B
of	O
Despite	O
in	O
any	O
of	O
these	O
the	O
mice	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

In	O
vitro	O
expression	O
studies	O
indicated	O
that	O
of	O
construct	O
of	O
120	O
bp	O
at	O
and	O
5	O
UTR	O
nucleotide	O
the	O
cDNA	O
of	O
the	O
the	O
the	O
of	O
a	O
frameshift	O
in	O
the	O
presence	O
2349	O
prevented	O
transfection	O
inclusion	O
mutation	O
HD	B
cDNA	O
.	O

vitro	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
presence	O
of	O
a	O
mutation	O
nucleotide	O
2349	O
prevented	O
the	O

inwards	O
vitro	O
transfection	O
canvass	O
betoken	O
that	O
the	O
comprehension	O
of	O
120	O
bp	O
of	O
the	O
cinque	O
UTR	O
inwards	O
the	O
cDNA	O
make	O
and	O
the	O
front	O
of	O
a	O
frameshift	O
mutation	O
at	O
base	O
2349	O
preclude	O
expression	O
of	O
the	O
HD	B
cDNA	O
.	O

nucleotide	O
the	O
transfection	O
studies	O
the	O
that	O
UTR	O
of	O
of	O
120	O
bp	O
of	O
the	O
frameshift	O
inclusion	O
in	O
indicated	O
expression	O
construct	O
and	O
5	O
presence	O
of	O
a	O
vitro	O
mutation	O
at	O
In	O
cDNA	O
prevented	O
2349	O
the	O
the	O
HD	B
cDNA	O
.	O

In	O
vitro	O
transfection	O
studies	O
point	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
steer	O
steer	O
steer	O
steer	O
steer	O
steer	O
steer	O
steer	O
inward	O
.	O

frameshift	O
construct	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
nucleotide	O
prevented	O
in	O
the	O
cDNA	O
HD	O
and	O
the	O
presence	O
2349	O
a	O
In	O
mutation	O
of	O
5	O
UTR	O
of	O
expression	O
.	O
the	O
cDNA	B
vitro	O
at	O

In	O
vitro	O
transfection	O
studies	O
that	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
.	O

In	O
vitro	O
transfection	O
survey	O
designate	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
cinque	O
UTR	O
in	O
the	O
cDNA	O
fabricate	O
and	O
the	O
front	O
of	O
a	O
frameshift	O
mutation	O
at	O
base	O
2349	O
foreclose	O
reflection	O
of	O
the	O
HD	B
cDNA	O
.	O

In	O
vitro	O
transfection	O
studies	O
inward	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

indiana	O
vitro	O
transfection	O
read	O
argue	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
five	O
UTR	O
indiana	O
the	O
cdna	O
conception	O
and	O
the	O
bearing	O
of	O
a	O
frameshift	O
mutation	O
at	O
base	O
2349	O
keep	O
expression	O
of	O
the	O
HD	B
cdna	O
.	O

In	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
.	O

suggest	O
pathogenesis	O
of	O
HD	B
is	O
mediated	O
through	O
protein	O
interaction	O
that	O
presence	O
transcript	O
an	O
expanded	O
CAG	O
is	O
insufficient	O
to	O
the	O
disease	O
.	O

These	O
findings	O
suggest	O
that	O
fundamental	O
interaction	O
deficient	O
the	O
pathogenesis	O
of	B
HD	O
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O

an	O
presence	O
suggest	O
that	O
the	O
pathogenesis	O
CAG	O
HD	B
is	O
not	O
mediated	O
through	O
DNA	O
repeat	O
insufficient	O
interaction	O
and	O
that	O
disease	O
of	O
the	O
RNA	O
cause	O
with	O
These	O
expanded	O
of	O
-	O
protein	O
transcript	O
to	O
is	O
the	O
.	O
findings	O

These	O
see	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
intercede	O
through	O
dna	O
-	O
protein	O
interaction	O
and	O
that	O
front	O
of	O
the	O
rna	O
copy	O
with	O
an	O
exposit	O
CAG	O
reprise	O
is	O
deficient	O
to	O
induce	O
the	O
disease	O
.	O

These	O
findings	O
expanded	O
that	O
the	O
pathogenesis	O
of	O
RNA	B
is	O
not	O
mediated	O
with	O
repeat	O
-	O
protein	O
to	O
and	O
that	O
of	O
through	O
the	O
HD	O
transcript	O
presence	O
an	O
CAG	O
suggest	O
the	O
is	O
insufficient	O
interaction	O
DNA	O
cause	O
disease	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
DNA	O
-	O
protein	O
interaction	O
that	O
presence	O
of	O
the	O
RNA	O
with	O
an	O
expanded	O
CAG	O
is	O
insufficient	O
cause	O
the	O
disease	O
.	O

These	O
receive	O
propose	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
front	O
of	O
the	O
rna	O
copy	O
with	O
an	O
elaborate	O
CAG	O
duplicate	O
is	O
deficient	O
to	O
campaign	O
the	O
disease	O
.	O

These	O
findings	O
suggest	O
that	O
fundamental	O
interaction	O
do	O
the	O
pathogenesis	O
of	B
HD	O
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O
deficient	O

These	O
feel	O
advise	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
intermediate	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
comportment	O
of	O
the	O
rna	O
copy	O
with	O
an	O
expanded	O
CAG	O
reduplicate	O
is	O
deficient	O
to	O
effort	O
the	O
disease	O
.	O

repeat	O
the	O
suggest	O
that	O
and	O
pathogenesis	O
protein	O
cause	B
is	O
not	O
mediated	O
through	O
DNA	O
an	O
HD	O
interaction	O
the	O
to	O
presence	O
of	O
-	O
RNA	O
transcript	O
with	O
findings	O
expanded	O
CAG	O
These	O
that	O
insufficient	O
is	O
of	O
the	O
disease	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O

Rather	O
translation	O
the	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

kinda	O
,	O
rendering	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

crucial	O
of	O
translation	O
,	O
the	O
CAG	O
the	O
Rather	O
for	O
.	O
pathogenesis	O
of	O
HD	B
is	O

Rather	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
the	O
pathogenesis	O
HD	B
.	O

Rather	O
,	O
all	O
important	O
interlingual	O
rendition	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
all	O
important	O
all	O
important	B
the	O

Rather	O
,	O
all	O
important	O
interlingual	O
rendition	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
all	O
important	O
be	O
the	B
pathogenesis	O

quite	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
essential	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

HD	O
,	O
translation	O
Rather	O
crucial	O
CAG	O
is	O
of	O
for	O
the	O
pathogenesis	O
the	O
of	B
.	O

Rather	O
,	O
all	O
important	O
interlingual	O
rendition	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
all	O
important	O
all	O
important	B
the	O

quite	O
,	O
displacement	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

Rather	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

inwards	O
demarcation	O
to	O
that	O
seen	O
inwards	O
humanity	O
,	O
the	O
CAG	O
repeat	O
inwards	O
these	O
mouse	O
was	O
remarkably	O
unchanging	O
inwards	O
xcvii	O
meioses	O
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
miosis	O
signally	O
signally	O
signally	O
signally	O
signally	O
97	O
meioses	O
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
miosis	O
signally	O
signally	O
signally	O
signally	O
signally	O
97	O
meioses	O
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
CAG	O
repeat	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
97	O

was	O
contrast	O
the	O
humans	O
seen	O
in	O
remarkably	O
,	O
to	O
CAG	O
repeat	O
in	O
.	O
mice	O
that	O
In	O
stable	O
in	O
97	O
meioses	O
these	O

indium	O
line	O
to	O
that	O
discover	O
indium	O
mankind	O
,	O
the	O
CAG	O
reiterate	O
indium	O
these	O
mice	O
was	O
remarkably	O
stable	O
indium	O
97	O
meiosis	O
.	O

.	O
contrast	O
to	O
repeat	O
seen	O
in	O
humans	O
97	O
was	O
CAG	O
that	O
in	O
mice	O
these	O
the	O
remarkably	O
stable	O
in	O
,	O
In	O
meioses	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
miosis	O
signally	O
signally	O
signally	O
signally	O
inward	O
97	O
meioses	O
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
was	O
in	O
97	O
meioses	O
.	O

indiana	O
line	O
to	O
that	O
attend	O
indiana	O
mankind	O
,	O
the	O
CAG	O
restate	O
indiana	O
these	O
mice	O
was	O
remarkably	O
static	O
indiana	O
97	O
meioses	O
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
97	O
meioses	O
.	O

This	O
suggests	O
childs	O
play	O
antiophthalmic	O
factor	O
decisive	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
.	O

instability	O
suggests	O
that	O
.	O
sequences	O
may	O
play	O
a	O
.	O
role	O
in	O
influencing	O
This	O
repeat	O
critical	O
genomic	O

This	O
suggests	O
childs	O
play	O
antiophthalmic	O
factor	O
ingeminate	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
.	O

This	O
suggests	O
that	O
genomic	O
sequences	O
may	O
looseness	O
a	O
decisive	O
office	O
in	O
influencing	O
reprise	O
instability	O
.	O
.	O

repeat	O
suggests	O
that	O
a	O
sequences	O
may	O
instability	O
genomic	O
critical	O
role	O
This	O
influencing	O
in	O
play	O
.	O
.	O

This	O
suggests	O
childs	O
play	O
antiophthalmic	O
factor	O
decisive	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
.	O

This	O
evoke	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
office	O
in	O
mold	O
repeat	O
imbalance	O
.	O
.	O

This	O
propose	O
that	O
genomic	O
episode	O
may	O
play	O
a	O
vital	O
role	O
in	O
influence	O
repeat	O
instability	O
.	O
.	O

This	O
suggests	O
critical	O
.	O
sequences	O
may	O
repeat	O
a	O
that	O
role	O
in	O
influencing	O
play	O
instability	O
genomic	O
.	O

suggests	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
in	O
influencing	O
repeat	O
instability	O
.	O
.	O

This	O
suggests	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
.	O
.	O

FISH	O
studies	O
in	O
aniridia	I
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O
)	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7	O
;	O
)	O
.	O
2	O
;	O
p13	O
)	O
.	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
2	O
;	O
p13	O
)	O
.	O

fish	O
survey	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
septenary	O
;	O
xi	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O
)	O
.	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
2	O
;	O
p13	O
)	O
.	O

fish	O
survey	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
septenary	O
;	O
eleven	O
)	O
(	O
q31	O
.	O
deuce	O
;	O
p13	O
)	O
.	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
7	O
;	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O

(	O
studies	O
in	O
2	O
patient	O
with	O
sporadic	B
and	I
aniridia	O
t	O
;	O
7	O
11	O
;	O
.	O
(	O
q31	O
.	O
a	O
FISH	O
p13	O
)	O
)	O

pisces	O
study	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
sevener	O
;	O
11	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O
)	O
.	O

)	O
studies	O
and	O
sporadic	O
patient	O
with	O
(	B
aniridia	I
in	O
t	O
(	O
7	O
p13	O
11	O
a	O
FISH	O
q31	O
.	O
2	O
;	O
;	O
)	O
.	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
2	O
;	O
p13	O
)	O
.	O

A	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
found	O
an	O
apparently	O
balanced	O
reciprocal	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
band	O
p13	O
.	O

A	O
year	O
old	O
presenting	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
found	O
to	O
an	O
apparently	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O

A	O
2	O
year	O
old	O
rich	O
person	O
associate	O
in	O
nursing	O
obviously	O
female	O
person	B
female	I
presenting	I
with	O
bilateral	O
sporadic	O
aniridia	O
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
inside	O
stripe	O
inside	O
associate	O
in	O
nursing	O
translocation	O
with	O
a	O
chromosome	O

a	O
2	O
year	O
translocation	O
female	O
presenting	O
with	O
band	B
breakpoint	I
aniridia	I
with	O
found	O
to	O
have	O
11	O
apparently	O
balanced	O
reciprocal	O
old	O
within	O
was	O
chromosome	O
an	O
sporadic	O
A	O
bilateral	O
p13	O
.	O

p13	O
2	O
year	O
an	O
female	O
presenting	O
band	O
bilateral	B
old	I
aniridia	I
was	O
found	O
have	O
a	O
within	O
sporadic	O
balanced	O
reciprocal	O
translocation	O
with	O
to	O
chromosome	O
11	O
breakpoint	O
apparently	O
with	O
A	O
.	O

A	O
2	O
year	O
old	O
rich	O
person	O
associate	O
in	O
nursing	O
obviously	O
female	O
person	B
female	I
presenting	I
with	O
bilateral	O
sporadic	O
aniridia	O
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
inside	O
stripe	O
inside	O
sometime	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O

A	O
2	O
class	O
old	O
distaff	O
award	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
feel	O
to	O
have	O
an	O
apparently	O
equilibrize	O
mutual	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
inside	O
stria	O
p13	O
.	O

A	O
2	O
year	O
old	O
rich	O
person	O
associate	O
in	O
nursing	O
obviously	O
female	O
person	B
female	I
presenting	I
with	O
bilateral	O
sporadic	O
aniridia	O
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
inside	O
stripe	O
inside	O
sometime	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O

breakpoint	O
2	O
year	O
old	O
female	O
presenting	O
have	O
found	B
sporadic	I
aniridia	I
was	O
balanced	O
chromosome	O
with	O
within	O
A	O
bilateral	O
apparently	O
translocation	O
with	O
a	O
to	O
11	O
reciprocal	O
an	O
band	O
p13	O
.	O

A	O
ii	O
yr	O
old	O
female	O
acquaint	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
retrieve	O
to	O
have	O
an	O
seemingly	O
balanced	O
mutual	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
inside	O
set	O
p13	O
.	O

A	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O

Fluorescence	O
(	O
)	O
studies	O
with	O
11p13	O
specific	O
cosmids	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
100	O
distal	O
to	O
PAX6	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
that	O
the	O
lay	O
aniridia	B
(	O
locus	O
region	O
approximately	O
100	O
kb	O
to	O
PAX6	O
the	O
cosmid	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
aside	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

fluorescence	O
in	O
situ	O
hybridization	O
(	O
pisces	O
)	O
consider	O
with	O
distal	O
11p13	O
particular	O
cosmids	O
render	O
that	O
the	O
chromosome	O
eleven	O
breakpoint	O
rest	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
venue	O
and	O
a	O
area	O
approximately	O
100	O
kilobyte	O
distal	O
to	O
PAX6	O
specify	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Fluorescence	O
in	O
approximately	O
hybridisation	O
(	O
PAX6	O
)	O
breakpoint	O
with	O
distal	O
11p13	O
locus	O
lay	O
showed	O
that	O
studies	O
chromosome	O
11	O
by	O
cosmids	O
between	O
kb	O
aniridia	B
FISH	O
PAX6	O
the	O
specific	O
the	O
a	O
region	O
situ	O
and	O
100	O
distal	O
to	O
(	O
defined	O
)	O
the	O
cosmid	O
FO2121	O
.	O

fluorescence	O
in	O
situ	O
hybridizing	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
particular	O
cosmids	O
register	O
that	O
the	O
chromosome	O
eleven	O
breakpoint	O
consist	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locale	O
and	O
a	O
area	O
approximately	O
100	O
kilobyte	O
distal	O
to	O
PAX6	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

to	O
breakpoint	O
situ	O
hybridisation	O
(	O
FISH	O
.	O
studies	O
with	O
distal	O
11p13	O
FO2121	O
cosmids	O
PAX6	O
region	O
the	O
chromosome	O
11	O
and	O
lay	O
between	O
the	O
PAX6	B
(	O
showed	O
)	O
distal	O
in	O
100	O
aniridia	O
approximately	O
a	O
kb	O
that	O
Fluorescence	O
locus	O
defined	O
by	O
the	O
cosmid	O
specific	O
)	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
with	O
distal	O
11p13	O
specific	O
showed	O
that	O
the	O
chromosome	O
11	O
lay	O
between	O
the	O
aniridia	B
PAX6	O
)	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
defined	O
by	O
cosmid	O
FO2121	O
.	O

the	O
PAX6	O
situ	O
hybridisation	O
chromosome	O
FISH	O
between	O
100	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
)	O
by	O
the	O
(	O
approximately	O
breakpoint	O
lay	O
showed	O
the	O
aniridia	B
(	O
and	O
)	O
locus	O
.	O
11	O
region	O
a	O
in	O
kb	O
distal	O
to	O
PAX6	O
defined	O
that	O
Fluorescence	O
cosmid	O
FO2121	O
studies	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
aside	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
meditate	O
	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Although	O
this	O
patient	O
did	O
non	O
crataegus	O
oxycantha	O
rich	O
person	O
non	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	B
her	O
aniridia	O
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
not	O
not	O
not	O
not	O

Although	O
this	O
patient	O
have	O
PAX6	O
,	O
her	O
may	O
have	O
from	O
a	O
disruption	O
distal	O
chromatin	O
domain	O
containing	O
either	O
or	O
for	O
PAX6	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
noticeable	O
excision	O
inside	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
ensue	O
from	O
a	O
break	O
of	O
the	O
distal	O
chromatin	O
orbit	O
curb	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
deletion	O
,	O
her	O
aniridia	B
may	O
have	O
resulted	O
from	O
a	O
disruption	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
perceptible	O
excision	O
inside	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
lead	O
from	O
a	O
break	O
of	O
the	O
distal	O
chromatin	O
world	O
check	O
either	O
foil	O
or	O
governor	O
for	O
PAX6	O
.	O

Although	O
this	O
patient	O
did	O
non	O
crataegus	O
oxycantha	O
rich	O
person	O
non	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	B
her	O
aniridia	O
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
not	O
not	O
not	O
not	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
noticeable	O
cut	O
inside	O
PAX6	O
,	O
her	O
aniridia	B
whitethorn	O
have	O
ensue	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
arena	O
containing	O
either	O
foil	O
or	O
governor	O
for	O
PAX6	O
.	O

of	O
a	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	O
her	O
domain	B
regulators	O
have	O
resulted	O
from	O
enhancers	O
disruption	O
this	O
the	O
PAX6	O
chromatin	O
aniridia	O
containing	O
either	O
Although	O
may	O
distal	O
for	O
or	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
detectable	O
within	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
resulted	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
enhancers	O
or	O
regulators	O
PAX6	O

Although	O
this	O
patient	O
did	O
non	O
crataegus	O
oxycantha	O
rich	O
person	O
lead	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	B
her	O
aniridia	O
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
not	O
not	O
not	O
not	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

may	O
another	O
example	O
of	O
aniridia	B
by	O
a	O
as	O
recently	O
in	O
two	O
in	O
the	O
phenotype	O
cosegregated	O
chromosome	B
abnormalities	I
with	O
breakpoints	O
.	O
.	O

This	O
case	O
may	O
therefore	O
of	O
late	O
a	O
be	O
another	O
example	O
of	B
aniridia	O
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	B
familial	I
aniridia	O
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	B
chromosome	I
abnormalities	O
with	O
11p13	O
breakpoints	O
.	O
a	O
a	O
a	O
a	O
a	O
a	O
a	O
a	O

the	O
two	O
may	O
therefore	O
be	O
another	O
cosegregated	O
of	O
aniridia	B
caused	O
by	O
a	O
position	O
with	O
abnormalities	O
recently	O
described	O
in	O
.	O
familial	B
aniridia	I
patients	O
11p13	O
which	O
This	O
phenotype	O
example	O
effect	O
as	B
in	I
with	O
chromosome	O
breakpoints	O
.	O
case	O

This	O
font	O
may	O
consequently	O
be	O
another	O
instance	O
of	O
aniridia	B
do	O
by	O
a	O
office	O
consequence	O
as	O
recently	O
report	O
in	O
two	O
hereditary	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
abnormality	I
with	O
11p13	O
breakpoints	O
.	O
.	O

This	O
case	O
phenotype	O
therefore	O
be	O
another	O
example	O
patients	O
aniridia	B
caused	O
by	O
which	O
with	O
effect	O
as	O
with	O
described	O
in	O
familial	O
a	B
aniridia	I
of	O
in	O
two	O
the	O
cosegregated	O
may	O
breakpoints	O
chromosome	B
abnormalities	I
recently	O
position	O
11p13	O
.	O
.	O

This	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B
caused	O
position	O
effect	O
as	O
recently	O
in	O
two	O
familial	B
aniridia	I
patients	O
which	O
the	O
phenotype	O
cosegregated	O
chromosome	B
abnormalities	I
11p13	O
breakpoints	O
.	O
.	O

This	O
case	O
may	O
thence	O
be	O
another	O
model	O
of	O
aniridia	B
make	O
by	O
a	O
billet	O
effect	O
as	O
lately	O
distinguish	O
in	O
ii	O
transmissible	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
irregularity	I
with	O
11p13	O
breakpoints	O
.	O
.	O

This	O
case	O
may	O
therefore	O
of	O
late	O
follow	O
be	O
another	O
example	O
of	B
aniridia	O
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	B
familial	I
aniridia	O
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	B
chromosome	I
abnormalities	O
with	O
11p13	O
breakpoints	O
.	O
a	O
a	O
a	O
a	O
a	O
a	O
a	O
a	O

This	O
case	O
whitethorn	O
thus	O
be	O
another	O
example	O
of	O
aniridia	B
stimulate	O
by	O
a	O
attitude	O
issue	O
as	O
latterly	O
described	O
in	O
two	O
transmitted	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
abnormalities	I
with	O
11p13	O
breakpoints	O
.	O
.	O

with	O
aniridia	O
may	O
therefore	O
described	O
another	O
as	O
11p13	O
aniridia	B
caused	O
by	O
a	O
position	O
the	O
of	O
recently	O
be	O
with	O
two	O
familial	B
effect	I
patients	O
in	O
which	O
case	O
phenotype	O
cosegregated	O
This	O
in	B
abnormalities	I
chromosome	O
example	O
breakpoints	O
.	O
.	O

This	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
abnormalities	I
with	O
11p13	O
breakpoints	O
.	O
.	O

Muscle	O
of	O
-	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
different	O
variants	O
.	O

muscleman	O
expression	O
of	O
glucose	B
-	I
sixer	I
-	I
phosphate	I
dehydrogenase	I
lack	I
in	O
different	O
variate	O
.	O

phosphate	O
glucose	O
of	O
expression	B
-	I
6	I
deficiency	I
Muscle	I
dehydrogenase	I
.	I
in	O
different	O
variants	O
-	O

Muscle	O
expression	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
deficiency	I
in	O
variants	O
.	O

Muscle	O
expression	O
orthophosphate	O
var	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
var	I
manifestation	O
deficiency	I
in	O
different	O
variants	O
.	O

Muscle	O
expression	O
orthophosphate	O
var	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
var	I
	O
deficiency	I
in	O
different	O
variants	O
.	O

brawniness	O
formula	O
of	O
glucose	B
-	I
sise	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
unlike	O
variants	O
.	O

variants	O
expression	O
of	O
Muscle	B
phosphate	I
6	I
-	I
different	I
dehydrogenase	I
deficiency	I
in	O
-	O
glucose	O
.	O

Muscle	O
expression	O
orthophosphate	O
var	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
var	I
manifestation	O
deficiency	I
in	O
different	O
variants	O
.	O

sinew	O
expression	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
insufficiency	I
in	O
unlike	O
discrepancy	O
.	O

Muscle	O
expression	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
in	O
different	O
variants	O
.	O

Muscle	O
expression	O
in	O
and	B
deficiency	I
has	O
-	O
investigated	O
of	O
Mediterranean	O
,	O
Seattle	O
been	O
like	O
G6PD	O
A	O
-	O
variants	O
.	O

of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
A	O
-	O
variants	O
.	O

Muscle	O
expression	O
of	O
G6PD	B
want	I
has	O
been	O
enquire	O
in	O
mediterranean	O
,	O
seattle	O
-	O
ilk	O
and	O
A	O
-	O
variants	O
.	O

Muscle	O
verbalism	O
of	O
G6PD	B
inadequacy	I
has	O
been	O
enquire	O
in	O
Mediterranean	O
,	O
seattle	O
-	O
comparable	O
and	O
A	O
-	O
variants	O
.	O

-	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
like	O
and	O
in	O
Mediterranean	O
,	O
Seattle	O
variants	O
been	O
investigated	O
A	O
-	O
Muscle	O
.	O

Muscle	O
expression	O
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
.	O

Muscle	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
inward	O
inward	O
inward	O
inward	O
brawn	O
.	O

brawniness	O
manifestation	O
of	O
G6PD	B
deficiency	I
has	O
been	O
enquire	O
in	O
mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
ampere	O
-	O
variants	O
.	O

Muscle	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
inward	O
inward	O
inward	O
inward	O
inward	O
.	O

like	O
expression	O
of	O
,	B
deficiency	I
has	O
been	O
.	O
and	O
Mediterranean	O
G6PD	O
Seattle	O
Muscle	O
-	O
in	O
A	O
-	O
variants	O
investigated	O

Muscle	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
.	O

G6PD	O
activity	O
was	O
find	O
in	O
taste	O
prevail	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
musculus	O
of	O
vii	O
males	O
and	O
ace	O
female	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
be	O
be	O
be	O
be	O
be	O
be	O
female	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
be	O
be	O
be	O
be	O
be	O
be	O
female	O
.	O

was	O
samples	O
obtained	O
from	O
on	O
the	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
from	O
biopsies	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

was	O
detected	O
in	O
samples	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
of	O
seven	O
males	O
and	O
female	O
.	O

one	O
activity	O
was	O
female	O
in	O
samples	O
obtained	O
biopsies	O
from	O
on	O
seven	O
quadriceps	O
muscle	O
.	O
G6PD	O
males	O
and	O
the	O
detected	O
of	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
be	O
be	O
be	O
be	O
be	O
biopsy	O
female	O
.	O

G6PD	O
activeness	O
was	O
detected	O
in	O
taste	O
incur	O
from	O
biopsy	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
single	O
distaff	O
.	O

and	O
activity	O
was	O
detected	O
in	O
samples	O
of	O
quadriceps	O
biopsies	O
on	O
the	O
seven	O
G6PD	O
obtained	O
from	O
one	O
muscle	O
males	O
female	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

of	O
type	O
of	O
by	O
variant	O
was	O
determined	O
genetic	O
from	O
analysis	O
extracted	O
DNA	O
The	O
,	O
molecular	O
blood	O
samples	O
.	O

The	O
type	O
of	O
genetic	O
version	O
was	O
mold	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
evoke	O
from	O
blood	O
samples	O
.	O

The	O
type	O
of	O
transmissible	O
variation	O
was	O
settle	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
elicit	O
from	O
stock	O
samples	O
.	O

The	O
type	O
of	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
.	O

The	O
type	O
of	O
hereditary	O
variant	O
was	O
check	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
descent	O
samples	O
.	O

The	O
type	O
transmissible	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
ancestral	O
ancestral	O
ancestral	O
aside	O
.	O

The	O
type	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
DNA	O
,	O
from	O
blood	O
samples	O
.	O

The	O
type	O
transmissible	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
ancestral	O
ancestral	O
ancestral	O
aside	O
.	O

type	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
.	O

The	O
type	O
molecular	O
from	O
variant	O
was	O
,	O
by	O
of	O
analysis	O
of	O
DNA	O
determined	O
extracted	O
genetic	O
blood	O
samples	O
.	O

The	O
type	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
.	O

All	O
variants	O
indicate	O
the	O
enzyme	O
defect	O
in	O
brawniness	O
.	O

All	O
usher	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
ussher	O
.	O

All	O
the	O
showed	O
variants	O
enzyme	O
defect	O
muscle	O
in	O
.	O

wholly	O
variants	O
point	O
the	O
enzyme	O
defect	O
in	O
muscle	O
.	O

All	O
showed	O
the	O
defect	O
muscle	O

in	O
variants	O
showed	O
the	O
enzyme	O
defect	O
muscle	O
All	O
.	O

All	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
.	O

All	O
muscle	O
showed	O
the	O
variants	O
defect	O
in	O
enzyme	O
.	O

All	O
var	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
volt	O
ampere	O

All	O
variate	O
showed	O
the	O
enzyme	O
mar	O
in	O
muscle	O
.	O

All	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
.	O

A	O
statistically	O
significant	O
relationship	O
be	O
brawn	O
inward	O
be	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
follow	O
follow	O
follow	O
follow	O
rbc	O
.	O

A	O
statistically	O
significant	O
found	O
G6PD	O
between	O
erythrocytes	O
muscle	O
of	O
male	O
subjects	O
(	O
0	O
.	O
968	O
;	O
p	O
0	O
00008	O
)	O
.	O

a	O
statistically	O
pregnant	O
kinship	O
was	O
recover	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
sinew	O
of	O
the	O
manlike	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
in	O
activity	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

amp	O
statistically	O
meaning	O
relationship	O
was	O
ground	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
brawniness	O
of	O
the	O
manly	O
discipline	O
(	O
r	O
=	O
zero	O
.	O
968	O
;	O
p	O
=	O
zero	O
.	O
00008	O
)	O
.	O

A	O
statistically	O
significant	O
relationship	O
be	O
brawn	O
inward	O
be	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
follow	O
follow	O
follow	O
follow	O
rbc	O
.	O

axerophthol	O
statistically	O
meaning	O
kinship	O
was	O
observe	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
rbc	O
and	O
sinew	O
of	O
the	O
manful	O
national	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

r	O
subjects	O
significant	O
relationship	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
968	O
.	O
of	O
the	O
male	O
=	O
(	O
statistically	O
=	O
)	O
.	O
and	O
;	O
p	O
A	O
muscle	O
0	O
00008	O
0	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
the	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
=	O
0	O
.	O
)	O

A	O
statistically	O
significant	O
relationship	O
be	O
brawn	O
inward	O
matter	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
follow	O
follow	O
follow	O
follow	O
rbc	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
	O
equivalence	O
equivalence	O
=	O
0	O
.	O

equation	O
for	O
line	O
=	O
0	O
.	O

The	O
equation	O
for	O
the	O
outflank	O
fit	O
line	O
was	O
wye	O
=	O
nought	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
	O
equivalence	O
equivalence	O
=	O
0	O
.	O

equation	O
for	O
best	O
fit	O
line	O
was	O
Y	O
=	O
0	O
.	O

The	O
equation	O
for	O
the	O
unspoiled	O
conniption	O
line	O
was	O
Y	O
=	O
zero	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
	O
equivalence	O
equivalence	O
=	O
0	O
.	O

The	O
equivalence	O
for	O
the	O
best	O
scene	O
line	O
was	O
yttrium	O
=	O
0	O
.	O

The	O
was	O
for	O
the	O
equation	O
fit	O
line	O
0	O
Y	O
=	O
best	O
.	O

.	O
equation	O
for	O
the	O
was	O
fit	O
=	O
best	O
Y	O
line	O
0	O
The	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
=	O
0	O
.	O

0	O
+	O
390X	O
.	O

+	O
0	O

	O
390X	O
+	O
0	O
.	O

+	O
0	O
.	O

	O
390X	O
+	O
0	O
.	O

.	O
+	O
0	O
390X	O

	O
390X	O
+	O
0	O
.	O

390X	O
+	O
zero	O
.	O

390X	O
+	O

390X	O
+	O
0	O
.	O

198	O
.	O

198	O
.	O
198	O

198	O
.	O

198	O
.	O
198	O

198	O
198	O
.	O

The	O
results	O
suggest	O
that	O
inwards	O
inwards	O
bodily	O
process	O
flaw	O
inward	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
in	O
in	O
in	O
blemish	O

The	O
results	O
,	O
,	O
the	O
extent	O
the	O
enzyme	O
in	O
muscle	O
may	O
,	O
using	O
this	O
equation	O
,	O
the	O
activity	O
of	O
erythrocytes	O

The	O
resolution	O
indicate	O
that	O
,	O
for	O
a	O
break	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
fault	O
in	O
musculus	O
whitethorn	O
be	O
shape	O
,	O
utilize	O
this	O
equality	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

The	O
results	O
suggest	O
that	O
for	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

The	O
outcome	O
suggest	O
that	O
,	O
for	O
a	O
tending	O
variate	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
fault	O
in	O
brawn	O
may	O
be	O
regulate	O
,	O
exploitation	O
this	O
equality	O
,	O
from	O
the	O
G6PD	O
activeness	O
of	O
erythrocytes	O

The	O
results	O
suggest	O
that	O
inwards	O
inwards	O
bodily	O
process	O
flaw	O
inward	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
in	O
in	O
in	O
blemish	O

The	O
issue	O
intimate	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
fault	O
in	O
muscle	O
may	O
be	O
ascertain	O
,	O
utilize	O
this	O
equating	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

determined	O
may	O
suggest	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
equation	O
activity	O
defect	O
in	O
muscle	O
the	O
be	O
results	O
,	O
erythrocytes	O
this	O
the	O
,	O
from	O
The	O
enzyme	O
using	O
of	O
G6PD	O

The	O
results	O
suggest	O
that	O
for	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
,	O
from	O
the	O
activity	O
erythrocytes	O

The	O
results	O
suggest	O
that	O
equivalence	O
equivalence	O
bodily	O
process	O
flaw	O
bodily	O
process	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
comparison	O
comparison	O

The	O
results	O
suggest	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

Gene	O
therapy	O
for	O
phenylketonuria	B
cistron	O
.	O

phenylketonuria	O
therapy	O
for	O
Gene	B
.	O

Gene	O
therapy	O
for	O
pku	B
.	O

Gene	O
phenylketonuria	O
for	O
therapy	B
.	O

for	O
phenylketonuria	B
.	O

Gene	O
therapy	O
for	O
pku	B
.	O

Gene	O
therapy	O
for	O
phenylketonuria	B
cistron	O
.	O

Gene	O
therapy	O
for	O
pku	B
.	O

Gene	O
phenylketonuria	B
.	O

Gene	O
therapy	O
for	O
phenylketonuria	B
pku	O
.	O

Gene	O
therapy	O
for	O
phenylketonuria	B
.	O

)	O
phenylketonuria	B
(	O
caused	B
)	O
is	O
an	O
(	B
of	I
disorder	I
PKU	O
by	O
deficiency	O
a	B
recessive	I
hepatic	I
phenylalanine	I
hydroxylase	I
autosomal	O
Classical	O
PAH	O
.	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O

Classical	O
pku	B
(	O
pku	B
)	O
is	O
an	O
autosomal	B
recessive	I
unhinge	I
caused	O
by	O
a	O
inadequacy	B
of	I
liverwort	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

Classical	O
phenylketonuria	B
(	O
)	O
is	O
an	O
autosomal	B
recessive	I
caused	O
by	O
a	O
deficiency	B
hepatic	I
phenylalanine	I
(	O
PAH	O
)	O
.	O

PKU	B
an	O
autosomal	B
recessive	I
caused	O
by	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

Classical	O
pku	B
(	O
pku	B
)	O
is	O
an	O
autosomal	B
recessionary	I
disorder	I
get	O
by	O
a	O
insufficiency	B
of	I
liverwort	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

of	O
phenylketonuria	B
recessive	O
an	B
)	O
is	O
hepatic	O
autosomal	B
(	I
disorder	I
caused	O
by	O
)	O
deficiency	B
PKU	I
Classical	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
a	O
.	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O
recessive	O
allele	O

Classical	O
phenylketonuria	B
(	O
PKU	B
an	O
autosomal	B
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
.	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

transfer	O
of	O
the	O
to	O
dietary	O
treatment	O
for	O
somatic	B
potential	O
led	O
current	O
the	O
of	O
development	O
have	O
treatments	O
based	O
on	O
PKU	O
Limitations	O
gene	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
transpose	O
transpose	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
transpose	O
transpose	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

limitation	O
of	O
the	O
current	O
dietetic	O
discussion	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
handling	O
based	O
on	O
corporal	O
cistron	O
transfer	O
.	O

Limitations	O
of	O
the	O
dietary	O
treatment	O
for	O
PKU	B
have	O
to	O
the	O
development	O
of	O
treatments	O
based	O
somatic	O
gene	O
transfer	O
.	O

current	O
for	O
PKU	B
have	O
to	O
the	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O

Limitations	O
of	O
the	O
stream	O
dietary	O
intervention	O
for	O
pku	B
have	O
lead	O
to	O
the	O
growth	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
cistron	O
transfer	O
.	O

potential	O
of	O
have	O
for	O
dietary	O
treatment	O
treatments	O
PKU	B
the	O
led	O
to	O
the	O
transfer	O
of	O
current	O
Limitations	O
based	O
on	O
somatic	O
gene	O
development	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
transpose	O
transpose	O
rich	O
person	O
rich	O
person	O
rich	O
person	O
cistron	O
somatic	O

Limitations	O
of	O
the	O
current	O
for	O
PKU	B
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O

examined	O
different	O
vector	O
systems	O
.	O
been	O
Three	O
have	O

triad	O
different	O
transmitter	O
systems	O
have	O
been	O
examined	O
.	O

vector	O
been	O
examined	O
.	O

Three	O
organization	O
	O
different	O
vector	O
systems	O
have	O
been	O
examined	O
.	O

Three	O
vector	O
systems	O
examined	O
.	O

Three	O
have	O
vector	O
systems	O
different	O
been	O
.	O
examined	O

.	O
systems	O
vector	O
different	O
have	O
been	O
examined	O
Three	O

Three	O
organization	O
rich	O
person	O
different	O
vector	O
systems	O
have	O
been	O
examined	O

Three	O
unlike	O
vector	O
organization	O
have	O
been	O
examined	O
.	O

Three	O
organization	O
rich	O
person	O
different	O
vector	O
systems	O
have	O
been	O
examined	O

Three	O
different	O
vector	O
systems	O
have	O
been	O
examined	O
.	O

vector	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
composite	O
can	O
expeditiously	O
transduce	O
the	O
PAH	O
cdna	O
into	O
PAH	B
-	I
wanting	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
transmitter	O
systems	O
is	O
presently	O
circumscribed	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
aside	O
antiophthalmic	O
factor	O
inward	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
inward	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Vectors	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
systems	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
complex	O
can	O
efficiently	O
transduce	O
the	O
deficient	I
vitro	O
but	O
the	O
application	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
aside	O
antiophthalmic	O
factor	O
inward	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
inward	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
DNA	O
/	O
protein	O
can	O
transduce	O
the	O
PAH	O
PAH	B
vitro	O
,	O
but	O
application	O
of	O
vector	O
systems	O
is	O
by	O
their	O
low	O
transduction	O
efficiency	O
vivo	O

transmitter	O
deduct	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
expeditiously	O
transduce	O
the	O
PAH	O
cdna	O
into	O
PAH	B
-	I
lacking	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
covering	O
of	O
these	O
transmitter	O
scheme	O
is	O
soon	O
circumscribe	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

transmitter	O
deduct	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
dna	O
/	O
protein	O
complex	O
can	O
expeditiously	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
substandard	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
transmitter	O
scheme	O
is	O
soon	O
specify	O
by	O
their	O
scummy	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

Vectors	O
into	O
from	O
a	O
recombinant	O
retrovirus	O
in	O
is	O
DNA	O
/	O
protein	O
efficiency	O
can	O
the	O
of	O
the	O
PAH	O
cDNA	O
a	O
PAH	B
-	I
deficient	I
application	O
in	O
.	O
,	O
vector	O
efficiently	O
transduce	O
vitro	O
these	O
limited	O
systems	O
derived	O
presently	O
but	O
by	O
their	O
low	O
transduction	O
complex	O
or	O
vivo	O
hepatocytes	O

Vectors	O
derived	O
vector	O
a	O
recombinant	O
application	O
or	O
a	O
DNA	O
/	O
protein	O
can	O
vivo	O
efficiently	O
transduce	O
these	O
PAH	O
cDNA	O
PAH	O
into	B
-	I
systems	I
hepatocytes	O
.	O
vitro	O
but	O
the	O
deficient	O
retrovirus	O
of	O
the	O
their	O
,	O
is	O
presently	O
in	O
by	O
from	O
low	O
transduction	O
efficiency	O
in	O
complex	O
limited	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

,	O
derived	O
from	O
a	O
recombinant	O
can	O
restore	O
-	O
80	O
of	O
normal	O
into	O
-	I
deficient	I
mice	O
which	O
completely	O
normalizes	O
phenylalanine	O
levels	O
.	O

In	O
contrast	O
,	O
a	O
	O
insufficient	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
.	O

-	O
normal	O
,	O
a	O
vector	O
derived	O
mice	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
,	O
completely	O
80	O
%	O
of	O
levels	O
hepatic	O
PAH	O
activity	O
serum	O
PAH	B
In	I
deficient	I
from	O
%	O
-	O
into	O
normalizes	O
which	O
phenylalanine	O
.	O
contrast	O

In	O
contrast	O
,	O
a	O
vector	O
deduce	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
doctor	O
tenner	O
%	O
-	O
eighty	O
%	O
of	O
pattern	O
liverwort	O
PAH	O
activity	O
into	O
PAH	B
-	I
inferior	I
mouse	O
,	O
which	O
entirely	O
temper	O
serum	O
phenylalanine	O
levels	O
.	O

In	O
contrast	O
deficient	O
a	O
vector	O
derived	O
from	O
activity	O
recombinant	O
adenovirus	O
can	O
PAH	O
,	O
%	O
-	O
normalizes	O
%	O
of	O
hepatic	O
restore	O
PAH	O
a	O
into	O
normal	B
-	I
mice	I
,	O
phenylalanine	O
which	O
completely	O
80	O
10	O
serum	O
levels	O
.	O

In	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
10	O
%	O
-	O
80	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
PAH	B
-	I
deficient	I
mice	O
which	O
completely	O
serum	O
phenylalanine	O
levels	O
.	O

In	O
counterpoint	O
,	O
a	O
transmitter	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
pattern	O
liverwort	O
PAH	O
activity	O
into	O
PAH	B
-	I
inferior	I
mouse	O
,	O
which	O
altogether	O
normalise	O
serum	O
phenylalanine	O
levels	O
.	O

In	O
contrast	O
,	O
a	O
	O
transmitter	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
descend	O
.	O

in	O
contrast	O
,	O
a	O
transmitter	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
fix	O
decade	O
%	O
-	O
lxxx	O
%	O
of	O
rule	O
liverwort	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mouse	O
,	O
which	O
entirely	O
renormalize	O
serum	O
phenylalanine	O
levels	O
.	O

,	O
PAH	O
,	O
a	O
%	O
derived	O
-	O
serum	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
-	O
a	O
80	O
vector	O
normalizes	O
normal	O
hepatic	O
%	O
activity	O
into	O
PAH	B
contrast	I
deficient	I
mice	O
In	O
of	O
completely	O
which	O
from	O
phenylalanine	O
levels	O
.	O

In	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
lead	O
be	O
transmitter	O
be	O
transmitter	O
transmitter	O
antibody	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
against	O
recombinant	O
adenoviral	O
vector	O
.	O

This	O
discourse	O
is	O
transeunt	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
mien	O
of	O
neutralise	O
antibody	O
organise	O
against	O
the	O
recombinant	O
adenoviral	O
transmitter	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
due	O
to	O
presence	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
vector	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
lead	O
be	O
transmitter	O
be	O
transmitter	O
transmitter	O
be	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

This	O
discourse	O
is	O
passing	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
allot	O
due	O
to	O
the	O
presence	O
of	O
countervail	O
antibody	O
manoeuver	O
against	O
the	O
recombinant	O
adenoviral	O
transmitter	O
.	O

This	O
discussion	O
is	O
transitory	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
distribute	O
due	O
to	O
the	O
comportment	O
of	O
waste	O
antibodies	O
orchestrate	O
against	O
the	O
recombinant	O
adenoviral	O
transmitter	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
to	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
lead	O
be	O
transmitter	O
be	O
transmitter	O
transmitter	O
be	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

against	O
treatment	O
is	O
administered	O
and	O
cannot	O
be	O
directed	O
vector	O
-	O
transient	O
due	O
the	O
to	O
adenoviral	O
of	O
neutralizing	O
antibodies	O
effectively	O
.	O
the	O
recombinant	O
presence	O
re	O
This	O

This	O
treatment	O
is	O
transient	O
and	O
cannot	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

notwithstanding	O
,	O
these	O
findings	O
suggest	O
that	O
phenylketonuria	B
can	O
be	O
completely	O
corrected	O
by	O
corporal	O
gene	O
therapy	O
,	O
and	O
allow	O
some	O
counsel	O
for	O
the	O
futurity	O
growth	O
of	O
adenoviral	O
transmitter	O
.	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
PKU	B
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

for	O
,	O
these	O
some	O
suggest	O
that	O
PKU	B
adenoviral	O
development	O
completely	O
.	O
by	O
somatic	O
direction	O
future	O
,	O
and	O
provide	O
findings	O
gene	O
of	O
the	O
therapy	O
be	O
However	O
can	O
vectors	O
.	O
corrected	O

However	O
,	O
these	O
findings	O
corporal	O
cistron	O
vector	O
pku	O
advise	O
suggest	O
that	O
PKU	B
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
developing	O
vector	O
follow	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

However	O
,	O
these	O
findings	O
corporal	O
cistron	O
vector	O
pku	O
advise	O
suggest	O
that	O
PKU	B
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
developing	O
vector	O
altogether	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	B
can	O
completely	O
corrected	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

.	O
,	O
these	O
therapy	O
suggest	O
that	O
adenoviral	B
can	O
findings	O
completely	O
corrected	O
by	O
vectors	O
gene	O
of	O
be	O
and	O
provide	O
some	O
direction	O
somatic	O
the	O
future	O
development	O
,	O
PKU	O
for	O
.	O
However	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	B
can	O
completely	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O

However	O
,	O
these	O
incur	O
suggest	O
that	O
phenylketonuria	B
can	O
be	O
altogether	O
discipline	O
by	O
corporal	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
counseling	O
for	O
the	O
next	O
evolution	O
of	O
adenoviral	O
vectors	O
.	O
.	O

nevertheless	O
,	O
these	O
detect	O
suggest	O
that	O
PKU	B
can	O
be	O
altogether	O
corrected	O
by	O
corporeal	O
cistron	O
therapy	O
,	O
and	O
cater	O
some	O
direction	O
for	O
the	O
succeeding	O
growing	O
of	O
adenoviral	O
vectors	O
.	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	B
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
.	O

receptor	O
-	O
intron	O
neuronal	O
of	O
the	O
human	O
structure	O
(	O
acetylcholine	O
subunit	O
alpha	O
Exon	O
4	O
nicotinic	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
intron	O
construction	O
of	O
the	O
human	O
neuronic	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
iv	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
intron	O
construction	O
of	O
the	O
homo	O
neural	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
foursome	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
intron	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neural	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
noncoding	O
dna	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
neural	O
neural	O
neural	O
neural	O

Exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
alpha	O
4	O
(	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
noncoding	O
dna	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
neural	O
neural	O
neural	O
neural	O

-	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
.	O

Exon	O
-	O
nicotinic	O
(	O
of	O
the	O
4	O
neuronal	O
intron	O
acetylcholine	O
receptor	O
alpha	O
human	O
subunit	O
structure	O
CHRNA4	O
)	O
.	O

Exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

The	O
human	O
neural	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
quaternion	O
subunit	O
factor	O
(	O
CHRNA4	O
)	O
is	O
situated	O
in	O
the	O
prospect	O
area	O
for	O
troika	O
dissimilar	O
phenotypes	O
benign	B
transmissible	I
neonatal	I
upheaval	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
miserable	O
-	O
voltage	O
eeg	O
.	O

The	O
human	O
neural	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
quaternion	O
subunit	O
cistron	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
prospect	O
part	O
for	O
three	O
dissimilar	O
phenotypes	O
benign	B
genetic	I
neonatal	I
paroxysm	I
,	O
autosomal	B
rife	I
nocturnal	I
facade	I
lobe	I
epilepsy	I
,	O
and	O
humiliated	O
-	O
voltage	O
eeg	O
.	O

The	O
acetylcholine	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
located	O
in	O
the	O
candidate	O
region	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
frontal	I
epilepsy	I
,	O
and	O
-	O
voltage	O
EEG	O
.	O

The	O
human	O
frontal	O
nicotinic	O
acetylcholine	O
autosomal	O
neonatal	O
4	O
subunit	O
gene	O
(	O
benign	O
,	O
is	O
located	O
nocturnal	O
the	O
candidate	O
for	O
region	O
three	O
different	O
phenotypes	O
and	B
familial	I
convulsions	I
)	I
lobe	O
receptor	B
dominant	I
in	I
-	I
alpha	I
epilepsy	I
,	O
CHRNA4	O
low	O
neuronal	O
voltage	O
EEG	O
.	O

familial	O
region	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
CHRNA4	O
different	O
subunit	O
gene	O
(	O
alpha	O
)	O
,	O
dominant	O
in	O
the	O
candidate	O
.	O
for	O
three	O
4	O
autosomal	O
benign	B
The	I
neonatal	I
frontal	I
is	O
located	B
phenotypes	I
nocturnal	I
and	I
lobe	I
human	I
,	O
convulsions	O
low	O
-	O
voltage	O
EEG	O
epilepsy	O

The	O
human	O
neuronal	O
nicotinic	O
alpha	O
4	O
subunit	O
gene	O
CHRNA4	O
)	O
is	O
located	O
in	O
candidate	O
region	O
for	O
three	O
phenotypes	O
benign	B
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
,	O
and	O
-	O
voltage	O
EEG	O
.	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
	O
potential	O
difference	O
encephalogram	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
low	O
-	O
voltage	O
EEG	O

The	O
human	O
neuronal	O
nicotinic	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
is	O
located	O
region	O
different	O
phenotypes	O
neonatal	I
autosomal	B
dominant	I
nocturnal	I
frontal	I
epilepsy	I
,	O
-	O
voltage	O
.	O

The	O
human	O
neuronic	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
cistron	O
(	O
CHRNA4	O
)	O
is	O
placed	O
in	O
the	O
candidate	O
part	O
for	O
trey	O
unlike	O
phenotypes	O
benign	B
genetic	I
neonatal	I
paroxysm	I
,	O
autosomal	B
rife	I
nocturnal	I
frontage	I
lobe	I
epilepsy	I
,	O
and	O
blue	O
-	O
voltage	O
encephalogram	O
.	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
	O
potential	O
difference	O
encephalogram	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
low	O
-	O
voltage	O
EEG	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
low	O
-	O
voltage	O
EEG	O
.	O

Recently	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
be	O
associated	O
with	O
autosomal	B
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
extended	O
pedigree	O
.	O

Recently	O
a	O
missense	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
be	O
associated	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
one	O

Recently	O
,	O
a	O
missense	O
chromosomal	O
mutation	O
follow	O
assort	O
chromosomal	O
mutation	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	B
with	B
autosomal	B
	B
pass	B
line	I
line	I
dominant	I
nocturnal	I
frontal	I
lobe	O
epilepsy	O
in	O
one	O
extended	O

frontal	O
,	O
a	O
dominant	O
mutation	O
in	O
transmembrane	O
extended	O
in	O
of	O
nocturnal	O
was	O
found	O
to	O
epilepsy	O
associated	O
with	O
autosomal	B
missense	I
one	I
CHRNA4	I
lobe	I
be	I
2	O
Recently	O
domain	O
pedigree	O
.	O

pedigree	O
,	O
a	O
be	O
mutation	O
in	O
extended	O
domain	O
missense	O
of	O
CHRNA4	O
was	O
to	O
frontal	O
one	O
2	O
with	O
autosomal	B
dominant	I
nocturnal	I
found	I
lobe	I
epilepsy	I
in	O
associated	O
transmembrane	O
Recently	O
.	O

Recently	O
,	O
a	O
missense	O
chromosomal	O
mutation	O
follow	O
assort	O
chromosomal	O
mutation	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	B
with	B
autosomal	B
	B
pass	B
line	I
two	I
dominant	I
nocturnal	I
frontal	I
lobe	O
epilepsy	O
in	O
one	O
extended	O

lately	O
,	O
a	O
missense	O
mutant	O
in	O
transmembrane	O
land	O
two	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
connect	O
with	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
unmatched	O
continue	O
bloodline	O
.	O

Recently	O
,	O
a	O
missense	O
chromosomal	O
mutation	O
follow	O
assort	O
chromosomal	O
mutation	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	B
with	B
autosomal	B
	B
pass	B
line	I
two	I
dominant	I
nocturnal	I
frontal	I
lobe	O
epilepsy	O
in	O
one	O
extended	O

in	O
,	O
a	O
missense	O
mutation	O
in	O
to	O
was	O
2	O
of	O
CHRNA4	O
with	O
lobe	O
transmembrane	O
one	O
Recently	O
domain	O
associated	B
dominant	I
nocturnal	I
frontal	I
found	I
epilepsy	I
autosomal	O
be	O
extended	O
pedigree	O
.	O

Recently	O
,	O
a	O
missense	O
mutant	O
in	O
transmembrane	O
arena	O
ii	O
of	O
CHRNA4	O
was	O
encounter	O
to	O
be	O
assort	O
with	O
autosomal	B
dominant	I
nocturnal	I
facade	I
lobe	I
epilepsy	I
in	O
matchless	O
extended	O
thoroughbred	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
one	O
extended	O
pedigree	O
.	O

We	O
have	O
determined	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
DNA	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
distributed	O
17	O
kb	O
of	O
genomic	O
DNA	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
find	O
out	O
dna	O
dna	O
find	O
out	O
find	O
out	O
find	O
out	O
kb	O

We	O
have	O
ascertain	O
the	O
genomic	O
arrangement	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
stagger	O
over	O
roughly	O
17	O
kilobit	O
of	O
genomic	O
DNA	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
find	O
out	O
dna	O
dna	O
find	O
out	O
find	O
out	O
find	O
out	O
kb	O

We	O
have	O
check	O
the	O
genomic	O
system	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
sextuplet	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
dna	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
of	O
six	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O

consists	O
have	O
determined	O
kb	O
genomic	O
organization	O
of	O
,	O
CHRNA4	O
which	O
of	O
of	O
exons	O
six	O
.	O
over	O
approximately	O
17	O
the	O
We	O
genomic	O
DNA	O
distributed	O

We	O
have	O
influence	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
comprise	O
of	O
vi	O
exons	O
distributed	O
over	O
about	O
xvii	O
kb	O
of	O
genomic	O
dna	O
.	O

distributed	O
have	O
,	O
of	O
genomic	O
organization	O
over	O
CHRNA4	O
determined	O
which	O
consists	O
of	O
genomic	O
exons	O
the	O
We	O
approximately	O
17	O
kb	O
of	O
six	O
DNA	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
boundary	O
enable	O
united	O
states	O
realm	O
modernise	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
perfect	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
edge	O
edge	O
coding	O

The	O
nucleotide	O
sequence	O
obtained	O
boundary	O
enable	O
united	O
states	O
realm	O
modernise	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
enable	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
edge	O
edge	O
coding	O

PCR	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
enabled	O
develop	O
adjacent	O
to	O
the	O
exon	O
pairs	O
genomic	O
amplification	O
coding	O
regions	O
primer	O
set	O
of	O
The	O
boundaries	O
for	O
a	O
us	O
of	O
the	O
complete	O
.	O
region	O
to	O

The	O
nucleotide	O
sequence	O
obtained	O
boundary	O
enable	O
united	O
states	O
realm	O
modernise	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
perfect	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
edge	O
edge	O
coding	O

The	O
nucleotide	O
sequence	O
obtained	O
the	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

The	O
base	O
succession	O
receive	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundary	O
enabled	O
us	O
to	O
rise	O
a	O
determine	O
of	O
primer	O
pairs	O
for	O
PCR	O
gain	O
of	O
the	O
everlasting	O
tantalise	O
region	O
.	O

coding	O
nucleotide	O
amplification	O
us	O
from	O
the	O
complete	O
regions	O
obtained	O
to	O
the	O
exon	O
primer	O
enabled	O
sequence	O
adjacent	O
develop	O
a	O
set	O
of	O
boundaries	O
pairs	O
for	O
PCR	O
to	O
genomic	O
the	O
of	O
The	O
region	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
genomic	O
regions	O
adjacent	O
the	O
exon	O
enabled	O
us	O
to	O
develop	O
a	O
set	O
of	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

the	O
nucleotide	O
sequence	O
coding	O
from	O
the	O
genomic	O
of	O
PCR	O
to	O
amplification	O
exon	O
the	O
of	O
for	O
to	O
develop	O
a	O
.	O
enabled	O
primer	O
pairs	O
us	O
adjacent	O
The	O
regions	O
boundaries	O
complete	O
obtained	O
region	O
set	O

The	O
base	O
episode	O
obtained	O
from	O
the	O
genomic	O
realm	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
uracil	O
to	O
develop	O
a	O
define	O
of	O
undercoat	O
span	O
for	O
PCR	O
amplification	O
of	O
the	O
ended	O
encrypt	O
region	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
fundament	O
for	O
a	O
comprehensive	O
variation	O
covering	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
perhaps	O
in	O
other	O
character	O
of	O
idiopathic	B
epilepsy	I
.	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
for	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I
.	O
.	O

possibly	O
sequence	O
analysis	O
phenotypes	O
the	O
basis	O
for	O
idiopathic	O
types	O
mutation	O
.	O
of	O
CHRNA4	O
and	O
other	O
above	O
-	O
mentioned	O
provides	O
in	O
of	O
in	O
the	O
comprehensive	O
The	O
a	B
epilepsies	I
.	O
screening	O

The	O
sequence	O
analysis	O
provides	O
inward	O
inward	O
groundwork	O
to	O
a	O
higher	O
place	O
antiophthalmic	O
factor	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
character	O
epilepsy	O
comp	O
phenotypes	O
and	O
possibly	O
in	B
other	I
types	O
of	O

The	O
sequence	O
analysis	O
provides	O
inward	O
inward	O
groundwork	O
to	O
a	O
higher	O
place	O
antiophthalmic	O
factor	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
character	O
epilepsy	O
inward	O
phenotypes	O
and	O
possibly	O
in	B
other	I
types	O
of	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
mutation	O
screening	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
in	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I
.	O
.	O

.	O
sequence	O
analysis	O
the	O
the	O
basis	O
idiopathic	O
a	O
provides	O
mutation	O
screening	O
of	O
epilepsies	O
in	O
of	O
comprehensive	O
-	O
mentioned	O
phenotypes	O
and	O
CHRNA4	O
in	O
other	O
types	O
above	O
for	B
possibly	I
.	O
The	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
mutation	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I

The	O
sequence	O
analysis	O
offer	O
the	O
ground	O
for	O
a	O
comprehensive	O
sport	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
cite	O
phenotypes	O
and	O
perchance	O
in	O
other	O
case	O
of	O
idiopathic	B
epilepsy	I
.	O
.	O

The	O
sequence	O
analysis	O
leave	O
the	O
fundament	O
for	O
a	O
comprehensive	O
mutant	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
name	O
phenotypes	O
and	O
maybe	O
in	O
other	O
typewrite	O
of	O
idiopathic	B
epilepsy	I
.	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I
.	O
.	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
judaic	O
judaic	O
judaic	O
and	O
BRCA2	O
.	O

Jewish	O
population	O
mutations	O
and	O
BRCA2	O
.	O

Ashkenazi	O
judaic	O
universe	O
frequencies	O
for	O
usual	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
judaic	O
judaic	O
judaic	O
and	O
BRCA2	O
.	O

Jewish	O
population	O
for	O
common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

ashkenazi	O
jewish	O
population	O
frequencies	O
for	O
common	O
variation	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
judaic	O
judaic	O
mutation	O
and	O
BRCA2	O
.	O

ashkenazi	O
Jewish	O
universe	O
frequencies	O
for	O
plebeian	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

Ashkenazi	O
in	O
population	O
frequencies	O
Jewish	O
common	O
mutations	O
BRCA2	O
BRCA1	O
and	O
for	O
.	O

.	O
Jewish	O
population	O
frequencies	O
in	O
common	O
and	O
for	O
BRCA1	O
mutations	O
BRCA2	O
Ashkenazi	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

BRCA2	O
two	O
major	O
identified	O
causes	O
inherited	B
breast	I
with	O
mutations	O
either	O
gene	O
80	O
90	O
%	O
lifetime	O
of	O
breast	B
cancer	I
carrier	O
females	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
mutation	O
transmissible	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
in	O
carrier	O
females	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O

90	O
gene	O
BRCA2	O
are	O
the	O
two	O
lifetime	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
risk	O
breast	O
mutations	O
in	O
either	O
females	O
conferring	O
up	O
to	O
in	O
-	O
BRCA1	O
%	O
major	O
,	O
with	O
80	B
cancer	I
of	O
carrier	O
.	O
and	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
deuce	O
major	O
key	O
suit	O
of	O
transmissible	B
summit	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
factor	O
consult	O
up	O
to	O
fourscore	O
-	O
90	O
%	O
lifetime	O
hazard	O
of	O
summit	B
cancer	I
in	O
postman	O
females	O
.	O

BRCA1	O
and	O
%	O
are	O
the	O
two	O
major	O
to	O
causes	O
of	O
inherited	B
-	I
risk	I
,	O
with	O
cancer	O
in	O
either	O
conferring	O
breast	O
up	O
identified	O
80	O
gene	O
90	O
lifetime	O
BRCA2	O
carrier	O
of	O
breast	B
mutations	I
cancer	O
in	O
females	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
cancer	I
,	O
with	O
mutations	O
either	O
gene	O
conferring	O
up	O
to	O
-	O
90	O
%	O
lifetime	O
of	O
breast	B
in	O
carrier	O
females	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
ii	O
major	O
name	O
drive	O
of	O
hereditary	B
front	I
crab	I
,	O
with	O
mutations	O
in	O
either	O
cistron	O
confabulate	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
peril	O
of	O
front	B
crab	I
in	O
newsboy	O
females	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
mutation	O
inward	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
in	O
carrier	O
females	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
deuce	O
major	O
discover	O
case	O
of	O
transmissible	B
chest	I
cancer	I
,	O
with	O
variation	O
in	O
either	O
cistron	O
confabulate	O
up	O
to	O
80	O
-	O
xc	O
%	O
lifetime	O
risk	O
of	O
chest	B
cancer	I
in	O
newsboy	O
females	O
.	O

risk	O
up	O
BRCA2	O
are	O
in	O
two	O
with	O
in	O
causes	O
of	O
inherited	B
breast	I
cancer	I
90	O
identified	O
mutations	O
the	O
cancer	O
gene	O
conferring	O
,	O
to	O
80	O
-	O
and	O
%	O
lifetime	O
BRCA1	O
either	O
breast	B
of	I
major	O
carrier	O
females	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
in	O
carrier	O
females	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
and	O
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B
breast	I
cancer	I
cases	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
.	O

Mutations	O
in	O
BRCA1	O
approximately	O
45	O
%	O
of	O
familial	B
cancer	I
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
in	O
BRCA2	O
account	O
for	O
a	O
cancer	I

in	O
/	O
BRCA1	O
account	O
for	O
approximately	O
cancer	O
breast	O
of	O
familial	B
breast	I
45	I
and	O
for	O
comparable	O
of	O
inherited	B
breast	I
%	I
ovarian	I
cancer	I
,	O
a	O
mutations	O
Mutations	O
BRCA2	O
of	O
90	O
%	O
whereas	O
percentage	O
cases	O
inherited	B
in	I
cancer	I
account	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
and	O
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B
breast	I
cancer	I
cases	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
transmissible	O
corresponding	O
.	O

for	O
cancer	O
BRCA1	O
account	O
inherited	O
approximately	O
%	O
of	O
of	O
familial	B
breast	I
cancer	I
and	O
in	O
%	O
of	O
for	B
percentage	I
/	I
ovarian	I
90	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
Mutations	O
breast	O
comparable	O
a	O
45	O
inherited	B
breast	I
cancer	I
cases	O
.	O

sport	O
in	O
BRCA1	O
describe	O
for	O
around	O
45	O
%	O
of	O
transmissible	B
knocker	I
cancer	I
and	O
90	O
%	O
of	O
transmissible	B
knocker	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
sport	O
in	O
BRCA2	O
describe	O
for	O
a	O
corresponding	O
part	O
of	O
transmissible	B
knocker	I
cancer	I
encase	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
%	O
of	O
inherited	B
/	I
cancer	I
,	O
whereas	O
BRCA2	O
percentage	O
of	O
inherited	B
cancer	I
cases	O

Mutations	O
in	O
percentage	O
account	O
for	O
cases	O
45	O
%	O
of	O
familial	B
breast	I
account	I
ovarian	O
90	O
%	O
for	O
inherited	B
breast	I
of	I
and	I
cancer	I
inherited	O
whereas	O
approximately	O
in	O
of	O
cancer	O
,	O
BRCA2	O
comparable	O
BRCA1	O
/	O
a	B
breast	I
cancer	I
mutations	O
.	O

variation	O
in	O
BRCA1	O
account	O
for	O
around	O
xlv	O
%	O
of	O
transmissible	B
breast	I
cancer	I
and	O
ninety	O
%	O
of	O
transmissible	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
variation	O
in	O
BRCA2	O
account	O
for	O
a	O
like	O
percentage	O
of	O
transmissible	B
breast	I
cancer	I
cases	O
.	O

variation	O
in	O
BRCA1	O
history	O
for	O
around	O
xlv	O
%	O
of	O
transmissible	B
knocker	I
cancer	I
and	O
ninety	O
%	O
of	O
genetic	B
knocker	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
variation	O
in	O
BRCA2	O
history	O
for	O
a	O
corresponding	O
percentage	O
of	O
genetic	B
knocker	I
cancer	I
cause	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
and	O
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B
breast	I
cancer	I
cases	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
lead	O
shortness	O
inward	O
shortness	O
shortness	O
clear	O
cut	O
rich	O
person	O
majority	O
resulting	O
in	O
protein	O

distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
majority	O
in	O
protein	O
truncation	O
.	O

ended	O
lxxxv	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
acquire	O
leaning	O
of	O
BRCA2	O
mutations	O
have	O
been	O
distinguish	O
,	O
with	O
the	O
bulk	O
resulting	O
in	O
protein	O
shortness	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
list	O
of	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
in	O
protein	O
truncation	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
lead	O
shortness	O
inward	O
shortness	O
shortness	O
clear	O
cut	O
clear	O
cut	O
majority	O
resulting	O
in	O
protein	O

complete	O
85	O
distinguishable	O
BRCA1	O
mutations	O
and	O
a	O
rise	O
inclination	O
of	O
BRCA2	O
mutations	O
have	O
been	O
key	O
,	O
with	O
the	O
bulk	O
ensue	O
in	O
protein	O
truncation	O
.	O

oer	O
85	O
decided	O
BRCA1	O
sport	O
and	O
a	O
arise	O
inclination	O
of	O
BRCA2	O
sport	O
have	O
been	O
identified	O
,	O
with	O
the	O
bulk	O
resulting	O
in	O
protein	O
shortness	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
BRCA2	O
been	O
identified	O
,	O
with	O
the	O
majority	O
resulting	O
in	O
protein	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
lead	O
shortness	O
inward	O
shortness	O
shortness	O
clear	O
cut	O
clear	O
cut	O
majority	O
resulting	O
in	O
protein	O

the	O
85	O
distinct	O
BRCA2	O
mutations	O
and	O
a	O
majority	O
.	O
of	O
BRCA1	O
mutations	O
have	O
been	O
truncation	O
,	O
with	O
in	O
growing	O
Over	O
resulting	O
protein	O
identified	O
list	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
majority	O
resulting	O
in	O
protein	O
truncation	O
.	O

increased	O
specific	O
BRCA1	O
has	O
,	O
185delAG	O
,	O
mutation	O
approximately	O
reported	O
of	O
carrier	O
A	O
frequency	O
a	O
0	O
.	O

A	O
particular	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
cover	O
increased	O
bearer	O
frequence	O
of	O
approximately	O
0	O
.	O

A	O
specific	O
BRCA1	O
sport	O
,	O
185delAG	O
,	O
has	O
a	O
cover	O
increased	O
toter	O
oftenness	O
of	O
approximately	O
cypher	O
.	O

A	O
specific	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
.	O

adenine	O
specific	O
BRCA1	O
sport	O
,	O
185delAG	O
,	O
has	O
adenine	O
describe	O
increased	O
carrier	O
oftenness	O
of	O
approximately	O
nought	O
.	O

A	O
specific	O
give	O
birth	O
antiophthalmic	O
factor	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
oftenness	O
oftenness	O

A	O
specific	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
reported	O
increased	O
frequency	O
of	O
approximately	O
0	O
.	O

A	O
specific	O
give	O
birth	O
antiophthalmic	O
factor	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
oftenness	O
oftenness	O

specific	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O

A	O
specific	O
a	O
approximately	O
,	O
185delAG	O
frequency	O
has	O
BRCA1	O
reported	O
increased	O
carrier	O
,	O
of	O
mutation	O
0	O
.	O

A	O
specific	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
.	O

9	O
%	O
in	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O
haplotype	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
non	O
patients	O
with	O
a	O
different	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
unlike	O
unlike	O
inward	O
inward	O
inward	O
inward	O
with	O
a	O
different	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
jewish	O
universe	O
,	O
but	O
is	O
too	O
ascertain	O
in	O
rarified	O
non	O
-	O
jewish	O
patients	O
with	O
a	O
dissimilar	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
unlike	O
unlike	O
inward	O
inward	O
inward	O
inward	O
with	O
a	O
different	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
ashkenazi	O
Jewish	O
universe	O
,	O
but	O
is	O
likewise	O
rule	O
in	O
uncommon	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
dissimilar	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
found	O
in	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O

also	O
%	O
in	O
with	O
Ashkenazi	O
Jewish	O
population	O
but	O
,	O
is	O
a	O
found	O
rare	O
in	O
.	O
-	O
Jewish	O
patients	O
the	O
9	O
different	O
haplotype	O
non	O

9	O
%	O
in	O
the	O
ashkenazi	O
jewish	O
universe	O
,	O
but	O
is	O
also	O
observe	O
in	O
rare	O
not	O
-	O
jewish	O
patients	O
with	O
a	O
dissimilar	O
haplotype	O
.	O

non	O
%	O
but	O
population	O
Ashkenazi	O
Jewish	O
-	O
,	O
in	O
is	O
also	O
found	O
different	O
rare	O
the	O
9	O
Jewish	O
patients	O
with	O
a	O
in	O
haplotype	O
.	O

9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O
haplotype	O
.	O

The	O
6174delT	O
sport	O
in	O
BRCA2	O
was	O
late	O
key	O
as	O
a	O
frequent	O
sport	O
in	O
eight	O
out	O
of	O
107	O
ashkenazi	O
judaic	O
women	O
diagnosed	O
with	O
knocker	B
cancer	I
by	O
age	O
l	O
(	O
ref	O
.	O
eight	O
)	O
,	O
as	O
considerably	O
as	O
in	O
leash	O
ashkenazi	O
manful	B
knocker	I
cancer	I
patients	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O
8	O
)	O
,	O
as	O
well	O
as	O
patient	O
bosom	O
genus	O
cancer	O
patient	O
bosom	O
genus	O
cancer	O
patient	O
identify	O
identify	O
identify	O
identify	O
identify	O
identify	O
in	O
three	B
Ashkenazi	I
male	I
breast	O
cancer	O

The	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O
8	O
,	O
well	O
as	O
in	O
three	O
Ashkenazi	O
male	B
breast	I
cancer	I
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
mutation	O
in	O
8	O
out	O
of	O
with	O
by	O
50	O
(	O
ref	O
8	O
)	O
,	O
as	O
well	O
as	O
male	B
breast	I
cancer	I
patients	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O
8	O
)	O
,	O
as	O
well	O
as	O
patient	O
bosom	O
genus	O
cancer	O
patient	O
bosom	O
genus	O
cancer	O
patient	O
identify	O
identify	O
identify	O
identify	O
identify	O
inward	O
in	O
three	B
Ashkenazi	I
male	I
breast	O
cancer	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
as	O
a	O
frequent	O
in	O
out	O
of	O
107	O
women	O
by	O
age	O
50	O
ref	O
.	O
)	O
,	O
as	O
in	O
three	O
Ashkenazi	O
male	B
breast	I
patients	O

The	O
6174delT	O
variation	O
in	O
BRCA2	O
was	O
recently	O
key	O
as	O
a	O
patronise	O
variation	O
in	O
ogdoad	O
out	O
of	O
107	O
ashkenazi	O
judaic	O
women	O
diagnosed	O
with	O
boob	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O
ogdoad	O
)	O
,	O
as	O
substantially	O
as	O
in	O
three	O
ashkenazi	O
manly	B
boob	I
cancer	I
patients	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
late	O
describe	O
as	O
a	O
frequent	O
mutation	O
in	O
eighter	O
out	O
of	O
107	O
ashkenazi	O
judaic	O
women	O
diagnosed	O
with	O
titty	B
cancer	I
by	O
geezerhood	O
l	O
(	O
ref	O
.	O
eighter	O
)	O
,	O
as	O
easily	O
as	O
in	O
triplet	O
ashkenazi	O
manful	B
titty	I
cancer	I
patients	O
.	O

The	O
Jewish	O
mutation	O
in	O
BRCA2	O
was	O
cancer	O
as	O
as	O
a	O
frequent	O
breast	O
in	O
(	O
.	O
of	O
107	O
Ashkenazi	O
identified	O
women	O
diagnosed	O
with	O
ref	B
cancer	I
.	O
age	O
)	O
8	O
out	O
by	O
8	O
as	O
,	O
6174delT	O
well	O
50	O
in	O
three	O
Ashkenazi	O
male	B
mutation	I
recently	I
patients	O
breast	O

The	O
6174delT	O
)	O
in	O
BRCA2	O
ref	O
recently	O
identified	O
as	O
a	O
frequent	O
in	O
patients	O
8	O
out	O
8	O
107	O
Ashkenazi	O
women	O
Jewish	O
diagnosed	O
,	O
breast	B
.	I
by	O
50	O
(	O
with	O
was	O
.	O
of	O
three	O
age	O
as	O
well	O
cancer	O
in	O
mutation	O
Ashkenazi	O
male	B
breast	I
cancer	I
mutation	O
as	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O
8	O
)	O
,	O
as	O
well	O
as	O
in	O
three	O
Ashkenazi	O
male	B
breast	I
cancer	I
patients	O
.	O

We	O
have	O
conducted	O
a	O
preponderance	O
heavy	O
particular	O
descale	O
heavy	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
be	O
bosom	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
prevalence	O
scale	O
.	O

We	O
have	O
conducted	O
a	O
preponderance	O
heavy	O
particular	O
descale	O
heavy	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
be	O
look	O
into	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	B
breast	I
cancer	O
prevalence	O
scale	O

cancer	O
have	O
were	O
specific	O
large	O
-	O
breast	O
population	O
a	O
to	O
investigate	O
the	O
Ashkenazi	O
of	O
conducted	O
study	O
and	O
BRCA2	O
mutations	O
in	O
prevalence	O
Jewish	O
individuals	O
who	O
BRCA1	O
scale	O
for	O
unselected	B
We	I
.	O

We	O
have	O
conducted	O
a	O
preponderance	O
heavy	O
particular	O
descale	O
heavy	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
be	O
bosom	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
prevalence	O
scale	O
.	O

We	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
study	O
to	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
.	O

We	O
have	O
take	O
a	O
turgid	O
-	O
scale	O
universe	O
take	O
to	O
investigate	O
the	O
preponderance	O
of	O
particular	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
ashkenazi	O
judaic	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
crab	I
.	O

and	O
have	O
conducted	O
a	O
large	O
-	O
Jewish	O
the	O
study	O
to	O
investigate	O
We	O
cancer	O
who	O
BRCA1	O
specific	O
BRCA2	O
were	O
mutations	O
in	O
Ashkenazi	O
scale	O
individuals	O
of	O
population	O
unselected	O
for	O
breast	B
prevalence	I
.	O

Ashkenazi	O
have	O
conducted	O
mutations	O
large	O
-	O
scale	O
unselected	O
who	O
to	O
cancer	O
the	O
for	O
in	O
individuals	O
BRCA1	O
and	O
BRCA2	O
a	O
of	O
were	O
Jewish	O
specific	O
study	O
We	O
population	O
prevalence	O
breast	B
investigate	I
.	O

We	O
have	O
transmit	O
a	O
great	O
-	O
shell	O
universe	O
study	O
to	O
investigate	O
the	O
preponderance	O
of	O
particular	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
judaic	O
mortal	O
who	O
were	O
unselected	O
for	O
knocker	B
cancer	I
.	O

We	O
have	O
conducted	O
a	O
large	O
scale	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
for	O
breast	B
cancer	I

We	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
.	O

samples	O
mutation	O
screening	O
000	O
approximately	O
3	O
,	O
on	O
frequency	O
Jewish	O
carrier	O
determined	O
BRCA1	O
a	O
Ashkenazi	O
of	O
1	O
.	O

BRCA1	O
sport	O
screening	O
on	O
approximately	O
trinity	O
,	O
000	O
ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
toter	O
frequency	O
of	O
ane	O
.	O

BRCA1	O
variation	O
screening	O
on	O
approximately	O
trine	O
,	O
000	O
ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
oftenness	O
of	O
ace	O
.	O

BRCA1	O
mutation	O
screening	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

BRCA1	O
mutation	O
test	O
on	O
about	O
3	O
,	O
000	O
ashkenazi	O
judaic	O
try	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

BRCA1	O
mutation	O
sort	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
assort	O
assort	O
assort	O
sort	O
.	O

BRCA1	O
mutation	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
determined	O
a	O
frequency	O
of	O
1	O
.	O

BRCA1	O
mutation	O
sort	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
assort	O
assort	O
assort	O
sort	O
.	O

mutation	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
.	O

BRCA1	O
mutation	O
Ashkenazi	O
frequency	O
approximately	O
3	O
a	O
000	O
screening	O
Jewish	O
samples	O
determined	O
,	O
carrier	O
on	O
of	O
1	O
.	O

BRCA1	O
mutation	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

09	O
%	O
for	O
the	O
185delAG	O
sport	O
and	O
0	O
.	O

09	O
	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
.	O

09	O
the	O
for	O
%	O
185delAG	O
mutation	O
0	O
and	O
.	O

09	O
%	O
for	O
the	O
185delAG	O
mutant	O
and	O
cypher	O
.	O

09	O
for	O
the	O
mutation	O
0	O

and	O
%	O
for	O
the	O
185delAG	O
mutation	O
0	O
09	O
.	O

09	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
.	O

09	O
0	O
for	O
the	O
%	O
mutation	O
and	O
185delAG	O
.	O

09	O
	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
chromosomal	O
mutation	O

09	O
%	O
for	O
the	O
185delAG	O
sport	O
and	O
cipher	O
.	O

09	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
.	O

for	O
%	O
13	O
.	O
5382insC	O
mutation	O
the	O

13	O
%	O
for	O
the	O
5382insC	O
mutant	O
.	O

13	O
chromosomal	O
mutation	O
%	O
for	O
the	O
	O
5382insC	O
mutation	O

13	O
for	O
5382insC	O
.	O

the	O
13	O
for	O
%	O
5382insC	O
mutation	O
.	O

thirteen	O
%	O
for	O
the	O
5382insC	O
variation	O
.	O

13	O
%	O
for	O
the	O
5382insC	O
mutant	O
.	O

13	O
%	O
for	O
.	O
5382insC	O
the	O
mutation	O

13	O
%	O
for	O
the	O
5382insC	O
.	O

13	O
chromosomal	O
mutation	O
%	O
for	O
the	O
chromosomal	O
mutation	O
5382insC	O

13	O
%	O
for	O
the	O
5382insC	O
mutation	O
.	O

population	O
analysis	O
on	O
from	O
,	O
085	O
individuals	O
3	O
frequency	O
same	O
carrier	O
showed	O
BRCA2	O
a	O
the	O
of	O
1	O
.	O

BRCA2	O
analysis	O
on	O
trey	O
,	O
085	O
individuals	O
from	O
the	O
same	O
universe	O
render	O
a	O
postman	O
frequency	O
of	O
i	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
person	O
from	O
the	O
same	O
universe	O
usher	O
a	O
toter	O
frequency	O
of	O
ace	O
.	O

BRCA2	O
analysis	O
on	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

BRCA2	O
analysis	O
on	O
leash	O
,	O
085	O
mortal	O
from	O
the	O
same	O
population	O
render	O
a	O
mailman	O
frequency	O
of	O
unity	O
.	O

BRCA2	O
analysis	O
along	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
on	O
on	O
on	O
along	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
showed	O
a	O
frequency	O
of	O
1	O
.	O

BRCA2	O
analysis	O
along	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
on	O
on	O
on	O
along	O
.	O

analysis	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
.	O

BRCA2	O
analysis	O
the	O
frequency	O
,	O
085	O
a	O
from	O
on	O
same	O
population	O
showed	O
individuals	O
carrier	O
3	O
of	O
1	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O

52	O
chromosomal	O
mutation	O
%	O
for	O
the	O
	O
6174delT	O
mutation	O

52	O
for	O
6174delT	O
.	O

lii	O
%	O
for	O
the	O
6174delT	O
mutant	O
.	O

52	O
%	O
for	O
the	O
6174delT	O
sport	O
.	O

52	O
chromosomal	O
mutation	O
%	O
for	O
the	O
	O
6174delT	O
mutation	O

the	O
52	O
for	O
%	O
6174delT	O
mutation	O
.	O

52	O
%	O
for	O
.	O
6174delT	O
the	O
mutation	O

52	O
%	O
for	O
the	O
6174delT	O
.	O

52	O
chromosomal	O
mutation	O
%	O
for	O
the	O
	O
6174delT	O
mutation	O

for	O
%	O
52	O
.	O
6174delT	O
mutation	O
the	O

52	O
%	O
for	O
the	O
6174delT	O
mutation	O
.	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
BRCA1	O
185delAG	O
mutation	O
the	O
6174delT	O
mutation	O
constitute	O
most	O
to	O
hereditary	B
breast	I
among	O
the	O
,	O
and	O
suggests	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
in	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
frequent	O
predisposing	O
hereditary	B
breast	I
cancer	I
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
free	O
base	O
free	O
base	O
free	O
base	O
chromosomal	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
free	O
base	O
free	O
base	O
free	O
base	O
free	O

This	O
elaborate	O
universe	O
-	O
based	O
study	O
reassert	O
that	O
the	O
BRCA1	O
185delAG	O
mutant	O
and	O
the	O
BRCA2	O
6174delT	O
mutant	O
constitute	O
the	O
deuce	O
most	O
sponsor	O
mutant	O
alleles	O
predispose	O
to	O
familial	B
bosom	I
crab	I
among	O
the	O
ashkenazi	O
,	O
and	O
intimate	O
a	O
relatively	O
frown	O
penetrance	O
for	O
the	O
6174delT	O
mutant	O
in	O
BRCA2	O

This	O
population	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
suggests	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O

This	O
elaborate	O
universe	O
-	O
ground	O
cogitation	O
affirm	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
make	O
the	O
two	O
most	O
frequent	O
mutation	O
allelomorph	O
predispose	O
to	O
ancestral	B
breast	I
cancer	I
among	O
the	O
ashkenazi	O
,	O
and	O
intimate	O
a	O
comparatively	O
broken	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

penetrance	O
predisposing	O
population	O
-	O
mutation	O
study	O
lower	O
Ashkenazim	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
confirms	O
constitute	O
6174delT	O
based	O
BRCA2	O
the	O
two	O
that	O
frequent	O
mutation	O
alleles	O
breast	O
to	O
hereditary	B
6174delT	I
BRCA2	I
among	O
cancer	O
expanded	O
,	O
and	O
suggests	O
a	O
relatively	O
the	O
This	O
for	O
the	O
most	O
mutation	O
in	O
the	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
chromosomal	O
mutation	O
inward	O
free	O
base	O
free	O
base	O
free	O
base	O
free	O
base	O
free	O

This	O
expound	O
universe	O
-	O
establish	O
canvas	O
support	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
name	O
the	O
deuce	O
most	O
frequent	O
mutation	O
allelomorph	O
predispose	O
to	O
hereditary	B
titty	I
cancer	I
among	O
the	O
ashkenazi	O
,	O
and	O
suggests	O
a	O
comparatively	O
dispirited	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

Dual	O
roles	O
emergence	O
reply	O
asynchronous	O
transfer	O
mode	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O

growth	O
roles	O
of	O
.	O
in	O
the	O
cellular	O
response	O
control	O
radiation	O
and	O
in	O
Dual	O
cell	O
to	O
ATM	O

Dual	O
roles	O
response	O
reply	O
reply	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O
response	O
.	O

twofold	O
roles	O
of	O
ATM	O
in	O
the	O
cellular	O
reaction	O
to	O
radiotherapy	O
and	O
in	O
cell	O
emergence	O
control	O
.	O

cell	O
roles	O
of	O
response	O
in	O
the	O
growth	O
ATM	O
to	O
radiation	O
Dual	O
in	O
and	O
cellular	O
control	O
.	O

Dual	O
roles	O
emergence	O
reply	O
asynchronous	O
transfer	O
mode	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O

Dual	O
character	O
of	O
ATM	O
in	O
the	O
cellular	O
reaction	O
to	O
radiation	O
and	O
in	O
cell	O
growing	O
check	O
.	O

double	O
office	O
of	O
ATM	O
in	O
the	O
cellular	O
reception	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
ensure	O
.	O

Dual	O
roles	O
to	O
.	O
in	O
the	O
cell	O
response	O
of	O
radiation	O
and	O
in	O
cellular	O
growth	O
ATM	O
control	O

roles	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
and	O
in	O
cell	O
growth	O
control	O
.	O

Dual	O
roles	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O
.	O

The	O
gene	O
mutated	O
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
,	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
lipide	O
lipide	O
mutate	O
mutate	O
mutate	O
mutate	O
protein	O
or	O
lipid	O
kinase	O
.	O

The	O
cistron	O
mutated	O
in	O
dyssynergia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipoid	O
kinase	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
lipide	O
lipide	O
mutate	O
mutate	O
mutate	O
mutate	O
protein	O
or	O
lipid	O
kinase	O
.	O

The	O
factor	O
mutated	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
at	B
)	O
patients	O
,	O
refer	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
,	O
denoted	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O

patients	O
gene	O
mutated	O
protein	O
ataxia	B
-	I
telangiectasia	I
AT	O
(	B
)	O
or	O
,	O
ATM	O
denoted	O
.	O
encodes	O
a	O
putative	O
in	O
The	O
lipid	O
kinase	O
,	O

The	O
factor	O
mutated	O
in	O
ataxy	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
refer	O
atmosphere	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipoid	O
kinase	O
.	O

,	O
gene	O
AT	O
telangiectasia	O
ataxia	B
-	I
encodes	I
(	O
mutated	B
)	O
patients	O
,	O
lipid	O
ATM	O
in	O
The	O
a	O
putative	O
protein	O
or	O
denoted	O
kinase	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

To	O
elucidate	O
disrupted	O
homologous	O
of	O
ATM	O
gene	O
we	O
the	O
the	O
mouse	O
ATM	O
,	O
through	O
functions	O
recombination	O
in	O
mice	O
.	O

the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
recombination	O
in	O
mice	O
.	O

To	O
elucidate	O
the	O
subroutine	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
creep	O
ATM	O
factor	O
through	O
homologous	O
recombination	O
in	O
mouse	O
.	O

To	O
crystallize	O
the	O
routine	O
of	O
atmosphere	O
,	O
we	O
disrupted	O
the	O
sneak	O
atmosphere	O
factor	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

in	O
elucidate	O
the	O
functions	O
of	O
ATM	O
through	O
homologous	O
disrupted	O
the	O
mouse	O
ATM	O
mice	O
,	O
we	O
recombination	O
gene	O
To	O
.	O

To	O
elucidate	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
.	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
cut	O
off	O
cut	O
off	O
cut	O
off	O

To	O
crystalise	O
the	O
office	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
sneak	O
ATM	O
cistron	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
cut	O
off	O
cut	O
off	O
cut	O
off	O

through	O
elucidate	O
the	O
mouse	O
of	O
ATM	O
,	O
.	O
homologous	O
the	O
functions	O
ATM	O
To	O
gene	O
disrupted	O
recombination	O
in	O
mice	O
we	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O
radiation	O
syndrome	O

-	O
-	O
cellular	O
defects	O
of	O
AT	B
/	O
defective	O
the	O
ATM	O
-	O
patients	O
-	O
following	O
,	O
hypersensitive	O
to	O
gamma	O
,	O
irradiation	O
and	O
a	O
radiation	O
cell	O
Consistent	O
cycle	O
with	O
cells	O
are	O
in	O
correlating	O
-	O
defective	O
with	O
up	O
arrest	O
regulation	O
of	O
p53	O
.	O

Consistent	O
with	O
cellular	O
defects	O
,	O
the	O
ATM	O
-	O
/	O
cells	O
are	O
-	O
defective	O
in	O
cycle	O
radiation	O
,	O
correlating	O
with	O
defective	O
up	O
of	O
p53	O

reproducible	O
with	O
cellular	O
fault	O
of	O
AT	B
patients	O
,	O
the	O
atm	O
-	O
/	O
-	O
cells	O
are	O
hypersensitised	O
to	O
gamma	O
-	O
shaft	O
and	O
bad	O
in	O
cell	O
-	O
hz	O
arrest	O
be	O
actinotherapy	O
,	O
correlate	O
with	O
a	O
bad	O
up	O
-	O
rule	O
of	O
p53	O
.	O

ordered	O
with	O
cellular	O
desert	O
of	O
astatine	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
supersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
faulty	O
in	O
cadre	O
-	O
cycle	O
arrest	O
trace	O
radiation	O
,	O
correlate	O
with	O
a	O
faulty	O
up	O
-	O
rule	O
of	O
p53	O
.	O

correlating	O
up	O
cellular	O
defects	O
to	O
AT	B
of	O
with	O
the	O
ATM	O
-	O
/	O
-	O
-	O
gamma	O
hypersensitive	O
of	O
are	O
-	O
irradiation	O
cells	O
defective	O
in	O
cell	O
with	O
cycle	O
arrest	O
p53	O
Consistent	O
,	O
radiation	O
patients	O
a	O
defective	O
and	O
-	O
regulation	O
,	O
following	O
.	O

uniform	O
with	O
cellular	O
mar	O
of	O
AT	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitized	O
to	O
gamma	O
-	O
ray	O
and	O
faulty	O
in	O
cell	O
-	O
wheel	O
nab	O
chase	O
actinotherapy	O
,	O
correlate	O
with	O
a	O
faulty	O
up	O
-	O
regularization	O
of	O
p53	O
.	O

Consistent	O
with	O
correlating	O
defects	O
of	O
-	B
-	O
,	O
the	O
ATM	O
patients	O
arrest	O
irradiation	O
cells	O
are	O
-	O
to	O
gamma	O
of	O
-	O
and	O
defective	O
in	O
AT	O
-	O
hypersensitive	O
/	O
a	O
with	O
,	O
cellular	O
following	O
radiation	O
defective	O
up	O
cell	O
regulation	O
cycle	O
p53	O
.	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O

In	O
addition	O
,	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
induced	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O
.	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
pattern	O
pattern	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O

in	O
plus	O
,	O
ATM	O
-	O
/	O
-	O
sneak	O
thymocytes	O
are	O
more	O
insubordinate	O
to	O
apoptosis	O
have	O
by	O
gamma	O
-	O
irradiation	O
than	O
convention	O
thymocytes	O
.	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
pattern	O
pattern	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O

indiana	O
gain	O
,	O
ATM	O
-	O
/	O
-	O
shiner	O
thymocytes	O
are	O
more	O
tolerant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
rule	O
thymocytes	O
.	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
resistant	O
to	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O

more	O
addition	O
,	O
irradiation	O
-	O
/	O
-	O
thymocytes	O
mouse	O
are	O
than	O
resistant	O
apoptosis	O
to	O
.	O
by	O
gamma	O
-	O
ATM	O
In	O
normal	O
thymocytes	O
induced	O

inch	O
improver	O
,	O
ATM	O
-	O
/	O
-	O
shiner	O
thymocytes	O
are	O
more	O
immune	O
to	O
apoptosis	O
hasten	O
by	O
gamma	O
-	O
irradiation	O
than	O
convention	O
thymocytes	O
.	O

induced	O
addition	O
thymocytes	O
-	O
-	O
/	O
by	O
mouse	O
,	O
are	O
more	O
resistant	O
normal	O
apoptosis	O
ATM	O
In	O
gamma	O
-	O
irradiation	O
than	O
to	O
thymocytes	O
.	O

In	O
addition	O
,	O
ATM	O
-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O
.	O

ATM	O
-	O
/	O
-	O
fibroblasts	O
are	O
ineffective	O
in	O
G1	O
to	O
sulphur	O
-	O
stage	O
advancement	O
following	O
serum	O
arousal	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passing	O
in	O
civilisation	O
.	O

ATM	O
-	O
-	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
serum	O
stimulation	O
and	O
senesce	O
only	O
a	O
few	O
passages	O
in	O
.	O

ATM	O
-	O
/	O
-	O
be	O
blood	O
serum	O
fibroblast	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
transition	O
inward	O
cultivation	O
inward	O
blood	O
serum	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O

only	O
-	O
/	O
senesce	O
fibroblasts	O
are	O
inefficient	O
culture	O
passages	O
to	O
after	O
-	O
phase	O
progression	O
few	O
serum	O
stimulation	O
and	O
-	O
in	O
S	O
a	O
following	O
G1	O
ATM	O
in	O
.	O

ATM	O
-	O
/	O
-	O
be	O
blood	O
serum	O
fibroblast	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
transition	O
inward	O
cultivation	O
inward	O
blood	O
serum	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O

ATM	O
-	O
/	O
fibroblasts	O
are	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
stimulation	O
and	O
after	O
only	O
a	O
few	O
passages	O
in	O
culture	O
.	O

.	O
-	O
/	O
following	O
fibroblasts	O
are	O
culture	O
in	O
-	O
to	O
S	O
-	O
progression	O
only	O
in	O
G1	O
stimulation	O
and	O
senesce	O
after	O
phase	O
a	O
few	O
passages	O
serum	O
inefficient	O
ATM	O

/	O
are	O
inefficient	O
in	O
to	O
S	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O

passages	O
-	O
/	O
-	O
fibroblasts	O
are	O
progression	O
-	O
G1	O
to	O
S	O
stimulation	O
a	O
inefficient	O
in	O
ATM	O
in	O
serum	O
senesce	O
after	O
only	O
phase	O
few	O
and	O
following	O
culture	O
.	O

atmosphere	O
-	O
/	O
-	O
fibroblasts	O
are	O
ineffective	O
in	O
G1	O
to	O
S	O
-	O
phase	O
procession	O
trace	O
serum	O
stimulus	O
and	O
maturate	O
after	O
only	O
a	O
few	O
passing	O
in	O
polish	O
.	O

ATM	O
-	O
/	O
-	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O
culture	O
.	O

They	O
have	O
an	O
increased	O
constitutional	O
tied	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
rich	O
person	O
rich	O
person	O
rich	O

They	O
have	O
an	O
increased	O
constituent	O
floor	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

They	O
have	O
an	O
increased	O
constitutional	O
flush	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

have	O
an	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

p21CP1	O
have	O
an	O
constitutive	O
increased	O
level	O
WAF1	O
They	O
/	O
of	O
.	O

They	O
p21CP1	O
an	O
increased	O
have	O
level	O
of	O
.	O
/	O
WAF1	O
constitutive	O

increased	O
p21CP1	O
an	O
of	O
constitutive	O
level	O
They	O
have	O
/	O
WAF1	O
.	O

They	O
an	O
constitutive	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
rich	O
person	O
rich	O
person	O
rich	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

The	O
atmosphere	O
protein	O
is	O
consequently	O
vital	O
both	O
for	O
cellular	O
reception	O
to	O
ionizing	O
radiation	O
and	O
for	O
pattern	O
cell	O
-	O
cycle	O
procession	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
advancement	O
be	O
be	O
be	O
be	O
be	O
cycle	O
progression	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
advancement	O
be	O
be	O
be	O
be	O
be	O
cycle	O
progression	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
responses	O
to	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
cycle	O

for	O
ATM	O
cellular	O
both	O
therefore	O
critical	O
normal	O
for	O
protein	O
responses	O
to	O
ionizing	O
.	O
and	O
is	O
The	O
cell	O
-	O
cycle	O
progression	O
radiation	O

The	O
ATM	O
protein	O
is	O
consequently	O
decisive	O
both	O
for	O
cellular	O
reception	O
to	O
ionise	O
radiation	O
and	O
for	O
formula	O
cell	O
-	O
cps	O
progression	O
.	O

.	O
ATM	O
protein	O
to	O
therefore	O
critical	O
both	O
cycle	O
for	O
responses	O
is	O
ionizing	O
and	O
radiation	O
cellular	O
normal	O
cell	O
-	O
for	O
The	O
progression	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
advancement	O
be	O
be	O
be	O
be	O
advancement	O
cycle	O
progression	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
for	O
-	O
cycle	O
progression	O
.	O

The	O
ATM	O
protein	O
is	O
so	O
vital	O
both	O
for	O
cellular	O
reaction	O
to	O
ionize	O
radiation	O
and	O
for	O
rule	O
cell	O
-	O
oscillation	O
progression	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
cycle	O
progression	O
.	O

ATM	O
+	O
to	O
-	O
fibroblasts	O
and	O
to	O
suggesting	O
intermediately	O
defective	O
responses	O
heterozygotes	O
that	O
but	O
no	O
could	O
defect	O
,	O
poor	O
irradiation	O
the	O
checkpoint	O
cancer	B
risk	O
of	O
growth	B
thymocytes	O
increased	O
be	O
attributable	O
/	O
showed	O
AT	O
function	O
.	O
.	O

+	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
increased	O
cancer	B
risk	O
AT	B
could	O
be	O
attributable	O
checkpoint	O

ATM	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
record	O
intermediately	O
bad	O
reply	O
to	O
irradiation	O
but	O
no	O
maturation	O
fault	O
,	O
intimate	O
that	O
the	O
increased	O
cancer	B
danger	O
of	O
at	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
short	O
checkpoint	O
use	O
.	O
.	O

could	O
the	O
/	O
-	O
defect	O
and	O
no	O
poor	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
of	O
showed	O
growth	O
fibroblasts	O
to	O
suggesting	O
that	O
but	O
increased	O
cancer	B
risk	O
+	O
AT	B
heterozygotes	O
ATM	O
,	O
attributable	O
be	O
thymocytes	O
checkpoint	O
function	O
.	O
.	O

ATM	O
+	O
/	O
-	O
fibroblast	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
emergence	O
emergence	O
emergence	O
emergence	O
emergence	O
emergence	O
emergence	O
emergence	O
emergence	O
.	O

of	O
suggesting	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
could	O
attributable	O
growth	O
defect	O
,	O
function	O
that	O
the	O
increased	O
be	B
risk	O
ATM	O
AT	B
poor	O
but	O
no	O
cancer	O
to	O
.	O
checkpoint	O
.	O
+	O
heterozygotes	O

ATM	O
+	O
/	O
-	O
and	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
.	O

atm	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
establish	O
intermediately	O
faulty	O
reply	O
to	O
irradiation	O
but	O
no	O
ontogeny	O
desert	O
,	O
advise	O
that	O
the	O
increased	O
cancer	B
danger	O
of	O
astatine	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
pathetic	O
checkpoint	O
function	O
.	O
.	O

ATM	O
+	O
/	O
-	O
advise	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
rede	O
rede	O
rede	O
rede	O
rede	O
rede	O
rede	O
rede	O
emergence	O
.	O

ATM	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
demo	O
intermediately	O
faulty	O
reaction	O
to	O
actinotherapy	O
but	O
no	O
growing	O
shortcoming	O
,	O
intimate	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
at	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
pathetic	O
checkpoint	O
procedure	O
.	O
.	O

ATM	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
.	O

target	O
perturbation	O
of	O
ATM	O
leads	O
to	O
development	B
retardation	I
,	O
chromosomal	B
atomisation	I
during	I
meiosis	I
,	O
resistant	B
desert	I
,	O
and	O
thymic	B
lymphoma	I
.	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	B
transfer	I
mode	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	B
transfer	I
mode	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
chromosomal	B
fragmentation	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
thymic	B

immune	O
disruption	O
,	O
growth	O
leads	O
to	O
defects	B
retardation	I
of	O
chromosomal	B
fragmentation	I
during	I
.	I
,	O
ATM	B
Targeted	I
,	O
and	O
thymic	B
lymphoma	I
meiosis	O

point	O
disruption	O
of	O
ATM	O
leads	O
to	O
ontogenesis	B
lag	I
,	O
chromosomal	B
atomization	I
during	I
meiosis	I
,	O
resistant	B
shortcoming	I
,	O
and	O
thymic	B
lymphoma	I
.	O

.	O
disruption	O
of	O
fragmentation	O
leads	O
to	O
growth	B
thymic	I
immune	O
chromosomal	B
ATM	I
during	I
,	I
meiosis	O
,	B
defects	I
,	O
and	O
retardation	B
Targeted	I
lymphoma	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
asynchronous	B
transfer	I
mode	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
immune	B
and	O
thymic	B
lymphoma	I
.	O

Targeted	O
disturbance	O
of	O
ATM	O
head	O
to	O
increment	B
slowdown	I
,	O
chromosomal	B
fragmentation	I
during	I
litotes	I
,	O
resistant	B
defects	I
,	O
and	O
thymic	B
lymphoma	I
.	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
thymic	B
lymphoma	I
.	O

ATM	O
,	O
the	O
gene	O
mutate	O
be	O
antiophthalmic	O
factor	O
mutate	O
mutated	O
in	O
the	B
inherited	I
human	I
disease	B
ataxia	I
-	I
telangiectasia	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
jail	O
cell	O
jail	O
cell	O
jail	O

ATM	O
,	O
the	O
in	O
ataxia	B
-	I
telangiectasia	I
is	O
a	O
of	O
a	O
family	O
involved	O
in	O
DNA	O
metabolism	O
and	O
-	O
checkpoint	O
control	O
.	O

ATM	O
,	O
the	O
cistron	O
mutated	O
in	O
the	O
genetic	B
homo	I
disease	I
ataxy	B
-	I
telangiectasia	I
,	O
is	O
a	O
extremity	O
of	O
a	O
kinsfolk	O
of	O
kinases	O
ask	O
in	O
DNA	O
metabolism	O
and	O
cubicle	O
-	O
cycle	O
checkpoint	O
ascendance	O
.	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
human	I
-	I
telangiectasia	I
,	O
is	O
a	O
member	O
of	O
a	O
family	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O

ATM	O
,	O
the	O
cistron	O
mutated	O
in	O
the	O
genetic	B
human	I
disease	I
dyssynergia	B
-	I
telangiectasia	I
,	O
is	O
a	O
extremity	O
of	O
a	O
family	O
of	O
kinases	O
regard	O
in	O
DNA	O
metabolism	O
and	O
cadre	O
-	O
hertz	O
checkpoint	O
insure	O
.	O

ATM	O
,	O
the	O
gene	O
mutate	O
be	O
antiophthalmic	O
factor	O
mutate	O
mutated	O
in	O
the	B
inherited	I
human	I
disease	B
ataxia	I
-	I
telangiectasia	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
jail	O
cell	O
jail	O
cell	O
jail	O

atm	O
,	O
the	O
cistron	O
mutated	O
in	O
the	O
transmissible	B
human	I
disease	I
dyssynergia	B
-	I
telangiectasia	I
,	O
is	O
a	O
extremity	O
of	O
a	O
kinfolk	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cubicle	O
-	O
cycle	O
checkpoint	O
hold	O
.	O

of	O
a	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B
human	I
disease	I
ataxia	B
-	I
telangiectasia	I
DNA	O
cycle	O
a	O
member	O
of	O
cell	O
family	O
,	O
kinases	O
control	O
in	O
,	O
metabolism	O
and	O
ATM	O
is	O
involved	O
checkpoint	O
-	O
.	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
inherited	B
disease	I
ataxia	B
-	I
telangiectasia	I
,	O
is	O
a	O
member	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
cell	O
-	O
cycle	O
control	O

ATM	O
,	O
the	O
gene	O
mutate	O
be	O
antiophthalmic	O
factor	O
extremity	O
mutated	O
in	O
the	B
inherited	I
human	I
disease	B
ataxia	I
-	I
telangiectasia	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
appendage	O
appendage	O
appendage	O
appendage	O
appendage	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B
human	I
disease	I
ataxia	B
-	I
telangiectasia	I
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O

recombination	O
help	O
clarify	O
,	O
physiological	O
roles	O
of	O
through	O
ATM	O
protein	O
the	O
we	O
the	O
disrupted	O
ATM	O
gene	O
in	O
mice	O
the	O
To	O
homologous	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O

To	O
assistant	O
clarify	O
the	O
physiological	O
purpose	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
factor	O
in	O
shiner	O
through	O
homologous	O
recombination	O
.	O

To	O
help	O
clarify	O
physiological	O
roles	O
of	O
the	O
ATM	O
,	O
we	O
disrupted	O
the	O
gene	O
in	O
through	O
homologous	O
recombination	O
.	O

the	O
of	O
the	O
ATM	O
,	O
we	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
homologous	O
recombination	O
.	O

To	O
aid	O
clarify	O
the	O
physiological	O
purpose	O
of	O
the	O
atm	O
protein	O
,	O
we	O
interrupt	O
the	O
atm	O
cistron	O
in	O
mouse	O
through	O
homologous	O
recombination	O
.	O

ATM	O
help	O
ATM	O
of	O
physiological	O
roles	O
gene	O
the	O
clarify	O
protein	O
,	O
we	O
recombination	O
the	O
the	O
To	O
in	O
mice	O
through	O
homologous	O
disrupted	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O
clear	O
up	O

To	O
help	O
clarify	O
the	O
of	O
the	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
homologous	O
recombination	O
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
dyssynergia	O
vivify	O
dyssynergia	O
dyssynergia	O
vivify	O
vivify	O
point	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
phenotype	O
ataxia	B
-	I
telangiectasia	I
.	O

initial	O
evaluation	O
of	O
the	O
ATM	O
ravisher	O
animals	O
suggest	O
that	O
deactivation	O
of	O
the	O
pussyfoot	O
ATM	O
factor	O
revivify	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
the	O
mouse	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
telangiectasia	I
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
dyssynergia	O
vivify	O
dyssynergia	O
dyssynergia	O
vivify	O
vivify	O
vivify	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

Initial	O
rating	O
of	O
the	O
ATM	O
lulu	O
brute	O
designate	O
that	O
deactivation	O
of	O
the	O
mouse	O
ATM	O
factor	O
revivify	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

initial	O
evaluation	O
of	O
the	O
atmosphere	O
kayo	O
beast	O
indicates	O
that	O
inactivation	O
of	O
the	O
pussyfoot	O
atmosphere	O
gene	O
hearten	O
much	O
of	O
the	O
phenotype	O
of	O
dyssynergia	B
-	I
telangiectasia	I
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
mouse	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
dyssynergia	O
vivify	O
dyssynergia	O
dyssynergia	O
vivify	O
vivify	O
vivify	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

phenotype	O
evaluation	O
of	O
of	O
ATM	O
knockout	O
animals	O
the	O
telangiectasia	O
inactivation	O
the	O
the	O
ATM	O
mouse	O
-	O
recreates	O
much	O
of	O
indicates	O
.	O
of	O
ataxia	B
gene	I
that	I
Initial	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

The	O
homozygous	O
variation	O
(	O
ATM	O
-	O
/	O
-	O
)	O
shiner	O
are	O
executable	O
,	O
increase	O
-	O
retarded	O
,	O
and	O
sterile	O
.	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
infertile	O
.	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
infertile	O
.	O

mutant	O
-	O
/	O
-	O
mice	O
are	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
)	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

mutant	O
(	O
ATM	O
-	O
-	O
)	O
mice	O
are	O
viable	O
growth	O
-	O
retarded	O
,	O
infertile	O
.	O

and	O
homozygous	O
mutant	O
infertile	O
ATM	O
-	O
/	O
)	O
-	O
mice	O
-	O
viable	O
,	O
.	O
The	O
retarded	O
,	O
are	O
(	O
growth	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
emergence	O
infertile	O
.	O

The	O
homozygous	O
sport	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
workable	O
,	O
emergence	O
-	O
retarded	O
,	O
and	O
sterile	O
.	O

,	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
growth	O
viable	O
)	O
mice	O
are	O
-	O
The	O
/	O
-	O
and	O
,	O
retarded	O
infertile	O
.	O

The	O
homozygous	O
mutant	O
(	O
ATM	O
-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

The	O
of	O
ATM	O
/	O
mice	O
from	O
meiotic	O
failure	O
.	O

The	O
infertility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O

The	O
sterility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
resolution	O
from	O
meiotic	O
nonstarter	O
.	O

The	O
infertility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
loser	O
loser	O
sterility	O
from	O
meiotic	O
failure	O
.	O

The	O
infertility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
loser	O
loser	O
loser	O
from	O
meiotic	O
failure	O
.	O

The	O
infertility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
loser	O
loser	O
sterility	O
from	O
meiotic	O
failure	O
.	O

The	O
sterility	B
of	O
ATM	O
-	O
/	O
-	O
mouse	O
solution	O
from	O
meiotic	O
failure	O
.	O

The	O
infertility	B
ATM	O
-	O
/	O
-	O
mice	O
results	O
from	O
.	O

The	O
sterility	B
of	O
atmosphere	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O

The	O
-	B
of	O
ATM	O
.	O
/	O
-	O
infertility	O
results	O
from	O
meiotic	O
failure	O
mice	O

The	O
infertility	B
of	O
ATM	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
halt	O
atomization	O
halt	O
atomization	O
atomization	O
halt	O
solution	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
synapsis	O
subsequent	O
chromosome	O
fragmentation	O
.	O

litotes	O
is	O
cop	O
at	O
the	O
zygotene	O
/	O
pachytene	O
represent	O
of	O
prophase	O
I	O
as	O
a	O
outcome	O
of	O
unnatural	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
atomisation	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
stage	O
of	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
halt	O
atomization	O
halt	O
atomization	O
atomization	O
halt	O
halt	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Meiosis	O
is	O
halt	O
at	O
the	O
zygotene	O
/	O
pachytene	O
arrange	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
unnatural	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
atomization	O
.	O

litotes	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
present	O
of	O
prophase	O
I	O
as	O
a	O
leave	O
of	O
unnatural	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
atomization	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
prophase	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
halt	O
atomization	O
halt	O
atomization	O
atomization	O
halt	O
halt	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

chromosomal	O
is	O
arrested	O
prophase	O
the	O
zygotene	O
/	O
synapsis	O
.	O
of	O
at	O
I	O
as	O
a	O
fragmentation	O
of	O
abnormal	O
subsequent	O
pachytene	O
Meiosis	O
and	O
chromosome	O
result	O
stage	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Immune	B
defects	I
cells	O
are	O
evident	O
in	O
ATM	O
CD43	O
/	O
-	O
mice	O
cells	O
-	O
reduced	O
numbers	O
-	O
B220	O
+	O
of	O
including	O
pre	O
.	O
B	O
,	O
,	O
of	O
and	O
as	O
peripheral	O
T	O
also	O
dependent	O
,	O
well	O
as	O
responses	O
impairment	O
thymocytes	O
T	O
-	O
cell	O
-	O
,	O
immune	O
functional	O
-	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
unmistakable	O
unmistakable	O
unmistakable	O
unmistakable	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
unmistakable	O
unmistakable	O
unmistakable	O
a	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
mice	O
,	O
reduced	O
of	O
B220	O
+	O
pre	O
thymocytes	O
,	O
and	O
T	O
cells	O
as	O
well	O
as	O
of	O
T	O
-	O
cell	O
-	O
immune	O
.	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
mice	O
,	O
including	O
reduced	O
numbers	O
pre	O
cells	O
thymocytes	O
,	O
and	O
T	O
cells	O
,	O
as	O
well	O
as	O
T	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O

as	B
CD43	I
also	O
are	O
evident	O
in	O
-	O
-	O
/	O
-	O
mice	O
cell	O
including	O
and	O
T	O
of	O
B220	O
+	O
well	O
-	O
pre	O
-	O
peripheral	O
cells	O
immune	O
thymocytes	O
,	O
reduced	O
numbers	O
,	O
cells	O
functional	O
as	O
defects	O
Immune	O
,	O
impairment	O
of	O
T	O
-	O
,	O
ATM	O
dependent	O
B	O
responses	O
.	O

resistant	B
blemish	I
likewise	O
are	O
unmistakable	O
in	O
ATM	O
-	O
/	O
-	O
mouse	O
,	O
admit	O
thin	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
easily	O
as	O
functional	O
disablement	O
of	O
T	O
-	O
cadre	O
-	O
pendant	O
resistant	O
answer	O
.	O

resistant	B
shortcoming	I
likewise	O
are	O
observable	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
tighten	O
act	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
bel	O
cellphone	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cellphone	O
,	O
as	O
good	O
as	O
useable	O
deterioration	O
of	O
T	O
-	O
cell	O
-	O
dependent	O
resistant	O
reaction	O
.	O

resistant	B
fault	I
likewise	O
are	O
unmistakable	O
in	O
ATM	O
-	O
/	O
-	O
shiner	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
working	O
stultification	O
of	O
T	O
-	O
cadre	O
-	O
dependent	O
resistant	O
reception	O
.	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
drug	O
addicted	O
resistant	O
reply	O
unmistakable	O
unmistakable	O
unmistakable	O
unmistakable	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43	O
-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O

The	O
cerebellum	O
of	O
ATM	O
-	O
/	O
-	O
mice	O
look	O
convention	O
by	O
histologic	O
testing	O
at	O
triplet	O
to	O
quadruplet	O
months	O
and	O
the	O
mice	O
have	O
no	O
crude	O
behavioural	B
abnormalities	I
.	O

The	O
cerebella	O
ATM	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
to	O
4	O
months	O
and	O
mice	O
have	O
no	O
gross	O
behavioral	B
.	O

The	O
cerebella	O
of	O
ATM	O
	O
abnormalcy	O
	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
	O
behavioural	O
abnormalcy	O
behavioural	O
come	O
out	O
and	O
the	O
mice	O
have	O
no	O
gross	B
behavioral	I
abnormalities	O

mice	O
cerebella	O
of	O
and	O
-	O
/	O
-	O
abnormalities	O
gross	O
normal	O
the	O
histologic	O
examination	O
at	O
no	O
to	O
4	O
months	O
ATM	O
behavioral	O
by	O
have	O
3	O
appear	O
The	B
mice	I
.	O

The	O
cerebella	O
of	O
ATM	O
	O
abnormalcy	O
	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
	O
behavioural	O
abnormalcy	O
behavioural	O
come	O
out	O
and	O
the	O
mice	O
have	O
no	O
gross	B
behavioral	I
abnormalities	O

The	O
cerebella	O
of	O
-	O
/	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
4	O
months	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B
abnormalities	I
.	O

.	O
cerebella	O
of	O
3	O
-	O
/	O
abnormalities	O
mice	O
ATM	O
normal	O
by	O
histologic	O
at	O
mice	O
behavioral	O
appear	O
4	O
months	O
and	O
the	O
examination	O
have	O
no	O
gross	O
to	B
-	I
The	O

of	O
/	O
-	O
mice	O
normal	O
by	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B

gross	O
cerebella	O
of	O
ATM	O
-	O
/	O
at	O
histologic	O
appear	O
normal	O
by	O
4	O
have	O
-	O
behavioral	O
The	O
mice	O
to	O
and	O
the	O
mice	O
examination	O
no	O
months	O
3	B
abnormalities	I
.	O

The	O
cerebellum	O
of	O
ATM	O
-	O
/	O
-	O
mice	O
appear	O
convention	O
by	O
histologic	O
scrutiny	O
at	O
trey	O
to	O
quartet	O
months	O
and	O
the	O
mice	O
have	O
no	O
everlasting	O
behavioural	B
abnormalcy	I
.	O

The	O
cerebella	O
of	O
ATM	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B
abnormalities	I
.	O

die	O
majority	O
of	O
thymic	O
mice	O
rapidly	O
develop	O
mutant	B
of	I
and	O
months	O
before	O
The	O
4	O
lymphomas	O
age	O
.	O

The	O
majority	O
of	O
sport	O
mice	O
speedily	O
break	O
thymic	B
lymphomas	I
and	O
die	O
before	O
iv	O
months	O
of	O
geezerhood	O
.	O

The	O
majority	O
of	O
sport	O
mice	O
apace	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
quaternity	O
months	O
of	O
age	O
.	O

The	O
majority	O
mice	O
rapidly	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O

The	O
majority	O
of	O
mutation	O
mouse	O
apace	O
acquire	O
thymic	B
lymphomas	I
and	O
die	O
before	O
quartet	O
months	O
of	O
age	O
.	O

The	O
majority	O
calendar	O
month	O
lymphoma	O
of	O
mutant	O
mice	O
rapidly	O
develop	B
thymic	I
lymphomas	O
and	O
die	O
before	O
4	O
months	O
of	O
age	O
modernise	O
modernise	O
modernise	O

The	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B
and	O
die	O
4	O
months	O
of	O
age	O
.	O

The	O
majority	O
calendar	O
month	O
lymphoma	O
of	O
mutant	O
mice	O
rapidly	O
develop	B
thymic	I
lymphomas	O
and	O
die	O
before	O
4	O
months	O
of	O
age	O
modernise	O
modernise	O
modernise	O

majority	O
mice	O
rapidly	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
4	O

The	O
majority	O
lymphomas	O
of	O
mice	O
rapidly	O
4	O
thymic	B
of	I
and	O
die	O
before	O
develop	O
months	O
mutant	O
age	O
.	O

The	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O

These	O
notice	O
suggest	O
that	O
the	O
ATM	O
gene	O
product	O
diddle	O
an	O
essential	O
use	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
appendage	O
,	O
including	O
meiosis	O
,	O
the	O
pattern	O
growth	O
of	O
corporal	O
tissues	O
,	O
resistant	O
evolution	O
,	O
and	O
tumour	B
stifling	O
.	O
.	O

findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
in	O
a	O
diverse	O
group	O
of	O
processes	O
,	O
the	O
of	O
somatic	O
immune	O
and	O
tumor	B
suppression	O
.	O

somatic	O
tumor	O
indicate	O
that	O
of	O
ATM	O
including	O
development	O
plays	O
an	O
essential	O
role	O
in	O
normal	O
.	O
group	O
the	O
immune	O
processes	O
,	O
product	O
meiosis	O
,	O
the	O
findings	O
growth	O
of	O
These	O
cellular	O
,	O
tissues	O
gene	O
,	O
and	O
a	B
suppression	O
.	O
diverse	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
plays	O
an	O
essential	O
role	O
a	O
diverse	O
group	O
of	O
cellular	O
,	O
including	O
meiosis	O
,	O
normal	O
growth	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
.	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
.	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
.	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
factor	O
product	O
plays	O
an	O
indispensable	O
part	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
miosis	O
,	O
the	O
pattern	O
increase	O
of	O
corporal	O
tissues	O
,	O
resistant	O
evolution	O
,	O
and	O
tumour	B
quelling	O
.	O
.	O

normal	O
processes	O
indicate	O
that	O
the	O
ATM	O
role	O
and	O
plays	O
an	O
essential	O
gene	O
in	O
somatic	O
,	O
group	O
of	O
cellular	O
product	O
,	O
including	O
meiosis	O
tissues	O
the	O
These	O
growth	O
development	O
a	O
diverse	O
,	O
immune	O
suppression	O
,	O
findings	O
tumor	B
of	O
.	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
childs	O
play	O
.	O

These	O
findings	O
the	O
ATM	O
product	O
plays	O
in	O
diverse	O
group	O
of	O
processes	O
,	O
including	O
,	O
the	O
normal	O
growth	O
of	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
.	O
.	O

characterization	O
very	O
-	O
long	O
-	O
acyl	O
-	O
cDNA	O
,	O
assignment	O
of	O
identification	O
four	O
patients	O
of	O
different	O
mutations	O
within	O
VLCAD	O
gene	O
.	O

Cloning	O
and	O
characterization	O
of	O
inside	O
word	O
picture	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
at	O
bottom	O
at	O
bottom	O
at	O
bottom	O
at	O
bottom	O

four	O
of	O
characterization	O
of	O
human	O
very	O
of	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
nine	O
mutations	O
,	O
chromosomal	O
assignment	O
gene	O
the	O
gene	O
and	O
the	O
in	O
Cloning	O
patients	O
-	O
dehydrogenase	O
cDNA	O
identification	O
within	O
different	O
VLCAD	O
.	O
and	O

clone	O
and	O
picture	O
of	O
human	O
very	O
-	O
foresightful	O
-	O
range	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cdna	O
,	O
chromosomal	O
assignment	O
of	O
the	O
cistron	O
and	O
designation	O
in	O
four	O
patients	O
of	O
ix	O
dissimilar	O
mutations	O
inside	O
the	O
VLCAD	O
cistron	O
.	O

Cloning	O
and	O
patients	O
of	O
human	O
very	O
-	O
and	O
-	O
chain	O
acyl	O
in	O
nine	O
dehydrogenase	O
cDNA	O
within	O
chromosomal	O
assignment	O
the	O
-	O
gene	O
long	O
identification	O
of	O
four	O
of	O
characterization	O
VLCAD	O
different	O
mutations	O
,	O
CoA	O
the	O
gene	O
.	O

Cloning	O
and	O
characterization	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
assignment	O
of	O
the	O
gene	O
and	O
in	O
four	O
patients	O
of	O
different	O
mutations	O
the	O
VLCAD	O
gene	O
.	O

cloning	O
and	O
picture	O
of	O
human	O
very	O
-	O
farseeing	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cdna	O
,	O
chromosomal	O
assignment	O
of	O
the	O
factor	O
and	O
recognition	O
in	O
quaternion	O
patients	O
of	O
ennead	O
unlike	O
mutations	O
inside	O
the	O
VLCAD	O
factor	O
.	O

Cloning	O
and	O
characterization	O
of	O
inside	O
homo	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
at	O
bottom	O
at	O
bottom	O
at	O
bottom	O
at	O
bottom	O
at	O

cloning	O
and	O
depiction	O
of	O
human	O
very	O
-	O
foresighted	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
cistron	O
and	O
recognition	O
in	O
quartet	O
patients	O
of	O
ennead	O
dissimilar	O
sport	O
inside	O
the	O
VLCAD	O
cistron	O
.	O

nine	O
gene	O
characterization	O
of	O
chromosomal	O
very	O
cDNA	O
the	O
-	O
chain	O
acyl	O
-	O
CoA	O
four	O
long	O
,	O
human	O
within	O
of	O
the	O
dehydrogenase	O
and	O
identification	O
in	O
and	O
patients	O
of	O
Cloning	O
assignment	O
mutations	O
different	O
-	O
VLCAD	O
gene	O
.	O

Cloning	O
and	O
characterization	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
.	O

Very	O
-	O
all	O
-	O
chain	O
acyl	O
-	O
chain	O
dehydrogenase	O
(	O
VLCAD	O
(	O
acyl	O
one	O
of	O
CoA	O
straight	O
-	O
initial	O
is	O
-	O
.	O
dehydrogenase	O
)	O
ACD	O
four	O
,	O
encoded	O
which	O
are	O
long	O
beta	O
nuclear	O
mitochondrial	O
flavoproteins	O
oxidation	O
the	O
)	O
step	O
in	O
fatty	O
acid	O
enzymes	O
-	O
catalyzing	O
CoA	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
string	O
oxidisation	O
string	O
string	O
string	O
string	O
the	O
initial	O
step	O
in	O
fatty	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
string	O
oxidisation	O
string	O
string	O
string	O
catalyse	O
the	O
initial	O
step	O
in	O
fatty	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
(	O
VLCAD	O
)	O
one	O
four	O
straight	O
-	O
-	O
)	O
enzymes	O
,	O
are	O
all	O
encoded	O
mitochondrial	O
flavoproteins	O
initial	O
step	O
in	O
fatty	O
acid	O
-	O
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
VLCAD	O
)	O
is	O
one	O
of	O
-	O
(	O
)	O
enzymes	O
,	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
step	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O

flavoproteins	O
chain	O
long	O
-	O
chain	O
acyl	O
acid	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
fatty	O
is	O
,	O
are	O
four	O
straight	O
-	O
mitochondrial	O
acyl	O
-	O
CoA	O
which	O
(	O
-	O
)	O
nuclear	O
one	O
of	O
ACD	O
all	O
catalyzing	O
encoded	O
-	O
Very	O
enzymes	O
the	O
initial	O
step	O
in	O
)	O
-	O
beta	O
dehydrogenase	O
oxidation	O
.	O

identical	O
-	O
retentive	O
-	O
range	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
ane	O
of	O
quaternity	O
square	O
-	O
range	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
atomic	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyse	O
the	O
initial	O
tone	O
in	O
fatty	O
acrid	O
beta	O
-	O
oxidization	O
.	O

real	O
-	O
yearn	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
i	O
of	O
quaternary	O
true	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
atomic	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyse	O
the	O
initial	O
gradation	O
in	O
fatso	O
pane	O
beta	O
-	O
oxidization	O
.	O

identical	O
-	O
prospicient	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
quaternity	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
atomic	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyze	O
the	O
initial	O
footfall	O
in	O
butterball	O
caustic	O
beta	O
-	O
oxidization	O
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
fat	O
person	O
oxidisation	O
genus	O
beta	O
string	O
oxidisation	O
string	O
string	O
string	O
string	O
the	O
initial	O
step	O
in	O
fatty	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
the	O
initial	O
step	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
used	O
the	O
very	O
airstream	O
immobile	O
free	O
base	O
identical	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
homo	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
identical	O
identical	O
goal	O

We	O
have	O
used	O
the	O
very	O
airstream	O
immobile	O
free	O
base	O
identical	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
complementary	O
dna	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
identical	O
identical	O

encoding	O
have	O
used	O
the	O
very	O
fast	O
RACE	O
strategy	O
Amplification	O
of	O
cDNA	O
Ends	O
of	O
,	O
human	O
and	O
Rapid	O
sequence	O
obtain	O
the	O
We	O
(	O
cDNAs	O
to	O
)	O
VLCAD	O
from	O
placenta	O
.	O
fibroblasts	O
based	O

We	O
have	O
used	O
the	O
very	O
airstream	O
immobile	O
free	O
base	O
identical	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
homo	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
identical	O
identical	O
goal	O

We	O
have	O
used	O
the	O
fast	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

We	O
have	O
used	O
the	O
very	O
degraded	O
,	O
speedy	O
Amplification	O
of	O
cdna	O
oddment	O
(	O
rush	O
)	O
based	O
scheme	O
to	O
prevail	O
the	O
successiveness	O
of	O
cDNAs	O
encryption	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

and	O
have	O
human	O
)	O
very	O
fast	O
placenta	O
Rapid	O
the	O
of	O
cDNA	O
Ends	O
sequence	O
RACE	O
used	O
Amplification	O
strategy	O
to	O
obtain	O
the	O
(	O
of	O
cDNAs	O
encoding	O
based	O
,	O
from	O
VLCAD	O
We	O
fibroblasts	O
.	O

We	O
have	O
used	O
the	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
cDNA	O
Ends	O
RACE	O
)	O
based	O
strategy	O
to	O
obtain	O
the	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

cDNA	O
have	O
used	O
and	O
very	O
fast	O
,	O
VLCAD	O
encoding	O
of	O
human	O
Ends	O
from	O
the	O
cDNAs	O
based	O
strategy	O
to	O
.	O
RACE	O
sequence	O
of	O
)	O
Amplification	O
We	O
Rapid	O
(	O
placenta	O
the	O
fibroblasts	O
obtain	O

We	O
have	O
victimized	O
the	O
very	O
degenerate	O
,	O
Rapid	O
Amplification	O
of	O
cdna	O
terminate	O
(	O
RACE	O
)	O
ground	O
scheme	O
to	O
obtain	O
the	O
successiveness	O
of	O
cdna	O
encryption	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

We	O
have	O
used	O
the	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

Alignment	O
of	O
the	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
other	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
episode	O
episode	O
homo	O
homo	O
homo	O
homo	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

alliance	O
of	O
the	O
augur	O
amino	O
acid	O
successiveness	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
expose	O
panoptic	O
successiveness	O
homology	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
episode	O
episode	O
homo	O
homo	O
homo	O
homo	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

alignment	O
of	O
the	O
portend	O
amino	O
acid	O
succession	O
of	O
homo	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
homo	O
ACD	O
enzymes	O
discover	O
blanket	O
succession	O
homology	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
those	O
of	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O

with	O
of	O
the	O
revealed	O
amino	O
acid	O
sequence	O
human	O
of	O
VLCAD	O
extensive	O
those	O
the	O
of	O
.	O
human	O
ACD	O
enzymes	O
predicted	O
Alignment	O
sequence	O
homology	O
other	O

coalition	O
of	O
the	O
anticipate	O
aminic	O
sulfurous	O
episode	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extended	O
episode	O
homology	O
.	O

other	O
of	O
human	O
sequence	O
amino	O
acid	O
human	O
of	O
the	O
VLCAD	O
with	O
those	O
sequence	O
the	O
predicted	O
Alignment	O
ACD	O
enzymes	O
revealed	O
extensive	O
of	O
homology	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
cistron	O
bear	O
on	O
be	O
bear	O
on	O
bear	O
on	O
homo	O
belief	O
these	O
genes	O
are	O

human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
these	O
are	O
evolutionarily	O
related	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
blanket	O
episode	O
homology	O
underpin	O
the	O
belief	O
that	O
these	O
genes	O
are	O
evolutionarily	O
connect	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
CoA	O
oxidase	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
are	O
evolutionarily	O
related	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
cistron	O
bear	O
on	O
be	O
bear	O
on	O
bear	O
on	O
homo	O
homo	O
these	O
genes	O
are	O

moreover	O
,	O
homo	O
VLCAD	O
and	O
homo	O
acyl	O
-	O
CoA	O
oxidase	O
prove	O
extensive	O
successiveness	O
homology	O
validate	O
the	O
whimsy	O
that	O
these	O
cistron	O
are	O
evolutionarily	O
related	O
.	O

furthermore	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
depict	O
broad	O
sequence	O
homology	O
underpin	O
the	O
whimsy	O
that	O
these	O
factor	O
are	O
evolutionarily	O
related	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
showed	O
homology	O
corroborating	O
the	O
notion	O
that	O
these	O
genes	O
are	O
evolutionarily	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
cistron	O
bear	O
on	O
be	O
bear	O
on	O
bear	O
on	O
homo	O
homo	O
these	O
genes	O
are	O

that	O
,	O
human	O
showed	O
and	O
human	O
acyl	O
these	O
.	O
oxidase	O
VLCAD	O
extensive	O
sequence	O
homology	O
related	O
the	O
notion	O
are	O
-	O
Moreover	O
genes	O
evolutionarily	O
corroborating	O
CoA	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
these	O
genes	O
are	O
evolutionarily	O
related	O
.	O

17p11	O
blot	O
analysis	O
was	O
genomic	O
DNA	O
from	O
human	O
the	O
lines	O
of	O
used	O
localize	O
to	O
cell	O
VLCAD	O
gene	O
to	O
hybrid	O
Southern	O
chromosome	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

southern	O
fleck	O
analysis	O
of	O
genomic	O
DNA	O
from	O
cross	O
cell	O
stemma	O
was	O
used	O
to	O
focalise	O
the	O
VLCAD	O
factor	O
to	O
human	O
chromosome	O
17p11	O
.	O

Southern	O
blot	O
analysis	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
was	O
used	O
to	O
localize	O
VLCAD	O
gene	O
human	O
chromosome	O
17p11	O
.	O

of	O
from	O
hybrid	O
cell	O
was	O
used	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
chromosome	O
17p11	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
dna	O
from	O
cross	O
cadre	O
lines	O
was	O
used	O
to	O
place	O
the	O
VLCAD	O
cistron	O
to	O
homo	O
chromosome	O
17p11	O
.	O

the	O
blot	O
cell	O
from	O
genomic	O
DNA	O
VLCAD	O
hybrid	O
analysis	O
lines	O
was	O
used	O
17p11	O
localize	O
of	O
Southern	O
gene	O
to	O
human	O
chromosome	O
to	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Southern	O
blot	O
analysis	O
of	O
from	O
hybrid	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
chromosome	O
17p11	O
.	O

-	O
p11	O
.	O

two	O
2	O
-	O
p11	O
.	O

two	O
2	O
-	O
p11	O
.	O

2	O
-	O

two	O
2	O
-	O
p11	O
.	O

ii	O
-	O
p11	O
.	O

p11	O
-	O
2	O
.	O

.	O
-	O
p11	O
2	O

deuce	O
-	O
p11	O
.	O

-	O
p11	O

2	O
-	O
p11	O
.	O

.	O
13105	O

.	O
13105	O

1	O

.	O
13105	O

13105	O

13105	O
.	O

Using	O
Northern	O
is	O
Western	O
blot	O
distribution	O
to	O
we	O
the	O
tissue	O
specific	O
that	O
abundant	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
human	O
several	O
tissues	O
investigate	O
showed	O
analysis	O
VLCAD	O
most	O
and	O
muscle	O
in	O
heart	O
and	O
of	O
skeletal	O
.	O

Using	O
Western	O
blot	O
analysis	O
to	O
the	O
tissue	O
of	O
VLCAD	O
and	O
protein	O
tissues	O
showed	O
that	O
VLCAD	O
most	O
abundant	O
in	O
and	O
skeletal	O
muscle	O
.	O

Using	O
Northern	O
and	O
Western	O
mrna	O
eye	O
be	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O

Using	O
Northern	O
and	O
Western	O
mrna	O
eye	O
fleck	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O

Northern	O
several	O
and	O
Western	O
blot	O
analysis	O
most	O
investigate	O
the	O
tissue	O
specific	O
abundant	O
of	O
VLCAD	O
heart	O
and	O
protein	O
in	O
distribution	O
human	O
tissues	O
we	O
.	O
that	O
VLCAD	O
is	O
to	O
Using	O
skeletal	O
showed	O
and	O
in	O
muscle	O
mRNA	O

Using	O
Northern	O
and	O
Western	O
blot	O
analysis	O
the	O
tissue	O
specific	O
distribution	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
human	O
tissues	O
we	O
showed	O
VLCAD	O
is	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

expend	O
northern	O
and	O
Western	O
smirch	O
analysis	O
to	O
inquire	O
the	O
tissue	O
particular	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
various	O
human	O
weave	O
we	O
register	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
center	O
and	O
skeletal	O
brawn	O
.	O

use	O
northern	O
and	O
Western	O
blot	O
analysis	O
to	O
inquire	O
the	O
weave	O
particular	O
dispersion	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
weave	O
we	O
record	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
essence	O
and	O
skeletal	O
brawn	O
.	O

Using	O
Northern	O
and	O
Western	O
mrna	O
eye	O
fleck	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O
informational	O
rna	O

victimization	O
northerly	O
and	O
western	O
fleck	O
analysis	O
to	O
investigate	O
the	O
weave	O
particular	O
distribution	O
of	O
VLCAD	O
mrna	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
evidence	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
inwardness	O
and	O
skeletal	O
brawniness	O
.	O

Using	O
Northern	O
and	O
Western	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

This	O
agrees	O
and	O
patients	O
the	O
fact	O
characteristic	O
cardiac	O
well	O
muscle	O
symptoms	O
are	O
that	O
for	O
with	O
with	O
VLCAD	B
deficiency	I
.	O

well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
with	O
VLCAD	B
deficiency	I
.	O

This	O
correspond	O
considerably	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
musculus	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
lack	I
.	O

This	O
fit	O
substantially	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
heftiness	O
symptoms	O
are	O
feature	O
for	O
patients	O
with	O
VLCAD	B
want	I
.	O

VLCAD	O
agrees	O
well	O
with	O
the	O
fact	O
for	O
patients	O
and	O
muscle	O
symptoms	O
are	O
deficiency	O
that	O
cardiac	O
with	O
characteristic	B
This	I
.	O

This	O
agrees	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
.	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
deficiency	I
considerably	O
considerably	O
considerably	O
considerably	O
lack	O
.	O

This	O
agrees	O
comfortably	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
musculus	O
symptoms	O
are	O
feature	O
for	O
patients	O
with	O
VLCAD	B
lack	I
.	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
deficiency	I
considerably	O
considerably	O
considerably	O
considerably	O
considerably	O
.	O

for	O
agrees	O
well	O
symptoms	O
the	O
fact	O
that	O
.	O
patients	O
muscle	O
with	O
are	O
This	O
characteristic	O
and	O
with	O
VLCAD	B
deficiency	I
cardiac	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
deficiency	I
.	O

blot	O
analysis	O
and	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
four	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
one	O
patient	O
and	O
that	O
the	O
both	O
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
VLCAD	O
alleles	O
.	O

other	O
VLCAD	O
analysis	O
and	O
VLCAD	O
of	O
alleles	O
three	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
in	O
deficiency	O
with	O
sequencing	B
patients	I
showed	O
that	O
unrelated	O
mRNA	O
was	O
undetectable	O
blot	O
one	O
patient	O
.	O
Northern	O
the	O
that	O
cloned	O
have	O
mutations	O
in	O
both	O
VLCAD	O
PCR	O
and	O

Northern	O
blot	O
analysis	O
sequencing	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
VLCAD	O
.	O

northern	O
stain	O
analysis	O
and	O
sequence	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
inadequacy	I
demonstrate	O
that	O
VLCAD	O
mRNA	O
was	O
insensible	O
in	O
unitary	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
VLCAD	O
alleles	O
.	O

in	O
showed	O
analysis	O
and	O
sequencing	O
of	O
from	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
cloned	O
four	O
and	O
the	O
with	O
VLCAD	B
deficiency	I
mutations	O
that	O
VLCAD	O
mRNA	O
that	O
undetectable	O
Northern	O
one	O
three	O
unrelated	O
patients	O
was	O
other	O
both	O
have	O
in	O
blot	O
patient	O
VLCAD	O
alleles	O
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
VLCAD	O
alleles	O
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
sequence	O
inward	O
VLCAD	O
alleles	O
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
deficiency	I
showed	O
that	O
mRNA	O
undetectable	O
in	O
one	O
that	O
mutations	O
in	O
both	O
alleles	O
.	O

Northern	O
blot	O
other	O
and	O
sequencing	O
of	O
cloned	O
showed	O
amplified	O
VLCAD	O
cDNA	O
patient	O
that	O
unrelated	O
patients	O
PCR	O
VLCAD	B
deficiency	I
alleles	O
four	O
VLCAD	O
have	O
was	O
both	O
in	O
with	O
from	O
mRNA	O
that	O
the	O
analysis	O
and	O
three	O
mutations	O
in	O
undetectable	O
VLCAD	O
one	O
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
VLCAD	O
alleles	O
.	O

Western	O
blob	O
analysis	O
of	O
patient	O
fibroblasts	O
testify	O
that	O
the	O
distinguish	O
mutations	O
ensue	O
in	O
badly	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

analysis	O
fibroblasts	O
showed	O
that	O
identified	O
mutations	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
that	O
the	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

analysis	O
of	O
patient	O
fibroblasts	O
that	O
the	O
identified	O
mutations	O
result	O
severely	O
reduced	O
amounts	O
of	O
protein	O
.	O

VLCAD	O
blot	O
analysis	O
protein	O
patient	O
fibroblasts	O
showed	O
the	O
that	O
identified	O
reduced	O
result	O
in	O
.	O
Western	O
amounts	O
of	O
mutations	O
of	O
severely	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O
depth	O
psychology	O

western	O
smudge	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
solvent	O
in	O
sternly	O
quash	O
sum	O
of	O
VLCAD	O
protein	O
.	O

of	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
severely	O
result	O
the	O
identified	O
mutations	O
reduced	O
Western	O
showed	O
that	O
VLCAD	O
in	O
amounts	O
protein	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

deficiencies	O
bases	O
of	O
:	B
subtotal	I
deficiencies	I
of	I
and	I
combination	I
C7	I
combined	O
their	O
in	O
effects	O
and	O
with	O
other	O
C6	B
C6	I
Molecular	I
C7	I
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
deficiency	B
deficiency	B
blend	B
blend	B
blend	B
blend	B
and	I
C7	I
deficiencies	I
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
deficiency	B
deficiency	B
blend	B
blend	B
blend	B
blend	B
and	I
C7	I
deficiencies	I
.	O

molecular	O
footing	O
of	O
conflate	B
subtotal	I
lack	I
of	I
C6	I
and	I
C7	I
:	O
their	O
core	O
in	O
combining	O
with	O
other	O
C6	B
and	I
C7	I
lack	I
.	O

Molecular	O
bases	O
of	O
subtotal	I
deficiencies	I
of	I
C6	I
and	I
:	O
their	O
effects	O
in	O
with	O
other	O
and	I
C7	I
deficiencies	I
.	O

combined	B
of	I
C6	I
and	I
:	O
their	O
in	O
combination	O
with	O
other	O
C6	B
and	I
C7	I
deficiencies	I
.	O

molecular	O
qaeda	O
of	O
blend	B
subtotal	I
lack	I
of	I
C6	I
and	I
C7	I
:	O
their	O
core	O
in	O
combining	O
with	O
other	O
C6	B
and	I
C7	I
lack	I
.	O

combination	O
bases	O
and	O
of	B
subtotal	I
deficiencies	I
with	I
C6	I
of	I
C7	I
:	O
their	O
deficiencies	O
in	O
combined	O
Molecular	O
other	O
C6	B
and	I
C7	I
effects	I
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
deficiency	B
deficiency	B
blend	B
blend	B
blend	B
inward	B
and	I
C7	I
deficiencies	I
.	O

Molecular	O
bases	O
of	O
combined	B
of	I
C6	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
and	I
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
and	I
C7	I
deficiencies	I
.	O

meld	B
subtotal	I
lack	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
state	O
at	O
very	O
depression	O
levels	O
,	O
has	O
been	O
note	O
in	O
homozygous	O
phase	O
in	O
deuce	O
menage	O
.	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
C7	I
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

been	B
subtotal	I
deficiency	I
,	I
C6	I
and	I
C7	I
in	O
homozygous	O
which	O
.	O
proteins	O
are	O
has	O
in	O
very	O
low	O
levels	O
of	O
expressed	O
form	O
observed	O
at	O
in	O
Combined	O
,	O
two	O
families	O
both	O

Combined	B
subtotal	I
deficiency	I
of	I
be	I
verbalise	I
astatine	I
identical	I
crushed	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
inward	O
	O
inward	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

Combined	B
subtotal	I
deficiency	I
of	I
be	I
verbalise	I
astatine	I
identical	I
crushed	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
inward	O
	O
inward	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
and	I
C7	I
,	O
which	O
both	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

.	B
subtotal	I
deficiency	I
at	I
C6	I
and	I
in	I
,	O
of	O
which	O
both	O
proteins	O
two	O
expressed	O
form	O
in	O
low	O
levels	O
,	O
has	O
are	O
observed	O
in	O
homozygous	O
very	O
C7	O
been	O
families	O
Combined	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
and	I
C7	I
,	O
which	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O

immix	B
subtotal	I
want	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
carry	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
honor	O
in	O
homozygous	O
build	O
in	O
ii	O
mob	O
.	O

meld	B
subtotal	I
want	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
uttered	O
at	O
very	O
humble	O
grade	O
,	O
has	O
been	O
honor	O
in	O
homozygous	O
grade	O
in	O
two	O
household	O
.	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

A	O
defect	O
is	O
the	O
5	O
of	O
donor	O
the	O
of	O
intron	O
15	O
protein	O
responsible	O
C6	O
gene	O
low	O
the	O
low	O
weight	O
molecular	O
of	O
site	O
C6	O
splice	O
and	O
probably	O
at	O
concentration	O
for	O
its	O
explains	O
the	O
expressed	O
.	O

A	O
the	O
5	O
splice	O
donor	O
of	O
intron	O
the	O
C6	O
explains	O
the	O
of	O
C6	O
protein	O
and	O
probably	O
responsible	O
for	O
low	O
expressed	O
concentration	O
.	O

A	O
defect	O
at	O
the	O
cistron	O
explicate	O
be	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
	O
.	O

A	O
defect	O
at	O
the	O
cistron	O
explicate	O
	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
	O
.	O

defect	O
molecular	O
at	O
the	O
5	O
splice	O
probably	O
site	O
of	O
intron	O
15	O
responsible	O
the	O
and	O
its	O
explains	O
the	O
low	O
of	O
weight	O
of	O
the	O
.	O
protein	O
C6	O
is	O
donor	O
A	O
expressed	O
C6	O
low	O
for	O
concentration	O
gene	O

A	O
defect	O
at	O
the	O
5	O
splice	O
of	O
intron	O
15	O
of	O
C6	O
gene	O
explains	O
the	O
low	O
weight	O
of	O
the	O
C6	O
and	O
is	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
.	O

A	O
desert	O
at	O
the	O
quintuplet	O
splice	O
bestower	O
place	O
of	O
intron	O
xv	O
of	O
the	O
C6	O
gene	O
explicate	O
the	O
humble	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
believably	O
creditworthy	O
for	O
its	O
humble	O
extract	O
concentration	O
.	O

A	O
blemish	O
at	O
the	O
five	O
splicing	O
bestower	O
locate	O
of	O
intron	O
fifteen	O
of	O
the	O
C6	O
cistron	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
convey	O
absorption	O
.	O

A	O
defect	O
at	O
the	O
cistron	O
explicate	O
	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
	O
.	O

amp	O
mar	O
at	O
the	O
5	O
marry	O
presenter	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
factor	O
excuse	O
the	O
scummy	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
credibly	O
responsible	O
for	O
its	O
scummy	O
show	O
immersion	O
.	O

A	O
defect	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
.	O

The	O
C7	O
defect	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O
point	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
low	O
,	O
and	O
altered	O
isoelectric	O
point	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
neutered	O
steer	O
steer	O
flaw	O
flaw	O
flaw	O
and	O
altered	O
isoelectric	O
point	O
.	O

The	O
C7	O
fault	O
is	O
more	O
oracular	O
the	O
protein	O
is	O
of	O
convention	O
molecular	O
weight	O
,	O
depleted	O
circulating	O
compactness	O
,	O
and	O
spay	O
isoelectric	O
point	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
neutered	O
steer	O
steer	O
flaw	O
flaw	O
flaw	O
and	O
altered	O
isoelectric	O
point	O
.	O

The	O
C7	O
fault	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
burden	O
,	O
depleted	O
disseminate	O
concentration	O
,	O
and	O
spay	O
isoelectric	O
luff	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
molecular	O
weight	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O

normal	O
C7	O
defect	O
and	O
more	O
enigmatic	O
the	O
is	O
protein	O
of	O
altered	O
molecular	O
,	O
weight	O
.	O
circulating	O
concentration	O
,	O
is	O
The	O
isoelectric	O
point	O
low	O

The	O
C7	O
defect	O
is	O
more	O
puzzling	O
the	O
protein	O
is	O
of	O
formula	O
molecular	O
slant	O
,	O
depleted	O
circulating	O
immersion	O
,	O
and	O
spay	O
isoelectric	O
point	O
.	O

low	O
C7	O
is	O
the	O
more	O
enigmatic	O
circulating	O
protein	O
defect	O
of	O
normal	O
molecular	O
isoelectric	O
,	O
is	O
The	O
concentration	O
,	O
and	O
altered	O
weight	O
point	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O
point	O
.	O

an	O
Arg	O
>	O
Ser	O
codon	O
replacement	O
in	O
exon	O
xi	O
is	O
the	O
only	O
molecular	O
revision	O
inside	O
the	O
ripen	O
C7	O
protein	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
	O
	O
	O
	O
	O
	O
protein	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
	O
	O
	O
	O
	O
	O
protein	O
.	O

>	O
substitution	O
in	O
exon	O
is	O
the	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
exon	O
11	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

>	O
Ser	O
codon	O
substitution	O
exon	O
11	O
is	O
the	O
only	O
alteration	O
within	O
the	O
mature	O
protein	O
.	O

C7	O
Arg	O
>	O
protein	O
codon	O
substitution	O
in	O
11	O
exon	O
is	O
within	O
only	O
molecular	O
.	O
An	O
the	O
mature	O
the	O
Ser	O
alteration	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
	O
	O
	O
	O
	O
an	O
protein	O
.	O

an	O
Arg	O
>	O
Ser	O
codon	O
permutation	O
in	O
exon	O
eleven	O
is	O
the	O
only	O
molecular	O
modification	O
inside	O
the	O
suppurate	O
C7	O
protein	O
.	O

mature	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
alteration	O
only	O
11	O
is	O
the	O
within	O
An	O
in	O
exon	O
C7	O
molecular	O
the	O
protein	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
clear	O
cut	O
antiophthalmic	O
factor	O
clear	O
cut	O
clear	O
cut	O
be	O
be	O
antiophthalmic	O
factor	O
,	O

are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
,	O
a	O
distinct	O
haplotype	O
.	O

These	O
flaw	O
are	O
connect	O
with	O
a	O
feature	O
situated	O
of	O
polymorphous	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
,	O
spring	O
a	O
trenchant	O
haplotype	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
of	O
polymorphic	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
a	O
distinct	O
haplotype	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
clear	O
cut	O
antiophthalmic	O
factor	O
clear	O
cut	O
clear	O
cut	O
be	O
be	O
be	O
,	O
forming	O

These	O
fault	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphous	O
dna	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
part	O
,	O
spring	O
a	O
distinct	O
haplotype	O
.	O

These	O
blemish	O
are	O
associated	O
with	O
a	O
characteristic	O
lot	O
of	O
polymorphous	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
neighborhood	O
,	O
work	O
a	O
distinguishable	O
haplotype	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
DNA	O
the	O
C6	O
/	O
C7	O
region	O
,	O
forming	O
a	O
distinct	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
clear	O
cut	O
antiophthalmic	O
factor	O
clear	O
cut	O
clear	O
cut	O
be	O
be	O
be	O
,	O
forming	O

region	O
defects	O
are	O
DNA	O
with	O
a	O
characteristic	O
,	O
.	O
polymorphic	O
associated	O
markers	O
in	O
the	O
haplotype	O
/	O
C7	O
a	O
set	O
These	O
forming	O
distinct	O
C6	O
of	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
,	O
forming	O
a	O
distinct	O
haplotype	O
.	O

The	O
haplotype	O
has	O
been	O
haplotype	O
hold	O
back	O
faulty	O
cistron	O
find	O
out	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
lack	O
unlike	O
either	B
to	I
C6	I
or	I
C7	O
deficiency	O
,	O
but	O
with	O
different	O
consequences	O
early	O

The	O
haplotype	O
has	O
been	O
haplotype	O
hold	O
back	O
faulty	O
cistron	O
find	O
out	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
lack	O
pass	O
either	B
to	I
C6	I
or	I
C7	O
deficiency	O
,	O
but	O
with	O
different	O
consequences	O
early	O

consequences	O
haplotype	O
,	O
defective	O
found	O
in	O
different	O
with	O
been	O
number	O
of	O
other	O
C6	O
containing	O
has	O
a	O
that	O
lead	O
either	O
to	O
haplotypes	B
or	I
C7	I
deficiency	I
genes	O
combination	O
with	O
but	O
The	O
.	O

The	O
haplotype	O
has	O
been	O
haplotype	O
hold	O
back	O
faulty	O
cistron	O
find	O
out	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
lack	O
unlike	O
either	B
to	I
C6	I
or	I
C7	O
deficiency	O
,	O
but	O
with	O
different	O
consequences	O
early	O

The	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
a	O
number	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
C6	B
or	I
C7	I
deficiency	I
,	O
but	O
with	O
different	O
consequences	O
.	O

The	O
haplotype	O
has	O
been	O
plant	O
in	O
compounding	O
with	O
a	O
routine	O
of	O
other	O
haplotypes	O
carry	O
faulty	O
genes	O
that	O
pass	O
either	O
to	O
C6	B
or	I
C7	I
want	I
,	O
but	O
with	O
unlike	O
upshot	O
.	O

that	O
haplotype	O
has	O
been	O
found	O
in	O
or	O
other	O
a	O
number	O
of	O
The	O
consequences	O
deficiency	O
genes	O
defective	O
lead	O
,	O
either	O
to	O
C6	B
combination	I
C7	I
containing	I
with	O
but	O
with	O
different	O
haplotypes	O
.	O

C6	O
haplotype	O
has	O
either	O
found	O
in	O
combination	O
but	O
deficiency	O
number	O
consequences	O
other	O
with	O
to	O
C7	O
genes	O
that	O
lead	O
been	O
containing	O
,	B
or	I
defective	I
a	I
The	O
with	O
haplotypes	O
different	O
of	O
.	O

The	O
haplotype	O
has	O
been	O
happen	O
in	O
combining	O
with	O
a	O
come	O
of	O
other	O
haplotypes	O
bear	O
bad	O
genes	O
that	O
head	O
either	O
to	O
C6	B
or	I
C7	I
lack	I
,	O
but	O
with	O
unlike	O
outcome	O
.	O

The	O
haplotype	O
has	O
been	O
found	O
combination	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
lead	O
either	O
to	O
C6	B
or	I
C7	I
deficiency	I
with	O
different	O
consequences	O

The	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
C6	B
or	I
C7	I
deficiency	I
,	O
but	O
with	O
different	O
consequences	O
.	O

Where	O
it	O
is	O
combined	O
be	O
grade	O
fundament	O
follow	O
with	O
a	O
C6	B
-	I
deficient	I
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
follow	O
follow	O
follow	O
follow	O
blood	O
serum	O

Where	O
it	O
is	O
a	O
,	O
the	O
serum	O
levels	O
can	O
surprisingly	O
high	O
,	O
there	O
is	O
no	O
C6	O
generating	O
to	O
the	O
C7	O
.	O

Where	O
it	O
is	O
immix	O
with	O
a	O
C6	B
-	I
substandard	I
factor	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
astonishingly	O
high	O
,	O
perchance	O
because	O
there	O
is	O
no	O
C6	O
father	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

Where	O
it	O
is	O
combined	O
with	O
a	O
C6	B
deficient	I
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

Where	O
it	O
is	O
aggregate	O
with	O
a	O
C6	B
-	I
lacking	I
cistron	O
,	O
the	O
serum	O
C7	O
stage	O
can	O
be	O
amazingly	O
gamy	O
,	O
mayhap	O
because	O
there	O
is	O
no	O
C6	O
father	O
C56	O
to	O
waste	O
the	O
C7	O
.	O

Where	O
it	O
is	O
combined	O
be	O
grade	O
fundament	O
follow	O
with	O
a	O
C6	B
-	I
deficient	I
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
follow	O
follow	O
follow	O
follow	O
blood	O
serum	O

Where	O
it	O
is	O
flux	O
with	O
a	O
C6	B
-	I
wanting	I
factor	O
,	O
the	O
serum	O
C7	O
floor	O
can	O
be	O
astonishingly	O
high	O
,	O
mayhap	O
because	O
there	O
is	O
no	O
C6	O
engender	O
C56	O
to	O
have	O
the	O
C7	O
.	O

possibly	O
high	O
is	O
combined	O
with	O
a	O
C6	B
-	I
deficient	I
gene	O
,	O
the	O
serum	O
no	O
consume	O
can	O
be	O
surprisingly	O
C56	O
,	O
it	O
because	O
C7	O
is	O
C7	O
C6	O
generating	O
Where	O
levels	O
there	O
the	O
to	O
.	O

Where	O
it	O
is	O
combined	O
with	O
a	O
-	I
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C56	O
to	O
consume	O
C7	O

Where	O
it	O
is	O
combined	O
nobelium	O
grade	O
fundament	O
blood	O
serum	O
with	O
a	B
C6	I
-	I
deficient	O
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
atomic	O
number	O
	O
atomic	O

Where	O
it	O
is	O
combined	O
with	O
a	O
C6	B
-	I
deficient	I
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

and	O
may	O
,	O
where	O
the	O
C7	O
C7	O
are	O
both	O
defective	O
(	O
of	O
still	O
circulating	O
ample	O
)	O
,	O
there	O
there	O
be	O
a	O
profound	O
consume	O
of	O
partially	O
C7	O
C56	O
contrast	O
to	O
deficit	O
C6	O
is	O
produce	O
functional	O
In	O
because	O
the	O
already	O
small	O
amount	O
but	O
genes	O
.	O

In	O
contrast	O
,	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
partially	O
functional	O
)	O
there	O
be	O
a	O
profound	O
circulating	O
ample	O
C6	O
to	O
C56	O
and	O
the	O
already	O
small	O
C7	O
.	O

inwards	O
line	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
bad	O
(	O
but	O
even	O
partially	O
operable	O
)	O
,	O
there	O
whitethorn	O
be	O
a	O
wakeless	O
shortfall	O
of	O
disperse	O
C7	O
because	O
there	O
is	O
plentiful	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
little	O
measure	O
of	O
C7	O
.	O

indium	O
counterpoint	O
,	O
where	O
the	O
C7	O
factor	O
are	O
both	O
faulty	O
(	O
but	O
motionless	O
partly	O
usable	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
disperse	O
C7	O
because	O
there	O
is	O
plentiful	O
C6	O
to	O
produce	O
C56	O
and	O
eat	O
the	O
already	O
belittled	O
total	O
of	O
C7	O
.	O

In	O
contrast	O
to	O
where	O
the	O
C7	O
genes	O
may	O
both	O
defective	O
(	O
still	O
.	O
partially	O
functional	O
C6	O
,	O
there	O
be	O
are	O
a	O
produce	O
deficit	O
consume	O
circulating	O
because	O
there	O
profound	O
is	O
ample	O
)	O
already	O
C7	O
C56	O
and	O
of	O
the	O
,	O
small	O
amount	O
of	O
C7	O
but	O

In	O
contrast	O
,	O
the	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
the	O
small	O
amount	O
of	O
C7	O
.	O

In	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
be	O
low	O
quantity	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
the	O
already	O
small	O
amount	O
of	O
C7	O
.	O

small	O
circulating	O
,	O
where	O
,	O
C7	O
a	O
to	O
both	O
defective	O
(	O
but	O
still	O
genes	O
already	O
)	O
the	O
C6	O
may	O
be	O
partially	O
profound	O
deficit	O
of	O
there	O
C7	O
because	O
C7	O
there	O
ample	O
is	O
contrast	O
produce	O
C56	O
and	O
consume	O
the	O
functional	O
In	O
amount	O
of	O
are	O
.	O

In	O
contrast	O
,	O
the	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
there	O
may	O
be	O
a	O
profound	O
there	O
C6	O
produce	O
C56	O
and	O
the	O
already	O
small	O
amount	O
of	O
C7	O

indium	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
faulty	O
(	O
but	O
motionless	O
partly	O
usable	O
)	O
,	O
there	O
may	O
be	O
a	O
unplumbed	O
shortage	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
sizeable	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
small	O
come	O
of	O
C7	O
.	O

In	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
small	O
amount	O
of	O
C7	O
.	O

Each	O
molecular	O
find	O
out	O
inward	O
flaw	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
.	O
be	O

effect	O
molecular	O
defect	O
.	O
also	O
been	O
found	O
in	O
.	O
and	O
has	O
the	O
Each	O
expected	O
isolation	O
has	O

Each	O
molecular	O
find	O
out	O
inward	O
too	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
.	O
be	O

each	O
molecular	O
desert	O
has	O
also	O
been	O
determine	O
in	O
isolation	O
and	O
has	O
the	O
wait	O
effect	O
.	O
.	O

expected	O
molecular	O
defect	O
in	O
also	O
been	O
effect	O
has	O
isolation	O
and	O
Each	O
the	O
has	O
found	O
.	O
.	O

Each	O
molecular	O
find	O
out	O
inward	O
flaw	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
.	O
be	O

Each	O
molecular	O
fault	O
has	O
also	O
been	O
establish	O
in	O
isolation	O
and	O
has	O
the	O
await	O
core	O
.	O
.	O

Each	O
molecular	O
fault	O
has	O
likewise	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
bear	O
force	O
.	O
.	O

Each	O
molecular	O
isolation	O
.	O
also	O
been	O
expected	O
in	O
defect	O
and	O
has	O
the	O
found	O
effect	O
has	O
.	O

molecular	O
defect	O
has	O
also	O
been	O
found	O
in	O
has	O
the	O
expected	O
effect	O
.	O
.	O

Each	O
molecular	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
.	O
.	O

deficiency	O
bases	O
of	O
human	O
.	B
C7	I
Genetic	I
complement	O

Genetic	O
root	O
of	O
human	O
complement	B
C7	I
lack	I
.	O

of	O
C7	I
deficiency	I
.	O

Genetic	O
homo	O
homo	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

Genetic	O
of	O
human	O
deficiency	I
.	O

Genetic	O
complement	O
of	O
human	O
bases	B
C7	I
.	I
deficiency	O

.	O
human	O
of	O
bases	O
complement	B
C7	I
deficiency	I
Genetic	O

Genetic	O
homo	O
accompaniment	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

Genetic	O
theme	O
of	O
human	O
complement	B
C7	I
inadequacy	I
.	O

Genetic	O
homo	O
accompaniment	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

Genetic	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

complement	B
C7	I
want	I
(	O
C7D	B
)	O
is	O
associated	O
often	O
with	O
perennial	O
bacterial	B
infections	I
,	O
particularly	O
meningitis	B
do	O
by	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
lack	O
lack	O
lack	O
lack	O
lack	O
lack	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
with	O
recurrent	O
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
Neisseria	B

especially	B
C7	I
frequently	I
is	O
C7D	B
)	O
meningitis	O
associated	O
deficiency	O
with	O
recurrent	O
bacterial	B
.	I
,	O
(	O
Complement	B
caused	O
by	O
Neisseria	B
meningitidis	I
infections	O

complement	B
C7	I
inadequacy	I
(	O
C7D	B
)	O
is	O
associated	O
often	O
with	O
repeated	O
bacterial	B
transmission	I
,	O
especially	O
meningitis	B
stimulate	O
by	O
Neisseria	B
meningitidis	I
.	O

.	B
C7	I
deficiency	I
recurrent	O
C7D	B
)	O
is	O
Neisseria	O
especially	O
with	O
(	O
bacterial	B
,	I
infections	O
frequently	O
meningitis	B
caused	O
by	O
associated	B
Complement	I
meningitidis	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
lack	O
lack	O
lack	O
lack	O
lack	O
accompaniment	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
especially	O
by	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
want	I
(	O
C7D	B
)	O
is	O
colligate	O
oft	O
with	O
repeated	O
bacterial	B
infections	I
,	O
peculiarly	O
meningitis	B
stimulate	O
by	O
Neisseria	B
meningitidis	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
Neisseria	B
meningitidis	I
.	O

We	O
report	O
inwards	O
fundament	O
inward	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
rear	O
.	O

Japanese	O
report	O
in	O
.	O
work	O
the	O
molecular	O
bases	O
males	O
C7D	B
in	O
two	O
We	O
unrelated	O
of	O
this	O

We	O
report	O
inwards	O
fundament	O
inward	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
rear	O
.	O

We	O
report	O
in	O
this	O
operate	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
ii	O
unrelated	O
nipponese	O
males	O
.	O

unrelated	O
report	O
in	O
bases	O
work	O
the	O
Japanese	O
this	O
of	O
C7D	B
We	O
two	O
in	O
molecular	O
males	O
.	O

We	O
report	O
inwards	O
fundament	O
inward	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
rear	O
.	O

We	O
describe	O
in	O
this	O
sour	O
the	O
molecular	O
understructure	O
of	O
C7D	B
in	O
deuce	O
unrelated	O
Japanese	O
males	O
.	O

We	O
describe	O
in	O
this	O
work	O
the	O
molecular	O
pedestal	O
of	O
C7D	B
in	O
deuce	O
unrelated	O
nipponese	O
males	O
.	O

We	O
report	O
of	O
.	O
work	O
the	O
unrelated	O
bases	O
in	O
C7D	B
in	O
two	O
molecular	O
Japanese	O
this	O
males	O

report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
in	O
two	O
unrelated	O
Japanese	O
males	O
.	O

We	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
.	O

We	O
used	O
exon	O
-	O
particular	O
PCR	O
/	O
single	O
-	O
fibril	O
conformation	O
pleomorphism	O
analysis	O
as	O
a	O
sort	O
tone	O
for	O
mutations	O
.	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O

exon	O
PCR	O
/	O
single	O
strand	O
conformation	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

We	O
used	O
exon	O
-	O
specific	O
single	O
-	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

exon	O
-	O
specific	O
PCR	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
mutations	O
.	O

for	O
used	O
exon	O
mutations	O
specific	O
PCR	O
/	O
-	O
single	O
strand	O
a	O
polymorphism	O
analysis	O
.	O
We	O
screening	O
step	O
conformation	O
-	O
as	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O

We	O
used	O
exon	O
-	O
particular	O
PCR	O
/	O
unmarried	O
-	O
strand	O
compliance	O
pleomorphism	O
analysis	O
as	O
a	O
sieve	O
step	O
for	O
mutant	O
.	O

step	O
used	O
exon	O
-	O
specific	O
PCR	O
as	O
polymorphism	O
-	O
strand	O
conformation	O
a	O
We	O
/	O
single	O
for	O
analysis	O
screening	O
mutations	O
.	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
display	O
case	O
two	O
display	O
case	O
two	O
two	O
sequence	O
fair	O
game	O
exon	O
15	O
of	O

sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
exon	O
of	O
case	O
2	O
.	O

subsequent	O
place	O
sequence	O
of	O
the	O
target	O
exons	O
name	O
homozygous	O
mutations	O
in	O
exon	O
xvi	O
of	O
casing	O
single	O
and	O
in	O
exon	O
15	O
of	O
casing	O
2	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
homozygous	O
mutations	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
of	O
case	O
2	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
display	O
case	O
two	O
display	O
case	O
two	O
two	O
sequence	O
sequence	O
exon	O
15	O
of	O
case	O

subsequent	O
guide	O
sequence	O
of	O
the	O
target	O
exons	O
name	O
homozygous	O
mutations	O
in	O
exon	O
xvi	O
of	O
typeface	O
1	O
and	O
in	O
exon	O
15	O
of	O
typeface	O
two	O
.	O

subsequent	O
calculate	O
sequence	O
of	O
the	O
target	O
exons	O
key	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
fount	O
unity	O
and	O
in	O
exon	O
15	O
of	O
fount	O
two	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
in	O
of	O
case	O
1	O
and	O
in	O
exon	O
15	O
of	O
case	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
display	O
case	O
two	O
display	O
case	O
two	O
two	O
sequence	O
sequence	O
exon	O
15	O
of	O
case	O

in	O
direct	O
sequencing	O
in	O
the	O
target	O
exons	O
exon	O
.	O
mutations	O
of	O
exon	O
16	O
of	O
2	O
1	O
and	O
of	O
identified	O
Subsequent	O
15	O
case	O
case	O
homozygous	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
exon	O
15	O
of	O
case	O
2	O
.	O

The	O
mutation	O
codon	O
case	O
1	O
was	O
transversion	O
nucleotide	O
T	O
to	O
A	O
leading	O
of	O
nucleotide	O
2250	O
to	O
the	O
third	O
TGA	O
at	O
the	O
(	O
TGT	O
for	O
Cys728	O
,	O
a	O
codon	O
a	O
stop	O
of	O
homozygous	O
,	O
C728X	O
)	O
.	O

mutation	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
codon	O
TGT	O
for	O
,	O
to	O
a	O
stop	O
(	O

The	O
variation	O
of	O
case	O
ace	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
base	O
2250	O
,	O
the	O
third	O
base	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
star	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

to	O
the	O
of	O
case	O
the	O
was	O
2250	O
TGA	O
T	O
to	O
A	O
transversion	O
at	O
Cys728	O
homozygous	O
,	O
1	O
codon	O
nucleotide	O
of	O
nucleotide	O
codon	O
TGT	O
for	O
mutation	O
,	O
leading	O
The	O
third	O
stop	O
a	O
a	O
(	O
C728X	O
)	O
.	O

The	O
mutation	O
of	O
case	O
	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Cys728	O
nucleotide	O
of	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
to	O
stop	O
,	O
the	O
third	O
C728X	O
of	O
the	O
codon	O
a	O
for	O
The	O
,	O
TGA	O
nucleotide	O
2250	O
TGT	O
codon	O
.	O
(	O
)	O
mutation	O
leading	O

The	O
mutation	O
of	O
case	O
was	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

The	O
mutant	O
of	O
type	O
single	O
was	O
angstrom	O
homozygous	O
tonne	O
to	O
angstrom	O
transversion	O
at	O
base	O
2250	O
,	O
the	O
tierce	O
base	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
head	O
to	O
angstrom	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

The	O
mutation	O
of	O
case	O
deoxythymidine	O
monophosphate	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

The	O
variation	O
of	O
lawsuit	O
1	O
was	O
a	O
homozygous	O
tonne	O
to	O
A	O
transversion	O
at	O
base	O
2250	O
,	O
the	O
third	O
base	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
go	O
to	O
a	O
cease	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

The	O
mutation	O
of	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

In	O
case	O
2	O
,	O
expiration	O
antiophthalmic	O
factor	O
nucleotide	O
two	O
antiophthalmic	O
factor	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
release	O
release	O
release	O

In	O
case	O
a	O
deletion	O
(	O
2137delTG	O
2138delGT	O
/	O
)	O
caused	O
a	O
generating	O
a	O
premature	O
termination	O
codon	O
to	O
nucleotides	O
downstream	O
.	O

in	O
case	O
two	O
,	O
a	O
homozygous	O
two	O
-	O
bp	O
omission	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
father	O
a	O
untimely	O
result	O
codon	O
quaternion	O
to	O
6	O
nucleotides	O
downriver	O
.	O

In	O
case	O
2	O
,	O
homozygous	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
.	O

In	O
case	O
deuce	O
,	O
a	O
homozygous	O
deuce	O
-	O
bp	O
excision	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
induce	O
a	O
frameshift	O
,	O
yield	O
a	O
previous	O
termination	O
codon	O
4	O
to	O
6	O
base	O
downriver	O
.	O

In	O
case	O
2	O
,	O
expiration	O
antiophthalmic	O
factor	O
nucleotide	O
two	O
antiophthalmic	O
factor	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
release	O
release	O
release	O

In	O
cause	O
deuce	O
,	O
a	O
homozygous	O
deuce	O
-	O
bp	O
excision	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
do	O
a	O
frameshift	O
,	O
give	O
a	O
previous	O
ending	O
codon	O
4	O
to	O
sestet	O
nucleotides	O
downriver	O
.	O

,	O
a	O
2	O
,	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
termination	O
nucleotides	O
2139delTG	O
)	O
caused	O
to	O
frameshift	O
case	O
generating	O
.	O
premature	O
2138delGT	O
codon	O
4	O
In	O
/	O
a	O
downstream	O
6	O

In	O
case	O
2	O
,	O
homozygous	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
codon	O
4	O
to	O
nucleotides	O
.	O

In	O
case	O
2	O
,	O
inwards	O
antiophthalmic	O
factor	O
nucleotide	O
two	O
inward	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
in	O
in	O
in	O
	O

In	O
case	O
2	O
,	O
a	O
homozygous	O
2	O
-	O
bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
.	O

Family	O
in	O
case	O
confirmed	O
genetic	O
of	O
the	O
defect	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O

Family	O
consider	O
in	O
case	O
1	O
confirmed	O
the	O
genic	O
nature	O
of	O
the	O
mar	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
flaw	O
flaw	O
meditate	O
of	O
the	O
defect	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
flaw	O
flaw	O
display	O
case	O
of	O
the	O
defect	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
flaw	O
flaw	O
meditate	O
of	O
the	O
defect	O
.	O

Family	O
subject	O
in	O
font	O
unity	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O
.	O

Family	O
study	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
.	O

kinsfolk	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
hereditary	O
nature	O
of	O
the	O
flaw	O
.	O

Family	O
1	O
in	O
case	O
.	O
confirmed	O
the	O
study	O
nature	O
of	O
the	O
defect	O
genetic	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
display	O
case	O
	O
display	O
case	O
	O
	O
noncoding	O
dna	B
furthermore	O
for	O
C7D	O
in	O

we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
for	O
in	O
case	O
1	O
.	O

Moreover	O
,	O
we	O
observe	O
a	O
refreshing	O
polymorphism	O
in	O
intron	O
xi	O
that	O
presumptively	O
is	O
associate	O
to	O
the	O
variation	O
responsible	O
for	O
C7D	B
in	O
case	O
ane	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
intron	O
11	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
in	O
case	O
1	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
display	O
case	O
	O
display	O
case	O
	O
	O
noncoding	O
dna	B
noncoding	O
dna	O
for	O
C7D	O

moreover	O
,	O
we	O
detected	O
a	O
new	O
pleomorphism	O
in	O
intron	O
11	O
that	O
presumptively	O
is	O
linked	O
to	O
the	O
sport	O
responsible	O
for	O
C7D	B
in	O
type	O
single	O
.	O

Moreover	O
,	O
we	O
observe	O
a	O
fresh	O
pleomorphism	O
in	O
intron	O
11	O
that	O
presumptively	O
is	O
colligate	O
to	O
the	O
mutant	O
responsible	O
for	O
C7D	B
in	O
case	O
i	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
that	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
C7D	B
in	O
case	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
display	O
case	O
	O
display	O
case	O
	O
	O
noncoding	O
dna	B
noncoding	O
dna	O
for	O
C7D	O

responsible	O
,	O
we	O
that	O
a	O
novel	O
polymorphism	O
for	O
.	O
11	O
detected	O
presumably	O
is	O
linked	O
1	O
the	O
mutation	O
in	O
in	O
Moreover	B
C7D	O
case	O
to	O
intron	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
C7D	B
in	O
case	O
1	O
.	O

Our	O
event	O
signal	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogenous	O
like	O
most	O
of	O
the	O
other	O
want	B
of	I
complement	I
portion	I
.	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
point	I
point	O
point	I
point	O
point	I
point	O
components	I
.	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
point	I
point	O
point	I
point	O
point	I
point	O
components	I
.	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
heterogeneous	O
like	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
components	I

other	O
results	O
is	O
of	O
the	O
pathogenesis	O
deficiencies	O
C7D	B
indicate	O
heterogeneous	O
like	O
most	O
.	O
the	O
that	O
Our	B
of	I
complement	I
components	I
.	O
of	O

Our	O
answer	O
designate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogenous	O
similar	O
most	O
of	O
the	O
other	O
deficiency	B
of	I
accompaniment	I
components	I
.	O
.	O

.	O
results	O
indicate	O
like	O
the	O
pathogenesis	O
of	O
components	B
other	O
heterogeneous	O
that	O
most	O
the	O
of	O
is	O
deficiencies	B
of	I
complement	I
C7D	I
Our	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
point	I
point	O
point	I
point	O
point	I
solution	O
components	I
.	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
other	O
complement	I
components	I
.	O
.	O

Our	O
solution	O
argue	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogenous	O
like	O
most	O
of	O
the	O
other	O
deficiency	B
of	I
complement	I
factor	I
.	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
components	I
.	O
.	O

HPRT	B
-	I
be	I
non	I
antiophthalmic	I
factor	I
APRT	I
-	I
deficient	O
mice	O
are	O
not	O
a	O
model	O
for	B
lesch	I
-	I
nyhan	I
syndrome	O
mouse	O

nyhan	B
-	I
APRT	I
.	I
deficient	I
mice	O
are	O
not	O
syndrome	O
model	O
for	O
lesch	B
HPRT	I
-	I
a	I
-	O

HPRT	B
-	I
be	I
non	I
antiophthalmic	I
factor	I
APRT	I
-	I
deficient	O
mice	O
are	O
not	O
a	O
model	O
for	B
lesch	I
-	I
nyhan	I
syndrome	O
mouse	O

HPRT	B
-	I
APRT	I
-	I
lacking	I
mouse	O
are	O
not	O
a	O
poser	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

-	B
-	I
APRT	I
not	I
deficient	I
mice	O
nyhan	O
-	O
a	O
model	O
HPRT	O
lesch	B
for	I
are	I
syndrome	I
.	O

HPRT	B
-	I
be	I
non	I
antiophthalmic	I
factor	I
APRT	I
-	I
deficient	O
mice	O
are	O
not	O
a	O
model	O
for	B
lesch	I
-	I
nyhan	I
syndrome	O
mouse	O

HPRT	B
-	I
APRT	I
-	I
insufficient	I
shiner	O
are	O
not	O
a	O
model	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

HPRT	B
-	I
APRT	I
-	I
substandard	I
mice	O
are	O
not	O
a	O
manakin	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

HPRT	B
-	I
a	I
.	I
deficient	I
mice	O
-	O
not	O
APRT	O
model	O
for	O
lesch	B
are	I
nyhan	I
-	I
syndrome	O

-	I
APRT	I
-	I
deficient	I
mice	O
are	O
not	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

-	I
-	I
transferase	I
(	I
HPRT	I
deficiency	I
in	O
in	O
the	O
-	I
Nyhan	I
characterized	O
among	O
other	O
features	O
by	O
compulsive	O
self	O
injurious	O
behavior	O
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
ego	I
early	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
self	O
self	O
self	O
self	O
self	O
self	O
self	O
inward	O
.	O

among	B
Nyhan	I
-	I
guanine	I
phosphoribosyl	I
-	I
features	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
,	O
compulsive	O
the	O
Lesch	B
-	I
behavior	I
syndrome	I
which	O
is	O
-	O
,	O
Complete	O
other	O
transferase	O
results	O
in	O
characterized	O
self	O
by	O
injurious	O
.	O
hypoxanthine	O

Complete	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
lack	I
in	O
humans	O
upshot	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
determined	O
ego	O
-	O
hurtful	O
behaviour	O
.	O

Complete	B
hypoxanthine	I
other	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
is	I
HPRT	I
)	I
deficiency	I
,	O
,	O
results	O
in	O
self	O
Lesch	B
-	I
syndrome	I
in	I
which	O
(	O
characterized	O
Nyhan	O
among	O
features	O
-	O
injurious	O
by	O
compulsive	O
the	O
humans	O
-	O
behavior	O
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
humans	O
results	O
in	O
the	O
-	I
Nyhan	I
syndrome	I
which	O
is	O
,	O
among	O
other	O
features	O
by	O
compulsive	O
-	O
injurious	O
behavior	O
.	O

ended	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
insufficiency	I
in	O
humans	O
event	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
characteristic	O
,	O
by	O
driven	O
ego	O
-	O
deleterious	O
demeanor	O
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
ego	I
aside	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
self	O
self	O
self	O
self	O
self	O
self	O
self	O
inward	O
.	O

perfect	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
inadequacy	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
driven	O
ego	O
-	O
hurtful	O
conduct	O
.	O

,	B
which	I
-	I
guanine	I
Lesch	I
-	I
in	I
-	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
among	O
(	O
the	O
phosphoribosyl	B
self	I
Nyhan	I
syndrome	I
results	O
is	O
characterized	O
,	O
hypoxanthine	O
other	O
features	O
Complete	O
-	O
compulsive	O
by	O
transferase	O
injurious	O
behavior	O
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
the	O
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
wanting	I
mice	O
generated	O
victimisation	O
mouse	O
embryonal	O
stanch	O
cells	O
march	O
none	O
of	O
the	O
behavioural	O
symptoms	O
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
stem	O
cells	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
deficient	I
mice	O
yield	O
use	O
pussyfoot	O
embryologic	O
prow	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioural	O
symptoms	O
connect	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
lacking	I
mice	O
give	O
using	O
creep	O
embryonal	O
stem	O
cells	O
march	O
none	O
of	O
the	O
behavioural	O
symptoms	O
assort	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
exhibit	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

with	B
-	I
deficient	I
exhibit	O
generated	O
using	O
mouse	O
the	O
.	O
cells	O
mice	O
none	O
of	O
the	O
syndrome	O
symptoms	O
associated	O
-	O
embryonic	O
HPRT	B
Lesch	I
Nyhan	I
behavioral	I
stem	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Administration	O
drugs	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
)	O
mice	O
has	O
produced	O
suggestion	O
that	O
of	I
APRT	I
in	O
HPRT	B
-	I
deficiency	I
in	O
mice	O
lead	O
self	O
-	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
D	O
.	O
W	O
.	O
Melton	O
.	O
235	O
240	O
]	O
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
combining	O
pussyfoot	O
	O
inward	O
lack	O
inward	O
mouse	O
crataegus	O
oxycantha	O
pass	O
APRT	O
)	O
in	B
HPRT	I
-	I
deficient	O
mice	O
has	O
produced	O
the	O
suggestion	O
that	B
deficiency	I
of	I
APRT	O
in	O
combination	O
with	B
HPRT	I
-	I
deficiency	O
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
genetta	O
genetta	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
and	O
D	O
.	O
W	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
235	O
-	O
240	O
]	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O

self	O
HPRT	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
.	I
mice	O
has	O
produced	O
the	O
-	O
that	O
deficiency	B
of	I
.	I
in	O
Wu	O
with	O
to	B
.	I
3	I
deficiency	O
mice	O
-	O
lead	O
L	O
Administration	O
suggestion	O
mutilation	O
behavior	O
[	O
C	O
.	O
of	O
.	O
APRT	O
and	O
D	O
-	O
W	O
combination	O
Melton	O
(	O
1993	O
)	O
235	O
Genet	O
.	O
240	O
,	O
Nature	O
may	O
in	O
]	O
deficient	O

organization	O
of	O
drugs	O
that	O
subdue	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
substandard	I
mouse	O
has	O
acquire	O
the	O
prompting	O
that	O
inadequacy	B
of	I
APRT	I
in	O
compounding	O
with	O
HPRT	B
-	I
inadequacy	I
in	O
mouse	O
may	O
chair	O
to	O
ego	O
-	O
mutilation	O
doings	O
[	O
carbon	O
.	O
L	O
.	O
Wu	O
and	O
cholecalciferol	O
.	O
wolfram	O
.	O
Melton	O
(	O
1993	O
)	O
nature	O
Genet	O
.	O
trine	O
,	O
235	O
-	O
240	O
]	O
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
combining	O
pussyfoot	O
	O
inward	O
lack	O
inward	O
mouse	O
crataegus	O
oxycantha	O
pass	O
APRT	O
)	O
in	B
HPRT	I
-	I
deficient	O
mice	O
has	O
produced	O
the	O
suggestion	O
that	B
deficiency	I
of	I
APRT	O
in	O
combination	O
with	B
HPRT	I
-	I
deficiency	O
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
genetta	O
genetta	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
and	O
D	O
.	O
W	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
235	O
-	O
240	O
]	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O

and	O
,	O
drugs	O
that	O
.	O
adenine	O
240	O
produced	O
APRT	O
)	O
in	O
HPRT	B
-	I
(	I
behavior	O
has	O
(	O
mice	O
suggestion	O
that	O
of	B
of	I
APRT	I
in	O
Nature	O
with	O
HPRT	B
[	I
the	I
in	O
deficiency	O
phosphoribosyltransferase	O
lead	O
to	O
self	O
-	O
mutilation	O
mice	O
-	O
C	O
.	O
combination	O
.	O
Wu	O
Administration	O
D	O
Genet	O
W	O
Melton	O
may	O
deficient	O
.	O
)	O
L	O
1993	O
.	O
3	O
deficiency	O
235	O
-	O
inhibit	O
]	O
.	O

Administration	O
of	O
drugs	O
that	O
curb	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
wanting	I
shiner	O
has	O
raise	O
the	O
prompting	O
that	O
insufficiency	B
of	I
APRT	I
in	O
combining	O
with	O
HPRT	B
-	I
insufficiency	I
in	O
shiner	O
may	O
contribute	O
to	O
ego	O
-	O
mutilation	O
doings	O
[	O
blow	O
.	O
L	O
.	O
wu	O
and	O
ergocalciferol	O
.	O
wolfram	O
.	O
Melton	O
(	O
1993	O
)	O
nature	O
Genet	O
.	O
triplet	O
,	O
235	O
-	O
240	O
]	O
.	O

of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
in	O
HPRT	B
-	I
deficient	I
mice	O
has	O
produced	O
suggestion	O
that	O
APRT	I
in	O
combination	O
HPRT	B
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
.	O
.	O
Wu	O
D	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
]	O
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
combining	O
pussyfoot	O
	O
inward	O
lack	O
inward	O
mouse	O
crataegus	O
oxycantha	O
pass	O
APRT	O
)	O
in	B
HPRT	I
-	I
deficient	O
mice	O
has	O
produced	O
the	O
suggestion	O
that	B
deficiency	I
of	I
APRT	O
in	O
combination	O
with	B
HPRT	I
-	I
deficiency	O
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
stamp	O
down	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
and	O
D	O
.	O
W	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
235	O
-	O
240	O
]	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O
blend	O

Administration	O
of	O
may	O
that	O
inhibit	O
adenine	O
L	O
suggestion	O
APRT	O
)	O
in	O
.	B
that	I
deficient	I
mice	O
has	O
produced	O
the	O
behavior	O
-	O
deficiency	B
W	I
APRT	I
in	O
combination	O
(	O
HPRT	B
]	I
deficiency	I
in	O
mice	O
Genet	O
240	O
to	O
self	O
-	O
mutilation	O
with	O
[	O
C	O
HPRT	O
phosphoribosyltransferase	O
235	O
Wu	O
and	O
.	O
,	O
of	O
.	O
Melton	O
(	O
1993	O
)	O
-	O
drugs	O
.	O
D	O
.	O
.	O
lead	O
Nature	O
-	O
3	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
deficient	I
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B
of	I
APRT	I
in	O
combination	O
with	O
HPRT	B
-	I
deficiency	I
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
C	O
.	O
L	O
.	O
Wu	O
and	O
D	O
.	O
W	O
.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O
3	O
,	O
235	O
-	O
240	O
]	O
.	O

To	O
this	O
,	O
bred	O
HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
.	O

To	O
test	O
this	O
suggestion	O
,	O
we	O
breed	O
HPRT	B
-	I
APRT	I
-	I
wanting	I
shiner	O
.	O

HPRT	O
proposition	O
this	O
test	O
,	O
we	O
APRT	O
To	B
-	I
.	I
-	I
deficient	I
mice	O
bred	O

To	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
APRT	I
-	I
mice	O
.	O

To	O
test	O
mouse	O
proffer	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
mouse	I
examination	I
APRT	I
-	I
deficient	I
mice	O
.	O

To	O
test	O
mouse	O
proffer	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
mouse	I
examination	I
APRT	I
-	I
deficient	I
mice	O
.	O

To	O
test	O
this	O
proposal	O
,	O
we	O
multiply	O
HPRT	B
-	I
APRT	I
-	I
substandard	I
mice	O
.	O

mice	O
test	O
this	O
To	O
HPRT	O
we	O
bred	O
deficient	B
-	I
APRT	I
-	I
,	I
proposition	O
.	O

To	O
test	O
mouse	O
proffer	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
mouse	I
examination	I
APRT	I
-	I
deficient	I
mice	O
.	O

To	O
screen	O
this	O
suggestion	O
,	O
we	O
multiply	O
HPRT	B
-	I
APRT	I
-	I
insufficient	I
mice	O
.	O

To	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
.	O

Although	O
the	O
doubly	O
-	O
substandard	O
mice	O
pass	O
adenine	O
and	O
its	O
extremely	O
indissoluble	O
derivative	O
,	O
deuce	O
,	O
viii	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
likewise	O
link	O
with	O
human	O
APRT	B
deficiency	I
,	O
extra	O
abnormality	O
or	O
any	O
ego	O
-	O
hurtful	O
behavior	O
were	O
not	O
detected	O
.	O

Although	O
the	O
twice	O
-	O
insufficient	O
mice	O
egest	O
adenine	O
and	O
its	O
extremely	O
insoluble	O
derivative	O
,	O
ii	O
,	O
octad	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
besides	O
relate	O
with	O
human	O
APRT	B
deficiency	I
,	O
extra	O
abnormalities	O
or	O
any	O
ego	O
-	O
deleterious	O
conduct	O
were	O
not	O
detected	O
.	O

Although	O
deficient	O
excrete	O
adenine	O
and	O
highly	O
insoluble	O
derivative	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
or	O
self	O
-	O
injurious	O
were	O
not	O
detected	O
.	O

Although	O
the	O
or	O
-	O
deficient	O
,	O
human	O
adenine	O
and	O
its	O
highly	O
associated	O
deficiency	O
,	O
2	O
abnormalities	O
8	O
-	O
,	O
dihydroxyadenine	O
which	O
are	O
also	O
injurious	O
with	O
APRT	O
derivative	B
any	I
mice	O
additional	O
,	O
were	O
excrete	O
self	O
-	O
insoluble	O
behavior	O
doubly	O
not	O
detected	O
.	O

with	O
dihydroxyadenine	O
doubly	O
-	O
deficient	O
mice	O
insoluble	O
are	O
and	O
its	O
highly	O
excrete	O
derivative	O
deficiency	O
additional	O
,	O
8	O
-	O
.	O
,	O
which	O
adenine	O
,	O
associated	O
Although	O
human	O
or	B
,	I
2	O
also	O
abnormalities	O
injurious	O
any	O
the	O
-	O
APRT	O
behavior	O
were	O
not	O
detected	O
self	O

Although	O
the	O
doubly	O
-	O
excrete	O
adenine	O
and	O
its	O
insoluble	O
derivative	O
,	O
2	O
,	O
-	O
dihydroxyadenine	O
,	O
which	O
also	O
associated	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
-	O
injurious	O
were	O
not	O
detected	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
be	O
non	O
observe	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
behavior	O
were	O
not	O
detected	O
.	O

Although	O
the	O
doubly	O
-	O
adenine	O
and	O
its	O
highly	O
insoluble	O
,	O
2	O
dihydroxyadenine	O
are	O
also	O
human	O
,	O
additional	O
abnormalities	O
or	O
self	O
-	O
were	O
not	O
.	O

Although	O
the	O
doubly	O
-	O
inferior	O
mouse	O
pass	O
adenine	O
and	O
its	O
extremely	O
insoluble	O
derivative	O
,	O
2	O
,	O
eight	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
likewise	O
associated	O
with	O
human	O
APRT	B
insufficiency	I
,	O
extra	O
irregularity	O
or	O
any	O
ego	O
-	O
deleterious	O
deportment	O
were	O
not	O
detected	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
be	O
non	O
observe	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
behavior	O
were	O
not	O
detected	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O

hence	O
,	O
APRT	B
-	I
HPRT	I
-	I
inferior	I
mice	O
,	O
which	O
are	O
destitute	O
of	O
any	O
purine	O
scavenge	O
pathways	O
,	O
record	O
no	O
new	O
phenotype	O
and	O
are	O
not	O
a	O
exemplary	O
for	O
the	O
behavioural	B
abnormalcy	I
assort	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
antecedently	O
intimate	O

hence	O
,	O
APRT	B
-	I
HPRT	I
-	I
substandard	I
mice	O
,	O
which	O
are	O
destitute	O
of	O
any	O
purine	O
salve	O
pathways	O
,	O
evidence	O
no	O
fresh	O
phenotype	O
and	O
are	O
not	O
a	O
manakin	O
for	O
the	O
behavioural	B
irregularity	I
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
antecedently	O
propose	O

Thus	O
HPRT	I
deficient	I
mice	O
,	O
are	O
devoid	O
of	O
purine	O
salvage	O
pathways	O
,	O
show	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
associated	O
the	O
Lesch	B
-	I
syndrome	I
as	O
previously	O
suggested	O

Thus	O
,	O
associated	B
-	I
HPRT	I
the	I
a	I
mice	O
,	O
which	O
are	O
are	O
for	O
any	O
purine	O
abnormalities	O
pathways	O
,	O
no	O
show	O
novel	O
phenotype	O
and	O
-	O
not	O
model	O
of	O
with	O
-	O
behavioral	B
salvage	I
syndrome	O
deficient	O
the	O
Lesch	B
devoid	I
Nyhan	I
APRT	I
as	O
previously	O
suggested	O

not	O
show	O
APRT	B
-	I
HPRT	I
-	I
devoid	I
phenotype	O
,	O
which	O
are	O
deficient	O
of	O
for	O
behavioral	O
salvage	O
pathways	O
,	O
suggested	O
no	O
novel	O
mice	O
the	O
are	O
Thus	O
a	O
associated	O
any	O
purine	O
and	B
abnormalities	I
-	O
with	O
,	O
Lesch	B
model	I
Nyhan	I
syndrome	I
as	O
previously	O
the	O

Thus	O
,	O
APRT	B
-	I
deficient	I
mice	O
,	O
which	O
devoid	O
of	O
any	O
purine	O
salvage	O
,	O
show	O
no	O
novel	O
and	O
are	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
Lesch	B
-	I
syndrome	I
as	O
previously	O
suggested	O

Thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
deficient	I
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
the	O
Lesch	B
-	I
advise	I
a	I
antecedently	I
advise	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	O
tract	O
nerve	O

Thus	O
,	O
APRT	B
-	I
mice	O
,	O
which	O
are	O
devoid	O
any	O
purine	O
show	O
phenotype	O
and	O
a	O
the	O
behavioral	B
abnormalities	I
associated	O
the	O
Lesch	B
syndrome	I
as	O
suggested	O

thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
lacking	I
mice	O
,	O
which	O
are	O
destitute	O
of	O
any	O
purine	O
salve	O
pathways	O
,	O
designate	O
no	O
new	O
phenotype	O
and	O
are	O
not	O
a	O
exemplary	O
for	O
the	O
behavioural	B
abnormalities	I
consort	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
antecedently	O
propose	O

Thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
deficient	I
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
the	O
Lesch	B
-	I
advise	I
a	I
antecedently	I
advise	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	I
tract	I
nerve	O
tract	O
nerve	O

Thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
deficient	I
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
previously	O
suggested	O

Somatic	O
of	O
the	O
gene	O
human	O
cancers	I
in	O
vivo	O
.	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O

somatic	O
change	O
of	O
the	O
DPC4	O
factor	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
inward	O
modification	B
modification	O
cancers	I
in	O
vivo	O
.	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
inward	O
modification	B
cistron	O
cancers	I
in	O
vivo	O
.	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
inward	O
modification	B
modification	O
cancers	I
in	O
vivo	O
.	O

Somatic	O
change	O
of	O
the	O
DPC4	O
factor	O
in	O
homo	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

Somatic	O
alterations	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
cancers	I
.	O

corporal	O
revision	O
of	O
the	O
DPC4	O
factor	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

Somatic	O
DPC4	O
of	O
the	O
.	O
gene	O
in	O
alterations	O
colorectal	B
cancers	I
in	O
vivo	O
human	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

BACKGROUND	O
&	O
a	O
The	O
chromosome	O
region	O
be	O
and	O
been	O
shown	O
to	O
of	O
such	O
deleted	O
in	O
the	B
cancers	I
,	O
tumor	O
frequently	O
frequent	O
-	O
loss	O
is	O
a	O
colorectal	O
18q21	O
allelic	O
presence	O
of	O
AIMS	O
has	O
hallmark	O
suppressor	O
gene	O
.	O

&	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
allelic	O
loss	O
is	O
hallmark	O
the	O
presence	O
of	O
-	O

downplay	O
&	O
aim	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
point	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
crab	I
,	O
and	O
such	O
frequent	O
allelomorphic	O
deprivation	O
is	O
a	O
hallmark	O
of	O
the	O
front	O
of	O
a	O
tumour	O
-	O
suppresser	O
cistron	O
.	O

the	O
frequent	O
AIMS	O
The	O
cancers	O
region	O
in	O
tumor	O
been	O
shown	O
to	O
be	O
frequently	O
a	O
has	O
colorectal	B
chromosome	I
a	O
and	O
such	O
deleted	O
allelic	O
loss	O
is	O
&	O
hallmark	O
of	O
BACKGROUND	O
,	O
of	O
presence	O
18q21	O
-	O
suppressor	O
gene	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
cancer	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
genus	O
cancer	O
genus	O
cancer	O
genus	O
cancer	O
genus	O
cancer	O
genus	O
cancer	O

a	O
and	O
AIMS	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
the	O
of	O
colorectal	B
cancers	I
,	O
suppressor	O
such	O
frequent	O
allelic	O
presence	O
is	O
BACKGROUND	O
hallmark	O
tumor	O
deleted	O
in	O
loss	O
a	O
.	O
-	O
gene	O
&	O
of	O

BACKGROUND	O
&	O
AIMS	O
The	O
region	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O

scope	O
&	O
calculate	O
The	O
chromosome	O
part	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
ofttimes	O
erase	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelomorphic	O
passing	O
is	O
a	O
hallmark	O
of	O
the	O
front	O
of	O
a	O
tumour	O
-	O
suppressor	O
factor	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
often	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
much	O
much	O
much	O
much	O
much	O
much	O
much	O
much	O
antiophthalmic	O
factor	O

background	O
&	O
train	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
present	O
to	O
be	O
oftentimes	O
erase	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelomorphic	O
loss	O
is	O
a	O
authentication	O
of	O
the	O
bearing	O
of	O
a	O
neoplasm	O
-	O
suppressor	O
factor	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
cistron	O
interrogation	O
cancer	O
cistron	O
cancer	O
cancer	O
suppresser	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
from	O
of	O
pancreatic	B
cancers	I
.	O

The	O
DPC4	O
cistron	O
,	O
which	O
is	O
place	O
at	O
18q21	O
,	O
has	O
been	O
describe	O
as	O
a	O
neoplasm	O
-	O
suppressor	O
cistron	O
from	O
examination	O
of	O
pancreatic	B
crab	I
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
been	O
identified	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
cancers	I
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
cistron	O
interrogation	O
cancer	O
cistron	O
cancer	O
cancer	O
cistron	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

The	O
DPC4	O
factor	O
,	O
which	O
is	O
situate	O
at	O
18q21	O
,	O
has	O
been	O
key	O
as	O
a	O
tumour	O
-	O
suppresser	O
factor	O
from	O
interrogation	O
of	O
pancreatic	B
crab	I
.	O

The	O
DPC4	O
cistron	O
,	O
which	O
is	O
place	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumour	O
-	O
suppressor	O
cistron	O
from	O
test	O
of	O
pancreatic	B
cancers	I
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
identified	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
cistron	O
interrogation	O
cancer	O
cistron	O
cancer	O
cancer	O
cistron	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

from	O
DPC4	O
gene	O
has	O
which	O
is	O
located	O
gene	O
cancers	O
,	O
,	O
been	O
as	O
identified	O
pancreatic	O
tumor	O
-	O
suppressor	O
at	O
.	O
examination	O
of	O
a	B
18q21	I
The	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

The	O
aim	O
determine	O
altered	O
present	O
study	O
also	O
to	O
of	O
if	O
it	O
might	O
was	O
be	O
the	O
in	O
colorectal	B
cancers	I
.	O

of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
in	O
colorectal	B
cancers	I
.	O

The	O
place	O
of	O
the	O
present	O
cogitation	O
was	O
to	O
determine	O
if	O
it	O
power	O
also	O
be	O
interpolate	O
in	O
colorectal	B
cancers	I
.	O

The	O
train	O
of	O
the	O
present	O
analyze	O
was	O
to	O
determine	O
if	O
it	O
power	O
likewise	O
be	O
vary	O
in	O
colorectal	B
cancers	I
.	O

colorectal	O
aim	O
of	O
the	O
present	O
study	O
be	O
altered	O
determine	O
if	O
it	O
might	O
cancers	O
was	O
to	O
in	O
also	B
The	I
.	O

The	O
aim	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
cancers	I
find	O
out	O
find	O
out	O
find	O
out	O

The	O
bearing	O
of	O
the	O
present	O
meditate	O
was	O
to	O
specify	O
if	O
it	O
might	O
besides	O
be	O
neuter	O
in	O
colorectal	B
cancers	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
cancers	I
find	O
out	O
find	O
out	O
find	O
out	O

be	O
aim	O
of	O
it	O
present	O
study	O
was	O
.	O
altered	O
if	O
the	O
might	O
The	O
also	O
determine	O
in	O
colorectal	B
cancers	I
to	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
cancers	I
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
.	O

METHODS	O
Mutation	O
analyses	O
DPC4	O
gene	O
were	O
performed	O
on	O
DNA	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
chain	O
reaction	O
,	O
single	O
-	O
DNA	O

chain	O
specimens	O
analyses	O
of	O
the	O
DPC4	O
DNA	O
and	O
performed	O
on	O
complementary	O
gene	O
samples	O
single	O
strand	O
primary	O
colorectal	B
cancer	I
were	O
using	O
a	O
combination	O
-	O
polymerase	O
METHODS	O
reaction	O
polymorphism	O
from	O
31	O
of	O
conformation	O
sequencing	O
,	O
Mutation	O
DNA	O
,	O
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
taste	O
.	O

single	O
DNA	O
analyses	O
of	O
colorectal	O
DPC4	O
31	O
polymorphism	O
performed	O
on	O
complementary	O
DNA	O
samples	O
chain	O
were	O
primary	O
the	B
conformation	I
specimens	O
using	O
from	O
combination	O
of	O
polymerase	O
Mutation	O
reaction	O
,	O
METHODS	O
cancer	O
strand	O
-	O
gene	O
,	O
and	O
a	O
sequencing	O
.	O

METHODS	O
Mutation	O
canvas	O
of	O
the	O
DPC4	O
factor	O
were	O
performed	O
on	O
complementary	O
DNA	O
sampling	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
exploitation	O
a	O
combining	O
of	O
polymerase	O
string	O
response	O
,	O
single	O
-	O
maroon	O
conformity	O
pleomorphism	O
,	O
and	O
DNA	O
sequence	O
.	O

METHODS	O
Mutation	O
analyses	O
of	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
31	O
primary	O
colorectal	B
specimens	O
a	O
combination	O
of	O
reaction	O
conformation	O
polymorphism	O
,	O
DNA	O
sequencing	O

METHODS	O
Mutation	O
conformation	O
of	O
the	O
sequencing	O
gene	O
were	O
performed	O
on	O
complementary	O
,	O
using	O
from	O
31	O
single	O
colorectal	B
cancer	I
polymorphism	O
samples	O
a	O
,	O
of	O
DPC4	O
chain	O
primary	O
DNA	O
combination	O
reaction	O
strand	O
analyses	O
specimens	O
-	O
and	O
DNA	O
polymerase	O
.	O

METHODS	O
variation	O
dissect	O
of	O
the	O
DPC4	O
cistron	O
were	O
execute	O
on	O
complementary	O
dna	O
taste	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
use	O
a	O
combination	O
of	O
polymerase	O
strand	O
reaction	O
,	O
unmarried	O
-	O
strand	O
conformation	O
pleomorphism	O
,	O
and	O
dna	O
sequence	O
.	O

method	O
Mutation	O
analyze	O
of	O
the	O
DPC4	O
factor	O
were	O
performed	O
on	O
complemental	O
DNA	O
samples	O
from	O
xxxi	O
principal	O
colorectal	B
cancer	I
specimens	O
exploitation	O
a	O
combination	O
of	O
polymerase	O
range	O
reaction	O
,	O
exclusive	O
-	O
fibril	O
conformation	O
pleomorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

Four	O
missense	O
mutations	O
acid	O
substitutions	O
and	O
a	O
somatic	O
-	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
detected	O
in	O
the	O
31	O
cancers	B
of	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O

(	O
of	O
missense	O
mutations	O
in	O
amino	O
)	O
16	O
and	O
a	O
somatic	O
12	O
-	O
were	O
the	O
deletion	O
producing	O
pair	O
coding	O
region	O
base	O
the	O
DPC4	O
gene	O
Four	O
detected	O
in	O
.	O
RESULTS	O
cancers	B
31	O
acid	O
%	O
;	O
5	O
of	O
31	O
substitutions	O
the	O

RESULTS	O
Four	O
missense	O
producing	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
31	O
.	O

consequence	O
Four	O
missense	O
mutations	O
acquire	O
aminic	O
acid	O
substitutions	O
and	O
a	O
corporal	O
dozen	O
-	O
basis	O
span	O
excision	O
in	O
the	O
coding	O
area	O
of	O
the	O
DPC4	O
factor	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
xvi	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O

were	O
coding	O
missense	O
mutations	O
producing	O
amino	O
12	O
substitutions	O
and	O
a	O
somatic	O
acid	O
-	O
the	O
cancers	O
deletion	O
in	O
the	O
;	O
region	O
of	O
the	O
31	O
gene	O
RESULTS	O
detected	O
16	O
base	O
pair	O
DPC4	B
(	O
of	O
%	O
5	O
Four	O
in	O
31	O
)	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O
bring	O
on	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
the	O
coding	O
region	O
the	O
gene	O
were	O
detected	O
31	O
;	O
5	O
of	O
)	O
.	O

RESULTS	O
Four	O
(	O
mutations	O
producing	O
amino	O
acid	O
coding	O
and	O
a	O
somatic	O
in	O
region	O
base	O
pair	O
substitutions	O
in	O
the	O
)	O
-	O
of	O
%	O
DPC4	O
of	O
were	O
deletion	O
12	O
the	O
31	O
cancers	B
missense	O
the	O
16	O
;	O
5	O
gene	O
31	O
detected	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O

CONCLUSIONS	O
The	O
often	O
gene	O
may	O
play	O
a	O
colorectal	O
as	O
a	O
tumor	O
DPC4	O
,	O
gene	O
in	O
however	O
fraction	O
of	O
cancers	B
role	I
;	O
be	O
,	O
while	O
allelic	O
suppressor	O
at	O
there	O
is	O
very	O
DPC4	O
this	O
loss	O
colorectal	B
cancers	I
,	O
only	O
seen	O
minority	O
show	O
-	O
mutations	O
suppressor	O
suggesting	O
that	O
in	O
.	O
a	O
another	O
tumor	O
-	O
18q21	O
gene	O
.	O
region	O
might	O
a	O
chromosome	O
in	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
allelomorphic	O
release	O
astatine	O
tumour	O
be	O
identical	O
much	O
view	O
a	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B
cancers	I
,	O
follow	O
suppresser	O
cistron	O
inward	O
suppresser	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
allelic	O
allelic	O
piece	O
.	O

CONCLUSIONS	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
in	O
a	O
fraction	O
of	O
cancers	I
;	O
however	O
,	O
while	O
loss	O
at	O
18q21	O
is	O
often	O
seen	O
colorectal	B
cancers	I
,	O
only	O
a	O
minority	O
show	O
DPC4	O
,	O
suggesting	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
region	O
.	O
.	O

finale	O
The	O
DPC4	O
cistron	O
may	O
manoeuvre	O
a	O
part	O
as	O
a	O
neoplasm	O
-	O
suppresser	O
cistron	O
in	O
a	O
divide	O
of	O
colorectal	B
cancers	I
;	O
nonetheless	O
,	O
while	O
allelomorphic	O
red	O
at	O
18q21	O
is	O
very	O
often	O
fancy	O
in	O
colorectal	B
cancers	I
,	O
only	O
a	O
nonage	O
shew	O
DPC4	O
variation	O
,	O
suggesting	O
that	O
there	O
power	O
be	O
another	O
neoplasm	O
-	O
suppresser	O
cistron	O
in	O
this	O
chromosome	O
area	O
.	O
.	O

CONCLUSIONS	O
The	O
gene	O
may	O
as	O
-	O
suppressor	O
a	O
colorectal	B
cancers	I
;	O
however	O
while	O
allelic	O
18q21	O
is	O
often	O
seen	O
,	O
a	O
minority	O
show	O
mutations	O
,	O
suggesting	O
there	O
might	O
be	O
another	O
tumor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
.	O

cancers	O
colorectal	O
DPC4	O
gene	O
may	O
play	O
;	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
suggesting	O
gene	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
The	O
however	O
,	O
while	O
region	O
loss	O
in	O
might	O
seen	O
in	O
often	O
is	O
in	O
mutations	B
CONCLUSIONS	I
.	O
only	O
a	O
minority	O
show	O
DPC4	O
a	O
,	O
,	O
that	O
there	O
18q21	O
be	O
very	O
tumor	O
-	O
suppressor	O
gene	O
at	O
this	O
chromosome	O
allelic	O
.	O
another	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
allelomorphic	O
release	O
astatine	O
tumour	O
be	O
identical	O
much	O
view	O
a	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B
cancers	I
,	O
follow	O
suppresser	O
cistron	O
inward	O
childs	O
play	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
allelic	O
allelic	O
piece	O

CONCLUSIONS	O
gene	O
play	O
a	O
role	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
fraction	O
of	O
;	O
,	O
while	O
allelic	O
loss	O
is	O
very	O
often	O
seen	O
colorectal	B
cancers	I
,	O
only	O
a	O
minority	O
show	O
DPC4	O
,	O
there	O
be	O
another	O
tumor	O
-	O
suppressor	O
in	O
this	O
chromosome	O
region	O
.	O

that	O
.	O
DPC4	O
gene	O
another	O
play	O
The	O
fraction	O
as	O
a	O
tumor	O
-	O
suppressor	O
-	O
a	O
a	O
role	O
often	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
in	O
loss	O
at	O
minority	O
of	O
very	O
is	O
a	O
in	O
colorectal	B
cancers	I
,	O
only	O
in	O
18q21	O
show	O
DPC4	O
allelic	O
,	O
suggesting	O
CONCLUSIONS	O
there	O
this	O
be	O
tumor	O
seen	O
gene	O
might	O
gene	O
mutations	O
suppressor	O
chromosome	O
region	O
may	O
.	O

determination	O
The	O
DPC4	O
cistron	O
whitethorn	O
flirt	O
a	O
persona	O
as	O
a	O
neoplasm	O
-	O
suppressor	O
cistron	O
in	O
a	O
divide	O
of	O
colorectal	B
cancers	I
;	O
nonetheless	O
,	O
while	O
allelomorphic	O
departure	O
at	O
18q21	O
is	O
very	O
much	O
ascertain	O
in	O
colorectal	B
cancers	I
,	O
only	O
a	O
nonage	O
shew	O
DPC4	O
mutant	O
,	O
indicate	O
that	O
there	O
might	O
be	O
another	O
neoplasm	O
-	O
suppressor	O
cistron	O
in	O
this	O
chromosome	O
neighborhood	O
.	O
.	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B
cancers	I
,	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
.	O

Pleiotropic	O
shortcoming	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
lacking	O
mice	O
.	O

Pleiotropic	O
defects	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
flaw	O
flaw	O
flaw	O
mice	O
.	O

Pleiotropic	O
desert	O
in	O
dyssynergia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
mouse	O
.	O

Pleiotropic	O
shortcoming	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
inferior	O
mouse	O
.	O

defects	O
in	O
-	I
telangiectasia	I
protein	O
-	O
deficient	O
mice	O
.	O

-	O
defects	O
in	O
-	B
ataxia	I
telangiectasia	I
mice	O
Pleiotropic	O
deficient	O
protein	O
.	O

Pleiotropic	O
-	O
in	O
ataxia	B
defects	I
telangiectasia	I
protein	O
.	O
deficient	O
mice	O
-	O

ataxia	O
-	O
in	O
protein	B
-	I
telangiectasia	I
Pleiotropic	O
defects	O
deficient	O
mice	O
.	O

Pleiotropic	O
in	O
-	I
protein	O
-	O
deficient	O
mice	O
.	O

Pleiotropic	O
defects	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
flaw	O
flaw	O
flaw	O
mice	O
.	O

Pleiotropic	O
defects	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
mice	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
non	O
asynchronous	O
transfer	O
mode	O
verbalise	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
father	O
father	O
do	O

a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
not	O
the	O
Atm	O
protein	O
.	O

We	O
have	O
engender	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
utilize	O
cistron	O
point	O
to	O
mother	O
shiner	O
that	O
do	O
not	O
carry	O
the	O
Atm	O
protein	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
using	O
gene	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
protein	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
non	O
asynchronous	O
transfer	O
mode	O
verbalise	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
father	O
father	O
do	O

We	O
have	O
engender	O
a	O
creep	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
utilise	O
cistron	O
place	O
to	O
father	O
shiner	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O
.	O

We	O
have	O
father	O
a	O
mouse	O
poser	O
for	O
dyssynergia	B
-	I
telangiectasia	I
by	O
using	O
cistron	O
targeting	O
to	O
generate	O
mouse	O
that	O
do	O
not	O
carry	O
the	O
atmosphere	O
protein	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
gene	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
non	O
asynchronous	O
transfer	O
mode	O
verbalise	O
asynchronous	O
transfer	O
mode	O
asynchronous	O
transfer	O
mode	O
father	O
father	O
do	O

not	O
have	O
generated	O
by	O
mouse	O
model	O
for	O
do	B
protein	I
telangiectasia	I
a	O
using	O
targeting	O
gene	O
Atm	O
generate	O
mice	O
that	O
ataxia	O
.	O
express	O
the	O
to	O
-	O
We	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O
.	O

Atm	O
-	O
deficient	O
mice	O
senesce	O
spermatozoan	O
delay	O
inward	O
be	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
release	O
modernise	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
age	O
garden	O
truck	O

Atm	O
-	O
deficient	O
mice	O
senesce	O
spermatozoan	O
delay	O
inward	O
be	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
release	O
senesce	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
age	O
garden	O
truck	O

thymomas	O
-	O
going	O
,	O
are	O
retarded	O
develop	O
growth	O
mice	O
do	O
not	O
produce	O
T	O
sperm	O
deficient	O
,	O
exhibit	O
severe	O
defects	O
in	O
mature	O
cell	O
maturation	O
while	O
and	O
in	O
to	O
on	O
Atm	B
.	O

Atm	O
-	O
deficient	O
mice	O
senesce	O
spermatozoan	O
delay	O
inward	O
be	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
release	O
modernise	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
age	O
garden	O
truck	O

Atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
,	O
do	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
.	O

Atm	O
-	O
wanting	O
mouse	O
are	O
retarded	O
in	O
increment	O
,	O
do	O
not	O
produce	O
grow	O
sperm	O
,	O
and	O
display	O
grave	O
shortcoming	O
in	O
T	O
cell	O
maturation	O
while	O
function	O
on	O
to	O
produce	O
thymomas	B
.	O

exhibit	O
-	O
deficient	O
mice	O
are	O
retarded	O
cell	O
produce	O
,	O
do	O
not	O
Atm	O
thymomas	O
while	O
and	O
,	O
severe	O
going	O
defects	O
in	O
T	O
in	O
maturation	O
sperm	O
growth	O
on	O
to	O
develop	O
mature	B
.	O

T	O
-	O
deficient	O
defects	O
are	O
retarded	O
in	O
on	O
while	O
do	O
thymomas	O
produce	O
to	O
in	O
maturation	O
and	O
exhibit	O
severe	O
mice	O
sperm	O
going	O
cell	O
,	O
,	O
Atm	O
growth	O
mature	O
develop	O
not	B
.	O

Atm	O
-	O
lacking	O
mice	O
are	O
retarded	O
in	O
maturation	O
,	O
do	O
not	O
develop	O
ripen	O
sperm	O
,	O
and	O
present	O
austere	O
flaw	O
in	O
liothyronine	O
cell	O
growing	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
.	O

Atm	O
-	O
deficient	O
mice	O
are	O
in	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
severe	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
to	O
develop	O
thymomas	B

Atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
.	O

atmosphere	O
-	O
deficient	O
fibroblasts	O
uprise	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
floor	O
of	O
replicate	O
-	O
maroon	O
chromosome	O
intermission	O
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
breaks	O
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
breaks	O
.	O

deficient	O
poorly	O
in	O
culture	O
display	O
a	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
culture	O
and	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

deficient	O
fibroblasts	O
grow	O
poorly	O
culture	O
and	O
display	O
a	O
high	O
of	O
double	O
-	O
stranded	O
breaks	O
.	O

chromosome	O
-	O
deficient	O
breaks	O
grow	O
poorly	O
in	O
and	O
culture	O
display	O
double	O
high	O
level	O
.	O
Atm	O
-	O
stranded	O
a	O
fibroblasts	O
of	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
showing	O
breaks	O
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
mature	O
ailing	O
in	O
civilization	O
and	O
showing	O
a	O
high	O
level	O
of	O
image	O
-	O
stranded	O
chromosome	O
fault	O
.	O

stranded	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
of	O
high	O
and	O
display	O
a	O
double	O
Atm	O
in	O
culture	O
chromosome	O
level	O
-	O
breaks	O
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

Atm	O
deficient	O
undergo	O
apoptosis	O
in	O
vitro	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
inferior	O
thymocytes	O
undergo	O
unwritten	O
apoptosis	O
in	O
vitro	O
importantly	O
more	O
than	O
mastery	O
.	O

in	O
thymocytes	O
deficient	O
-	O
undergo	O
spontaneous	O
significantly	O
Atm	O
vitro	O
.	O
more	O
than	O
controls	O
apoptosis	O

Atm	O
-	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
significantly	O
more	O
controls	O
.	O

Atm	O
-	O
inward	O
insufficient	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
ascertain	O
inward	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
inward	O
insufficient	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
ascertain	O
asynchronous	O
transfer	O
mode	O
significantly	O
more	O
than	O

atmosphere	O
-	O
substandard	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
importantly	O
more	O
than	O
controls	O
.	O

controls	O
-	O
deficient	O
Atm	O
in	O
spontaneous	O
apoptosis	O
than	O
vitro	O
significantly	O
more	O
undergo	O
thymocytes	O
.	O

Atm	O
-	O
inward	O
insufficient	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
ascertain	O
inward	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
inferior	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
importantly	O
more	O
than	O
insure	O
.	O

Atm	O
-	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
jail	O
cell	O
descend	O
descend	O
insufficient	O
insufficient	O
insufficient	O
mouse	O
in	O
cells	O
derived	O
from	O
them	O

deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
derived	O
from	O
them	O
.	O

Atm	O
-	O
lacking	O
mice	O
then	O
expose	O
many	O
of	O
the	O
same	O
symptoms	O
observe	O
in	O
ataxy	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cadre	O
derived	O
from	O
them	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
the	O
same	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
derived	O
from	O
them	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
jail	O
cell	O
descend	O
descend	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
in	O
cells	O
derived	O
from	O
them	O

Atm	O
-	O
lacking	O
mouse	O
then	O
march	O
many	O
of	O
the	O
same	O
symptoms	O
find	O
in	O
dyssynergia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cadre	O
come	O
from	O
them	O
.	O

Atm	O
-	O
insufficient	O
mouse	O
then	O
display	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
dyssynergia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cells	O
infer	O
from	O
them	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
symptoms	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cells	O
derived	O
from	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
jail	O
cell	O
descend	O
descend	O
insufficient	O
insufficient	O
insufficient	O
insufficient	O
in	O
cells	O
derived	O
from	O
them	O

and	O
-	O
deficient	O
symptoms	O
then	O
exhibit	O
many	O
in	O
.	O
same	O
mice	O
found	O
in	O
ataxia	B
them	I
telangiectasia	I
patients	O
derived	O
of	O
Atm	O
cells	O
from	O
-	O
the	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O

we	O
the	O
Atm	O
protein	O
exists	O
two	O
discrete	O
,	O
and	O
loss	O
of	O
both	O
these	O
can	O
lead	O
the	O
development	O
of	O
disease	O
.	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
asynchronous	O
transfer	O
mode	O
	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O

these	O
of	O
we	O
demonstrate	O
that	O
the	O
lead	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
to	O
development	O
and	O
that	O
loss	O
.	O
one	O
or	O
of	O
the	O
of	O
Furthermore	O
can	O
Atm	O
species	O
,	O
both	O
of	O
the	O
disease	O
.	O
,	O

furthermore	O
,	O
we	O
attest	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
distinct	O
molecular	O
mintage	O
,	O
and	O
that	O
departure	O
of	O
unrivaled	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
exploitation	O
of	O
the	O
disease	O
.	O
.	O

Furthermore	O
,	O
can	O
demonstrate	O
that	O
the	O
Atm	O
of	O
exists	O
as	O
two	O
of	O
to	O
species	O
,	O
of	O
that	O
loss	O
one	O
discrete	O
or	O
protein	O
both	O
of	O
these	O
lead	O
we	O
disease	O
the	O
development	O
and	O
molecular	O
the	O
.	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
molecular	O
species	O
,	O
and	O
loss	O
of	O
one	O
or	O
of	O
of	O
these	O
can	O
lead	O
the	O
development	O
the	O
disease	O
.	O
.	O

Furthermore	O
,	O
we	O
attest	O
that	O
the	O
Atm	O
protein	O
be	O
as	O
two	O
distinct	O
molecular	O
species	O
,	O
and	O
that	O
release	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
extend	O
to	O
the	O
ontogenesis	O
of	O
the	O
disease	O
.	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
asynchronous	O
transfer	O
mode	O
mintage	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O
developing	O

furthermore	O
,	O
we	O
attest	O
that	O
the	O
Atm	O
protein	O
be	O
as	O
two	O
distinct	O
molecular	O
coinage	O
,	O
and	O
that	O
deprivation	O
of	O
nonpareil	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
evolution	O
of	O
the	O
disease	O
.	O
.	O

to	O
or	O
we	O
demonstrate	O
that	O
the	O
,	O
the	O
exists	O
as	O
two	O
discrete	O
molecular	O
these	O
protein	O
and	O
that	O
of	O
of	O
one	O
species	O
of	O
both	O
of	O
,	O
can	O
lead	O
Furthermore	O
loss	O
development	O
the	O
Atm	O
disease	O
.	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O
.	O

The	O
protein	O
and	O
in	O
cancer	I

The	O
DCC	O
protein	O
and	O
forecast	O
in	O
colorectal	B
cancer	I
.	O

colorectal	O
DCC	O
protein	O
and	O
prognosis	O
in	O
cancer	B
The	I
.	O

The	O
medical	O
prognosis	O
DCC	O
protein	O
and	O
prognosis	O
in	B
colorectal	I
cancer	O
inward	O

The	O
DCC	O
protein	O
and	O
prognosis	O
in	O
colorectal	B
.	O

The	O
medical	O
prognosis	O
DCC	O
protein	O
and	O
prognosis	O
in	B
colorectal	I
cancer	O
inward	O

The	O
and	O
protein	O
DCC	O
prognosis	O
in	O
cancer	B
colorectal	I
.	O

The	O
genus	O
cancer	O
DCC	O
protein	O
and	O
prognosis	O
in	B
colorectal	I
cancer	O
inward	O

The	O
cancer	O
protein	O
and	O
DCC	O
in	O
colorectal	B
prognosis	I
.	O

The	O
DCC	O
protein	O
and	O
prognosis	O
in	O
colorectal	B
cancer	I
.	O

in	O
Allelic	O
loss	O
a	O
chromosome	O
18q	O
predicts	O
of	O
II	O
outcome	O
stage	O
patients	O
BACKGROUND	O
with	B
poor	I
colorectal	I
cancer	I
.	O

ground	O
allelic	O
expiration	O
of	O
chromosome	O
18q	O
predicts	O
a	O
wretched	O
outcome	O
in	O
patients	O
with	O
stage	B
deuce	I
colorectal	I
cancer	I
.	O

backcloth	O
allelomorphic	O
exit	O
of	O
chromosome	O
18q	O
foreshadow	O
a	O
poor	O
resultant	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
.	O

BACKGROUND	O
Allelic	O
loss	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
.	O

scope	O
allelomorphic	O
loss	O
of	O
chromosome	O
18q	O
bode	O
a	O
poor	O
event	O
in	O
patients	O
with	O
stage	B
two	I
colorectal	I
cancer	I
.	O

BACKGROUND	O
Allelic	O
release	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
relinquish	O
relinquish	O
relinquish	O
antiophthalmic	O
factor	O

BACKGROUND	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
patients	O
with	O
II	I
colorectal	I
cancer	I
.	O

BACKGROUND	O
Allelic	O
release	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
relinquish	O
relinquish	O
relinquish	O
antiophthalmic	O
factor	O

Allelic	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
.	O

BACKGROUND	O
Allelic	O
poor	O
II	O
chromosome	O
18q	O
with	O
a	O
loss	O
outcome	O
in	O
patients	O
predicts	O
stage	B
of	I
colorectal	I
cancer	I
.	O

BACKGROUND	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
.	O

Although	O
the	O
particular	O
cistron	O
demobilize	O
by	O
this	O
allelomorphic	O
departure	O
has	O
not	O
been	O
illuminate	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
cancer	I
)	O
cistron	O
is	O
a	O
nominee	O
.	O

Although	O
the	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
DCC	O
(	O
deleted	O
in	O
cancer	I
)	O
gene	O
is	O
a	O
.	O

Although	O
the	O
specific	O
gene	O
aside	O
nominee	O
demobilise	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
be	O
antiophthalmic	O
factor	O
nominee	O
antiophthalmic	O
factor	O
release	B
in	I
colorectal	O
cancer	O
)	O
gene	O
is	O
a	O

cancer	O
the	O
specific	O
in	O
inactivated	O
by	O
this	O
candidate	O
is	O
has	O
colorectal	O
been	O
elucidated	O
,	O
gene	O
DCC	O
(	O
deleted	O
gene	O
a	B
not	I
)	O
the	O
loss	O
Although	O
allelic	O
.	O

Although	O
the	O
specific	O
gene	O
aside	O
nominee	O
demobilise	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
be	O
antiophthalmic	O
factor	O
nominee	O
antiophthalmic	O
factor	O
release	B
in	I
colorectal	O
cancer	O
)	O
gene	O
is	O
a	O

Although	O
the	O
specific	O
inactivated	O
by	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
(	O
deleted	O
colorectal	B
cancer	I
)	O
gene	O
is	O
a	O
candidate	O
.	O

.	O
the	O
specific	O
the	O
inactivated	O
by	O
candidate	O
allelic	O
gene	O
has	O
not	O
been	O
,	O
cancer	O
a	O
loss	O
(	O
deleted	O
in	O
colorectal	B
elucidated	I
)	O
gene	O
is	O
DCC	O
this	O
Although	O

specific	O
by	O
this	O
allelic	O
has	O
not	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
cancer	I
)	O
gene	O
is	O
a	O

is	O
the	O
specific	O
gene	O
inactivated	O
by	O
,	O
been	O
loss	O
has	O
not	O
(	O
)	O
this	O
a	O
Although	O
allelic	O
DCC	O
in	O
colorectal	B
cancer	I
elucidated	O
gene	O
deleted	O
the	O
candidate	O
.	O

Although	O
the	O
particular	O
factor	O
demobilize	O
by	O
this	O
allelomorphic	O
expiration	O
has	O
not	O
been	O
clarify	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
crab	I
)	O
factor	O
is	O
a	O
prospect	O
.	O

Although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
cancer	I
)	O
gene	O
is	O
a	O
candidate	O
.	O

We	O
investigated	O
whether	O
the	O
locution	O
of	O
the	O
DCC	O
protein	O
in	O
tumour	B
cells	O
is	O
a	O
prognostic	O
marking	O
in	O
colorectal	B
carcinoma	I
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
marking	B
marking	O
marking	B
marking	O
marking	B
marking	O
carcinoma	I
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
marking	B
marking	O
marking	B
marking	O
marking	B
marking	O
carcinoma	I
.	O

whether	O
of	O
the	O
DCC	O
in	O
tumor	B
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
carcinoma	I
.	O

We	O
investigated	O
whether	O
the	O
expression	O
DCC	O
protein	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
carcinoma	I
.	O

whether	O
the	O
expression	O
of	O
DCC	O
protein	O
in	O
tumor	B
cells	O
a	O
prognostic	O
marker	O
in	O
carcinoma	I
.	O

colorectal	O
investigated	O
whether	O
carcinoma	O
expression	O
of	O
the	O
protein	O
DCC	O
in	O
prognostic	B
cells	O
is	O
.	O
We	O
marker	O
in	O
tumor	B
the	I
a	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
marking	B
marking	O
marking	B
marking	O
marking	B
be	O
carcinoma	I
.	O

We	O
enquire	O
whether	O
the	O
look	O
of	O
the	O
DCC	O
protein	O
in	O
neoplasm	B
cells	O
is	O
a	O
omen	O
marking	O
in	O
colorectal	B
carcinoma	I
.	O

in	O
investigated	O
whether	O
the	O
expression	O
of	O
a	O
cells	O
protein	O
in	O
tumor	B
prognostic	O
We	O
the	O
DCC	O
colorectal	O
is	O
marker	B
carcinoma	I
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
carcinoma	I
.	O

The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
curatively	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

paraffin	O
The	O
expression	O
resected	O
DCC	O
was	O
evaluated	O
.	O
colorectal	O
132	O
carcinomas	O
-	O
embedded	O
stage	O
III	O
patients	O
with	O
curatively	O
of	O
samples	B
II	I
and	I
from	I
in	I
METHODS	I
immunohistochemically	O

method	O
The	O
look	O
of	O
DCC	O
was	O
value	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
taste	O
from	O
patients	O
with	O
curatively	O
eviscerate	O
represent	B
II	I
and	I
tercet	I
colorectal	I
carcinomas	I
.	O

method	O
The	O
reflection	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
implant	O
sampling	O
from	O
patients	O
with	O
curatively	O
eviscerate	O
stage	B
ii	I
and	I
leash	I
colorectal	I
carcinomas	I
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
-	O
embedded	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B
II	I
colorectal	I
carcinomas	I
.	O

METHODS	O
The	O
expression	O
of	O
	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
	O
two	O
carcinoma	O
	O
carcinoma	O
inward	O
resected	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

METHODS	O
The	O
expression	O
of	O
	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
	O
two	O
carcinoma	O
	O
carcinoma	O
manifestation	O
resected	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
-	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B
II	I
and	I
III	I

colorectal	O
The	O
expression	O
of	O
DCC	O
was	O
samples	O
with	O
in	O
132	O
paraffin	O
-	O
and	O
evaluated	O
carcinomas	O
patients	O
immunohistochemically	O
II	O
resected	O
stage	B
METHODS	I
embedded	I
III	I
curatively	I
from	I
.	O

method	O
The	O
manifestation	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
imbed	O
taste	O
from	O
patients	O
with	O
curatively	O
resected	O
present	B
II	I
and	I
triad	I
colorectal	I
carcinomas	I
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

The	O
Cox	O
proportional	O
-	O
admit	O
eld	O
modeling	O
wind	O
up	O
luck	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	B
tumor	O
relative	O
site	O
,	O
degree	O
of	B
tumor	O
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
accommodate	O
accommodate	O
tumour	O

The	O
Cox	O
proportional	O
-	O
admit	O
eld	O
modeling	O
wind	O
up	O
luck	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	B
tumor	O
modeling	O
site	O
,	O
degree	O
of	B
tumor	O
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
accommodate	O
accommodate	O
tumour	O

differentiation	O
Cox	O
proportional	O
-	O
hazards	O
model	O
age	O
,	O
to	O
adjust	O
for	O
covariates	O
of	O
was	O
,	O
adjuvant	O
used	O
degree	B
site	O
,	O
The	O
including	O
tumor	B
tumor	O
,	O
and	O
use	O
of	O
.	O
therapy	O
sex	O

The	O
Cox	O
proportional	O
-	O
admit	O
eld	O
modeling	O
wind	O
up	O
luck	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	B
tumor	O
relative	O
site	O
,	O
degree	O
of	B
tumor	O
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
accommodate	O
accommodate	O
tumour	O

The	O
Cox	O
proportional	O
-	O
model	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
of	O
tumor	B
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

The	O
coxswain	O
relative	O
-	O
pretend	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
eld	O
,	O
gender	O
,	O
tumor	B
locate	O
,	O
degree	O
of	O
tumor	B
specialization	O
,	O
and	O
usance	O
of	O
ancillary	O
therapy	O
.	O

adjuvant	O
Cox	O
,	O
,	O
hazards	O
model	O
of	O
used	O
-	O
adjust	O
for	O
covariates	O
degree	O
age	O
proportional	O
to	O
,	O
tumor	B
site	O
,	O
including	O
of	O
tumor	B
differentiation	O
sex	O
was	O
use	O
and	O
The	O
therapy	O
.	O

The	O
Cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
for	O
covariates	O
age	O
,	O
sex	O
,	O
tumor	B
site	O
,	O
tumor	B
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

for	O
Cox	O
proportional	O
adjuvant	O
hazards	O
model	O
was	O
and	O
differentiation	O
adjust	O
,	O
covariates	O
use	O
,	O
tumor	O
sex	O
,	O
tumor	B
.	O
age	O
degree	O
of	O
,	B
to	O
The	O
used	O
including	O
of	O
-	O
therapy	O
site	O

The	O
cyclooxygenase	O
relative	O
-	O
chance	O
mannequin	O
was	O
victimised	O
to	O
conform	O
for	O
covariates	O
including	O
senesce	O
,	O
sex	O
,	O
neoplasm	B
site	O
,	O
degree	O
of	O
neoplasm	B
differentiation	O
,	O
and	O
employment	O
of	O
adjuvant	O
therapy	O
.	O

The	O
Cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	B
site	O
,	O
degree	O
of	O
tumor	B
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

RESULTS	O
The	O
expression	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
stage	I
III	I
colorectal	I
carcinomas	I

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
both	O
and	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
	I
carcinoma	I
carcinoma	I
manifestation	I
manifestation	I
manifestation	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
substantial	O
cocksure	O
prognosticative	O
factor	O
for	O
selection	O
in	O
both	O
degree	B
II	I
and	I
degree	I
trey	I
colorectal	I
carcinomas	I
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
	I
carcinoma	I
carcinoma	I
manifestation	I
manifestation	I
manifestation	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

RESULTS	O
The	O
locution	O
of	O
DCC	O
was	O
a	O
solid	O
positive	O
prognosticative	O
factor	O
for	O
survival	O
in	O
both	O
present	B
two	I
and	I
present	I
threesome	I
colorectal	I
carcinomas	I
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
for	O
survival	O
both	O
stage	B
II	I
and	I
stage	I
III	I
colorectal	I

factor	O
The	O
expression	O
stage	O
DCC	O
was	O
a	O
positive	O
strong	O
predictive	O
III	O
for	O
in	O
survival	O
.	O
stage	B
II	I
and	I
of	I
RESULTS	I
colorectal	I
carcinomas	I
both	O

solvent	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
potent	O
cocksure	O
predictive	O
constituent	O
for	O
endurance	O
in	O
both	O
stage	B
II	I
and	I
stage	I
trinity	I
colorectal	I
carcinomas	I
.	O

both	O
The	O
positive	O
a	O
DCC	O
was	O
stage	O
strong	O
expression	O
predictive	O
factor	O
for	O
colorectal	O
in	O
of	O
RESULTS	B
II	I
and	I
stage	I
III	I
survival	I
carcinomas	I
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

In	O
patients	O
with	O
stage	O
deuce	O
disease	O
whose	O
tumors	B
evince	O
DCC	O
,	O
the	O
quint	O
-	O
twelvemonth	O
survival	O
order	O
was	O
94	O
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
94	O
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
94	O
.	O

with	O
disease	O
whose	O
tumors	B
DCC	O
,	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O

In	O
patients	O
with	O
stage	O
II	O
tumors	B
expressed	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O

with	O
stage	O
II	O
disease	O
tumors	B
expressed	O
DCC	O
,	O
the	O
-	O
year	O
survival	O
rate	O
94	O
.	O

was	O
patients	O
with	O
94	O
II	O
disease	O
whose	O
expressed	B
tumors	O
DCC	O
year	O
the	O
five	O
.	O
In	O
survival	O
rate	O
,	O
stage	O
-	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
verbalise	O
yr	O
94	O
.	O

inwards	O
patients	O
with	O
degree	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
phoebe	O
-	O
class	O
endurance	O
rate	O
was	O
xciv	O
.	O

rate	O
patients	O
with	O
stage	O
II	O
disease	O
-	O
the	B
expressed	O
DCC	O
,	O
year	O
In	O
whose	O
tumors	O
was	O
five	O
survival	O
94	O
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O

tumors	O
percent	O
,	O
DCC	O
in	O
patients	O
with	O
whereas	B
rate	I
negative	I
survival	I
,	O
3	O
the	O
-	O
was	O
61	O
.	O

ternion	O
pct	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
veto	I
tumors	I
,	O
the	O
survival	O
range	O
was	O
61	O
.	O

ternary	O
pct	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
range	O
was	O
lxi	O
.	O

3	O
percent	O
,	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O

trine	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumour	I
,	O
the	O
selection	O
pace	O
was	O
lxi	O
.	O

3	O
percent	O
be	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
follow	O
follow	O
follow	O
grade	O
.	O

3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
,	O
the	O
rate	O
was	O
61	O
.	O

3	O
percent	O
be	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
follow	O
follow	O
follow	O
grade	O
.	O

percent	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
.	O

3	O
percent	O
-	O
rate	O
in	O
patients	O
the	O
DCC	B
,	I
negative	I
tumors	I
,	O
with	O
survival	O
whereas	O
was	O
61	O
.	O

3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O

sextuplet	O
percent	O
(	O
phosphorus	O
<	O
cypher	O
.	O
001	O
)	O
.	O

6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
percentage	O
percentage	O
percentage	O
.	O

6	O
percent	O
(	O
phosphorus	O
<	O
nought	O
.	O
001	O
)	O
.	O

sixer	O
pct	O
(	O
P	O
<	O
cipher	O
.	O
001	O
)	O
.	O

6	O
(	O
P	O
0	O
.	O
001	O
)	O
.	O

001	O
.	O
(	O
<	O
P	O
0	O
.	O
6	O
)	O
percent	O

6	O
001	O
(	O
P	O
percent	O
0	O
<	O
.	O
)	O
.	O

001	O
P	O
(	O
percent	O
<	O
0	O
.	O
6	O
)	O
.	O

6	O
P	O
<	O
0	O
001	O

6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
percentage	O
percentage	O
percentage	O
.	O

6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
with	O
III	I
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O

In	O
patients	O
with	O
stage	B
tierce	I
disease	I
,	O
the	O
various	O
survival	O
grass	O
were	O
ilx	O
.	O

the	O
stage	O
with	O
patients	B
III	I
disease	I
survival	O
In	O
respective	O
.	O
rates	O
were	O
59	O
,	O

In	O
patients	O
with	O
stage	B
III	I
disease	I
,	O
the	O
survival	O
rates	O
59	O
.	O

In	O
patients	O
	O
several	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
	O
	O
survival	O
rates	O
were	O
59	O
.	O

In	O
patients	O
	O
several	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
	O
inward	O
survival	O
rates	O
were	O
59	O
.	O

In	O
patients	O
with	O
stage	B
ternion	I
disease	I
,	O
the	O
various	O
endurance	O
grade	O
were	O
59	O
.	O

59	O
patients	O
with	O
In	B
the	I
disease	I
,	O
were	O
respective	O
survival	O
rates	O
III	O
stage	O
.	O

In	O
patients	O
	O
several	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
	O
	O
survival	O
rates	O
were	O
59	O
.	O

In	O
patients	O
with	O
degree	B
III	I
disease	I
,	O
the	O
several	O
selection	O
rates	O
were	O
ilx	O
.	O

In	O
patients	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O

3	O
percent	O
and	O
33	O
	O
.	O

33	O
percent	O
and	O
3	O
.	O

3	O
pct	O
and	O
33	O
.	O

3	O
33	O
and	O
percent	O
.	O

and	O
33	O
.	O

ternion	O
percent	O
and	O
33	O
.	O

3	O
percent	O
and	O
33	O
	O
.	O

terzetto	O
percent	O
and	O
33	O
.	O

3	O
33	O
.	O

3	O
percent	O
and	O
33	O
percentage	O
.	O

3	O
percent	O
and	O
33	O
.	O

2	O
pct	O
(	O
P	O
=	O
cypher	O
.	O
03	O
)	O
.	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
percentage	O
percentage	O
percentage	O
.	O

deuce	O
percent	O
(	O
p	O
=	O
cypher	O
.	O
03	O
)	O
.	O

two	O
pct	O
(	O
phosphorus	O
=	O
0	O
.	O
03	O
)	O
.	O

2	O
(	O
P	O
0	O
.	O
03	O
)	O
.	O

03	O
.	O
(	O
=	O
P	O
0	O
.	O
2	O
)	O
percent	O

2	O
03	O
(	O
P	O
percent	O
0	O
=	O
.	O
)	O
.	O

03	O
P	O
(	O
percent	O
=	O
0	O
.	O
2	O
)	O
.	O

2	O
P	O
=	O
0	O
03	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
percentage	O
percentage	O
percentage	O
.	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

II	O
DCC	O
is	O
patients	O
prognostic	O
marker	O
in	O
a	O
colorectal	O
stage	B
III	I
or	I
CONCLUSIONS	I
stage	I
with	I
cancer	I
.	O

last	O
DCC	O
is	O
a	O
portent	O
marker	O
in	O
patients	O
with	O
stage	B
ii	I
or	I
stage	I
ternion	I
colorectal	I
crab	I
.	O

conclusion	O
DCC	O
is	O
a	O
prodigy	O
marker	O
in	O
patients	O
with	O
stage	B
deuce	I
or	I
stage	I
ternary	I
colorectal	I
cancer	I
.	O

CONCLUSIONS	O
DCC	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
.	O

close	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
degree	B
deuce	I
or	I
degree	I
terzetto	I
colorectal	I
cancer	I
.	O

CONCLUSIONS	O
DCC	O
patient	O
be	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
patient	O
role	O
patient	O
role	O

CONCLUSIONS	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
stage	B
II	I
stage	I
III	I
colorectal	I
cancer	I
.	O

CONCLUSIONS	O
DCC	O
patient	O
be	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
patient	O
role	O
patient	O
role	O

DCC	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I

CONCLUSIONS	O
DCC	O
with	O
colorectal	O
prognostic	O
marker	O
stage	O
patients	O
is	O
stage	B
II	I
or	I
in	I
III	I
a	I
cancer	I
.	O

CONCLUSIONS	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
	O
cancer	O
	O
cancer	O
cancer	O
two	O
patient	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
behave	O
stage	B
III	I
cancers	I
.	O

In	O
level	B
deuce	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
discover	O
a	O
subgroup	O
of	O
patients	O
with	O
wound	O
that	O
do	O
comparable	O
level	B
threesome	I
cancers	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
of	O
DCC	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
stage	B
III	I
cancers	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
	O
cancer	O
	O
cancer	O
cancer	O
two	O
two	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

inch	O
degree	B
deuce	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
describe	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
comport	O
like	O
degree	B
trinity	I
crab	I
.	O

indium	O
degree	B
ii	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
key	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
act	O
like	O
degree	B
trine	I
cancers	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
identifies	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B
III	I

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
	O
cancer	O
	O
cancer	O
cancer	O
two	O
two	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

that	O
stage	B
II	I
identifies	I
carcinomas	I
,	O
the	O
behave	O
.	O
DCC	O
colorectal	O
a	O
subgroup	O
of	O
cancers	O
with	O
lesions	O
stage	O
absence	O
In	O
like	B
III	I
patients	I
of	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
patient	O
patient	O
find	O
out	O
group	O
of	O

findings	O
may	O
implications	O
group	O
of	O
patients	O

These	O
findings	O
may	O
olibanum	O
have	O
remedial	O
implications	O
in	O
this	O
radical	O
of	O
patients	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
patient	O
patient	O
find	O
out	O
group	O
of	O

findings	O
may	O
have	O
therapeutic	O
implications	O
in	O
this	O
group	O
of	O
patients	O

These	O
determine	O
may	O
olibanum	O
have	O
therapeutic	O
significance	O
in	O
this	O
group	O
of	O
patients	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
patient	O
patient	O
inward	O
group	O
of	O
patients	O

These	O
get	O
may	O
thus	O
have	O
cure	O
significance	O
in	O
this	O
group	O
of	O
patients	O

These	O
in	O
may	O
thus	O
findings	O
therapeutic	O
implications	O
of	O
this	O
group	O
have	O
patients	O

patients	O
findings	O
may	O
thus	O
in	O
therapeutic	O
group	O
have	O
this	O
implications	O
of	O
These	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
group	O
of	O
patients	O

the	O
of	O
anxiety	B
a	I
related	I
traits	I
with	O
-	O
regulatory	O
in	O
gene	O
serotonin	O
Association	O
transporter	O
polymorphism	O
region	O
.	O

association	O
of	O
anxiousness	B
-	I
related	I
traits	I
with	O
a	O
pleomorphism	O
in	O
the	O
serotonin	O
transporter	O
factor	O
regulative	O
region	O
.	O

connexion	O
of	O
anxiousness	B
-	I
related	I
traits	I
with	O
a	O
pleomorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulative	O
realm	O
.	O

Association	O
of	O
related	I
traits	I
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O

connexion	O
of	O
anxiousness	B
-	I
related	I
traits	I
with	O
a	O
pleomorphism	O
in	O
the	O
serotonin	O
transporter	O
cistron	O
regulatory	O
part	O
.	O

Association	O
of	O
antiophthalmic	O
factor	O
anxiousness	B
anxiety	I
-	I
related	I
traits	O
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
disquiet	O
disquiet	O
disquiet	O

Association	O
of	O
anxiety	B
-	I
related	I
traits	I
with	O
a	O
in	O
the	O
transporter	O
gene	O
regulatory	O
region	O
.	O

Association	O
of	O
antiophthalmic	O
factor	O
anxiousness	B
anxiety	I
-	I
related	I
traits	O
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
disquiet	O
disquiet	O
disquiet	O

of	O
related	I
traits	I
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O

Association	O
of	O
polymorphism	B
regulatory	I
related	I
traits	I
transporter	O
a	O
anxiety	O
in	O
the	O
serotonin	O
with	O
gene	O
-	O
region	O
.	O

Association	O
of	O
anxiety	B
-	I
related	I
traits	I
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O

Transporter	O
of	O
(	O
5	O
-	O
or	O
5	O
-	O
)	O
has	O
been	O
implicated	O
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
used	O
uptake	O
-	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
)	O
has	O
anxiety	B
and	O
animal	O
is	O
of	O
action	O
of	O
widely	O
uptake	O
-	O
and	O
antianxiety	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
dose	O
be	O
be	O
dose	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Transporter	O
-	O
help	O
ingestion	O
of	O
serotonin	O
(	O
fin	O
-	O
hydroxytryptamine	O
or	O
fin	O
-	O
HT	O
)	O
has	O
been	O
concerned	O
in	O
anxiousness	B
in	O
humans	O
and	O
carnal	O
pattern	O
and	O
is	O
the	O
site	O
of	O
litigate	O
of	O
widely	O
secondhand	O
ingestion	O
-	O
suppress	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Transporter	O
-	O
action	O
uptake	O
of	O
-	O
(	O
in	O
-	O
hydroxytryptamine	O
or	O
is	O
anxiety	O
HT	O
)	O
5	O
been	O
implicated	O
antidepressant	O
-	B
in	O
widely	O
and	O
serotonin	O
models	O
has	O
5	O
humans	O
site	O
of	O
facilitated	O
the	O
of	O
used	O
uptake	O
animal	O
inhibiting	O
and	O
and	O
antianxiety	O
drugs	O
.	O

conveyer	O
-	O
alleviate	O
consumption	O
of	O
serotonin	O
(	O
quint	O
-	O
hydroxytryptamine	O
or	O
quint	O
-	O
HT	O
)	O
has	O
been	O
concerned	O
in	O
anxiousness	B
in	O
humans	O
and	O
carnal	O
example	O
and	O
is	O
the	O
situation	O
of	O
activeness	O
of	O
widely	O
utilise	O
consumption	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

uptake	O
in	O
facilitated	O
uptake	O
of	O
serotonin	O
.	O
5	O
-	O
hydroxytryptamine	O
or	O
drugs	O
-	O
models	O
of	O
has	O
been	O
implicated	O
the	O
anxiety	B
in	O
humans	O
-	O
animal	O
HT	O
and	O
used	O
-	O
of	O
and	O
action	O
site	O
widely	O
)	O
Transporter	O
is	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
5	O
(	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
-	O
hydroxytryptamine	O
or	O
5	O
HT	O
)	O
has	O
been	O
implicated	O
anxiety	B
in	O
humans	O
and	O
models	O
and	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
inhibiting	O
antidepressant	O
antianxiety	O
drugs	O
.	O

and	O
models	O
facilitated	O
uptake	O
been	O
serotonin	O
in	O
of	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
(	O
antidepressant	O
has	O
of	O
action	O
in	O
anxiety	B
HT	O
humans	O
and	O
animal	O
the	O
and	O
is	O
.	O
implicated	O
of	O
site	O
-	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
)	O
Transporter	O
antianxiety	O
drugs	O
5	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
dose	O
be	O
be	O
dose	O
be	O
be	O
be	O
be	O
be	O
be	O
be	O
wide	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
regulative	O
realm	O
regulative	O
realm	O
realm	O
antiophthalmic	O
factor	O
homo	O
in	O
its	O
upstream	O
regulatory	O
region	O

-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
in	O
upstream	O
regulatory	O
region	O
.	O

Human	O
cinque	O
-	O
HT	O
conveyor	O
(	O
cinque	O
-	O
HTT	O
)	O
cistron	O
transcription	O
is	O
inflect	O
by	O
a	O
park	O
pleomorphism	O
in	O
its	O
upstream	O
regulative	O
region	O
.	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
HTT	O
)	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
upstream	O
regulatory	O
region	O
.	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
regulative	O
realm	O
regulative	O
realm	O
realm	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
in	O
its	O
upstream	O
regulatory	O

homo	O
phoebe	O
-	O
HT	O
transporter	O
(	O
phoebe	O
-	O
HTT	O
)	O
cistron	O
transcription	O
is	O
inflect	O
by	O
a	O
uncouth	O
polymorphism	O
in	O
its	O
upriver	O
regulative	O
region	O
.	O

Human	O
fivesome	O
-	O
HT	O
transporter	O
(	O
fivesome	O
-	O
HTT	O
)	O
factor	O
transcription	O
is	O
regulate	O
by	O
a	O
coarse	O
pleomorphism	O
in	O
its	O
upstream	O
regulative	O
part	O
.	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
gene	O
modulated	O
by	O
a	O
common	O
polymorphism	O
in	O
its	O
upstream	O
regulatory	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
regulative	O
realm	O
regulative	O
realm	O
realm	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
in	O
its	O
upstream	O
regulatory	O

polymorphism	O
5	O
-	O
gene	O
transporter	O
(	O
5	O
in	O
.	O
)	O
HT	O
transcription	O
is	O
modulated	O
region	O
a	O
common	O
upstream	O
-	O
Human	O
its	O
regulatory	O
by	O
HTT	O

Human	O
5	O
-	O
HT	O
transporter	O
(	O
5	O
-	O
HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
in	O
its	O
upstream	O
regulatory	O
region	O
.	O

The	O
short	O
variant	O
of	O
	O
pleomorphism	O
cistron	O
plugger	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
	O
	O
	O
	O
	O
.	O

The	O
short	O
variant	O
polymorphism	O
of	O
the	O
5	O
HTT	O
gene	O
,	O
resulting	O
in	O
-	O
HTT	O
expression	O
and	O
5	O
HT	O
in	O
lymphoblasts	O
.	O

The	O
unforesightful	O
form	O
of	O
the	O
pleomorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
v	O
-	O
HTT	O
cistron	O
booster	O
,	O
lead	O
in	O
minify	O
v	O
-	O
HTT	O
expression	O
and	O
v	O
-	O
HT	O
intake	O
in	O
lymphoblasts	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
transcriptional	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
.	O

The	O
short	O
version	O
of	O
the	O
pleomorphism	O
shorten	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
cinque	O
-	O
HTT	O
cistron	O
showman	O
,	O
resulting	O
in	O
fall	O
cinque	O
-	O
HTT	O
formulation	O
and	O
cinque	O
-	O
HT	O
ingestion	O
in	O
lymphoblasts	O
.	O

The	O
short	O
variant	O
of	O
	O
pleomorphism	O
cistron	O
plugger	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
	O
	O
	O
	O
	O
.	O

The	O
dead	O
form	O
of	O
the	O
pleomorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
factor	O
showman	O
,	O
leave	O
in	O
diminish	O
5	O
-	O
HTT	O
saying	O
and	O
5	O
-	O
HT	O
consumption	O
in	O
lymphoblasts	O
.	O

decreased	O
resulting	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
expression	O
uptake	O
gene	O
promoter	O
,	O
-	O
in	O
short	O
5	O
lymphoblasts	O
HTT	O
-	O
and	O
5	O
The	O
HTT	O
-	O
in	O
HT	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
the	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
-	O
HT	O
uptake	O
lymphoblasts	O

The	O
short	O
variant	O
of	O
	O
pleomorphism	O
cistron	O
var	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
	O
	O
	O
	O
	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5	O
-	O
HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5	O
-	O
HTT	O
expression	O
and	O
5	O
-	O
HT	O
uptake	O
in	O
lymphoblasts	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
main	I
main	I
main	I
main	I
main	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
.	O

Association	O
subject	O
in	O
ii	O
independent	O
samples	O
totaling	O
505	O
soul	O
disclose	O
that	O
the	O
5	O
-	O
HTT	O
pleomorphism	O
invoice	O
for	O
terzetto	O
to	O
quartet	O
percent	O
of	O
summate	O
fluctuation	O
and	O
sevener	O
to	O
9	O
percent	O
of	O
hereditary	O
variant	O
in	O
anxiousness	B
-	I
related	I
personality	I
traits	I
in	O
soul	O
as	O
well	O
as	O
sibships	O
.	O
.	O

Association	O
studies	O
inherited	O
two	O
independent	O
-	O
totaling	O
505	O
individuals	O
revealed	O
that	O
5	O
well	O
-	O
HTT	O
of	O
accounts	O
for	O
to	O
3	O
4	O
.	O
of	O
samples	O
variation	O
7	O
to	O
.	O
9	O
percent	O
polymorphism	O
personality	O
and	O
in	O
anxiety	B
total	I
related	I
in	I
traits	I
in	O
individuals	O
as	O
the	O
sibships	O
as	O
variance	O
percent	O

Association	O
7	O
in	O
two	O
independent	O
samples	O
the	O
percent	O
individuals	O
revealed	O
that	O
totaling	O
5	O
to	O
variation	O
polymorphism	O
accounts	O
for	O
505	O
to	O
4	O
percent	O
-	O
total	O
as	O
and	O
.	O
-	O
inherited	O
3	O
of	O
9	O
variance	O
HTT	O
anxiety	B
as	I
related	I
personality	I
traits	I
in	O
studies	O
in	O
well	O
of	O
sibships	O
.	O
individuals	O

connexion	O
studies	O
in	O
two	O
mugwump	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
pleomorphism	O
accounts	O
for	O
trinity	O
to	O
4	O
pct	O
of	O
come	O
variance	O
and	O
seven	O
to	O
ix	O
pct	O
of	O
transmissible	O
discrepancy	O
in	O
anxiousness	B
-	I
colligate	I
personality	I
traits	I
in	O
individuals	O
as	O
considerably	O
as	O
sibships	O
.	O
.	O

Association	O
studies	O
in	O
independent	O
samples	O
totaling	O
505	O
individuals	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
percent	O
total	O
variation	O
and	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
anxiety	B
-	I
traits	I
individuals	O
as	O
well	O
as	O
.	O

two	O
independent	O
samples	O
totaling	O
505	O
revealed	O
that	O
HTT	O
for	O
3	O
percent	O
variation	O
and	O
7	O
to	O
percent	O
of	O
in	O
anxiety	B
related	I
personality	I
as	O
as	O
sibships	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
main	I
main	I
main	I
main	I
	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
.	O

anxiety	O
variation	O
in	O
two	O
accounts	O
samples	O
4	O
inherited	O
individuals	O
revealed	O
that	O
the	O
5	O
totaling	O
personality	O
polymorphism	O
independent	O
.	O
3	O
to	O
-	O
percent	O
of	O
total	O
to	O
and	O
7	O
as	O
sibships	O
percent	O
9	O
studies	O
variance	O
in	O
traits	B
-	I
related	I
HTT	I
Association	I
in	O
individuals	O
505	O
well	O
as	O
of	O
.	O
for	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
a	I
considerably	I
a	I
main	I
main	I
main	I
main	I
main	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
.	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
betwixt	O
betwixt	O
betwixt	O
diastrophic	B
dysplasia	I
.	O

and	O
genotypic	O
type	I
diastrophic	B
dysplasia	I
.	O

phenotypical	O
and	O
genotypic	O
intersection	O
between	O
atelosteogenesis	B
case	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
betwixt	O
betwixt	O
betwixt	O
diastrophic	B
dysplasia	I
.	O

and	O
genotypic	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

phenotypical	O
and	O
genotypic	O
convergence	O
between	O
atelosteogenesis	B
type	I
two	I
and	O
diastrophic	B
dysplasia	I
.	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
betwixt	O
betwixt	O
genotypical	O
diastrophic	B
dysplasia	I
.	O

phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
case	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

Phenotypic	O
2	O
genotypic	O
overlap	O
and	O
atelosteogenesis	B
type	I
dysplasia	I
and	O
diastrophic	B
between	I
.	O

.	O
and	O
genotypic	O
overlap	O
2	O
atelosteogenesis	B
diastrophic	I
between	I
and	O
type	B
dysplasia	I
Phenotypic	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

mutation	O
in	O
the	O
diastrophic	B
dysplasia	I
sulphate	O
conveyor	O
factor	O
DTDST	O
have	O
been	O
assort	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
consist	O
,	O
in	O
rate	O
of	O
increase	O
badness	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
character	I
two	I
(	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
character	I
1B	I
(	O
ACG1B	B
)	O
.	O

Mutations	O
in	O
,	O
diastrophic	B
dysplasia	I
(	O
transporter	O
gene	O
DTDST	O
have	O
been	O
with	O
1B	O
a	O
family	O
)	O
chondrodysplasias	B
that	O
,	O
comprises	O
in	O
.	O
of	O
sulfate	O
severity	O
diastrophic	O
dysplasia	B
)	I
(	O
DTD	B
of	O
)	O
,	B
type	I
2	I
increasing	O
AO2	B
the	O
,	O
and	O
achondrogenesis	B
type	I
associated	I
ACG1B	O
(	B
atelosteogenesis	O
order	O

Mutations	O
diastrophic	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
associated	O
DTD	O
DTDST	O
have	O
been	O
transporter	O
with	O
dysplasia	O
severity	O
of	O
chondrodysplasias	B
that	O
gene	O
,	O
in	O
order	O
(	O
increasing	O
(	O
,	O
.	B
a	I
,	O
comprises	B
)	O
(	O
atelosteogenesis	B
family	I
2	I
type	O
AO2	B
)	O
,	O
and	O
in	B
type	I
1B	I
of	O
ACG1B	B
)	O
achondrogenesis	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulphate	O
conveyer	O
cistron	O
DTDST	O
have	O
been	O
consort	O
with	O
a	O
household	O
of	O
chondrodysplasias	B
that	O
represent	O
,	O
in	O
regularize	O
of	O
increase	O
hardness	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
ii	I
(	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

Mutations	O
in	O
the	O
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
order	O
increasing	O
severity	O
,	O
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
2	I
(	O
,	O
achondrogenesis	B
type	I
1B	I
(	O
.	O

diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
have	O
been	O
family	O
that	O
comprises	O
order	O
severity	O
,	O
diastrophic	B
dysplasia	I
DTD	B
)	O
type	I
2	I
AO2	B
)	O
type	I
(	O
ACG1B	B
)	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
inward	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

2	O
severity	O
the	O
diastrophic	B
chondrodysplasias	I
sulfate	O
in	O
,	O
DTDST	O
have	O
been	O
associated	O
with	O
transporter	O
)	O
of	O
dysplasia	B
.	O
comprises	O
,	O
a	O
order	O
of	O
increasing	O
dysplasia	O
,	O
diastrophic	B
type	I
ACG1B	O
DTD	B
(	O
in	O
atelosteogenesis	B
type	I
,	I
(	O
AO2	B
family	O
Mutations	O
and	O
achondrogenesis	B
gene	I
1B	I
(	O
)	B
)	O
that	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
character	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO	B
-	I
2	I
,	O
one	O
with	O
DTD	B
,	O
and	O
associate	O
in	O
nursing	O
average	O
	O
associate	O
in	O
nursing	O
average	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
one	O
with	O
an	B
intermediate	O
phenotype	B
(	O
AO2	O

To	O
teach	O
more	O
about	O
the	O
molecular	O
base	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
contemplate	O
fibroblast	O
civilization	O
of	O
troika	O
unexampled	O
patients	O
nonpareil	O
with	O
AO	B
-	I
2	I
,	O
nonpareil	O
with	O
DTD	B
,	O
and	O
nonpareil	O
with	O
an	O
average	O
phenotype	O
(	O
AO2	B
/	O
DTD	B
)	O
.	O

To	O
learn	O
one	O
about	O
the	O
and	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
genotype	O
AO2	O
-	O
phenotype	O
,	O
,	O
we	O
fibroblast	O
studied	O
cultures	O
.	O
three	O
molecular	O
patients	O
with	O
AO	O
)	B
-	I
2	I
correlations	O
with	O
one	O
DTD	B
,	O
new	O
one	O
more	O
an	O
intermediate	O
phenotype	O
(	O
about	B
DTD	O
/	B
with	O
of	O

To	O
with	O
more	O
about	O
the	O
molecular	O
about	O
2	O
DTDST	B
chondrodysplasias	I
and	O
basis	O
genotype	O
AO	O
patients	O
correlations	O
,	O
we	O
of	O
fibroblast	O
cultures	O
of	O
and	O
new	O
/	O
one	O
.	O
-	B
one	I
studied	I
,	O
-	O
with	O
phenotype	B
,	O
(	O
one	O
with	O
an	O
intermediate	O
learn	O
DTD	O
AO2	B
three	O
DTD	B
)	O
phenotype	O

To	O
hear	O
more	O
about	O
the	O
molecular	O
groundwork	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
canvas	O
fibroblast	O
acculturation	O
of	O
trine	O
modern	O
patients	O
unrivaled	O
with	O
AO	B
-	I
ii	I
,	O
unrivaled	O
with	O
DTD	B
,	O
and	O
unrivaled	O
with	O
an	O
intermediate	O
phenotype	O
(	O
AO2	B
/	O
DTD	B
)	O
.	O

To	O
learn	O
more	O
the	O
molecular	O
basis	O
of	O
DTDST	B
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
of	O
new	O
patients	O
one	O
AO	B
-	I
2	I
,	O
one	O
with	O
,	O
and	O
an	O
phenotype	O
(	O
AO2	B
/	O
.	O

about	O
the	O
molecular	O
basis	O
of	O
chondrodysplasias	I
and	O
phenotype	O
we	O
studied	O
of	O
patients	O
one	O
with	O
AO	B
2	I
,	O
DTD	B
,	O
one	O
with	O
(	O
/	O
DTD	B
)	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO	B
-	I
2	I
,	O
one	O
with	O
DTD	B
,	O
and	O
associate	O
in	O
nursing	O
average	O
	O
associate	O
in	O
nursing	O
average	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
one	O
with	O
an	B
intermediate	O
phenotype	B
(	O
AO2	O

,	O
patients	O
more	O
about	O
,	O
molecular	O
cultures	O
one	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
basis	O
with	O
correlations	O
the	O
.	O
studied	O
fibroblast	O
-	O
of	O
three	O
new	O
AO	O
one	O
with	O
(	B
DTD	I
2	I
-	O
learn	O
with	O
DTD	B
an	O
and	O
one	O
phenotype	O
To	O
intermediate	O
phenotype	O
of	O
AO2	B
/	O
,	B
)	O
we	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO	B
-	I
2	I
,	O
one	O
with	O
DTD	B
,	O
and	O
associate	O
in	O
nursing	O
average	O
	O
associate	O
in	O
nursing	O
average	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
one	O
with	O
an	B
intermediate	O
phenotype	B
(	O
AO2	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO	B
-	I
2	I
,	O
one	O
with	O
DTD	B
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
AO2	B
/	O
DTD	B
)	O
.	O

Reduced	O
of	O
inorganic	O
into	O
was	O
in	O
all	O
three	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
three	O

abridge	O
incorporation	O
of	O
inorganic	O
sulphate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
tierce	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
	O
	O
internalization	O
in	O
all	O
three	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
	O
	O
internalization	O
in	O
all	O
three	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
	O
	O
internalization	O
in	O
all	O
three	O
.	O

decreased	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
recover	O
in	O
all	O
trinity	O
.	O

Reduced	O
incorporation	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulphate	O
into	O
supermolecule	O
was	O
found	O
in	O
all	O
tercet	O
.	O

Reduced	O
sulfate	O
of	O
inorganic	O
.	O
into	O
macromolecules	O
incorporation	O
found	O
in	O
all	O
three	O
was	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
three	O
.	O

of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
transition	O
predicting	O
a	O
substitution	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

for	O
of	O
the	O
in	O
patients	O
was	O
found	O
.	O
of	O
heterozygous	O
DTDST	O
a	O
c862t	O
the	O
loop	O
a	O
R279W	O
substitution	O
three	O
transition	O
third	O
extracellular	O
predicting	O
be	O
Each	O
to	O

Each	O
of	O
the	O
troika	O
patients	O
was	O
find	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
conversion	O
presage	O
a	O
R279W	O
replacement	O
in	O
the	O
third	O
extracellular	O
coil	O
of	O
DTDST	O
.	O

apiece	O
of	O
the	O
trey	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
conversion	O
omen	O
a	O
R279W	O
switch	O
in	O
the	O
third	O
extracellular	O
eyelet	O
of	O
DTDST	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
a	O
c862t	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
of	O
DTDST	O
.	O

Each	O
of	O
the	O
three	O
patient	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
grummet	O
thirdly	O
grummet	O
grummet	O
follow	O
follow	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

Each	O
of	O
the	O
three	O
patient	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
grummet	O
thirdly	O
grummet	O
grummet	O
follow	O
permutation	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
a	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
extracellular	O
loop	O

of	O
of	O
the	O
three	O
patients	O
was	O
transition	O
R279W	O
be	O
heterozygous	O
for	O
a	O
extracellular	O
found	O
DTDST	O
a	O
to	O
third	O
in	O
the	O
Each	O
c862t	O
loop	O
substitution	O
predicting	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
feel	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
modulation	O
omen	O
a	O
R279W	O
exchange	O
in	O
the	O
tertiary	O
extracellular	O
intertwine	O
of	O
DTDST	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
"	O
Finnish	O
"	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O

In	O
two	O
(	O
DTD	B
/	O
DTD	B
)	O
no	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
-	O
conformation	O
polymorphism	O
of	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
patients	O
may	O
compound	O
heterozygotes	O
for	O
the	O
Finnish	O
mutation	O
uncharacterized	O
the	O
DNA	O
level	O
,	O
which	O
reduced	O
expression	O
DTDST	O
.	O

In	O
analysis	O
patients	O
uncharacterized	O
at	B
wild	O
AO2	B
/	O
DTD	B
)	O
,	O
may	O
other	O
chain	O
mutation	O
of	O
found	O
,	O
but	O
polymerase	O
structural	O
heterozygotes	O
"	O
and	O
the	O
reduced	O
strand	O
conformation	O
polymorphism	O
patients	O
of	O
for	O
cDNA	O
showed	O
reduced	O
mRNA	O
DNA	O
was	O
single	O
and	O
-	O
type	O
level	O
allele	O
these	O
two	O
expression	O
the	O
be	O
compound	O
reaction	O
fibroblast	O
the	O
amplification	O
DTDST	O
"	O
)	O
(	O
as	O
yet	O
(	O
DTD	O
no	O
levels	O
,	O
mutation	O
Finnish	O
which	O
causes	O
-	O
two	O
of	O
DTDST	O
.	O

inward	O
deuce	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
geomorphologic	O
mutation	O
was	O
bump	O
,	O
but	O
polymerase	O
chain	O
reaction	O
gain	O
and	O
ace	O
-	O
chain	O
conformation	O
pleomorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
establish	O
tighten	O
mRNA	O
raze	O
of	O
the	O
tempestuous	O
-	O
case	O
DTDST	O
allelomorph	O
these	O
deuce	O
patients	O
whitethorn	O
be	O
deepen	O
heterozygotes	O
for	O
the	O
"	O
finnish	O
"	O
mutation	O
(	O
as	O
notwithstanding	O
uncharacterized	O
at	O
the	O
DNA	O
layer	O
)	O
,	O
which	O
induce	O
tighten	O
face	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
"	O
Finnish	O
"	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O
complementary	O
dna	O

In	O
two	O
patients	O
and	O
,	O
no	O
other	O
mutation	O
was	O
,	O
but	O
polymerase	O
amplification	O
and	O
single	O
-	O
strand	O
polymorphism	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
type	O
DTDST	O
allele	O
these	O
two	O
for	O
Finnish	O
mutation	O
(	O
as	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
reduced	O
expression	O
of	O
DTDST	O
.	O

"	O
reduced	O
of	O
Finnish	O
DTD	B
and	O
AO2	B
/	O
cDNA	B
)	O
,	O
no	O
and	O
analysis	O
mutation	O
DNA	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
the	O
single	O
-	O
be	O
strand	O
as	O
these	O
of	O
fibroblast	O
DTD	O
showed	O
uncharacterized	O
mRNA	O
levels	O
-	O
the	O
wild	O
compound	O
type	O
DTDST	O
allele	O
expression	O
two	O
patients	O
may	O
conformation	O
(	O
heterozygotes	O
for	O
the	O
of	O
patients	O
In	O
was	O
reduced	O
which	O
yet	O
(	O
at	O
other	O
mutation	O
level	O
)	O
,	O
polymorphism	O
causes	O
two	O
structural	O
"	O
DTDST	O
.	O

inward	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
geomorphological	O
mutant	O
was	O
found	O
,	O
but	O
polymerase	O
range	O
response	O
elaboration	O
and	O
one	O
-	O
filament	O
conformation	O
pleomorphism	O
analysis	O
of	O
fibroblast	O
cdna	O
present	O
reduced	O
mRNA	O
dismantle	O
of	O
the	O
waste	O
-	O
character	O
DTDST	O
allelomorph	O
these	O
two	O
patients	O
may	O
be	O
intensify	O
heterozygotes	O
for	O
the	O
"	O
suomi	O
"	O
mutant	O
(	O
as	O
however	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
look	O
of	O
DTDST	O
.	O

causes	O
two	O
patients	O
two	O
cDNA	B
and	O
AO2	B
at	O
DTD	B
,	O
)	O
and	O
other	O
structural	O
mutation	O
was	O
for	O
,	O
but	O
polymerase	O
chain	O
reaction	O
analysis	O
-	O
single	O
reduced	O
Finnish	O
conformation	O
polymorphism	O
amplification	O
of	O
fibroblast	O
DTD	O
showed	O
expression	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
reduced	O
allele	O
"	O
the	O
DTDST	O
may	O
be	O
In	O
heterozygotes	O
)	O
level	O
.	O
strand	O
"	O
mutation	O
(	O
(	O
yet	O
uncharacterized	O
/	O
as	O
DNA	O
the	O
found	O
of	O
which	O
compound	O
DTDST	O
no	O
,	O
patients	O
these	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
DTD	B
,	O
no	O
other	O
structural	O
mutation	O
was	O
,	O
but	O
polymerase	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
of	O
fibroblast	O
showed	O
mRNA	O
levels	O
the	O
type	O
DTDST	O
allele	O
patients	O
may	O
heterozygotes	O
for	O
"	O
Finnish	O
(	O
as	O
yet	O
uncharacterized	O
the	O
DNA	O
level	O
)	O
reduced	O
expression	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
"	O
Finnish	O
"	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
DTDST	O
.	O

The	O
third	O
)	O
(	O
with	O
compounded	B
)	O
418	O
the	O
R279W	O
mutation	O
delta	O
predicting	O
a	O
novel	O
with	O
,	O
the	O
of	O
deletion	O
cytosine	O
had	O
(	O
AO2	O
c418	O
,	O
patient	O
termination	O
a	O
frameshift	O
mutation	O
with	O
premature	O
.	O

The	O
(	O
with	O
AO2	B
)	O
the	O
R279W	O
with	O
a	O
mutation	O
,	O
cytosine	O
(	O
delta	O
c418	O
,	O
predicting	O
a	O
with	O
premature	O
termination	O
.	O

The	O
third	O
patient	O
(	O
new	O
chromosomal	O
mutation	O
untimely	O
with	B
AO2	O
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
newly	O
newly	O
newly	O
newly	O
newly	O
newly	O
antiophthalmic	O

The	O
third	O
patient	O
(	O
new	O
chromosomal	O
mutation	O
give	O
birth	B
with	O
AO2	O
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
newly	O
newly	O
newly	O
newly	O
newly	O
newly	O

third	O
deletion	O
patient	O
(	O
with	O
AO2	B
,	O
had	O
the	O
R279W	O
mutation	O
predicting	O
with	O
c418	O
frameshift	O
mutation	O
,	O
the	O
compounded	O
of	O
cytosine	O
418	O
.	O
delta	O
a	O
)	O
)	O
The	O
premature	O
(	O
with	O
a	O
termination	O
novel	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
the	O
R279W	O
mutation	O
compounded	O
a	O
novel	O
mutation	O
,	O
the	O
of	O
cytosine	O
418	O
(	O
c418	O
)	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
sport	O
combine	O
with	O
a	O
refreshing	O
sport	O
,	O
the	O
excision	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
call	O
a	O
frameshift	O
with	O
untimely	O
termination	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
variation	O
intensify	O
with	O
a	O
fresh	O
variation	O
,	O
the	O
cut	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
augur	O
a	O
frameshift	O
with	O
untimely	O
termination	O
.	O

The	O
third	O
patient	O
(	O
new	O
chromosomal	O
mutation	O
give	O
birth	B
with	O
AO2	O
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
newly	O
newly	O
newly	O
newly	O
newly	O
newly	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
fresh	O
mutation	O
,	O
the	O
cut	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
foreshadow	O
a	O
frameshift	O
with	O
previous	O
endpoint	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
mrna	O
grade	O
mrna	O
grade	O
grade	O
observation	O
codon	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
stop	O
reduce	O
mRNA	O
levels	O
.	O

too	O
the	O
delta	O
c418	O
allelomorph	O
was	O
underrepresented	O
in	O
the	O
cdna	O
,	O
in	O
accordance	O
with	O
former	O
watching	O
that	O
untimely	O
stop	O
codons	O
concentrate	O
mRNA	O
levels	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
the	O
cDNA	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
reduce	O
mRNA	O
levels	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
mrna	O
grade	O
mrna	O
grade	O
grade	O
observation	O
observation	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

besides	O
the	O
delta	O
c418	O
allelomorph	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
premature	O
observance	O
that	O
untimely	O
stop	O
codons	O
deoxidise	O
mRNA	O
levels	O
.	O

likewise	O
the	O
delta	O
c418	O
allelomorph	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
old	O
observations	O
that	O
old	O
check	O
codons	O
reduce	O
mRNA	O
storey	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
,	O
with	O
previous	O
observations	O
that	O
premature	O
stop	O
codons	O
reduce	O
mRNA	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
mrna	O
grade	O
mrna	O
grade	O
grade	O
observation	O
observation	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

premature	O
the	O
delta	O
,	O
allele	O
was	O
underrepresented	O
stop	O
.	O
cDNA	O
c418	O
in	O
accordance	O
with	O
levels	O
observations	O
that	O
reduce	O
in	O
Also	O
codons	O
mRNA	O
previous	O
the	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
intersection	O
condition	O
betwixt	O
condition	O
condition	O
antiophthalmic	O
factor	O
condition	O
the	O
overlap	O
between	O
these	O
conditions	O

of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
the	O
between	O
these	O
conditions	O
.	O

The	O
comportment	O
of	O
the	O
DTDST	O
R279W	O
sport	O
in	O
a	O
tally	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
punctuate	O
the	O
overlap	O
between	O
these	O
shape	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
a	O
total	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
between	O
these	O
conditions	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
intersection	O
condition	O
betwixt	O
condition	O
condition	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
the	O
overlap	O
between	O
these	O

The	O
bearing	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
entire	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
accent	O
the	O
intersection	O
between	O
these	O
check	O
.	O

The	O
comportment	O
of	O
the	O
DTDST	O
R279W	O
sport	O
in	O
a	O
come	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasise	O
the	O
intersection	O
between	O
these	O
consideration	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
of	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
the	O
overlap	O
between	O
these	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
intersection	O
condition	O
betwixt	O
condition	O
condition	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
the	O
overlap	O
between	O
these	O

emphasizes	O
presence	O
of	O
of	O
DTDST	O
R279W	O
mutation	O
the	O
.	O
total	O
the	O
11	O
patients	O
with	O
conditions	B
or	O
DTD	B
between	O
in	O
The	O
overlap	O
these	O
AO2	O
a	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O

This	O
variation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
ogdoad	O
study	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
earmark	O
some	O
residuary	O
action	O
of	O
the	O
sulphate	O
conveyer	O
.	O
.	O

This	O
mutation	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
that	O
it	O
allows	O
some	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O

This	O
mutation	O
has	O
not	O
advise	O
thence	O
be	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
sulphate	O
car	O
transporter	O
sulphate	O
car	O
transporter	O
inward	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O

activity	O
mutation	O
has	O
some	O
been	O
found	O
so	O
.	O
sulfate	O
8	O
residual	O
ACG1B	B
patients	O
,	O
the	O
that	O
it	O
allows	O
not	O
transporter	O
analyzed	O
of	O
suggesting	O
in	O
This	O
far	O
.	O

This	O
mutation	O
has	O
not	O
advise	O
thence	O
be	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
sulphate	O
car	O
transporter	O
sulphate	O
car	O
transporter	O
inward	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O

This	O
mutation	O
has	O
been	O
found	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
it	O
allows	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O
.	O

.	O
mutation	O
has	O
suggesting	O
been	O
found	O
.	O
far	O
not	O
8	O
analyzed	O
ACG1B	B
,	O
activity	O
transporter	O
in	O
it	O
allows	O
some	O
residual	O
patients	O
of	O
the	O
sulfate	O
that	O
so	O
This	O

has	O
found	O
so	O
far	O
8	O
analyzed	O
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O

sulfate	O
mutation	O
has	O
not	O
been	O
found	O
,	O
ACG1B	O
in	O
8	O
analyzed	O
it	B
of	O
so	O
transporter	O
This	O
far	O
that	O
some	O
residual	O
activity	O
patients	O
the	O
allows	O
suggesting	O
.	O
.	O

This	O
sport	O
has	O
not	O
been	O
plant	O
so	O
interahamwe	O
in	O
octonary	O
study	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
countenance	O
some	O
residuary	O
activity	O
of	O
the	O
sulphate	O
transporter	O
.	O
.	O

This	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O
.	O

syndrome	O
of	O
WASP	O
phenotype	O
,	O
mutation	O
hotspots	O
-	O
patients	O
-	O
mutations	O
disparities	O
24	O
in	O
genotype	O
with	O
the	O
Wiskott	B
and	I
Identification	I
Aldrich	I
.	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
wasp	B
wasp	B
wasp	B
wasp	B
wasp	B
wasp	B
-	I
Aldrich	I
syndrome	I
.	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
wasp	B
wasp	B
wasp	B
wasp	B
wasp	B
wasp	B
-	I
Aldrich	I
syndrome	I
.	O

recognition	O
of	O
wasp	O
mutations	O
,	O
variation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparity	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Identification	O
of	O
WASP	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
phenotype	O
disparities	O
in	O
24	O
with	O
the	O
-	I
Aldrich	I
syndrome	I
.	O

mutations	O
hotspots	O
and	O
genotype	O
phenotype	O
disparities	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

identification	O
of	O
WASP	O
mutant	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparity	O
in	O
xxiv	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

patients	O
of	O
genotype	O
hotspots	O
,	O
mutation	O
with	O
and	O
WASP	O
-	O
phenotype	O
disparities	O
syndrome	O
24	O
mutations	O
Identification	O
the	O
Wiskott	B
-	I
Aldrich	I
in	I
.	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
wasp	B
wasp	B
wasp	B
wasp	B
wasp	B
chromosomal	B
mutation	I
-	I
Aldrich	I
syndrome	O

Identification	O
of	O
WASP	O
mutations	O
hotspots	O
and	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
.	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
aside	O
heterogeneousness	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
extensive	O
clinical	O
heterogeneity	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
aside	O
heterogeneousness	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
inward	O
extensive	O
clinical	O
heterogeneity	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
aside	O
heterogeneousness	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
aside	O
extensive	O
clinical	O
heterogeneity	O
.	O

WAS	O
in	B
-	I
Aldrich	I
syndrome	I
(	O
-	B
be	O
,	O
an	O
X	B
WAS	I
linked	I
WASP	I
,	I
caused	O
by	O
mutation	O
)	O
the	O
recently	O
to	O
)	O
encoding	O
The	B
protein	O
known	O
immunodeficiency	O
disease	O
gene	O
is	O
with	O
isolated	O
Wiskott	O
associated	O
(	O
extensive	O
clinical	O
heterogeneity	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
)	O
,	O
an	O
X	B
-	I
immunodeficiency	I
disease	I
in	O
isolated	O
gene	O
protein	O
)	O
,	O
is	O
known	O
be	O
associated	O
clinical	O
heterogeneity	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
personify	B
)	O
,	O
an	O
ex	B
-	I
yoke	I
immunodeficiency	I
disease	I
caused	O
by	O
mutant	O
in	O
the	O
latterly	O
marooned	O
factor	O
encryption	O
personify	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
cognize	O
to	O
be	O
associated	O
with	O
broad	O
clinical	O
heterogeneousness	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
be	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
have	O
by	O
sport	O
in	O
the	O
late	O
separated	O
cistron	O
encode	O
be	B
protein	O
(	O
wasp	O
)	O
,	O
is	O
cognize	O
to	O
be	O
associated	O
with	O
wide	O
clinical	O
heterogeneousness	O
.	O

is	O
associated	B
-	I
Aldrich	I
by	I
(	O
clinical	B
known	O
,	O
an	O
X	B
-	I
linked	I
WAS	I
mutation	I
caused	O
syndrome	O
disease	O
in	O
the	O
immunodeficiency	O
isolated	O
gene	O
encoding	O
Wiskott	B
protein	O
(	O
heterogeneity	O
The	O
,	O
)	O
WAS	O
to	O
be	O
recently	O
with	O
extensive	O
)	O
WASP	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
follow	B
)	O
,	O
an	O
cristal	B
-	I
tie	I
immunodeficiency	I
disease	I
induce	O
by	O
mutant	O
in	O
the	O
recently	O
disjunct	O
cistron	O
encode	O
follow	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
affiliate	O
with	O
wide	O
clinical	O
heterogeneousness	O
.	O

The	O
Wiskott	B
is	I
Aldrich	I
syndrome	I
with	O
X	B
)	O
,	O
an	O
WAS	B
(	I
the	I
immunodeficiency	I
disease	I
in	O
by	O
mutation	O
clinical	O
linked	O
recently	O
isolated	O
gene	O
(	O
WAS	B
caused	O
-	O
to	O
known	O
,	O
-	O
WASP	O
)	O
be	O
associated	O
encoding	O
extensive	O
protein	O
heterogeneity	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O

cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
wasp	O
genotypes	O
are	O
too	O
extremely	O
variable	O
among	O
embody	B
patients	O
,	O
but	O
the	O
kinship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
undecipherable	O
.	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
WASP	O
also	O
highly	O
variable	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

phenotype	O
mutation	O
data	O
relationship	O
revealed	O
that	O
WASP	O
disease	O
in	O
also	O
.	O
variable	O
among	O
of	B
genotype	O
,	O
but	O
the	O
have	O
WAS	O
this	O
with	O
patients	O
are	O
Cumulative	O
genotypes	O
remains	O
unclear	O
highly	O

Cumulative	O
mutation	O
data	O
have	O
find	O
out	O
be	O
patient	O
wasp	O
discover	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	B
WAS	O
patients	O
,	O
but	O
the	O
inward	O
stay	O
be	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O

Cumulative	O
mutation	O
data	O
have	O
find	O
out	O
be	O
patient	O
wasp	O
discover	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	B
WAS	O
patients	O
,	O
but	O
the	O
inward	O
stay	O
rich	O
person	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
also	O
highly	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
relationship	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

.	O
mutation	O
data	O
patients	O
revealed	O
that	O
disease	O
genotypes	O
have	O
also	O
highly	O
variable	O
remains	O
WAS	B
this	O
are	O
but	O
the	O
relationship	O
of	O
among	O
with	O
genotype	O
in	O
,	O
WASP	O
phenotype	O
unclear	O
Cumulative	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
also	O
variable	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
relationship	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O

cumulative	O
mutation	O
datum	O
have	O
disclose	O
that	O
WASP	O
genotypes	O
are	O
also	O
extremely	O
variable	O
among	O
be	B
patients	O
,	O
but	O
the	O
kinship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
clay	O
indecipherable	O
.	O

cumulative	O
mutant	O
information	O
have	O
unveil	O
that	O
WASP	O
genotypes	O
are	O
likewise	O
extremely	O
variable	O
among	O
embody	B
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
stiff	O
unclear	O
.	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

To	O
issue	O
we	O
characterized	O
mutations	O
24	O
unrelated	O
WAS	B
including	O
classical	O
WAS	B
and	O
boys	O
expressing	O
forms	O
of	O
the	O
and	O
then	O
examined	O
the	O
degree	O
correlation	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
severity	O
.	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
completely	O
admit	O
inward	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
completely	O
antecedently	O
release	O
wasp	O
mutation	O
release	O
wasp	O
inclemency	O
release	O
wasp	O
inclemency	O
correlational	O
statistics	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
completely	O
admit	O
inward	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
completely	O
antecedently	O
release	O
wasp	O
mutation	O
release	O
wasp	O
inclemency	O
release	O
wasp	O
inclemency	O
boy	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

the	O
forms	O
this	O
issue	O
we	O
characterized	O
WAS	O
mutations	O
in	O
24	O
unrelated	O
WASP	B
patients	O
of	O
the	O
18	O
boys	O
with	O
disease	O
classical	O
WAS	B
and	O
examined	O
boys	O
all	O
mild	O
WASP	O
,	O
with	O
severe	O
,	O
degree	O
then	O
including	O
To	O
well	O
of	O
correlation	O
of	O
these	O
address	O
and	O
as	O
6	O
previously	O
published	O
as	O
mutations	O
expressing	O
disease	O
severity	O
.	O

previously	O
expressing	O
this	O
issue	O
we	O
characterized	O
WAS	O
boys	O
in	O
24	O
unrelated	O
WAS	B
patients	O
severity	O
correlation	O
18	O
mutations	O
,	O
severe	O
classical	O
with	B
and	O
6	O
boys	O
address	O
mild	O
forms	O
of	O
with	O
disease	O
the	O
WASP	O
then	O
examined	O
the	O
degree	O
of	O
including	O
of	O
these	O
as	O
well	O
as	O
all	O
To	O
published	O
.	O
mutations	O
disease	O
and	O
,	O
WASP	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
completely	O
admit	O
inward	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
completely	O
antecedently	O
release	O
wasp	O
mutation	O
release	O
wasp	O
inclemency	O
release	O
wasp	O
inclemency	O
boy	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

To	O
address	O
issue	O
WASP	O
mutations	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
degree	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

To	O
address	O
,	O
issue	O
we	O
characterized	O
WASP	O
severe	O
in	O
24	O
unrelated	O
boys	B
classical	O
,	O
including	O
and	O
boys	O
with	O
correlation	O
patients	O
WAS	B
mutations	O
6	O
WAS	O
expressing	O
.	O
of	O
then	O
the	O
disease	O
this	O
as	O
and	O
examined	O
the	O
previously	O
of	O
mild	O
of	O
these	O
as	O
well	O
forms	O
all	O
degree	O
WASP	O
published	O
18	O
with	O
disease	O
severity	O
mutations	O

To	O
treat	O
this	O
issue	O
we	O
characterized	O
wasp	O
mutations	O
in	O
24	O
unrelated	O
cost	B
patients	O
,	O
including	O
eighteen	O
boys	O
with	O
stark	O
authoritative	O
cost	B
and	O
sixer	O
boys	O
state	O
soft	O
kind	O
of	O
the	O
disease	O
,	O
and	O
then	O
test	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
antecedently	O
write	O
wasp	O
mutations	O
with	O
disease	O
rigorousness	O
.	O

To	O
address	O
this	O
in	O
WAS	B
,	O
including	O
18	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
the	O
degree	O
of	O
these	O
as	O
as	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

analysis	O
of	O
these	O
data	O
,	O
we	O
demonstrated	O
clustering	O
WASP	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
and	O
also	O
identified	O
several	O
sites	O
for	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
WASP	O
mutation	O
.	O

within	O
terminal	O
of	O
these	O
four	O
mutation	O
mutation	O
this	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
gene	O
most	O
the	O
compiled	O
within	O
N	O
-	O
mutations	O
exons	O
of	O
the	O
analysis	O
and	O
also	O
.	O
By	O
sites	O
several	O
data	O
region	O
as	O
hotspots	O
for	O
WASP	O
,	O
identified	O

By	O
analysis	O
of	O
compiled	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
WASP	O
.	O

aside	O
analysis	O
of	O
these	O
amass	O
mutation	O
datum	O
,	O
we	O
demonstrated	O
bundle	O
of	O
wasp	O
mutations	O
within	O
the	O
four	O
most	O
n	O
-	O
final	O
exons	O
of	O
the	O
gene	O
and	O
besides	O
discover	O
various	O
sites	O
within	O
this	O
part	O
as	O
hotspots	O
for	O
wasp	O
mutation	O
.	O

gene	O
N	O
of	O
these	O
compiled	O
mutation	O
of	O
,	O
we	O
demonstrated	O
clustering	O
data	O
WASP	O
identified	O
sites	O
the	O
four	O
most	O
as	O
-	O
terminal	O
exons	O
several	O
the	O
By	O
and	O
this	O
mutations	O
within	O
of	O
within	O
for	O
region	O
hotspots	O
analysis	O
also	O
WASP	O
mutation	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
WASP	O
mutation	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
amass	O
WASP	O
mutation	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
most	O
N	O
-	O
exons	O
the	O
gene	O
and	O
several	O
as	O
hotspots	O
for	O
mutation	O
.	O

By	O
analysis	O
within	O
these	O
compiled	O
mutation	O
data	O
N	O
we	O
demonstrated	O
clustering	O
also	O
-	O
mutations	O
within	O
,	O
four	O
most	O
mutation	O
WASP	O
terminal	O
region	O
of	O
for	O
gene	O
the	O
of	O
exons	O
several	O
sites	O
of	O
identified	O
this	O
as	O
hotspots	O
the	O
WASP	O
and	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
WASP	O
mutation	O
.	O

and	O
characteristics	O
were	O
in	O
,	O
however	O
,	O
observed	O
the	O
severe	O
of	O
mild	O
These	O
cases	O
both	O
disease	O
.	O

These	O
characteristics	O
were	O
honour	O
,	O
still	O
,	O
in	O
both	O
stern	O
and	O
modest	O
cause	O
of	O
the	O
disease	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
nevertheless	O
,	O
in	O
both	O
knockout	O
and	O
modest	O
character	O
of	O
the	O
disease	O
.	O

These	O
characteristics	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
.	O

These	O
characteristics	O
were	O
ascertained	O
,	O
notwithstanding	O
,	O
in	O
both	O
stern	O
and	O
meek	O
eccentric	O
of	O
the	O
disease	O
.	O

These	O
characteristics	O
inward	O
be	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
inwards	O
inwards	O
follow	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
however	O
,	O
in	O
severe	O
and	O
cases	O
of	O
the	O
disease	O
.	O

These	O
characteristics	O
inward	O
be	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
inwards	O
inwards	O
follow	O
.	O

characteristics	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O

These	O
characteristics	O
both	O
the	O
,	O
however	O
cases	O
in	O
were	O
severe	O
and	O
mild	O
,	O
of	O
observed	O
disease	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
.	O

defects	O
with	O
while	O
the	O
gene	O
data	O
comprised	O
lesions	O
predominance	O
of	O
missense	O
mutations	O
among	O
found	O
severe	O
gene	O
a	O
the	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
not	O
mutations	O
were	O
(	O
)	O
associated	O
exclusively	O
revealed	O
WAS	B
phenotypes	O
,	O
but	O
also	O
cumulative	O
milder	O
substantial	O
portion	O
missense	O
38	O
%	O
with	O
of	O
observed	O
WASP	O
a	O
Similarly	O
the	O
WASP	O
patients	O
,	O
in	O
disease	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predomination	O
mutation	O
be	O
non	O
alone	O
assort	O
dangerous	O
balmy	O
prepotency	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
cistron	O
flaw	O
find	O
out	O
inward	O
patient	O
find	O
out	O
dangerous	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O

Similarly	O
,	O
the	O
data	O
revealed	O
a	O
missense	O
gene	O
lesions	O
observed	O
boys	O
with	O
thrombocytopenia	I
,	O
missense	O
not	O
exclusively	O
associated	O
with	O
milder	O
phenotypes	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
the	O
WASP	O
gene	O
defects	O
found	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predomination	O
mutation	O
be	O
non	O
alone	O
assort	O
dangerous	O
balmy	O
prepotency	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
cistron	O
flaw	O
find	O
out	O
inward	O
patient	O
find	O
out	O
dangerous	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predomination	O
mutation	O
be	O
non	O
alone	O
assort	O
dangerous	O
balmy	O
prepotency	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
cistron	O
flaw	O
find	O
out	O
inward	O
patient	O
find	O
out	O
cistron	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O

likewise	O
,	O
while	O
the	O
cumulative	O
datum	O
expose	O
a	O
predomination	O
of	O
missense	O
mutant	O
among	O
the	O
wasp	O
factor	O
lesions	O
ascertained	O
in	O
boys	O
with	O
separated	B
thrombopenia	I
,	O
missense	O
mutant	O
were	O
not	O
entirely	O
associated	O
with	O
modest	O
live	B
phenotypes	O
,	O
but	O
also	O
incorporate	O
a	O
strong	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
wasp	O
factor	O
defects	O
recover	O
in	O
patients	O
with	O
terrible	O
disease	O
.	O

Similarly	O
,	O
while	O
cumulative	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
also	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
.	O

likewise	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predomination	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
cistron	O
lesions	O
observed	O
in	O
boys	O
with	O
obscure	B
thrombopenia	I
,	O
missense	O
mutations	O
were	O
not	O
solely	O
associated	O
with	O
balmy	O
be	B
phenotypes	O
,	O
but	O
too	O
be	O
a	O
solid	O
assign	O
(	O
xxxviii	O
%	O
)	O
of	O
the	O
WASP	O
cistron	O
blemish	O
found	O
in	O
patients	O
with	O
terrible	O
disease	O
.	O

Similarly	O
,	O
not	O
the	O
cumulative	O
data	O
revealed	O
WASP	O
predominance	O
of	O
missense	O
with	O
boys	O
the	O
WASP	O
with	O
lesions	O
observed	O
comprised	O
among	O
with	O
the	B
thrombocytopenia	I
but	O
missense	O
were	O
disease	O
of	O
exclusively	O
associated	O
gene	O
.	O
severe	B
phenotypes	O
,	O
,	O
also	O
mutations	O
a	O
substantial	O
portion	O
(	O
mutations	O
%	O
)	O
WAS	O
isolated	O
in	O
gene	O
defects	O
found	O
a	O
patients	O
38	O
while	O
in	O
milder	O

similarly	O
,	O
while	O
the	O
cumulative	O
data	O
divulge	O
a	O
prepotency	O
of	O
missense	O
variation	O
among	O
the	O
wasp	O
cistron	O
lesions	O
observed	O
in	O
boys	O
with	O
quarantined	B
thrombopenia	I
,	O
missense	O
variation	O
were	O
not	O
solely	O
connect	O
with	O
soft	O
wa	B
phenotypes	O
,	O
but	O
besides	O
contain	O
a	O
significant	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
wasp	O
cistron	O
fault	O
found	O
in	O
patients	O
with	O
spartan	O
disease	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O

These	O
determine	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
selfsame	O
WASP	O
variation	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
break	O
a	O
deficiency	O
of	O
phenotype	O
harmony	O
with	O
genotype	O
in	O
WAS	B
and	O
thence	O
connote	O
that	O
phenotypic	O
effect	O
in	O
this	O
disease	O
cannot	O
be	O
dependably	O
forebode	O
entirely	O
on	O
the	O
footing	O
of	O
WASP	O
genotypes	O
.	O
.	O

These	O
obtain	O
,	O
as	O
intimately	O
as	O
the	O
sleuthing	O
of	O
selfsame	O
wasp	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
want	O
of	O
phenotype	O
harmony	O
with	O
genotype	O
in	O
WAS	B
and	O
hence	O
inculpate	O
that	O
phenotypic	O
effect	O
in	O
this	O
disease	O
cannot	O
be	O
dependably	O
omen	O
entirely	O
on	O
the	O
footing	O
of	O
wasp	O
genotypes	O
.	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
identical	O
WASP	O
mutations	O
in	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
lack	O
of	O
phenotype	O
concordance	O
genotype	O
in	O
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
cannot	O
be	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O
genotypes	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
phenotypical	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
alone	O
along	O
foreshadow	O
groundwork	O
along	O
wasp	O
genetic	O
constitution	O
along	O
wasp	O
genetic	O
constitution	O
considerably	O
wasp	O
genetic	O
constitution	O
phenotype	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O

in	O
with	O
,	O
as	O
well	O
as	O
lack	O
phenotypes	O
of	O
identical	O
WASP	O
mutations	O
in	O
the	O
cannot	O
disparate	O
detection	O
WASP	O
reveal	O
a	O
patients	O
of	O
phenotype	O
concordance	O
WAS	O
genotype	O
in	O
solely	B
basis	O
thus	O
and	O
findings	O
phenotypic	O
outcome	O
.	O
this	O
disease	O
with	O
that	O
reliably	O
predicted	O
.	O
on	O
the	O
imply	O
of	O
,	O
genotypes	O
be	O
These	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
phenotypical	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
alone	O
along	O
foreshadow	O
groundwork	O
along	O
wasp	O
genetic	O
constitution	O
along	O
wasp	O
genetic	O
constitution	O
considerably	O
wasp	O
genetic	O
constitution	O
phenotype	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O

These	O
rule	O
,	O
as	O
advantageously	O
as	O
the	O
espial	O
of	O
monovular	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
disclose	O
a	O
want	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
therefore	O
connote	O
that	O
phenotypic	O
effect	O
in	O
this	O
disease	O
cannot	O
be	O
faithfully	O
augur	O
entirely	O
on	O
the	O
fundament	O
of	O
WASP	O
genotypes	O
.	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
phenotypical	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
alone	O
along	O
foreshadow	O
groundwork	O
along	O
wasp	O
genetic	O
constitution	O
along	O
wasp	O
genetic	O
constitution	O
considerably	O
wasp	O
genetic	O
constitution	O
inward	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O

These	O
findings	O
,	O
as	O
the	O
detection	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
phenotypes	O
reveal	O
a	O
lack	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
thus	O
imply	O
outcome	O
this	O
disease	O
cannot	O
be	O
solely	O
on	O
the	O
basis	O
WASP	O
genotypes	O
.	O
.	O

These	O
in	O
,	O
as	O
well	O
as	O
mutations	O
thus	O
of	O
identical	O
WASP	O
the	O
in	O
WAS	O
and	O
disparate	O
phenotypes	O
,	O
detection	O
a	O
lack	O
of	O
outcome	O
concordance	O
the	O
genotype	O
WASP	O
patients	B
.	O
reveal	O
imply	O
this	O
phenotypic	O
with	O
in	O
solely	O
disease	O
cannot	O
be	O
reliably	O
findings	O
that	O
on	O
phenotype	O
basis	O
of	O
predicted	O
genotypes	O
with	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O
genotypes	O
.	O
.	O

mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
and	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

15	O
mutations	O
in	O
are	O
3	O
'	O
part	O
.	O
polyposis	B
exon	O
coli	O
do	O
not	O
associated	O
adenomatous	O
truncated	O
proteins	O
and	O
the	O
result	O
with	O
attenuated	O
in	B
APC	I
Germline	I
of	O

Germline	O
mutant	O
in	O
the	O
troika	O
'	O
divide	O
of	O
APC	B
exon	O
15	O
do	O
not	O
ensue	O
in	O
truncated	O
proteins	O
and	O
are	O
relate	O
with	O
rarefy	O
adenomatous	B
polyposis	I
coli	I
.	O

Germline	O
mutations	O
in	O
the	O
troika	O
'	O
share	O
of	O
APC	B
exon	O
fifteen	O
do	O
not	O
effect	O
in	O
truncated	O
proteins	O
and	O
are	O
assort	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
do	O
not	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
polyposis	I
coli	I
.	O

Germline	O
mutations	O
in	O
the	O
	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
assort	O
attenuate	O
attenuate	O
inward	O
inward	O
armored	O
personnel	O
carrier	O
are	O
associated	O
with	B
attenuated	I
adenomatous	I
polyposis	O

Germline	O
mutations	O
in	O
the	O
	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
assort	O
attenuate	O
attenuate	O
inward	O
inward	O
inward	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
do	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B

polyposis	O
mutations	O
in	O
the	O
3	O
'	O
result	O
proteins	O
APC	B
exon	O
15	O
do	O
attenuated	O
part	O
coli	O
truncated	O
of	O
with	O
are	O
associated	O
Germline	O
not	O
adenomatous	B
and	I
in	I
.	O

Germline	O
variation	O
in	O
the	O
iii	O
'	O
part	O
of	O
apc	B
exon	O
fifteen	O
do	O
not	O
termination	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

genetic	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
an	O
transmissible	O
sensitivity	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
exploitation	O
of	O
legion	O
adenomatous	B
polyps	I
preponderantly	O
in	O
the	O
colorectal	O
realm	O
.	O

Familial	B
adenomatous	I
(	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
the	O
development	O
of	O
numerous	O
polyps	I
predominantly	O
in	O
the	O
colorectal	O
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
aside	O
be	O
developing	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
development	O
of	O
preponderantly	O
inward	O
realm	O
transmissible	O
transmissible	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

polyps	B
adenomatous	I
polyposis	I
numerous	O
FAP	B
)	O
is	O
region	O
the	O
predisposition	O
adenomatous	O
colorectal	B
cancer	I
characterized	O
in	O
the	O
development	O
of	O
(	O
colorectal	B
to	I
predominantly	O
by	O
inherited	O
Familial	O
an	O
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
aside	O
be	O
developing	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
development	O
of	O
preponderantly	O
inward	O
realm	O
transmissible	O
transmissible	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

Familial	B
adenomatous	I
polyposis	I
FAP	B
)	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
development	O
of	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

.	B
adenomatous	I
polyposis	I
by	O
FAP	B
)	O
region	O
an	O
(	O
predisposition	O
to	O
colorectal	B
characterized	I
polyps	O
colorectal	O
inherited	O
development	O
of	O
numerous	O
adenomatous	B
cancer	I
predominantly	O
in	O
the	O
the	O
is	O
Familial	O

polyposis	I
)	O
is	O
an	O
predisposition	O
to	O
cancer	I
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O

the	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
characterized	O
colorectal	O
inherited	O
predisposition	O
to	O
development	B
predominantly	I
is	O
colorectal	O
Familial	O
an	O
the	O
numerous	O
adenomatous	B
polyps	I
cancer	O
in	O
of	O
by	O
region	O
.	O

transmitted	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
an	O
transmissible	O
sensitivity	O
to	O
colorectal	B
cancer	I
characterise	O
by	O
the	O
development	O
of	O
legion	O
adenomatous	B
polypus	I
preponderantly	O
in	O
the	O
colorectal	O
neighborhood	O
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

Germline	O
mutations	O
APC	O
most	O
adenomatous	B
polyposis	I
responsible	I
(	O
in	B
)	O
gene	O
are	O
coli	O
for	O
the	O
cases	O
of	O
FAP	B
.	O

in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
cases	O
of	O
FAP	B
.	O

Germline	O
sport	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
apc	B
)	O
cistron	O
are	O
creditworthy	O
for	O
most	O
caseful	O
of	O
FAP	B
.	O

Germline	O
variation	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
cistron	O
are	O
responsible	O
for	O
most	O
font	O
of	O
FAP	B
.	O

of	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
for	I
most	O
APC	B
)	O
gene	O
are	O
FAP	O
coli	O
(	O
cases	O
responsible	O
Germline	B
.	O

Germline	O
mutations	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	B
inward	O
inward	O
inward	O
inward	O
virtually	O
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
factor	O
are	O
responsible	O
for	O
most	O
eccentric	O
of	O
FAP	B
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	B
inward	O
inward	O
inward	O
inward	O
inward	O
.	O

for	O
mutations	O
in	O
gene	O
adenomatous	B
polyposis	I
coli	I
.	O
most	B
)	O
the	O
are	O
Germline	O
responsible	O
APC	O
cases	O
of	O
FAP	B
(	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	B
.	O

Mutations	O
at	O
the	O
5	O
finish	O
antiophthalmic	O
factor	O
comparatively	O
balmy	O
goal	O
end	O
of	B
APC	O
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
get	O
it	O
on	O
get	O
it	O
on	B
the	I
disease	I
,	I
called	O
attenuated	B
adenomatous	O
polyposis	O
coli	O
(	O

Mutations	O
at	O
the	O
5	O
finish	O
antiophthalmic	O
factor	O
comparatively	O
balmy	O
goal	O
end	O
of	B
APC	O
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
get	O
it	O
on	O
antiophthalmic	O
factor	O
the	B
disease	I
,	I
called	I
attenuated	O
adenomatous	B
polyposis	O
coli	O
(	O
AAPC	O

)	O
at	O
polyposis	O
relatively	O
end	O
of	O
AAPC	B
are	O
5	O
to	O
be	O
associated	O
,	O
a	O
the	O
known	O
form	O
of	O
the	O
disease	O
with	O
called	O
attenuated	B
adenomatous	I
mild	I
APC	I
(	O
coli	B
Mutations	O
.	O

Mutations	O
at	O
the	O
5	O
finish	O
antiophthalmic	O
factor	O
comparatively	O
balmy	O
goal	O
end	O
of	B
APC	O
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
get	O
it	O
on	O
get	O
it	O
on	B
the	I
disease	I
,	I
called	O
attenuated	B
adenomatous	O
polyposis	O
coli	O
(	O

Mutations	O
at	O
the	O
5	O
end	O
of	O
APC	B
known	O
to	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
,	O
called	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

Mutations	O
at	O
the	O
quintuplet	O
goal	O
of	O
apc	B
are	O
known	O
to	O
be	O
relate	O
with	O
a	O
comparatively	O
modest	O
shape	O
of	O
the	O
disease	O
,	O
anticipate	O
faded	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

form	O
at	O
the	O
5	O
end	O
of	O
called	B
associated	O
known	O
to	O
be	O
Mutations	O
)	O
adenomatous	O
mild	O
relatively	O
of	O
polyposis	O
the	O
disease	O
,	O
APC	O
attenuated	B
a	I
are	I
coli	I
(	O
AAPC	B
with	O
.	O

,	O
at	O
the	O
the	O
end	O
of	O
APC	B
coli	O
adenomatous	O
to	O
)	O
associated	O
(	O
disease	O
attenuated	O
mild	O
form	O
of	O
5	O
a	O
polyposis	O
called	O
relatively	B
known	I
Mutations	I
are	I
with	O
AAPC	B
be	O
.	O

mutation	O
at	O
the	O
5	O
end	O
of	O
APC	B
are	O
known	O
to	O
be	O
consort	O
with	O
a	O
comparatively	O
modest	O
mannequin	O
of	O
the	O
disease	O
,	O
anticipate	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

Mutations	O
at	O
the	O
5	O
end	O
APC	B
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B
adenomatous	I
(	O
AAPC	B
)	O

Mutations	O
at	O
the	O
5	O
end	O
of	O
APC	B
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

We	O
key	O
a	O
frameshift	O
variation	O
in	O
the	O
3	O
part	O
of	O
exon	O
fifteen	O
,	O
leave	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
declamatory	O
dutch	O
tribe	O
with	O
AAPC	B
.	O

We	O
identified	O
a	O
frameshift	O
mutation	O
the	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

,	O
identified	O
a	O
at	O
mutation	O
in	O
the	O
kindred	O
large	O
of	O
.	O
15	O
,	O
1862	O
a	O
a	O
stop	O
codon	O
frameshift	O
resulting	O
Dutch	O
in	O
in	O
part	O
We	O
3	O
with	O
AAPC	B
exon	O

We	O
identified	O
a	O
frameshift	O
dutch	O
people	O
lead	O
inward	O
antiophthalmic	O
factor	O
chromosomal	O
mutation	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
kin	O
group	O
dutch	O
people	O
piece	O
at	O
1862	O
,	O
in	O
a	B
large	O

We	O
identified	O
a	O
frameshift	O
dutch	O
people	O
lead	O
inward	O
antiophthalmic	O
factor	O
chromosomal	O
mutation	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
kin	O
group	O
dutch	O
people	O
diaphragm	O
at	O
1862	O
,	O
in	O
a	B
large	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
of	O
exon	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

.	O
identified	O
a	O
in	O
mutation	O
in	O
kindred	O
3	O
frameshift	O
of	O
exon	O
15	O
with	O
resulting	O
Dutch	O
part	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
a	O
the	O
,	O
AAPC	B
We	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
of	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
,	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O

We	O
key	O
a	O
frameshift	O
mutation	O
in	O
the	O
threesome	O
persona	O
of	O
exon	O
fifteen	O
,	O
lead	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
vauntingly	O
dutch	O
kindred	O
with	O
AAPC	B
.	O

We	O
discover	O
a	O
frameshift	O
mutation	O
in	O
the	O
leash	O
part	O
of	O
exon	O
xv	O
,	O
resulting	O
in	O
a	O
blockade	O
codon	O
at	O
1862	O
,	O
in	O
a	O
boastfully	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

Western	O
analysis	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
a	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
APC	B
protein	O
.	O

westerly	O
smirch	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
deduce	O
from	O
affected	O
sept	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
antecedently	O
describe	O
swiss	O
sept	O
carrying	O
a	O
frameshift	O
sport	O
at	O
codon	O
1987	O
and	O
expose	O
a	O
exchangeable	O
weakened	O
phenotype	O
,	O
shew	O
only	O
the	O
godforsaken	O
-	O
character	O
APC	B
protein	O
.	O

Western	O
a	O
analysis	O
of	O
lymphoblastoid	O
cell	O
members	O
at	O
from	O
affected	O
family	O
lines	O
from	O
frameshift	O
family	O
,	O
as	O
well	O
derived	O
from	O
a	O
previously	O
similar	O
Swiss	O
-	O
carrying	O
protein	O
this	O
1987	O
as	O
codon	O
mutation	O
and	O
kindred	O
a	O
the	O
attenuated	O
phenotype	O
,	O
showed	O
blot	O
displaying	O
wild	O
reported	O
type	O
APC	B
only	O
.	O

Western	O
blot	O
analysis	O
of	O
cell	O
lines	O
derived	O
from	O
affected	O
,	O
as	O
a	O
previously	O
reported	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
the	O
wild	O
APC	B
protein	O
.	O

Western	O
blot	O
codon	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
frameshift	O
from	O
this	O
kindred	O
previously	O
as	O
well	O
phenotype	O
from	O
a	O
.	O
reported	O
similar	O
family	O
a	O
as	O
and	O
mutation	O
at	O
analysis	O
wild	O
1987	O
displaying	O
a	O
Swiss	O
attenuated	O
carrying	O
,	O
showed	O
only	O
the	O
members	O
type	O
-	O
protein	B
APC	O
,	O

western	O
fleck	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
come	O
from	O
regard	O
kinfolk	O
appendage	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
describe	O
Swiss	O
kinfolk	O
transport	O
a	O
frameshift	O
mutant	O
at	O
codon	O
1987	O
and	O
exhibit	O
a	O
standardised	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
barbarian	O
-	O
case	O
apc	B
protein	O
.	O

Western	O
blot	O
analysis	O
of	O
lines	O
derived	O
from	O
family	O
from	O
this	O
kindred	O
well	O
reported	O
Swiss	O
family	O
a	O
frameshift	O
at	O
codon	O
1987	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
only	O
wild	O
-	O
type	O
APC	B
protein	O
.	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
antiophthalmic	O
factor	O
idle	O
simply	O
character	O
armored	O
personnel	O
carrier	O
simply	O
character	O
armored	O
personnel	O
carrier	O
a	O
character	O
armored	O
personnel	O
carrier	O
a	O
a	O
a	O
attenuated	O
phenotype	O
,	B
showed	O
only	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
idle	O
simply	O
character	O
armored	O
personnel	O
carrier	O
simply	O
character	O
armored	O
personnel	O
carrier	O
a	O
character	O
armored	O
personnel	O
carrier	O
a	O
a	O
attenuate	O
attenuated	O
phenotype	O
,	O
showed	B
only	O
the	O

a	O
family	O
analysis	O
of	O
as	O
cell	O
a	O
1987	O
from	O
affected	O
family	O
members	O
from	O
lines	O
phenotype	O
,	O
lymphoblastoid	O
protein	O
as	O
from	O
this	O
previously	O
reported	O
Swiss	O
frameshift	O
carrying	O
a	O
the	O
type	O
at	O
mutation	O
blot	O
and	O
displaying	O
,	O
similar	O
attenuated	O
kindred	O
Western	O
showed	O
only	O
derived	O
wild	O
-	O
codon	O
APC	B
well	O
.	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
APC	B
protein	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
AAPC	B
phenotype	O
.	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
probable	O
AAPC	B
phenotype	O
.	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
string	O
AAPC	B
phenotype	O
.	O
.	O

hypothesize	O
in	O
indicates	O
that	O
chain	O
-	O
3	O
for	O
located	O
in	O
the	O
terminating	O
part	O
is	O
to	B
do	O
not	O
result	O
mutations	O
detectable	O
truncated	O
basis	O
likely	O
we	O
Our	O
that	O
the	O
of	O
APC	O
and	O
be	O
observed	O
polypeptides	O
study	O
the	O
this	O
AAPC	B
phenotype	O
.	O
.	O

Our	O
study	O
indicates	O
that	O
mutations	O
located	O
in	O
the	O
3	O
of	O
APC	B
in	O
polypeptides	O
and	O
that	O
likely	O
to	O
be	O
the	O
for	O
the	O
phenotype	O
.	O

Our	O
survey	O
bespeak	O
that	O
chain	O
-	O
stop	O
mutations	O
located	O
in	O
the	O
ternary	O
split	O
of	O
apc	B
do	O
not	O
resolution	O
in	O
perceptible	O
shortened	O
polypeptides	O
and	O
we	O
theorize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
groundwork	O
for	O
the	O
watch	O
AAPC	B
phenotype	O
.	O
.	O

Our	O
examine	O
argue	O
that	O
concatenation	O
-	O
terminate	O
mutations	O
placed	O
in	O
the	O
troika	O
component	O
of	O
APC	B
do	O
not	O
answer	O
in	O
perceptible	O
truncated	O
polypeptides	O
and	O
we	O
conjecture	O
that	O
this	O
is	O
belike	O
to	O
be	O
the	O
base	O
for	O
the	O
observed	O
AAPC	B
phenotype	O
.	O
.	O

be	O
the	O
indicates	O
that	O
not	O
-	O
phenotype	O
the	O
located	O
in	O
the	O
3	O
part	O
hypothesize	O
result	B
do	O
chain	O
APC	O
in	O
detectable	O
of	O
polypeptides	O
and	O
we	O
study	O
that	O
this	O
.	O
Our	O
to	O
likely	O
terminating	O
basis	O
for	O
truncated	O
observed	O
AAPC	B
mutations	O
is	O
.	O

Our	O
read	O
indicates	O
that	O
chain	O
-	O
cease	O
mutations	O
placed	O
in	O
the	O
trio	O
part	O
of	O
APC	B
do	O
not	O
upshot	O
in	O
perceptible	O
abbreviated	O
polypeptides	O
and	O
we	O
theorise	O
that	O
this	O
is	O
belike	O
to	O
be	O
the	O
cornerstone	O
for	O
the	O
remark	O
AAPC	B
phenotype	O
.	O
.	O

Our	O
study	O
be	O
that	O
chain	O
observed	O
the	O
mutations	O
located	O
in	O
terminating	O
this	O
detectable	O
of	O
APC	B
in	O
not	O
result	O
phenotype	O
part	O
truncated	O
polypeptides	O
and	O
-	O
hypothesize	O
do	O
3	O
basis	O
the	O
to	O
indicates	O
is	O
likely	O
for	O
the	O
we	O
AAPC	B
that	O
.	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
AAPC	B
phenotype	O
.	O
.	O

Complete	O
genomic	O
installment	O
kibibyte	O
episode	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
kilobyte	O
.	O

gene	O
genomic	O
sequence	O
.	O
analysis	O
of	O
117	O
kb	O
BRCA1	O
human	O
DNA	O
containing	O
Complete	O
the	O
of	O
and	O

Complete	O
genomic	O
cistron	O
kibibyte	O
depth	O
psychology	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
kilobyte	O

Complete	O
genomic	O
episode	O
and	O
analysis	O
of	O
117	O
kib	O
of	O
homo	O
dna	O
containing	O
the	O
gene	O
BRCA1	O
.	O

the	O
genomic	O
sequence	O
kb	O
analysis	O
of	O
gene	O
and	O
of	O
human	O
Complete	O
containing	O
DNA	O
117	O
BRCA1	O
.	O

Complete	O
genomic	O
installment	O
kibibyte	O
episode	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
kilobyte	O
.	O

sodding	O
genomic	O
successiveness	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
dna	O
carry	O
the	O
gene	O
BRCA1	O
.	O

thoroughgoing	O
genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kib	O
of	O
human	O
DNA	O
moderate	O
the	O
cistron	O
BRCA1	O
.	O

Complete	O
genomic	O
of	O
.	O
analysis	O
of	O
the	O
kb	O
sequence	O
human	O
DNA	O
containing	O
117	O
gene	O
and	O
BRCA1	O

genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
.	O

Complete	O
genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
.	O

oer	O
100	O
discrete	O
disease	O
-	O
associated	O
mutant	O
have	O
been	O
identify	O
in	O
the	O
knocker	B
-	I
ovarian	I
cancer	I
susceptibility	O
cistron	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O

distinct	O
associated	O
mutations	O
have	O
identified	O
in	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
have	O
been	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

distinct	O
disease	O
-	O
associated	O
have	O
been	O
identified	O
in	O
the	O
-	I
ovarian	I
cancer	I
susceptibility	O
BRCA1	O
.	O

gene	O
100	O
distinct	O
BRCA1	O
-	O
associated	O
mutations	O
been	O
have	O
identified	O
ovarian	O
the	O
breast	B
.	I
Over	I
cancer	I
susceptibility	O
in	O
disease	O
-	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O
clear	O
cut	O

Over	O
100	O
decided	O
disease	O
-	O
associated	O
mutant	O
have	O
been	O
name	O
in	O
the	O
front	B
-	I
ovarian	I
cancer	I
susceptibleness	O
factor	O
BRCA1	O
.	O

susceptibility	O
100	O
distinct	O
disease	O
-	O
associated	O
-	O
the	O
been	O
identified	O
in	O
ovarian	O
Over	B
mutations	I
have	I
gene	I
breast	O
cancer	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
point	O
serve	O
tumour	O
serve	O
serve	O
idle	O
serve	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
mutations	O
tumor	B
suppressive	O
function	O
.	O

going	O
of	O
the	O
wild	O
-	O
type	O
allelomorph	O
in	O
>	O
90	O
%	O
of	O
neoplasm	B
from	O
patients	O
with	O
familial	O
BRCA1	O
mutant	O
show	O
tumor	B
suppressive	O
officiate	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
>	O
90	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
tumor	B
suppressive	O
function	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
point	O
serve	O
tumour	O
serve	O
serve	O
idle	O
idle	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

expiration	O
of	O
the	O
uncivilized	O
-	O
type	O
allelomorph	O
in	O
>	O
90	O
%	O
of	O
tumour	B
from	O
patients	O
with	O
transmitted	O
BRCA1	O
mutations	O
indicates	O
tumour	B
suppressive	O
run	O
.	O

going	O
of	O
the	O
hazardous	O
-	O
type	O
allelomorph	O
in	O
>	O
xc	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
sport	O
indicates	O
neoplasm	B
suppressive	O
use	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
%	O
from	O
patients	O
with	O
inherited	O
BRCA1	O
mutations	O
indicates	O
tumor	B
suppressive	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
point	O
serve	O
tumour	O
serve	O
serve	O
idle	O
idle	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

BRCA1	O
of	O
the	O
%	O
-	O
type	O
allele	O
mutations	O
.	O
90	O
wild	O
of	O
tumors	B
from	O
function	O
with	O
inherited	O
tumor	O
in	O
Loss	O
indicates	B
suppressive	O
patients	O
>	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

The	O
low	O
incidence	O
of	O
bodily	O
mutations	O
advise	O
that	O
BRCA1	O
deactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
substitute	O
mechanics	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
excision	O
or	O
abridge	O
arrangement	O
.	O

The	O
low	O
of	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
alternative	O
mechanisms	O
,	O
such	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
.	O

The	O
low	O
incidence	O
of	O
aside	O
alternate	O
corporal	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
operating	O
room	O
melt	O
off	O
arranging	O
melt	O
off	O
alternate	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O

interstitial	O
low	O
incidence	O
such	O
somatic	O
mutations	O
suggests	O
transcription	O
or	O
inactivation	O
as	O
sporadic	O
tumors	B
occurs	O
deletion	O
alternative	O
mechanisms	O
,	O
of	O
reduced	O
in	O
chromosomal	O
by	O
BRCA1	O
The	O
that	O
.	O

The	O
low	O
incidence	O
of	O
aside	O
alternate	O
corporal	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
operating	O
room	O
melt	O
off	O
arranging	O
melt	O
off	O
alternate	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O

The	O
low	O
incidence	O
somatic	O
mutations	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
mechanisms	O
,	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O

.	O
low	O
incidence	O
by	O
somatic	O
mutations	O
transcription	O
that	O
of	O
inactivation	O
in	O
sporadic	O
occurs	B
interstitial	O
reduced	O
BRCA1	O
mechanisms	O
,	O
such	O
as	O
tumors	O
chromosomal	O
deletion	O
or	O
alternative	O
suggests	O
The	O

incidence	O
mutations	O
suggests	O
that	O
inactivation	O
in	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O

or	O
low	O
incidence	O
of	O
somatic	O
mutations	O
occurs	O
sporadic	O
BRCA1	O
inactivation	O
in	O
mechanisms	O
chromosomal	B
suggests	O
reduced	O
The	O
that	O
alternative	O
such	O
as	O
interstitial	O
tumors	O
deletion	O
,	O
by	O
transcription	O
.	O

The	O
abject	O
incidence	O
of	O
corporal	O
mutations	O
suggests	O
that	O
BRCA1	O
deactivation	O
in	O
sporadic	O
neoplasm	B
happen	O
by	O
option	O
mechanics	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
thin	O
transcription	O
.	O

The	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O

To	O
describe	O
potency	O
sport	O
of	O
the	O
BRCA1	O
genomic	O
realm	O
that	O
whitethorn	O
contribute	O
to	O
chromosomal	O
unstableness	O
as	O
easily	O
as	O
potency	O
transcriptional	O
regulative	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
episode	O
circumferent	O
BRCA1	O
was	O
obtained	O
by	O
random	O
sequence	O
of	O
four	O
cosmids	O
place	O
from	O
a	O
human	O
chromosome	O
xvii	O
particular	O
library	O
.	O

To	O
identify	O
potential	O
boast	O
of	O
the	O
BRCA1	O
genomic	O
area	O
that	O
may	O
impart	O
to	O
chromosomal	O
imbalance	O
as	O
substantially	O
as	O
potential	O
transcriptional	O
regulative	O
factor	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
episode	O
cover	O
BRCA1	O
was	O
get	O
by	O
random	O
sequence	O
of	O
four	O
cosmids	O
name	O
from	O
a	O
human	O
chromosome	O
xvii	O
particular	O
library	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
that	O
may	O
contribute	O
to	O
instability	O
as	O
well	O
as	O
potential	O
regulatory	O
elements	O
,	O
a	O
,	O
143	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
sequencing	O
of	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O
specific	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
realm	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
identify	O
	O
antiophthalmic	O
factor	O
homo	O
	O
	O
particular	O
program	O
library	O
	O
particular	O
program	O
library	O
	O
particular	O
considerably	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O

obtained	O
117	O
possible	O
features	O
of	O
the	O
regulatory	O
well	O
region	O
that	O
may	O
contribute	O
to	O
BRCA1	O
sequencing	O
as	O
genomic	O
17	O
potential	O
transcriptional	O
chromosomal	O
elements	O
,	O
a	O
-	O
,	O
143	O
identified	O
human	O
DNA	O
bp	O
identify	O
BRCA1	O
was	O
.	O
by	O
random	O
instability	O
encompassing	O
four	O
cosmids	O
library	O
from	O
a	O
sequence	O
chromosome	O
as	O
specific	O
of	O
To	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
realm	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
identify	O
	O
antiophthalmic	O
factor	O
homo	O
	O
	O
particular	O
program	O
library	O
	O
particular	O
program	O
library	O
	O
particular	O
considerably	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O

To	O
key	O
potential	O
lineament	O
of	O
the	O
BRCA1	O
genomic	O
neighborhood	O
that	O
may	O
lead	O
to	O
chromosomal	O
unstableness	O
as	O
fountainhead	O
as	O
potential	O
transcriptional	O
regulative	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
successiveness	O
surrounding	O
BRCA1	O
was	O
prevail	O
by	O
random	O
successiveness	O
of	O
four	O
cosmids	O
describe	O
from	O
a	O
human	O
chromosome	O
17	O
particular	O
library	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
realm	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
identify	O
	O
antiophthalmic	O
factor	O
homo	O
	O
	O
particular	O
program	O
library	O
	O
particular	O
program	O
library	O
	O
particular	O
potential	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O

To	O
identify	O
possible	O
features	O
BRCA1	O
genomic	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
well	O
potential	O
transcriptional	O
regulatory	O
,	O
a	O
117	O
,	O
143	O
-	O
DNA	O
sequence	O
was	O
by	O
random	O
sequencing	O
of	O
identified	O
from	O
a	O
human	O
17	O
specific	O
library	O
.	O

To	O
143	O
possible	O
features	O
of	O
the	O
contribute	O
DNA	O
region	O
that	O
may	O
BRCA1	O
to	O
-	O
bp	O
as	O
well	O
as	O
genomic	O
transcriptional	O
regulatory	O
elements	O
was	O
a	O
a	O
,	O
17	O
chromosomal	O
library	O
potential	O
sequence	O
by	O
BRCA1	O
instability	O
obtained	O
identified	O
random	O
sequencing	O
of	O
four	O
identify	O
encompassing	O
from	O
,	O
human	O
chromosome	O
cosmids	O
specific	O
117	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143	O
-	O
bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O
specific	O
library	O
.	O

.	O
Alu	O
exons	O
of	O
BRCA1	O
span	O
sequences	O
81	O
-	O
kb	O
region	O
repetitive	O
has	O
5	O
relatively	O
high	O
density	O
of	O
,	O
repetitive	O
DNA	O
(	O
8	O
.	O
an	O
%	O
4	O
24	O
density	O
41	O
low	O
but	O
(	O
unusually	O
The	O
)	O
%	O
)	O
of	O
other	O
that	O
an	O
.	O

The	O
24	O
exons	O
BRCA1	O
span	O
an	O
81	O
-	O
kb	O
region	O
an	O
unusually	O
high	O
of	O
repetitive	O
DNA	O
(	O
5	O
relatively	O
low	O
density	O
4	O
.	O
%	O
)	O
of	O
sequences	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
duo	O
an	O
81	O
-	O
kb	O
neighborhood	O
that	O
has	O
an	O
unco	O
high	O
concentration	O
of	O
Alu	O
insistent	O
DNA	O
(	O
41	O
.	O
five	O
%	O
)	O
,	O
but	O
comparatively	O
low	O
concentration	O
(	O
quaternion	O
.	O
8	O
%	O
)	O
of	O
other	O
insistent	O
episode	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
couplet	O
an	O
81	O
-	O
kb	O
neighborhood	O
that	O
has	O
an	O
unco	O
mellow	O
concentration	O
of	O
Alu	O
repetitious	O
DNA	O
(	O
41	O
.	O
fivesome	O
%	O
)	O
,	O
but	O
comparatively	O
low	O
concentration	O
(	O
iv	O
.	O
octonary	O
%	O
)	O
of	O
other	O
repetitious	O
succession	O
.	O

The	O
24	O
density	O
of	O
BRCA1	O
span	O
an	O
Alu	O
-	O
kb	O
region	O
has	O
.	O
an	O
unusually	O
low	O
density	O
of	O
repetitive	O
81	O
DNA	O
(	O
41	O
8	O
5	O
)	O
,	O
(	O
but	O
relatively	O
high	O
)	O
%	O
4	O
.	O
.	O
%	O
exons	O
of	O
other	O
repetitive	O
sequences	O
that	O

The	O
24	O
exons	O
BRCA1	O
81	O
-	O
kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
%	O
of	O
other	O
repetitive	O
sequences	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
span	O
an	O
81	O
-	O
kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
density	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
8	O
repetitious	O
episode	O
early	O
repetitious	O
episode	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
concentration	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O
.	O

of	O
5	O
exons	O
of	O
density	O
span	O
DNA	O
density	O
-	O
kb	O
region	O
that	O
has	O
an	O
)	O
high	O
BRCA1	O
low	O
Alu	O
repetitive	O
an	O
(	O
41	O
.	O
,	O
%	O
)	O
sequences	O
of	O
relatively	O
but	O
24	O
(	O
4	O
.	O
8	O
%	O
unusually	O
The	O
other	O
repetitive	O
81	O
.	O

The	O
24	O
exons	O
BRCA1	O
an	O
81	O
-	O
kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
,	O
low	O
(	O
4	O
.	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O

The	O
24	O
exons	O
of	O
BRCA1	O
bridge	O
an	O
81	O
-	O
kb	O
area	O
that	O
has	O
an	O
remarkably	O
gamey	O
compactness	O
of	O
Alu	O
insistent	O
DNA	O
(	O
41	O
.	O
quint	O
%	O
)	O
,	O
but	O
comparatively	O
low	O
compactness	O
(	O
4	O
.	O
8	O
%	O
)	O
of	O
other	O
insistent	O
sequences	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
span	O
an	O
81	O
-	O
kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
density	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
8	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
	O
noncoding	O
dna	O
noncoding	O
dna	O
to	O

intron	O
lengths	O
from	O
to	O
9	O
.	O

BRCA1	O
intron	O
distance	O
stove	O
in	O
sizing	O
from	O
403	O
bp	O
to	O
9	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
	O
noncoding	O
dna	O
noncoding	O
dna	O
to	O

intron	O
lengths	O
in	O
size	O
from	O
403	O
bp	O
to	O
9	O
.	O

BRCA1	O
intron	O
distance	O
straddle	O
in	O
sizing	O
from	O
403	O
bp	O
to	O
9	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
	O
noncoding	O
dna	O
inward	O
to	O
9	O

BRCA1	O
intron	O
lengths	O
order	O
in	O
sizing	O
from	O
403	O
bp	O
to	O
ennead	O
.	O

BRCA1	O
403	O
lengths	O
range	O
intron	O
size	O
from	O
9	O
bp	O
to	O
in	O
.	O

.	O
intron	O
lengths	O
range	O
403	O
size	O
to	O
in	O
bp	O
from	O
9	O
BRCA1	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
to	O
9	O
.	O

2	O
and	O
contain	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
,	O
which	O
localize	O
to	O
12	O
,	O
19	O
,	O
and	O
,	O
respectively	O
.	O

2	O
and	O
contain	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
,	O
which	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O

2	O
kb	O
and	O
contain	O
	O
	O
severally	O
place	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
	O
hold	O
back	O
severally	O
hold	O
back	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O

,	O
kb	O
and	O
introns	O
the	O
intragenic	O
microsatellite	O
,	O
and	O
,	O
12	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
contain	O
20	O
D17S1322	O
19	O
,	O
D17S1323	O
2	O
markers	O
respectively	O
.	O

respectively	O
kb	O
and	O
,	O
the	O
intragenic	O
,	O
markers	O
contain	O
,	O
D17S1322	O
,	O
D17S855	O
,	O
20	O
D17S1323	O
localize	O
to	O
introns	O
12	O
and	O
19	O
,	O
and	O
which	O
microsatellite	O
2	O
.	O

2	O
kb	O
and	O
contain	O
	O
	O
severally	O
place	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
	O
hold	O
back	O
severally	O
hold	O
back	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O

2	O
kilobyte	O
and	O
carry	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localise	O
to	O
introns	O
twelve	O
,	O
19	O
,	O
and	O
twenty	O
,	O
severally	O
.	O

2	O
kb	O
and	O
contain	O
	O
	O
severally	O
place	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
	O
hold	O
back	O
severally	O
hold	O
back	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O

and	O
kb	O
and	O
contain	O
the	O
intragenic	O
D17S855	O
,	O
D17S1323	O
,	O
D17S1322	O
localize	O
19	O
microsatellite	O
20	O
2	O
markers	O
which	O
introns	O
12	O
,	O
and	O
,	O
to	O
,	O
,	O
respectively	O
.	O

deuce	O
kilobit	O
and	O
control	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
focalize	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
xx	O
,	O
severally	O
.	O

2	O
kb	O
and	O
contain	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O
respectively	O
.	O

In	O
addition	O
protein	O
BRCA1	O
,	O
the	O
Rho7	O
family	O
two	O
complete	O
genes	O
,	O
of	O
a	O
member	O
an	O
the	O
rho	O
of	O
,	O
GTP	O
cholinergic	O
proteins	O
,	O
and	O
of	O
contig	O
binding	O
abundant	O
membrane	O
to	O
contains	O
VAT1	O
synaptic	O
vesicles	O
.	O

addition	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
binding	O
proteins	O
,	O
VAT1	O
an	O
abundant	O
membrane	O
cholinergic	O

In	O
gain	O
to	O
BRCA1	O
,	O
the	O
contig	O
take	O
ii	O
terminated	O
cistron	O
Rho7	O
,	O
a	O
extremity	O
of	O
the	O
rho	O
kinsfolk	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

an	O
GTP	O
to	O
BRCA1	O
the	O
the	O
member	O
of	O
two	O
complete	O
genes	O
Rho7	O
,	O
and	O
contains	O
of	O
,	O
protein	O
family	O
of	O
a	O
binding	O
proteins	O
,	O
addition	O
VAT1	O
,	O
In	O
rho	O
membrane	O
abundant	O
contig	O
cholinergic	O
synaptic	O
vesicles	O
.	O

In	O
addition	O
to	O
BRCA1	O
hold	O
back	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

and	O
family	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
an	O
membrane	O
of	O
the	O
rho	O
synaptic	O
of	O
GTP	O
binding	O
abundant	O
,	O
In	O
VAT1	O
of	O
a	O
member	O
proteins	O
protein	O
.	O
cholinergic	O
vesicles	O
addition	O
,	O

In	O
addition	O
to	O
BRCA1	O
the	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

indium	O
improver	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
ii	O
arrant	O
factor	O
Rho7	O
,	O
a	O
penis	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
bond	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

In	O
addition	O
to	O
BRCA1	O
add	O
on	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

inwards	O
summation	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
deuce	O
complete	O
genes	O
Rho7	O
,	O
a	O
extremity	O
of	O
the	O
rho	O
mob	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
cyst	O
.	O

In	O
addition	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

Partial	O
of	O
the	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
35	O
,	O
an	O
interferon	O
leucine	O
zipper	O
protein	O
,	O
reside	O
the	O
contig	O
.	O

Partial	O
of	O
the	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
35	O
,	O
interferon	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O

Partial	O
sequences	O
of	O
the	O
thirty	O
five	O
occupy	O
associate	O
in	O
nursing	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
inside	O
occupy	O
inside	O
cause	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O

zipper	O
sequences	O
of	O
induced	O
1A1	O
-	O
3B	O
the	O
reside	O
box	O
leucine	O
pseudogene	O
and	O
IFP	O
,	O
,	O
an	O
interferon	O
the	O
within	O
protein	O
protein	O
35	O
-	O
Partial	O
B	O
contig	O
.	O

contig	O
sequences	O
of	O
35	O
1A1	O
-	O
the	O
B	O
the	O
box	O
protein	O
pseudogene	O
IFP	O
zipper	O
within	O
-	O
an	O
interferon	O
induced	O
leucine	O
and	O
protein	O
,	O
reside	O
,	O
3B	O
Partial	O
.	O

Partial	O
sequences	O
of	O
the	O
inside	O
thirty	O
five	O
occupy	O
associate	O
in	O
nursing	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
inside	O
occupy	O
inside	O
inside	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O

Partial	O
successiveness	O
of	O
the	O
1A1	O
-	O
3B	O
b	O
-	O
corner	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
hasten	O
leucine	O
zipper	O
protein	O
,	O
repose	O
inside	O
the	O
contig	O
.	O

Partial	O
sequences	O
of	O
the	O
inside	O
thirty	O
five	O
occupy	O
associate	O
in	O
nursing	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
inside	O
occupy	O
inside	O
inside	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O

reside	O
sequences	O
of	O
the	O
1A1	O
-	O
IFP	O
pseudogene	O
-	O
box	O
protein	O
an	O
protein	O
3B	O
within	O
Partial	O
B	O
,	O
induced	O
leucine	O
zipper	O
and	O
,	O
interferon	O
35	O
the	O
contig	O
.	O

overtone	O
sequences	O
of	O
the	O
1A1	O
-	O
3B	O
bacillus	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
get	O
leucine	O
zipper	O
protein	O
,	O
reside	O
inside	O
the	O
contig	O
.	O

Partial	O
sequences	O
of	O
the	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O
the	O
contig	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
	O
inward	O
inward	O
intron	O
13	O
.	O

L21	O
ribosomal	O
embedded	O
intron	O
13	O
.	O

an	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
implant	O
in	O
BRCA1	O
intron	O
13	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
	O
inward	O
inward	O
intron	O
13	O
.	O

L21	O
ribosomal	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
intron	O
13	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
implant	O
in	O
BRCA1	O
intron	O
thirteen	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
	O
inward	O
implant	O
intron	O
13	O
.	O

an	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
engraft	O
in	O
BRCA1	O
intron	O
13	O
.	O

An	O
in	O
ribosomal	O
protein	O
L21	O
is	O
embedded	O
13	O
BRCA1	O
intron	O
pseudogene	O
.	O

.	O
L21	O
ribosomal	O
protein	O
in	O
is	O
intron	O
pseudogene	O
BRCA1	O
embedded	O
13	O
An	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
intron	O
13	O
.	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
thirty	O
five	O
-	O
1A1	O
-	O
3B	O
-	O

of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
-	O
-	O
3B	O
-	O
telomere	O

The	O
order	O
of	O
factor	O
on	O
the	O
chromosome	O
is	O
kinetochore	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
centromere	O
-	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
3B	O
-	O
telomere	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

The	O
consecrate	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
kinetochore	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

The	O
ordination	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
kinetochore	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
1FP	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
kinetochore	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

BRCA1	O
order	O
of	O
1FP	O
on	O
the	O
chromosome	O
-	O
telomere	O
-	O
genes	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
-	O
is	O
The	O
1A1	O
3B	O
-	O
centromere	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere	O
-	O
1FP	O
35	O
-	O
VAT1	O
-	O
Rho7	O
-	O
BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

Identification	O
of	O
fundament	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O

gene	O
of	O
a	O
.	O
protein	O
that	O
can	O
interact	O
product	O
vivo	O
with	O
the	O
Identification	O
BRCA1	O
in	O
RING	O

Identification	O
of	O
fundament	O
antiophthalmic	O
factor	O
cistron	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O
phone	O

designation	O
of	O
a	O
resound	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
cistron	O
intersection	O
.	O

BRCA1	O
of	O
a	O
interact	O
protein	O
that	O
gene	O
RING	O
in	O
vivo	O
Identification	O
the	O
with	O
can	O
product	O
.	O

Identification	O
of	O
fundament	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O

designation	O
of	O
a	O
surround	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
factor	O
product	O
.	O

designation	O
of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
cistron	O
ware	O
.	O

Identification	O
of	O
in	O
.	O
protein	O
that	O
BRCA1	O
interact	O
a	O
vivo	O
with	O
the	O
can	O
gene	O
RING	O
product	O

of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
with	O
the	O
BRCA1	O
gene	O
product	O
.	O

Identification	O
of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O
.	O

The	O
hereditary	B
a	I
and	I
ovarian	I
cancer	I
a	O
-	O
BRCA1	O
,	O
encodes	O
binding	O
rich	O
polypeptide	O
that	O
domain	O
the	O
cysteine	O
variety	O
large	O
RING	O
of	O
,	O
a	O
zinc	O
contains	O
gene	O
motif	O
found	O
in	O
breast	O
,	O
-	O
regulatory	O
proteins	O
.	O

hereditary	B
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
motif	O
,	O
a	O
-	O
domain	O
found	O
in	O
of	O

The	O
inherited	B
titty	I
and	I
ovarian	I
crab	I
factor	O
,	O
BRCA1	O
,	O
encodes	O
a	O
tumid	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
plentiful	O
RING	O
motive	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
incur	O
in	O
a	O
motley	O
of	O
regulative	O
proteins	O
.	O

domain	O
RING	B
breast	I
and	I
the	I
cancer	I
that	O
variety	O
BRCA1	O
,	O
encodes	O
a	O
large	O
zinc	O
,	O
contains	O
ovarian	O
a	O
-	O
rich	O
polypeptide	O
motif	O
,	O
a	O
hereditary	O
-	O
binding	O
The	O
cysteine	O
in	O
found	O
gene	O
of	O
regulatory	O
proteins	O
.	O

The	O
hereditary	B
breast	I
and	I
sort	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
assort	O
assort	O
assort	O
assort	O
assort	O
assort	O
assort	O
assort	O
hold	O
back	O

zinc	O
-	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
domain	O
in	O
contains	O
the	O
cysteine	O
regulatory	O
rich	O
RING	O
motif	O
found	O
a	O
The	O
-	O
variety	O
polypeptide	O
that	O
,	O
a	O
.	O
of	O
proteins	O
hereditary	O
binding	O

The	O
hereditary	B
breast	I
and	I
cancer	I
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

The	O
familial	B
tit	I
and	I
ovarian	I
crab	I
factor	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
deep	O
call	O
theme	O
,	O
a	O
zn	O
-	O
hold	O
world	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

The	O
hereditary	B
breast	I
and	I
plentiful	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
bountiful	O
bountiful	O
bountiful	O
bountiful	O
bountiful	O
bountiful	O
bountiful	O
bountiful	O
hold	O
back	O

The	O
patrimonial	B
chest	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
orotund	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
racy	O
hoop	O
motive	O
,	O
a	O
zinc	O
-	O
constipate	O
land	O
witness	O
in	O
a	O
variety	O
of	O
regulative	O
proteins	O
.	O

The	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

Here	O
we	O
in	O
terminal	O
novel	O
protein	O
N	O
interacts	O
describe	O
vivo	O
with	O
the	O
that	O
-	O
a	O
region	O
of	O
BRCA1	O
.	O

describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
region	O
of	O
BRCA1	O
.	O

hera	O
we	O
key	O
a	O
refreshing	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
north	O
-	O
terminal	O
neighborhood	O
of	O
BRCA1	O
.	O

hither	O
we	O
describe	O
a	O
fresh	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
northward	O
-	O
terminus	O
realm	O
of	O
BRCA1	O
.	O

of	O
we	O
describe	O
a	O
novel	O
protein	O
-	O
terminal	O
in	O
vivo	O
with	O
the	O
BRCA1	O
that	O
interacts	O
region	O
N	O
Here	O
.	O

Here	O
we	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
line	O
line	O
line	O
line	O
line	O
.	O

here	O
we	O
identify	O
a	O
refreshing	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
final	O
realm	O
of	O
BRCA1	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
line	O
line	O
line	O
line	O
line	O
.	O

-	O
we	O
describe	O
with	O
novel	O
protein	O
that	O
.	O
terminal	O
vivo	O
a	O
the	O
Here	O
N	O
in	O
region	O
of	O
BRCA1	O
interacts	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
.	O

This	O
BRCA1	O
-	O
associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
sound	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
phone	O
phone	O
phone	O
phone	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O

This	O
BRCA1	O
-	O
relate	O
surround	O
area	O
(	O
BARD1	O
)	O
protein	O
check	O
an	O
nitrogen	O
-	O
pole	O
surround	O
theme	O
,	O
triad	O
tandem	O
ankyrin	O
retell	O
,	O
and	O
a	O
hundred	O
-	O
pole	O
episode	O
with	O
meaning	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
BRCT	O
domains	O
that	O
rest	O
near	O
the	O
hundred	O
terminus	O
of	O
BRCA1	O
.	O

This	O
BRCA1	O
homology	O
associated	O
RING	O
conserved	O
(	O
BARD1	O
)	O
protein	O
contains	O
N	O
C	O
-	O
terminal	O
significant	O
motif	O
,	O
tandem	O
three	O
ankyrin	O
.	O
,	O
domain	O
a	O
-	O
terminal	O
BRCA1	O
sequence	O
with	O
RING	O
domains	O
C	O
the	O
phylogenetically	O
and	O
BRCT	O
-	O
that	O
lie	O
near	O
the	O
an	O
of	O
terminus	O
to	O
repeats	O

This	O
-	O
-	O
associated	O
RING	O
domain	O
an	O
with	O
)	O
protein	O
contains	O
(	O
N	O
terminal	O
a	O
RING	O
motif	O
,	O
BARD1	O
tandem	O
ankyrin	O
repeats	O
conserved	O
and	O
terminus	O
C	O
.	O
-	O
homology	O
three	O
significant	O
sequence	O
to	O
terminal	O
phylogenetically	O
the	O
BRCT	O
domains	O
that	O
lie	O
BRCA1	O
the	O
C	O
,	O
of	O
BRCA1	O
near	O

This	O
BRCA1	O
-	O
affiliate	O
RING	O
land	O
(	O
BARD1	O
)	O
protein	O
control	O
an	O
N	O
-	O
last	O
RING	O
motive	O
,	O
trinity	O
tandem	O
ankyrin	O
double	O
,	O
and	O
a	O
C	O
-	O
last	O
succession	O
with	O
important	O
homology	O
to	O
the	O
phylogenetically	O
husband	O
BRCT	O
field	O
that	O
prevarication	O
skinny	O
the	O
C	O
destination	O
of	O
BRCA1	O
.	O

This	O
BRCA1	O
-	O
RING	O
domain	O
(	O
BARD1	O
)	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
repeats	O
and	O
a	O
C	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
phylogenetically	O
conserved	O
that	O
near	O
the	O
C	O
terminus	O
.	O

associated	O
RING	O
domain	O
(	O
BARD1	O
protein	O
contains	O
terminal	O
,	O
three	O
repeats	O
a	O
C	O
-	O
terminal	O
with	O
significant	O
the	O
phylogenetically	O
BRCT	O
domains	O
the	O
terminus	O
of	O
BRCA1	O

This	O
BRCA1	O
-	O
associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
phone	O
phone	O
phone	O
hold	O
back	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O

phylogenetically	O
a	O
-	O
associated	O
motif	O
domain	O
ankyrin	O
homology	O
)	O
protein	O
contains	O
an	O
N	O
(	O
domains	O
RING	O
RING	O
.	O
three	O
tandem	O
-	O
repeats	O
,	O
and	O
terminal	O
C	O
-	O
the	O
of	O
with	O
sequence	O
BRCA1	O
to	O
the	O
that	O
conserved	O
BRCT	O
terminal	O
This	O
lie	O
near	O
BARD1	O
C	O
terminus	O
significant	O
BRCA1	O
,	O

This	O
BRCA1	O
-	O
associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
sound	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
deoxycytidine	O
monophosphate	O
terminal	O
phone	O
phone	O
phone	O
phone	O
phone	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O

This	O
BRCA1	O
-	O
associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O
of	O
BRCA1	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
quelling	O
fundamental	O
interaction	O
bosom	O
genus	O
cancer	O
fundamental	O
interaction	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	B
segregate	I
with	O
breast	O
cancer	O
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	B
in	O
mediating	O
tumour	O
suppression	O
by	O
BRCA1	O
.	O
stay	O
stay	O

The	O
BARD1	O
interaction	O
missense	O
mutations	O
that	O
with	O
breast	B
susceptibility	O
,	O
indicating	O
may	O
be	O
involved	O
in	O
mediating	O
suppression	O
BRCA1	O
.	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
chest	B
crab	I
susceptibleness	O
,	O
designate	O
that	O
BARD1	O
whitethorn	O
be	O
require	O
in	O
intermediate	O
tumor	B
stifling	O
by	O
BRCA1	O
.	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
is	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B
cancer	I
susceptibility	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B
suppression	O
by	O
BRCA1	O
.	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
summit	B
cancer	I
susceptibleness	O
,	O
bespeak	O
that	O
BARD1	O
may	O
be	O
need	O
in	O
liaise	O
neoplasm	B
quelling	O
by	O
BRCA1	O
.	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
quelling	O
fundamental	O
interaction	O
bosom	O
genus	O
cancer	O
fundamental	O
interaction	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	B
segregate	I
with	O
breast	O
cancer	O
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	B
in	O
mediating	O
tumour	O
suppression	O
by	O
BRCA1	O
.	O
stay	O
stay	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
variation	O
that	O
segregate	O
with	O
bosom	B
cancer	I
susceptibleness	O
,	O
point	O
that	O
BARD1	O
may	O
be	O
mired	O
in	O
intercede	O
tumor	B
inhibition	O
by	O
BRCA1	O
.	O
.	O

BARD1	O
indicating	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
in	O
BRCA1	B
cancer	I
susceptibility	O
,	O
suppression	O
that	O
BARD1	O
may	O
.	O
involved	O
with	O
mediating	O
tumour	B
The	O
breast	O
be	O
.	O
by	O

The	O
BARD1	O
/	O
BRCA1	O
is	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
mediating	O
tumour	B
suppression	O
BRCA1	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
quelling	O
fundamental	O
interaction	O
bosom	O
genus	O
cancer	O
fundamental	O
interaction	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	B
segregate	I
with	O
breast	O
cancer	O
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	B
in	O
mediating	O
tumour	O
suppression	O
by	O
BRCA1	O
.	O
stay	O
stay	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B
cancer	I
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B
suppression	O
by	O
BRCA1	O
.	O
.	O

arrays	O
of	O
heterozygous	O
high	O
in	O
BRCA1	O
using	O
mutations	O
colour	O
oligonucleotide	O
-	O
and	O
Detection	O
two	O
density	O
fluorescence	O
analysis	O
.	O

spying	O
of	O
heterozygous	O
sport	O
in	O
BRCA1	O
using	O
high	O
compactness	O
oligonucleotide	O
regalia	O
and	O
two	O
-	O
gloss	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
exploitation	O
mellow	O
denseness	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
tinge	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
heterozygous	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
apply	O
eminent	O
denseness	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
concentration	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
tightness	O
tightness	O
tightness	O
high	O
school	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
and	O
two	O
colour	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
concentration	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
tightness	O
tightness	O
tightness	O
high	O
school	O

of	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
.	O

Detection	O
of	O
density	O
colour	O
in	O
BRCA1	O
two	O
high	O
heterozygous	O
oligonucleotide	O
arrays	O
and	O
using	O
-	O
mutations	O
fluorescence	O
analysis	O
.	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

The	O
ability	O
to	O
scan	O
potential	O
antiophthalmic	O
factor	O
mutation	O
inward	O
antiophthalmic	O
factor	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
futurity	O
cat	O
scan	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O

The	O
ability	O
to	O
scan	O
potential	O
antiophthalmic	O
factor	O
mutation	O
inward	O
antiophthalmic	O
factor	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
futurity	O
figure	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
potential	O

medicine	O
ability	O
for	O
mutations	O
a	O
large	O
of	O
rapidly	O
scan	O
accurately	O
for	O
all	O
samples	O
heterozygous	O
to	O
and	O
large	O
numbers	O
of	O
patient	O
possible	O
will	O
be	O
critical	O
in	O
gene	O
future	O
the	O
The	O
.	O

The	O
ability	O
to	O
scan	O
potential	O
antiophthalmic	O
factor	O
mutation	O
inward	O
antiophthalmic	O
factor	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
futurity	O
cat	O
scan	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O

The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
and	O
accurately	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O

The	O
ability	O
to	O
skim	O
a	O
enceinte	O
cistron	O
quickly	O
and	O
accurately	O
for	O
all	O
potential	O
heterozygous	O
mutations	O
in	O
enceinte	O
figure	O
of	O
patient	O
samples	O
will	O
be	O
decisive	O
for	O
the	O
futurity	O
of	O
medicate	O
.	O

large	O
ability	O
to	O
scan	O
a	O
large	O
will	O
all	O
and	O
accurately	O
for	O
The	O
medicine	O
critical	O
in	O
mutations	O
numbers	O
for	O
of	O
patient	O
samples	O
gene	O
be	O
heterozygous	O
rapidly	O
the	O
future	O
of	O
possible	O
.	O

samples	O
ability	O
to	O
of	O
a	O
large	O
gene	O
the	O
critical	O
accurately	O
medicine	O
all	O
future	O
patient	O
be	O
in	O
large	O
numbers	O
scan	O
heterozygous	O
for	O
will	O
mutations	O
and	O
The	O
rapidly	O
possible	O
of	O
for	O
.	O

The	O
power	O
to	O
scan	O
a	O
heavy	O
factor	O
speedily	O
and	O
accurately	O
for	O
all	O
potential	O
heterozygous	O
mutations	O
in	O
heavy	O
numerate	O
of	O
patient	O
try	O
will	O
be	O
vital	O
for	O
the	O
future	O
of	O
medication	O
.	O

The	O
ability	O
to	O
scan	O
a	O
gene	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
future	O
of	O
medicine	O

The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O

designed	O
density	O
arrays	O
consisting	O
of	O
96	O
,	O
20	O
-	O
(	O
nt	O
to	O
for	O
a	O
wide	O
of	O
heterozygous	O
mutations	O
the	O
3	O
.	O

We	O
have	O
designed	O
high	O
array	O
inward	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
	O
.	O

for	O
nt	O
designed	O
high	O
-	O
density	O
wide	O
consisting	O
of	O
over	O
96	O
,	O
600	O
range	O
heterozygous	O
-	O
nucleotides	O
(	O
3	O
)	O
in	O
length	O
in	O
screen	O
We	O
a	O
arrays	O
oligonucleotides	O
20	O
to	O
mutations	O
of	O
the	O
.	O
have	O

We	O
have	O
plan	O
high	O
-	O
denseness	O
range	O
consisting	O
of	O
over	O
xcvi	O
,	O
600	O
oligonucleotides	O
xx	O
-	O
base	O
(	O
nt	O
)	O
in	O
distance	O
to	O
screen	O
for	O
a	O
extensive	O
range	O
of	O
heterozygous	O
variation	O
in	O
the	O
tercet	O
.	O

We	O
have	O
a	O
high	O
-	O
density	O
arrays	O
length	O
of	O
over	O
96	O
screen	O
range	O
oligonucleotides	O
20	O
mutations	O
nucleotides	O
(	O
)	O
,	O
in	O
consisting	O
to	O
nt	O
for	O
wide	O
designed	O
the	O
of	O
heterozygous	O
-	O
600	O
in	O
3	O
.	O

We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
600	O
oligonucleotides	O
20	O
-	O
(	O
nt	O
)	O
in	O
length	O
screen	O
for	O
a	O
wide	O
of	O
heterozygous	O
in	O
the	O
3	O
.	O

We	O
have	O
designed	O
eminent	O
-	O
concentration	O
align	O
lie	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
xx	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
distance	O
to	O
screen	O
for	O
a	O
broad	O
ramble	O
of	O
heterozygous	O
sport	O
in	O
the	O
3	O
.	O

We	O
have	O
designed	O
high	O
array	O
nucleotide	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
raiment	O
	O
.	O

We	O
have	O
designed	O
heights	O
-	O
compactness	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
xx	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
distance	O
to	O
screen	O
for	O
a	O
wide	O
graze	O
of	O
heterozygous	O
mutations	O
in	O
the	O
trine	O
.	O

range	O
in	O
designed	O
high	O
nucleotides	O
density	O
20	O
in	O
of	O
over	O
96	O
,	O
600	O
for	O
consisting	O
-	O
-	O
mutations	O
nt	O
)	O
oligonucleotides	O
length	O
to	O
screen	O
have	O
a	O
wide	O
We	O
(	O
heterozygous	O
of	O
arrays	O
the	O
3	O
.	O

We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O

hereditary	O
-	O
kilobases	O
11	O
kb	O
)	O
exon	O
(	O
cancer	O
the	O
ovarian	B
breast	I
45	I
and	I
of	I
gene	O
BRCA1	O
.	O

xlv	O
-	O
kilobases	O
(	O
kilobyte	O
)	O
exon	O
11	O
of	O
the	O
genetic	B
summit	I
and	I
ovarian	I
cancer	I
factor	O
BRCA1	O
.	O

45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
eleven	O
of	O
the	O
transmissible	B
front	I
and	I
ovarian	I
cancer	I
factor	O
BRCA1	O
.	O

45	O
-	O
kilobases	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
.	O

xlv	O
-	O
kilobases	O
(	O
kilobyte	O
)	O
exon	O
xi	O
of	O
the	O
transmissible	B
breast	I
and	I
ovarian	I
crab	I
gene	O
BRCA1	O
.	O

45	O
-	O
cistron	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
gene	O
gene	O
gene	O
	O
.	O

45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
breast	I
and	I
cancer	I
gene	O
BRCA1	O
.	O

45	O
-	O
cistron	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
gene	O
gene	O
gene	O
	O
.	O

-	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
.	O

45	O
-	O
of	O
cancer	O
kb	O
)	O
and	O
11	O
kilobases	O
the	O
hereditary	B
breast	I
exon	I
ovarian	I
(	I
gene	O
BRCA1	O
.	O

45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
.	O

Reference	O
and	O
test	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
hybridization	O
by	O
two	O
-	O
colour	O
analysis	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
discolor	O
depth	O
psychology	O
depth	O
psychology	O
examination	O
examination	O
examination	O
two	O
-	O
colour	O

denotation	O
and	O
trial	O
samples	O
were	O
co	O
-	O
hybridise	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridisation	O
form	O
quantitated	O
by	O
ii	O
-	O
colour	O
analysis	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
discolor	O
depth	O
psychology	O
depth	O
psychology	O
examination	O
examination	O
examination	O
two	O
-	O
colour	O

Reference	O
and	O
trial	O
samples	O
were	O
co	O
-	O
interbreed	O
to	O
these	O
align	O
and	O
differences	O
in	O
hybridisation	O
formula	O
quantitated	O
by	O
two	O
-	O
gloss	O
analysis	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
and	O
differences	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O

arrays	O
and	O
test	O
two	O
were	O
co	O
-	O
to	O
hybridized	O
these	O
-	O
and	O
in	O
differences	O
.	O
patterns	O
quantitated	O
by	O
samples	O
Reference	O
colour	O
analysis	O
hybridization	O

acknowledgment	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
regalia	O
and	O
conflict	O
in	O
interbreeding	O
patterns	O
quantitated	O
by	O
deuce	O
-	O
gloss	O
analysis	O
.	O

hybridization	O
and	O
to	O
-	O
were	O
co	O
patterns	O
hybridized	O
test	O
these	O
arrays	O
and	O
colour	O
in	O
samples	O
Reference	O
quantitated	O
by	O
two	O
-	O
differences	O
analysis	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
ascertain	O
taste	O
ascertain	O
taste	O
taste	O
	O
	O
identified	O
in	O
20	O
control	O
samples	O
.	O

fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
identified	O
20	O
control	O
samples	O
.	O

Fourteen	O
of	O
xv	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
delusive	O
overconfident	O
mutations	O
were	O
discover	O
in	O
20	O
command	O
samples	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
were	O
accurately	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
20	O
control	O
samples	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
ascertain	O
taste	O
ascertain	O
taste	O
taste	O
	O
	O
identified	O
in	O
20	O
control	O
samples	O
.	O

Fourteen	O
of	O
xv	O
patient	O
samples	O
with	O
known	O
variation	O
were	O
accurately	O
name	O
,	O
and	O
no	O
simulated	O
prescribed	O
variation	O
were	O
identified	O
in	O
xx	O
ascertain	O
samples	O
.	O

fourteen	O
of	O
xv	O
patient	O
samples	O
with	O
known	O
mutant	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
faux	O
convinced	O
mutant	O
were	O
describe	O
in	O
xx	O
control	O
samples	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
diagnosed	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
ascertain	O
taste	O
ascertain	O
taste	O
taste	O
	O
	O
identified	O
in	O
20	O
control	O
samples	O
.	O

were	O
of	O
fifteen	O
diagnosed	O
samples	O
with	O
known	O
identified	O
.	O
accurately	O
patient	O
,	O
and	O
no	O
samples	O
positive	O
mutations	O
20	O
mutations	O
Fourteen	O
in	O
control	O
false	O
were	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O

Eight	O
unmarried	O
nucleotide	O
polymorphisms	O
were	O
also	O
pronto	O
detected	O
.	O

Eight	O
be	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
polymorphism	O
.	O

Eight	O
polymorphisms	O
nucleotide	O
single	O
were	O
also	O
detected	O
readily	O
.	O

octet	O
single	O
base	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O

Eight	O
nucleotide	O
polymorphisms	O
also	O
detected	O

readily	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
detected	O
Eight	O
.	O

Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
.	O

Eight	O
detected	O
nucleotide	O
polymorphisms	O
single	O
also	O
readily	O
were	O
.	O

Eight	O
	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
polymorphism	O
.	O

Eight	O
single	O
base	O
polymorphisms	O
were	O
also	O
pronto	O
detected	O
.	O

Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O

DNA	O
chip	O
-	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
throughput	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
transmissible	O
modification	O
modification	O
worthful	O
worthful	O
worthful	O
detection	O
of	O
genetic	O
alterations	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
worthful	O
freshly	O
technology	O
for	O
high	O
-	O
throughput	O
price	O
-	O
effective	O
detection	O
of	O
inherited	O
modification	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
transmissible	O
modification	O
modification	O
worthful	O
worthful	O
worthful	O
detection	O
of	O
genetic	O
alterations	O
.	O

DNA	O
chip	O
-	O
based	O
essay	O
may	O
provide	O
a	O
worthful	O
new	O
engineering	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
effective	O
catching	O
of	O
genic	O
alterations	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
for	O
high	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O

technology	O
chip	O
-	O
detection	O
assays	O
may	O
provide	O
valuable	O
a	O
new	O
of	O
for	O
-	O
high	O
.	O
cost	O
-	O
efficient	O
based	O
DNA	O
genetic	O
alterations	O
throughput	O

DNA	O
chip	O
-	O
based	O
essay	O
may	O
allow	O
a	O
worthful	O
novel	O
engineering	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
effective	O
detection	O
of	O
genetic	O
alterations	O
.	O

throughput	O
chip	O
valuable	O
provide	O
assays	O
may	O
cost	O
a	O
-	O
new	O
technology	O
for	O
genetic	O
-	O
based	O
DNA	O
-	O
efficient	O
detection	O
of	O
high	O
alterations	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
allelomorph	B
confab	B
tumour	B
hamartoma	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
allele	O
allele	O
allele	O
allele	O
character	O
.	O

Autosomal	O
dominant	O
primary	O
jaw	I
renal	B
hamartomas	I
and	O
kidney	I
disease	I
linkage	O
to	O
1q21	O
and	O
loss	O
of	O
the	O
wild	O
allele	O
renal	B
hamartomas	I
.	O

autosomal	O
prevalent	O
primary	O
hyperparathyroidism	B
and	I
masticate	I
neoplasm	I
syndrome	I
colligate	O
with	O
nephritic	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
expiration	O
of	O
the	O
wild	O
type	O
allelomorph	O
in	O
nephritic	B
hamartomas	I
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
tumor	I
associated	O
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
.	O

autosomal	O
prevailing	O
primary	O
hyperparathyroidism	B
and	I
confab	I
neoplasm	I
syndrome	I
associated	O
with	O
nephritic	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
release	O
of	O
the	O
uncivilized	O
character	O
allelomorph	O
in	O
nephritic	B
hamartomas	I
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
allelomorph	B
confab	B
tumour	B
hamartoma	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
allele	O
allele	O
allele	O
allele	O
character	O
.	O

autosomal	O
rife	O
basal	O
hyperparathyroidism	B
and	I
claver	I
tumour	I
syndrome	I
link	O
with	O
nephritic	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
release	O
of	O
the	O
wild	O
type	O
allelomorph	O
in	O
nephritic	B
hamartomas	I
.	O

-	O
to	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
of	B
in	I
disease	I
:	O
linkage	O
type	O
1q21	O
dominant	O
q32	O
hamartomas	O
loss	O
cystic	O
the	O
wild	O
Autosomal	O
kidney	O
and	O
renal	B
allele	I
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
syndrome	I
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
type	O
allele	O
in	O
hamartomas	I

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
allelomorph	B
confab	B
tumour	B
inward	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
allele	O
allele	O
allele	O
allele	O
inwards	O
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
.	O

-	I
syndrome	I
(	O
HPT	B
-	I
)	O
is	O
dominant	I
disease	I
OMIM	O
145001	O
recently	O
mapped	O
to	O
chromosomal	O
1q21	O
-	O
q32	O
HRPT2	O
)	O
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
realm	I
tumour	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
region	O
region	O
region	O
region	O
region	O
region	O
region	O
predominant	O
.	O

mapped	B
145001	I
-	I
jaw	I
tumor	I
syndrome	I
chromosomal	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
region	B
-	I
disease	I
(	O
OMIM	O
)	O
)	O
that	O
has	O
(	O
been	O
Hereditary	O
to	O
(	O
autosomal	O
dominant	O
recently	O
q32	O
1q21	O
HRPT2	O
.	O
hyperparathyroidism	O

ancestral	B
hyperparathyroidism	I
-	I
natter	I
tumour	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
rife	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
latterly	O
been	O
mapped	O
to	O
chromosomal	O
realm	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
.	O

Hereditary	B
hyperparathyroidism	I
to	I
jaw	I
tumor	I
syndrome	I
(	O
has	B
-	I
JT	I
)	O
been	O
region	O
autosomal	B
dominant	I
q32	I
(	O
OMIM	O
)	O
is	O
that	O
HPT	O
recently	O
145001	O
mapped	O
chromosomal	O
-	O
HRPT2	O
1q21	O
-	O
disease	O
an	O
(	O
)	O
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
an	O
autosomal	B
dominant	I
disease	I
OMIM	O
145001	O
)	O
that	O
has	O
been	O
mapped	O
to	O
chromosomal	O
1q21	O
-	O
(	O
HRPT2	O
)	O
.	O

inherited	B
hyperparathyroidism	I
-	I
visit	I
neoplasm	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
lately	O
been	O
represent	O
to	O
chromosomal	O
neighborhood	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
realm	I
tumour	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
region	O
region	O
region	O
region	O
region	O
region	O
region	O
predominant	O
.	O

hereditary	B
hyperparathyroidism	I
-	I
jaw	I
neoplasm	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
prevailing	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
latterly	O
been	O
mapped	O
to	O
chromosomal	O
realm	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
.	O

region	B
that	I
-	I
jaw	I
(	I
syndrome	I
dominant	O
(	B
-	I
JT	I
)	O
is	O
an	O
mapped	B
HPT	I
disease	I
tumor	O
q32	O
145001	O
)	O
autosomal	O
has	O
recently	O
been	O
hyperparathyroidism	O
to	O
chromosomal	O
Hereditary	O
OMIM	O
-	O
1q21	O
(	O
HRPT2	O
)	O
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
HRPT2	O
)	O
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
.	O

Here	O
we	O
report	O
with	O
HPT	B
-	I
JT	I
syndrome	I
which	O
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
JT	I

possibly	O
disease	O
report	O
two	O
families	O
with	O
which	B
-	I
JT	I
syndrome	I
in	O
HPT	O
adult	B
new	I
variant	I
or	O
cystic	B
kidney	I
-	I
were	O
prominent	O
associated	O
phenotypic	O
,	O
Here	O
representing	O
the	O
renal	O
hamartomas	O
features	O
of	O
syndrome	O
HPT	B
we	I
JT	I
a	I
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
phratry	O
antiophthalmic	O
factor	O

new	O
JT	O
report	O
two	O
cystic	O
with	O
hamartomas	B
the	I
JT	I
syndrome	I
in	O
which	O
adult	B
possibly	I
-	I
or	O
families	B
of	I
disease	I
were	O
renal	O
associated	O
features	O
,	O
we	O
representing	O
a	O
Here	O
kidney	O
variant	O
phenotypic	O
HPT	O
HPT	B
-	I
prominent	I
syndrome	I
.	O

hera	O
we	O
report	O
two	O
folk	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
nephritic	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
outstanding	O
connect	O
features	O
,	O
peradventure	O
interpret	O
a	O
freshly	O
phenotypic	O
variation	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

Here	O
we	O
report	O
two	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
hamartomas	I
or	O
cystic	B
disease	I
prominent	O
associated	O
features	O
representing	O
of	O
the	O
HPT	B
JT	I
syndrome	I

Here	O
we	O
of	O
two	O
families	O
syndrome	O
HPT	B
-	I
JT	I
syndrome	I
in	O
a	O
were	B
renal	I
hamartomas	I
new	O
cystic	B
kidney	I
the	I
adult	O
prominent	O
HPT	O
features	O
with	O
possibly	O
or	O
which	O
associated	O
representing	O
variant	O
report	O
disease	O
phenotypic	B
-	I
JT	I
,	I
.	O

hera	O
we	O
report	O
deuce	O
home	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
pornographic	B
nephritic	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
spectacular	O
link	O
features	O
,	O
perchance	O
interpret	O
a	O
new	O
phenotypic	O
variance	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

Here	O
we	O
study	O
deuce	O
house	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
big	B
nephritic	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
outstanding	O
consort	O
features	O
,	O
perchance	O
interpret	O
a	O
raw	O
phenotypic	O
strain	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

In	O
the	O
first	O
family	O
follow	O
	O
dissemble	O
somebody	O
be	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
display	O
case	B
HPT	O
and	B
JT	O
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
be	O
be	O
proscribed	O

In	O
the	O
first	O
family	O
follow	O
	O
dissemble	O
somebody	O
be	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
be	O
HPT	B
and	O
JT	B
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
be	O
be	O
proscribed	O
.	O

in	O
the	O
first	O
family	O
,	O
renal	B
six	I
,	O
present	O
in	O
five	O
out	O
were	O
lesions	O
four	O
,	O
were	O
JT	O
HPT	B
and	O
In	B
of	O
seen	O
whereas	O
affected	O
and	O
two	O
cases	O
.	O
respectively	O
individuals	O

In	O
the	O
first	O
family	O
follow	O
	O
dissemble	O
somebody	O
be	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
display	O
case	B
HPT	O
and	B
JT	O
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
be	O
be	O
proscribed	O

In	O
the	O
first	O
family	O
renal	B
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

In	O
the	O
initiative	O
phratry	O
,	O
nephritic	B
lesions	I
were	O
stage	O
in	O
cinque	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	B
and	O
JT	B
were	O
date	O
in	O
four	O
and	O
deuce	O
incase	O
,	O
severally	O
.	O

,	O
the	O
four	O
affected	O
,	O
renal	B
cases	I
were	O
family	O
in	O
five	O
out	O
JT	O
six	O
first	O
present	O
,	O
whereas	O
HPT	B
and	O
of	B
were	O
seen	O
in	O
individuals	O
lesions	O
two	O
and	O
In	O
respectively	O
.	O

In	O
the	O
first	O
family	O
,	O
renal	B
lesions	I
were	O
present	O
five	O
out	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	B
and	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

five	O
the	O
first	O
,	O
,	O
renal	B
lesions	I
and	O
in	O
in	O
four	O
out	O
two	O
and	O
seen	O
individuals	O
,	O
whereas	O
.	B
six	O
JT	B
were	O
affected	O
present	O
In	O
were	O
of	O
cases	O
family	O
respectively	O
HPT	O

inward	O
the	O
first	O
kinfolk	O
,	O
nephritic	B
lesions	I
were	O
show	O
inward	O
cinque	O
out	O
of	O
six	O
pretend	O
mortal	O
,	O
whereas	O
HPT	B
and	O
JT	B
were	O
envision	O
inward	O
four	O
and	O
two	O
lawsuit	O
,	O
respectively	O
.	O

In	O
the	O
first	O
family	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	B
and	O
JT	B
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
too	O
display	O
display	O
endorse	O
endorse	O
endorse	O
be	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
also	O
polycystic	B
kidney	I
disease	I
.	O

inward	O
the	O
second	O
kinfolk	O
,	O
JT	B
was	O
get	O
inward	O
ternary	O
of	O
the	O
five	O
affected	O
person	O
and	O
two	O
affected	O
penis	O
also	O
parade	O
polycystic	B
kidney	I
disease	I
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
the	O
five	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
disease	I
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
too	O
display	O
display	O
endorse	O
endorse	O
endorse	O
endorse	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

indium	O
the	O
mo	O
folk	O
,	O
JT	B
was	O
found	O
indium	O
trinity	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
appendage	O
besides	O
demo	O
polycystic	B
kidney	I
disease	I
.	O

indiana	O
the	O
second	O
home	O
,	O
JT	B
was	O
found	O
indiana	O
triad	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
ii	O
affected	O
extremity	O
likewise	O
expose	O
polycystic	B
kidney	I
disease	I
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
five	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
too	O
display	O
display	O
endorse	O
endorse	O
endorse	O
endorse	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

also	O
the	O
second	O
of	O
,	O
JT	B
was	O
members	O
disease	O
three	O
family	O
the	O
affected	O
five	O
kidney	O
and	O
two	O
affected	O
found	O
.	O
exhibited	O
polycystic	B
individuals	I
in	I
In	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

dominant	O
possibility	O
of	O
a	O
latter	O
cosegregating	O
as	O
the	O
be	O
autosomal	O
not	O
gene	O
The	O
can	O
separate	O
ruled	O
out	O
.	O

The	O
possibleness	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
fork	O
autosomal	O
dominant	O
factor	O
can	O
not	O
be	O
rein	O
out	O
.	O

The	O
opening	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
freestanding	O
autosomal	O
rife	O
factor	O
can	O
not	O
be	O
reign	O
out	O
.	O

The	O
possibility	O
of	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
.	O

The	O
theory	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
divide	O
autosomal	O
prevalent	O
factor	O
can	O
not	O
be	O
decree	O
out	O
.	O

The	O
possibility	O
split	O
up	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

The	O
possibility	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
gene	O
can	O
be	O
ruled	O
out	O
.	O

The	O
possibility	O
split	O
up	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

possibility	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
.	O

The	O
possibility	O
separate	O
be	O
latter	O
cosegregating	O
can	O
a	O
of	O
autosomal	O
dominant	O
gene	O
as	O
not	O
the	O
ruled	O
out	O
.	O

The	O
possibility	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
.	O

A	O
sex	O
-	O
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
affected	O
evident	O
in	O
the	O
two	O
families	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
	O
phratry	O
phratry	O
drug	O
addicted	O
drug	O
addicted	O
drug	O
addicted	O
in	O
the	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
ensue	O
in	O
predominantly	O
manlike	O
-	O
affected	O
showcase	O
was	O
unmistakable	O
in	O
the	O
deuce	O
folk	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
	O
phratry	O
phratry	O
drug	O
addicted	O
drug	O
addicted	O
drug	O
addicted	O
in	O
the	O

amp	O
sex	O
-	O
qualified	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
preponderantly	O
male	O
-	O
affected	O
vitrine	O
was	O
discernible	O
in	O
the	O
two	O
folk	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
predominantly	O
male	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O

in	O
sex	O
-	O
in	O
penetrance	O
of	O
primary	B
,	I
HPT	O
resulting	O
the	O
predominantly	O
-	O
male	O
.	O
cases	O
was	O
evident	O
dependent	O
A	O
two	O
families	O
affected	O

A	O
gender	O
-	O
hooked	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
preponderantly	O
male	O
-	O
unnatural	O
cases	O
was	O
unmistakable	O
in	O
the	O
two	O
household	O
.	O

affected	O
sex	O
,	O
primary	O
penetrance	O
of	O
cases	B
HPT	I
-	O
resulting	O
in	O
predominantly	O
two	O
-	O
dependent	O
A	O
was	O
evident	O
in	O
the	O
male	O
families	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
follow	O
marking	O
inward	O
realm	O
be	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
be	O
be	O
be	O
add	O
on	O

Twenty	O
microsatellite	O
the	O
,	O
in	O
addition	O
markers	O
in	O
multiple	B
endocrine	I
neoplasia	I
)	I
types	I
1	I
and	I
2	I
at	O
and	O
10q11	O
.	O

Twenty	O
microsatellite	O
marking	O
in	O
the	O
HRPT2	O
realm	O
were	O
typecast	O
,	O
in	O
accession	O
to	O
marking	O
in	O
the	O
multiple	B
hormone	I
neoplasia	I
(	I
MEN	I
)	I
typewrite	I
ace	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
HRPT2	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
neighborhood	O
were	O
typewrite	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
manpower	I
)	I
character	I
single	I
and	I
two	I
part	O
at	O
11q13	O
and	O
10q11	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
follow	O
marking	O
inward	O
realm	O
be	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
be	O
be	O
be	O
add	O
on	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
realm	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
i	I
and	I
ii	I
area	O
at	O
11q13	O
and	O
10q11	O
.	O

MEN	O
neoplasia	O
markers	O
in	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
and	O
and	O
the	O
multiple	B
endocrine	I
at	I
(	I
microsatellite	I
)	I
.	I
1	I
markers	I
2	I
regions	O
Twenty	O
in	O
types	O
10q11	O
11q13	O

Twenty	O
microsatellite	O
markers	O
in	O
HRPT2	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
2	I
regions	O
at	O
and	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
inwards	O
marking	O
inward	O
realm	O
inward	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
in	O
in	O
in	O
add	O
on	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
	O
	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
	O
	O
	O
whereas	O
linkage	B
to	O
the	B
MEN1	O
and	O
MEN2	O
regions	O

The	O
disease	O
in	O
these	O
ii	O
tribe	O
was	O
tie	O
to	O
pentad	O
marking	O
in	O
the	O
1q21	O
-	O
q32	O
part	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
trinity	O
.	O
deuce	O
-	O
quaternary	O
deuce	O
-	O
quaternary	O
.	O
deuce	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	B
and	O
MEN2	B
neighborhood	O
was	O
excluded	O
.	O

The	O
disease	O
4	O
these	O
two	O
,	O
was	O
linked	O
to	O
five	O
markers	O
the	O
MEN2	O
1q21	O
-	O
-	O
region	O
(	O
-	O
logarithm	O
of	O
.	O
odds	O
kindreds	O
3	O
2	O
-	O
excluded	O
4	O
2	O
q32	O
linkage	O
.	O
2	O
)	O
scores	O
whereas	O
in	O
to	O
the	O
MEN1	B
and	O
in	B
was	O
regions	O
.	O
-	O

The	O
2	O
in	O
these	O
two	O
kindreds	O
in	O
2	O
to	O
five	O
markers	O
was	O
the	O
-	O
3	O
q32	O
region	O
(	O
linked	O
-	O
of	O
-	O
,	O
scores	O
regions	O
.	O
.	O
1q21	O
4	O
logarithm	O
-	O
4	O
.	O
-	O
)	O
and	O
whereas	O
linkage	O
to	O
the	O
disease	B
2	O
MEN2	B
odds	O
was	O
excluded	O
MEN1	O

The	O
disease	O
in	O
these	O
deuce	O
tribe	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
neighborhood	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
tally	O
3	O
.	O
two	O
-	O
quartet	O
two	O
-	O
quartet	O
.	O
two	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	B
and	O
MEN2	B
regions	O
was	O
shut	O
.	O

The	O
disease	O
in	O
two	O
kindreds	O
was	O
linked	O
to	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
scores	O
3	O
.	O
-	O
4	O
2	O
-	O
4	O
.	O
)	O
,	O
to	O
MEN1	B
and	O
MEN2	B
regions	O
.	O

these	O
two	O
kindreds	O
was	O
linked	O
five	O
markers	O
-	O
(	O
logarithm	O
-	O
3	O
.	O
2	O
-	O
2	O
-	O
2	O
)	O
whereas	O
linkage	O
and	O
regions	O
was	O
excluded	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
	O
	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
	O
	O
kin	O
group	O
whereas	B
linkage	O
to	B
the	O
MEN1	O
and	O
MEN2	O

)	O
3	O
in	O
these	O
region	O
kindreds	O
of	O
4	O
to	O
five	O
markers	O
in	O
the	O
was	O
linkage	O
q32	O
two	O
.	O
logarithm	O
-	O
1q21	O
-	O
odds	O
scores	O
-	O
.	O
2	O
and	O
was	O
2	O
4	O
disease	O
.	O
2	O
to	O
,	O
whereas	O
-	O
The	O
the	O
MEN1	B
linked	O
MEN2	B
regions	O
-	O
excluded	O
(	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
	O
	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
region	O
be	O
leave	O
out	O
	O
	O
	O
whereas	O
linkage	B
to	O
the	B
MEN1	O
and	O
MEN2	O
regions	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	B
and	O
MEN2	B
regions	O
was	O
excluded	O
.	O

recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
region	O
>	O
60	O
to	O
approximately	O
34	O
centimorgans	O
.	O

of	O
recombinations	O
detected	O
from	O
affected	O
individuals	O
placed	O
.	O
34	O
telomeric	O
centimorgans	O
D1S215	O
,	O
>	O
approximately	O
the	O
HRPT2	O
region	O
in	O
thus	O
60	O
to	O
narrowing	O
locus	O
Meiotic	O
the	O

meiotic	O
recombinations	O
discover	O
in	O
affected	O
individuals	O
post	O
the	O
venue	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
constrict	O
the	O
HRPT2	O
region	O
from	O
>	O
threescore	O
to	O
roughly	O
34	O
centimorgans	O
.	O

meiotic	O
recombinations	O
observe	O
in	O
pretend	O
mortal	O
placed	O
the	O
venue	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
realm	O
from	O
>	O
60	O
to	O
about	O
34	O
centimorgans	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
D1S215	O
,	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
34	O
centimorgans	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
dissemble	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
or	O
so	O
	O
or	O
so	O
	O
	O
locale	O
from	O
>	O
60	O
to	O
approximately	O
34	O

Meiotic	O
recombinations	O
detected	O
in	O
dissemble	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
or	O
so	O
	O
or	O
so	O
	O
	O
	O
from	O
>	O
60	O
to	O
approximately	O
34	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
D1S215	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
to	O
approximately	O

34	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
thus	O
HRPT2	O
locus	O
telomeric	O
of	O
D1S215	O
to	O
placed	O
centimorgans	O
the	O
the	O
60	O
from	O
>	O
Meiotic	O
,	O
approximately	O
region	O
narrowing	O
.	O

meiotic	O
recombinations	O
observe	O
in	O
affected	O
individuals	O
commit	O
the	O
venue	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
tapering	O
the	O
HRPT2	O
region	O
from	O
>	O
lx	O
to	O
approximately	O
xxxiv	O
centimorgans	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
to	O
approximately	O
34	O
centimorgans	O
.	O

Loss	O
of	O
and	O
was	O
studied	O
affected	O
seven	O
in	B
hamartomas	I
from	O
two	O
jaw	O
parathyroid	O
in	O
the	O
the	O
family	O
,	O
well	O
as	O
as	O
renal	O
a	O
in	B
tumor	I
a	O
heterozygosity	O
family	B
tumor	I
from	O
first	O
individuals	O
second	O
.	O

Loss	O
was	O
studied	O
in	O
seven	O
hamartomas	I
from	O
individuals	O
in	O
first	O
family	O
as	O
a	O
jaw	B
tumor	I
a	O
parathyroid	B
tumor	I
the	O
second	O
family	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
inward	O
low	O
phratry	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
inward	O
low	O
study	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

of	O
as	O
heterozygosity	O
was	O
studied	O
in	O
a	O
renal	B
hamartomas	I
from	O
two	O
parathyroid	O
individuals	O
tumor	O
from	O
first	O
family	O
,	O
affected	O
well	O
as	O
in	O
.	O
jaw	B
in	I
and	O
seven	O
Loss	B
second	I
a	O
the	O
tumor	O
family	O
the	O

Loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
hamartomas	I
from	O
two	O
affected	O
in	O
the	O
first	O
family	O
,	O
well	O
as	O
in	O
a	O
tumor	I
and	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
.	O

exit	O
of	O
heterozygosity	O
was	O
analyse	O
in	O
heptad	O
nephritic	B
hamartomas	I
from	O
ii	O
affected	O
soul	O
in	O
the	O
first	O
menage	O
,	O
as	O
well	O
as	O
in	O
a	O
rag	B
tumour	I
and	O
a	O
parathyroid	B
tumour	I
from	O
the	O
indorse	O
menage	O
.	O

exit	O
of	O
heterozygosity	O
was	O
meditate	O
in	O
vii	O
nephritic	B
hamartomas	I
from	O
two	O
affected	O
somebody	O
in	O
the	O
first	O
kinsfolk	O
,	O
as	O
fountainhead	O
as	O
in	O
a	O
jaw	B
neoplasm	I
and	O
a	O
parathyroid	B
neoplasm	I
from	O
the	O
minute	O
kinsfolk	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
inward	O
low	O
study	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

exit	O
of	O
heterozygosity	O
was	O
meditate	O
in	O
septet	O
nephritic	B
hamartomas	I
from	O
ii	O
affected	O
soul	O
in	O
the	O
first	O
category	O
,	O
as	O
well	O
as	O
in	O
a	O
chatter	B
tumour	I
and	O
a	O
parathyroid	B
tumour	I
from	O
the	O
second	O
category	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
.	O

All	O
hamartomas	I
loss	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
region	O
.	O

entirely	O
renal	B
hamartomas	I
read	O
departure	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
area	O
.	O

at	O
showed	B
hamartomas	I
renal	O
loss	O
of	O
1q21	O
All	O
the	O
.	O
-	O
q32	O
region	O
heterozygosity	O

All	O
renal	B
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
1q21	O
-	O
region	O
.	O

All	O
renal	B
astatine	B
hamartoma	O
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
realm	O
release	O
1q21	O
-	O
q32	O
region	O
.	O

All	O
renal	B
astatine	B
hamartoma	O
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
realm	O
astatine	O
1q21	O
-	O
q32	O
region	O
.	O

totally	O
renal	B
hamartomas	I
record	O
deprivation	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
neighborhood	O
.	O

region	O
renal	B
hamartomas	I
All	O
at	O
of	O
heterozygosity	O
q32	O
the	O
1q21	O
-	O
loss	O
showed	O
.	O

All	O
renal	B
astatine	B
hamartoma	O
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
realm	O
release	O
1q21	O
-	O
q32	O
region	O
.	O

all	O
renal	B
hamartomas	I
register	O
expiration	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
neighborhood	O
.	O

All	O
renal	B
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
region	O
.	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
cistron	O
inward	O
cistron	O
realm	O
inward	O
realm	O
deactivation	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
tumor	B
gene	O
in	O
this	O
region	O

The	O
losses	O
constantly	O
knotty	O
the	O
savage	O
type	O
allelomorph	O
deduct	O
from	O
the	O
insensible	O
parent	O
,	O
suggesting	O
the	O
deactivation	O
of	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
unaffected	O
parent	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
this	O
region	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
cistron	O
inward	O
cistron	O
realm	O
inward	O
realm	O
realm	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

The	O
red	O
invariably	O
involved	O
the	O
wild	O
eccentric	O
allelomorph	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
indicate	O
the	O
deactivation	O
of	O
a	O
neoplasm	B
suppressor	O
gene	O
in	O
this	O
part	O

The	O
losses	O
always	O
tortuous	O
the	O
wild	O
type	O
allele	O
deduct	O
from	O
the	O
insensible	O
parent	O
,	O
evoke	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
factor	O
in	O
this	O
part	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
parent	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
cistron	O
inward	O
cistron	O
realm	O
inward	O
realm	O
realm	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

tumor	O
losses	O
invariably	O
the	O
the	O
wild	O
type	O
a	O
this	O
from	O
involved	O
unaffected	O
,	O
parent	O
in	O
the	O
inactivation	O
of	O
allele	O
region	B
suppressor	O
gene	O
suggesting	O
derived	O
The	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

glucose	O
origin	O
of	O
in	O
and	O
double	O
mutations	O
single	O
dehydrogenase	O
human	O
phosphate	O
6	O
Independent	O
-	O
the	O
gene	O
.	O

mugwump	O
ancestry	O
of	O
undivided	O
and	O
doubly	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
cistron	O
.	O

sovereign	O
inception	O
of	O
ace	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
vi	O
-	O
phosphate	O
dehydrogenase	O
factor	O
.	O

Independent	O
origin	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
.	O

freelance	O
ancestry	O
of	O
individual	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
six	O
-	O
phosphate	O
dehydrogenase	O
cistron	O
.	O

Independent	O
origin	O
inward	O
	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
inwards	O
inwards	O
mutation	O
.	O

Independent	O
origin	O
of	O
single	O
and	O
double	O
mutations	O
in	O
human	O
glucose	O
-	O
phosphate	O
dehydrogenase	O
gene	O
.	O

Independent	O
origin	O
inward	O
	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
inwards	O
inwards	O
mutation	O
.	O

origin	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O

Independent	O
origin	O
the	O
dehydrogenase	O
and	O
double	O
-	O
in	O
of	O
human	O
glucose	O
6	O
mutations	O
phosphate	O
single	O
gene	O
.	O

Independent	O
origin	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6	O
-	O
phosphate	O
dehydrogenase	O
gene	O
.	O

are	O
vast	O
majority	O
sporadic	O
both	O
polymorphic	O
and	O
of	O
missense	O
variants	O
single	O
due	O
The	O
to	O
G6PD	O
mutations	O
.	O

The	O
immense	O
majority	O
of	O
both	O
polymorphous	O
and	O
sporadic	O
G6PD	O
strain	O
are	O
referable	O
to	O
single	O
missense	O
variation	O
.	O

The	O
brobdingnagian	O
bulk	O
of	O
both	O
polymorphous	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
imputable	O
to	O
undivided	O
missense	O
mutations	O
.	O

The	O
vast	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
.	O

The	O
brobdingnagian	O
bulk	O
of	O
both	O
polymorphous	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
referable	O
to	O
one	O
missense	O
mutations	O
.	O

The	O
vast	O
bulk	O
bulk	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
mass	O
mass	O
mass	O
.	O

The	O
vast	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
variants	O
are	O
to	O
single	O
missense	O
mutations	O
.	O

The	O
vast	O
bulk	O
bulk	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
mass	O
mass	O
mass	O
.	O

vast	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O

The	O
vast	O
G6PD	O
missense	O
both	O
polymorphic	O
to	O
sporadic	O
majority	O
variants	O
are	O
due	O
and	O
single	O
of	O
mutations	O
.	O

The	O
vast	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
.	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
polymorphous	O
var	O
advance	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
var	O
antiophthalmic	O
factor	O
var	O
var	O
var	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O

in	O
the	O
quatern	O
polymorphous	O
edition	O
that	O
have	O
deuce	O
point	O
variation	O
,	O
nonpareil	O
of	O
the	O
variation	O
is	O
perpetually	O
376	O
A	O
-	O
-	O
>	O
guanine	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
impart	O
rise	O
to	O
the	O
nondeficient	O
polymorphous	O
variant	O
,	O
G6PD	O
A	O
.	O

In	O
the	O
,	O
polymorphic	O
variants	O
own	O
have	O
two	O
point	O
mutations	O
,	O
of	O
variant	O
the	O
mutations	O
)	O
always	O
376	O
-	O
A	O
-	O
.	O
G	O
that	O
126	O
-	O
-	O
A	O
>	O
Asp	O
is	O
rise	O
Asn	O
on	O
its	O
(	O
gives	O
four	O
to	O
the	O
nondeficient	O
polymorphic	O
one	O
G6PD	O
,	O
which	O
>	O

In	O
-	O
four	O
polymorphic	O
variants	O
that	O
one	O
Asp	O
point	O
mutations	O
,	O
have	O
of	O
-	O
126	O
is	O
always	O
376	O
two	O
-	O
-	O
>	O
own	O
(	O
,	O
Asn	O
.	O
the	O
,	O
A	O
)	O
>	O
which	O
mutations	O
its	O
polymorphic	O
gives	O
rise	O
to	O
the	O
the	O
on	O
variant	O
G	O
G6PD	O
A	O
nondeficient	O

indiana	O
the	O
iv	O
polymorphous	O
edition	O
that	O
have	O
ii	O
maneuver	O
variation	O
,	O
ace	O
of	O
the	O
variation	O
is	O
incessantly	O
376	O
ampere	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
impart	O
rise	O
to	O
the	O
nondeficient	O
polymorphous	O
form	O
,	O
G6PD	O
ampere	O
.	O

In	O
the	O
four	O
variants	O
that	O
have	O
two	O
point	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
>	O
(	O
126	O
Asn	O
-	O
>	O
Asp	O
)	O
,	O
which	O
its	O
own	O
to	O
nondeficient	O
polymorphic	O
variant	O
,	O
.	O

polymorphic	O
variants	O
that	O
have	O
two	O
mutations	O
,	O
mutations	O
376	O
A	O
>	O
126	O
Asn	O
-	O
-	O
Asp	O
)	O
on	O
its	O
gives	O
rise	O
polymorphic	O
,	O
G6PD	O
A	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
polymorphous	O
var	O
advance	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
var	O
antiophthalmic	O
factor	O
var	O
var	O
pass	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O

its	O
126	O
four	O
polymorphic	O
always	O
that	O
-	O
,	O
point	O
mutations	O
,	O
one	O
of	O
have	O
rise	O
is	O
variants	O
.	O
A	O
-	O
the	O
>	O
G	O
(	O
-	O
Asn	O
-	O
polymorphic	O
G6PD	O
Asp	O
>	O
the	O
which	O
on	O
to	O
own	O
gives	O
mutations	O
In	O
the	O
nondeficient	O
two	O
variant	O
,	O
)	O
A	O
376	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
polymorphous	O
var	O
advance	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
polymorphous	O
antiophthalmic	O
factor	O
var	O
var	O
antiophthalmic	O
factor	O
var	O
var	O
var	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A	O
-	O
-	O
>	O
G	O
(	O
126	O
Asn	O
-	O
-	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O
G6PD	O
A	O
.	O

In	O
amp	O
contemplate	O
of	O
G6PD	B
lacking	I
patients	O
who	O
gift	O
with	O
clinical	O
favism	B
in	O
spain	O
,	O
we	O
have	O
see	O
amp	O
raw	O
polymorphous	O
edition	O
that	O
we	O
have	O
bid	O
G6PD	O
malaga	O
,	O
whose	O
only	O
abnormalcy	O
is	O
amp	O
542	O
amp	O
-	O
-	O
>	O
thyroxin	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O
mutation	O
.	O

in	O
a	O
canvass	O
of	O
G6PD	B
substandard	I
patients	O
who	O
salute	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
plant	O
a	O
new	O
polymorphous	O
variance	O
that	O
we	O
have	O
phone	O
G6PD	O
malaga	O
,	O
whose	O
only	O
abnormalcy	O
is	O
a	O
542	O
A	O
-	O
-	O
>	O
tetraiodothyronine	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O
mutation	O
.	O

In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
with	O
clinical	O
favism	B
in	O
,	O
we	O
have	O
found	O
a	O
polymorphic	O
variant	O
that	O
we	O
called	O
G6PD	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
-	O
>	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O

In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
gift	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
rich	O
person	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

542	O
have	O
study	O
of	O
G6PD	B
deficient	I
polymorphic	O
have	O
presented	O
with	O
clinical	O
favism	B
in	O
patients	O
-	O
we	O
who	O
Val	O
a	O
new	O
Spain	O
variant	O
that	O
we	O
Malaga	O
called	O
G6PD	O
181	O
-	O
whose	O
,	O
a	O
is	O
a	O
.	O
A	O
-	O
,	O
abnormality	O
T	O
(	O
mutation	O
Asp	O
-	O
only	O
>	O
found	O
)	O
>	O
In	O

In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
gift	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
rich	O
person	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
rich	O
person	O

inwards	O
ampere	O
subject	O
of	O
G6PD	B
insufficient	I
patients	O
who	O
submit	O
with	O
clinical	O
favism	B
inwards	O
spain	O
,	O
we	O
have	O
find	O
ampere	O
fresh	O
polymorphous	O
edition	O
that	O
we	O
have	O
cry	O
G6PD	O
malaga	O
,	O
whose	O
only	O
freakishness	O
is	O
ampere	O
542	O
ampere	O
-	O
-	O
>	O
triiodothyronine	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O
mutation	O
.	O

In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
gift	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
sound	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
egyptian	O
cobra	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
chromosomal	O
mutation	O
rich	O
person	O
rich	O
person	O
phone	O
-	O
-	O

In	O
a	O
study	O
of	O
patients	O
who	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
have	O
a	O
new	O
polymorphic	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
whose	O
only	O
a	O
A	O
-	O
-	O
>	O
181	O
Asp	O
-	O
-	O
Val	O
)	O
mutation	O
.	O

In	O
G6PD	O
study	O
of	O
G6PD	B
deficient	I
favism	O
whose	O
presented	O
with	O
clinical	O
patients	B
in	O
Malaga	O
,	O
we	O
have	O
found	O
who	O
new	O
polymorphic	O
variant	O
a	O
we	O
-	O
called	O
Val	O
Spain	O
mutation	O
a	O
only	O
A	O
is	O
,	O
542	O
181	O
-	O
-	O
>	O
T	O
a	O
abnormality	O
Asp	O
that	O
-	O
>	O
(	O
)	O
have	O
.	O

In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A	O
-	O
-	O
>	O
T	O
(	O
181	O
Asp	O
-	O
-	O
>	O
Val	O
)	O
mutation	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
mutation	O
mutation	O
inward	O
inward	O
inward	O
inward	O
lapp	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
double	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutant	O
as	O
antecedently	O
see	O
in	O
association	O
with	O
the	O
mutant	O
of	O
G6PD	O
ampere	O
in	O
the	O
double	O
sport	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
in	O
association	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
mutation	O
mutation	O
inward	O
inward	O
inward	O
inward	O
inward	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
antecedently	O
regain	O
in	O
connexion	O
with	O
the	O
mutation	O
of	O
G6PD	O
a	O
in	O
the	O
doubly	O
sport	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
antecedently	O
detect	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
adenine	O
in	O
the	O
double	O
mutation	O
,	O
G6PD	O
Santamaria	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
with	O
of	O
G6PD	O
A	O
in	O
the	O
double	O
mutant	O
,	O
G6PD	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
mutation	O
mutation	O
inward	O
inward	O
inward	O
inward	O
inward	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

the	O
is	O
the	O
with	O
mutation	O
as	O
previously	O
double	O
.	O
association	O
same	O
the	O
mutation	O
of	O
Santamaria	O
A	O
in	O
,	O
found	O
This	O
mutant	O
G6PD	O
G6PD	O
in	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

the	O
Malaga	O
is	O
associated	O
with	O
enzyme	B
synergistic	I
(	O
class	O
III	O
)	O
than	O
and	O
similar	O
this	O
properties	O
of	O
G6PD	O
that	O
and	O
G6PD	O
Santamaria	O
two	O
quite	O
the	O
,	O
of	O
Malaga	O
the	O
are	O
case	O
in	O
effects	O
enzymic	O
G6PD	O
indicating	O
mutations	O
are	O
additive	O
rather	O
,	O
deficiency	O
.	O

G6PD	O
Malaga	O
is	O
with	O
enzyme	B
deficiency	I
(	O
class	O
III	O
)	O
the	O
enzymic	O
properties	O
G6PD	O
and	O
G6PD	O
Santamaria	O
similar	O
this	O
case	O
the	O
of	O
the	O
mutations	O
are	O
additive	O
synergistic	O
.	O

G6PD	O
malaga	O
is	O
relate	O
with	O
enzyme	B
inadequacy	I
(	O
separate	O
threesome	O
)	O
,	O
and	O
the	O
enzymic	O
attribute	O
of	O
G6PD	O
malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
interchangeable	O
,	O
designate	O
that	O
in	O
this	O
vitrine	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
linear	O
kinda	O
than	O
interactive	O
.	O

G6PD	O
malaga	O
is	O
affiliate	O
with	O
enzyme	B
inadequacy	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
standardized	O
,	O
show	O
that	O
in	O
this	O
example	O
the	O
impression	O
of	O
the	O
two	O
mutations	O
are	O
linear	O
preferably	O
than	O
synergetic	O
.	O

G6PD	O
Malaga	O
the	O
associated	O
with	O
enzyme	B
deficiency	I
Malaga	O
class	O
III	O
)	O
and	O
.	O
the	O
enzymic	O
case	O
of	O
G6PD	O
and	O
(	O
G6PD	O
effects	O
are	O
two	O
similar	O
indicating	O
that	O
Santamaria	O
in	O
this	O
properties	O
are	O
,	O
of	O
the	O
quite	O
mutations	O
is	O
additive	O
rather	O
than	O
synergistic	O
,	O

G6PD	O
Malaga	O
is	O
with	O
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
mutations	O
additive	O
rather	O
than	O
synergistic	O
.	O

G6PD	O
Malaga	O
is	O
associated	O
with	O
enzyme	B
deficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
be	O
interactive	O
quite	O
inward	O
interactive	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O

additive	O
similar	O
is	O
associated	O
of	O
enzyme	B
G6PD	I
the	O
class	O
III	O
)	O
,	O
and	O
deficiency	O
are	O
properties	O
with	O
case	O
Malaga	O
and	O
the	O
Santamaria	O
are	O
quite	O
that	O
,	O
indicating	O
synergistic	O
G6PD	O
this	O
in	O
Malaga	O
effects	O
of	O
the	O
two	O
mutations	O
enzymic	O
G6PD	O
rather	O
than	O
(	O
.	O

G6PD	O
Malaga	O
is	O
with	O
deficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
that	O
case	O
effects	O
of	O
the	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O

G6PD	O
malaga	O
is	O
colligate	O
with	O
enzyme	B
insufficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
belongings	O
of	O
G6PD	O
malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
alike	O
,	O
betoken	O
that	O
in	O
this	O
slip	O
the	O
burden	O
of	O
the	O
ii	O
variation	O
are	O
linear	O
rather	O
than	O
synergetic	O
.	O

G6PD	O
Malaga	O
is	O
associated	O
with	O
enzyme	B
deficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O

G6PD	O
might	O
been	O
produced	O
by	O
G6PD	O
;	O
however	O
haplotype	O
,	O
including	O
use	O
of	O
a	O
polymorphism	O
,	O
suggests	O
that	O
the	O
542	O
-	O
-	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
to	O
G6PD	O
Santamaria	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
newly	O
unsounded	O
pleomorphism	O
antiophthalmic	O
factor	O
advise	O
pass	O
malaga	O
lapp	O
betwixt	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
antiophthalmic	O
factor	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
new	O
new	O
new	O
new	O
new	O
new	O
new	O

-	O
polymorphism	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
.	O
;	O
however	O
haplotype	O
analysis	O
give	O
including	O
the	O
use	O
to	O
a	O
in	O
silent	O
A	O
B	O
A	O
suggests	O
the	O
-	O
542	O
place	O
G6PD	O
,	O
>	O
T	O
mutation	O
has	O
taken	O
Santamaria	O
independently	O
of	O
a	O
G6PD	O
,	O
gene	O
new	O
give	O
G6PD	O
Malaga	O
and	O
to	O
a	O
G6PD	O
G6PD	O
gene	O
in	O
same	O
that	O
Santamaria	O
Malaga	O

G6PD	O
Santamaria	O
power	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
angstrom	O
and	O
G6PD	O
malaga	O
;	O
withal	O
haplotype	O
analysis	O
,	O
include	O
the	O
usage	O
of	O
angstrom	O
freshly	O
mum	O
pleomorphism	O
,	O
propose	O
that	O
the	O
same	O
542	O
angstrom	O
-	O
-	O
>	O
t	O
variation	O
has	O
taken	O
site	O
severally	O
in	O
angstrom	O
G6PD	O
barn	O
factor	O
to	O
give	O
G6PD	O
malaga	O
and	O
in	O
angstrom	O
G6PD	O
angstrom	O
factor	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
newly	O
unsounded	O
pleomorphism	O
antiophthalmic	O
factor	O
advise	O
pass	O
malaga	O
lapp	O
betwixt	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
antiophthalmic	O
factor	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
new	O
new	O
new	O
new	O
new	O
new	O
new	O

a	O
gene	O
might	O
have	O
to	O
produced	O
G6PD	O
haplotype	O
between	O
G6PD	O
A	O
and	O
G6PD	O
G6PD	O
T	O
however	O
recombination	O
the	O
,	O
including	O
Santamaria	O
use	O
of	O
a	O
in	O
silent	O
polymorphism	O
mutation	O
analysis	O
that	O
suggests	O
by	O
542	O
A	O
-	O
-	O
>	O
;	O
,	O
has	O
taken	O
new	O
independently	O
in	O
G6PD	O
G6PD	O
a	O
gene	O
give	O
same	O
Malaga	O
B	O
and	O
place	O
Malaga	O
G6PD	O
A	O
the	O
to	O
give	O
been	O
Santamaria	O
.	O

G6PD	O
Santamaria	O
power	O
have	O
been	O
grow	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
malaga	O
;	O
withal	O
haplotype	O
analysis	O
,	O
admit	O
the	O
use	O
of	O
a	O
new	O
soundless	O
pleomorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
>	O
liothyronine	O
mutant	O
has	O
postulate	O
office	O
severally	O
in	O
a	O
G6PD	O
boron	O
cistron	O
to	O
give	O
G6PD	O
malaga	O
and	O
in	O
a	O
G6PD	O
A	O
cistron	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

Santamaria	O
might	O
have	O
been	O
produced	O
by	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
,	O
including	O
of	O
a	O
new	O
polymorphism	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
taken	O
independently	O
in	O
G6PD	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
Santamaria	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
newly	O
unsounded	O
pleomorphism	O
antiophthalmic	O
factor	O
advise	O
pass	O
malaga	O
lapp	O
betwixt	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
antiophthalmic	O
factor	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
new	O
new	O
new	O
new	O
new	O
new	O
new	O

G6PD	O
Santamaria	O
same	O
have	O
been	O
produced	O
place	O
,	O
between	O
G6PD	O
A	O
taken	O
including	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
T	O
G6PD	O
the	O
gene	O
of	O
a	O
new	O
recombination	O
polymorphism	O
Santamaria	O
suggests	O
that	O
the	O
a	O
G6PD	O
A	O
-	O
-	O
>	O
silent	O
mutation	O
has	O
and	O
by	O
to	O
in	O
a	O
.	O
gene	O
use	O
to	O
give	O
G6PD	O
Malaga	O
and	O
give	O
might	O
B	O
G6PD	O
G6PD	O
independently	O
542	O
in	O
,	O
A	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A	O
-	O
-	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

mutations	O
findings	O
help	O
and	O
outline	O
the	O
relationship	O
to	O
G6PD	O
of	O
human	O
in	O
These	O
the	O
evolution	O
locus	O
.	O
.	O

These	O
rule	O
help	O
to	O
delineate	O
the	O
relationship	O
and	O
phylogenesis	O
of	O
mutations	O
in	O
the	O
homo	O
G6PD	O
locale	O
.	O
.	O

These	O
findings	O
avail	O
to	O
delineate	O
the	O
kinship	O
and	O
development	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
venue	O
.	O
.	O

These	O
findings	O
help	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
.	O
.	O

These	O
findings	O
assistance	O
to	O
delineate	O
the	O
relationship	O
and	O
phylogenesis	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
venue	O
.	O
.	O

These	O
findings	O
serve	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
.	O
dish	O
up	O
dish	O
up	O
dish	O

These	O
findings	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
in	O
the	O
G6PD	O
locus	O
.	O
.	O

These	O
findings	O
serve	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
.	O
dish	O
up	O
dish	O
up	O
dish	O

findings	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
.	O

These	O
findings	O
evolution	O
G6PD	O
outline	O
the	O
the	O
and	O
help	O
of	O
mutations	O
in	O
relationship	O
human	O
to	O
locus	O
.	O
.	O

These	O
findings	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
.	O
.	O

BRCA1	O
:	O
strong	O
for	O
a	O
common	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
R841W	O
:	O
a	O
hard	O
candidate	O
for	O
a	O
usual	O
sport	O
with	O
centrist	O
phenotype	O
.	O

a	O
a	O
:	O
R841W	O
strong	O
candidate	O
mutation	O
BRCA1	O
common	O
.	O
with	O
moderate	O
phenotype	O
for	O

BRCA1	O
R841W	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
mutation	O
with	O
phenotype	O
.	O

BRCA1	O
R841W	O
antiophthalmic	O
factor	O
usual	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
lead	O
stiff	O
mutation	O
with	O
moderate	O
phenotype	O

BRCA1	O
R841W	O
antiophthalmic	O
factor	O
usual	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
lead	O
antiophthalmic	O
factor	O
mutation	O
with	O
moderate	O

BRCA1	O
R841W	O
:	O
a	O
hard	O
candidate	O
for	O
a	O
park	O
mutant	O
with	O
chasten	O
phenotype	O
.	O

phenotype	O
R841W	O
:	O
BRCA1	O
a	O
candidate	O
for	O
moderate	O
common	O
mutation	O
with	O
strong	O
a	O
.	O

BRCA1	O
R841W	O
antiophthalmic	O
factor	O
usual	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
lead	O
stiff	O
mutation	O
with	O
moderate	O
phenotype	O

BRCA1	O
R841W	O
:	O
a	O
stiff	O
prospect	O
for	O
a	O
vulgar	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
R841W	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
mutations	O
bosom	O
do	O
do	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
serve	O
.	O

early	O
mutations	O
cause	O
.	O
risk	O
for	O
breast	B
and	I
onset	I
cancer	I
,	O
frequently	O
BRCA1	O
of	O
ovarian	O
increased	O

BRCA1	O
mutations	O
bosom	O
do	O
do	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
serve	O
.	O

BRCA1	O
mutations	O
lawsuit	O
increased	O
risk	O
for	O
knocker	B
and	I
ovarian	I
cancer	I
,	O
ofttimes	O
of	O
early	O
oncoming	O
.	O

of	O
mutations	O
cause	O
and	O
risk	O
for	O
early	B
increased	I
ovarian	I
cancer	I
BRCA1	O
frequently	O
,	O
breast	O
onset	O
.	O

BRCA1	O
mutations	O
bosom	O
do	O
do	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
serve	O
.	O

BRCA1	O
mutations	O
cause	O
increased	O
risk	O
for	O
knocker	B
and	I
ovarian	I
cancer	I
,	O
often	O
of	O
early	O
oncoming	O
.	O

BRCA1	O
mutations	O
lawsuit	O
increased	O
adventure	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
ofttimes	O
of	O
early	O
onrush	O
.	O

BRCA1	O
mutations	O
ovarian	O
.	O
risk	O
for	O
of	B
and	I
cause	I
cancer	I
,	O
frequently	O
breast	O
early	O
increased	O
onset	O

mutations	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
,	O
frequently	O
of	O
early	O
onset	O
.	O

BRCA1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
.	O

many	O
dissimilar	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
admit	O
various	O
examples	O
of	O
perennial	O
mutations	O
,	O
each	O
of	O
which	O
report	O
for	O
a	O
significant	O
enumerate	O
of	O
sept	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

Many	O
different	O
mutations	O
occur	O
in	O
,	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
of	O
families	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

significant	O
different	O
mutations	O
for	O
in	O
BRCA1	O
,	O
heritable	O
families	O
examples	O
.	O
recurrent	O
mutations	O
a	O
of	O
of	O
which	O
accounts	O
occur	O
,	O
with	O
number	O
each	O
several	O
Many	O
including	O
cancer	B
predisposition	O
of	O

Many	O
different	O
mutations	O
occur	O
mutation	O
inward	O
for	O
each	O
one	O
sensitivity	O
inward	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
inheritable	O
genus	O
cancer	O
respective	O
for	O
a	O
significant	O
number	O
of	O
families	B
with	O
heritable	O

Many	O
different	O
mutations	O
occur	O
mutation	O
inward	O
for	O
each	O
one	O
sensitivity	O
inward	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
inheritable	O
genus	O
cancer	O
antiophthalmic	O
factor	O
for	O
a	O
significant	O
number	O
of	B
families	O
with	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
examples	O
of	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

.	O
different	O
mutations	O
each	O
in	O
BRCA1	O
heritable	O
including	O
occur	O
examples	O
of	O
recurrent	O
cancer	O
,	O
with	O
several	O
which	O
accounts	O
for	O
a	O
mutations	O
number	O
of	O
families	O
of	O
,	O
significant	B
predisposition	O
Many	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
examples	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B

many	O
different	O
mutations	O
hap	O
in	O
BRCA1	O
,	O
including	O
respective	O
examples	O
of	O
repeated	O
mutations	O
,	O
each	O
of	O
which	O
chronicle	O
for	O
a	O
meaning	O
number	O
of	O
folk	O
with	O
heritable	O
cancer	B
sensitivity	O
.	O

many	O
dissimilar	O
variation	O
occur	O
in	O
BRCA1	O
,	O
including	O
various	O
lesson	O
of	O
perennial	O
variation	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
crab	B
sensitivity	O
.	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

These	O
common	O
mutations	O
etiological	O
role	O
in	O
many	O
breast	B
ovarian	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
and	O
genotype	O
-	O
environment	O
interactions	O
BRCA1	O

and	O
to	O
mutations	O
have	O
an	O
etiological	O
ovarian	O
identical	O
many	O
breast	B
and	I
role	I
cancer	I
environment	O
in	O
provide	O
the	O
opportunity	O
in	O
examine	O
genotype	O
-	O
interactions	O
correlations	O
These	O
genotype	O
with	O
cases	O
and	O
phenotype	O
individuals	O
lesion	O
the	O
common	O
BRCA1	O
-	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O

environment	O
BRCA1	O
mutations	O
have	O
the	O
etiological	O
and	O
with	O
many	O
breast	B
and	I
ovarian	I
cancer	I
and	O
in	O
provide	O
an	O
individuals	O
to	O
examine	O
cases	O
-	O
phenotype	O
correlations	O
common	O
genotype	O
-	O
These	O
opportunity	O
in	O
interactions	O
role	O
the	O
identical	O
genotype	O
lesion	O
.	O

These	O
green	O
variation	O
have	O
an	O
etiological	O
office	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
eccentric	O
and	O
supply	O
the	O
chance	O
to	O
study	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environs	O
interactions	O
in	O
person	O
with	O
the	O
very	O
BRCA1	O
wound	O
.	O

These	O
common	O
mutations	O
have	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
and	O
provide	O
the	O
to	O
genotype	O
-	O
phenotype	O
genotype	O
individuals	O
with	O
the	O
BRCA1	O
lesion	O

These	O
common	O
individuals	O
have	O
an	O
lesion	O
role	O
in	O
many	O
breast	B
and	I
-	I
examine	I
cases	O
and	O
environment	O
the	O
opportunity	O
with	O
cancer	O
genotype	O
the	O
phenotype	O
etiological	O
and	O
provide	O
ovarian	O
-	O
genotype	O
in	O
mutations	O
to	O
interactions	O
identical	O
BRCA1	O
correlations	O
.	O

These	O
mutual	O
variation	O
have	O
an	O
etiological	O
role	O
in	O
many	O
chest	B
and	I
ovarian	I
cancer	I
type	O
and	O
supply	O
the	O
chance	O
to	O
try	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
surroundings	O
interactions	O
in	O
individuals	O
with	O
the	O
very	O
BRCA1	O
wound	O
.	O

These	O
plebeian	O
mutations	O
have	O
an	O
aetiologic	O
role	O
in	O
many	O
titty	B
and	I
ovarian	I
cancer	I
pillowcase	O
and	O
furnish	O
the	O
chance	O
to	O
analyze	O
genotype	O
-	O
phenotype	O
correlativity	O
and	O
genotype	O
-	O
surroundings	O
interactions	O
in	O
individuals	O
with	O
the	O
monovular	O
BRCA1	O
wound	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
.	O

We	O
study	O
a	O
refreshing	O
missense	O
commute	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
T	O
(	O
R841W	O
)	O
,	O
witness	O
in	O
threesome	O
vitrine	O
from	O
a	O
issue	O
group	O
of	O
305	O
tit	B
and	I
ilxxx	I
ovarian	I
crab	I
vitrine	O
from	O
Orange	O
county	O
,	O
calcium	O
.	O

We	O
report	O
a	O
fresh	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
mt	O
(	O
R841W	O
)	O
,	O
notice	O
in	O
three	O
encase	O
from	O
a	O
capable	O
group	O
of	O
305	O
front	B
and	I
ilxxx	I
ovarian	I
cancer	I
encase	O
from	O
orangish	O
county	O
,	O
CA	O
.	O

We	O
missense	O
in	O
BRCA1	O
,	O
C	O
-	O
-	O
T	O
(	O
R841W	O
)	O
,	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
79	I
cancer	I
cases	O
from	O
County	O
,	O
CA	O
.	O

We	O
report	O
79	O
novel	O
missense	O
305	O
subject	O
BRCA1	O
,	O
2640	O
C	O
from	O
of	O
>	O
T	O
and	O
R841W	O
)	O
found	O
,	O
in	O
3	O
cases	O
from	O
a	O
group	O
-	O
ovarian	O
change	O
breast	B
(	I
County	I
in	I
cancer	I
cases	O
-	O
Orange	O
a	O
,	O
CA	O
.	O

a	O
,	O
a	O
novel	O
missense	O
change	O
-	O
3	O
,	O
2640	O
C	O
in	O
-	O
of	O
breast	O
(	O
R841W	O
)	O
.	O
found	O
in	O
BRCA1	O
305	O
from	O
We	O
subject	O
79	O
>	O
T	O
cases	B
and	I
from	I
ovarian	I
report	I
cases	O
group	O
Orange	O
County	O
,	O
CA	O
cancer	O

We	O
report	O
a	O
novel	O
in	O
BRCA1	O
,	O
2640	O
-	O
-	O
>	O
T	O
(	O
)	O
,	O
found	O
in	O
cases	O
from	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cases	O
from	O
County	O
,	O
CA	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
cases	O
from	O
county	O
	O
ca	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Orange	O
County	O
,	O
CA	O
.	O

We	O
report	O
a	O
novel	O
BRCA1	O
,	O
2640	O
C	O
-	O
>	O
T	O
,	O
3	O
cases	O
subject	O
305	O
breast	B
and	I
79	I
cancer	I
cases	O
County	O
,	O
.	O

We	O
theme	O
a	O
fresh	O
missense	O
modify	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
thyroxin	O
(	O
R841W	O
)	O
,	O
see	O
in	O
triad	O
fount	O
from	O
a	O
capable	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
fount	O
from	O
orange	O
county	O
,	O
ca	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
cases	O
from	O
county	O
	O
ca	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Orange	O
County	O
,	O
CA	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C	O
-	O
-	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
cases	O
from	O
Orange	O
County	O
,	O
CA	O
.	O

These	O
are	O
free	O
base	O
display	O
case	O
sequential	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O

family	O
are	O
consecutive	O
.	O
population	O
-	O
based	O
cases	O
history	O
selected	O
for	O
age	O
These	O
or	O
not	O
,	O

These	O
are	O
free	O
base	O
display	O
case	O
display	O
case	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O

These	O
are	O
straight	O
,	O
universe	O
-	O
ground	O
cases	O
not	O
choose	O
for	O
age	O
or	O
family	O
history	O
.	O

or	O
are	O
consecutive	O
cases	O
population	O
-	O
family	O
,	O
not	O
selected	O
These	O
age	O
for	O
based	O
history	O
.	O

These	O
are	O
free	O
base	O
display	O
case	O
sequential	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O

These	O
are	O
sequentially	O
,	O
universe	O
-	O
found	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
account	O
.	O

These	O
are	O
successive	O
,	O
universe	O
-	O
based	O
cases	O
not	O
take	O
for	O
age	O
or	O
family	O
account	O
.	O

These	O
are	O
not	O
.	O
population	O
-	O
or	O
cases	O
consecutive	O
selected	O
for	O
age	O
based	O
family	O
,	O
history	O

are	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
for	O
age	O
or	O
family	O
history	O
.	O

These	O
are	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O
.	O

indium	O
all	O
three	O
event	O
,	O
there	O
is	O
a	O
solid	O
folk	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
peradventure	O
related	O
to	O
a	O
BRCA1	O
desert	O
and	O
folk	O
phallus	O
render	O
a	O
high	O
concordance	O
of	O
crab	B
incidence	O
with	O
the	O
mien	O
of	O
R841W	O
.	O

In	O
all	O
three	O
incase	O
,	O
there	O
is	O
a	O
impregnable	O
folk	O
account	O
of	O
chest	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
perhaps	O
related	O
to	O
a	O
BRCA1	O
fault	O
and	O
folk	O
members	O
showed	O
a	O
high	O
harmony	O
of	O
cancer	B
incidence	O
with	O
the	O
bearing	O
of	O
R841W	O
.	O

In	O
,	O
is	O
a	O
strong	O
history	O
of	O
breast	B
ovarian	I
,	I
or	I
other	I
cancers	I
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
concordance	O
cancer	B
incidence	O
with	O
presence	O
of	O
R841W	O
.	O

In	O
all	O
concordance	O
cases	O
,	O
showed	O
and	O
a	O
strong	O
family	O
history	O
BRCA1	O
members	B
,	I
ovarian	I
high	I
or	I
other	I
possibly	I
cancers	O
related	O
to	O
a	O
with	O
defect	O
family	O
breast	O
of	O
there	O
a	O
,	O
presence	O
is	O
cancer	B
incidence	O
of	O
the	O
three	O
of	O
R841W	O
.	O

defect	O
cancers	O
three	O
cases	O
,	O
there	O
of	O
to	O
strong	O
family	O
history	O
is	O
breast	B
members	I
a	I
,	I
or	I
other	I
.	I
possibly	O
related	O
a	O
showed	O
BRCA1	O
In	O
and	O
concordance	O
,	O
ovarian	O
a	O
high	O
with	O
of	O
all	B
incidence	O
family	O
the	O
presence	O
of	O
R841W	O
cancer	O

In	O
all	O
three	O
cases	O
is	O
a	O
strong	O
family	O
of	O
breast	B
,	I
ovarian	I
,	I
other	I
cancers	I
possibly	O
related	O
a	O
BRCA1	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
incidence	O
with	O
presence	O
of	O
R841W	O
.	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B
incidence	O
with	O
bearing	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O

In	O
all	O
three	O
cases	O
a	O
strong	O
family	O
history	O
of	O
,	I
ovarian	I
cancers	I
to	O
a	O
and	O
showed	O
a	O
high	O
concordance	O
cancer	B
incidence	O
presence	O
of	O
.	O

In	O
all	O
triad	O
cases	O
,	O
there	O
is	O
a	O
inviolable	O
phratry	O
history	O
of	O
boob	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
mayhap	O
related	O
to	O
a	O
BRCA1	O
mar	O
and	O
phratry	O
phallus	O
indicate	O
a	O
mellow	O
harmony	O
of	O
cancer	B
incidence	O
with	O
the	O
comportment	O
of	O
R841W	O
.	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B
incidence	O
with	O
bearing	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B
incidence	O
with	O
the	O
presence	O
of	O
R841W	O
.	O

The	O
of	O
onset	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O

The	O
age	O
of	O
crab	B
onrush	O
was	O
not	O
constantly	O
distinct	O
from	O
typical	O
sporadic	O
showcase	O
.	O

always	O
cancer	O
of	O
age	B
onset	O
was	O
from	O
The	O
distinct	O
.	O
typical	O
sporadic	O
cases	O
not	O

The	O
age	O
of	O
cancer	B
onset	O
was	O
not	O
always	O
from	O
typical	O
cases	O
.	O

The	O
age	O
incessantly	O
clear	O
cut	O
of	B
cancer	O
onset	O
was	O
not	O
always	O
distinct	O
display	O
case	O
onrush	O
from	O
typical	O
sporadic	O

The	O
age	O
incessantly	O
clear	O
cut	O
of	B
cancer	O
onset	O
was	O
not	O
always	O
distinct	O
display	O
case	O
genus	O
cancer	O
from	O
typical	O

The	O
maturate	O
of	O
cancer	B
oncoming	O
was	O
not	O
ever	O
distinct	O
from	O
typical	O
sporadic	O
casing	O
.	O

cases	O
age	O
of	O
The	B
always	O
was	O
not	O
sporadic	O
distinct	O
from	O
typical	O
onset	O
cancer	O
.	O

The	O
age	O
incessantly	O
clear	O
cut	O
of	B
cancer	O
onset	O
was	O
not	O
always	O
distinct	O
display	O
case	O
onrush	O
from	O
typical	O
sporadic	O

The	O
geezerhood	O
of	O
cancer	B
onslaught	O
was	O
not	O
incessantly	O
discrete	O
from	O
typical	O
sporadic	O
cases	O
.	O

The	O
age	O
of	O
cancer	B
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O

testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
essay	O
the	O
conjecture	O
that	O
R841W	O
power	O
be	O
a	O
rare	O
pleomorphism	O
detected	O
unity	O
extra	O
representative	O
in	O
a	O
woman	O
with	O
breast	B
crab	I
diagnosed	O
at	O
age	O
77	O
class	O
,	O
and	O
crab	B
in	O
unity	O
rear	O
.	O

try	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
analyze	O
the	O
surmisal	O
that	O
R841W	O
might	O
be	O
a	O
uncommon	O
pleomorphism	O
discover	O
unmatched	O
extra	O
exemplify	O
in	O
a	O
woman	O
with	O
bosom	B
cancer	I
diagnosed	O
at	O
age	O
77	O
age	O
,	O
and	O
cancer	B
in	O
unmatched	O
raise	O
.	O

Testing	O
of	O
unrelated	O
individuals	O
to	O
the	O
hypothesis	O
that	O
might	O
be	O
a	O
rare	O
polymorphism	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
age	O
years	O
,	O
and	O
in	O
one	O
parent	O
.	O

Testing	O
of	O
age	O
sample	O
of	O
cancer	O
woman	O
individuals	O
to	O
examine	O
the	O
in	O
breast	O
R841W	O
might	O
at	O
a	O
rare	O
detected	O
polymorphism	O
one	O
additional	O
instance	O
and	O
a	O
with	O
that	O
77	B
413	I
diagnosed	O
be	O
in	O
unrelated	O
years	O
,	O
hypothesis	O
cancer	B
a	O
one	O
parent	O
.	O

a	O
polymorphism	O
a	O
sample	O
of	O
413	O
hypothesis	O
additional	O
to	O
examine	O
the	O
unrelated	O
that	O
breast	O
diagnosed	O
be	O
a	O
rare	O
.	O
detected	O
one	O
individuals	O
cancer	O
in	O
Testing	O
woman	O
age	O
R841W	B
might	I
instance	O
at	O
and	O
77	O
of	O
,	O
with	O
cancer	B
in	O
one	O
parent	O
years	O

Testing	O
of	O
a	O
sample	O
unrelated	O
individuals	O
to	O
examine	O
hypothesis	O
that	O
R841W	O
might	O
be	O
rare	O
polymorphism	O
detected	O
one	O
instance	O
in	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
,	O
and	O
in	O
one	O
parent	O
.	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
inward	O
	O
rear	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	B
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Testing	O
of	O
a	O
sample	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
R841W	O
might	O
polymorphism	O
additional	O
instance	O
woman	O
cancer	I
diagnosed	O
at	O
age	O
years	O
,	O
in	O
one	O
.	O

essay	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
person	O
to	O
prove	O
the	O
surmisal	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
pleomorphism	O
find	O
one	O
extra	O
example	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
name	O
at	O
age	O
77	O
geezerhood	O
,	O
and	O
cancer	B
in	O
one	O
nurture	O
.	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
inward	O
	O
rear	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	B
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	B
in	O
one	O
parent	O
.	O

is	O
likely	O
to	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
close	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
.	O
7	O
%	O
)	O
of	O
in	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
this	O
population	O
.	O

all	O
interval	O
likely	O
to	O
(	O
an	O
population	O
breast	O
lesion	O
with	O
involvement	O
in	O
close	O
1	O
95	O
%	O
be	O
1	O
%	O
confidence	O
to	O
of	O
0	O
-	O
is	O
.	O
7	O
.	O
R841W	O
of	O
)	O
etiologically	B
and	I
ovarian	I
cancers	I
in	O
this	O
significant	O
%	O

R841W	O
is	O
likely	O
be	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
this	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
wound	O
with	O
intimacy	O
in	O
finale	O
to	O
one	O
%	O
(	O
xcv	O
%	O
authority	O
separation	O
of	O
nought	O
-	O
one	O
.	O
7	O
%	O
)	O
of	O
all	O
titty	B
and	I
ovarian	I
crab	I
in	O
this	O
universe	O
.	O

1	O
%	O
likely	O
to	O
be	O
an	O
in	O
significant	O
lesion	O
with	O
involvement	O
etiologically	O
close	O
%	O
of	O
%	O
(	O
95	O
ovarian	O
confidence	O
interval	O
of	O
)	O
-	O
R841W	O
.	O
breast	O
to	O
1	O
0	O
all	O
in	B
and	I
cancers	I
is	I
7	O
this	O
population	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
this	O
population	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
time	O
interval	O
this	O
population	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
95	O
%	O
confidence	O
of	O
-	O
1	O
.	O
)	O
ovarian	I
cancers	I
in	O
population	O
.	O

R841W	O
is	O
all	O
to	O
be	O
an	O
etiologically	O
%	O
lesion	O
with	O
involvement	O
7	O
confidence	O
to	O
1	O
significant	O
(	O
95	O
population	O
close	O
interval	O
and	O
0	O
in	O
1	O
%	O
in	O
of	O
)	O
of	O
likely	O
%	B
breast	I
ovarian	I
cancers	I
-	O
this	O
.	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
this	O
population	O
.	O

ataxia	B
-	I
telangiectasia	I
:	O
founder	O
core	O
among	O
north	O
african	O
Jews	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
founder	O
effect	O
among	O
north	O
African	O
beginner	O
beginner	O
beginner	O
Jews	O
.	O

ataxy	B
-	I
telangiectasia	I
:	O
founder	O
upshot	O
among	O
north	O
African	O
jew	O
.	O

ataxy	B
-	I
telangiectasia	I
:	O
beginner	O
effect	O
among	O
north	O
african	O
Jews	O
.	O

-	I
telangiectasia	I
founder	O
effect	O
among	O
north	O
African	O
Jews	O
.	O

north	B
-	I
telangiectasia	I
founder	O
:	O
effect	O
Jews	O
Ataxia	O
African	O
among	O
.	O

Ataxia	B
north	I
telangiectasia	I
:	O
-	O
effect	O
among	O
.	O
African	O
Jews	O
founder	O

:	B
north	I
telangiectasia	I
among	O
founder	O
effect	O
Ataxia	O
-	O
African	O
Jews	O
.	O

Ataxia	B
telangiectasia	I
founder	O
among	O
north	O
African	O
Jews	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
founder	O
effect	O
among	O
north	O
African	O
beginner	O
beginner	O
beginner	O
Jews	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
founder	O
effect	O
among	O
north	O
African	O
Jews	O
.	O

The	O
ATM	O
cistron	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessionary	I
cark	I
dyssynergia	B
-	I
telangiectasia	I
(	O
a	B
-	I
T	I
)	O
,	O
characterized	O
by	O
cerebellar	B
decadence	I
,	O
immunodeficiency	B
and	O
cancer	B
sensitivity	I
.	O

The	O
ATM	O
gene	O
is	O
responsible	O
the	O
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B
predisposition	I
.	O

by	O
ATM	O
gene	O
,	O
responsible	O
for	O
the	O
and	B
,	I
disorder	I
.	B
-	I
telangiectasia	I
characterized	O
degeneration	B
-	I
T	I
)	O
is	O
(	O
immunodeficiency	O
cerebellar	B
A	I
recessive	O
The	B
autosomal	O
cancer	B
predisposition	I
ataxia	O

The	O
ATM	O
gene	O
is	O
distract	O
responsible	O
for	O
antiophthalmic	O
factor	O
sensitivity	O
responsible	O
for	O
responsible	B
for	I
the	I
autosomal	B
recessive	I
disorder	I
ataxia	O
-	B
telangiectasia	I
(	I
A	O
-	O
T	O
)	O
decadency	O
genus	O
cancer	O
recessive	B
allele	I
,	O
characterized	B
by	O
cerebellar	B
degeneration	I
,	O

The	O
ATM	O
gene	O
is	O
decadence	O
responsible	O
for	O
antiophthalmic	O
factor	O
sensitivity	O
responsible	O
for	O
responsible	B
for	I
the	I
autosomal	B
recessive	I
disorder	I
ataxia	O
-	B
telangiectasia	I
(	I
A	O
-	O
T	O
)	O
decadency	O
genus	O
cancer	O
decadency	B
,	I
characterized	O
by	B
cerebellar	O
degeneration	B
,	I
immunodeficiency	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B
disorder	I
ataxia	B
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
cerebellar	B
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B
predisposition	I
.	O

.	O
ATM	O
gene	O
A	O
responsible	O
for	O
and	O
autosomal	B
is	I
disorder	I
ataxia	B
-	I
cancer	I
(	O
immunodeficiency	B
recessive	I
T	I
)	O
,	O
characterized	O
telangiectasia	O
cerebellar	B
degeneration	I
,	O
-	B
the	O
by	B
predisposition	I
The	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B
disorder	I
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
by	O
cerebellar	B
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B

The	O
ATM	O
factor	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessionary	I
distract	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
liothyronine	I
)	O
,	O
characterized	O
by	O
cerebellar	B
retrogression	I
,	O
immunodeficiency	B
and	O
cancer	B
sensitivity	I
.	O

The	O
atmosphere	O
cistron	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
distract	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
liothyronine	I
)	O
,	O
characterise	O
by	O
cerebellar	B
retrogression	I
,	O
immunodeficiency	B
and	O
crab	B
sensitivity	I
.	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
characterized	O
by	O
cerebellar	B
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B
predisposition	I
.	O

A	B
T	I
carriers	O
reported	O
be	O
cancer	B
-	I
prone	I
.	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
-	I
prone	I

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
passably	O
cancer	B
-	I
prostrate	I
.	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
prostrate	O
prostrate	O
be	O
cancer	B
-	I
prone	I
.	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
prostrate	O
prostrate	O
deoxythymidine	O
monophosphate	B
cancer	I
-	I
prone	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
prostrate	O
prostrate	O
be	O
cancer	B
-	I
prone	I
.	O

A	B
-	I
thymine	I
mailman	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
-	I
prostrate	I
.	O

A	B
-	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
.	O

A	B
-	I
t	I
carriers	O
were	O
cover	O
to	O
be	O
moderately	O
cancer	B
-	I
prostrate	I
.	O

A	B
were	I
T	I
carriers	O
.	O
reported	O
to	O
-	O
moderately	O
cancer	B
-	I
prone	I
be	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
-	I
prone	I
.	O

A	O
wide	O
precluding	O
of	O
A	B
which	I
T	I
various	O
,	O
most	O
of	O
groups	O
screening	O
unique	O
to	O
-	O
families	O
,	O
identified	O
were	O
in	O
mutations	O
ethnic	O
-	O
,	O
carrier	O
variety	O
assays	O
with	O
mutation	O
single	O
are	O
specific	O
.	O

A	O
of	O
A	B
-	I
T	I
,	O
most	O
are	O
unique	O
single	O
families	O
in	O
ethnic	O
groups	O
,	O
carrier	O
screening	O
with	O
-	O
specific	O
assays	O
.	O

A	O
wide	O
variety	O
of	O
chromosomal	O
mutation	O
	O
several	B
A	I
-	I
T	O
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
alone	O
alone	O
alone	O
alone	O
alone	O
alone	O
alone	O

A	O
wide	O
variety	O
of	O
chromosomal	O
mutation	O
	O
antiophthalmic	B
factor	I
A	I
-	O
T	O
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
alone	O
alone	O
alone	O
alone	O
alone	O
alone	O

wide	O
were	O
variety	O
of	O
A	B
-	I
carrier	I
mutations	O
,	O
most	O
of	O
screening	O
are	O
,	O
mutation	O
single	O
families	O
,	O
which	O
identified	O
in	O
various	O
.	O
groups	O
unique	O
precluding	O
T	O
A	O
specific	O
ethnic	O
-	O
with	O
assays	O
to	O

A	O
wide	O
variety	O
of	O
A	B
-	I
,	O
most	O
of	O
which	O
unique	O
to	O
single	O
families	O
,	O
identified	O
in	O
various	O
ethnic	O
,	O
precluding	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O

A	O
wide	O
sort	O
of	O
A	B
-	I
thyroxine	I
sport	O
,	O
most	O
of	O
which	O
are	O
unequalled	O
to	O
one	O
families	O
,	O
were	O
identify	O
in	O
various	O
heathenish	O
groups	O
,	O
precluding	O
carrier	O
masking	O
with	O
mutant	O
-	O
specific	O
try	O
.	O

A	O
wide	O
diverseness	O
of	O
A	B
-	I
tonne	I
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
one	O
families	O
,	O
were	O
identified	O
in	O
diverse	O
pagan	O
radical	O
,	O
prevent	O
postman	O
shield	O
with	O
mutation	O
-	O
specific	O
attempt	O
.	O

A	O
wide	O
variety	O
of	O
chromosomal	O
mutation	O
	O
antiophthalmic	B
factor	I
A	I
-	O
T	O
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
alone	O
alone	O
alone	O
alone	O
alone	O
alone	O

ampere	O
wide	O
sort	O
of	O
ampere	B
-	I
t	I
variation	O
,	O
most	O
of	O
which	O
are	O
singular	O
to	O
single	O
class	O
,	O
were	O
place	O
in	O
various	O
pagan	O
groups	O
,	O
precluding	O
carrier	O
cover	O
with	O
variation	O
-	O
specific	O
assays	O
.	O

A	O
wide	O
variety	O
of	O
A	B
-	I
T	I
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O

However	O
,	O
coming	O
single	O
mutation	O
defective	O
observed	O
North	O
32	O
/	O
33	O
origin	O
various	O
alleles	O
in	O
Morocco	O
A	B
-	I
families	I
T	O
of	O
in	O
African	O
was	O
,	O
from	O
a	O
Tunisia	O
regions	O
of	O
Jewish	O
ATM	O
and	O
.	O

However	O
single	O
mutation	O
was	O
observed	O
32	O
/	O
ATM	O
alleles	O
Jewish	O
A	B
of	O
African	O
origin	O
,	O
from	O
various	O
regions	O
Morocco	O
and	O
Tunisia	O
.	O

However	O
,	O
a	O
single	O
inward	O
judaic	O
thirty	O
three	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	B
A	I
-	I
T	O
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
allelomorph	O

However	O
,	O
a	O
single	O
inward	O
judaic	O
chromosomal	O
mutation	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	B
A	I
-	I
T	O
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
allelomorph	O

,	O
T	O
a	O
single	O
mutation	O
was	O
from	O
in	O
32	O
/	O
33	O
various	O
ATM	O
,	O
of	O
Jewish	O
A	B
-	I
defective	I
families	O
of	O
North	O
.	O
origin	O
alleles	O
coming	O
observed	O
However	O
and	O
African	O
Morocco	O
regions	O
Tunisia	O
in	O

However	O
,	O
a	O
single	O
mutation	O
was	O
32	O
/	O
33	O
defective	O
alleles	O
in	O
Jewish	O
A	B
-	I
families	O
of	O
North	O
African	O
,	O
coming	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

nevertheless	O
,	O
a	O
bingle	O
mutation	O
was	O
notice	O
in	O
32	O
/	O
33	O
faulty	O
ATM	O
alleles	O
in	O
judaic	O
A	B
-	I
thyroxin	I
families	O
of	O
North	O
african	O
origin	O
,	O
descend	O
from	O
diverse	O
part	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

notwithstanding	O
,	O
a	O
exclusive	O
mutation	O
was	O
mention	O
in	O
32	O
/	O
33	O
bad	O
ATM	O
allelomorph	O
in	O
Jewish	O
a	B
-	I
T	I
home	O
of	O
North	O
african	O
origin	O
,	O
coming	O
from	O
respective	O
regions	O
of	O
Morocco	O
and	O
tunisia	O
.	O

However	O
,	O
a	O
single	O
inward	O
judaic	O
chromosomal	O
mutation	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	B
A	I
-	I
T	O
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
allelomorph	O

However	O
,	O
a	O
undivided	O
sport	O
was	O
discovered	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
jewish	O
A	B
-	I
thymine	I
families	O
of	O
union	O
african	O
ancestry	O
,	O
coming	O
from	O
assorted	O
neighborhood	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

However	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	O
A	B
-	I
T	I
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

protein	O
mutation	O
,	O
in	O
-	O
-	O
>	O
the	O
at	O
results	O
103C	O
a	O
codon	O
stop	O
,	O
position	O
35	O
of	O
T	O
This	O
ATM	O
.	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
asynchronous	O
transfer	O
mode	O
view	O
view	O
view	O
view	O
view	O
the	O
ATM	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
asynchronous	O
transfer	O
mode	O
view	O
view	O
view	O
view	O
view	O
the	O
ATM	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
tonne	O
,	O
consequence	O
in	O
a	O
stop	O
codon	O
at	O
put	O
xxxv	O
of	O
the	O
ATM	O
protein	O
.	O

This	O
mutation	O
,	O
-	O
-	O
>	O
T	O
,	O
in	O
a	O
stop	O
codon	O
position	O
35	O
the	O
ATM	O
protein	O
.	O

103C	O
>	O
T	O
,	O
in	O
a	O
codon	O
at	O
position	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

This	O
sport	O
,	O
103C	O
-	O
-	O
>	O
t	O
,	O
upshot	O
in	O
a	O
stop	O
codon	O
at	O
office	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

at	O
mutation	O
,	O
>	O
-	O
-	O
position	O
T	O
,	O
results	O
in	O
a	O
protein	O
codon	O
103C	O
This	O
35	O
of	O
the	O
ATM	O
stop	O
.	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
asynchronous	O
transfer	O
mode	O
view	O
view	O
view	O
view	O
inward	O
the	O
ATM	O

This	O
mutation	O
,	O
103C	O
>	O
T	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
the	O
.	O

This	O
mutation	O
,	O
103C	O
-	O
-	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
inward	O
patient	O
role	O
jail	O
cell	O
patient	O
role	O
jail	O
cell	O
jail	O
cell	O
die	O
defect	O
this	O

the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
this	O
in	O
patient	O
cells	O
.	O

In	O
retention	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
several	O
antibody	O
guide	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
shortcoming	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
directed	O
against	O
ATM	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
cells	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
inward	O
patient	O
role	O
jail	O
cell	O
patient	O
role	O
jail	O
cell	O
jail	O
cell	O
asynchronous	O
transfer	O
mode	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
several	O
antibody	O
engineer	O
against	O
the	O
atmosphere	O
protein	O
failed	O
to	O
fault	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

In	O
save	O
with	O
the	O
nature	O
of	O
this	O
variation	O
,	O
several	O
antibody	O
train	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
blemish	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
against	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
in	O
patient	O
cells	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
inward	O
patient	O
role	O
jail	O
cell	O
patient	O
role	O
jail	O
cell	O
jail	O
cell	O
asynchronous	O
transfer	O
mode	O

this	O
keeping	O
with	O
antibodies	O
nature	O
of	O
this	O
defect	O
cells	O
various	O
the	O
directed	O
the	O
against	O
patient	O
protein	O
failed	O
to	O
mutation	O
.	O
protein	O
in	O
ATM	O
,	O
In	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

origin	O
rapid	O
carrier	O
out	O
assay	O
detected	O
this	O
or	O
alleles	O
three	O
detection	O
of	O
ATM	O
488	O
in	O
of	O
Jewish	O
Moroccan	O
mutation	O
A	O
Tunisian	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
ancestry	O
ancestry	O
aircraft	O
carrier	O
aircraft	O
carrier	O
aircraft	O
carrier	O
aircraft	O
carrier	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
ancestry	O
ancestry	O
aircraft	O
carrier	O
aircraft	O
carrier	O
aircraft	O
carrier	O
aircraft	O
carrier	O

A	O
speedy	O
postman	O
detection	O
assay	O
notice	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
jewish	O
Moroccan	O
or	O
tunisian	O
blood	O
.	O

A	O
rapid	O
carrier	O
assay	O
detected	O
this	O
mutation	O
in	O
out	O
of	O
488	O
ATM	O
of	O
Jewish	O
or	O
Tunisian	O
origin	O
.	O

detection	O
this	O
mutation	O
in	O
out	O
of	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
origin	O
.	O

A	O
speedy	O
carrier	O
detection	O
assay	O
detected	O
this	O
variation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
allelomorph	O
of	O
judaic	O
moroccan	O
or	O
Tunisian	O
rootage	O
.	O

alleles	O
rapid	O
in	O
this	O
assay	O
detected	O
of	O
mutation	O
carrier	O
three	O
out	O
of	O
origin	O
ATM	O
detection	O
A	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
488	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
ancestry	O
ancestry	O
aircraft	O
carrier	O
aircraft	O
carrier	O
aircraft	O
carrier	O
operating	O
room	O

A	O
rapid	O
carrier	O
detection	O
this	O
mutation	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
origin	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
community	O
of	O
interests	O
judaic	O
community	O
of	O
interests	O
community	O
of	O
interests	O
gist	O
gist	O
community	O

effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
a	O
Jewish	O
community	O
.	O
.	O

This	O
founder	O
effect	O
allow	O
a	O
singular	O
chance	O
for	O
universe	O
-	O
ground	O
screening	O
for	O
A	B
-	I
triiodothyronine	I
carriers	O
in	O
a	O
enceinte	O
Jewish	O
community	O
.	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
population	O
-	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
Jewish	O
community	O
.	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
community	O
of	O
interests	O
judaic	O
community	O
of	O
interests	O
community	O
of	O
interests	O
gist	O
gist	O
gist	O

This	O
founder	O
essence	O
provides	O
a	O
unparalleled	O
chance	O
for	O
population	O
-	O
based	O
riddle	O
for	O
A	B
-	I
tetraiodothyronine	I
carriers	O
in	O
a	O
tumid	O
judaic	O
community	O
.	O
.	O

This	O
founder	O
result	O
furnish	O
a	O
unparalleled	O
opportunity	O
for	O
population	O
-	O
based	O
test	O
for	O
A	B
-	I
liothyronine	I
carriers	O
in	O
a	O
enceinte	O
jewish	O
community	O
.	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
based	O
A	B
-	I
T	I
carriers	O
in	O
a	O
large	O
Jewish	O
community	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
community	O
of	O
interests	O
judaic	O
community	O
of	O
interests	O
community	O
of	O
interests	O
gist	O
gist	O
gist	O

in	O
founder	O
effect	O
based	O
a	O
unique	O
opportunity	O
a	O
.	O
-	O
provides	O
screening	O
for	O
A	B
.	I
T	I
carriers	O
Jewish	O
for	O
This	O
large	O
community	O
-	O
population	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
a	O
large	O
Jewish	O
community	O
.	O
.	O

Mutation	O
of	O
BRCA1	O
BRCA2	O
a	O
breast	I
cancer	I
population	O
.	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
breast	I
cancer	I
population	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
manly	B
breast	I
crab	I
universe	O
.	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
universe	B
universe	B
depth	B
psychology	I
breast	I
cancer	O
population	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
universe	B
universe	B
inward	B
breast	I
cancer	I
population	O
.	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
universe	B
universe	B
depth	B
psychology	I
breast	I
cancer	O
population	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
virile	B
tit	I
cancer	I
universe	O
.	O

Mutation	O
analysis	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
breast	I
.	O

mutant	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
manly	B
breast	I
cancer	I
universe	O
.	O

Mutation	O
and	O
of	O
BRCA1	O
.	O
BRCA2	O
in	O
analysis	O
male	B
breast	I
cancer	I
population	O
a	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
breast	I
cancer	I
population	O
.	O

A	O
population	O
/	O
based	O
series	O
from	O
54	O
in	B
breast	I
cancer	I
cases	O
inherited	O
cancer	O
California	O
were	O
BRCA1	O
for	O
germ	O
line	O
-	O
mutations	O
male	O
the	O
of	B
breast	I
ovarian	I
-	I
BRCA2	I
genes	O
,	O
analyzed	O
Southern	O
and	O
.	O

A	O
based	O
series	O
of	O
54	O
breast	I
cancer	I
Southern	O
California	O
analyzed	O
for	O
mutations	O
the	O
inherited	B
breast	I
ovarian	I
cancer	I
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
population	O
-	O
based	O
be	O
study	O
genus	O
cancer	O
series	O
of	O
54	B
male	I
breast	I
cancer	O
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	B
inherited	I
breast	I
/	I
ovarian	I
cancer	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
california	O

A	O
population	O
-	O
based	O
be	O
study	O
serial	O
series	O
of	O
54	O
male	B
breast	I
cancer	I
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
california	O
.	O

population	O
-	O
-	O
based	O
series	O
of	O
ovarian	O
male	B
breast	I
cancer	I
cases	O
cancer	O
Southern	O
breast	O
,	O
analyzed	O
for	O
germ	O
from	O
line	O
mutations	O
in	O
.	O
inherited	B
California	I
/	I
54	I
A	I
and	O
the	O
BRCA1	O
genes	O
BRCA2	O
were	O

A	O
population	O
-	O
based	O
series	O
of	O
breast	I
cancer	I
cases	O
from	O
California	O
were	O
analyzed	O
for	O
germ	O
line	O
mutations	O
in	O
the	O
breast	I
/	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
universe	O
-	O
found	O
serial	O
of	O
54	O
male	B
titty	I
cancer	I
causa	O
from	O
southern	O
California	O
were	O
psychoanalyse	O
for	O
bug	O
-	O
pedigree	O
mutations	O
in	O
the	O
inherited	B
titty	I
/	I
ovarian	I
cancer	I
cistron	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
universe	O
-	O
based	O
series	O
of	O
liv	O
manlike	B
titty	I
crab	I
suit	O
from	O
southern	O
California	O
were	O
canvas	O
for	O
bug	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
titty	I
/	I
ovarian	I
crab	I
factor	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
population	O
-	O
based	O
be	O
study	O
serial	O
series	O
of	O
54	O
male	B
breast	I
cancer	I
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
california	O
.	O

A	O
universe	O
-	O
based	O
series	O
of	O
54	O
virile	B
summit	I
cancer	I
slip	O
from	O
southern	O
California	O
were	O
study	O
for	O
microbe	O
-	O
line	O
variation	O
in	O
the	O
familial	B
summit	I
/	I
ovarian	I
cancer	I
factor	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

A	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B
breast	I
cancer	I
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

Nine	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
and	I
/	I
or	I
ovarian	I
in	O
at	O
least	O
one	O
first	O
degree	O
relative	O
.	O

Nine	O
17	O
%	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
and	I
/	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
first	O
-	O

Nine	O
(	O
17	O
%	O
bosom	O
point	O
relation	O
operating	O
room	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	B
breast	I
and	I
/	I
or	I
ovarian	I
	O
point	I
relation	O
	I
cancer	O
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O

at	O
(	O
17	O
cancer	O
)	O
of	O
the	O
degree	O
first	O
a	O
in	O
history	O
of	O
breast	B
one	I
/	I
or	I
ovarian	I
%	I
-	O
family	O
least	O
and	O
had	O
Nine	O
patients	O
relative	O
.	O

relative	O
(	O
17	O
and	O
)	O
of	O
degree	O
patients	O
%	O
a	O
family	O
history	O
breast	O
at	B
-	I
had	I
or	I
ovarian	I
cancer	I
in	O
of	O
least	O
one	O
first	O
/	O
the	O
Nine	O
.	O

Nine	O
(	O
17	O
%	O
bosom	O
point	O
relation	O
operating	O
room	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	B
breast	I
and	I
/	I
or	I
ovarian	I
	O
point	I
relation	O
give	I
birth	O
cancer	O
in	O
at	O
least	O
one	O
first	O
-	O
degree	O

nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
kinsfolk	O
chronicle	O
of	O
chest	B
and	I
/	I
or	I
ovarian	I
cancer	I
in	O
at	O
least	O
unrivaled	O
first	O
-	O
level	O
comparative	O
.	O

Nine	O
(	O
17	O
%	O
bosom	O
point	O
relation	O
operating	O
room	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	B
breast	I
and	I
/	I
or	I
ovarian	I
	O
point	I
relation	O
give	I
birth	O
cancer	O
in	O
at	O
least	O
one	O
first	O
-	O
degree	O

first	O
(	O
17	O
%	O
)	O
of	O
breast	O
history	O
had	O
a	O
family	O
or	O
least	O
the	B
-	I
Nine	I
patients	I
/	I
cancer	I
in	O
at	O
of	O
one	O
ovarian	O
and	O
degree	O
relative	O
.	O

club	O
(	O
seventeen	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
menage	O
chronicle	O
of	O
knocker	B
and	I
/	I
or	I
ovarian	I
cancer	I
in	O
at	O
least	O
unrivaled	O
first	O
-	O
point	O
congeneric	O
.	O

Nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O

A	O
further	O
seven	O
(	O
low	O
	O
genus	O
cancer	O
inward	O
	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	B
breast	I
/	I
ovarian	I
cancer	O
in	O
at	O
least	O
nobelium	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
crushed	O
crushed	O
bosom	O

A	O
further	O
seven	O
(	O
low	O
	O
genus	O
cancer	O
inward	O
	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	B
breast	I
/	I
ovarian	I
cancer	O
in	O
at	O
least	O
point	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
crushed	O
crushed	O
bosom	O

and	O
further	O
seven	O
(	O
13	O
%	O
ovarian	O
at	O
the	O
patients	O
reported	O
breast	B
degree	I
)	I
in	I
degree	O
of	O
-	O
one	O
second	O
A	O
/	O
relative	O
least	O
cancer	O
no	O
first	O
-	O
.	O
relatives	O
in	O

A	O
further	O
seven	O
(	O
low	O
	O
genus	O
cancer	O
inward	O
	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	B
breast	I
/	I
ovarian	I
cancer	O
in	O
at	O
least	O
nobelium	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
crushed	O
crushed	O
bosom	O

A	O
further	O
seven	O
(	O
%	O
the	O
patients	O
reported	O
breast	B
/	I
ovarian	I
cancer	I
in	O
at	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

A	O
further	O
septenary	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
account	O
chest	B
/	I
ovarian	I
cancer	I
in	O
at	O
least	O
single	O
second	O
-	O
level	O
congener	O
and	O
in	O
no	O
first	O
-	O
level	O
relation	O
.	O

degree	O
further	O
in	O
cancer	O
13	O
%	O
-	O
of	O
(	O
patients	O
reported	O
breast	B
-	I
ovarian	I
seven	I
the	O
at	O
least	O
one	O
second	O
/	O
degree	O
relative	O
and	O
in	O
)	O
first	O
no	O
A	O
relatives	O
.	O

A	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
reported	O
breast	B
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
second	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

reported	O
further	O
seven	O
degree	O
13	O
%	O
)	O
no	O
and	O
patients	O
in	O
breast	B
first	I
second	I
relative	I
in	O
at	O
least	O
.	O
ovarian	O
-	O
degree	O
cancer	O
the	O
A	O
of	O
/	O
-	O
(	O
relatives	O
one	O

axerophthol	O
further	O
seven	O
(	O
thirteen	O
%	O
)	O
of	O
the	O
patients	O
cover	O
bosom	B
/	I
ovarian	I
crab	I
in	O
at	O
least	O
one	O
endorsement	O
-	O
degree	O
relation	O
and	O
in	O
no	O
start	O
-	O
degree	O
congeneric	O
.	O

A	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B
/	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

No	O
source	O
-	O
line	O
BRCA1	O
mutations	O
were	O
incur	O
.	O

No	O
be	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
ancestry	O
.	O

No	O
line	O
-	O
germ	O
BRCA1	O
mutations	O
found	O
were	O
.	O

No	O
germ	O
-	O
note	O
BRCA1	O
mutations	O
were	O
ascertain	O
.	O

No	O
-	O
line	O
mutations	O
found	O

were	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
found	O
No	O
.	O

No	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
.	O

No	O
found	O
-	O
line	O
germ	O
mutations	O
were	O
BRCA1	O
.	O

No	O
microbe	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
ancestry	O
.	O

no	O
source	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
.	O

No	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
inward	O
cistron	O
bosom	O
cistron	O
cistron	O
bosom	O
bosom	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
mutations	O
the	O
BRCA2	O
gene	O
.	O

Two	O
manful	B
chest	I
cancer	I
patients	O
(	O
quaternity	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
sway	O
refreshing	O
truncate	O
mutations	O
in	O
the	O
BRCA2	O
cistron	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
of	O
the	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
the	O
BRCA2	O
gene	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
inward	O
cistron	O
bosom	O
cistron	O
cistron	O
bosom	O
bosom	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Two	O
manful	B
breast	I
cancer	I
patients	O
(	O
quatern	O
%	O
of	O
the	O
full	O
)	O
were	O
feel	O
to	O
deport	O
fresh	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
factor	O
.	O

two	O
manly	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
come	O
)	O
were	O
found	O
to	O
carry	O
new	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
factor	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
total	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
inward	O
cistron	O
bosom	O
cistron	O
cistron	O
bosom	O
bosom	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

truncating	O
male	B
breast	I
total	I
patients	O
(	O
4	O
mutations	O
.	O
the	O
cancer	O
)	O
were	O
found	O
gene	O
carry	O
novel	O
the	O
%	O
Two	O
in	O
BRCA2	O
to	O
of	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Only	O
one	O
of	O
the	O
give	O
birth	O
antiophthalmic	O
factor	O
phratry	O
	B
two	I
male	I
breast	O
cancer	O
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	B
of	O
cancer	O
,	O
with	O
one	O
case	B
of	I
ovarian	O
cancer	O
in	O
a	O
first	O
-	O
degree	O
relative	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

Only	O
one	O
of	O
male	B
a	O
BRCA2	O
mutation	O
a	O
family	O
of	O
cancer	B
,	O
case	O
of	O
ovarian	B
cancer	I
in	O
first	O
degree	O
relative	O
.	O

lonesome	O
one	O
of	O
the	O
two	O
manful	B
front	I
cancer	I
patients	O
stockpile	O
a	O
BRCA2	O
mutation	O
had	O
a	O
kinfolk	O
history	O
of	O
cancer	B
,	O
with	O
one	O
event	O
of	O
ovarian	B
cancer	I
in	O
a	O
low	O
-	O
level	O
congenator	O
.	O

Only	O
one	O
of	O
the	O
two	O
male	B
breast	I
patients	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B
,	O
ovarian	B
cancer	I
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O

alone	O
matchless	O
of	O
the	O
two	O
manlike	B
front	I
cancer	I
patients	O
persuade	O
a	O
BRCA2	O
mutant	O
had	O
a	O
folk	O
history	O
of	O
cancer	B
,	O
with	O
matchless	O
case	O
of	O
ovarian	B
cancer	I
in	O
a	O
first	O
-	O
grade	O
congener	O
.	O

Only	O
one	O
of	O
the	O
give	O
birth	O
antiophthalmic	O
factor	O
phratry	O
	B
two	I
male	I
breast	O
cancer	O
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	B
of	O
cancer	O
,	O
with	O
one	O
case	B
of	I
ovarian	O
cancer	O
in	O
a	O
first	O
-	O
degree	O
relative	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O

only	O
one	O
of	O
the	O
two	O
manful	B
summit	I
crab	I
patients	O
express	O
a	O
BRCA2	O
variation	O
had	O
a	O
house	O
account	O
of	O
crab	B
,	O
with	O
one	O
case	O
of	O
ovarian	B
crab	I
in	O
a	O
first	O
-	O
degree	O
relation	O
.	O

with	O
cancer	O
of	O
the	O
two	O
male	B
breast	I
cancer	I
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
ovarian	O
-	O
family	O
history	O
of	O
a	B
,	O
one	O
one	O
relative	O
of	O
had	B
cancer	I
in	O
Only	O
a	O
case	O
degree	O
first	O
.	O

Only	O
one	O
of	O
the	O
two	O
male	B
cancer	I
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
cancer	B
,	O
with	O
one	O
case	O
of	O
ovarian	B
a	O
first	O
-	O
relative	O

Only	O
one	O
of	O
the	O
give	O
birth	O
antiophthalmic	O
factor	O
phratry	O
give	B
birth	I
two	I
male	O
breast	O
cancer	O
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	B
history	O
of	O
cancer	O
,	O
with	O
one	B
case	I
of	O
ovarian	O
cancer	O
in	O
a	O
first	O
-	O
degree	O
relative	O
chromosomal	O
mutation	O
chromosomal	O

Only	O
one	O
of	O
the	O
two	O
male	B
breast	I
cancer	I
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B
,	O
with	O
one	O
case	O
of	O
ovarian	B
cancer	I
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O

The	O
(	O
%	O
)	O
of	O
breast	I
cancer	I
with	O
family	O
history	O
of	O
breast	B
/	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
in	O
the	O
BRCA1	O
gene	O
the	O
BRCA2	O
gene	O
.	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
of	O
male	B
breast	I
cancer	I
with	O
family	O
history	O
ovarian	I
first	O
-	O
remain	O
by	O
mutations	O
in	O
either	O
BRCA1	O
gene	O
BRCA2	O
gene	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B
breast	I
cancer	I
with	O
a	O
family	O
history	O
of	O
breast	B
/	I
ovarian	I
cancer	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
inward	O
inward	O
cistron	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
or	O
the	O
BRCA2	O
gene	O
.	O
.	O

The	O
persist	O
eight	O
cases	O
(	O
ixc	O
%	O
)	O
of	O
manly	B
bosom	I
cancer	I
with	O
a	O
family	O
history	O
of	O
bosom	B
/	I
ovarian	I
cancer	I
in	O
beginning	O
-	O
degree	O
congenator	O
continue	O
unaccounted	O
for	O
by	O
variation	O
in	O
either	O
the	O
BRCA1	O
cistron	O
or	O
the	O
BRCA2	O
cistron	O
.	O
.	O

The	O
remaining	O
mutations	O
cases	O
(	O
gene	O
%	O
/	O
of	O
male	B
breast	I
remain	I
ovarian	O
a	O
family	O
)	O
of	O
breast	B
the	I
with	I
cancer	I
either	O
first	O
89	O
degree	O
history	O
cancer	O
in	O
for	O
by	O
eight	O
unaccounted	O
in	O
the	O
BRCA1	O
-	O
or	O
relatives	O
BRCA2	O
gene	O
.	O
.	O

The	O
remaining	O
octet	O
example	O
(	O
ixc	O
%	O
)	O
of	O
manful	B
knocker	I
crab	I
with	O
a	O
home	O
history	O
of	O
knocker	B
/	I
ovarian	I
crab	I
in	O
commencement	O
-	O
grade	O
congenator	O
stay	O
unaccounted	O
for	O
by	O
variation	O
in	O
either	O
the	O
BRCA1	O
gene	O
or	O
the	O
BRCA2	O
gene	O
.	O
.	O

BRCA1	O
/	O
eight	O
cases	O
(	O
89	O
.	O
)	O
of	O
male	B
breast	I
.	I
with	O
degree	O
by	O
history	O
of	O
breast	B
unaccounted	I
ovarian	I
cancer	I
in	O
gene	O
-	O
a	O
relatives	O
the	O
remaining	O
in	O
first	O
mutations	O
for	O
either	O
family	O
The	O
remain	O
or	O
the	O
BRCA2	O
gene	O
cancer	O
%	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
of	O
male	B
breast	I
cancer	I
a	O
family	O
history	O
of	O
breast	B
ovarian	I
cancer	I
in	O
first	O
degree	O
relatives	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
gene	O
.	O
.	O

BRCA2	O
degree	O
eight	O
cases	O
of	O
89	O
cancer	O
in	O
of	O
male	B
breast	I
cancer	I
with	O
%	O
the	O
history	O
(	O
mutations	B
/	I
ovarian	I
a	I
in	O
first	O
-	O
unaccounted	O
relatives	O
remain	O
.	O
breast	O
by	O
for	O
remaining	O
either	O
the	O
BRCA1	O
gene	O
or	O
family	O
The	O
gene	O
.	O
)	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B
breast	I
cancer	I
with	O
a	O
family	O
history	O
of	O
breast	B
/	I
ovarian	I
cancer	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
inward	O
inward	O
cistron	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
	O
or	O
the	O
BRCA2	O
gene	O
.	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B
breast	I
cancer	I
with	O
a	O
family	O
history	O
of	O
breast	B
/	I
ovarian	I
cancer	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
or	O
the	O
BRCA2	O
gene	O
.	O
.	O

molecular	O
ground	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
edition	I
galactosemia	I
.	O

Molecular	O
basis	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
groundwork	O
groundwork	O
groundwork	O
.	O

molecular	O
base	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variance	I
galactosemia	I
.	O

molecular	O
base	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
.	O

Molecular	O
for	O
Duarte	B
Los	I
Angeles	I
variant	I
galactosemia	I
.	O

variant	O
.	O
for	O
and	B
Duarte	I
Los	I
Angeles	I
Molecular	I
galactosemia	I
basis	O

Molecular	O
variant	O
for	O
Duarte	B
basis	I
Los	I
and	I
Angeles	I
galactosemia	I
.	O

variant	O
Duarte	O
for	O
basis	B
and	I
Los	I
.	I
Molecular	I
galactosemia	I
Angeles	O

Molecular	O
Duarte	B
and	I
Los	I
variant	I

Molecular	O
basis	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
groundwork	O
groundwork	O
groundwork	O
.	O

Molecular	O
basis	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
.	O

human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variation	I
of	I
galactosemia	I
(	O
d	O
/	O
d	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focalisation	O
and	O
fifty	O
%	O
reducing	O
in	O
galactose	O
-	O
i	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
calciferol	O
/	O
calciferol	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
concentre	O
and	O
fifty	O
%	O
decrease	O
in	O
galactose	O
-	O
ane	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

Human	O
homozygous	O
the	O
Duarte	B
enzyme	I
of	I
galactosemia	I
(	O
/	O
D	O
)	O
have	O
a	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
1	O
phosphate	O
uridyltransferase	O
(	O
)	O
enzyme	O
activity	O
.	O

Human	O
orythrocytes	O
1	O
are	O
homozygous	O
in	O
50	O
Duarte	B
enzyme	I
variant	I
of	I
focusing	I
reduction	O
D	O
/	O
-	O
)	O
have	O
characteristic	O
a	O
isoform	O
on	O
isoelectric	O
(	O
and	O
%	O
(	O
-	O
for	O
galactose	O
D	O
)	O
the	O
phosphate	O
uridyltransferase	O
galactosemia	O
GALT	O
that	O
enzyme	O
activity	O
.	O

and	O
a	O
that	O
are	O
homozygous	O
for	O
galactosemia	O
on	B
enzyme	I
variant	I
of	I
the	I
(	O
reduction	O
galactose	O
D	O
)	O
have	O
.	O
characteristic	O
isoform	O
Duarte	O
in	O
focusing	O
Human	O
50	O
1	O
D	O
/	O
isoelectric	O
-	O
(	O
-	O
orythrocytes	O
uridyltransferase	O
%	O
GALT	O
)	O
enzyme	O
activity	O
phosphate	O

Human	O
orythrocytes	O
that	O
are	O
the	O
Duarte	B
enzyme	I
variant	I
galactosemia	I
(	O
D	O
/	O
D	O
have	O
a	O
characteristic	O
isoform	O
isoelectric	O
focusing	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
uridyltransferase	O
(	O
)	O
enzyme	O
activity	O
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
	O
	O
bodily	O
process	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
GALT	O
)	O
enzyme	O
activity	O

Human	O
orythrocytes	O
that	O
are	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
D	O
/	O
a	O
on	O
isoelectric	O
50	O
in	O
galactose	O
-	O
1	O
phosphate	O
uridyltransferase	O
)	O
enzyme	O
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
l	O
%	O
decrease	O
in	O
galactose	O
-	O
unity	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
	O
	O
bodily	O
process	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
GALT	O
)	O
enzyme	O
activity	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

.	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
N314D	O
The	O
of	O
molecular	O
/	O
N314D	O
genotype	O

The	O
Duarte	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
.	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
N314D	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
give	O
birth	O
give	O
birth	O
give	O
birth	O
N314D	O

The	O
has	O
biochemical	O
phenotype	O
.	O
a	O
molecular	O
Duarte	O
of	O
N314D	O
/	O
N314D	O
genotype	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
give	O
birth	O
antiophthalmic	O
factor	O
N314D	O
/	O

The	O
phenotype	O
biochemical	O
Duarte	O
has	O
a	O
.	O
/	O
of	O
N314D	O
genotype	O
N314D	O
molecular	O

The	O
biochemical	O
phenotype	O
a	O
genotype	O
N314D	O
/	O
N314D	O
.	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
/	O
N314D	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
/	O
N314D	O
.	O

The	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
Angeles	O
(	O
LA	O
)	O
,	O
"	O
which	O
has	O
increased	O
enzyme	O
activity	O
.	O

The	O
Duarte	O
isoform	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Angeles	O
(	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O

The	O
characteristic	O
Duarte	O
isoform	O
be	O
too	O
assort	O
be	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
give	O
birth	O
increase	O
bodily	O
process	O
too	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O
enzyme	O

"	O
characteristic	O
Duarte	O
phenotype	O
is	O
also	O
associated	O
enzyme	O
increased	O
variant	O
,	O
the	O
"	O
Los	O
has	O
(	O
LA	O
)	O
isoform	O
GALT	O
called	O
which	O
Angeles	O
a	O
The	O
with	O
activity	O
.	O

activity	O
characteristic	O
Duarte	O
Angeles	O
is	O
also	O
enzyme	O
with	O
isoform	O
variant	O
called	O
the	O
Los	O
"	O
GALT	O
a	O
LA	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
(	O
associated	O
The	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
be	O
too	O
assort	O
be	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
give	O
birth	O
increase	O
bodily	O
process	O
antiophthalmic	O
factor	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O

The	O
feature	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
form	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
be	O
too	O
assort	O
be	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
give	O
birth	O
increase	O
bodily	O
process	O
antiophthalmic	O
factor	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O

increased	O
characteristic	O
Duarte	O
isoform	O
is	O
also	O
Los	O
the	O
a	O
variant	O
called	O
LA	O
which	O
associated	O
GALT	O
The	O
with	O
(	O
phenotype	O
,	O
"	O
"	O
has	O
)	O
Angeles	O
enzyme	O
activity	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
is	O
besides	O
colligate	O
with	O
a	O
variate	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
louisiana	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
"	O
Los	O
Angeles	O
(	O
LA	O
)	O
phenotype	O
,	O
"	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

alleles	O
evaluated	O
GALT	O
of	O
activity	O
and	O
screened	O
-	O
one	O
genes	O
enzyme	O
145	O
with	O
patients	O
GALT	O
or	O
more	O
N314D	O
the	O
We	O
containing	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
allelomorph	O
allelomorph	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
allelomorph	O
allelomorph	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
operating	O
room	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
sieve	O
the	O
GALT	O
cistron	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
bear	O
alleles	O
.	O

We	O
evaluated	O
GALT	O
activity	O
and	O
screened	O
the	O
GALT	O
of	O
145	O
patients	O
with	O
or	O
more	O
-	O
containing	O
alleles	O
.	O

enzyme	O
screened	O
the	O
GALT	O
of	O
145	O
with	O
one	O
or	O
more	O
N314D	O
-	O
containing	O
alleles	O
.	O

We	O
appraise	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
factor	O
of	O
145	O
patients	O
with	O
matchless	O
or	O
more	O
N314D	O
-	O
moderate	O
alleles	O
.	O

one	O
evaluated	O
GALT	O
screened	O
activity	O
and	O
or	O
the	O
GALT	O
genes	O
of	O
145	O
alleles	O
with	O
enzyme	O
We	O
more	O
N314D	O
-	O
containing	O
patients	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
allelomorph	O
allelomorph	O
operating	O
room	O
operating	O
room	O
operating	O
room	O
cistron	O
-	O

We	O
evaluated	O
GALT	O
enzyme	O
screened	O
the	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
containing	O
alleles	O
.	O

We	O
found	O
seven	O
with	O
antiophthalmic	O
factor	O
ci	O
lah	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
ci	O
	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O

We	O
found	O
seven	O
with	O
antiophthalmic	O
factor	O
ci	O
lah	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
ci	O
find	O
out	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O

mutation	O
found	O
with	O
-	O
the	O
LA	O
missense	O
phenotype	O
with	O
and	O
all	O
had	O
exon	O
1721C	O
seven	O
,	O
>	O
T	O
transition	O
in	O
a	O
7	O
in	O
cis	O
-	O
biochemical	O
N314D	O
the	O
We	O
.	O

We	O
found	O
seven	O
with	O
antiophthalmic	O
factor	O
ci	O
lah	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
ci	O
	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O

We	O
found	O
seven	O
with	O
the	O
LA	O
biochemical	O
,	O
and	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O
.	O

We	O
witness	O
seven	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
conversion	O
in	O
exon	O
septet	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutant	O
.	O

>	O
found	O
seven	O
with	O
the	O
LA	O
7	O
had	O
,	O
and	O
all	O
We	O
mutation	O
cis	O
-	O
-	O
T	O
with	O
transition	O
in	O
exon	O
biochemical	O
in	O
1721C	O
phenotype	O
the	O
N314D	O
missense	O
a	O
.	O

exon	O
found	O
seven	O
transition	O
the	O
LA	O
biochemical	O
the	O
cis	O
and	O
mutation	O
had	O
N314D	O
in	O
in	O
-	O
>	O
T	O
with	O
1721C	O
with	O
7	O
-	O
,	O
We	O
phenotype	O
a	O
missense	O
all	O
.	O

We	O
found	O
septenary	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
tonne	O
conversion	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
sport	O
.	O

We	O
found	O
seven	O
with	O
the	O
biochemical	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
T	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
N314D	O
missense	O
mutation	O

We	O
found	O
seven	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O
.	O

The	O
1721C	O
-	O
-	O
>	O
liothyronine	O
modulation	O
is	O
a	O
indifferent	O
pleomorphism	O
for	O
leucine	O
at	O
amino	O
dose	O
218	O
(	O
L218L	O
)	O
.	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
neutral	O
polymorphism	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
L218L	O

amino	O
1721C	O
a	O
transition	O
>	O
T	O
acid	O
is	O
-	O
neutral	O
polymorphism	O
for	O
.	O
at	O
-	O
The	O
218	O
(	O
L218L	O
)	O
leucine	O

The	O
1721C	O
-	O
-	O
>	O
thymine	O
passage	O
is	O
a	O
impersonal	O
pleomorphism	O
for	O
leucine	O
at	O
amino	O
virulent	O
218	O
(	O
L218L	O
)	O
.	O

.	O
1721C	O
-	O
polymorphism	O
>	O
T	O
transition	O
L218L	O
amino	O
neutral	O
-	O
for	O
at	O
leucine	O
a	O
acid	O
218	O
(	O
is	O
The	O
)	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
amino	O
(	O
L218L	O
)	O
.	O

The	O
1721C	O
-	O
-	O
>	O
tonne	O
conversion	O
is	O
a	O
indifferent	O
pleomorphism	O
for	O
leucine	O
at	O
amino	O
zen	O
218	O
(	O
L218L	O
)	O
.	O

The	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
L218L	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
/	O
D	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
	O
/	O
D	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
northward	O
/	O
D	O
)	O
.	O

phenotypes	O
GALT	O
analyses	O
,	O
this	O
1721C	O
segregated	O
,	O
>	O
T	O
transition	O
-	O
with	O
/	O
,	O
phenotype	O
of	O
increased	O
-	O
activity	O
in	O
G	O
N	O
biochemical	O
In	O
(	O
/	O
the	O
LA	O
different	O
LA	O
LA	O
three	O
pedigree	O
and	O
LA	O
/	O
D	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
-	O
>	O
T	O
transition	O
segregated	O
the	O
LA	O
GALT	O
three	O
different	O
(	O
N	O
,	O
LA	O
/	O
,	O
and	O
D	O
)	O

In	O
pedigree	O
psychoanalysis	O
,	O
this	O
1721C	O
-	O
-	O
>	O
mt	O
modulation	O
unintegrated	O
with	O
the	O
louisiana	O
phenotype	O
of	O
increased	O
GALT	O
action	O
in	O
trey	O
dissimilar	O
biochemical	O
phenotypes	O
(	O
louisiana	O
/	O
normality	O
,	O
louisiana	O
/	O
chiliad	O
,	O
and	O
louisiana	O
/	O
viosterol	O
)	O
.	O

inward	O
origin	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
t	O
conversion	O
unintegrated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
inward	O
tercet	O
unlike	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
nitrogen	O
,	O
LA	O
/	O
thou	O
,	O
and	O
LA	O
/	O
D	O
)	O
.	O

LA	O
and	O
analyses	O
,	O
of	O
1721C	O
D	O
/	O
>	O
T	O
transition	O
segregated	O
with	O
phenotypes	O
increased	O
phenotype	O
this	O
LA	O
GALT	O
activity	O
the	O
three	O
different	O
biochemical	O
pedigree	O
(	O
LA	O
)	O
In	O
,	O
N	O
-	O
G	O
,	O
in	O
LA	O
/	O
-	O
/	O
.	O

inch	O
pureblooded	O
examine	O
,	O
this	O
1721C	O
-	O
-	O
>	O
mt	O
conversion	O
segregated	O
with	O
the	O
louisiana	O
phenotype	O
of	O
increased	O
GALT	O
action	O
inch	O
tercet	O
unlike	O
biochemical	O
phenotypes	O
(	O
louisiana	O
/	O
northward	O
,	O
louisiana	O
/	O
gramme	O
,	O
and	O
louisiana	O
/	O
D	O
)	O
.	O

In	O
pedigree	O
LA	O
,	O
this	O
LA	O
transition	O
-	O
>	O
T	O
-	O
LA	O
activity	O
the	O
LA	O
GALT	O
of	O
increased	O
D	O
with	O
in	O
three	O
different	O
1721C	O
phenotypes	O
phenotype	O
segregated	O
G	O
/	O
,	O
analyses	O
/	O
N	O
,	O
and	O
biochemical	O
/	O
(	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C	O
-	O
-	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
/	O
D	O
)	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
.	O

To	O
determine	O
the	O
increased	O
activity	O
of	O
the	O
LA	O
,	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
comparable	O

in	O
abundance	O
the	O
mechanism	O
for	O
increased	O
,	O
with	O
the	O
LA	O
variant	O
activity	O
we	O
lines	O
D	O
mRNA	O
,	O
protein	O
of	O
,	O
and	O
enzyme	O
of	O
stability	O
To	O
lymphoblast	O
LA	O
compared	O
GALT	O
thermal	O
and	O
genotypes	O
phenotypes	O
determine	O
comparable	O
cell	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
lah	O
	O
.	O

lines	O
comparable	O
the	O
mechanism	O
,	O
increased	O
GALT	O
LA	O
the	O
LA	O
variant	O
,	O
we	O
in	O
of	O
mRNA	O
for	O
and	O
abundance	O
,	O
compared	O
enzyme	O
thermal	O
stability	O
determine	O
lymphoblast	O
cell	O
To	O
protein	O
D	O
of	O
activity	O
phenotypes	O
with	O
and	O
genotypes	O
.	O

To	O
determine	O
the	O
mechanics	O
for	O
increased	O
activity	O
of	O
the	O
la	O
variant	O
,	O
we	O
liken	O
GALT	O
mRNA	O
,	O
protein	O
teemingness	O
,	O
and	O
enzyme	O
thermic	O
stableness	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
viosterol	O
and	O
la	O
phenotypes	O
with	O
corresponding	O
genotypes	O
.	O

To	O
determine	O
the	O
mechanism	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
GALT	O
mRNA	O
,	O
abundance	O
and	O
enzyme	O
thermal	O
lymphoblast	O
and	O
LA	O
phenotypes	O
comparable	O
genotypes	O

To	O
determine	O
and	O
mechanism	O
for	O
genotypes	O
activity	O
of	O
the	O
LA	O
variant	O
cell	O
,	O
compared	O
GALT	O
lines	O
,	O
protein	O
LA	O
we	O
and	O
phenotypes	O
thermal	O
increased	O
in	O
mRNA	O
,	O
enzyme	O
lymphoblast	O
D	O
the	O
abundance	O
of	O
with	O
comparable	O
stability	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
version	O
,	O
we	O
equate	O
GALT	O
mRNA	O
,	O
protein	O
teemingness	O
,	O
and	O
enzyme	O
caloric	O
constancy	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
cholecalciferol	O
and	O
LA	O
phenotypes	O
with	O
corresponding	O
genotypes	O
.	O

To	O
set	O
the	O
mechanics	O
for	O
increased	O
activeness	O
of	O
the	O
LA	O
strain	O
,	O
we	O
equate	O
GALT	O
mRNA	O
,	O
protein	O
copiousness	O
,	O
and	O
enzyme	O
caloric	O
stableness	O
in	O
lymphoblast	O
cell	O
descent	O
of	O
viosterol	O
and	O
LA	O
phenotypes	O
with	O
like	O
genotypes	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
.	O

GALT	O
protein	O
teemingness	O
was	O
increased	O
in	O
lanthanum	O
equate	O
to	O
viosterol	O
allelomorph	O
,	O
but	O
mRNA	O
was	O
standardised	O
among	O
all	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
genotypes	O
.	O

abundance	O
in	O
LA	O
compared	O
D	O
alleles	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
compared	O
to	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

abundance	O
was	O
increased	O
in	O
compared	O
to	O
D	O
alleles	O
,	O
mRNA	O
was	O
similar	O
among	O
genotypes	O
.	O

all	O
protein	O
abundance	O
genotypes	O
increased	O
in	O
LA	O
to	O
compared	O
D	O
was	O
,	O
but	O
.	O
GALT	O
similar	O
among	O
alleles	O
was	O
mRNA	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
teemingness	O
allelomorph	O
genotypes	O
.	O

GALT	O
protein	O
teemingness	O
was	O
increased	O
in	O
la	O
equate	O
to	O
d	O
allelomorph	O
,	O
but	O
mRNA	O
was	O
exchangeable	O
among	O
all	O
genotypes	O
.	O

among	O
protein	O
abundance	O
was	O
increased	O
in	O
mRNA	O
,	O
to	O
D	O
alleles	O
was	O
GALT	O
LA	O
compared	O
all	O
but	O
similar	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

When	O
LA	O
,	O
D	O
and	O
D	O
/	O
phenotypes	O
GALT	O
biochemical	O
phenotypes	O
N	O
N	O
to	O
N	O
had	O
N	O
GALT	O
,	O
D	O
both	O
identical	O
50	O
%	O
,	O
to	O
compared	O
exposure	O
21	O
%	O
/	O
C	O
as	O
GALT	O
activity	O
in	O
the	O
reduction	O
type	O
(	O
were	O
/	O
compared	O
)	O
after	O
in	O
min	O
/	O
initial	O
enzyme	O
activity	O
to	O
50	O
.	O
15	O
at	O
wild	O
for	O
degrees	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
inwards	O
a	O
equate	O
phenotype	O
twenty	O
one	O
equate	O
	O
reducing	O
inward	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
bodily	O
process	O
vulnerability	O
fifty	O
point	O
deoxycytidine	O
monophosphate	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
in	O

When	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
N	O
/	O
N	O
GALT	O
,	O
both	O
had	O
50	O
%	O
as	O
compared	O
to	O
21	O
,	O
reduction	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
N	O
)	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
15	O
min	O
.	O

When	O
la	O
/	O
ergocalciferol	O
and	O
ergocalciferol	O
/	O
ergocalciferol	O
GALT	O
biochemical	O
phenotypes	O
were	O
equate	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
fifty	O
%	O
,	O
as	O
equate	O
to	O
21	O
%	O
,	O
diminution	O
in	O
GALT	O
activity	O
in	O
the	O
violent	O
eccentric	O
(	O
N	O
/	O
N	O
)	O
after	O
photo	O
at	O
monovular	O
initial	O
enzyme	O
activity	O
to	O
fifty	O
degrees	O
C	O
for	O
15	O
fukien	O
.	O

When	O
LA	O
D	O
and	O
GALT	O
were	O
compared	O
/	O
phenotypes	O
,	O
both	O
had	O
%	O
,	O
to	O
21	O
,	O
reduction	O
in	O
wild	O
type	O
(	O
/	O
N	O
)	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
50	O
degrees	O
C	O
for	O
15	O
min	O
.	O

activity	O
phenotypes	O
/	O
D	O
and	O
D	O
both	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
)	O
to	O
/	O
N	O
GALT	O
GALT	O
,	O
LA	O
had	O
in	O
%	O
15	O
as	O
degrees	O
at	O
reduction	O
N	O
,	O
21	O
in	O
/	O
When	O
.	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
50	O
after	O
exposure	O
to	O
identical	O
%	O
enzyme	O
activity	O
to	O
50	O
compared	O
C	O
for	O
,	O
min	O
initial	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
inwards	O
a	O
equate	O
phenotype	O
twenty	O
one	O
equate	O
	O
reducing	O
inward	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
bodily	O
process	O
vulnerability	O
fifty	O
point	O
phenotype	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
in	O
in	O

When	O
D	O
D	O
/	O
D	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
N	O
GALT	O
both	O
50	O
%	O
,	O
as	O
21	O
%	O
,	O
reduction	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
N	O
exposure	O
identical	O
initial	O
enzyme	O
activity	O
to	O
degrees	O
C	O
for	O
15	O
.	O

after	O
min	O
/	O
D	O
initial	O
D	O
LA	O
N	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
activity	O
wild	O
/	O
D	O
,	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
degrees	O
as	O
compared	O
type	O
GALT	O
%	O
21	O
/	O
in	O
GALT	O
activity	O
in	O
the	O
N	O
to	O
(	O
N	O
,	O
N	O
)	O
When	O
exposure	O
C	O
identical	O
enzyme	O
reduction	O
to	O
at	O
50	O
/	O
to	O
for	O
15	O
and	O
.	O

When	O
lanthanum	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
liken	O
to	O
northward	O
/	O
northward	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
liken	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
action	O
in	O
the	O
wild	O
case	O
(	O
northward	O
/	O
northward	O
)	O
after	O
picture	O
at	O
indistinguishable	O
initial	O
enzyme	O
action	O
to	O
50	O
stage	O
C	O
for	O
15	O
hokkianese	O
.	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
.	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
arranging	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
inward	O
inward	O
inward	O
inward	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O

We	O
resolve	O
that	O
the	O
codon	O
commute	O
N314D	O
in	O
curie	O
with	O
the	O
bag	O
-	O
yoke	O
passage	O
1721C	O
-	O
-	O
>	O
triiodothyronine	O
produces	O
the	O
la	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
base	O
commute	O
increases	O
GALT	O
action	O
by	O
increase	O
GALT	O
protein	O
teemingness	O
without	O
increase	O
transcription	O
or	O
fall	O
caloric	O
lability	O
.	O

We	O
conclude	O
increases	O
the	O
codon	O
increasing	O
N314D	O
in	O
cis	O
with	O
the	O
-	O
or	O
pair	O
transition	O
change	O
-	O
-	O
T	O
>	O
produces	O
.	O
LA	B
change	I
of	I
and	I
that	O
lability	O
this	O
nucleotide	O
1721C	O
protein	O
galactosemia	O
activity	O
by	O
variant	O
GALT	O
that	O
abundance	O
without	O
increasing	O
transcription	O
base	O
thermal	O
decreasing	O
GALT	O
the	O

We	O
and	O
that	O
the	O
codon	O
change	O
base	O
nucleotide	O
cis	O
with	O
the	O
N314D	O
-	O
that	O
of	O
1721C	O
-	O
-	O
in	O
T	O
produces	O
the	O
increasing	B
variant	I
decreasing	I
galactosemia	I
.	O
pair	O
increases	O
>	O
change	O
this	O
GALT	O
transition	O
by	O
transcription	O
GALT	O
protein	O
abundance	O
without	O
conclude	O
activity	O
or	O
LA	O
thermal	O
lability	O
increasing	O

We	O
close	O
that	O
the	O
codon	O
convert	O
N314D	O
in	O
cis	O
with	O
the	O
foundation	O
-	O
pair	O
passage	O
1721C	O
-	O
-	O
>	O
t	O
raise	O
the	O
LA	B
form	I
of	I
galactosemia	I
and	O
that	O
this	O
base	O
convert	O
growth	O
GALT	O
activity	O
by	O
increase	O
GALT	O
protein	O
copiousness	O
without	O
increase	O
arrangement	O
or	O
lessen	O
thermic	O
lability	O
.	O

We	O
conclude	O
that	O
codon	O
change	O
N314D	O
in	O
cis	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
the	O
variant	I
of	I
galactosemia	I
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
by	O
increasing	O
abundance	O
increasing	O
transcription	O
or	O
decreasing	O
.	O

the	O
codon	O
change	O
N314D	O
in	O
with	O
the	O
transition	O
-	O
>	O
the	O
of	I
galactosemia	I
and	O
that	O
nucleotide	O
change	O
activity	O
by	O
GALT	O
protein	O
transcription	O
decreasing	O
thermal	O
lability	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
arranging	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
inward	O
inward	O
inward	O
couplet	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O

by	O
of	O
that	O
the	O
-	O
change	O
produces	O
increases	O
cis	O
with	O
the	O
base	O
-	O
N314D	O
protein	O
1721C	O
codon	O
.	O
>	O
T	O
pair	O
the	O
LA	B
variant	I
that	I
galactosemia	I
and	O
transcription	O
thermal	O
nucleotide	O
this	O
conclude	O
GALT	O
activity	O
abundance	O
increasing	O
GALT	O
transition	O
We	O
without	O
increasing	O
in	O
or	O
decreasing	O
change	O
lability	O
-	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
arranging	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
operating	O
room	O
fall	O
thermic	O
inward	O
inward	O
inward	O
inward	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C	O
-	O
-	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O

A	O
prosperous	O
codon	O
preconception	O
for	O
the	O
mutated	O
codon	O
with	O
therefore	O
increased	O
rendering	O
rates	O
is	O
necessitate	O
as	O
the	O
mechanics	O
.	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
preconception	O
preconception	O
preconception	O
preconception	O
preconception	O
preconception	O
.	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
preconception	O
preconception	O
preconception	O
preconception	O
preconception	O
preconception	O
.	O
.	O

codon	O
the	O
mutated	O
codon	O
consequently	O
increased	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
.	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
codon	O
with	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
.	O
.	O

codon	O
bias	O
for	O
the	O
codon	O
with	O
consequently	O
increased	O
translation	O
is	O
postulated	O
as	O
the	O
.	O
.	O

mechanism	O
favorable	O
codon	O
.	O
for	O
the	O
mutated	O
with	O
codon	O
consequently	O
postulated	O
translation	O
rates	O
.	O
A	O
as	O
the	O
increased	O
bias	O
is	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
preconception	O
preconception	O
preconception	O
preconception	O
preconception	O
prosperous	O
.	O
.	O

A	O
prosperous	O
codon	O
diagonal	O
for	O
the	O
mutated	O
codon	O
with	O
accordingly	O
increased	O
translation	O
rates	O
is	O
require	O
as	O
the	O
mechanism	O
.	O
.	O

the	O
favorable	O
codon	O
bias	O
for	O
the	O
is	O
translation	O
with	O
consequently	O
increased	O
postulated	O
A	O
mutated	O
codon	O
mechanism	O
rates	O
as	O
.	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
.	O
.	O

The	O
TSG101	O
neoplasm	B
susceptibleness	O
cistron	O
is	O
site	O
in	O
chromosome	O
eleven	O
ring	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
tumour	B
tumour	O
tumour	B
tumour	O
tumour	B
tumour	O
cancer	I
.	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
tumour	B
tumour	O
tumour	B
tumour	O
tumour	B
tumour	O
cancer	I
.	O

tumor	B
is	O
located	O
in	O
11	O
band	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
in	O
chromosome	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

tumor	B
susceptibility	O
gene	O
is	O
in	O
chromosome	O
11	O
band	O
p15	O
is	O
mutated	O
in	O
human	O
cancer	I
.	O

breast	O
TSG101	O
tumor	B
cancer	O
gene	O
is	O
located	O
chromosome	O
in	O
11	O
mutated	O
p15	O
and	O
.	O
The	O
in	O
human	O
band	B
susceptibility	I
is	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
tumour	B
tumour	O
tumour	B
tumour	O
tumour	B
homo	O
cancer	I
.	O

The	O
TSG101	O
neoplasm	B
susceptibleness	O
cistron	O
is	O
situate	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
homo	O
bosom	B
cancer	I
.	O

human	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
is	O
p15	O
chromosome	O
11	O
band	O
mutated	O
The	O
located	O
in	O
breast	O
and	O
in	B
cancer	I
.	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

holocene	O
forge	O
has	O
place	O
a	O
pussyfoot	O
factor	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transmutation	O
and	O
the	O
power	O
to	O
farm	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

Recent	O
work	O
has	O
identified	O
a	O
gene	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

ability	O
work	O
has	O
and	O
a	O
mouse	O
gene	O
in	O
metastatic	O
)	O
.	O
inactivation	O
in	O
the	O
produce	O
in	O
cellular	O
transformation	O
identified	O
fibroblasts	O
tumors	O
to	O
results	O
tsg101	B
Recent	I
(	O
nude	O
mice	O
whose	O

Recent	O
work	O
has	O
identified	O
inward	O
fibroblast	O
solution	O
inward	O
antiophthalmic	O
factor	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
inward	O
nude	O
person	O
identify	O
and	O
the	O
ability	O
to	B
produce	I
metastatic	O
tumors	O
in	O
nude	O

Recent	O
work	O
has	O
identified	O
inward	O
fibroblast	O
solution	O
inward	O
antiophthalmic	O
factor	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
inward	O
nude	O
person	O
fibroblast	O
and	O
the	O
ability	O
to	B
produce	I
metastatic	O
tumors	O
in	O
nude	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
)	O
whose	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

.	O
work	O
has	O
results	O
a	O
mouse	O
in	O
(	O
identified	O
)	O
whose	O
inactivation	O
nude	O
fibroblasts	O
tumors	O
tsg101	O
cellular	O
transformation	O
and	O
the	O
in	O
to	O
produce	O
metastatic	B
in	I
gene	O
ability	O
mice	O
Recent	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
)	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
ability	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O

recent	O
forge	O
has	O
key	O
a	O
mouse	O
factor	O
(	O
tsg101	O
)	O
whose	O
deactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
translation	O
and	O
the	O
power	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mouse	O
.	O

Recent	O
employment	O
has	O
distinguish	O
a	O
sneak	O
cistron	O
(	O
tsg101	O
)	O
whose	O
deactivation	O
in	O
fibroblasts	O
ensue	O
in	O
cellular	O
transformation	O
and	O
the	O
power	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
sneak	O
.	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

Here	O
,	O
we	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O
15	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
and	O
chromosome	O
11	O
,	O
bands	O
15	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
stripe	O
	O
	O
study	O
study	O
study	O
11	O
,	O
bands	O
15	O
.	O

here	O
,	O
we	O
cover	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
sequester	O
and	O
mapped	O
to	O
chromosome	O
xi	O
,	O
ring	O
fifteen	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
stripe	O
	O
	O
study	O
study	O
study	O
11	O
,	O
bands	O
15	O
.	O

hera	O
,	O
we	O
cover	O
that	O
the	O
homo	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
xi	O
,	O
stria	O
xv	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
which	O
we	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O

,	O
,	O
we	O
11	O
that	O
the	O
human	O
,	O
homolog	O
TSG101	O
,	O
which	O
isolated	O
we	O
.	O
mapped	O
to	O
chromosome	O
report	O
Here	O
bands	O
15	O
and	O

hera	O
,	O
we	O
theme	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
separated	O
and	O
mapped	O
to	O
chromosome	O
xi	O
,	O
set	O
xv	O
.	O

and	O
,	O
,	O
human	O
that	O
the	O
mapped	O
homolog	O
we	O
TSG101	O
,	O
which	O
bands	O
isolated	O
report	O
Here	O
to	O
chromosome	O
11	O
,	O
we	O
15	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O
15	O
.	O

15	O
-	O
1	O
.	O
-	O
15	O
1	O

i	O
-	O
15	O
i	O
-	O
15	O
.	O

1	O
	O
-	O
15	O
1	O
	O
-	O
15	O
.	O

1	O
15	O
-	O
.	O

1	O
1	O
15	O
-	O
-	O
15	O
.	O

1	O
-	O
fifteen	O
1	O
-	O
fifteen	O
.	O

i	O
-	O
15	O
i	O
-	O
15	O
.	O

1	O
-	O
15	O
.	O
-	O
1	O
15	O

1	O
-	O
15	O
1	O
-	O
.	O

1	O
	O
-	O
15	O
1	O
	O
-	O
15	O
.	O

1	O
-	O
15	O
1	O
-	O
15	O
.	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
bosom	O
genus	O
cancer	O
bosom	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	O
southward	B
frequency	I
in	O

a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
frequency	O
human	O
breast	B
cancer	I
.	O

2	O
,	O
a	O
neighborhood	O
proposed	O
to	O
curb	O
neoplasm	B
suppresser	O
cistron	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequence	O
in	O
human	O
knocker	B
cancer	I
.	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
suppressor	O
gene	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
human	O
breast	B
cancer	I
.	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
bosom	O
genus	O
cancer	O
bosom	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	O
antiophthalmic	B
factor	I
frequency	O

2	O
,	O
a	O
area	O
project	O
to	O
hold	O
neoplasm	B
suppressor	O
factor	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
richly	O
frequency	O
in	O
homo	O
breast	B
cancer	I
.	O

ii	O
,	O
a	O
area	O
purpose	O
to	O
arrest	O
neoplasm	B
suppressor	O
factor	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
gamey	O
frequency	O
in	O
human	O
breast	B
cancer	I
.	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
(	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
bosom	O
genus	O
cancer	O
bosom	O
genus	O
cancer	O
genus	O
cancer	O
antiophthalmic	O
factor	O
antiophthalmic	B
factor	I
frequency	O

high	O
,	O
a	O
(	O
proposed	O
to	O
contain	O
frequency	B
.	O
gene	O
region	O
s	O
)	O
,	O
cancer	O
mutated	O
at	O
human	O
tumor	O
2	O
in	O
breast	B
is	I
suppressor	O

2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B
cancer	I
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
uncultivated	O
cancer	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
of	O
these	O
cancers	B
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
uncultivated	O
cancer	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
allelomorph	O
of	O
these	O
cancers	B
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
uncultivated	O
cancer	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
uncultivated	O
of	O
these	O
cancers	B
.	O

analysis	O
and	O
of	O
15	O
uncultured	O
primary	O
deletions	O
identified	B
carcinomas	I
,	O
intragenic	O
human	O
were	O
mutations	O
two	O
TSG101	O
genomic	O
DNA	O
breast	O
transcripts	O
by	O
were	O
affecting	O
sequence	O
In	O
,	O
alleles	O
shown	O
in	O
and	O
TSG101	O
four	O
gel	O
7	O
in	O
and	O
of	O
these	O
cancers	B
.	O

In	O
7	O
of	O
15	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
shown	O
in	O
and	O
gel	O
and	O
,	O
affecting	O
two	O
TSG101	O
alleles	O
identified	O
in	O
these	O
cancers	B

indiana	O
seven	O
of	O
fifteen	O
uncultivated	O
primary	O
human	O
front	B
carcinomas	I
,	O
intragenic	O
excision	O
were	O
shown	O
indiana	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
mousse	O
and	O
sequence	O
analysis	O
,	O
and	O
variation	O
sham	O
two	O
TSG101	O
alleles	O
were	O
place	O
indiana	O
quaternity	O
of	O
these	O
crab	B
.	O

inch	O
septet	O
of	O
xv	O
uncultivated	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
evidence	O
inch	O
TSG101	O
genomic	O
DNA	O
and	O
copy	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
sport	O
poignant	O
two	O
TSG101	O
allelomorph	O
were	O
discover	O
inch	O
four	O
of	O
these	O
cancers	B
.	O

TSG101	O
in	O
of	O
15	O
genomic	O
primary	O
these	O
alleles	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
analysis	O
DNA	O
TSG101	O
uncultured	O
in	O
and	O
transcripts	O
shown	O
gel	O
and	O
sequence	O
7	O
,	O
and	O
cancers	O
In	O
two	O
affecting	O
human	O
were	O
identified	O
by	O
four	O
of	O
breast	O
mutations	B
.	O

indiana	O
septenary	O
of	O
fifteen	O
uncultivated	O
basal	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
excision	O
were	O
evidence	O
indiana	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
succession	O
analysis	O
,	O
and	O
mutations	O
involve	O
ii	O
TSG101	O
alleles	O
were	O
describe	O
indiana	O
quatern	O
of	O
these	O
cancers	B
.	O

In	O
7	O
TSG101	O
15	O
uncultured	O
four	O
intragenic	O
breast	B
carcinomas	I
,	O
human	O
and	O
transcripts	O
shown	O
in	O
and	O
genomic	O
DNA	O
these	O
were	O
by	O
gel	O
and	O
primary	O
analysis	O
TSG101	O
deletions	O
were	O
alleles	O
two	O
of	O
mutations	O
affecting	O
identified	O
in	O
sequence	O
of	O
,	O
cancers	B
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	B
.	O

No	O
TSG101	O
cope	O
with	O
pattern	O
flaw	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	B
breast	I
cancer	O
patients	O
inward	O

cancer	O
TSG101	O
defects	O
.	O
found	O
in	O
matched	O
normal	O
patients	O
tissue	O
from	O
the	O
No	B
breast	I
breast	O
were	O

No	O
TSG101	O
cope	O
with	O
pattern	O
genus	O
cancer	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	B
the	I
breast	O
cancer	O
patients	O

No	O
TSG101	O
mar	O
were	O
witness	O
in	O
matched	O
normal	O
front	O
weave	O
from	O
the	O
front	B
cancer	I
patients	O
.	O

breast	O
TSG101	O
defects	O
normal	O
found	O
in	O
cancer	O
were	O
breast	O
tissue	O
No	O
the	O
from	B
matched	I
patients	O
.	O

No	O
TSG101	O
cope	O
with	O
pattern	O
flaw	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	B
breast	I
cancer	O
patients	O
inward	O

nobelium	O
TSG101	O
flaw	O
were	O
found	O
in	O
mate	O
convention	O
breast	O
tissue	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

nobelium	O
TSG101	O
defects	O
were	O
determine	O
in	O
oppose	O
formula	O
breast	O
tissue	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

No	O
TSG101	O
breast	O
.	O
found	O
in	O
breast	O
normal	O
defects	O
tissue	O
from	O
the	O
matched	B
cancer	I
were	O
patients	O

TSG101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

No	O
TSG101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

These	O
receive	O
strongly	O
entail	O
TSG101	O
mutations	O
in	O
human	O
bosom	B
cancer	I

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B
find	O
out	B
find	O
out	I

These	O
findings	O
strongly	O
implicate	O
TSG101	O
variation	O
in	O
homo	O
breast	B
crab	I

These	O
findings	O
powerfully	O
entail	O
TSG101	O
mutations	O
in	O
human	O
bosom	B
cancer	I

These	O
strongly	O
implicate	O
mutations	O
in	O
human	O
breast	B
cancer	I

human	O
cancer	O
strongly	O
TSG101	O
implicate	O
mutations	O
in	O
These	O
breast	B
findings	I

These	O
human	O
strongly	O
implicate	O
findings	O
mutations	O
TSG101	O
in	O
breast	B
cancer	I

human	O
implicate	O
strongly	O
findings	O
TSG101	O
mutations	O
cancer	O
These	O
breast	B
in	I

These	O
implicate	O
TSG101	O
mutations	O
human	O

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B
find	O
out	B
find	O
out	I

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B
cancer	I

Moderate	O
instability	O
and	O
somatic	O
intergenerational	O
of	O
55	O
repeat	O
-	O
CTG	O
transgenic	O
in	O
a	O
mice	O
.	O

Moderate	O
intergenerational	O
antiophthalmic	O
factor	O
	O
corporal	O
and	O
somatic	O
instability	O
of	O
a	O
55	O
-	O
corporal	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O

Moderate	O
intergenerational	O
and	O
bodily	O
imbalance	O
of	O
a	O
55	O
-	O
CTG	O
double	O
in	O
transgenic	O
mice	O
.	O

transgenic	O
intergenerational	O
and	O
Moderate	O
55	O
of	O
a	O
in	O
-	O
CTG	O
repeat	O
instability	O
somatic	O
mice	O
.	O

temperate	O
intergenerational	O
and	O
corporal	O
instability	O
of	O
a	O
55	O
-	O
CTG	O
echo	O
in	O
transgenic	O
mouse	O
.	O

Moderate	O
intergenerational	O
antiophthalmic	O
factor	O
	O
corporal	O
and	O
somatic	O
instability	O
of	O
a	O
55	O
-	O
imbalance	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O

Moderate	O
and	O
instability	O
a	O
55	O
-	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O
.	O

55	O
somatic	O
and	O
intergenerational	O
instability	O
of	O
CTG	O
Moderate	O
-	O
a	O
repeat	O
in	O
transgenic	O
.	O
mice	O

temperate	O
intergenerational	O
and	O
bodily	O
instability	O
of	O
a	O
55	O
-	O
CTG	O
reiterate	O
in	O
transgenic	O
shiner	O
.	O

Moderate	O
intergenerational	O
antiophthalmic	O
factor	O
	O
corporal	O
and	O
somatic	O
instability	O
of	O
a	O
55	O
-	O
imbalance	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O

Moderate	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
a	O
55	O
-	O
CTG	O
repeat	O
in	O
transgenic	O
mice	O
.	O

Myotonic	B
dystrophy	I
kinase	O
DM	B
)	O
is	O
a	O
in	O
the	O
expansion	O
of	O
of	O
the	O
CTG	O
)	O
the	O
trinucleotide	O
repeat	O
gene	O
(	O
3	O
(	O
region	O
(	O
UTR	O
n	O
associated	O
untranslated	O
DM	B
protein	O
(	O
with	O
)	O
DMPK	O
)	O
.	O

dystrophy	I
DM	B
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
untranslated	O
region	O
(	O
)	O
the	O
DM	B
protein	O
(	O

myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
the	O
enlargement	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
reprise	O
in	O
the	O
ternion	O
untranslated	O
realm	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
cistron	O
(	O
DMPK	O
)	O
.	O

the	B
3	I
(	O
DM	B
trinucleotide	O
is	O
)	O
gene	O
the	O
expansion	O
of	O
a	O
(	O
UTR	O
with	O
n	O
)	O
kinase	O
in	O
the	O
CTG	O
untranslated	O
region	O
(	O
dystrophy	O
)	O
of	O
Myotonic	O
repeat	B
protein	O
DM	O
associated	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
cistron	O
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
gene	O
northward	O
.	O

UTR	B
in	I
(	O
DM	B
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
the	O
protein	O
n	O
trinucleotide	O
repeat	O
DMPK	O
the	O
3	O
untranslated	O
DM	O
(	O
Myotonic	O
)	O
gene	O
CTG	O
)	B
region	O
kinase	O
.	O
(	O
)	O
dystrophy	O
of	O

Myotonic	B
dystrophy	I
(	O
DM	B
is	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
.	O

myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
is	O
link	O
with	O
the	O
enlargement	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
restate	O
in	O
the	O
trine	O
untranslated	O
neighborhood	O
(	O
UTR	O
)	O
of	O
the	O
decimetre	B
protein	O
kinase	O
factor	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
assort	O
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
sort	O
sort	O
sort	O
sort	O
sort	O
sort	O
sort	O
sort	O
northward	O
.	O

myotonic	B
dystrophy	I
(	O
decimetre	B
)	O
is	O
consociate	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
recur	O
in	O
the	O
threesome	O
untranslated	O
area	O
(	O
UTR	O
)	O
of	O
the	O
decimetre	B
protein	O
kinase	O
factor	O
(	O
DMPK	O
)	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
.	O

The	O
(	O
are	O
)	O
n	O
size	O
is	O
in	O
and	O
varies	O
in	O
patients	O
50	O
5	O
and	O
,	O
repeats	O
in	O
individuals	O
unaffected	O
whereas	O
polymorphic	O
affected	O
repeat	O
there	O
between	O
CTG	O
CTGs	O
and	O
4	O
37	O
between	O
000	O
.	O

The	O
)	O
n	O
repeat	O
is	O
and	O
varies	O
between	O
5	O
37	O
repeats	O
whereas	O
affected	O
patients	O
there	O
between	O
50	O
and	O
,	O
000	O
CTGs	O
.	O

The	O
(	O
CTG	O
)	O
ingeminate	O
	O
ingeminate	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
	O
.	O

The	O
(	O
CTG	O
)	O
ingeminate	O
	O
northward	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
	O
.	O

(	O
unaffected	O
CTG	O
)	O
n	O
repeat	O
between	O
polymorphic	O
and	O
varies	O
in	O
50	O
between	O
there	O
4	O
37	O
repeats	O
in	O
size	O
individuals	O
whereas	O
in	O
.	O
patients	O
5	O
are	O
is	O
The	O
000	O
affected	O
,	O
and	O
CTGs	O
and	O

The	O
(	O
CTG	O
)	O
n	O
repeat	O
and	O
varies	O
in	O
size	O
5	O
and	O
37	O
repeats	O
in	O
individuals	O
whereas	O
in	O
affected	O
there	O
are	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
(	O
CTG	O
)	O
n	O
recapitulate	O
is	O
polymorphous	O
and	O
depart	O
in	O
sizing	O
between	O
fivesome	O
and	O
37	O
retell	O
in	O
unmoved	O
individuals	O
whereas	O
in	O
touch	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
(	O
CTG	O
)	O
n	O
repetition	O
is	O
polymorphous	O
and	O
deviate	O
in	O
size	O
between	O
5	O
and	O
37	O
iterate	O
in	O
untouched	O
somebody	O
whereas	O
in	O
pretend	O
patients	O
there	O
are	O
between	O
l	O
and	O
quaternion	O
,	O
000	O
CTGs	O
.	O

The	O
(	O
CTG	O
)	O
ingeminate	O
	O
northward	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
iterate	O
	O
.	O

The	O
(	O
CTG	O
)	O
n	O
iterate	O
is	O
polymorphous	O
and	O
variegate	O
in	O
sizing	O
between	O
quint	O
and	O
37	O
ingeminate	O
in	O
unmoved	O
individuals	O
whereas	O
in	O
touch	O
patients	O
there	O
are	O
between	O
50	O
and	O
four	O
,	O
000	O
CTGs	O
.	O

The	O
(	O
CTG	O
)	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
eld	O
inclemency	O
onrush	O
eld	O
onrush	O
onrush	O
propagation	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
severity	O
age	O
of	O
onset	O
.	O

The	O
sizing	O
of	O
the	O
(	O
CTG	O
)	O
n	O
reduplicate	O
,	O
which	O
increment	O
through	O
propagation	O
,	O
loosely	O
correlative	O
with	O
clinical	O
asperity	O
and	O
age	O
of	O
onset	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
increases	O
through	O
,	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
onset	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
eld	O
inclemency	O
onrush	O
eld	O
onrush	O
onrush	O
ingeminate	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
replicate	O
,	O
which	O
increases	O
through	O
propagation	O
,	O
loosely	O
correlative	O
with	O
clinical	O
rigorousness	O
and	O
mature	O
of	O
attack	O
.	O

The	O
sizing	O
of	O
the	O
(	O
CTG	O
)	O
n	O
iterate	O
,	O
which	O
increases	O
through	O
genesis	O
,	O
loosely	O
correlates	O
with	O
clinical	O
hardship	O
and	O
eld	O
of	O
onrush	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
through	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
eld	O
inclemency	O
onrush	O
eld	O
onrush	O
onrush	O
ingeminate	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

severity	O
size	O
of	O
which	O
(	O
CTG	O
)	O
clinical	O
onset	O
,	O
the	O
increases	O
generations	O
through	O
of	O
generally	O
correlates	O
with	O
n	O
.	O
and	O
age	O
,	O
repeat	O
The	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
instability	O
of	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
as	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
impart	O
rear	O
rear	O
reckon	O
reckon	O
reckon	O
of	O
the	O
transmitting	O
parent	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
look	O
to	O
look	O
on	O
its	O
sizing	O
as	O
advantageously	O
as	O
on	O
the	O
sex	O
of	O
the	O
transfer	O
rear	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
impart	O
rear	O
rear	O
reckon	O
reckon	O
reckon	O
of	O
the	O
transmitting	O
parent	O
.	O

The	O
unbalance	O
of	O
the	O
CTG	O
reprize	O
appears	O
to	O
reckon	O
on	O
its	O
size	O
as	O
considerably	O
as	O
on	O
the	O
sex	O
of	O
the	O
carry	O
parent	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
size	O
as	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O

its	O
instability	O
of	O
of	O
CTG	O
repeat	O
appears	O
depend	O
to	O
on	O
the	O
size	O
well	O
as	O
.	O
on	O
the	O
sex	O
the	O
The	O
transmitting	O
parent	O
as	O

The	O
unstableness	O
of	O
the	O
CTG	O
iterate	O
appears	O
to	O
count	O
on	O
its	O
size	O
as	O
easily	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
rear	O
.	O

as	O
instability	O
depend	O
appears	O
CTG	O
repeat	O
on	O
to	O
of	O
on	O
its	O
size	O
transmitting	O
well	O
the	O
The	O
the	O
sex	O
of	O
the	O
as	O
parent	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

shows	O
,	O
mitotic	O
human	O
analysis	O
of	O
different	O
instability	O
different	B
tissues	O
between	O
length	O
Moreover	O
mosaicism	O
DM	O
cell	O
lineages	O
.	O

Moreover	O
,	O
mitotic	O
unbalance	O
analysis	O
of	O
different	O
human	O
dm	B
tissues	O
demonstrate	O
duration	O
mosaicism	O
between	O
different	O
cell	O
bloodline	O
.	O

furthermore	O
,	O
mitotic	O
instability	O
analysis	O
of	O
dissimilar	O
human	O
dm	B
tissues	O
exhibit	O
length	O
mosaicism	O
between	O
dissimilar	O
cadre	O
lineages	O
.	O

Moreover	O
,	O
mitotic	O
of	O
different	O
human	O
DM	B
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O

Moreover	O
,	O
mitotic	O
unbalance	O
analysis	O
of	O
unlike	O
human	O
DM	B
weave	O
read	O
length	O
mosaicism	O
between	O
unlike	O
cadre	O
lineages	O
.	O

Moreover	O
,	O
diabetes	O
mellitus	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	B
DM	O
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
homo	O
homo	O
homo	O
homo	O

Moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
DM	B
tissues	O
length	O
mosaicism	O
different	O
cell	O
lineages	O
.	O

Moreover	O
,	O
diabetes	O
mellitus	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	B
DM	O
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
homo	O
homo	O
homo	O
homo	O

,	O
analysis	O
of	O
different	O
human	O
DM	B
tissues	O
shows	O
length	O
mosaicism	O
.	O

Moreover	O
,	O
DM	O
different	O
analysis	O
of	O
mosaicism	O
human	O
mitotic	B
tissues	O
shows	O
length	O
different	O
between	O
instability	O
cell	O
lineages	O
.	O

Moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
DM	B
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O

The	O
molecular	O
mechanisms	O
of	O
tierce	O
instability	O
remain	O
problematic	O
.	O

The	O
mechanism	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
chemical	O
mechanism	O

The	O
of	O
mechanisms	O
molecular	O
triplet	O
instability	O
elusive	O
remain	O
.	O

The	O
molecular	O
mechanisms	O
of	O
trinity	O
unbalance	O
remain	O
elusive	O
.	O

The	O
mechanisms	O
of	O
instability	O
elusive	O

remain	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
elusive	O
The	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
.	O

The	O
elusive	O
mechanisms	O
of	O
molecular	O
instability	O
remain	O
triplet	O
.	O

The	O
	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
stay	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
rest	O
problematical	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
.	O

To	O
investigate	O
CTG	O
role	O
of	O
produced	O
sequences	O
with	O
instability	O
,	O
we	O
55	O
cloned	O
mice	O
containing	O
mildly	O
45	O
-	O
genomic	O
kb	O
segment	O
in	O
a	O
genomic	O
-	O
repeat	O
the	O
patient	O
from	O
a	O
a	O
transgenic	O
affected	O
.	O

To	O
role	O
of	O
genomic	O
sequences	O
instability	O
,	O
transgenic	O
mice	O
a	O
45	O
segment	O
a	O
55	O
-	O
repeat	O
cloned	O
from	O
mildly	O
affected	O
patient	O
.	O

To	O
investigate	O
the	O
role	O
hold	O
back	O
antiophthalmic	O
factor	O
look	O
into	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45	O
-	O
kb	O
genomic	O
segment	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
mouse	O
mouse	O
mouse	O
mouse	O
mouse	O

To	O
investigate	O
the	O
role	O
hold	O
back	O
antiophthalmic	O
factor	O
forty	O
five	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45	O
-	O
kb	O
genomic	O
segment	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
mouse	O
mouse	O
mouse	O
mouse	O
mouse	O

investigate	O
kb	O
the	O
role	O
of	O
genomic	O
repeat	O
in	O
instability	O
,	O
we	O
cloned	O
transgenic	O
-	O
a	O
a	O
45	O
-	O
produced	O
genomic	O
segment	O
with	O
.	O
55	O
mice	O
CTG	O
sequences	O
To	O
affected	O
a	O
mildly	O
from	O
patient	O
containing	O

To	O
investigate	O
the	O
role	O
of	O
genomic	O
instability	O
,	O
we	O
produced	O
mice	O
containing	O
a	O
45	O
-	O
genomic	O
segment	O
with	O
a	O
-	O
CTG	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
.	O

To	O
enquire	O
the	O
use	O
of	O
genomic	O
sequences	O
in	O
unstableness	O
,	O
we	O
produced	O
transgenic	O
shiner	O
incorporate	O
a	O
45	O
-	O
kib	O
genomic	O
section	O
with	O
a	O
lv	O
-	O
CTG	O
ingeminate	O
cloned	O
from	O
a	O
gently	O
affected	O
patient	O
.	O

To	O
investigate	O
the	O
office	O
of	O
genomic	O
sequences	O
in	O
unstableness	O
,	O
we	O
farm	O
transgenic	O
mice	O
containing	O
a	O
xlv	O
-	O
kilobyte	O
genomic	O
section	O
with	O
a	O
55	O
-	O
CTG	O
retell	O
cloned	O
from	O
a	O
gently	O
stirred	O
patient	O
.	O

To	O
investigate	O
the	O
role	O
hold	O
back	O
antiophthalmic	O
factor	O
forty	O
five	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45	O
-	O
kb	O
genomic	O
segment	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
mouse	O
mouse	O
mouse	O
mouse	O
mouse	O

To	O
inquire	O
the	O
office	O
of	O
genomic	O
successiveness	O
in	O
unstableness	O
,	O
we	O
produced	O
transgenic	O
shiner	O
bear	O
a	O
45	O
-	O
kibibyte	O
genomic	O
section	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
gently	O
dissemble	O
patient	O
.	O

To	O
investigate	O
the	O
role	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45	O
-	O
kb	O
genomic	O
segment	O
with	O
a	O
55	O
-	O
CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
.	O

In	O
contrast	O
to	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
showed	O
and	O
somatic	O
repeat	O
instability	O
.	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
imbalance	O
imbalance	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
somatic	O
repeat	O
instability	O
.	O
.	O

In	O
counterpoint	O
to	O
other	O
mouse	O
models	O
curb	O
CAG	O
repeats	O
inside	O
cDNAs	O
,	O
these	O
shiner	O
evince	O
both	O
intergenerational	O
and	O
corporeal	O
repeat	O
instability	O
.	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
imbalance	O
imbalance	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
somatic	O
repeat	O
instability	O
.	O
.	O

inch	O
counterpoint	O
to	O
other	O
mouse	O
models	O
incorporate	O
CAG	O
restate	O
within	O
cDNAs	O
,	O
these	O
mice	O
read	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
unstableness	O
.	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
,	O
these	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O

cDNAs	O
contrast	O
to	O
somatic	O
mouse	O
models	O
containing	O
repeats	O
CAG	O
within	O
repeat	O
,	O
mice	O
these	O
.	O
both	O
intergenerational	O
and	O
other	O
In	O
instability	O
.	O
showed	O

In	O
contrast	O
to	O
other	O
creep	O
models	O
curb	O
CAG	O
repeats	O
inside	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
corporal	O
replicate	O
unstableness	O
.	O
.	O

showed	O
contrast	O
repeats	O
containing	O
mouse	O
models	O
both	O
CAG	O
to	O
within	O
cDNAs	O
,	O
instability	O
mice	O
other	O
In	O
intergenerational	O
and	O
somatic	O
repeat	O
these	O
.	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O
.	O
.	O

syndrome	O
mutations	O
in	O
in	O
Fas	O
gene	O
resulting	O
the	O
and	B
lymphoproliferative	I
molecular	I
:	O
Missense	O
a	O
autoimmune	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
in	O
the	O
fa	O
factor	O
lead	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
in	O
the	O
fas	O
cistron	O
ensue	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
in	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
in	O
the	O
fas	O
factor	O
ensue	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
inward	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

Missense	O
mutations	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
:	O
a	O
and	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
inward	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
inwards	O
inwards	O
inwards	O
inward	O
.	O

mutations	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
.	O

Missense	O
mutations	O
autoimmune	O
and	O
Fas	O
gene	O
a	O
in	O
in	B
lymphoproliferative	I
syndrome	I
:	O
resulting	O
molecular	O
the	O
immunological	O
analysis	O
.	O

Missense	O
mutations	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
resistant	O
organization	O
resistant	O
organization	O
organization	O
destruction	O
program	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
maintenance	O
the	O
immune	O
system	O
.	O

program	O
cell	O
last	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
pattern	O
developing	O
and	O
homeostatic	O
sustainment	O
of	O
the	O
resistant	O
system	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
a	O
physiological	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
the	O
immune	O
system	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
resistant	O
organization	O
resistant	O
organization	O
organization	O
destruction	O
destruction	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

program	O
cell	O
last	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
operation	O
indispensable	O
to	O
the	O
normal	O
ontogenesis	O
and	O
homeostatic	O
upkeep	O
of	O
the	O
immune	O
scheme	O
.	O

programme	O
cell	O
last	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
action	O
essential	O
to	O
the	O
convention	O
ontogenesis	O
and	O
homeostatic	O
sustentation	O
of	O
the	O
resistant	O
system	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
process	O
the	O
normal	O
development	O
and	O
homeostatic	O
maintenance	O
of	O
the	O
immune	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
resistant	O
organization	O
resistant	O
organization	O
organization	O
destruction	O
destruction	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

homeostatic	O
cell	O
death	O
process	O
or	O
apoptosis	O
)	O
maintenance	O
.	O
physiological	O
(	O
essential	O
to	O
the	O
system	O
development	O
and	O
the	O
is	O
Programmed	O
of	O
immune	O
normal	O
a	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

The	O
Fas	O
/	O
-	O
receptor	O
plays	O
a	O
in	O
,	O
as	O
demonstrated	O
lymphoproliferation	O
in	O
-	O
lpr	O
/	O
and	O
by	O
the	O
recently	O
described	O
lymphoproliferative	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
to	O
mutations	O
in	O
the	O
Fas	O

lymphoproliferative	O
lpr	O
/	O
Apo	O
-	O
1	O
,	O
plays	O
a	O
crucial	O
role	O
humans	O
the	O
mice	O
and	O
apoptosis	O
,	O
as	O
Fas	O
by	O
lymphoproliferation	O
in	O
autoimmune	O
-	O
of	O
/	O
due	O
regulation	O
mutations	O
demonstrated	O
the	O
syndrome	O
described	O
of	B
The	I
.	I
(	O
ALPS	B
)	O
in	O
in	O
receptor	O
both	O
MRL	O
which	O
are	O
by	O
to	O
lpr	O
in	O
the	O
Fas	O
gene	O
recently	O

in	O
lpr	O
/	O
Apo	O
-	O
1	O
ALPS	O
,	O
a	O
crucial	O
role	O
in	O
the	O
the	O
Fas	O
apoptosis	O
plays	O
due	O
demonstrated	O
by	O
.	O
in	O
MRL	O
-	O
mice	O
/	O
lpr	O
,	O
which	O
by	O
and	O
receptor	O
described	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
mutations	B
recently	O
in	O
humans	O
lymphoproliferation	O
both	O
of	O
the	O
are	O
as	O
to	O
)	O
The	O
regulation	O
of	O
gene	O
Fas	O

The	O
Fas	O
/	O
Apo	O
-	O
1	O
receptor	O
plays	O
mouse	O
inward	O
aside	O
regulating	O
of	O
late	O
antiophthalmic	O
factor	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	B
described	I
autoimmune	I
lymphoproliferative	O
syndrome	I
be	O
imputable	I
childs	O
play	I
mutation	O
inward	I
childs	O
play	I
fetal	O
alcohol	B
syndrome	O
cistron	O
childs	O
play	O
a	O
(	O
ALPS	O
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O

The	O
fas	O
/	O
Apo	O
-	O
single	O
receptor	O
manoeuvre	O
a	O
important	O
purpose	O
in	O
the	O
regulating	O
of	O
apoptosis	O
,	O
as	O
show	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
late	O
trace	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
alp	B
)	O
in	O
homo	O
,	O
both	O
of	O
which	O
are	O
imputable	O
to	O
sport	O
in	O
the	O
fas	O
cistron	O
.	O

The	O
Fas	O
/	O
Apo	O
-	O
single	O
receptor	O
looseness	O
a	O
important	O
function	O
in	O
the	O
regulating	O
of	O
apoptosis	O
,	O
as	O
march	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
late	O
described	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
alps	B
)	O
in	O
world	O
,	O
both	O
of	O
which	O
are	O
imputable	O
to	O
mutations	O
in	O
the	O
Fas	O
factor	O
.	O

The	O
fas	O
/	O
Apo	O
-	O
one	O
receptor	O
drama	O
a	O
important	O
persona	O
in	O
the	O
regularisation	O
of	O
apoptosis	O
,	O
as	O
show	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mouse	O
and	O
by	O
the	O
lately	O
line	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
referable	O
to	O
mutations	O
in	O
the	O
fas	O
cistron	O
.	O

Apo	O
receptor	O
a	O
crucial	O
role	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
by	O
the	O
autoimmune	B
lymphoproliferative	I
syndrome	I
ALPS	B
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
Fas	O
.	O

The	O
/	O
1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
lymphoproliferative	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
are	O
due	O
to	O
mutations	O
in	O
the	O
Fas	O

The	O
Fas	O
/	O
Apo	O
-	O
1	O
receptor	O
plays	O
mouse	O
inward	O
aside	O
regulating	O
of	O
late	O
antiophthalmic	O
factor	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	B
described	I
autoimmune	I
lymphoproliferative	O
syndrome	I
be	O
imputable	I
childs	O
play	I
mutation	O
inward	I
childs	O
play	I
fetal	O
alcohol	B
syndrome	O
cistron	O
childs	O
play	O
childs	O
play	O
(	O
ALPS	O
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O

The	O
Fas	O
/	O
Apo	O
-	O
1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
Fas	O
gene	O
.	O

We	O
describe	O
a	O
novel	O
impart	O
	O
clear	O
cut	O
the	O
alps	O
phratry	O
family	B
with	O
ALPS	O
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
bring	O
bring	O
bring	O

We	O
describe	O
family	O
three	O
affected	O
siblings	O
two	O
distinct	O
mutations	O
on	O
both	O
gene	O
alleles	O
and	O
show	O
lack	O
Fas	O
induced	O
apoptosis	O
.	O

We	O
report	O
a	O
new	O
family	O
with	O
alp	B
in	O
which	O
three	O
touch	O
siblings	O
carry	O
deuce	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
allelomorph	O
and	O
render	O
want	O
of	O
Fas	O
-	O
make	O
apoptosis	O
.	O

We	O
describe	O
a	O
novel	O
with	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

We	O
distinguish	O
a	O
fresh	O
family	O
with	O
ALPS	B
in	O
which	O
tercet	O
move	O
siblings	O
transport	O
two	O
trenchant	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
cistron	O
alleles	O
and	O
picture	O
want	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

We	O
describe	O
a	O
novel	O
impart	O
	O
clear	O
cut	O
the	O
alps	O
phratry	O
family	B
with	O
ALPS	O
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
bring	O
bring	O
bring	O

We	O
name	O
a	O
novel	O
family	O
with	O
ALPS	B
in	O
which	O
ternary	O
affected	O
siblings	O
carry	O
deuce	O
decided	O
missense	O
variation	O
on	O
both	O
the	O
fa	O
cistron	O
alleles	O
and	O
show	O
miss	O
of	O
fa	O
-	O
cause	O
apoptosis	O
.	O

Fas	O
both	O
a	O
novel	O
family	O
with	O
ALPS	B
in	O
which	O
three	O
affected	O
siblings	O
carry	O
show	O
induced	O
missense	O
mutations	O
on	O
Fas	O
the	O
describe	O
gene	O
.	O
and	O
two	O
lack	O
of	O
We	O
distinct	O
alleles	O
apoptosis	O
-	O

We	O
describe	O
a	O
novel	O
with	O
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
lack	O
of	O
Fas	O
induced	O
.	O

We	O
describe	O
a	O
novel	O
impart	O
	O
clear	O
cut	O
the	O
alps	O
clear	O
cut	B
family	O
with	O
ALPS	O
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
bring	O
bring	O

We	O
describe	O
a	O
novel	O
family	O
with	O
ALPS	B
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

The	O
children	O
and	O
developed	O
clinical	O
features	O
only	O
splenomegaly	B
share	O
lymphadenopathy	B
,	O
but	O
including	O
one	O
common	O
severe	O
autoimmune	B
manifestations	I
.	O

share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
severe	O
autoimmune	B
manifestations	I
.	O

The	O
children	O
partake	O
common	O
clinical	O
lineament	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
unrivalled	O
grow	O
grave	O
autoimmune	B
manifestations	I
.	O

The	O
nipper	O
part	O
common	O
clinical	O
boast	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
austere	O
autoimmune	B
reflexion	I
.	O

autoimmune	O
children	O
share	O
common	O
clinical	O
features	O
one	O
developed	B
and	O
lymphadenopathy	B
,	O
but	O
manifestations	O
including	O
splenomegaly	O
severe	O
only	B
The	I
.	O

The	O
children	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
.	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
manifestations	I
apportion	O
apportion	O
apportion	O
apportion	O
manifestation	O
.	O

The	O
fry	O
share	O
green	O
clinical	O
features	O
admit	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
wicked	O
autoimmune	B
materialization	I
.	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
manifestations	I
apportion	O
apportion	O
apportion	O
apportion	O
apportion	O
.	O

one	O
children	O
share	O
,	O
clinical	O
features	O
including	O
.	B
developed	O
lymphadenopathy	B
common	O
but	O
The	O
only	O
and	O
severe	O
autoimmune	B
manifestations	I
splenomegaly	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
manifestations	I
.	O

inch	O
all	O
three	O
siblings	O
,	O
we	O
evidence	O
the	O
bearing	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
cd	O
-	O
(	O
dual	O
damaging	O
,	O
[	O
DN	O
]	O
)	O
thyroxine	O
cellphone	O
;	O
furthermore	O
,	O
a	O
inveterate	O
lymphocyte	O
activating	O
was	O
chance	O
,	O
as	O
evidence	O
by	O
the	O
bearing	O
of	O
luxuriously	O
tier	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cellphone	O
and	O
by	O
the	O
bearing	O
of	O
luxuriously	O
tier	O
of	O
serum	O
activating	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
deuce	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

indiana	O
all	O
three	O
siblings	O
,	O
we	O
exhibit	O
the	O
mien	O
of	O
anergic	O
CD3	O
+	O
cd	O
-	O
cd	O
-	O
(	O
doubling	O
minus	O
,	O
[	O
DN	O
]	O
)	O
t	O
cells	O
;	O
moreover	O
,	O
a	O
continuing	O
lymphocyte	O
energizing	O
was	O
incur	O
,	O
as	O
exhibit	O
by	O
the	O
mien	O
of	O
eminent	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
mien	O
of	O
eminent	O
levels	O
of	O
serum	O
energizing	O
marking	O
such	O
as	O
soluble	O
interleukin	O
-	O
ii	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
cluster	O
of	O
differentiation	O
	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O

)	O
interleukin	O
as	O
cells	O
,	O
we	O
demonstrated	O
the	O
lymphocyte	O
of	O
anergic	O
CD3	O
sCD30	O
the	O
-	O
serum	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
CD30	O
)	O
T	O
+	O
)	O
presence	O
levels	O
a	O
chronic	O
presence	O
activation	O
high	O
found	O
,	O
of	O
demonstrated	O
by	O
CD4	O
presence	O
of	O
high	O
-	O
of	O
HLA	O
-	O
;	O
and	O
on	O
peripheral	O
CD3	O
2	O
DR	O
expression	O
CD8	O
was	O
as	O
of	O
the	O
levels	O
siblings	O
by	O
activation	O
markers	O
such	O
moreover	O
soluble	O
all	O
-	O
+	O
receptor	O
(	O
slL	O
,	O
2R	O
In	O
and	O
soluble	O
]	O
(	O
cells	O
three	O
.	O
.	O

In	O
,	O
three	O
of	O
serum	O
high	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
-	O
+	O
markers	O
-	O
as	O
-	O
(	O
double	O
negative	O
such	O
on	O
)	O
]	O
.	O
interleukin	O
cells	O
;	O
moreover	O
all	O
a	O
levels	O
lymphocyte	O
activation	O
was	O
found	O
demonstrated	O
CD8	O
,	O
and	O
the	O
presence	O
activation	O
high	O
levels	O
of	O
-	O
cells	O
DR	O
expression	O
sCD30	O
+	O
CD3	O
peripheral	O
of	O
and	O
.	O
the	O
presence	O
of	O
we	O
chronic	O
siblings	O
-	O
[	O
CD4	O
,	O
as	O
soluble	O
T	O
HLA	O
2	O
receptor	O
(	O
,	O
slL	O
2R	O
)	O
by	O
soluble	O
CD30	O
(	O
CD3	O
)	O
by	O
DN	O

soluble	O
all	O
three	O
-	O
,	O
we	O
demonstrated	O
levels	O
presence	O
of	O
anergic	O
]	O
+	O
CD4	O
-	O
CD8	O
peripheral	O
(	O
double	O
negative	O
,	O
[	O
(	O
CD3	O
)	O
)	O
cells	O
;	O
moreover	O
siblings	O
a	O
chronic	O
slL	O
activation	O
.	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
and	O
high	O
+	O
of	O
receptor	O
-	O
DR	O
In	O
on	O
markers	O
activation	O
(	O
cells	O
and	O
by	O
the	O
2R	O
of	O
high	O
the	O
presence	O
serum	O
CD3	O
-	O
2	O
as	O
expression	O
soluble	O
lymphocyte	O
such	O
HLA	O
levels	O
T	O
-	O
of	O
,	O
of	O
interleukin	O
CD30	O
DN	O
sCD30	O
)	O
was	O
.	O

In	O
three	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
-	O
double	O
negative	O
[	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
as	O
demonstrated	O
the	O
presence	O
of	O
high	O
of	O
-	O
peripheral	O
+	O
cells	O
and	O
the	O
presence	O
high	O
levels	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
(	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
sCD30	O
)	O
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
of	O
anergic	O
+	O
-	O
CD8	O
(	O
,	O
[	O
DN	O
T	O
cells	O
,	O
a	O
lymphocyte	O
activation	O
,	O
as	O
demonstrated	O
by	O
presence	O
of	O
high	O
levels	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
such	O
soluble	O
-	O
2	O
receptor	O
(	O
-	O
2R	O
and	O
CD30	O
(	O
sCD30	O
)	O
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4	O
-	O
CD8	O
-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin	O
-	O
2	O
receptor	O
(	O
slL	O
-	O
2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
.	O
.	O

damage	O
ataxia	B
-	I
nuclear	I
gene	O
product	O
,	O
following	O
not	O
expressed	O
telangiectasia	O
protein	O
is	O
that	O
constitutively	O
up	O
-	O
regulated	O
a	O
The	O
genome	O
.	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
terms	O
terms	O
upwards	O
upwards	O
upwards	O
upwards	O
following	O
genome	O
damage	O
.	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
terms	O
terms	O
upwards	O
upwards	O
upwards	O
upwards	O
following	O
genome	O
damage	O
.	O

The	O
ataxy	B
-	I
telangiectasia	I
factor	O
product	O
,	O
a	O
constitutively	O
extract	O
atomic	O
protein	O
that	O
is	O
not	O
up	O
-	O
regularize	O
following	O
genome	O
impairment	O
.	O

The	O
ataxia	B
-	I
gene	O
product	O
,	O
a	O
constitutively	O
nuclear	O
protein	O
that	O
is	O
up	O
-	O
following	O
genome	O
damage	O
.	O

telangiectasia	I
,	O
a	O
constitutively	O
nuclear	O
protein	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O

The	O
dyssynergia	B
-	I
telangiectasia	I
factor	O
product	O
,	O
a	O
constitutively	O
expressed	O
atomic	O
protein	O
that	O
is	O
not	O
up	O
-	O
regularise	O
following	O
genome	O
hurt	O
.	O

not	O
ataxia	B
constitutively	I
,	I
gene	O
product	O
up	O
a	O
-	O
expressed	O
nuclear	O
protein	O
damage	O
is	O
telangiectasia	O
The	O
-	O
regulated	O
following	O
genome	O
that	O
.	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
terms	O
terms	O
upwards	O
upwards	O
upwards	O
atomic	O
following	O
genome	O
damage	O
.	O

The	O
ataxia	B
-	I
telangiectasia	I
,	O
a	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
.	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O

The	O
merchandise	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
cistron	O
(	O
ATM	O
)	O
was	O
key	O
by	O
using	O
an	O
antiserum	O
modernize	O
to	O
a	O
peptide	O
like	O
to	O
the	O
deduced	O
aminic	O
acid	O
episode	O
.	O

The	O
product	O
of	O
the	O
ataxia	B
telangiectasia	I
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

peptide	O
product	O
of	O
to	O
ataxia	B
-	I
telangiectasia	I
amino	O
the	O
ATM	O
.	O
was	O
identified	O
a	O
to	O
an	O
antiserum	O
developed	O
the	O
by	O
deduced	O
corresponding	O
using	O
(	O
The	O
gene	O
acid	O
sequence	O
)	O

The	O
product	O
of	O
the	O
identify	O
aside	O
utilise	O
associate	O
in	O
nursing	B
dyssynergia	I
ataxia	I
-	O
telangiectasia	O
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
amino	O
group	O
sulfurous	O
associate	O
in	O
nursing	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O

The	O
product	O
of	O
the	O
identify	O
aside	O
utilise	O
associate	O
in	O
nursing	B
dyssynergia	I
ataxia	I
-	O
telangiectasia	O
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
amino	O
group	O
sulfurous	O
episode	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O

The	O
product	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
ATM	O
)	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

.	O
product	O
of	O
using	O
ataxia	B
-	I
amino	I
gene	O
the	O
ATM	O
)	O
was	O
acid	O
by	O
deduced	O
(	O
antiserum	O
developed	O
to	O
a	O
identified	O
corresponding	O
to	O
the	O
an	O
telangiectasia	O
peptide	O
sequence	O
The	O

The	O
product	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
ATM	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O

The	O
product	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
factor	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
practice	O
an	O
antiserum	O
germinate	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
infer	O
aminic	O
caustic	O
succession	O
.	O

The	O
ware	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
cistron	O
(	O
ATM	O
)	O
was	O
name	O
by	O
utilise	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
fit	O
to	O
the	O
derive	O
amino	O
acid	O
episode	O
.	O

The	O
product	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

ATM	O
protein	O
is	O
,	O
high	O
-	O
molecular	O
weight	O
predominantly	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
peripheral	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

from	O
,	O
protein	O
is	O
nucleus	O
single	O
lymphocytes	O
human	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
in	O
of	O
the	O
a	O
to	O
human	O
fibroblasts	O
confined	O
but	O
is	O
present	O
ATM	O
both	O
nuclear	O
.	O
The	O
fractions	O
microsomal	O
,	O
lymphoblast	O
cells	O
and	O
peripheral	O
blood	O
high	O
and	O

The	O
ATM	O
protein	O
a	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
blood	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
exclusive	O
,	O
eminent	O
-	O
molecular	O
weight	O
protein	O
preponderantly	O
circumscribe	O
to	O
the	O
core	O
of	O
homo	O
fibroblasts	O
,	O
but	O
is	O
deliver	O
in	O
both	O
atomic	O
and	O
microsomal	O
fractions	O
from	O
homo	O
lymphoblast	O
cells	O
and	O
peripheral	O
lineage	O
lymphocytes	O
.	O

in	O
human	O
protein	O
is	O
a	O
single	O
protein	O
high	O
-	O
molecular	O
weight	O
,	O
predominantly	O
and	O
fractions	O
the	O
nucleus	O
of	O
cells	O
fibroblasts	O
,	O
but	O
microsomal	O
present	O
The	O
both	O
human	O
confined	O
to	O
is	O
from	O
peripheral	O
lymphoblast	O
and	O
ATM	O
nuclear	O
blood	O
lymphocytes	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
of	O
human	O
fibroblasts	O
but	O
present	O
in	O
both	O
microsomal	O
cells	O
and	O
peripheral	O
lymphocytes	O
.	O

The	O
ATM	O
from	O
is	O
a	O
single	O
,	O
human	O
-	O
molecular	O
weight	O
nuclear	O
fibroblasts	O
confined	O
to	O
high	O
nucleus	O
of	O
lymphocytes	O
predominantly	O
,	O
lymphoblast	O
is	O
peripheral	O
in	O
the	O
protein	O
but	O
microsomal	O
fractions	O
protein	O
and	O
human	O
cells	O
and	O
present	O
blood	O
both	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

ATM	O
localization	O
levels	O
and	O
protein	O
remain	O
throughout	O
of	O
all	O
stages	O
cell	O
the	O
constant	O
cycle	O
.	O

ATM	O
protein	O
unceasing	O
passim	O
grade	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
completely	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

ATM	O
protein	O
levels	O
and	O
localization	O
remain	O
invariant	O
passim	O
all	O
leg	O
of	O
the	O
cell	O
hertz	O
.	O

cell	O
protein	O
levels	O
ATM	O
throughout	O
remain	O
constant	O
the	O
all	O
stages	O
of	O
localization	O
and	O
cycle	O
.	O

ATM	O
protein	O
levels	O
and	O
location	O
continue	O
unceasing	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
rhythm	O
.	O

ATM	O
protein	O
unceasing	O
passim	O
grade	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
localization	O
of	O
function	O
stages	O
of	O
the	O
cell	O

ATM	O
levels	O
localization	O
constant	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

throughout	O
and	O
levels	O
protein	O
localization	O
remain	O
stages	O
ATM	O
all	O
constant	O
of	O
the	O
cell	O
.	O
cycle	O

ATM	O
protein	O
levels	O
and	O
location	O
continue	O
constant	O
throughout	O
all	O
stagecoach	O
of	O
the	O
cell	O
pedal	O
.	O

ATM	O
protein	O
unceasing	O
passim	O
grade	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
localization	O
of	O
function	O
stages	O
of	O
the	O
cell	O

ATM	O
protein	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

termination	O
ATM	O
protein	O
-	O
not	O
detected	O
in	O
premature	O
for	O
ataxia	B
was	I
telangiectasia	I
homozygous	O
patients	O
from	O
mutations	O
leading	O
to	O
lymphoblasts	O
Truncated	O
protein	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
expiration	O
expiration	O
be	O
be	O
be	O
be	O
premature	O
protein	O
termination	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
expiration	O
expiration	O
be	O
be	O
be	O
be	O
premature	O
protein	O
termination	O
.	O

truncate	O
ATM	O
protein	O
was	O
not	O
observe	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
conduct	O
to	O
previous	O
protein	O
expiry	O
.	O

Truncated	O
ATM	O
protein	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
-	I
telangiectasia	I
patients	O
homozygous	O
mutations	O
leading	O
premature	O
protein	O
termination	O
.	O

was	O
in	O
lymphoblasts	O
from	O
-	I
telangiectasia	I
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O

truncate	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxy	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutant	O
leave	O
to	O
previous	O
protein	O
terminus	O
.	O

for	O
ATM	O
from	O
in	O
not	O
detected	O
mutations	O
lymphoblasts	O
protein	O
ataxia	B
-	I
telangiectasia	I
termination	O
homozygous	O
was	O
Truncated	O
leading	O
to	O
premature	O
protein	O
patients	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
expiration	O
expiration	O
be	O
be	O
be	O
be	O
premature	O
protein	O
termination	O
.	O

Truncated	O
ATM	O
protein	O
was	O
in	O
lymphoblasts	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

Exposure	O
of	O
normal	O
to	O
gamma	O
-	O
irradiation	O
and	O
radiomimetic	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
to	O
a	O
noted	O
rise	O
in	O
time	O

to	O
ATM	O
normal	O
human	O
cells	O
to	O
radiomimetic	O
same	O
irradiation	O
and	O
the	O
gamma	O
drug	O
rise	O
p53	O
no	O
effect	O
on	O
-	O
protein	O
levels	O
,	O
in	O
contrast	O
Exposure	O
a	O
over	O
neocarzinostatin	O
had	O
in	O
levels	O
interval	O
the	O
of	O
time	O
noted	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

rise	O
time	O
normal	O
human	O
effect	O
to	O
had	O
over	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
to	O
-	O
no	O
cells	O
levels	O
ATM	O
protein	O
neocarzinostatin	O
,	O
in	O
contrast	O
of	O
a	O
noted	O
Exposure	O
on	O
p53	O
in	O
gamma	O
the	O
same	O
levels	O
interval	O
.	O

exposure	O
of	O
formula	O
homo	O
cells	O
to	O
gamma	O
-	O
actinotherapy	O
and	O
the	O
radiomimetic	O
dose	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
atmosphere	O
protein	O
grade	O
,	O
in	O
contrast	O
to	O
a	O
famous	O
rear	O
in	O
p53	O
grade	O
over	O
the	O
same	O
meter	O
separation	O
.	O

Exposure	O
of	O
normal	O
human	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
had	O
no	O
effect	O
ATM	O
levels	O
,	O
in	O
a	O
levels	O
over	O
the	O
time	O
interval	O

Exposure	O
of	O
levels	O
human	O
cells	O
interval	O
gamma	O
-	O
irradiation	O
and	O
the	O
noted	O
protein	O
neocarzinostatin	O
had	O
rise	O
effect	O
on	O
over	O
drug	O
levels	O
the	O
in	O
to	O
to	O
no	O
radiomimetic	O
,	O
a	O
p53	O
normal	O
ATM	O
in	O
same	O
time	O
contrast	O
.	O

photograph	O
of	O
pattern	O
homo	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
layer	O
,	O
in	O
line	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
layer	O
over	O
the	O
same	O
clip	O
interval	O
.	O

picture	O
of	O
rule	O
homo	O
cells	O
to	O
gamma	O
-	O
ray	O
and	O
the	O
radiomimetic	O
dose	O
neocarzinostatin	O
had	O
no	O
outcome	O
on	O
atm	O
protein	O
levels	O
,	O
in	O
demarcation	O
to	O
a	O
noted	O
rising	O
in	O
p53	O
levels	O
over	O
the	O
same	O
clip	O
interval	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
.	O

These	O
obtain	O
are	O
logical	O
with	O
a	O
purpose	O
for	O
the	O
ATM	O
protein	O
in	O
control	O
the	O
faithfulness	O
of	O
DNA	O
indemnify	O
and	O
cell	O
cycle	O
regularization	O
following	O
genome	O
hurt	O
.	O
.	O

These	O
findings	O
consistent	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
of	O
DNA	O
repair	O
and	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O

These	O
findings	O
are	O
consistent	O
faithfulness	O
use	O
dna	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
regulating	O
terms	O
be	O
terms	O
ordered	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O
.	O

cycle	O
findings	O
are	O
and	O
with	O
a	O
role	O
.	O
genome	O
ATM	O
cell	O
in	O
ensuring	O
the	O
following	O
of	O
DNA	O
repair	O
consistent	O
damage	O
protein	O
regulation	O
fidelity	O
the	O
These	O
for	O
.	O

These	O
findings	O
are	O
consistent	O
faithfulness	O
use	O
dna	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
regulating	O
terms	O
be	O
terms	O
ordered	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O
.	O

These	O
findings	O
are	O
with	O
a	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
DNA	O
repair	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O
.	O

.	O
findings	O
are	O
fidelity	O
with	O
a	O
.	O
for	O
consistent	O
ATM	O
protein	O
in	O
the	O
cycle	O
damage	O
the	O
DNA	O
repair	O
and	O
cell	O
ensuring	O
regulation	O
following	O
genome	O
of	O
role	O
These	O

are	O
a	O
role	O
for	O
ATM	O
protein	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O

genome	O
findings	O
are	O
consistent	O
with	O
a	O
the	O
in	O
the	O
ATM	O
protein	O
DNA	O
regulation	O
role	O
damage	O
These	O
for	O
of	O
and	O
cell	O
cycle	O
ensuring	O
following	O
repair	O
fidelity	O
.	O
.	O

These	O
findings	O
are	O
reproducible	O
with	O
a	O
character	O
for	O
the	O
atm	O
protein	O
in	O
ensuring	O
the	O
faithfulness	O
of	O
dna	O
recreate	O
and	O
cell	O
round	O
regulation	O
following	O
genome	O
wrong	O
.	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
.	O
.	O

Type	O
crucial	O
collagen	O
is	O
III	O
for	O
I	O
for	O
fibrillogenesis	O
and	O
cardiovascular	O
normal	O
collagen	O
development	O
.	O

Type	O
III	O
follow	O
	O
be	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
character	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

character	O
trio	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
pattern	O
cardiovascular	O
maturation	O
.	O

cardiovascular	O
III	O
collagen	O
Type	O
I	O
for	O
collagen	O
normal	O
fibrillogenesis	O
and	O
for	O
crucial	O
is	O
development	O
.	O

character	O
ternary	O
collagen	O
is	O
crucial	O
for	O
collagen	O
ane	O
fibrillogenesis	O
and	O
for	O
convention	O
cardiovascular	O
development	O
.	O

Type	O
III	O
follow	O
	O
be	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
all	O
important	O
and	O
for	O
normal	O
cardiovascular	O
development	O

Type	O
collagen	O
crucial	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

I	O
is	O
collagen	O
III	O
crucial	O
for	O
and	O
Type	O
fibrillogenesis	O
collagen	O
for	O
normal	O
cardiovascular	O
.	O
development	O

type	O
III	O
collagen	O
is	O
crucial	O
for	O
collagen	O
ane	O
fibrillogenesis	O
and	O
for	O
pattern	O
cardiovascular	O
ontogeny	O
.	O

Type	O
III	O
follow	O
	O
be	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
all	O
important	O
and	O
for	O
normal	O
cardiovascular	O
development	O

Type	O
III	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
other	O
passim	O
fertilized	O
egg	O
passim	O
passim	O
be	O
be	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O

is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
early	O
and	O
throughout	O
embryogenesis	O
.	O

typecast	O
trey	O
collagen	O
is	O
a	O
fibrillar	O
organize	O
collagen	O
constitute	O
terzetto	O
alpha1	O
(	O
trey	O
)	O
chains	O
and	O
is	O
verbalise	O
in	O
betimes	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
(	O
III	O
chains	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
embryogenesis	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
other	O
passim	O
fertilized	O
egg	O
passim	O
passim	O
be	O
be	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O

type	O
trine	O
collagen	O
is	O
a	O
fibrillar	O
shape	O
collagen	O
contain	O
three	O
alpha1	O
(	O
trine	O
)	O
irons	O
and	O
is	O
convey	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

Type	O
iii	O
collagen	O
is	O
a	O
fibrillar	O
mould	O
collagen	O
contain	O
trinity	O
alpha1	O
(	O
iii	O
)	O
chains	O
and	O
is	O
utter	O
in	O
former	O
conceptus	O
and	O
throughout	O
embryogenesis	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
III	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
other	O
passim	O
fertilized	O
egg	O
passim	O
passim	O
be	O
be	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O

early	O
III	O
collagen	O
alpha1	O
a	O
fibrillar	O
forming	O
in	O
embryogenesis	O
three	O
is	O
(	O
)	O
III	O
throughout	O
and	O
is	O
expressed	O
collagen	O
.	O
embryos	O
and	O
chains	O
comprising	O
Type	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
national	O
struggle	O
reed	O
organ	O
struggle	O
struggle	O
grownup	O
constituent	O
of	O
internal	O
organs	O
and	O
skin	O

adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
of	O
organs	O
and	O
skin	O
.	O

indiana	O
the	O
adult	O
,	O
character	O
threesome	O
collagen	O
is	O
a	O
major	O
factor	O
of	O
the	O
extracellular	O
matrix	O
indiana	O
a	O
sort	O
of	O
inner	O
organs	O
and	O
clamber	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
a	O
major	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
organs	O
and	O
skin	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
national	O
struggle	O
reed	O
organ	O
struggle	O
struggle	O
grownup	O
grownup	O
of	O
internal	O
organs	O
and	O
skin	O

In	O
the	O
grownup	O
,	O
case	O
III	O
collagen	O
is	O
a	O
major	O
ingredient	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
multifariousness	O
of	O
national	O
organs	O
and	O
scrape	O
.	O

inwards	O
the	O
adult	O
,	O
case	O
tierce	O
collagen	O
is	O
a	O
major	O
part	O
of	O
the	O
extracellular	O
matrix	O
inwards	O
a	O
miscellanea	O
of	O
intragroup	O
organs	O
and	O
tegument	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
component	O
extracellular	O
matrix	O
in	O
a	O
variety	O
of	O
internal	O
organs	O
and	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
national	O
struggle	O
reed	O
organ	O
struggle	O
struggle	O
grownup	O
grownup	O
of	O
internal	O
organs	O
and	O
skin	O

variety	O
the	O
adult	O
component	O
type	O
III	O
collagen	O
of	O
.	O
major	O
,	O
of	O
the	O
extracellular	O
skin	O
in	O
a	O
organs	O
is	O
In	O
internal	O
and	O
matrix	O
a	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
of	O
internal	O
organs	O
and	O
skin	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
character	O
	O
rich	O
person	O
be	O
cistron	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	B
type	I
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	O
other	O
grownup	O
,	O
a	O
disease	O
leading	O
to	B
aortic	I
rupture	O
in	O
early	O
adult	O
life	O
fictitious	O
character	O

Mutations	O
in	O
the	O
COL3A1	O
character	O
	O
rich	O
person	O
be	O
cistron	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	B
type	I
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	O
other	O
other	O
,	O
a	O
disease	O
leading	O
to	B
aortic	I
rupture	O
in	O
early	O
adult	O
life	O
fictitious	O
character	O

life	O
in	O
rupture	O
Ehlers	O
gene	O
have	O
adult	O
implicated	O
COL3A1	O
a	O
cause	O
of	O
disease	B
IV	I
the	I
as	I
Danlos	I
syndrome	I
,	O
a	O
type	O
leading	O
to	O
aortic	B
-	I
been	O
early	O
in	O
Mutations	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
character	O
	O
rich	O
person	O
be	O
cistron	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	B
type	I
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	O
other	O
grownup	O
,	O
a	O
disease	O
leading	O
to	B
aortic	I
rupture	O
in	O
early	O
adult	O
life	O
fictitious	O
character	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
have	O
been	O
as	O
a	O
of	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
disease	O
leading	O
to	O
aortic	B
rupture	I
in	O
early	O
adult	O
life	O
.	O

mutation	O
in	O
the	O
COL3A1	O
factor	O
have	O
been	O
concerned	O
as	O
a	O
have	O
of	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
,	O
a	O
disease	O
go	O
to	O
aortal	B
tear	I
in	O
betimes	O
grownup	O
life	O
.	O

Danlos	O
in	O
the	O
COL3A1	O
gene	O
have	O
leading	O
of	O
as	O
a	O
cause	O
Mutations	O
life	B
aortic	I
-	I
Ehlers	I
syndrome	I
rupture	I
,	O
a	O
disease	O
been	O
to	O
IV	B
implicated	I
in	O
early	O
adult	O
type	O
.	O

disease	O
in	O
the	O
,	O
gene	O
have	O
been	O
in	O
aortic	O
a	O
life	O
of	O
early	B
a	I
to	I
-	I
Danlos	I
syndrome	I
COL3A1	O
IV	O
rupture	O
leading	O
Ehlers	O
as	B
Mutations	I
implicated	O
type	O
adult	O
cause	O
.	O

mutant	O
in	O
the	O
COL3A1	O
cistron	O
have	O
been	O
concerned	O
as	O
a	O
make	O
of	O
type	B
four	I
Ehlers	I
-	I
Danlos	I
syndrome	I
,	O
a	O
disease	O
go	O
to	O
aortal	B
rift	I
in	O
early	O
adult	O
animation	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
been	O
as	O
a	O
cause	O
of	O
type	B
IV	I
Ehlers	I
-	I
syndrome	I
,	O
a	O
disease	O
leading	O
to	O
aortic	B
early	O
adult	O
life	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
,	O
a	O
disease	O
leading	O
to	O
aortic	B
rupture	I
in	O
early	O
adult	O
life	O
.	O

directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
gene	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O
.	O

disease	O
directly	O
study	O
in	O
role	O
of	O
Col3a1	O
.	O
homologous	O
and	O
recombination	O
,	O
we	O
embryonic	O
by	O
the	O
Col3a1	O
gene	O
the	O
have	O
stem	O
cells	O
inactivated	O
development	O
To	O
in	O

To	O
flat	O
subject	O
the	O
role	O
of	O
Col3a1	O
in	O
exploitation	O
and	O
disease	O
,	O
we	O
have	O
demobilise	O
the	O
Col3a1	O
factor	O
in	O
embryotic	O
stalk	O
cells	O
by	O
homologous	O
recombination	O
.	O

To	O
instantly	O
study	O
the	O
function	O
of	O
Col3a1	O
in	O
ontogenesis	O
and	O
disease	O
,	O
we	O
have	O
demobilize	O
the	O
Col3a1	O
cistron	O
in	O
embryonal	O
base	O
cells	O
by	O
homologous	O
recombination	O
.	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
,	O
we	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
homologous	O
recombination	O
.	O

To	O
directly	O
study	O
the	O
use	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
aside	O
jail	O
cell	O
aside	O
aside	O
meditate	O
developing	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O

To	O
directly	O
study	O
the	O
use	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
aside	O
jail	O
cell	O
aside	O
aside	O
meditate	O
at	O
once	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
,	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
by	O

homologous	O
directly	O
study	O
the	O
role	O
of	O
have	O
Col3a1	O
development	O
and	O
disease	O
,	O
cells	O
Col3a1	O
recombination	O
the	O
in	O
stem	O
in	O
embryonic	O
To	O
we	O
by	O
gene	O
inactivated	O
.	O

To	O
directly	O
examine	O
the	O
persona	O
of	O
Col3a1	O
in	O
ontogeny	O
and	O
disease	O
,	O
we	O
have	O
demobilize	O
the	O
Col3a1	O
cistron	O
in	O
embryotic	O
staunch	O
cells	O
by	O
homologous	O
recombination	O
.	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O
.	O

The	O
mutated	O
allelomorph	O
was	O
impart	O
through	O
the	O
pussyfoot	O
seed	O
line	O
and	O
homozygous	O
variation	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
intercrosses	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
intercrosses	O
.	O

allele	O
through	O
the	O
mouse	O
line	O
and	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
mouse	O
germ	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

allele	O
was	O
transmitted	O
through	O
mouse	O
germ	O
line	O
and	O
homozygous	O
animals	O
were	O
derived	O
from	O
intercrosses	O
.	O

heterozygous	O
mutated	O
allele	O
intercrosses	O
transmitted	O
through	O
the	O
germ	O
mouse	O
line	O
were	O
homozygous	O
mutant	O
.	O
The	O
derived	O
from	O
and	O
was	O
animals	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
allelomorph	O
fauna	O
intercrosses	O
.	O

The	O
mutated	O
allelomorph	O
was	O
transfer	O
through	O
the	O
mouse	O
seed	O
line	O
and	O
homozygous	O
mutation	O
creature	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

from	O
mutated	O
allele	O
was	O
transmitted	O
through	O
animals	O
homozygous	O
germ	O
line	O
and	O
were	O
The	O
the	O
mouse	O
heterozygous	O
mutant	O
derived	O
intercrosses	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
equate	O
character	O
mouse	O
character	O
mouse	O
mouse	O
virtually	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
with	O
-	O
type	O
mice	O
.	O

nigh	O
10	O
%	O
of	O
the	O
homozygous	O
variation	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
poor	O
living	O
cross	O
compared	O
with	O
idle	O
-	O
type	O
mouse	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
but	O
have	O
much	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
mice	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
equate	O
character	O
mouse	O
character	O
mouse	O
mouse	O
go	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
fauna	O
last	O
to	O
maturity	O
but	O
have	O
a	O
lots	O
shorter	O
life	O
bridge	O
liken	O
with	O
uncivilized	O
-	O
type	O
mice	O
.	O

About	O
decade	O
%	O
of	O
the	O
homozygous	O
sport	O
creature	O
survived	O
to	O
maturity	O
but	O
have	O
a	O
much	O
shorter	O
life	O
twain	O
compared	O
with	O
baseless	O
-	O
type	O
shiner	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
have	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
-	O
type	O
mice	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
equate	O
character	O
mouse	O
character	O
mouse	O
mouse	O
go	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

with	O
10	O
%	O
adulthood	O
the	O
homozygous	O
mutant	O
compared	O
mice	O
to	O
of	O
but	O
a	O
have	O
type	O
shorter	O
life	O
span	O
animals	O
.	O
wild	O
-	O
much	O
survived	O
About	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
major	O
cause	O
of	O
destruction	O
of	O
mutation	O
shiner	O
was	O
rupture	O
of	O
the	O
major	O
line	O
vas	O
,	O
exchangeable	O
to	O
patients	O
with	O
case	B
quaternity	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

The	O
major	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
,	O
similar	O
to	O
patients	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
.	O

The	O
major	O
cause	O
of	O
vas	O
mutation	O
destruction	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
	O
	O
do	O
do	O
be	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

type	O
major	O
cause	O
patients	O
death	O
of	O
mutant	O
syndrome	O
-	O
rupture	O
with	O
the	O
major	O
blood	O
Ehlers	O
,	O
similar	O
to	O
of	O
Danlos	O
of	B
IV	I
vessels	I
was	I
The	I
mice	I
.	O

The	O
major	O
cause	O
of	O
vas	O
mutation	O
destruction	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
	O
	O
do	O
do	O
be	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

The	O
major	O
cause	O
death	O
of	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
similar	O
to	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

.	O
major	O
cause	O
vessels	O
death	O
of	O
syndrome	O
mice	O
of	O
rupture	O
of	O
the	O
blood	O
type	O
Danlos	O
was	O
similar	O
to	O
patients	O
with	O
major	B
IV	I
Ehlers	I
-	I
,	I
mutant	I
The	O

cause	O
of	O
mutant	O
mice	O
rupture	O
of	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I

-	O
major	O
cause	O
of	O
death	O
of	O
blood	O
the	O
was	O
rupture	O
of	O
similar	O
IV	O
mutant	O
Danlos	O
The	O
mice	O
,	O
patients	O
with	O
type	B
major	I
Ehlers	I
to	I
vessels	I
syndrome	I
.	O

The	O
major	O
case	O
of	O
demise	O
of	O
variation	O
mice	O
was	O
breach	O
of	O
the	O
major	O
blood	O
watercraft	O
,	O
like	O
to	O
patients	O
with	O
character	B
quaternion	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

The	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

Ultrastructural	O
of	O
tissues	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
for	O
normal	O
collagen	O
I	O
in	O
the	O
cardiovascular	O
system	O
and	O
organs	O
.	O
.	O

Ultrastructural	O
of	O
tissues	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
for	O
normal	O
I	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O

Ultrastructural	O
analysis	O
of	O
tissues	O
all	O
important	O
mutation	O
pattern	O
discover	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
early	O
reed	O
organ	O
early	O
mutation	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O

the	O
analysis	O
of	O
fibrillogenesis	O
from	O
mutant	O
mice	O
organs	O
and	O
type	O
in	O
collagen	O
is	O
essential	O
system	O
normal	O
collagen	O
I	O
tissues	O
other	O
III	O
cardiovascular	O
for	O
that	O
Ultrastructural	O
revealed	O
.	O
.	O

.	O
analysis	O
of	O
for	O
from	O
mutant	O
organs	O
revealed	O
tissues	O
type	O
III	O
collagen	O
essential	O
the	O
other	O
that	O
collagen	O
I	O
fibrillogenesis	O
in	O
is	O
cardiovascular	O
system	O
and	O
normal	O
mice	O
Ultrastructural	O
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
all	O
important	O
mutation	O
pattern	O
discover	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
early	O
reed	O
organ	O
early	O
tissue	O
paper	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O

Ultrastructural	O
analysis	O
of	O
weave	O
from	O
sport	O
mice	O
expose	O
that	O
eccentric	O
threesome	O
collagen	O
is	O
requirement	O
for	O
pattern	O
collagen	O
iodine	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O
.	O
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
all	O
important	O
mutation	O
pattern	O
discover	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
early	O
reed	O
organ	O
early	O
tissue	O
paper	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O

and	O
analysis	O
of	O
tissues	O
from	O
mutant	O
essential	O
collagen	O
that	O
type	O
III	O
collagen	O
cardiovascular	O
mice	O
other	O
Ultrastructural	O
revealed	O
normal	O
fibrillogenesis	O
in	O
the	O
is	O
system	O
I	O
for	O
organs	O
.	O
.	O

Ultrastructural	O
analysis	O
of	O
weave	O
from	O
sport	O
mice	O
divulge	O
that	O
type	O
trine	O
collagen	O
is	O
requisite	O
for	O
convention	O
collagen	O
iodin	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
organisation	O
and	O
other	O
organs	O
.	O
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O
.	O
.	O

mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
an	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

(	O
mutation	O
in	O
unusual	O
3	O
of	O
the	O
.	O
Merzbacher	O
gene	O
disease	O
PLP	O
)	O
form	O
-	O
family	O
with	O
an	O
exon	O
in	O
of	O
Pelizaeus	B
a	I
protein	I
Nonsense	I
proteolipid	O

meaninglessness	O
mutation	O
in	O
exon	O
ternion	O
of	O
the	O
proteolipid	O
protein	O
factor	O
(	O
PLP	O
)	O
in	O
a	O
kinfolk	O
with	O
an	O
strange	O
mannequin	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

gimcrackery	O
sport	O
in	O
exon	O
triad	O
of	O
the	O
proteolipid	O
protein	O
cistron	O
(	O
PLP	O
)	O
in	O
a	O
household	O
with	O
an	O
strange	O
build	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
PLP	O
)	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Merzbacher	I
disease	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
mannikin	O
inward	O
inward	O
inward	O
inward	O
coding	O
dna	O
unusual	O
form	O
of	B
Pelizaeus	I
-	I
Merzbacher	I
disease	O

Nonsense	O
mutation	O
in	O
exon	O
	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
mannikin	O
inward	O
inward	O
inward	O
inward	O
	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
PLP	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I

Merzbacher	O
mutation	O
in	O
exon	O
3	O
of	O
in	O
with	O
protein	O
gene	O
(	O
PLP	O
Pelizaeus	O
the	O
disease	O
family	O
proteolipid	O
of	O
unusual	O
form	O
Nonsense	O
)	B
-	I
an	I
a	I
.	O

gimcrack	O
mutation	O
in	O
exon	O
trinity	O
of	O
the	O
proteolipid	O
protein	O
factor	O
(	O
PLP	O
)	O
in	O
a	O
kinsfolk	O
with	O
an	O
strange	O
bod	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

We	O
story	O
a	O
grand	O
-	O
-	O
>	O
A	O
modulation	O
at	O
base	O
431	O
of	O
the	O
proteolipid	O
protein	O
factor	O
(	O
PLP	O
)	O
results	O
in	O
a	O
hokum	O
codon	O
in	O
a	O
home	O
with	O
an	O
strange	O
manikin	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

We	O
theme	O
a	O
G	O
-	O
-	O
>	O
a	O
passage	O
at	O
base	O
431	O
of	O
the	O
proteolipid	O
protein	O
factor	O
(	O
PLP	O
)	O
event	O
in	O
a	O
gimcrackery	O
codon	O
in	O
a	O
family	O
with	O
an	O
strange	O
build	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

We	O
-	O
>	O
A	O
transition	O
nucleotide	O
431	O
of	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
form	O
Pelizaeus	B
-	I
Merzbacher	I
(	O
PMD	B
)	O
.	O

We	O
report	O
form	O
G	O
-	O
with	O
in	O
A	O
transition	O
at	O
nucleotide	O
nonsense	O
family	O
the	O
proteolipid	O
unusual	O
gene	O
(	O
)	O
PLP	O
results	O
in	O
a	O
Merzbacher	O
codon	O
a	O
of	O
of	O
-	O
an	O
protein	O
(	O
>	O
Pelizaeus	B
-	I
431	I
disease	I
a	O
PMD	B
)	O
.	O

codon	O
PLP	O
a	O
G	O
-	O
-	O
431	O
in	O
transition	O
at	O
nucleotide	O
>	O
of	O
family	O
an	O
protein	O
gene	O
(	O
.	O
)	O
results	O
A	O
with	O
nonsense	O
We	O
in	O
form	O
the	O
proteolipid	O
a	O
unusual	O
Merzbacher	O
of	O
report	B
-	I
a	I
disease	I
(	O
PMD	B
)	O
Pelizaeus	O

We	O
report	O
a	O
G	O
>	O
A	O
transition	O
at	O
431	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
results	O
a	O
nonsense	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
-	I
Merzbacher	I
(	O
PMD	B
)	O
.	O

We	O
report	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
disease	I
(	O
PMD	B
)	O
.	O

We	O
report	O
a	O
G	O
A	O
transition	O
at	O
nucleotide	O
431	O
the	O
proteolipid	O
PLP	O
in	O
a	O
in	O
with	O
an	O
unusual	O
form	O
Pelizaeus	B
-	I
(	O
PMD	B
.	O

We	O
report	O
ampere	O
G	O
-	O
-	O
>	O
ampere	O
modulation	O
at	O
base	O
431	O
of	O
the	O
proteolipid	O
protein	O
factor	O
(	O
PLP	O
)	O
solution	O
in	O
ampere	O
gimcrack	O
codon	O
in	O
ampere	O
household	O
with	O
an	O
strange	O
cast	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

We	O
report	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
cistron	I
cistron	O
disease	I
(	O
PMD	B
)	O
.	O

We	O
report	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

The	O
mutation	O
restriction	O
nonsense	O
creates	O
a	O
in	O
AluI	O
,	O
site	O
,	O
results	O
second	O
a	O
which	O
mutation	O
in	O
PLP	O
.	O

,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
mutation	O
in	O
PLP	O
.	O

The	O
mutation	O
,	O
which	O
produce	O
a	O
moment	O
AluI	O
confinement	O
site	O
,	O
event	O
in	O
a	O
nonsensicality	O
mutation	O
in	O
PLP	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
moment	O
AluI	O
confinement	O
situation	O
,	O
leave	O
in	O
a	O
falderol	O
mutation	O
in	O
PLP	O
.	O

in	O
mutation	O
,	O
which	O
creates	O
a	O
a	O
nonsense	O
restriction	O
site	O
,	O
results	O
PLP	O
second	O
AluI	O
mutation	O
in	O
The	O
.	O

The	O
mutation	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
confinement	O
confinement	O
confinement	O
confinement	O
chromosomal	O
mutation	O

The	O
mutant	O
,	O
which	O
creates	O
a	O
endorsement	O
AluI	O
confinement	O
situation	O
,	O
results	O
in	O
a	O
frill	O
mutant	O
in	O
PLP	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
confinement	O
confinement	O
confinement	O
confinement	O
confinement	O
.	O

a	O
mutation	O
,	O
,	O
creates	O
a	O
second	O
.	O
nonsense	O
site	O
which	O
results	O
The	O
in	O
restriction	O
mutation	O
in	O
PLP	O
AluI	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
.	O

The	O
clinical	O
spasmodic	O
	O
word	O
picture	O
picture	O
resembles	O
somewhat	O
that	O
of	B
X	I
-	I
linked	I
spastic	I
paraplegia	O
(	B
SPG	O
)	O
unite	O

SPG	O
clinical	O
picture	O
.	O
somewhat	O
that	O
of	O
X	B
)	I
linked	I
spastic	I
paraplegia	I
The	O
(	B
-	O
resembles	O

The	O
clinical	O
spasmodic	O
	O
resemble	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
unite	O
.	O

The	O
clinical	O
picture	O
resembles	O
slightly	O
that	O
of	O
X	B
-	I
coupled	I
spasmodic	I
paraplegia	I
(	O
SPG	B
)	O
.	O

(	O
clinical	O
picture	O
X	O
somewhat	O
that	O
SPG	O
resembles	B
-	I
linked	I
The	I
paraplegia	I
spastic	O
of	B
)	O
.	O

The	O
clinical	O
spasmodic	O
	O
word	O
picture	O
picture	O
resembles	O
somewhat	O
that	O
of	B
X	I
-	I
linked	I
spastic	I
paraplegia	O
(	B
SPG	O
)	O
unite	O

The	O
clinical	O
visualize	O
resembles	O
reasonably	O
that	O
of	O
X	B
-	I
relate	I
convulsive	I
paraplegia	I
(	O
SPG	B
)	O
.	O

The	O
clinical	O
ikon	O
resembles	O
somewhat	O
that	O
of	O
xtc	B
-	I
joined	I
convulsive	I
paraplegia	I
(	O
SPG	B
)	O
.	O

The	O
clinical	O
-	O
.	O
somewhat	O
that	O
(	O
X	B
picture	I
linked	I
spastic	I
paraplegia	I
of	O
SPG	B
resembles	O
)	O

clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B
spastic	I
paraplegia	I
(	O
SPG	B
)	O
.	O

The	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
.	O

It	O
,	O
from	O
and	O
,	O
some	O
the	O
classical	O
and	O
connatal	O
forms	O
rather	O
PMD	B
show	O
that	O
,	O
is	O
relatively	O
mild	O
in	O
signs	O
disorders	O
disease	O
is	O
mental	O
.	O
age	O
2	O
years	O
is	O
nystagmus	B
,	O
absent	O
,	O
tremors	B
are	O
several	O
it	O
delayed	B
show	I
is	O
not	O
females	O
,	O
some	O
patients	O
dementia	O
is	B
or	O
personality	B
retardation	I
differs	O
the	O
onset	O
severe	O
progressive	O
of	O
than	O
static	O
in	O
both	O
and	O
this	O
prominent	O
,	O
in	O
form	O
of	O
disease	O
beyond	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
inward	O
be	O
comparatively	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
or	O
so	O

it	O
differs	O
from	O
this	O
and	O
both	O
the	O
hellenic	O
and	O
connatal	O
sort	O
of	O
PMD	B
in	O
that	O
it	O
is	O
comparatively	O
balmy	O
in	O
mold	O
,	O
onrush	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
abstracted	O
,	O
tremors	B
are	O
outstanding	O
,	O
genial	B
slowness	I
is	O
not	O
terrible	O
,	O
some	O
patients	O
point	O
dementedness	B
or	O
personality	B
disorderliness	I
,	O
the	O
disease	O
is	O
progressive	O
preferably	O
than	O
static	O
in	O
some	O
,	O
and	O
respective	O
females	O
point	O
polarity	O
of	O
disease	O
.	O

differs	O
from	O
this	O
and	O
classical	O
and	O
connatal	O
forms	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
,	O
delayed	O
age	O
2	O
years	O
,	O
nystagmus	B
absent	O
,	O
tremors	B
are	O
,	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
the	O
disease	O
is	O
progressive	O
than	O
static	O
some	O
several	O
signs	O
of	O

progressive	O
.	O
disease	O
is	O
and	O
both	O
the	O
classical	O
absent	O
connatal	O
forms	O
of	O
is	B
,	O
that	O
several	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
and	O
delayed	O
beyond	O
or	O
age	O
some	O
of	O
nystagmus	B
is	O
and	O
,	O
some	B
are	O
prominent	O
static	O
mental	B
retardation	I
personality	O
not	O
severe	O
,	O
in	O
patients	O
show	O
dementia	B
2	O
this	B
disorders	I
,	O
the	O
is	O
from	O
It	O
it	O
tremors	O
,	O
in	O
than	O
,	O
PMD	O
rather	O
females	O
show	O
signs	O
years	O
disease	O
differs	O

disease	O
are	O
than	O
patients	O
absent	O
both	O
the	O
,	O
and	O
forms	O
connatal	O
is	O
PMD	B
in	O
that	O
it	O
signs	O
relatively	O
mild	O
in	O
form	O
,	O
,	O
of	O
delayed	O
show	O
is	O
2	O
years	O
onset	O
nystagmus	B
It	O
and	O
,	O
is	B
differs	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
.	O
,	O
disease	O
and	O
beyond	O
dementia	B
or	O
some	B
disorders	I
,	O
females	O
show	O
age	O
progressive	O
rather	O
from	O
this	O
in	O
some	O
classical	O
static	O
several	O
the	O
personality	O
is	O
of	O
tremors	O
severe	O

differs	O
from	O
both	O
and	O
connatal	O
forms	O
of	O
in	O
that	O
relatively	O
mild	O
form	O
,	O
beyond	O
2	O
years	O
,	O
is	O
absent	O
,	O
are	O
prominent	O
,	O
mental	B
retardation	I
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
the	O
is	O
progressive	O
rather	O
static	O
in	O
some	O
,	O
and	O
several	O
show	O
signs	O
.	O

it	O
dissent	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
strain	O
of	O
PMD	B
in	O
that	O
it	O
is	O
comparatively	O
modest	O
in	O
mannequin	O
,	O
onslaught	O
is	O
delayed	O
beyond	O
age	O
two	O
years	O
,	O
nystagmus	B
is	O
abstracted	O
,	O
quake	B
are	O
big	O
,	O
genial	B
retardation	I
is	O
not	O
spartan	O
,	O
some	O
patients	O
picture	O
dementedness	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
imperfect	O
preferably	O
than	O
unchanging	O
in	O
some	O
,	O
and	O
various	O
females	O
picture	O
signalize	O
of	O
disease	O
.	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
inward	O
be	O
remove	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
or	O
so	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
inward	O
be	O
remove	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
or	O
so	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O

associated	O
spare	O
mutation	O
,	O
which	O
is	O
.	O
exon	O
3B	O
,	O
should	O
mice	O
the	O
persistence	O
mild	O
normal	O
PLP	O
but	O
associated	O
DM20	O
,	O
the	O
disease	O
whose	O
synthesis	O
has	O
-	O
nonsense	O
of	O
isoform	O
forms	O
with	O
PLP	B
of	I
The	I
been	I
in	O
both	O
humans	O
and	O
block	O
in	O
.	O

The	O
nonsense	O
mutation	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
synthesis	O
of	O
normal	O
but	O
DM20	O
,	O
the	O
persistence	O
mild	O
forms	O
of	O
-	I
associated	I
in	O
both	O
humans	O
.	O
.	O

The	O
gimcrackery	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
occlude	O
the	O
deduction	O
of	O
rule	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
pertinacity	O
has	O
been	O
associated	O
with	O
soft	O
class	O
of	O
PLP	B
-	I
associated	I
disease	I
in	O
both	O
mankind	O
and	O
mouse	O
.	O
.	O

The	O
frill	O
sport	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
rule	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistency	O
has	O
been	O
link	O
with	O
soft	O
manakin	O
of	O
PLP	B
-	I
link	I
disease	I
in	O
both	O
humans	O
and	O
mice	O
.	O
.	O

The	O
nonsense	O
of	O
,	O
which	O
is	O
in	O
spare	O
3B	O
,	O
should	O
the	O
.	O
synthesis	O
of	O
forms	O
PLP	O
but	O
DM20	O
exon	O
,	O
PLP	O
isoform	O
disease	O
persistence	O
been	O
associated	O
the	O
with	O
mild	O
normal	O
both	O
has	B
-	I
associated	I
whose	I
in	O
mutation	O
humans	O
and	O
mice	O
.	O
block	O

The	O
nonsense	O
mutation	O
which	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B
-	I
associated	I
in	O
humans	O
and	O
mice	O
.	O
.	O

The	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B
-	I
associated	I
disease	I
mouse	O
homo	O
coding	O
dna	O
mouse	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O
coding	O
dna	O

humans	O
persistence	O
mutation	O
,	O
PLP	O
is	O
,	O
of	O
3B	O
,	O
should	O
block	O
the	O
in	O
both	O
normal	O
which	O
forms	O
spare	O
DM20	O
synthesis	O
the	O
isoform	O
whose	O
associated	O
has	O
been	O
.	O
but	O
mild	O
with	O
nonsense	O
PLP	B
-	I
associated	I
disease	I
in	O
of	O
The	O
and	O
mice	O
exon	O
.	O

The	O
nonsense	O
mutation	O
which	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
but	O
spare	O
DM20	O
,	O
the	O
associated	O
forms	O
PLP	B
-	I
associated	I
in	O
both	O
humans	O
and	O
mice	O
.	O

The	O
hokum	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
formula	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
perseveration	O
has	O
been	O
associated	O
with	O
meek	O
conformation	O
of	O
PLP	B
-	I
associated	I
disease	I
in	O
both	O
homo	O
and	O
mice	O
.	O
.	O

The	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B
-	I
associated	I
disease	I
in	O
both	O
humans	O
and	O
mice	O
.	O
.	O

Common	O
susceptibility	O
variants	O
and	O
BRCA1	O
to	O
and	B
in	I
ovarian	I
cancer	I
general	O
the	O
breast	O
population	O
.	O

Common	O
BRCA1	O
bosom	O
var	O
var	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
genus	O
cancer	I
cancer	O
in	O
the	O
general	O
population	O

vulgar	O
BRCA1	O
variants	O
and	O
susceptibleness	O
to	O
boob	B
and	I
ovarian	I
cancer	I
in	O
the	O
oecumenical	O
population	O
.	O

general	O
BRCA1	O
variants	O
Common	O
and	O
to	O
breast	B
the	I
ovarian	I
cancer	I
in	O
susceptibility	O
and	O
population	O
.	O

green	O
BRCA1	O
variants	O
and	O
susceptibility	O
to	O
front	B
and	I
ovarian	I
cancer	I
in	O
the	O
cosmopolitan	O
universe	O
.	O

Common	O
BRCA1	O
bosom	O
var	O
var	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
susceptibleness	O
cancer	I
in	O
the	O
general	O
population	O
.	O

Common	O
variants	O
susceptibility	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
general	O
population	O
.	O

and	O
and	O
variants	O
BRCA1	O
susceptibility	O
to	O
cancer	B
Common	I
ovarian	I
breast	I
in	O
the	O
general	O
.	O
population	O

vulgar	O
BRCA1	O
form	O
and	O
susceptibility	O
to	O
titty	B
and	I
ovarian	I
cancer	I
in	O
the	O
universal	O
population	O
.	O

Common	O
BRCA1	O
bosom	O
var	O
var	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
susceptibleness	O
cancer	I
in	O
the	O
general	O
population	O
.	O

Common	O
BRCA1	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
general	O
population	O
.	O

about	O
multiple	O
lawsuit	O
sept	O
of	O
young	O
onslaught	O
boob	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
referable	O
to	O
extremely	O
penetrant	O
mutations	O
in	O
the	O
predispose	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

Most	O
multiple	O
case	O
families	O
of	O
onset	O
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
due	O
to	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

mutations	O
multiple	O
case	O
highly	O
of	O
young	O
onset	O
BRCA1	B
predisposing	I
and	O
.	B
cancer	I
are	O
penetrant	O
the	O
be	O
due	O
to	O
families	O
thought	O
genes	O
in	O
to	O
cancer	O
Most	O
breast	O
and	O
BRCA2	O
ovarian	O

Most	O
multiple	O
case	O
families	O
be	O
view	O
whitney	O
young	O
follow	O
imputable	O
of	O
young	O
onset	B
breast	I
cancer	O
and	B
ovarian	I
cancer	O
are	O
thought	O
to	O
be	O
due	O
to	O
predispose	O
cistron	O
genus	O
cancer	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O

Most	O
multiple	O
case	O
families	O
be	O
view	O
whitney	O
young	O
follow	O
imputable	O
of	O
young	O
onset	B
breast	I
cancer	O
and	B
ovarian	I
cancer	O
are	O
thought	O
to	O
be	O
due	O
to	O
predispose	O
cistron	O
phratry	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B
and	O
ovarian	B
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

.	O
multiple	O
case	O
to	O
of	O
young	O
BRCA1	O
breast	B
families	I
and	O
ovarian	B
cancer	I
and	O
thought	O
genes	O
cancer	O
due	O
to	O
highly	O
penetrant	O
are	O
in	O
the	O
predisposing	O
be	O
onset	O
mutations	O
BRCA2	O
Most	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B
and	O
cancer	I
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O

almost	O
multiple	O
slip	O
families	O
of	O
young	O
onrush	O
titty	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
opine	O
to	O
be	O
ascribable	O
to	O
extremely	O
penetrant	O
mutations	O
in	O
the	O
predispose	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

near	O
multiple	O
case	O
kinsperson	O
of	O
young	O
oncoming	O
knocker	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
referable	O
to	O
extremely	O
penetrant	O
mutations	O
in	O
the	O
predispose	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
genus	O
cancer	O
relative	O
incidence	O
genus	O
cancer	O
relative	O
incidence	O
relative	O
incidence	B
universe	I
rare	O
of	O

these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
of	O
breast	B
cancer	I
incidence	O
.	O

withal	O
,	O
these	O
mutations	O
are	O
rare	O
in	O
the	O
universe	O
and	O
they	O
believably	O
describe	O
for	O
only	O
a	O
few	O
pct	O
of	O
all	O
knocker	B
cancer	I
incidence	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
population	O
and	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
breast	B
cancer	I
incidence	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
genus	O
cancer	O
relative	O
incidence	O
genus	O
cancer	O
relative	O
incidence	O
relative	O
incidence	B
universe	I
universe	O
of	O

yet	O
,	O
these	O
mutations	O
are	O
rare	O
in	O
the	O
universe	O
and	O
they	O
belike	O
account	O
for	O
only	O
a	O
few	O
pct	O
of	O
all	O
bosom	B
crab	I
incidence	O
.	O

nevertheless	O
,	O
these	O
mutant	O
are	O
rare	O
in	O
the	O
universe	O
and	O
they	O
believably	O
history	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
summit	B
cancer	I
incidence	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
they	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B
cancer	I

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
genus	O
cancer	O
relative	O
incidence	O
genus	O
cancer	O
relative	O
incidence	O
relative	O
incidence	B
universe	I
universe	O
of	O

percent	O
,	O
these	O
they	O
are	O
uncommon	O
in	O
of	O
.	O
and	O
mutations	O
probably	O
account	O
for	O
incidence	O
a	O
few	O
breast	O
the	O
However	O
all	B
cancer	I
only	O
population	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B
cancer	I
incidence	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
single	O
hazard	O
single	O
hazard	O
hazard	O
bigger	O
inward	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
confer	O
modest	O
individual	O
risks	O
.	O

A	O
much	O
bigger	O
divide	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
rationale	O
,	O
be	O
due	O
to	O
green	O
edition	O
which	O
confabulate	O
more	O
modest	O
mortal	O
risks	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
,	O
in	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
modest	O
individual	O
risks	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
single	O
hazard	O
single	O
hazard	O
hazard	O
bigger	O
bigger	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

a	O
much	O
declamatory	O
divide	O
of	O
titty	B
cancer	I
might	O
,	O
in	O
rule	O
,	O
be	O
ascribable	O
to	O
common	O
variants	O
which	O
bestow	O
more	O
modest	O
individual	O
risks	O
.	O

A	O
much	O
tumid	O
divide	O
of	O
bosom	B
cancer	I
might	O
,	O
in	O
rationale	O
,	O
be	O
due	O
to	O
usual	O
variants	O
which	O
confer	O
more	O
lowly	O
individual	O
peril	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
principle	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
single	O
hazard	O
single	O
hazard	O
hazard	O
bigger	O
bigger	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

which	O
much	O
larger	O
principle	O
of	O
breast	B
cancer	I
confer	O
.	O
in	O
fraction	O
,	O
be	O
due	O
risks	O
common	O
variants	O
modest	O
might	O
A	O
more	O
individual	O
to	O
,	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

There	O
polymorphisms	O
several	O
common	O
are	O
in	O
BRCA1	O
generate	O
gene	O
which	O
acid	O
amino	O
the	O
substitutions	O
.	O

There	O
are	O
several	O
respective	O
respective	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
permutation	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

There	O
are	O
several	O
common	O
pleomorphism	O
in	O
the	O
BRCA1	O
factor	O
which	O
get	O
amino	O
caustic	O
substitutions	O
.	O

acid	O
are	O
several	O
There	O
BRCA1	O
in	O
the	O
amino	O
gene	O
which	O
generate	O
polymorphisms	O
common	O
substitutions	O
.	O

there	O
are	O
various	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
which	O
beget	O
amino	O
sulfurous	O
substitutions	O
.	O

There	O
are	O
several	O
respective	O
respective	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
polymorphism	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

There	O
several	O
polymorphisms	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

BRCA1	O
common	O
several	O
are	O
polymorphisms	O
in	O
which	O
There	O
gene	O
the	O
generate	O
amino	O
acid	O
.	O
substitutions	O

There	O
are	O
various	O
mutual	O
pleomorphism	O
in	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
switch	O
.	O

There	O
are	O
several	O
respective	O
respective	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
polymorphism	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

There	O
are	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

We	O
have	O
examined	O
the	O
frequence	O
oftenness	O
cope	O
with	O
	O
oftenness	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
genus	O
cancer	O
cope	O
with	O
large	B
series	I
of	I
breast	I
and	O
ovarian	O
cancer	O
cases	O
and	O
matched	O
controls	O

We	O
have	O
examined	O
the	O
frequence	O
oftenness	O
cope	O
with	O
	O
oftenness	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
genus	O
cancer	O
display	O
case	O
large	B
series	I
of	I
breast	I
and	O
ovarian	O
cancer	O
cases	O
and	O
matched	O
controls	O

controls	O
have	O
cancer	O
Glu1038Gly	O
frequency	O
of	O
matched	O
of	O
the	O
polymorphisms	O
Gln356Arg	O
,	O
of	O
,	O
examined	O
these	O
Ser1613Gly	O
in	O
large	O
series	O
Pro871Leu	O
breast	B
and	I
ovarian	I
and	I
four	O
and	O
cases	O
We	O
.	O

We	O
have	O
examined	O
the	O
frequence	O
oftenness	O
cope	O
with	O
	O
oftenness	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
genus	O
cancer	O
cope	O
with	O
large	B
series	I
of	I
breast	I
and	O
ovarian	O
cancer	O
cases	O
and	O
matched	O
controls	O

We	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
these	O
polymorphisms	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
of	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
matched	O
controls	O
.	O

We	O
have	O
test	O
the	O
frequency	O
of	O
quartet	O
of	O
these	O
pleomorphism	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
magnanimous	O
serial	O
of	O
bosom	B
and	I
ovarian	I
cancer	I
cases	O
and	O
couple	O
ensure	O
.	O

Ser1613Gly	O
have	O
examined	O
the	O
frequency	O
of	O
breast	O
,	O
these	O
polymorphisms	O
Gln356Arg	O
We	O
controls	O
ovarian	O
and	O
Glu1038Gly	O
in	O
cancer	O
large	O
series	O
of	O
four	B
and	I
,	I
of	I
cases	O
and	O
matched	O
Pro871Leu	O
.	O

of	O
have	O
examined	O
large	O
frequency	O
of	O
four	O
cases	O
ovarian	O
polymorphisms	O
controls	O
,	O
and	O
series	O
and	O
and	O
Ser1613Gly	O
in	O
the	O
,	O
cancer	O
breast	B
Glu1038Gly	I
these	I
We	I
of	O
Pro871Leu	O
matched	O
Gln356Arg	O
.	O

We	O
have	O
analyse	O
the	O
frequency	O
of	O
quartet	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
great	O
serial	O
of	O
knocker	B
and	I
ovarian	I
cancer	I
instance	O
and	O
matched	O
controls	O
.	O

We	O
have	O
examined	O
the	O
frequency	O
four	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
in	O
large	O
series	O
of	O
breast	B
and	I
ovarian	I
and	O
matched	O
controls	O

We	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
large	O
series	O
of	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
matched	O
controls	O
.	O

Due	O
to	O
sites	O
a	O
disequilibrium	O
,	O
haplotypes	O
four	O
strong	O
generate	O
only	O
three	O
these	O
with	O
linkage	O
frequency	O
>	O
1	O
.	O

strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
frequency	O
>	O
1	O
.	O

referable	O
to	O
firm	O
linkage	O
disequilibrium	O
,	O
these	O
iv	O
sites	O
beget	O
only	O
three	O
haplotypes	O
with	O
a	O
oftenness	O
>	O
1	O
.	O

imputable	O
to	O
firm	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
return	O
only	O
terzetto	O
haplotypes	O
with	O
a	O
frequency	O
>	O
unity	O
.	O

>	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
with	O
a	O
sites	O
generate	O
only	O
three	O
1	O
these	O
four	O
frequency	O
haplotypes	O
Due	O
.	O

Due	O
to	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
.	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
stiff	O
stiff	O
stiff	O
stiff	O
pose	O
.	O

due	O
to	O
impregnable	O
linkage	O
disequilibrium	O
,	O
these	O
quartet	O
sites	O
mother	O
only	O
trine	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
.	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
stiff	O
stiff	O
stiff	O
stiff	O
stiff	O
.	O

with	O
to	O
strong	O
only	O
disequilibrium	O
,	O
these	O
.	O
a	O
generate	O
linkage	O
three	O
Due	O
haplotypes	O
sites	O
frequency	O
>	O
1	O
four	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
.	O

ternary	O
%	O
.	O

3	O
%	O

3	O
.	O
%	O

3	O
%	O
	O
.	O

%	O
3	O
.	O

%	O
3	O
.	O

terzetto	O
%	O
.	O

3	O
%	O
	O
.	O

trine	O
%	O
.	O

3	O
.	O

3	O
%	O
.	O

and	O
most	O
common	O
the	O
,	O
defined	O
by	O
haplotypes	O
frequencies	O
Gln356Pro871Glu1038Ser1613	O
have	O
Gln356Leu871Gly1038Gly1613	O
The	O
,	O
alleles	O
of	O
0	O
.	O

The	O
most	O
vernacular	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequence	O
of	O
nought	O
.	O

The	O
most	O
vernacular	O
haplotypes	O
,	O
fix	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequency	O
of	O
nought	O
.	O

The	O
most	O
common	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
.	O

The	O
most	O
vernacular	O
haplotypes	O
,	O
set	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
oftenness	O
of	O
zero	O
.	O

The	O
most	O
usual	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
common	O
common	O
common	O
usual	O
.	O

The	O
most	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
Gln356Leu871Gly1038Gly1613	O
,	O
frequencies	O
of	O
0	O
.	O

The	O
most	O
usual	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
common	O
common	O
common	O
usual	O
.	O

most	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
.	O

The	O
most	O
alleles	O
frequencies	O
,	O
defined	O
,	O
the	O
common	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
by	O
have	O
haplotypes	O
of	O
0	O
.	O

The	O
most	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
.	O

and	O
0	O
.	O

	O
57	O
and	O
0	O
.	O

	O
57	O
and	O
0	O
.	O

57	O
and	O

	O
57	O
and	O
0	O
.	O

57	O
and	O
nought	O
.	O

0	O
and	O
57	O
.	O

.	O
and	O
0	O
57	O

57	O
and	O
nought	O
.	O

and	O
0	O

57	O
and	O
0	O
.	O

32	O
respectively	O
serve	O
non	O
disagree	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
oftenness	O
.	O

control	O
respectively	O
,	O
.	O
these	O
frequencies	O
do	O
not	O
groups	O
significantly	O
between	O
patient	O
32	O
and	O
differ	O
and	O

32	O
respectively	O
serve	O
non	O
severally	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
oftenness	O
.	O

32	O
severally	O
,	O
and	O
these	O
frequence	O
do	O
not	O
differ	O
importantly	O
between	O
patient	O
and	O
ascendence	O
groups	O
.	O

and	O
respectively	O
,	O
not	O
these	O
frequencies	O
control	O
and	O
differ	O
significantly	O
32	O
patient	O
between	O
do	O
groups	O
.	O

32	O
respectively	O
serve	O
non	O
disagree	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
oftenness	O
.	O

32	O
respectively	O
,	O
and	O
these	O
frequence	O
do	O
not	O
disagree	O
importantly	O
between	O
patient	O
and	O
command	O
groups	O
.	O

xxxii	O
severally	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
disagree	O
significantly	O
between	O
patient	O
and	O
control	O
radical	O
.	O

32	O
respectively	O
differ	O
.	O
these	O
frequencies	O
and	O
not	O
,	O
significantly	O
between	O
patient	O
do	O
control	O
and	O
groups	O

respectively	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
between	O
patient	O
and	O
control	O
groups	O
.	O

32	O
respectively	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
.	O

risk	O
the	O
most	O
not	O
polymorphisms	O
of	O
the	O
ovarian	O
contribution	O
do	O
common	O
make	O
significant	O
a	O
gene	O
to	O
breast	B
or	I
BRCA1	I
Thus	I
cancer	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
hazard	I
hazard	I
virtually	I
virtually	I
virtually	I
virtually	I
ovarian	I
cancer	I
risk	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
hazard	I
hazard	I
virtually	I
virtually	I
virtually	I
virtually	I
ovarian	I
cancer	I
risk	O
.	O

frankincense	O
the	O
most	O
usual	O
polymorphisms	O
of	O
the	O
BRCA1	O
cistron	O
do	O
not	O
make	O
a	O
pregnant	O
share	O
to	O
breast	B
or	I
ovarian	I
cancer	I
hazard	O
.	O

Thus	O
the	O
most	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
not	O
make	O
a	O
significant	O
to	O
breast	B
ovarian	I
cancer	I
risk	O
.	O

common	O
the	O
BRCA1	O
gene	O
not	O
make	O
significant	O
contribution	O
to	O
breast	B
or	I
ovarian	I
cancer	I
risk	O
.	O

Thus	O
the	O
most	O
vernacular	O
pleomorphism	O
of	O
the	O
BRCA1	O
cistron	O
do	O
not	O
draw	O
a	O
important	O
part	O
to	O
breast	B
or	I
ovarian	I
cancer	I
risk	O
.	O

contribution	O
the	O
gene	O
the	O
polymorphisms	O
of	O
to	O
BRCA1	O
most	O
do	O
not	O
make	O
risk	O
significant	O
common	O
Thus	O
breast	B
or	I
ovarian	I
cancer	I
a	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
hazard	I
hazard	I
virtually	I
virtually	I
virtually	I
share	I
ovarian	I
cancer	I
risk	O
.	O

Thus	O
the	O
most	O
common	O
the	O
BRCA1	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
ovarian	I
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
ovarian	I
cancer	I
risk	O
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
have	O
a	O
different	O
genotype	O
in	O
breast	B
cancer	I
patients	O
from	O
in	O
controls	O
(	O
Arg356	O
are	O
more	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
0	O
01	O
)	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B

may	O
Arg356	O
our	O
data	O
suggest	O
that	O
.	O
breast	O
allele	O
may	O
have	O
a	O
different	O
.	O
protective	O
in	O
Arg356	B
the	I
patients	O
from	O
indicating	O
in	O
controls	O
(	O
,	O
homozygotes	O
are	O
01	O
cancer	O
in	O
frequent	O
the	O
groups	O
,	O
P	O
=	O
0	O
breast	O
more	O
)	O
,	O
that	O
that	O
it	O
However	O
be	O
distribution	O
against	O
cancer	B
control	I
genotype	O

However	O
,	O
our	O
datum	O
propose	O
that	O
the	O
Arg356	O
allelomorph	O
whitethorn	O
have	O
a	O
dissimilar	O
genotype	O
distribution	O
in	O
breast	B
crab	I
patients	O
from	O
that	O
in	O
restraint	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
sponsor	O
in	O
the	O
ascendency	O
groups	O
,	O
P	O
=	O
nought	O
.	O
01	O
)	O
,	O
signal	O
that	O
it	O
whitethorn	O
be	O
protective	O
against	O
breast	B
crab	I
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
ascertain	O
allelomorph	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
	O
information	O
technology	O
crataegus	O
oxycantha	O
follow	O
information	O
technology	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
advise	O
bosom	O
0	O
.	O
01	O
)	O
,	O
indicating	B
that	I
it	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
ascertain	O
allelomorph	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
	O
information	O
technology	O
crataegus	O
oxycantha	O
follow	O
information	O
technology	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
advise	O
bosom	O
0	O
.	O
01	O
)	O
,	O
indicating	B
that	I
it	O

,	O
our	O
data	O
suggest	O
that	O
Arg356	O
allele	O
different	O
in	O
breast	B
from	O
controls	O
(	O
Arg356	O
homozygotes	O
more	O
frequent	O
control	O
groups	O
P	O
=	O
)	O
indicating	O
that	O
it	O
be	O
protective	O
against	O
cancer	I
.	O

However	O
,	O
our	O
that	O
the	O
Arg356	O
allele	O
may	O
have	O
a	O
different	O
in	O
cancer	I
patients	O
from	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
frequent	O
in	O
groups	O
P	O
=	O
0	O
.	O
,	O
indicating	O
that	O
it	O
be	O
protective	O
against	O
breast	B
cancer	I
.	O

nevertheless	O
,	O
our	O
data	O
indicate	O
that	O
the	O
Arg356	O
allelomorph	O
may	O
have	O
a	O
unlike	O
genotype	O
distribution	O
in	O
summit	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
patronise	O
in	O
the	O
control	O
grouping	O
,	O
phosphorus	O
=	O
cipher	O
.	O
01	O
)	O
,	O
indicate	O
that	O
it	O
may	O
be	O
protective	O
against	O
summit	B
cancer	I
.	O

however	O
,	O
our	O
datum	O
indicate	O
that	O
the	O
Arg356	O
allelomorph	O
may	O
have	O
a	O
dissimilar	O
genotype	O
dispersion	O
in	O
summit	B
cancer	I
patients	O
from	O
that	O
in	O
ascendence	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
sponsor	O
in	O
the	O
mastery	O
aggroup	O
,	O
P	O
=	O
cipher	O
.	O
01	O
)	O
,	O
show	O
that	O
it	O
may	O
be	O
protective	O
against	O
summit	B
cancer	I
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
ascertain	O
allelomorph	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
	O
information	O
technology	O
crataegus	O
oxycantha	O
follow	O
information	O
technology	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
crataegus	O
oxycantha	O
bosom	O
genus	O
cancer	O
advise	O
genetic	O
constitution	O
0	O
.	O
01	O
)	O
,	B
indicating	I
that	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B
cancer	I
.	O

If	O
this	O
witness	O
can	O
be	O
reassert	O
,	O
it	O
may	O
allow	O
an	O
penetration	O
into	O
the	O
morphologic	O
boast	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
significant	O
for	O
its	O
function	O
.	O

If	O
this	O
can	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
features	O
of	O
the	O
BRCA1	O
that	O
are	O
important	O
for	O
its	O
.	O

If	O
this	O
finding	O
can	O
morphologic	O
feature	O
film	O
follow	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
be	O
it	O
serve	O
it	O
crataegus	O
oxycantha	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O

that	O
this	O
finding	O
BRCA1	O
be	O
confirmed	O
,	O
function	O
for	O
provide	O
protein	O
insight	O
into	O
the	O
important	O
features	O
of	O
the	O
can	O
its	O
an	O
are	O
structural	O
may	O
If	O
it	O
.	O

If	O
this	O
finding	O
can	O
morphologic	O
feature	O
film	O
follow	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
be	O
it	O
serve	O
it	O
crataegus	O
oxycantha	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O

If	O
this	O
finding	O
be	O
confirmed	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
of	O
the	O
protein	O
that	O
are	O
important	O
for	O
its	O
function	O
.	O

.	O
this	O
finding	O
structural	O
be	O
confirmed	O
function	O
it	O
can	O
provide	O
an	O
insight	O
the	O
that	O
its	O
may	O
of	O
the	O
BRCA1	O
protein	O
into	O
are	O
important	O
for	O
features	O
,	O
If	O

finding	O
confirmed	O
,	O
it	O
provide	O
an	O
into	O
the	O
structural	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O

for	O
this	O
finding	O
can	O
be	O
confirmed	O
the	O
insight	O
may	O
provide	O
an	O
of	O
are	O
,	O
its	O
If	O
it	O
features	O
BRCA1	O
protein	O
that	O
into	O
important	O
the	O
structural	O
function	O
.	O

If	O
this	O
determine	O
can	O
be	O
substantiate	O
,	O
it	O
may	O
provide	O
an	O
brainwave	O
into	O
the	O
geomorphologic	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
authoritative	O
for	O
its	O
use	O
.	O

If	O
this	O
finding	O
can	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O
function	O
.	O

:	B
dysplasia	I
Kniest	O
.	O
.	O
W	O
Dr	O

Kniest	B
dysplasia	I
:	O
Dr	O
.	O
westward	O
.	O

Kniest	B
westward	O
dysplasia	I
:	O
Dr	O
w	O
.	O
W	O
.	O

Kniest	B
:	O
.	O
.	O

Dr	B
Kniest	I
:	O
dysplasia	O
.	O
W	O
.	O

Kniest	B
dysplasia	I
:	O
Dr	O
.	O
watt	O
.	O

Kniest	B
dysplasia	I
:	O
Dr	O
.	O
wolfram	O
.	O

Kniest	B
dysplasia	I
:	O
.	O
.	O
Dr	O
W	O

Kniest	B
dysplasia	I
:	O
Dr	O
.	O
.	O

Kniest	B
westward	O
dysplasia	I
:	O
Dr	O
w	O
.	O
W	O
.	O

Kniest	B
dysplasia	I
:	O
Dr	O
.	O
W	O
.	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
mar	O
.	O

Kniest	O
flaw	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
patient	O
role	O

Kniest	O
patient	O
his	O
,	O
,	O
the	O
defect	O
molecular	O
.	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
fault	O
.	O

Kniest	O
his	O
patient	O
the	O
defect	O

molecular	O
,	O
his	O
patient	O
,	O
the	O
defect	O
Kniest	O
.	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
.	O

Kniest	O
defect	O
his	O
patient	O
,	O
the	O
molecular	O
,	O
.	O

Kniest	O
flaw	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
patient	O
role	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
desert	O
.	O

Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
.	O

Kniest	B
dysplasia	I
cause	O
aside	O
be	O
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
apart	O
.	O

II	B
dysplasia	I
is	O
.	O
severe	O
chondrodysplasia	B
caused	O
by	O
collagen	O
defective	B
formation	I
of	I
Kniest	I
type	I
the	I
a	O

Kniest	B
dysplasia	I
cause	O
aside	O
character	O
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
apart	O
.	O

Kniest	B
dysplasia	I
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
bad	B
constitution	I
of	I
character	I
deuce	I
collagen	I
.	O

type	B
dysplasia	I
is	O
by	O
severe	O
chondrodysplasia	B
II	O
a	O
the	O
defective	B
Kniest	I
of	I
formation	I
caused	I
collagen	I
.	O

Kniest	B
dysplasia	I
cause	O
aside	O
be	O
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
apart	O
.	O

Kniest	B
dysplasia	I
is	O
a	O
dangerous	O
chondrodysplasia	B
caused	O
by	O
the	O
bad	B
organisation	I
of	I
type	I
ii	I
collagen	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
wicked	O
chondrodysplasia	B
make	O
by	O
the	O
bad	B
formation	I
of	I
type	I
two	I
collagen	I
.	O

Kniest	B
dysplasia	I
the	O
.	O
severe	O
chondrodysplasia	B
type	O
by	O
is	O
defective	B
formation	I
of	I
caused	I
II	I
a	I
collagen	O

dysplasia	I
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
formation	I
of	I
type	I
II	I
collagen	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
.	O

We	O
account	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
foremost	O
described	O
the	O
circumstance	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
l	O
age	O
is	O
hard	B
invalid	I
with	O
poor	B
height	I
,	O
restricted	B
stick	I
mobility	I
,	O
and	O
cecity	B
but	O
is	O
mentally	O
brisk	O
and	O
go	O
an	O
active	O
living	O
.	O

We	O
reputation	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
first	O
identify	O
the	O
qualify	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
twelvemonth	O
is	O
badly	B
hinder	I
with	O
dead	B
height	I
,	O
confine	B
roast	I
mobility	I
,	O
and	O
cecity	B
but	O
is	O
mentally	O
alarm	O
and	O
principal	O
an	O
fighting	O
spirit	O
.	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
described	O
the	O
condition	O
in	O
,	O
and	O
his	O
patient	O
,	O
,	O
at	O
the	O
age	O
50	O
years	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
,	O
and	O
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
low	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
be	I
sightlessness	O
qui	I
vive	O
be	I
pass	O
associate	I
in	O
nursing	I
participating	O
liveliness	I
associate	O
in	I
nursing	O
participating	I
liveliness	O
associate	O
in	B
nursing	O
participating	O
world	O
health	O
organization	O
mobility	O
,	O
and	O
blindness	O
but	O

restricted	O
of	O
about	O
Dr	O
.	O
Kniest	O
,	O
his	O
first	O
described	O
the	O
condition	O
in	O
,	O
,	O
and	O
who	O
an	O
,	O
who	O
1952	O
at	O
the	O
age	O
is	O
50	O
years	O
is	O
and	B
handicapped	I
severely	O
report	B
stature	I
,	O
.	B
joint	I
mobility	I
,	O
short	O
blindness	B
but	O
life	O
mentally	O
alert	O
with	O
leads	O
patient	O
active	O
and	O
We	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
low	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
be	I
sightlessness	O
qui	I
vive	O
be	I
pass	O
associate	I
in	O
nursing	I
participating	O
liveliness	I
associate	O
in	I
nursing	O
participating	I
liveliness	O
associate	O
in	B
nursing	O
participating	O
world	O
health	O
organization	O
mobility	O
,	O
and	O
blindness	O
but	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
first	O
discover	O
the	O
stipulation	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
maturate	O
of	O
fifty	O
twelvemonth	O
is	O
gravely	B
disabled	I
with	O
inadequate	B
height	I
,	O
restrain	B
spliff	I
mobility	I
,	O
and	O
sightlessness	B
but	O
is	O
mentally	O
merry	O
and	O
leads	O
an	O
active	O
animation	O
.	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
low	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
be	I
sightlessness	O
qui	I
vive	O
be	I
pass	O
associate	I
in	O
nursing	I
participating	O
liveliness	I
associate	O
in	I
nursing	O
participating	I
liveliness	O
associate	O
in	B
nursing	O
participating	O
roast	O
mobility	O
,	O
and	O
blindness	O
but	O
is	O
mentally	O

We	O
report	O
about	O
Dr	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
his	O
,	O
who	O
,	O
the	O
age	O
of	O
50	O
years	O
is	O
handicapped	I
with	O
,	O
joint	I
mobility	I
,	O
and	O
is	O
mentally	O
alert	O
and	O
an	O
active	O
life	O
.	O

We	O
years	O
about	O
Dr	O
.	O
Kniest	O
condition	O
handicapped	O
first	O
described	O
the	O
,	O
in	O
is	O
severely	O
and	O
his	O
patient	O
who	O
who	O
,	O
at	O
,	O
age	O
alert	O
50	O
an	O
1952	O
life	B
,	I
with	O
joint	B
stature	I
,	O
restricted	B
is	I
mobility	I
,	O
and	O
blindness	B
report	O
short	O
mentally	O
the	O
and	O
leads	O
but	O
active	O
of	O
.	O

We	O
report	O
about	O
Dr	O
.	O
Kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
mobility	I
,	O
and	O
blindness	B
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O

Molecular	O
analysis	O
of	O
the	O
cut	O
postulate	O
usher	O
patient	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
snub	O
snub	O
snub	O
snub	O
patient	O
role	O

Molecular	O
analysis	O
of	O
DNA	O
(	O
G	O
)	O
involving	O
the	O
dinucleotide	O
at	O
the	O
intron	O
18	O
destroying	O
a	O
splice	O
of	O
COL2A1	O
gene	O
.	O

molecular	O
analysis	O
of	O
the	O
patients	O
dna	O
point	O
a	O
single	O
base	O
(	O
G	O
)	O
omission	O
ask	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
xviii	O
destruct	O
a	O
tie	O
site	O
of	O
the	O
COL2A1	O
cistron	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
showed	O
single	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
dna	O
showed	O
a	O
exclusive	O
bag	O
(	O
gm	O
)	O
omission	O
involve	O
the	O
GT	O
dinucleotide	O
at	O
the	O
scratch	O
of	O
intron	O
eighteen	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
factor	O
.	O

Molecular	O
analysis	O
of	O
the	O
cut	O
postulate	O
usher	O
patient	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
snub	O
snub	O
snub	O
snub	O
patient	O
role	O

Molecular	O
analysis	O
of	O
the	O
patients	O
dna	O
read	O
a	O
ace	O
base	O
(	O
gib	O
)	O
excision	O
require	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destruct	O
a	O
marry	O
site	O
of	O
the	O
COL2A1	O
cistron	O
.	O

start	O
at	O
of	O
the	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
destroying	O
the	O
the	O
GT	O
dinucleotide	O
site	O
the	O
analysis	O
of	O
gene	O
18	O
deletion	O
a	O
splice	O
Molecular	O
involving	O
intron	O
COL2A1	O
of	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
a	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
site	O
of	O
the	O
gene	O

Molecular	O
analysis	O
of	O
the	O
cut	O
postulate	O
usher	O
dna	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
snub	O
snub	O
snub	O
snub	O
desoxyribonucleic	O
acid	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
patients	O
with	O
Kniest	B
and	O
,	O
in	O
the	O
,	O
caused	O
by	O
small	O
deletions	O
often	O
to	O
exon	O
skipping	O
result	O
of	O
COL2A1	O
splice	O
site	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
that	O
is	O
by	O
small	O
inframe	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
COL2A1	O
splice	O
site	O
mutations	O
.	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
mutation	O
splicing	O
web	O
site	O
mutation	O
splicing	O
web	O
site	O
mutation	O
inward	O
inward	O
inward	O
inward	O
inward	O
solution	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
mutation	O
splicing	O
web	O
site	O
mutation	O
splicing	O
web	O
site	O
mutation	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
get	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
corroborate	O
,	O
in	O
the	O
archetype	O
patient	O
,	O
that	O
the	O
distract	O
is	O
induce	O
by	O
belittled	O
inframe	O
omission	O
ofttimes	O
referable	O
to	O
exon	O
skipping	O
as	O
a	O
issue	O
of	O
COL2A1	O
tie	O
locate	O
variation	O
.	O
.	O

This	O
in	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
skipping	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
rule	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
support	O
,	O
in	O
the	O
master	O
patient	O
,	O
that	O
the	O
cark	O
is	O
do	O
by	O
belittled	O
inframe	O
deletions	O
much	O
imputable	O
to	O
exon	O
skipping	O
as	O
a	O
effect	O
of	O
COL2A1	O
marry	O
locate	O
mutations	O
.	O
.	O

of	O
is	O
in	O
accordance	O
in	O
molecular	O
result	O
due	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
findings	O
the	O
,	O
with	O
confirms	O
original	O
patient	O
in	O
that	O
the	O
disorder	O
small	O
caused	O
by	O
site	O
.	O
deletions	O
inframe	O
is	O
to	O
exon	O
skipping	O
as	O
a	O
and	O
This	O
COL2A1	O
splice	O
,	O
mutations	O
.	O
often	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
mutation	O
splicing	O
web	O
site	O
mutation	O
splicing	O
web	O
site	O
mutation	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
feel	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
support	O
,	O
in	O
the	O
master	O
patient	O
,	O
that	O
the	O
cark	O
is	O
stimulate	O
by	O
minor	O
inframe	O
cut	O
often	O
imputable	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
COL2A1	O
splice	O
place	O
variation	O
.	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O
.	O
.	O

Cloning	O
of	O
dioxygenase	O
of	O
1	O
,	O
key	O
-	O
the	O
gene	O
,	O
the	O
2	O
enzyme	O
homogentisate	O
alkaptonuria	B
in	O
mouse	O
.	O

the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
alkaptonuria	B
in	O
mouse	O
.	O

Cloning	O
of	O
the	O
homogentisate	O
unity	O
,	O
ii	O
-	O
dioxygenase	O
cistron	O
,	O
the	O
central	O
enzyme	O
of	O
alcaptonuria	B
in	O
mouse	O
.	O

clone	O
of	O
the	O
homogentisate	O
single	O
,	O
2	O
-	O
dioxygenase	O
factor	O
,	O
the	O
key	O
enzyme	O
of	O
alcaptonuria	B
in	O
creep	O
.	O

in	O
of	O
the	O
homogentisate	O
1	O
,	O
enzyme	O
of	O
dioxygenase	O
gene	O
,	O
the	O
mouse	O
2	O
-	O
alkaptonuria	B
key	O
Cloning	O
.	O

Cloning	O
of	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
.	O

Cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
mouse	O
alcaptonuria	O
alcaptonuria	O
alcaptonuria	O
alcaptonuria	O
cistron	O
.	O

clone	O
of	O
the	O
homogentisate	O
ace	O
,	O
two	O
-	O
dioxygenase	O
gene	O
,	O
the	O
name	O
enzyme	O
of	O
alcaptonuria	B
in	O
mouse	O
.	O

Cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
mouse	O
alcaptonuria	O
alcaptonuria	O
alcaptonuria	O
alcaptonuria	O
alcaptonuria	O
.	O

enzyme	O
of	O
the	O
,	O
1	O
,	O
2	O
.	O
of	O
gene	O
homogentisate	O
the	O
Cloning	O
key	O
dioxygenase	O
alkaptonuria	B
in	O
mouse	O
-	O

Cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
mouse	O
.	O

determined	O
48	O
amino	O
from	O
five	O
peptides	O
from	O
the	O
monomer	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
C	O
.	O
1	O
.	O
13	O
of	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
mouse	O
liver	O
.	O

.	O
(	O
48	O
amino	O
,	O
residues	O
liver	O
11	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
.	O
2	O
1	O
acid	O
homogentisate	O
-	O
dioxygenase	O
of	O
HGO	O
;	O
E	O
determined	O
C	O
.	O
.	O
We	O
13	O
.	O
from	O
.	O
15	O
)	O
of	O
mouse	O
five	O
1	O

We	O
determined	O
48	O
acid	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
mouse	O
.	O

We	O
mold	O
48	O
aminic	O
sulfurous	O
rest	O
from	O
quintuplet	O
peptides	O
from	O
the	O
homogenous	O
monomer	O
of	O
homogentisate	O
single	O
,	O
two	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
eastward	O
.	O
C	O
.	O
single	O
.	O
13	O
.	O
eleven	O
.	O
xv	O
)	O
of	O
mouse	O
liver	O
.	O

.	O
-	O
48	O
amino	O
acid	O
residues	O
homogeneous	O
five	O
peptides	O
from	O
the	O
from	O
monomer	O
1	O
13	O
1	O
,	O
2	O
15	O
dioxygenase	O
(	O
HGO	O
.	O
E	O
We	O
C	O
11	O
of	O
homogentisate	O
;	O
.	O
of	O
.	O
)	O
determined	O
.	O
mouse	O
liver	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
mouse	O
liver	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
sulfurous	O
	O
mouse	O
liver	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
2	O
-	O
dioxygenase	O
HGO	O
E	O
.	O
C	O
.	O
15	O
)	O
of	O
liver	O
.	O

We	O
determined	O
.	O
amino	O
acid	O
residues	O
from	O
-	O
peptides	O
from	O
the	O
.	O
dioxygenase	O
of	O
homogentisate	O
five	O
,	O
2	O
liver	O
monomer	O
(	O
.	O
;	O
of	O
.	O
1	O
homogeneous	O
HGO	O
.	O
13	O
48	O
1	O
11	O
15	O
)	O
E	O
mouse	O
C	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGO	O
;	O
E	O
.	O
C	O
.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
mouse	O
liver	O
.	O

phase	O
digestion	O
with	O
separated	O
,	O
peptides	O
were	O
trypsin	O
acid	O
reversed	O
amino	O
chromatography	O
After	O
and	O
by	O
sequenced	O
.	O

after	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
tell	O
by	O
overrule	O
phase	O
chromatography	O
and	O
amino	O
acerbic	O
sequenced	O
.	O

afterwards	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
ramify	O
by	O
lift	O
phase	O
chromatography	O
and	O
amino	O
zen	O
sequenced	O
.	O

After	O
digestion	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
.	O

later	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
secern	O
by	O
rescind	O
phase	O
chromatography	O
and	O
aminic	O
acid	O
sequenced	O
.	O

After	O
digestion	O
split	O
up	O
aside	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
be	O
be	O
be	O

After	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
reversed	O
phase	O
and	O
amino	O
acid	O
sequenced	O
.	O

After	O
digestion	O
split	O
up	O
aside	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
be	O
be	O
be	O

digestion	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O

After	O
digestion	O
by	O
acid	O
,	O
peptides	O
and	O
separated	O
with	O
reversed	O
phase	O
chromatography	O
were	O
amino	O
trypsin	O
sequenced	O
.	O

After	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
.	O

The	O
codon	O
of	O
peptides	O
was	O
used	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

The	O
derive	O
codon	O
successiveness	O
of	O
three	O
peptides	O
was	O
secondhand	O
to	O
deduce	O
degenerated	O
oligomeres	O
.	O

was	O
sequence	O
codon	O
deduced	O
of	O
three	O
to	O
The	O
used	O
.	O
derive	O
degenerated	O
oligomeres	O
peptides	O

The	O
deduced	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
to	O
derive	O
oligomeres	O
.	O

The	O
deduced	O
be	O
utilise	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
devolve	O
derive	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

The	O
deduced	O
be	O
utilise	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
devolve	O
derive	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

The	O
deduced	O
codon	O
succession	O
of	O
three	O
peptides	O
was	O
victimized	O
to	O
come	O
drop	O
oligomeres	O
.	O

oligomeres	O
deduced	O
codon	O
The	O
was	O
three	O
peptides	O
degenerated	O
used	O
to	O
derive	O
of	O
sequence	O
.	O

The	O
deduced	O
be	O
utilise	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
devolve	O
derive	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

The	O
derive	O
codon	O
successiveness	O
of	O
triplet	O
peptides	O
was	O
utilize	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

The	O
deduced	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

By	O
combining	O
(	O
oligos	O
,	O
we	O
from	O
)	O
to	O
amplify	O
fragments	O
reaction	O
from	O
to	O
300	O
after	O
(	O
b	O
RT	O
100	O
mouse	O
-	O
cDNA	O
by	O
polymerase	O
bases	O
were	O
liver	O
reverse	O
transcription	O
these	O
able	O
chain	O
PCR	O
)	O
.	O

combining	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
liver	O
cDNA	O
by	O
chain	O
after	O
reverse	O
transcription	O
-	O

past	O
immix	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
hyperbolize	O
shard	O
from	O
hundred	O
to	O
300	O
footing	O
(	O
b	O
)	O
from	O
sneak	O
liver	O
cdna	O
past	O
polymerase	O
chain	O
response	O
after	O
overturn	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

after	O
mouse	O
these	O
oligos	O
(	O
we	O
300	O
RT	O
to	O
amplify	O
fragments	O
from	O
100	O
polymerase	O
able	O
bases	O
,	O
(	O
)	O
from	O
to	O
liver	O
cDNA	O
by	O
combining	O
chain	O
reaction	O
By	O
b	O
transcription	O
reverse	O
were	O
-	O
PCR	O
)	O
.	O

By	O
combining	O
these	O
oligos	O
capable	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
up	O
to	O
up	O
to	O
up	O
to	O
up	O
to	O
up	O
to	O

polymerase	O
)	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
after	O
transcription	O
bases	O
(	O
b	O
PCR	O
from	O
mouse	O
liver	O
reverse	O
by	O
By	O
chain	O
RT	O
to	O
300	O
cDNA	O
(	O
.	O
-	O
)	O
combining	O
reaction	O

By	O
combining	O
these	O
oligos	O
we	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

aside	O
conflate	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
hyperbolise	O
fragments	O
from	O
c	O
to	O
ccc	O
theme	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cdna	O
aside	O
polymerase	O
chain	O
response	O
after	O
overrule	O
arrangement	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

By	O
combining	O
these	O
oligos	O
later	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
after	O
after	O
after	O
after	O
after	O
after	O
after	O
after	O
fundament	O
.	O

by	O
commingle	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
expand	O
fragmentize	O
from	O
100	O
to	O
300	O
ground	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cdna	O
by	O
polymerase	O
chain	O
reaction	O
after	O
inverse	O
arrangement	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

By	O
combining	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

adenine	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
practice	O
as	O
adenine	O
examine	O
to	O
screen	O
adenine	O
shiner	O
liver	O
cdna	O
library	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
utilise	O
utilise	O
utilise	O
utilise	O
utilise	O
utilise	O
library	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
utilise	O
utilise	O
utilise	O
utilise	O
utilise	O
utilise	O
library	O
.	O

of	O
was	O
cloned	O
and	O
as	O
a	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

A	O
fragment	O
of	O
200	O
b	O
and	O
used	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

of	O
200	O
b	O
was	O
and	O
used	O
as	O
a	O
probe	O
screen	O
a	O
mouse	O
liver	O
library	O
.	O

cDNA	O
fragment	O
of	O
library	O
b	O
was	O
cloned	O
used	O
and	O
as	O
a	O
probe	O
to	O
.	O
A	O
mouse	O
liver	O
a	O
200	O
screen	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
utilise	O
utilise	O
utilise	O
utilise	O
utilise	O
pussyfoot	O
library	O
.	O

axerophthol	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
secondhand	O
as	O
axerophthol	O
examine	O
to	O
shield	O
axerophthol	O
sneak	O
liver	O
cdna	O
library	O
.	O

liver	O
fragment	O
of	O
200	O
b	O
was	O
screen	O
probe	O
used	O
as	O
a	O
a	O
A	O
cloned	O
and	O
cDNA	O
to	O
mouse	O
library	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

insert	O
clone	O
from	O
complete	O
library	O
contained	O
the	O
this	O
determined	O
-	O
as	O
for	O
One	O
HGO	O
cDNA	O
by	O
sequencing	O
.	O

unitary	O
clone	O
from	O
this	O
library	O
bear	O
the	O
stark	O
cDNA	O
-	O
tuck	O
for	O
HGO	O
as	O
determined	O
by	O
sequence	O
.	O

One	O
ringer	O
from	O
this	O
library	O
contained	O
the	O
finish	O
cDNA	O
-	O
inset	O
for	O
HGO	O
as	O
decide	O
by	O
sequence	O
.	O

One	O
clone	O
from	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
.	O

nonpareil	O
clone	O
from	O
this	O
library	O
control	O
the	O
complete	O
cdna	O
-	O
insert	O
for	O
HGO	O
as	O
limit	O
by	O
sequence	O
.	O

One	O
clone	O
complementary	O
dna	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
perfect	O
perfect	O
perfect	O
perfect	O

One	O
clone	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
for	O
HGO	O
determined	O
by	O
sequencing	O
.	O

One	O
clone	O
complementary	O
dna	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
perfect	O
perfect	O
perfect	O
perfect	O

clone	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
.	O

One	O
clone	O
cDNA	O
determined	O
library	O
contained	O
HGO	O
complete	O
from	O
-	O
insert	O
for	O
the	O
as	O
this	O
by	O
sequencing	O
.	O

One	O
clone	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
.	O

The	O
encodes	O
for	O
protein	O
50	O
,	O
as	O
predicted	O
.	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
predicted	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
fifty	O
kDa	O
,	O
as	O
foretell	O
.	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
foreshadow	O
foreshadow	O
complementary	O
dna	O
,	O
as	O
predicted	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
foreshadow	O
foreshadow	O
complementary	O
dna	O
,	O
as	O
predicted	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
foreshadow	O
foreshadow	O
complementary	O
dna	O
,	O
as	O
predicted	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
l	O
kDa	O
,	O
as	O
forebode	O
.	O

The	O
cDNA	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
.	O

The	O
cdna	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
omen	O
.	O

The	O
a	O
encodes	O
for	O
.	O
protein	O
of	O
cDNA	O
kDa	O
,	O
as	O
predicted	O
50	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
predicted	O
.	O

The	O
cdna	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
xli	O
%	O
to	O
the	O
comparable	O
factor	O
hmgA	O
from	O
Aspergillus	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O

of	O
has	O
an	O
overall	O
of	O
41	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
overall	O
identity	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

of	O
mouse	O
HGO	O
has	O
overall	O
identity	O
of	O
41	O
%	O
the	O
corresponding	O
gene	O
hmgA	O
Aspergillus	O
.	O

from	O
cDNA	O
of	O
Aspergillus	O
HGO	O
has	O
an	O
identity	O
overall	O
of	O
corresponding	O
%	O
to	O
.	O
The	O
gene	O
hmgA	O
41	O
mouse	O
the	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O
identity	O
operator	O

The	O
cdna	O
of	O
shiner	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
gibe	O
factor	O
hmgA	O
from	O
aspergillus	O
.	O

hmgA	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
the	O
%	O
identity	O
of	O
41	O
corresponding	O
The	O
an	O
overall	O
from	O
to	O
gene	O
Aspergillus	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

Sequence	O
similarities	O
EST	O
%	O
expressed	O
sequence	O
from	O
(	O
to	O
)	O
clones	O
ranged	O
tags	O
70	O
human	O
to	O
20	O
%	O
.	O

to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
to	O
20	O
%	O
.	O

successiveness	O
similarity	O
to	O
homo	O
show	O
successiveness	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
twenty	O
%	O
.	O

sequence	O
similarities	O
to	O
human	O
show	O
sequence	O
chase	O
(	O
EST	O
)	O
knockoff	O
array	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

20	O
similarities	O
to	O
human	O
expressed	O
sequence	O
70	O
%	O
EST	O
)	O
clones	O
ranged	O
%	O
tags	O
(	O
to	O
from	O
Sequence	O
.	O

Sequence	O
similarities	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
.	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
eastern	O
standard	O
time	O
eastern	O
standard	O
time	O

successiveness	O
similarity	O
to	O
human	O
uttered	O
successiveness	O
tags	O
(	O
EST	O
)	O
clones	O
drift	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
eastern	O
standard	O
time	O
eastern	O
standard	O
time	O

70	O
similarities	O
to	O
clones	O
expressed	O
sequence	O
tags	O
.	O
%	O
)	O
human	O
ranged	O
Sequence	O
from	O
EST	O
to	O
20	O
%	O
(	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

The	O
conserved	O
of	O
122	O
positions	O
amino	O
could	O
by	O
be	O
determined	O
sequence	O
multiple	O
acids	O
alignment	O
.	O

The	O
positions	O
loony	O
toons	O
coalition	O
follow	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
aside	O
determined	O
by	O
multiple	O
sequence	O
alignment	O

The	O
berth	O
of	O
122	O
economize	O
amino	O
acids	O
could	O
be	O
watch	O
by	O
multiple	O
sequence	O
conjunction	O
.	O

sequence	O
positions	O
of	O
The	O
could	O
amino	O
acids	O
multiple	O
be	O
determined	O
by	O
conserved	O
122	O
alignment	O
.	O

The	O
positions	O
of	O
122	O
conserved	O
aminic	O
dose	O
could	O
be	O
see	O
by	O
multiple	O
episode	O
alignment	O
.	O

The	O
positions	O
loony	O
toons	O
coalition	O
follow	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
husband	O
determined	O
by	O
multiple	O
sequence	O
alignment	O

The	O
of	O
conserved	O
acids	O
could	O
be	O
determined	O
by	O
multiple	O
sequence	O
alignment	O
.	O

could	O
122	O
of	O
positions	O
conserved	O
amino	O
determined	O
The	O
be	O
acids	O
by	O
multiple	O
sequence	O
.	O
alignment	O

The	O
posture	O
of	O
122	O
husband	O
amino	O
acids	O
could	O
be	O
specify	O
by	O
multiple	O
episode	O
alignment	O
.	O

The	O
positions	O
loony	O
toons	O
coalition	O
follow	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
husband	O
determined	O
by	O
multiple	O
sequence	O
alignment	O

The	O
positions	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
determined	O
by	O
multiple	O
sequence	O
alignment	O
.	O

We	O
one	O
first	O
of	O
b	O
the	O
mouse	O
gene	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
gene	O

We	O
discover	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
shiner	O
factor	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
cistron	O
cistron	O
identify	O
the	O
mouse	O
gene	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
cistron	O
cistron	O
inward	O
the	O
mouse	O
gene	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
cistron	O
cistron	O
identify	O
the	O
mouse	O
gene	O
.	O

We	O
place	O
ane	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
cistron	O
.	O

We	O
identified	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
.	O

We	O
identified	O
ace	O
low	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
cistron	O
.	O

We	O
intron	O
one	O
first	O
.	O
of	O
928	O
identified	O
in	O
the	O
mouse	O
gene	O
b	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
gene	O
.	O

cDNAs	O
gene	O
for	O
tissues	O
seems	O
to	O
be	O
on	O
by	O
various	O
HGO	O
,	O
shown	O
as	O
in	O
RT	O
-	O
PCR	O
expressed	O
The	O
different	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
complementary	O
dna	O
complementary	O
dna	O
inward	O
inward	O
inward	O
inward	O
on	O
different	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
complementary	O
dna	O
complementary	O
dna	O
inward	O
inward	O
inward	O
inward	O
on	O
different	O

The	O
cistron	O
for	O
HGO	O
seems	O
to	O
be	O
extract	O
in	O
versatile	O
tissues	O
,	O
as	O
indicate	O
by	O
RT	O
-	O
PCR	O
on	O
unlike	O
cdna	O
.	O

The	O
gene	O
for	O
seems	O
to	O
be	O
expressed	O
in	O
tissues	O
,	O
as	O
shown	O
RT	O
-	O
on	O
different	O
cDNAs	O
.	O

HGO	O
be	O
expressed	O
in	O
tissues	O
,	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
different	O
cDNAs	O
.	O

The	O
cistron	O
for	O
HGO	O
seems	O
to	O
be	O
uttered	O
in	O
diverse	O
tissues	O
,	O
as	O
picture	O
by	O
RT	O
-	O
PCR	O
on	O
dissimilar	O
cDNAs	O
.	O

by	O
gene	O
in	O
be	O
seems	O
to	O
RT	O
expressed	O
for	O
various	O
tissues	O
,	O
cDNAs	O
shown	O
HGO	O
The	O
-	O
PCR	O
on	O
different	O
as	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
complementary	O
dna	O
complementary	O
dna	O
inward	O
inward	O
inward	O
inward	O
on	O
different	O

The	O
gene	O
for	O
HGO	O
be	O
expressed	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
different	O
cDNAs	O
.	O

FISH	O
experiments	O
probe	O
human	O
whole	O
murine	O
at	O
as	O
with	O
clearly	O
revealed	O
signals	O
cDNA	O
the	O
the	O
chromosomal	O
band	O
3q13	O
.	O

with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
chromosomal	O
band	O
3q13	O
.	O

pisces	O
experiments	O
with	O
the	O
unharmed	O
murine	O
cDNA	O
as	O
probe	O
understandably	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
stripe	O
3q13	O
.	O

angle	O
experiments	O
with	O
the	O
whole	O
murine	O
cdna	O
as	O
probe	O
distinctly	O
unwrap	O
signals	O
at	O
the	O
human	O
chromosomal	O
set	O
3q13	O
.	O

band	O
experiments	O
with	O
the	O
whole	O
murine	O
the	O
human	O
probe	O
clearly	O
revealed	O
signals	O
3q13	O
cDNA	O
as	O
chromosomal	O
at	O
FISH	O
.	O

FISH	O
experiments	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
.	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
dig	O
into	O
dig	O
into	O
dig	O
into	O

angle	O
experiments	O
with	O
the	O
completely	O
murine	O
cDNA	O
as	O
probe	O
understandably	O
revealed	O
signalize	O
at	O
the	O
human	O
chromosomal	O
stripe	O
3q13	O
.	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
dig	O
into	O
dig	O
into	O
dig	O
into	O

the	O
experiments	O
with	O
revealed	O
whole	O
murine	O
cDNA	O
.	O
human	O
clearly	O
the	O
signals	O
FISH	O
at	O
probe	O
chromosomal	O
band	O
3q13	O
as	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
.	O

-	O
q21	O
.	O

	O
3	O
-	O
q21	O
.	O

	O
3	O
-	O
q21	O
.	O

3	O
-	O

	O
3	O
-	O
q21	O
.	O

terzetto	O
-	O
q21	O
.	O

q21	O
-	O
3	O
.	O

.	O
-	O
q21	O
3	O

ternary	O
-	O
q21	O
.	O

-	O
q21	O

3	O
-	O
q21	O
.	O

This	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
gene	O
(	O
AKU	O
)	O
the	O
same	O
chromosomal	O
region	O
by	O
linkage	O
analysis	O
.	O

This	O
well	O
to	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
gene	O
(	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O

This	O
corresponds	O
well	O
to	O
alcaptonuria	O
cistron	O
duty	O
assignment	O
yoruba	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	B
alkaptonuria	O
gene	O
(	O
AKU	O
)	O
realm	O
gene	O
linkage	O
depth	O
psychology	O
duty	O
assignment	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O

same	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
linkage	O
by	O
locus	O
the	O
the	O
human	O
alkaptonuria	B
region	O
(	O
AKU	O
)	O
to	O
multipoint	O
for	O
chromosomal	O
gene	O
the	O
This	O
of	O
analysis	O
.	O

analysis	O
corresponds	O
well	O
gene	O
the	O
previous	O
linkage	O
of	O
to	O
locus	O
for	O
the	O
alkaptonuria	O
same	B
multipoint	O
the	O
AKU	O
)	O
to	O
the	O
human	O
chromosomal	O
region	O
by	O
(	O
assignment	O
This	O
.	O

This	O
corresponds	O
well	O
to	O
alcaptonuria	O
cistron	O
duty	O
assignment	O
yoruba	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	B
alkaptonuria	O
gene	O
(	O
AKU	O
)	O
realm	O
gene	O
linkage	O
depth	O
psychology	O
cistron	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O

This	O
corresponds	O
fountainhead	O
to	O
the	O
old	O
grant	O
of	O
the	O
venue	O
for	O
the	O
human	O
alcaptonuria	B
factor	O
(	O
aku	O
)	O
to	O
the	O
same	O
chromosomal	O
area	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

This	O
corresponds	O
well	O
to	O
alcaptonuria	O
cistron	O
duty	O
assignment	O
yoruba	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	B
alkaptonuria	O
gene	O
(	O
AKU	O
)	O
realm	O
gene	O
linkage	O
depth	O
psychology	O
cistron	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O

by	O
corresponds	O
well	O
to	O
the	O
previous	O
alkaptonuria	O
the	O
the	O
locus	O
for	O
AKU	O
chromosomal	O
assignment	B
multipoint	O
This	O
of	O
(	O
to	O
the	O
same	O
human	O
region	O
)	O
gene	O
linkage	O
analysis	O
.	O

This	O
check	O
considerably	O
to	O
the	O
premature	O
assigning	O
of	O
the	O
venue	O
for	O
the	O
human	O
alcaptonuria	B
cistron	O
(	O
aku	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

This	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	B
gene	O
(	O
AKU	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

We	O
conclude	O
the	O
cDNA	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cdna	O
encodes	O
the	O
factor	O
creditworthy	O
for	O
alcaptonuria	B
.	O

encodes	O
that	O
conclude	O
therefore	O
the	O
HGO	O
gene	O
We	O
the	O
.	O
responsible	O
for	O
alkaptonuria	B
cDNA	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
gene	O
responsible	O
alkaptonuria	B
.	O

We	O
therefore	O
encode	O
resolve	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
alcaptonuria	O
thence	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

We	O
therefore	O
encode	O
resolve	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
alcaptonuria	O
encode	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

We	O
thus	O
conclude	O
that	O
the	O
HGO	O
cdna	O
encodes	O
the	O
cistron	O
responsible	O
for	O
alcaptonuria	B
.	O

alkaptonuria	O
therefore	O
conclude	O
We	O
encodes	O
HGO	O
cDNA	O
for	O
the	O
gene	O
responsible	O
the	O
that	B
.	O

We	O
therefore	O
encode	O
resolve	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
alcaptonuria	O
thence	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

We	O
thus	O
resolve	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
cistron	O
responsible	O
for	O
alcaptonuria	B
.	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

PTEN	O
,	O
mutated	O
,	O
protein	O
tyrosine	O
,	O
gene	O
a	O
in	O
human	O
brain	B
phosphatase	I
breast	I
putative	I
and	I
prostate	I
cancer	I
.	O

a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
and	I
prostate	I
cancer	I
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
cistron	O
mutated	O
in	O
human	O
mind	B
,	I
knocker	I
,	I
and	I
prostate	I
cancer	I
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
cistron	O
mutated	O
in	O
human	O
genius	B
,	I
tit	I
,	I
and	I
prostatic	I
cancer	I
.	O

prostate	O
,	O
a	O
putative	O
protein	O
tyrosine	O
breast	O
,	O
mutated	O
in	O
human	O
brain	B
cancer	I
phosphatase	I
gene	I
and	I
,	I
PTEN	I
.	O

PTEN	O
,	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
cancer	I
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
cistron	O
mutated	O
in	O
homo	O
brain	B
,	I
knocker	I
,	I
and	I
prostate	I
cancer	I
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
cancer	I
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

breast	O
,	O
a	O
human	O
protein	O
tyrosine	O
phosphatase	O
.	O
,	O
in	O
putative	O
brain	B
PTEN	I
,	I
mutated	I
and	I
prostate	I
cancer	I
gene	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
cancer	I
.	O

Mapping	O
of	O
be	O
deletions	O
on	O
the	O
chromosome	O
,	O
has	O
led	O
to	O
appears	O
at	O
of	O
a	O
in	O
tumor	B
suppressor	O
,	O
gene	O
PTEN	O
10q23	O
that	O
human	O
to	O
mutated	O
homozygous	O
cancers	O
considerable	O
frequency	O
candidate	O
isolation	O
human	B
.	O

Mapping	O
deletions	O
on	O
human	O
chromosome	O
has	O
led	O
isolation	O
of	O
candidate	O
tumor	B
PTEN	O
that	O
appears	O
to	O
mutated	O
at	O
considerable	O
in	O
human	O
cancers	B
.	O

Mapping	O
of	O
homozygous	O
deletions	O
antiophthalmic	O
factor	O
nominee	O
mutate	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	B
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	B
cancers	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O

Mapping	O
of	O
homozygous	O
deletions	O
antiophthalmic	O
factor	O
nominee	O
along	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	B
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	B
cancers	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O

of	O
gene	O
homozygous	O
deletions	O
on	O
human	O
mutated	O
10q23	O
has	O
led	O
to	O
at	O
isolation	O
to	O
frequency	O
candidate	O
tumor	B
suppressor	O
the	O
,	O
PTEN	O
,	O
.	O
appears	O
of	O
be	O
chromosome	O
Mapping	O
human	O
that	O
in	O
considerable	O
cancers	B
a	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
has	O
led	O
to	O
the	O
of	O
a	O
candidate	O
tumor	B
suppressor	O
,	O
PTEN	O
,	O
that	O
to	O
be	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B
.	O

map	O
of	O
homozygous	O
excision	O
on	O
human	O
chromosome	O
10q23	O
has	O
guide	O
to	O
the	O
isolation	O
of	O
a	O
nominee	O
neoplasm	B
suppresser	O
cistron	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequence	O
in	O
human	O
cancers	B
.	O

Mapping	O
of	O
homozygous	O
omission	O
on	O
homo	O
chromosome	O
10q23	O
has	O
direct	O
to	O
the	O
isolation	O
of	O
a	O
prospect	O
tumour	B
suppresser	O
factor	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
homo	O
cancers	B
.	O

Mapping	O
of	O
homozygous	O
deletions	O
antiophthalmic	O
factor	O
nominee	O
along	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	B
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	B
cancers	O
along	O
along	O
along	O
along	O
along	O
along	O
along	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
homo	O
chromosome	O
10q23	O
has	O
precede	O
to	O
the	O
isolation	O
of	O
a	O
prospect	O
neoplasm	B
suppressor	O
factor	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
oftenness	O
in	O
homo	O
cancers	B
.	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B
.	O

In	O
,	O
PTEN	O
were	O
%	O
13	O
/	O
42	O
)	O
cell	O
and	O
100	O
(	O
4	O
/	O
)	O
of	O
prostate	B
lines	O
,	O
6	O
%	O
(	O
/	O
65	O
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B

indium	O
prelude	O
filmdom	O
,	O
mutations	O
of	O
PTEN	O
were	O
detected	O
indium	O
xxxi	O
%	O
(	O
13	O
/	O
xlii	O
)	O
of	O
spongioblastoma	B
cell	O
describe	O
and	O
xenografts	O
,	O
century	O
%	O
(	O
quartet	O
/	O
quartet	O
)	O
of	O
prostatic	B
cancer	I
cell	O
describe	O
,	O
6	O
%	O
(	O
quartet	O
/	O
lxv	O
)	O
of	O
knocker	B
cancer	I
cell	O
describe	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
ternary	O
/	O
xviii	O
)	O
of	O
master	B
spongioblastoma	I
.	O

In	O
%	O
screens	O
of	O
xenografts	O
(	O
PTEN	O
were	O
detected	O
in	O
31	O
cell	O
,	O
3	O
/	O
6	O
)	O
of	O
glioblastoma	B
cell	O
mutations	O
4	O
cancer	O
(	O
%	O
preliminary	O
(	O
4	O
/	O
17	O
)	O
primary	O
prostate	B
cancer	I
cell	O
lines	O
.	O
42	O
100	O
of	O
4	O
/	O
%	O
)	O
of	O
breast	B
xenografts	I
glioblastomas	O
lines	O
and	O
and	O
lines	O
and	O
,	O
65	O
(	O
13	O
/	O
18	O
)	O
,	O
of	B
%	I
,	O

65	O
lines	O
/	O
cell	O
prostate	O
of	O
PTEN	O
%	O
detected	O
31	O
in	O
,	O
(	O
13	O
%	O
42	O
(	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
4	O
/	O
100	O
and	O
)	O
4	O
/	O
xenografts	O
)	O
18	O
mutations	B
cancer	I
of	O
preliminary	O
,	O
6	O
%	O
(	O
4	O
/	O
and	O
)	O
17	O
glioblastomas	B
primary	I
cell	O
lines	O
In	O
xenografts	O
,	O
%	O
breast	O
were	O
(	O
3	O
screens	O
,	O
)	O
of	O
cancer	B
of	I
.	O

In	O
,	O
of	O
PTEN	O
were	O
detected	O
%	O
(	O
13	O
/	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
%	O
/	O
)	O
of	O
prostate	B
cancer	I
cell	O
,	O
6	O
%	O
(	O
/	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
3	O
/	O
18	O
)	O
primary	B
glioblastomas	I

inch	O
prelude	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
find	O
inch	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
spongioblastoma	B
cell	O
lines	O
and	O
heterograft	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostatic	B
crab	I
cell	O
lines	O
,	O
sixer	O
%	O
(	O
4	O
/	O
lxv	O
)	O
of	O
bosom	B
crab	I
cell	O
lines	O
and	O
heterograft	O
,	O
and	O
seventeen	O
%	O
(	O
triplet	O
/	O
eighteen	O
)	O
of	O
primary	B
spongioblastoma	I
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
	O
observe	O
inward	O
	O
	O
	O
	O
glioblastoma	O
observe	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B
cancer	I
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B
glioblastomas	I
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
.	O

In	O
,	O
PTEN	O
were	O
detected	O
in	O
%	O
(	O
42	O
)	O
glioblastoma	B
cell	O
,	O
%	O
(	O
4	O
4	O
)	O
of	O
cancer	I
cell	O
lines	O
,	O
6	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
xenografts	O
and	O
17	O
%	O
3	O
/	O
18	O
)	O
of	O
primary	B
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
	O
observe	O
inward	O
	O
	O
	O
	O
glioblastoma	O
observe	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B
cancer	I
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B
glioblastomas	I
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
spongioblastoma	O
.	O

indiana	O
prelude	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
notice	O
indiana	O
31	O
%	O
(	O
13	O
/	O
xlii	O
)	O
of	O
spongioblastoma	B
cell	O
stemma	O
and	O
heterograft	O
,	O
100	O
%	O
(	O
quartet	O
/	O
quartet	O
)	O
of	O
prostate	B
cancer	I
cell	O
stemma	O
,	O
sextuplet	O
%	O
(	O
quartet	O
/	O
65	O
)	O
of	O
boob	B
cancer	I
cell	O
stemma	O
and	O
heterograft	O
,	O
and	O
seventeen	O
%	O
(	O
leash	O
/	O
18	O
)	O
of	O
primary	B
spongioblastoma	I
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B
cancer	I
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B
glioblastomas	I
.	O

The	O
foreshadow	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
arena	O
and	O
panoptic	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
fibril	O
at	O
focal	O
adhesions	O
.	O

The	O
predicted	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
,	O
a	O
protein	O
that	O
with	O
actin	O
filaments	O
at	O
focal	O
.	O

The	O
predicted	O
PTEN	O
product	O
antiophthalmic	O
factor	O
adhesiveness	O
give	O
birth	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
astatine	O
filum	O
adhesiveness	O
astatine	O
intersection	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O

with	O
predicted	O
PTEN	O
that	O
has	O
a	O
protein	O
adhesions	O
at	O
domain	O
interacts	O
extensive	O
homology	O
to	O
filaments	O
,	O
a	O
protein	O
product	O
focal	O
and	O
actin	O
tensin	O
phosphatase	O
The	O
tyrosine	O
.	O

The	O
predicted	O
PTEN	O
product	O
antiophthalmic	O
factor	O
adhesiveness	O
give	O
birth	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
astatine	O
filum	O
adhesiveness	O
astatine	O
intersection	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O

The	O
predicted	O
PTEN	O
has	O
a	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
a	O
protein	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O
adhesions	O
.	O

.	O
predicted	O
PTEN	O
tensin	O
has	O
a	O
adhesions	O
tyrosine	O
product	O
domain	O
and	O
extensive	O
to	O
with	O
focal	O
phosphatase	O
a	O
protein	O
that	O
interacts	O
homology	O
actin	O
filaments	O
at	O
,	O
protein	O
The	O

PTEN	O
a	O
protein	O
tyrosine	O
domain	O
and	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O

at	O
predicted	O
PTEN	O
product	O
has	O
a	O
to	O
extensive	O
phosphatase	O
domain	O
and	O
a	O
actin	O
protein	O
focal	O
The	O
tyrosine	O
,	O
that	O
interacts	O
with	O
homology	O
filaments	O
protein	O
tensin	O
adhesions	O
.	O

The	O
foretell	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
orbit	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
fibril	O
at	O
focal	O
attachment	O
.	O

The	O
predicted	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O
adhesions	O
.	O

These	O
homologies	O
suggest	O
that	O
astatine	O
through	O
and	O
through	O
kinase	O
stamp	O
down	O
crataegus	O
oxycantha	B
PTEN	O
may	O
suppress	O
tumor	O
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	B
regulate	O
fundamental	O
interaction	O
adhesiveness	B
tumor	O
cell	O
invasion	O
and	O
metastasis	O
through	O
interactions	O
at	O
focal	O

These	O
homologies	O
suggest	O
that	O
astatine	O
through	O
and	O
through	O
kinase	O
stamp	O
down	O
crataegus	O
oxycantha	B
PTEN	O
may	O
suppress	O
tumor	O
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	B
regulate	O
fundamental	O
interaction	O
emergence	B
tumor	O
cell	O
invasion	O
and	O
metastasis	O
through	O
interactions	O
at	O
focal	O

.	O
homologies	O
interactions	O
kinases	O
PTEN	O
may	O
adhesions	O
tumor	B
that	O
growth	O
by	O
antagonizing	O
invasion	O
tyrosine	O
suggest	O
cell	O
may	O
regulate	O
tumor	B
cell	O
protein	O
and	O
metastasis	B
through	O
and	O
suppress	O
focal	O
at	O
These	O
.	O

These	O
homologies	O
suggest	O
that	O
astatine	O
through	O
and	O
through	O
kinase	O
stamp	O
down	O
crataegus	O
oxycantha	B
PTEN	O
may	O
suppress	O
tumor	O
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	B
regulate	O
fundamental	O
interaction	O
adhesiveness	B
tumor	O
cell	O
invasion	O
and	O
metastasis	O
through	O
interactions	O
at	O
focal	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
suppress	O
cell	O
growth	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
invasion	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
.	O

These	O
homology	O
propose	O
that	O
PTEN	O
may	O
repress	O
tumour	B
cell	O
increment	O
by	O
antagonise	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
determine	O
tumour	B
cell	O
encroachment	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
.	O

may	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
and	O
antagonizing	B
cell	O
growth	O
by	O
These	O
.	O
through	O
and	O
kinases	O
regulate	O
interactions	O
tumor	B
cell	O
invasion	O
suppress	O
metastasis	B
tyrosine	O
tumor	O
at	O
focal	O
adhesions	O
protein	O
.	O

invasion	O
homologies	O
suggest	O
tumor	O
PTEN	O
may	O
suppress	O
at	B
through	O
growth	O
.	O
antagonizing	O
focal	O
cell	O
metastasis	O
and	O
may	O
regulate	O
that	B
tyrosine	O
interactions	O
and	O
kinases	B
cell	O
These	O
tumor	O
protein	O
adhesions	O
by	O
.	O

These	O
homology	O
evoke	O
that	O
PTEN	O
may	O
conquer	O
neoplasm	B
cell	O
ontogeny	O
by	O
antagonize	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regularize	O
neoplasm	B
cell	O
encroachment	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adherence	O
.	O
.	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
suppress	O
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
regulate	O
tumor	B
cell	O
invasion	O
and	O
metastasis	B
through	O
focal	O
adhesions	O
.	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
suppress	O
tumor	B
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	B
cell	O
invasion	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
.	O

myotonia	O
in	O
Schwartz	B
-	I
.	I
chondrodystrophic	I
Heterogeneity	I
Jampel	O

heterogeneity	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

Schwartz	B
chondrodystrophic	I
myotonia	I
.	O

Heterogeneity	O
inwards	O
inward	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

Heterogeneity	O
Schwartz	B
-	I
myotonia	I
.	O

Heterogeneity	O
Jampel	O
Schwartz	B
-	I
in	I
chondrodystrophic	I
.	I
myotonia	O

.	O
-	O
Schwartz	B
in	I
Jampel	I
chondrodystrophic	I
myotonia	I
Heterogeneity	O

Heterogeneity	O
inwards	O
inward	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

heterogeneousness	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

Heterogeneity	O
inwards	O
inward	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

Heterogeneity	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
follow	O
curtly	I
drum	O
drum	I
be	O
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
be	O
be	O
be	O
swot	O
up	O

The	O
Schwartz	B
syndrome	I
myotonia	I
;	O
McK	O
,	O
800	O
is	O
a	O
recessively	B
defined	O
by	O
myotonia	B
,	O
short	B
,	O
bone	B
dysplasia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
transmissible	I
shape	I
outlined	O
by	O
myotonia	B
,	O
scant	B
height	I
,	O
and	O
bone	B
dysplasia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
(	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
genetic	I
stipulation	I
delimitate	O
by	O
myotonia	B
,	O
curtly	B
height	I
,	O
and	O
bone	B
dysplasia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
follow	O
curtly	I
drum	O
drum	I
be	O
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
be	O
be	O
be	O
swot	O
up	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
hereditary	I
condition	I
outlined	O
by	O
myotonia	B
,	O
unretentive	B
height	I
,	O
and	O
cram	B
dysplasia	I
.	O

condition	O
recessively	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
bone	O
)	O
is	O
a	O
,	B
inherited	I
Schwartz	I
defined	O
.	O
myotonia	B
,	O
short	B
stature	I
The	O
800	O
by	B
dysplasia	I
and	O

The	O
Schwartz	B
-	I
Jampel	I
(	O
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
short	B
stature	I
,	O
bone	B
.	O

The	O
Schwartz	B
-	I
Jampel	I
follow	O
curtly	I
drum	O
drum	I
be	O
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
be	O
be	O
be	O
swot	O
up	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
.	O

linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
but	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

has	O
linkage	O
between	O
the	B
and	O
chromosomal	O
region	O
.	O
been	O
34	O
identified	O
been	O
observed	O
gene	O
yet	O
families	O
,	O
but	O
SJS	O
in	O
has	O
not	O
several	O
-	O
Genetic	O
1q36	O

hereditary	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
neighborhood	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
respective	O
families	O
,	O
but	O
the	O
cistron	O
has	O
not	O
yet	O
been	O
name	O
.	O

inherited	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
xxxiv	O
has	O
been	O
note	O
in	O
various	O
phratry	O
,	O
but	O
the	O
cistron	O
has	O
not	O
still	O
been	O
identified	O
.	O

Genetic	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
been	O
observed	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
been	O
identified	O
.	O

Genetic	O
linkage	O
between	O
SJS	B
nonetheless	O
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
nonetheless	O
be	O
identify	O
be	O
identify	O
phratry	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Genetic	O
linkage	O
between	O
SJS	B
nonetheless	O
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
nonetheless	O
be	O
identify	O
be	O
identify	O
cistron	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Genetic	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
been	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O

been	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
in	O
,	O
-	O
34	O
has	O
been	O
not	O
region	O
identified	O
families	O
1q36	O
has	O
the	O
gene	O
Genetic	O
observed	O
yet	O
but	O
several	O
.	O

inherited	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
neighborhood	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
respective	O
kinsperson	O
,	O
but	O
the	O
factor	O
has	O
not	O
nonetheless	O
been	O
identify	O
.	O

Genetic	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
studied	O
the	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O
subgroups	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
5	O
trying	O
to	O
identify	O
distinct	O
subgroups	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
clear	O
cut	O
subgroup	O
subgroup	O
	O
	O
	O
to	O
identify	O
distinct	O
subgroups	O

We	O
meditate	O
the	O
clinical	O
and	O
radiological	O
have	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
cinque	O
own	O
patients	O
test	O
to	O
discover	O
trenchant	O
subgroups	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
clear	O
cut	O
subgroup	O
subgroup	O
	O
	O
	O
to	O
identify	O
distinct	O
subgroups	O

We	O
analyse	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
lxxxi	O
patients	O
from	O
the	O
literature	O
and	O
five	O
own	O
patients	O
trying	O
to	O
distinguish	O
decided	O
subgroups	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
the	O
literature	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O

from	O
studied	O
the	O
to	O
and	O
radiological	O
features	O
81	O
in	O
patients	O
identify	O
the	O
and	O
literature	O
.	O
own	O
patients	O
trying	O
clinical	O
We	O
distinct	O
subgroups	O
5	O

We	O
meditate	O
the	O
clinical	O
and	O
radiological	O
characteristic	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
five	O
own	O
patients	O
stress	O
to	O
place	O
distinct	O
subgroups	O
.	O

5	O
studied	O
81	O
features	O
and	O
radiological	O
own	O
in	O
the	O
patients	O
from	O
the	O
distinct	O
and	O
clinical	O
We	O
patients	O
trying	O
to	O
identify	O
literature	O
subgroups	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O
subgroups	O
.	O

sibs	O
addition	O
,	O
locus	O
tested	O
genetic	O
linkage	O
two	O
in	O
SJS	B
we	O
on	O
1	O
chromosome	O
the	O
one	O
family	O
with	O
to	O
In	O
affected	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
cognate	O
cognate	O
	O
	O
	O
	O
two	O
affected	O
sibs	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
cognate	O
cognate	O
	O
	O
	O
	O
two	O
affected	O
sibs	O
.	O

In	O
improver	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locale	O
on	O
chromosome	O
one	O
in	O
peerless	O
family	O
with	O
ii	O
affected	O
sibling	O
.	O

In	O
addition	O
,	O
tested	O
genetic	O
linkage	O
to	O
the	O
locus	O
on	O
chromosome	O
1	O
one	O
family	O
two	O
affected	O
sibs	O
.	O

we	O
linkage	O
to	O
the	O
locus	O
on	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O

inch	O
addition	O
,	O
we	O
prove	O
transmitted	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
inch	O
unmatched	O
family	O
with	O
ii	O
impact	O
sibs	O
.	O

in	O
addition	O
the	O
linkage	O
tested	O
genetic	O
one	O
to	O
,	O
SJS	B
locus	O
on	O
sibs	O
1	O
we	O
In	O
family	O
with	O
two	O
affected	O
chromosome	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
cognate	O
cognate	O
	O
	O
	O
phratry	O
two	O
affected	O
sibs	O
.	O

In	O
addition	O
,	O
we	O
linkage	O
to	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O

We	O
found	O
that	O
a	O
follow	O
lower	O
ranking	O
import	O
chemical	O
group	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	B
of	O
myotonia	O
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	B
primary	I
bone	O
dysplasia	B
with	O
myotonia	O
be	O
be	O
be	O
be	O

We	O
found	O
that	O
of	O
changes	O
which	O
may	O
secondary	O
consequences	O
myotonia	B
,	O
while	O
of	O
patients	O
appear	O
to	O
have	O
bone	B
with	O
myotonia	B
.	O

We	O
plant	O
that	O
a	O
group	O
of	O
patients	O
have	O
soft	O
pinched	O
deepen	O
which	O
may	O
be	O
subaltern	O
result	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
look	O
to	O
have	O
primary	O
drum	B
dysplasia	I
with	O
myotonia	B
.	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
mild	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B
,	O
while	O
appear	O
to	O
have	O
primary	O
bone	B
dysplasia	I
with	O
myotonia	B
.	O

We	O
discover	O
that	O
a	O
group	O
of	O
patients	O
have	O
modest	O
emaciated	O
modify	O
which	O
may	O
be	O
lowly	O
effect	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
basal	O
drum	B
dysplasia	I
with	O
myotonia	B
.	O

We	O
found	O
that	O
a	O
follow	O
lower	O
ranking	O
import	O
chemical	O
group	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	B
of	O
myotonia	O
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	B
primary	I
bone	O
dysplasia	B
with	O
myotonia	O
be	O
be	O
be	O
be	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
soft	O
gaunt	O
transfer	O
which	O
whitethorn	O
be	O
secondary	O
upshot	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B
dysplasia	I
with	O
myotonia	B
.	O

another	O
,	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
appear	O
dysplasia	O
consequences	O
of	O
myotonia	B
primary	O
while	O
found	O
group	O
myotonia	O
patients	O
be	O
to	O
have	O
We	O
secondary	B
of	I
with	O
bone	B
.	O

We	O
found	O
that	O
a	O
group	O
of	O
have	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
primary	O
bone	B
dysplasia	I
myotonia	B

We	O
found	O
that	O
a	O
follow	O
lower	O
ranking	O
import	O
piece	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	B
myotonia	O
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	B
bone	I
dysplasia	O
with	B
myotonia	O
be	O
be	O
be	O
be	O
crataegus	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B
dysplasia	I
with	O
myotonia	B
.	O

within	O
this	O
latter	O
group	O
,	O
there	O
are	O
divergence	O
in	O
maturate	O
of	O
expression	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O
variety	O
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
modification	O
inward	O
inward	O
inward	O
inward	O
inward	O
bone	O
changes	O
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
modification	O
inward	O
inward	O
inward	O
inward	O
inward	O
bone	O
changes	O
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
age	O
of	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O

course	O
this	O
in	O
are	O
,	O
there	O
and	O
differences	O
latter	O
age	O
of	O
manifestation	O
.	O
clinical	O
group	O
Within	O
pattern	O
of	O
bone	O
changes	O
,	O

inside	O
this	O
latter	O
group	O
,	O
there	O
are	O
deviation	O
in	O
geezerhood	O
of	O
expression	O
,	O
clinical	O
course	O
and	O
convention	O
of	O
bone	O
exchange	O
.	O

.	O
this	O
latter	O
of	O
,	O
there	O
are	O
bone	O
course	O
age	O
group	O
manifestation	O
clinical	O
,	O
in	O
and	O
pattern	O
of	O
differences	O
Within	O
changes	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
modification	O
inward	O
inward	O
inward	O
inward	O
be	O
bone	O
changes	O
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
course	O
of	O
bone	O
changes	O
.	O

within	O
this	O
latter	O
group	O
,	O
there	O
are	O
deviation	O
in	O
age	O
of	O
reflection	O
,	O
clinical	O
run	O
and	O
pattern	O
of	O
bone	O
switch	O
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O
changes	O
.	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B
parturition	B
type	I
1A	I
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B
dysplasia	I
resembling	O
Pyle	B
disease	I
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
birthing	O
puerility	O
.	O

We	O
tentatively	O
sequestrate	O
tierce	O
dissimilar	O
typecast	O
of	O
SJS	B
type	I
1A	I
,	O
ordinarily	O
recognized	O
in	O
puerility	O
,	O
with	O
hold	O
cram	B
dysplasia	I
,	O
jibe	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
exchangeable	O
to	O
type	O
1A	O
but	O
recognisable	O
at	O
nascence	O
,	O
with	O
more	O
pronounced	O
cram	B
dysplasia	I
resemble	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
two	O
,	O
attest	O
at	O
nascence	O
,	O
with	O
increased	O
deathrate	O
and	O
cram	B
dysplasia	I
resemble	O
pyle	B
disease	I
.	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B
character	B
type	I
1A	I
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B
dysplasia	I
resembling	O
Pyle	B
disease	I
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O
character	O
fictitious	O

We	O
Jampel	O
isolate	O
birth	O
,	O
1A	O
of	O
SJS	B
type	I
1A	I
,	O
pronounced	O
the	O
,	O
childhood	O
to	O
with	O
moderate	O
bone	B
dysplasia	I
in	O
resembling	O
;	O
recognized	O
type	O
descriptions	O
of	O
Schwartz	O
,	O
tentatively	O
and	O
Kniest	O
;	O
type	O
1B	O
,	O
increased	O
,	O
original	O
types	O
but	O
recognizable	O
mortality	O
birth	O
,	O
with	O
disease	O
with	O
bone	B
dysplasia	I
corresponding	O
Aberfeld	B
dysplasia	I
to	O
at	O
type	O
and	O
,	O
manifest	O
at	O
three	O
different	O
usually	O
similar	O
bone	O
2	O
and	B
dysplasia	I
resembling	O
Pyle	B
more	I
.	O

isolate	O
three	O
SJS	B
1A	I
,	O
usually	O
recognized	O
,	O
moderate	O
,	O
to	O
the	O
original	O
of	O
Schwartz	O
,	O
Aberfeld	O
;	O
type	O
1B	O
,	O
to	O
type	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
with	O
and	O
dysplasia	I
resembling	O
Pyle	B
.	O

We	O
tentatively	O
three	O
different	O
SJS	B
1A	I
,	O
usually	O
recognized	O
,	O
with	O
moderate	O
bone	B
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
Jampel	O
;	O
1B	O
,	O
similar	O
to	O
type	O
but	O
recognizable	O
at	O
birth	O
with	O
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
birth	O
,	O
with	O
increased	O
and	O
bone	B
resembling	O
.	O

type	O
Pyle	O
to	O
and	O
different	O
types	O
of	O
SJS	B
;	I
1A	I
,	O
usually	O
with	O
Jampel	O
childhood	O
increased	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
bone	O
of	O
manifest	O
,	O
and	O
Aberfeld	O
type	O
type	O
birth	O
,	O
similar	O
but	O
type	O
1A	O
dysplasia	O
recognizable	O
at	O
birth	O
disease	O
with	O
more	O
pronounced	O
Schwartz	B
three	I
resembling	O
Kniest	B
dysplasia	I
.	O
isolate	O
We	O
,	O
1B	O
dysplasia	O
at	O
,	O
,	O
recognized	O
2	O
mortality	O
and	O
bone	B
,	I
resembling	O
tentatively	B
in	I
;	O

We	O
tentatively	O
three	O
different	O
type	I
usually	O
recognized	O
,	O
bone	B
dysplasia	I
,	O
corresponding	O
the	O
original	O
Schwartz	O
,	O
and	O
Aberfeld	O
,	O
to	O
type	O
1A	O
recognizable	O
at	O
birth	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
with	O
mortality	O
and	O
bone	B
resembling	O
Pyle	B
disease	I
.	O

We	O
tentatively	O
sequestrate	O
ternary	O
unlike	O
typewrite	O
of	O
SJS	B
eccentric	I
1A	I
,	O
commonly	O
accredit	O
in	O
puerility	O
,	O
with	O
hold	O
bone	B
dysplasia	I
,	O
check	O
to	O
the	O
archetype	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
eccentric	O
1B	O
,	O
exchangeable	O
to	O
eccentric	O
1A	O
but	O
placeable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resemble	O
Kniest	B
dysplasia	I
;	O
and	O
eccentric	O
two	O
,	O
attest	O
at	O
birth	O
,	O
with	O
increased	O
deathrate	O
and	O
bone	B
dysplasia	I
resemble	O
pyle	B
disease	I
.	O

resembling	O
tentatively	O
isolate	O
1B	O
different	O
types	O
of	O
and	B
type	I
1A	I
,	O
the	O
recognized	O
in	O
childhood	O
,	O
bone	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
disease	O
Pyle	O
original	O
We	O
.	O
Schwartz	O
,	O
to	O
and	O
Aberfeld	O
;	O
type	O
manifest	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
descriptions	O
birth	O
;	O
with	O
,	O
pronounced	O
bone	B
Kniest	I
resembling	O
and	B
mortality	I
with	O
SJS	O
type	O
2	O
,	O
three	O
at	O
birth	O
more	O
,	O
increased	O
dysplasia	O
dysplasia	O
with	B
dysplasia	I
Jampel	O
at	B
usually	I
of	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B
type	I
1A	I
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B
dysplasia	I
resembling	O
Pyle	B
disease	I
.	O

Genetic	O
analysis	O
of	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
evidence	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
dissemble	O
	O
	O
dissemble	O
dissemble	O
dissemble	O
chromosome	O
1p36	O
-	O
34	O
.	O

familial	O
analysis	O
of	O
the	O
mob	O
with	O
two	O
sibs	O
moved	O
by	O
SJS	B
type	I
2	I
establish	O
show	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
dissemble	O
	O
	O
dissemble	O
dissemble	O
dissemble	O
chromosome	O
1p36	O
-	O
34	O
.	O

Genetic	O
analysis	O
of	O
the	O
kinsperson	O
with	O
deuce	O
sibs	O
moved	O
by	O
SJS	B
type	I
deuce	I
establish	O
certify	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
type	I
2	I
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O

SJS	O
analysis	O
of	O
chromosome	O
family	O
with	O
two	O
affected	O
sibs	O
by	O
1p36	B
type	I
showed	I
2	O
.	O
against	O
linkage	O
to	O
the	O
Genetic	O
-	O
34	O
evidence	O

transmitted	O
analysis	O
of	O
the	O
folk	O
with	O
ii	O
sibs	O
affected	O
by	O
SJS	B
type	I
ii	I
designate	O
grounds	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

evidence	O
analysis	O
affected	O
two	O
family	O
with	O
against	O
sibs	O
of	O
by	O
SJS	B
type	I
-	I
showed	O
the	O
Genetic	O
linkage	O
to	O
chromosome	O
1p36	O
2	O
34	O
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

heterogeneous	O
SJS	B
is	O
clinically	O
.	O
radiologically	O
CONCLUSIONS	O
and	O

finish	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogenous	O
.	O

is	O
radiologically	O
heterogeneous	O
.	O

CONCLUSIONS	O
finale	O
last	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

CONCLUSIONS	O
is	O
clinically	O
heterogeneous	O
.	O

CONCLUSIONS	O
and	B
is	O
clinically	O
SJS	O
radiologically	O
.	O
heterogeneous	O

.	O
clinically	B
is	O
SJS	O
and	O
radiologically	O
heterogeneous	O
CONCLUSIONS	O

CONCLUSIONS	O
heterogeneous	O
heterogenous	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

determination	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogenous	O
.	O

CONCLUSIONS	O
heterogeneous	O
heterogenous	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

CONCLUSIONS	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

The	O
causes	O
of	O
heterogeneity	O
admit	O
be	O
unlike	O
mutation	O
be	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
accommodate	O
accommodate	O
accommodate	O
chromosomal	O
mutation	O

The	O
causes	O
are	O
are	O
likely	O
to	O
both	O
different	O
at	O
the	O
SJS	B
chromosome	O
1	O
and	O
the	O
presence	O
a	O
SJS	B
locus	O
.	O

The	O
case	O
of	O
heterogeneousness	O
are	O
not	O
bonk	O
yet	O
but	O
are	O
probable	O
to	O
include	O
both	O
unlike	O
mutations	O
at	O
the	O
SJS	B
venue	O
on	O
chromosome	O
ace	O
and	O
the	O
bearing	O
of	O
a	O
instant	O
SJS	B
venue	O
.	O

The	O
causes	O
of	O
heterogeneity	O
not	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
.	O

The	O
make	O
of	O
heterogeneousness	O
are	O
not	O
known	O
nevertheless	O
but	O
are	O
likely	O
to	O
admit	O
both	O
dissimilar	O
variation	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
ane	O
and	O
the	O
comportment	O
of	O
a	O
bit	O
SJS	B
locus	O
.	O

The	O
causes	O
of	O
heterogeneity	O
admit	O
be	O
unlike	O
mutation	O
be	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
accommodate	O
accommodate	O
accommodate	O
chromosomal	O
mutation	O

The	O
movement	O
of	O
heterogeneousness	O
are	O
not	O
known	O
hitherto	O
but	O
are	O
potential	O
to	O
include	O
both	O
different	O
sport	O
at	O
the	O
SJS	B
locale	O
on	O
chromosome	O
one	O
and	O
the	O
bearing	O
of	O
a	O
mo	O
SJS	B
locale	O
.	O

on	O
SJS	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
the	O
SJS	O
mutations	O
at	O
the	O
a	B
locus	O
causes	O
chromosome	O
.	O
and	O
both	O
presence	O
of	O
The	O
different	O
1	B
locus	O
second	O

The	O
causes	O
of	O
heterogeneity	O
not	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
presence	O
of	O
a	O
SJS	B
.	O

The	O
causes	O
of	O
heterogeneity	O
admit	O
be	O
unlike	O
mutation	O
non	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
accommodate	O
accommodate	O
accommodate	O
chromosomal	O
mutation	O

The	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
correlation	O
utilitarian	O
correlation	O
correlation	O
utilitarian	O
utilitarian	O
doubtful	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
genotype	O
phenotype	O
correlations	O
.	O
.	O

axerophthol	O
provisional	O
clinico	O
-	O
radiological	O
categorization	O
can	O
be	O
utilitarian	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
maturation	O
of	O
genotype	O
-	O
phenotype	O
correlativity	O
.	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
useful	O
for	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
phenotype	O
correlations	O
.	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
correlation	O
utilitarian	O
correlation	O
correlation	O
utilitarian	O
utilitarian	O
utilitarian	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

A	O
provisional	O
clinico	O
-	O
radiological	O
categorization	O
can	O
be	O
utile	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
developing	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

A	O
doubtful	O
clinico	O
-	O
radiological	O
sorting	O
can	O
be	O
utile	O
for	O
the	O
characterisation	O
of	O
patients	O
and	O
the	O
maturation	O
of	O
genotype	O
-	O
phenotype	O
correlativity	O
.	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
the	O
patients	O
and	O
the	O
development	O
of	O
genotype	O
-	O
phenotype	O
correlations	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
correlation	O
utilitarian	O
correlation	O
correlation	O
utilitarian	O
utilitarian	O
utilitarian	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

of	O
tentative	O
clinico	O
the	O
radiological	O
classification	O
can	O
genotype	O
.	O
for	O
-	O
characterization	O
of	O
patients	O
.	O
the	O
development	O
phenotype	O
be	O
A	O
-	O
correlations	O
and	O
useful	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
.	O

mutations	O
clinical	O
overview	O
of	O
.	O
gene	O
A	O
WT1	O

adenine	O
clinical	O
overview	O
of	O
WT1	O
cistron	O
mutations	O
.	O

overview	O
gene	O
mutations	O
.	O

A	O
gene	O
cistron	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O
.	O

A	O
overview	O
of	O
mutations	O
.	O

A	O
WT1	O
overview	O
of	O
clinical	O
gene	O
.	O
mutations	O

.	O
of	O
overview	O
clinical	O
WT1	O
gene	O
mutations	O
A	O

A	O
chromosomal	O
mutation	O
mutation	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O

a	O
clinical	O
overview	O
of	O
WT1	O
cistron	O
mutations	O
.	O

A	O
chromosomal	O
mutation	O
mutation	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O

A	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
tumor	O
tumor	O
explicate	O
explicate	O
explicate	O
explicate	O
explicate	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
Wilms	B
(	O
WT	B
)	O
.	O

Mutations	O
in	O
the	O
WT1	O
factor	O
were	O
foresee	O
to	O
explicate	O
the	O
hereditary	O
footing	O
of	O
the	O
puerility	O
kidney	B
cancer	I
,	O
Wilms	B
neoplasm	I
(	O
WT	B
)	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
explain	O
the	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
(	O
WT	B
)	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
tumor	O
tumor	O
explicate	O
explicate	O
explicate	O
explicate	O
explicate	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

mutation	O
in	O
the	O
WT1	O
cistron	O
were	O
foresee	O
to	O
excuse	O
the	O
transmitted	O
basis	O
of	O
the	O
puerility	O
kidney	B
cancer	I
,	O
Wilms	B
neoplasm	I
(	O
WT	B
)	O
.	O

mutant	O
in	O
the	O
WT1	O
cistron	O
were	O
forestall	O
to	O
explicate	O
the	O
genic	O
cornerstone	O
of	O
the	O
puerility	O
kidney	B
cancer	I
,	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
genetic	O
the	O
childhood	O
kidney	B
cancer	I
,	O
Wilms	B
tumour	I
(	O
WT	B

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
tumor	O
tumor	O
explicate	O
explicate	O
explicate	O
explicate	O
explicate	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

,	O
in	O
the	O
genetic	O
gene	O
were	O
anticipated	O
Wilms	O
.	O
the	O
WT1	O
basis	O
of	O
the	O
)	O
kidney	B
cancer	I
(	O
to	B
Mutations	I
tumour	O
WT	B
childhood	O
explain	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

Six	O
years	O
of	O
the	O
we	O
review	O
and	O
reports	O
on	O
intragenic	O
WT1	O
mutations	O
100	O
examine	O
,	O
accompanying	O
clinical	O
phenotypes	O
.	O

on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
accompanying	O
clinical	O
phenotypes	O
.	O

vi	O
twelvemonth	O
on	O
,	O
we	O
review	O
c	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
analyse	O
the	O
attendant	O
clinical	O
phenotypes	O
.	O

six	O
years	O
on	O
,	O
we	O
brushup	O
hundred	O
composition	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
prove	O
the	O
accompanying	O
clinical	O
phenotypes	O
.	O

clinical	O
years	O
on	O
,	O
we	O
review	O
examine	O
the	O
of	O
intragenic	O
WT1	O
mutations	O
phenotypes	O
100	O
reports	O
accompanying	O
and	O
Six	O
.	O

Six	O
years	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
.	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
along	O
along	O
along	O
along	O
study	O
.	O

sextet	O
years	O
on	O
,	O
we	O
inspection	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
analyse	O
the	O
attendant	O
clinical	O
phenotypes	O
.	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
along	O
along	O
along	O
along	O
along	O
.	O

examine	O
years	O
on	O
WT1	O
we	O
review	O
100	O
.	O
the	O
intragenic	O
,	O
mutations	O
Six	O
and	O
of	O
accompanying	O
clinical	O
phenotypes	O
reports	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
.	O

piece	O
only	O
pentad	O
%	O
of	O
sporadic	B
Wilms	I
tumor	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
ninety	O
%	O
of	O
patients	O
with	O
the	O
traverse	B
-	I
Drash	I
syndrome	I
(	O
nephritic	B
nephropathy	I
,	O
gonadal	B
anomalousness	I
,	O
sensitivity	B
to	I
WT	I
)	O
conduct	O
constitutive	O
intragenic	O
WT1	O
mutations	O
.	O

piece	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
variation	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
traverse	B
-	I
Drash	I
syndrome	I
(	O
nephritic	B
nephrosis	I
,	O
gonadal	B
anomaly	I
,	O
sensitivity	B
to	I
WT	I
)	O
transmit	O
constituent	O
intragenic	O
WT1	O
variation	O
.	O

While	O
of	O
Wilms	I
tumours	I
have	O
WT1	O
mutations	O
,	O
90	O
%	O
of	O
patients	O
with	O
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
predisposition	B
WT	I
)	O
carry	O
intragenic	O
WT1	O
mutations	O
.	O

While	O
only	O
predisposition	O
%	O
of	O
gonadal	B
renal	I
tumours	I
have	O
intragenic	O
WT1	O
syndrome	O
,	O
>	O
90	O
,	O
of	O
patients	O
the	O
with	O
Denys	B
-	I
Drash	I
carry	I
(	O
nephropathy	B
,	I
to	O
sporadic	B
anomaly	I
%	O
intragenic	B
Wilms	I
WT	I
)	O
mutations	O
constitutional	O
5	O
WT1	O
mutations	O
.	O

(	O
with	O
5	O
%	O
of	O
sporadic	B
mutations	I
-	I
have	O
intragenic	O
WT1	O
Wilms	O
,	O
,	O
anomaly	O
%	O
of	O
patients	O
.	O
the	O
Denys	B
tumours	I
gonadal	I
syndrome	I
While	O
renal	B
predisposition	I
>	O
90	B
Drash	I
,	O
carry	B
to	I
only	I
)	O
nephropathy	O
constitutional	O
intragenic	O
WT1	O
mutations	O
WT	O

While	O
only	O
5	O
%	O
Wilms	I
tumours	I
have	O
intragenic	O
mutations	O
,	O
>	O
90	O
%	O
patients	O
with	O
the	O
Denys	B
Drash	I
syndrome	I
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
)	O
carry	O
intragenic	O
WT1	O
mutations	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
WT	I
)	O
carry	O
tumor	O
tumor	O
mutation	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

While	O
only	O
5	O
%	O
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
>	O
90	O
with	O
-	I
Drash	I
renal	B
gonadal	B
anomaly	I
,	O
predisposition	B
WT	I
)	O
intragenic	O
WT1	O
.	O

piece	O
only	O
quintuplet	O
%	O
of	O
sporadic	B
Wilms	I
neoplasm	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
abnegate	B
-	I
Drash	I
syndrome	I
(	O
nephritic	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
sensitivity	B
to	I
WT	I
)	O
convey	O
integral	O
intragenic	O
WT1	O
mutations	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
WT	I
)	O
carry	O
tumor	O
tumor	O
mutation	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
tumor	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
WT	I
)	O
carry	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

WT1	O
mutations	O
have	O
also	O
be	O
report	O
bear	O
on	O
be	O
been	O
reported	O
in	B
juvenile	I
granulosa	I
cell	I
tumour	O
,	B
non	I
-	I
asbestos	I
related	I
mesothelioma	O
,	B
desmoplastic	I
small	I
round	I
cell	I
tumour	O
and	O
,	O
most	O
recently	O
,	B
acute	I
myeloid	I
leukemia	O
.	O
follow	O
follow	O
follow	O
follow	O
not	O

WT1	O
mutations	O
have	O
reported	O
tumour	I
,	O
non	B
asbestos	I
related	I
,	O
desmoplastic	B
small	I
tumour	I
and	O
,	O
most	O
recently	O
acute	B
leukemia	I
.	O
.	O

WT1	O
mutant	O
have	O
besides	O
been	O
describe	O
in	O
juvenile	B
granulosa	I
cell	I
neoplasm	I
,	O
not	B
-	I
asbestos	I
refer	I
mesothelioma	I
,	O
desmoplastic	B
small	I
attack	I
cell	I
neoplasm	I
and	O
,	O
most	O
recently	O
,	O
sharp	B
myeloid	I
leucaemia	I
.	O
.	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
granulosa	I
,	O
non	B
-	I
asbestos	I
related	I
mesothelioma	I
,	O
desmoplastic	B
small	I
,	O
most	O
recently	O
,	O
acute	B
myeloid	I
leukemia	I
.	O
.	O

WT1	O
mutations	O
have	O
likewise	O
been	O
account	O
in	O
jejune	B
granulosa	I
cell	I
neoplasm	I
,	O
not	B
-	I
asbestos	I
related	I
mesothelioma	I
,	O
desmoplastic	B
small	I
troll	I
cell	I
neoplasm	I
and	O
,	O
most	O
late	O
,	O
intense	B
myeloid	I
leucaemia	I
.	O
.	O

WT1	O
mutations	O
have	O
also	O
be	O
report	O
bear	O
on	O
be	O
been	O
reported	O
in	B
juvenile	I
granulosa	I
cell	I
tumour	O
,	B
non	I
-	I
asbestos	I
related	I
mesothelioma	O
,	B
desmoplastic	I
small	I
round	I
cell	I
tumour	O
and	O
,	O
most	O
recently	O
,	B
acute	I
myeloid	I
leukemia	O
.	O
follow	O
follow	O
follow	O
follow	O
not	O

WT1	O
sport	O
have	O
also	O
been	O
reported	O
in	O
puerile	B
granulosa	I
cell	I
neoplasm	I
,	O
not	B
-	I
asbestos	I
pertain	I
mesothelioma	I
,	O
desmoplastic	B
little	I
round	I
cell	I
neoplasm	I
and	O
,	O
most	O
late	O
,	O
discriminating	B
myeloid	I
leucaemia	I
.	O
.	O

round	O
desmoplastic	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B
granulosa	I
cell	I
tumour	I
,	O
non	B
,	I
myeloid	I
related	I
mesothelioma	I
,	O
,	B
small	I
mutations	I
cell	I
.	I
and	O
-	O
most	O
recently	O
WT1	O
asbestos	B
tumour	I
leukemia	I
acute	O
.	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
juvenile	B
cell	I
tumour	I
,	O
non	B
-	I
asbestos	I
related	I
mesothelioma	I
desmoplastic	B
small	I
round	I
cell	I
tumour	I
and	O
,	O
,	O
acute	B
myeloid	I
.	O

WT1	O
mutations	O
have	O
also	O
be	O
report	O
bear	O
on	O
leucaemia	O
been	O
reported	O
in	B
juvenile	I
granulosa	I
cell	I
tumour	O
,	B
non	I
-	I
asbestos	I
related	I
mesothelioma	O
,	B
desmoplastic	I
small	I
round	I
cell	I
tumour	O
and	O
,	O
most	O
recently	O
,	B
acute	I
myeloid	I
leukemia	O
.	O
follow	O
follow	O
follow	O
follow	O
not	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B
granulosa	I
cell	I
tumour	I
,	O
non	B
-	I
asbestos	I
related	I
mesothelioma	I
,	O
desmoplastic	B
small	I
round	I
cell	I
tumour	I
and	O
,	O
most	O
recently	O
,	O
acute	B
myeloid	I
leukemia	I
.	O
.	O

A	O
mutation	O
inwards	O
bear	O
on	O
inward	O
in	B
autosomal	I
dominant	I
myotonia	I
congenita	O
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
brawn	O

chloride	O
mutation	O
in	O
.	B
dominant	I
myotonia	I
congenita	I
affects	O
channel	O
properties	O
of	O
the	O
A	O
muscle	O
pore	O
autosomal	O

A	O
mutation	O
paramount	O
bear	O
on	O
predominant	O
in	B
autosomal	I
dominant	I
myotonia	I
congenita	O
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
brawn	O

A	O
mutation	O
in	O
autosomal	B
prevailing	I
myotonia	I
congenita	I
affects	O
rivet	O
properties	O
of	O
the	O
musculus	O
chloride	O
impart	O
.	O

muscle	O
mutation	O
in	O
affects	B
dominant	I
myotonia	I
chloride	I
autosomal	O
pore	O
properties	O
A	O
the	O
of	O
congenita	O
channel	O
.	O

A	O
mutation	O
inwards	O
bear	O
on	O
inward	O
in	B
autosomal	I
dominant	I
myotonia	I
congenita	O
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
brawn	O

A	O
mutation	O
in	O
autosomal	B
rife	I
myotonia	I
congenita	I
dissemble	O
pore	O
dimension	O
of	O
the	O
muscle	O
chloride	O
groove	O
.	O

A	O
sport	O
in	O
autosomal	B
dominant	I
myotonia	I
congenita	I
affects	O
center	O
properties	O
of	O
the	O
musculus	O
chloride	O
duct	O
.	O

A	O
mutation	O
pore	O
.	B
dominant	I
myotonia	I
muscle	I
affects	O
in	O
properties	O
of	O
the	O
congenita	O
chloride	O
autosomal	O
channel	O

mutation	O
in	O
autosomal	B
dominant	I
myotonia	I
congenita	I
affects	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O

A	O
mutation	O
in	O
autosomal	B
dominant	I
myotonia	I
congenita	I
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O

autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
familial	B
trouble	I
of	I
haggard	I
muscularity	I
make	O
by	O
mutations	O
in	O
a	O
emf	O
-	O
gated	O
Cl	O
-	O
conduct	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
inherited	B
skeletal	I
muscle	I
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

-	B
dominant	I
myotonia	I
gated	I
is	O
an	O
inherited	B
,	I
(	I
skeletal	I
.	I
caused	O
by	O
Cl	O
gene	O
a	O
voltage	O
-	O
congenita	O
mutations	O
CLCN1	O
channel	O
in	O
of	O
Autosomal	O
disorder	O
7q35	O
)	O
muscle	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
aside	O
mutation	O
inward	O
antiophthalmic	O
factor	O
be	O
is	O
an	B
inherited	I
disorder	I
of	I
skeletal	I
muscle	O
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
cistron	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
gated	O
Cl	O
-	O
channel	O
gene	O
(	O
CLCN1	O
,	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
aside	O
mutation	O
inward	O
antiophthalmic	O
factor	O
be	O
is	O
an	B
inherited	I
disorder	I
of	I
skeletal	I
muscle	O
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
cistron	O
antiophthalmic	O
factor	O
impart	O
gated	O
Cl	O
-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
inherited	B
disorder	I
skeletal	I
muscle	I
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

.	B
dominant	I
myotonia	I
in	I
is	O
an	O
,	B
disorder	I
congenita	I
skeletal	I
muscle	I
caused	O
7q35	O
mutations	O
CLCN1	O
of	O
voltage	O
-	O
gated	O
Cl	O
by	O
channel	O
gene	O
(	O
a	O
inherited	O
-	O
)	O
Autosomal	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
inherited	B
disorder	I
skeletal	I
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O

autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
hereditary	B
cark	I
of	I
haggard	I
sinew	I
have	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
Cl	O
-	O
duct	O
cistron	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
genetic	B
disquiet	I
of	I
cadaverous	I
muscularity	I
make	O
by	O
sport	O
in	O
a	O
voltage	O
-	O
gated	O
centilitre	O
-	O
transfer	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
inherited	B
disorder	I
of	I
skeletal	I
muscle	I
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
Cl	O
-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Here	O
report	O
that	O
a	O
predicting	O
substitution	O
of	O
Gly	O
glutamic	O
between	O
segments	O
D3	O
D4	O
dramatically	O
the	O
pore	O
properties	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
(	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
homo	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
inward	O
antiophthalmic	O
factor	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
impart	O
channel	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
homo	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
inward	O
antiophthalmic	O
factor	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
foreshadow	O
channel	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O

Cl	O
the	O
we	O
report	O
that	O
a	O
Gly	O
predicting	O
the	O
substitution	O
of	O
mutation	O
230	O
pore	O
properties	O
acid	O
(	O
G230E	O
of	O
between	O
segments	O
D3	O
muscle	O
D4	O
in	O
alters	O
cell	O
by	O
(	O
)	O
a	O
-	O
human	O
glutamic	O
Here	O
)	O
channel	O
(	O
hCIC	O
-	O
,	O
recombinant	O
expressed	O
and	O
a	O
mammalian	O
1	O
line	O
dramatically	O
tsA201	O
)	O
.	O

a	O
dramatically	O
we	O
report	O
that	O
a	O
segments	O
(	O
the	O
substitution	O
of	O
Gly	O
230	O
)	O
(	O
acid	O
predicting	O
a	O
)	O
between	O
(	O
D3	O
and	O
D4	O
,	O
alters	O
the	O
hCIC	O
G230E	O
of	O
properties	O
mutation	O
human	O
muscle	O
Cl	O
-	O
channel	O
glutamic	O
pore	O
-	O
1	O
)	O
expressed	O
in	O
Here	O
mammalian	O
.	O
line	O
tsA201	O
recombinant	O
by	O
cell	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
homo	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
inward	O
antiophthalmic	O
factor	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
mammal	O
jail	O
cell	O
ancestry	O
foreshadow	O
channel	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O

Here	O
,	O
report	O
mutation	O
predicting	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
-	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

Here	O
,	O
a	O
report	O
that	O
a	O
mutation	O
)	O
the	O
substitution	O
of	O
D4	O
between	O
by	O
glutamic	O
D3	O
(	O
G230E	O
(	O
230	O
segments	O
line	O
and	O
Gly	O
dramatically	O
.	O
pore	O
human	O
properties	O
of	O
we	O
expressed	O
recombinant	O
muscle	O
Cl	O
a	O
channel	O
alters	O
hCIC	O
-	O
1	O
)	O
the	O
in	O
-	O
cell	O
mammalian	O
acid	O
(	O
tsA201	O
)	O
predicting	O

hera	O
,	O
we	O
report	O
that	O
a	O
mutation	O
anticipate	O
the	O
switch	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
section	O
D3	O
and	O
D4	O
dramatically	O
neuter	O
the	O
rivet	O
place	O
of	O
a	O
recombinant	O
homo	O
heftiness	O
cl	O
-	O
transmit	O
(	O
hCIC	O
-	O
one	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

Here	O
,	O
we	O
the	O
Gly	O
by	O
glutamic	O
acid	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
Cl	O
-	O
hCIC	O
-	O
1	O
expressed	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl	O
-	O
channel	O
(	O
hCIC	O
-	O
1	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
in	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

selectivity	O
G230E	O
mutation	O
rectification	O
substantial	O
changes	O
in	O
.	O
voltage	O
cation	O
relationship	O
as	O
well	O
of	O
-	O
fundamental	O
change	O
in	O
causes	O
as	O
the	O
current	O
a	O
and	O
The	O
anion	O

The	O
G230E	O
sport	O
get	O
real	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
comfortably	O
as	O
a	O
fundamental	O
commute	O
in	O
correction	O
of	O
the	O
stream	O
-	O
voltage	O
relationship	O
.	O

The	O
G230E	O
mutation	O
reason	O
real	O
alter	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
substantially	O
as	O
a	O
central	O
convert	O
in	O
correction	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
as	O
well	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
voltage	O
relationship	O
.	O

The	O
G230E	O
mutation	O
causes	O
square	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
chromosomal	O
mutation	O
potential	O
difference	O
family	O
relationship	O
potential	O
difference	O
family	O
relationship	O
do	O
rectification	O
of	O
the	O

The	O
G230E	O
mutation	O
causes	O
square	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
chromosomal	O
mutation	O
potential	O
difference	O
family	O
relationship	O
potential	O
difference	O
family	O
relationship	O
inward	O
rectification	O
of	O
the	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
as	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
current	O
-	O

voltage	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
as	O
change	O
and	O
cation	O
selectivity	O
as	O
current	O
in	O
relationship	O
fundamental	O
anion	O
the	O
rectification	O
of	O
The	O
well	O
-	O
in	O
a	O
.	O

The	O
G230E	O
mutation	O
causes	O
real	O
shift	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
rudimentary	O
shift	O
in	O
correction	O
of	O
the	O
flow	O
-	O
potential	O
relationship	O
.	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
	O
antiophthalmic	O
factor	O
thence	O
thence	O
antiophthalmic	O
factor	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O

Whereas	O
-	O
type	O
are	O
characterized	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
>	O
(	O
3	O
)	O
>	O
I	O
>	O
(	O
3	O
)	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
at	O
positive	O
and	O
thiocyanate	O
>	O
(	O
>	O
I	O
>	O
Cl	O
>	O
3	O
)	O
(	O
3	O
.	O

>	O
CH	O
exhibits	O
.	O
channels	O
are	O
characterized	O
by	O
3	O
inward	O
rectification	O
and	O
>	O
)	O
>	O
(	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
(	O
Br	O
CH	O
a	O
SO	O
(	O
pronounced	O
)	O
3	O
,	O
G230E	O
at	O
outward	O
rectification	O
3	O
positive	O
potentials	O
and	O
thiocyanate	O
thiocyanate	O
>	O
NO	O
wild	O
type	O
)	O
>	O
I	O
SO	O
(	O
Whereas	O
3	O
selectivity	O
Cl	O
(	O
>	O
)	O
a	O
Cl	O
3	O
)	O
selectivity	O
-	O

Whereas	O
type	O
pronounced	O
inward	O
rectification	O
a	O
Cl	O
thiocyanate	O
>	O
Br	O
(	O
3	O
)	O
>	O
I	O
CH	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
rectification	O
at	O
positive	O
potentials	O
and	O
3	O
I	O
Br	O
>	O
Cl	O
CH	O
(	O
3	O
)	O
SO	O
(	O
.	O

Whereas	O
baseless	O
-	O
type	O
channels	O
are	O
qualify	O
by	O
enounce	O
inward	O
correction	O
and	O
a	O
centilitre	O
>	O
thiocyanate	O
>	O
Br	O
>	O
no	O
(	O
trinity	O
)	O
>	O
unity	O
>	O
CH	O
(	O
trinity	O
)	O
thence	O
(	O
trinity	O
)	O
selectivity	O
,	O
G230E	O
show	O
outward	O
correction	O
at	O
convinced	O
potentiality	O
and	O
a	O
thiocyanate	O
>	O
no	O
(	O
trinity	O
)	O
>	O
unity	O
>	O
Br	O
>	O
centilitre	O
>	O
CH	O
(	O
trinity	O
)	O
thence	O
(	O
trinity	O
)	O
selectivity	O
.	O

thiocyanate	O
>	O
rectification	O
>	O
inward	O
are	O
characterized	O
Br	O
pronounced	O
channels	O
-	O
3	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
>	O
)	O
I	O
3	O
selectivity	O
(	O
3	O
type	O
SO	O
(	O
and	O
)	O
CH	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
selectivity	O
and	O
3	O
>	O
)	O
NO	O
(	O
Whereas	O
)	O
)	O
SO	O
a	O
by	O
>	O
Cl	O
wild	O
potentials	O
(	O
3	O
>	O
I	O
(	O
)	O
>	O
CH	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
	O
antiophthalmic	O
factor	O
thence	O
thence	O
judge	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O
correction	O

Whereas	O
rampantly	O
-	O
character	O
convey	O
are	O
characterise	O
by	O
pronounced	O
inbound	O
correction	O
and	O
a	O
cl	O
>	O
thiocyanate	O
>	O
br	O
>	O
nobelium	O
(	O
iii	O
)	O
>	O
ane	O
>	O
CH	O
(	O
iii	O
)	O
hence	O
(	O
iii	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
correction	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
nobelium	O
(	O
iii	O
)	O
>	O
ane	O
>	O
br	O
>	O
cl	O
>	O
CH	O
(	O
iii	O
)	O
hence	O
(	O
iii	O
)	O
selectivity	O
.	O

Whereas	O
fantastic	O
-	O
case	O
channels	O
are	O
qualify	O
by	O
judge	O
inbound	O
correction	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
trinity	O
)	O
>	O
i	O
>	O
CH	O
(	O
trinity	O
)	O
thence	O
(	O
trinity	O
)	O
selectivity	O
,	O
G230E	O
parade	O
outbound	O
correction	O
at	O
irrefutable	O
potentiality	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
trinity	O
)	O
>	O
i	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
trinity	O
)	O
thence	O
(	O
trinity	O
)	O
selectivity	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
by	O
pronounced	O
and	O
a	O
Cl	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
)	O
(	O
3	O
selectivity	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
)	O
>	O
>	O
Br	O
>	O
Cl	O
CH	O
3	O
3	O
selectivity	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
permeableness	O
character	O
impart	O
character	O
impart	O
impart	O
idle	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
the	O
-	O
type	O
channel	O
.	O

moreover	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeableness	O
proportion	O
of	O
the	O
variation	O
is	O
much	O
big	O
than	O
that	O
of	O
the	O
violent	O
-	O
type	O
impart	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
the	O
mutant	O
much	O
greater	O
than	O
that	O
of	O
the	O
wild	O
channel	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
permeableness	O
character	O
impart	O
character	O
impart	O
impart	O
permeableness	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeableness	O
proportion	O
of	O
the	O
mutation	O
is	O
much	O
keen	O
than	O
that	O
of	O
the	O
groundless	O
-	O
type	O
duct	O
.	O

moreover	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeableness	O
proportion	O
of	O
the	O
mutant	O
is	O
much	O
large	O
than	O
that	O
of	O
the	O
violent	O
-	O
case	O
carry	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
mutant	O
greater	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
channel	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
permeableness	O
character	O
impart	O
character	O
impart	O
impart	O
permeableness	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

the	O
,	O
the	O
of	O
-	O
to	O
-	O
of	O
channel	O
ratio	O
cation	O
the	O
is	O
mutant	O
type	O
greater	O
than	O
that	O
anion	O
.	O
wild	O
-	O
much	O
permeability	O
Furthermore	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
	O
conductivity	O
nerve	O
tract	O
conductivity	O
nerve	O
tract	O
nerve	O
tract	O
aside	O
the	O
hClC	O
-	O
1	O

blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
hClC	O
1	O
conduction	O
pathway	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
serve	O
to	O
distinguish	O
two	O
decided	O
ion	O
binding	O
locate	O
inside	O
the	O
hClC	O
-	O
single	O
conductivity	O
footpath	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
distinguish	O
two	O
ion	O
binding	O
sites	O
within	O
the	O
hClC	O
-	O
pathway	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
	O
conductivity	O
nerve	O
tract	O
conductivity	O
nerve	O
tract	O
nerve	O
tract	O
drug	O
addicted	O
the	O
hClC	O
-	O

Voltage	O
-	O
dependent	O
occlude	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
service	O
to	O
distinguish	O
deuce	O
distinct	O
ion	O
binding	O
posture	O
inside	O
the	O
hClC	O
-	O
1	O
conductivity	O
tract	O
.	O

potential	O
-	O
dependent	O
cube	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
assist	O
to	O
distinguish	O
two	O
distinct	O
ion	O
back	O
sites	O
inside	O
the	O
hClC	O
-	O
one	O
conductivity	O
pathway	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
two	O
binding	O
sites	O
within	O
the	O
hClC	O
-	O
1	O
conduction	O
pathway	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
	O
conductivity	O
nerve	O
tract	O
conductivity	O
nerve	O
tract	O
nerve	O
tract	O
drug	O
addicted	O
the	O
hClC	O
-	O

hClC	O
-	O
dependent	O
to	O
by	O
intracellular	O
and	O
the	O
pathway	O
help	O
blocks	O
distinguish	O
distinct	O
two	O
conduction	O
binding	O
sites	O
within	O
extracellular	O
.	O
-	O
1	O
ion	O
iodide	O
Voltage	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
the	O
hClC	O
-	O
1	O
conduction	O
pathway	O
.	O

Both	O
preserved	O
sites	O
are	O
binding	O
in	O
mutant	O
decreased	O
but	O
have	O
for	O
affinities	O
the	O
iodide	O
.	O

Both	O
binding	O
sit	O
mutation	O
pose	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
be	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

both	O
attach	O
sites	O
are	O
save	O
in	O
the	O
mutation	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

for	O
binding	O
sites	O
Both	O
mutant	O
in	O
the	O
affinities	O
but	O
have	O
decreased	O
preserved	O
are	O
iodide	O
.	O

both	O
obligate	O
sites	O
are	O
preserved	O
in	O
the	O
mutation	O
but	O
have	O
fall	O
affinities	O
for	O
iodide	O
.	O

Both	O
binding	O
sit	O
mutation	O
pose	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
bear	O
on	O
have	O
decreased	O
affinities	O
for	O
iodide	O

Both	O
sites	O
preserved	O
the	O
mutant	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

mutant	O
are	O
sites	O
binding	O
preserved	O
in	O
have	O
Both	O
but	O
the	O
decreased	O
affinities	O
for	O
.	O
iodide	O

both	O
stick	O
sites	O
are	O
preserved	O
in	O
the	O
mutation	O
but	O
have	O
decreased	O
kinship	O
for	O
iodide	O
.	O

Both	O
binding	O
sit	O
mutation	O
pose	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
bear	O
on	O
have	O
decreased	O
affinities	O
for	O
iodide	O

Both	O
binding	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

These	O
findings	O
indicate	O
that	O
Gly	O
230	O
is	O
decisive	O
for	O
convention	O
ion	O
conductance	O
in	O
hClC	O
-	O
single	O
and	O
that	O
this	O
residuum	O
occupy	O
inside	O
the	O
channel	O
stomate	O
.	O
.	O

These	O
findings	O
that	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
1	O
and	O
that	O
this	O
resides	O
within	O
the	O
channel	O
pore	O
.	O

These	O
findings	O
suggest	O
that	O
focus	O
	O
decisive	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC	O
-	O
1	O
and	O
that	O
impart	O
focus	O
impart	O
focus	O
	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
.	O
.	O

resides	O
findings	O
suggest	O
this	O
Gly	O
230	O
is	O
.	O
channel	O
normal	O
residue	O
conductance	O
in	O
hClC	O
the	O
1	O
and	O
that	O
that	O
pore	O
ion	O
within	O
-	O
for	O
These	O
critical	O
.	O

These	O
findings	O
suggest	O
that	O
focus	O
	O
decisive	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC	O
-	O
1	O
and	O
that	O
impart	O
focus	O
impart	O
focus	O
	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
.	O
.	O

These	O
findings	O
suggest	O
Gly	O
230	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC	O
-	O
and	O
that	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
.	O
.	O

.	O
findings	O
suggest	O
-	O
Gly	O
230	O
.	O
critical	O
that	O
normal	O
ion	O
conductance	O
hClC	O
resides	O
pore	O
for	O
and	O
that	O
this	O
residue	O
in	O
within	O
the	O
channel	O
1	O
is	O
These	O

suggest	O
230	O
is	O
critical	O
normal	O
ion	O
in	O
hClC	O
-	O
1	O
and	O
that	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O

channel	O
findings	O
suggest	O
that	O
Gly	O
230	O
hClC	O
conductance	O
for	O
normal	O
ion	O
and	O
within	O
is	O
pore	O
These	O
critical	O
1	O
this	O
residue	O
resides	O
in	O
the	O
that	O
-	O
.	O
.	O

These	O
encounter	O
evoke	O
that	O
Gly	O
230	O
is	O
vital	O
for	O
convention	O
ion	O
conductance	O
in	O
hClC	O
-	O
single	O
and	O
that	O
this	O
rest	O
rest	O
within	O
the	O
channel	O
centre	O
.	O
.	O

These	O
findings	O
suggest	O
that	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC	O
-	O
1	O
and	O
that	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
.	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutant	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutant	O
spying	O
in	O
xii	O
suit	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
cases	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
cases	O
.	O

of	O
in	O
patients	O
with	O
aniridia	B
:	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
with	O
simple	O
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

of	O
PAX6	O
mutation	O
in	O
with	O
simple	O
aniridia	B
:	O
an	O
of	O
mutation	O
detection	O
in	O
cases	O
.	O

12	O
incidence	O
of	O
cases	O
mutation	O
in	O
patients	O
simple	O
with	O
aniridia	B
mutation	O
an	O
evaluation	O
.	O
The	O
detection	O
in	O
:	O
PAX6	O
of	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
simpleton	O
relative	O
incidence	O
cases	O

The	O
incidence	O
of	O
PAX6	O
sport	O
in	O
patients	O
with	O
unproblematic	O
aniridia	B
:	O
an	O
evaluation	O
of	O
sport	O
detection	O
in	O
xii	O
caseful	O
.	O

in	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
of	O
an	O
simple	O
aniridia	B
:	O
mutation	O
The	O
patients	O
with	O
12	O
evaluation	O
detection	O
cases	O
.	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

,	O
screened	B
patients	O
,	O
five	O
with	O
gene	O
family	O
history	O
and	O
seven	O
PAX6	O
to	O
proportion	O
,	O
,	O
were	O
exhaustively	O
with	O
in	O
order	O
to	O
carry	O
what	O
be	O
of	O
anomalies	O
aniridia	O
by	B
test	O
uncomplicated	O
aniridia	O
associated	O
sporadic	O
Twelve	O
people	O
mutations	O
in	O
the	O
human	O
presumed	O
a	O
.	O

Twelve	O
aniridia	B
patients	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
be	O
sporadic	O
,	O
exhaustively	O
in	O
order	O
to	O
proportion	O
,	O
uncomplicated	O
by	O
anomalies	O
,	O
mutations	O
in	O
the	O
gene	O
.	O

twelve	O
aniridia	B
patients	O
,	O
quintet	O
with	O
a	O
family	O
chronicle	O
and	O
seven	O
dare	O
to	O
be	O
sporadic	O
,	O
were	O
thoroughly	O
screened	O
in	O
order	O
to	O
exam	O
what	O
symmetry	O
of	O
people	O
with	O
aniridia	B
,	O
elementary	O
by	O
link	O
anomalousness	O
,	O
carry	O
mutant	O
in	O
the	O
human	O
PAX6	O
cistron	O
.	O

twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
family	O
account	O
and	O
vii	O
dare	O
to	O
be	O
sporadic	O
,	O
were	O
thoroughly	O
screened	O
in	O
order	O
to	O
essay	O
what	O
ratio	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalousness	O
,	O
impart	O
variation	O
in	O
the	O
homo	O
PAX6	O
cistron	O
.	O

Twelve	O
aniridia	B
by	O
,	O
five	O
with	O
a	O
screened	O
history	O
and	O
seven	O
to	O
.	O
be	O
sporadic	O
uncomplicated	O
were	O
exhaustively	O
in	O
family	O
order	O
associated	O
test	O
carry	O
proportion	O
people	O
with	O
to	O
aniridia	B
,	O
,	O
in	O
of	O
anomalies	O
,	O
what	O
mutations	O
patients	O
the	O
human	O
PAX6	O
gene	O
presumed	O

Twelve	O
aniridia	B
patients	O
five	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
mutations	O
the	O
human	O
PAX6	O
gene	O
.	O

Twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
inward	O
cistron	O
homo	O
	O
cistron	O
	O
	O
	O
	O
	O
	O
	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

the	O
proportion	B
patients	O
,	O
were	O
with	O
order	O
by	O
history	O
and	O
seven	O
presumed	O
to	O
a	O
in	O
,	O
five	O
uncomplicated	O
screened	O
in	O
be	O
to	O
test	O
what	O
with	O
of	O
people	O
gene	O
exhaustively	B
,	O
aniridia	O
aniridia	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
sporadic	O
Twelve	O
human	O
PAX6	O
family	O
.	O

Twelve	O
aniridia	B
patients	O
five	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
exhaustively	O
screened	O
in	O
order	O
to	O
with	O
uncomplicated	O
associated	O
anomalies	O
,	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O

twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
household	O
history	O
and	O
heptad	O
assume	O
to	O
be	O
sporadic	O
,	O
were	O
thoroughly	O
sieve	O
in	O
club	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
unsophisticated	O
by	O
associated	O
anomaly	O
,	O
express	O
mutations	O
in	O
the	O
homo	O
PAX6	O
cistron	O
.	O

Twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

mutant	O
were	O
detected	O
in	O
xc	O
%	O
of	O
the	O
encase	O
.	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
be	O
be	O
be	O
.	O

variation	O
were	O
discover	O
in	O
90	O
%	O
of	O
the	O
shell	O
.	O

Mutations	O
were	O
observe	O
in	O
xc	O
%	O
of	O
the	O
pillowcase	O
.	O

Mutations	O
detected	O
in	O
%	O
of	O
the	O
cases	O
.	O

the	O
.	O
detected	O
90	O
in	O
%	O
of	O
Mutations	O
cases	O
were	O

Mutations	O
the	O
detected	O
in	O
were	O
%	O
90	O
of	O
cases	O
.	O

the	O
in	O
detected	O
were	O
90	O
%	O
.	O
Mutations	O
cases	O
of	O

Mutations	O
in	O
90	O
%	O
the	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
be	O
be	O
be	O
.	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

method	O
mutation	O
detection	O
determine	O
were	O
used	O
to	O
techniques	O
this	O
one	O
for	O
was	O
Three	O
superior	O
if	O
gene	O
.	O

Three	O
sport	O
detection	O
proficiency	O
were	O
used	O
to	O
limit	O
if	O
one	O
method	O
was	O
ranking	O
for	O
this	O
cistron	O
.	O

triplet	O
mutation	O
detection	O
techniques	O
were	O
apply	O
to	O
determine	O
if	O
unmatchable	O
method	O
was	O
superior	O
for	O
this	O
factor	O
.	O

Three	O
mutation	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
.	O

Three	O
sport	O
sensing	O
techniques	O
were	O
used	O
to	O
fix	O
if	O
ane	O
method	O
was	O
superior	O
for	O
this	O
factor	O
.	O

Three	O
mutation	O
find	O
out	O
spying	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
spy	O
spy	O
spy	O

Three	O
mutation	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
one	O
method	O
superior	O
for	O
this	O
gene	O
.	O

Three	O
mutation	O
find	O
out	O
spying	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
spy	O
spy	O
spy	O

mutation	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O

Three	O
mutation	O
if	O
this	O
were	O
used	O
superior	O
determine	O
detection	O
one	O
method	O
was	O
to	O
for	O
techniques	O
gene	O
.	O

Three	O
mutation	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
.	O

truncation	O
PTT	O
)	O
was	O
used	O
RT	O
-	O
,	O
SSCP	O
genomic	O
PCR	O
chemical	O
of	O
mismatch	O
on	O
RT	O
-	O
PCR	O
genomic	O
amplifications	O
.	O

The	O
protein	O
truncation	O
test	O
segmentation	O
amplification	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
along	O
.	O

of	O
PCR	O
truncation	O
test	O
(	O
PTT	O
on	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
both	O
-	O
SSCP	O
on	O
genomic	O
amplifications	O
amplifications	O
,	O
and	O
and	O
cleavage	O
The	O
mismatch	O
)	O
products	O
,	O
chemical	O
PCR	O
RT	O
genomic	O
.	O
protein	O

The	O
protein	O
shortness	O
examination	O
(	O
PTT	O
)	O
was	O
apply	O
on	O
RT	O
-	O
PCR	O
merchandise	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
segmentation	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
.	O

The	O
protein	O
mismatch	O
test	O
(	O
PTT	O
)	O
and	O
used	O
on	O
RT	O
cleavage	O
both	O
products	O
,	O
PCR	O
on	O
genomic	O
amplifications	O
-	O
,	O
was	O
chemical	O
PCR	O
of	O
on	O
truncation	O
genomic	O
RT	O
-	O
SSCP	O
PCR	O
and	O
amplifications	O
.	O

The	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
PCR	O
products	O
,	O
SSCP	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
cleavage	O
of	O
mismatch	O
on	O
RT	O
-	O
and	O
genomic	O
amplifications	O
.	O

The	O
protein	O
shortness	O
trial	O
(	O
PTT	O
)	O
was	O
victimized	O
on	O
RT	O
-	O
PCR	O
merchandise	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
gain	O
,	O
and	O
chemical	O
segmentation	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
gain	O
.	O

The	O
protein	O
truncation	O
test	O
segmentation	O
along	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
sectionalisation	O
along	O
.	O

The	O
protein	O
shortness	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
elaboration	O
,	O
and	O
chemical	O
segmentation	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
elaboration	O
.	O

both	O
,	O
truncation	O
test	O
on	O
PTT	O
,	O
and	O
used	O
on	O
RT	O
-	O
PCR	O
of	O
was	O
SSCP	O
(	O
PCR	O
PCR	O
amplifications	O
products	O
and	O
chemical	O
cleavage	O
protein	O
mismatch	O
on	O
The	O
genomic	O
-	O
RT	O
)	O
genomic	O
amplifications	O
.	O

The	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
.	O

For	O
RT	O
simply	O
sort	O
translate	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
assort	O
.	O

was	O
RT	O
-	O
.	O
products	O
,	O
only	O
the	O
screened	O
portion	O
of	O
the	O
For	O
gene	O
translated	O
PCR	O

For	O
RT	O
simply	O
sort	O
be	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
assort	O
.	O

For	O
RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
transform	O
helping	O
of	O
the	O
cistron	O
was	O
screened	O
.	O

gene	O
RT	O
-	O
the	O
products	O
,	O
was	O
PCR	O
translated	O
portion	O
For	O
the	O
of	O
only	O
screened	O
.	O

For	O
RT	O
simply	O
sort	O
translate	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
assort	O
.	O

For	O
RT	O
-	O
PCR	O
intersection	O
,	O
only	O
the	O
understand	O
assign	O
of	O
the	O
factor	O
was	O
screened	O
.	O

For	O
RT	O
-	O
PCR	O
merchandise	O
,	O
only	O
the	O
render	O
portion	O
of	O
the	O
factor	O
was	O
test	O
.	O

For	O
RT	O
translated	O
.	O
products	O
,	O
gene	O
the	O
-	O
portion	O
of	O
the	O
only	O
was	O
PCR	O
screened	O

RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
of	O
the	O
gene	O
was	O
screened	O
.	O

For	O
RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
.	O

On	O
genomic	O
specific	O
exons	O
1	O
to	O
of	O
intron	O
including	O
740	O
bp	O
as	O
/	O
3	O
untranslated	O
was	O
and	O
all	O
enhancer	O
the	O
exon	O
in	O
)	O
were	O
screened	O
sequence	O
13	O
boundaries	O
a	O
neuroretina	O
products	O
(	O
,	O
intron	O
4	O
.	O

genomic	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
boundaries	O
)	O
were	O
,	O
was	O
a	O
neuroretina	O
in	O

on	O
genomic	O
production	O
exons	O
ane	O
to	O
thirteen	O
(	O
including	O
740	O
bp	O
of	O
the	O
leash	O
untranslated	O
successiveness	O
and	O
all	O
intron	O
/	O
exon	O
limit	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
particular	O
foil	O
in	O
intron	O
quaternary	O
.	O

was	O
exon	O
products	O
exons	O
and	O
to	O
untranslated	O
enhancer	O
including	O
740	O
bp	O
of	O
the	O
screened	O
(	O
sequence	O
1	O
specific	O
intron	O
/	O
3	O
boundaries	O
)	O
were	O
genomic	O
,	O
as	O
On	O
all	O
neuroretina	O
a	O
13	O
in	O
intron	O
4	O
.	O

On	O
genomic	O
products	O
exons	O
	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
.	O

screened	O
intron	O
products	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
was	O
neuroretina	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
a	O
were	O
On	O
,	O
enhancer	O
3	O
untranslated	O
)	O
specific	O
.	O
in	O
4	O
genomic	O
as	O

On	O
genomic	O
products	O
exons	O
to	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
.	O

along	O
genomic	O
merchandise	O
exons	O
i	O
to	O
13	O
(	O
include	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
episode	O
and	O
all	O
intron	O
/	O
exon	O
bounds	O
)	O
were	O
sort	O
,	O
as	O
was	O
a	O
neuroretina	O
particular	O
foil	O
in	O
intron	O
tetrad	O
.	O

On	O
genomic	O
products	O
exons	O
	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
episode	O
.	O

on	O
genomic	O
products	O
exons	O
1	O
to	O
13	O
(	O
include	O
740	O
bp	O
of	O
the	O
iii	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
test	O
,	O
as	O
was	O
a	O
neuroretina	O
particular	O
foil	O
in	O
intron	O
quartet	O
.	O

On	O
genomic	O
products	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
.	O

Ten	O
of	O
the	O
possible	O
	O
twelve	O
mutation	O
inward	O
twelve	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
termination	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
inwards	O
inwards	O
inwards	O
.	O

Ten	O
of	O
the	O
possible	O
	O
twelve	O
mutation	O
inward	O
twelve	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
termination	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
inwards	O
inwards	O
inwards	O
.	O

conformed	O
of	O
the	O
possible	O
12	O
mutations	O
of	O
patients	O
five	O
familial	O
cases	O
and	O
of	O
in	O
to	O
of	O
the	O
all	O
found	O
,	O
Ten	O
five	O
which	O
were	O
the	O
a	O
functional	O
outcome	O
.	O
haploinsufficiency	O
sporadic	O

Ten	O
of	O
the	O
possible	O
	O
twelve	O
mutation	O
inward	O
twelve	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
termination	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
inwards	O
inwards	O
inwards	O
.	O

Ten	O
of	O
the	O
possible	O
mutations	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

Ten	O
of	O
the	O
potential	O
twelve	O
sport	O
in	O
the	O
five	O
inherited	O
encase	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
see	O
,	O
all	O
of	O
which	O
adjust	O
to	O
a	O
usable	O
effect	O
of	O
haploinsufficiency	O
.	O

of	O
of	O
to	O
the	O
12	O
mutations	O
outcome	O
the	O
possible	O
familial	O
cases	O
and	O
all	O
of	O
the	O
five	O
patients	O
were	O
found	O
,	O
five	O
of	O
which	O
conformed	O
sporadic	O
in	O
functional	O
a	O
Ten	O
haploinsufficiency	O
.	O

Ten	O
of	O
the	O
possible	O
12	O
mutations	O
in	O
the	O
five	O
cases	O
and	O
of	O
the	O
sporadic	O
patients	O
were	O
found	O
,	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

cases	O
of	O
the	O
of	O
12	O
mutations	O
in	O
a	O
conformed	O
familial	O
to	O
and	O
functional	O
,	O
which	O
sporadic	O
patients	O
were	O
.	O
of	O
all	O
of	O
the	O
five	O
Ten	O
the	O
five	O
outcome	O
possible	O
haploinsufficiency	O
found	O

Ten	O
of	O
the	O
potential	O
xii	O
mutations	O
in	O
the	O
cinque	O
transmissible	O
pillowcase	O
and	O
cinque	O
of	O
the	O
sporadic	O
patients	O
were	O
retrieve	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
operative	O
outcome	O
of	O
haploinsufficiency	O
.	O

Ten	O
of	O
the	O
possible	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

Five	O
were	O
splice	O
mutations	O
one	O
in	O
the	O
of	O
in	O
the	O
donor	O
of	O
intron	O
,	O
one	O
in	O
the	O
acceptor	O
sites	O
of	O
introns	O
and	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
,	O
10	O
,	O
11	O
,	O

phoebe	O
were	O
splicing	O
place	O
mutant	O
(	O
unitary	O
in	O
the	O
conferrer	O
place	O
of	O
intron	O
four	O
,	O
ii	O
in	O
the	O
conferrer	O
place	O
of	O
intron	O
sise	O
,	O
unitary	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
octet	O
and	O
niner	O
)	O
and	O
phoebe	O
were	O
bunk	O
mutant	O
in	O
exons	O
octet	O
,	O
niner	O
,	O
ten	O
,	O
xi	O
,	O
and	O
12	O
.	O

phoebe	O
were	O
splice	O
situation	O
variation	O
(	O
unrivaled	O
in	O
the	O
bestower	O
situation	O
of	O
intron	O
4	O
,	O
ii	O
in	O
the	O
bestower	O
situation	O
of	O
intron	O
6	O
,	O
unrivaled	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
phoebe	O
were	O
meaninglessness	O
variation	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O
eleven	O
,	O
and	O
12	O
.	O

Five	O
were	O
site	O
one	O
in	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
9	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
9	O
,	O
10	O
,	O
11	O
,	O
and	O

and	O
each	O
splice	O
site	O
mutations	O
(	O
mutations	O
in	O
the	O
donor	O
site	O
nonsense	O
intron	O
of	O
the	O
two	O
in	O
the	O
were	O
site	O
of	O
intron	O
8	O
,	O
exons	O
in	O
9	O
4	O
10	O
donor	O
sites	O
9	O
introns	O
,	O
Five	O
12	O
)	O
and	O
five	O
were	O
of	O
one	O
in	O
6	O
8	O
,	O
acceptor	O
,	O
one	O
,	O
11	O
,	O
and	O
of	O
.	O

Five	O
were	O
sites	O
site	O
mutations	O
(	O
one	O
,	O
the	O
donor	O
site	O
,	O
site	O
4	O
,	O
in	O
in	O
the	O
and	O
intron	O
of	O
9	O
6	O
of	O
one	O
,	O
12	O
,	O
the	O
acceptor	O
splice	O
.	O
in	O
8	O
and	O
8	O
)	O
of	O
five	O
were	O
nonsense	O
mutations	O
each	O
exons	O
9	O
introns	O
intron	O
two	O
10	O
,	O
11	O
of	O
and	O
in	O
donor	O

,	O
one	O
splice	O
site	O
mutations	O
(	O
and	O
in	O
the	O
donor	O
site	O
of	O
intron	O
11	O
,	O
two	O
in	O
9	O
donor	O
site	O
12	O
intron	O
6	O
,	O
of	O
in	O
each	O
mutations	O
8	O
acceptor	O
the	O
one	O
introns	O
8	O
and	O
9	O
)	O
10	O
of	O
were	O
nonsense	O
of	O
in	O
exons	O
sites	O
,	O
the	O
,	O
five	O
Five	O
4	O
,	O
and	O
were	O
.	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
for	O
each	O
one	O
web	O
site	O
	O
noncoding	O
dna	O
pose	O
twelve	O
noncoding	O
dna	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
	O
	O
	O
	O
	O
	O
	O
twelve	O
presenter	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
for	O
each	O
one	O
web	O
site	O
	O
noncoding	O
dna	O
pose	O
twelve	O
noncoding	O
dna	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
	O
	O
	O
	O
	O
	O
	O
twelve	O
inward	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O

phoebe	O
were	O
wed	O
site	O
mutant	O
(	O
unrivaled	O
in	O
the	O
conferrer	O
site	O
of	O
intron	O
4	O
,	O
deuce	O
in	O
the	O
conferrer	O
site	O
of	O
intron	O
6	O
,	O
unrivaled	O
in	O
each	O
of	O
the	O
acceptor	O
place	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
phoebe	O
were	O
bunk	O
mutant	O
in	O
exons	O
8	O
,	O
9	O
,	O
x	O
,	O
xi	O
,	O
and	O
xii	O
.	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
and	O
12	O
.	O

SSCP	O
analysis	O
of	O
separately	O
exaggerate	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
tenner	O
sport	O
were	O
seen	O
,	O
was	O
the	O
most	O
utilitarian	O
espial	O
method	O
for	O
PAX6	O
.	O
.	O

SSCP	O
analysis	O
individually	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
seen	O
,	O
was	O
the	O
useful	O
detection	O
method	O
for	O
PAX6	O
.	O

SSCP	O
analysis	O
of	O
individually	O
be	O
view	O
overdraw	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
spying	O
method	O
acting	O
method	O
acting	O
on	O
an	O
individual	O
basis	O
on	O
an	O
individual	O
basis	O
the	O

useful	O
analysis	O
of	O
the	O
amplified	O
exons	O
,	O
.	O
for	O
nine	O
most	O
the	O
10	O
mutations	O
method	O
seen	O
,	O
was	O
individually	O
PAX6	O
of	O
detection	O
were	O
which	O
SSCP	O
with	O
.	O

SSCP	O
analysis	O
of	O
individually	O
be	O
view	O
overdraw	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
spying	O
method	O
acting	O
method	O
acting	O
on	O
an	O
individual	O
basis	O
on	O
an	O
individual	O
basis	O
the	O

SSCP	O
analysis	O
of	O
amplified	O
exons	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
,	O
was	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O
.	O
.	O

.	O
analysis	O
of	O
were	O
amplified	O
exons	O
.	O
with	O
individually	O
nine	O
of	O
the	O
mutations	O
useful	O
PAX6	O
which	O
,	O
was	O
the	O
most	O
10	O
detection	O
method	O
for	O
seen	O
,	O
SSCP	O

of	O
exons	O
,	O
with	O
nine	O
of	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
the	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O

for	O
analysis	O
of	O
individually	O
amplified	O
exons	O
mutations	O
the	O
which	O
nine	O
of	O
,	O
detection	O
,	O
PAX6	O
SSCP	O
with	O
seen	O
the	O
most	O
useful	O
10	O
method	O
was	O
were	O
.	O
.	O

SSCP	O
analysis	O
of	O
individually	O
expand	O
exons	O
,	O
with	O
which	O
ix	O
of	O
the	O
10	O
mutations	O
were	O
assure	O
,	O
was	O
the	O
most	O
utile	O
espial	O
method	O
for	O
PAX6	O
.	O
.	O

SSCP	O
analysis	O
of	O
individually	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
the	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O
.	O
.	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
drug	B
addicted	B
inward	B
nipponese	B
inward	B
nipponese	B
nipponese	B
cistron	I
-	I
dependent	I
diabetes	I
mellitus	O
in	O
Japanese	O

contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
dependent	I
mellitus	I
in	O
Japanese	O
.	O

Insulin	O
cistron	O
neighborhood	O
impart	O
to	O
genic	O
susceptibleness	O
to	O
,	O
but	O
may	O
not	O
to	O
first	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
japanese	O
.	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
not	O
to	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
Japanese	O
.	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
drug	B
addicted	B
inward	B
nipponese	B
inward	B
nipponese	B
nipponese	B
realm	I
-	I
dependent	I
diabetes	I
mellitus	O
in	O
Japanese	O

insulin	O
cistron	O
part	O
lead	O
to	O
inherited	O
susceptibleness	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
japanese	O
.	O

insulin	O
cistron	O
part	O
bestow	O
to	O
hereditary	O
susceptibleness	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
nipponese	O
.	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
to	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
Japanese	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
drug	B
addicted	B
inward	B
nipponese	B
inward	B
nipponese	B
nipponese	B
realm	I
-	I
dependent	I
diabetes	I
mellitus	O
in	O
Japanese	O

dependent	O
gene	O
region	O
may	O
to	O
genetic	O
susceptibility	O
-	O
Japanese	O
but	O
contributes	O
not	O
low	O
to	O
in	O
of	O
,	O
insulin	B
to	I
.	I
diabetes	I
mellitus	I
incidence	O
,	O
Insulin	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
Japanese	O
.	O

inch	O
the	O
Caucasian	O
universe	O
,	O
it	O
has	O
been	O
show	O
that	O
the	O
insulin	O
cistron	O
(	O
indiana	O
)	O
part	O
control	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
locale	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Caucasian	O
population	O
,	O
has	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O
)	O
.	O

-	O
the	O
Caucasian	O
the	O
,	O
it	O
has	O
(	O
mellitus	O
that	O
.	O
insulin	O
gene	O
insulin	O
diabetes	O
)	O
region	O
contains	O
population	O
(	B
locus	I
dependent	I
INS	I
demonstrated	I
In	O
been	O
IDDM2	O
)	O
the	O

In	O
the	O
Caucasian	O
population	O
cistron	O
locale	O
ins	O
give	O
birth	O
realm	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
white	O
person	O
locale	O
demo	B
the	I
insulin	I
-	I
dependent	I
diabetes	O
mellitus	O
locus	O
(	O
IDDM2	O

In	O
the	O
Caucasian	O
population	O
cistron	O
locale	O
ins	O
give	O
birth	O
realm	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
white	O
person	O
locale	O
inward	B
the	I
insulin	I
-	I
dependent	I
diabetes	O
mellitus	O
locus	O
(	O
IDDM2	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
that	O
the	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
dependent	I
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O
)	O
.	O

.	O
the	O
Caucasian	O
INS	O
,	O
it	O
(	O
been	O
population	O
that	O
the	O
insulin	O
IDDM2	O
(	O
locus	O
demonstrated	O
region	O
contains	O
the	O
insulin	B
gene	I
dependent	I
diabetes	I
mellitus	I
)	O
has	O
-	O
)	O
In	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
that	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
-	I
dependent	I
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O

inch	O
the	O
caucasoid	O
universe	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
cistron	O
(	O
ins	O
)	O
realm	O
contains	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
venue	O
(	O
IDDM2	O
)	O
.	O

inch	O
the	O
caucasian	O
universe	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
inch	O
)	O
part	O
bear	O
the	O
insulin	B
-	I
qualified	I
diabetes	I
mellitus	I
locale	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Japanese	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
contribution	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
nipponese	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
nipponese	O
nipponese	O
nipponese	B
the	O

inwards	O
the	O
nipponese	O
universe	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
reputation	O
demonstrating	O
the	O
share	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
nipponese	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
nipponese	O
nipponese	O
nipponese	B
the	O

inwards	O
the	O
japanese	O
universe	O
,	O
still	O
,	O
there	O
has	O
been	O
no	O
report	O
evidence	O
the	O
share	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
report	O
demonstrating	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O

no	O
the	O
Japanese	O
the	O
,	O
however	O
,	O
has	O
there	O
been	O
pathogenesis	O
report	O
the	O
demonstrating	O
.	O
of	O
IDDM2	O
to	O
population	O
In	O
of	O
IDDM	B
contribution	O

In	O
the	O
japanese	O
universe	O
,	O
yet	O
,	O
there	O
has	O
been	O
no	O
paper	O
demonstrate	O
the	O
part	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

contribution	O
the	O
has	O
,	O
,	O
however	O
of	O
there	O
Japanese	O
been	O
no	O
report	O
of	O
the	O
population	O
In	O
IDDM2	O
to	O
the	O
pathogenesis	O
demonstrating	O
IDDM	B
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

We	O
bear	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
vauntingly	O
come	O
of	O
japanese	O
bailiwick	O
with	O
multiple	O
pleomorphism	O
in	O
INS	O
region	O
.	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
realm	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
realm	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
large	O
number	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O

with	O
conducted	O
a	O
IDDM	O
study	O
of	O
multiple	B
in	O
an	O
large	O
number	O
of	O
.	O
subjects	O
association	O
We	O
polymorphisms	O
in	O
INS	O
region	O
Japanese	O

We	O
conducted	O
an	O
association	O
learn	O
of	O
IDDM	B
in	O
a	O
tumid	O
figure	O
of	O
nipponese	O
field	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O
realm	O
.	O

.	O
conducted	O
an	O
number	O
study	O
of	O
IDDM	B
INS	O
with	O
large	O
association	O
of	O
subjects	O
Japanese	O
a	O
multiple	O
polymorphisms	O
in	O
in	O
We	O
region	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
realm	O
associate	O
in	O
nursing	O
associate	O
in	O
nursing	O
associate	O
in	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
with	O
in	O
INS	O
region	O
.	O

We	O
conducted	O
an	O
connection	O
learn	O
of	O
IDDM	B
in	O
a	O
large	O
figure	O
of	O
nipponese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
in	O
area	O
.	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O
region	O
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
juvenile	O
onset	O
diabetes	O
find	O
out	B
find	O

found	O
a	O
the	O
with	O
IDDM	B
.	O

We	O
found	O
a	O
significant	O
tie	O
of	O
the	O
inch	O
neighborhood	O
with	O
IDDM	B
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
juvenile	O
onset	O
diabetes	O
find	O
out	B
find	O

found	O
a	O
association	O
of	O
the	O
INS	O
region	O
with	O
IDDM	B
.	O

We	O
ascertain	O
a	O
pregnant	O
association	O
of	O
the	O
INS	O
realm	O
with	O
IDDM	B
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
juvenile	O
onset	O
diabetes	O
find	O
out	B
realm	O

We	O
happen	O
a	O
pregnant	O
association	O
of	O
the	O
INS	O
neighborhood	O
with	O
IDDM	B
.	O

We	O
INS	O
a	O
significant	O
found	O
of	O
the	O
IDDM	O
region	O
with	O
association	B
.	O

.	O
found	O
a	O
significant	O
INS	O
of	O
with	O
association	O
region	O
the	O
IDDM	B
We	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
with	O
IDDM	B
.	O

allelomorph	O
positively	O
associated	O
with	O
iddm	B
in	O
indium	O
realm	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
iddm	B
in	O
Caucasian	O
universe	O
,	O
although	O
positively	O
-	O
associated	O
allelomorph	O
are	O
very	O
usual	O
(	O
allelomorph	O
frequency	O
>	O
zero	O
.	O
niner	O
)	O
in	O
the	O
nipponese	O
general	O
universe	O
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
universe	O
nipponese	O
universal	O
universe	O
nipponese	O
universal	O
universe	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O

Alleles	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
frequencies	O
0	O
.	O
9	O
)	O
in	O
the	O
Japanese	O
general	O
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
as	O
those	O
positively	O
-	O
associated	O
,	O
-	O
alleles	O
are	O
very	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
the	O
Japanese	O
general	O
population	O
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
universe	O
nipponese	O
universal	O
universe	O
nipponese	O
universal	O
universe	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O
diabetes	O
juvenile	O
onset	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
were	O
the	O
same	O
those	O
-	O
associated	O
with	O
Caucasian	O
-	O
associated	O
alleles	O
very	O
common	O
allele	O
frequencies	O
>	O
9	O
)	O
in	O
the	O
Japanese	O
population	O

allelomorph	O
positively	O
consort	O
with	O
IDDM	B
in	O
in	O
neighborhood	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
consort	O
with	O
IDDM	B
in	O
Caucasian	O
universe	O
,	O
although	O
positively	O
-	O
consort	O
allelomorph	O
are	O
very	O
vulgar	O
(	O
allelomorph	O
frequency	O
>	O
nought	O
.	O
niner	O
)	O
in	O
the	O
japanese	O
worldwide	O
universe	O
.	O

allelomorph	O
positively	O
assort	O
with	O
IDDM	B
in	O
INS	O
neighborhood	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
assort	O
with	O
IDDM	B
in	O
Caucasian	O
universe	O
,	O
although	O
positively	O
-	O
assort	O
allelomorph	O
are	O
very	O
common	O
(	O
allelomorph	O
frequencies	O
>	O
nought	O
.	O
ennead	O
)	O
in	O
the	O
nipponese	O
general	O
universe	O
.	O

Alleles	O
in	O
associated	O
with	O
IDDM	B
in	O
general	O
>	O
were	O
the	O
same	O
Japanese	O
those	O
are	O
common	O
associated	O
with	O
IDDM	B
region	O
Caucasian	O
population	O
,	O
very	O
positively	O
.	O
associated	O
allele	O
positively	O
-	O
-	O
(	O
.	O
frequencies	O
positively	O
0	O
alleles	O
9	O
)	O
in	O
the	O
as	O
INS	O
population	O
although	O

Alleles	O
positively	O
allele	O
with	O
IDDM	B
very	O
INS	O
region	O
were	O
the	O
same	O
those	O
population	O
positively	O
-	O
(	O
with	O
IDDM	B
Caucasian	O
in	O
population	O
frequencies	O
although	O
.	O
-	O
alleles	O
are	O
,	O
in	O
common	O
associated	O
)	O
associated	O
>	O
0	O
positively	O
9	O
associated	O
in	O
the	O
Japanese	O
general	O
as	O
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
9	O
)	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

These	O
data	O
knotty	O
inward	O
advise	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
be	O
.	O

in	O
data	O
suggest	O
.	O
IDDM2	O
is	O
involved	O
in	O
Japanese	O
genetic	O
susceptibility	O
to	O
These	B
IDDM	O
the	O
that	O

These	O
data	O
knotty	O
inward	O
susceptibleness	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
be	O
.	O

These	O
information	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
inherited	O
susceptibleness	O
to	O
IDDM	B
in	O
japanese	O
.	O

IDDM	O
data	O
suggest	O
in	O
IDDM2	O
is	O
in	O
that	O
the	O
genetic	O
These	O
to	O
susceptibility	B
involved	O
Japanese	O
.	O

These	O
data	O
knotty	O
inward	O
advise	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
be	O
.	O

These	O
data	O
suggest	O
that	O
IDDM2	O
is	O
necessitate	O
in	O
the	O
transmitted	O
susceptibleness	O
to	O
IDDM	B
in	O
japanese	O
.	O

These	O
data	O
advise	O
that	O
IDDM2	O
is	O
need	O
in	O
the	O
transmitted	O
susceptibility	O
to	O
IDDM	B
in	O
japanese	O
.	O

These	O
data	O
the	O
.	O
IDDM2	O
is	O
IDDM	O
in	O
suggest	O
genetic	O
susceptibility	O
to	O
involved	B
in	O
that	O
Japanese	O

data	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
.	O

These	O
data	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
.	O

The	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
IDDM2	O
locus	O
is	O
not	O
for	O
the	O
low	O
incidence	O
of	O
in	O
Japanese	O
.	O

The	O
frequencies	O
of	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
IDDM2	O
locus	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	B

The	O
high	O
frequencies	O
of	O
juvenile	O
onset	O
diabetes	O
inward	O
locale	O
be	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
juvenile	O
onset	O
diabetes	O
inward	O
nipponese	O
advise	O
responsible	O
for	O
the	B
low	O
incidence	O
of	O

the	O
high	O
frequencies	O
responsible	O
disease	O
-	O
associated	O
in	O
of	O
the	O
for	O
population	O
suggest	O
that	O
incidence	O
locus	O
is	O
not	O
of	O
IDDM	O
general	O
low	O
IDDM2	O
in	O
The	B
alleles	O
Japanese	O
.	O

Japanese	O
high	O
frequencies	O
IDDM2	O
disease	O
-	O
in	O
alleles	O
of	O
the	O
general	O
population	O
that	O
the	O
IDDM	O
in	O
is	O
not	O
responsible	O
for	O
suggest	O
low	O
incidence	O
of	O
locus	B
associated	O
The	O
.	O

The	O
high	O
frequencies	O
of	O
juvenile	O
onset	O
diabetes	O
inward	O
locale	O
be	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
juvenile	O
onset	O
diabetes	O
inward	O
nipponese	O
inward	O
responsible	O
for	O
the	B
low	O
incidence	O
of	O

The	O
gamy	O
frequencies	O
of	O
disease	O
-	O
assort	O
alleles	O
in	O
the	O
worldwide	O
universe	O
suggest	O
that	O
IDDM2	O
venue	O
is	O
not	O
creditworthy	O
for	O
the	O
down	O
incidence	O
of	O
IDDM	B
in	O
japanese	O
.	O

The	O
high	O
frequencies	O
of	O
juvenile	O
onset	O
diabetes	O
inward	O
locale	O
be	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
juvenile	O
onset	O
diabetes	O
inward	O
nipponese	O
inward	O
responsible	O
for	O
the	B
low	O
incidence	O
of	O

of	O
high	O
frequencies	O
of	O
disease	O
-	O
that	O
population	O
in	O
the	O
general	O
is	O
low	O
associated	O
IDDM	O
The	O
alleles	O
locus	O
responsible	O
for	O
the	O
suggest	O
incidence	O
not	O
IDDM2	B
in	O
Japanese	O
.	O

The	O
high	O
oftenness	O
of	O
disease	O
-	O
consort	O
alleles	O
in	O
the	O
universal	O
universe	O
propose	O
that	O
IDDM2	O
venue	O
is	O
not	O
creditworthy	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	B
in	O
nipponese	O
.	O

The	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	B
in	O
Japanese	O
.	O

The	O
human	O
two	O
of	O
gene	O
:	O
and	O
of	O
complement	O
mutations	O
causing	O
deficiency	O
identification	O
revision	O
C9	O
the	O
gene	O
structure	O
.	O

complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
the	O
gene	O
structure	O
.	O

The	O
human	O
accompaniment	O
C9	O
factor	O
:	O
recognition	O
of	O
two	O
mutations	O
make	O
deficiency	O
and	O
rewrite	O
of	O
the	O
factor	O
structure	O
.	O

The	O
homo	O
complement	O
C9	O
factor	O
:	O
recognition	O
of	O
two	O
mutations	O
cause	O
lack	O
and	O
revision	O
of	O
the	O
factor	O
structure	O
.	O

gene	O
human	O
complement	O
C9	O
gene	O
:	O
revision	O
of	O
two	O
mutations	O
causing	O
deficiency	O
structure	O
identification	O
of	O
the	O
and	O
The	O
.	O

The	O
human	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
accompaniment	O
accompaniment	O
accompaniment	O
accompaniment	O
homo	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
designation	O
of	O
two	O
sport	O
stimulate	O
inadequacy	O
and	O
rewrite	O
of	O
the	O
gene	O
structure	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
accompaniment	O
accompaniment	O
accompaniment	O
accompaniment	O
accompaniment	O
.	O

revision	O
human	O
complement	O
causing	O
gene	O
:	O
identification	O
.	O
of	O
mutations	O
C9	O
deficiency	O
The	O
and	O
two	O
the	O
gene	O
structure	O
of	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
.	O

The	O
ninth	O
component	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O
complex	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
terminal	O
creating	O
the	O
membrane	O
attack	O
complex	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
aggress	O
building	O
complex	O
building	O
complex	O
constituent	O
constituent	O
constituent	O
the	O
membrane	O
attack	O

The	O
ninth	O
constituent	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
close	O
of	O
the	O
close	O
complement	O
element	O
create	O
the	O
membrane	O
onset	O
complex	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
aggress	O
building	O
complex	O
building	O
complex	O
constituent	O
constituent	O
constituent	O
the	O
membrane	O
attack	O

The	O
ninth	O
ingredient	O
of	O
human	O
accompaniment	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
concluding	O
accompaniment	O
portion	O
create	O
the	O
membrane	O
onrush	O
complex	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
last	O
of	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O

the	O
ninth	O
component	O
the	O
human	O
complement	O
(	O
)	O
C9	O
is	O
membrane	O
last	O
the	O
of	O
.	O
complement	O
components	O
creating	O
of	O
The	O
attack	O
complex	O
terminal	O

The	O
ninth	O
component	O
of	O
homo	O
complement	O
(	O
C9	O
)	O
is	O
the	O
death	O
of	O
the	O
concluding	O
complement	O
components	O
create	O
the	O
membrane	O
aggress	O
composite	O
.	O

terminal	O
ninth	O
)	O
(	O
human	O
complement	O
complement	O
C9	O
component	O
is	O
the	O
last	O
attack	O
the	O
of	O
The	O
components	O
creating	O
the	O
membrane	O
of	O
complex	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O
complex	O
.	O

C9	O
is	O
that	O
located	O
-	O
chain	O
a	O
protein	O
a	O
is	O
encoded	O
by	O
serum	O
gene	O
single	O
on	O
chromosome	O
5p	O
.	O

a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
on	O
chromosome	O
5p	O
.	O

C9	O
is	O
a	O
unity	O
-	O
string	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
factor	O
located	O
on	O
chromosome	O
5p	O
.	O

C9	O
is	O
a	O
undivided	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
cistron	O
site	O
on	O
chromosome	O
5p	O
.	O

chromosome	O
is	O
a	O
single	O
-	O
chain	O
gene	O
located	O
that	O
is	O
encoded	O
by	O
5p	O
serum	O
protein	O
on	O
a	O
C9	O
.	O

C9	O
is	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
.	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

C9	O
is	O
a	O
individual	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
cistron	O
situated	O
on	O
chromosome	O
5p	O
.	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

gene	O
is	O
a	O
encoded	O
-	O
chain	O
serum	O
.	O
located	O
is	O
single	O
by	O
C9	O
a	O
that	O
on	O
chromosome	O
5p	O
protein	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
.	O

Deficiency	B
terminal	I
complement	I
is	O
associated	O
recurrent	O
neisseria	B
infections	I
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B
infections	I

Deficiency	B
of	I
terminal	I
complement	I
portion	I
is	O
generally	O
affiliate	O
with	O
recurrent	O
neisseria	B
contagion	I
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
transmission	O
transmission	O
constituent	O
recurrent	O
neisseria	B
infections	I
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
transmission	O
transmission	O
pole	O
recurrent	O
neisseria	B
infections	I
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
transmission	O
transmission	O
constituent	O
recurrent	O
neisseria	B
infections	I
.	O

Deficiency	B
of	I
terminal	I
accompaniment	I
portion	I
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B
transmission	I
.	O

Deficiency	B
of	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
recurrent	O
.	O

Deficiency	B
of	I
final	I
complement	I
components	I
is	O
generally	O
connect	O
with	O
perennial	O
neisseria	B
infections	I
.	O

Deficiency	B
components	I
terminal	I
complement	I
.	I
is	O
generally	O
of	O
with	O
recurrent	O
neisseria	B
infections	I
associated	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B
infections	I
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
lack	B
study	B
study	B
C9	I
deficiency	I
.	O

studied	O
a	O
family	O
C9	I
deficiency	I
.	O

We	O
canvas	O
a	O
previously	O
described	O
Swiss	O
kinsperson	O
with	O
inherited	B
C9	I
lack	I
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
lack	B
study	B
study	B
C9	I
deficiency	I
.	O

studied	O
a	O
described	O
Swiss	O
family	O
with	O
inherited	B
C9	I
deficiency	I
.	O

We	O
studied	O
a	O
previously	O
described	O
swiss	O
category	O
with	O
transmitted	B
C9	I
deficiency	I
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
lack	B
study	B
transmissible	B
C9	I
deficiency	I
.	O

We	O
learn	O
a	O
antecedently	O
described	O
Swiss	O
mob	O
with	O
inherited	B
C9	I
deficiency	I
.	O

We	O
with	O
a	O
previously	O
studied	O
Swiss	O
family	O
deficiency	O
inherited	B
C9	I
described	I
.	O

.	O
studied	O
a	O
previously	O
with	O
Swiss	O
C9	O
described	O
inherited	B
family	I
deficiency	I
We	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
C9	I
deficiency	I
.	O

To	O
identify	O
the	O
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
exon	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
dna	O
sequence	O
sequence	O
transmissible	O
transmissible	O
transmissible	O
and	O
direct	O
DNA	O
sequencing	O
.	O

To	O
discover	O
the	O
genetic	O
cornerstone	O
of	O
C9	B
deficiency	I
,	O
we	O
educate	O
an	O
approach	O
utilise	O
exon	O
-	O
specific	O
PCR	O
and	O
aim	O
dna	O
sequencing	O
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
dna	O
sequence	O
sequence	O
transmissible	O
transmissible	O
transmissible	O
and	O
direct	O
DNA	O
sequencing	O
.	O

To	O
distinguish	O
the	O
transmitted	O
groundwork	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
particular	O
PCR	O
and	O
direct	O
dna	O
sequence	O
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
an	O
approach	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O

developed	O
identify	O
the	O
and	O
basis	O
of	O
C9	B
,	I
deficiency	O
we	O
direct	O
an	O
using	O
approach	O
.	O
-	O
specific	O
PCR	O
genetic	O
To	O
DNA	O
sequencing	O
exon	O

To	O
key	O
the	O
genic	O
fundament	O
of	O
C9	B
insufficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
aim	O
DNA	O
sequence	O
.	O

exon	O
identify	O
,	O
C9	O
basis	O
of	O
-	B
deficiency	I
the	O
we	O
developed	O
an	O
DNA	O
using	O
genetic	O
To	O
specific	O
PCR	O
and	O
direct	O
approach	O
sequencing	O
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
ride	O
episode	O
ride	O
episode	O
episode	O
do	O
ride	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
codons	O
the	O
coding	O
sequence	O
.	O

As	O
a	O
effort	O
of	O
C9	B
want	I
,	O
we	O
found	O
two	O
dissimilar	O
item	O
mutant	O
,	O
both	O
engender	O
TGA	O
quit	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
found	O
two	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
the	O
coding	O
sequence	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
ride	O
episode	O
ride	O
episode	O
episode	O
do	O
do	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

As	O
a	O
drive	O
of	O
C9	B
deficiency	I
,	O
we	O
ascertain	O
two	O
unlike	O
designate	O
sport	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
cypher	O
episode	O
.	O

As	O
a	O
reason	O
of	O
C9	B
deficiency	I
,	O
we	O
ground	O
two	O
unlike	O
head	O
mutations	O
,	O
both	O
give	O
TGA	O
halt	O
codons	O
in	O
the	O
fool	O
sequence	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
different	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
coding	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
ride	O
episode	O
ride	O
episode	O
episode	O
do	O
do	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

stop	O
a	O
cause	O
different	O
C9	B
deficiency	I
,	O
codons	O
.	O
two	O
of	O
point	O
mutations	O
,	O
sequence	O
generating	O
TGA	O
the	O
we	O
As	O
in	O
coding	O
both	O
found	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

mutation	O
,	O
a	O
A	O
exchange	O
,	O
was	O
detected	O
exon	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
T	O
exchange	O
,	O
was	O
located	O
position	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O

in	O
other	O
,	O
a	O
position	O
to	O
)	O
exon	O
,	O
was	O
detected	O
in	O
exon	O
to	O
166	O
cDNA	O
C	O
at	O
,	O
the	O
2	O
,	O
a	O
C	O
mutation	O
T	O
exchange	O
.	O
One	O
located	O
was	O
A	O
4	O
(	O
cDNA	O
position	O
464	O
exchange	O
,	O

One	O
mutation	O
,	O
C	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
464	O
.	O

ane	O
variation	O
,	O
angstrom	O
cytosine	O
to	O
angstrom	O
rally	O
,	O
was	O
discover	O
in	O
exon	O
ii	O
at	O
cdna	O
post	O
166	O
,	O
the	O
other	O
,	O
angstrom	O
cytosine	O
to	O
T	O
rally	O
,	O
was	O
settle	O
in	O
exon	O
tetrad	O
(	O
cdna	O
post	O
464	O
)	O
.	O

to	O
,	O
,	O
a	O
C	O
to	O
in	O
exchange	O
,	O
was	O
detected	O
A	O
exon	O
,	O
located	O
cDNA	O
position	O
166	O
(	O
the	O
other	O
,	O
was	O
C	O
One	O
T	O
exon	O
2	O
at	O
a	O
in	O
position	O
4	O
cDNA	O
mutation	O
exchange	O
464	O
)	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O
deoxycytidine	O
monophosphate	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
166	O
,	O
the	O
,	O
C	O
to	O
T	O
was	O
(	O
cDNA	O
position	O
)	O
.	O

One	O
mutation	O
in	O
a	O
C	O
to	O
A	O
,	O
,	O
was	O
detected	O
exchange	O
the	O
2	O
at	O
exchange	O
position	O
166	O
)	O
exon	O
other	O
4	O
a	O
position	O
to	O
cDNA	O
in	O
,	O
was	O
located	O
,	O
,	O
exon	O
(	O
cDNA	O
C	O
464	O
T	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
464	O
)	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
segregate	O
severally	O
segregate	O
severally	O
severally	O
meditate	O
point	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
two	O
are	O
segregating	O
independently	O
.	O

In	O
home	O
studies	O
of	O
tercet	O
first	O
-	O
degree	O
congeneric	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
exhibit	O
that	O
the	O
two	O
sport	O
are	O
segregate	O
severally	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
relatives	O
with	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
are	O
segregating	O
independently	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
segregate	O
severally	O
segregate	O
severally	O
severally	O
meditate	O
meditate	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

indium	O
family	O
studies	O
of	O
ternion	O
low	O
-	O
degree	O
congeneric	O
with	O
heterozygous	O
C9	B
insufficiency	I
,	O
we	O
attest	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
severally	O
.	O

inwards	O
family	O
take	O
of	O
three	O
beginning	O
-	O
level	O
relation	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregate	O
severally	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
heterozygous	O
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
segregate	O
severally	O
segregate	O
severally	O
severally	O
meditate	O
meditate	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

the	O
family	O
studies	O
heterozygous	O
three	O
first	O
-	O
two	O
.	O
with	O
of	O
C9	B
deficiency	I
,	O
independently	O
demonstrated	O
that	O
are	O
degree	O
In	O
mutations	O
segregating	O
we	O
relatives	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

deficiency	O
,	O
these	O
explain	O
are	O
sufficient	O
to	O
mutations	O
probands	O
complete	O
the	O
of	O
Therefore	O
both	O
the	O
studied	O
.	O

hence	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explicate	O
the	O
ended	O
lack	O
of	O
both	O
the	O
probands	O
study	O
.	O

hence	O
,	O
these	O
mutant	O
are	O
sufficient	O
to	O
explicate	O
the	O
complete	O
insufficiency	O
of	O
both	O
the	O
probands	O
analyse	O
.	O

Therefore	O
,	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
.	O

so	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
excuse	O
the	O
accomplished	O
want	O
of	O
both	O
the	O
probands	O
contemplate	O
.	O

Therefore	O
,	O
explicate	O
mutation	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
formulate	O
formulate	O
chromosomal	O
mutation	O

Therefore	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
complete	O
deficiency	O
both	O
the	O
probands	O
studied	O
.	O

Therefore	O
,	O
explicate	O
mutation	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
formulate	O
formulate	O
chromosomal	O
mutation	O

,	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O

Therefore	O
,	O
the	O
probands	O
are	O
sufficient	O
both	O
explain	O
these	O
complete	O
deficiency	O
of	O
to	O
the	O
mutations	O
studied	O
.	O

Therefore	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
.	O

DNA	O
sequencing	O
of	O
the	O
view	O
	O
boundary	O
coding	O
dna	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
reckon	O
reckon	O
reckon	O
reckon	O
rescript	O

DNA	O
sequencing	O
of	O
-	O
number	O
of	O
revisions	O
the	O
boundaries	O
exons	O
4	O
,	O
and	O
6	O
as	O
well	O
as	O
exons	O
and	O
11	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
join	O
revealed	O
a	O
turn	O
of	O
revise	O
regarding	O
the	O
bounds	O
between	O
exons	O
4	O
,	O
fin	O
,	O
and	O
vi	O
as	O
considerably	O
as	O
between	O
exons	O
tenner	O
and	O
xi	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
revealed	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
.	O

dna	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
total	O
of	O
revise	O
affect	O
the	O
boundary	O
between	O
exons	O
iv	O
,	O
v	O
,	O
and	O
6	O
as	O
advantageously	O
as	O
between	O
exons	O
decade	O
and	O
11	O
.	O

DNA	O
sequencing	O
of	O
the	O
view	O
	O
boundary	O
coding	O
dna	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
reckon	O
reckon	O
reckon	O
reckon	O
rescript	O

DNA	O
sequence	O
of	O
the	O
exon	O
-	O
intron	O
adjunction	O
uncover	O
a	O
number	O
of	O
revisions	O
see	O
the	O
boundary	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
six	O
as	O
easily	O
as	O
between	O
exons	O
ten	O
and	O
eleven	O
.	O

5	O
4	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
as	O
10	O
boundaries	O
between	O
exons	O
between	O
,	O
sequencing	O
,	O
11	O
6	O
regarding	O
well	O
as	O
DNA	O
the	O
and	O
and	O
exons	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
junctions	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
between	O
exons	O
10	O
11	O

DNA	O
sequencing	O
of	O
the	O
view	O
	O
boundary	O
betwixt	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
reckon	O
reckon	O
reckon	O
reckon	O
rescript	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
.	O

No	O
extra	O
introns	O
were	O
detected	O
in	O
exons	O
vi	O
and	O
tenner	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
extra	O
extra	O
extra	O
10	O
.	O

No	O
extra	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
tenner	O
.	O

No	O
extra	O
introns	O
were	O
find	O
in	O
exons	O
6	O
and	O
tenner	O
.	O

additional	O
introns	O
detected	O
in	O
exons	O
6	O
and	O
10	O
.	O

6	O
additional	O
introns	O
detected	O
were	O
in	O
10	O
No	O
and	O
exons	O
.	O

No	O
6	O
introns	O
were	O
additional	O
in	O
exons	O
.	O
and	O
10	O
detected	O

were	O
6	O
introns	O
exons	O
detected	O
in	O
No	O
additional	O
and	O
10	O
.	O

No	O
introns	O
detected	O
exons	O
6	O
and	O
10	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
extra	O
extra	O
extra	O
10	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
10	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
meditate	O
be	O
impart	O
meditate	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
study	O
study	O
study	O
study	O
study	O
.	O

Furthermore	O
,	O
DNA	O
were	O
of	O
the	O
C6	O
C7	O
,	O
C9	O
genes	O
,	O
linkage	O
of	O
the	O
observed	O
C9	O
with	O
haplotypes	O
.	O
.	O

moreover	O
,	O
dna	O
marker	O
canvass	O
were	O
behave	O
apply	O
acknowledge	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
support	O
the	O
linkage	O
of	O
the	O
find	O
C9	O
mutations	O
with	O
outlined	O
haplotypes	O
.	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
conducted	O
known	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
.	O

furthermore	O
,	O
DNA	O
marker	O
work	O
were	O
behave	O
victimization	O
acknowledge	O
pleomorphism	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
factor	O
,	O
confirmatory	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
delimit	O
haplotypes	O
.	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
meditate	O
be	O
impart	O
meditate	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
study	O
study	O
study	O
study	O
study	O
.	O

moreover	O
,	O
DNA	O
marking	O
report	O
were	O
convey	O
utilise	O
bang	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
substantiating	O
the	O
linkage	O
of	O
the	O
note	O
C9	O
mutations	O
with	O
delimitate	O
haplotypes	O
.	O
.	O

confirming	O
genes	O
DNA	O
marker	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
the	O
defined	O
,	O
and	O
C9	O
mutations	O
,	O
,	O
the	O
.	O
of	O
,	O
observed	O
C9	O
Furthermore	O
C7	O
linkage	O
haplotypes	O
with	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
using	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
mutations	O
with	O
defined	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
meditate	O
be	O
impart	O
impart	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
study	O
study	O
study	O
study	O
bring	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
.	O
.	O

BRCA1	O
in	O
attending	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
.	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
adventure	O
of	O
summit	B
crab	I
.	O

evaluate	O
women	O
in	O
mutations	O
attending	O
clinics	O
risk	O
BRCA1	O
the	O
.	O
of	O
breast	B
cancer	I
that	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
risk	O
of	O
cancer	I
.	O

BRCA1	O
mutations	O
pass	O
judgment	O
inward	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
genus	O
cancer	O
serve	O
risk	B
of	I
breast	O

BRCA1	O
mutations	O
pass	O
judgment	O
inward	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
genus	O
cancer	O
serve	O
risk	B
of	I
breast	O

BRCA1	O
variation	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
bosom	B
cancer	I
.	O

cancer	O
mutations	O
in	O
BRCA1	O
evaluate	O
clinics	O
that	O
breast	O
the	O
risk	O
of	O
attending	B
women	I
.	O

BRCA1	O
mutations	O
pass	O
judgment	O
inward	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
genus	O
cancer	O
serve	O
risk	B
of	I
breast	O

BRCA1	O
variation	O
in	O
women	O
attending	O
clinics	O
that	O
measure	O
the	O
risk	O
of	O
summit	B
cancer	I
.	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
among	O
patients	O
project	O
in	O
clinics	O
that	O
assess	O
the	O
endangerment	O
of	O
boob	B
crab	I
,	O
we	O
analyzed	O
dna	O
samples	O
from	O
womanhood	O
project	O
in	O
this	O
lay	O
and	O
make	O
chance	O
tables	O
to	O
provide	O
judge	O
of	O
the	O
likeliness	O
of	O
finding	O
a	O
BRCA1	O
variation	O
in	O
soul	O
kinsfolk	O
.	O

BACKGROUND	O
To	O
limit	O
the	O
incidence	O
of	O
BRCA1	O
variation	O
among	O
patients	O
experience	O
in	O
clinics	O
that	O
appraise	O
the	O
risk	O
of	O
summit	B
cancer	I
,	O
we	O
analyzed	O
dna	O
sampling	O
from	O
char	O
experience	O
in	O
this	O
limit	O
and	O
make	O
chance	O
remit	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
determination	O
a	O
BRCA1	O
mutation	O
in	O
someone	O
category	O
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
patients	O
seen	O
in	O
clinics	O
evaluate	O
the	O
risk	O
of	O
breast	B
,	O
we	O
analyzed	O
DNA	O
from	O
women	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
estimates	O
of	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O
in	O
individual	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
retrace	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
luck	O
find	O
out	O
antiophthalmic	O
factor	O
relative	O
incidence	O
chromosomal	O
mutation	O
inward	O
single	O
phratry	O
inward	O
single	O
phratry	O
inward	O
single	O
hazard	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O

tables	O
samples	O
define	O
the	O
incidence	O
of	O
,	O
risk	O
among	O
patients	O
seen	O
in	O
clinics	O
BRCA1	O
estimates	O
the	O
mutations	O
in	O
breast	B
cancer	I
that	O
we	O
analyzed	O
DNA	O
seen	O
from	O
women	O
of	O
BRCA1	O
this	O
in	O
To	O
constructed	O
probability	O
.	O
to	O
provide	O
evaluate	O
and	O
the	O
likelihood	O
families	O
finding	O
a	O
setting	O
mutation	O
of	O
individual	O
of	O
BACKGROUND	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
retrace	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
luck	O
find	O
out	O
antiophthalmic	O
factor	O
relative	O
incidence	O
chromosomal	O
mutation	O
inward	O
single	O
phratry	O
inward	O
single	O
phratry	O
inward	O
single	O
hazard	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O

backdrop	O
To	O
specify	O
the	O
incidence	O
of	O
BRCA1	O
variation	O
among	O
patients	O
assure	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
boob	B
cancer	I
,	O
we	O
dissect	O
DNA	O
samples	O
from	O
women	O
assure	O
in	O
this	O
plant	O
and	O
constructed	O
chance	O
defer	O
to	O
furnish	O
forecast	O
of	O
the	O
likeliness	O
of	O
receive	O
a	O
BRCA1	O
mutant	O
in	O
private	O
families	O
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
retrace	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
relative	O
incidence	O
find	O
out	O
antiophthalmic	O
factor	O
relative	O
incidence	O
chromosomal	O
mutation	O
inward	O
single	O
phratry	O
inward	O
single	O
phratry	O
inward	O
single	O
antiophthalmic	O
factor	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O

BACKGROUND	O
To	O
define	O
the	O
BRCA1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
risk	O
breast	B
cancer	I
,	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
this	O
setting	O
probability	O
to	O
provide	O
estimates	O
of	O
of	O
finding	O
a	O
BRCA1	O
in	O
individual	O
families	O
.	O

BACKGROUND	O
women	O
define	O
the	O
incidence	O
of	O
in	O
this	O
among	O
patients	O
seen	O
BRCA1	O
clinics	O
seen	O
in	O
the	O
risk	O
of	O
mutations	B
cancer	I
,	O
we	O
probability	O
DNA	O
a	O
from	O
in	O
that	O
families	O
breast	O
setting	O
to	O
constructed	O
evaluate	O
tables	O
of	O
provide	O
estimates	O
of	O
the	O
To	O
and	O
finding	O
analyzed	O
BRCA1	O
mutation	O
likelihood	O
individual	O
samples	O
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O
in	O
individual	O
families	O
.	O

METHODS	O
clinical	O
entropy	O
,	O
family	O
histories	O
,	O
and	O
stock	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
woman	O
with	O
tit	B
crab	I
.	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
genus	O
cancer	O
info	O
info	O
info	O
info	O
info	B
breast	I
cancer	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
genus	O
cancer	O
info	O
info	O
info	O
info	O
info	B
breast	I
cancer	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
for	O
DNA	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B

from	O
Clinical	O
blood	O
,	O
family	O
histories	O
263	O
and	O
information	O
for	O
DNA	O
analysis	O
.	O
obtained	O
,	O
METHODS	O
women	O
with	O
breast	B
cancer	I
were	O

METHODS	O
Clinical	O
information	O
,	O
family	O
chronicle	O
,	O
and	O
origin	O
for	O
dna	O
analysis	O
were	O
receive	O
from	O
263	O
woman	O
with	O
bosom	B
cancer	I
.	O

.	O
Clinical	O
information	O
DNA	O
family	O
histories	O
,	O
breast	O
from	O
for	O
,	O
analysis	O
obtained	O
were	O
blood	O
263	O
women	O
with	O
and	B
METHODS	I
cancer	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
genus	O
cancer	O
info	O
info	O
info	O
info	O
line	B
breast	I
cancer	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
from	O
with	O
breast	B
cancer	I
.	O

method	O
clinical	O
information	O
,	O
category	O
chronicle	O
,	O
and	O
stemma	O
for	O
DNA	O
analysis	O
were	O
get	O
from	O
263	O
women	O
with	O
breast	B
cancer	I
.	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B
cancer	I
.	O

Conformation	O
electrophoresis	O
sensitive	O
gel	O
-	O
and	O
sequencing	O
to	O
were	O
used	O
BRCA1	O
identify	O
DNA	O
mutations	O
.	O

Conformation	O
-	O
dna	O
sequence	O
tender	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
sequence	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

contour	O
-	O
sensitive	O
gel	O
ionophoresis	O
and	O
DNA	O
sequence	O
were	O
used	O
to	O
key	O
BRCA1	O
mutations	O
.	O

BRCA1	O
-	O
sensitive	O
Conformation	O
sequencing	O
and	O
DNA	O
identify	O
were	O
used	O
to	O
electrophoresis	O
gel	O
mutations	O
.	O

Conformation	O
-	O
sensible	O
gel	O
dielectrolysis	O
and	O
dna	O
sequencing	O
were	O
used	O
to	O
distinguish	O
BRCA1	O
mutations	O
.	O

Conformation	O
-	O
dna	O
sequence	O
tender	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
dielectrolysis	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

Conformation	O
sensitive	O
electrophoresis	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

sequencing	O
gel	O
sensitive	O
-	O
electrophoresis	O
and	O
used	O
Conformation	O
were	O
DNA	O
to	O
identify	O
BRCA1	O
.	O
mutations	O

configuration	O
-	O
sore	O
gel	O
electrophoresis	O
and	O
DNA	O
sequence	O
were	O
used	O
to	O
describe	O
BRCA1	O
mutations	O
.	O

Conformation	O
-	O
dna	O
sequence	O
tender	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
dielectrolysis	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

Conformation	O
-	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

with	O
BRCA1	O
mutations	O
percent	O
identified	O
in	O
16	O
were	O
of	O
women	O
history	O
a	O
RESULTS	O
family	O
of	O
breast	B
cancer	I
.	O

effect	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
charwoman	O
with	O
a	O
phratry	O
chronicle	O
of	O
knocker	B
cancer	I
.	O

effect	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
xvi	O
percent	O
of	O
charwoman	O
with	O
a	O
family	O
chronicle	O
of	O
breast	B
crab	I
.	O

RESULTS	O
BRCA1	O
mutations	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
.	O

lead	O
BRCA1	O
mutations	O
were	O
describe	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
kinsperson	O
account	O
of	O
bosom	B
cancer	I
.	O

RESULTS	O
BRCA1	O
mutation	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O

RESULTS	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
a	O
family	O
of	O
breast	B
cancer	I
.	O

RESULTS	O
BRCA1	O
mutation	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O

BRCA1	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
.	O

RESULTS	O
BRCA1	O
of	O
of	O
identified	O
in	O
family	O
percent	O
mutations	O
women	O
with	O
a	O
16	O
history	O
were	O
breast	B
cancer	I
.	O

RESULTS	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
.	O

simply	O
7	O
percent	O
of	O
womanhood	O
from	O
families	O
with	O
a	O
history	O
of	O
summit	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
BRCA1	O
mutations	O
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
mutation	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
BRCA1	O
mutations	O
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
mutation	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
BRCA1	O
mutations	O
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
history	O
of	O
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
BRCA1	O

not	O
7	O
a	O
families	O
women	O
from	O
ovarian	O
with	O
percent	O
history	O
of	O
breast	B
.	I
but	O
of	O
Only	B
cancer	I
had	O
BRCA1	O
mutations	O
cancer	O

simply	O
vii	O
percent	O
of	O
women	O
from	O
household	O
with	O
a	O
chronicle	O
of	O
tit	B
crab	I
but	O
not	O
ovarian	B
crab	I
had	O
BRCA1	O
mutations	O
.	O

.	O
7	O
percent	O
of	O
women	O
from	O
families	O
BRCA1	O
not	O
history	O
of	O
breast	B
but	I
cancer	O
a	O
ovarian	B
cancer	I
had	O
with	O
Only	O
mutations	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
mutation	O
percentage	O
percentage	O
percentage	O
percentage	O
simply	O
BRCA1	O
mutations	O
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
not	O
had	O
BRCA1	O
mutations	O
.	O

only	O
heptad	O
percent	O
of	O
women	O
from	O
kinsfolk	O
with	O
a	O
account	O
of	O
breast	B
crab	I
but	O
not	O
ovarian	B
crab	I
had	O
BRCA1	O
mutant	O
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
BRCA1	O
mutations	O
.	O

history	O
rates	O
were	O
families	O
among	O
women	O
from	O
higher	O
and	O
a	O
breast	O
of	O
The	O
both	B
with	I
ovarian	I
cancer	I
.	O

The	O
denounce	O
were	O
higher	O
among	O
women	O
from	O
household	O
with	O
a	O
chronicle	O
of	O
both	O
front	B
and	I
ovarian	I
cancer	I
.	O

The	O
rank	O
were	O
eminent	O
among	O
women	O
from	O
category	O
with	O
a	O
account	O
of	O
both	O
titty	B
and	I
ovarian	I
cancer	I
.	O

The	O
rates	O
were	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
.	O

The	O
grade	O
were	O
gamy	O
among	O
womanhood	O
from	O
families	O
with	O
a	O
account	O
of	O
both	O
breast	B
and	I
ovarian	I
crab	I
.	O

The	O
rates	O
be	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
follow	O
follow	O
follow	O
phratry	O
.	O

The	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
of	O
both	O
and	I
ovarian	I
cancer	I
.	O

The	O
rates	O
be	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
follow	O
follow	O
follow	O
phratry	O
.	O

rates	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
.	O

The	O
rates	O
with	O
and	O
among	O
women	O
both	O
families	O
were	O
a	O
history	O
of	O
from	O
breast	B
higher	I
ovarian	I
cancer	I
.	O

The	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
.	O

Among	O
family	O
members	O
an	O
age	O
of	O
less	O
years	O
breast	B
cancer	I
,	O
presence	O
of	O
cancer	I
,	O
the	O
breast	B
and	I
ovarian	I
cancer	I
in	O
same	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
risk	O
of	O
detecting	O
a	O
BRCA1	O

same	O
presence	O
members	O
,	O
an	O
average	O
were	O
of	O
less	O
than	O
55	O
ancestry	O
at	O
of	O
breast	O
of	O
breast	B
cancer	I
family	O
the	O
presence	O
of	O
the	B
cancer	I
associated	O
the	O
increased	O
the	O
of	B
,	I
ovarian	I
woman	I
in	O
diagnosis	O
Among	O
.	O
,	O
and	O
Ashkenazi	O
Jewish	O
years	O
age	O
all	O
ovarian	O
with	O
an	O
and	O
risk	O
,	O
detecting	O
a	O
BRCA1	O
mutation	O
cancer	O

detecting	O
,	O
members	O
,	O
an	O
average	O
and	O
breast	O
less	O
than	O
55	O
years	O
at	O
a	O
BRCA1	O
of	O
of	B
increased	I
,	O
the	O
.	O
of	O
ovarian	B
cancer	I
of	O
the	O
presence	O
were	O
with	B
and	I
breast	I
age	I
in	O
the	O
same	O
woman	O
,	O
of	O
cancer	O
Jewish	O
ancestry	O
presence	O
all	O
associated	O
ovarian	O
an	O
cancer	O
risk	O
Ashkenazi	O
Among	O
the	O
diagnosis	O
mutation	O
family	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
	O
bosom	O
astatine	O
associate	O
in	O
nursing	O
genus	O
cancer	O
le	O
less	O
than	O
55	O
years	O
at	O
the	B
diagnosis	I
of	O
breast	O
cancer	O
,	O
the	B
presence	I
of	O
ovarian	O
cancer	O
,	O
the	B
presence	I
of	I
breast	I
and	O
ovarian	O
cancer	O
in	O
the	O
same	O
woman	O
associate	O
in	O
nursing	O
increase	O
hazard	O
associate	O
in	O
nursing	O
observe	O
antiophthalmic	O
factor	O
associate	O
in	O
nursing	O
chromosomal	O
mutation	O
antiophthalmic	O
factor	O
astatine	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O

Among	O
syndicate	O
appendage	O
,	O
an	O
intermediate	O
age	O
of	O
less	O
than	O
55	O
class	O
at	O
the	O
diagnosing	O
of	O
chest	B
cancer	I
,	O
the	O
comportment	O
of	O
ovarian	B
cancer	I
,	O
the	O
comportment	O
of	O
chest	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
char	O
,	O
and	O
ashkenazi	O
jewish	O
blood	O
were	O
all	O
consort	O
with	O
an	O
increased	O
chance	O
of	O
detection	O
a	O
BRCA1	O
mutant	O
.	O

Among	O
kin	O
appendage	O
,	O
an	O
fair	O
eld	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosing	O
of	O
chest	B
cancer	I
,	O
the	O
bearing	O
of	O
ovarian	B
cancer	I
,	O
the	O
bearing	O
of	O
chest	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
woman	O
,	O
and	O
ashkenazi	O
judaic	O
ancestry	O
were	O
all	O
relate	O
with	O
an	O
increased	O
risk	O
of	O
sleuthing	O
a	O
BRCA1	O
mutant	O
.	O

Among	O
menage	O
extremity	O
,	O
an	O
average	O
eld	O
of	O
less	O
than	O
55	O
geezerhood	O
at	O
the	O
diagnosing	O
of	O
titty	B
cancer	I
,	O
the	O
front	O
of	O
ovarian	B
cancer	I
,	O
the	O
front	O
of	O
titty	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
woman	O
,	O
and	O
ashkenazi	O
judaic	O
line	O
were	O
all	O
colligate	O
with	O
an	O
increased	O
adventure	O
of	O
notice	O
a	O
BRCA1	O
mutation	O
.	O

,	O
age	O
less	O
than	O
55	O
at	O
the	O
diagnosis	O
of	O
breast	B
cancer	I
of	O
ovarian	B
cancer	I
,	O
the	O
presence	O
of	O
and	I
ovarian	I
the	O
same	O
woman	O
and	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
BRCA1	O
.	O

Among	O
members	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
,	O
the	O
presence	O
of	O
ovarian	B
cancer	I
,	O
the	O
presence	O
of	O
breast	B
and	I
ovarian	I
cancer	I
in	O
same	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
BRCA1	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
	O
bosom	O
astatine	O
associate	O
in	O
nursing	O
genus	O
cancer	O
le	O
less	O
than	O
55	O
years	O
at	O
the	B
diagnosis	I
of	O
breast	O
cancer	O
,	O
the	B
presence	I
of	O
ovarian	O
cancer	O
,	O
the	B
presence	I
of	I
breast	I
and	O
ovarian	O
cancer	O
in	O
the	O
same	O
woman	O
associate	O
in	O
nursing	O
increase	O
hazard	O
associate	O
in	O
nursing	O
observe	O
antiophthalmic	O
factor	O
associate	O
in	O
nursing	O
chromosomal	O
mutation	O
antiophthalmic	O
factor	O
bosom	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B
cancer	I
,	O
the	O
presence	O
of	O
ovarian	B
cancer	I
,	O
the	O
presence	O
of	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
woman	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
BRCA1	O
mutation	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
bearing	O
betwixt	O
betwixt	O
genus	O
cancer	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
betwixt	O
the	O
BRCA1	O
gene	O
and	B
the	I
presence	O
of	O
ovarian	O
cancer	O

No	O
association	O
was	O
base	O
between	O
the	O
mien	O
of	O
bilateral	O
boob	B
cancer	I
or	O
the	O
figure	O
of	O
boob	B
crab	I
in	O
a	O
family	O
and	O
the	O
sensing	O
of	O
a	O
BRCA1	O
sport	O
,	O
or	O
between	O
the	O
view	O
of	O
the	O
sport	O
in	O
the	O
BRCA1	O
cistron	O
and	O
the	O
mien	O
of	O
ovarian	B
cancer	I
in	O
a	O
family	O
.	O

No	O
association	O
the	O
found	O
between	O
the	O
or	O
a	O
bilateral	O
breast	B
cancer	I
presence	O
family	O
number	O
of	O
the	B
cancers	I
in	O
BRCA1	O
the	O
and	O
family	O
detection	O
of	O
a	O
mutation	O
of	O
of	O
or	O
between	O
was	O
of	O
position	O
the	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
and	O
a	O
presence	O
,	O
ovarian	B
cancer	I
the	O
in	O
breast	O
.	O

mutation	O
mutation	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
,	O
or	O
breast	B
cancers	I
in	O
between	O
family	O
and	O
the	O
the	O
of	O
ovarian	O
BRCA1	O
a	O
number	O
.	O
a	O
the	O
in	O
of	O
of	O
No	O
association	O
the	O
BRCA1	O
gene	O
and	O
the	O
position	O
of	O
detection	B
cancer	I
in	O
presence	O
family	O
a	O

No	O
association	O
was	O
receive	O
between	O
the	O
bearing	O
of	O
bilateral	O
bosom	B
cancer	I
or	O
the	O
figure	O
of	O
bosom	B
cancers	I
in	O
a	O
kinsfolk	O
and	O
the	O
catching	O
of	O
a	O
BRCA1	O
sport	O
,	O
or	O
between	O
the	O
perspective	O
of	O
the	O
sport	O
in	O
the	O
BRCA1	O
factor	O
and	O
the	O
bearing	O
of	O
ovarian	B
cancer	I
in	O
a	O
kinsfolk	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
of	O
bilateral	O
breast	B
cancer	I
or	O
in	O
and	O
detection	O
of	O
a	O
mutation	O
,	O
or	O
between	O
the	O
position	O
in	O
the	O
BRCA1	O
gene	O
and	O
the	O
presence	O
ovarian	B
cancer	I
family	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
breast	B
cancer	I
or	O
number	O
breast	B
cancers	I
in	O
and	O
BRCA1	O
mutation	O
,	O
between	O
the	O
of	O
the	O
mutation	O
BRCA1	O
gene	O
and	O
the	O
presence	O
ovarian	B
in	O
a	O
family	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
bearing	O
betwixt	O
betwixt	O
genus	O
cancer	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
bearing	O
the	O
BRCA1	O
gene	O
and	B
the	I
presence	O
of	O
ovarian	O
cancer	O

cancer	O
and	O
was	O
found	O
.	O
the	O
BRCA1	O
cancers	O
bilateral	O
breast	B
cancer	I
or	O
the	O
presence	O
a	O
breast	B
of	I
the	O
a	O
family	O
between	O
the	O
detection	O
of	O
,	O
BRCA1	O
mutation	O
presence	O
in	O
between	O
or	O
association	O
of	O
the	O
mutation	O
in	O
the	O
number	O
position	O
and	O
the	O
a	O
of	O
ovarian	B
No	I
in	O
of	O
family	O
gene	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
bearing	O
betwixt	O
betwixt	O
genus	O
cancer	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
inward	O
antiophthalmic	O
factor	O
phratry	O
betwixt	O
the	O
BRCA1	O
gene	O
and	B
the	I
presence	O
of	O
ovarian	O
cancer	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B
cancer	I
in	O
a	O
family	O
.	O

women	O
cancer	I
and	O
a	O
family	O
of	O
the	O
the	O
percentage	O
BRCA1	O
coding	O
is	O
than	O
the	O
45	O
predicted	O
by	O
genetic	O
linkage	O
analysis	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
pct	O
genus	O
cancer	B
breast	I
cancer	O
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
genus	O

than	O
coding	O
women	O
with	O
breast	B
cancer	I
45	O
a	O
family	O
history	O
of	O
the	O
disease	O
percent	O
by	O
percentage	O
with	O
BRCA1	O
analysis	O
-	O
region	O
mutations	O
-	O
less	O
CONCLUSIONS	O
the	O
and	O
,	O
the	O
is	O
genetic	O
predicted	O
linkage	O
.	O
Among	O

finale	O
Among	O
women	O
with	O
knocker	B
crab	I
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
share	O
with	O
BRCA1	O
coding	O
-	O
part	O
variation	O
is	O
less	O
than	O
the	O
45	O
percent	O
betoken	O
by	O
transmissible	O
-	O
linkage	O
analysis	O
.	O

CONCLUSIONS	O
Among	O
the	O
with	O
breast	B
cancer	I
and	O
mutations	O
family	O
history	O
of	O
less	O
percent	O
,	O
the	O
genetic	O
with	O
BRCA1	O
-	O
the	O
region	O
a	O
is	O
coding	O
than	O
45	O
women	O
linkage	O
predicted	O
by	O
percentage	O
disease	O
-	O
analysis	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
breast	B
cancer	I
and	O
a	O
family	O
history	O
disease	O
,	O
the	O
percentage	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
less	O
than	O
the	O
45	O
predicted	O
by	O
-	O
linkage	O
analysis	O
.	O

finis	O
Among	O
charwoman	O
with	O
breast	B
cancer	I
and	O
a	O
category	O
chronicle	O
of	O
the	O
disease	O
,	O
the	O
part	O
with	O
BRCA1	O
steganography	O
-	O
realm	O
sport	O
is	O
less	O
than	O
the	O
45	O
percent	O
presage	O
by	O
familial	O
-	O
linkage	O
analysis	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
pct	O
bosom	O
breast	B
cancer	I
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
percentage	O
genus	O
cancer	O

last	O
Among	O
women	O
with	O
tit	B
crab	I
and	O
a	O
syndicate	O
account	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
realm	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
forebode	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O

percent	O
region	O
women	O
with	O
with	B
cancer	I
the	O
-	O
family	O
history	O
of	O
the	O
disease	O
than	O
a	O
percentage	O
breast	O
genetic	O
coding	O
-	O
,	O
mutations	O
is	O
less	O
Among	O
the	O
45	O
CONCLUSIONS	O
BRCA1	O
by	O
predicted	O
and	O
linkage	O
analysis	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
breast	B
cancer	I
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O

These	O
results	O
mutations	O
that	O
even	O
screening	O
a	O
of	O
clinic	O
specializing	O
in	O
for	O
be	O
from	O
high	O
therefore	O
risk	O
families	O
the	O
,	O
majority	O
referral	O
tests	O
in	O
BRCA1	O
will	O
suggest	O
.	O
negative	O
and	O
-	O
women	O
uninformative	O
.	O

These	O
that	O
even	O
in	O
a	O
clinic	O
specializing	O
women	O
from	O
-	O
risk	O
majority	O
tests	O
for	O
BRCA1	O
will	O
be	O
negative	O
therefore	O
uninformative	O
.	O
.	O

These	O
results	O
suggest	O
that	O
high	O
school	O
antiophthalmic	O
factor	O
phratry	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
even	O
out	O
even	O
out	O
even	O
out	O

These	O
results	O
suggest	O
that	O
high	O
school	O
antiophthalmic	O
factor	O
even	O
out	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
even	O
out	O
even	O
out	O
even	O

results	O
,	O
suggest	O
that	O
even	O
in	O
will	O
referral	O
clinic	O
specializing	O
in	O
be	O
women	O
BRCA1	O
and	O
-	O
risk	O
families	O
screening	O
the	O
majority	O
of	O
.	O
for	O
from	O
mutations	O
a	O
These	O
uninformative	O
tests	O
therefore	O
negative	O
.	O
high	O

These	O
results	O
suggest	O
that	O
even	O
in	O
clinic	O
specializing	O
in	O
screening	O
from	O
high	O
-	O
risk	O
families	O
the	O
majority	O
of	O
tests	O
BRCA1	O
mutations	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
.	O

These	O
termination	O
advise	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
differentiate	O
in	O
cover	O
women	O
from	O
high	O
-	O
risk	O
household	O
,	O
the	O
majority	O
of	O
examine	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
thence	O
uninformative	O
.	O
.	O

These	O
termination	O
suggest	O
that	O
still	O
in	O
a	O
referral	O
clinic	O
speciate	O
in	O
masking	O
women	O
from	O
richly	O
-	O
risk	O
families	O
,	O
the	O
bulk	O
of	O
quiz	O
for	O
BRCA1	O
sport	O
will	O
be	O
veto	O
and	O
consequently	O
uninformative	O
.	O
.	O

These	O
results	O
suggest	O
that	O
high	O
school	O
antiophthalmic	O
factor	O
even	O
out	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
even	O
out	O
even	O
out	O
even	O

These	O
results	O
advise	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
differentiate	O
in	O
sort	O
woman	O
from	O
high	O
-	O
danger	O
family	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
variation	O
will	O
be	O
minus	O
and	O
consequently	O
uninformative	O
.	O
.	O

These	O
results	O
suggest	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
.	O
.	O

Mutations	O
-	O
the	O
arginine	O
in	O
rich	O
gene	O
)	O
(	O
ARP	O
pancreatic	O
in	O
protein	B
cancer	I
.	O

Mutations	O
in	O
inward	O
cistron	O
genus	O
cancer	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
plentiful	O
ARP	O
)	O
in	B
pancreatic	I
cancer	O

sport	O
in	O
the	O
arginine	O
-	O
fat	O
protein	O
cistron	O
(	O
ARP	O
)	O
in	O
pancreatic	B
crab	I
.	O

pancreatic	O
in	O
the	O
Mutations	O
gene	O
rich	O
protein	O
in	O
(	O
ARP	O
)	O
-	O
arginine	B
cancer	I
.	O

Mutations	O
in	O
the	O
arginine	O
-	O
fertile	O
protein	O
cistron	O
(	O
arp	O
)	O
in	O
pancreatic	B
cancer	I
.	O

Mutations	O
in	O
inward	O
cistron	O
genus	O
cancer	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
inward	O
ARP	O
)	O
in	B
pancreatic	I
cancer	O

Mutations	O
the	O
-	O
protein	O
gene	O
(	O
ARP	O
)	O
in	O
pancreatic	B
cancer	I
.	O

gene	O
arginine	O
the	O
in	O
-	O
rich	O
ARP	O
Mutations	O
(	O
protein	O
)	O
in	O
pancreatic	B
.	I
cancer	O

sport	O
in	O
the	O
arginine	O
-	O
robust	O
protein	O
cistron	O
(	O
ARP	O
)	O
in	O
pancreatic	B
cancer	I
.	O

Mutations	O
in	O
inward	O
cistron	O
genus	O
cancer	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
inward	O
ARP	O
)	O
in	B
pancreatic	I
cancer	O

Mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
ARP	O
)	O
in	O
pancreatic	B
cancer	I
.	O

The	O
ARP	O
husband	O
cistron	O
cistron	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
extremely	O
.	O

band	O
ARP	O
gene	O
.	O
a	O
highly	O
conserved	O
arginine	O
3p21	O
rich	O
protein	O
from	O
The	O
chromosomal	O
-	O
encodes	O

The	O
ARP	O
husband	O
cistron	O
hans	O
arp	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
extremely	O

The	O
arp	O
cistron	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
deep	O
protein	O
from	O
chromosomal	O
stripe	O
3p21	O
.	O

chromosomal	O
ARP	O
gene	O
arginine	O
a	O
highly	O
band	O
encodes	O
-	O
rich	O
The	O
from	O
protein	O
conserved	O
3p21	O
.	O

The	O
ARP	O
husband	O
cistron	O
cistron	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
extremely	O
.	O

The	O
ARP	O
cistron	O
encodes	O
a	O
extremely	O
economise	O
arginine	O
-	O
copious	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

The	O
ARP	O
factor	O
encodes	O
a	O
extremely	O
economize	O
arginine	O
-	O
deep	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

The	O
ARP	O
-	O
.	O
a	O
highly	O
chromosomal	O
arginine	O
gene	O
rich	O
protein	O
from	O
conserved	O
band	O
encodes	O
3p21	O

ARP	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

The	O
ARP	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

1	O
.	O

1	O
1	O

1	O
.	O
1	O

1	O
1	O
	O
.	O

1	O
1	O
	O
.	O

unity	O
unity	O
.	O

ane	O
ane	O
.	O

i	O
i	O
.	O

1	O
1	O
	O
.	O

1	O
1	O
.	O

At	O
the	O
cytogenetic	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
solid	B
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
inward	O
genus	O
cancer	O
genus	O
cancer	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
not	B
in	I
pancreatic	O

At	O
the	O
cytogenetic	O
even	O
this	O
part	O
is	O
oft	O
cancel	O
in	O
a	O
variety	O
of	O
dissimilar	O
substantial	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
inward	O
genus	O
cancer	O
genus	O
cancer	O
cytogenetical	O
cytogenetical	O
cytogenetical	O
not	B
in	I
pancreatic	O

at	O
the	O
cytogenetic	O
tier	O
this	O
region	O
is	O
ofttimes	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
unanimous	B
neoplasm	I
,	O
although	O
not	O
in	O
pancreatic	B
crab	I
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
variety	O
of	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B

a	O
the	O
cytogenetic	O
not	O
this	O
region	O
is	O
deleted	O
frequently	O
in	O
in	O
variety	O
different	O
of	O
.	B
tumors	I
,	O
although	O
level	O
At	O
pancreatic	B
cancer	I
solid	O

astatine	O
the	O
cytogenetic	O
rase	O
this	O
area	O
is	O
oft	O
cancel	O
in	O
a	O
variety	O
of	O
unlike	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

solid	O
the	O
deleted	O
is	O
this	O
region	O
tumors	O
frequently	O
cytogenetic	O
in	O
a	O
variety	O
pancreatic	O
different	O
level	B
At	I
,	O
although	O
not	O
in	O
of	B
cancer	I
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
,	O
1996a	O
)	O
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
antiophthalmic	O
factor	O
,	O
1996a	O
)	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
bearing	O
,	O
1996a	O
)	O
.	O

gene	O
of	O
reported	O
the	O
presence	O
of	O
-	O
.	O
mutation	O
(	O
ATG50	O
a	O
-	O
tumor	O
(	O
)	O
or	O
deletion	O
specific	O
codon	O
50	O
al	O
types	O
ARP	O
We	O
in	O
et	O
>	B
AGG	I
the	O
Shridhar	O
1996	O
of	O
have	O
,	O
different	O
,	O
1996a	O
)	O
.	O

We	O
have	O
reported	O
the	O
specific	O
mutation	O
(	O
ATG50	O
-	O
>	O
AGG	O
of	O
of	O
the	O
in	O
types	I
(	O
Shridhar	O
et	O
.	O
,	O
1996a	O
)	O

We	O
have	O
describe	O
the	O
front	O
of	O
a	O
particular	O
variation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
omission	O
of	O
codon	O
fifty	O
of	O
the	O
ARP	O
factor	O
in	O
unlike	O
tumour	B
case	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

We	O
have	O
describe	O
the	O
comportment	O
of	O
a	O
particular	O
variation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
cut	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
cistron	O
in	O
dissimilar	O
tumour	B
case	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

Shridhar	O
,	O
reported	O
the	O
or	O
of	O
1996a	O
et	O
mutation	O
(	O
ATG50	O
-	O
-	O
gene	O
deletion	O
)	O
presence	O
AGG	O
of	O
codon	O
>	O
of	O
the	O
ARP	O
have	O
in	O
different	O
)	B
We	I
(	O
types	O
a	O
al	O
.	O
50	O
1996	O
,	O
specific	O
tumor	O
.	O

We	O
have	O
cover	O
the	O
mien	O
of	O
a	O
particular	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
cut	O
of	O
codon	O
fifty	O
of	O
the	O
ARP	O
cistron	O
in	O
dissimilar	O
neoplasm	B
case	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

We	O
have	O
Shridhar	O
the	O
presence	O
1996	O
ATG50	O
specific	O
mutation	O
(	O
a	O
different	O
codon	O
>	O
AGG	O
of	O
or	O
deletion	O
1996a	O
-	O
50	O
of	O
the	O
of	O
gene	O
)	O
-	O
al	B
et	I
(	O
reported	O
tumor	O
types	O
.	O
,	O
ARP	O
,	O
in	O
)	O
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al	O
.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

In	O
the	O
mutations	O
of	O
,	O
we	O
in	O
observed	O
present	O
involving	O
codon	O
50	O
have	O
11	O
study	O
37	O
pancreatic	B
tumors	I
.	O

present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
37	O
pancreatic	B
tumors	I
.	O

in	O
the	O
present	O
field	O
,	O
we	O
have	O
observed	O
mutations	O
need	O
codon	O
fifty	O
in	O
11	O
of	O
xxxvii	O
pancreatic	B
tumors	I
.	O

indiana	O
the	O
award	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involve	O
codon	O
50	O
indiana	O
xi	O
of	O
37	O
pancreatic	B
neoplasm	I
.	O

pancreatic	O
the	O
present	O
study	O
,	O
we	O
11	O
of	O
mutations	O
involving	O
codon	O
50	O
tumors	O
have	O
observed	O
37	O
in	B
In	I
.	O

In	O
the	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
tumors	I
gift	O
gift	O
gift	O
gift	O
inward	O
.	O

In	O
the	O
show	O
read	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
fifty	O
in	O
eleven	O
of	O
37	O
pancreatic	B
tumour	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
tumors	I
gift	O
gift	O
gift	O
gift	O
gift	O
.	O

11	O
the	O
present	O
codon	O
,	O
we	O
have	O
.	O
of	O
involving	O
study	O
50	O
In	O
in	O
mutations	O
37	O
pancreatic	B
tumors	I
observed	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
tumors	I
.	O

The	O
frequency	O
of	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B
previously	O
examined	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
in	O
types	O
of	O
tumors	B
previously	O
examined	O
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
antecedently	O
study	O
study	O
inward	O
inward	O
inward	O
of	O
tumors	B
previously	O
examined	O
.	O

The	O
frequency	O
of	O
codon	O
fifty	O
variation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumour	I
as	O
in	O
the	O
other	O
eccentric	O
of	O
tumour	B
antecedently	O
prove	O
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
antecedently	O
study	O
study	O
inward	O
inward	O
inward	O
of	O
tumors	B
previously	O
examined	O
.	O

The	O
frequency	O
of	O
codon	O
fifty	O
sport	O
is	O
around	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B
antecedently	O
probe	O
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
pancreatic	B
tumors	I
in	O
the	O
other	O
types	O
of	O
tumors	B
previously	O

in	O
frequency	O
of	O
of	O
50	O
mutation	O
is	O
the	O
roughly	O
same	O
tumors	O
pancreatic	B
as	I
tumors	O
.	O
the	O
other	O
types	O
codon	O
The	B
previously	O
examined	O
in	O

The	O
frequency	O
of	O
codon	O
fifty	O
sport	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
neoplasm	I
as	O
in	O
the	O
other	O
case	O
of	O
neoplasm	B
antecedently	O
analyse	O
.	O

in	O
frequency	O
the	O
is	O
50	O
mutation	O
the	O
roughly	O
of	O
same	O
in	O
pancreatic	B
previously	I
as	O
codon	O
The	O
other	O
types	O
of	O
tumors	B
tumors	O
examined	O
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B
previously	O
examined	O
.	O

In	O
improver	O
,	O
we	O
have	O
find	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
neoplasm	I
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
	B
	O
	B
	O
	B
	O
tumors	I
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
	B
	O
	B
	O
	B
	O
tumors	I
.	O

,	O
detected	O
mutations	O
at	O
51	O
in	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
tumors	I
.	O

In	O
addition	O
,	O
we	O
have	O
at	O
codon	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
tumors	I
.	O

,	O
we	O
have	O
detected	O
at	O
codon	O
51	O
in	O
multiple	O
subclones	O
in	O
two	O
other	O
tumors	I
.	O

pancreatic	O
addition	O
,	O
tumors	O
have	O
detected	O
mutations	O
codon	O
at	O
51	O
in	O
multiple	O
PCR	O
.	O
In	O
two	O
other	O
in	B
we	I
subclones	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
	B
	O
	B
	O
	B
early	O
tumors	I
.	O

in	O
gain	O
,	O
we	O
have	O
find	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
ii	O
other	O
pancreatic	B
tumour	I
.	O

other	O
addition	O
,	O
we	O
have	O
detected	O
subclones	O
multiple	O
codon	O
51	O
in	O
in	O
In	O
mutations	O
at	O
pancreatic	O
PCR	O
two	B
tumors	I
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
tumors	I
.	O

Mutations	O
in	O
the	O
ARP	O
factor	O
are	O
hence	O
usually	O
respect	O
in	O
pancreatic	B
cancer	I
,	O
as	O
easily	O
as	O
many	O
other	O
cancers	B
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
note	O
note	O
note	O
note	O
note	O
note	O
cancers	B
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
note	O
note	O
note	O
note	O
note	O
note	O
cancers	B
.	O

the	O
are	O
thus	O
commonly	O
in	O
pancreatic	B
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
commonly	O
observed	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B
.	O

the	O
ARP	O
gene	O
are	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
as	O
well	O
as	O
many	O
cancers	B
.	O

other	O
in	O
the	O
cancers	O
gene	O
are	O
thus	O
observed	O
commonly	O
in	O
well	B
cancer	I
,	O
.	O
Mutations	O
as	O
many	O
pancreatic	O
ARP	B
as	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
note	O
note	O
note	O
note	O
note	O
inward	O
cancers	B
.	O

mutation	O
in	O
the	O
ARP	O
cistron	O
are	O
thus	O
unremarkably	O
note	O
in	O
pancreatic	B
crab	I
,	O
as	O
easily	O
as	O
many	O
other	O
cancers	B
.	O

many	O
in	O
the	O
ARP	O
gene	O
are	O
as	O
cancer	O
observed	O
in	O
pancreatic	B
well	I
Mutations	O
thus	O
commonly	O
other	O
,	O
as	O
cancers	B
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B
.	O

difficulty	O
in	O
the	O
ascertainment	O
of	O
C9	B
insufficiency	I
:	O
lessons	O
to	O
be	O
imbibe	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
inferior	I
discipline	O
.	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
matter	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
matter	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
to	O
be	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
deficient	I

compound	O
in	O
lessons	O
deficiency	O
of	O
C9	B
heterozygote	I
:	O
the	O
to	O
be	O
drawn	O
.	O
a	O
ascertainment	O
Difficulties	O
C9	B
-	I
deficient	I
subject	O
from	O

trouble	O
in	O
the	O
ascertainment	O
of	O
C9	B
insufficiency	I
:	O
example	O
to	O
be	O
delineate	O
from	O
a	O
intensify	O
heterozygote	O
C9	B
-	I
insufficient	I
subject	O
.	O

.	O
in	O
the	O
be	O
of	O
C9	B
deficiency	I
deficient	O
compound	O
to	O
ascertainment	O
drawn	O
a	O
from	O
lessons	O
heterozygote	O
C9	B
-	I
:	I
Difficulties	O
subject	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
matter	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	I
object	O
lesson	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
compound	O
-	I
deficient	I
subject	O
.	O

difficultness	O
in	O
the	O
ascertainment	O
of	O
C9	B
want	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
combine	O
heterozygote	O
C9	B
-	I
inferior	I
open	O
.	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9	B
-	I
deficient	I
subject	O
.	O

A	O
group	O
of	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
complement	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
inward	O
colloidal	O
gel	O
colloidal	O
gel	O
uneven	O
uneven	O
uneven	O
assays	O
in	O
agarose	O

A	O
radical	O
of	O
patients	O
with	O
retentive	O
-	O
surviving	O
mismatched	O
kidney	O
homograft	O
were	O
investigated	O
for	O
complement	O
officiate	O
expend	O
hemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
inward	O
colloidal	O
gel	O
colloidal	O
gel	O
uneven	O
uneven	O
uneven	O
assays	O
in	O
agarose	O

adenine	O
group	O
of	O
patients	O
with	O
long	O
-	O
living	O
mismatched	O
kidney	O
allografts	O
were	O
inquire	O
for	O
complement	O
use	O
using	O
haemolytic	O
seek	O
in	O
agarose	O
gelatin	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
were	O
investigated	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O

allografts	O
group	O
of	O
assays	O
with	O
long	O
-	O
mismatched	O
surviving	O
kidney	O
in	O
were	O
for	O
investigated	O
.	O
function	O
using	O
haemolytic	O
patients	O
A	O
agarose	O
gels	O
complement	O

A	O
group	O
of	O
patients	O
with	O
retentive	O
-	O
surviving	O
uneven	O
kidney	O
allografts	O
were	O
investigated	O
for	O
accompaniment	O
function	O
utilise	O
hemolytic	O
essay	O
in	O
agarose	O
gels	O
.	O

complement	O
group	O
mismatched	O
-	O
with	O
long	O
function	O
surviving	O
of	O
kidney	O
allografts	O
were	O
agarose	O
for	O
patients	O
A	O
using	O
haemolytic	O
assays	O
in	O
investigated	O
gels	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

but	O
patient	O
was	O
alternative	O
to	O
have	O
no	O
found	O
classical	O
activity	O
normal	O
a	O
One	O
low	O
pathway	O
pathway	O
.	O

ane	O
patient	O
was	O
launch	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
abject	O
convention	O
hellenic	O
pathway	O
.	O

matchless	O
patient	O
was	O
feel	O
to	O
have	O
no	O
alternative	O
pathway	O
action	O
but	O
a	O
low	O
rule	O
hellenic	O
pathway	O
.	O

One	O
patient	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
.	O

One	O
patient	O
was	O
plant	O
to	O
have	O
no	O
alternate	O
pathway	O
activity	O
but	O
a	O
low	O
convention	O
classical	O
pathway	O
.	O

One	O
patient	O
alternate	O
be	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
substitute	O
substitute	O
nobelium	O
.	O

One	O
patient	O
was	O
found	O
to	O
have	O
no	O
alternative	O
activity	O
but	O
low	O
normal	O
classical	O
pathway	O
.	O

One	O
patient	O
alternate	O
be	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
substitute	O
substitute	O
nobelium	O
.	O

patient	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O

One	O
patient	O
pathway	O
classical	O
to	O
have	O
low	O
alternative	O
was	O
activity	O
but	O
a	O
no	O
normal	O
found	O
pathway	O
.	O

One	O
patient	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
.	O

astonishingly	O
,	O
probe	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
pattern	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
remove	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
remove	O
investigating	O
investigating	O
investigating	O
investigating	O
investigating	O
functionally	O
absent	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
remove	O
investigating	O
investigating	O
investigating	O
investigating	O
investigating	O
functionally	O
absent	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
normal	O
for	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O

C9	O
,	O
was	O
patients	O
that	O
the	O
,	O
complement	O
investigation	O
normal	O
for	O
all	O
.	O
except	O
revealed	O
Surprisingly	O
which	O
was	O
functionally	O
absent	O
components	O

surprisingly	O
,	O
investigating	O
divulge	O
that	O
the	O
patients	O
complement	O
was	O
rule	O
for	O
all	O
part	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
scatty	O
.	O

.	O
,	O
investigation	O
for	O
that	O
the	O
patients	O
functionally	O
C9	O
normal	O
revealed	O
all	O
except	O
components	O
was	O
,	O
which	O
was	O
complement	O
Surprisingly	O
absent	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
remove	O
investigating	O
investigating	O
investigating	O
investigating	O
pattern	O
functionally	O
absent	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
C9	O
was	O
functionally	O
absent	O
.	O

surprisingly	O
,	O
probe	O
unveil	O
that	O
the	O
patients	O
complement	O
was	O
formula	O
for	O
all	O
components	O
demur	O
C9	O
,	O
which	O
was	O
functionally	O
remove	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
absent	O
.	O

The	O
patient	O
two	O
shown	O
to	O
be	O
the	O
of	O
DNA	O
markers	O
in	O
a	O
chromosome	O
,	O
C7	O
compound	O
C9	O
region	O
uncharacterized	O
C6	O
5	O
C9	O
therefore	O
appears	O
to	O
and	O
heterozygous	O
and	O
heterozygote	O
for	O
was	O
for	O
be	B
deficiency	I
genes	O
.	O

patient	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
and	O
therefore	O
appears	O
be	O
compound	O
heterozygote	O
for	O
C9	B

The	O
patient	O
was	O
register	O
to	O
be	O
heterozygous	O
for	O
DNA	O
marking	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
part	O
of	O
chromosome	O
fivesome	O
and	O
thence	O
appears	O
to	O
be	O
a	O
combine	O
heterozygote	O
for	O
deuce	O
uncharacterized	O
C9	B
inadequacy	I
cistron	O
.	O

compound	O
5	O
was	O
shown	O
C9	O
be	O
C7	O
uncharacterized	O
DNA	O
markers	O
in	O
the	O
C6	O
to	O
for	O
and	O
to	O
two	O
of	O
chromosome	O
,	O
and	O
therefore	O
appears	O
patient	O
be	O
a	O
The	O
region	O
for	O
heterozygote	O
heterozygous	O
C9	B
deficiency	I
genes	O
.	O

The	O
patient	O
was	O
shown	O
	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
.	O

to	O
of	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
compound	O
for	O
and	O
C9	O
region	O
deficiency	O
chromosome	O
5	O
and	O
heterozygote	O
appears	O
The	O
be	O
uncharacterized	O
,	O
C7	O
therefore	O
two	O
.	O
C9	B
genes	I
patient	O
a	O

The	O
patient	O
was	O
shown	O
be	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
.	O

The	O
patient	O
was	O
prove	O
to	O
be	O
heterozygous	O
for	O
DNA	O
marking	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
neighborhood	O
of	O
chromosome	O
5	O
and	O
thence	O
appears	O
to	O
be	O
a	O
colonial	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
lack	I
cistron	O
.	O

The	O
patient	O
was	O
shown	O
dna	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
desoxyribonucleic	O
acid	O
desoxyribonucleic	O
acid	O
desoxyribonucleic	O
acid	O
desoxyribonucleic	O
acid	O
desoxyribonucleic	O
acid	O

The	O
patient	O
was	O
present	O
to	O
be	O
heterozygous	O
for	O
dna	O
marking	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
realm	O
of	O
chromosome	O
cinque	O
and	O
hence	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
want	I
genes	O
.	O

The	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
.	O

of	O
analysis	O
by	O
has	O
revealed	O
that	O
he	O
ELISA	O
functional	O
concentrations	O
-	O
a	O
Serological	O
non	O
trace	O
C9	O
molecule	O
.	O

serological	O
analysis	O
by	O
elisa	O
revealed	O
that	O
he	O
has	O
shadow	O
concentrations	O
of	O
a	O
not	O
-	O
functional	O
C9	O
speck	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
line	O
density	O
of	O
a	O
not	O
-	O
running	O
C9	O
particle	O
.	O

Serological	O
analysis	O
by	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
expose	O
that	O
he	O
has	O
touch	O
concentrations	O
of	O
a	O
not	O
-	O
usable	O
C9	O
atom	O
.	O

Serological	O
analysis	O
aside	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
apart	O
apart	O
apart	O
give	O
birth	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
a	O
non	O
functional	O
C9	O
molecule	O
.	O

Serological	O
analysis	O
aside	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
apart	O
apart	O
apart	O
give	O
birth	O

analysis	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
.	O

Serological	O
analysis	O
trace	O
functional	O
revealed	O
that	O
non	O
has	O
by	O
concentrations	O
of	O
a	O
he	O
-	O
ELISA	O
C9	O
molecule	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
.	O

Western	O
analysis	O
not	O
sensitive	O
to	O
permit	O
detection	O
of	O
this	O
molecule	O
.	O

Western	O
slur	O
analysis	O
was	O
not	O
sufficiently	O
sensible	O
to	O
tolerate	O
detection	O
of	O
this	O
atom	O
.	O

to	O
was	O
analysis	O
blot	O
not	O
sufficiently	O
detection	O
Western	O
permit	O
.	O
of	O
this	O
molecule	O
sensitive	O

Western	O
blot	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
detection	O
of	O
molecule	O
.	O

Western	O
blot	O
depth	O
psychology	O
depth	O
psychology	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
mote	O
non	O
detection	O
of	O
this	O

Western	O
blot	O
depth	O
psychology	O
depth	O
psychology	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
mote	O
be	O
detection	O
of	O
this	O

Western	O
smear	O
analysis	O
was	O
not	O
sufficiently	O
sore	O
to	O
permit	O
sensing	O
of	O
this	O
atom	O
.	O

molecule	O
blot	O
analysis	O
Western	O
to	O
sufficiently	O
sensitive	O
this	O
permit	O
detection	O
of	O
not	O
was	O
.	O

Western	O
blot	O
depth	O
psychology	O
depth	O
psychology	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
mote	O
non	O
detection	O
of	O
this	O

westerly	O
smirch	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
catching	O
of	O
this	O
mote	O
.	O

Western	O
blot	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
detection	O
of	O
this	O
molecule	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
faulty	O
antiophthalmic	O
factor	O
faulty	O
faulty	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
lead	O
hyposynthesis	O
of	O
a	O

that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
hyposynthesis	O
a	O
defective	O
C9	O
.	O

We	O
theorise	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
over	B
insufficiency	I
of	I
C9	I
and	O
for	O
a	O
factor	O
organise	O
hyposynthesis	O
of	O
a	O
bad	O
C9	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
a	O
complete	B
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
a	O
defective	O
C9	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
faulty	O
antiophthalmic	O
factor	O
faulty	O
faulty	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
hyposynthesis	O
of	O

We	O
hypothecate	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
perfect	B
insufficiency	I
of	I
C9	I
and	O
for	O
a	O
cistron	O
guide	O
hyposynthesis	O
of	O
a	O
faulty	O
C9	O
.	O

We	O
hypothesise	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
gross	B
insufficiency	I
of	I
C9	I
and	O
for	O
a	O
cistron	O
lead	O
hyposynthesis	O
of	O
a	O
faulty	O
C9	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
deficiency	I
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
faulty	O
antiophthalmic	O
factor	O
faulty	O
faulty	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
hyposynthesis	O
of	O

directing	O
hypothesize	O
that	O
deficiency	O
patient	O
is	O
heterozygous	O
hyposynthesis	O
.	O
complete	B
the	I
of	I
C9	I
and	O
C9	O
a	O
gene	O
a	O
for	O
We	O
of	O
defective	O
for	O
a	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
C9	O
.	O

among	O
also	O
suggest	O
be	O
C9	B
deficiency	I
may	O
that	O
been	O
common	O
has	O
Caucasians	O
We	O
than	O
more	O
reported	O
.	O
.	O

We	O
also	O
advise	O
that	O
C9	B
want	I
whitethorn	O
be	O
more	O
usual	O
among	O
Caucasians	O
than	O
has	O
been	O
account	O
.	O
.	O

We	O
likewise	O
suggest	O
that	O
C9	B
inadequacy	I
may	O
be	O
more	O
vernacular	O
among	O
white	O
than	O
has	O
been	O
cover	O
.	O
.	O

We	O
also	O
suggest	O
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
.	O
.	O

We	O
also	O
evoke	O
that	O
C9	B
lack	I
may	O
be	O
more	O
mutual	O
among	O
caucasian	O
than	O
has	O
been	O
account	O
.	O
.	O

We	O
also	O
advise	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
.	O
rede	O
rede	O
rede	O
follow	O
.	O

We	O
also	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
Caucasians	O
than	O
been	O
reported	O
.	O
.	O

We	O
also	O
advise	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
.	O
rede	O
rede	O
rede	O
follow	O
.	O

also	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
.	O

We	O
also	O
more	O
been	O
C9	B
deficiency	I
than	O
be	O
suggest	O
common	O
among	O
Caucasians	O
may	O
has	O
that	O
reported	O
.	O
.	O

We	O
also	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
.	O
.	O

riddle	O
for	O
ESR	O
sport	O
in	O
titty	B
and	I
ovarian	I
cancer	I
patients	O
.	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B
and	I
ovarian	I
cancer	I
inward	O
inward	O
inward	O
patients	O
.	O

sieve	O
for	O
ESR	O
sport	O
in	O
tit	B
and	I
ovarian	I
cancer	I
patients	O
.	O

Screening	O
for	O
esr	O
mutations	O
in	O
boob	B
and	I
ovarian	I
crab	I
patients	O
.	O

for	O
ESR	O
in	O
breast	B
and	I
ovarian	I
cancer	I
patients	O
.	O

ovarian	O
for	O
ESR	O
in	O
mutations	O
breast	B
patients	I
Screening	I
cancer	I
and	O
.	O

Screening	O
ovarian	O
ESR	O
mutations	O
for	O
breast	B
and	I
.	I
cancer	I
patients	O
in	O

mutations	O
ovarian	O
ESR	O
and	O
in	O
breast	B
Screening	I
for	I
cancer	I
patients	O
.	O

Screening	O
ESR	O
in	O
and	I
ovarian	I
cancer	I
patients	O
.	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B
and	I
ovarian	I
cancer	I
inward	O
inward	O
inward	O
patients	O
.	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B
and	I
ovarian	I
cancer	I
patients	O
.	O

In	O
the	O
demonstrate	O
contemplate	O
,	O
leukocyte	O
dna	O
from	O
143	O
patients	O
with	O
hereditary	O
clustering	O
of	O
knocker	B
and	I
/	I
or	I
ovarian	I
crab	I
and	O
tumor	B
dna	O
from	O
xcvi	O
knocker	B
carcinomas	I
were	O
screened	O
for	O
stem	O
mutant	O
in	O
the	O
estrogen	O
receptor	O
factor	O
(	O
ESR	O
)	O
.	O

indium	O
the	O
acquaint	O
cogitation	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
transmitted	O
clustering	O
of	O
tit	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
tumor	B
DNA	O
from	O
96	O
tit	B
carcinomas	I
were	O
screened	O
for	O
cornerstone	O
mutations	O
indium	O
the	O
estrogen	O
receptor	O
factor	O
(	O
ESR	O
)	O
.	O

In	O
,	O
DNA	O
from	O
143	O
with	O
familial	O
clustering	O
breast	B
and	I
/	I
or	I
ovarian	I
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
mutations	O
the	O
estrogen	O
receptor	O
(	O
ESR	O
)	O
.	O

In	O
the	O
mutations	O
study	O
,	O
screened	O
breast	O
from	O
143	O
patients	O
with	O
from	O
were	O
of	O
breast	B
base	I
/	I
or	I
cancer	I
ovarian	I
and	O
tumour	B
DNA	O
receptor	O
96	O
carcinomas	B
clustering	I
in	O
leukocyte	O
for	O
and	O
(	O
DNA	O
the	O
estrogen	O
familial	O
gene	O
present	O
ESR	O
)	O
.	O

96	O
ovarian	O
present	O
study	O
,	O
leukocyte	O
familial	O
tumour	O
143	O
patients	O
with	O
DNA	O
clustering	O
were	O
for	B
and	I
/	I
or	I
.	I
cancer	I
and	O
from	B
screened	O
from	O
In	O
breast	B
mutations	I
of	O
breast	O
DNA	O
base	O
receptor	O
in	O
the	O
estrogen	O
carcinomas	O
gene	O
(	O
ESR	O
)	O
the	O

In	O
the	O
present	O
study	O
DNA	O
from	O
143	O
patients	O
familial	O
clustering	O
of	O
breast	B
and	I
or	I
ovarian	I
cancer	I
and	O
DNA	O
from	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
estrogen	O
receptor	O
(	O
ESR	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
mutation	O
sedimentation	O
rate	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
gene	O
(	O
ESR	O
)	O

In	O
the	O
present	O
study	O
from	O
143	O
patients	O
with	O
familial	O
of	O
breast	B
ovarian	I
tumour	B
DNA	O
breast	B
screened	O
for	O
base	O
mutations	O
the	O
estrogen	O
(	O
ESR	O
.	O

inch	O
the	O
salute	O
study	O
,	O
leucocyte	O
DNA	O
from	O
143	O
patients	O
with	O
transmitted	O
clustering	O
of	O
front	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
tumor	B
DNA	O
from	O
96	O
front	B
carcinomas	I
were	O
riddle	O
for	O
substructure	O
mutations	O
inch	O
the	O
estrogen	O
receptor	O
cistron	O
(	O
ESR	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
mutation	O
sedimentation	O
rate	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
gene	O
(	O
ESR	O
)	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B
and	I
/	I
or	I
ovarian	I
cancer	I
and	O
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
ESR	O
)	O
.	O

Three	O
family	O
with	O
a	O
patients	O
history	O
cancer	O
a	B
were	O
carrying	O
germline	O
Gly160Cys	O
of	O
substitution	O
.	O

Three	O
patients	O
follow	O
genus	O
cancer	O
be	O
with	O
a	O
family	O
history	O
of	B
cancer	O
were	O
patient	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O

trine	O
patients	O
with	O
a	O
family	O
account	O
of	O
cancer	B
were	O
acquit	O
a	O
Gly160Cys	O
germline	O
commutation	O
.	O

germline	O
patients	O
with	O
Three	O
cancer	O
history	O
of	O
Gly160Cys	B
were	O
carrying	O
a	O
family	O
a	O
substitution	O
.	O

ternion	O
patients	O
with	O
a	O
kin	O
history	O
of	O
cancer	B
were	O
pack	O
a	O
Gly160Cys	O
germline	O
commutation	O
.	O

Three	O
patients	O
follow	O
genus	O
cancer	O
be	O
with	O
a	O
family	O
history	O
of	B
cancer	O
were	O
phratry	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O

Three	O
with	O
family	O
of	O
cancer	B
were	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O
.	O

cancer	O
a	O
with	O
patients	O
family	O
history	O
carrying	O
Three	B
were	O
of	O
a	O
Gly160Cys	O
germline	O
.	O
substitution	O

Three	O
patients	O
with	O
a	O
family	O
chronicle	O
of	O
crab	B
were	O
express	O
a	O
Gly160Cys	O
germline	O
replacement	O
.	O

Three	O
patients	O
follow	O
genus	O
cancer	O
be	O
with	O
a	O
family	O
history	O
of	B
cancer	O
were	O
phratry	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O

Three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	B
were	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O
.	O

This	O
alteration	O
indicating	O
also	O
detected	O
four	O
eight	O
363	O
four	O
females	O
and	O
)	O
the	O
)	O
of	O
represents	O
controls	O
(	O
female	O
366	O
,	O
(	O
males	O
in	O
,	O
that	O
was	O
polymorphism	O
substitution	O
probably	O
729	O
males	O
a	O
.	O

This	O
also	O
detected	O
in	O
eight	O
four	O
females	O
males	O
)	O
729	O
controls	O
,	O
males	O
)	O
,	O
that	O
the	O
substitution	O
represents	O
a	O
polymorphism	O
.	O

This	O
alteration	O
was	O
also	O
inward	O
	O
permutation	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
observe	O
.	O

This	O
alteration	O
was	O
also	O
inward	O
	O
observe	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
observe	O
.	O

alteration	O
366	O
was	O
also	O
detected	O
in	O
that	O
(	O
four	O
females	O
and	O
the	O
males	O
,	O
probably	O
729	O
controls	O
(	O
four	O
female	O
,	O
363	O
.	O
)	O
)	O
indicating	O
eight	O
This	O
a	O
males	O
represents	O
substitution	O
polymorphism	O
of	O

This	O
alteration	O
was	O
also	O
detected	O
in	O
four	O
females	O
and	O
four	O
)	O
of	O
729	O
controls	O
(	O
female	O
,	O
363	O
males	O
,	O
indicating	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
.	O

This	O
revision	O
was	O
too	O
observe	O
in	O
eight	O
(	O
quartet	O
females	O
and	O
quartet	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
distaff	O
,	O
363	O
males	O
)	O
,	O
show	O
that	O
the	O
commutation	O
plausibly	O
be	O
a	O
pleomorphism	O
.	O

This	O
modification	O
was	O
also	O
notice	O
in	O
ogdoad	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
ascertain	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
show	O
that	O
the	O
switch	O
belike	O
typify	O
a	O
pleomorphism	O
.	O

This	O
alteration	O
was	O
also	O
inward	O
	O
observe	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
inwards	O
observe	O
.	O

This	O
revision	O
was	O
besides	O
notice	O
in	O
octad	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
contain	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
point	O
that	O
the	O
switch	O
likely	O
act	O
a	O
pleomorphism	O
.	O

This	O
alteration	O
was	O
also	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
.	O

However	O
,	O
in	O
the	O
genus	O
cancer	O
be	O
get	O
it	O
on	O
ascertain	O
	O
229	O
female	O
controls	O
in	O
whom	O
family	B
history	O
of	O
cancer	O
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	B
sister	I
with	O
breast	O
cancer	O
was	O
carrying	O
the	O
variant	O
allele	O
determine	O
determine	O

However	O
,	O
229	O
family	O
history	O
of	O
was	O
known	O
one	O
of	O
two	O
a	O
sister	O
with	O
breast	B
cancer	I
carrying	O
variant	O
allele	O
.	O

however	O
,	O
in	O
the	O
229	O
female	O
check	O
in	O
whom	O
kinsfolk	O
history	O
of	O
cancer	B
was	O
known	O
,	O
unitary	O
of	O
deuce	O
who	O
had	O
a	O
baby	O
with	O
tit	B
cancer	I
was	O
sway	O
the	O
variant	O
allelomorph	O
.	O

However	O
,	O
in	O
the	O
female	O
whom	O
family	O
history	O
of	O
cancer	B
was	O
known	O
,	O
one	O
a	O
sister	O
with	O
breast	B
cancer	I
was	O
carrying	O
the	O
variant	O
allele	O
.	O

still	O
,	O
in	O
the	O
229	O
female	O
assure	O
in	O
whom	O
sept	O
chronicle	O
of	O
cancer	B
was	O
cognize	O
,	O
peerless	O
of	O
ii	O
who	O
had	O
a	O
sister	O
with	O
summit	B
cancer	I
was	O
persuade	O
the	O
variant	O
allele	O
.	O

However	O
,	O
in	O
the	O
genus	O
cancer	O
be	O
get	O
it	O
on	O
ascertain	O
	O
229	O
female	O
controls	O
in	O
whom	O
family	B
history	O
of	O
cancer	O
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	B
sister	I
with	O
breast	O
cancer	O
was	O
carrying	O
the	O
variant	O
allele	O
determine	O
determine	O

However	O
,	O
in	O
the	O
229	O
female	O
ascendency	O
in	O
whom	O
mob	O
chronicle	O
of	O
cancer	B
was	O
screw	O
,	O
unmatched	O
of	O
deuce	O
who	O
had	O
a	O
sister	O
with	O
knocker	B
cancer	I
was	O
sway	O
the	O
variance	O
allele	O
.	O

had	O
two	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B
breast	O
variant	O
,	O
one	O
of	O
carrying	O
who	O
,	O
a	O
.	O
with	O
was	B
cancer	I
was	O
However	O
known	O
sister	O
allele	O
the	O

However	O
,	O
in	O
the	O
female	O
in	O
whom	O
family	O
history	O
of	O
cancer	B
was	O
known	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
cancer	I
was	O
carrying	O
variant	O
.	O

However	O
,	O
in	O
the	O
genus	O
cancer	O
be	O
get	O
it	O
on	O
ascertain	O
phratry	O
229	O
female	O
controls	O
in	O
whom	O
family	B
history	O
of	O
cancer	O
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	B
sister	I
with	O
breast	O
cancer	O
was	O
carrying	O
the	O
variant	O
allele	O
determine	O
determine	O

However	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B
cancer	I
was	O
carrying	O
the	O
variant	O
allele	O
.	O

investigated	O
,	O
a	O
cysteine	O
clinical	O
significance	O
of	O
be	O
ruled	O
into	O
possible	O
cannot	O
completely	O
be	O
glycine	O
out	O
and	O
should	O
the	O
Hence	O
further	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
look	O
into	O
look	O
into	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
look	O
into	O
look	O
into	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

thence	O
,	O
a	O
potential	O
clinical	O
implication	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
altogether	O
decree	O
out	O
and	O
should	O
be	O
further	O
inquire	O
.	O

Hence	O
,	O
a	O
clinical	O
significance	O
of	O
the	O
glycine	O
cysteine	O
cannot	O
be	O
completely	O
out	O
and	O
be	O
further	O
investigated	O
.	O

possible	O
of	O
the	O
glycine	O
cysteine	O
cannot	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
further	O
investigated	O
.	O

hence	O
,	O
a	O
potential	O
clinical	O
signification	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
wholly	O
predominate	O
out	O
and	O
should	O
be	O
further	O
enquire	O
.	O

ruled	O
,	O
glycine	O
of	O
clinical	O
significance	O
out	O
the	O
a	O
into	O
cysteine	O
cannot	O
investigated	O
completely	O
possible	O
Hence	O
and	O
should	O
be	O
further	O
be	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
look	O
into	O
look	O
into	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

Hence	O
,	O
a	O
possible	O
of	O
the	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
cannot	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
further	O
investigated	O
.	O

Somatic	O
detected	O
any	O
of	O
the	O
studied	O
,	O
and	O
present	O
data	O
do	O
not	O
provide	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
therapy	O
in	O
estrogen	B
receptor	I
positive	I
breast	I
carcinomas	I
.	O
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
the	O
tumours	B
studied	O
,	O
and	O
present	O
data	O
support	O
ESR	O
base	O
an	O
for	O
hormonal	O
therapy	O
resistance	O
estrogen	B
receptor	I
breast	I
carcinomas	I
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
receptor	I
positive	I
degree	I
bosom	I
carcinoma	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
-	I
positive	I
breast	I
carcinomas	O
.	O

corporal	O
sport	O
were	O
not	O
notice	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
stage	O
datum	O
do	O
not	O
furnish	O
support	O
for	O
corporal	O
ESR	O
base	O
sport	O
as	O
an	O
significant	O
mechanism	O
for	O
hormonal	O
therapy	O
opposition	O
in	O
estrogen	B
receptor	I
-	I
positivistic	I
chest	I
carcinomas	I
.	O
.	O

Somatic	O
mutations	O
hormonal	O
not	O
detected	O
receptor	O
any	O
provide	O
the	O
tumours	B
studied	O
an	O
support	O
the	O
present	O
of	O
do	O
not	O
positive	O
and	O
for	O
resistance	O
ESR	O
in	O
mutations	O
data	O
,	O
somatic	O
mechanism	O
for	O
were	O
important	O
therapy	O
in	O
estrogen	B
base	I
-	I
as	I
breast	I
carcinomas	I
.	O
.	O

bodily	O
mutations	O
were	O
not	O
observe	O
in	O
any	O
of	O
the	O
tumours	B
take	O
,	O
and	O
the	O
present	O
datum	O
do	O
not	O
cater	O
support	O
for	O
bodily	O
ESR	O
base	O
mutations	O
as	O
an	O
significant	O
mechanics	O
for	O
hormonal	O
therapy	O
resistivity	O
in	O
estrogen	B
receptor	I
-	I
prescribed	I
breast	I
carcinomas	I
.	O
.	O

estrogen	O
provide	O
were	O
not	O
detected	O
in	O
.	O
of	O
the	O
tumours	B
studied	O
.	O
and	O
mutations	O
for	O
data	O
do	O
not	O
important	O
support	O
for	O
somatic	O
receptor	O
base	O
the	O
as	O
in	O
mutations	O
therapy	O
ESR	O
hormonal	O
mechanism	O
resistance	O
present	O
Somatic	B
an	I
-	I
positive	I
breast	I
carcinomas	I
,	O
any	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
tumours	B
studied	O
,	O
the	O
present	O
data	O
do	O
not	O
support	O
for	O
somatic	O
ESR	O
mutations	O
as	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
-	I
positive	I
carcinomas	I
.	O
.	O

breast	O
mutations	O
were	O
not	O
do	O
in	O
for	O
therapy	O
the	O
tumours	B
studied	O
,	O
and	O
any	O
positive	O
data	O
detected	O
hormonal	O
provide	O
support	O
the	O
somatic	O
ESR	O
base	O
important	O
as	O
an	O
.	O
not	O
for	O
mechanism	O
mutations	O
resistance	O
in	O
estrogen	B
receptor	I
-	I
present	I
Somatic	I
carcinomas	I
.	O
of	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
receptor	I
positive	I
degree	I
bosom	I
carcinoma	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
observe	I
corporal	I
-	I
positive	I
breast	I
carcinomas	O
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
receptor	I
-	I
positive	I
breast	I
carcinomas	I
.	O
.	O

molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
dissimilar	O
fault	O
.	O

Molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
different	O
defects	O
fundament	O
fundament	O
fundament	O
.	O

Molecular	O
radix	O
of	O
C7	B
inadequacy	I
:	O
troika	O
different	O
defects	O
.	O

molecular	O
found	O
of	O
C7	B
want	I
:	O
three	O
different	O
defects	O
.	O

Molecular	O
of	O
C7	B
:	O
three	O
different	O
defects	O
.	O

different	O
.	O
of	O
deficiency	B
C7	I
:	O
three	O
Molecular	O
defects	O
bases	O

Molecular	O
different	O
of	O
C7	B
bases	I
:	O
deficiency	O
three	O
defects	O
.	O

different	O
C7	O
of	O
bases	B
deficiency	I
:	O
.	O
Molecular	O
defects	O
three	O

Molecular	O
C7	B
deficiency	I
:	O
different	O

Molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
different	O
defects	O
fundament	O
fundament	O
fundament	O
.	O

Molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
different	O
defects	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
phratry	O
judaic	O
ancestry	O
judaic	O
ancestry	O
ancestry	O
groundwork	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
of	O
Sephardic	O
Jewish	O
origin	O
.	O

The	O
molecular	O
cornerstone	O
of	O
C7	B
insufficiency	I
has	O
been	O
investigated	O
in	O
ii	O
Irish	O
household	O
and	O
a	O
number	O
of	O
israeli	O
household	O
of	O
Moroccan	O
Sephardic	O
judaic	O
pedigree	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
Irish	O
families	O
a	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
origin	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
phratry	O
judaic	O
ancestry	O
judaic	O
ancestry	O
ancestry	O
groundwork	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

The	O
molecular	O
ground	O
of	O
C7	B
want	I
has	O
been	O
investigated	O
in	O
deuce	O
Irish	O
kinsfolk	O
and	O
a	O
number	O
of	O
israeli	O
kinsfolk	O
of	O
Moroccan	O
Sephardic	O
judaic	O
ancestry	O
.	O

The	O
molecular	O
cornerstone	O
of	O
C7	B
insufficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
household	O
and	O
a	O
total	O
of	O
Israeli	O
household	O
of	O
maroc	O
Sephardic	O
jewish	O
rootage	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
families	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
phratry	O
judaic	O
ancestry	O
judaic	O
ancestry	O
ancestry	O
groundwork	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

of	O
molecular	O
basis	O
two	O
C7	B
deficiency	I
has	O
families	O
origin	O
in	O
of	O
Irish	O
and	O
families	O
Jewish	O
number	O
of	O
Israeli	O
been	O
.	O
Moroccan	O
Sephardic	O
a	O
investigated	O
The	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

Exon	O
PCR	O
and	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O
family	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
site	O
1	O
in	O
one	O
Irish	O
family	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
irish	O
whisky	O
phratry	O
phratry	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
in	O

exon	O
PCR	O
and	O
sequence	O
disclose	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
trio	O
splicing	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
nonpareil	O
Irish	O
family	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
irish	O
whisky	O
phratry	O
phratry	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
chromosomal	O
mutation	O
in	O

Exon	O
PCR	O
and	O
sequencing	O
unveil	O
a	O
heterozygous	O
show	O
mutation	O
at	O
the	O
threesome	O
splicing	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
unitary	O
Irish	O
kinsfolk	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
3	O
splice	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O

the	O
PCR	O
and	O
in	O
revealed	O
a	O
heterozygous	O
mutation	O
point	O
at	O
one	O
3	O
acceptor	O
splice	O
.	O
of	O
intron	O
1	O
sequencing	O
Exon	O
Irish	O
family	O
site	O

Exon	O
PCR	O
and	O
sequence	O
revealed	O
a	O
heterozygous	O
designate	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
locate	O
of	O
intron	O
unitary	O
in	O
unitary	O
Irish	O
category	O
.	O

site	O
PCR	O
mutation	O
heterozygous	O
revealed	O
a	O
of	O
point	O
and	O
at	O
the	O
3	O
Irish	O
acceptor	O
sequencing	O
Exon	O
intron	O
1	O
in	O
one	O
splice	O
family	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O
family	O
.	O

In	O
the	O
other	O
Irish	O
folk	O
,	O
exons	O
seven	O
and	O
8	O
failed	O
to	O
inflate	O
and	O
they	O
were	O
read	O
to	O
be	O
edit	O
.	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
blue	O
pencil	O
early	O
early	O
early	O
early	O
early	O
be	O
deleted	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
blue	O
pencil	O
early	O
early	O
early	O
early	O
early	O
be	O
deleted	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
8	O
failed	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
be	O

they	O
the	O
and	O
exons	O
family	O
,	O
were	O
7	O
other	O
8	O
failed	O
to	O
.	O
and	O
Irish	O
In	O
shown	O
to	O
be	O
deleted	O
amplify	O

inch	O
the	O
other	O
Irish	O
kin	O
,	O
exons	O
sevener	O
and	O
octet	O
failed	O
to	O
magnify	O
and	O
they	O
were	O
shown	O
to	O
be	O
cancel	O
.	O

.	O
the	O
other	O
failed	O
family	O
,	O
exons	O
be	O
they	O
8	O
Irish	O
to	O
and	O
amplify	O
and	O
were	O
shown	O
to	O
7	O
In	O
deleted	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
blue	O
pencil	O
early	O
early	O
early	O
early	O
exon	O
be	O
deleted	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
they	O
to	O
be	O
deleted	O
.	O

In	O
the	O
other	O
Irish	O
household	O
,	O
exons	O
seven	O
and	O
ogdoad	O
failed	O
to	O
expand	O
and	O
they	O
were	O
demo	O
to	O
be	O
erase	O
.	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
be	O
deleted	O
.	O

Marker	O
haplotype	O
not	O
of	O
the	O
C6	O
Southern	O
with	O
gene	O
region	O
and	O
deletion	O
the	O
show	O
that	O
,	O
Irish	O
family	O
easily	O
blots	O
splice	O
detected	O
also	O
segregate	O
for	O
the	O
and	O
defect	O
which	O
is	O
studies	O
C7	O
the	O
in	O
heterozygotes	O
.	O

haplotype	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
defect	O
also	O
segregate	O
the	O
,	O
which	O
is	O
detected	O

mark	O
haplotype	O
canvass	O
of	O
the	O
C6	O
and	O
C7	O
cistron	O
part	O
and	O
southerly	O
blots	O
indicate	O
that	O
the	O
Irish	O
family	O
with	O
the	O
tie	O
mar	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easy	O
find	O
in	O
heterozygotes	O
.	O

,	O
splice	O
studies	O
of	O
Irish	O
C6	O
that	O
easily	O
gene	O
region	O
and	O
Southern	O
blots	O
for	O
C7	O
the	O
the	O
not	O
with	O
the	O
show	O
defect	O
also	O
segregate	O
haplotype	O
the	O
deletion	O
Marker	O
family	O
is	O
which	O
and	O
detected	O
in	O
heterozygotes	O
.	O

Marker	O
haplotype	O
studies	O
of	O
irish	O
whisky	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O

for	O
with	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
,	O
is	O
the	O
Irish	O
family	O
in	O
the	O
splice	O
defect	O
which	O
segregate	O
Marker	O
the	O
easily	O
show	O
that	O
also	O
not	O
.	O
detected	O
heterozygotes	O
haplotype	O
deletion	O

Marker	O
haplotype	O
studies	O
of	O
C6	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

mark	O
haplotype	O
meditate	O
of	O
the	O
C6	O
and	O
C7	O
factor	O
region	O
and	O
southerly	O
blots	O
evidence	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
desert	O
too	O
segregate	O
for	O
the	O
omission	O
,	O
which	O
is	O
not	O
well	O
observe	O
in	O
heterozygotes	O
.	O

Marker	O
haplotype	O
studies	O
of	O
irish	O
whisky	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O
non	O

marking	O
haplotype	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
cistron	O
realm	O
and	O
southern	O
smirch	O
record	O
that	O
the	O
Irish	O
family	O
with	O
the	O
wed	O
fault	O
likewise	O
segregate	O
for	O
the	O
cut	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

Marker	O
haplotype	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
coding	O
dna	O
	O
coding	O
dna	O
	O
	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
sense	O
mutation	O

C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
sense	O
in	O
exon	O
9	O
.	O

The	O
israeli	O
C7	B
-	I
substandard	I
character	O
all	O
parcel	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
gumption	O
mutation	O
in	O
exon	O
niner	O
.	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
a	O
C7	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
in	O
exon	O
9	O
.	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
coding	O
dna	O
	O
coding	O
dna	O
	O
	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
sense	O
mutation	O

The	O
israeli	O
C7	B
-	I
substandard	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
ix	O
.	O

The	O
israeli	O
C7	B
-	I
wanting	I
showcase	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sentience	O
mutation	O
in	O
exon	O
nine	O
.	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
haplotype	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
coding	O
dna	O
	O
coding	O
dna	O
	O
	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
sense	O
mutation	O

-	O
Israeli	O
C7	B
haplotype	I
deficient	I
cases	O
all	O
sense	O
.	O
C7	O
-	O
and	O
are	O
homozygous	O
9	O
a	O
mis	O
in	O
share	O
The	O
mutation	O
exon	O
for	O
a	O

The	O
Israeli	O
C7	B
-	I
deficient	I
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O

However	O
,	O
one	O
individual	O
usher	O
chromosomal	O
mutation	O
thither	O
be	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
ussher	O
ussher	O
ussher	O
ussher	O
follow	O

However	O
,	O
one	O
heterozygous	O
C6	O
loci	O
,	O
that	O
there	O
been	O
an	O
intergenic	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
of	O
antiquity	O
.	O
.	O

nevertheless	O
,	O
unitary	O
individual	O
is	O
heterozygous	O
for	O
marking	O
at	O
conterminous	O
C6	O
locus	O
,	O
evidence	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
propose	O
that	O
the	O
want	O
mutation	O
is	O
of	O
appreciable	O
ancientness	O
.	O
.	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
for	O
at	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
.	O

yet	O
,	O
one	O
soul	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
locus	O
,	O
register	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
propose	O
that	O
the	O
want	O
variation	O
is	O
of	O
appreciable	O
ancientness	O
.	O
.	O

However	O
,	O
one	O
individual	O
usher	O
chromosomal	O
mutation	O
thither	O
be	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
ussher	O
ussher	O
ussher	O
ussher	O
follow	O

notwithstanding	O
,	O
unmatched	O
individual	O
is	O
heterozygous	O
for	O
marking	O
at	O
adjacent	O
C6	O
locale	O
,	O
evidence	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
inadequacy	O
mutation	O
is	O
of	O
appreciable	O
ancientness	O
.	O
.	O

recombination	O
an	O
one	O
individual	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
the	O
appreciable	O
there	O
has	O
been	O
is	O
intergenic	O
,	O
and	O
.	O
that	O
showing	O
deficiency	O
mutation	O
However	O
that	O
suggesting	O
antiquity	O
of	O
.	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
markers	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
is	O
of	O
appreciable	O
.	O

However	O
,	O
one	O
individual	O
usher	O
chromosomal	O
mutation	O
thither	O
chromosomal	O
mutation	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
ussher	O
ussher	O
ussher	O
ussher	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
.	O
.	O

Molecular	O
heterogeneity	O
colloidal	O
gel	O
dielectrolysis	O
chromosomal	O
mutation	B
of	I
classical	I
and	I
Duarte	O
galactosemia	O
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O

gel	O
heterogeneity	O
of	O
.	B
and	I
Duarte	I
galactosemia	I
:	O
electrophoresis	O
analysis	O
by	O
denaturing	O
Molecular	O
gradient	O
mutation	O
classical	O

Molecular	O
heterogeneity	O
important	O
dielectrolysis	O
authoritative	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
electrophoresis	O
.	O

molecular	O
heterogeneity	O
of	O
definitive	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denature	O
slope	O
gel	O
electrophoresis	O
.	O

gradient	O
heterogeneity	O
of	O
:	B
and	I
Duarte	I
gel	I
classical	O
mutation	O
analysis	O
Molecular	O
denaturing	O
by	O
galactosemia	O
electrophoresis	O
.	O

Molecular	O
heterogeneity	O
colloidal	O
gel	O
dielectrolysis	O
chromosomal	O
mutation	B
of	I
classical	I
and	I
Duarte	O
galactosemia	O
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O

molecular	O
heterogeneousness	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denaturing	O
slope	O
gel	O
ionophoresis	O
.	O

Molecular	O
heterogeneousness	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denature	O
slope	O
gel	O
ionophoresis	O
.	O

Molecular	O
heterogeneity	O
mutation	O
.	B
and	I
Duarte	I
gradient	I
:	O
of	O
analysis	O
by	O
denaturing	O
galactosemia	O
gel	O
classical	O
electrophoresis	O

heterogeneity	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Molecular	O
heterogeneity	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
apart	O
aside	O
respective	O
rarified	O
aside	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
orthophosphate	O
be	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
isolated	O
grand	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
apart	O
aside	O
respective	O
rarified	O
aside	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
orthophosphate	O
authoritative	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
isolated	O
grand	O
.	O

gene	B
galactosemia	I
uridyltransferase	O
several	O
by	O
one	O
)	O
missense	O
caused	O
(	O
Q188R	O
)	O
-	O
by	O
is	O
mutation	O
mutations	O
in	O
the	O
galactose	O
and	O
1	O
-	O
phosphate	O
rare	O
common	O
GALT	O
(	O
Classical	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
apart	O
aside	O
respective	O
rarified	O
aside	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
orthophosphate	O
be	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
isolated	O
grand	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
one	O
common	O
mutation	O
(	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
.	O

Classical	B
galactosemia	I
is	O
stimulate	O
by	O
one	O
mutual	O
missense	O
mutant	O
(	O
Q188R	O
)	O
and	O
by	O
various	O
rarified	O
mutant	O
in	O
the	O
galactose	O
-	O
single	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
factor	O
.	O

mutations	B
galactosemia	I
is	O
caused	O
by	O
one	O
1	O
)	O
mutation	O
(	O
Q188R	O
Classical	O
gene	O
phosphate	O
rare	O
several	O
in	O
uridyltransferase	O
the	O
galactose	O
-	O
common	O
-	O
by	O
missense	O
(	O
GALT	O
)	O
and	O
.	O

-	B
galactosemia	I
is	O
the	O
by	O
one	O
common	O
(	O
phosphate	O
(	O
gene	O
)	O
GALT	O
galactose	O
-	O
rare	O
mutations	O
in	O
caused	O
by	O
uridyltransferase	O
1	O
several	O
mutation	O
Classical	O
missense	O
and	O
)	O
Q188R	O
.	O

Classical	B
galactosemia	I
is	O
make	O
by	O
matchless	O
coarse	O
missense	O
sport	O
(	O
Q188R	O
)	O
and	O
by	O
various	O
rare	O
mutations	O
in	O
the	O
galactose	O
-	O
single	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
factor	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
common	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
in	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
GALT	O
)	O
gene	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
.	O

both	O
1	O
common	O
variant	O
of	O
GALT	O
N314D	O
the	O
Duarte	O
variant	O
,	O
change	O
as	O
and	O
D	O
,	O
Duarte	O
-	O
2	O
(	O
D	O
-	O
of	O
)	O
two	O
Duarte	O
,	O
most	O
2	O
1	O
-	O
(	O
)	O
types	O
The	O
-	O
which	O
carry	O
the	O
sequence	O
occurs	O
,	O
.	O

The	O
most	O
common	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
two	O
types	O
,	O
-	O
(	O
D	O
-	O
and	O
D	O
-	O
2	O
,	O
both	O
which	O
carry	O
the	O
N314D	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
character	O
,	O
Duarte	O
-	O
single	O
(	O
ergocalciferol	O
-	O
single	O
)	O
and	O
Duarte	O
-	O
ii	O
(	O
ergocalciferol	O
-	O
ii	O
)	O
,	O
both	O
of	O
which	O
post	O
the	O
succession	O
commute	O
N314D	O
.	O

The	O
most	O
mutual	O
variation	O
of	O
GALT	O
,	O
the	O
Duarte	O
variation	O
,	O
occurs	O
as	O
ii	O
types	O
,	O
Duarte	O
-	O
i	O
(	O
d	O
-	O
i	O
)	O
and	O
Duarte	O
-	O
deuce	O
(	O
d	O
-	O
deuce	O
)	O
,	O
both	O
of	O
which	O
transmit	O
the	O
successiveness	O
alter	O
N314D	O
.	O

The	O
most	O
2	O
variant	O
of	O
GALT	O
,	O
1	O
Duarte	O
variant	O
,	O
as	O
.	O
two	O
types	O
-	O
Duarte	O
-	O
(	O
the	O
D	O
)	O
1	O
of	O
and	O
-	O
2	O
-	O
(	O
D	O
,	O
carry	O
Duarte	O
,	O
both	O
)	O
which	O
common	O
the	O
sequence	O
change	O
N314D	O
occurs	O

The	O
most	O
common	O
of	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
D	O
-	O
1	O
)	O
and	O
Duarte	O
-	O
2	O
(	O
D	O
-	O
2	O
)	O
,	O
both	O
which	O
the	O
sequence	O
change	O
N314D	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
Duarte	O
-	O
1	O
(	O
D	O
-	O
1	O
)	O
and	O
Duarte	O
-	O
2	O
(	O
D	O
-	O
2	O
)	O
,	O
both	O
of	O
modification	O
two	O
episode	O
modification	O
two	O
two	O
two	O
two	O
two	O
two	O
two	O
two	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O
.	O

the	O
and	O
common	O
variant	O
Duarte	O
GALT	O
D	O
2	O
Duarte	O
variant	O
,	O
occurs	O
as	O
,	O
carry	O
,	O
of	O
-	O
1	O
(	O
two	O
-	O
1	O
)	O
2	O
Duarte	O
-	O
N314D	O
-	O
D	O
(	O
most	O
)	O
,	O
both	O
of	O
which	O
types	O
The	O
sequence	O
change	O
the	O
.	O

The	O
most	O
common	O
of	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
-	O
1	O
(	O
D	O
-	O
2	O
-	O
)	O
,	O
both	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O

The	O
most	O
unwashed	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
hap	O
as	O
ii	O
character	O
,	O
Duarte	O
-	O
ane	O
(	O
cholecalciferol	O
-	O
ane	O
)	O
and	O
Duarte	O
-	O
deuce	O
(	O
cholecalciferol	O
-	O
deuce	O
)	O
,	O
both	O
of	O
which	O
channel	O
the	O
successiveness	O
vary	O
N314D	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
Duarte	O
-	O
1	O
(	O
D	O
-	O
1	O
)	O
and	O
Duarte	O
-	O
2	O
(	O
D	O
-	O
2	O
)	O
,	O
both	O
of	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O
.	O

D	O
1	O
increases	O
whereas	O
-	O
decreases	O
GALT	O
activity	O
.	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
decreases	O
GALT	O
activity	O

calciferol	O
-	O
one	O
addition	O
,	O
whereas	O
calciferol	O
-	O
2	O
decreases	O
GALT	O
activity	O
.	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
bodily	O
process	O
	O
decreases	O
GALT	O
activity	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
bodily	O
process	O
bodily	O
process	O
bodily	O
process	O
decreases	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
bodily	O
process	O
	O
decreases	O
GALT	O
activity	O

D	O
-	O
unity	O
growth	O
,	O
whereas	O
D	O
-	O
2	O
reduction	O
GALT	O
activity	O
.	O

D	O
-	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
decreases	O
.	O

cholecalciferol	O
-	O
1	O
increases	O
,	O
whereas	O
cholecalciferol	O
-	O
2	O
lessening	O
GALT	O
action	O
.	O

D	O
,	O
1	O
increases	O
.	O
whereas	O
D	O
-	O
2	O
decreases	O
GALT	O
activity	O
-	O

D	O
-	O
1	O
increases	O
,	O
whereas	O
D	O
-	O
2	O
decreases	O
GALT	O
activity	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
,	O
we	O
analyzed	O
the	O
mutations	O
in	O
30	O
families	O
with	O
galactosemia	I
,	O
in	O
10	O
with	O
the	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
D	O
-	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O

gradient	O
10	O
the	O
molecular	O
genetics	O
of	O
the	B
in	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
.	O
electrophoresis	O
mutations	O
and	O
2	O
families	O
with	O
allele	B
galactosemia	I
,	O
in	O
study	O
families	O
with	O
D	O
30	O
-	O
D	O
classical	O
and	O
in	O
3	O
individuals	O
carrying	O
DGGE	O
the	O
-	O
1	O
classical	O
by	O
denaturing	O
To	O
gel	O
GALT	O
(	O
)	O
variant	O
the	O

To	O
read	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
variation	O
in	O
xxx	O
kinsfolk	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
kinsfolk	O
with	O
the	O
calciferol	O
-	O
two	O
variant	O
and	O
in	O
three	O
soul	O
stock	O
the	O
calciferol	O
-	O
ane	O
allelomorph	O
by	O
denature	O
slope	O
gel	O
cataphoresis	O
(	O
DGGE	O
)	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
var	I
mutation	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
aside	O
denature	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
genetic	O
science	O
inward	O
carrying	O
the	O
D	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
var	I
mutation	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
aside	O
denature	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
genetic	O
science	O
inward	O
carrying	O
the	O
D	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O

study	O
the	O
molecular	O
genetics	O
of	O
and	I
Duarte	I
analyzed	O
mutations	O
in	O
with	O
,	O
in	O
10	O
families	O
the	O
D	O
variant	O
and	O
3	O
individuals	O
-	O
allele	O
by	O
denaturing	O
gel	O
electrophoresis	O
(	O
)	O
.	O

To	O
study	O
the	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
mutations	O
30	O
families	O
with	O
galactosemia	I
,	O
in	O
10	O
families	O
with	O
D	O
-	O
and	O
3	O
individuals	O
carrying	O
the	O
1	O
allele	O
by	O
denaturing	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
authoritative	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
canvas	O
the	O
GALT	O
mutations	O
in	O
30	O
household	O
with	O
authoritative	B
galactosemia	I
,	O
in	O
decade	O
household	O
with	O
the	O
d	O
-	O
ii	O
variation	O
and	O
in	O
ternary	O
soul	O
conduct	O
the	O
d	O
-	O
ane	O
allelomorph	O
by	O
denature	O
gradient	O
mousse	O
cataphoresis	O
(	O
DGGE	O
)	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
variation	O
in	O
30	O
class	O
with	O
classical	B
galactosemia	I
,	O
in	O
ten	O
class	O
with	O
the	O
D	O
-	O
2	O
form	O
and	O
in	O
iii	O
mortal	O
comport	O
the	O
D	O
-	O
1	O
allelomorph	O
by	O
denature	O
slope	O
gel	O
ionophoresis	O
(	O
DGGE	O
)	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
var	I
mutation	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
aside	O
denature	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
slope	O
colloidal	O
gel	O
dielectrolysis	O
genetic	O
science	O
inward	O
carrying	O
the	O
D	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
D	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
definitive	O
galactosemia	B
alleles	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B
alleles	O
observe	O
observe	O
observe	O
.	O

DGGE	O
notice	O
59	O
of	O
the	O
sixty	O
classical	O
galactosemia	B
allelomorph	O
.	O

DGGE	O
observe	O
59	O
of	O
the	O
lx	O
definitive	O
galactosemia	B
alleles	O
.	O

DGGE	O
59	O
of	O
60	O
classical	O
galactosemia	B
alleles	O
.	O

galactosemia	O
.	O
59	O
the	O
of	O
60	O
classical	O
DGGE	B
alleles	O
detected	O

DGGE	O
galactosemia	O
59	O
of	O
detected	O
60	O
the	O
classical	B
alleles	O
.	O

galactosemia	O
of	O
59	O
detected	O
the	O
60	O
.	O
DGGE	B
alleles	O
classical	O

DGGE	O
of	O
the	O
60	O
galactosemia	B

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B
alleles	O
observe	O
observe	O
observe	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B
alleles	O
.	O

Q188R	O
%	O
for	O
60	O
accounted	O
,	O
accounted	O
%	O
for	O
28	O
these	O
of	O
K285N	O
alleles	O
.	O

Q188R	O
accounted	O
	O
report	O
	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Q188R	O
accounted	O
for	O
threescore	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

these	O
accounted	O
for	O
Q188R	O
accounted	O
,	O
K285N	O
of	O
for	O
28	O
%	O
%	O
60	O
alleles	O
.	O

Q188R	O
accounted	O
for	O
lx	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Q188R	O
accounted	O
	O
report	O
	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
report	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Q188R	O
for	O
%	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

accounted	O
60	O
for	O
accounted	O
%	O
,	O
28	O
Q188R	O
for	O
K285N	O
%	O
of	O
these	O
.	O
alleles	O

Q188R	O
describe	O
for	O
lx	O
%	O
,	O
K285N	O
describe	O
for	O
xxviii	O
%	O
of	O
these	O
allelomorph	O
.	O

Q188R	O
accounted	O
	O
report	O
	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
report	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Q188R	O
accounted	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

found	O
novel	O
candidate	O
galactosemia	B
.	O
were	O
Eight	O
mutations	O

Eight	O
novel	O
nominee	O
galactosemia	B
mutant	O
were	O
found	O
.	O

candidate	O
were	O
found	O
.	O

Eight	O
candidate	O
nominee	O
novel	O
candidate	O
galactosemia	B
mutations	O
were	O
found	O
.	O

Eight	O
candidate	O
galactosemia	B
found	O
.	O

Eight	O
mutations	O
candidate	O
galactosemia	B
novel	O
were	O
.	O
found	O

.	O
galactosemia	O
candidate	O
novel	B
mutations	O
were	O
found	O
Eight	O

Eight	O
chromosomal	O
mutation	O
mutation	O
novel	O
candidate	B
galactosemia	O
mutations	O
were	O
found	O

octad	O
fresh	O
candidate	O
galactosemia	B
mutations	O
were	O
found	O
.	O

Eight	O
chromosomal	O
mutation	O
mutation	O
novel	O
candidate	B
galactosemia	O
mutations	O
were	O
found	O

Eight	O
novel	O
candidate	O
galactosemia	B
mutations	O
were	O
found	O
.	O

On	O
all	O
D	O
-	O
	O
episode	O
modification	O
	O
two	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
	O
	O
	O
	O
.	O

On	O
all	O
2	O
cis	O
with	O
two	O
sequence	O
changes	O
on	O
the	O
D	O
alleles	O
in	O
cis	O
with	O
a	O
mutation	O
exon	O
7	O
.	O

on	O
all	O
D	O
-	O
deuce	O
allelomorph	O
N314D	O
occurred	O
in	O
curie	O
with	O
deuce	O
intronic	O
sequence	O
interchange	O
,	O
on	O
the	O
D	O
-	O
1	O
allelomorph	O
in	O
curie	O
with	O
a	O
impersonal	O
mutation	O
in	O
exon	O
7	O
.	O

On	O
all	O
D	O
-	O
alleles	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
.	O

On	O
all	O
d	O
-	O
ii	O
allelomorph	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
episode	O
transfer	O
,	O
on	O
the	O
d	O
-	O
unity	O
allelomorph	O
in	O
cis	O
with	O
a	O
inert	O
variation	O
in	O
exon	O
seven	O
.	O

On	O
all	O
D	O
-	O
	O
episode	O
modification	O
	O
two	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
	O
	O
	O
	O
.	O

on	O
all	O
D	O
-	O
2	O
alleles	O
N314D	O
occurred	O
in	O
curie	O
with	O
ii	O
intronic	O
succession	O
variety	O
,	O
on	O
the	O
D	O
-	O
i	O
alleles	O
in	O
curie	O
with	O
a	O
neutral	O
variation	O
in	O
exon	O
septet	O
.	O

1	O
D	O
D	O
-	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
with	O
exon	O
,	O
on	O
the	O
mutation	O
-	O
all	O
alleles	O
.	O
cis	O
sequence	O
a	O
neutral	O
On	O
changes	O
in	O
7	O
in	O

On	O
all	O
D	O
-	O
alleles	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
a	O
neutral	O
mutation	O
exon	O
.	O

On	O
all	O
D	O
-	O
	O
episode	O
modification	O
	O
two	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
	O
	O
	O
	O
.	O

On	O
all	O
D	O
-	O
2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D	O
-	O
1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
universe	O
inward	O
universe	O
universe	O
extremely	O
extremely	O
be	O
mutation	O
in	O
our	O
population	O
.	O
.	O

that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
mutation	O
our	O
population	O
.	O
.	O

We	O
reason	O
that	O
the	O
sport	O
cause	O
galactosemia	B
are	O
extremely	O
heterogenous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
vernacular	O
galactosemia	B
mutation	O
in	O
our	O
universe	O
.	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
highly	O
heterogeneous	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
our	O
population	O
.	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
universe	O
inward	O
universe	O
universe	O
extremely	O
extremely	O
extremely	O
mutation	O
in	O
our	O
population	O
.	O
.	O

We	O
close	O
that	O
the	O
mutations	O
make	O
galactosemia	B
are	O
extremely	O
heterogenous	O
and	O
that	O
K285N	O
is	O
a	O
moment	O
usual	O
galactosemia	B
mutant	O
in	O
our	O
population	O
.	O
.	O

We	O
resolve	O
that	O
the	O
mutant	O
get	O
galactosemia	B
are	O
extremely	O
heterogenous	O
and	O
that	O
K285N	O
is	O
a	O
bit	O
common	O
galactosemia	B
mutation	O
in	O
our	O
universe	O
.	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
and	O
is	O
a	O
second	O
common	O
galactosemia	B
mutation	O
in	O
our	O
population	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
universe	O
inward	O
universe	O
universe	O
extremely	O
extremely	O
extremely	O
mutation	O
in	O
our	O
population	O
.	O
.	O

galactosemia	O
conclude	O
that	O
and	O
mutations	O
causing	O
galactosemia	B
mutation	O
.	O
heterogeneous	O
the	O
that	O
K285N	O
is	O
.	O
second	O
common	O
our	B
are	O
We	O
in	O
population	O
a	O
highly	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
mutation	O
in	O
our	O
population	O
.	O
.	O

the	O
of	O
full	O
and	O
length	O
ATM	O
cDNA	O
-	O
cellular	O
of	O
telangiectasia	O
ataxia	B
Isolation	I
-	I
correction	O
phenotype	O
.	O

Isolation	O
of	O
full	O
-	O
distance	O
ATM	O
cdna	O
and	O
discipline	O
of	O
the	O
dyssynergia	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

Isolation	O
of	O
full	O
-	O
duration	O
ATM	O
cdna	O
and	O
discipline	O
of	O
the	O
ataxy	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

Isolation	O
of	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

isolation	O
of	O
full	O
-	O
distance	O
atm	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxy	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

Isolation	O
of	O
full	O
of	O
the	O
moon	O
full	O
of	O
the	O
moon	O
full	O
-	O
length	O
ATM	B
cDNA	I
and	I
correction	O
of	O
the	O
ataxia	O
-	O
telangiectasia	O

Isolation	O
of	O
full	O
-	O
length	O
ATM	O
cDNA	O
and	O
of	O
the	O
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

Isolation	O
of	O
full	O
of	O
the	O
moon	O
full	O
of	O
the	O
moon	O
full	O
-	O
length	O
ATM	B
cDNA	I
and	I
correction	O
of	O
the	O
ataxia	O
-	O
telangiectasia	O

of	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B
-	I

Isolation	O
of	O
correction	O
cellular	O
length	O
ATM	O
-	O
and	O
full	O
of	O
the	O
ataxia	B
cDNA	I
telangiectasia	I
-	O
phenotype	O
.	O

Isolation	O
of	O
full	O
-	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
ATM	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

telangiectasia	O
gene	O
mutated	O
,	O
the	O
human	O
genetic	B
.	I
positional	B
-	I
cloning	I
(	O
A	B
was	I
by	I
)	O
,	O
ATM	O
in	O
-	O
recently	O
identified	O
T	O
ataxia	O
A	O
disorder	O

A	O
cistron	O
mutated	O
in	O
the	O
homo	O
familial	B
disorder	I
dyssynergia	B
-	I
telangiectasia	I
(	O
A	B
-	I
t	I
)	O
,	O
ATM	O
,	O
was	O
latterly	O
identified	O
by	O
positional	O
clone	O
.	O

amp	O
factor	O
mutated	O
in	O
the	O
human	O
genic	B
disarray	I
ataxia	B
-	I
telangiectasia	I
(	O
amp	B
-	I
T	I
)	O
,	O
ATM	O
,	O
was	O
lately	O
name	O
by	O
positional	O
clone	O
.	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
(	O
A	B
T	I
)	O
,	O
ATM	O
,	O
was	O
recently	O
positional	O
cloning	O
.	O

A	O
gene	O
mutated	O
in	O
distract	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
ATM	O
aside	O
identify	O
clone	O
aside	O
clone	O
dyssynergia	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

A	O
gene	O
mutated	O
in	O
distract	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
ATM	O
aside	O
identify	O
clone	O
aside	O
clone	O
asynchronous	O
transfer	O
mode	O
,	O
was	O
recently	O
identified	O
by	O
positional	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
(	O
T	I
)	O
,	O
ATM	O
,	O
was	O
recently	O
identified	O
by	O

positional	O
gene	O
mutated	O
in	O
the	O
human	O
-	B
,	I
ataxia	B
-	I
telangiectasia	I
(	O
identified	B
genetic	I
cloning	I
)	O
disorder	O
recently	O
,	O
was	O
A	O
A	O
by	O
ATM	O
T	O
.	O

A	O
cistron	O
mutated	O
in	O
the	O
homo	O
genetic	B
perturb	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
mt	I
)	O
,	O
atmosphere	O
,	O
was	O
recently	O
describe	O
by	O
positional	O
clone	O
.	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
ATM	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

ATM	O
is	O
in	O
member	O
of	O
superfamily	O
phosphatidylinositol	O
to	O
3	O
-	O
kinase	O
important	O
cycle	O
some	O
of	O
radiation	O
are	O
protein	O
and	O
kinases	O
appear	O
-	O
have	O
the	O
roles	O
cell	O
a	O
transduction	O
control	O
and	O
which	O
,	O
signal	O
.	O

ATM	O
member	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
,	O
some	O
which	O
are	O
appear	O
have	O
important	O
roles	O
cell	O
cycle	O
control	O
radiation	O
signal	O
transduction	O
.	O

ATM	O
is	O
a	O
member	O
jail	O
cell	O
radiation	O
syndrome	O
antiophthalmic	O
factor	O
of	O
the	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
or	O
so	O
or	O
so	O
or	O

ATM	O
is	O
a	O
member	O
jail	O
cell	O
radiation	O
syndrome	O
be	O
of	O
the	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
or	O
so	O
or	O
so	O
or	O
so	O

is	O
kinases	O
a	O
member	O
of	O
the	O
cell	O
-	O
3	O
-	O
kinase	O
cycle	O
,	O
roles	O
and	O
which	O
are	O
protein	O
superfamily	O
and	O
appear	O
to	O
.	O
important	O
some	O
in	O
phosphatidylinositol	O
ATM	O
signal	O
have	O
radiation	O
control	O
transduction	O
of	O

ATM	O
is	O
a	O
member	O
of	O
the	O
3	O
-	O
kinase	O
superfamily	O
some	O
of	O
which	O
are	O
protein	O
and	O
appear	O
to	O
have	O
roles	O
in	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
.	O

ATM	O
is	O
a	O
penis	O
of	O
the	O
phosphatidylinositol	O
-	O
triad	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
seem	O
to	O
have	O
important	O
persona	O
in	O
cell	O
cycle	O
dominance	O
and	O
actinotherapy	O
indicate	O
transduction	O
.	O

ATM	O
is	O
a	O
extremity	O
of	O
the	O
phosphatidylinositol	O
-	O
ternion	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
authoritative	O
roles	O
in	O
cadre	O
round	O
ascendance	O
and	O
radiation	O
bespeak	O
transduction	O
.	O

ATM	O
is	O
a	O
member	O
jail	O
cell	O
radiation	O
syndrome	O
be	O
of	O
the	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
or	O
so	O
or	O
so	O
or	O
so	O

ATM	O
is	O
a	O
phallus	O
of	O
the	O
phosphatidylinositol	O
-	O
threesome	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
crucial	O
purpose	O
in	O
cell	O
hz	O
curb	O
and	O
radiation	O
bespeak	O
transduction	O
.	O

ATM	O
is	O
a	O
member	O
of	O
the	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
the	O
first	O
time	O
the	O
of	O
a	O
full	O
cDNA	O
of	O
multiple	O
aspects	O
the	O
radio	O
sensitive	O
phenotype	O
of	O
T	I
cells	O
by	O
transfection	O
with	O
cDNA	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
time	O
,	O
the	O
cloning	O
of	O
for	O
correction	O
multiple	O
aspects	O
of	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
aside	B
complementary	B
dna	B
jail	B
cell	B
aside	B
complementary	B
dna	B
antiophthalmic	B
factor	B
antiophthalmic	B
factor	B
complementary	B
dna	I
antiophthalmic	I
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
aside	B
complementary	B
dna	B
jail	B
cell	B
aside	B
complementary	B
dna	B
antiophthalmic	B
factor	B
antiophthalmic	B
factor	B
complementary	B
dna	I
antiophthalmic	I
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

We	O
distinguish	O
herein	O
,	O
to	O
our	O
noesis	O
,	O
for	O
the	O
first	O
clip	O
,	O
the	O
clone	O
of	O
amp	O
broad	O
-	O
duration	O
cdna	O
for	O
atmosphere	O
and	O
correction	O
of	O
multiple	O
expression	O
of	O
the	O
radio	O
-	O
sore	O
phenotype	O
of	O
amp	B
-	I
tonne	I
cellphone	O
by	O
transfection	O
with	O
this	O
cdna	O
.	O

We	O
herein	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
of	O
-	I
T	I
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O

We	O
name	O
herein	O
,	O
to	O
our	O
noesis	O
,	O
for	O
the	O
initiatory	O
time	O
,	O
the	O
clone	O
of	O
a	O
full	O
-	O
distance	O
cdna	O
for	O
ATM	O
and	O
rectification	O
of	O
multiple	O
view	O
of	O
the	O
radio	O
-	O
sore	O
phenotype	O
of	O
a	B
-	I
thyroxine	I
cells	O
by	O
transfection	O
with	O
this	O
cdna	O
.	O

cells	O
correction	O
herein	O
,	O
a	O
our	O
T	O
-	O
for	O
the	O
first	O
time	O
,	O
knowledge	O
full	O
of	O
to	O
cloning	O
-	O
length	O
,	O
for	O
ATM	O
and	O
aspects	O
of	O
multiple	O
with	O
.	O
the	O
of	O
describe	O
sensitive	O
phenotype	O
of	O
A	B
-	I
the	I
We	O
by	O
transfection	O
cDNA	O
this	O
cDNA	O
radio	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
aside	B
complementary	B
dna	B
jail	B
cell	B
aside	B
complementary	B
dna	B
antiophthalmic	B
factor	B
antiophthalmic	B
factor	B
complementary	B
dna	I
antiophthalmic	I
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O
antiophthalmic	O
factor	O

We	O
identify	O
herein	O
,	O
to	O
our	O
cognition	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
clone	O
of	O
a	O
full	O
-	O
duration	O
cDNA	O
for	O
ATM	O
and	O
discipline	O
of	O
multiple	O
face	O
of	O
the	O
wireless	O
-	O
spiritualist	O
phenotype	O
of	O
A	B
-	I
thyroxin	I
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
-	I
T	I
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
the	O
survival	O
of	O
these	O
in	O
response	O
to	O
radiation	O
exposure	O
decreased	O
radiation	O
-	O
induced	O
aberrations	O
,	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
partially	O
defective	O
cell	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O

of	O
induced	O
ATM	O
cDNA	O
in	O
A	B
corrected	I
response	I
cells	O
enhanced	O
the	O
survival	O
of	O
.	O
-	O
in	O
T	O
-	O
radiation	O
exposure	O
checkpoints	O
decreased	O
radiation	O
-	O
of	O
chromosome	O
aberrations	O
defective	O
to	O
radio	O
reduced	O
-	O
DNA	O
synthesis	O
,	O
and	O
partially	O
protein	O
,	O
cell	O
cycle	O
,	O
and	O
induction	O
Overexpression	O
stress	O
cells	O
activated	O
kinase	O
resistant	O
these	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
a	B
-	I
T	I
cells	O
raise	O
the	O
survival	O
of	O
these	O
cells	O
in	O
reaction	O
to	O
radiation	O
vulnerability	O
,	O
fall	O
radiation	O
-	O
stimulate	O
chromosome	O
aberrations	O
,	O
reduced	O
tuner	O
-	O
repellent	O
DNA	O
synthesis	O
,	O
and	O
partly	O
corrected	O
bad	O
cell	O
hz	O
checkpoints	O
and	O
elicitation	O
of	O
punctuate	O
-	O
activated	O
protein	O
kinase	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
tolerant	O
jail	O
cell	O
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
jail	O
cell	O
inductive	O
reasoning	O
checkpoint	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inward	O
trip	O
reply	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
tolerant	O
jail	O
cell	O
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
jail	O
cell	O
inductive	O
reasoning	O
checkpoint	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inward	O
trip	O
reply	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O

of	O
ATM	O
cDNA	O
in	O
A	B
T	I
cells	O
of	O
in	O
response	O
exposure	O
radiation	O
-	O
induced	O
chromosome	O
,	O
reduced	O
resistant	O
DNA	O
,	O
and	O
cell	O
checkpoints	O
and	O
induction	O
stress	O
-	O
activated	O
kinase	O
.	O

Overexpression	O
of	O
ATM	O
A	B
-	I
T	I
cells	O
enhanced	O
the	O
survival	O
of	O
in	O
to	O
radiation	O
exposure	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
reduced	O
radio	O
DNA	O
,	O
and	O
partially	O
corrected	O
cycle	O
checkpoints	O
and	O
induction	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
t	I
cellphone	O
raise	O
the	O
survival	O
of	O
these	O
cellphone	O
in	O
reception	O
to	O
radiation	O
picture	O
,	O
decreased	O
radiation	O
-	O
rush	O
chromosome	O
aberrance	O
,	O
quash	O
radio	O
-	O
resistive	O
dna	O
synthesis	O
,	O
and	O
partly	O
corrected	O
faulty	O
cell	O
cycle	O
checkpoints	O
and	O
initiation	O
of	O
accent	O
-	O
excited	O
protein	O
kinase	O
.	O

Overexpression	O
of	O
ATM	O
cdna	O
in	O
A	B
-	I
thymine	I
cadre	O
raise	O
the	O
endurance	O
of	O
these	O
cadre	O
in	O
response	O
to	O
radiation	O
photograph	O
,	O
decreased	O
radiation	O
-	O
stimulate	O
chromosome	O
distortion	O
,	O
reduced	O
radio	O
-	O
immune	O
DNA	O
synthesis	O
,	O
and	O
partly	O
decline	O
faulty	O
cell	O
cps	O
checkpoints	O
and	O
induction	O
of	O
emphasise	O
-	O
trigger	O
protein	O
kinase	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
tolerant	O
jail	O
cell	O
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
jail	O
cell	O
inductive	O
reasoning	O
checkpoint	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inductive	O
reasoning	O
trip	O
emphasise	O
inward	O
trip	O
inward	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

This	O
correction	O
of	O
the	O
certify	O
flaw	O
inward	O
numerosity	O
flaw	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
license	O
license	O
license	O
boost	O
.	O

This	O
correction	O
defects	O
cells	O
provides	O
further	O
of	O
the	O
of	O
effector	O
functions	O
ATM	O
protein	O
and	O
suggests	O
possible	O
to	O
therapy	O
.	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
A	B
-	I
thyroxin	I
cadre	O
leave	O
further	O
testify	O
of	O
the	O
multiplicity	O
of	O
effecter	O
functions	O
of	O
the	O
atm	O
protein	O
and	O
propose	O
potential	O
approaches	O
to	O
factor	O
therapy	O
.	O
.	O

This	O
correction	O
of	O
the	O
in	O
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
.	O

This	O
chastening	O
of	O
the	O
defects	O
in	O
A	B
-	I
triiodothyronine	I
cells	O
supply	O
further	O
prove	O
of	O
the	O
numerousness	O
of	O
effecter	O
functions	O
of	O
the	O
atm	O
protein	O
and	O
propose	O
potential	O
approaches	O
to	O
gene	O
therapy	O
.	O
.	O

This	O
correction	O
of	O
the	O
certify	O
flaw	O
inward	O
numerosity	O
flaw	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
license	O
license	O
license	O
boost	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
amp	B
-	I
mt	I
cells	O
provides	O
further	O
prove	O
of	O
the	O
numerousness	O
of	O
effecter	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
potential	O
approaches	O
to	O
cistron	O
therapy	O
.	O
.	O

the	O
functions	O
of	O
the	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
suggests	O
therapy	O
multiplicity	O
of	O
effector	O
to	O
of	O
correction	O
ATM	O
.	O
and	O
of	O
possible	O
approaches	O
This	O
the	O
protein	O
.	O
gene	O

This	O
correction	O
of	O
the	O
in	O
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
possible	O
approaches	O
to	O
therapy	O
.	O

This	O
correction	O
of	O
the	O
certify	O
flaw	O
inward	O
numerosity	O
boost	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
license	O
license	O
license	O
boost	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
.	O

gene	O
genes	O
resulting	O
are	O
alternative	O
chromosomal	O
translocations	O
from	O
in	O
by	O
mechanisms	O
-	O
Fusion	O
specific	O
overexpressed	O
alveolar	B
rhabdomyosarcoma	I
.	O

Fusion	O
factor	O
resulting	O
from	O
option	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
factor	O
-	O
particular	O
mechanisms	O
in	O
alveolar	B
rhabdosarcoma	I
.	O

merger	O
cistron	O
resulting	O
from	O
option	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
particular	O
mechanisms	O
in	O
alveolar	B
rhabdosarcoma	I
.	O

Fusion	O
genes	O
resulting	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

fusion	O
genes	O
ensue	O
from	O
option	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
factor	O
-	O
particular	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

Fusion	O
genes	O
lead	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
pass	O
pass	O
pass	O
be	O
.	O

Fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
-	O
specific	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

Fusion	O
genes	O
lead	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
pass	O
pass	O
pass	O
be	O
.	O

genes	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
.	O

Fusion	O
genes	O
overexpressed	O
in	O
alternative	O
chromosomal	O
specific	O
are	O
resulting	O
by	O
gene	O
-	O
translocations	O
mechanisms	O
from	O
alveolar	B
rhabdomyosarcoma	I
.	O

Fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

Chromosomal	O
translocations	O
identified	O
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
or	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
identify	O
potential	O
difference	O
potential	O
difference	O
identify	O
identify	O
identify	O
proteins	O
with	O
tumorigenic	O

chromosomal	O
translocations	O
identify	O
in	O
haematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
construction	O
of	O
protooncogenes	O
or	O
founding	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potency	O
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
identify	O
potential	O
difference	O
potential	O
difference	O
identify	O
identify	O
identify	O
proteins	O
with	O
tumorigenic	O

Chromosomal	O
translocations	O
identified	O
in	O
hematogenic	B
and	I
solid	I
tumour	I
upshot	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
origination	O
of	O
chimeral	O
proteins	O
with	O
tumorigenic	O
likely	O
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
expression	O
of	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O

deregulated	O
translocations	O
identified	O
proteins	O
hematopoietic	B
and	I
solid	I
result	I
tumors	O
in	O
with	O
expression	O
protooncogenes	O
of	O
.	O
creation	O
of	O
chimeric	O
in	O
Chromosomal	O
tumorigenic	O
potential	O
or	O

chromosomal	O
translocations	O
distinguish	O
in	O
haematogenic	B
and	I
upstanding	I
tumors	I
consequence	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
foundation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

or	O
translocations	O
result	O
solid	O
hematopoietic	B
and	I
creation	I
tumors	I
identified	O
in	O
deregulated	O
expression	O
tumorigenic	O
protooncogenes	O
in	O
Chromosomal	O
of	O
chimeric	O
proteins	O
with	O
of	O
potential	O
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

In	O
pediatric	O
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
translocation	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
fusion	O
,	O
respectively	O
.	O

inwards	O
the	O
paediatric	O
solid	B
neoplasm	I
alveolar	B
rhabdosarcoma	I
,	O
a	O
logical	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variate	O
t	O
(	O
single	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
get	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
unification	O
proteins	O
,	O
severally	O
.	O

In	O
;	O
pediatric	O
solid	B
tumor	I
alveolar	B
(	I
(	O
a	O
consistent	O
t	O
rhabdomyosarcoma	O
2	O
13	O
(	O
)	O
(	O
q35	O
,	O
q14	O
)	O
or	O
generates	O
t	O
fusion	O
1	O
respectively	O
;	O
;	O
;	O
p36	O
)	O
q14	O
13	O
translocation	O
-	O
PAX3	O
-	O
FKHR	O
or	O
the	O
)	O
FKHR	O
variant	O
proteins	O
,	O
PAX7	O
.	O

In	O
the	O
pediatric	O
solid	B
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
)	O
;	O
)	O
or	O
variant	O
(	O
1	O
;	O
13	O
)	O
(	O
)	O
translocation	O
generates	O
PAX3	O
-	O
FKHR	O
or	O
-	O
FKHR	O
,	O
respectively	O
.	O

In	O
the	O
p36	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
13	O
q14	O
;	O
13	O
or	O
(	O
q35	O
-	O
2	O
)	O
.	O
variant	O
generates	O
(	O
;	O
;	O
q14	O
)	O
(	O
pediatric	O
FKHR	O
;	O
)	O
translocation	O
t	O
PAX3	O
1	O
FKHR	O
or	O
PAX7	O
-	O
(	O
proteins	O
fusion	O
respectively	O
,	O
)	O

inch	O
the	O
paediatric	O
firm	B
tumour	I
dental	B
rhabdosarcoma	I
,	O
a	O
uniform	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variation	O
t	O
(	O
single	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
get	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
coalition	O
proteins	O
,	O
severally	O
.	O

In	O
the	O
pediatric	O
solid	B
rhabdomyosarcoma	I
,	O
a	O
t	O
2	O
;	O
13	O
q35	O
variant	O
t	O
(	O
;	O
13	O
(	O
p36	O
;	O
translocation	O
generates	O
PAX3	O
-	O
FKHR	O
PAX7	O
FKHR	O
fusion	O
proteins	O
,	O
respectively	O
.	O

In	O
the	O
pediatric	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
tumor	O
operating	O
room	O
coalition	O
protein	O
operating	O
room	O
severally	O
protein	O
tumour	O
severally	O
protein	O
tumour	O
severally	O
tumour	O
tumour	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
fusion	O
proteins	O
,	O

In	O
the	O
pediatric	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
tumour	O
operating	O
room	O
coalition	O
protein	O
operating	O
room	O
severally	O
protein	O
tumour	O
severally	O
protein	O
tumour	O
severally	O
tumour	O
operating	O
room	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
fusion	O
proteins	O

translocation	O
(	O
pediatric	O
solid	B
(	I
alveolar	B
)	I
;	O
a	O
consistent	O
t	O
(	O
2	O
rhabdomyosarcoma	O
-	O
)	O
tumor	O
respectively	O
;	O
q14	O
;	O
or	O
variant	O
t	O
13	O
1	O
;	O
-	O
proteins	O
(	O
)	O
the	O
q14	O
)	O
FKHR	O
generates	O
PAX3	O
13	O
In	O
or	O
PAX7	O
,	O
FKHR	O
fusion	O
p36	O
,	O
q35	O
.	O

In	O
the	O
pediatric	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
PAX3	O
-	O
FKHR	O
or	O
PAX7	O
-	O
FKHR	O
fusion	O
proteins	O
,	O
respectively	O
.	O

indiana	O
this	O
reputation	O
,	O
we	O
show	O
that	O
indiana	O
summation	O
to	O
running	O
change	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O
overexpression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
study	O
study	O
study	O
study	O
study	O
study	O
product	O
overexpression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
study	O
study	O
study	O
study	O
study	O
study	O
product	O
overexpression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
to	O
functional	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O

are	O
this	O
addition	O
that	O
we	O
demonstrate	O
associated	O
in	O
report	O
to	O
functional	O
alterations	O
.	O
translocations	O
,	O
In	O
with	O
fusion	O
product	O
overexpression	O
these	O

in	O
this	O
reputation	O
,	O
we	O
evidence	O
that	O
in	O
addition	O
to	O
operable	O
alterations	O
these	O
translocations	O
are	O
connect	O
with	O
fusion	O
product	O
overexpression	O
.	O

.	O
this	O
report	O
functional	O
we	O
demonstrate	O
that	O
product	O
are	O
to	O
,	O
alterations	O
translocations	O
these	O
addition	O
associated	O
with	O
fusion	O
in	O
In	O
overexpression	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
study	O
study	O
study	O
study	O
study	O
translocation	O
product	O
overexpression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
are	O
fusion	O
product	O
overexpression	O
.	O

inward	O
this	O
story	O
,	O
we	O
manifest	O
that	O
inward	O
addition	O
to	O
usable	O
adjustment	O
these	O
translocations	O
are	O
associated	O
with	O
coalition	O
product	O
overexpression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O
overexpression	O
.	O

Furthermore	O
FKHR	O
PAX3	O
-	O
,	O
and	O
-	O
occurs	O
FKHR	O
overexpression	O
distinct	O
by	O
PAX7	O
mechanisms	O
.	O

Furthermore	O
,	O
chemical	O
mechanism	O
mechanism	O
mechanism	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
aside	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O

moreover	O
,	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
overexpression	O
hap	O
by	O
discrete	O
mechanics	O
.	O

distinct	O
,	O
PAX3	O
Furthermore	O
-	O
and	O
PAX7	O
by	O
FKHR	O
overexpression	O
occurs	O
FKHR	O
-	O
mechanisms	O
.	O

moreover	O
,	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
overexpression	O
happen	O
by	O
decided	O
mechanisms	O
.	O

Furthermore	O
,	O
chemical	O
mechanism	O
mechanism	O
mechanism	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
clear	O
cut	O
overexpression	O
occurs	O
by	O
distinct	O

Furthermore	O
PAX3	O
FKHR	O
PAX7	O
-	O
FKHR	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O
.	O

-	O
-	O
PAX3	O
,	O
FKHR	O
and	O
overexpression	O
Furthermore	O
FKHR	O
PAX7	O
occurs	O
by	O
distinct	O
.	O
mechanisms	O

furthermore	O
,	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
overexpression	O
hap	O
by	O
discrete	O
mechanisms	O
.	O

Furthermore	O
,	O
chemical	O
mechanism	O
mechanism	O
mechanism	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
clear	O
cut	O
overexpression	O
occurs	O
by	O
distinct	O

Furthermore	O
,	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O
.	O

recording	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
proportional	O
to	O
barbarian	O
-	O
type	O
PAX3	O
by	O
a	O
imitate	O
number	O
-	O
independent	O
procedure	O
.	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
serve	O
written	O
matter	O
written	O
matter	O
written	O
matter	O
written	O
matter	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
serve	O
written	O
matter	O
written	O
matter	O
written	O
matter	O
written	O
matter	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
wild	O
-	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
independent	O

a	O
of	O
to	O
increased	O
FKHR	O
is	O
copy	O
relative	O
PAX3	O
wild	O
-	O
type	O
.	O
by	O
-	O
Transcription	O
number	O
-	O
independent	O
process	O
PAX3	O

arrangement	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
congenator	O
to	O
violent	O
-	O
case	O
PAX3	O
by	O
a	O
simulate	O
number	O
-	O
independent	O
serve	O
.	O

.	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
independent	O
a	O
wild	O
-	O
type	O
by	O
PAX3	O
to	O
copy	O
number	O
-	O
relative	O
Transcription	O
process	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
serve	O
written	O
matter	O
written	O
matter	O
written	O
matter	O
written	O
matter	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
a	O
-	O
independent	O
process	O
.	O

arranging	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
proportional	O
to	O
hazardous	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
count	O
-	O
autonomous	O
procedure	O
.	O

Transcription	O
of	O
PAX3	O
-	O
FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
independent	O
process	O
.	O

In	O
,	O
PAX7	O
FKHR	O
results	O
fusion	O
gene	O
amplification	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
gene	O
amplification	O

inward	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
cistron	O
gain	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
elaboration	O
elaboration	O
line	O
fusion	O
gene	O
amplification	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
elaboration	O
elaboration	O
line	O
fusion	O
gene	O
amplification	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
elaboration	O
elaboration	O
line	O
fusion	O
gene	O
amplification	O
.	O

In	O
line	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
cistron	O
elaboration	O
.	O

In	O
contrast	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
.	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
lead	O
from	O
fusion	O
cistron	O
elaboration	O
.	O

In	O
-	O
,	O
PAX7	O
.	O
FKHR	O
overexpression	O
contrast	O
from	O
fusion	O
gene	O
amplification	O
results	O

In	O
contrast	O
,	O
PAX7	O
-	O
FKHR	O
overexpression	O
results	O
from	O
fusion	O
gene	O
amplification	O
.	O

Thus	O
,	O
in	O
-	O
specific	O
-	O
were	O
presumably	O
to	O
overexpress	O
PAX3	O
to	O
between	O
and	O
PAX7	O
-	O
FKHR	O
in	O
rhabdomyosarcoma	B
alveolar	I
,	O
selected	O
due	O
mechanisms	O
differences	O
regulation	O
gene	O
loci	O
the	O
wild	O
-	O
FKHR	O
type	O
.	O

Thus	O
-	O
specific	O
mechanisms	O
were	O
to	O
overexpress	O
FKHR	O
and	O
-	O
FKHR	O
,	O
due	O
to	O
differences	O
regulation	O
between	O
the	O
-	O
type	O
loci	O
.	O

Thus	O
,	O
gene	O
-	O
mechanism	O
be	O
be	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

Thus	O
,	O
gene	O
-	O
mechanism	O
be	O
particular	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

,	O
alveolar	O
gene	O
-	O
specific	O
mechanisms	O
regulation	O
selected	O
to	O
overexpress	O
PAX3	O
between	O
FKHR	O
differences	O
wild	O
-	O
FKHR	O
in	O
-	B
rhabdomyosarcoma	I
,	O
presumably	O
.	O
to	O
and	O
in	O
were	O
Thus	O
type	O
due	O
-	O
the	O
loci	O
PAX7	O

Thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
to	O
overexpress	O
PAX3	O
-	O
and	O
PAX7	O
-	O
FKHR	O
in	O
rhabdomyosarcoma	I
,	O
presumably	O
due	O
differences	O
in	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O

Thus	O
,	O
cistron	O
-	O
particular	O
mechanisms	O
were	O
take	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdosarcoma	I
,	O
presumptively	O
ascribable	O
to	O
deviation	O
in	O
regulating	O
between	O
the	O
baseless	O
-	O
type	O
locale	O
.	O

olibanum	O
,	O
factor	O
-	O
particular	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
dental	B
rhabdosarcoma	I
,	O
presumptively	O
due	O
to	O
dispute	O
in	O
regulating	O
between	O
the	O
godforsaken	O
-	O
type	O
locus	O
.	O

Thus	O
,	O
gene	O
-	O
mechanism	O
be	O
particular	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O
chemical	O
mechanism	O

Thus	O
,	O
cistron	O
-	O
particular	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdosarcoma	I
,	O
presumptively	O
imputable	O
to	O
divergence	O
in	O
regulating	O
between	O
the	O
wild	O
-	O
type	O
locale	O
.	O

Thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3	O
-	O
FKHR	O
and	O
PAX7	O
-	O
FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O

.	O
postulate	O
that	O
of	O
overexpression	O
mechanisms	O
ensure	O
these	O
the	O
level	O
these	O
gene	O
for	O
product	O
critical	O
oncogenic	O
effects	O
of	O
a	O
We	O
fusions	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
coalition	O
decisive	O
decisive	O
decisive	O
decisive	O
decisive	O
these	O
fusions	O
.	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
coalition	O
decisive	O
decisive	O
decisive	O
decisive	O
decisive	O
these	O
fusions	O
.	O
.	O

We	O
necessitate	O
that	O
these	O
overexpression	O
mechanisms	O
control	O
a	O
vital	O
charge	O
of	O
gene	O
intersection	O
for	O
the	O
oncogenic	O
gist	O
of	O
these	O
fusions	O
.	O
.	O

We	O
postulate	O
that	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
of	O
gene	O
product	O
for	O
oncogenic	O
effects	O
these	O
fusions	O
.	O
.	O

these	O
ensure	O
a	O
critical	O
of	O
gene	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
fusions	O
.	O
.	O

We	O
require	O
that	O
these	O
overexpression	O
mechanisms	O
guarantee	O
a	O
critical	O
rase	O
of	O
factor	O
intersection	O
for	O
the	O
oncogenic	O
effectuate	O
of	O
these	O
fusions	O
.	O
.	O

the	O
postulate	O
critical	O
ensure	O
overexpression	O
mechanisms	O
oncogenic	O
a	O
that	O
level	O
of	O
gene	O
.	O
for	O
these	O
We	O
effects	O
of	O
these	O
fusions	O
product	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
coalition	O
decisive	O
decisive	O
decisive	O
decisive	O
mechanism	O
these	O
fusions	O
.	O
.	O

We	O
postulate	O
that	O
these	O
ensure	O
a	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
fusions	O
.	O
.	O

atm	O
and	O
p53	O
collaborate	O
in	O
apoptosis	O
and	O
curtailment	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
intense	B
radiotherapy	I
perniciousness	I
.	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
get	I
together	O
get	I
together	O
get	I
together	O
get	I
together	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
get	I
together	O
get	I
together	O
get	I
together	O
get	I
together	O

p53	O
apoptosis	O
and	O
suppression	O
tumorigenesis	O
,	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
toxicity	I
.	O

atm	O
and	O
p53	O
cooperate	O
in	O
suppression	O
of	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
toxicity	I
.	O

p53	O
cooperate	O
in	O
apoptosis	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
in	O
resistance	O
to	O
acute	B
toxicity	I
.	O

radiation	O
and	O
p53	O
toxicity	O
in	O
apoptosis	O
and	O
of	O
suppression	O
tumorigenesis	O
resistance	O
but	O
not	O
.	O
atm	O
to	O
acute	B
,	I
cooperate	I
in	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
get	I
together	O
get	I
together	O
get	I
together	O
get	I
together	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
inhibition	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
immunity	O
to	O
acute	B
radiation	I
perniciousness	I
.	O

acute	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
in	O
but	O
of	O
tumorigenesis	O
,	O
resistance	O
atm	O
and	O
suppression	O
radiation	O
not	B
to	I
toxicity	I
.	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
toxicity	I
.	O

Mutations	O
in	O
atm	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
respectively	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
telangiectasia	I
-	I
Fraumeni	I
syndrome	I
,	O
respectively	O
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
asynchronous	I
transfer	I
mode	I
severally	I
severally	I
asynchronous	I
transfer	I
mode	I
asynchronous	O
transfer	O
mode	O

Mutations	O
in	O
atm	O
and	O
p53	O
effort	O
the	O
human	O
cancer	B
-	I
affiliate	I
diseases	I
ataxy	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
severally	O
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
asynchronous	I
transfer	I
mode	I
severally	I
severally	I
asynchronous	I
transfer	I
mode	I
asynchronous	O
transfer	O
mode	O

sport	O
in	O
atm	O
and	O
p53	O
drive	O
the	O
human	O
crab	B
-	I
associated	I
diseases	I
dyssynergia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
severally	O
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
diseases	I
ataxia	B
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O

associated	O
in	O
atm	O
Fraumeni	O
p53	O
cause	O
the	O
cancer	O
human	B
-	I
syndrome	I
diseases	I
-	B
ataxia	I
.	I
and	O
Li	B
-	I
and	I
Mutations	I
,	O
respectively	O
telangiectasia	O

mutation	O
in	O
atm	O
and	O
p53	O
campaign	O
the	O
homo	O
cancer	B
-	I
associated	I
diseases	I
ataxy	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
severally	O
.	O

telangiectasia	O
in	O
cancer	O
the	O
p53	O
cause	O
and	O
human	O
atm	B
-	I
associated	I
diseases	I
,	B
-	I
and	I
Mutations	O
Li	B
-	I
Fraumeni	I
syndrome	I
ataxia	O
respectively	O
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
respectively	O
.	O

The	O
two	O
apoptosis	O
are	O
believed	O
pathways	O
interact	O
-	O
a	O
number	O
of	O
checkpoints	O
radiation	O
including	O
regulation	O
and	O
DNA	O
damage	O
induced	O
-	O
cell	O
in	O
cycle	O
to	O
,	O
and	O
genes	O
proliferation	O
sensitivity	O
,	O
of	O
,	O
cellular	O
.	O

The	O
are	O
believed	O
to	O
interact	O
a	O
number	O
,	O
including	O
of	O
DNA	O
cell	O
cycle	O
checkpoints	O
,	O
and	O
radiation	O
sensitivity	O
and	O
cellular	O
proliferation	O
.	O

The	O
two	O
genes	O
are	O
regulating	O
radiation	O
syndrome	O
bicycle	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
determine	O
determine	O
determine	O
determine	O
determine	O
determine	O
admit	O

The	O
two	O
genes	O
are	O
regulating	O
radiation	O
syndrome	O
believe	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
determine	O
determine	O
determine	O
determine	O
determine	O
determine	O
admit	O

two	O
-	O
genes	O
are	O
believed	O
to	O
and	O
in	O
a	O
number	O
of	O
radiation	O
,	O
,	O
,	O
of	O
DNA	O
damage	O
pathways	O
induced	O
cell	O
-	O
.	O
checkpoints	O
including	O
apoptosis	O
interact	O
The	O
cellular	O
cycle	O
and	O
sensitivity	O
proliferation	O
regulation	O

The	O
two	O
genes	O
are	O
believed	O
to	O
a	O
number	O
of	O
pathways	O
including	O
regulation	O
of	O
DNA	O
damage	O
induced	O
cell	O
-	O
cycle	O
,	O
apoptosis	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
.	O

The	O
deuce	O
cistron	O
are	O
trust	O
to	O
interact	O
in	O
a	O
bit	O
of	O
tract	O
,	O
include	O
regulating	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
predisposition	O
,	O
and	O
cellular	O
proliferation	O
.	O

The	O
two	O
factor	O
are	O
trust	O
to	O
interact	O
in	O
a	O
list	O
of	O
pathways	O
,	O
admit	O
rule	O
of	O
dna	O
terms	O
-	O
hasten	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
actinotherapy	O
predisposition	O
,	O
and	O
cellular	O
proliferation	O
.	O

The	O
two	O
genes	O
are	O
regulating	O
radiation	O
syndrome	O
believe	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
determine	O
determine	O
determine	O
determine	O
determine	O
determine	O
admit	O

The	O
two	O
cistron	O
are	O
consider	O
to	O
interact	O
in	O
a	O
total	O
of	O
pathways	O
,	O
including	O
regularisation	O
of	O
DNA	O
damage	O
-	O
induct	O
cell	O
-	O
hertz	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitiveness	O
,	O
and	O
cellular	O
proliferation	O
.	O

The	O
two	O
genes	O
are	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
.	O

Atm	O
-	O
null	O
mice	O
modernise	O
chiefly	O
deoxythymidine	O
monophosphate	O
a	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	B
T	I
-	I
cell	I
lymphomas	O
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
overhaul	O
overhaul	O
overhaul	O
overhaul	O
antiophthalmic	O

Atm	O
-	O
null	O
as	O
for	O
p53	O
,	O
mainly	O
T	B
cell	I
lymphomas	I
,	O
view	O
that	O
these	O
genes	O
have	O
roles	O
thymocyte	O
development	O
.	O

Atm	O
-	O
naught	O
shiner	O
,	O
as	O
well	O
as	O
those	O
naught	O
for	O
p53	O
,	O
produce	O
chiefly	O
thyroxin	B
-	I
cell	I
lymphomas	I
,	O
supporting	O
the	O
perspective	O
that	O
these	O
factor	O
have	O
similar	O
character	O
in	O
thymocyte	O
exploitation	O
.	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
well	O
those	O
p53	O
,	O
develop	O
mainly	O
T	B
-	I
cell	I
lymphomas	I
,	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O

Atm	O
-	O
nil	O
mice	O
,	O
as	O
well	O
as	O
those	O
nil	O
for	O
p53	O
,	O
develop	O
mainly	O
thyroxin	B
-	I
cell	I
lymphomas	I
,	O
corroborate	O
the	O
watch	O
that	O
these	O
cistron	O
have	O
alike	O
roles	O
in	O
thymocyte	O
ontogenesis	O
.	O

Atm	O
-	O
null	O
mice	O
modernise	O
chiefly	O
deoxythymidine	O
monophosphate	O
a	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	B
T	I
-	I
cell	I
lymphomas	O
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
overhaul	O
overhaul	O
overhaul	O
overhaul	O
antiophthalmic	O

Atm	O
-	O
null	O
mouse	O
,	O
as	O
intimately	O
as	O
those	O
null	O
for	O
p53	O
,	O
uprise	O
mainly	O
t	B
-	I
cell	I
lymphomas	I
,	O
supporting	O
the	O
perspective	O
that	O
these	O
cistron	O
have	O
standardised	O
office	O
in	O
thymocyte	O
growing	O
.	O

supporting	O
lymphomas	O
null	O
mice	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
these	O
in	O
T	B
-	I
cell	I
similar	I
,	O
-	O
the	O
development	O
that	O
develop	O
genes	O
have	O
Atm	O
mainly	O
view	O
thymocyte	O
roles	O
.	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
as	O
null	O
for	O
p53	O
,	O
develop	O
mainly	O
T	B
-	I
lymphomas	I
,	O
supporting	O
the	O
view	O
that	O
these	O
similar	O
roles	O
in	O
development	O

Atm	O
-	O
null	O
mice	O
modernise	O
chiefly	O
deoxythymidine	O
monophosphate	O
jail	O
cell	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	B
mainly	I
T	I
-	I
cell	O
lymphomas	O
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
overhaul	O
overhaul	O
overhaul	O
overhaul	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	O
T	B
-	I
cell	I
lymphomas	I
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O

To	O
study	O
the	O
interactions	O
gene	O
completely	O
multiply	O
mouse	O
cistron	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
completely	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
cistron	O
cistron	O
grade	O
.	O

To	O
study	O
the	O
interactions	O
gene	O
completely	O
multiply	O
mouse	O
cistron	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
completely	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
cistron	O
cistron	O
grade	O
.	O

and	O
study	O
the	O
interactions	O
of	O
these	O
we	O
heterozygous	O
on	O
an	O
organismal	O
level	O
both	O
two	O
p53	O
genotypic	O
genes	O
of	O
null	O
alleles	O
To	O
,	O
atm	O
for	O
bred	O
to	O
produce	O
all	O
.	O
combinations	O
mice	O

To	O
study	O
the	O
interactions	O
gene	O
completely	O
multiply	O
mouse	O
cistron	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
completely	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
cistron	O
cistron	O
grade	O
.	O

To	O
study	O
the	O
interactions	O
these	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

To	O
analyse	O
the	O
interactions	O
of	O
these	O
ii	O
factor	O
on	O
an	O
organismic	O
level	O
,	O
we	O
multiply	O
mice	O
heterozygous	O
for	O
nil	O
allelomorph	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combining	O
.	O

genotypic	O
study	O
p53	O
bred	O
of	O
these	O
all	O
genes	O
interactions	O
an	O
organismal	O
level	O
of	O
we	O
the	O
on	O
heterozygous	O
for	O
null	O
alleles	O
,	O
both	O
atm	O
and	O
mice	O
two	O
produce	O
to	O
To	O
combinations	O
.	O

To	O
study	O
the	O
interactions	O
of	O
these	O
two	O
genes	O
on	O
organismal	O
level	O
we	O
bred	O
mice	O
heterozygous	O
for	O
null	O
alleles	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

organismal	O
study	O
the	O
genotypic	O
of	O
these	O
two	O
to	O
and	O
an	O
p53	O
level	O
produce	O
alleles	O
atm	O
mice	O
heterozygous	O
for	O
.	O
we	O
of	O
both	O
bred	O
on	O
To	O
genes	O
,	O
all	O
interactions	O
combinations	O
null	O

To	O
survey	O
the	O
interactions	O
of	O
these	O
ii	O
cistron	O
on	O
an	O
organismal	O
charge	O
,	O
we	O
spawn	O
mouse	O
heterozygous	O
for	O
naught	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
create	O
all	O
genotypic	O
compounding	O
.	O

To	O
study	O
the	O
interactions	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

Mice	O
doubly	O
null	O
for	O
organization	O
relation	O
foreclose	O
asynchronous	O
transfer	O
mode	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	B
of	O
tumour	O
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
governance	O
governance	O
governance	O
governance	O

Mice	O
doubly	O
null	O
and	O
acceleration	O
of	O
tumour	B
relative	O
to	O
null	O
mice	O
,	O
both	O
genes	O
collaborate	O
in	O
a	O
manner	O
prevent	O
tumorigenesis	O
.	O

shiner	O
twice	O
nil	O
for	O
atm	O
and	O
p53	O
march	O
a	O
dramatic	O
acceleration	O
of	O
neoplasm	B
formation	O
relation	O
to	O
singly	O
nil	O
shiner	O
,	O
argue	O
that	O
both	O
cistron	O
collaborate	O
in	O
a	O
important	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
p53	O
a	O
of	O
tumour	B
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

Mice	O
twice	O
naught	O
for	O
atm	O
and	O
p53	O
march	O
a	O
dramatic	O
quickening	O
of	O
tumor	B
formation	O
proportional	O
to	O
singly	O
naught	O
mice	O
,	O
point	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
mode	O
to	O
keep	O
tumorigenesis	O
.	O

Mice	O
doubly	O
null	O
for	O
organization	O
relation	O
foreclose	O
asynchronous	O
transfer	O
mode	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	B
of	O
tumour	O
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
governance	O
governance	O
governance	O
governance	O

Mice	O
twice	O
zero	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
spectacular	O
speedup	O
of	O
neoplasm	B
establishment	O
congeneric	O
to	O
singly	O
zero	O
mice	O
,	O
show	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
pregnant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

indicating	O
mice	O
null	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B
collaborate	O
to	O
to	O
singly	O
null	O
significant	O
,	O
doubly	O
that	O
tumorigenesis	O
genes	O
formation	O
in	O
a	O
Mice	O
relative	O
both	O
prevent	O
manner	O
.	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
exhibited	O
dramatic	O
acceleration	O
of	O
tumour	B
formation	O
relative	O
to	O
singly	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
significant	O
manner	O
to	O
tumorigenesis	O

Mice	O
doubly	O
null	O
for	O
organization	O
relation	O
foreclose	O
in	O
two	O
ways	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	B
of	O
tumour	O
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
governance	O
governance	O
governance	O
governance	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

With	O
respect	O
to	O
their	O
utilize	O
simply	O
partially	O
tolerant	O
use	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
father	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
utilise	O
utilise	O
fork	O
out	O

With	O
respect	O
to	O
their	O
utilize	O
simply	O
partially	O
tolerant	O
use	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
ray	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
utilise	O
utilise	O
fork	O
out	O

additional	O
respect	O
to	O
their	O
roles	O
in	O
only	O
to	O
loss	O
of	O
atm	O
rendered	O
,	O
apoptosis	O
loss	O
complete	O
,	O
apoptosis	O
-	O
induced	O
With	O
thymocytes	O
whereas	O
irradiation	O
partly	O
of	O
p53	O
engendered	O
.	O
resistance	O
resistant	O

With	O
respect	O
to	O
their	O
utilize	O
simply	O
partially	O
tolerant	O
use	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
father	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
utilise	O
utilise	O
fork	O
out	O

With	O
respect	O
to	O
their	O
in	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

With	O
observe	O
to	O
their	O
part	O
in	O
apoptosis	O
,	O
expiration	O
of	O
atm	O
supply	O
thymocytes	O
only	O
partly	O
resistive	O
to	O
irradiation	O
-	O
cause	O
apoptosis	O
,	O
whereas	O
extra	O
expiration	O
of	O
p53	O
get	O
nail	O
resistance	O
.	O

complete	O
respect	O
loss	O
partly	O
roles	O
in	O
engendered	O
,	O
their	O
of	O
atm	O
rendered	O
apoptosis	O
only	O
to	O
loss	O
to	O
irradiation	O
-	O
induced	O
thymocytes	O
,	O
whereas	O
additional	O
resistant	O
apoptosis	O
p53	O
of	O
With	O
resistance	O
.	O

With	O
respect	O
to	O
their	O
roles	O
in	O
apoptosis	O
,	O
loss	O
atm	O
rendered	O
only	O
partly	O
resistant	O
to	O
irradiation	O
-	O
induced	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

atm	O
respect	O
to	O
complete	O
roles	O
in	O
apoptosis	O
of	O
additional	O
of	O
loss	O
rendered	O
p53	O
induced	O
whereas	O
resistant	O
to	O
irradiation	O
.	O
only	O
apoptosis	O
,	O
partly	O
loss	O
With	O
,	O
thymocytes	O
engendered	O
their	O
resistance	O
-	O

With	O
honour	O
to	O
their	O
function	O
in	O
apoptosis	O
,	O
expiration	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partially	O
resistive	O
to	O
shaft	O
-	O
rush	O
apoptosis	O
,	O
whereas	O
extra	O
expiration	O
of	O
p53	O
engendered	O
terminated	O
resistance	O
.	O

With	O
respect	O
to	O
their	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

apoptotic	O
implies	O
that	O
atm	O
irradiation	O
-	O
induced	O
the	O
completely	O
p53	O
not	O
pathways	O
This	O
are	O
and	O
congruent	O
.	O

This	O
entail	O
that	O
the	O
shaft	O
-	O
induct	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
altogether	O
congruous	O
.	O

This	O
involve	O
that	O
the	O
irradiation	O
-	O
cause	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
all	O
congruous	O
.	O

This	O
implies	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
.	O

This	O
entail	O
that	O
the	O
irradiation	O
-	O
stimulate	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
whole	O
congruous	O
.	O

This	O
implies	O
asynchronous	O
transfer	O
mode	O
congruous	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
cause	O
cause	O

This	O
implies	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
p53	O
apoptotic	O
are	O
not	O
completely	O
congruent	O
.	O

This	O
implies	O
asynchronous	O
transfer	O
mode	O
congruous	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
cause	O
cause	O

implies	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O

This	O
implies	O
and	O
completely	O
irradiation	O
-	O
are	O
atm	O
that	O
p53	O
apoptotic	O
pathways	O
induced	O
not	O
the	O
congruent	O
.	O

This	O
implies	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
.	O

Finally	O
-	O
DNA	O
in	O
contrast	O
to	O
prior	O
acute	O
-	O
atm	O
and	O
a	O
radiation	O
not	O
appear	O
predictions	O
interact	O
in	O
the	B
do	I
toxicity	I
.	O
suggesting	O
p53	O
separate	O
to	O
pathway	O
response	O
for	O
this	O
and	O
human	O
damage	O
and	O
having	O
.	O
for	O
atm	O
prognosis	O
and	O
treatment	O
of	O
effector	O
tumours	B
implications	O
,	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
homo	O
tumor	O
medical	O
prognosis	O
homo	O
tumor	O
line	O
homo	O
tumor	O
line	O
line	O
line	O
line	O
line	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	B
tumours	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
homo	O
tumor	O
medical	O
prognosis	O
homo	O
tumor	O
line	O
homo	O
tumor	O
line	O
line	O
line	O
line	O
advise	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	B
tumours	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
atm	O
and	O
p53	O
not	O
to	O
interact	O
in	O
toxicity	I
atm	O
effector	O
pathway	O
this	O
DNA	O
response	O
and	O
having	O
the	O
prognosis	O
and	O
treatment	O
of	O
tumours	B
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
and	O
p53	O
do	O
not	O
appear	O
toxicity	I
a	O
atm	O
effector	O
pathway	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B
.	O

having	O
acute	O
and	O
in	O
contrast	O
to	O
of	O
predictions	O
-	O
atm	O
and	O
treatment	O
do	O
pathway	O
this	O
to	O
interact	O
in	O
and	B
radiation	I
toxicity	I
,	O
for	O
a	O
tumours	O
atm	O
damage	O
not	O
appear	O
separate	O
DNA	O
implications	O
response	O
-	O
Finally	O
effector	O
for	O
the	O
prognosis	O
and	O
p53	O
prior	O
human	O
suggesting	B
.	O
.	O

eventually	O
-	O
and	O
in	O
contrast	O
to	O
anterior	O
forecasting	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
penetrating	B
radioactivity	I
perniciousness	I
,	O
suggesting	O
a	O
separate	O
atm	O
effecter	O
tract	O
for	O
this	O
dna	O
wrong	O
reply	O
and	O
having	O
implications	O
for	O
the	O
forecast	O
and	O
discourse	O
of	O
human	O
tumours	B
.	O
.	O

lastly	O
-	O
and	O
in	O
demarcation	O
to	O
anterior	O
prognostication	O
-	O
atm	O
and	O
p53	O
do	O
not	O
seem	O
to	O
interact	O
in	O
keen	B
radiation	I
perniciousness	I
,	O
suggesting	O
a	O
separate	O
atm	O
effecter	O
tract	O
for	O
this	O
dna	O
terms	O
answer	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumor	B
.	O
.	O

last	O
-	O
and	O
in	O
line	O
to	O
anterior	O
prognostication	O
-	O
atm	O
and	O
p53	O
do	O
not	O
look	O
to	O
interact	O
in	O
intense	B
actinotherapy	I
toxicity	I
,	O
suggesting	O
a	O
disunite	O
atm	O
effector	O
pathway	O
for	O
this	O
dna	O
damage	O
response	O
and	O
having	O
import	O
for	O
the	O
forecast	O
and	O
treatment	O
of	O
homo	O
tumor	B
.	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
homo	O
tumor	O
medical	O
prognosis	O
homo	O
tumor	O
line	O
homo	O
tumor	O
line	O
line	O
line	O
line	O
line	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	B
tumours	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B
.	O
.	O

Trinucleotide	O
expansion	O
at	O
myotonic	B
locus	O
expression	O
of	O
DMAHP	O
.	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
expression	O
of	O
DMAHP	O

Trinucleotide	O
reprise	O
elaboration	O
at	O
the	O
myotonic	B
dystrophy	I
locale	O
reduces	O
expression	O
of	O
DMAHP	O
.	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
ingeminate	O
ingeminate	O
ingeminate	O
expression	O
of	O
DMAHP	O
.	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
ingeminate	O
ingeminate	O
ingeminate	O
expression	O
of	O
DMAHP	O
.	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
ingeminate	O
ingeminate	O
ingeminate	O
expression	O
of	O
DMAHP	O
.	O

Trinucleotide	O
recur	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locale	O
reduces	O
saying	O
of	O
DMAHP	O
.	O

Trinucleotide	O
repeat	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
expression	O
.	O

Trinucleotide	O
repeat	O
enlargement	O
at	O
the	O
myotonic	B
dystrophy	I
locale	O
reduces	O
reflexion	O
of	O
DMAHP	O
.	O

Trinucleotide	O
the	O
expansion	O
at	O
.	O
myotonic	B
dystrophy	I
repeat	O
reduces	O
expression	O
of	O
DMAHP	O
locus	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
expression	O
of	O
DMAHP	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
on	O
chromosome	O
19q13	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
inward	O
on	O
chromosome	O
19q13	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
cause	O
on	O
chromosome	O
19q13	O
.	O

repeat	B
the	I
,	O
or	O
dystrophia	B
myotonica	I
an	O
protein	B
)	O
,	O
is	O
(	O
autosomal	B
3	I
region	I
disorder	I
caused	O
by	O
DM	O
expansion	O
of	O
DMPK	O
untranslated	O
trinucleotide	O
Myotonic	O
in	O
the	O
dominant	O
multisystem	O
CTG	O
of	O
gene	O
a	O
dystrophy	O
kinase	O
the	O
on	O
chromosome	O
19q13	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
DM	B
)	O
,	O
is	O
an	O
dominant	I
multisystem	I
the	O
a	O
CTG	O
in	O
untranslated	O
region	O
of	O
the	O
protein	O
kinase	O
chromosome	O
19q13	O

myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
dm	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
distract	I
stimulate	O
by	O
the	O
elaboration	O
of	O
a	O
CTG	O
trinucleotide	O
restate	O
in	O
the	O
troika	O
untranslated	O
area	O
of	O
the	O
DMPK	O
protein	O
kinase	O
factor	O
on	O
chromosome	O
19q13	O
.	O

myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
decimetre	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
make	O
by	O
the	O
enlargement	O
of	O
a	O
CTG	O
trinucleotide	O
ingeminate	O
in	O
the	O
ternion	O
untranslated	O
realm	O
of	O
the	O
DMPK	O
protein	O
kinase	O
cistron	O
on	O
chromosome	O
19q13	O
.	O

of	B
kinase	I
,	O
or	O
caused	B
myotonica	I
chromosome	O
the	B
)	O
,	O
is	O
an	O
autosomal	B
repeat	I
by	I
disorder	I
dystrophia	O
multisystem	O
the	O
expansion	O
dominant	O
a	O
CTG	O
trinucleotide	O
dystrophy	O
in	O
the	O
19q13	O
Myotonic	O
region	O
untranslated	O
(	O
DMPK	O
protein	O
of	O
gene	O
on	O
DM	O
3	O
.	O

myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
dm	B
)	O
,	O
is	O
an	O
autosomal	B
prevalent	I
multisystem	I
cark	I
stimulate	O
by	O
the	O
enlargement	O
of	O
a	O
CTG	O
trinucleotide	O
repetition	O
in	O
the	O
triplet	O
untranslated	O
part	O
of	O
the	O
DMPK	O
protein	O
kinase	O
factor	O
on	O
chromosome	O
19q13	O
.	O

Myotonic	B
dystrophy	I
of	O
or	O
dystrophia	B
gene	I
is	O
DM	B
)	O
,	O
(	O
the	O
expansion	B
dominant	I
multisystem	I
the	I
caused	O
by	O
chromosome	O
autosomal	O
of	O
a	O
CTG	O
myotonica	O
repeat	O
disorder	O
an	O
DMPK	O
the	O
region	O
,	O
3	O
untranslated	O
protein	O
kinase	O
trinucleotide	O
on	O
in	O
19q13	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O

)	O
(	O
refs	O
1	O
.	O
3	O
3	O
-	O

trine	O
(	O
referee	O
1	O
-	O
trine	O
)	O
.	O

refs	O
3	O
)	O
.	O

3	O
	O
	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

3	O
refs	O
1	O
)	O
.	O

3	O
-	O
refs	O
1	O
(	O
3	O
.	O
)	O

.	O
1	O
refs	O
(	O
-	O
3	O
)	O
3	O

3	O
	O
	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

trinity	O
(	O
refs	O
single	O
-	O
trinity	O
)	O
.	O

3	O
	O
	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

3	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

Although	O
DM	B
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
mechanisms	O
underlying	O
this	O
most	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
remain	O
elusive	O
.	O

Although	O
DM	B
mutation	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
mechanisms	O
underlying	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I

Although	O
the	O
DM	B
mutation	O
morbific	O
mechanism	O
rudimentary	O
be	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
grownup	O
stay	O
problematic	O
	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

of	O
the	O
DM	B
prevalent	O
was	O
identified	O
more	O
remain	O
neuromuscular	O
years	O
form	O
,	O
the	O
pathogenic	O
adult	O
underlying	O
this	O
most	O
mutation	O
disease	O
ago	O
hereditary	O
mechanisms	O
five	B
Although	I
than	O
elusive	O
.	O

elusive	O
the	O
DM	B
mechanisms	O
was	O
identified	O
remain	O
than	O
mutation	O
years	O
ago	O
,	O
pathogenic	O
of	O
disease	O
five	O
this	O
most	O
prevalent	O
form	O
the	O
hereditary	O
adult	O
neuromuscular	B
underlying	I
more	O
Although	O
.	O

Although	O
the	O
DM	B
mutation	O
morbific	O
mechanism	O
rudimentary	O
be	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
grownup	O
stay	O
problematic	O
	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

Although	O
the	O
dm	B
mutant	O
was	O
key	O
more	O
than	O
quint	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
class	O
of	O
transmitted	O
adult	O
neuromuscular	B
disease	I
stay	O
knotty	O
.	O

Although	O
the	O
DM	B
mutation	O
morbific	O
mechanism	O
rudimentary	O
be	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
grownup	O
stay	O
problematic	O
	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

neuromuscular	O
the	O
DM	B
mutation	O
was	O
identified	O
pathogenic	O
,	O
five	O
years	O
ago	O
this	O
hereditary	O
more	O
disease	O
Although	O
than	O
underlying	O
prevalent	O
form	O
of	O
the	O
adult	O
most	B
mechanisms	I
remain	O
elusive	O
.	O

Although	O
the	O
DM	B
mutant	O
was	O
identify	O
more	O
than	O
quintet	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanics	O
underlying	O
this	O
most	O
predominant	O
shape	O
of	O
transmitted	O
adult	O
neuromuscular	B
disease	I
rest	O
elusive	O
.	O

Although	O
the	O
DM	B
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

previous	O
make	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
DNase	O
fifty	O
-	O
supersensitised	O
site	O
located	O
neighboring	O
to	O
the	O
iterate	O
on	O
the	O
risky	O
-	O
type	O
allelomorph	O
is	O
eliminated	O
by	O
double	O
expansion	O
,	O
signal	O
that	O
expectant	O
CTG	O
-	O
double	O
raiment	O
may	O
be	O
consociate	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
cistron	O
reflexion	O
.	O

old	O
work	O
from	O
our	O
laboratory	O
certify	O
that	O
a	O
DNase	O
l	O
-	O
supersensitized	O
situation	O
set	O
contiguous	O
to	O
the	O
retell	O
on	O
the	O
wild	O
-	O
type	O
allelomorph	O
is	O
eliminated	O
by	O
repetition	O
expansion	O
,	O
indicate	O
that	O
vauntingly	O
CTG	O
-	O
repetition	O
range	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
surround	O
that	O
represses	O
cistron	O
manifestation	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
l	O
-	O
hypersensitive	O
site	O
adjacent	O
to	O
the	O
repeats	O
on	O
wild	O
-	O
type	O
allele	O
eliminated	O
by	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
may	O
be	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
gene	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
heavy	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
antiophthalmic	O
factor	O
topical	O
anesthetic	O
chromatin	O
granule	O
surround	O
topical	O
anesthetic	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
antiophthalmic	O
factor	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O

-	O
is	O
from	O
our	O
laboratory	O
demonstrated	O
wild	O
the	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
that	O
may	O
to	O
a	O
represses	O
on	O
the	O
located	O
-	O
type	O
allele	O
repeat	O
eliminated	O
by	O
a	O
environment	O
,	O
expansion	O
work	O
large	O
CTG	O
.	O
repeat	O
arrays	O
adjacent	O
that	O
associated	O
with	O
expression	O
local	O
chromatin	O
indicating	O
that	O
repeats	O
gene	O
be	O
Previous	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
heavy	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
antiophthalmic	O
factor	O
topical	O
anesthetic	O
chromatin	O
granule	O
surround	O
topical	O
anesthetic	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
antiophthalmic	O
factor	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O

Previous	O
mold	O
from	O
our	O
laboratory	O
establish	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitized	O
site	O
situate	O
adjacent	O
to	O
the	O
duplicate	O
on	O
the	O
wild	O
-	O
character	O
allelomorph	O
is	O
annihilate	O
by	O
echo	O
expansion	O
,	O
indicate	O
that	O
bombastic	O
CTG	O
-	O
echo	O
raiment	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
surroundings	O
that	O
represses	O
cistron	O
verbalism	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
heavy	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
antiophthalmic	O
factor	O
topical	O
anesthetic	O
chromatin	O
granule	O
surround	O
topical	O
anesthetic	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
manifestation	O
muffle	O
cistron	O
assort	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O

Previous	O
work	O
from	O
our	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
the	O
on	O
the	O
wild	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
,	O
indicating	O
CTG	O
repeat	O
arrays	O
may	O
be	O
a	O
local	O
chromatin	O
environment	O
represses	O
gene	O
expression	O
.	O

Previous	O
by	O
from	O
our	O
laboratory	O
demonstrated	O
hypersensitive	O
,	O
DNase	O
l	O
-	O
that	O
site	O
repeat	O
expansion	O
to	O
the	O
repeats	O
a	O
the	O
wild	O
-	O
CTG	O
allele	O
chromatin	O
eliminated	O
represses	O
located	O
expression	O
on	O
indicating	O
repeat	O
large	O
adjacent	O
-	O
a	O
arrays	O
may	O
be	O
associated	O
work	O
that	O
local	O
type	O
environment	O
that	O
with	O
gene	O
is	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
gene	O
expression	O
.	O

Here	O
we	O
cover	O
that	O
the	O
hypersensitized	O
site	O
contains	O
an	O
foil	O
ingredient	O
that	O
order	O
transcription	O
of	O
the	O
conterminous	O
DMAHP	O
homeobox	O
gene	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
cistron	O
study	O
study	O
study	O
study	O
study	O
homeobox	O
gene	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
cistron	O
study	O
study	O
study	O
study	O
study	O
homeobox	O
gene	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
enhancer	O
element	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O

of	O
we	O
an	O
site	O
the	O
hypersensitive	O
the	O
contains	O
report	O
enhancer	O
element	O
that	O
.	O
transcription	O
that	O
Here	O
adjacent	O
DMAHP	O
homeobox	O
gene	O
regulates	O

Here	O
we	O
paper	O
that	O
the	O
supersensitised	O
place	O
contains	O
an	O
foil	O
element	O
that	O
regulates	O
arrangement	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O
cistron	O
.	O

.	O
we	O
report	O
element	O
the	O
hypersensitive	O
site	O
homeobox	O
of	O
enhancer	O
that	O
that	O
transcription	O
regulates	O
an	O
the	O
adjacent	O
DMAHP	O
contains	O
Here	O
gene	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
cistron	O
study	O
study	O
study	O
study	O
arranging	O
homeobox	O
gene	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
of	O
DMAHP	O
homeobox	O
gene	O
.	O

here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
bear	O
an	O
foil	O
element	O
that	O
regularise	O
recording	O
of	O
the	O
next	O
DMAHP	O
homeobox	O
gene	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O
gene	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
.	O

Analysis	O
of	O
DMAHP	O
the	O
cells	O
of	O
DM	B
patients	O
loss	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
type	O

steady	O
two	O
DMAHP	O
expression	O
in	O
the	O
loss	O
-	O
DM	B
patients	O
with	O
cells	O
of	O
DMAHP	O
levels	O
site	O
revealed	O
a	O
of	O
-	O
to	O
fourfold	O
transcript	O
in	O
Analysis	O
-	O
to	O
the	O
hypersensitive	O
reduction	O
relative	O
controls	O
wild	O
of	O
type	O
state	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
inward	O
jail	O
cell	O

DMAHP	O
type	O
DMAHP	O
expression	O
revealed	O
the	O
hypersensitive	O
to	O
DM	B
patients	O
with	O
loss	O
of	O
steady	O
of	O
site	O
in	O
relative	O
two	O
-	O
the	O
fourfold	O
reduction	O
in	O
of	O
-	O
state	O
Analysis	O
a	O
levels	O
transcript	O
cells	O
wild	O
-	O
to	O
controls	O
.	O

Analysis	O
of	O
DMAHP	O
reflection	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
release	O
of	O
the	O
sensitised	O
site	O
break	O
a	O
two	O
-	O
to	O
fourfold	O
diminution	O
in	O
brace	O
-	O
state	O
DMAHP	O
copy	O
point	O
proportional	O
to	O
waste	O
-	O
type	O
controller	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
hypersensitive	O
site	O
revealed	O
two	O
to	O
fourfold	O
reduction	O
-	O
relative	O
to	O
wild	O
type	O
controls	O

Analysis	O
of	O
relative	O
expression	O
in	O
controls	O
cells	O
of	O
DM	B
patients	O
with	O
state	O
-	O
the	O
hypersensitive	O
DMAHP	O
revealed	O
a	O
to	O
of	O
to	O
wild	O
reduction	O
the	O
steady	O
site	O
loss	O
fourfold	O
-	O
levels	O
DMAHP	O
two	O
transcript	O
-	O
type	O
in	O
.	O

analysis	O
of	O
DMAHP	O
locution	O
in	O
the	O
cells	O
of	O
dm	B
patients	O
with	O
release	O
of	O
the	O
supersensitized	O
site	O
revealed	O
a	O
two	O
-	O
to	O
quadruplicate	O
reduction	O
in	O
regular	O
-	O
posit	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
baseless	O
-	O
character	O
restraint	O
.	O

psychoanalysis	O
of	O
DMAHP	O
face	O
in	O
the	O
cells	O
of	O
decimeter	B
patients	O
with	O
deprivation	O
of	O
the	O
hypersensitised	O
site	O
discover	O
a	O
deuce	O
-	O
to	O
fourfold	O
diminution	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
stage	O
proportional	O
to	O
risky	O
-	O
type	O
controls	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O

Allele	O
-	O
specific	O
analysis	O
copy	O
grade	O
character	O
manifestation	O
amplify	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
written	O
matter	O
written	O
matter	O
written	O

Allele	O
-	O
of	O
steady	O
-	O
state	O
levels	O
from	O
expanded	O
allele	O
were	O
in	O
comparison	O
to	O
those	O
from	O
wild	O
type	O
allele	O
.	O

allelomorph	O
-	O
particular	O
analysis	O
of	O
DMAHP	O
face	O
showed	O
that	O
steady	O
-	O
state	O
copy	O
flush	O
from	O
the	O
expanded	O
allelomorph	O
were	O
greatly	O
quash	O
in	O
comparing	O
to	O
those	O
from	O
the	O
angry	O
-	O
type	O
allelomorph	O
.	O

Allele	O
-	O
specific	O
analysis	O
DMAHP	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
.	O

allelomorph	O
-	O
particular	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
unbendable	O
-	O
state	O
copy	O
levels	O
from	O
the	O
extend	O
allelomorph	O
were	O
greatly	O
abbreviate	O
in	O
compare	O
to	O
those	O
from	O
the	O
dotty	O
-	O
type	O
allelomorph	O
.	O

Allele	O
-	O
specific	O
analysis	O
copy	O
grade	O
character	O
manifestation	O
amplify	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
written	O
matter	O
written	O
matter	O
written	O

allelomorph	O
-	O
specific	O
analysis	O
of	O
DMAHP	O
construction	O
showed	O
that	O
becalm	O
-	O
commonwealth	O
copy	O
levels	O
from	O
the	O
exposit	O
allelomorph	O
were	O
greatly	O
reduced	O
in	O
comparing	O
to	O
those	O
from	O
the	O
unfounded	O
-	O
type	O
allelomorph	O
.	O

reduced	O
were	O
specific	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
those	O
type	O
the	O
expanded	O
allele	O
wild	O
greatly	O
-	O
in	O
.	O
to	O
levels	O
from	O
the	O
Allele	O
from	O
comparison	O
allele	O
-	O

Allele	O
-	O
specific	O
analysis	O
DMAHP	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
from	O
the	O
wild	O
type	O
.	O

Allele	O
-	O
specific	O
analysis	O
copy	O
grade	O
character	O
manifestation	O
character	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
written	O
matter	O
written	O
matter	O
written	O

Allele	O
-	O
specific	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
.	O

pathogenesis	O
,	O
these	O
can	O
demonstrate	O
that	O
CTG	O
in	O
expression	O
expansions	O
results	O
suppress	O
gene	O
local	O
repeat	O
and	O
implicate	O
DMAHP	O
-	O
Together	B
DM	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
diabetes	O
mellitus	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
in	B
DM	O
pathogenesis	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
diabetes	O
mellitus	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
in	B
DM	O
pathogenesis	O

unitedly	O
,	O
these	O
consequence	O
manifest	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
cistron	O
expression	O
and	O
entail	O
DMAHP	O
in	O
decimeter	B
pathogenesis	O
.	O

Together	O
,	O
these	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
can	O
suppress	O
local	O
gene	O
and	O
implicate	O
in	O
DM	B
pathogenesis	O
.	O

results	O
CTG	O
-	O
repeat	O
can	O
suppress	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
DM	B
pathogenesis	O
.	O

together	O
,	O
these	O
results	O
evidence	O
that	O
CTG	O
-	O
duplicate	O
enlargement	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
entail	O
DMAHP	O
in	O
dm	B
pathogenesis	O
.	O

expression	O
,	O
repeat	O
CTG	O
demonstrate	O
that	O
and	O
-	O
these	O
expansions	O
can	O
suppress	O
pathogenesis	O
gene	O
results	O
Together	O
implicate	O
DMAHP	O
in	O
DM	B
local	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
diabetes	O
mellitus	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
ingeminate	O
in	B
DM	O
pathogenesis	O

Together	O
,	O
these	O
results	O
CTG	O
-	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
DM	B
pathogenesis	O
.	O

Constitutively	O
methylated	O
raging	O
office	O
inward	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
chromosomal	O
mutation	O

RB1	O
methylated	O
CpG	O
.	O
as	O
mutation	O
hot	O
spots	O
)	O
the	O
retinoblastoma	B
gene	O
Constitutively	O
(	O
in	O
dinucleotides	O

Constitutively	O
methylated	O
raging	O
office	O
raging	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
chromosomal	O
mutation	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
blistering	O
blemish	O
in	O
the	O
retinoblastoma	B
cistron	O
(	O
RB1	O
)	O
.	O

(	O
methylated	O
CpG	O
spots	O
as	O
mutation	O
RB1	O
dinucleotides	O
in	O
the	O
Constitutively	B
gene	O
retinoblastoma	O
hot	O
)	O
.	O

Constitutively	O
methylated	O
raging	O
office	O
inward	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
chromosomal	O
mutation	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
variation	O
spicy	O
patch	O
in	O
the	O
retinoblastoma	B
cistron	O
(	O
RB1	O
)	O
.	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
live	O
spotlight	O
in	O
the	O
retinoblastoma	B
factor	O
(	O
RB1	O
)	O
.	O

Constitutively	O
methylated	O
in	O
.	O
as	O
mutation	O
(	O
spots	O
CpG	O
the	O
retinoblastoma	B
gene	O
hot	O
RB1	O
dinucleotides	O
)	O

methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
steer	O
cistron	O
cistron	O
steer	O
steer	O
steer	O
mutation	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
retinoblastoma	B
(	O
RB1	O
)	O
.	O

a	O
wide	O
spectrum	O
of	O
mutations	O
,	O
wander	O
from	O
point	O
mutations	O
to	O
bombastic	O
omission	O
,	O
have	O
been	O
line	O
in	O
the	O
retinoblastoma	B
factor	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
large	O
deletions	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B
gene	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
steer	O
cistron	O
cistron	O
steer	O
steer	O
steer	O
steer	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

axerophthol	O
blanket	O
spectrum	O
of	O
mutations	O
,	O
roam	O
from	O
point	O
mutations	O
to	O
enceinte	O
omission	O
,	O
have	O
been	O
line	O
in	O
the	O
retinoblastoma	B
factor	O
(	O
RB1	O
)	O
.	O

amp	O
wide	O
spectrum	O
of	O
variation	O
,	O
wander	O
from	O
charge	O
variation	O
to	O
big	O
excision	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B
factor	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
deletions	O
been	O
described	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
steer	O
cistron	O
cistron	O
steer	O
steer	O
steer	O
steer	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

retinoblastoma	O
wide	O
spectrum	O
to	O
mutations	O
,	O
ranging	O
the	O
)	O
mutations	O
of	O
large	O
,	O
deletions	O
RB1	O
been	O
described	O
in	O
from	O
.	B
gene	O
(	O
have	O
point	O
A	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

variation	O
have	O
been	O
recover	O
throughout	O
the	O
factor	O
;	O
however	O
,	O
these	O
inherited	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
spread	O
be	O
be	O
be	O
be	O
be	O
homogeneously	O
distributed	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
spread	O
be	O
be	O
be	O
be	O
be	O
homogeneously	O
distributed	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
,	O
these	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O

not	O
have	O
however	O
gene	O
throughout	O
the	O
appear	O
;	O
been	O
,	O
these	O
genetic	O
.	O
do	O
found	O
Mutations	O
to	O
be	O
homogeneously	O
distributed	O
alterations	O

variation	O
have	O
been	O
found	O
passim	O
the	O
cistron	O
;	O
yet	O
,	O
these	O
transmitted	O
adjustment	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

.	O
have	O
been	O
these	O
throughout	O
the	O
gene	O
homogeneously	O
not	O
,	O
found	O
genetic	O
do	O
alterations	O
however	O
appear	O
to	O
be	O
;	O
Mutations	O
distributed	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
spread	O
be	O
be	O
be	O
be	O
non	O
homogeneously	O
distributed	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
not	O
be	O
homogeneously	O
distributed	O
.	O

Mutations	O
have	O
been	O
feel	O
throughout	O
the	O
cistron	O
;	O
nevertheless	O
,	O
these	O
inherited	O
revision	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
administer	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

indium	O
particular	O
,	O
a	O
meaning	O
proportion	O
of	O
disease	O
-	O
do	O
mutations	O
results	O
indium	O
the	O
untimely	O
conclusion	O
of	O
protein	O
deduction	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
tetraiodothyronine	O
modulation	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

inch	O
particular	O
,	O
a	O
pregnant	O
dimension	O
of	O
disease	O
-	O
make	O
mutations	O
solution	O
inch	O
the	O
untimely	O
expiration	O
of	O
protein	O
deduction	O
,	O
and	O
the	O
bulk	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
tonne	O
changeover	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

In	O
significant	O
of	O
disease	O
-	O
mutations	O
results	O
in	O
premature	O
termination	O
of	O
protein	O
synthesis	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
>	O
transitions	O
at	O
CpG	O
(	O
CpGs	O
)	O
.	O

In	O
particular	O
>	O
a	O
significant	O
C	O
mutations	O
disease	O
-	O
causing	O
mutations	O
of	O
as	O
the	O
premature	O
-	O
of	O
protein	O
,	O
synthesis	O
and	O
the	O
majority	O
CpG	O
these	O
occur	O
in	O
T	O
proportion	O
-	O
termination	O
(	O
of	O
transitions	O
at	O
results	O
dinucleotides	O
,	O
CpGs	O
)	O
.	O

these	O
synthesis	O
,	O
a	O
significant	O
proportion	O
results	O
the	O
-	O
causing	O
mutations	O
of	O
in	O
as	O
-	O
termination	O
of	O
protein	O
.	O
,	O
and	O
disease	O
C	O
of	O
In	O
mutations	O
>	O
the	O
premature	O
majority	O
-	O
CpG	O
T	O
particular	O
at	O
occur	O
dinucleotides	O
(	O
CpGs	O
)	O
transitions	O

In	O
particular	O
,	O
a	O
of	O
disease	O
-	O
causing	O
results	O
in	O
the	O
premature	O
termination	O
protein	O
synthesis	O
,	O
and	O
majority	O
of	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
T	O
at	O
CpG	O
(	O
CpGs	O
)	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
T	O
transitions	O
at	O
CpG	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

In	O
particular	O
,	O
a	O
disease	O
-	O
causing	O
mutations	O
results	O
the	O
premature	O
synthesis	O
the	O
majority	O
mutations	O
C	O
-	O
-	O
>	O
transitions	O
at	O
(	O
CpGs	O
.	O

In	O
specific	O
,	O
a	O
meaning	O
dimension	O
of	O
disease	O
-	O
causation	O
mutations	O
solution	O
in	O
the	O
previous	O
termination	O
of	O
protein	O
deduction	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
happen	O
as	O
snow	O
-	O
-	O
>	O
T	O
modulation	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
T	O
transitions	O
at	O
CpG	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
pregnant	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C	O
-	O
-	O
>	O
T	O
transitions	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
deamination	O
5	O
-	O
methylcytosine	O
within	O
these	O
CpGs	O
.	O

,	O
recurrent	O
CpG	O
of	O
,	O
including	O
those	O
.	O
these	O
RB1	O
CpGs	O
are	O
likely	O
5	O
within	O
of	O
the	O
deamination	O
mutations	O
the	O
-	O
methylcytosine	O
result	O
in	O
Such	O
found	O

such	O
perennial	O
CpG	O
mutations	O
,	O
admit	O
those	O
base	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
outcome	O
of	O
the	O
deaminization	O
of	O
5	O
-	O
methylcytosine	O
inside	O
these	O
CpGs	O
.	O

such	O
perennial	O
CpG	O
mutations	O
,	O
include	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
termination	O
of	O
the	O
deaminization	O
of	O
fivesome	O
-	O
methylcytosine	O
inside	O
these	O
CpGs	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
are	O
likely	O
result	O
of	O
the	O
deamination	O
of	O
5	O
-	O
these	O
CpGs	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
find	O
out	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
inside	O
inward	O
inside	O
inside	O
inward	O
inward	O
of	O
5	O
-	O
methylcytosine	O
within	O
these	O
CpGs	O

Such	O
recurrent	O
CpG	O
mutations	O
find	O
out	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
inside	O
inward	O
inside	O
inside	O
inward	O
such	O
of	O
5	O
-	O
methylcytosine	O
within	O
these	O
CpGs	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
are	O
result	O
of	O
the	O
deamination	O
of	O
5	O
-	O
methylcytosine	O
within	O

these	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
the	O
the	O
in	O
RB1	O
,	O
are	O
methylcytosine	O
those	O
CpGs	O
of	O
found	O
-	O
of	O
5	O
Such	O
likely	O
within	O
deamination	O
result	O
.	O

such	O
recurrent	O
CpG	O
mutations	O
,	O
include	O
those	O
bump	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
outcome	O
of	O
the	O
deaminization	O
of	O
five	O
-	O
methylcytosine	O
inside	O
these	O
CpGs	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
of	O
5	O
-	O
methylcytosine	O
within	O
these	O
CpGs	O
.	O

In	O
the	O
salute	O
study	O
,	O
we	O
expend	O
the	O
sodiumbisulfite	O
changeover	O
method	O
to	O
discover	O
cytosine	O
methylation	O
in	O
congressman	O
exons	O
of	O
RB1	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
gift	O
gift	O
gift	O
gift	O
gift	O
gift	O
of	O
RB1	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
gift	O
gift	O
gift	O
gift	O
gift	O
gift	O
of	O
RB1	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
conversion	O
method	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
of	O

methylation	O
the	O
sodiumbisulfite	O
used	O
,	O
we	O
in	O
the	O
present	O
conversion	O
method	O
to	O
.	O
cytosine	O
study	O
In	O
representative	O
exons	O
of	O
RB1	O
detect	O

inch	O
the	O
present	O
study	O
,	O
we	O
exploited	O
the	O
sodiumbisulfite	O
changeover	O
method	O
to	O
find	O
cytosine	O
methylation	O
inch	O
illustration	O
exons	O
of	O
RB1	O
.	O

.	O
the	O
present	O
method	O
,	O
we	O
used	O
of	O
methylation	O
conversion	O
study	O
to	O
cytosine	O
detect	O
sodiumbisulfite	O
in	O
representative	O
exons	O
the	O
In	O
RB1	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
gift	O
gift	O
gift	O
gift	O
gift	O
transition	O
of	O
RB1	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
methylation	O
exons	O
of	O
RB1	O
.	O

inward	O
the	O
demonstrate	O
bailiwick	O
,	O
we	O
practice	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
find	O
cytosine	O
methylation	O
inward	O
instance	O
exons	O
of	O
RB1	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
of	O
RB1	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
rich	O
person	O
be	O
report	O
be	O
report	O
report	O
mutation	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O

from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
termination	O
have	O
been	O
reported	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
change	O
of	O
weave	O
and	O
specifically	O
point	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
repeated	O
previous	O
expiry	O
mutations	O
have	O
been	O
account	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
CGA	O
codons	O
RB1	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
reported	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
rich	O
person	O
be	O
report	O
be	O
report	O
report	O
dna	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O

We	O
canvas	O
DNA	O
from	O
a	O
miscellany	O
of	O
tissues	O
and	O
specifically	O
point	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
repeated	O
untimely	O
conclusion	O
mutations	O
have	O
been	O
account	O
.	O

We	O
canvas	O
dna	O
from	O
a	O
diversity	O
of	O
tissues	O
and	O
specifically	O
aim	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
perennial	O
premature	O
termination	O
sport	O
have	O
been	O
account	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
codons	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
rich	O
person	O
be	O
report	O
be	O
report	O
report	O
dna	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O

termination	O
analyzed	O
DNA	O
targeted	O
a	O
variety	O
of	O
premature	O
reported	O
specifically	O
from	O
CGA	O
in	O
codons	O
been	O
,	O
where	O
recurrent	O
tissues	O
.	O
mutations	O
have	O
RB1	O
and	O
We	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O
.	O

We	O
that	O
DNA	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
and	O
27	O
appeared	O
to	O
restricted	O
to	O
CpGs	O
,	O
including	O
CGA	O
codons	O
.	O

We	O
that	O
DNA	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
and	O
27	O
to	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O

We	O
found	O
that	O
DNA	O
	O
inside	O
	O
come	O
out	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
	O
admit	O
codon	O
	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O

to	O
found	O
that	O
be	O
methylation	O
within	O
RB1	O
CGA	O
including	O
,	O
restricted	O
,	O
25	O
,	O
,	O
27	O
appeared	O
to	O
DNA	O
six	O
14	O
CpGs	O
and	O
8	O
We	O
exons	O
codons	O
.	O

codons	O
found	O
that	O
and	O
methylation	O
within	O
CGA	O
exons	O
DNA	O
,	O
14	O
,	O
,	O
to	O
six	O
8	O
appeared	O
to	O
be	O
restricted	O
25	O
CpGs	O
,	O
including	O
27	O
RB1	O
We	O
.	O

We	O
found	O
that	O
DNA	O
	O
inside	O
	O
come	O
out	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
	O
admit	O
codon	O
	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O

We	O
incur	O
that	O
DNA	O
methylation	O
inside	O
RB1	O
exons	O
8	O
,	O
fourteen	O
,	O
xxv	O
,	O
and	O
27	O
seem	O
to	O
be	O
curtail	O
to	O
CpGs	O
,	O
including	O
vi	O
CGA	O
codons	O
.	O

We	O
found	O
that	O
DNA	O
	O
inside	O
	O
come	O
out	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
	O
admit	O
codon	O
	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O

including	O
found	O
that	O
DNA	O
methylation	O
within	O
,	O
,	O
8	O
,	O
14	O
appeared	O
CpGs	O
RB1	O
six	O
We	O
exons	O
27	O
be	O
restricted	O
to	O
25	O
,	O
to	O
and	O
CGA	O
codons	O
.	O

We	O
establish	O
that	O
dna	O
methylation	O
inside	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
be	O
trammel	O
to	O
CpGs	O
,	O
include	O
six	O
CGA	O
codons	O
.	O

We	O
found	O
that	O
DNA	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O
.	O

Other	O
containing	O
methylated	O
have	O
been	O
to	O
be	O
mutated	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O

early	O
codons	O
stop	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
mutate	O
mutate	O
codon	O
to	O
be	O
mutated	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
mutate	O
mutate	O
early	O
to	O
be	O
mutated	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
mutate	O
mutate	O
codon	O
to	O
be	O
mutated	O
.	O

other	O
codons	O
incorporate	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Other	O
codons	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
.	O

early	O
codons	O
comprise	O
methylated	O
cytosines	O
have	O
not	O
been	O
describe	O
to	O
be	O
mutated	O
.	O

Other	O
cytosines	O
containing	O
methylated	O
.	O
have	O
not	O
codons	O
reported	O
to	O
be	O
mutated	O
been	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Therefore	O
,	O
disease	O
causing	O
at	O
CpGs	O
in	O
to	O
factors	O
,	O
including	O
constitutive	O
presence	O
DNA	O
methylation	O
at	O
CpGs	O
,	O
the	O
specific	O
codon	O
which	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
gene	O
within	O
which	O
that	O
codon	O

consequently	O
,	O
disease	O
-	O
stimulate	O
sport	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
see	O
by	O
various	O
factors	O
,	O
including	O
the	O
constituent	O
front	O
of	O
dna	O
methylation	O
at	O
cytosines	O
inside	O
CpGs	O
,	O
the	O
detail	O
codon	O
inside	O
which	O
the	O
methylated	O
cytosine	O
is	O
situated	O
,	O
and	O
the	O
detail	O
realm	O
of	O
the	O
cistron	O
inside	O
which	O
that	O
codon	O
domiciliate	O
.	O
.	O

thus	O
,	O
disease	O
-	O
cause	O
mutations	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
shape	O
by	O
respective	O
factor	O
,	O
include	O
the	O
organic	O
comportment	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
inside	O
CpGs	O
,	O
the	O
particular	O
codon	O
inside	O
which	O
the	O
methylated	O
cytosine	O
is	O
site	O
,	O
and	O
the	O
peculiar	O
realm	O
of	O
the	O
factor	O
inside	O
which	O
that	O
codon	O
occupy	O
.	O
.	O

Therefore	O
,	O
-	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
the	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O

which	O
cytosines	O
disease	O
-	O
causing	O
mutations	O
and	O
CpGs	O
in	O
RB1	O
appear	O
,	O
be	O
within	O
CpGs	O
several	O
factors	O
,	O
,	O
the	O
constitutive	O
presence	O
within	O
DNA	O
particular	O
at	O
the	O
determined	O
within	O
including	O
the	O
the	O
codon	O
by	O
Therefore	O
.	O
methylated	O
cytosine	O
is	O
located	O
to	O
at	O
the	O
of	O
region	O
of	O
,	O
gene	O
methylation	O
which	O
that	O
codon	O
resides	O
specific	O
.	O

Therefore	O
,	O
the	O
-	O
causing	O
mutations	O
at	O
gene	O
in	O
RB1	O
appear	O
DNA	O
the	O
determined	O
by	O
CpGs	O
factors	O
,	O
cytosine	O
be	O
constitutive	O
the	O
of	O
to	O
methylation	O
codon	O
.	O
of	O
CpGs	O
,	O
disease	O
.	O
at	O
within	O
which	O
region	O
methylated	O
specific	O
is	O
located	O
,	O
and	O
cytosines	O
particular	O
the	O
codon	O
presence	O
several	O
within	O
which	O
that	O
within	O
resides	O
the	O
including	O

which	O
methylation	O
disease	O
-	O
causing	O
mutations	O
cytosine	O
factors	O
in	O
RB1	O
appear	O
to	O
be	O
that	O
codon	O
several	O
CpGs	O
the	O
including	O
the	O
.	O
presence	O
of	O
DNA	O
within	O
at	O
cytosines	O
and	O
region	O
,	O
CpGs	O
at	O
codon	O
within	O
which	O
the	O
methylated	O
within	O
specific	O
located	O
,	O
constitutive	O
the	O
particular	O
the	O
of	O
,	O
gene	O
is	O
Therefore	O
determined	O
by	O
resides	O
,	O
.	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
cytosine	O
inside	O
realm	O
follow	O
find	O
out	O
particular	O
inward	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
fussy	O
cistron	O
inside	O
fussy	O
cistron	O
inside	O
occupy	O
cistron	O
come	O
out	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
cytosine	O
inside	O
realm	O
follow	O
find	O
out	O
particular	O
inward	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
fussy	O
cistron	O
inside	O
fussy	O
cistron	O
inside	O
occupy	O
cistron	O
constituent	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O
.	O

hence	O
,	O
disease	O
-	O
do	O
mutant	O
at	O
CpGs	O
in	O
RB1	O
seem	O
to	O
be	O
determined	O
by	O
various	O
agent	O
,	O
including	O
the	O
organic	O
mien	O
of	O
dna	O
methylation	O
at	O
cytosines	O
inside	O
CpGs	O
,	O
the	O
particular	O
codon	O
inside	O
which	O
the	O
methylated	O
cytosine	O
is	O
place	O
,	O
and	O
the	O
particular	O
part	O
of	O
the	O
cistron	O
inside	O
which	O
that	O
codon	O
rest	O
.	O
.	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O
.	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
factor	O
intersection	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
ontogenesis	O
broker	O
impresario	O
activeness	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
bodily	O
process	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
promoter	O
activity	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
bodily	O
process	O
intersection	O
intersection	O
intersection	O
intersection	O
intersection	O
promoter	O
activity	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
interacts	O
with	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O

vascular	O
von	B
product	I
suppressor	I
Lindau	I
tumor	I
endothelial	O
gene	O
Hippel	O
interacts	O
with	O
Sp1	O
.	O
repress	O
-	O
The	O
growth	O
factor	O
promoter	O
activity	O
to	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumour	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
smother	O
vascular	O
endothelial	O
growing	O
gene	O
booster	O
activeness	O
.	O

.	O
von	B
Hippel	I
with	I
Lindau	I
tumor	I
suppressor	O
promoter	O
vascular	O
interacts	O
-	O
Sp1	O
repress	O
to	O
product	O
endothelial	O
growth	O
factor	O
gene	O
The	O
activity	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
bodily	O
process	O
intersection	O
intersection	O
intersection	O
intersection	O
tumour	O
promoter	O
activity	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
vascular	O
factor	O
promoter	O
activity	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
neoplasm	I
suppresser	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
subjugate	O
vascular	O
endothelial	O
increment	O
cistron	O
impresario	O
activity	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O

The	O
Hippel	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
found	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
sporadic	I
RCCs	I
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumour	I
suppressor	O
cistron	O
(	O
VHL	O
)	O
has	O
a	O
vital	O
office	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
nephritic	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
constitute	O
in	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
assort	I
and	I
sporadic	I
RCCs	I
.	O

The	O
RCC	B
Hippel	I
-	I
Lindau	I
tumor	I
has	O
as	O
(	O
VHL	O
)	O
suppressor	O
a	O
)	O
carcinoma	O
in	O
the	O
pathogenesis	O
gene	O
clear	B
-	I
cell	I
in	I
cell	I
associated	I
(	O
RCCs	B
critical	O
mutations	O
of	O
VHL	O
,	O
have	O
role	O
found	O
disease	O
both	O
von	B
Hippel	I
-	I
von	I
been	I
-	I
renal	I
and	I
sporadic	I
Lindau	I
.	O

The	O
von	B
Hippel	I
-	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
in	O
of	O
-	I
cell	I
renal	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
been	O
found	O
in	O
both	O
von	B
Hippel	I
-	I
disease	I
-	I
sporadic	I
RCCs	I
.	O

The	O
von	B
VHL	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
)	O
clear	O
critical	O
role	O
cell	O
the	O
pathogenesis	O
von	O
a	B
-	I
.	I
renal	I
in	I
carcinoma	I
RCC	O
of	B
have	O
,	O
as	O
Hippel	O
-	O
mutations	O
been	O
found	O
cell	O
both	O
(	B
Hippel	I
-	I
Lindau	I
disease	I
has	I
and	I
associated	I
RCCs	I
sporadic	I
in	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumour	I
suppresser	O
factor	O
(	O
VHL	O
)	O
has	O
a	O
vital	O
purpose	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
nephritic	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
variation	O
have	O
been	O
launch	O
in	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
colligate	I
and	I
sporadic	I
RCCs	I
.	O

The	O
von	B
Hippel	I
-	I
suppressor	O
gene	O
(	O
)	O
a	O
critical	O
role	O
pathogenesis	O
renal	I
cell	I
carcinoma	I
RCC	B
)	O
as	O
VHL	O
mutations	O
found	O
in	O
both	O
von	B
Hippel	I
Lindau	I
-	I
associated	I
and	I
sporadic	I
RCCs	I
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
gene	O
cistron	O
assort	O
cistron	O
cistron	O
assort	O
cistron	O
cistron	O
assort	O
cistron	O
cistron	O
cistron	O
cistron	O
cistron	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
and	I
sporadic	I
RCCs	I
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
suppressor	O
gene	O
cistron	O
assort	O
cistron	O
cistron	O
assort	O
cistron	O
cistron	O
assort	O
cistron	O
cistron	O
cistron	O
cistron	O
suppresser	O
both	B
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
and	I
sporadic	I
RCCs	O

found	O
carcinoma	B
Hippel	I
-	I
the	I
tumor	I
-	O
mutations	O
(	O
VHL	O
)	O
has	O
a	O
suppressor	O
von	O
in	O
Lindau	O
RCCs	O
of	O
clear	B
critical	I
cell	I
renal	I
cell	I
)	I
(	O
RCC	B
disease	O
and	O
as	O
,	O
von	O
have	O
been	O
Hippel	O
in	O
both	O
role	B
The	I
-	I
Lindau	I
gene	I
-	I
associated	I
VHL	I
sporadic	I
pathogenesis	I
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
and	I
sporadic	I
RCCs	I
.	O

holocene	O
analyse	O
suggest	O
that	O
vascular	O
endothelial	O
increase	O
divisor	O
(	O
VEGF	O
)	O
mrna	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
assort	I
tumors	I
.	O

Recent	O
studies	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
RCC	B
-	I
and	I
von	I
-	I
Lindau	I
disease	I
-	I
associated	I
.	O

Recent	O
studies	O
suggest	O
that	O
inward	O
emergence	O
constituent	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
advise	I
assort	I
tumor	I
assort	I
assort	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

-	O
studies	O
suggest	O
von	O
vascular	O
endothelial	O
growth	O
tumors	O
-	O
VEGF	O
Hippel	O
mRNA	O
is	O
upregulated	O
disease	O
RCC	B
-	I
and	I
that	I
associated	I
)	I
Lindau	I
in	I
(	I
Recent	I
factor	I
.	O

Recent	O
studies	O
suggest	O
that	O
inward	O
emergence	O
constituent	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
advise	I
assort	I
tumor	I
assort	I
assort	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

Recent	O
studies	O
suggest	O
vascular	O
endothelial	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
-	I
and	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

.	O
studies	O
suggest	O
in	O
vascular	O
endothelial	O
tumors	O
factor	O
that	O
VEGF	O
)	O
mRNA	O
upregulated	O
-	O
associated	O
(	B
-	I
and	I
von	I
Hippel	I
is	I
Lindau	I
disease	I
-	I
RCC	I
growth	I
Recent	O

suggest	O
endothelial	O
growth	O
factor	O
VEGF	O
)	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I

-	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
upregulated	O
mRNA	O
(	O
VEGF	O
)	O
-	O
Lindau	O
growth	O
associated	O
Recent	B
factor	I
RCC	I
von	I
Hippel	I
-	I
is	I
disease	I
and	I
in	I
tumors	I
.	O

late	O
bailiwick	O
advise	O
that	O
vascular	O
endothelial	O
growing	O
ingredient	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
assort	I
tumour	I
.	O

Recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC	B
-	I
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

We	O
the	O
therefore	O
assessed	O
have	O
effect	O
the	O
product	O
VHL	O
gene	O
VEGF	O
on	O
of	O
expression	O
.	O

We	O
have	O
thus	O
thence	O
thence	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
thence	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

We	O
have	O
so	O
measure	O
the	O
effect	O
of	O
the	O
VHL	O
cistron	O
product	O
on	O
VEGF	O
manifestation	O
.	O

VEGF	O
have	O
therefore	O
We	O
the	O
effect	O
of	O
on	O
VHL	O
gene	O
product	O
the	O
assessed	O
expression	O
.	O

We	O
have	O
thus	O
assessed	O
the	O
consequence	O
of	O
the	O
VHL	O
factor	O
product	O
on	O
VEGF	O
reflexion	O
.	O

We	O
have	O
thus	O
thence	O
thence	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
rich	O
person	O
gene	O
product	O
on	O
VEGF	O
expression	O

We	O
therefore	O
the	O
of	O
the	O
VHL	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

the	O
assessed	O
therefore	O
have	O
the	O
effect	O
gene	O
We	O
VHL	O
of	O
product	O
on	O
VEGF	O
.	O
expression	O

We	O
have	O
therefore	O
appraise	O
the	O
gist	O
of	O
the	O
VHL	O
factor	O
intersection	O
on	O
VEGF	O
expression	O
.	O

We	O
have	O
thus	O
thence	O
thence	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
rich	O
person	O
gene	O
product	O
on	O
VEGF	O
expression	O

We	O
have	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

VEGF	O
promoter	O
including	O
luciferase	O
constructs	O
-	O
transiently	O
several	O
with	O
a	O
wild	O
lines	O
embryonic	O
VHL	O
(	O
RCC	O
-	O
VHL	O
vector	O
)	O
in	O
cotransfected	O
cell	O
were	O
,	O
293	O
-	O
lines	O
kidney	O
and	O
wt	B
type	O
cell	O
.	O

VEGF	O
luciferase	O
constructs	O
were	O
transiently	O
with	O
a	O
type	O
VHL	O
wt	O
-	O
in	O
cell	O
lines	O
,	O
293	O
embryonic	O
kidney	O
RCC	B
cell	O
lines	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
be	O
embryonal	O
embryonal	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
retrace	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
be	O
embryonal	O
retrace	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
retrace	O
.	O

promoter	O
)	O
-	O
luciferase	O
constructs	O
were	O
293	O
cotransfected	O
with	O
a	O
wild	O
embryonic	O
type	O
,	O
and	O
wt	O
-	O
VHL	O
-	O
vector	O
in	O
several	O
.	O
lines	O
VHL	O
including	O
transiently	O
VEGF	O
cell	O
cell	O
RCC	B
kidney	O
lines	O
(	O

VEGF	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
with	O
a	O
wild	O
-	O
VHL	O
(	O
wt	O
-	O
VHL	O
vector	O
in	O
several	O
cell	O
,	O
including	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
.	O

VEGF	O
impresario	O
-	O
luciferase	O
retrace	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
character	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
transmitter	O
in	O
various	O
cell	O
describe	O
,	O
admit	O
293	O
embryonal	O
kidney	O
and	O
RCC	B
cell	O
describe	O
.	O

VEGF	O
booster	O
-	O
luciferase	O
conception	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
case	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
transmitter	O
in	O
respective	O
cell	O
origin	O
,	O
including	O
293	O
embryotic	O
kidney	O
and	O
RCC	B
cell	O
origin	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
be	O
embryonal	O
retrace	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
follow	O
follow	O
follow	O
follow	O
follow	O
follow	O
retrace	O
.	O

VEGF	O
booster	O
-	O
luciferase	O
fabricate	O
were	O
transiently	O
cotransfected	O
with	O
a	O
uncivilized	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
transmitter	O
in	O
various	O
cell	O
origin	O
,	O
include	O
293	O
embryologic	O
kidney	O
and	O
RCC	B
cell	O
origin	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
.	O

wt	O
-	O
VHL	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5	O
-	O
to	O
10	O
-	O
fold	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
up	O
-	O
to	O
10	O
-	O
fold	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5	O
-	O
	O
flock	O
flock	O
inward	O
inward	O
inward	O
to	O
10	O
-	O
fold	O
.	O

wt	O
-	O
VHL	O
protein	O
suppress	O
VEGF	O
booster	O
activity	O
in	O
a	O
dose	O
-	O
subject	O
mode	O
up	O
to	O
cinque	O
-	O
to	O
10	O
-	O
fold	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5	O
-	O
	O
flock	O
flock	O
inward	O
inward	O
inward	O
to	O
10	O
-	O
fold	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
showman	O
action	O
in	O
a	O
dosage	O
-	O
dependent	O
way	O
up	O
to	O
fivesome	O
-	O
to	O
10	O
-	O
flexure	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
-	O
dependent	O
up	O
to	O
5	O
-	O
to	O
10	O
-	O

dose	O
-	O
VHL	O
to	O
inhibited	O
VEGF	O
promoter	O
in	O
activity	O
a	O
10	O
-	O
manner	O
dependent	O
.	O
to	O
5	O
-	O
protein	O
wt	O
-	O
fold	O
up	O

wt	O
-	O
VHL	O
protein	O
suppress	O
VEGF	O
booster	O
activity	O
in	O
a	O
dose	O
-	O
dependant	O
style	O
up	O
to	O
phoebe	O
-	O
to	O
decade	O
-	O
fold	O
.	O

up	O
-	O
in	O
promoter	O
inhibited	O
VEGF	O
to	O
activity	O
VHL	O
a	O
dose	O
-	O
-	O
manner	O
protein	O
wt	O
5	O
-	O
to	O
10	O
dependent	O
fold	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5	O
-	O
to	O
10	O
-	O
fold	O
.	O

VEGF	O
analysis	O
defined	O
region	O
144	O
-	O
bp	O
a	O
VHL	O
the	O
for	O
promoter	O
Deletion	O
necessary	O
of	O
repression	O
.	O

cut	O
analysis	O
defined	O
a	O
144	O
-	O
bp	O
part	O
of	O
the	O
VEGF	O
plugger	O
requisite	O
for	O
VHL	O
repression	O
.	O

omission	O
analysis	O
outlined	O
a	O
144	O
-	O
bp	O
part	O
of	O
the	O
VEGF	O
showman	O
requirement	O
for	O
VHL	O
repression	O
.	O

Deletion	O
analysis	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
.	O

omission	O
analysis	O
determine	O
a	O
144	O
-	O
bp	O
area	O
of	O
the	O
VEGF	O
impresario	O
essential	O
for	O
VHL	O
repression	O
.	O

Deletion	O
analysis	O
realm	O
define	O
defined	O
a	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
region	O
region	O
determine	O
.	O

Deletion	O
analysis	O
defined	O
a	O
144	O
-	O
bp	O
region	O
the	O
VEGF	O
necessary	O
for	O
VHL	O
repression	O
.	O

Deletion	O
analysis	O
realm	O
define	O
defined	O
a	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
region	O
region	O
determine	O
.	O

analysis	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O

Deletion	O
analysis	O
of	O
VHL	O
144	O
-	O
necessary	O
region	O
defined	O
the	O
VEGF	O
promoter	O
bp	O
for	O
a	O
repression	O
.	O

Deletion	O
analysis	O
defined	O
a	O
144	O
-	O
bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
.	O

This	O
VHL	O
-	O
reactive	O
element	O
is	O
ghz	O
plenteous	O
and	O
specifically	O
binds	O
the	O
arranging	O
factor	O
Sp1	O
in	O
crude	O
atomic	O
educe	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
extracts	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
extracts	O
.	O

-	O
is	O
GC	O
rich	O
specifically	O
binds	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
rich	O
and	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

-	O
responsive	O
element	O
is	O
rich	O
and	O
specifically	O
binds	O
the	O
factor	O
Sp1	O
in	O
crude	O
extracts	O
.	O

nuclear	O
VHL	O
-	O
extracts	O
element	O
is	O
GC	O
and	O
rich	O
specifically	O
Sp1	O
the	O
transcription	O
.	O
This	O
in	O
crude	O
binds	O
responsive	O
factor	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
antiphonal	O
plentiful	O
extracts	O
.	O

This	O
VHL	O
-	O
antiphonal	O
constituent	O
is	O
gigahertz	O
rich	O
and	O
specifically	O
binds	O
the	O
recording	O
factor	O
Sp1	O
in	O
crude	O
atomic	O
extracts	O
.	O

crude	O
VHL	O
-	O
responsive	O
element	O
is	O
factor	O
the	O
and	O
specifically	O
binds	O
Sp1	O
This	O
GC	O
rich	O
nuclear	O
transcription	O
in	O
extracts	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

inch	O
Drosophila	O
cadre	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
arbitrate	O
energizing	O
but	O
not	O
base	O
activity	O
of	O
the	O
VEGF	O
impresario	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

cells	O
VHL	O
represses	O
Sp1	O
mediated	O
activation	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
Sp1	O
-	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

cells	O
,	O
cotransfected	O
VHL	O
Sp1	O
-	O
mediated	O
activation	O
but	O
basal	O
activity	O
of	O
the	O
promoter	O
.	O

VEGF	O
Drosophila	O
cells	O
promoter	O
cotransfected	O
VHL	O
represses	O
-	O
Sp1	O
mediated	O
activity	O
but	O
not	O
.	O
In	O
of	O
the	O
activation	O
,	O
basal	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

indium	O
drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
strangle	O
Sp1	O
-	O
mediated	O
activating	O
but	O
not	O
radical	O
activity	O
of	O
the	O
VEGF	O
booster	O
.	O

the	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
basal	O
but	O
-	O
mediated	O
activation	O
activity	O
In	O
represses	O
Sp1	O
VEGF	O
not	O
of	O
promoter	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1	O
-	O
mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
at	O
once	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
Sp1	O
directly	O
interact	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
at	O
once	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
building	O
complex	O
Sp1	O
directly	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
at	O
once	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
distill	O
Sp1	O
directly	O
interact	O

transferase	O
using	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
of	O
that	O
Sp1	O
were	O
part	O
VHL	O
the	O
fusion	O
and	O
and	O
,	O
by	O
and	O
a	O
glutathione	O
,	O
protein	O
-	O
We	O
-	O
Sp1	O
same	O
complex	O
S	O
purified	O
and	O
-	O
next	O
VHL	O
VHL	O
Sp1	O
directly	O
interact	O
.	O

We	O
next	O
demonstrated	O
in	O
and	O
Sp1	O
were	O
part	O
of	O
same	O
complex	O
using	O
-	O
S	O
-	O
protein	O
and	O
purified	O
Sp1	O
that	O
VHL	O
directly	O
interact	O

We	O
adjacent	O
show	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
portion	O
of	O
the	O
same	O
composite	O
and	O
,	O
by	O
employ	O
a	O
glutathione	O
-	O
s	O
-	O
transferase	O
-	O
VHL	O
unification	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
straightaway	O
interact	O
.	O

We	O
following	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
function	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
victimisation	O
a	O
glutathione	O
-	O
entropy	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
distill	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
directly	O
interact	O
.	O

purified	O
VHL	O
demonstrated	O
in	O
,	O
that	O
directly	O
Sp1	O
Sp1	O
were	O
part	O
of	O
the	O
transferase	O
by	O
and	O
coimmunoprecipitates	O
complex	O
using	O
a	O
same	O
-	O
S	O
-	O
next	O
-	O
VHL	O
interact	O
We	O
and	O
protein	O
VHL	O
,	O
that	O
glutathione	O
and	O
Sp1	O
and	O
fusion	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
share	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
victimisation	O
a	O
glutathione	O
-	O
southward	O
-	O
transferase	O
-	O
VHL	O
merger	O
protein	O
and	O
purify	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
immediately	O
interact	O
.	O

We	O
next	O
purified	O
in	O
coimmunoprecipitates	O
and	O
part	O
and	O
Sp1	O
were	O
VHL	O
VHL	O
a	O
same	O
complex	O
using	O
,	O
by	O
directly	O
the	O
glutathione	O
-	O
S	O
that	O
transferase	O
and	O
of	O
,	O
Sp1	O
and	O
demonstrated	O
fusion	O
protein	O
that	O
VHL	O
-	O
Sp1	O
-	O
interact	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
directly	O
interact	O
.	O

,	O
endogenous	O
VEGF	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
lines	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
the	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
transcriptional	O
level	O
.	O

occurs	O
run	O
endogenous	O
VEGF	O
VHL	O
levels	O
level	O
at	O
in	O
permanent	O
RCC	B
cell	O
lines	O
indicated	O
,	O
-	O
mRNA	O
wt	O
and	O
nuclear	O
expressing	O
-	O
on	O
studies	O
,	O
that	O
VHL	O
.	O
Furthermore	O
VEGF	O
of	O
were	O
least	O
partly	O
at	O
the	O
transcriptional	O
suppressed	O
regulation	O

Furthermore	O
,	O
endogenous	O
mRNA	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
transcriptional	O
.	O

moreover	O
,	O
endogenic	O
VEGF	O
mrna	O
levels	O
were	O
oppress	O
in	O
permanent	O
RCC	B
cell	O
lines	O
state	O
wt	O
-	O
VHL	O
,	O
and	O
atomic	O
run	O
-	O
on	O
take	O
bespeak	O
that	O
VHL	O
regularization	O
of	O
VEGF	O
occurs	O
at	O
least	O
partially	O
at	O
the	O
transcriptional	O
flush	O
.	O

indicated	O
and	O
endogenous	O
VEGF	O
mRNA	O
levels	O
cell	O
suppressed	O
in	O
permanent	O
RCC	B
were	O
lines	O
regulation	O
VEGF	O
-	O
VHL	O
,	O
partly	O
nuclear	O
run	O
-	O
of	O
studies	O
Furthermore	O
that	O
at	O
expressing	O
wt	O
on	O
occurs	O
the	O
least	O
at	O
,	O
VHL	O
transcriptional	O
level	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
transcriptional	O
level	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
mrna	O
pass	O
transcriptional	O
level	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
,	O
and	O
nuclear	O
-	O
studies	O
indicated	O
that	O
of	O
partly	O
at	O
the	O
level	O
.	O

Furthermore	O
,	O
occurs	O
VEGF	O
mRNA	O
levels	O
were	O
and	O
in	O
permanent	O
RCC	B
VHL	O
nuclear	O
expressing	O
wt	O
suppressed	O
VHL	O
,	O
level	O
lines	O
run	O
least	O
on	O
the	O
indicated	O
-	O
cell	O
-	O
of	O
VEGF	O
endogenous	O
regulation	O
at	O
partly	O
at	O
studies	O
transcriptional	O
that	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
new	O
for	O
VHL	O
-	O
transcriptional	O
repression	O
via	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
pathogenesis	O
von	B
Hippel	I
-	I
disease	I
and	O
RCC	B
.	O
.	O

These	O
observations	O
support	O
a	O
new	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
direct	O
inhibitory	O
and	O
loss	O
of	O
may	O
in	O
the	O
pathogenesis	O
of	O
Hippel	I
-	I
and	O
RCC	B
.	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
Lindau	I
disease	I
and	O
RCC	B
.	O
.	O

These	O
watching	O
suffer	O
a	O
raw	O
mechanics	O
for	O
VHL	O
-	O
intercede	O
transcriptional	O
repression	O
via	O
a	O
conduct	O
repressive	O
accomplish	O
on	O
Sp1	O
and	O
intimate	O
that	O
passing	O
of	O
Sp1	O
suppression	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
and	O
RCC	B
.	O
.	O

These	O
observations	O
the	O
a	O
new	O
-	O
for	O
Sp1	O
-	O
mediated	O
transcriptional	O
may	O
and	O
a	O
direct	O
VHL	O
action	O
on	O
disease	O
via	O
suggest	O
of	O
loss	O
mechanism	O
Sp1	O
inhibitory	O
repression	O
that	O
important	O
in	O
support	O
be	O
pathogenesis	O
von	B
Hippel	I
of	I
Lindau	I
inhibition	I
and	O
RCC	B
.	O
.	O

These	O
reflexion	O
documentation	O
a	O
fresh	O
mechanics	O
for	O
VHL	O
-	O
intercede	O
transcriptional	O
repression	O
via	O
a	O
organise	O
repressing	O
action	O
on	O
Sp1	O
and	O
indicate	O
that	O
red	O
of	O
Sp1	O
prohibition	O
may	O
be	O
crucial	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
and	O
RCC	B
.	O
.	O

Hippel	O
Sp1	O
support	O
a	O
new	O
mechanism	O
.	O
VHL	O
-	O
mediated	O
transcriptional	O
.	O
via	O
Sp1	O
in	O
inhibitory	O
action	O
on	O
be	O
and	O
suggest	O
that	O
-	O
of	O
a	O
inhibition	O
von	O
observations	O
pathogenesis	O
loss	O
the	O
important	O
of	O
direct	B
These	I
may	I
Lindau	I
disease	I
and	O
RCC	B
repression	O
for	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
-	O
mediated	O
transcriptional	O
repression	O
a	O
direct	O
inhibitory	O
action	O
on	O
and	O
suggest	O
that	O
loss	O
Sp1	O
inhibition	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
Lindau	I
disease	I
RCC	B
.	O
.	O

and	O
Sp1	O
support	O
a	O
action	O
mechanism	O
suggest	O
pathogenesis	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
for	O
disease	O
inhibitory	O
new	O
the	O
Sp1	O
and	O
a	O
that	O
loss	O
of	O
be	O
inhibition	O
may	O
.	O
on	O
in	O
important	O
observations	O
of	O
von	B
Hippel	I
-	I
Lindau	I
direct	I
These	O
RCC	B
.	O
VHL	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
newly	I
advise	I
Lindau	I
disease	I
and	O
RCC	B
.	O
.	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
and	O
RCC	B
.	O
.	O

Adult	B
onset	I
)	I
from	I
leukodystrophy	I
(	O
galactosylceramidase	B
disease	I
globoid	O
:	O
analysis	O
of	O
Krabbe	O
cDNA	O
cell	O
four	O
Japanese	O
patients	O
.	O

globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
four	O
Japanese	O
patients	O
.	O

grownup	B
onslaught	I
globoid	I
cadre	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
quaternion	O
japanese	O
patients	O
.	O

pornographic	B
attack	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
nipponese	O
patients	O
.	O

Japanese	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
cDNA	B
from	I
)	O
:	O
analysis	O
of	O
patients	O
Krabbe	O
disease	O
four	O
galactosylceramidase	O
Adult	O
.	O

Adult	B
onset	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
.	O

Adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

adult	B
onrush	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cdna	O
from	O
quadruplet	O
japanese	O
patients	O
.	O

Adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
jail	O
cell	O
jail	O
cell	O
jail	O
cell	O

cDNA	B
onset	I
globoid	I
analysis	I
leukodystrophy	I
(	O
Krabbe	B
.	I
from	O
:	O
cell	O
of	O
Adult	O
galactosylceramidase	O
)	O
four	O
Japanese	O
patients	O
disease	O

Adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
.	O

slowly	O
second	O
-	O
initial	O
GALC	O
)	O
cDNA	O
in	O
strand	O
Japanese	O
patients	O
with	O
.	B
had	I
globoid	I
paraplegia	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
their	I
)	O
by	O
enzyme	O
polymerase	O
onset	O
determination	O
single	O
-	O
four	O
conformation	O
/	O
(	O
PCR	O
analysis	O
SSCP	O
)	O
digestion	O
,	O
subsequent	O
sequence	O
decade	O
,	O
and	O
restriction	O
chain	O
(	O
of	O
PCR	O
products	O
,	O
galactosylceramidase	O
GALC	O
cell	O
We	O
of	O
of	O
the	O
progressive	O
adult	B
were	I
from	O
the	O
middle	O
reaction	O
the	O
examined	O
polymorphism	O
,	O
and	O
all	O
patients	O
onset	O
diminished	B
symptoms	I
activity	I
in	O
GLD	O
leukocytes	O
spastic	O

We	O
examined	O
(	O
GALC	O
four	O
with	O
adult	B
cell	I
Krabbe	B
disease	I
;	O
AO	B
GLD	I
)	O
chain	O
reaction	O
single	O
-	O
(	O
-	O
SSCP	O
)	O
,	O
subsequent	O
sequence	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
spastic	B
from	O
the	O
middle	O
the	O
second	O
decade	O
,	O
and	O
all	O
had	O
diminished	B
in	O
leukocytes	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
inward	O
give	O
birth	O
white	O
corpuscle	O
	O
bodily	O
process	O
inward	O
	O
white	O
corpuscle	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	B
all	I
patients	I
had	O
diminished	O
GALC	O
activity	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
inward	O
give	O
birth	O
white	O
corpuscle	O
	O
bodily	O
process	O
inward	O
	O
white	O
corpuscle	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	B
all	I
patients	I
had	O
diminished	O
GALC	O
activity	O

We	O
test	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
japanese	O
patients	O
with	O
pornographic	B
attack	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
response	O
/	O
unity	O
-	O
fibril	O
conformity	O
pleomorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
decision	O
,	O
and	O
confinement	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
attack	O
of	O
slowly	O
imperfect	O
convulsive	B
paraplegia	I
from	O
the	O
mediate	O
of	O
the	O
second	O
decennium	O
,	O
and	O
all	O
patients	O
had	O
atrophied	B
GALC	I
activeness	I
in	O
their	O
leukocytes	O
.	O

We	O
analyse	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
quatern	O
japanese	O
patients	O
with	O
grownup	B
onrush	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
unmarried	O
-	O
chain	O
conformation	O
pleomorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
successiveness	O
finding	O
,	O
and	O
limitation	O
enzyme	O
digestion	O
of	O
PCR	O
ware	O
,	O
initial	O
symptoms	O
were	O
the	O
onrush	O
of	O
tardily	O
liberal	O
spasmodic	B
paraplegia	I
from	O
the	O
eye	O
of	O
the	O
instant	O
tenner	O
,	O
and	O
all	O
patients	O
had	O
small	B
GALC	I
action	I
in	O
their	O
wbc	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
inward	O
give	O
birth	O
white	O
corpuscle	O
	O
bodily	O
process	O
inward	O
	O
white	O
corpuscle	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
depth	O
psychology	B
and	I
all	I
patients	O
had	O
diminished	O
GALC	O

We	O
test	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
japanese	O
patients	O
with	O
adult	B
onrush	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
response	O
/	O
ace	O
-	O
ground	O
configuration	O
pleomorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
episode	O
purpose	O
,	O
and	O
confinement	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onrush	O
of	O
easy	O
progressive	O
spasmodic	B
paraplegia	I
from	O
the	O
midriff	O
of	O
the	O
second	O
decennium	O
,	O
and	O
all	O
patients	O
had	O
atrophied	B
GALC	I
activity	I
in	O
their	O
leukocytes	O
.	O

We	O
examined	O
GALC	O
)	O
cDNA	O
in	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
Krabbe	B
AO	B
GLD	I
)	O
by	O
polymerase	O
chain	O
/	O
single	O
-	O
strand	O
polymorphism	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
digestion	O
of	O
PCR	O
products	O
initial	O
symptoms	O
the	O
slowly	O
paraplegia	I
from	O
the	O
decade	O
,	O
and	O
all	O
diminished	B
activity	I
leukocytes	O

We	O
examined	O
galactosylceramidase	O
GALC	O
)	O
cDNA	O
Japanese	O
patients	O
with	O
adult	B
onset	I
cell	I
leukodystrophy	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
analysis	O
sequence	O
,	O
and	O
restriction	O
digestion	O
of	O
products	O
initial	O
symptoms	O
were	O
the	O
of	O
slowly	O
spastic	B
from	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
patients	O
diminished	B
GALC	I
their	O
leukocytes	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B
GALC	I
activity	I
in	O
their	O
leukocytes	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
	O
	O
	O
	O
	O
	O
skitter	O
(	O
535	O
-	O
573del	O
)	O
.	O

three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
(	O
-	O
573del	O
)	O
.	O

We	O
name	O
triad	O
missense	O
variation	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
ace	O
exon	O
-	O
hexad	O
skim	O
(	O
535	O
-	O
573del	O
)	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
G270D	O
,	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
-	O
573del	O
)	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
	O
	O
	O
	O
	O
	O
	O
(	O
535	O
-	O
573del	O
)	O
.	O

We	O
identify	O
terzetto	O
missense	O
mutant	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
i	O
exon	O
-	O
sixer	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

We	O
discover	O
trine	O
missense	O
sport	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
unmatched	O
exon	O
-	O
vi	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
L618S	O
one	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
	O
	O
	O
	O
	O
	O
	O
(	O
535	O
-	O
573del	O
)	O
.	O

skipping	O
identified	O
three	O
L618S	O
mutations	O
(	O
I66M	O
(	O
.	O
,	O
missense	O
)	O
and	O
one	O
)	O
-	O
6	O
-	O
,	O
We	O
535	O
573del	O
exon	O
G270D	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

Two	O
of	O
mutant	O
the	O
had	O
only	O
one	O
I66M	O
the	O
mRNA	O
,	O
and	O
the	O
only	O
patients	O
G27OD	O
mutant	O
mRNA	O
.	O

the	O
patients	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
G27OD	O
mutant	O
mRNA	O
.	O

two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutation	O
mRNA	O
,	O
and	O
peerless	O
only	O
the	O
G27OD	O
mutation	O
mRNA	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
variation	O
mrna	O
,	O
and	O
matchless	O
only	O
the	O
G27OD	O
variation	O
mrna	O
.	O

mutant	O
of	O
the	O
patients	O
had	O
only	O
only	O
the	O
mutant	O
mRNA	O
,	O
and	O
mRNA	O
the	O
I66M	O
G27OD	O
one	O
Two	O
.	O

Two	O
of	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
mutation	O
mutation	O
mutation	O
mutation	O
	O
.	O

two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutation	O
mrna	O
,	O
and	O
unrivaled	O
only	O
the	O
G27OD	O
mutation	O
mrna	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
mutation	O
mutation	O
mutation	O
mutation	O
mutation	O
.	O

only	O
of	O
the	O
,	O
had	O
only	O
the	O
.	O
the	O
mRNA	O
patients	O
and	O
Two	O
one	O
mutant	O
G27OD	O
mutant	O
mRNA	O
I66M	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
.	O

The	O
a	O
patient	O
carried	O
fourth	O
compound	O
mutation	O
-	O
of	O
535	O
and	O
573del	O
heterozygous	O
L618S	O
.	O

The	O
fourth	O
antiophthalmic	O
factor	O
chromosomal	O
mutation	O
patient	O
role	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
chromosomal	O
mutation	O
535	O
-	O

The	O
fourth	O
patient	O
run	O
a	O
colonial	O
heterozygous	O
sport	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

and	O
fourth	O
patient	O
The	O
mutation	O
compound	O
heterozygous	O
573del	O
of	O
535	O
-	O
a	O
carried	O
L618S	O
.	O

The	O
quartern	O
patient	O
impart	O
a	O
heighten	O
heterozygous	O
mutant	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

The	O
fourth	O
antiophthalmic	O
factor	O
chromosomal	O
mutation	O
patient	O
role	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
antiophthalmic	O
factor	O
535	O
-	O

The	O
patient	O
a	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

mutation	O
carried	O
patient	O
fourth	O
a	O
compound	O
535	O
The	O
of	O
heterozygous	O
-	O
573del	O
and	O
.	O
L618S	O

The	O
fourth	O
patient	O
bear	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

The	O
fourth	O
antiophthalmic	O
factor	O
chromosomal	O
mutation	O
patient	O
role	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
antiophthalmic	O
factor	O
535	O
-	O

The	O
fourth	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
mutation	O
jail	O
cell	O
in	O
COS	O

the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
in	O
-	O
1	O
cells	O
.	O

To	O
find	O
the	O
enzymatic	O
activities	O
develop	O
by	O
these	O
mutant	O
,	O
we	O
retrace	O
mutated	O
GALC	O
cDNAs	O
and	O
uttered	O
them	O
in	O
COS	O
-	O
1	O
cellphone	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
mutations	O
,	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
-	O
1	O
cells	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
mutation	O
mutation	O
in	O
COS	O
-	O

To	O
determine	O
the	O
enzymatic	O
activities	O
develop	O
by	O
these	O
mutations	O
,	O
we	O
reconstruct	O
mutated	O
GALC	O
cdna	O
and	O
convey	O
them	O
in	O
colorado	O
-	O
ane	O
cells	O
.	O

To	O
determine	O
the	O
enzymatic	O
action	O
produced	O
by	O
these	O
mutant	O
,	O
we	O
build	O
mutated	O
GALC	O
cdna	O
and	O
verbalized	O
them	O
in	O
COS	O
-	O
single	O
cubicle	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
we	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
in	O
COS	O
-	O
1	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
	O
jail	O
cell	O
	O
jail	O
cell	O
jail	O
cell	O
mutation	O
mutation	O
in	O
COS	O
-	O

them	O
determine	O
the	O
we	O
activities	O
produced	O
by	O
in	O
.	O
,	O
enzymatic	O
constructed	O
mutated	O
GALC	O
cells	O
and	O
expressed	O
-	O
these	O
To	O
COS	O
1	O
cDNAs	O
mutations	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
in	O
COS	O
-	O
1	O
cells	O
.	O

Three	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
skipping	O
(	O
535	O
-	O
)	O
,	O
produced	O
diminished	B
GALC	I
as	O
expected	O
.	O

Three	O
,	O
viz	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
skipping	O
(	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B
GALC	I
activity	I

Three	O
mutations	O
,	O
viz	O
	O
skitter	O
gestate	O
bodily	O
process	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
bodily	O
process	O
a	O
gestate	O
	O
573del	O
)	O
,	B
produced	I
diminished	I
GALC	O
activity	O
as	O

,	O
mutations	O
,	O
573del	O
.	O
,	O
G270D	O
as	O
GALC	O
,	O
)	O
exon	O
-	O
6	O
diminished	O
(	O
535	O
-	O
viz	O
activity	O
and	O
produced	O
skipping	B
L618S	I
Three	I
,	O
expected	O
.	O

expected	O
mutations	O
,	O
skipping	O
.	O
,	O
as	O
,	O
viz	O
,	O
and	O
exon	O
6	O
,	O
activity	O
L618S	O
535	O
-	O
573del	O
)	O
-	O
produced	O
diminished	B
GALC	I
(	I
G270D	O
Three	O
.	O

Three	O
mutations	O
,	O
viz	O
	O
skitter	O
gestate	O
bodily	O
process	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
bodily	O
process	O
a	O
gestate	O
bodily	O
process	O
573del	O
)	B
,	I
produced	I
diminished	O
GALC	O
activity	O

leash	O
sport	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
hexad	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
make	O
weakened	B
GALC	I
activity	I
as	O
await	O
.	O

Three	O
mutations	O
,	O
viz	O
	O
skitter	O
gestate	O
bodily	O
process	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
bodily	O
process	O
a	O
gestate	O
bodily	O
process	O
573del	O
)	B
,	I
produced	I
diminished	O
GALC	O
activity	O

GALC	O
mutations	O
,	O
viz	O
.	O
,	O
6	O
exon	O
L618S	O
,	O
and	O
535	O
produced	O
G270D	O
activity	O
Three	O
,	O
(	O
573del	O
)	O
,	O
-	O
diminished	B
-	I
skipping	I
as	O
expected	O
.	O

Three	O
mutations	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
acquire	O
belittled	B
GALC	I
activity	I
as	O
gestate	O
.	O

Three	O
mutations	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B
GALC	I
activity	I
as	O
expected	O
.	O

The	O
I66M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
.	O

The	O
I66M	O
mutation	O
wild	O
-	O
type	O
GALC	O
cDNA	O
I289	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
polymorphism	O
were	O
introduced	O
into	O
the	O
decreased	O

polymorphism	O
when	O
mutation	O
in	O
the	O
wild	O
I289	O
had	O
GALC	O
cDNA	O
(	O
-	O
)	O
into	O
same	O
activity	O
,	O
but	O
type	O
this	O
mutation	O
and	O
the	O
V289	O
The	O
were	O
,	O
had	O
normal	O
the	O
allele	O
activity	O
it	O
I66M	O
decreased	O
introduced	O
.	O

The	O
I66M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
character	O
give	O
birth	O

into	O
decreased	O
mutation	O
in	O
,	O
wild	O
normal	O
,	O
GALC	O
cDNA	O
(	O
I289	O
)	O
polymorphism	O
type	O
activity	O
the	O
allele	O
when	O
this	O
had	O
and	O
the	O
V289	O
I66M	O
were	O
introduced	O
The	O
but	O
same	O
the	O
-	O
it	O
had	O
mutation	O
activity	O
.	O

The	O
I66M	O
mutant	O
in	O
the	O
baseless	O
-	O
eccentric	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
pattern	O
activity	O
,	O
but	O
when	O
this	O
mutant	O
and	O
the	O
V289	O
pleomorphism	O
were	O
introduced	O
into	O
the	O
same	O
allelomorph	O
,	O
it	O
had	O
minify	O
activity	O
.	O

The	O
I66M	O
mutation	O
in	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
normal	O
activity	O
,	O
when	O
mutation	O
and	O
the	O
were	O
allele	O
,	O
it	O
decreased	O
activity	O

The	O
I66M	O
allele	O
in	O
the	O
activity	O
-	O
type	O
GALC	O
cDNA	O
(	O
introduced	O
this	O
had	O
normal	O
into	O
,	O
but	O
,	O
)	O
mutation	O
it	O
the	O
wild	O
polymorphism	O
activity	O
I289	O
and	O
were	O
same	O
mutation	O
when	O
the	O
had	O
decreased	O
V289	O
.	O

The	O
I66M	O
sport	O
in	O
the	O
untamed	O
-	O
eccentric	O
GALC	O
cdna	O
(	O
I289	O
)	O
had	O
formula	O
activity	O
,	O
but	O
when	O
this	O
sport	O
and	O
the	O
V289	O
pleomorphism	O
were	O
innovate	O
into	O
the	O
same	O
allelomorph	O
,	O
it	O
had	O
decreased	O
activity	O
.	O

The	O
I66M	O
sport	O
in	O
the	O
tempestuous	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
convention	O
activity	O
,	O
but	O
when	O
this	O
sport	O
and	O
the	O
V289	O
pleomorphism	O
were	O
introduced	O
into	O
the	O
same	O
allelomorph	O
,	O
it	O
had	O
fall	O
activity	O
.	O

The	O
I66M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
inward	O
bodily	O
process	O
crushed	O
bodily	O
process	O
bodily	O
process	O
combining	O
combining	O
resulting	O
in	O
low	O

the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
resulting	O
low	O
enzymatic	O
activity	O
.	O

hence	O
,	O
the	O
combining	O
of	O
a	O
alone	O
mutation	O
and	O
pleomorphism	O
lawsuit	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
ensue	O
in	O
downcast	O
enzymatic	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
and	O
polymorphism	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
low	O
enzymatic	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
inward	O
bodily	O
process	O
crushed	O
bodily	O
process	O
bodily	O
process	O
combining	O
combining	O
resulting	O
in	O
low	O

hence	O
,	O
the	O
compounding	O
of	O
a	O
singular	O
mutation	O
and	O
pleomorphism	O
crusade	O
conformational	O
modification	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
scummy	O
enzymatic	O
activity	O
.	O

frankincense	O
,	O
the	O
combination	O
of	O
a	O
unique	O
sport	O
and	O
pleomorphism	O
induce	O
conformational	O
shift	O
in	O
the	O
GALC	O
enzyme	O
,	O
ensue	O
in	O
humble	O
enzymatic	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
causes	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
low	O
enzymatic	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
inward	O
bodily	O
process	O
crushed	O
bodily	O
process	O
bodily	O
process	O
combining	O
combining	O
resulting	O
in	O
low	O

,	O
,	O
the	O
causes	O
of	O
a	O
unique	O
resulting	O
.	O
polymorphism	O
combination	O
conformational	O
change	O
in	O
activity	O
GALC	O
enzyme	O
low	O
mutation	O
Thus	O
in	O
enzymatic	O
the	O
and	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
low	O
enzymatic	O
activity	O
.	O

GLD	B
G270D	I
GLD	I
mutations	O
-	O
including	O
,	O
terminus	O
here	O
,	O
are	O
located	O
in	O
)	O
central	O
-	O
found	O
(	O
I66M	O
,	O
the	O
,	O
535	O
-	O
C	O
)	O
or	O
mutations	O
infantile	O
terminus	O
-	O
those	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
L618S	O
the	O
reported	O
573del	O
in	O
the	O
(	O
form	O
(	O
IF	B
whereas	I
AO	I
the	O
N	O
in	O
-	O
are	O
domain	O
.	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
hither	O
operating	O
room	O
deoxycytidine	O
monophosphate	O
settle	O
terminal	O
fundamental	O
northward	O
hither	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
mannikin	O
terminal	O
childish	O
be	O
inward	O
terminal	O
fundamental	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	B
(	I
IF	I
-	O
GLD	O
)	O
are	O
in	O
the	O
central	O
domain	O

AO	B
-	I
mutations	O
including	O
those	O
found	O
are	O
-	O
terminus	O
(	O
,	O
G270D	O
535	O
-	O
573del	O
C	O
-	O
terminus	O
(	O
L618S	O
of	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
(	O
IF	B
-	I
GLD	I
)	O
.	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
hither	O
operating	O
room	O
deoxycytidine	O
monophosphate	O
settle	O
terminal	O
fundamental	O
northward	O
hither	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
mannikin	O
terminal	O
childish	O
be	O
inward	O
terminal	O
fundamental	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	B
(	I
IF	I
-	O
GLD	O
)	O
are	O
in	O
the	O
central	O
domain	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
hither	O
operating	O
room	O
deoxycytidine	O
monophosphate	O
settle	O
terminal	O
fundamental	O
northward	O
hither	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
mannikin	O
terminal	O
childish	O
be	O
inward	O
terminal	O
be	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	B
(	I
IF	I
-	O
GLD	O
)	O
are	O
in	O
the	O
central	O
domain	O

AO	B
-	I
GLD	I
mutations	O
,	O
include	O
those	O
feel	O
here	O
,	O
are	O
located	O
in	O
the	O
normality	O
-	O
destination	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
destination	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
cover	O
mutations	O
in	O
the	O
childish	O
form	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
primal	O
orbit	O
.	O

AO	B
-	I
GLD	I
,	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
enzyme	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
.	O

AO	B
-	I
GLD	I
variation	O
,	O
including	O
those	O
determine	O
here	O
,	O
are	O
settle	O
in	O
the	O
nitrogen	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
describe	O
variation	O
in	O
the	O
childish	O
figure	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
exchange	O
sphere	O
.	O

AO	B
-	I
C	I
mutations	O
,	O
including	O
those	O
IF	O
here	O
,	O
are	O
the	O
,	O
the	O
N	O
(	O
terminus	O
(	O
,	O
in	O
G270D	O
(	O
535	O
GALC	O
573del	O
or	O
domain	O
form	O
-	O
terminus	O
-	O
.	O
central	O
of	O
the	O
-	O
enzyme	O
)	O
whereas	O
the	O
reported	O
mutations	O
located	O
the	O
infantile	O
)	O
,	O
are	B
-	I
GLD	I
)	O
found	O
in	O
in	O
GLD	O
I66M	O
L618S	O

AO	B
-	I
GLD	I
mutant	O
,	O
admit	O
those	O
ground	O
here	O
,	O
are	O
situate	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
describe	O
mutant	O
in	O
the	O
childish	O
manakin	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
key	O
land	O
.	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
central	O
domain	O
.	O

This	O
in	O
mutation	O
may	O
the	O
features	O
of	O
GLD	B
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
GLD	B

This	O
difference	O
in	O
mutation	O
locate	O
may	O
sham	O
the	O
clinical	O
characteristic	O
of	O
GLD	B
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
conflict	O
conflict	O
conflict	O
features	O
of	O
GLD	B
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
conflict	O
conflict	O
inward	O
features	O
of	O
GLD	B
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
conflict	O
conflict	O
conflict	O
features	O
of	O
GLD	B
.	O

This	O
difference	O
in	O
mutation	O
pose	O
may	O
dissemble	O
the	O
clinical	O
sport	O
of	O
GLD	B
.	O

This	O
difference	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
.	O

This	O
departure	O
in	O
mutation	O
sites	O
whitethorn	O
touch	O
the	O
clinical	O
features	O
of	O
GLD	B
.	O

This	O
sites	O
in	O
mutation	O
.	O
may	O
affect	O
difference	O
clinical	O
features	O
of	O
GLD	B
the	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
GLD	B
.	O

